At IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
hour NN N
of IN N
infusion NN N
, , N
compared VBN N
with IN N
saline NN N
, , N
L-arginine JJ N
infusion NN N
increased VBD o
basal JJ o
forearm NN N
blood NN N
flow NN N
, , N
nitrite JJ N
and CC N
nitrate JJ N
( ( N
NOx NNP N
) ) N
, , N
and CC N
forearm NN N
cGMP NN N
release NN N
and CC N
decreased VBD o
endothelin-1 NN o
. . N

Group NNP N
A NNP N
was VBD N
restored VBN N
with IN N
prefabricated JJ N
glass-fiber JJ N
posts NNS N
and CC N
Artglass NNP N
polymer NN N
core NN N
; : N
group NN N
B NNP N
with IN N
prefabricated JJ N
glass-fiber JJ N
posts NNS N
and CC N
Charisma NNP N
composite JJ N
resin NN N
core NN N
; : N
and CC N
group NN N
C NNP N
with IN N
prefabricated JJ N
glass-fiber JJ N
posts NNS N
and CC N
AB NNP N
composite JJ N
resin NN N
core NN N
. . N

No DT N
significant JJ N
intergroup NN N
differences NNS N
in IN N
the DT N
trend NN N
of IN N
the DT N
two CD N
plasma NN N
proteins NNS N
( ( N
albumin NN N
, , N
transferrin NN N
) ) N
, , N
lymphocytes VBZ N
, , N
weight NN N
, , N
IL-6 NNP N
, , N
CPR NNP N
and CC N
TNFalpha NNP N
were VBD N
detected VBN N
. . N

RESULTS VB N
The DT N
decreased JJ o
levels NNS N
of IN N
serum NN N
trace NN N
elements NNS N
, , N
glutathione NN N
peroxidase NN N
activity NN N
and CC N
total JJ N
antioxidant JJ N
capacity NN N
, , N
and CC N
increased VBD o
malondialdehyde NN o
, , N
glutathion NN N
reductase NN N
was VBD N
observed VBN N
in IN N
cervical JJ N
cancer NN N
patients NNS p
when WRB N
compared VBN N
to TO N
healthy JJ N
controls NNS N
. . N

The DT N
changes NNS N
in IN N
RBC NNP N
EPA NNP N
content NN N
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
changes NNS N
in IN N
SBP NNP N
and CC N
DBP NNP N
and CC N
directly RB N
correlated VBN N
with IN N
the DT N
increases NNS o
in IN N
HDL NNP N
cholesterol NN N
and CC N
non-HDL JJ N
cholesterol NN N
concentrations NNS N
. . N

BACKGROUND IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
asymmetric JJ N
dimethylarginine NN N
( ( N
ADMA NNP N
) ) N
levels NNS N
could MD N
be VB N
elevated VBN N
and CC N
influence VB N
endothelin-1 JJ N
and CC N
nitric JJ N
oxide NN N
release NN N
and CC N
action NN N
in IN N
patients NNS p
with IN N
cardiac JJ N
syndrome NN N
X NNP N
( ( N
CSX NNP N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
slit-lamp JJ N
characteristics NNS N
of IN N
the DT N
corneal NN N
ulceration NN N
, , N
corrected VBN N
distance NN N
visual JJ N
acuity NN N
, , N
duration NN N
until IN N
healing VBG N
, , N
and CC N
complications NNS N
were VBD N
documented VBN N
in IN N
each DT N
group NN N
. . N

RG-CMH JJ N
intervention NN N
was VBD N
also RB N
associated VBN N
with IN N
a DT N
decrease NN o
in IN N
levels NNS N
of IN N
T NNP N
cells NNS N
, , N
helper JJR N
T NNP N
cells NNS N
, , N
cytotoxic NN N
T NNP N
cells NNS N
and CC N
natural JJ N
killer NN N
cells NNS N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

GD NNP N
caused VBD N
greater JJR N
fatigue NN N
, , N
hepatotoxicity NN N
, , N
neutropenia NN N
, , N
and CC N
thrombocytopenia NNS N
but CC N
not RB N
febrile JJ N
neutropenia NN N
; : N
CD NN N
caused VBD N
more JJR N
hand-foot JJ N
syndrome NN N
, , N
gastrointestinal JJ N
toxicity NN N
, , N
and CC N
mucositis NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
onset NN N
and CC N
average JJ N
root NN N
mean JJ N
square JJ N
amplitude NN N
of IN N
EMG NNP N
activity NN N
in IN N
the DT N
peroneal NN N
muscles NNS N
was VBD N
calculated VBN N
following VBG N
the DT N
release NN N
of IN N
a DT N
trap NN N
door NN N
mechanism NN N
causing VBG N
inversion NN N
. . N

Cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
samples NNS N
were VBD N
collected VBN N
during IN N
surgical JJ N
plane NN N
anesthesia NN N
and CC N
the DT N
collected JJ N
CSF NNP N
samples NNS N
were VBD N
used VBN N
to TO N
assay VB N
for IN N
human JJ N
IL-10 NNP N
, , N
rat VBZ N
IL-1 NNP N
, , N
rat VBZ N
IL-6 NNP N
, , N
and CC N
rat VB N
TNF- JJ N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Intra-operative JJ N
blood NN N
loss NN N
, , N
post-operative JJ N
blood NN N
loss NN N
, , N
blood NN N
transfusion NN N
rates NNS N
, , N
operative JJ N
morbidity NN N
, , N
uterine JJ N
blood NN N
flow NN N
and CC N
ovarian JJ N
function NN N
. . N

RESULTS NNP N
Both NNP N
nitric JJ N
oxide NN N
or CC N
iloprost NN N
attenuated JJ N
cardiopulmonary JJ N
bypass-induced JJ N
thrombocytopenia NN N
, , N
reduction NN N
of IN N
glycoprotein NN N
Ib NNP N
and CC N
glycoprotein VB N
IIb NNP N
levels NNS N
, , N
translocation NN N
of IN N
P-selectin NNP i
, , N
microparticle NN N
formation NN N
, , N
Mac-1 NNP N
upregulation NN N
, , N
and CC N
suppression NN N
of IN N
collagen-induced JJ N
aggregation NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
oral JJ N
dimercapto NN N
succinic JJ N
acid NN N
( ( N
DMSA NNP N
) ) N
therapy NN i
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
ages VBZ N
3-8 CD N
years NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
A NNP N
reduction NN N
in IN N
the DT N
median JJ N
pain NN N
score NN N
, , N
ulcer JJ N
size NN N
, , N
number NN N
of IN N
ulcers NNS N
, , N
or CC N
total JJ N
number NN N
of IN N
ulcer JJ N
episodes NNS N
. . N

CONCLUSION NNP N
Both NNP N
agents NNS N
, , N
enalapril NN N
and CC N
amlodipine NN N
, , N
reduced VBD N
blood NN N
pressure NN N
, , N
but CC N
only RB N
amlodipine VB N
reduced VBN N
platelet JJ N
aggregation NN N
and CC N
platelet NN N
production NN N
of IN N
malondialdehyde NN N
, , N
indicating VBG N
its PRP$ N
action NN N
on IN N
the DT N
arachidonic JJ N
acid NN N
metabolic JJ N
pathway NN N
. . N

Whether NNP N
n3 NN N
fatty RB N
acid JJ N
ethyl NN N
ester NN N
( ( N
FAEE NNP N
) ) N
supplementation NN N
improves VBZ N
arterial JJ N
stiffness NN N
in IN N
obese JJ N
participants NNS N
on IN N
a DT N
weight JJ N
loss NN N
diet NN N
has VBZ N
not RB N
yet RB N
been VBN N
investigated VBN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Quality NN N
of IN N
the DT N
visualization NN N
of IN N
the DT N
uterine JJ N
cavity NN N
, , N
procedure NN N
time NN N
, , N
complications NNS N
, , N
patient JJ N
discomfort NN N
, , N
and CC N
satisfaction NN N
rate NN N
. . N

Renal JJ N
plasma NN N
flow NN N
and CC N
MSA NNP N
increased VBD o
significantly RB o
during IN N
the DT N
insulin NN N
clamp NN N
, , N
whereas JJ N
renal JJ N
NE NNP N
and CC N
total JJ N
body NN N
NE NNP N
spillover NN N
remained VBD N
unchanged JJ N
, , N
suggesting VBG N
nonuniform JJ N
regional JJ N
sympathetic JJ N
nerve NN N
responses NNS N
to TO N
acute VB N
hyperinsulinemia NN N
. . N

Worn NNP N
contact NN N
lenses NNS N
were VBD N
analyzed VBN N
for IN N
lipid JJ N
uptake JJ N
using VBG N
high-performance NN N
liquid NN N
chromatography NN N
by IN N
two CD N
laboratories NNS N
: : N
Alcon NNP N
Laboratories NNPS N
( ( N
right JJ N
lens NNS N
total JJ N
uptake NN N
) ) N
and CC N
OTG NNP N
Research NNP N
& CC N
Consultancy NNP N
( ( N
left VBN N
lens VBZ N
total JJ N
uptake NN N
and CC N
individual JJ N
lipid JJ N
classes NNS N
) ) N
. . N

The DT N
results NNS N
of IN N
the DT N
releasing VBG N
factor NN N
combined VBD N
test NN N
with IN N
arginine JJ N
vasopressin NN N
were VBD N
compared VBN N
in IN N
the DT N
same JJ N
subjects NNS N
with IN N
a DT N
conventional JJ N
combined JJ N
test NN N
using VBG N
insulin NN N
together RB N
with IN N
thyrotrophin JJ N
releasing VBG N
hormone NN N
and CC N
luteinising VBG N
hormone NN N
releasing VBG N
hormone NN N
. . N

Effluent JJ N
carcinogen NN N
antigen-125 JJ N
levels NNS N
were VBD N
inversely RB N
correlated VBN N
with IN N
peritoneal JJ N
glucose JJ N
exposure NN N
during IN N
lactate NN N
but CC N
not RB N
bicarbonate VB N
APD NNP N
, , N
indicating VBG N
improved VBN N
in IN N
vivo JJ N
mesothelial NN N
cell NN N
tolerance NN N
of IN N
high-dose JJ N
glucose NN N
with IN N
the DT N
neutral-pH JJ N
PD NNP N
fluid NN N
with IN N
reduced VBN N
glucose JJ N
degradation NN N
product NN N
content NN N
. . N

BACKGROUND NNP N
Diltiazem NNP N
, , N
a DT N
calcium NN N
channel NN N
blocker NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
in IN N
atrial JJ N
fibrillation NN N
and/or IN N
atrial JJ N
flutter NN N
. . N

The DT N
antihypertensive JJ N
treatment NN N
decreased VBD o
serum JJ o
MDA NNP N
levels NNS N
but CC N
increased VBD o
SOD NNP o
content NN N
, , N
and CC N
probucol NN N
treatment NN N
exaggerated VBD N
these DT N
effects NNS N
, , N
with IN N
greater JJR N
reduction NN N
of IN N
serum NN N
MDA NNP N
levels NNS N
and CC N
greater JJR N
increase NN o
of IN N
SOD NNP N
content NN N
. . N

Secondary JJ N
end NN N
points NNS N
evaluated VBD N
overall JJ i
response NN N
rate NN N
( ( N
ORR NNP N
) ) N
, , N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
, , N
and CC N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
. . N

Eleven JJ N
patients NNS p
with IN N
well-documented JJ N
hepatorenal JJ N
syndrome NN N
were VBD N
studied VBN N
by IN N
measurement NN N
of IN N
blood NN N
volume NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
plasma VBP N
aldosterone JJ N
concentration NN N
, , N
renin JJ N
substrate NN N
concentration NN N
, , N
and CC N
plasma JJ N
renin NN N
activity NN N
. . N

Concerning VBG N
parameters NNS N
of IN N
bone NN N
turnover NN N
, , N
first RB N
ICTP NNP N
as IN N
marker NN N
of IN N
bone NN N
resorption NN N
showed VBD N
a DT N
significant JJ N
increase NN o
, , N
later RB N
on IN N
the DT N
marker NN N
of IN N
bone NN N
formation NN N
increased VBD o
as RB o
well RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Rate NNP N
of IN N
development NN N
of IN N
expanded JJ N
blastocysts NNS N
suitable JJ N
for IN N
transfer NN N
or CC N
vitrification NN N
( ( N
primary JJ N
outcome NN N
) ) N
, , N
fertilization NN N
, , N
aneuploidy NN N
, , N
and CC N
sustained VBD N
implantation NN N
. . N

The DT N
cumulative JJ N
dose NN N
response NN N
effect NN N
of IN N
eicosapentaenoic NN N
and CC N
docosahexaenoic JJ N
acid NN N
on IN N
blood NN N
pressure NN N
, , N
plasma NN N
lipid JJ N
profile NN N
and CC N
diet JJ N
pattern NN N
in IN N
mild NN N
to TO N
moderate VB N
essential JJ N
hypertensive JJ N
black JJ N
patients NNS p
. . N

CONCLUSION NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
When WRB N
methadone NN i
was VBD N
administered VBN N
by IN N
the DT N
SC NNP N
route NN N
, , N
the DT N
half-life NN N
was VBD N
longer RBR N
, , N
but CC N
the DT N
individual JJ N
variation NN N
in IN N
plasma JJ N
concentrations NNS N
was VBD N
greater JJR N
compared VBN N
with IN N
IV NNP N
administration NN N
. . N

CONCLUSIONS NNP N
Sublingual NNP N
micronized VBD N
HRT NNP N
favorably RB N
decreases VBZ o
serum NN N
and CC N
urine JJ N
markers NNS N
of IN N
bone NN N
metabolism NN N
, , N
prevents VBZ N
bone JJ N
loss NN N
, , N
and CC N
results NNS N
in IN N
a DT N
slight JJ N
increase NN o
in IN N
spine NN N
and CC N
hip NN N
bone NN N
mineral JJ N
density NN N
. . N

RESULTS VB N
A DT N
single JJ N
vaccination NN N
with IN N
either DT N
dose NN N
induced VBD N
substantial JJ N
increases NNS o
in IN N
H1N1 NNP N
A/California/07/2009 NNP N
hemagglutination NN N
inhibition NN N
( ( N
HI NNP N
) ) N
and CC N
neutralizing VBG N
( ( N
MN NNP N
) ) N
antibody NN N
titers NNS N
in IN N
both DT N
adult NN N
and CC N
elderly JJ N
subjects NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
; : N
secondary JJ N
endpoints NNS N
were VBD N
time NN N
from IN N
first JJ N
progression NN N
to TO N
death NN N
( ( N
TFPTD NNP N
) ) N
and CC N
tolerability NN N
. . N

CONCLUSIONS NNP N
Vilazodone NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
cardiac JJ N
repolarization NN N
, , N
heart NN N
rate NN N
, , N
PR NNP N
or CC N
QRS NNP N
interval JJ N
duration NN N
, , N
or CC N
ECG NNP N
morphology NN N
in IN N
healthy JJ N
adult NN N
participants NNS N
. . N

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Registration NNP N
included VBD N
hemodynamic JJ N
data NNS N
from IN N
the DT N
peripheral JJ N
artery NN N
and CC N
the DT N
pulmonary JJ N
artery NN N
, , N
and CC N
the DT N
measurement NN N
of IN N
cardiac JJ N
troponin NN N
I PRP N
( ( N
CTnI NNP N
) ) N
and CC N
creatine JJ N
kinase NN N
isoenzyme NN N
MB NNP N
( ( N
CK-MB NNP N
) ) N
values NNS N
. . N

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
effect NN N
of IN N
increased JJ o
carbohydrate NN N
and CC N
fiber NN N
intakes NNS N
on IN N
serum JJ N
short-chain JJ N
fatty JJ N
acids NNS N
( ( N
SCFAs NNP N
) ) N
and CC N
the DT N
relation NN N
between IN N
changes NNS N
in IN N
serum NN N
acetate NN N
and CC N
changes NNS N
in IN N
blood NN N
lipids NNS N
. . N

The DT N
oligonucleotide JJ N
primer NN N
pairs NNS N
for IN N
the DT N
microsatellite JJ N
DNA NN N
markers NNS N
were VBD N
D8S133 NNP N
, , N
D8S136 NNP N
, , N
D8S137 NNP N
, , N
ANK1 NNP N
on IN N
chromosome NN N
8p12-21 CD N
, , N
LPLTET NNP N
on IN N
chromosome NN N
8p22 CD N
, , N
and CC N
D17S855 NNP N
( ( N
intragenic JJ N
to TO N
the DT N
BRCA1 NNP N
gene NN N
) ) N
on IN N
chromosome NN N
17q21 CD N
. . N

GH NNP N
treatment NN N
did VBD N
not RB N
induce VB N
a DT N
further JJ N
increase NN o
in IN N
insulin JJ N
levels NNS N
during IN N
an DT N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
but CC N
significantly RB N
decreased VBD o
free JJ o
fatty JJ N
acid NN N
( ( N
FFA NNP N
) ) N
levels NNS N
during IN N
OGTT NNP N
. . N

The DT N
acid NN N
challenge NN N
after IN N
in IN N
situ JJ N
remineralization NN N
for IN N
both DT N
control NN N
and CC N
CPP-ACP-treated JJ N
lesions NNS N
resulted VBD N
in IN N
demineralization NN N
underneath IN N
the DT N
remineralized JJ N
zone NN N
, , N
indicating VBG N
that IN N
the DT N
remineralized JJ N
mineral NN N
was VBD N
more RBR N
resistant JJ N
to TO N
subsequent JJ N
acid NN N
challenge NN N
. . N

Before IN N
treatment NN N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN N
and CC N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
epidural JJ N
administration NN N
of IN N
lidocaine JJ N
plus CC N
ketamine JJ N
resulted VBN N
in IN N
longer JJR N
caudal NN N
analgesia NN N
in IN N
standing VBG N
conscious JJ N
dromedary JJ N
camels NNS N
compared VBN N
with IN N
the DT N
effect NN N
of IN N
administering VBG N
lidocaine JJ N
alone RB N
. . N

Changes NNS N
in IN N
total JJ N
cholesterol NN N
and CC N
LDL NNP N
cholesterol NN N
were VBD N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
factor NN N
VIIc NNP N
in IN N
the DT N
DYDR NNP N
group NN N
and CC N
negatively RB N
with IN N
changes NNS N
in IN N
factor NN N
VIIc NNP N
in IN N
the DT N
T-group NNP N
. . N

We PRP N
tested VBD N
the DT N
extent NN N
to TO N
which WDT N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
[ NNP N
N NNP N
( ( N
G NNP N
) ) N
-monomethyl-L-arginine NN N
( ( N
L-NMMA NNP N
) ) N
] NN N
can MD N
reverse VB N
the DT N
drop NN N
in IN N
blood NN N
pressure NN N
that WDT N
occurs VBZ N
after IN N
exercise NN N
in IN N
humans NNS N
. . N

Sixty CD N
7x3 CD N
mm NNS N
pressed VBN N
ceramic JJ N
discs NN N
of IN N
IPS NNP N
e.max NN i
were VBD N
fabricated VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
six CD N
groups NNS N
of IN N
different JJ N
dentin NN i
surface NN N
treatments NNS N
( ( N
control NN N
, , N
desensitizer NN N
, , N
disinfectant NN N
, , N
saliva NN N
, , N
blood NN N
, , N
and CC N
hydrogen VB N
peroxide NN N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
blood NN N
lipid NN N
, , N
fasting VBG N
glucose NN N
, , N
and CC N
insulin NN N
levels NNS N
and CC N
side NN N
effects NNS N
related VBN N
to TO N
elevated VBN N
blood NN N
pressure NN N
and CC N
increased VBD o
dietary JJ o
fiber NN N
intake NN N
. . N

The DT N
complete JJ N
inhibition NN N
rate NN N
of IN N
vomiting VBG N
was VBD N
as RB N
high JJ N
as IN N
71.4 CD N
% NN N
and CC N
92.3 CD N
% NN N
in IN N
the DT N
single JJ N
and CC N
combination NN N
groups NNS N
, , N
respectively RB N
, , N
showing VBG N
no DT N
significant JJ N
difference NN N
. . N

During IN N
the DT N
one CD N
year NN N
therapy IN i
the DT N
levels NNS N
of IN N
serum NN N
bilirubin NN N
, , N
uric JJ N
acid NN N
and CC N
triglycerides NNS N
were VBD N
significantly RB N
increased VBN o
in IN N
all DT N
groups NNS N
but CC N
the DT N
group NN N
treated VBD N
with IN N
metoprolol NN i
and CC N
hydralazine NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
PFS NNP N
, , N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
, , N
the DT N
overall JJ i
response NN N
rate NN N
( ( N
ORR NNP N
) ) N
and CC N
tolerability NN N
. . N

At IN N
T12 NNP N
, , N
before IN N
the DT N
allergen NN N
challenge NN N
, , N
serum NN N
ECP NNP N
levels NNS N
increased VBN o
in IN N
the DT N
placebo NN N
group NN N
and CC N
blood NN N
eosinophils NNS N
showed VBD N
a DT N
trend NN N
towards NNS N
lower JJR N
numbers NNS N
in IN N
the DT N
active JJ N
one NN N
. . N

Fibrinogen NN N
and CC N
plasminogen NN N
concentrations NNS N
in IN N
plasma NN N
, , N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
plasma NN N
and CC N
fibrinolytic JJ N
activity NN N
in IN N
concentrated JJ N
euglobulins NNS N
were VBD N
determined VBN N
before IN N
surgery NN N
and CC N
on IN N
the DT N
first JJ N
, , N
third JJ N
and CC N
seventh JJ N
postoperative JJ N
days NNS N
. . N

RESULTS NNP N
FMA NNP N
total JJ N
scores NNS N
were VBD N
significantly RB N
higher JJR N
and CC N
synergistic JJ N
shoulder NN N
abduction NN N
during IN N
reach NN N
was VBD N
less RBR N
in IN N
the DT N
MT NNP N
+ NNP N
MG NNP N
and CC N
MT NNP N
groups NNS N
compared VBN N
with IN N
the DT N
CT NNP N
group NN N
. . N

BACKGROUND NNP N
Characterization NNP N
of IN N
fatal JJ N
and CC N
non-fatal JJ N
reactions NNS N
to TO N
food NN N
indicates NNS N
that IN N
the DT N
majority NN N
of IN N
reactions NNS N
are VBP N
due JJ N
to TO N
the DT N
ingestion NN N
of IN N
prepared JJ N
foods NNS N
rather RB N
than IN N
the DT N
non-processed JJ N
allergen NN N
. . N

For IN N
all DT N
patients NNS p
, , N
synthesis NN N
of IN N
IL-1 NNP N
beta NN N
increased VBD o
constitutively RB o
and CC N
in IN N
response NN N
to TO N
immune-mediated JJ N
stimulants NNS N
( ( N
PHA NNP N
, , N
IL-2 NNP N
, , N
and CC N
mitochondrial JJ N
antigen NN N
) ) N
but CC N
not RB N
the DT N
bacterial JJ N
stimulants NNS N
LPS NNP N
or CC N
S NNP N
epidermidis NN N
. . N

BACKGROUND NNP N
Total NNP N
parenteral JJ N
nutrition NN N
( ( N
TPN NNP N
) ) N
supplemented VBD N
with IN N
glutamine NN N
( ( N
GLN NNP N
) ) N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
for IN N
patients NNS p
with IN N
bone NN N
marrow NN N
transplantation NN N
( ( N
BMT NNP N
) ) N
. . N

The DT N
changes NNS N
in IN N
systolic JJ N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
plasma NN N
TGs NNP N
, , N
C1 NNP N
, , N
and CC N
C2 NNP N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
WL+FAEE NNP N
group NN N
than IN N
in IN N
the DT N
WL NNP N
group NN N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
reduction NN N
of IN N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
HDL NNP N
, , N
LDL NNP N
and CC N
TGs NNP N
in IN N
OG NNP N
subjects NNS N
and CC N
a DT N
significant JJ N
increase NN o
of IN N
HDL NNP N
levels NNS N
. . N

By IN N
blocking VBG N
ileal NN N
bile NN N
acid NN N
transporter NN N
in IN N
the DT N
terminal NN N
ileum NN N
, , N
it PRP N
highly RB N
efficiently RB N
interrupts VBZ N
the DT N
enterohepatic JJ N
circulation NN N
of IN N
BAs NNP N
, , N
and CC N
should MD N
be VB N
of IN N
benefit NN N
to TO N
patients NNS p
with IN N
cholestatic JJ N
liver NN N
diseases NNS N
. . N

Biopsies NNS N
were VBD N
taken VBN N
from IN N
the DT N
gastric JJ N
antrum NN N
and CC N
corpus NN N
for IN N
determination NN N
of IN N
prostaglandin NN N
E2 NNP N
( ( N
PGE2 NNP N
) ) N
by IN N
ELISA NNP N
and CC N
cyclooxygenase NN N
( ( N
COX-1 JJ N
and CC N
COX-2 NNP N
) ) N
and CC N
nitric JJ N
oxide NN N
synthase NN N
( ( N
eNOS JJ N
and CC N
iNOS NN N
) ) N
by IN N
western JJ N
blot NN N
. . N

Venous JJ N
blood NN N
samples NNS N
were VBD N
obtained VBN N
for IN N
determination NN N
of IN N
serum JJ N
cytokines NNS N
including VBG N
interleukin-1beta JJ N
( ( N
IL-1beta NNP N
) ) N
, , N
tumor JJ N
necrosis NN N
factor-alpha NN N
( ( N
TNF-alpha NNP N
) ) N
, , N
RANKL NNP N
, , N
osteoprotegerin NN N
, , N
and CC N
markers NNS N
of IN N
bone NN N
formation NN N
and CC N
resorption NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
change NN N
in IN N
oxygen NN N
saturation NN N
, , N
respiratory NN N
rate NN N
, , N
and CC N
RDAI NNP N
score NN N
at IN N
any DT N
assessment JJ N
period NN N
. . N

Changes NNS N
in IN N
arterial JJ N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
or CC N
plasma VB N
beta-endorphin JJ N
, , N
cortisol NN N
, , N
and CC N
glucose JJ N
concentration NN N
did VBD N
not RB N
show VB N
any DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Blood NNP N
glucose NN N
and CC N
plasma JJ N
insulin NN N
and CC N
glucagon NN N
concentrations NNS N
rose VBD N
post-operatively RB N
whether IN N
or CC N
not RB N
insulin NN N
was VBD N
given VBN N
, , N
but CC N
the DT N
increment NN N
in IN N
insulin NN N
concentration NN N
was VBD N
significantly RB N
greater JJR N
when WRB N
insulin NN N
was VBD N
given VBN N
. . N

RESULTS VB N
The DT N
significantly RB N
raised VBN N
levels NNS N
of IN N
MDA NNP N
and CC N
SOD NNP N
, , N
and CC N
decreased JJ o
levels NNS N
of IN N
reduced VBN N
glutathione NN N
( ( N
GSH NNP N
) ) N
during IN N
uncontrolled JJ N
stage NN N
of IN N
diabetes NNS N
indicated VBD N
free JJ N
radical JJ N
stress NN N
induced VBD N
lipid JJ N
peroxidation NN N
. . N

Statistically RB N
significantly RB N
greater JJR N
improvement NN N
in IN N
ABC NNP N
Stereotypic NNP N
Behavior NNP N
and CC N
Hyperactivity NNP N
total JJ N
subscale NN N
scores NNS N
was VBD N
also RB N
consistent JJ N
across IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
. . N

Recent JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
the DT N
calcium NN N
channel NN N
blocking VBG N
agents NNS N
can MD N
inhibit VB N
experimentally RB N
induced JJ N
bronchoconstriction NN N
in IN N
asthmatics NNS N
, , N
but CC N
their PRP$ N
protective JJ N
action NN N
has VBZ N
been VBN N
variable JJ N
. . N

The DT N
tPA JJ N
mass NN N
concentrations NNS N
also RB N
dropped VBD N
, , N
both DT N
before IN N
and CC N
after IN N
VO NNP N
, , N
but CC N
tPA JJ N
activities NNS N
were VBD N
unchanged JJ N
, , N
as IN N
were VBD N
von JJ N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
levels NNS N
. . N

There EX N
were VBD N
significant JJ N
effects NNS N
for IN N
erosion NN N
( ( N
orange JJ N
juice NN N
produced VBD N
significantly RB N
more JJR N
erosion NN N
than IN N
water NN N
) ) N
and CC N
for IN N
abrasion NN N
( ( N
paste NN N
A DT N
was VBD N
significantly RB N
more RBR N
abrasive JJ N
to TO N
dentine VB N
than IN N
paste NN N
B NNP N
) ) N
. . N

As IN N
to TO N
the DT N
neuroendocrinological JJ N
effect NN N
, , N
cyproheptadine JJ N
augmentation NN N
did VBD N
not RB N
reduce VB N
the DT N
plasma NN N
prolactin NN i
level NN N
but CC N
did VBD N
induce VB N
a DT N
decrease NN o
in IN N
the DT N
plasma NN N
cortisol NN N
level NN N
. . N

Margarines NNS N
fortified VBN N
with IN N
? . N
acid NN N
, , N
eicosapentaenoic JJ N
acid NN N
, , N
or CC N
docosahexaenoic JJ N
acid NN N
alter IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
but CC N
do VBP N
not RB N
affect VB N
the DT N
antioxidant JJ N
status NN N
of IN N
healthy JJ N
adults NNS N
. . N

In IN N
summary JJ N
, , N
E10A NNP N
plus CC N
chemotherapy NN i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
therapeutic JJ N
approach NN N
in IN N
patients NNS p
with IN N
advanced JJ N
head NN N
and CC N
neck NN N
squamous JJ N
cell NN N
carcinoma NN N
or CC N
nasopharyngeal JJ N
carcinoma NN N
. . N

RESULTS VB N
The DT N
RV NNP N
pacing NN N
contributed VBD N
to TO N
significant JJ N
increase NN o
in IN N
left JJ N
atrial JJ N
volume NN N
, , N
left VBD N
ventricular JJ N
( ( N
LV NNP N
) ) N
end-systolic JJ N
volume NN N
, , N
and CC N
LV NNP N
mass NN N
compared VBN N
to TO N
BiV NNP N
pacing NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Peak-stimulated NNP N
LH NNP N
, , N
estradiol NN N
, , N
T NNP N
, , N
growth NN N
rate NN N
, , N
pubertal JJ N
progression NN N
, , N
and CC N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
. . N

Serum NNP N
calcium NN N
levels NNS N
decreased VBN o
in IN N
most JJS N
patients NNS p
after IN N
surgery NN N
, , N
but CC N
recovered VBD N
earliest JJS N
in IN N
Group NNP N
A. NNP N
Hypercalcemia NNP N
and CC N
PTH NNP N
inhibition NN N
did VBD N
not RB N
occur VB N
in IN N
gs NN N
A NNP N
and CC N
B NNP N
. . N

CONCLUSIONS NNP N
Nitric NNP N
oxide IN N
plus CC N
iloprost VB N
reduced VBN N
the DT N
deleterious JJ N
effects NNS N
of IN N
cardiopulmonary JJ N
bypass NN N
, , N
such JJ N
as IN N
thrombocytopenia NN N
, , N
platelet NN N
activation NN N
, , N
platelet-leukocyte JJ N
aggregate NN N
formation NN N
, , N
and CC N
suppression NN N
of IN N
platelet NN N
aggregative JJ N
responses NNS N
. . N

Cytosine NNP N
arabinoside NN N
( ( N
CA NNP N
) ) N
was VBD N
utilized VBN N
in IN N
efforts NNS N
to TO N
synchronize VB N
leukemic JJ N
cells NNS N
in IN N
DNA NNP N
synthesis NN N
for IN N
treatment NN N
with IN N
vincristine NN N
, , N
prednisone NN N
, , N
and CC N
L-asparaginase NNP N
in IN N
children NNS N
with IN N
acute JJ N
leukemia NN N
in IN N
relapse NN N
. . N

CONCLUSIONS NNP N
The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
ferulic JJ N
acid NN N
from IN N
rye NN N
bran NN N
is VBZ N
bioavailable JJ N
and CC N
that IN N
the DT N
urinary JJ N
concentration NN N
of IN N
ferulic JJ N
acid NN N
reflects VBZ N
the DT N
dietary JJ N
intake NN N
of IN N
this DT N
hydroxycinnamic JJ N
acid NN N
. . N

Main NNP N
outcome NN N
measures NNS N
were VBD N
best-corrected JJ N
visual JJ N
acuity NN N
, , N
central JJ N
retinal JJ N
thickness NN N
, , N
nuclear JJ N
density NN N
units NNS N
' POS N
changes NNS N
, , N
and CC N
rate NN N
of IN N
complications NNS N
. . N

Combined JJ N
administration NN N
of IN N
amino JJ N
acids NNS N
and CC N
glucose VB N
decreased VBN o
endogenous JJ N
glucose JJ N
production NN N
( ( N
P=.001 NNP N
) ) N
and CC N
stimulated VBN N
insulin NN N
secretion NN N
( ( N
P=.001 NNP N
) ) N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
the DT N
administration NN N
of IN N
amino JJ N
acids NNS N
alone RB N
. . N

Treatment NN N
with IN N
simvastatin NN i
or CC N
gemfibrozil NN N
in IN N
hypertensive JJ N
patients NNS p
in IN N
hydrochlorothiazide JJ i
monotherapy NN i
can MD N
reduce VB N
total JJ N
cholesterol NN N
and CC N
LDL-cholesterol NNP N
plasma NN N
levels NNS N
, , N
while IN N
significantly RB N
increasing VBG N
HDL NNP N
plasma NN N
levels NNS N
compared VBN N
to TO N
placebo VB N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
An DT N
oral JJ N
glutamine NN N
load NN N
in IN N
cirrhotic JJ i
patients NNS p
awaiting VBG N
liver JJ N
transplantation NN N
was VBD N
shown VBN N
to TO N
cause VB N
a DT N
rise NN N
in IN N
blood NN N
ammonia NN N
and CC N
psychometric NN N
abnormalities NNS N
which WDT N
were VBD N
reversed VBN N
by IN N
hepatic JJ N
transplantation NN N
. . N

Postprandial NNP N
triglyceride NN N
levels NNS N
tended VBD N
to TO N
be VB N
higher JJR N
after IN N
all DT N
fibre-rich JJ N
meals NNS N
, , N
but CC N
only RB N
significant JJ N
for IN N
oat NN N
powder NN N
and CC N
the DT N
mixed JJ N
meal NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
. . N

The DT N
vaccine NN N
response NN N
was VBD N
evaluated VBN N
as IN N
significant JJ N
increases NNS o
in IN N
levels NNS N
of IN N
influenza JJ N
hemagglutination-inhibition NN N
( ( N
HAI NNP N
) ) N
antibodies NNS N
and CC N
of IN N
IgG NNP N
antibodies NNS N
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
combined JJ N
treatments NNS N
significantly RB N
promoted VBD N
healing NN N
of IN N
rat NN N
gastric JJ N
ulcers NNS N
whereas VBP N
each DT N
agent NN N
alone RB N
had VBD N
no DT N
significant JJ N
effect NN N
as IN N
compared VBN N
with IN N
control NN N
( ( N
saline NN N
) ) N
. . N

Safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
combined JJ N
pentavalent NN N
diphtheria NN N
, , N
tetanus NN N
, , N
acellular JJ N
pertussis NN N
, , N
inactivated VBN N
poliovirus NN N
and CC N
Haemophilus NNP N
influenzae VBP N
type JJ N
b-tetanus JJ N
conjugate NN N
vaccine NN N
in IN N
infants NNS N
, , N
compared VBN N
with IN N
a DT N
whole JJ N
cell NN N
pertussis NN N
pentavalent NN N
vaccine NN N
. . N

On IN N
the DT N
basis NN N
of IN N
these DT N
results NNS N
, , N
it PRP N
seems VBZ N
that IN N
ginger NN N
has VBZ N
the DT N
potential JJ N
to TO N
decrease VB o
eicosanoid JJ N
levels NNS N
, , N
perhaps RB N
by IN N
inhibiting VBG N
their PRP$ N
synthesis NN N
from IN N
arachidonic JJ N
acid NN N
. . N

Importantly RB N
, , N
the DT N
number NN N
of IN N
deaths NNS N
related VBN N
to TO N
infections NNS N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
low JJ N
versus NN N
high JJ N
CD19 NNP N
group NN N
( ( N
P NNP N
< NNP N
.0202 NNP N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
of IN N
the DT N
change NN N
from IN N
baseline NN N
showed VBD N
that IN N
cilomilast NN N
did VBD N
not RB N
alter VB N
any DT N
sputum JJ N
endpoint NN N
or CC N
FEV1 NNP N
. . N

With IN N
the DT N
rHA NN N
fusion NN N
protein NN N
as IN N
antigen NN N
, , N
we PRP N
successfully RB N
prepared VBD N
and CC N
screened VBD N
specific JJ N
monoclonal JJ N
antibodys NN N
against IN N
the DT N
H5N1 NNP N
subtype NN N
AIV NNP N
, , N
which WDT N
indicated VBD N
that IN N
the DT N
rHA NN N
had VBD N
antigen VBN N
epitopes NNS N
and CC N
biofunctions NNS N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Metformin NNP N
therapy NN i
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN o
in IN N
total JJ N
T NNP N
, , N
LH NNP N
level NN N
, , N
LH/FSH NNP N
ratio NN N
, , N
insulin NN N
resistance NN N
, , N
and CC N
mean JJ N
BMI NNP N
. . N

The DT N
number NN N
of IN N
patients NNS p
developing VBG N
abnormal JJ N
liver NN N
function NN N
tests NNS N
( ( N
including VBG N
clinically RB N
significant JJ N
elevation NN N
) ) N
, , N
hemoglobin UH N
, , N
and CC N
creatinine JJ N
clearance NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
oral JJ N
diclofenac NN N
group NN N
. . N

Total JJ N
cholesterol NN N
, , N
triglycerides NNS N
, , N
HDL NNP N
and CC N
LDL NNP N
cholesterol NN N
fractions NNS N
were VBD N
determined VBN N
twice RB N
during IN N
an DT N
initial JJ N
4-week JJ N
washout NN N
phase NN N
, , N
and CC N
after IN N
a DT N
1- JJ N
, , N
3- JJ N
and CC N
6-month JJ N
active JJ N
hypotensive JJ N
drug NN N
phase NN N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
hospital JJ N
mortality NN N
and CC N
morbidity NN N
, , N
length NN N
of IN N
hospital NN N
stay NN N
, , N
and CC N
length NN N
of IN N
sick JJ N
leave VBP N
from IN N
work NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
hematologic JJ N
toxicity NN N
, , N
transfusion NN N
requirements NNS N
, , N
duration NN N
of IN N
fever NN N
, , N
and CC N
hepatic JJ N
toxicity NN N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

METHODS NNP N
Using NNP N
RT-PCR NNP N
, , N
expression NN N
of IN N
leptin NN i
genes NNS N
and CC N
leptin NN i
receptor NN N
genes NNS N
was VBD N
studied VBN N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
in IN N
women NNS N
with IN N
uterine JJ N
myomas NN N
, , N
untreated VBD N
or CC N
treated VBN N
with IN N
GnRH NNP N
analogue NN N
. . N

The DT N
rate NN N
of IN N
healing NN N
of IN N
gastric JJ N
lesions NNS N
occurred VBD N
more RBR N
rapidly RB N
as IN N
years NNS N
free JJ N
of IN N
infection NN N
accumulated VBN N
, , N
and CC N
was VBD N
more RBR N
pronounced JJ N
in IN N
less RBR N
advanced JJ N
lesions NNS N
. . N

Circadian JJ N
patterns NNS N
of IN N
plasma NN N
melatonin NN N
, , N
glucose NN N
, , N
lactic JJ N
acid NN N
, , N
and CC N
corticosterone NN N
were VBD N
maintained VBN N
in IN N
all DT N
rats NNS N
except IN N
those DT N
exposed VBN N
to TO N
constant VB N
bright JJ N
light NN N
or CC N
the DT N
highest JJS N
level NN N
of IN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

The DT N
effects NNS N
of IN N
chloroquine NN N
, , N
amodiaquine NN N
and CC N
chloroquine NN N
plus CC N
chlorpheniramine NN N
on IN N
the DT N
disposition NN N
kinetics NNS N
of IN N
the DT N
hepatomegaly NN N
associated VBN N
with IN N
acute NN N
, , N
uncomplicated JJ N
, , N
Plasmodium NNP N
falciparum NN N
malaria NN N
in IN N
children NNS N
. . N

Betamethasone NNP N
reduced VBD N
all DT N
three CD N
parameters NNS N
, , N
erythema NN N
, , N
scaling VBG N
and CC N
pruritus NN N
, , N
faster JJR N
than IN N
pimecrolimus NN N
, , N
but CC N
the DT N
differences NNS N
in IN N
reduction NN N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Accordingly RB N
, , N
the DT N
cerebral JJ N
metabolic NN N
ratio NN N
decreased VBD o
equally RB o
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
: : N
from IN N
5.8 CD N
at IN N
rest NN N
to TO N
1.7 CD N
and CC N
1.8 CD N
, , N
respectively RB N
. . N

At IN N
anaesthesia JJ N
induction NN N
, , N
serum JJ N
carnitine NN N
was VBD N
significantly RB N
increased VBN o
in IN N
treated JJ N
patients NNS p
, , N
but CC N
carnitine JJ N
concentrations NNS N
in IN N
the DT N
right JJ N
atrial JJ N
biopsy NN N
obtained VBN N
just RB N
before RB N
aortic JJ N
declamping NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Better NNP N
effects NNS N
on IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN N
and CC N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Consumption NN N
of IN N
industrial JJ N
trans NNS N
fatty JJ N
acids NNS N
( ( N
iTFA NN N
) ) N
increases VBZ o
LDL NNP N
cholesterol NN N
, , N
decreases VBZ o
HDL NNP N
cholesterol NN N
, , N
and CC N
is VBZ N
strongly RB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

Plasma NNP N
aldosterone NN N
levels NNS N
decreased VBN o
to TO N
a DT N
normal JJ N
range NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
and CC N
renal JJ N
plasma NN N
flow NN N
both DT N
increased VBN o
, , N
and CC N
urinary JJ N
excretion NN N
of IN N
sodium NN N
and CC N
potassium NN N
both DT N
returned VBN N
toward IN N
normal JJ N
. . N

BACKGROUND NNP N
Deletion NNP N
of IN N
the DT N
B-domain NNP N
of IN N
recombinant JJ N
blood NN N
coagulation NN N
factor NN N
VIII NNP N
( ( N
BDDrFVIII NNP N
) ) N
increases VBZ o
the DT N
manufacturing VBG N
yield NN N
of IN N
the DT N
product NN N
but CC N
does VBZ N
not RB N
impair VB N
in IN N
vitro NN N
or CC N
in IN N
vivo JJ N
functionality NN N
. . N

RESULTS JJ N
Meals NNS N
with IN N
rye NN N
bran NN N
gave VBD N
a DT N
lower JJR N
postprandial JJ N
glucose NN N
peak NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
, , N
and CC N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
women NNS N
compared VBN N
to TO N
men NNS N
. . N

Papanicolaou NNP N
smear NN N
showed VBD N
reactive JJ N
or CC N
reparative JJ N
changes NNS N
and CC N
karyopyknotic JJ i
index NN N
exhibited VBD N
a DT N
significant JJ N
increase NN o
in IN N
superficial JJ N
cells NNS N
in IN N
both DT N
groups NNS N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

The DT N
percentage NN N
of IN N
children NNS N
with IN N
detectable JJ N
antibodies NNS N
and CC N
the DT N
reciprocal JJ N
geometric JJ N
mean NN N
titers NNS N
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
at IN N
two CD N
months NNS N
of IN N
age NN N
for IN N
antibodies NNS N
to TO N
all DT N
three CD N
poliovirus NN N
types NNS N
. . N

Basal NNP N
nitric JJ N
oxide JJ N
synthesis NN N
of IN N
the DT N
renal JJ N
vasculature NN N
was VBD N
assessed VBN N
by IN N
the DT N
decrease NN o
in IN N
RPF NNP N
after IN N
inhibition NN N
of IN N
nitric JJ N
oxide JJ N
synthase NN N
with IN N
NG-monomethyl-L-arginine NNP N
( ( N
L-NMMA NNP N
; : N
4.25 CD N
mg/kg NN N
) ) N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
use NN N
of IN N
leukocyte JJ N
reduction NN N
filters NNS N
on IN N
the DT N
activity NN N
of IN N
polymorphonuclear NN N
neutrophils NNS N
( ( N
PMN NNP N
) ) N
in IN N
patients NNS p
undergoing VBG N
surgical JJ N
myocardial JJ N
revascularisation NN N
. . N

It PRP N
is VBZ N
an DT N
inhibitor NN N
of IN N
the DT N
enzyme NN N
that WDT N
converts VBZ N
angiotensin NN N
I PRP N
( ( N
Angiotensin NNP N
Converting NNP N
Enzyme NNP N
, , N
ACE NNP N
) ) N
into IN N
angiotensin NN N
II NNP N
as RB N
well RB N
as IN N
causing VBG N
the DT N
degradation NN N
of IN N
the DT N
vasodilator NN N
bradykinin NN N
into IN N
an DT N
inactive JJ N
heptapeptide NN N
. . N

In IN N
both DT N
groups NNS N
plasma VBP N
levels NNS N
of IN N
fibrinogen NN N
and CC N
factor NN N
VII NNP N
increased VBD o
while IN o
the DT N
capacity NN N
of IN N
coagulation NN N
inhibition NN N
was VBD N
affected VBN N
by IN N
increased JJ o
protein NN N
C NNP N
and CC N
decreased VBN o
protein NN N
S NNP N
levels NNS N
. . N

CONCLUSIONS NNP N
Enflurane NNP N
causes VBZ N
a DT N
decrease NN o
in IN N
ShvO2 NNP N
, , N
which WDT N
indicates VBZ N
an DT N
impairment NN N
of IN N
splanchnic JJ N
perfusion NN N
corresponding VBG N
to TO N
the DT N
reduction NN N
in IN N
CO NNP N
and CC N
MAP NNP N
in IN N
a DT N
dose-dependent JJ N
manner NN N
. . N

Cyclosporine-A NNP N
( ( N
CsA NNP N
) ) N
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
opening NN N
of IN N
the DT N
mitochondrial JJ N
permeability NN N
transition NN N
pore NN N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
play VB N
a DT N
key JJ N
role NN N
in IN N
myocardial JJ N
reperfusion NN N
injury NN N
. . N

Animal NNP N
studies NNS N
have VBP N
suggested VBN N
interspecies NNS N
differences NNS N
in IN N
brain NN N
norepinephrine NN N
( ( N
NE NNP N
) ) N
metabolism NN N
, , N
especially RB N
with IN N
regard NN N
to TO N
the DT N
relative JJ N
proportions NNS N
of IN N
3,4-dihydroxyphenylethyleneglycol JJ N
( ( N
DOPEG NNP N
) ) N
compared VBN N
to TO N
3-methoxy-4-hydroxyphenylethyleneglycol CD N
( ( N
MOPEG NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
mean JJ N
percentage NN N
decrease NN o
of IN N
AMH NNP N
levels NNS N
in IN N
the DT N
BC NNP N
group NN N
and CC N
LS NNP N
group NN N
at IN N
3- JJ N
, , N
6- JJ N
, , N
and CC N
12-month JJ N
follow-up NN N
. . N

Nausea NN N
was VBD N
noted VBN N
in IN N
71.4 CD N
% NN N
and CC N
46.2 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
inhibitory JJ N
effect NN N
tended VBD N
to TO N
be VB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

RESULTS NNP N
DMSA NNP N
greatly RB N
increased VBD o
the DT o
excretion NN N
of IN N
lead NN N
, , N
substantially RB N
increased VBN o
excretion NN N
of IN N
tin NN i
and CC N
bismuth NN N
, , N
and CC N
somewhat RB N
increased VBD o
the DT o
excretion NN N
of IN N
thallium NN N
, , N
mercury NN N
, , N
antimony NN N
, , N
and CC N
tungsten NNS N
. . N

Both DT N
cortisol NN N
and CC N
growth NN N
hormone NN N
responses VBZ N
to TO N
the DT N
releasing VBG N
factors NNS N
with IN N
arginine JJ N
vasopressin NN N
were VBD N
much RB N
greater JJR N
than IN N
those DT N
seen VBN N
with IN N
insulin NN N
induced VBN N
hypoglycaemia NN N
or CC N
the DT N
combined JJ N
releasing NN N
factors NNS N
without IN N
arginine JJ N
vasopressin NN N
. . N

UNLABELLED NN N
It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
cytarabine NN N
, , N
acting VBG N
by IN N
at IN N
least JJS N
two CD N
different JJ N
mechanisms NNS N
, , N
enhances VBZ N
the DT N
cytotoxic JJ N
effect NN N
of IN N
cisplatin NN i
in IN N
in IN N
vitro JJ N
systems NNS N
. . N

Administration NN N
of IN N
PU NNP N
significantly RB N
increased VBD o
urinary JJ o
flow NN N
rate NN N
though IN N
in IN N
the DT N
controls NNS N
urinary JJ N
flow NN N
rate NN N
decreased VBN o
, , N
size NN N
of IN N
the DT N
prostate NN N
diminished VBD N
and CC N
increased VBD o
, , o
respectively RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Balloon NNP N
insertion NN N
to TO N
delivery NN N
interval NN N
, , N
successful JJ N
ripening VBG N
rate NN N
, , N
cesarean JJ N
delivery NN N
rate NN N
, , N
maternal JJ N
adverse JJ N
events NNS N
and CC N
maternal JJ N
satisfaction NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
ECMO NNP N
circuit NN N
and CC N
samples NNS N
of IN N
blood NN N
were VBD N
evaluated VBN N
hourly RB N
for IN N
phase NN N
separation NN N
, , N
layering VBG N
out IN N
of IN N
the DT N
emulsion NN N
from IN N
blood NN N
, , N
agglutination NN N
, , N
and CC N
blood NN N
clots NNS N
. . N

We PRP N
sought VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
heme JJ N
oxygenase-1 JJ N
( ( N
HO-1 NNP N
) ) N
on IN N
this DT N
HBO NNP N
inhibition NN N
of IN N
iNOS JJ N
induction NN N
and CC N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ N
rat NN N
lungs NNS N
. . N

Furthermore RB N
, , N
the DT N
negative JJ N
mean NN N
change NN N
in IN N
lag NN N
time NN N
to TO N
oxidation NN N
found VBN N
in IN N
the DT N
PUFA-diet JJ N
group NN N
differed VBD N
significantly RB N
from IN N
the DT N
slightly RB N
positive JJ N
mean NN N
change NN N
found VBD N
in IN N
the DT N
MUFA-diet JJ N
group NN N
. . N

The DT N
primary JJ N
contributor NN N
to TO N
the DT N
plasma NN N
alkalosis NN N
was VBD N
an DT N
increased VBN o
[ NN N
SID NNP N
] NNP N
, , N
as IN N
a DT N
result NN N
of IN N
increased VBN o
plasma NN N
[ NN N
Na+ NNP N
] NNP N
and CC N
decreased VBD o
plasma NNS o
[ JJ N
Cl- NNP N
] NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
changes NNS N
in IN N
markers NNS N
of IN N
bone NN N
resorption NN N
( ( N
urine JJ N
N-telopeptide NNP N
cross-linked JJ N
collagen NN N
type NN N
I PRP N
) ) N
and CC N
formation NN N
( ( N
osteocalcin JJ i
, , N
N-terminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
, , N
and CC N
bone-specific JJ N
alkaline NN N
phosphatase NN N
) ) N
. . N

Behavioral JJ N
response NN N
variables NNS N
, , N
salivary JJ N
cortisol NN N
concentration NN N
, , N
WBC NNP N
count NN N
, , N
and CC N
serum JJ N
concentrations NNS N
of IN N
glucose NN N
, , N
prolactin NN i
, , N
haptoglobin NN N
, , N
and CC N
C-reactive JJ N
protein NN N
were VBD N
analyzed VBN N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
anastrozole NN N
and CC N
clomiphene NN N
citrate NN N
( ( N
CC NNP N
) ) N
on IN N
follicular NN N
development NN N
and CC N
ovulation NN N
in IN N
infertile JJ N
women NNS N
with IN N
ovulatory JJ N
dysfunction NN N
. . N

Cardiac NNP N
index NN N
and CC N
heart NN N
rate NN N
were VBD N
still RB N
reduced VBN N
14-21 CD N
% NN N
, , N
while IN N
total JJ N
peripheral JJ N
resistance NN N
was VBD N
unchanged JJ N
or CC N
slightly RB N
increased VBN o
( ( N
2-10 CD N
% NN N
) ) N
. . N

INCLUSION NNP N
CRITERIA NNP N
severe JJ N
coronary JJ N
stenosis NN N
of IN N
anterior JJ N
descending VBG N
coronary JJ N
artery NN N
; : N
no DT N
collateral NN N
flow NN N
on IN N
angiography NN N
; : N
at IN N
least JJS N
two CD N
normokinetic JJ N
segments NNS N
in IN N
the DT N
myocardial JJ N
region NN N
supplied VBN N
by IN N
the DT N
vessel NN N
being VBG N
bypassed VBN N
. . N

There EX N
was VBD N
a DT N
greater JJR N
increase NN o
of IN N
prolactin NN i
in IN N
the DT N
risperidone NN i
group NN N
, , N
while IN N
alanine JJ N
amino NN N
transferase NN N
( ( N
ALT NNP N
) ) N
had VBD N
further RBR N
increased VBN o
in IN N
the DT N
haloperidol NN N
group NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
demographic JJ N
data NNS N
, , N
mean JJ N
arterial JJ N
pressure NN N
, , N
heart NN N
rate NN N
or CC N
oxygen NN N
saturation NN N
between IN N
groups NNS N
. . N

The DT N
arginine-supplemented JJ N
group NN N
showed VBD N
a DT N
mean JJ N
natural JJ N
killer NN N
cell NN N
cytotoxicity NN N
increase NN o
of IN N
18.9 CD N
lytic JJ N
units NNS N
, , N
whereas IN N
the DT N
placebo NN N
group NN N
showed VBD N
an DT N
increase NN o
of IN N
0.3 CD N
lytic JJ N
units NNS N
. . N

CONCLUSIONS NNP N
First NNP N
, , N
the DT N
pharmacokinetics NNS N
of IN N
diltiazem NN N
in IN N
patients NNS p
with IN N
atrial JJ N
fibrillation NN N
or CC N
atrial JJ N
flutter NN N
is VBZ N
nonlinear JJ N
with IN N
an DT N
apparent JJ N
dose-dependent JJ N
decrease NN o
in IN N
systemic JJ N
clearance NN N
with IN N
increasing VBG N
infusion NN N
rate NN N
. . N

After IN N
treatment NN N
, , N
MPO NNP N
activity NN N
and CC N
MDA NNP N
levels NNS N
were VBD N
significantly RB N
reduced VBN N
; : N
SOD NNP N
activity NN N
and CC N
NOx NNP N
levels NNS N
were VBD N
significantly RB N
increased VBN o
with IN N
nebivolol NN i
but CC N
remained VBD N
unchanged JJ N
with IN N
metoprolol NN i
. . N

BACKGROUND NNP N
Imiquimod NNP N
is VBZ N
an DT N
immune JJ N
response NN N
modifier NN N
that IN N
up-regulates JJ N
cytokines NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
in IN N
clinical JJ N
studies NNS N
to TO N
reduce VB N
or CC N
clear VB N
basal NN N
cell NN N
carcinoma NN N
tumors NNS N
when WRB N
applied VBN N
topically RB N
. . N

Shocks NNS N
were VBD N
delivered VBN N
between IN N
the DT N
right JJ N
ventricular NN N
coil NN N
and CC N
either DT N
an DT N
active JJ N
can MD N
alone RB N
( ( N
single JJ N
coil NN N
) ) N
or CC N
an DT N
active JJ N
can MD N
with IN N
the DT N
proximal JJ N
atrial JJ N
coil NN N
( ( N
dual JJ N
coil NN N
) ) N
. . N

Impact NN N
of IN N
a DT N
fixed JJ N
combination NN N
of IN N
clindamycin JJ i
phosphate JJ N
1.2 CD N
% NN N
-benzoyl NNP N
peroxide RB N
2.5 CD N
% NN N
aqueous JJ N
gel NN N
on IN N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
moderate JJ N
to TO N
severe VB N
acne JJ N
vulgaris NN N
. . N

Both DT N
the DT N
absolute NN N
and CC N
percentage NN N
decreases NNS o
in IN N
mean JJ N
blood NN N
pressure NN N
induced VBN N
by IN N
nifedipine NN N
and CC N
the DT N
combination NN N
compared VBN N
with IN N
placebo NN N
were VBD N
similar JJ N
and CC N
significantly RB N
greater JJR N
than IN N
those DT N
induced VBN N
by IN N
chlorthalidone NN i
. . N

Outcomes NNS N
included VBD N
incidence NN N
of IN N
clinically RB N
significant JJ N
postoperative JJ N
pulmonary JJ N
complications NNS N
, , N
fever RB N
, , N
length NN N
of IN N
stay NN N
, , N
and CC N
restoration NN N
of IN N
mobility NN N
. . N

RESULTS NNP N
Expression NNP N
of IN N
leptin NN i
genes NNS N
was VBD N
demonstrated VBN N
both DT N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
, , N
and CC N
a DT N
similar JJ N
pattern NN N
of IN N
expression NN N
was VBD N
found VBN N
for IN N
leptin JJ i
receptor NN N
isoforms NNS N
. . N

An DT N
increased VBN o
[ NN N
Atot NNP N
] NNP N
, , N
due JJ N
to TO N
increased VBN o
[ NNP N
PP NNP N
] NNP N
and CC N
a DT N
sustained JJ N
increase NN o
in IN N
plasma JJ N
[ JJ N
acetate NN N
] NN N
, , N
contributed VBD N
a DT N
minor JJ N
acidifying NN N
effect NN N
. . N

A DT N
decrease NN o
in IN N
leg NN N
blood NN N
flow NN N
volume NN N
and CC N
a DT N
corresponding JJ N
increase NN o
in IN N
leg JJ N
peripheral JJ N
vascular JJ N
resistance NN N
were VBD N
noted VBN N
in IN N
the DT N
misoprostol NN N
group NN N
. . N

RESULTS VB N
A NNP N
statistically RB N
significant JJ N
10- JJ N
to TO N
20-fold JJ N
increase NN o
in IN N
urinary JJ N
levels NNS N
of IN N
cobalt NN N
and CC N
chromium NN N
was VBD N
observed VBN N
throughout IN N
the DT N
entire JJ N
follow-up NN N
in IN N
the DT N
MOM NNP N
group NN N
. . N

Despite IN N
a DT N
dose-dependent JJ N
suppression NN N
of IN N
sACE NN N
, , N
there EX N
were VBD N
no DT N
observed VBN N
statistically RB N
significant JJ N
differences NNS N
in IN N
ALDO NNP N
and CC N
A-II NNP N
suppression NN N
or CC N
escape NN N
with IN N
escalating VBG N
doses NNS N
of IN N
enalapril NN N
within IN N
each DT N
subgroup NN N
. . N

PegFeG-CSF NNP N
provided VBD N
the DT N
most RBS N
therapeutic JJ N
and CC N
sustainable JJ N
neutrophil JJ N
production NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT N
FIV-uninfected JJ N
and CC N
FIV-infected JJ N
cats NNS N
, , N
without IN N
the DT N
development NN N
of IN N
neutralizing VBG N
antibodies NNS N
. . N

We PRP N
examined VBD N
the DT N
prognostic JJ N
value NN N
of IN N
inflammatory JJ N
markers NNS N
( ( N
albumin NN N
, , N
white-cell JJ N
count NN N
and CC N
its PRP$ N
components NNS N
, , N
and CC N
platelets NNS N
) ) N
in IN N
pre-treated JJ N
patients NNS p
with IN N
advanced JJ N
renal JJ N
cell NN N
carcinoma NN N
( ( N
RCC NNP N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Overall NNP i
survival NN N
, , N
time NN N
to TO N
first JJ N
recurrence NN N
, , N
complication NN N
rates NNS N
, , N
and CC N
surgical JJ N
outcomes NNS N
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

The DT N
secondary JJ N
end NN N
points NNS N
were VBD N
the DT N
combined JJ N
incidence NN N
of IN N
death NN N
, , N
target NN N
lesion NN N
nonfatal JJ N
myocardial JJ N
infarction NN N
, , N
repeat NN N
angioplasty NN N
, , N
and CC N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
. . N

Bone NNP N
turnover NN N
was VBD N
determined VBN N
by IN N
ICTP NNP N
( ( N
type NN N
I PRP N
collagen VBP N
carboxyterminal JJ N
cross-linked JJ N
telopeptide NN N
) ) N
as IN N
parameter NN N
of IN N
bone NN N
resorption NN N
and CC N
PICP NNP N
( ( N
carboxyterminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
) ) N
as IN N
marker NN N
of IN N
bone NN N
formation NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
frequency NN N
of IN N
allelic JJ N
imbalance NN N
between IN N
primary JJ N
and CC N
metastatic JJ N
tumors NNS N
at IN N
any DT N
marker NN N
analyzed VBN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

METHODS NNP N
Forty NNP N
cases NNS N
with IN N
respiration NN N
and CC N
cardiac JJ N
arrest NN N
in IN N
the DT N
department NN N
of IN N
critical JJ N
care NN N
medicine NN N
were VBD N
randomly RB N
divided VBN N
into IN N
low JJ N
VT NNP N
ventilation NN N
group NN N
and CC N
conventional JJ N
VT NNP N
group NN N
. . N

Decreases NNS o
in IN N
serum NN N
prolactin NN i
concentrations NNS N
in IN N
response NN N
to TO N
perioperative JJ N
stress NN N
were VBD N
significantly RB N
smaller JJR N
in IN N
dogs NNS N
exposed VBN N
to TO N
sDAP VB N
, , N
compared VBN N
with IN N
findings NNS N
in IN N
dogs NNS N
exposed VBN N
to TO N
the DT N
sham NN N
treatment NN N
. . N

We PRP N
conclude VBP N
that DT N
cyclo-oxygenase NN N
is VBZ N
rapidly RB N
synthesised VBN N
in IN N
bradykinin-responsive JJ N
tissues NNS N
in IN N
vivo NN N
and CC N
that IN N
this DT N
reflects VBZ N
similarly RB N
rapid JJ N
enzyme JJ N
biosynthesis NN N
in IN N
tissues NNS N
that WDT N
produce VBP N
PGI2 NNP N
under IN N
basal NN N
conditions NNS N
. . N

CONCLUSION NN N
This DT N
study NN N
demonstrates VBZ N
an DT N
immunostimulatory JJ N
effect NN N
of IN N
the DT N
histamine-2-receptor JJ N
antagonist NN N
, , N
ranitidine NN N
, , N
both DT N
at IN N
the DT N
cellular JJ N
and CC N
mediator NN N
levels NNS N
in IN N
patients NNS p
after IN N
head JJ N
injury NN N
. . N

The DT N
absolute JJ N
number NN N
of IN N
blood NN N
and CC N
sputum NN N
eosinophils NNS N
did VBD N
not RB N
change VB N
significantly RB N
after IN N
allergen NN N
or CC N
placebo NN N
challenge NN N
( ( N
P NNP N
> NNP N
0.07 CD N
, , N
both DT N
comparisons NNS N
) ) N
. . N

METHODS NNP N
In IN N
ten NN N
paired JJ N
biopsies NNS N
, , N
crystallinity NN N
, , N
apparent JJ N
length NN N
and CC N
width/thickness NN N
of IN N
crystals NNS N
, , N
interplanar NN N
distances NNS N
, , N
and CC N
lattice JJ N
parameters NNS N
of IN N
unit NN N
cells NNS N
were VBD N
assessed VBN N
by IN N
X-ray JJ N
diffraction NN N
and CC N
selected VBN N
area NN N
electron NN N
diffraction NN N
. . N

Moreover RB N
, , N
in IN N
vitro JJ N
studies NNS N
have VBP N
suggested VBN N
the DT N
presence NN N
of IN N
anticoagulant JJ N
effects NNS N
of IN N
3-hydroxy-3-methylglutaryl JJ N
coenzyme NN N
A NNP N
reductase NN N
inhibitors NNS N
, , N
as IN N
lipopolysaccharide NN N
( ( N
LPS NNP N
) ) N
-induced VBD N
monocyte JJ N
tissue NN N
factor NN N
( ( N
TF NNP N
) ) N
was VBD N
suppressed VBN N
. . N

We PRP N
predicted VBD N
that IN N
, , N
under IN N
these DT N
circumstances NNS N
, , N
insulin-stimulated JJ N
endothelin-1 JJ N
( ( N
ET-1 NNP N
) ) N
action NN N
( ( N
assessed VBN N
with IN N
the DT N
type NN N
A NNP N
endothelin NN N
receptor NN N
antagonist IN N
BQ-123 NNP N
) ) N
would MD N
be VB N
augmented VBN N
in IN N
proportion NN N
to TO N
hyperinsulinemia NN N
. . N

Polysomnography NNP N
demonstrated VBD N
that IN N
the DT N
percentage NN N
of IN N
SWS NNP N
was VBD N
not RB N
different JJ N
when WRB N
saline NN N
and CC N
GHRH NNP N
antagonist VBP N
nights NNS N
were VBD N
compared VBN N
( ( N
P=0.607 NNP N
) ) N
; : N
other JJ N
quantifiable JJ N
sleep JJ N
parameters NNS N
were VBD N
also RB N
unchanged JJ N
. . N

No DT N
intergroup NN N
differences NNS N
were VBD N
found VBN N
with IN N
respect NN N
to TO N
the DT N
number NN N
of IN N
punctures NNS N
( ( N
mean JJ N
value NN N
1.6 CD N
+/- JJ N
0.83 CD N
) ) N
and CC N
the DT N
incidence NN N
of IN N
complications NNS N
. . N

In IN N
the DT N
chemokinesis NN N
assay NN N
, , N
the DT N
maximum JJ N
distance NN N
moved VBN N
by IN N
neutrophils NNS N
in IN N
the DT N
presence NN N
of IN N
C18:0 NNP N
PAF NNP N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
seen VBN N
with IN N
the DT N
C16:0 NNP N
compound NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
change NN N
from IN N
baseline NN N
in IN N
serum NN N
[ NN N
Na NNP N
( ( N
+ NNP N
) ) N
] VBP N
area NN N
under IN N
the DT N
curve NN N
. . N

Sporadic JJ N
increases NNS o
in IN N
transaminase NN N
levels NNS N
, , N
increases NNS o
in IN N
cholesterol NN N
and CC N
serum JJ N
creatinine NN N
levels NNS N
, , N
and CC N
decreases NNS o
in IN N
neutrophil NN N
and CC N
hemoglobin NN N
levels NNS N
were VBD N
observed VBN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time-matched JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
QT NNP N
interval NN N
corrected VBD N
for IN N
heart NN N
rate NN N
( ( N
QTc NNP N
) ) N
using VBG N
an DT N
individual JJ N
correction NN N
method NN N
( ( N
QTcI NNP N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
styrene NN N
maleic NN N
acid NN N
neocarzinostatin NN i
in IN N
Lipiodol NNP N
exerts VBZ N
a DT N
more RBR N
favorable JJ N
focal JJ N
therapeutic JJ N
effect NN N
than IN N
does VBZ N
epirubicin VB i
in IN N
Lipiodol NNP N
in IN N
the DT N
initial JJ N
treatment NN N
of IN N
hepatocellular JJ N
carcinoma NN N
. . N

METHODS NNP N
Variations NNP N
in IN N
SkBF NNP N
and CC N
Tsk NNP N
in IN N
adult NN N
volunteers NNS N
were VBD N
simultaneously RB N
recorded VBN N
with IN N
a DT N
thermostatic JJ N
laser NN N
Doppler NNP N
system NN N
during IN N
a DT N
20-minute JJ N
radiofrequency NN N
exposure NN N
session NN N
and CC N
a DT N
20-minute JJ N
sham NN N
session NN N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
vitamin JJ N
A-fortified JJ N
cooking NN N
oil NN N
ration NN N
; : N
to TO N
Control-1 NNP N
group NN N
with IN N
unfortified JJ N
cooking NN N
oil NN N
ration NN N
; : N
and CC N
to TO N
Control-2 NNP N
group NN N
without IN N
cooking VBG N
oil NN N
ration NN N
. . N

A DT N
pharmacologic JJ N
effect NN N
was VBD N
apparent JJ N
from IN N
a DT N
dose-dependent JJ N
statistically RB N
significant JJ N
decrease NN o
in IN N
the DT N
mean JJ N
prothrombin NN N
time NN N
in IN N
all DT N
N7-GP JJ N
groups NNS N
as IN N
compared VBN N
with IN N
placebo NN N
. . N

The DT N
ID NNP N
Group NNP N
, , N
following VBG N
OK-432 JJ N
injection NN N
, , N
had VBD N
a DT N
4.8 CD N
% NN N
incidence NN N
of IN N
fever NN N
and CC N
a DT N
52.4 CD N
% NN N
incidence NN N
of IN N
local JJ N
abscess NN N
formation NN N
at IN N
the DT N
injection NN N
site NN N
. . N

The DT N
down-regulation NN N
of IN N
co-transporter NN N
KCC2 NNP N
after IN N
spinal JJ N
cord NN N
transection NN N
in IN N
animals NNS N
leads NNS N
to TO N
the DT N
depolarising NN N
( ( N
excitatory NN N
) ) N
action NN N
of IN N
GABA NNP N
and CC N
glycine NN N
and CC N
thus RB N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
inhibitory JJ N
synaptic JJ N
efficiency NN N
. . N

It PRP N
was VBD N
observed VBN N
that IN N
the DT N
decrease NN o
in IN N
serum NN N
TC NNP N
, , N
LDL-C NNP N
and CC N
triglyceride NN N
levels NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
second JJ N
group NN N
than IN N
the DT N
first JJ N
group NN N
. . N

The DT N
authors NNS N
have VBP N
compared VBN N
the DT N
effects NNS N
of IN N
oral JJ N
temazepam NN i
, , N
a DT N
medium NN N
half-life JJ N
benzodiazepine NN N
vs IN N
oral JJ N
zolpidem NN N
, , N
a DT N
short JJ N
half-life JJ N
non-benzodiazepine JJ N
drug NN N
, , N
vs NN N
placebo NN N
. . N

In IN N
a DT N
tamoxifen NN N
randomised VBN N
patient JJ N
material NN N
, , N
absent JJ N
YAP1 NNP N
protein NN N
expression NN N
was VBD N
associated VBN N
with IN N
impaired JJ N
tamoxifen NN N
response NN N
which WDT N
was VBD N
significant JJ N
upon IN N
interaction NN N
analysis NN N
( ( N
p JJ N
= NNP N
0.042 CD N
) ) N
. . N

We PRP N
also RB N
sought VBD N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
BMD NNP N
loss NN N
, , N
including VBG N
markers NNS N
of IN N
systemic JJ N
inflammation NN N
[ NNP N
soluble JJ N
tumor NN N
necrosis NN N
factor-alpha JJ N
receptors NNS N
( ( N
sTNFR NN N
I PRP N
and CC N
II NNP N
) ) N
] NN N
. . N

No DT N
significant JJ N
difference NN N
in IN N
eradication NN N
rates NNS N
was VBD N
observed VBN N
among IN N
the DT N
three CD N
groups NNS N
both DT N
in IN N
intention NN N
to TO N
treat VB N
analysis NN N
and CC N
in IN N
per IN N
protocol NN N
analysis NN N
. . N

The DT N
subjects NNS N
lost VBD N
2.1 CD N
% NN N
of IN N
body NN N
weight NN N
during IN N
active JJ N
drug NN N
phase NN N
, , N
but CC N
there RB N
was VBD N
a DT N
rebound NN N
weight NN N
gain NN N
during IN N
the DT N
subsequent JJ N
placebo NN N
phase NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
logarithm NN N
of IN N
the DT N
heart NN N
rate NN N
, , N
recovery NN N
time NN N
or CC N
quality NN N
of IN N
recovery NN N
between IN N
the DT N
three CD N
induction NN N
groups NNS N
. . N

BACKGROUND NNP N
New NNP N
antibacterial JJ N
agents NNS N
with IN N
activity NN N
against IN N
pathogenic JJ N
strains NNS N
resistant VBP N
to TO N
established VBN N
antibiotics NNS N
are VBP N
needed VBN N
to TO N
treat VB N
patients NNS p
with IN N
secondarily RB N
infected VBN N
dermatitis NN N
( ( N
SID NNP N
) ) N
. . N

Five CD N
days NNS N
later RB N
, , N
we PRP N
only RB N
found VBD N
single-labelled JJ N
motor NN N
and CC N
sensory JJ N
neurons NNS N
in IN N
the DT N
normal JJ N
and CC N
end-to-end JJ N
coaptation NN N
groups NNS N
, , N
while IN N
some DT N
dual-labelled JJ N
neurons NNS N
can MD N
be VB N
identified VBN N
in IN N
end-to-side JJ N
coaptation NN N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Two CD N
samples NNS N
( ( N
pretest JJS N
, , N
posttest JJS N
) ) N
of IN N
salivary JJ N
cortisol NNS N
were VBD N
analyzed VBN N
using VBG N
an DT N
enzyme JJ N
immunoassay JJ N
kit NN N
; : N
the DT N
average NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

Impact NN N
of IN N
angiotensin NN N
II NNP N
receptor NN N
blocker NN N
therapy NN i
( ( N
olmesartan JJ N
or CC N
valsartan NN N
) ) N
on IN N
coronary JJ N
atherosclerotic JJ i
plaque NN N
volume NN N
measured VBN N
by IN N
intravascular JJ N
ultrasound NN N
in IN N
patients NNS p
with IN N
stable JJ N
angina JJ N
pectoris NN N
. . N

The DT N
change NN N
in IN N
heart NN N
rate NN N
and CC N
oxygen NN N
saturation NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
EBM NNP N
group NN N
and CC N
returned VBN N
to TO N
baseline VB N
values NNS N
sooner JJR N
than IN N
in IN N
the DT N
DW NNP N
group NN N
. . N

CONCLUSIONS NNP N
Moderately RB N
accelerated JJ N
fractionation NN N
is VBZ N
superior JJ N
to TO N
conventional JJ N
treatment NN N
in IN N
HNSCC NNP N
but CC N
the DT N
response NN N
is VBZ N
heterogeneous JJ N
and CC N
may MD N
be VB N
predicted VBN N
by IN N
high JJ N
expression NN N
of IN N
EGFr NNP N
and CC N
well/moderate JJ N
tumor NN N
differentiation NN N
. . N

SECONDARY NNP N
OUTCOMES NNP N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
, , N
evaluation NN N
of IN N
ECG NNP N
for IN N
ischaemia NN N
and CC N
QT NNP N
interval NN N
, , N
hypoglycaemic JJ N
and CC N
anti-hypertensive JJ N
medication NN N
and CC N
cardiovascular JJ N
events NNS N
. . N

BACKGROUND NNP N
XS0601 NNP N
, , N
consisting VBG N
of IN N
active JJ N
ingredients NNS N
( ( N
Chuangxiongol NNP N
and CC N
paeoniflorin NN N
) ) N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
inhibit VB N
arterial JJ N
neointimal JJ N
hyperplasia NN N
in IN N
animal JJ N
models NNS N
and CC N
in IN N
preliminary JJ N
human JJ N
studies NNS N
. . N

The DT N
presence NN N
of IN N
leishmanial JJ N
antigen NN N
( ( N
with IN N
BCG NNP N
) ) N
in IN N
the DT N
inoculum NN N
suppressed VBD N
the DT N
IgG NNP N
response NN N
to TO N
Mycobacterium NNP N
tuberculosis/Mycobacterium NN N
bovis-related JJ N
( ( N
PPD NNP N
and CC N
BCG NNP N
) ) N
, , N
but CC N
not RB N
M. NNP N
leprae-related JJ N
( ( N
MLSA NNP N
) ) N
-related VBD N
, , N
antigens NNS N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
overall JJ i
survival NN N
, , N
tumor NN N
response NN N
rate NN N
( ( N
Response NNP N
Evaluation NNP N
Criteria NNP N
in IN N
Solid NNP N
Tumors NNP N
) ) N
, , N
and CC N
safety NN N
. . N

Warfarin NNP N
was VBD N
started VBN N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
and CC N
the DT N
dosage NN N
was VBD N
adjusted VBN N
to TO N
maintain VB N
the DT N
thromboplastin JJ i
international JJ N
normalised VBN N
ratio NN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
2.5 CD N
. . N

MAIN NNP N
RESULTS NNP N
Rapid NNP N
injection NN N
was VBD N
less RBR N
painful JJ N
than IN N
after IN N
pretreatment NN N
with IN N
lidocaine JJ N
0.5 CD N
mg/kg NN N
, , N
but CC N
was VBD N
similar JJ N
to TO N
slow VB N
injection NN N
after IN N
pretreatment NN N
with IN N
lidocaine JJ N
1.0 CD N
mg/kg NN N
. . N

Folic NNP N
acid NN N
fortification NN N
has VBZ N
produced VBN N
a DT N
dramatic JJ N
increase NN o
in IN N
blood NN N
folate JJ N
concentrations NNS N
among IN N
reproductive JJ N
age NN N
women NNS N
, , N
and CC N
a DT N
reduction NN N
in IN N
neural JJ N
tube NN N
defect NN N
( ( N
NTD NNP N
) ) N
-affected VBD N
pregnancies NNS N
. . N

Two CD N
parameter NN N
estimates NNS N
, , N
the DT N
maximum JJ N
plasma JJ N
concentration NN N
( ( N
Cmax NNP i
) ) N
and CC N
the DT N
area NN N
under IN N
plasma JJ N
concentration NN N
vs. FW N
time NN N
curves NNS N
( ( N
AUCs NNP N
) ) N
, , N
were VBD N
used VBN N
to TO N
evaluate VB N
bioequivalence NN N
. . N

Norfloxacin NNP i
, , N
trimethoprim/sulfamethoxazole NN N
, , N
cytokines NNS N
, , N
nitric JJ N
oxide NN N
, , N
expression NN N
levels NNS N
of IN N
nuclear JJ N
factor NN N
( ( N
NF NNP N
) ) N
-kappaB NN N
and CC N
inhibitor NN N
of IN N
NF-kappaB NNP N
( ( N
IkB-alpha NNP N
) ) N
, , N
neutrophil JJ N
oxidative JJ N
burst NN N
, , N
and CC N
rate NN N
of IN N
apoptotic JJ i
events NNS N
were VBD N
determined VBN N
. . N

CONCLUSION NNP N
The DT N
combination NN N
of IN N
fluoxetine JJ N
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ N
ointment NN N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
fluoxetine VB N
alone RB N
in IN N
the DT N
treatment NN N
of IN N
premature JJ N
ejaculation NN N
. . N

CONCLUSION NNP N
Zoledronic NNP N
acid NN N
significantly RB N
reduced VBD N
skeletal JJ N
complications NNS N
compared VBN N
with IN N
placebo NN N
across IN N
multiple JJ N
end NN N
points NNS N
in IN N
Japanese JJ N
women NNS N
with IN N
bone NN N
metastases NNS N
from IN N
breast NN N
cancer NN N
. . N

HYPOTHESIS NNP N
Dermal NNP N
iontophoretic JJ N
administration NN N
of IN N
dexamethasone NN N
sodium NN N
phosphate NN N
will MD N
be VB N
significantly RB N
more RBR N
effective JJ N
in IN N
controlling VBG N
pain NN N
than IN N
a DT N
placebo NN N
in IN N
patients NNS p
with IN N
medial JJ N
or CC N
lateral JJ N
elbow NN N
epicondylitis NN N
. . N

CONCLUSION NNP N
Laparoscopic NNP N
stripping NN N
of IN N
ovarian JJ N
endometriotic JJ i
cyst NN N
significantly RB N
decreases VBZ o
serum JJ N
AMH NNP N
levels NNS N
and CC N
increases VBZ o
basal JJ N
FSH NNP N
levels NNS N
independent JJ N
from IN N
the DT N
method NN N
used VBN N
to TO N
obtain VB N
hemostasis NN N
on IN N
the DT N
ovarian JJ N
tissue NN N
. . N

RESULTS VB N
The DT N
mean JJ N
approach NN N
withdrawal NN N
problem NN N
composite JJ N
score NN N
was VBD N
significantly RB N
higher JJR N
before IN N
supplementation NN N
than IN N
after IN N
, , N
both DT N
in IN N
the DT N
placebo NN N
and CC N
in IN N
the DT N
gluten-casein JJ N
group NN N
. . N

Attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
remove VB N
endotoxin NN N
, , N
the DT N
main JJ N
cause NN N
of IN N
sepsis NN N
, , N
from IN N
the DT N
circulation NN N
using VBG N
polymyxin NN N
B NNP N
immobilized VBD N
fiber NN N
, , N
charcoal NN N
hemoperfusion NN N
, , N
and CC N
plasma NN N
or CC N
whole JJ N
blood NN N
exchange NN N
. . N

Outcome NN N
measures NNS N
were VBD N
the DT N
incidence NN N
of IN N
macular JJ N
edema NN N
, , N
retinal JJ N
thickness NN N
, , N
visual JJ N
acuity NN N
, , N
contrast NN N
sensitivity NN N
and CC N
presence NN N
of IN N
persistent JJ N
subretinal JJ N
fluid NN N
. . N

OBJECTIVE NN N
To TO N
compare VB N
efficacy NN N
of IN N
ultrasonography-guided JJ N
BRSB NNP N
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
( ( N
LAI NNP N
) ) N
in IN N
providing VBG N
postoperative JJ N
analgesia NN N
after IN N
pediatric JJ N
umbilical JJ N
hernia NN N
repair NN N
. . N

The DT N
effect NN N
of IN N
3- JJ N
( ( N
2-benzylmethylaminoethyl JJ N
) ) N
benzoic NN N
acid JJ N
methyl NN N
ester NN N
hydrochloride NN N
( ( N
PRL-8-53 NNP N
) ) N
on IN N
learning NN N
and CC N
on IN N
retention NN N
of IN N
verbal JJ N
information NN N
in IN N
human JJ N
subjects NNS N
was VBD N
investigated VBN N
. . N

CONCLUSIONS NNP N
Clopidogrel NNP N
plus CC N
acetylsalicylic JJ N
acid NN N
showed VBD N
significantly RB N
superior JJ N
antithrombotic JJ i
efficacy NN N
compared VBN N
with IN N
extended-release JJ N
dipyridamole JJ N
plus CC N
acetylsalicylic JJ N
acid NN N
in IN N
preventing VBG N
arterial JJ N
thrombogenesis NN N
in IN N
humans NNS N
. . N

No DT N
significant JJ N
dose NN N
related VBN N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
renal JJ N
clearance NN N
of IN N
3-MX JJ N
, , N
1-MU JJ N
and CC N
DMU NNP N
, , N
indicating VBG N
linear JJ N
urinary JJ N
excretion NN N
kinetics NNS N
of IN N
the DT N
metabolites NNS N
. . N

Volunteers NNS N
displayed VBD N
the DT N
expected VBN N
rise NN N
in IN N
peripheral JJ N
blood NN N
neutrophil NN N
count NN N
, , N
but CC N
no DT N
other JJ N
clinically RB N
relevant JJ N
changes NNS N
in IN N
hematology NN N
or CC N
clinical JJ N
chemistry NN N
were VBD N
observed VBN N
. . N

High-tone CD N
audiometry NN N
was VBD N
performed VBN N
when WRB N
possible JJ N
; : N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
hearing VBG N
loss NN N
( ( N
3/12 CD N
and CC N
3/11 CD N
) ) N
or CC N
prodromal JJ N
signs NNS N
of IN N
ototoxicity NN N
( ( N
5/12 CD N
and CC N
4/11 CD N
) ) N
. . N

Thrombin-antithrombin JJ N
III NNP N
complex NN N
, , N
fibrinogen NN N
degradation NN N
product NN N
and CC N
tissue NN N
plasminogen NN N
activator NN N
levels NNS N
, , N
reflecting VBG N
activation NN N
of IN N
the DT N
coagulation NN N
and CC N
fibrinolytic JJ N
systems NNS N
, , N
respectively RB N
, , N
decreased VBD o
uniformly RB o
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
a DT N
small JJ N
( ( N
1.1 CD N
? . N
5.6 CD N
s NN N
) ) N
but CC N
possibly RB N
beneficial JJ N
additional JJ N
effect NN N
when WRB N
combining VBG N
chronic JJ N
beta-alanine JJ N
supplementation NN N
with IN N
acute JJ N
sodium NN N
bicarbonate NN N
supplementation NN N
compared VBN N
with IN N
chronic JJ N
beta-alanine JJ N
supplementation NN N
alone RB N
. . N

Duration NN N
on IN N
treadmill NN N
and CC N
right JJ N
ventricular NN N
ejection NN N
fraction NN N
post NN N
exercise NN N
increased VBD o
, , o
while IN N
diastolic JJ N
and CC N
systolic JJ N
artery NN N
pressure NN N
decreased VBN o
significantly RB N
in IN N
both DT N
groups NNS N
. . N

OBJECTIVE NN N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Dan NNP N
Shao NNP N
Tang NNP N
( ( N
DST NNP N
) ) N
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
( ( N
IgAN NNP N
) ) N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

The DT N
great JJ N
dispersion NN N
of IN N
the DT N
results NNS N
of IN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
was VBD N
the DT N
plausible JJ N
cause NN N
of IN N
the DT N
lack NN N
of IN N
any DT N
significant JJ N
difference NN N
in IN N
this DT N
variable NN N
. . N

BACKGROUND NNP N
Patients NNPS N
with IN N
Raynaud NNP N
's POS N
syndrome NN N
have VBP N
abnormal JJ N
digital JJ N
vasoconstriction NN N
, , N
which WDT N
may MD N
be VB N
secondary JJ N
to TO N
impaired JJ N
synthesis NN N
of IN N
, , N
or CC N
impaired JJ N
sensitivity NN N
to TO N
, , N
nitric JJ N
oxide NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Significantly NNP N
lower JJR N
abdominal NN N
and CC N
shoulder NN N
tip NN N
pain NN N
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
vasovagal JJ N
reactions NNS N
were VBD N
observed VBN N
in IN N
group NN N
B NNP N
in IN N
comparison NN N
with IN N
group NN N
A NNP N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
change NN N
from IN N
baseline NN N
for IN N
peroneal JJ N
reaction NN N
time NN N
or CC N
average JJ N
peroneal JJ N
muscle NN N
activity NN N
at IN N
any DT N
post NN N
treatment NN N
time NN N
. . N

RESULTS NNP N
Histological NNP N
analysis NN N
, , N
PMNs/alveoli NNP N
ratio NN N
, , N
and CC N
wet/dry JJ N
weight NN N
ratio NN N
measurements NNS N
demonstrated VBD N
that IN N
LPS NNP N
caused VBD N
significant JJ N
lung JJ N
injury NN N
and CC N
HBO NNP N
and/or VBP N
hemin NN N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
lung NN N
injury NN N
. . N

RESULTS VB N
The DT N
biochemical JJ N
parameters NNS N
were VBD N
examined VBN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
differences NNS N
in IN N
the DT N
levels NNS N
of IN N
hemoglobin NN N
and CC N
hemotocrit NN N
before IN N
delivery NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
changes NNS N
in IN N
plasma NN N
lipids NNS N
, , N
A1C NNP N
, , N
fasting VBG N
glucose NN N
, , N
insulin NN N
sensitivity NN N
, , N
and CC N
anthropometric JJ N
measures NNS N
. . N

However RB N
, , N
neither CC N
the DT N
primary JJ N
end NN N
point NN N
( ( N
P NNP N
=.25 NNP N
) ) N
nor CC N
most JJS N
of IN N
the DT N
secondary JJ N
end NN N
points NNS N
demonstrated VBD N
a DT N
significant JJ N
benefit NN N
of IN N
rhNGF NN N
. . N

Superior JJ N
efficacy NN N
of IN N
clopidogrel NN N
plus CC N
acetylsalicylic JJ N
acid NNS N
compared VBN N
with IN N
extended-release JJ N
dipyridamole JJ N
plus CC N
acetylsalicylic JJ N
acid NN N
in IN N
preventing VBG N
arterial JJ N
thrombogenesis NN N
in IN N
healthy JJ N
volunteers NNS N
. . N

BACKGROUND IN N
The DT N
effect NN N
of IN N
L-arginine NNP N
and CC N
L-citrulline NNP N
on IN N
blood NN N
pressure NN N
and CC N
right JJ N
ventricular NN N
function NN N
in IN N
heart NN N
failure NN N
patients NNS p
with IN N
preserved JJ N
ejection NN N
fraction NN N
( ( N
HFpEF NNP N
) ) N
is VBZ N
unknown JJ N
. . N

RESULTS NNP N
Baseline NNP N
clinical JJ N
characteristics NNS N
of IN N
the DT N
allopurinol NN N
and CC N
placebo NN N
groups NNS N
demonstrated VBD N
no DT N
differences NNS N
in IN N
terms NNS N
of IN N
clinical JJ N
characteristics NNS N
, , N
endothelial JJ N
function NN N
and CC N
inflammatory JJ N
markers NNS N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
in IN N
the DT N
average JJ N
time NN N
spent VBN N
in IN N
the DT N
operating NN N
room NN N
or CC N
in IN N
the DT N
total JJ N
irrigation NN N
fluid NN N
used VBN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
observed VBN N
. . N

As IN N
demonstrated VBN N
by IN N
in IN N
vitro NN N
studies NNS N
, , N
cisplatin NN i
( ( N
CDDP NNP N
) ) N
is VBZ N
able JJ N
to TO N
down-regulate VB N
the DT N
AGAT NNP N
activity NN N
, , N
suggesting VBG N
that IN N
CDDP NNP N
could MD N
enhance VB N
the DT N
antitumor NN N
activity NN N
of IN N
TMZ NNP N
. . N

If IN N
so RB N
administered VBN N
it PRP N
would MD N
not RB N
increase VB o
bodily RB N
sodium JJ N
load NN N
and CC N
unlike IN N
isotonic JJ N
crystalloid NN N
solution NN N
it PRP N
dose VBD N
not RB N
cause JJ N
accumulation NN N
of IN N
water NN N
in IN N
the DT N
body NN N
on IN N
equipollent JJ N
basis NN N
. . N

Elevated VBN N
neutrophil JJ N
counts NNS N
, , N
elevated VBD N
platelet NN N
counts NNS N
, , N
and CC N
a DT N
high JJ N
neutrophil-lymphocyte JJ N
ratio NN N
were VBD N
significant JJ N
independent JJ N
predictors NNS N
for IN N
shorter JJR N
OS NNP N
in IN N
a DT N
model NN N
with IN N
established VBN N
prognostic JJ N
factors NNS N
. . N

Rapid JJ N
injection NN N
facilitated VBD N
LMA NNP N
insertion NN N
, , N
unlike IN N
slow JJ N
injection NN N
with IN N
lidocaine JJ N
0.5 CD N
mg/kg NN N
pretreatment NN N
, , N
and CC N
was VBD N
similarly RB N
successful JJ N
to TO N
slow VB N
injection NN N
after IN N
pretreatment NN N
with IN N
lidocaine JJ N
1.0 CD N
mg/kg NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
administration NN N
of IN N
tromethamine NN N
( ( N
THAM NNP N
) ) N
, , N
a DT N
buffer NN N
which WDT N
does VBZ N
not RB N
increase VB o
carbon NN N
dioxide NN N
production NN N
, , N
would MD N
modify VB N
these DT N
changes NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
healing VBG N
rate NN N
of IN N
the DT N
duodenal JJ N
ulcer NN N
after IN N
four CD N
weeks NNS N
, , N
86.7 CD N
% NN N
being VBG N
achieved VBN N
for IN N
both DT N
groups NNS N
. . N

Blood NNP N
pressure NN N
and CC N
total JJ N
peripheral JJ N
resistance NN N
responses NNS N
were VBD N
dependent JJ N
on IN N
pre- NN N
( ( N
antagonist/agonist NN N
) ) N
setting NN N
, , N
but CC N
heart NN N
rate NN N
and CC N
cardiac JJ N
output NN N
were VBD N
not RB N
influenced VBN N
by IN N
this DT N
factor NN N
. . N

Placental JJ N
growth NN N
factor NN N
( ( N
PlGF NNP N
) ) N
, , N
a DT N
member NN N
of IN N
the DT N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
family NN N
, , N
acts VBZ N
via IN N
the DT N
flt-1 JJ N
receptor NN N
and CC N
promotes VBZ N
endothelial JJ N
activation NN N
and CC N
macrophage NN N
recruitment NN N
into IN N
atherosclerotic JJ i
lesions NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
HSV-1 NNP N
DNA NNP N
copy NN N
numbers NNS N
in IN N
the DT N
tears NNS N
or CC N
saliva NN N
among IN N
any DT N
of IN N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
parameters NNS N
investigated VBN N
were VBD N
the DT N
peripheral JJ N
blood NN N
count NN N
( ( N
leucocytes NNS N
, , N
granulocytes NNS N
, , N
lymphocytes NNS N
, , N
monocytes NNS N
, , N
thrombocytes NNS N
, , N
hemoglobin NN N
, , N
hematocrit NN N
) ) N
and CC N
the DT N
incidence NN N
of IN N
infections NNS N
. . N

RESULTS NNP N
Only RB N
the DT N
sarpogrelate NN N
group NN N
showed VBD N
increases NNS o
in IN N
plasma NN N
adiponectin NN i
and CC N
decreases NNS o
in IN N
both DT N
plasma NN N
and CC N
urinary JJ N
monocyte NN N
chemoattractant JJ N
protein-1 JJ N
and CC N
albumin-to-creatinine JJ N
ratio NN N
levels NNS N
. . N

Hypotensive JJ N
effects NNS N
and CC N
influence NN N
on IN N
serum NN N
lipids NNS N
of IN N
SQ29,852 NNP N
, , N
a DT N
new JJ N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
, , N
in IN N
patients NNS p
with IN N
essential JJ N
hypertension NN N
: : N
a DT N
comparison NN N
with IN N
atenolol NN i
. . N

We PRP N
hypothesized VBD N
that IN N
there EX N
would MD N
be VB N
improved VBN N
fixation NN N
of IN N
high-porosity NN N
trabecular JJ N
metal NN N
( ( N
TM NNP N
) ) N
tibial JJ N
components NNS N
compared VBN N
to TO N
low-porosity JJ N
titanium NN N
pegged VBD N
porous JJ N
fiber-metal JJ N
( ( N
Ti NNP N
) ) N
polyethylene NN N
metal JJ N
backings NNS N
. . N

Two CD N
fluorescent JJ N
tracers NNS N
( ( N
true JJ N
blue NN N
and CC N
diamidino NN N
yellow NN N
) ) N
were VBD N
applied VBN N
to TO N
the DT N
proximal JJ N
ends NNS N
of IN N
tibial JJ N
and CC N
common JJ N
peroneal NN N
nerves NNS N
, , N
respectively RB N
after IN N
four CD N
or CC N
six CD N
months NNS N
of IN N
nerve DT N
coaptation NN N
. . N

Satisfaction NN N
rate NN N
, , N
operative JJ N
time NN N
, , N
discharge NN N
time NN N
, , N
complication NN N
rate NN N
, , N
reintervention NN N
rate NN N
, , N
and CC N
resumption NN N
of IN N
normal JJ N
activity NN N
were VBD N
evaluated VBN N
in IN N
each DT N
group NN N
. . N

AIMS NNP N
Adenosine NNP N
monophosphate NN N
( ( N
AMP NNP N
) ) N
acts VBZ N
indirectly RB N
via IN N
primed VBN N
airway RB N
mast JJ N
cells NNS N
to TO N
induce VB N
bronchial JJ N
hyper-responsiveness NN N
, , N
which WDT N
in IN N
turn NN N
correlates NNS N
with IN N
eosinophilic JJ N
asthmatic JJ N
inflammation NN N
and CC N
atopic JJ N
disease NN N
expression NN N
. . N

Importantly RB N
, , N
2D-STE JJ N
analysis NN N
demonstrated VBD N
the DT N
presence NN N
of IN N
subclinical JJ N
LV NNP N
systolic NN N
and CC N
diastolic JJ N
dysfunction NN N
with IN N
impaired JJ N
circumferential NN N
and CC N
longitudinal JJ N
strain NN N
and CC N
strain NN N
rate NN N
at IN N
the DT N
isovolumic JJ N
relaxation NN N
time NN N
. . N

Plasma NNP N
and CC N
urine JJ N
concentrations NNS N
of IN N
tyrosine NN N
and CC N
phenylalanine NN N
were VBD N
far RB N
higher JJR N
in IN N
the DT N
infants NNS N
fed VBP N
F1 NNP N
to TO N
F4 NNP N
, , N
especially RB N
F2 NNP N
and CC N
F4 NNP N
, , N
than IN N
in IN N
the DT N
infants NNS N
fed VBN N
BM NNP N
. . N

No DT N
differences NNS N
were VBD N
observed VBN N
in IN N
glucose JJ N
levels NNS N
, , N
insulin NN N
sensitivity NN N
index NN N
and CC N
lipid JJ N
profile NN N
as RB N
well RB N
as IN N
in IN N
biochemical JJ N
and CC N
cell NN N
count NN N
parameters NNS N
in IN N
any DT N
groups NNS N
. . N

Mexiletine NNP N
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
tendon NN N
reflexes NNS N
, , N
vibration NN N
threshold NN N
levels NNS N
, , N
beat-to-beat JJ N
variation NN N
in IN N
heart NN N
rate NN N
during IN N
deep JJ N
breathing NN N
, , N
and CC N
postural JJ N
blood NN N
pressure NN N
response NN N
. . N

About IN N
platelet NN N
5-HT JJ N
, , N
there EX N
is VBZ N
neither DT N
order NN N
x NNP N
treatment NN N
interaction NN N
, , N
nor CC N
treatment NN N
effect NN N
but CC N
a DT N
significant JJ N
order NN N
effect NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Significantly RB N
more JJR N
patients NNS p
in IN N
the DT N
AMX-CL NNP N
group NN N
than IN N
in IN N
the DT N
CAE NNP N
or CC N
CEC NNP N
group NN N
had VBD N
a DT N
side NN N
effect NN N
, , N
primarily RB N
diarrhea NN N
, , N
vomiting VBG N
, , N
or CC N
diaper JJ N
rash NN N
. . N

Nicotine NNP N
caused VBD N
a DT N
small JJ N
overall JJ i
reduction NN N
in IN N
global JJ N
cerebral JJ N
metabolism NN N
of IN N
glucose NN N
but CC N
, , N
when WRB N
the DT N
data NNS N
were VBD N
normalized VBN N
, , N
several JJ N
brain NN N
regions NNS N
showed VBD N
relative JJ N
increases NNS o
in IN N
activity NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
morning NN N
stiffness NN N
, , N
walking VBG N
time NN N
, , N
erythrocyte JJ N
sedimentation NN N
rate NN N
, , N
C-reactive JJ N
protein NN N
, , N
or CC N
rheumatoid VB N
factor NN N
between IN N
the DT N
groups NNS N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
a DT N
diminished JJ N
variability NN N
in IN N
performance NN N
in IN N
the DT N
tested JJ N
frequency NN N
bands NNS N
with IN N
Hydergine NNP N
, , N
the DT N
opposite JJ N
tendency NN N
being VBG N
obtained VBN N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
efficacy NN N
of IN N
Rioprostil NNP N
( ( N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
) ) N
is VBZ N
compared VBN N
with IN N
that DT N
of IN N
ranitidine NN N
in IN N
the DT N
recurrence NN N
prevention NN N
of IN N
duodenal JJ N
ulcer NN N
( ( N
s NN N
) ) N
. . N

BACKGROUND NNP N
Ischemic NNP N
preconditioning NN N
( ( N
IPC NNP N
) ) N
and CC N
anesthetic JJ N
preconditioning NN N
( ( N
APC NNP N
) ) N
have VBP N
been VBN N
reported VBN N
to TO N
attenuate VB N
ischemia-reperfusion NN N
( ( N
IR NNP N
) ) N
injury NN N
after IN N
liver JJ N
resection NN N
under IN N
continuous JJ N
inflow JJ N
occlusion NN N
. . N

Thus RB N
, , N
no DT N
dose JJ N
adjustment NN N
for IN N
either DT N
risperidone NN i
orgalantamine NN N
is VBZ N
necessary JJ N
when WRB N
these DT N
two CD N
drugs NNS N
are VBP N
administered VBN N
together RB N
in IN N
the DT N
dose JJ N
range NN N
evaluated VBD N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Positive NNP N
response NN N
was VBD N
defined VBN N
by IN N
a DT N
score NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
Clinical NNP N
Global NNP N
Impressions NNP N
, , N
Improvement NNP N
subscale NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival NN N
, , N
tumor NN N
response NN N
, , N
duration NN N
of IN N
response NN N
, , N
and CC N
time NN N
to TO N
response NN N
. . N

There EX N
was VBD N
no DT N
observed JJ N
effect NN N
on IN N
newborn JJ N
serum NN N
electrolyte NN N
levels NNS N
with IN N
amnioinfusion NN N
, , N
nor CC N
was VBD N
there EX N
any DT N
apparent JJ N
benefit NN N
of IN N
infusion NN N
of IN N
warmed JJ N
saline NN N
compared VBN N
with IN N
room-temperature JJ N
saline NN N
. . N

Icosapent NNP N
Ethyl NNP N
( ( N
Eicosapentaenoic NNP N
Acid NNP N
Ethyl NNP N
Ester NNP N
) ) N
: : N
Effects NNS N
Upon IN N
High-Sensitivity NNP N
C-Reactive JJ N
Protein NNP N
and CC N
Lipid NNP N
Parameters NNP N
in IN N
Patients NNP N
With IN N
Metabolic NNP N
Syndrome NNP N
. . N

RESULTS NN N
Before IN N
application NN N
of IN N
saline JJ N
solutions NNS N
, , N
mucociliary JJ N
clearance NN N
times NNS N
in IN N
the DT N
three CD N
patient NN N
treatment NN N
groups NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
delayed VBN N
, , N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

The DT N
incidence NN N
of IN N
shivering NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
misoprostol NN N
group NN N
whilst VBD N
that IN N
of IN N
vomiting NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
syntometrine NN N
group NN N
. . N

Daily JJ N
administration NN N
of IN N
2-chlorodeoxyadenosine JJ N
( ( N
Cladribine NNP N
, , N
CDA NNP N
) ) N
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
hairy NN N
cell NN N
leukemia NN N
, , N
but CC N
may MD N
cause VB N
severe JJ N
neutropenia NN N
and CC N
neutropenic JJ N
fever NN N
. . N

Experimentally RB N
, , N
two CD N
slotted VBD N
nails NNS N
, , N
the DT N
Grosse-Kempf NNP N
nail NN N
and CC N
the DT N
AO/ASIF NNP N
universal JJ N
femoral JJ N
nail NN N
, , N
were VBD N
compared VBN N
to TO N
the DT N
non-slotted JJ N
Grosse-Kempf NNP N
nail NN N
and CC N
control NN N
bone NN N
using VBG N
a DT N
cadaver JJ N
femoral JJ N
osteotomy NN N
. . N

The DT N
two CD N
groups NNS N
showed VBD N
no DT N
differences NNS N
in IN N
measurements NNS N
of IN N
peak JJ N
expiratory NN N
flow NN N
, , N
FEV1 NNP N
, , N
and CC N
FVC NNP N
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

BALF NNP N
levels NNS N
of IN N
total JJ N
protein NN N
, , N
neutrophils NNS N
, , N
and CC N
leukotriene JJ N
B4 NNP N
tended VBD N
to TO N
decrease VB o
in IN N
EPA+GLA NNP N
patients NNS p
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
as IN N
compared VBN N
with IN N
control NN N
patients NNS p
. . N

There EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
maximum JJ N
force NN N
measurements NNS N
and CC N
stimulation NN N
order NN N
, , N
which WDT N
was VBD N
not RB N
apparent JJ N
in IN N
the DT N
fatigue JJ N
time NN N
or CC N
FTI NNP N
measurements NNS N
. . N

Skeletal JJ N
muscle NN N
STARS NNP N
, , N
myocardian-related JJ N
transcription NN N
factor-A NN N
( ( N
MRTF-A NNP N
) ) N
and CC N
serum JJ N
response NN N
factor NN N
( ( N
SRF NNP N
) ) N
mRNA NN N
and CC N
protein NN N
, , N
as RB N
well RB N
as IN N
muscle NN N
cross-sectional JJ N
area NN N
and CC N
maximal JJ N
voluntary JJ N
contraction NN N
, , N
were VBD N
measured VBN N
. . N

RESULTS NNP N
Oral NNP N
NAA NNP N
resulted VBD N
in IN N
a DT N
profound NN N
plasma NN N
alkalosis NN N
marked VBN N
by IN N
decreased JJ o
plasma NN N
[ NNP N
H+ NNP N
] NNP N
and CC N
increased VBD o
plasma NN o
[ NN N
TCO2 NNP N
] NNP N
and CC N
[ NNP N
HCO3- NNP N
] NNP N
compared VBN N
to TO N
Control NNP N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
fluid JJ N
retention NN N
, , N
nausea NN N
, , N
fatigue NN N
, , N
skin JJ N
rash NN N
, , N
gastrointestinal JJ N
complaints NNS N
, , N
and CC N
myalgia NN N
. . N

BACKGROUND NNP N
Although IN N
moderate JJ N
caffeine NN i
ingestion NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
arrhythmogenic JJ N
, , N
caffeine JJ i
toxicity NN N
can MD N
cause VB N
severe JJ N
cardiac JJ N
arrhythmias NN N
, , N
including VBG N
atrial JJ N
fibrillation NN N
and CC N
ventricular JJ N
tachycardia NN N
. . N

Uterine JJ N
volume NN N
, , N
mean VB N
operating NN N
time NN N
, , N
uterine JJ N
weight NN N
, , N
drop NN N
in IN N
hemoglobin NN N
, , N
intraoperative JJ N
complications NNS N
, , N
conversions NNS N
to TO N
laparotomy VB N
, , N
and CC N
hospital NN N
stay NN N
were VBD N
recorded VBN N
. . N

Zoledronic JJ N
acid NN N
is VBZ N
significantly RB N
more RBR N
effective JJ N
than IN N
risedronate NN N
in IN N
increasing VBG N
lumbar NN N
spine NN N
( ( N
LS NNP N
) ) N
bone NN N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
in IN N
both DT N
prevention NN N
and CC N
treatment NN N
of IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

Similarly RB N
, , N
no DT N
effects NNS N
were VBD N
seen VBN N
on IN N
secondary JJ N
vascular JJ N
end NN N
points NNS N
, , N
except IN N
for IN N
a DT N
suggestion NN N
of IN N
protection NN N
versus NN N
strokes NNS N
and CC N
transient JJ N
ischemic JJ N
attacks NNS N
. . N

Urinary JJ N
aldosterone NN N
was VBD N
decreased VBN o
in IN N
a DT N
dose-dependent JJ N
fashion NN N
and CC N
its PRP$ N
changes NNS N
were VBD N
largely RB N
independent JJ N
fashion NN N
and CC N
its PRP$ N
changes NNS N
were VBD N
largely RB N
independent JJ N
of IN N
plasma JJ N
renin NN N
activity NN N
. . N

The DT N
neuroendocrine JJ N
effects NNS N
of IN N
sumatriptan JJ N
differ NN N
from IN N
those DT N
of IN N
previously RB N
described VBN N
5-HT-receptor JJ N
agonists NNS N
, , N
and CC N
may MD N
be VB N
a DT N
consequence NN N
of IN N
selective JJ N
activation NN N
of IN N
5-HT1D JJ N
or CC N
5-HT1B JJ N
receptors NNS N
. . N

The DT N
effects NNS N
of IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-oil NN N
distillers NNS N
dried VBD N
grains NNS N
with IN N
solubles NNS N
on IN N
growth NN N
performance NN N
, , N
nutrient JJ N
digestibility NN N
, , N
and CC N
fat JJ N
quality NN N
in IN N
finishing VBG N
pigs NNS N
. . N

The DT N
mean JJ N
extraction NN N
recovery NN N
for IN N
rilpivirine NN N
( ( N
94.9 CD N
% NN N
) ) N
and CC N
IS NNP N
( ( N
99.9 CD N
% NN N
) ) N
from IN N
spiked VBN N
plasma NN N
samples NNS N
was VBD N
consistent JJ N
and CC N
reproducible JJ N
. . N

Measurements NNS N
of IN N
American NNP N
Urological NNP N
Association NNP N
symptom VBD N
score RB N
, , N
peak JJ N
urine JJ N
flow NN N
rate NN N
and CC N
prostate NN N
specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
are VBP N
often RB N
followed VBN N
over RP N
time NN N
in IN N
urological JJ N
management NN N
. . N

Post NNP N
hoc NN N
analysis NN N
of IN N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ N
acid NNS N
versus VBP N
daily JJ N
oral JJ N
risedronate NN N
on IN N
lumbar NN N
spine NN N
bone NN N
mineral JJ N
density NN N
in IN N
different JJ N
subgroups NNS N
with IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

BACKGROUND NNP N
Experimental NNP N
data NNS N
in IN N
humans NNS N
on IN N
the DT N
contribution NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
and CC N
angiotensin NN N
II NNP N
type NN N
1 CD N
receptor NN N
blockers NNS N
to TO N
the DT N
nitric JJ N
oxide NN N
system NN N
of IN N
the DT N
renal JJ N
vasculature NN N
are VBP N
inconsistent JJ N
. . N

Overall JJ i
pTBA NN N
resulted VBD N
in IN N
an DT N
absolute NN N
risk NN N
reduction NN N
of IN N
5.9 CD N
% NN N
and CC N
a DT N
relative JJ N
risk NN N
reduction NN N
of IN N
10.4 CD N
% NN N
unfavorable JJ N
outcome NN N
( ( N
P=0.54 NNP N
) ) N
. . N

All DT N
patients NNS p
receiving VBG N
BMAC NNP N
experienced VBD N
improvements NNS N
in IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
, , N
but CC N
only RB N
those DT N
with IN N
NIHF NNP N
showed VBD N
improvements NNS N
in IN N
left JJ N
ventricular JJ N
end-systolic JJ N
diameter NN N
and CC N
B-type NNP N
natriuretic JJ N
peptide NN N
. . N

Heart NNP N
rate NN N
, , N
cardiac JJ N
index NN N
, , N
and CC N
mixed JJ N
venous JJ N
oxygen NN N
saturation NN N
increased VBD o
significantly RB o
during IN N
dopexamine JJ N
infusion NN N
, , N
whereas JJ N
systemic JJ N
vascular NN N
resistance NN N
was VBD N
reduced VBN N
. . N

Similarly RB N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
urinary JJ N
calcium NN N
and CC N
phosphorus JJ N
excretion NN N
or CC N
deterioration NN N
in IN N
kidney NN N
function NN N
were VBD N
detected VBN N
in IN N
patients NNS p
administered VBN N
paricalcitol NNS N
compared VBN N
with IN N
placebo NN N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
treatments NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
and CC N
the DT N
between-subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
4.17 CD N
, , N
d.f NN N
. . N

The DT N
immediate JJ N
response NN N
and CC N
the DT N
changes NNS N
in IN N
Mth-DRS NNP N
values NNS N
, , N
sputum NN N
eosinophils NNS N
and CC N
serum VB N
ECP NNP N
levels NNS N
following VBG N
the DT N
allergen NN N
challenge NN N
were VBD N
attenuated VBN N
in IN N
the DT N
active JJ N
group NN N
. . N

Serum NNP N
G-CSF NNP N
levels NNS N
during IN N
the DT N
rhG-CSF JJ N
therapy NN i
greatly RB N
exceeded VBD N
endogenous JJ N
G-CSF NNP N
levels NNS N
and CC N
were VBD N
mainly RB N
due JJ N
to TO N
the DT N
presence NN N
of IN N
exogenous JJ N
rhG-CSF NN N
rather RB N
than IN N
increased VBN o
levels NNS N
of IN N
endogenous JJ N
G-CSF NNP N
. . N

AIM NNP N
To TO N
determine VB N
whether IN N
immunotherapy NN i
with IN N
HPV6 NNP N
L1 NNP N
virus NN N
like IN N
particles NNS N
( ( N
VLPs NNP N
) ) N
without IN N
adjuvant NN N
( ( N
VLP NNP N
immunotherapy NN i
) ) N
reduces VBZ N
recurrence NN N
of IN N
genital JJ N
warts NNS N
following VBG N
destructive JJ N
therapy NN i
. . N

Circadian JJ N
rhythms NN N
in IN N
dietary JJ N
and CC N
water NN N
intake NN N
and CC N
levels NNS N
of IN N
plasma NN N
total JJ N
fatty JJ N
acids NNS N
and CC N
lipid JJ N
fractions NNS N
remained VBD N
entrained JJ N
during IN N
exposure NN N
to TO N
either DT N
control NN N
conditions NNS N
or CC N
low-intensity NN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

It PRP N
does VBZ N
not RB N
increase VB o
the DT N
mortality NN N
rate NN N
, , N
and CC N
the DT N
morbidity NN N
rate NN N
seems VBZ N
to TO N
be VB N
even RB N
lower JJR N
than IN N
that DT N
in IN N
OC NNP N
. . N

BACKGROUND NNP N
In IN N
the DT N
treatment NN N
of IN N
reflux NN N
oesophagitis NN N
, , N
H2-receptor NNP N
antagonists NNS N
are VBP N
still RB N
widely RB N
used VBN N
in IN N
spite NN N
of IN N
the DT N
apparent JJ N
higher JJR N
efficacy NN N
of IN N
proton NN N
pump NN N
inhibitors NNS N
. . N

Twelve NNP N
subjects NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
complained VBD N
of IN N
diminished JJ N
dark NN N
adaptability NN N
, , N
and CC N
nine CD N
subjects NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus IN N
one CD N
control NN N
subject NN N
had VBD N
mild JJ N
dermatological JJ N
alterations NNS N
. . N

As IN N
a DT N
secondary JJ N
objective NN N
, , N
changes NNS N
in IN N
injected JJ N
joint NN N
tenderness NN N
and CC N
swelling VBG N
scores NNS N
, , N
each DT N
measured VBN N
on IN N
a DT N
four-point JJ N
scale NN N
, , N
were VBD N
evaluated VBN N
. . N

Toxicity NN N
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
arms NNS N
for IN N
anemia NN N
, , N
leukopenia NN N
, , N
neutropenia NN N
, , N
thrombocytopenia NN N
, , N
fatigue NN N
, , N
constipation NN N
and CC N
arthralgias/myalgias NN N
. . N

RESULTS VB N
The DT N
authors NNS N
demonstrated VBD N
that IN N
total JJ N
and CC N
conjugated VBD N
bilirubin NN N
, , N
alkaline JJ N
phosphatase NN N
, , N
alanine JJ N
aminotransferase NN N
, , N
aspartate VBP N
amino JJ N
transferase NN N
and CC N
cholinesterase NN N
did VBD N
not RB N
change VB N
significantly RB N
during IN N
the DT N
5-days JJ N
observation NN N
period NN N
. . N

Similar JJ N
observations NNS N
were VBD N
found VBN N
when WRB N
the DT N
drug NN N
was VBD N
injected VBN N
in IN N
the DT N
diseased JJ N
coronary JJ N
arteries NNS N
in IN N
a DT N
small JJ N
dose NN N
( ( N
0.075 CD N
mg/kg NN N
) ) N
so IN N
that DT N
peripheral JJ N
effects NNS N
were VBD N
not RB N
present JJ N
. . N

In IN N
each DT N
patient NN N
, , N
an DT N
in IN N
vivo NN N
kinetic JJ N
study NN N
of IN N
apolipoprotein NN N
B NNP N
( ( N
ApoB NNP N
) ) N
-containing VBG N
lipoproteins NNS N
with IN N
[ JJ N
13C CD N
] JJ N
leucine NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

In IN N
contrast NN N
, , N
a DT N
significant JJ N
difference NN N
for IN N
better JJR N
EFS NNP N
( ( N
p=0.0015 NN N
) ) N
in IN N
the DT N
BCL2 NNP N
positive JJ N
group NN N
of IN N
the DT N
ABC NNP N
subgroups NNS N
subtypes NNS N
treated VBN N
with IN N
rituximab NN i
containing VBG N
chemotherapy NN i
. . N

The DT N
spontaneous JJ N
bone NN N
loss NN N
was VBD N
similar JJ N
at IN N
all PDT N
the DT N
skeletal JJ N
sites NNS N
measured VBD N
, , N
with IN N
a DT N
mean JJ N
spontaneous JJ N
loss NN N
in IN N
calcanean JJ N
BMD NNP N
of IN N
1.6 CD N
% NN N
over IN N
one CD N
year NN N
. . N

However RB N
, , N
urinary JJ N
calcium NN N
excretion NN N
was VBD N
markedly RB N
higher JJR N
and CC N
urinary JJ N
pH NN N
and CC N
bicarbonate NN N
excretion NN N
significantly RB N
lower JJR N
in IN N
cows NNS N
fed VBP N
the DT N
anion NN N
diet NN N
than IN N
in IN N
cows NNS N
fed VBP N
the DT N
cation NN N
diet NN N
. . N

After IN N
intravenous JJ N
adrenaline NN N
there EX N
was VBD N
a DT N
good JJ N
clinical JJ N
and CC N
biochemical JJ N
response NN N
, , N
but CC N
after IN N
endotracheal JJ N
adrenaline NN N
there EX N
was VBD N
no DT N
change NN N
in IN N
serum JJ N
adrenaline NN N
and CC N
no DT N
measurable JJ N
clinical JJ N
response NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN N
advanced JJ N
heart NN N
failure NN N
, , N
vasopressin NN N
receptor NN N
antagonism NN N
with IN N
conivaptan NN N
resulted VBN N
in IN N
favorable JJ N
changes NNS N
in IN N
hemodynamics NNS N
and CC N
urine JJ N
output NN N
without IN N
affecting VBG N
blood NN N
pressure NN N
or CC N
heart NN N
rate NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
concentrations NNS N
of IN N
ofloxacin NN i
and CC N
ciprofloxacin NN i
hydrochloride NN N
in IN N
aqueous JJ N
humor NN N
after IN N
topical JJ N
or CC N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
in IN N
eyes NNS N
with IN N
filtering VBG N
blebs NN N
. . N

Induction NNP N
treatment NN N
with IN N
ATG NNP N
has VBZ N
the DT N
advantage NN N
of IN N
a DT N
lower JJR N
incidence NN N
of IN N
acute JJ N
rejection NN N
, , N
but CC N
it PRP N
significantly RB N
increases VBZ o
adverse JJ N
events NNS N
, , N
particularly RB N
CMV NNP N
infection NN N
. . N

The DT N
AF NNP N
frequency NN N
decreased VBD o
similarly RB o
in IN N
both DT N
groups NNS N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
endpoint NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
meloxicam NN N
and CC N
a DT N
glucosamine-chondroitin JJ i
( ( N
Glu-Ch NNP N
) ) N
supplement NN N
in IN N
the DT N
management NN N
of IN N
feline NN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Subcutaneously NNP N
injected VBD N
rapid-acting JJ N
insulin NN N
analogs NNS N
do VBP N
not RB N
replicate VB N
physiologic JJ N
insulin NN N
action NN N
due JJ N
to TO N
delays NNS N
in IN N
their PRP$ N
onset NN N
and CC N
peak JJ N
action NN N
resulting VBG N
in IN N
postprandial JJ N
glucose JJ N
excursions NNS N
. . N

Bile NNP N
lipid JJ N
composition NN N
was VBD N
determined VBN N
and CC N
the DT N
saturation NN N
index NN N
calculated VBD N
before IN N
and CC N
after IN N
treatment NN N
, , N
on IN N
samples NNS N
collected VBN N
by IN N
duodenal JJ N
siphonage NN N
after IN N
caerulein JJ N
stimulation NN N
, , N
in IN N
both DT N
groups NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
eradication NN N
of IN N
Helicobacter NNP N
pylori FW N
( ( N
H.pylori NNP N
) ) N
in IN N
the DT N
patients NNS p
with IN N
duodenal JJ N
ulcer NN N
( ( N
Du NNP N
) ) N
upon IN N
the DT N
DU NNP N
recurrence NN N
. . N

Micronucleus NNP N
levels NNS N
in IN N
peripheral JJ N
lymphocytes NNS N
and CC N
changes NNS N
seen VBN N
after IN N
intervention NN N
were VBD N
studied VBN N
in IN N
relation NN N
to TO N
the DT N
MTHFR NNP N
C677T NNP N
genotype NN N
, , N
basal JJ N
homocysteine NN i
and CC N
plasma JJ N
folate NN N
levels NNS N
. . N

It PRP N
is VBZ N
therefore RB N
suggested VBN N
that IN N
a DT N
multiallergic JJ N
condition NN N
and CC N
the DT N
combination NN N
and/or JJ N
purification NN N
of IN N
allergen NN N
extracts NNS N
administered VBN N
during IN N
hyposensitization NN N
may MD N
influence VB N
the DT N
production NN N
of IN N
IgG NNP N
anti- JJ N
IgG NNP N
antibodies NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Serum NNP N
and CC N
urine JJ N
cotinine NN N
, , N
lung NN N
function NN N
, , N
and CC N
cytokines NNS N
IL-4 NNP N
, , N
IL-5 NNP N
, , N
IL-6 NNP N
, , N
tumor NN N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
-alpha NN N
, , N
and CC N
IFN-gamma NNP N
. . N

Mean NNP N
cumulative JJ N
change NN N
in IN N
milk NN N
yield NN N
and CC N
interval JJ N
change NN N
in IN N
milk NN N
yield NN N
were VBD N
greater JJR N
in IN N
cows NNS N
treated VBN N
with IN N
isotonic JJ N
saline NN N
solution NN N
than IN N
in IN N
cows NNS N
treated VBN N
with IN N
hypertonic JJ N
saline JJ N
solution NN N
. . N

BACKGROUND NNP N
Photodynamic NNP N
therapy NN i
( ( N
PDT NNP N
) ) N
with IN N
topical JJ N
5-aminolaevulinic JJ N
acid NN N
( ( N
ALA NNP N
) ) N
followed VBN N
by IN N
irradiation NN N
with IN N
incoherent JJ N
light NN N
( ( N
ALA-PDT NNP N
) ) N
for IN N
recalcitrant NN N
warts NNS N
have VBP N
had VBN N
beneficial JJ N
results NNS N
. . N

Serum NNP N
hormone-binding JJ N
globulin NN N
levels NNS N
increased VBN o
in IN N
41.4 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
37.5 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

After IN N
intake NN N
of IN N
amantadine NN N
, , N
a DT N
significant JJ N
dose-dependent JJ N
decrease NN o
of IN N
ICF NNP N
was VBD N
noticed VBN N
as RB N
well RB N
as IN N
a DT N
significant JJ N
increase NN o
of IN N
L-ICI NNP N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

In IN N
the DT N
montelukast/levocetirizine NN N
arm NN N
, , N
montelukast NN N
decreased VBD o
nasal JJ o
eosinophilia RB N
more RBR N
significantly RB N
than IN N
levocetirizine NN N
, , N
whereas NNS N
in IN N
reduction NN N
of IN N
sICAM-1 JJ N
all DT N
active JJ N
treatment NN N
options NNS N
were VBD N
equally RB N
effective JJ N
. . N

OBJECTIVE NN N
To TO N
compare VB N
levels NNS N
of IN N
serum NN N
LH NNP N
during IN N
continued VBN N
use NN N
of IN N
leuprolide JJ N
acetate NN N
( ( N
LA NNP N
) ) N
with IN N
levels NNS N
during IN N
the DT N
first JJ N
week NN N
after IN N
discontinuing VBG N
LA NNP N
. . N

Expression NN N
of IN N
OPN NNP N
protein NN N
was VBD N
increased VBN o
in IN N
AML NNP N
patients NNS p
both DT N
in IN N
BM NNP N
blasts NNS N
( ( N
IHC NNP N
) ) N
and CC N
in IN N
BM NNP N
serum NN N
( ( N
ELISA NNP N
) ) N
compared VBN N
with IN N
healthy JJ N
controls NNS N
. . N

Overall JJ i
, , N
these DT N
findings NNS N
indicate VBP N
that IN N
there EX N
are VBP N
no DT N
apparent JJ N
advantages NNS N
in IN N
toxicity NN N
and CC N
efficacy NN N
by IN N
giving VBG N
CDA NNP N
weekly RB N
rather RB N
than IN N
daily RB N
. . N

CONCLUSIONS NNP N
Trimegestone NNP N
was VBD N
associated VBN N
with IN N
less RBR N
procoagulant JJ N
changes NNS N
in IN N
factor NN N
VIIa NNP N
and CC N
factor NN N
VIIc NNP N
activity NN N
and CC N
larger JJR N
decrease NN o
in IN N
PAI-1 NNP N
activity NN N
compared VBN N
with IN N
the DT N
dydrogesterone NN N
preparation NN N
. . N

Side-effects NNS N
such JJ N
as IN N
hypotension NN N
, , N
nausea NN N
, , N
pruritus NN N
, , N
shivering NN N
, , N
and CC N
headache NN N
were VBD N
recorded VBN N
RESULTS NNP N
Demographic NNP N
data NNS N
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
higher JJR N
PR NNP N
and CC N
catD JJ N
concentrations NNS N
in IN N
diffuse NN N
adenocarcinomas NN N
, , N
and CC N
the DT N
overexpression NN N
of IN N
TAG-72 NNP N
in IN N
the DT N
intestinal JJ N
type NN N
, , N
support VB N
the DT N
existence NN N
of IN N
two CD N
modes NNS N
of IN N
gastric JJ N
carcinogenesis NN N
. . N

In IN N
one CD N
other JJ N
case NN N
an DT N
urticarial JJ N
rash NN N
appeared VBD N
, , N
but CC N
disappeared VBD N
spontaneously RB N
when WRB N
the DT N
drug NN N
was VBD N
temporarily RB N
stopped VBN N
and CC N
did VBD N
not RB N
reappear VB N
when WRB N
it PRP N
was VBD N
administered VBN N
again RB N
. . N

GLP-1 NNP N
did VBD N
not RB N
change VB N
perception NN N
of IN N
isobaric JJ N
distension NN N
but CC N
reduced VBD N
the DT N
perception NN N
score RB N
related VBN N
to TO N
corresponding VBG N
bag NN N
volume NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

RESULTS VB N
A DT N
significant JJ N
difference NN N
in IN N
improvement NN N
of IN N
overall JJ i
subjective JJ N
symptoms NNS N
in IN N
an DT N
intent-to-treat JJ N
analysis NN N
between IN N
groups NNS N
T NNP N
and CC N
C NNP N
was VBD N
found VBN N
at IN N
the DT N
follow-ups NNS N
. . N

Blood NNP N
chemistry NN N
monitoring NN N
indicated VBD N
that DT N
reduction NN N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
strongly RB N
correlated VBN N
with IN N
an DT N
increase NN o
in IN N
baseline JJ N
levels NNS N
of IN N
some DT N
enzymes NNS N
for IN N
niacin-treated JJ N
subjects NNS N
. . N

OBJECTIVES NNP N
So NNP N
far RB N
it PRP N
has VBZ N
not RB N
clearly RB N
been VBN N
demonstrated VBN N
that IN N
systematic JJ N
mediastinal JJ N
lymphadenectomy NN N
improves VBZ N
survival JJ N
in IN N
patients NNS p
with IN N
non-small JJ N
cell NN N
lung NN N
cancer NN N
. . N

QRHT NN N
can MD N
appropriately RB N
increase VB o
the DT N
levels NNS N
of IN N
glucose NN N
, , N
lactic JJ N
acid NN N
, , N
citric JJ N
acid NN N
, , N
high-density NN N
lipoprotein NN N
, , N
phosphatidylcholine NN N
, , N
glycerophosphate JJ N
choline NN N
, , N
hydroxybutyrate NN N
, , N
alanine NN N
, , N
and CC N
glutamate NN N
. . N

Dofequidar NNP N
fumarate NN N
( ( N
MS-209 NNP N
) ) N
in IN N
combination NN N
with IN N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
and CC N
fluorouracil NN N
for IN N
patients NNS p
with IN N
advanced JJ N
or CC N
recurrent JJ N
breast NN N
cancer NN N
. . N

Effects NNS N
of IN N
conjugated JJ N
linoleic JJ N
acid NN N
supplementation NN N
and CC N
exercise NN N
on IN N
post-heparin JJ N
lipoprotein NN N
lipase NN N
, , N
butyrylcholinesterase NN N
, , N
blood NN N
lipid JJ N
profile NN N
and CC N
glucose JJ N
metabolism NN N
in IN N
young JJ N
men NNS N
. . N

Peak-to-peak JJ N
and CC N
mean JJ N
systolic JJ N
pressure NN N
differences NNS N
across IN N
the DT N
valves NNS N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
B-S NNP N
than IN N
in IN N
the DT N
L-K NNP N
valves NNS N
, , N
particularly RB N
when WRB N
the DT N
small JJ N
valve NN N
sizes NNS N
were VBD N
compared VBN N
. . N

Taken VBN N
together RB N
, , N
these DT N
data NNS N
show VBP N
that IN N
the DT N
combination NN N
of IN N
nifedipine JJ N
+ FW N
chlorthalidone NN i
does VBZ N
not RB N
exert VB N
any DT N
additive JJ N
antihypertensive JJ N
effect NN N
compared VBN N
with IN N
nifedipine JJ N
alone NN N
. . N

Enteral JJ N
nutrition NN N
with IN N
eicosapentaenoic JJ N
acid NN N
, , N
gamma-linolenic JJ N
acid NN N
, , N
and CC N
antioxidants NNS N
reduces NNS N
alveolar JJ N
inflammatory JJ N
mediators NNS N
and CC N
protein NN N
influx NN N
in IN N
patients NNS p
with IN N
acute JJ N
respiratory NN N
distress NN N
syndrome NN N
. . N

Non-invasive JJ N
electrophysiological JJ N
techniques NNS N
were VBD N
used VBN N
to TO N
assess VB N
presynaptic JJ N
inhibition NN N
, , N
postsynaptic JJ N
inhibition NN N
and CC N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
in IN N
the DT N
spinal JJ N
cord NN N
. . N

Controlling VBG N
the DT N
dose NN N
of IN N
heparin NN N
with IN N
coagulation NN N
tests NNS N
resulted VBD N
in IN N
the DT N
administration NN N
of IN N
significantly RB N
larger JJR N
daily JJ N
doses NNS N
of IN N
heparin NN N
with IN N
intermittent JJ N
injections NNS N
than IN N
with IN N
continuous JJ N
infusion NN N
. . N

CONCLUSION NNP N
Plasma NNP N
endotoxin NN N
and CC N
cytokines NNS N
( ( N
TNF-alpha NNP N
, , N
IL-1 NNP N
beta NN N
, , N
IL-6 NNP N
and CC N
IL-8 NNP N
) ) N
can MD N
be VB N
removed VBN N
effectively RB N
with IN N
CRRT NNP N
in IN N
severely RB N
burned VBN N
patients NNS p
with IN N
sepsis NN N
. . N

Strength NN N
of IN N
hand NN N
grip NN N
was VBD N
the DT N
best JJS N
predictor NN N
of IN N
volume NN N
delivered VBN N
and CC N
was VBD N
more RBR N
strongly RB N
correlated VBN N
with IN N
volumes NNS N
delivered VBN N
by IN N
one CD N
rather RB N
than IN N
two CD N
hands NNS N
. . N

Correspondingly RB N
the DT N
decrease NN o
of IN N
plasma JJ N
renin NN N
activity NN N
( ( N
PRA NNP N
) ) N
and CC N
urinary JJ N
prostaglandin NN N
excretion NN N
( ( N
PGE2 NNP N
) ) N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS p
treated VBD N
initially RB N
with IN N
indomethacin NN i
. . N

Mean NNP N
prolactin NN i
of IN N
adult NN N
females NNS N
, , N
while IN N
similar JJ N
to TO N
that DT N
of IN N
adult NN N
males NNS N
at IN N
baseline NN N
, , N
was VBD N
2.2 CD N
times NNS N
male JJ N
levels NNS N
acutely RB N
and CC N
3.7 CD N
times NNS N
greater JJR N
in IN N
maintenance NN N
. . N

The DT N
achieved JJ N
rates NNS N
of IN N
remission NN N
and CC N
survival JJ N
time NN N
showed VBD N
an DT N
obvious JJ N
dependence NN N
on IN N
the DT N
histological JJ N
type NN N
of IN N
tumor NN N
and CC N
on IN N
the DT N
degree NN N
of IN N
differentiation NN N
. . N

We PRP N
conclude VBP N
that IN N
neither CC N
0.05 CD N
percent NN N
desonide NN N
ointment NN N
nor CC N
2.5 CD N
percent NN N
hydrocortisone NN N
ointment NN N
compromised VBD N
the DT N
HPA NNP N
axis NN N
of IN N
children NNS N
with IN N
atopic NN N
dermatitis NN N
treated VBD N
topically RB N
for IN N
four CD N
weeks NNS N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
amino JJ N
acids NNS N
L-arginine JJ N
and CC N
citrulline NN N
on IN N
endothelial JJ N
function NN N
in IN N
patients NNS p
in IN N
stable JJ N
diastolic NN N
and CC N
right JJ N
heart NN N
failure NN N
using VBG N
photoplethysmography NN N
. . N

Primary JJ N
hemostasis NN N
was VBD N
assessed VBN N
with IN N
a DT N
platelet NN N
function NN N
analyser NN N
( ( N
PFA-100 NNP N
) ) N
, , N
which WDT N
measures VBZ N
the DT N
closure NN N
time NN N
( ( N
CT NNP N
) ) N
of IN N
a DT N
collagen- JJ N
and CC N
epinephrine-coated JJ N
pore NN N
by IN N
aggregating VBG N
platelets NNS N
in IN N
flowing VBG N
blood NN N
. . N

Middle NNP N
cerebral JJ N
arterial JJ N
blood NN N
flow NN N
velocities NNS N
decreased VBN o
significantly RB N
after IN N
administration NN N
of IN N
isoflurane NN N
and CC N
propofol NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
. . N

Also RB N
here RB N
, , N
this DT N
was VBD N
contrasted VBN N
by IN N
better JJR N
EFS NNP N
( ( N
p=0.039 NN N
) ) N
in IN N
the DT N
LMO2 NNP N
positive JJ N
group NN N
of IN N
ABC NNP N
subtypes NNS N
when WRB N
treated VBN N
with IN N
the DT N
rituximab NN i
containing VBG N
regimen NNS N
. . N

Recombinant JJ N
murine NN N
GM-CSF NNP N
administration NN N
to TO N
neonatal JJ N
rats NNS N
has VBZ N
resulted VBN N
in IN N
neutrophilia JJ N
, , N
increased JJ o
neutrophil NN N
production NN N
, , N
and CC N
increased VBD o
survival NN o
of IN N
pups NNS N
during IN N
experimental JJ N
Staphylococcus NNP N
aureus NN N
sepsis NN N
. . N

Both DT N
groups NNS N
showed VBD N
improvement NN N
on IN N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
( ( N
PANSS NNP N
) ) N
scores NNS N
and CC N
Clinical NNP N
Global NNP N
Impression-Severity NNP N
( ( N
CGI-S NNP N
) ) N
scores VBZ N
. . N

A DT N
fenbendazole JJ N
oral JJ N
drench NN N
in IN N
addition NN N
to TO N
an DT N
ivermectin JJ i
pour-on JJ N
reduces NNS N
parasite JJ N
burden NN N
and CC N
improves VBZ N
feedlot NN N
and CC N
carcass NN N
performance NN N
of IN N
finishing VBG N
heifers NNS N
compared VBN N
with IN N
endectocides NNS N
alone RB N
. . N

CONCLUSION NNP N
Ixabepilone NNP N
, , N
with IN N
or CC N
without IN N
estramustine JJ N
phosphate NN N
, , N
is VBZ N
well RB N
tolerated VBN N
and CC N
has VBZ N
antitumor VBN N
activity NN N
in IN N
patients NNS p
with IN N
castrate JJ N
metastatic JJ N
prostate NN N
cancer NN N
. . N

In IN N
a DT N
previous JJ N
study NN N
it PRP N
was VBD N
demonstrated VBN N
that IN N
patients NNS p
with IN N
multiallergy JJ N
hyposensitized VBN N
with IN N
combined JJ N
allergen NN N
extracts NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
increase NN o
in IN N
IgG NNP N
anti-IgG JJ N
titres NNS N
during IN N
treatment NN N
. . N

BACKGROUND NNP N
An DT N
oral JJ N
formulation NN N
of IN N
ganciclovir NN N
( ( N
GCV NNP N
) ) N
was VBD N
recently RB N
approved VBN N
for IN N
the DT N
prevention NN N
of IN N
cytomegalovirus NN N
disease NN N
in IN N
solid JJ N
organ NN N
transplant JJ N
recipients NNS N
. . N

Consecutive JJ N
procedural JJ N
angiograms NNS N
of IN N
patients NNS p
randomly RB N
assigned VBN N
to TO N
EES NNP N
( ( N
n=669 NN N
) ) N
or CC N
PES NNP N
( ( N
n=333 RB N
) ) N
were VBD N
analysed VBN N
by IN N
an DT N
independent JJ N
angiographic JJ N
core NN N
laboratory NN N
. . N

B-TG NNP N
and CC N
PF4 NNP N
plasma NN N
levels NNS N
and CC N
ADP-induced NNP N
platelet NN N
aggregation NN N
were VBD N
determined VBN N
in IN N
basal NN N
conditions NNS N
, , N
and CC N
two CD N
hours NNS N
, , N
and CC N
seven CD N
and CC N
fourteen JJ N
days NNS N
after IN N
starting VBG N
with IN N
ASA NNP N
or CC N
placebo NN N
. . N

Initial JJ N
segmentation NN N
at IN N
baseline NN N
was VBD N
evaluated VBN N
to TO N
be VB N
satisfactory JJ N
in IN N
93.9 CD N
% NN N
of IN N
nodules NNS N
for IN N
P1 NNP N
, , N
84.4 CD N
% NN N
for IN N
P2 NNP N
, , N
and CC N
88.4 CD N
% NN N
for IN N
P3 NNP N
. . N

No DT N
other JJ N
plasma NN N
free JJ N
essential JJ N
fatty NN N
acid RB N
changed VBD N
during IN N
the DT N
trial NN N
, , N
although IN N
the DT N
HDL NNP N
: : N
cholesterol NN N
increased VBD o
slightly RB o
but CC N
non-significantly RB N
with IN N
an DT N
increase NN o
in IN N
EPA NNP N
and CC N
DHA NNP N
. . N

For IN N
both DT N
systolic JJ N
( ( N
SBP NNP N
) ) N
and CC N
diastolic JJ N
( ( N
DBP NNP N
) ) N
blood NN N
pressure NN N
, , N
change NN N
in IN N
polyunsaturated JJ N
fatty JJ N
acid NNS N
intake NN N
was VBD N
the DT N
strongest JJS N
dietary JJ N
predictor NN N
of IN N
BP NNP N
change NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
time NN N
between IN N
loading VBG N
dose NN N
and CC N
stent JJ N
deployment NN N
( ( N
35.2 CD N
in IN N
ticagrelor NN N
and CC N
42.7 CD N
min NN N
in IN N
clopidogrel NN N
, , N
p=0.36 NN N
) ) N
. . N

Overall JJ i
tolerability NN N
of IN N
both DT N
treatments NNS N
was VBD N
similar JJ N
to TO N
placebo VB N
, , N
and CC N
there EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
effects NNS N
on IN N
cardiac JJ N
repolarisation NN N
with IN N
either DT N
mizolastine NN N
or CC N
loratadine NN N
. . N

Comparative JJ N
effects NNS N
of IN N
valsartan JJ N
versus NN N
amlodipine NN N
on IN N
left JJ N
ventricular JJ N
mass NN N
and CC N
reactive JJ N
oxygen NN N
species NNS N
formation NN N
by IN N
monocytes NNS N
in IN N
hypertensive JJ N
patients NNS p
with IN N
left JJ N
ventricular JJ N
hypertrophy NN N
. . N

Changes NNS N
in IN N
biliary JJ N
ursodeoxycholic JJ N
acid NN N
correlated VBN N
significantly RB N
but CC N
weakly RB N
with IN N
the DT N
changes NNS N
in IN N
serum NN N
alkaline NN N
phosphatase NN N
, , N
AST NNP N
, , N
bilirubin NN N
, , N
and CC N
in IN N
Mayo NNP N
risk NN N
score NN N
. . N

BACKGROUND IN N
The DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
recombinant JJ N
human JJ N
antithrombin NN N
( ( N
rhAT NN N
) ) N
for IN N
restoring VBG N
heparin NN N
responsiveness NN N
in IN N
heparin NN N
resistant JJ N
patients NNS p
undergoing VBG N
cardiac JJ N
surgery NN N
. . N

BACKGROUND NNP N
A NNP N
new JJ N
aqueous JJ N
gel JJ N
formulation NN N
of IN N
dapsone NN N
has VBZ N
been VBN N
developed VBN N
that IN N
allows VBZ N
clinically-effective JJ N
doses NNS N
of IN N
dapsone NN N
to TO N
be VB N
administered VBN N
topically RB N
with IN N
minimal JJ N
systemic JJ N
absorption NN N
. . N

Acute JJ N
drug NN N
effects NNS N
were VBD N
recorded VBN N
, , N
focusing VBG N
on IN N
electrocardiography NN N
, , N
respiratory NN N
movements NNS N
, , N
arterial JJ N
blood NN N
oxygen NN N
saturation NN N
, , N
and CC N
electroencephalography NN N
( ( N
EEG NNP N
) ) N
. . N

Preclinical NNP N
and CC N
emerging VBG N
clinical JJ N
evidence NN N
show NN N
that IN N
the DT N
intracoronary JJ N
injection NN N
of IN N
autologous JJ N
bone NN N
marrow NN N
mononuclear JJ N
cells NNS N
( ( N
BMCs NNP N
) ) N
following VBG N
AMI NNP N
leads VBZ N
to TO N
improvement NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
function NN N
( ( N
LVEF NNP N
) ) N
. . N

All DT N
three CD N
studied VBD N
drugs NNS N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN o
in IN N
the DT N
reactance NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
decrease NN o
in IN N
resonant JJ N
frequency NN N
. . N

The DT N
significant JJ N
fall NN N
of IN N
MDA NNP N
and CC N
SOD NNP N
and CC N
increased VBD o
levels NNS o
of IN N
GSH NNP N
in IN N
blood NN N
in IN N
both DT N
groups NNS N
after IN N
control NN N
revealed VBD N
beneficial JJ N
effects NNS N
of IN N
glycemic JJ N
control NN N
on IN N
oxidative JJ N
stress NN N
. . N

Therefore RB N
, , N
the DT N
potentiating VBG N
effect NN N
of IN N
sevoflurane NN N
seems VBZ N
to TO N
be VB N
mainly RB N
of IN N
PD NNP N
origin NN N
, , N
probably RB N
due JJ N
to TO N
an DT N
increased VBN o
sensitivity NN N
of IN N
the DT N
neuromuscular JJ N
junction NN N
. . N

Overall JJ i
, , N
acetate NN N
, , N
butyrate NN N
, , N
and CC N
total JJ N
SCFA NNP N
concentrations NNS N
were VBD N
higher JJR N
when WRB N
participants NNS N
consumed VBD N
RS NNP N
compared VBN N
with IN N
entry NN N
and CC N
NSP NNP N
diets NNS N
, , N
but CC N
individual JJ N
responses NNS N
varied VBD N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
postulated VBN N
that IN N
alteration NN N
of IN N
central JJ N
cholinergic JJ N
transmission NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT N
anesthetics NNS N
produce VBP N
unconsciousness JJ N
. . N

Statistically RB N
significant JJ N
changes NNS N
in IN N
fatigue NN N
, , N
pain NN N
, , N
appetite NN N
, , N
diarrhea NN N
, , N
and CC N
global JJ N
QOL NNP N
scores NNS N
were VBD N
detected VBN N
during IN N
RT NNP N
. . N

RESULTS NNP N
Effectiveness NNP N
of IN N
the DT N
GHRH NNP N
antagonist NN N
was VBD N
validated VBN N
in IN N
all DT N
subjects NNS N
by IN N
demonstrating VBG N
93+/-1.8 CD N
% NN N
( ( N
P=0.012 NNP N
) ) N
suppression NN N
of IN N
GH NNP N
response NN N
to TO N
a DT N
GHRH NNP N
bolus NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
included VBD N
cardiovascular JJ N
events NNS N
, , N
development NN N
of IN N
persistent JJ N
AF NNP N
, , N
left VBD N
atrial JJ N
dimension NN N
, , N
and CC N
quality-of-life NN N
( ( N
QOL NNP N
) ) N
. . N

It PRP N
causes VBZ N
membrane JJ N
depolarisation NN N
of IN N
sensory JJ N
neurons NNS N
, , N
which WDT N
release VBP N
CGRP NNP N
, , N
SP NNP N
and CC N
other JJ N
pain NN N
peptides NNS N
; : N
excitation NN N
is VBZ N
followed VBN N
by IN N
a DT N
refractory NN N
state NN N
, , N
causing VBG N
inactivation NN N
. . N

The DT N
vaginal JJ N
insert NN N
was VBD N
removed VBN N
for IN N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
entry NN N
into IN N
active JJ N
labor NN N
, , N
adequate JJ N
cervical JJ N
ripening NN N
, , N
or CC N
abnormality NN N
of IN N
uterine JJ N
contractile NN N
pattern NN N
or CC N
fetal JJ N
cardiac JJ N
activity NN N
. . N

The DT N
main JJ N
adverse JJ N
events NNS N
were VBD N
gastrointestinal JJ N
disorders NNS N
( ( N
2.5 CD N
% NN N
) ) N
and CC N
pruritus NN N
( ( N
2.5 CD N
% NN N
) ) N
; : N
safety NN N
profiles NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
safety NN N
evaluation NN N
was VBD N
performed VBN N
during IN N
the DT N
28-day JJ N
follow-up NN N
and CC N
serum NN N
samples NNS N
for IN N
anti-rabies NNS N
antibody JJ N
titration NN N
were VBD N
collected VBN N
on IN N
D0 NNP N
( ( N
before IN N
injection NN N
) ) N
D3 NNP N
, , N
D7 NNP N
, , N
D14 NNP N
and CC N
D28 NNP N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
meloxicam NN N
resulted VBN N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
mobility NN N
and CC N
activity NN N
levels NNS N
of IN N
cats NNS N
with IN N
OA NNP N
until IN N
the DT N
placebo NN N
was VBD N
introduced VBN N
. . N

CONCLUSIONS NNP N
Left NNP N
ventricular JJ N
thrombosis NN N
is VBZ N
not RB N
reduced VBN N
, , N
and CC N
may MD N
even RB N
be VB N
increased VBN o
, , N
by IN N
early JJ N
moderate NN N
to TO N
severe VB N
mitral JJ N
regurgitation NN N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

Thus RB N
metformin JJ N
treatment NN N
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
insulin NN N
sensitivity NN N
, , N
blood NN N
pressure NN N
or CC N
sympathetic JJ N
activity NN N
in IN N
this DT N
small JJ N
group NN N
of IN N
patients NNS p
. . N

The DT N
total JJ N
effectiveness NN N
rate NN N
was VBD N
77.69 CD N
% NN N
( ( N
94/121 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
, , N
71.56 CD N
% NN N
( ( N
78/109 CD N
) ) N
in IN N
those DT N
with IN N
complications NNS N
. . N

Hydrocortisone CD N
infusion NN N
induced VBD N
an DT N
increase NN o
of IN N
mean JJ N
arterial JJ N
pressure NN N
, , N
systemic JJ N
vascular NN N
resistance NN N
, , N
and CC N
a DT N
decline NN N
of IN N
heart NN N
rate NN N
, , N
cardiac JJ N
index NN N
, , N
and CC N
norepinephrine JJ N
requirement NN N
. . N

It PRP N
has VBZ N
been VBN N
confirmed VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
ACEIs NNP N
) ) N
and CC N
angiotensin $ N
II NNP N
receptor NN N
blockers NNS N
( ( N
ARBs NNP N
) ) N
reduce VB N
urinary JJ N
protein NN N
excretion NN N
and CC N
attenuate VB N
the DT N
development NN N
of IN N
renal JJ N
injury NN N
. . N

Mecamylamine NNP N
increased VBD o
several JJ o
measures NNS N
of IN N
cigarette NN N
smoking NN N
, , N
including VBG N
number NN N
of IN N
cigarettes NNS N
, , N
number NN N
of IN N
puffs NNS N
per IN N
cigarette NN N
, , N
and CC N
expired VBD N
air NN N
carbon NN N
monoxide NN N
level NN N
. . N

Median JJ N
remedication NN N
times NNS N
with IN N
both DT N
doses NNS N
of IN N
ibuprofen JJ N
arginate NN N
were VBD N
similar JJ N
to TO N
those DT N
with IN N
both DT N
doses NNS N
of IN N
ibuprofen NN N
, , N
ranging VBG N
from IN N
4.0 CD N
to TO N
5.2 CD N
hours NNS N
. . N

Secondary JJ N
outcomes NNS N
include VBP N
the DT N
effect NN N
of IN N
amlodipine NN N
therapy NN i
on IN N
systolic JJ N
and CC N
diastolic JJ N
function NN N
, , N
strain NN N
and CC N
strain NN N
rate NN N
and CC N
liver NN N
iron NN N
content NN N
. . N

Neither DT N
budesonide NN N
nor CC N
fluticasone NN N
produced VBD N
significant JJ N
suppression NN N
of IN N
plasma NN N
osteocalcin NN i
, , N
although IN N
the DT N
higher JJR N
doses NNS N
of IN N
both DT N
drugs NNS N
significantly RB N
reduced VBD N
fasting JJ N
urinary JJ N
calcium NN N
levels NNS N
. . N

Only RB N
two CD N
groups NNS N
( ( N
Optibond NNP N
FL NNP N
and CC N
G NNP N
Bond NNP N
) ) N
presented VBD N
equal JJ N
percentages NNS N
of IN N
marginal JJ N
adaptation NN N
on IN N
enamel NN N
and CC N
dentin NN i
; : N
in IN N
the DT N
other JJ N
groups NNS N
, , N
the DT N
rate NN N
of IN N
degradation NN N
was VBD N
product NN N
dependent NN N
. . N

Significant JJ N
differences NNS N
in IN N
complications NNS N
occurring VBG N
more RBR N
in IN N
phlebectomy NN N
than IN N
in IN N
compression NN N
sclerotherapy NN i
therapy NN i
were VBD N
blisters NNS N
, , N
teleangiectatic JJ N
matting NN N
, , N
scar NN N
formation NN N
, , N
and CC N
bruising VBG N
from IN N
bandaging VBG N
. . N

Histological JJ N
examination NN N
of IN N
biopsies NNS N
taken VBN N
from IN N
the DT N
abrasions NNS N
of IN N
two CD N
volunteers NNS N
showed VBD N
the DT N
dermis NN N
remained VBD N
intact JJ N
, , N
making VBG N
the DT N
model NN N
highly RB N
suitable JJ N
for IN N
the DT N
study NN N
of IN N
superficial JJ N
wounds NNS N
. . N

Patients NNS N
treated VBN N
with IN N
allopurinol NN N
showed VBD N
less RBR N
myocardial JJ N
production NN N
of IN N
free JJ N
radicals NNS N
, , N
indicating VBG N
that IN N
its PRP$ N
protective JJ N
effect NN N
may MD N
be VB N
due JJ N
to TO N
its PRP$ N
antioxidative JJ N
properties NNS N
. . N

Survival NNP N
curve NN N
analyses NNS N
revealed VBD N
little JJ N
difference NN N
between IN N
these DT N
groups NNS N
for IN N
major JJ N
vascular JJ N
end NN N
points NNS N
, , N
total JJ N
mortality NN N
, , N
all DT N
amputations NNS N
, , N
or CC N
myocardial JJ N
infarctions NNS N
. . N

Our PRP$ N
goal NN N
was VBD N
to TO N
evaluate VB N
retrograde VB N
bone NN N
marrow NN N
cell NN N
delivery NN N
in IN N
patients NNS p
with IN N
either DT N
ischemic JJ N
heart NN N
failure NN N
( ( N
IHF NNP N
) ) N
or CC N
nonischemic JJ N
heart NN N
failure NN N
( ( N
NIHF NNP N
) ) N
. . N

The DT N
effects NNS N
of IN N
eprosartan NN N
on IN N
RPF NNP N
are VBP N
mediated VBN N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
by IN N
an DT N
increased JJ o
bioavailability NN N
of IN N
nitric JJ N
oxide NN N
in IN N
the DT N
renal JJ N
vasculature NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
noninferiority NN N
of IN N
9-month JJ N
target NN N
vessel JJ N
failure NN N
defined VBD N
as IN N
cardiac JJ N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
or CC N
target VB N
vessel JJ N
revascularization NN N
. . N

For IN N
hypnosis NN N
, , N
synergistic JJ N
interaction NN N
was VBD N
found VBN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
the DT N
combination NN N
having VBG N
1.44 CD N
times NNS N
the DT N
potency NN N
of IN N
the DT N
individual JJ N
agents NNS N
. . N

In IN N
contrast NN N
to TO N
alkaline VB N
phosphatase NN N
, , N
a DT N
fall NN N
in IN N
inflammatory JJ N
activity NN N
stimulated VBN N
and CC N
impairment NN N
of IN N
functional JJ N
capacity NN N
significantly RB N
decreased VBD o
osteocalcin JJ o
levels NNS N
in IN N
patients NNS p
with IN N
RA NNP N
. . N

Blood NNP N
loss NN N
during IN N
parenchymal JJ N
transection NN N
and CC N
speed NN N
of IN N
transection NN N
were VBD N
the DT N
primary JJ N
endpoints NNS N
, , N
whereas IN N
the DT N
degree NN N
of IN N
postoperative JJ N
liver JJ N
injury NN N
and CC N
morbidity NN N
were VBD N
secondary JJ N
endpoints NNS N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
Naproxen NNP N
, , N
Novafen NNP N
and CC N
Tramadol NNP N
taken VBN N
immediately RB N
after IN N
treatment NN N
reduced VBD N
postoperative JJ N
pain NN N
following VBG N
pulpectomy NN N
and CC N
root JJ N
canal JJ N
preparation NN N
of IN N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
RA NNP N
with IN N
IL-1Ra NNP N
resulted VBD N
in IN N
reduced JJ N
mononuclear NN N
cell NN N
infiltration NN N
of IN N
synovial JJ N
membrane NN N
, , N
which WDT N
may MD N
represent VB N
the DT N
in IN N
vivo JJ N
inhibition NN N
of IN N
biologically RB N
relevant JJ N
IL-1ss-mediated JJ N
pathogenic JJ N
effects NNS N
. . N

CONCLUSIONS NNP N
The DT N
recombinant JJ N
human JJ N
porphobilinogen NN N
deaminase NN N
enzyme JJ N
preparation NN N
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
to TO N
administer VB N
and CC N
effective JJ N
for IN N
removal NN N
of IN N
the DT N
accumulated JJ N
metabolite NN N
porphobilinogen NN N
from IN N
plasma NN N
and CC N
urine NN N
. . N

There EX N
is VBZ N
evidence NN N
that IN N
patients NNS p
with IN N
Chagas NNP N
heart NN N
disease NN N
have VBP N
lower JJR N
Se NNP N
levels NNS N
than IN N
healthy JJ N
individuals NNS N
and CC N
patients NNS p
with IN N
T. NNP N
cruzi NN N
infection NN N
without IN N
of IN N
cardiac JJ N
disease NN N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ N
dreaming NN N
following VBG N
the DT N
use NN N
of IN N
morphine NN N
and CC N
pentazocine NN N
as IN N
premedicants NNS N
in IN N
an DT N
otherwise RB N
standard JJ N
anaesthetic JJ N
sequence NN N
is VBZ N
compared VBN N
in IN N
healthy JJ N
volunteers NNS N
. . N

However RB N
, , N
the DT N
present JJ N
data NNS N
can MD N
not RB N
exclude VB N
the DT N
possibility NN N
that IN N
the DT N
neuroendocrine JJ N
changes NNS N
reflect VBP N
nonspecific JJ N
stress NN N
responses NNS N
or CC N
changes NNS N
in IN N
pituitary JJ N
blood NN N
flow NN N
. . N

Results NNS N
favored VBD N
a DT N
muscle NN N
protein-sparing JJ N
effect NN N
of IN N
exercise NN N
, , N
as IN N
a DT N
significant JJ N
decrease NN o
in IN N
creatinine JJ N
excretion NN N
in IN N
controls NNS N
only RB N
suggested VBD N
muscle NN N
protein NN N
loss NN N
associated VBN N
with IN N
inactivity NN N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
studied JJ N
parameters NNS N
between IN N
the DT N
test NN N
and CC N
the DT N
control NN N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Following VBG N
drug NN N
administration NN N
the DT N
decrease NN o
in IN N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
and CC N
the DT N
increase NN o
in IN N
heart NN N
rate NN N
were VBD N
statistically RB N
significant JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Irradiation NNP N
within IN N
16-20 JJ N
h NN N
before IN N
operation NN N
and CC N
use NN N
of IN N
NSAID NNP N
( ( N
Voltaren NNP N
resinat NN N
) ) N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
relevant JJ N
heterotopic NN N
ossification NN N
after IN N
total JJ N
hip NN N
replacement NN N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
the DT N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
mean JJ N
blood NN N
loss NN N
. . N

INTERVENTIONS NNP N
PDT NNP N
with IN N
the DT N
Ciaglia NNP N
technique NN N
using VBG N
the DT N
Ciaglia NNP N
PDT NNP N
introducer NN N
set NN N
and CC N
the DT N
Griggs NNP N
technique NN N
using VBG N
a DT N
Griggs NNP N
PDT NNP N
kit NN N
and CC N
guidewire NN N
dilating NN N
forceps NNS N
. . N

DISCUSSION NNP N
Combined NNP N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplementation NN N
proved VBD N
superior JJ N
to TO N
calcium VB N
alone RB N
in IN N
reducing VBG N
the DT N
number NN N
of IN N
falls NNS N
and CC N
improving VBG N
muscle NN N
function NN N
in IN N
community-dwelling JJ N
older NN N
individuals NNS N
. . N

The DT N
study NN N
described VBD N
here RB N
investigates VBZ N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
glycerol NN N
lidocaine NN N
eardrops VBZ N
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
abacterial JJ N
otitis NN N
externa NN N
( ( N
CAS NNP N
No NNP N
. . N

From IN N
ECG NNP N
no DT N
significant JJ N
ST NNP N
deviations NNS N
were VBD N
found VBN N
and CC N
no DT N
significant JJ N
changes NNS N
regarding VBG N
B-Hb NNP N
, , N
blood NN N
pressure NN N
or CC N
pulse NN N
were VBD N
observed VBN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Lanthanum NNP N
carbonate NN N
( ( N
Fosrenol NNP N
) ) N
is VBZ N
a DT N
new JJ N
non-aluminum JJ N
, , N
non-calcium JJ N
phosphate NN N
binder NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
in IN N
patients NNS p
with IN N
end-stage JJ N
renal JJ N
disease NN N
( ( N
ESRD NNP N
) ) N
. . N

Prolonged JJ N
infusion NN N
of IN N
low-dose JJ N
gemcitabine NN N
and CC N
cisplatin NN i
( ( N
GC NNP N
) ) N
proved VBD N
to TO N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
patients NNS p
with IN N
advanced JJ N
bladder NN N
cancer NN N
. . N

RESULTS VB N
A NNP N
significative JJ N
reduction NN N
of IN N
angina NN N
crisis NN N
number NN N
, , N
duration NN N
, , N
intensity NN N
and CC N
the DT N
number NN N
of IN N
sublingual JJ N
nitrates NNS N
doses NNS N
were VBD N
observed VBN N
equally RB N
in IN N
both DT N
groups NNS N
. . N

The DT N
relative JJ N
increase NN o
in IN N
glucose JJ N
turnover NN N
during IN N
ATP NNP N
infusion NN N
compared VBN N
with IN N
baseline NN N
showed VBD N
a DT N
significant JJ N
correlation NN N
with IN N
the DT N
ATP NNP N
dose NN N
( ( N
r=0.58 NN N
, , N
P=0.02 NNP N
) ) N
. . N

MEASUREMENTS NNP N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
incidence NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
in IN N
patients NNS p
with IN N
adequate JJ N
bilateral JJ N
venograms NNS N
; : N
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
hemorrhage NN N
. . N

A DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
active JJ N
drugs NNS N
and CC N
placebo NN N
, , N
while IN N
no DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
among IN N
the DT N
three CD N
drugs NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
overall JJ i
survival NN N
, , N
with IN N
a DT N
median NN N
of IN N
19.4 CD N
and CC N
21.5 CD N
months NNS N
for IN N
CP NNP N
and CC N
cisplatin NN i
, , N
respectively RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
NCX-4016 NNP N
on IN N
gastrointestinal JJ N
mucosa NN N
and CC N
platelet NN N
functions NNS N
in IN N
healthy JJ N
human JJ N
volunteers NNS N
. . N

These DT N
results NNS N
were VBD N
accomplished VBN N
by IN N
two CD N
applications NNS N
per IN N
day NN N
as IN N
compared VBN N
to TO N
the DT N
four CD N
necessary JJ N
applications NNS N
of IN N
Plc NNP N
, , N
on IN N
a DT N
half JJ N
daily JJ N
pilocarpine NN N
dose NN N
with IN N
Polym NNP N
. . N

The DT N
functional JJ N
role NN N
of IN N
the DT N
jejunum NN N
and CC N
ileum NN N
with IN N
regard NN N
to TO N
peripheral JJ N
plasma NN N
levels NNS N
of IN N
intact JJ N
neurotensin JJ N
and CC N
NH2-terminal JJ N
immunoreactivity NN N
of IN N
neurotensin NN N
was VBD N
studied VBN N
by IN N
using VBG N
jejunoileal JJ N
bypass NN N
as IN N
a DT N
model NN N
. . N

[ VB N
The DT N
effect NN N
of IN N
losartan JJ N
versus NN N
atenolol NN i
on IN N
cardiovascular JJ N
morbidity NN N
and CC N
mortality NN N
in IN N
patients NNS p
with IN N
diabetes NNS N
mellitus NNS N
in IN N
the DT N
LIFE-study NNP N
] NNP N
. . N

The DT N
effect NN N
of IN N
metformin NN N
and CC N
insulin NN N
on IN N
sympathetic JJ N
nerve NN N
activity NN N
, , N
norepinephrine JJ N
spillover NN N
and CC N
blood NN N
pressure NN N
in IN N
obese JJ N
, , N
insulin JJ N
resistant NN N
, , N
normoglycemic JJ N
, , N
hypertensive JJ N
men NNS N
. . N

A DT N
dose-dependent JJ N
reduction NN N
in IN N
plasma NN N
Abeta NNP N
was VBD N
demonstrated VBN N
, , N
and CC N
changes NNS N
in IN N
plasma NN N
Abeta NNP N
concentrations NNS N
were VBD N
temporally RB N
related VBN N
to TO N
the DT N
pharmacokinetic JJ N
characteristics NNS N
of IN N
LY450139 NNP N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
simultaneously RB N
administered VBN N
didanosine NN N
( ( N
ddI NN N
) ) N
on IN N
the DT N
absorption NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
itraconazole NN N
. . N

On IN N
the DT N
first JJ N
postoperative JJ N
day NN N
, , N
the DT N
increase NN o
in IN N
the DT N
mean JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
IP NNP N
patients NNS p
. . N

Topical JJ N
PUVA NNP N
, , N
etretinate NN N
, , N
and CC N
combined VBN N
PUVA NNP N
and CC N
etretinate VB N
for IN N
palmoplantar JJ N
pustulosis NN N
: : N
comparison NN N
of IN N
therapeutic JJ N
efficacy NN N
and CC N
the DT N
influences NNS N
of IN N
tonsillar JJ N
and CC N
dental JJ N
focal JJ N
infections NNS N
. . N

Thus RB N
, , N
patients NNS p
with IN N
acute JJ N
myocardial JJ N
infarction NN N
treated VBN N
with IN N
emergency NN N
angioplasty NN N
had VBD N
significantly RB N
less RBR N
severe JJ N
residual JJ N
coronary JJ N
stenosis NN N
and CC N
exercise-induced JJ N
periinfarct NN N
ischemia NN N
than IN N
did VBD N
those DT N
treated VBN N
with IN N
intracoronary JJ N
streptokinase NN N
. . N

Biofeedback NNP N
reduced VBD N
the DT N
duration NN N
of IN N
headaches NNS N
by IN N
1.9 CD N
days NNS N
, , N
and CC N
the DT N
frequency NN N
of IN N
days NNS N
when WRB N
headache NN N
intensity NN N
was VBD N
? . N
by IN N
2.4 CD N
times NNS N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
analgesic JJ N
effect NN N
of IN N
lidocaine NN N
and CC N
a DT N
combination NN N
of IN N
lidocaine NN N
and CC N
ketamine NN N
following VBG N
epidural JJ N
administration NN N
in IN N
dromedary JJ N
camels NNS N
. . N

Immune NNP N
globulin NN N
therapy NN i
had VBD N
no DT N
effect NN N
on IN N
respiratory NN N
distress NN N
syndrome NN N
, , N
bronchopulmonary JJ N
dysplasia NN N
, , N
intracranial JJ N
hemorrhage NN N
, , N
the DT N
duration NN N
of IN N
hospitalization NN N
, , N
or CC N
mortality NN N
. . N

Treatment NN N
with IN N
palifermin NN N
showed VBD N
beneficial JJ N
effects NNS N
on IN N
mucositis NN N
, , N
but CC N
no DT N
significant JJ N
effect NN N
on IN N
engraftment NN N
, , N
acute JJ N
graft-versus-host JJ N
disease NN N
( ( N
GVHD NNP N
) ) N
, , N
or CC N
early JJ N
survival NN N
. . N

However RB N
, , N
the DT N
influence NN N
of IN N
pH NN N
on IN N
cerebral JJ N
lactate JJ N
uptake NN N
and CC N
, , N
in IN N
turn NN N
, , N
on IN N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
during IN N
exercise NN N
is VBZ N
not RB N
known VBN N
. . N

The DT N
formation NN N
of IN N
perindoprilat NN N
was VBD N
slightly RB N
reduced VBN N
in IN N
the DT N
group NN N
also RB N
receiving VBG N
hydrochlorothiazide NN i
and CC N
there EX N
was VBD N
a DT N
very RB N
small JJ N
reduction NN N
in IN N
ACE NNP N
inhibition NN N
in IN N
this DT N
group NN N
. . N

Metformin NNP N
, , N
naltrexone NN N
, , N
or CC N
the DT N
combination NN N
of IN N
prednisolone NN N
and CC N
antiandrogenic JJ N
oral JJ N
contraceptives NNS N
as IN N
first-line JJ N
therapy NN i
in IN N
hyperinsulinemic JJ N
women NNS N
with IN N
polycystic JJ N
ovary JJ N
syndrome NN N
. . N

Secondary JJ N
efficacy NN N
endpoints NNS N
included VBD N
pain NN N
intensity NN N
difference NN N
( ( N
PID NNP N
) ) N
and CC N
pain NN N
relief NN N
( ( N
PR NNP N
) ) N
throughout IN N
the DT N
60-min JJ N
post-dose JJ N
assessment NN N
period NN N
. . N

CONCLUSION NNP N
Loss NNP N
of IN N
LH NNP N
after IN N
stopping VBG N
LA NNP N
is VBZ N
likely JJ N
to TO N
be VB N
clinically RB N
important JJ N
in IN N
ovarian JJ N
stimulation NN N
regimens NNS N
that WDT N
use VBP N
pure JJ N
FSH NNP N
with IN N
LA NNP N
in IN N
ultrashort JJ N
protocols NNS N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
long-term JJ N
effects NNS N
of IN N
finasteride NN N
on IN N
pressure-flow JJ N
parameters NNS N
in IN N
men NNS N
with IN N
urodynamically RB N
documented VBN N
bladder NN N
outflow JJ N
obstruction NN N
( ( N
BOO NNP N
) ) N
. . N

CONCLUSION NNP N
Combination NNP N
treatment NN N
with IN N
minoxidil NN N
and CC N
lignocaine NN N
helps VBZ N
in IN N
faster RBR N
healing NN N
of IN N
anal JJ N
fissures NNS N
and CC N
provides VBZ N
better RBR N
symptomatic JJ N
relief NN N
than IN N
either DT N
drug NN N
alone RB N
. . N

In IN N
contrast NN N
, , N
serum JJ N
insulin NN N
levels NNS N
, , N
C-peptide NNP N
levels NNS N
, , N
and CC N
serum JJ N
glibenclamide NN N
profiles NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
enalapril NN N
and CC N
placebo NN N
. . N

CONCLUSION NNP N
An DT N
increase NN o
in IN N
mammographic JJ N
density NN N
was VBD N
demonstrated VBN N
in IN N
most JJS N
subjects NNS N
undergoing VBG N
continuous JJ N
combined VBN N
HRT NNP N
and CC N
was VBD N
most RBS N
pronounced JJ N
in IN N
subjects NNS N
with IN N
a DT N
lower JJR N
baseline NN N
density NN N
percentage NN N
. . N

Main NNP N
outcome NN N
measures NNS N
were VBD N
incidence NN N
of IN N
clomiphene NN N
resistance NN N
, , N
monofollicular JJ N
response NN N
, , N
fasting VBG N
insulin/glucose JJ N
ratio NN N
, , N
serum NN N
testosterone NN N
, , N
and CC N
pregnancy NN N
rates NNS N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Subnormal NNP N
bone NN N
mineral NN N
density NN N
( ( N
BMD NNP N
) ) N
and CC N
increased JJ o
fracture NN N
risk NN N
are VBP N
described VBN N
in IN N
patients NNS p
with IN N
growth NN N
hormone NN N
deficiency NN N
( ( N
GHD NNP N
) ) N
. . N

Two CD N
subjects NNS N
receiving VBG N
VPA NNP N
developed VBD N
increased VBN o
serum NN N
ammonia NN N
levels NNS N
, , N
one CD N
with IN N
an DT N
associated JJ N
parent NN N
report NN N
of IN N
slurred JJ N
speech NN N
and CC N
mild JJ N
cognitive JJ N
slowing NN N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
the DT N
between IN N
subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
5.85 CD N
, , N
d.f NN N
. . N

Simultaneously RB N
, , N
this DT N
intervention NN N
increased VBD o
interferon- JJ o
( ( N
IFN- NNP N
) ) N
level NN N
and CC N
unchanged JJ N
interleukin-4 JJ N
level NN N
, , N
as RB N
well RB N
as IN N
, , N
decreased VBD o
myeloperoxidase NN o
( ( N
MPO NNP N
) ) N
and CC N
interleukin-6 JJ N
levels NNS N
in IN N
plasma NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
showed VBD N
that IN N
artificial JJ N
recurrent NN N
caries NNS N
can MD N
be VB N
reduced VBN N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
a DT N
glass-ionomer JJ N
liner NN N
under IN N
amalgam JJ N
restorations NNS N
. . N

The DT N
potential JJ N
antioxidative JJ N
effect NN N
of IN N
the DT N
rye NN N
bran NN N
intervention NN N
was VBD N
investigated VBN N
by IN N
measuring VBG N
low-density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
susceptibility NN N
to TO N
copper VB N
oxidation NN N
ex FW N
vivo NN N
. . N

DISCUSSION NNP N
Data NNP N
suggest NN N
that IN N
PDS NNP N
suture NN N
can MD N
protect VB N
against IN N
development NN N
of IN N
aseptic JJ N
sternal JJ N
complications NNS N
following VBG N
median JJ N
sternotomy NN N
in IN N
high-risk JJ N
patients NNS p
with IN N
little JJ N
body NN N
mass NN N
. . N

This DT N
procedure NN N
is VBZ N
associated VBN N
with IN N
significantly RB N
less JJR N
blood JJ N
loss NN N
and CC N
shorter JJR N
hospitalization NN N
; : N
however RB N
, , N
it PRP N
is VBZ N
associated VBN N
with IN N
significantly RB N
longer RBR N
operating VBG N
time NN N
. . N

Ischaemia NNP N
reduction NN N
with IN N
iCSO NN N
was VBD N
greatest VBN N
at IN N
a DT N
CFI NNP N
of IN N
0.05-0.20 NNP N
, , N
whereas NN N
in IN N
the DT N
low JJ N
and CC N
high JJ N
CFI NNP N
range VBP N
the DT N
effect NN N
of IN N
iCSO NN N
was VBD N
absent JJ N
. . N

RESULTS NNP N
Clozapine NNP N
tended VBD N
to TO N
reduce VB N
chorea NN N
in IN N
neuroleptic JJ N
naive JJ N
patients NNS p
only RB N
( ( N
AIMS NNP N
) ) N
; : N
improvement NN N
seemed VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS p
receiving VBG N
higher JJR N
doses NNS N
of IN N
clozapine NN N
. . N

CONCLUSION NNP N
Lumbar NNP N
interlaminar JJ N
epidural JJ N
injections NNS N
of IN N
local JJ N
anesthetic JJ N
with IN N
or CC N
without IN N
steroids NNS N
provide VBP N
relief NN N
in IN N
a DT N
significant JJ N
proportion NN N
of IN N
patients NNS p
with IN N
lumbar JJ N
central JJ N
spinal JJ N
stenosis NN N
. . N

We PRP N
used VBD N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
TMS NNP N
) ) N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
single JJ N
doses NNS N
of IN N
amantadine NN N
on IN N
human JJ N
motor NN N
cortex NN N
excitability NN N
in IN N
normal JJ N
subjects NNS N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
placebo NN N
, , N
the DT N
egg NN N
negative JJ N
conversion NN N
rates NNS N
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
6.5 CD N
, , N
29.7 CD N
and CC N
7.9 CD N
% NN N
. . N

OBJECTIVE NN N
To TO N
observe VB N
the DT N
effect NN N
of IN N
Fuzheng NNP N
Yiliu NNP N
Granule NNP N
( ( N
FZYLG NNP N
) ) N
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
( ( N
NF-kappa NNP N
B NNP N
) ) N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
. . N

When WRB N
compared VBN N
against IN N
the DT N
control NN N
, , N
this DT N
regimen NNS N
produced VBD N
reduction NN N
of IN N
drain NN N
loss NN N
and CC N
total JJ N
blood NN N
loss NN N
, , N
whereas IN N
the DT N
IOPO NNP N
regimen NNS N
did VBD N
not RB N
. . N

BACKGROUND NNP N
Azimilide NNP N
dihydrochloride NN N
( ( N
azimilide IN N
) ) N
is VBZ N
an DT N
investigational JJ N
antiarrhythmic JJ N
drug NN N
that WDT N
has VBZ N
been VBN N
tested VBN N
in IN N
patients NNS p
with IN N
a DT N
variety NN N
of IN N
arrhythmias NN N
. . N

Our PRP$ N
observations NNS N
suggest VBP N
that IN N
a DT N
fat JJ N
high NN N
in IN N
stearic JJ N
acid NN N
might MD N
affect VB N
Lp NNP N
[ VB N
a DT N
] NN N
in IN N
a DT N
different JJ N
way NN N
than IN N
fats NNS N
high JJ N
in IN N
palmitic JJ N
and CC N
myristic+lauric JJ N
acid NN N
. . N

There EX N
were VBD N
no DT N
associations NNS N
between IN N
the DT N
risk NN N
of IN N
venous JJ N
thrombosis NN N
and CC N
total JJ N
cholesterol NN N
, , N
low JJ N
density NN N
lipoprotein-cholesterol NN N
, , N
high JJ N
density NN N
lipoprotein-cholesterol NN N
, , N
triglycerides NNS N
, , N
glucose NN N
or CC N
smoking NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
increases NNS o
in IN N
any DT N
other JJ N
reactogenicity NN N
events NNS N
or CC N
adverse JJ N
events NNS N
in IN N
the DT N
vaccine NN N
recipients NNS N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

An DT N
open JJ N
, , N
parallel JJ N
group NN N
comparison NN N
of IN N
quinapril NN N
and CC N
captopril NN N
, , N
when WRB N
added VBN N
to TO N
diuretic JJ N
therapy NN i
, , N
in IN N
the DT N
treatment NN N
of IN N
elderly JJ N
patients NNS p
with IN N
heart NN N
failure NN N
. . N

ACE NNP N
inhibitors NNS N
may MD N
cause VB N
a DT N
temporary JJ N
increase NN o
of IN N
the DT N
insulin NN N
sensitivity NN N
, , N
which WDT N
leads VBZ N
to TO N
an DT N
increased VBN o
risk NN N
of IN N
hypoglycemia NN N
under IN N
these DT N
conditions NNS N
. . N

However RB N
, , N
the DT N
time NN N
of IN N
recovery NN N
showed VBD N
a DT N
significant JJ N
decrease NN o
only RB N
in IN N
the DT N
LED NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
clonidine NN N
produces VBZ N
a DT N
dose-dependent JJ N
increase NN o
in IN N
the DT N
sweating NN N
threshold NN N
but CC N
does VBZ N
not RB N
reduce VB N
the DT N
gain NN N
of IN N
sweating NN N
. . N

A DT N
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
azithromycin NN i
for IN N
the DT N
treatment NN N
of IN N
chlamydia NN N
( ( N
Chlamydophila NNP N
felis RB N
) ) N
infection NN N
in IN N
cats NNS N
. . N

Additional JJ N
significant JJ N
toxic NN N
effects NNS N
included VBD N
nausea NN N
and CC N
vomiting NN N
, , N
hypotension NN N
, , N
leukopenia NN N
, , N
thrombocytopenia NN N
, , N
and CC N
evidence NN N
of IN N
hepatic JJ N
toxicity NN N
. . N

The DT N
prevalence NN N
of IN N
beta-lactamase-producing JJ N
organisms NNS N
in IN N
the DT N
pharynx NN N
, , N
however RB N
, , N
was VBD N
increased VBN o
after IN N
treatment NN N
with IN N
penicillin NN i
, , N
whereas IN N
no DT N
change NN N
was VBD N
noted VBN N
following VBG N
treatment NN N
with IN N
cefaclor NN N
. . N

AIM NNP N
To TO N
compare VB N
Desflurane NNP N
( ( N
D NNP N
) ) N
versus NN N
Sevoflurane NNP N
( ( N
S NNP N
) ) N
on IN N
hepatic JJ N
, , N
renal JJ N
functions NNS N
, , N
haemodynamics NNS N
and CC N
perioperative JJ N
course NN N
for IN N
cirrhotic JJ i
patients NNS p
undergoing VBG N
major JJ N
liver NN N
resection NN N
. . N

The DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
the DT N
plasma NN N
DNA NNP N
samples VBZ N
form VB N
middle-and-late JJ N
stage NN N
tumor NN N
patients NNS p
receiving VBG N
chemotherapy NN i
was VBD N
detected VBN N
before IN N
and CC N
after IN N
treatment NN N
using VBG N
nested JJ N
methylation-specific JJ N
polymerase NN N
chain NN N
reaction NN N
( ( N
MSP NNP N
) ) N
. . N

Aspirin NNP N
and CC N
nonsteroidal JJ N
antiinflammatory NN N
drugs NNS N
( ( N
NSAIDs NNP N
) ) N
damage VBP N
the DT N
gastroduodenal JJ N
epithelium NN N
by IN N
two CD N
mechanisms NNS N
: : N
direct JJ N
toxic NN N
effects NNS N
and CC N
effects NNS N
related VBN N
to TO N
the DT N
depletion NN N
of IN N
endogenous JJ N
prostaglandins NNS N
. . N

Four CD N
parameters NNS N
were VBD N
followed VBN N
: : N
serum-specific JJ N
IgE NNP N
against IN N
antigen NN N
E NNP N
, , N
total JJ N
blocking VBG N
antibody NN N
against IN N
antigen NN N
E NNP N
, , N
local JJ N
and CC N
systemic JJ N
reactions NNS N
to TO N
injection NN N
therapy NN i
, , N
and CC N
symptom NN N
score NN N
indices NNS N
. . N

A DT N
small JJ N
but CC N
significant JJ N
increase NN o
( ( N
relative JJ N
to TO N
prevaccination VB N
level NN N
) ) N
in IN N
response NN N
to TO N
MLSA NNP N
, , N
but CC N
not RB N
to TO N
BCG NNP N
or CC N
PPD NNP N
was VBD N
observed VBN N
in IN N
the DT N
non-BCG-vaccinated JJ N
groups NNS N
. . N

However RB N
, , N
whereas JJ N
pain NN N
scores NNS N
increased VBD o
during IN o
the DT N
day NN N
on IN N
twice-daily JJ N
CR NNP N
morphine NN N
( ( N
P=0.0108 NNP N
) ) N
, , N
they PRP N
remained VBD N
stable JJ N
on IN N
OAD NNP N
morphine NN N
. . N

OBJECTIVE NNP N
Previous NNP N
studies NNS N
have VBP N
suggested VBN N
that IN N
post-irradiation NN N
GH NNP N
insufficiency NN N
results NNS N
from IN N
a DT N
loss NN N
of IN N
GHRH NNP N
secretion NN N
, , N
since IN N
many JJ N
patients NNS p
were VBD N
able JJ N
to TO N
release VB N
GH NNP N
following VBG N
exogenous JJ N
GHRH NNP N
stimulation NN N
. . N

RESULTS NNP N
Regarding NNP N
chemical NN N
and CC N
clinical JJ N
pregnancy NN N
rates NNS N
, , N
the DT N
number NN N
of IN N
retrieved JJ N
oocytes NNS N
was VBD N
significantly RB N
higher JJR N
and CC N
OHSS NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
antagonist NN N
group NN N
. . N

INTERPRETATION NNP N
Prophylactic NNP N
VT NNP N
ablation NN N
before IN N
defibrillator NN N
implantation NN N
seemed VBD N
to TO N
prolong VB N
time NN N
to TO N
recurrence NN N
of IN N
VT NNP N
in IN N
patients NNS p
with IN N
stable JJ N
VT NNP N
, , N
previous JJ N
myocardial JJ N
infarction NN N
, , N
and CC N
reduced VBD N
LVEF NNP N
. . N

Analgesic JJ N
efficacy NN N
, , N
maternal JJ N
side NN N
effects NNS N
, , N
changes NNS N
in IN N
the DT N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
and CC N
duration NN N
of IN N
labor NN N
were VBD N
assessed VBN N
. . N

BACKGROUND NNP N
Omeprazole NNP N
and CC N
famotidine VB N
both DT N
reduce VB N
severity NN N
of IN N
exercise-induced JJ N
gastritis NN N
, , N
but CC N
administering VBG N
famotidine NN N
is VBZ N
easier JJR N
than IN N
administering VBG N
omeprazole JJ N
during IN N
racing VBG N
competition NN N
. . N

RATIONALE NNP N
Continuous NNP N
positive JJ N
airway NN N
pressure NN N
( ( N
CPAP NNP N
) ) N
use NN N
is VBZ N
associated VBN N
with IN N
reduced JJ N
motor NN N
vehicle NN N
accidents NNS N
in IN N
patients NNS p
with IN N
obstructive JJ N
sleep NN N
apnea NN N
( ( N
OSA NNP N
) ) N
. . N

The DT N
P-ESDM NNP N
group NN N
reported VBD N
no DT N
increase NN o
in IN N
parenting VBG N
stress NN N
, , N
whereas IN N
the DT N
Community NNP N
group NN N
experienced VBD N
an DT N
increase NN o
over IN N
the DT N
same JJ N
3-month JJ N
period NN N
. . N

Atrial JJ N
flutter NN N
cycle NN N
length NN N
and CC N
atrial JJ N
monophasic JJ N
action NN N
potential JJ N
duration NN N
recorded VBN N
from IN N
the DT N
right JJ N
atrium NN N
during IN N
atrial JJ N
flutter NN N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
following VBG N
infusion NN N
of IN N
ibutilide NN N
, , N
procainamide NN N
, , N
or CC N
placebo NN N
. . N

The DT N
pulsatility NN N
index NN N
and CC N
resistivity NN N
index NN N
increased VBD o
significantly RB o
only RB N
after IN N
the DT N
propofol NN N
infusion NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
YDJ NNP N
played VBD N
a DT N
role NN N
in IN N
clearing VBG N
HR-HPV NNP N
infection NN N
and CC N
reversing VBG N
the DT N
cervical JJ N
precancerous JJ N
changes NNS N
possibly RB N
through IN N
down-regulating NN N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
and CC N
lowering VBG N
the DT N
telomerase NN N
activation NN N
. . N

Results NNS N
of IN N
a DT N
phase NN N
I/II NNP N
trial NN N
of IN N
recombinant JJ N
human JJ N
granulocyte-macrophage NN N
colony-stimulating NN N
factor NN N
in IN N
very RB N
low JJ N
birthweight NN N
neonates NNS N
: : N
significant JJ N
induction NN N
of IN N
circulatory NN N
neutrophils NNS N
, , N
monocytes NNS N
, , N
platelets NNS N
, , N
and CC N
bone NN N
marrow NN N
neutrophils NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
alveolar JJ N
macrophages NNS N
from IN N
BAL NNP N
showed VBD N
a DT N
decrease NN o
in IN N
the DT N
ability NN N
to TO N
phagocytose VB N
unopsonized JJ N
Candida NNP N
albicans NNS N
and CC N
a DT N
decrease NN o
in IN N
superoxide JJ N
production NN N
. . N

We PRP N
investigated VBD N
long-term JJ N
effects NNS N
of IN N
calcium NN N
and CC N
vitamin NN N
D NNP N
on IN N
falls NNS N
and CC N
parameters NNS N
of IN N
muscle NN N
function NN N
in IN N
community-dwelling JJ N
elderly JJ N
women NNS N
and CC N
men NNS N
. . N

However RB N
, , N
inadequate JJ N
intake NN N
of IN N
vegetable JJ N
and CC N
fruit NN N
is VBZ N
a DT N
concern NN N
in IN N
Japan.We NNP N
therefore RB N
produced VBD N
a DT N
juice NN N
mixture NN N
of IN N
fresh JJ N
fruit NN N
and CC N
komatsuna NN N
( ( N
Brassica NNP N
rapa VBZ N
L. NNP N
var NN N
. . N

Relation NN N
of IN N
improvement NN N
in IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
with IN N
atorvastatin NN i
to TO N
reductions NNS N
in IN N
hospitalizations NNS N
for IN N
heart NN N
failure NN N
( ( N
from IN N
the DT N
Treating NNP N
to TO N
New NNP N
Targets NNP N
[ NNP N
TNT NNP N
] NNP N
study NN N
) ) N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanism NN N
of IN N
Feiyangqin NNP N
Rectum NNP N
Condensed VBD N
Liquid NNP N
( ( N
FRCL NNP N
) ) N
in IN N
treating VBG N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
. . N

BACKGROUND NNP N
Consumption NNP N
of IN N
soluble JJ N
dietary JJ N
fibre NN N
is VBZ N
correlated VBN N
with IN N
decreased JJ o
postprandial JJ N
glucose NN N
and CC N
insulin NN N
responses NNS N
and CC N
hence NN N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

Acute NNP N
intravenous JJ N
L-arginine JJ N
infusion NN N
decreases VBZ o
endothelin-1 JJ N
levels NNS N
and CC N
improves VBZ N
endothelial JJ N
function NN N
in IN N
patients NNS p
with IN N
angina JJ N
pectoris NN N
and CC N
normal JJ N
coronary JJ N
arteriograms NNS N
: : N
correlation NN N
with IN N
asymmetric JJ N
dimethylarginine NN N
levels NNS N
. . N

PURPOSE NNP N
The DT N
role NN N
of IN N
antiviral JJ N
prophylaxis NN N
in IN N
preventing VBG N
hepatitis NN N
B NNP N
virus NN N
( ( N
HBV NNP N
) ) N
reactivation NN N
before IN N
rituximab-based JJ N
chemotherapy NN i
in IN N
patients NNS p
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
is VBZ N
unclear JJ N
. . N

The DT N
absolute JJ N
risks NNS N
of IN N
retinopathy NN N
and CC N
nephropathy JJ N
were VBD N
proportional JJ N
to TO N
the DT N
mean NN N
glycosylated VBD N
hemoglobin NN N
( ( N
HbA NNP N
( ( N
1c CD N
) ) N
) ) N
level NN N
over IN N
the DT N
follow-up JJ N
period NN N
preceding VBG N
each DT N
event NN N
. . N

The DT N
plasma NN N
PLP NNP N
concentrations NNS N
in IN N
maternal JJ N
and CC N
cord JJ N
blood NN N
were VBD N
highly RB N
correlated VBN N
and CC N
indicated VBD N
a DT N
dependence NN N
of IN N
fetal JJ N
vitamin NN N
B6 NNP N
nutrition NN N
on IN N
maternal JJ N
circulating NN N
PLP NNP N
. . N

CONCLUSIONS NNP N
This DT N
Phase NNP N
I PRP N
study VBP N
demonstrated VBD N
that IN N
CS NNP N
vaginal JJ N
gel NN N
was VBD N
safe JJ N
, , N
well RB N
tolerated VBN N
and CC N
acceptable JJ N
by IN N
HIV-infected JJ N
women NNS N
and CC N
their PRP$ N
male JJ N
partners NNS N
. . N

We PRP N
previously RB N
described VBD N
significant JJ N
reductions NNS N
in IN N
resting VBG N
energy NN N
expenditure NN N
( ( N
REE NNP N
) ) N
, , N
as IN N
measured VBN N
by IN N
indirect JJ N
calorimetry NN N
, , N
over IN N
the DT N
course NN N
of IN N
HSCT NNP N
. . N

RESULTS VB N
The DT N
oral JJ N
formulation NN N
of IN N
cetirizine/PSE NN N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
superior NN N
to TO N
placebo VB N
in IN N
improving VBG N
nasal JJ N
obstruction NN N
during IN N
both DT N
challenges NNS N
. . N

Overexpression NN N
of IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
and CC N
its PRP$ N
cellular JJ N
receptor NN N
KDR NNP N
( ( N
VEGFR-2 NNP N
) ) N
in IN N
the DT N
bone NN N
marrow NN N
of IN N
patients NNS p
with IN N
acute JJ N
myeloid NN N
leukemia NN N
. . N

The DT N
pain NN N
threshold NN N
and CC N
the DT N
summation NN N
threshold NN N
to TO N
electrical JJ N
stimuli NNS N
and CC N
the DT N
summation NN N
threshold NN N
to TO N
heat VB N
stimuli NNS N
increased VBN o
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine JJ i
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
flap NN N
designs NNS N
in IN N
operation NN N
time NN N
, , N
maximum JJ N
interincisal NN N
opening NN N
, , N
and CC N
the DT N
number NN N
of IN N
analgesics NNS N
taken VBN N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
hypothesis NN N
tested VBD N
was VBD N
that IN N
low JJ N
doses NNS N
of IN N
propranolol NN i
could MD N
alter VB N
bone NN N
properties NNS N
and CC N
enhance NN N
orthotopic RB N
endochondral JJ N
bone NN N
formation NN N
. . N

CONCLUSIONS NNP N
The DT N
interobserver JJ N
agreement NN N
of IN N
PB NNP N
delineation NN N
was VBD N
moderate JJ N
but CC N
was VBD N
improved VBN N
by IN N
the DT N
DR. NNP N
Major NNP N
deviations NNS N
could MD N
be VB N
identified VBN N
for IN N
the DT N
majority NN N
of IN N
centers NNS N
. . N

However RB N
, , N
predose JJ N
and CC N
postdose JJ N
ALDO NNP N
and CC N
A-II NNP N
levels NNS N
did VBD N
not RB N
differ VB N
between IN N
each DT N
genotype NN N
subgroup NN N
at IN N
baseline NN N
or CC N
by IN N
enalapril JJ N
dose NN N
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

RESULTS VB N
The DT N
mean JJ N
average JJ N
difference NN N
in IN N
femoral JJ N
neck NN N
resection NN N
height NN N
was VBD N
0.84 CD N
mm NN N
when WRB N
using VBG N
the DT N
osteotomy NN N
guide NN N
and CC N
1.69 CD N
mm NN N
without IN N
the DT N
guide NN N
. . N

The DT N
increase NN o
in IN N
the DT N
number NN N
of IN N
decayed JJ N
and CC N
filled JJ N
root NN N
surfaces NNS N
after IN N
one CD N
year NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
halothane NN N
group NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN o
of IN N
the DT N
mean JJ N
cortisol NN N
and CC N
glucose NN N
levels NNS N
after IN N
the DT N
start NN N
of IN N
surgery NN N
. . N

BACKGROUND NNP N
Combinations NNP N
of IN N
infero-temporal JJ N
and CC N
either DT N
supero-nasal JJ N
( ( N
'inferior-superior JJ N
' '' N
) ) N
or CC N
medial JJ N
percaruncular NN N
( ( N
'inferior-medial JJ N
' '' N
) ) N
injections NNS N
are VBP N
popular JJ N
double-injection NN N
techniques NNS N
for IN N
establishing VBG N
peribulbar NN N
block NN N
analgesia NN N
. . N

Except IN N
for IN N
neutropenia NN N
and CC N
leukopenia NN N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
excess NN N
of IN N
grade NN N
3/4 CD N
adverse JJ N
events NNS N
compared VBN N
with IN N
CAF NNP N
. . N

The DT N
most RBS N
common JJ N
treatment NN N
emergent JJ N
adverse JJ N
event NN N
was VBD N
( ( N
mostly RB N
mild VBN N
) ) N
retrograde NN N
ejaculation NN N
( ( N
silodosin JJ N
28.1 CD N
% NN N
of IN N
patients NNS p
, , N
placebo RB N
0.9 CD N
% NN N
) ) N
. . N

BACKGROUND NNP N
Talc NNP N
has VBZ N
been VBN N
generally RB N
accepted VBN N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
sclerosant NN N
for IN N
chemical NN N
pleurodesis NN N
, , N
although IN N
the DT N
optimal JJ N
route NN N
of IN N
administration NN N
remains VBZ N
unclear JJ N
. . N

CONCLUSION NNP N
Pazopanib NNP N
demonstrated VBD N
significant JJ N
improvement NN N
in IN N
PFS NNP N
and CC N
tumor NN N
response NN N
compared VBN N
with IN N
placebo NN N
in IN N
treatment-naive JJ N
and CC N
cytokine-pretreated JJ N
patients NNS p
with IN N
advanced JJ N
and/or NNS N
metastatic JJ N
RCC NNP N
. . N

Importantly RB N
, , N
no DT N
seizures NNS N
occurred VBD N
in IN N
these DT N
ill JJ N
neonates NNS N
who WP N
may MD N
potentially RB N
be VB N
at IN N
greater JJR N
risk NN N
of IN N
tramadol JJ N
toxicity NN N
compared VBN N
with IN N
adults NNS N
. . N

It PRP N
is VBZ N
suggested VBN N
, , N
in IN N
the DT N
light NN N
of IN N
previous JJ N
findings NNS N
, , N
that IN N
the DT N
inhibitory JJ N
effect NN N
of IN N
ANF NNP N
represents VBZ N
a DT N
non-selective JJ N
action NN N
of IN N
ANF NNP N
on IN N
aldosterone NN N
release NN N
. . N

Long-term JJ N
effects NNS N
of IN N
ezetimibe-plus-statin JJ i
therapy NN i
on IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
levels NNS N
as IN N
compared VBN N
with IN N
double-dose JJ N
statin NN i
therapy NN i
in IN N
patients NNS p
with IN N
coronary JJ N
artery NN N
disease NN N
. . N

CONCLUSIONS NNP N
Topical NNP N
administration NN N
of IN N
diclofenac NN N
was VBD N
effective JJ N
in IN N
maintaining VBG N
mydriasis NN N
during IN N
vitrectomy NN N
and CC N
in IN N
reducing VBG N
postoperative JJ N
pain NN N
and CC N
anterior JJ N
chamber NN N
flare NN N
as IN N
determined VBN N
by IN N
slit-lamp JJ N
evaluations NNS N
. . N

Secondary JJ N
assessments NNS N
examined VBD N
the DT N
effects NNS N
of IN N
the DT N
PGE1 NNP N
infusion NN N
on IN N
plasma NN N
mediated VBN N
suppression NN N
of IN N
PMN NNP N
superoxide JJ N
production NN N
and CC N
loss NN N
of IN N
PMN NNP N
granule NN N
enzyme NN N
content NN N
. . N

CONCLUSION NNP N
Pretreatment NNP N
with IN N
minidose JJ N
succinylcholine JJ N
causes VBZ N
no DT N
greater JJR N
incidence NN N
of IN N
fasciculations NNS N
than IN N
pancuronium NN N
in IN N
rapid-sequence JJ N
intubation NN N
of IN N
head NN N
trauma NN N
patients NNS p
in IN N
an DT N
ED NNP N
setting NN N
. . N

Skull-base JJ N
invasion NN N
was VBD N
classified VBN N
according VBG N
to TO N
the DT N
incidence NN N
of IN N
each DT N
site NN N
( ( N
type JJ N
I PRP N
sites NNS N
inside IN N
pharyngobasilar JJ N
fascia NN N
and CC N
clivus NN N
vs. FW N
type NN N
II NNP N
sites VBZ N
outside IN N
pharyngobasilar JJ N
fascia NN N
) ) N
. . N

The DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
decreased VBN o
in IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

A DT N
significant JJ N
increase NN o
in IN N
endometritis NN N
and CC N
a DT N
trend NN N
toward IN N
an DT N
increase NN o
in IN N
neonatal JJ N
infections NNS N
and CC N
cesarean JJ N
section NN N
rates NNS N
were VBD N
noted VBN N
with IN N
treatment NN N
. . N

Prevention NN N
of IN N
postoperative JJ N
hypocalcemia NN N
with IN N
routine JJ N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplements NNS N
in IN N
patients NNS p
with IN N
differentiated JJ N
papillary JJ N
thyroid NN N
carcinoma NN N
undergoing JJ N
total JJ N
thyroidectomy NN N
plus CC N
central JJ N
neck NN N
dissection NN N
. . N

Dose NNP N
distribution NN N
curves NNS N
in IN N
cross-section NN N
and CC N
midsagittal JJ N
planes NNS N
are VBP N
shown VBN N
and CC N
calculations NNS N
or CC N
equivalent JJ N
doses NNS N
at IN N
various JJ N
selected VBN N
points NNS N
using VBG N
Ellis NNP N
's POS N
nominal JJ N
single-dose JJ N
formula NN N
are VBP N
tabulated VBN N
. . N

Safety NN N
analysis NN N
demonstrated VBD N
no DT N
dose-dependent JJ N
increase NN o
in IN N
adverse JJ N
events NNS N
, , N
and CC N
no DT N
drug-related JJ N
increase NN o
in IN N
daytime JJ N
somnolence NN N
was VBD N
observed VBN N
. . N

OBJECTIVE NNP N
Preliminary NNP N
evidence NN N
suggests VBZ N
that IN N
omega-3 JJ N
fatty JJ N
acids NNS N
may MD N
reduce VB N
hyperactivity NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

AIM IN N
The DT N
aim NN N
of IN N
study NN N
was VBD N
test JJ N
efficacy NN N
of IN N
accelerated JJ N
postoperative JJ N
radiotherapy NN i
-- : N
concomitant JJ N
boost NN N
in IN N
patients NNS p
with IN N
advanced JJ N
larynx NN N
cancer NN N
. . N

BACKGROUND NNP N
Intravenous NNP N
cangrelor NN N
, , N
a DT N
rapid-acting NN N
, , N
reversible JJ N
adenosine NN N
diphosphate NN N
( ( N
ADP NNP N
) ) N
receptor NN N
antagonist NN N
, , N
might MD N
reduce VB N
ischemic JJ N
events NNS N
during IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

The DT N
fee NN N
for IN N
the DT N
As NNP N
test NN N
was VBD N
US NNP N
$ $ N
0.28 CD N
, , N
higher JJR N
than IN N
the DT N
cost NN N
of IN N
the DT N
test NN N
( ( N
US NNP N
$ $ N
0.16 CD N
) ) N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
fracture NN N
resistances NNS N
of IN N
pulpless NN N
teeth NNS N
restored VBD N
with IN N
FRC NNP N
( ( N
Fiber NNP N
Reinforced NNP N
Composite NNP N
) ) N
posts NNS N
and CC N
three CD N
kinds NNS N
of IN N
resin NN N
core NN N
material NN N
. . N

HBV NNP N
DNA NNP N
, , N
HBeAg NNP N
and CC N
liver JJ N
functions NNS N
were VBD N
detected VBN N
at IN N
different JJ N
time NN N
points NNS N
, , N
and CC N
the DT N
number NN N
of IN N
cells NNS N
that WDT N
secrete VBP N
IFN-gamma NNP N
were VBD N
detected VBN N
by IN N
ELISPOT NNP N
. . N

In IN N
the DT N
normal JJ N
men NNS N
, , N
insulin NN N
administration NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decline NN N
of IN N
basal NN N
plasma NN N
glucagon NN N
and CC N
C-peptide JJ N
levels NNS N
and CC N
in IN N
a DT N
clear-cut JJ N
decrease NN o
in IN N
the DT N
arginine-induced JJ N
glucagon NN N
response NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Acute NNP N
intermittent NN N
porphyria NN N
is VBZ N
an DT N
autosomal JJ N
dominant JJ N
disorder NN N
caused VBN N
by IN N
deficient JJ N
activity NN N
of IN N
the DT N
third JJ N
enzyme NN N
in IN N
the DT N
haem NN N
biosynthetic JJ N
pathway NN N
, , N
porphobilinogen NN N
deaminase NN N
. . N

Hormone CD N
replacement NN N
therapy NN i
producing VBG N
an DT N
effect NN N
equivalent NN N
to TO N
higher JJR N
oestradiol JJ N
concentrations NNS N
is VBZ N
likely JJ N
to TO N
increase VB o
the DT N
risk NN N
of IN N
side NN N
effects NNS N
without IN N
conferring VBG N
any DT N
additional JJ N
benefit NN N
. . N

The DT N
effect NN N
of IN N
modified VBN N
eggs NNS N
and CC N
an DT N
egg-yolk NN N
based VBN N
beverage NN N
on IN N
serum NN N
lutein NN N
and CC N
zeaxanthin JJ N
concentrations NNS N
and CC N
macular JJ N
pigment NN N
optical JJ N
density NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

Alpha NNP N
interferon NN N
has VBZ N
shown VBN N
initial JJ N
promise NN N
in IN N
the DT N
treatment NN N
of IN N
low-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
( ( N
NHL NNP N
) ) N
, , N
especially RB N
with IN N
the DT N
nodular JJ N
form NN N
of IN N
the DT N
disease NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
myocardial JJ N
protection NN N
during IN N
ischemia NN N
was VBD N
sufficient JJ N
to TO N
prevent VB N
significant JJ N
reductions NNS N
of IN N
myocardial JJ N
ATP NNP N
and CC N
creatine VB N
phosphate JJ N
irrespective NN N
of IN N
supplementation NN N
with IN N
CP NNP N
. . N

Standard-dose JJ N
lansoprazole NN N
is VBZ N
more RBR N
effective JJ N
than IN N
high-dose JJ N
ranitidine NN N
in IN N
achieving VBG N
endoscopic NN N
healing NN N
and CC N
symptom JJ N
relief NN N
in IN N
patients NNS p
with IN N
moderately RB N
severe JJ N
reflux NN N
oesophagitis NN N
. . N

This DT N
inhibition NN N
was VBD N
incomplete JJ N
because IN N
AII NNP N
levels NNS N
increased VBD o
markedly RB o
when WRB N
captopril NN N
was VBD N
given VBN N
( ( N
no DT N
treatment NN N
effect NN N
: : N
p NN N
< VBZ N
0.37 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
incidence NN N
of IN N
fever NN N
, , N
physiotherapist JJ N
time NN N
, , N
or CC N
the DT N
number NN N
of IN N
treatments NNS N
. . N

BACKGROUND NNP N
Catheter NNP N
ablation NN N
( ( N
CA NNP N
) ) N
and CC N
minimally RB N
invasive JJ N
surgical JJ N
ablation NN N
( ( N
SA NNP N
) ) N
have VBP N
become VBN N
accepted JJ N
therapy NN i
for IN N
antiarrhythmic JJ N
drug-refractory JJ N
atrial JJ N
fibrillation NN N
. . N

RESULTS VB N
The DT N
infiltrating JJ N
growth NN N
pattern NN N
was VBD N
significantly RB N
associated VBN N
with IN N
histological JJ N
subtype NN N
and CC N
lymphovascular JJ N
invasion NN N
, , N
while IN N
high-grade JJ N
budding NN N
was VBD N
significantly RB N
associated VBN N
with IN N
tumor NN N
grade NN N
and CC N
lymphovascular JJ N
invasion NN N
. . N

Supplementation NN N
with IN N
n3 JJ N
fatty JJ N
acid NN N
ethyl NN N
esters NNS N
increases VBZ o
large JJ N
and CC N
small JJ N
artery NN N
elasticity NN N
in IN N
obese JJ N
adults NNS N
on IN N
a DT N
weight JJ N
loss NN N
diet NN N
. . N

BACKGROUND NNP N
6-mercaptopurine NN N
has VBZ N
been VBN N
a DT N
standard JJ N
component NN N
of IN N
long-term JJ N
continuing VBG N
treatment NN N
for IN N
childhood NN N
lymphoblastic JJ N
leukaemia NN N
, , N
whereas JJ N
6-thioguanine NN N
has VBZ N
been VBN N
mainly RB N
used VBN N
for IN N
intensification NN N
courses NNS N
. . N

BACKGROUND NNP N
B-type NNP N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
levels NNS N
are VBP N
reliably RB N
elevated VBN N
in IN N
patients NNS p
with IN N
congestive JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
and CC N
therefore RB N
helpful JJ N
in IN N
its PRP$ N
diagnosis NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
myelosuppression NN N
and CC N
alopecia NN N
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
B NNP N
, , N
neuropathy NN N
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
group NN N
A NNP N
. . N

The DT N
combination NN N
of IN N
dietary JJ N
sodium NN N
restriction NN N
with IN N
blockade NN N
of IN N
the DT N
renin NN N
system NN N
by IN N
an DT N
ACE NNP N
inhibitor NN N
is VBZ N
a DT N
particularly RB N
effective JJ N
way NN N
to TO N
improve VB N
blood NN N
pressure NN N
control NN N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
Helicobacter NNP N
pylori-infected JJ N
gastric JJ N
mucosa NN N
evolves VBZ N
through IN N
stages NNS N
of IN N
chronic JJ N
gastritis NN N
, , N
intestinal JJ N
metaplasia NN N
( ( N
IM NNP N
) ) N
, , N
glandular JJ N
atrophy NN N
( ( N
GA NNP N
) ) N
, , N
and CC N
dysplasia NN N
before IN N
carcinoma NN N
develops NNS N
. . N

Both DT N
types NNS N
of IN N
radiation NN N
techniques NNS N
lowered VBD N
the DT N
incidence NN N
of IN N
loco-regional JJ N
recurrences NNS N
significantly RB N
, , N
but CC N
had VBD N
no DT N
significant JJ N
influence NN N
on IN N
the DT N
overall JJ i
survival NN N
. . N

PATIENTS NNP N
Two CD N
hundred VBD N
and CC N
one CD N
functional JJ N
class NN N
I PRP N
and CC N
II NNP N
patients NNS p
with IN N
definite JJ N
or CC N
classic JJ N
rheumatoid NN N
arthritis NN N
, , N
previously RB N
untreated VBN N
with IN N
disease NN N
modifying VBG N
antirheumatic JJ N
drugs NNS N
. . N

No DT N
marked JJ N
differences NNS N
in IN N
follow-up JJ N
new JJ N
and CC N
recurrent JJ N
caries NNS N
were VBD N
found VBN N
between IN N
the DT N
stannous JJ N
fluoride JJ N
gel NN N
control NN N
and CC N
IFRS NNP N
groups NNS N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
speed NN N
of IN N
kill NN N
of IN N
selamectin NN i
, , N
imidacloprid JJ N
, , N
and CC N
fipronil- NN N
( ( N
S NNP N
) ) N
-methoprene NN N
against IN N
Ctenocephalides NNP N
felis JJ N
infestations NNS N
on IN N
cats NNS N
for IN N
one CD N
month NN N
following VBG N
a DT N
single JJ N
treatment NN N
was VBD N
evaluated VBN N
. . N

The DT N
small JJ N
red JJ N
berry NN N
, , N
wolfberry NN N
( ( N
Fructus NNP N
barbarum VBZ N
L. NNP N
; : N
Gou NNP N
Qi NNP N
Zi NNP N
and CC N
Kei NNP N
Tze NNP N
) ) N
, , N
is VBZ N
one CD N
of IN N
the DT N
richest JJS N
natural JJ N
sources NNS N
of IN N
zeaxanthin NN N
. . N

Of IN N
the DT N
four CD N
in IN N
active JJ N
treatment NN N
that WDT N
sustained VBD N
improvement NN N
, , N
three CD N
had VBD N
a DT N
maximum JJ N
dose NN N
of IN N
0.13-0.15 JJ N
mg/kg/day NN N
, , N
while IN N
those DT N
who WP N
regressed VBD N
had VBD N
doses NNS N
? . N
mg/kg/day NN N
. . N

GHBP NNP N
was VBD N
measured VBN N
by IN N
ligand-mediated JJ N
immunofunctional JJ N
assay NN N
, , N
and CC N
serum JJ N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
was VBD N
determined VBN N
by IN N
RIA NNP N
after IN N
acid-ethanol JJ N
extraction NN N
, , N
using VBG N
a DT N
truncated JJ N
IGF-I JJ N
analog NN N
as IN N
the DT N
radioligand NN N
. . N

Appetite NNP N
loss NN N
developed VBD N
in IN N
92.9 CD N
% NN N
and CC N
41.7 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
prevention NN N
effect NN N
was VBD N
clearly RB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

We PRP N
also RB N
documented VBD N
a DT N
decline NN N
in IN N
mid-arm JJ N
muscle NN N
area NN N
, , N
suggesting VBG N
depletion NN N
of IN N
muscle NN N
mass NN N
, , N
while IN N
triceps NNS N
skinfold RB N
, , N
a DT N
marker NN N
of IN N
fat JJ N
stores NNS N
, , N
was VBD N
unchanged JJ N
. . N

Conversely RB N
, , N
all DT N
HuG-CSF-treated JJ N
cats NNS N
developed VBD N
neutralizing VBG N
antibodies NNS N
, , N
suggesting VBG N
cross-reactive JJ N
antibodies NNS N
to TO N
endogenous JJ N
G-CSF NNP N
in IN N
a DT N
majority NN N
of IN N
the DT N
cases NNS N
with IN N
severe JJ N
neutropenia NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
diarrhea RB N
, , N
hypertension NN N
, , N
hair NN N
color NN N
changes NNS N
, , N
nausea NN N
, , N
anorexia NN N
, , N
and CC N
vomiting NN N
. . N

CONCLUSIONS NNP N
Bonding NNP N
resin NN N
or CC N
liquid JJ N
polish JJ N
coatings NNS N
significantly RB N
reduce VB N
early JJ N
biofilm NN N
formation NN N
, , N
which WDT N
in IN N
turn NN N
might MD N
affect VB N
the DT N
overall JJ i
plaque NN N
accumulation NN N
on IN N
provisional JJ N
restorations NNS N
. . N

Gastroesophageal NNP N
reflux NN N
and CC N
tracheal JJ N
aspiration NN N
in IN N
the DT N
thoracotomy JJ N
position NN N
: : N
should MD N
ranitidine VB N
premedication NN N
be VB N
routine JJ N
? . N
UNLABELLED JJ N
Aspiration NN N
of IN N
gastric JJ N
contents NNS N
may MD N
contribute VB N
to TO N
pulmonary JJ N
complications NNS N
after IN N
thoracotomy NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
an DT N
antacid NN N
dose NN N
should MD N
be VB N
so RB N
great JJ N
that IN N
it PRP N
binds VBZ N
secreted JJ N
acid NN N
before IN N
the DT N
dose NN N
leaves VBZ N
the DT N
stomach NN N
. . N

The DT N
cure NN N
rate NN N
in IN N
the DT N
treated JJ N
group NN N
was VBD N
obviously RB N
superior JJ N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
increased VBD o
ADMA NNP o
levels NNS N
play VBP N
a DT N
role NN N
in IN N
the DT N
abnormal JJ N
vascular JJ N
reactivity NN N
that WDT N
is VBZ N
observed VBN N
in IN N
patients NNS p
with IN N
CSX NNP N
. . N

The DT N
mechanism NN N
of IN N
action NN N
of IN N
vortioxetine NN N
is VBZ N
thought VBN N
to TO N
be VB N
related VBN N
to TO N
direct JJ N
modulation NN N
of IN N
serotonin NN N
( ( N
5-HT JJ N
) ) N
receptor NN N
activity NN N
and CC N
inhibition NN N
of IN N
the DT N
serotonin NN N
transporter NN N
. . N

Mitral JJ N
surgery NN N
allows VBZ N
an DT N
immediate JJ N
surgical JJ N
auricular NN N
remodeling NN N
and CC N
besides NNS N
in IN N
those DT N
cases NNS N
in IN N
which WDT N
sinus NN N
rhythm NN N
is VBZ N
reached VBN N
, , N
it PRP N
is VBZ N
followed VBN N
by IN N
a DT N
late JJ N
remodeling NN N
. . N

Significant JJ N
preservation NN N
of IN N
platelet NN N
numbers NNS N
and CC N
function NN N
were VBD N
shown VBN N
without IN N
significant JJ N
haemodynamic JJ N
problems NNS N
, , N
but CC N
no DT N
effect NN N
on IN N
cerebral JJ N
deficits NNS N
could MD N
be VB N
found VBN N
. . N

Corrected VBN N
TIMI NNP N
frame NN N
count NN N
was VBD N
furthermore RB N
lower JJR N
in IN N
the DT N
nicorandil NN N
group NN N
( ( N
21.0+/-9.1 JJ N
versus NN N
25.1+/-14.1 CD N
; : N
P=0.0009 NNP N
) ) N
. . N

Clinical JJ N
benefits NNS N
of IN N
concurrent JJ N
capecitabine NN N
and CC N
cisplatin NN i
versus NN N
concurrent NN N
cisplatin NN i
and CC N
5-flurouracil JJ N
in IN N
locally RB N
advanced JJ N
squamous JJ N
cell NN N
head NN N
and CC N
neck NN N
cancer NN N
. . N

Intradermal JJ N
injection NN N
of IN N
the DT N
C16:0 NNP N
and CC N
C18:0 NNP N
PAF NNP N
homologues NNS N
induced VBD N
dose-dependent JJ N
increases NNS o
in IN N
weal JJ N
volume NN N
and CC N
flare JJ N
area NN N
responses NNS N
which WDT N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

End NN N
points NNS N
were VBD N
patient JJ N
and CC N
graft NN N
survival NN N
, , N
acute NN N
and CC N
chronic JJ N
rejection NN N
, , N
and CC N
incidence NN N
of IN N
steroid JJ N
side NN N
effects NNS N
during IN N
the DT N
first JJ N
year NN N
after IN N
LT NNP N
. . N

Labetalol NNP i
exerted VBD N
a DT N
net JJ N
inhibitory NN N
effect NN N
on IN N
plasma NN N
renin NN N
activity NN N
, , N
which WDT N
was VBD N
related VBN N
to TO N
basal VB N
renin NN N
values NNS N
and CC N
was VBD N
already RB N
maximal JJ N
at IN N
the DT N
lowest JJS N
doses NNS N
. . N

In IN N
enalapril JJ N
group NN N
, , N
the DT N
reduced JJ N
values NNS N
of IN N
systolic JJ N
blood NN N
pressure NN N
and CC N
pulse JJ N
pressure NN N
in IN N
central JJ N
aorta NNS N
were VBD N
significantly RB N
larger JJR N
than IN N
those DT N
in IN N
brachial JJ N
artery NN N
. . N

Low-dose JJ N
growth NN N
hormone NN N
treatment NN N
with IN N
diet JJ N
restriction NN N
accelerates VBZ N
body JJ N
fat JJ N
loss NN N
, , N
exerts VBZ N
anabolic JJ N
effect NN N
and CC N
improves VBZ N
growth NN N
hormone NN N
secretory NN N
dysfunction NN N
in IN N
obese JJ N
adults NNS N
. . N

PURPOSE NN N
To TO N
compare VB N
the DT N
Eppendorf NNP N
PO2 NNP N
histograph NN N
and CC N
the DT N
alkaline NN N
comet NN N
assay VBP N
as IN N
methods NNS N
of IN N
measuring VBG N
tumor NN N
hypoxia NN N
in IN N
patients NNS p
with IN N
head-and-neck JJ N
squamous JJ N
cell NN N
carcinomas NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
overall JJ i
response NN N
rate NN N
[ NNP N
complete JJ N
clinical JJ N
response NN N
( ( N
CCR NNP N
) ) N
plus CC N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
] NN N
. . N

Mean NNP N
arterial JJ N
pressure NN N
and CC N
heart NN N
rate NN N
were VBD N
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
induction NN N
, , N
immediately RB N
after IN N
intubation NN N
and CC N
every DT N
minute NN N
for IN N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

The DT N
mean JJ N
volumes NNS N
of IN N
contrast NN N
agent NN N
used VBN N
and CC N
prehydration NN N
given VBN N
for IN N
each DT N
of IN N
the DT N
three CD N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.83 CD N
) ) N
. . N

Because IN N
DHA NNP N
is VBZ N
a DT N
highly RB N
unsaturated JJ N
fatty JJ N
acid NN N
, , N
it PRP N
could MD N
serve VB N
as IN N
a DT N
target NN N
for IN N
free-radical JJ N
induced JJ N
oxidation NN N
, , N
resulting VBG N
in IN N
increased VBN o
oxidative JJ N
stress NN N
. . N

Erythrocyte NNP N
deformability NN N
, , N
endothelin NN N
levels NNS N
, , N
and CC N
renal JJ N
function NN N
in IN N
cyclosporin-treated JJ N
renal JJ N
transplant NN N
recipients NNS N
: : N
effects NNS N
of IN N
intervention NN N
with IN N
fish JJ N
oil NN N
and CC N
corn NN N
oil NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
microcystic JJ N
or CC N
tarsal JJ N
conjunctiva JJ N
response NN N
, , N
lens VBZ N
comfort NN N
, , N
refractive JJ N
change NN N
, , N
or CC N
visual JJ N
acuity NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
L-arginine NNP N
and CC N
citrulline NN N
to TO N
patients NNS p
with IN N
HFpEF NNP N
improved VBD N
right JJ N
ventricular NN N
function NN N
by IN N
increasing VBG N
right JJ N
ventricular NN N
ejection NN N
fraction NN N
, , N
and CC N
probably RB N
decreasing VBG N
systolic JJ N
pulmonary JJ N
artery NN N
pressure NN N
. . N

Safety NN N
, , N
pharmacokinetics NNS N
and CC N
pharmocodynamics NNS N
of IN N
recombinant JJ N
human JJ N
porphobilinogen NN N
deaminase NN N
in IN N
healthy JJ N
subjects NNS N
and CC N
asymptomatic JJ N
carriers NNS N
of IN N
the DT N
acute JJ N
intermittent NN N
porphyria NNS N
gene NN N
who WP N
have VBP N
increased VBN o
porphyrin NN N
precursor NN N
excretion NN N
. . N

RESULTS NNP N
PROP NNP N
taste NN N
phenotype NN N
and CC N
taste NN N
receptor NN N
genotype NN N
were VBD N
not RB N
associated VBN N
with IN N
NRT NNP N
usage NN N
or CC N
sensory JJ N
response NN N
to TO N
NRT NNP N
, , N
after IN N
adjusting VBG N
for IN N
other JJ N
factors NNS N
. . N

Nasal NNP N
versus NN N
oronasal RB N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
masks NNS N
for IN N
obstructive JJ N
sleep JJ N
apnea NN N
: : N
a DT N
pilot NN N
investigation NN N
of IN N
pressure NN N
requirement NN N
, , N
residual JJ N
disease NN N
, , N
and CC N
leak NN N
. . N

Because IN N
these DT N
cells NNS N
may MD N
survive VB N
in IN N
transplant JJ N
recipients NNS N
for IN N
a DT N
long JJ N
time NN N
, , N
recipients NNS N
of IN N
blood NN N
stem NN N
cells NNS N
may MD N
be VB N
less JJR N
immunocompromised JJ N
than IN N
recipients NNS N
of IN N
marrow NN N
. . N

RESULTS NNP N
In IN N
response NN N
to TO N
insulin VB N
compared VBN N
with IN N
placebo NN N
, , N
we PRP N
found VBD N
a DT N
significant JJ N
CBF NNP N
decrease NN o
in IN N
the DT N
hypothalamus NN N
in IN N
both DT N
lean JJ N
and CC N
overweight/obese JJ N
participants NNS N
. . N

RESULTS VB N
The DT N
level NN N
of IN N
ACTH NNP N
and CC N
CORT NNP N
in IN N
plasma NN N
decreased VBN o
and CC N
lymphocyte JJ N
proliferative JJ N
reaction NN N
reduced VBN N
in IN N
patients NNS p
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
Across NNP N
studies NNS N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
children NNS N
receiving VBG N
LAIV NNP N
had VBD N
a DT N
? . N
2-fold JJ N
increase NN o
in IN N
strain-specific JJ N
IgA NNP N
ratio NN N
compared VBN N
with IN N
placebo NN N
recipients NNS N
. . N

Neither DT N
was VBD N
subjective JJ N
improvement NN N
significant JJ N
, , N
with IN N
29.2 CD N
% NN N
vs. FW N
27.3 CD N
% NN N
of IN N
the DT N
women NNS N
reporting VBG N
improvement NN N
in IN N
the DT N
amount NN N
of IN N
urinary JJ N
leakage NN N
. . N

Similar JJ N
challenge NN N
vehicle NN N
recipes NNS N
were VBD N
used VBN N
, , N
the DT N
only JJ N
difference NN N
being VBG N
the DT N
lower JJR N
fat JJ N
content NN N
( ( N
22.9 CD N
% NN N
compared VBN N
with IN N
31.5 CD N
% NN N
) ) N
. . N

Postoperative JJ N
respiratory NN N
mechanics NNS N
, , N
however RB N
, , N
were VBD N
not RB N
significantly RB N
improved VBN N
and CC N
delayed VBN N
respiratory NN N
depression NN N
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
. . N

Primary JJ N
endpoints NNS N
are VBP N
modelled VBN N
cardiovascular JJ N
risk NN N
at IN N
one CD N
year NN N
, , N
and CC N
cardiovascular JJ N
mortality NN N
and CC N
morbidity NN N
at IN N
five CD N
years NNS N
after IN N
diagnosis NN N
of IN N
diabetes NNS N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
is VBZ N
mediated VBN N
at IN N
least JJS N
in IN N
part NN N
via IN N
interruption NN N
of IN N
central JJ N
cholinergic NN N
muscarinic JJ N
transmission NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
maternal JJ N
vital JJ N
parameters NNS N
, , N
fetal JJ N
heart NN N
rate NN N
( ( N
FHR NNP N
) ) N
or CC N
Apgar NNP N
scores NNS N
between IN N
the DT N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Delivery NNP N
success NN N
rate NN N
, , N
maternal JJ N
perineal NN N
and CC N
vaginal JJ N
injuries NNS N
, , N
maternal JJ N
anaesthetic JJ N
requirements NNS N
, , N
neonatal JJ N
scalp NN N
and CC N
facial JJ N
injuries NNS N
. . N

Physiological JJ N
responses NNS N
, , N
such JJ N
as IN N
water NN N
turnover NN N
, , N
surface NN N
temperature NN N
, , N
and CC N
rectal JJ N
temperature NN N
, , N
as RB N
well RB N
as IN N
drinking VBG N
behavior NN N
of IN N
sheep NN N
were VBD N
also RB N
evaluated VBN N
. . N

CONCLUSIONS NNP N
The DT N
Er NNP N
, , N
Cr NNP N
: : N
YSGG NNP N
laser NN N
system NN N
is VBZ N
effective JJ N
for IN N
preparation NN N
of IN N
Class NNP N
I PRP N
, , N
III NNP N
and CC N
V NNP N
cavities NNS N
and CC N
resin NN N
restorations NNS N
are VBP N
retained VBN N
by IN N
lased JJ N
tooth NN N
surfaces NNS N
. . N

Functional JJ N
studies NNS N
between IN N
the DT N
cross-over NN N
periods NNS N
showed VBD N
flow-rate JJ N
values NNS N
close RB N
to TO N
normal JJ N
, , N
with IN N
an DT N
increase NN o
in IN N
residual JJ N
volume NN N
and CC N
functional JJ N
residual JJ N
capacity NN N
. . N

INTERPRETATION NNP N
AND CC N
CONCLUSIONS NNP N
Both NNP N
schemes NNS N
of IN N
chemotherapy NN i
followed VBN N
by IN N
radiotherapy NN i
produce VBP N
high JJ N
percentages NNS N
of IN N
CR NNP N
, , N
low JJ N
risk NN N
of IN N
relapse NN N
and CC N
an DT N
acceptable JJ N
toxicity NN N
. . N

BACKGROUND NNP N
2-Chloroprocaine JJ N
( ( N
2-CP JJ N
) ) N
used VBN N
for IN N
lumbar JJ N
epidural JJ N
anesthesia NN N
( ( N
LEA NNP N
) ) N
reportedly RB N
decreases VBZ o
the DT N
efficacy NN N
of IN N
epidural JJ N
morphine NN N
( ( N
EM NNP N
) ) N
administered VBD N
for IN N
post-cesarean JJ N
section NN N
( ( N
CS NNP N
) ) N
analgesia NN N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
no DT N
difference NN N
in IN N
the DT N
total JJ N
time NN N
for IN N
catheter NN N
placement NN N
, , N
because IN N
puncture NN N
was VBD N
performed VBN N
faster RB N
when WRB N
aided VBN N
by IN N
sonography NN N
. . N

Interruption NN N
of IN N
treatment NN N
in IN N
the DT N
TOTO NNP N
group NN N
did VBD N
not RB N
result VB N
in IN N
a DT N
better JJR N
gain NN N
in IN N
height JJ N
standard NN N
deviation NN N
score VBD N
H-SDSCA NNP N
when WRB N
compared VBN N
with IN N
the DT N
TTOO NNP N
group NN N
. . N

Increased VBN o
fibrinolytic JJ N
capacity NN N
was VBD N
indicated VBN N
by IN N
elevated JJ N
activity NN N
and CC N
reduced JJ N
antigen NN N
levels NNS N
of IN N
tissue NN N
plasminogen NN N
activator NN N
and CC N
reduced JJ N
activity NN N
and CC N
concentration NN N
of IN N
tissue NN N
plasminogen NN N
activator NN N
inhibitor NN N
. . N

Effects NNS N
of IN N
reducing VBG N
dietary JJ N
[ NN N
( ( N
Na+ NNP N
+ NNP N
K+ NNP N
) ) N
- : N
( ( N
Cl- JJ N
+ NNP N
SO4= NNP N
) ) N
] NN N
on IN N
the DT N
rate NN N
of IN N
calcium NN N
mobilisation NN N
by IN N
dairy NN N
cows NNS N
at IN N
parturition NN N
. . N

Both DT N
group NN N
A NNP N
and CC N
group NN N
GA NNP N
demonstrated VBD N
a DT N
preservation NN N
of IN N
circulating VBG N
AT-III NNP N
when WRB N
compared VBN N
to TO N
group NN N
C NNP N
; : N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
GA NNP N
. . N

Evaluations NNS N
included VBD N
Clinician NNP N
's POS N
Erythema NNP N
Assessment NNP N
( ( N
CEA NNP N
) ) N
, , N
Patient NNP N
's POS N
Self-Assessment JJ N
( ( N
PSA NNP N
) ) N
, , N
Chroma NNP N
Meter NNP N
measurements NNS N
and CC N
adverse JJ N
events NNS N
. . N

However RB N
, , N
DAS28 NNP N
remission NN N
rates NNS N
were VBD N
higher JJR N
( ( N
even RB N
when WRB N
using VBG N
the DT N
lower JJR N
cut NN N
point NN N
) ) N
than IN N
the DT N
SDAI NNP N
and CC N
CDAI NNP N
remission NN N
rates NNS N
. . N

The DT N
rate NN N
of IN N
surgical JJ N
reattachment NN N
of IN N
the DT N
retina NN N
was VBD N
found VBN N
to TO N
be VB N
similar JJ N
with IN N
either DT N
technique NN N
over IN N
a DT N
minimum JJ N
follow-up JJ N
period NN N
of IN N
one CD N
year NN N
. . N

CONCLUSIONS NNP N
Prophylactic NNP N
cranial JJ N
irradiation NN N
given VBN N
to TO N
patients NNS p
with IN N
small-cell JJ N
lung NN N
cancer NN N
in IN N
complete JJ N
remission NN N
decreases VBZ o
the DT N
risk NN N
of IN N
brain NN N
metastasis NN N
threefold VBD N
without IN N
a DT N
significant JJ N
increase NN o
in IN N
complications NNS N
. . N

On IN N
the DT N
ATEC NNP N
, , N
sensory/cognitive JJ N
awareness NN N
significantly RB N
improved VBN N
( ( N
p JJ N
= NNP N
0.0367 CD N
) ) N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Indomethacin NNP i
did VBD N
not RB N
reduce VB N
the DT N
frequency NN N
of IN N
dose JJ N
reductions NNS N
for IN N
toxic JJ N
side-effects NNS N
and CC N
did VBD N
not RB N
permit VB N
the DT N
administration NN N
of IN N
higher JJR N
interferon NN N
doses NNS N
. . N

Immunogenicity NN N
was VBD N
measured VBN N
by IN N
specific JJ N
IgG NNP N
( ( N
Mite NNP N
) ) N
and CC N
IgG4 NNP N
( ( N
Mite NNP N
) ) N
, , N
by IN N
antibody-blocking JJ N
properties NNS N
on IN N
basophil NN N
activation NN N
, , N
and CC N
by IN N
the DT N
T NNP N
cell NN N
subset NN N
transcription NN N
factors NNS N
Foxp3 NNP N
, , N
T-bet NNP N
, , N
and CC N
GATA-3 NNP N
. . N

DISCUSSION NNP N
Greater NNP N
vital JJ N
bone NN N
fill NN N
in IN N
the DT N
PUT NNP N
group NN N
may MD N
be VB N
attributable JJ N
to TO N
earlier RBR N
and CC N
greater JJR N
vascular JJ N
invasion NN N
of IN N
the DT N
carrier NN N
material NN N
. . N

Some DT N
case NN N
reports NNS N
mention NN N
that IN N
Spironolactone NNP N
, , N
a DT N
mineral JJ N
corticoid NN N
antagonist NN N
and CC N
aldosterone NN N
antagonist NN N
, , N
reduces NNS N
binging VBG N
in IN N
patients NNS p
with IN N
bulimia JJ N
nervosa NN N
. . N

The DT N
mean JJ N
satisfaction NN N
grading NN N
was VBD N
9.2 CD N
on IN N
a DT N
visual JJ N
analogue NN N
scale NN N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
8.1 CD N
in IN N
controls NNS N
( ( N
p=0.004 NN N
) ) N
. . N

Although IN N
the DT N
sedative JJ N
with IN N
IV NNP N
form NN N
might MD N
appear VB N
sooner NN N
, , N
IM NNP N
form NN N
of IN N
midazolam NN i
can MD N
be VB N
effectively RB N
used VBN N
in IN N
patient NN N
with IN N
limited JJ N
IV NNP N
access NN N
. . N

CONCLUSIONS NNP N
Unrecognized NNP N
overnight VBD N
hypoglycaemia NN N
in IN N
children NNS N
and CC N
adolescents NNS N
on IN N
pituitary JJ N
hormone NN N
replacement NN N
is VBZ N
uncommon JJ N
but CC N
BG NNP N
levels NNS N
quickly RB N
become VBP N
abnormal JJ N
when WRB N
treatment NN N
and CC N
meals NNS N
are VBP N
omitted VBN N
. . N

Although IN N
biopsy JJ N
fragmentation NN N
was VBD N
commoner NN N
with IN N
the DT N
suction NN N
needle NN N
, , N
the DT N
length NN N
and CC N
volume NN N
of IN N
the DT N
largest JJS N
core NN N
obtained VBN N
was VBD N
similar JJ N
to TO N
results NNS N
with IN N
the DT N
sheathed JJ N
needle NN N
. . N

OUTCOMES NNP N
MEASURED NNP N
Primary NNP N
study NN N
outcomes NNS N
were VBD N
changes NNS N
in IN N
systolic JJ N
blood NN N
pressure NN N
( ( N
SBP NNP N
) ) N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
instances NNS N
of IN N
tissue NN N
orientation NN N
loss NN N
in IN N
the DT N
scalpel NN N
or CC N
marker NN N
arms NNS N
, , N
nor CC N
were VBD N
there EX N
any DT N
visible JJ N
score NN N
mark NN N
scars NNS N
at IN N
follow-up NN N
. . N

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
In IN N
the DT N
placebo NN N
condition NN N
, , N
sleep JJ N
inertia NN N
was VBD N
manifested VBN N
as IN N
significantly RB N
impaired JJ N
psychomotor NN N
vigilance NN N
upon IN N
awakening VBG N
from IN N
the DT N
naps NNS N
. . N

Statistically RB N
significant JJ N
changes NNS N
in IN N
systolic JJ N
blood NN N
pressure NN N
, , N
mean JJ N
arterial JJ N
pressure NN N
, , N
and CC N
heart NN N
rate NN N
were VBD N
not RB N
considered VBN N
clinically RB N
significant JJ N
. . N

The DT N
PRL NNP N
response NN N
to TO N
TRH NNP N
was VBD N
lower JJR N
in IN N
both DT N
group NN N
I PRP N
and CC N
group NN N
II NNP N
obese VBZ N
men NNS N
than IN N
in IN N
normal JJ N
controls NNS N
and CC N
was VBD N
similar JJ N
between IN N
group NN N
I PRP N
and CC N
group NN N
II NNP N
. . N

CONCLUSIONS NNP N
Postprandial NNP N
glucose NN N
, , N
insulin NN N
and CC N
triglyceride JJ N
concentrations NNS N
are VBP N
influenced VBN N
by IN N
dietary JJ N
fibre-rich JJ N
meals NNS N
, , N
depending VBG N
on IN N
fibre NN N
source NN N
, , N
dose NN N
of IN N
soluble JJ N
and CC N
total JJ N
fibre NN N
and CC N
possibly RB N
gender NN N
. . N

Energy NNP N
intake NN N
and CC N
amount NN N
of IN N
carbohydrate NN N
ingested VBN N
by IN N
both DT N
groups NNS N
diminished VBD N
over IN N
the DT N
trial NN N
, , N
whereas IN N
the DT N
consumption NN N
of IN N
protein NN N
and CC N
fibre NN N
increased VBD o
and CC o
lipid JJ N
ingestion NN N
remained VBD N
unchanged JJ N
. . N

There EX N
was VBD N
a DT N
suggestion NN N
that IN N
ATRA NNP N
reduced VBD N
relapse NN N
in IN N
patients NNS p
with IN N
lower JJR N
MN1 NNP N
levels NNS N
, , N
but CC N
no DT N
significant JJ N
effect NN N
on IN N
overall JJ i
survival NN N
. . N

Split-course JJ N
therapy NN i
resulted VBD N
in IN N
a DT N
significantly RB N
better JJR N
survival NN N
rate NN N
in IN N
cases NNS N
of IN N
large JJ N
cell NN N
carcinoma NN N
but CC N
the DT N
number NN N
of IN N
cases NNS N
was VBD N
small JJ N
. . N

We PRP N
conclude VBP N
that DT N
desmopressin NN N
is VBZ N
not RB N
useful JJ N
in IN N
reducing VBG N
blood NN N
loss NN N
or CC N
blood NN N
product NN N
requirements NNS N
in IN N
patients NNS p
with IN N
excessive JJ N
immediate JJ N
postoperative JJ N
bleeding NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
antishivering VBG N
effect NN N
of IN N
clonidine NN N
results NNS N
from IN N
central JJ N
thermoregulatory JJ N
inhibition NN N
rather RB N
than IN N
a DT N
specific JJ N
peripheral JJ N
action NN N
on IN N
thermogenic JJ N
muscular JJ N
activity NN N
. . N

CONCLUSION NNP N
Sequential NNP N
erlotinib NN N
and CC N
docetaxel NN i
was VBD N
not RB N
more RBR N
effective JJ N
than IN N
docetaxel RB i
alone JJ N
as IN N
second-line JJ N
treatment NN N
for IN N
advanced JJ N
NSCLC NNP N
with IN N
wild-type JJ N
or CC N
unknown JJ N
EGFR NNP N
status NN N
. . N

Control NNP N
and CC N
experimental JJ N
tests NNS N
were VBD N
also RB N
performed VBN N
in IN N
seven CD N
male JJ N
patients NNS p
with IN N
subclinical JJ N
hypothyroidism NN N
and CC N
were VBD N
repeated VBN N
in IN N
the DT N
same JJ N
obese JJ N
subjects NNS N
after IN N
substantial JJ N
weight JJ N
loss NN N
. . N

Reduction NN N
in IN N
sympathetic JJ N
tone NN N
by IN N
CLO NNP N
resulted VBD N
in IN N
a DT N
decreased JJ o
tolerance NN N
to TO N
tilt VB N
in IN N
three CD N
out IN N
of IN N
eight CD N
controls NNS N
and CC N
in IN N
all PDT N
the DT N
NMS NNP N
patients NNS p
. . N

When WRB N
administered VBN N
intravenously RB N
, , N
antazoline JJ N
exerts VBZ N
a DT N
strong JJ N
antiarrhythmic JJ N
effect NN N
on IN N
supraventricular JJ N
arrhythmia NN N
, , N
especially RB N
on IN N
AF NNP N
, , N
facilitating VBG N
rapid JJ N
conversion NN N
to TO N
sinus VB N
rhythm NN N
. . N

Atenolol NNP i
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
. . N

ATP NNP N
infusion NN N
has VBZ N
been VBN N
found VBN N
to TO N
significantly RB N
inhibit VB N
loss NN N
of IN N
body NN N
weight NN N
, , N
fat JJ N
mass NN N
and CC N
fat-free JJ N
mass NN N
in IN N
patients NNS p
with IN N
advanced JJ N
lung NN N
cancer NN N
. . N

However RB N
, , N
the DT N
change NN N
in IN N
cortisol JJ N
level NN N
was VBD N
uncorrelated VBN N
with IN N
the DT N
change NN N
in IN N
report NN N
of IN N
acute JJ N
stress NN N
; : N
females NNS N
reported VBD N
higher JJR N
levels NNS N
of IN N
stress NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ibuprofen NN N
on IN N
gastric JJ N
mucosa NN N
and CC N
enzymes NNS N
involved VBN N
in IN N
gastroprotection NN N
in IN N
healthy JJ N
volunteers NNS N
. . N

Besides IN N
, , N
adverse JJ N
reactions NNS N
occurred VBD N
less RBR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
demonstrate VBP N
that IN N
ZES NNP N
has VBZ N
similar JJ N
clinical JJ N
safety NN N
and CC N
efficacy NN N
compared VBN N
with IN N
PES NNP N
in IN N
simple JJ N
and CC N
medium JJ N
complexity NN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

Rye NNP N
bran NN N
bread NN N
intake VB N
elevates NNS N
urinary JJ N
excretion NN N
of IN N
ferulic JJ N
acid NN N
in IN N
humans NNS N
, , N
but CC N
does VBZ N
not RB N
affect VB N
the DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
oxidation VB N
ex FW N
vivo FW N
. . N

CONCLUSIONS NNP N
Amiprilose NNP N
HCl NNP N
has VBZ N
significant JJ N
anti-inflammatory JJ N
activity NN N
and CC N
a DT N
favorable JJ N
safety NN N
profile NN N
when WRB N
used VBN N
as IN N
the DT N
sole JJ N
antirheumatic JJ N
therapy NN i
in IN N
patients NNS p
with IN N
active JJ N
rheumatoid NN N
arthritis NN N
. . N

We PRP N
previously RB N
demonstrated VBD N
that IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
production NN N
and CC N
mRNA JJ N
expression NN N
from IN N
stimulated VBN N
neonatal JJ N
mononuclear JJ N
cells NNS N
are VBP N
significantly RB N
less JJR N
than IN N
that DT N
from IN N
adult NN N
cells NNS N
. . N

PURPOSE NN N
To TO N
test VB N
the DT N
effect NN N
of IN N
valacyclovir NN N
alone RB N
and CC N
with IN N
aspirin NN N
on IN N
the DT N
asymptomatic JJ N
shedding NN N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS N
and CC N
saliva NN N
of IN N
healthy JJ N
individuals NNS N
. . N

Skillful NNP N
laser NN N
ablation NN N
can MD N
remove VB N
any DT N
volume NN N
of IN N
human JJ N
papillomavirus-associated JJ N
vulvar NN N
disease NN N
but CC N
can MD N
not RB N
prevent VB N
reactivation NN N
of IN N
the DT N
surrounding VBG N
latent JJ N
viral JJ N
reservoir NN N
during IN N
postoperative JJ N
healing NN N
. . N

BACKGROUND NNP N
Rapid NNP N
conversion NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
to TO N
sinus VB N
rhythm NN N
may MD N
be VB N
achieved VBN N
by IN N
the DT N
administration NN N
of IN N
class NN N
IA NNP N
, , N
IC NNP N
and CC N
III NNP N
antiarrhythmic JJ N
drugs NNS N
or CC N
vernakalant JJ N
hydrochloride NN N
. . N

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
intravenous JJ N
human JJ N
secretin NN i
is VBZ N
not RB N
effective JJ N
in IN N
changing VBG N
behaviour NN N
and CC N
communication NN N
in IN N
children NNS N
with IN N
ASD NNP N
when WRB N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
degree NN N
of IN N
ventilatory NN N
limitation NN N
, , N
as IN N
expressed VBN N
by IN N
the DT N
Ve/maximum NNP N
voluntary JJ N
ventilation NN N
ratio NN N
, , N
was VBD N
similar JJ N
in IN N
both DT N
conditions NNS N
in IN N
patients NNS p
with IN N
COPD NNP N
. . N

The DT N
mean JJ N
serum NN N
potassium NN N
was VBD N
elevated VBN N
by IN N
0.3 CD N
mmol/l NNS N
after IN N
addition NN N
of IN N
enalapril NN N
to TO N
the DT N
diuretic JJ N
treatment NN N
, , N
but CC N
none NN N
of IN N
the DT N
patients NNS p
developed VBD N
hyperkalaemia NN N
. . N

CONCLUSIONS VB N
A NNP N
dose NN N
of IN N
2,500 CD N
IU NNP N
enoxaparin/day NN N
does VBZ N
not RB N
cause VB N
more RBR N
bleeding JJ N
complications NNS N
than IN N
SH NNP N
5,000 CD N
IU NNP N
three CD N
times NNS N
daily RB N
when WRB N
used VBN N
to TO N
prevent VB N
thrombosis NN N
. . N

Loratadine NNP N
, , N
which WDT N
served VBD N
as IN N
a DT N
positive JJ N
control NN N
, , N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN N
for IN N
most JJS N
endpoints NNS N
, , N
validating VBG N
the DT N
study NN N
results NNS N
. . N

Propofol NNP N
decreased VBD o
mean JJ o
arterial JJ N
blood NN N
pressure NN N
and CC N
systemic JJ N
vascular JJ N
resistance NN N
immediately RB N
after IN N
IoA NNP N
but CC N
did VBD N
not RB N
change VB N
heart NN N
rate NN N
, , N
cardiac JJ N
output NN N
, , N
or CC N
oxygen NN N
delivery NN N
. . N

We PRP N
have VBP N
monitored VBN N
the DT N
effect NN N
of IN N
cyclosporin NN N
administered VBN N
during IN N
a DT N
planned JJ N
programme NN N
of IN N
third-party JJ N
blood NN N
transfusions NNS N
on IN N
the DT N
development NN N
of IN N
both DT N
cytotoxic JJ N
and CC N
anti-idiotypic JJ N
antibodies NNS N
. . N

PURPOSE NN N
To TO N
evaluate VB N
the DT N
additional JJ N
therapeutic JJ N
effect NN N
of IN N
single JJ N
intravitreal NN N
bevacizumab NN i
injection NN N
on IN N
standard JJ N
laser NN N
treatment NN N
in IN N
the DT N
management NN N
of IN N
proliferative JJ N
diabetic JJ N
retinopathy NN N
. . N

Clomiphene NNP N
citrate NN N
induction NN N
resulted VBD N
in IN N
higher JJR N
ovulation NN N
rates NNS N
and CC N
thicker NN N
endometrium NN N
in IN N
the DT N
metformin NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Some DT N
side-effects NNS N
, , N
such JJ N
as IN N
posttransplant JJ N
diabetes NNS N
mellitus NNS N
and CC N
probably RB N
some DT N
lipid JJ N
abnormalities NNS N
, , N
could MD N
rather RB N
be VB N
traced VBN N
to TO N
a DT N
higher JJR N
dose NN N
of IN N
steroids NNS N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
No NNP N
medical JJ N
treatment NN N
is VBZ N
available JJ N
for IN N
polycystic JJ N
liver NN N
disease NN N
, , N
a DT N
frequent JJ N
manifestation NN N
of IN N
autosomal-dominant JJ N
polycystic JJ N
kidney NN N
disease NN N
( ( N
ADPKD NNP N
) ) N
. . N

Thus RB N
, , N
endurance JJ N
physical JJ N
activity NN N
improves VBZ N
the DT N
fibrinolytic JJ N
risk NN N
factor NN N
profile NN N
by IN N
reducing VBG N
PAI-1 NNP N
while IN N
leaving VBG N
tPA JJ N
activity NN N
unaffected VBD N
, , N
independently RB N
of IN N
food NN N
composition NN N
. . N

The DT N
study NN N
showed VBD N
a DT N
relatively RB N
small JJ N
weight NN N
gain NN N
an DT N
average NN N
of IN N
0.9 CD N
kg NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
1.3 CD N
kg NN N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Intra-luminal NNP N
nicotine NN N
significantly RB N
reduces VBZ N
both DT N
smooth JJ N
muscle NN N
tone NN N
and CC N
contractile NN N
activity NN N
in IN N
the DT N
recto-sigmoid JJ N
colon NN N
in IN N
both DT N
normal JJ N
subjects NNS N
and CC N
patients NNS p
with IN N
UC NNP N
. . N

CONCLUSIONS NNP N
No NNP N
clear JJ N
benefit NN N
in IN N
terms NNS N
of IN N
response NN N
rates NNS N
, , N
median JJ N
TTP NNP N
or CC N
OS NNP N
was VBD N
shown VBN N
with IN N
the DT N
combination NN N
of IN N
TMZ NNP N
+ NNP N
CDDP NNP N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
SH NNP N
can MD N
alter VB N
autonomic JJ N
modulation NN N
of IN N
heart NN N
rate NN N
and CC N
cause NN N
increased VBD o
inhomogeneity NN o
of IN N
ventricular JJ N
recovery NN N
times NNS N
. . N

We PRP N
conclude VBP N
that DT N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
effectively RB N
reduced VBD N
the DT N
incidence NN N
and CC N
extent NN N
of IN N
postoperative JJ N
adhesions NNS N
, , N
even RB N
in IN N
patients NNS p
with IN N
severe JJ N
endometriosis NN N
. . N

CONCLUSION NNP N
FNB NNP N
with IN N
0.5 CD N
% NN N
bupivacaine NN N
provided VBN N
longer JJR N
time NN N
to TO N
first JJ N
analgesic JJ N
and CC N
lower RBR N
narcotic JJ i
requirements NNS N
after IN N
patellar JJ N
tendon NN N
graft NN N
ACL NNP N
reconstruction NN N
when WRB N
compared VBN N
to TO N
0.25 CD N
% NN N
bupivacaine NN N
. . N

DEBR NNP N
alone RB N
showed VBD N
reductions NNS N
in IN N
tooth DT N
mobility NN N
and CC N
PPD NNP N
and CC N
a DT N
significantly RB N
smaller JJR N
gain NN N
in IN N
CPAL NNP N
than IN N
in IN N
presplint NN N
teeth NNS N
treated VBN N
with IN N
BRG NNP N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
changes NNS N
in IN N
VE NNP N
were VBD N
accompanied VBN N
by IN N
decreases NNS o
in IN N
mean NN N
and CC N
peak JJ N
inspiratory NN N
and CC N
expiratory NN N
flow NN N
rates NNS N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
demonstrated VBD N
that IN N
this DT N
remifentanil JJ N
regimen NNS N
provided VBD N
significantly RB N
more RBR N
rapid JJ N
recovery NN N
and CC N
used VBD N
significantly RB N
less JJR N
propofol JJ N
compared VBN N
with IN N
the DT N
fentanyl JJ N
regimen NNS N
. . N

Effects NNS N
of IN N
supplementation NN N
of IN N
whole JJ N
corn NN N
germ NN N
on IN N
reproductive JJ N
performance NN N
, , N
calf JJ N
performance NN N
, , N
and CC N
leptin JJS i
concentration NN N
in IN N
primiparous JJ N
and CC N
mature JJ N
beef NN N
cows NNS N
. . N

CONCLUSIONS NNP N
Weight NNP N
gain NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
AN NNP N
subjects NNS N
and CC N
more RBR N
likely JJ N
to TO N
occur VB N
in IN N
younger JJR N
subjects NNS N
with IN N
a DT N
higher JJR N
baseline NN N
weight VBD N
z-score NN N
. . N

METHODS NNP N
Seventy-six JJ N
patients NNS p
with IN N
esophageal JJ N
gastric JJ N
carcinoma NN N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
FZYLG NNP N
group NN N
and CC N
the DT N
control NN N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
fenretinide NN N
showed VBD N
a DT N
lack NN N
of IN N
effect NN N
on IN N
the DT N
DNA NNP N
content NN N
distribution NN N
and CC N
the DT N
morphology NN N
of IN N
urothelial JJ N
cells NNS N
obtained VBN N
in IN N
serial JJ N
bladder NN N
washings NNS N
. . N

The DT N
effects NNS N
on IN N
platelet NN N
and CC N
endothelial JJ N
function NN N
, , N
either RB N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitors NNS N
or CC N
angiotensin NN N
receptor NN N
antagonists NNS N
, , N
are VBP N
still RB N
not RB N
well RB N
understood RB N
. . N

Ventilation NNP N
( ( N
Ve NNP N
) ) N
, , N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
blood NN N
pressure NN N
, , N
and CC N
muscle NN N
sympathetic JJ N
nervous JJ N
activity NN N
( ( N
MSNA NNP N
) ) N
data NNS N
were VBD N
continuously RB N
obtained VBN N
. . N

Long-term JJ N
use NN N
of IN N
Viozan NNP N
( ( N
sibenadet JJ N
HCl NNP N
) ) N
in IN N
patients NNS p
with IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
: : N
results NNS N
of IN N
a DT N
1-year JJ N
study NN N
. . N

Recombinant JJ N
human JJ N
TSH NNP N
has VBZ N
been VBN N
developed VBN N
to TO N
facilitate VB N
monitoring NN N
for IN N
thyroid JJ N
carcinoma NN N
recurrence NN N
or CC N
persistence NN N
without IN N
the DT N
attendant JJ N
morbidity NN N
of IN N
hypothyroidism NN N
seen VBN N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
. . N

This DT N
beneficial JJ N
effect NN N
of IN N
HBO NNP N
involves VBZ N
inhibition NN N
of IN N
inducible JJ N
nitric JJ N
oxide NN N
synthase NN N
( ( N
iNOS NN N
) ) N
expression NN N
and CC N
subsequent JJ N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
biosynthesis NN N
. . N

The DT N
immunological JJ N
trends NNS N
observed VBN N
in IN N
vitro JJ N
support NN N
an DT N
important JJ N
role NN N
for IN N
histamine NN N
in IN N
the DT N
induction NN N
of IN N
immunosuppression NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
response NN N
to TO N
the DT N
mitogen NN N
phytohemagglutinin NN N
. . N

Serum NNP N
concentrations NNS N
of IN N
hemoglobin NN N
levels NNS N
, , N
follicle-stimulating JJ N
hormone NN N
, , N
and CC N
liver RB N
enzymes NNS N
were VBD N
obtained VBN N
, , N
and CC N
endometrial JJ N
samples NNS N
, , N
symptoms NNS N
, , N
and CC N
menstrual JJ N
bleeding NN N
were VBD N
also RB N
assessed VBN N
. . N

NFV NNP N
pharmacokinetic JJ N
measurements NNS N
were VBD N
not RB N
statistically RB N
different JJ N
between IN N
the DT N
treatment NN N
groups NNS N
, , N
yet RB N
exposure NN N
to TO N
the DT N
NFV NNP N
metabolite NN N
, , N
M8 NNP N
, , N
was VBD N
significantly RB N
higher JJR N
in IN N
subjects NNS N
receiving VBG N
RTV NNP N
. . N

Intravitreal NNP N
bevacizumab NN i
injection NN N
was VBD N
well RB N
tolerated VBN N
and CC N
could MD N
be VB N
used VBN N
as IN N
primary JJ N
treatment NN N
in IN N
patients NNS p
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
perfused VBN N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
. . N

BACKGROUND NNP N
Mirror NNP N
therapy NN i
( ( N
MT NNP N
) ) N
and CC N
mesh JJ N
glove NN N
( ( N
MG NNP N
) ) N
afferent NN N
stimulation NN N
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
motor NN N
impairment NN N
after IN N
stroke NN N
. . N

Yet RB N
, , N
the DT N
effects NNS N
of IN N
MECC NNP N
on IN N
the DT N
intraoperative JJ N
microvascular JJ N
perfusion NN N
in IN N
comparison NN N
with IN N
conventional JJ N
extracorporeal JJ N
circulation NN N
( ( N
CECC NNP N
) ) N
have VBP N
not RB N
been VBN N
studied VBN N
so RB N
far RB N
. . N

In IN N
a DT N
prespecified JJ N
analysis NN N
of IN N
the DT N
LIFE-study NNP N
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
losartan NN N
and CC N
atenolol NN i
on IN N
cardiovascular JJ N
morbidity NN N
and CC N
mortality NN N
in IN N
diabetic JJ N
patients NNS p
. . N

Group NNP N
I PRP N
initially RB N
received VBD N
professional JJ N
mechanical JJ N
tooth-cleaning NN N
, , N
tongue-scraping NN N
, , N
chlorhexidine NN N
treatment NN N
, , N
and CC N
oral JJ N
hygiene NN N
instructions NNS N
concentrated VBD N
on IN N
the DT N
approximal JJ N
surfaces NNS N
most RBS N
colonized VBN N
by IN N
S. NNP N
mutans NNS N
. . N

Before IN N
and CC N
after IN N
treatment NN N
, , N
blood NN N
samples NNS N
were VBD N
collected VBN N
and CC N
the DT N
flow-mediated JJ N
dilation NN N
( ( N
FMD NNP N
) ) N
and CC N
isosorbide JJ N
dinitrate NN N
( ( N
ISDN NNP N
) ) N
-mediated VBD N
dilation NN N
of IN N
the DT N
brachial JJ N
artery NN N
were VBD N
performed VBN N
. . N

[ JJ N
Effects NNS N
of IN N
shuxuening VBG N
injection NN N
on IN N
the DT N
levels NNS N
of IN N
serum NN N
matrix RBS N
metalloproteinase-9 JJ N
and CC N
tissue JJ N
inhibitor NN N
of IN N
metalloproteinase-1 NN N
in IN N
acute NN N
exacerbated VBD N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
patients NNS p
] VBP N
. . N

PURPOSE NN N
To TO N
evaluate VB N
the DT N
treatment NN N
outcomes RB N
after IN N
guided VBN N
tissue NN N
regeneration NN N
( ( N
GTR NNP N
) ) N
with IN N
a DT N
bioabsorbable JJ N
membrane NN N
in IN N
Class NNP N
II NNP N
furcation NN N
defects NNS N
in IN N
mandibular JJ N
molars NNS N
. . N

Comparative NNP N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
eprinomectin JJ i
versus NN N
ivermectin NN i
, , N
and CC N
field NN N
efficacy NN N
of IN N
eprinomectin NN i
only RB N
, , N
for IN N
the DT N
treatment NN N
of IN N
chorioptic JJ N
mange NN N
in IN N
alpacas NN N
. . N

CONCLUSIONS NNP N
Both NNP N
IBMC NNP N
and CC N
PMMC NNP N
are VBP N
successful JJ N
means NNS N
of IN N
providing VBG N
relief NN N
from IN N
severe JJ N
mitral JJ N
stenosis NN N
with IN N
a DT N
gain NN N
in IN N
valve JJ N
area NN N
and CC N
reduction NN N
in IN N
transmitral JJ N
gradient NN N
. . N

Although IN N
amantadine NN N
has VBZ N
several JJ N
mechanisms NNS N
of IN N
action NN N
, , N
the DT N
NMDA-receptor NNP N
antagonism NN N
seems VBZ N
to TO N
be VB N
the DT N
most RBS N
relevant JJ N
effect NN N
on IN N
cortical JJ N
excitability NN N
. . N

This DT N
might MD N
result VB N
from IN N
potentiation NN N
of IN N
arterial JJ N
baroreflexes NNS N
, , N
but CC N
whether IN N
or CC N
not RB N
PUFA NNP N
enhance NN N
baroreflex NN N
function NN N
has VBZ N
never RB N
been VBN N
studied VBN N
in IN N
humans NNS N
. . N

BACKGROUND NNP N
Femoral NNP N
nerve NN N
block NN N
( ( N
FNB NNP N
) ) N
with IN N
varying VBG N
concentrations NNS N
of IN N
bupivacaine NN N
is VBZ N
often RB N
used VBN N
for IN N
postoperative JJ N
analgesia NN N
after IN N
anterior JJ N
cruciate NN N
ligament NN N
( ( N
ACL NNP N
) ) N
reconstruction NN N
. . N

CONCLUSIONS NNP N
Gemcitabine NNP N
plus CC N
erlotinib NN N
is VBZ N
more RBR N
effective JJ N
than IN N
gemcitabine VB N
alone JJ N
for IN N
treating VBG N
metastatic JJ N
pancreatic JJ N
cancer NN N
patients NNS p
, , N
especially RB N
those DT N
with IN N
EGFR NNP N
mutations NNS N
. . N

The DT N
numbers NNS N
of IN N
supplemental JJ N
injections NNS N
required VBN N
at IN N
each DT N
observation NN N
period NN N
and CC N
the DT N
total JJ N
volume NN N
of IN N
injectate NN N
required VBN N
to TO N
produce VB N
ocular JJ N
and CC N
lid JJ N
akinesia NN N
were VBD N
compared VBN N
. . N

MEASUREMENTS NNP N
Main NNP N
outcomes NNS N
were VBD N
12-month JJ N
changes NNS N
from IN N
baseline NN N
in IN N
bone NN N
formation NN N
and CC N
resorption NN N
markers NNS N
and CC N
bone NN N
mass NN N
measured VBD N
according VBG N
to TO N
quantitative JJ N
ultrasound JJ N
scanning NN N
. . N

There EX N
was VBD N
a DT N
poor JJ N
correlation NN N
between IN N
microscopy NN N
and CC N
culture NN N
of IN N
the DT N
bile NN N
for IN N
bacteria NNS N
and CC N
there EX N
was VBD N
no DT N
increase NN o
in IN N
sepsis NN N
when WRB N
bacteria NNS N
were VBD N
observed VBN N
on IN N
microscopy NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
impaired JJ N
metabolism NN N
of IN N
BK NNP N
induced VBN N
by IN N
ACE NNP N
inhibitors NNS N
may MD N
relate VB N
to TO N
the DT N
manifestation NN N
of IN N
cough NN N
in IN N
hypertensive JJ N
patients NNS p
receiving VBG N
ACE NNP N
inhibitors NNS N
. . N

The DT N
inhibitors NNS N
of IN N
cAMP-dependent JJ N
protein NN N
kinase NN N
( ( N
PKA NNP N
) ) N
and CC N
AMP-activated JJ N
protein NN N
kinase NN N
( ( N
AMPK NNP N
) ) N
blocked VBD N
acetate-induced JJ N
eNOS JJ N
phosphorylation NN N
in IN N
the DT N
early JJ N
and CC N
the DT N
late JJ N
phase NN N
respectively RB N
. . N

Bone NNP N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
of IN N
lumbar NN N
spine NN N
( ( N
L1-L4 NNP N
) ) N
and CC N
proximal JJ N
femur NN N
were VBD N
determined VBN N
using VBG N
dual JJ N
X-ray JJ N
absorptiometry NN N
at IN N
baseline NN N
and CC N
after IN N
one CD N
year NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
of IN N
CS NNP N
as IN N
a DT N
function NN N
of IN N
HOA NNP N
increase NN o
for IN N
the DT N
Planoscan NNP N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
four CD N
cases NNS N
( ( N
12.9 CD N
% NN N
) ) N
the DT N
sentinel NN N
lymph NN N
node NN N
was VBD N
the DT N
only JJ N
site NN N
of IN N
metastasis NN N
, , N
all DT N
of IN N
them PRP N
being VBG N
detected VBN N
by IN N
association NN N
of IN N
hematoxylin NN N
and CC N
eosin NN N
and CC N
immunohistochemical JJ N
examination NN N
. . N

CONCLUSIONS VB N
A DT N
decreased JJ o
incidence NN N
of IN N
nephrotoxicity NN N
provides VBZ N
evidence NN N
of IN N
a DT N
real JJ N
clinical JJ N
benefit NN N
to TO N
patient VB N
management NN N
in IN N
patients NNS p
with IN N
hematologic JJ N
malignancies NNS N
. . N

Short-term JJ N
effects NNS N
of IN N
prednisolone NN N
and CC N
dexamethasone NN N
on IN N
circulating VBG N
concentrations NNS N
of IN N
leptin NN i
and CC N
sex NN N
hormone-binding JJ N
globulin NN N
in IN N
children NNS N
being VBG N
treated VBN N
for IN N
acute JJ N
lymphoblastic JJ N
leukaemia NN N
. . N

Adverse JJ N
events NNS N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
previously RB N
with IN N
sumatriptan NNS N
and CC N
were VBD N
mostly RB N
mild JJ N
to TO N
moderate VB N
in IN N
intensity NN N
, , N
short-lived JJ N
, , N
and CC N
resolved VBD N
spontaneously RB N
. . N

However RB N
, , N
ER NNP N
status NN N
had VBD N
no DT N
effect NN N
on IN N
overall JJ i
survival NN N
( ( N
30.0 CD N
months NNS N
for IN N
CAF NNP N
v FW N
29.3 CD N
months NNS N
for IN N
CAFTH NNP N
) ) N
. . N

The DT N
degree NN N
of IN N
protection NN N
by IN N
heparin NN N
against IN N
adenosine-induced JJ N
bronchoconstriction NN N
was VBD N
not RB N
correlated VBN N
with IN N
that DT N
against IN N
methacholine-induced JJ N
bronchoconstriction NN N
( ( N
r JJ N
= NN N
0.60 CD N
, , N
NS NNP N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
We PRP N
recorded VBD N
the DT N
number NN N
of IN N
transfusions NNS N
, , N
the DT N
number NN N
of IN N
donor JJ N
exposures NNS N
, , N
and CC N
various JJ N
clinical JJ N
and CC N
physiologic JJ N
outcomes NNS N
. . N

In IN N
experimental JJ N
studies NNS N
, , N
activation NN N
of IN N
the DT N
inflammatory JJ N
regulator NN N
, , N
nuclear JJ N
factor NN N
kappa NN N
B NNP N
( ( N
NFlB NNP N
) ) N
, , N
contributes VBZ N
to TO N
endothelial JJ N
activation NN N
and CC N
reduced JJ N
nitric JJ N
oxide NN N
production NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
ozone NN N
and CC N
sodium NN N
ascorbate NN N
on IN N
resin-dentin JJ i
microtensile NN N
bond NN N
strength NN N
( ( N
? . N
) ) N
. . N

Amphotericin NNP i
B NNP N
in IN N
children NNS N
with IN N
malignant JJ N
disease NN N
: : N
a DT N
comparison NN N
of IN N
the DT N
toxicities NNS N
and CC N
pharmacokinetics NNS N
of IN N
amphotericin NN i
B NNP N
administered VBN N
in IN N
dextrose JJ N
versus NN N
lipid JJ N
emulsion NN N
. . N

In IN N
contrast NN N
, , N
YHO NNP N
not RB N
only RB N
increased VBD o
basal NN o
plasma NN N
NorEpi NNP N
levels NNS N
and CC N
MSNA NNP N
, , N
but CC N
also RB N
prevented VBD N
syncope NN N
in IN N
seven CD N
out IN N
of IN N
eight CD N
patients NNS p
. . N

Effects NNS N
of IN N
intravenous JJ N
iron NN N
combined VBN N
with IN N
low-dose JJ N
recombinant JJ N
human JJ N
erythropoietin NN i
on IN N
transfusion NN N
requirements NNS N
in IN N
iron-deficient JJ N
patients NNS p
undergoing VBG N
bilateral JJ N
total JJ N
knee NN N
replacement NN N
arthroplasty NN N
. . N

The DT N
study NN N
was VBD N
undertaken VBN N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prednisone- NN N
and CC N
triple-treatment JJ N
upon IN N
bone JJ N
mineral NN N
content NN N
( ( N
BMC NNP N
) ) N
and CC N
vitamin $ N
D NNP N
metabolism NN N
. . N

Nine NNP N
cases NNS N
not RB N
excluded VBN N
by IN N
central JJ N
pathology NN N
review NN N
were VBD N
PML-RAR NNP N
alpha JJ N
negative JJ N
, , N
and CC N
notably RB N
, , N
none NN N
of IN N
five CD N
of IN N
these DT N
cases NNS N
treated VBD N
with IN N
ATRA NNP N
achieved VBD N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
. . N

The DT N
combination NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
could MD N
provide VB N
a DT N
higher JJR N
degree NN N
of IN N
blockade NN N
of IN N
the DT N
renin-angiotensin NN N
system NN N
than IN N
either DT N
agent JJ N
alone RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
efficacy NN N
endpoints NNS N
were VBD N
intra-individual JJ N
differences NNS N
( ( N
test-reference NN N
) ) N
in IN N
mean JJ N
Hb NNP N
levels NNS N
and CC N
mean JJ N
weekly JJ N
dose/kg NN N
of IN N
body NN N
weight NN N
. . N

Fever NNP N
( ( N
> CD N
or CC N
=38.5 VB N
degrees NNS N
C NNP N
) ) N
and CC N
other JJ N
complications NNS N
( ( N
including VBG N
infections NNS N
) ) N
occurring VBG N
between IN N
admission NN N
and CC N
discharge NN N
( ( N
or CC N
death NN N
) ) N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Handgrip NNP N
and CC N
quadriceps JJ N
strength NN N
decreased VBD o
following VBG o
surgery NN N
, , N
but CC N
not RB N
to TO N
a DT N
significantly RB N
different JJ N
extent NN N
in IN N
the DT N
placebo NN N
and CC N
supplemented VBD N
groups NNS N
. . N

The DT N
difference NN N
in IN N
CR NNP N
rates NNS N
among IN N
both DT N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
even RB N
when WRB N
calculated VBN N
according VBG N
to TO N
the DT N
stage NN N
or CC N
histologic JJ N
grouping NN N
. . N

BACKGROUND IN N
The DT N
short-term JJ N
effects NNS N
of IN N
denopamine NN N
, , N
an DT N
orally RB N
available JJ N
beta-stimulant JJ N
, , N
on IN N
exercise NN N
capacity NN N
were VBD N
studied VBN N
in IN N
patients NNS p
with IN N
chronic JJ N
heart NN N
failure NN N
. . N

BACKGROUND NNP N
Sitaxsentan NNP N
is VBZ N
a DT N
highly RB N
selective JJ N
endothelin-A JJ N
receptor NN N
antagonist NN N
that WDT N
was VBD N
recently RB N
withdrawn VBN N
by IN N
the DT N
manufacturer NN N
because IN N
of IN N
a DT N
pattern NN N
of IN N
idiosyncratic JJ N
liver JJ N
injury NN N
. . N

BACKGROUND NNP N
Long-chain NNP N
n-3 JJ N
polyunsaturated VBD N
fatty JJ N
acids NNS N
have VBP N
variable JJ N
effects NNS N
on IN N
LDL NNP N
cholesterol NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
docosahexaenoic NN N
acid NN N
( ( N
DHA NNP N
) ) N
are VBP N
uncertain JJ N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
the DT N
profile NN N
of IN N
serum JJ N
phosphorus NN N
during IN N
titration NN N
and CC N
parathyroid NN N
hormone NN N
, , N
calcium NN N
, , N
and CC N
calcium NN N
x NN N
phosphorus NN N
( ( N
Ca NNP N
x NNP N
P NNP N
) ) N
product NN N
levels NNS N
. . N

FINDINGS NNP N
Weal NNP N
size NN N
, , N
and CC N
thus RB N
envenomisation NN N
, , N
increased VBD o
as IN o
the DT N
time NN N
from IN N
stinging VBG N
to TO N
removal NN N
of IN N
the DT N
sting NN N
increased VBD o
, , o
even RB N
within IN N
a DT N
few JJ N
seconds NNS N
. . N

Significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
duration NN N
of IN N
convalescence NN N
too RB N
( ( N
group NN N
A DT N
9.3+/-7.2 JJ N
days NNS N
; : N
group NN N
B NNP N
12.1+/-7 CD N
. . N

Furthermore RB N
, , N
there EX N
were VBD N
identical JJ N
shortening NN N
of IN N
inspiratory JJ N
time NN N
and CC N
prolongation NN N
of IN N
duty NN N
ratio NN N
( ( N
inspiratory JJ N
time/duration NN N
of IN N
a DT N
breath NN N
) ) N
in IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
alpha-Linolenic JJ N
acid JJ N
concentrations NNS N
in IN N
the DT N
plasma NN N
phospholipid JJ N
fraction NN N
increased VBD o
significantly RB o
in IN N
both DT N
groups NNS N
during IN N
the DT N
experimental JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

Blood NNP N
pressure NN N
reduction NN N
was VBD N
significant JJ N
in IN N
these DT N
all DT N
groups NNS N
and CC N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
blood NN N
pressure NN N
reduction NN N
among IN N
the DT N
groups NNS N
. . N

Similarly RB N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
digoxin NN N
pharmacokinetics NNS N
were VBD N
observed VBN N
when WRB N
digoxin NN N
was VBD N
administered VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
donepezil NN N
. . N

Pretreatment NN N
with IN N
ranitidine NN N
had VBD N
no DT N
effect NN N
on IN N
the DT N
disposition NN N
of IN N
intravenously RB N
administered VBN N
triazolam NN i
but CC N
significantly RB N
increased VBD o
the DT o
area NN N
under IN N
the DT N
serum JJ N
drug NN N
concentration-time JJ N
curve NN N
of IN N
oral JJ N
triazolam NN i
. . N

Unopposed VBN N
estrogen NN N
increases NNS o
total JJ N
plasma JJ N
factor NN N
VII NNP N
, , N
but CC N
not RB N
active JJ N
factor NN N
VII NNP N
-- : N
a DT N
short-term JJ N
placebo-controlled JJ N
study NN N
in IN N
healthy JJ N
postmenopausal NN N
women NNS N
. . N

CONCLUSION NNP N
The DT N
potential JJ N
role NN N
of IN N
finasteride NN N
on IN N
hematuria NNS N
related VBN N
to TO N
BPH NNP N
may MD N
be VB N
the DT N
suppressive JJ N
effect NN N
on IN N
MVD NNP N
in IN N
the DT N
suburethral JJ N
tissue NN N
of IN N
prostate NN N
. . N

We PRP N
compared VBN N
the DT N
periods NNS N
with IN N
and CC N
without IN N
Na+ NNP N
modeling NN N
: : N
no DT N
differences NNS N
were VBD N
found VBN N
in IN N
weight NN N
gained VBN N
interdialysis NN N
, , N
mean JJ N
blood NN N
pressure NN N
predialysis NN N
and CC N
postdialysis NN N
, , N
and CC N
hemoconcentration NN N
. . N

Both DT N
products NNS N
were VBD N
safe JJ N
, , N
with IN N
no DT N
serious JJ N
adverse JJ N
events NNS N
, , N
and CC N
in IN N
particular JJ N
, , N
no DT N
anaphylactic JJ N
reactions NNS N
or CC N
serum NN N
sickness NN N
was VBD N
reported VBN N
. . N

The DT N
InsuPatch NNP N
( ( N
IP NNP N
) ) N
is VBZ N
a DT N
novel JJ N
insulin NN N
infusion NN N
site NN N
warming VBG N
device NN N
developed VBD N
to TO N
accelerate VB N
insulin NN N
action NN N
by IN N
increasing VBG N
blood NN N
flow NN N
to TO N
the DT N
area NN N
of IN N
insulin NN N
absorption NN N
. . N

Furthermore RB N
, , N
temperature NN N
elevation NN N
is VBZ N
dependent JJ N
on IN N
both DT N
the DT N
duration NN N
and CC N
the DT N
intensity NN N
of IN N
the DT N
activity NN N
, , N
which WDT N
may MD N
eventually RB N
affect VB N
1RM CD N
performance NN N
. . N

Similarly RB N
, , N
the DT N
rate NN N
of IN N
change NN N
in IN N
aortic JJ N
PWV NNP N
was VBD N
significantly RB N
decreased VBN o
with IN N
the DT N
use NN N
of IN N
the DT N
high-flux JJ N
polyamide NN N
membrane NN N
. . N

CONCLUSIONS NNP N
Neridronate NNP N
is VBZ N
an DT N
effective JJ N
treatment NN N
in IN N
preventing VBG N
bone NN N
loss NN N
in IN N
the DT N
hip NN N
and CC N
lumbar NN N
spine NN N
in IN N
men NNS N
receiving VBG N
ADT NNP N
for IN N
prostate NN N
cancer NN N
. . N

After IN N
acute JJ N
salt NN N
loading NN N
, , N
borderline JJ N
subjects NNS N
with IN N
high JJ N
intralymphocytic JJ N
sodium NN N
showed VBD N
a DT N
significant JJ N
greater JJR N
natriuresis NN N
whereas RBR N
intralymphocytic JJ N
sodium NN N
increased VBD o
only RB o
in IN N
those DT N
subjects NNS N
in IN N
whom WP N
it PRP N
was VBD N
initially RB N
normal JJ N
. . N

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
imidapril NN N
on IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
patients NNS p
with IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

Overall JJ i
, , N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN N
CRP NNP N
, , N
IL-6 NNP N
, , N
IL-10 NNP N
, , N
and CC N
sTNF-R2 NNS N
were VBD N
observed VBN N
after IN N
the DT N
vitamin NN N
D NNP N
supplementation NN N
period NN N
. . N

Mean JJ N
blood NN N
flow NN N
through IN N
the DT N
brachial JJ N
artery NN N
was VBD N
1680+/-156 JJ N
and CC N
1450+/-221 JJ N
mL/min NNS N
three CD N
months NNS N
after IN N
surgery NN N
for IN N
the DT N
PTFE NNP N
and CC N
the DT N
BB-AVF NNP N
group NN N
, , N
respectively RB N
. . N

RESULTS VB N
The DT N
incidence NN N
of IN N
DIND NNP N
was VBD N
lower RBR N
in IN N
the DT N
pTBA NN N
group NN N
( ( N
P=0.30 NNP N
) ) N
and CC N
fewer JJR N
patients NNS p
required VBN N
therapeutic JJ N
angioplasty NN N
to TO N
treat VB N
DIND NNP N
( ( N
P=0.03 NNP N
) ) N
. . N

The DT N
poor JJ N
metabolizer NN N
demonstrated VBN N
in IN N
both DT N
oral JJ N
formulations NNS N
high JJ N
plasma NN N
concentrations NNS N
, , N
increased VBD o
AUCs NNP o
and CC N
prolonged VBD N
terminal JJ N
half-lives NNS N
as RB N
well RB N
as IN N
increased VBN o
renal JJ N
excretion NN N
of IN N
prajmalium NN N
bitartrate NN N
. . N

However RB N
, , N
median JJ N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
and CC N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
were VBD N
significantly RB N
longer RBR N
in IN N
patients NNS p
treated VBN N
with IN N
concomitant JJ N
chemoradiotherapy NN i
. . N

Mean NNP N
bactericidal NN N
activity NN N
in IN N
CSF NNP N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
ceftriaxone NN N
than IN N
in IN N
the DT N
conventional JJ N
treatment NN N
group NN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
therapy NN i
. . N

Both DT N
angiotensin JJ N
receptor NN N
blockers NNS N
( ( N
ARB NNP N
) ) N
and CC N
the DT N
DASH NNP N
( ( N
Dietary NNP N
Approaches NNP N
to TO N
Stop NNP N
Hypertension NNP N
) ) N
diet VBP N
effectively RB N
lower JJR N
blood NN N
pressure NN N
in IN N
hypertensive JJ N
patients NNS p
. . N

Lp NNP N
[ VBZ N
a DT N
] JJ N
concentrations NNS N
were VBD N
not RB N
associate JJ N
with IN N
changes NNS N
in IN N
tissue-plasminogen NN N
activator NN N
( ( N
t-PA JJ N
) ) N
activity NN N
, , N
factor NN N
VII NNP N
coagualant NN N
activity NN N
, , N
or CC N
plasma NN N
LDL NNP N
cholesterol NN N
. . N

Median JJ N
response NN N
duration NN N
, , N
time NN N
to TO N
treatment NN N
failure NN N
, , N
and CC N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
were VBD N
similar JJ N
in IN N
each DT N
arm NN N
. . N

CONCLUSION NNP N
Electro-acupuncture NN N
may MD N
reduce VB N
immunologic JJ N
damage NN N
caused VBN N
by IN N
chemotherapy NN i
, , N
thus RB N
it PRP N
can MD N
be VB N
used VBN N
as IN N
the DT N
auxiliary JJ N
therapy NN i
for IN N
patients NNS p
undergoing JJ N
chemotherapy NN i
. . N

Infrared NNP N
LED NNP N
irradiation NN N
applied VBD N
during IN N
high-intensity NN N
treadmill NN N
training VBG N
improves NNS N
maximal JJ N
exercise NN N
tolerance NN N
in IN N
postmenopausal JJ N
women NNS N
: : N
a DT N
6-month JJ N
longitudinal JJ N
study NN N
. . N

In IN N
vivo JJ N
skin JJ N
penetration NN N
studies NNS N
showed VBD N
that IN N
epidermal JJ N
exposure NN N
to TO N
bioelastic JJ N
thromboxane NN N
synthetase NN N
inhibitor NN N
( ( N
TSI NNP N
) ) N
matrix NN N
resulted VBD N
in IN N
local JJ N
tissue NN N
concentrations NNS N
of IN N
TSI NNP N
sufficient NN N
for IN N
thromboxane NN N
synthetase NN N
inhibition NN N
. . N

Levamisole RB N
appeared VBD N
to TO N
adversely RB N
affect VB N
CR NNP N
rates NNS N
in IN N
nodular JJ N
mixed JJ N
and CC N
nodular JJ N
large-cell NN N
lymphoma NN N
and CC N
CR NNP N
duration NN N
in IN N
patients NNS p
with IN N
unfavorable JJ N
histology NN N
ML NNP N
. . N

CONCLUSION NNP N
GnRH NNP N
antagonists NNS N
are VBP N
more RBR N
effective JJ N
, , N
safe JJ N
and CC N
a DT N
well RB N
tolerated JJ N
alternative NN N
to TO N
agonists NNS N
for IN N
assisted JJ N
reproduction NN N
cycles NNS N
in IN N
PCOS NNP N
patients NNS p
. . N

BMC NNP N
fell VBD N
rapidly RB N
and CC N
similarly RB N
in IN N
both DT N
groups NNS N
, , N
demonstrating VBG N
that IN N
the DT N
triple-treatment NN N
has VBZ N
no DT N
preventive JJ N
effect NN N
on IN N
corticosteroid NN N
induced VBN N
osteopenia NN N
. . N

Compared VBN N
with IN N
the DT N
intake NN N
of IN N
commercial JJ N
vegetable JJ N
juice NN N
, , N
the DT N
intake NN N
of IN N
fresh JJ N
fruit NN N
and CC N
B. NNP N
rapa NN N
juice NN N
is VBZ N
highly RB N
effective JJ N
in IN N
reducing VBG N
serum NN N
cholesterol NN N
. . N

No DT N
episodes NNS N
of IN N
apnoea NN N
were VBD N
recorded VBN N
in IN N
the DT N
remifentanil NN N
groups NNS N
, , N
while IN N
administration NN N
of IN N
fentanyl NN N
resulted VBN N
in IN N
apnoea NN N
in IN N
three CD N
animals NNS N
( ( N
one CD N
at IN N
each DT N
dose JJ N
level NN N
) ) N
. . N

Vaginal JJ N
tolerance NN N
tests NNS N
were VBD N
performed VBN N
with IN N
a DT N
new JJ N
potential JJ N
microbicidal NN N
and CC N
spermicidal JJ N
product NN N
, , N
an DT N
acid-buffering JJ N
vaginal JJ N
gel NN N
( ( N
Acidform NNP N
) ) N
without IN N
or CC N
with IN N
nonoxynol-9 JJ N
( ( N
N-9 NNP N
) ) N
. . N

BACKGROUND IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
dietary JJ N
intervention NN N
can MD N
inhibit VB N
the DT N
development NN N
of IN N
recurrent NN N
colorectal NN N
adenomas NN N
, , N
which WDT N
are VBP N
precursors NNS N
of IN N
most JJS N
large-bowel JJ N
cancers NNS N
. . N

In IN N
addition NN N
, , N
blood NN N
cardioplegic JJ N
solution NN N
samples NNS N
were VBD N
collected VBN N
in IN N
Group NNP N
I PRP N
from IN N
the DT N
lines NNS N
proximal NN N
and CC N
distal NN N
to TO N
the DT N
filter NN N
during IN N
first JJ N
and CC N
last JJ N
administration NN N
. . N

Free JJ N
estradiol NN N
decreased VBN o
in IN N
53.85 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
37.5 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

Results NNS N
also RB N
indicated VBD N
that IN N
children NNS N
reported VBD N
more RBR N
anxiety NN N
and CC N
exhibited VBD N
more RBR N
behavioral JJ N
distress NN N
in IN N
the DT N
CB NNP N
group NN N
than IN N
in IN N
the DT N
hypnosis NN N
group NN N
. . N

Previous JJ N
investigators NNS N
have VBP N
demonstrated VBN N
enhanced JJ N
detection NN N
of IN N
atrial JJ N
defects NNS N
by IN N
the DT N
dye-dilution NN N
technique NN N
after IN N
delivery NN N
of IN N
contrast NN N
medium NN N
into IN N
the DT N
inferior NN N
rather RB N
than IN N
the DT N
superior JJ N
vena NN N
cava NN N
. . N

Mollosil NNP N
Plus NNP N
showed VBD N
a DT N
performance NN N
comparable JJ N
to TO N
that DT N
of IN N
Molloplast NNP N
B NNP N
, , N
and CC N
the DT N
other JJ N
materials NNS N
had VBD N
slightly RB N
lower JJR N
performance NN N
especially RB N
in IN N
terms NNS N
of IN N
fungal JJ N
colonization NN N
. . N

Medium NN N
chain NN N
triglyceride JJ N
oil NN N
consumption NN N
as IN N
part NN N
of IN N
a DT N
weight JJ N
loss NN N
diet NN N
does VBZ N
not RB N
lead VB N
to TO N
an DT N
adverse JJ N
metabolic NN N
profile NN N
when WRB N
compared VBN N
to TO N
olive JJ N
oil NN N
. . N

The DT N
secondary JJ N
variables NNS N
showed VBD N
no DT N
notable JJ N
differences NNS N
with IN N
respect NN N
to TO N
lung NN N
function NN N
, , N
exacerbations NNS N
or CC N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

The DT N
levels NNS N
of IN N
the DT N
systolic NN N
and CC N
diastolic JJ N
pressures NNS N
at IN N
entry NN N
were VBD N
not RB N
predictive JJ N
of IN N
the DT N
dose NN N
of IN N
nifedipine NN N
required VBN N
for IN N
effective JJ N
blood NN N
pressure NN N
control NN N
. . N

After IN N
ovarian JJ N
stimulation NN N
with IN N
clomiphene NN N
and CC N
human JJ N
menopausal NN N
gonadotrophin NN N
( ( N
HMG NNP N
) ) N
, , N
the DT N
beneficial JJ N
effect NN N
of IN N
supporting VBG N
the DT N
luteal NN N
phase NN N
has VBZ N
never RB N
been VBN N
scientifically RB N
demonstrated VBN N
. . N

RESULTS VB N
The DT N
plasma JJ N
levels NNS N
of IN N
ADA NNP N
in IN N
patients NNS p
with IN N
chronic JJ N
schizophrenia NN N
who WP N
received VBD N
clozapine NN N
were VBD N
significantly RB N
higher JJR N
than IN N
patients NNS p
who WP N
received VBD N
haloperidol NN N
. . N

Inhibition NN N
of IN N
increased JJ o
central JJ N
sympathetic JJ N
vasoconstrictor NN N
outflow NN N
is VBZ N
one CD N
mechanism NN N
by IN N
which WDT N
nocturnal JJ N
CPAP NNP N
reduces NNS N
awake VBP N
BP NNP N
in IN N
HF NNP N
patients NNS p
with IN N
moderate JJ N
to TO N
severe VB N
OSA NNP N
. . N

The DT N
HA NNP N
gene NN N
of IN N
the DT N
H5N1 NNP N
subtype NN N
of IN N
avian JJ N
influenza NN N
virus NN N
( ( N
AIV NNP N
) ) N
was VBD N
inserted VBN N
into IN N
the DT N
pBCX NN N
vector NN N
and CC N
expressed VBD N
efficiently RB N
in IN N
Escherichia NNP N
coli NN N
BL21 NNP N
( ( N
DE3 NNP N
) ) N
. . N

Our PRP$ N
study NN N
shows VBZ N
that IN N
use NN N
of IN N
a DT N
small JJ N
dose NN N
of IN N
subconjunctival JJ N
5-FU JJ N
provides VBZ N
significantly RB N
lower JJR N
postoperative JJ N
intraocular JJ N
pressure NN N
than IN N
does VBZ N
no DT N
antimetabolite JJ N
treatment NN N
. . N

Therefore RB N
, , N
we PRP N
hypothesized VBD N
that IN N
enhanced VBD N
mTOR NNS N
signaling VBG N
might MD N
be VB N
responsible JJ N
for IN N
the DT N
greater JJR N
muscle NN N
protein NN N
synthesis NN N
when WRB N
leucine-enriched JJ N
EAA+CHOs NNP N
are VBP N
ingested VBN N
during IN N
postexercise JJ N
recovery NN N
. . N

These DT N
tests NNS N
showed VBD N
a DT N
total JJ N
failure NN N
of IN N
the DT N
benzimidazole NN N
, , N
imidothiazole NN N
, , N
macrocyclic JJ N
lactone NN N
and CC N
salicylanilide JJ N
groups NNS N
of IN N
anthelmintics NNS N
to TO N
control VB N
H. NNP N
contortus JJ N
infections NNS N
of IN N
sheep NN N
and CC N
goats NNS N
on IN N
all DT N
farms NNS N
. . N

PARTICIPANTS NNP N
Consecutive NNP N
postmenopausal NN N
women NNS N
( ( N
N=130 NNP N
; : N
mean JJ N
age NN N
? . N
SD NNP N
, , N
65.44 CD N
) ) N
with IN N
mild JJ N
CVI NNP N
. . N

OBJECTIVE NN N
To TO N
determine VB N
if IN N
any DT N
differences NNS N
exist VBP N
in IN N
healing NN N
and CC N
complications NNS N
between IN N
reamed VBN N
and CC N
unreamed JJ N
nailing NN N
in IN N
patients NNS p
with IN N
tibial JJ N
shaft NN N
fractures NNS N
. . N

The DT N
Ultracision NNP N
dissector NN N
has VBZ N
been VBN N
widely RB N
used VBN N
in IN N
laparoscopic NN N
surgery NN N
and CC N
is VBZ N
documented VBN N
to TO N
be VB N
safe JJ N
and CC N
fast JJ N
for IN N
cutting VBG N
and CC N
coagulating VBG N
tissue NN N
. . N

Use NNP N
of IN N
high-dose JJ N
cytarabine NN N
to TO N
enhance VB N
cisplatin JJ i
cytotoxicity-effects NNS N
on IN N
the DT N
response NN N
and CC N
overall JJ i
survival NN N
rates NNS N
of IN N
advanced JJ N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS p
. . N

PURPOSE NNP N
Sulindac NNP N
is VBZ N
a DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
effective JJ N
in IN N
regressing VBG N
adenomas NN N
in IN N
patients NNS p
with IN N
familial JJ N
adenomatous JJ N
polyposis NN N
( ( N
FAP NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN N
, , N
headache NN N
, , N
diarrhea NN N
and CC N
pyrexia NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

BACKGROUND NNP N
Studies NNPS N
all DT N
over IN N
the DT N
world NN N
reported VBD N
that IN N
smoking VBG N
relapses NNS N
occur VBP N
during IN N
the DT N
first JJ N
two CD N
weeks NNS N
after IN N
a DT N
quit NN N
date NN N
. . N

Treatment NN N
of IN N
vaginal JJ N
adenosis NN N
with IN N
the DT N
carbon NN N
dioxide NN N
laser NN N
did VBD N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
development NN N
of IN N
new JJ N
dysplasia NN N
in IN N
the DT N
DES-exposed JJ N
offspring NN N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
shear JJ N
bond NN N
strength NN N
of IN N
brackets NNS N
bonded VBN N
with IN N
resin-modified JJ N
glass-ionomer JJ N
cement NN N
( ( N
RMGIC NNP N
) ) N
using VBG N
various JJ N
methods NNS N
of IN N
enamel JJ N
conditioning NN N
. . N

The DT N
effects NNS N
and CC N
changes NNS N
of IN N
the DT N
indexes NNS N
including VBG N
renal JJ N
function NN N
, , N
hematuria NN N
, , N
proteinuria NN N
, , N
blood NN N
IgA NNP N
before IN N
and CC N
after IN N
treatment NN N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Single NNP N
and CC N
short-term JJ N
dosing NN N
with IN N
levocetirizine NN N
conferred VBN N
similar JJ N
improvements NNS N
in IN N
bronchial JJ N
hyper-responsiveness NN N
to TO N
AMP NNP N
challenge NN N
, , N
which WDT N
was VBD N
unrelated JJ N
to TO N
prechallenge VB N
airway RB N
calibre NN N
. . N

A DT N
prothrombin JJ N
time NN N
( ( N
PT NNP N
) ) N
ratio NN N
( ( N
patient JJ N
PT NNP N
divided VBN N
by IN N
control NN N
PT NNP N
) ) N
between IN N
1.3 CD N
and CC N
2.5 CD N
was VBD N
considered VBN N
to TO N
be VB N
in IN N
the DT N
therapeutic JJ N
range NN N
. . N

Before IN N
, , N
during IN N
, , N
and CC N
after IN N
the DT N
procedure NN N
, , N
infant JJ N
stress NN N
was VBD N
evaluated VBN N
by IN N
heart NN N
rate NN N
, , N
respiration NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
and CC N
transcutaneous JJ N
oxygen NN N
saturation NN N
. . N

The DT N
changes NNS N
between IN N
pre-treatment NN N
and CC N
the DT N
eight-week JJ N
follow-up NN N
also RB N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
group NN N
A NNP N
compared VBN N
with IN N
group NN N
B NNP N
( ( N
p=0.03 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
detection NN N
of IN N
lymph NN N
nodes NNS N
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.56 CD N
) ) N
. . N

A DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
increases NNS o
induced VBD N
sputum JJ N
inflammatory JJ N
markers NNS N
in IN N
non-asthmatic JJ N
subjects NNS N
with IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
: : N
correlation NN N
with IN N
plasma JJ N
interleukin-5 NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
enflurane NN N
and CC N
isoflurane NN N
on IN N
hepatic JJ N
venous JJ N
oxygen NN N
saturation NN N
( ( N
ShvO2 NNP N
) ) N
and CC N
splanchnic JJ N
oxygen NN N
( ( N
O2 NNP N
) ) N
extraction NN N
. . N

CONCLUSIONS NNP N
Trocar-guided NNP N
transvaginal JJ N
synthetic JJ N
mesh NN N
for IN N
advanced JJ N
anterior JJ N
POP NNP N
repair NN N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
anatomical JJ N
success NN N
rate NN N
for IN N
the DT N
anterior JJ N
compartment NN N
compared VBN N
with IN N
traditional JJ N
colporrhaphy NN N
. . N

Suggestive JJ N
but CC N
non-significant JJ N
results NNS N
were VBD N
found VBN N
in IN N
Vineland NNP N
Adaptive NNP N
Behaviour NNP N
Scales NNP N
( ( N
Communication NNP N
Sub-domain NNP N
) ) N
and CC N
ADOS NNP N
stereotyped VBD N
and CC N
restricted VBD N
behaviour NN N
domain NN N
. . N

BACKGROUND NNP N
Nicotine NNP N
may MD N
be VB N
of IN N
therapeutic JJ N
value NN N
in IN N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
, , N
although IN N
its PRP$ N
mechanism NN N
of IN N
action NN N
has VBZ N
not RB N
been VBN N
established VBN N
. . N

Upregulation NN N
of IN N
endogenous JJ N
synthesis NN N
of IN N
the DT N
major JJ N
protein NN N
on IN N
HDL NNP N
particles NNS N
, , N
apolipoprotein RB N
A-I NNP N
( ( N
apoA-I NN N
) ) N
, , N
represents VBZ N
a DT N
novel JJ N
approach NN N
to TO N
generation NN N
of IN N
new JJ N
HDL NNP N
particles NNS N
. . N

UNLABELLED NNP N
Breast NNP N
lymphoscintigraphy NN N
using VBG N
( ( N
99m CD N
) ) N
Tc-sulfur CD N
colloid NN N
( ( N
( ( N
99m CD N
) ) N
Tc-SC NN N
) ) N
is VBZ N
well RB N
established VBN N
in IN N
clinical JJ N
practice NN N
for IN N
staging VBG N
patients NNS p
with IN N
breast JJ N
carcinoma NN N
. . N

CONTEXT NNP N
Nerve NNP N
growth NN N
factor NN N
is VBZ N
a DT N
neurotrophic JJ N
factor NN N
that WDT N
promotes VBZ N
the DT N
survival NN N
of IN N
small JJ N
fiber NNP N
sensory JJ N
neurons NNS N
and CC N
sympathetic JJ N
neurons NNS N
in IN N
the DT N
peripheral JJ N
nervous JJ N
system NN N
. . N

Plasma NN N
AT NNP N
, , N
lipid-standardized JJ N
AT NNP N
, , N
and CC N
LDL NNP N
AT NNP N
levels NNS N
rose VBD N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
both DT N
the DT N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
groups NNS N
compared VBN N
with IN N
baseline NN N
. . N

The DT N
plasma NN N
triglyceride IN N
level NN N
and CC N
the DT N
triglyceride JJ N
distribution NN N
within IN N
the DT N
individual JJ N
lipoprotein NN N
fractions NNS N
were VBD N
not RB N
altered VBN N
in IN N
any DT N
consistent JJ N
manner NN N
by IN N
the DT N
addition NN N
of IN N
guar NN N
. . N

An DT N
experimental JJ N
model NN N
of IN N
HPAT NNP N
axis NN N
inhibited VBN N
by IN N
corticosterone NN N
( ( N
CORT NNP N
) ) N
was VBD N
established VBN N
to TO N
observe VB N
the DT N
effect NN N
of IN N
EB NNP N
on IN N
relevant JJ N
indices NNS N
of IN N
HPAT NNP N
axis NN N
. . N

The DT N
slight JJ N
increase NN o
in IN N
local JJ N
recurrence NN N
rate NN N
in IN N
transfused JJ N
patients NNS p
appears VBZ N
to TO N
be VB N
related VBN N
to TO N
complicated VBN N
, , N
in IN N
particular JJ N
rectal NN N
, , N
surgery NN N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
exogenous JJ N
bile NN N
acid NN N
therapy NN i
in IN N
patients NNS p
with IN N
poor JJ N
pouch JJ N
function NN N
after IN N
restorative JJ N
proctocolectomy NN N
for IN N
ulcerative JJ N
colitis NN N
. . N

In IN N
the DT N
placebo NN N
control NN N
group NN N
an DT N
increase NN o
in IN N
micronuclei NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
was VBD N
detected VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
period NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
rate NN N
of IN N
in IN N
vivo JJ N
platelet NN N
accumulation NN N
on IN N
Dacron NNP N
grafts NNS N
can MD N
be VB N
quantitated VBN N
and CC N
that IN N
ASA NNP N
+ NNP N
DPM NNP N
reduced VBD N
this DT N
rate NN N
in IN N
man NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
for IN N
the DT N
volume NN N
of IN N
drained JJ N
blood NN N
, , N
transfusion NN N
requirements NNS N
, , N
knee JJ N
motion NN N
or CC N
wound NN N
status NN N
. . N

Moreover RB N
, , N
the DT N
increased VBN o
level NN N
of IN N
HMGB1 NNP N
exhibited VBD N
in IN N
a DT N
late JJ N
stage NN N
of IN N
CCI NNP N
was VBD N
inhibited VBN N
by IN N
exogenous JJ N
overexpression NN N
of IN N
hIL-10 NN N
in IN N
the DT N
CCI NNP N
model NN N
. . N

The DT N
relapse-free JJ N
survival NN N
was VBD N
significantly RB N
improved VBN N
by IN N
60Co CD N
radiation NN N
in IN N
Stage NNP N
II NNP N
patients NNS p
, , N
but CC N
was VBD N
unaffected VBN N
by IN N
radiation NN N
in IN N
the DT N
other JJ N
subgroups NNS N
. . N

The DT N
intervention NN N
group NN N
showed VBD N
less JJR N
decline NN N
in IN N
function NN N
, , N
as IN N
measured VBN N
by IN N
disability NN N
days NNS N
and CC N
lower JJR N
scores NNS N
on IN N
the DT N
Health NNP N
Assessment NNP N
Questionnaire NNP N
. . N

Furthermore RB N
, , N
when WRB N
analyzed VBN N
by IN N
Ki67 NNP N
immunohistochemistry NN N
, , N
letrozole NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
tamoxifen NN N
in IN N
reducing VBG N
tumor NN N
proliferation NN N
( ( N
P=0.0009 NNP N
) ) N
. . N

Other JJ N
studies NNS N
found VBD N
that IN N
there EX N
is VBZ N
an DT N
aerobic JJ N
( ( N
in IN N
the DT N
gastrointestinal JJ N
tract NN N
) ) N
oxidation NN N
of IN N
ferrous JJ N
ion NN N
to TO N
ferric VB N
ion NN N
caused VBN N
in IN N
iron-paracetamol NN N
in IN N
vivo JJ N
reactions NNS N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
results NNS N
provide VBP N
evidence NN N
for IN N
increased JJ o
expression NN N
of IN N
VEGF/VEGFR-2 NNP N
of IN N
leukemic JJ N
blasts NNS N
and CC N
correlation NN N
with IN N
angiogenesis NN N
in IN N
the DT N
bone NN N
marrow NN N
of IN N
AML NNP N
patients NNS p
. . N

As IN N
in IN N
other JJ N
indications NNS N
, , N
the DT N
growth NN N
velocity NN N
in IN N
these DT N
patients NNS p
is VBZ N
more JJR N
marked JJ N
during IN N
the DT N
first JJ N
year NN N
of IN N
treatment NN N
and CC N
then RB N
decreases NNS o
. . N

Recombinant JJ N
human JJ N
granulocyte NN N
and CC N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
and CC N
GM-CSF NNP N
) ) N
administered VBD N
following VBG N
cytotoxic NN N
chemotherapy NNS i
have VBP N
a DT N
similar JJ N
ability NN N
to TO N
mobilize VB N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
trimetazidine NN N
and CC N
propranolol NN i
at IN N
the DT N
doses NNS N
studied VBN N
have VBP N
similar JJ N
efficacy NN N
in IN N
patients NNS p
with IN N
stable JJ N
angina JJ N
pectoris NN N
. . N

BACKGROUND NNP N
Although IN N
indomethacin NN i
is VBZ N
effective JJ N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
( ( N
HO NNP N
) ) N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
, , N
side NN N
effects NNS N
are VBP N
frequently RB N
observed VBN N
. . N

CONCLUSION NNP N
Further NNP N
evaluation NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
validity NN N
of IN N
the DT N
observed JJ N
reduction NN N
in IN N
infection-related JJ N
deaths NNS N
in IN N
patients NNS p
treated VBN N
with IN N
interferon NN N
gamma NN N
. . N

A DT N
low JJ N
mean JJ N
8-oxo-dG JJ N
concentration NN N
is VBZ N
seen VBN N
in IN N
DNA NNP N
of IN N
women NNS N
from IN N
all DT N
five CD N
countries NNS N
, , N
and CC N
of IN N
men NNS N
from IN N
France NNP N
and CC N
Spain NNP N
. . N

In IN N
peripheral JJ N
blood NN N
monocytes NNS N
, , N
human JJ N
leukocyte VBD N
antigen-DR JJ N
expression NN N
was VBD N
only RB N
slightly RB N
depressed VBN N
, , N
whereas NNS N
in IN N
vitro JJ N
phagocytosis NN N
and CC N
the DT N
monocyte-activating JJ N
cytokine JJ N
interleukin-12 NN N
increased VBD o
. . o

The DT N
incidence NN N
of IN N
degeneration NN N
and CC N
necrosis NN N
in IN N
the DT N
squamous JJ N
epithelium NN N
adjacent NN N
to TO N
carcinoma VB N
was VBD N
higher RBR N
in IN N
the DT N
chemotherapy NN i
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

RESULTS JJ N
Complication NNP N
rate NN N
was VBD N
5.26 CD N
% NN N
for IN N
group NN N
A NNP N
( ( N
none NN N
needed VBN N
conversion NN N
) ) N
and CC N
4.68 CD N
% NN N
for IN N
group NN N
B NNP N
. . N

BACKGROUND NNP N
Unsedated VBD N
transnasal JJ N
endoscopy NN N
( ( N
TNE NNP N
) ) N
may MD N
be VB N
safer JJR N
and CC N
less RBR N
expensive JJ N
than IN N
standard JJ N
endoscopy NN N
( ( N
SE NNP N
) ) N
for IN N
detecting VBG N
Barrett NNP N
's POS N
esophagus NN N
( ( N
BE NNP N
) ) N
. . N

Polyunsaturated VBN N
fatty JJ N
acids NNS N
arachidonic JJ N
acid NN N
( ( N
ARA NNP N
) ) N
and CC N
docosahexaenoic JJ N
acid NN N
( ( N
DHA NNP N
) ) N
may MD N
have VB N
key JJ N
role NN N
in IN N
brain NN N
network NN N
maturation NN N
. . N

Renal JJ N
function NN N
was VBD N
assessed VBN N
by IN N
measurement NN N
of IN N
the DT N
glomerular JJ N
filtration NN N
rate NN N
( ( N
single JJ N
bolus IN N
51Cr-EDTA JJ N
technique NN N
) ) N
and CC N
by IN N
the DT N
urinary JJ N
albumin JJ N
excretion NN N
rate NN N
( ( N
radioimmunoassay NN N
) ) N
. . N

The DT N
pattern NN N
of IN N
ipilimumab-induced JJ N
antibody NN N
titers NNS N
to TO N
microbial JJ N
flora NN N
and CC N
the DT N
histologic NN N
features NNS N
and CC N
location NN N
of IN N
the DT N
inflammation NN N
were VBD N
distinct JJ N
from IN N
classic JJ N
IBD NNP N
. . N

A DT N
similar JJ N
pattern NN N
of IN N
increased VBN o
skin NN N
reaction NN N
toxicity NN N
occurred VBD N
with IN N
both DT N
study NN N
creams NNS N
compared VBN N
with IN N
the DT N
dry JJ N
powder NN N
regimen NNS N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
cryotherapy NN i
, , N
the DT N
diode NN N
laser NN N
was VBD N
more RBR N
convenient JJ N
, , N
technically RB N
easier JJR N
to TO N
administer VB N
, , N
and CC N
better RB N
tolerated VBN N
by IN N
the DT N
patient NN N
. . N

Effects NNS N
of IN N
a DT N
low-salt JJ N
diet NN N
and CC N
of IN N
acute JJ N
salt NN N
loading VBG N
on IN N
blood NN N
pressure NN N
and CC N
intralymphocytic JJ N
sodium NN N
concentration NN N
in IN N
young JJ N
subjects NNS N
with IN N
borderline JJ N
hypertension NN N
. . N

RESULTS JJ N
Freedom-from-treatment-failure NNP N
( ( N
FFTF NNP N
) ) N
and CC N
survival NN N
( ( N
SV NNP N
) ) N
curves VBZ N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
20- JJ N
, , N
30- JJ N
, , N
and CC N
40-Gy JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
ropinirole NN N
is VBZ N
more RBR N
effective JJ N
than IN N
levodopa JJS N
SR NNP N
in IN N
the DT N
treatment NN N
of IN N
RLS NNP N
in IN N
patients NNS p
on IN N
chronic JJ N
hemodialysis NN N
. . N

Under IN N
OT NNP N
activation NN N
differences NNS N
between IN N
genotypes NNS N
were VBD N
more RBR N
evident JJ N
( ( N
though IN N
not RB N
statistically RB N
significantly RB N
increased VBN o
) ) N
and CC N
RT NNP N
were VBD N
accelerated VBN N
in IN N
homozygotic JJ i
risk NN N
allele NN N
carriers NNS N
. . N

CONCLUSION NN N
In IN N
this DT N
population NN N
, , N
the DT N
efficacy NN N
and CC N
tolerability NN N
observed VBN N
with IN N
amlodipine JJ N
maleate NN N
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
with IN N
amlodipine JJ N
besylate NN N
. . N

Fulvestrant NNP N
continued VBD N
to TO N
be VB N
well RB N
tolerated VBN N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
lower JJR N
incidence NN N
of IN N
joint JJ N
disorders NNS N
compared VBN N
with IN N
anastrozole NN N
( ( N
P NNP N
= NNP N
0.0234 CD N
) ) N
. . N

Increases NNS o
in IN N
serum NN N
PSA NNP N
in IN N
men NNS N
receiving VBG N
dutasteride NN N
should MD N
be VB N
considered VBN N
suspicious JJ N
and CC N
serial JJ N
PSA NNP N
measurements NNS N
should MD N
be VB N
used VBN N
to TO N
evaluate VB N
changes NNS N
from IN N
nadir NN N
. . N

OBJECTIVES NNP N
To TO N
present VB N
clinical JJ N
evidence NN N
with IN N
botulinum NN N
toxin NN N
A NNP N
( ( N
BTX-A NNP N
) ) N
suggesting VBG N
an DT N
antinociceptive JJ N
role NN N
in IN N
patients NNS p
with IN N
interstitial JJ N
cystitis NN N
( ( N
IC NNP N
) ) N
. . N

[ JJ N
Biological NNP N
and CC N
clinical JJ N
effects NNS N
of IN N
oral JJ N
magnesium NN N
and CC N
associated VBN N
magnesium-vitamin JJ N
B6 NNP N
administration NN N
on IN N
certain JJ N
disorders NNS N
observed VBN N
in IN N
infantile JJ N
autism NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

However RB N
, , N
a DT N
slight JJ N
tendency NN N
towards IN N
an DT N
increase NN o
in IN N
the DT N
GOT NNP N
, , N
GPT NNP N
and CC N
LDH NNP N
was VBD N
observed VBN N
, , N
which WDT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Effect NN N
of IN N
finasteride NN N
on IN N
serum NN N
androstenedione NN N
and CC N
risk NN N
of IN N
prostate NN N
cancer NN N
within IN N
the DT N
prostate NN N
cancer NN N
prevention NN N
trial NN N
: : N
differential JJ N
effect NN N
on IN N
high- NN N
and CC N
low-grade JJ N
disease NN N
. . N

The DT N
apparent JJ N
arrest NN N
of IN N
progressive JJ N
joint JJ N
damage NN N
seen VBN N
in IN N
four CD N
patients NNS p
after IN N
treatment NN N
with IN N
IL-1Ra NNP N
was VBD N
associated VBN N
with IN N
reduced JJ N
intimal JJ N
layer NN N
macrophage NN N
accumulation NN N
in IN N
all DT N
patients NNS p
. . N

Our PRP$ N
study NN N
demonstrates VBZ N
a DT N
reversible JJ N
depression NN N
of IN N
myocardial JJ N
contractility NN N
and CC N
hemodynamic JJ N
alterations NNS N
during IN N
rapid JJ N
permissive JJ N
hypercapnia NN N
which WDT N
were VBD N
attenuated VBN N
by IN N
buffering VBG N
with IN N
THAM NNP N
. . N

CONCLUSION NNP N
The DT N
combination NN N
of IN N
resistive JJ N
underwater NN N
exercises NNS N
and CC N
interferential JJ N
current JJ N
therapy NN i
is VBZ N
a DT N
potentially RB N
valuable JJ N
treatment NN N
for IN N
patients NNS p
with IN N
juvenile JJ N
idiopathic JJ N
arthritis NN N
. . N

In IN N
terms NNS N
of IN N
percentage NN N
the DT N
greatest JJS N
change NN N
was VBD N
found VBN N
in IN N
reactance NN N
, , N
in IN N
relation NN N
to TO N
the DT N
initial JJ N
value NN N
, , N
followed VBN N
by IN N
Raw NNP N
and CC N
FEV1 NNP N
. . N

The DT N
incidence NN N
rate NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
, , N
viral JJ N
infections NNS N
and CC N
fungal JJ N
infections NNS N
was VBD N
similar JJ N
across IN N
groups NNS N
during IN N
the DT N
LTE NNP N
. . N

BACKGROUND NNP N
Contrary NNP N
to TO N
aerobic VB N
exercise NN N
, , N
strength NN N
training NN N
( ( N
ST NNP N
) ) N
is VBZ N
associated VBN N
with IN N
decreased JJ o
central JJ N
arterial JJ N
compliance NN N
in IN N
young JJ N
men NNS N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS N
recovering VBG N
from IN N
mild JJ N
acute JJ N
pancreatitis NN N
typically RB N
receive VBP N
a DT N
clear JJ N
liquid NN N
diet NN N
( ( N
CLD NNP N
) ) N
when WRB N
ready JJ N
to TO N
initiate VB N
oral JJ N
nutrition NN N
. . N

Bradykinin NNP N
B2 NNP N
receptor NN N
antagonism NN N
decreased VBD o
intraoperative JJ o
fibrinolytic JJ N
capacity NN N
as RB N
much RB N
as IN N
EACA NNP N
, , N
but CC N
only RB N
EACA NNP N
decreased VBD o
D-dimer NNP o
formation NN N
and CC N
tended VBD N
to TO N
decrease VB o
postoperative JJ N
bleeding NN N
. . N

Blood NNP N
flow NN N
velocity NN N
tended VBD N
to TO N
be VB N
higher JJR N
in IN N
the DT N
MECC NNP N
group NN N
, , N
with IN N
a DT N
significant JJ N
intergroup NN N
difference NN N
after IN N
aortic JJ N
crossclamping NN N
( ( N
T2 NNP N
) ) N
. . N

The DT N
increase NN o
in IN N
insulin JJ N
sensitivity NN N
induced VBN N
by IN N
fasting VBG N
was VBD N
comparable JJ N
to TO N
the DT N
increase NN o
in IN N
insulin JJ N
sensitivity NN N
induced VBN N
by IN N
fasting VBG N
combined VBN N
with IN N
pegvisomant NN N
. . N

From IN N
the DT N
pantoprazole NN N
plasma NN N
concentration NN N
vs. FW N
time NN N
curves NNS N
, , N
the DT N
pharmacokinetic JJ N
parameters NNS N
AUC NNP N
( ( N
last JJ N
) ) N
and CC N
C NNP N
( ( N
max NN i
) ) N
were VBD N
obtained VBN N
, , N
with IN N
and CC N
without IN N
food NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
the DT N
changes NNS N
of IN N
endogenous JJ N
estrogen NN N
and CC N
the DT N
concentration NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
( ( N
CETP NNP N
) ) N
in IN N
the DT N
serum NN N
of IN N
Chinese JJ N
women NNS N
was VBD N
investigated VBN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
torasemide NN N
is VBZ N
suitable JJ N
for IN N
the DT N
treatment NN N
of IN N
sodium NN N
retention NN N
in IN N
patients NNS p
with IN N
cirrhosis NN N
and CC N
ascites NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
FNB NNP N
using VBG N
0.25 CD N
% NN N
or CC N
0.5 CD N
% NN N
bupivacaine NN N
provided VBN N
better RBR N
analgesia NN N
with IN N
less JJR N
effect NN N
on IN N
quadriceps NNS N
strengths NNS N
after IN N
ACL NNP N
reconstruction NN N
. . N

However RB N
, , N
the DT N
results NNS N
should MD N
be VB N
confirmed VBN N
in IN N
further JJ N
studies NNS N
with IN N
a DT N
placebo NN N
group NN N
to TO N
rule VB N
out IN N
the DT N
placebo NN N
effect NN N
. . N

Permissive NNP N
hypercapnia NN N
resulted VBD N
in IN N
significant JJ N
decreases NNS o
in IN N
systemic JJ N
vascular JJ N
resistance NN N
( ( N
SVR NNP N
) ) N
and CC N
increases VBZ o
in IN N
cardiac JJ N
output NN N
( ( N
Q NNP N
) ) N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
ophthalmic JJ N
timolol NN i
and CC N
time NN N
of IN N
administration NN N
on IN N
cardiovascular JJ N
and CC N
respiratory JJ N
functions NNS N
in IN N
healthy JJ N
young JJ N
male NN N
volunteers NNS N
. . N

In IN N
comparison NN N
to TO N
the DT N
Ca NNP N
( ( N
++ NNP N
) ) N
-blocker NN N
Gallopamil NNP N
the DT N
antiischemic JJ N
effects NNS N
of IN N
Enoximone NNP N
were VBD N
more RBR N
pronounced JJ N
, , N
a DT N
synergistic JJ N
action NN N
was VBD N
, , N
however RB N
, , N
observed VBD N
. . N

RESULTS VB N
The DT N
facial JJ N
swelling NN N
measurements NNS N
and CC N
VAS NNP N
scores NNS N
were VBD N
lower JJR N
in IN N
the DT N
envelope NN N
flap NN N
group NN N
compared VBN N
to TO N
the DT N
triangular JJ N
flap NN N
group NN N
. . N

A DT N
gradual JJ N
increase NN o
of IN N
AP-1 NNP N
activation NN N
was VBD N
found VBN N
in IN N
non-progressive JJ N
and CC N
progressive JJ N
phases NNS N
of IN N
atherosclerosis NN N
respectively RB N
( ( N
P NNP N
< NNP N
0.044 CD N
) ) N
. . N

The DT N
percentage NN N
of IN N
ST NNP N
resolution NN N
did VBD N
not RB N
show VB N
any DT N
differences NNS N
between IN N
groups NNS N
( ( N
84.8 CD N
in IN N
ticagrelor NN N
vs. FW N
70.8 CD N
in IN N
clopidogrel NN N
, , N
p=0.36 NN N
) ) N
. . N

However RB N
, , N
a DT N
significant JJ N
interaction NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
was VBD N
found VBN N
between IN N
the DT N
treatment NN N
and CC N
the DT N
number NN N
of IN N
invaded JJ N
lymph NN N
nodes NNS N
. . N

The DT N
itching NN N
and CC N
burning NN N
symptoms NNS N
were VBD N
not RB N
severe JJ N
and CC N
can MD N
be VB N
explained VBN N
by IN N
the DT N
preservative JJ N
benzyl NN N
alcohol NN N
present NN N
in IN N
the DT N
CS NNP N
gel NN N
. . N

The DT N
effect NN N
of IN N
a DT N
single JJ N
oral JJ N
dose NN N
on IN N
the DT N
responses NNS N
of IN N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
to TO N
isoprenaline VB N
infusion NN N
has VBZ N
been VBN N
studied VBN N
in IN N
healthy JJ N
volunteers NNS N
. . N

Plasma NNP N
level NN N
of IN N
ISDN NNP N
and CC N
the DT N
mononitrates NNS N
, , N
measured VBD N
one CD N
and CC N
four CD N
hours NNS N
after IN N
drug NN N
intake NN N
, , N
rose VBD N
almost RB N
linearly JJ N
in IN N
relation NN N
to TO N
dose VB N
. . N

However RB N
, , N
the DT N
inherent JJ N
heterogeneity NN N
in IN N
nasal JJ N
antibody NN N
levels NNS N
and CC N
variability NN N
in IN N
nasal JJ N
specimen NNS N
collection NN N
hinders VBZ N
the DT N
precise JJ N
evaluation NN N
of IN N
mucosal NN N
antibody NN N
responses NNS N
. . N

[ JJ N
Whole NNP N
gut NN N
irrigation NN N
with IN N
isotonic JJ N
mannitol NN N
solution NN N
in IN N
the DT N
treatment NN N
of IN N
gastrointestinal JJ N
bleeding NN N
due JJ N
to TO N
cirrhosis NN N
: : N
a DT N
controlled VBN N
study NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

These DT N
data NNS N
support NN N
the DT N
concept NN N
that IN N
P-selectin NNP i
on IN N
the DT N
microvascular JJ N
endothelium NN N
is VBZ N
critical JJ N
to TO N
both DT N
acute JJ N
vascular NN N
occlusion NN N
and CC N
chronically RB N
impaired JJ N
microvascular JJ N
blood NN N
flow NN N
in IN N
SCD NNP N
. . N

Duration NN N
of IN N
granulocytopenia NN N
was VBD N
reduced VBN N
in IN N
the DT N
G-CSF NNP N
group NN N
, , N
but CC N
thrombocytopenia NN N
was VBD N
prolonged VBN N
, , N
and CC N
the DT N
number NN N
of IN N
platelet NN N
transfusions NNS N
was VBD N
increased VBN o
. . N

It PRP N
became VBD N
evident JJ N
that IN N
the DT N
recurrence NN N
rate NN N
in IN N
the DT N
doxorubicin NN i
or CC N
epirubicin JJ i
instillation NN N
arm NN N
was VBD N
lower JJR N
that IN N
in IN N
the DT N
no DT N
instillation NN N
arm NN N
. . N

Glucocorticoid NNP N
receptor NN N
( ( N
GR NNP N
) ) N
binding NN N
and CC N
neurotransmitter JJ N
concentrations NNS N
were VBD N
measured VBN N
in IN N
stress-related JJ N
brain NN N
regions NNS N
, , N
and CC N
histological JJ N
analyses NNS N
of IN N
the DT N
adrenal JJ N
were VBD N
performed VBN N
. . N

The DT N
sites NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
( ( N
implemented VBN N
the DT N
intervention NN N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
continued VBN N
usual JJ N
training NN N
) ) N
. . N

Importantly RB N
, , N
administration NN N
of IN N
propranolol NN i
attenuated VBN N
this DT N
impairment NN N
, , N
with IN N
the DT N
ASD NNP N
group NN N
performing VBG N
significantly RB N
better RBR N
in IN N
the DT N
propranolol NN i
condition NN N
than IN N
the DT N
placebo JJ N
condition NN N
. . N

The DT N
relapse NN N
rates NNS N
were VBD N
62.5 CD N
% NN N
for IN N
gradual JJ N
placebo NN N
substitution NN N
and CC N
12.5 CD N
% NN N
for IN N
continued JJ N
risperidone NN i
; : N
this DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

The DT N
two CD N
groups NNS N
had VBD N
a DT N
similar JJ N
3-year JJ N
disease-free JJ N
survival NN N
, , N
progression NN N
free JJ N
survival NN N
, , N
and CC N
overall JJ i
survival NN N
, , N
i.e NN N
. . N

The DT N
primary JJ N
( ( N
efficacy NN N
) ) N
end NN N
point NN N
is VBZ N
the DT N
occurrence NN N
of IN N
unnecessary JJ N
angiography NN N
as IN N
defined VBN N
by IN N
a DT N
normal JJ N
( ( N
> JJ N
0.8 CD N
) ) N
invasive JJ N
fractional JJ N
flow NN N
reserve NN N
. . N

Terbinafine NN N
levels NNS N
were VBD N
determined VBN N
by IN N
high JJ N
pressure NN N
liquid NN N
chromatography NN N
with IN N
tandem JJ N
mass NN N
detection NN N
( ( N
HPLC-MS/MS NNP N
) ) N
and CC N
the DT N
lower JJR N
limit NN N
of IN N
quantification NN N
was VBD N
set VBN N
at IN N
9.99 CD N
ng/mL NNS N
. . N

ECG NNP N
, , N
MAP NNP N
, , N
HR NNP N
, , N
CVP NNP N
, , N
continuous JJ N
cardiac NN N
output NN N
( ( N
CCO NNP N
) ) N
index NN N
and CC N
BIS NNP N
were VBD N
continuously RB N
monitored VBN N
during IN N
anesthesia NN N
. . N

Second JJ N
, , N
using VBG N
a DT N
sigmoidal JJ N
Emax NNP i
model NN N
, , N
there EX N
is VBZ N
a DT N
strong JJ N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent JJ N
heart NN N
rate NN N
reduction NN N
. . N

During IN N
the DT N
break NN N
between IN N
sets NNS N
, , N
the DT N
participants NNS N
either CC N
rested VBN N
( ( N
control VB N
[ NNP N
CON NNP N
] NNP N
) ) N
or CC N
completed VBN N
a DT N
static JJ N
stretching NN N
protocol NN N
( ( N
static JJ N
stretch NN N
[ NNP N
SS NNP N
] NNP N
) ) N
. . N

However RB N
, , N
retention NN N
of IN N
calcium NN N
, , N
phosphorus NN N
( ( N
both DT N
formulas NN N
) ) N
, , N
and CC N
zinc NN N
( ( N
Similac NNP N
With IN N
Whey NNP N
+ NNP N
Iron NNP N
) ) N
was VBD N
inadequate JJ N
to TO N
meet VB N
estimated JJ N
fetal JJ N
requirements NNS N
. . N

Serum NNP N
and CC N
ascitic JJ N
levels NNS N
of IN N
tumor NN N
necrosis NN N
factor-alpha JJ N
, , N
interferon-gamma JJ N
, , N
interleukin-12 JJ N
, , N
and CC N
nitric JJ N
oxide NN N
were VBD N
significantly RB N
lower JJR N
in IN N
peak NN N
than IN N
in IN N
trough JJ N
samples NNS N
. . N

BACKGROUND NNP N
Angiotensin-converting NNP N
enzyme NN N
inhibitors NNS N
provide VBP N
hemodynamic JJ N
and CC N
symptomatic JJ N
benefit NN N
and CC N
are VBP N
associated VBN N
with IN N
improved JJ N
survival NN N
in IN N
patients NNS p
with IN N
congestive JJ N
heart NN N
failure NN N
. . N

Differential JJ N
effects NNS N
of IN N
vitamin NN N
K1 NNP N
on IN N
AFP NNP N
and CC N
DCP NNP N
levels NNS N
in IN N
patients NNS p
with IN N
unresectable JJ N
HCC NNP N
and CC N
in IN N
HCC NNP N
cell NN N
lines NNS N
. . N

Number NNP N
of IN N
negative JJ N
life NN N
events NNS N
was VBD N
a DT N
significant JJ N
predictor NN N
of IN N
parenting VBG N
stress NN N
and CC N
sense NN N
of IN N
competence NN N
across IN N
both DT N
groups NNS N
. . N

The DT N
difference NN N
in IN N
proportions NNS N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
minus CC N
TISSEEL NNP N
VH NNP N
, , N
was VBD N
1.4 CD N
% NN N
with IN N
a DT N
standard JJ N
error NN N
of IN N
3.70 CD N
% NN N
. . N

RESULTS NNP N
All PDT N
the DT N
approaches NNS N
were VBD N
able JJ N
to TO N
markedly RB N
reduce VB N
the DT N
PD NNP N
values NNS N
from IN N
the DT N
baseline NN N
to TO N
the DT N
other JJ N
evaluation NN N
periods NNS N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Risperidone NN i
and CC N
donepezil NN N
are VBP N
both DT N
metabolized VBN N
through IN N
cytochrome NN N
P450 NNP N
2D6 CD N
and CC N
3A4 CD N
, , N
raising VBG N
the DT N
possibility NN N
of IN N
drug NN N
interactions NNS N
with IN N
combination NN N
therapy NN i
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
isoniazid NN N
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN N
in IN N
tuberculin JJ N
skin JJ N
test-positive JJ N
and CC N
negative JJ N
individuals NNS N
with IN N
HIV NNP N
infection NN N
. . N

Additionally RB N
, , N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
was VBD N
found VBN N
in IN N
terms NNS N
of IN N
uroporphyrin NN N
I PRP N
, , N
heptacarboxyporphyrin NN N
I PRP N
, , N
hexacarboxyporphyrin NN N
and CC N
pentacarboxyporphyrin NN N
I PRP N
. . N

CONCLUSION NNP N
Recurrence NNP N
rate NN N
is VBZ N
reduced VBN N
to TO N
one-third JJ N
after IN N
tension-free JJ N
herniotomies NNS N
as IN N
compared VBN N
with IN N
the DT N
conventionel NN N
herniotomies NNS N
without IN N
increase NN o
in IN N
complication NN N
rate NN N
. . N

Low-dose JJ N
, , N
prolonged JJ N
infusion NN N
gemcitabine NN N
in IN N
combination NN N
with IN N
cisplatin NN i
is VBZ N
not RB N
inferior JJ N
to TO N
the DT N
standard JJ N
GC NNP N
regimen NNS N
with IN N
favorable JJ N
toxicity NN N
profile NN N
and CC N
less RBR N
financial JJ N
costs NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
significant JJ N
trends NNS N
within IN N
or CC N
between IN N
treatment NN N
groups NNS N
on IN N
the DT N
C-SSRS NNP N
, , N
laboratory NN N
values NNS N
, , N
electrocardiogram NN N
, , N
or CC N
vital JJ N
sign NN N
parameters NNS N
. . N

RESULTS NNP N
Baseline NNP N
spontaneous JJ N
activity NN N
in IN N
all DT N
subjects NNS N
showed VBD N
both DT N
high- JJ N
and CC N
low-frequency JJ N
components NNS N
; : N
in IN N
three CD N
patients NNS p
with IN N
UC NNP N
, , N
the DT N
low-frequency NN N
activity NN N
was VBD N
of IN N
high JJ N
amplitude NN N
. . N

The DT N
requirements NNS N
for IN N
respiratory JJ N
support NN N
and CC N
adverse JJ N
effects NNS N
were VBD N
also RB N
significantly RB N
lower JJR N
when WRB N
using VBG N
the DT N
bispectral JJ N
index NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

PURPOSE NN N
To TO N
compare VB N
the DT N
microbiologic JJ N
yields NNS N
and CC N
complication NN N
rates NNS N
associated VBN N
with IN N
vitreous JJ N
needle JJ N
tap NN N
and CC N
vitreous JJ N
biopsy NN N
in IN N
the DT N
Endophthalmitis NNP N
Vitrectomy NNP N
Study NNP N
( ( N
EVS NNP N
) ) N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
basal NN N
and CC N
peak JJ N
concentrations NNS N
of IN N
luteinising VBG N
hormone NN N
, , N
follicle NN N
stimulating VBG N
hormone NN N
, , N
thyroid JJ N
stimulating VBG N
hormone NN N
, , N
and CC N
prolactin NN i
. . N

CONCLUSIONS NNP N
Pravastatin NNP i
led VBD N
to TO N
significant JJ N
early JJ N
reduction NN N
of IN N
a DT N
wide JJ N
range NN N
of IN N
cardiovascular JJ N
events NNS N
in IN N
post-MI JJ N
women NNS N
with IN N
average JJ N
cholesterol NN N
levels NNS N
. . N

AX-CPT JJ N
performance NN N
was VBD N
assessed VBN N
following VBG N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
propranolol NN i
( ( N
a DT N
beta NN N
adrenergic JJ N
antagonist NN N
) ) N
and CC N
following VBG N
placebo NN N
( ( N
sugar NN N
pill NN N
) ) N
administration NN N
. . N

While IN N
not RB N
all DT N
results NNS N
were VBD N
statistically RB N
significant JJ N
at IN N
conventional JJ N
levels NNS N
, , N
intervention NN N
effects NNS N
were VBD N
positive JJ N
in IN N
virtually RB N
all DT N
cases NNS N
and CC N
effect NN N
magnitudes NNS N
frequently RB N
were VBD N
large JJ N
. . N

BACKGROUND IN N
The DT N
present JJ N
study NN N
was VBD N
aimed VBN N
at IN N
determining VBG N
the DT N
role NN N
warm JJ N
saline NN N
rinse NN N
in IN N
the DT N
prevention NN N
of IN N
alveolar JJ N
osteitis NN N
following VBG N
dental JJ N
extractions NNS N
. . N

Pre-treatment JJ N
disease NN N
scores NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
meloxicam NN N
group NN N
for IN N
owner NN N
mobility NN N
( ( N
p=0.01 NN N
) ) N
and CC N
veterinary JJ N
lameness NN N
( ( N
p=0.02 NN N
) ) N
. . N

CONCLUSIONS NNP N
Epoetin NNP i
zeta NN N
is VBZ N
therapeutically RB N
equivalent JJ N
to TO N
epoetin VB i
alfa NN N
in IN N
the DT N
maintenance NN N
of IN N
target NN N
Hb NNP N
levels NNS N
in IN N
patients NNS p
with IN N
renal JJ N
anaemia NN N
. . N

Peripheral JJ N
natural JJ N
killer NN N
( ( N
NK NNP N
) ) N
and CC N
LAK NNP N
activities NNS N
were VBD N
augmented VBN N
in IN N
all DT N
patients NNS p
and CC N
total JJ N
white JJ N
blood NN N
cell NN N
counts NNS N
were VBD N
increased VBN o
during IN N
IS-IL-2 NNP N
therapy NN i
. . N

Immunization NN N
triggered VBD N
significant JJ N
increases NNS o
in IN N
anti-tetanus JJ N
and CC N
anti-diphtheria JJ N
IgG NNP N
levels NNS N
over IN N
each DT N
group NN N
's POS N
pre-Td JJ N
baseline NN N
levels NNS N
and CC N
those DT N
of IN N
an DT N
unvaccinated JJ N
control NN N
group NN N
. . N

YAP1 NNP N
downregulation NN N
resulted VBD N
in IN N
increased JJ o
progesterone NN N
receptor NN N
( ( N
PgR NNP N
) ) N
expression NN N
and CC N
a DT N
delayed NN N
and CC N
weaker JJR N
tamoxifen NN N
in IN N
support NN N
of IN N
the DT N
clinical JJ N
data NNS N
. . N

This DT N
study NN N
summarizes VBZ N
the DT N
treatment NN N
effect NN N
of IN N
zoledronic JJ N
acid JJ N
infusion NN N
on IN N
lumbar NN N
spine NN N
bone NN N
mineral JJ N
density NN N
in IN N
different JJ N
subgroups NNS N
with IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

Diastolic NNP N
duration NN N
was VBD N
calculated VBN N
by IN N
subtracting VBG N
the DT N
electromechanical JJ N
systole NN N
from IN N
the DT N
R-R NNP N
interval NN N
and CC N
expressed VBD N
as IN N
a DT N
percentage NN N
of IN N
the DT N
cardiac JJ N
cycle NN N
( ( N
% NN N
D NNP N
) ) N
. . N

Efficacy NNP N
outcome JJ N
measures NNS N
included VBD N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
irritability NN N
subscale NN N
and CC N
the DT N
Clinical JJ N
Global NNP N
Impression-Improvement NN N
score NN N
( ( N
CGI-I NNP N
) ) N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
long-term JJ N
safety NN N
and CC N
efficacy NN N
after IN N
intracoronary JJ N
injection NN N
of IN N
autologous JJ N
mononuclear JJ N
bone NN N
marrow NN N
cells NNS N
( ( N
mBMCs NN N
) ) N
in IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
. . N

This DT N
increased VBN o
morbidity NN N
mainly RB N
seemed VBD N
to TO N
be VB N
caused VBN N
by IN N
symptoms NNS N
usually RB N
associated VBN N
with IN N
respiratory JJ N
tract JJ N
infection NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

METHODS JJ N
Participants NNS N
were VBD N
pregnant JJ N
women NNS N
( ( N
N=56 NNP N
) ) N
, , N
with IN N
past JJ N
histories NNS N
of IN N
MDD/PPMD NNP N
but CC N
not RB N
depressed VBN N
in IN N
their PRP$ N
current JJ N
pregnancy NN N
. . N

In IN N
the DT N
oat NN N
cereal NN N
group NN N
, , N
a DT N
trend NN N
was VBD N
observed VBN N
for IN N
a DT N
lower JJR N
total JJ N
insulin NN N
response NN N
to TO N
a DT N
glucose JJ N
load NN N
, , N
suggesting VBG N
improved VBN N
insulin JJ N
sensitivity NN N
. . N

CONCLUSION NNP N
VIP NNP N
combination NN N
chemotherapy NN i
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ N
time NN N
to TO N
progression NN N
and CC N
overall JJ i
survival NN N
over IN N
VP NNP N
therapy NN i
in IN N
patients NNS p
with IN N
extensive JJ N
SCLC NNP N
. . N

We PRP N
conclude VBP N
that DT N
ofloxacin NN i
in IN N
both DT N
oral JJ N
and CC N
parenteral JJ N
forms NNS N
is VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

The DT N
incidence NN N
of IN N
mucosal NN N
trauma NN N
, , N
sore RB N
throat NN N
, , N
and CC N
hemodynamic JJ N
responses NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
techniques NNS N
. . N

Mean JJ N
time NN N
intervals NNS N
to TO N
delivery NN N
, , N
need NN N
for IN N
oxytocin JJ i
augmentation NN N
, , N
and CC N
routes NNS N
of IN N
delivery NN N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

PoCT NNP N
device NN N
operators NNS N
were VBD N
provided VBN N
with IN N
a DT N
colour-coded JJ N
QC NNP N
Result NNP N
Sheet NNP N
and CC N
QC NNP N
Action NNP N
Sheet NNP N
for IN N
on-site JJ N
recording NN N
and CC N
interpreting NN N
of IN N
their PRP$ N
results NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
vertical JJ N
migration NN N
of IN N
the DT N
device NN N
into IN N
the DT N
femoral JJ N
head NN N
between IN N
the DT N
implants NNS N
used VBN N
( ( N
p JJ N
= NNP N
0.3 CD N
) ) N
. . N

We PRP N
hypothesized VBD N
that IN N
higher JJR N
amounts NNS N
of IN N
wear NN N
particles NNS N
result VBP N
in IN N
increased JJ o
release NN N
of IN N
metal NN N
ions NNS N
and CC N
ultimately RB N
lead JJ N
to TO N
an DT N
increased VBN o
incidence NN N
of IN N
metal NN N
allergy NN N
. . N

The DT N
peroxisome JJ N
proliferator-activated JJ N
receptor-gamma JJ N
agonist NN N
pioglitazone NN N
increases VBZ o
number NN N
and CC N
function NN N
of IN N
endothelial JJ N
progenitor NN N
cells NNS N
in IN N
patients NNS p
with IN N
coronary JJ N
artery NN N
disease NN N
and CC N
normal JJ N
glucose JJ N
tolerance NN N
. . N

BACKGROUND NNP N
Quick NNP N
change NN N
( ( N
QC NNP N
) ) N
and CC N
double JJ N
pumping NN N
( ( N
DP NNP N
) ) N
are VBP N
common JJ N
methods NNS N
of IN N
substituting VBG N
the DT N
infusion NN N
of IN N
inotropes NNS N
given VBN N
through IN N
intravenous JJ N
pump NN N
. . N

In IN N
the DT N
clonidine NN N
plus CC N
naltrexone NN N
protocol NN N
, , N
clonidine NN N
was VBD N
administered VBN N
and CC N
naltrexone NN N
was VBD N
administered VBN N
in IN N
increasing VBG N
doses NNS N
over IN N
five CD N
days NNS N
. . N

Subjects NNS N
underwent JJ N
pre- JJ N
and CC N
post-treatment JJ N
lab NN N
testing VBG N
to TO N
evaluate VB N
plasma NN N
reduced VBN N
glutathione NN N
, , N
oxidized VBD N
glutathione NN N
, , N
cysteine NN i
, , N
taurine NN N
, , N
free JJ N
and CC N
total JJ N
sulfate NN N
, , N
and CC N
whole-blood JJ N
glutathione NN N
levels NNS N
. . N

Active JJ N
treatments NNS N
and CC N
placebo NNS N
were VBD N
comparable JJ N
as RB N
far RB N
as IN N
concerns NNS N
occurrence IN N
of IN N
side-effects NNS N
( ( N
12-20 CD N
% NN N
) ) N
including VBG N
galactorrhoea NN N
, , N
breast NN N
tenderness NN N
and CC N
menstrual JJ N
changes NNS N
. . N

RESULTS NN N
At IN N
posttest NN N
, , N
a DT N
significant JJ N
increase NN o
in IN N
cardiovascular JJ N
fitness NN N
and CC N
decrease NN o
in IN N
BMI NNP N
were VBD N
found VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
No NNP N
evidence NN N
is VBZ N
provided VBN N
for IN N
the DT N
efficacy NN N
of IN N
repeated JJ N
doses NNS N
of IN N
porcine NN N
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
autism NN N
. . N

[ JJ N
Long-term JJ N
effects NNS N
of IN N
7-year JJ N
growth NN N
hormone CD N
substitution NN N
on IN N
bone NN N
metabolism NN N
, , N
bone NN N
density NN N
, , N
and CC N
bone NN N
quality NN N
in IN N
growth NN N
hormone-deficient JJ N
adults NNS N
] POS N
. . N

CONCLUSIONS NNP N
Ranolazine NNP N
, , N
when WRB N
added VBN N
to TO N
concurrent VB N
antidiabetes NNS N
treatment NN N
, , N
lowers NNS N
FPG NNP N
and CC N
A1C NNP N
in IN N
patients NNS p
with IN N
cardiovascular JJ N
disease NN N
and CC N
poorly RB N
controlled VBN N
diabetes NNS N
. . N

Although IN N
fibric JJ N
acid NN N
derivatives NNS N
increase VBP o
serum JJ N
HDL-C NNP N
levels NNS N
and CC N
decrease VB o
triglyceride NN N
levels NNS N
, , N
their PRP$ N
effects NNS N
on IN N
renal JJ N
function NN N
are VBP N
largely RB N
unknown JJ N
. . N

Comparative JJ N
evaluation NN N
of IN N
calcium NN N
hydroxide NN N
and CC N
zinc NN N
oxide RB N
eugenol RB N
as IN N
root JJ N
canal JJ N
filling NN N
materials NNS N
for IN N
primary JJ N
molars NNS N
: : N
a DT N
clinical JJ N
and CC N
radiographic JJ N
study NN N
. . N

Use NNP N
of IN N
ampicillin/sulbactam JJ N
results NNS N
in IN N
a DT N
significantly RB N
lower JJR N
SWI NNP N
rate NN N
than IN N
use NN N
of IN N
cefoxitin NN i
, , N
which WDT N
may MD N
be VB N
a DT N
result NN N
of IN N
improved JJ N
enterococcal JJ N
and CC N
Bacteroides NNP N
coverage NN N
. . N

However RB N
, , N
the DT N
pharmacodynamic NN N
( ( N
PD NNP N
) ) N
effects NNS N
of IN N
the DT N
PDE NNP N
inhibitor NN N
pentoxifylline NN N
on IN N
platelet NN N
function NN N
profiles NNS N
in IN N
DM NNP N
patients NNS p
receiving VBG N
DAPT NNP N
are VBP N
unknown JJ N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
number NN N
of IN N
attempts NNS N
at IN N
esophageal JJ N
intubation NN N
, , N
the DT N
amount NN N
of IN N
sedation NN N
used VBN N
, , N
and CC N
the DT N
examination NN N
time NN N
. . N

Renal JJ N
function NN N
was VBD N
assessed VBN N
by IN N
serially RB N
measuring VBG N
the DT N
serum NN N
creatinine NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
( ( N
using VBG N
Cr51-EDTA NNP N
) ) N
, , N
and CC N
24-h JJ N
urinary JJ N
protein NN N
excretion NN N
. . N

Skeletal-related JJ N
events NNS N
( ( N
SREs NNP N
) ) N
were VBD N
defined VBN N
as IN N
pathologic JJ N
bone NN N
fractures NNS N
, , N
spinal JJ N
cord NN N
compression NN N
, , N
surgery NN N
to TO N
bone VB N
, , N
radiation NN N
therapy NN i
to TO N
bone VB N
, , N
and CC N
hypercalcemia NN N
of IN N
malignancy NN N
. . N

Triptorelin NNP N
decreased VBD o
uterine JJ o
volume NN N
, , N
calculated VBN N
by IN N
ultrasonography NN N
, , N
by IN N
26.5 CD N
% NN N
in IN N
group NN N
A NNP N
, , N
whereas IN N
the DT N
volume NN N
remained VBD N
unchanged JJ N
in IN N
group NN N
B NNP N
. . N

AIM NNP N
This DT N
study NN N
compares VBZ N
the DT N
effects NNS N
of IN N
laparoscopic JJ N
lymphadenectomy JJ N
versus IN N
those DT N
of IN N
abdominal JJ N
lymphadenectomy NN N
in IN N
patients NNS p
with IN N
endometrial JJ N
cancer NN N
. . N

BACKGROUND NNP N
Because IN N
of IN N
the DT N
widespread JJ N
existence NN N
of IN N
Neisseria NNP N
gonorrhoeae NN N
resistant NN N
to TO N
penicillin VB i
or CC N
tetracycline VB N
, , N
ceftriaxone NN N
is VBZ N
now RB N
recommended VBN N
for IN N
the DT N
treatment NN N
of IN N
gonorrhea NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
pharmacokinetics NNS N
of IN N
corifollitropin NN N
alfa NN N
and CC N
rFSH NN N
are VBP N
quite RB N
different JJ N
but CC N
their PRP$ N
induced JJ N
pharmacodynamic JJ N
effects NNS N
at IN N
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

Onset NNP N
of IN N
complete JJ N
motor NN N
blockade NN N
was VBD N
fastest JJS N
and CC N
the DT N
degree NN N
of IN N
motor NN N
blockade NN N
was VBD N
most RBS N
profound JJ N
with IN N
the DT N
mixture NN N
containing VBG N
equal JJ N
proportions NNS N
of IN N
lidocaine NN N
and CC N
bupivacaine NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
angiographic JJ N
restenosis NN N
tended VBD N
to TO N
be VB N
lower JJR N
with IN N
warfarin NN N
, , N
none NN N
of IN N
these DT N
differences NNS N
was VBD N
significant JJ N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
cabergoline NN N
( ( N
Dostinex NNP N
, , N
a DT N
dopamine JJ N
agonist NN N
) ) N
on IN N
the DT N
myoma NN N
growth NN N
compared VBN N
to TO N
Diphereline NNP N
( ( N
a DT N
gonadotropin-releasing NN N
hormone NN N
agonist NN N
) ) N
. . N

This DT N
is VBZ N
a DT N
prospective JJ N
study NN N
that WDT N
compares VBZ N
the DT N
effects NNS N
of IN N
calcium NN N
acetate NN N
and CC N
sevelamer NN N
on IN N
coronary JJ N
calcification NN N
( ( N
CAC NNP N
) ) N
and CC N
bone $ N
histology NN N
. . N

Platelet NNP N
membrane NN N
glycoprotein NN N
Ib NNP N
and CC N
glycoprotein NN N
IIb/IIIa NNP N
, , N
P-selectin NNP i
, , N
platelet-derived JJ N
microparticles NNS N
, , N
leukocyte JJ N
CD11b/CD18 NNP N
( ( N
Mac-1 NNP N
) ) N
, , N
and CC N
platelet-leukocyte JJ N
aggregate NN N
were VBD N
quantified VBN N
by IN N
means NNS N
of IN N
flow JJ N
cytometry NN N
. . N

This DT N
suggests VBZ N
that IN N
the DT N
use NN N
of IN N
maintenance NN N
therapy NN i
in IN N
maximally RB N
tolerated VBN N
doses NNS N
may MD N
be VB N
associated VBN N
with IN N
an DT N
increased VBN o
survival NN N
in IN N
childhood NN N
ALL NNP N
. . N

No DT N
serious JJ N
clinical JJ N
or CC N
laboratory JJ N
adverse JJ N
events NNS N
occurred VBD N
, , N
and CC N
no DT N
anti-evolocumab JJ i
antibody NN N
development NN N
was VBD N
detected VBN N
during IN N
the DT N
study NN N
. . N

A DT N
high JJ N
dose NN N
of IN N
either DT N
eprosartan NN N
or CC N
enalapril VB N
significantly RB N
decreased VBN o
the DT N
indices NNS N
of IN N
platelet NN N
activation NN N
and CC N
endothelial JJ N
dysfunction NN N
in IN N
hypertensive JJ N
patients NNS p
. . N

Tolfenamic NNP N
acid NN N
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
prostaglandin JJ N
biosynthesis NN N
, , N
which WDT N
has VBZ N
been VBN N
proved VBN N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
migraine NN N
attacks NNS N
. . N

RESULTS NNP N
Ecstasy NNP N
users NNS N
showed VBD N
a DT N
broad JJ N
pattern NN N
of IN N
statistically RB N
significant JJ N
, , N
but CC N
clinically RB N
small JJ N
, , N
impairment NN N
of IN N
memory NN N
and CC N
prolonged JJ N
reaction NN N
times NNS N
. . N

CONCLUSIONS NNP N
PI NNP N
was VBD N
an DT N
earlier JJR N
, , N
clearer JJR N
and CC N
more RBR N
sensitive JJ N
indicator NN N
of IN N
the DT N
development NN N
of IN N
epidural-induced JJ N
sympathectomy NN N
than IN N
either DT N
skin JJ N
temperature NN N
or CC N
MAP NNP N
. . N

CONCLUSION VB N
The DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
was VBD N
more RBR N
successful JJ N
for IN N
the DT N
internal JJ N
cardioversion NN N
of IN N
both DT N
persistent JJ N
and CC N
induced JJ N
AF NNP N
in IN N
patients NNS p
( ( N
in IN N
terms NNS N
of IN N
leading VBG N
edge NN N
voltage NN N
) ) N
. . N

Vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
and CC N
its PRP$ N
cellular JJ N
receptor NN N
VEGFR-2 NNP N
have VBP N
been VBN N
implicated VBN N
as IN N
the DT N
main JJ N
endothelial JJ N
pathway NN N
required VBN N
for IN N
tumor NN N
neovascularization NN N
. . N

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
transdermal JJ N
estradiol NNS N
combined VBN N
with IN N
long-cycle NN N
progestins NNS N
was VBD N
associated VBN N
with IN N
no DT N
net JJ N
activation NN N
of IN N
coagulation NN N
despite IN N
reduced JJ N
levels NNS N
of IN N
coagulation NN N
inhibitors NNS N
. . N

Autologous JJ N
platelets NNS N
were VBD N
labelled VBN N
and CC N
re-injected JJ N
seven CD N
days NNS N
following VBG N
surgery NN N
and CC N
the DT N
graft NN N
thrombogenicity NN N
index NN N
calculated VBD N
as IN N
the DT N
daily JJ N
rise NN N
in IN N
the DT N
ratio NN N
of IN N
emissions NNS N
from IN N
the DT N
graft NN N
over IN N
a DT N
reference NN N
site NN N
. . N

However RB N
, , N
this DT N
could MD N
not RB N
be VB N
confirmed VBN N
using VBG N
estimates NNS N
from IN N
the DT N
Bergman NNP N
Minimal NNP N
Model NNP N
, , N
perhaps RB N
because IN N
of IN N
our PRP$ N
small JJ N
sample NN N
size NN N
. . N

Predicting VBG N
Overall JJ i
Survival NNP N
After IN N
Stereotactic NNP N
Ablative NNP N
Radiation NNP N
Therapy NNP N
in IN N
Early-Stage NNP N
Lung NNP N
Cancer NNP N
: : N
Development NNP N
and CC N
External NNP N
Validation NNP N
of IN N
the DT N
Amsterdam NNP N
Prognostic NNP N
Model NNP N
. . N

Two-week JJ N
indwelling NN N
did VBD N
not RB N
increase VB o
the DT N
risk NN N
of IN N
infection NN N
compared VBN N
with IN N
1-week JJ N
indwelling NN N
at IN N
any DT N
of IN N
the DT N
sites NNS N
in IN N
critically RB N
ill JJ N
patients NNS p
. . N

CONCLUSION NN N
Improvements NNS N
to TO N
whole VB N
body NN N
insulin JJ N
sensitivity NN N
after IN N
short-term JJ N
aerobic JJ N
exercise NN N
training NN N
are VBP N
due JJ N
to TO N
gains NNS N
in IN N
peripheral JJ N
, , N
not RB N
heptic JJ N
insulin NN N
sensitivity NN N
. . N

OBJECTIVE NN N
To TO N
observe VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
probucol NN N
on IN N
serum NN N
malondialdehyde NN N
( ( N
MDA NNP N
) ) N
and CC N
superoxide JJ N
dismutase NN N
( ( N
SOD NNP N
) ) N
in IN N
patients NNS p
with IN N
primary JJ N
hypertension NN N
. . N

On IN N
stepwise NN N
logistic JJ N
regression NN N
analysis NN N
, , N
hepatitis NN N
B NNP N
virus NN N
DNA NNP N
, , N
AST NNP N
and CC N
a DT N
history NN N
of IN N
acute JJ N
hepatitis NN N
predicted VBD N
response NN N
independently RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

To TO N
obtain VB N
the DT N
bioactive JJ N
antigen NN N
proteins NNS N
in IN N
large JJ N
quantities NNS N
, , N
a DT N
new JJ N
protein NN N
expression NN N
vector NN N
pBCX NN N
was VBD N
constructed VBN N
, , N
which WDT N
is VBZ N
based VBN N
on IN N
the DT N
pET32a NN N
vector NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
cutaneous JJ N
vasodilation NN N
in IN N
response NN N
to TO N
acupuncture VB N
stimulation NN N
may MD N
not RB N
occur VB N
through IN N
an DT N
axon JJ N
reflex NN N
as IN N
previously RB N
reported VBN N
. . N

AIM NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
acetazolamide NN N
on IN N
cystoid NN N
macular NN N
oedema NN N
( ( N
CMO NNP N
) ) N
in IN N
patients NNS p
with IN N
Behcet NNP N
's POS N
disease NN N
. . N

For IN N
the DT N
first JJ N
time NN N
, , N
this DT N
study NN N
has VBZ N
revealed VBN N
that IN N
acute JJ N
smoking NN N
speeds VBZ N
the DT N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ N
habitual JJ N
smokers NNS N
. . N

RESULTS NNP N
We PRP N
observed VBD N
an DT N
advantage NN N
of IN N
omega-3 JJ N
fatty JJ N
acids NNS N
compared VBN N
with IN N
placebo NN N
for IN N
hyperactivity NN N
and CC N
stereotypy NN N
, , N
each DT N
with IN N
a DT N
large JJ N
effect NN N
size NN N
. . N

It PRP N
is VBZ N
essential JJ N
to TO N
provide VB N
an DT N
adequate JJ N
amount NN N
of IN N
rumen-degradable JJ N
nitrogen NN N
( ( N
RDN NNP N
) ) N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
in IN N
the DT N
rumen NNS N
on IN N
straw-based JJ N
diets NNS N
. . N

Time NN N
to TO N
extubation NN N
, , N
morphine NN N
and CC N
midazolam NN i
amounts NNS N
, , N
hourly RB N
pain NN N
scores NNS N
, , N
and CC N
seizure NN N
activity NN N
were VBD N
compared VBN N
using VBG N
an DT N
intention-to-treat JJ N
and CC N
per-protocol JJ N
analysis NN N
. . N

The DT N
suppressive JJ N
activity NN N
of IN N
the DT N
patient NN N
plasma NN N
was VBD N
assayed VBN N
by IN N
measurement NN N
of IN N
normal JJ N
PMN NNP N
superoxide NN N
production NN N
relative JJ N
to TO N
normal JJ N
control NN N
plasma NN N
( ( N
ratio JJ N
P NNP N
: : N
C NNP N
) ) N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
for IN N
mean JJ N
change NN N
in IN N
Fridericia NNP N
's POS N
correction NN N
of IN N
QT NNP N
during IN N
the DT N
trial NN N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
document VB N
the DT N
clinical JJ N
consequences NNS N
of IN N
this DT N
finding NN N
, , N
for IN N
example NN N
in IN N
severe JJ N
asthmatic JJ N
patients NNS p
. . N

In IN N
the DT N
subgroup NN N
of IN N
Avastin-treated JJ N
eyes NNS N
, , N
multivariate NN N
analysis NN N
identified VBN N
hemoglobin JJ N
A1c NNP N
as IN N
the DT N
strongest JJS N
predictor NN N
of IN N
proliferative JJ N
diabetic JJ N
retinopathy NN N
recurrence NN N
( ( N
p=0.033 NN N
) ) N
. . N

BACKGROUND NNP N
An DT N
imbalance NN N
in IN N
the DT N
excitatory/inhibitory JJ N
systems NNS N
with IN N
abnormalities NNS N
in IN N
the DT N
glutamatergic NN N
pathways VBZ N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
autism NN N
. . N

RATIONALE NNP N
( ( N
+/- JJ N
) ) N
3,4-Methylenedioxymethamphetamine CD N
( ( N
MDMA NNP N
or CC N
ecstasy NN N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
cause VB N
long JJ N
term NN N
damage NN N
to TO N
serotonergic VB N
cerebral JJ N
neurons NNS N
in IN N
animals NNS N
. . N

Bradykinin NNP N
increases VBZ o
during IN N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
and CC N
stimulates VBZ N
the DT N
release NN N
of IN N
nitric JJ N
oxide NN N
, , N
inflammatory JJ N
cytokines NNS N
, , N
and CC N
tissue-type JJ N
plasminogen NN N
activator NN N
( ( N
t-PA JJ N
) ) N
, , N
acting VBG N
through IN N
its PRP$ N
B2 NNP N
receptor NN N
. . N

Previous JJ N
reports NNS N
suggested VBD N
that IN N
CD19+ NNP N
B NNP N
cells NNS N
are VBP N
markedly RB N
increased VBN o
in IN N
myeloma NN N
patients NNS p
and CC N
that IN N
this DT N
population NN N
shares NNS N
clonotypic VBD N
rearrangements NNS N
with IN N
the DT N
malignant JJ N
plasma NN N
cell NN N
. . N

CONCLUSIONS NNP N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
, , N
which WDT N
is VBZ N
available JJ N
over-the-counter JJ N
, , N
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
neck NN N
pain NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
Rating VBG N
Scale NNP N
( ( N
total JJ N
score NN N
) ) N
. . N

RESULTS NN N
After IN N
treatments NNS N
, , N
statistically RB N
significant JJ N
improvements NNS N
in IN N
the DT N
baseline NN N
KP NNP N
were VBD N
observed VBN N
in IN N
erythema NN N
and CC N
melanin NN N
index NN N
of IN N
mexameter NN N
on IN N
treated JJ N
upper JJ N
arms NNS N
. . N

We PRP N
have VBP N
recently RB N
shown VBN N
that IN N
total JJ N
TFPI NNP N
activity NN N
, , N
plasma VBP N
free JJ N
TFPI NNP N
antigen NN N
, , N
and CC N
heparin NN N
releasable JJ N
TFPI NNP N
were VBD N
partially RB N
depleted VBN N
during IN N
repeated VBN N
and CC N
continuous JJ N
i.v NN N
. . N

However RB N
, , N
severe JJ N
anemia NN N
and CC N
febrile JJ N
neutropenia NN N
are VBP N
statistically RB N
more RBR N
frequent JJ N
in IN N
the DT N
VNR/CDDP NNP N
arm NN N
than IN N
in IN N
the DT N
DCT/CDDP NNP N
one NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
rate NN N
of IN N
thrombolytic JJ N
use NN N
, , N
90-day JJ N
functional JJ N
outcomes NNS N
, , N
incidence NN N
of IN N
intracerebral JJ N
hemorrhages NNS N
, , N
and CC N
technical JJ N
observations NNS N
. . N

Vancomycin NNP i
was VBD N
added VBN N
in IN N
all DT N
cases NNS N
of IN N
persistent JJ N
fever NN N
in IN N
the DT N
ceftazidime NN N
arm NN N
, , N
but CC N
only RB N
when WRB N
there EX N
was VBD N
microbiologically RB N
documented VBN N
resistance NN N
in IN N
the DT N
piperacillin/tazobactam NN N
arm NN N
. . N

However RB N
, , N
DPP-4 NNP N
inhibitors NNS N
also RB N
reduce VB N
fasting VBG N
blood NN N
glucose NN N
, , N
an DT N
unexpected JJ N
effect NN N
because IN N
circulating VBG N
levels NNS N
of IN N
active JJ N
GIP NNP N
and CC N
GLP-1 NNP N
are VBP N
low JJ N
in IN N
the DT N
postabsorptive JJ N
state NN N
. . N

There EX N
was VBD N
a DT N
mean JJ N
increase NN o
in IN N
serum JJ N
creatinine NN N
concentration NN N
associated VBN N
with IN N
CSA NNP N
; : N
no DT N
persons NNS N
were VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
for IN N
this DT N
reason NN N
. . N

Especially RB N
for IN N
patients NNS p
with IN N
pulmonary JJ N
tuberculosis NN N
or CC N
aged VBN N
patients NNS p
with IN N
primary JJ N
bladder NN N
tumors NNS N
, , N
mitoxantrone NN N
and CC N
doxorubicin NN i
may MD N
be VB N
the DT N
tolerable JJ N
and CC N
effective JJ N
intravesical JJ N
agents NNS N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
mortality NN N
, , N
morbidity NN N
or CC N
incapacity NN N
for IN N
work NN N
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
. . N

With IN N
the DT N
low JJ N
infusion NN N
rate NN N
, , N
arterial JJ N
pressure NN N
increased VBD o
to TO o
its PRP$ N
control NN N
value NN N
during IN N
operation NN N
; : N
it PRP N
remained VBD N
at IN N
the DT N
postinduction NN N
value NN N
with IN N
high JJ N
infusion NN N
rates NNS N
. . N

Fecal JJ N
SCFA NNP N
levels NNS N
varied VBD N
widely RB N
among IN N
participants NNS N
at IN N
entry NN N
( ( N
butyrate JJ N
concentrations NNS N
: : N
3.5-32.6 JJ N
mmol/kg NN N
; : N
butyrate JJ N
excretions NNS N
: : N
0.3-18.2 JJ N
mmol/48 NN N
h NN N
) ) N
. . N

Two CD N
patients NNS p
who WP N
received VBD N
phenoxymethylpenicillin NN i
and CC N
two CD N
given VBN N
doxycycline VBP N
subsequently RB N
developed VBN N
major JJ N
manifestations NNS N
of IN N
Lyme NNP N
borreliosis NN N
; : N
these DT N
did VBD N
not RB N
occur VB N
in IN N
patients NNS p
receiving VBG N
azithromycin NN i
. . N

Studies NNS N
performed VBN N
on IN N
airway NN N
smooth JJ N
muscle NN N
in IN N
vitro NNS N
have VBP N
indicated VBN N
that IN N
salmeterol NN N
is VBZ N
a DT N
partial JJ N
agonist NN N
on IN N
the DT N
beta2-receptor NN N
in IN N
comparison NN N
to TO N
formoterol VB N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
for IN N
evaluations NNS N
of IN N
overall JJ i
pain NN N
intensity NN N
, , N
analgesic JJ N
efficacy NN N
, , N
or CC N
adverse JJ N
events NNS N
. . N

The DT N
incidence NN N
of IN N
hot JJ N
flashes NNS N
increased VBD o
significantly RB o
over IN N
baseline NN N
in IN N
the DT N
10-mg JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
5-mg JJ N
group NN N
. . N

Topical JJ N
tetracaine NN N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
pain NN N
score NN N
, , N
although IN N
it PRP N
did VBD N
lead VB N
to TO N
faster VB N
recovery NN N
times NNS N
. . N

No DT N
trends NNS N
in IN N
heart NN N
rate NN N
or CC N
ECG NNP N
parameters NNS N
, , N
including VBG N
the DT N
QTc NNP N
interval NN N
and CC N
T-wave NNP N
morphology NN N
, , N
were VBD N
observed VBN N
. . N

CONCLUSION NN N
At IN N
mean JJ N
5-year JJ N
angiography NN N
in IN N
largely RB N
asymptomatic JJ N
patients NNS p
, , N
the DT N
selection NN N
of IN N
arterial JJ N
or CC N
venous JJ N
conduit NN N
for IN N
the DT N
second JJ N
graft NN N
has VBZ N
not RB N
significantly RB N
affected JJ N
patency NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
central JJ N
effects NNS N
of IN N
captopril NN N
and CC N
enalapril NN N
were VBD N
minor JJ N
and CC N
not RB N
constant JJ N
in IN N
young JJ N
healthy JJ N
men NNS N
. . N

CONCLUSION NN N
There EX N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
any DT N
difference NN N
in IN N
discomfort NN N
scores NNS N
between IN N
the DT N
ocular JJ N
irrigation NN N
fluids NNS N
when WRB N
used VBN N
without IN N
the DT N
MTL NNP N
. . N

BACKGROUND IN N
The DT N
sources NNS N
and CC N
the DT N
impact NN N
of IN N
maternal JJ N
bacteria NNS N
on IN N
the DT N
initial JJ N
inoculum NN N
of IN N
the DT N
intestinal JJ N
microflora NN N
of IN N
newborn JJ N
infants NNS N
remain VBP N
elusive JJ N
. . N

Rapid JJ N
absorption NN N
, , N
with IN N
most JJS N
Cmax NNP i
values NNS N
from IN N
50-60 JJ N
micrograms/ml NN N
reached VBD N
within IN N
1.5-3 JJ N
h NN N
, , N
was VBD N
found VBN N
for IN N
both DT N
tablet JJ N
formulations NNS N
. . N

CONCLUSIONS NNP N
Lesser NNP N
concentrations NNS N
of IN N
ropivacaine NN N
and CC N
fentanyl JJ N
provide NN N
comparable JJ N
analgesia NN N
with IN N
less JJR N
motor NN N
block NN N
despite IN N
the DT N
use NN N
of IN N
similar JJ N
amounts NNS N
of IN N
ropivacaine NN N
and CC N
fentanyl NN N
. . N

In IN N
conclusion NN N
, , N
1-yr JJ N
treatment NN N
with IN N
melatonin NN N
increased VBN o
BMD NNP N
at IN N
femoral JJ N
neck NN N
in IN N
a DT N
dose-dependent JJ N
manner NN N
, , N
while IN N
high-dose JJ N
melatonin NN N
increased VBD o
vBMD NN o
in IN N
the DT N
spine NN N
. . N

Using VBG N
analysis NN N
of IN N
variance NN N
and CC N
chi-square NN N
tests NNS N
, , N
we PRP N
found VBD N
no DT N
difference NN N
in IN N
any DT N
of IN N
these DT N
parameters NNS N
between IN N
the DT N
two CD N
patients NNS p
groups NNS N
. . N

These DT N
results NNS N
are VBP N
in IN N
accordance NN N
with IN N
the DT N
hypothesis NN N
that IN N
the DT N
nephrotoxic JJ N
effect NN N
of IN N
cyclosporin NN N
A NNP N
results NNS N
from IN N
a DT N
preferential JJ N
constriction NN N
of IN N
afferent JJ N
glomerular JJ N
vessels NNS N
. . N

Similar JJ N
trends NNS N
were VBD N
noted VBN N
for IN N
changes NNS N
in IN N
the DT N
% NN N
of IN N
sites NNS N
with IN N
bleeding VBG N
on IN N
probing VBG N
in IN N
the DT N
0.01 CD N
% NN N
P-113 NNP N
group NN N
. . N

RESULTS VB N
The DT N
demographic JJ N
and CC N
other JJ N
baseline NN N
parameters NNS N
such JJ N
as IN N
indications NNS N
for IN N
extractions NNS N
were VBD N
comparable JJ N
among IN N
the DT N
study NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Nasotracheal NNP N
intubation NN N
under IN N
CTSC NNP N
guidance NN N
increases VBZ o
the DT N
success NN N
rate NN N
of IN N
airway NN N
instrumentation NN N
, , N
and CC N
also RB N
reduces VBZ N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
epistaxis NN N
. . N

[ JJ N
Comparison NNP N
of IN N
three CD N
analgesic JJ N
methods NNS N
for IN N
postoperative JJ N
pain NN N
relief NN N
and CC N
their PRP$ N
effects NNS N
on IN N
plasma JJ N
interleukin-6 JJ N
concentration NN N
following VBG N
radical JJ N
surgery NN N
for IN N
gastric JJ N
carcinoma NN N
] NN N
. . N

RESULTS NNP N
Both NNP N
MDD NNP N
patients NNS p
and CC N
age-matched JJ N
controls NNS N
demonstrated VBD N
a DT N
significant JJ N
reaction NN N
time NN N
( ( N
RT NNP N
) ) N
and CC N
P3b NNP N
latency NN N
differences NNS N
between IN N
predicted VBN N
and CC N
random JJ N
targets NNS N
. . N

CONCLUSIONS NNP N
Although IN N
probably RB N
not RB N
arrhythmogenic JJ N
in IN N
normal JJ N
subjects NNS N
, , N
moderate JJ N
caffeine NN i
ingestion NN N
does VBZ N
produce VB N
a DT N
small JJ N
but CC N
statistically RB N
significant JJ N
prolongation NN N
of IN N
signal-averaged JJ N
QRS NNP N
complexes NNS N
. . N

Estrogen NNP N
replacement NN N
therapy NN i
is VBZ N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
hot JJ N
flashes NNS N
, , N
but CC N
its PRP$ N
use NN N
is VBZ N
controversial JJ N
in IN N
breast NN N
cancer NN N
survivors NNS N
. . N

The DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
Version NNP N
( ( N
ABC-CV NNP N
) ) N
and CC N
Clinical JJ N
Global NNP N
Impressions NNP N
( ( N
CGI NNP N
) ) N
scale NN N
were VBD N
used VBN N
as IN N
outcome JJ N
variables NNS N
. . N

Gastrointestinal JJ N
side NN N
effects NNS N
and CC N
hand-foot JJ N
syndrome NN N
were VBD N
more JJR N
common JJ N
with IN N
combination NN N
therapy NN i
, , N
whereas JJ N
myalgia NN N
, , N
arthralgia NN N
, , N
and CC N
neutropenic JJ N
fever/sepsis NN N
were VBD N
more JJR N
common JJ N
with IN N
single-agent JJ N
docetaxel NN i
. . N

CONCLUSION NNP N
Topical NNP N
bupivacaine NN N
decreases VBZ o
postoperative JJ N
pain NN N
scores NNS N
significantly RB N
compared VBN N
with IN N
placebo NN N
in IN N
women NNS N
undergoing VBG N
laparoscopic NN N
tubal JJ N
sterilization NN N
with IN N
silastic JJ N
bands NNS N
. . N

LIMITATIONS NNP N
Carryover NNP N
effects NNS N
limited VBD N
the DT N
power NN N
to TO N
detect VB N
significant JJ N
changes NNS N
in IN N
endothelial-derived JJ N
vasoregulators NNS N
, , N
and CC N
future JJ N
studies NNS N
will MD N
require VB N
parallel JJ N
trial NN N
designs NNS N
. . N

The DT N
primary NN N
study VBD N
end JJ N
point NN N
was VBD N
the DT N
grading NN N
of IN N
acute NN N
and CC N
late JJ N
nonhematologic NN N
toxicities NNS N
( ( N
mucositis NN N
, , N
dysphagia NN N
, , N
xerostomia NN N
) ) N
induced VBN N
by IN N
radiochemotherapy NN i
. . N

AIMS NNP N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
synthetic JJ N
GLP-1 NNP N
on IN N
fundus NN N
tone NN N
and CC N
volume NN N
waves NNS N
, , N
gastric JJ N
compliance NN N
, , N
and CC N
perception NN N
of IN N
gastric JJ N
distension NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
of IN N
hirsute JJ N
women NNS N
with IN N
third JJ N
generation NN N
OCs NNP N
containing VBG N
desogestrel NN N
results NNS N
in IN N
a DT N
significant JJ N
increase NN o
in IN N
sex NN N
hormone-binding JJ N
globulin NN N
and CC N
decrease NN o
in IN N
free JJ N
testosterone NN N
and CC N
3alpha-androstanediol JJ N
glucuronide NN N
. . N

Furthermore RB N
, , N
we PRP N
investigated VBD N
the DT N
perfusate NN N
of IN N
the DT N
graft NN N
liver NN N
in IN N
both DT N
groups NNS N
and CC N
detected JJ N
signs NNS N
of IN N
a DT N
decreased JJ o
t-PA JJ N
release NN N
in IN N
the DT N
infusion NN N
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
intake NN N
of IN N
lean JJ N
fish NN N
at IN N
least JJS N
four CD N
times NNS N
per IN N
week NN N
could MD N
reduce VB N
blood NN N
pressure NN N
levels NNS N
in IN N
CHD NNP N
patients NNS p
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
heart NN N
rate NN N
throughout IN N
maintenance NN N
therapy NN i
with IN N
propranolol NN i
, , N
which WDT N
continued VBD N
through IN N
the DT N
tenth JJ N
hospital NN N
day NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Statistically NNP N
significant JJ N
correlations NNS N
between IN N
smoking NN N
and CC N
nutrient JJ N
intake NN N
, , N
HbA1c NNP N
, , N
and CC N
serum VB N
lipid JJ N
levels NNS N
. . N

Fibula NNP N
, , N
scapula NN N
, , N
iliac JJ N
crest NN N
, , N
rib NN N
, , N
and CC N
metatarsal NN N
as RB N
well RB N
as IN N
the DT N
radial JJ N
forearm NN N
osseocutaneous JJ N
flaps NNS N
have VBP N
all DT N
been VBN N
utilized VBN N
for IN N
this DT N
purpose NN N
. . N

Individuals NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
anti-Helicobacter JJ N
pylori NN N
triple JJ N
therapy NN i
and/or NN N
dietary JJ N
supplementation NN N
with IN N
ascorbic JJ N
acid NN N
, , N
beta-carotene JJ N
, , N
or CC N
their PRP$ N
corresponding JJ N
placebos NNS N
. . N

We PRP N
also RB N
compared VBN N
changes NNS N
in IN N
other JJ N
ABC-C JJ N
subscale NN N
scores NNS N
and CC N
Clinical NNP N
Global NNP N
Impressions-Improvement NNP N
( ( N
CGI-I NNP N
) ) N
scale NN N
scores NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

Furthermore RB N
, , N
significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
CARS NNP N
score NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
raw JJ N
CM NNP N
group NN N
only RB N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN N
with IN N
which WDT N
gallium NN N
interfered VBD N
with IN N
readings NNS N
or CC N
time NN N
to TO N
complete VB N
the DT N
study NN N
. . N

Patients NNS N
with IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
or CC N
anaplastic JJ N
lymphoma NN N
kinase NN N
genomic JJ N
tumor NN N
aberrations NNS N
should MD N
have VB N
disease NN N
progression NN N
on IN N
FDA-approved NNP N
therapy NN i
for IN N
these DT N
aberrations NNS N
prior VBP N
to TO N
receiving VBG N
ramucirumab NN i
. . N

YDJ NNP N
external JJ N
lotion NN N
and CC N
YDJ NNP N
cream NN N
were VBD N
applied VBN N
to TO N
patients NNS p
in IN N
the DT N
treatment NN N
group NN N
, , N
while IN N
normal JJ N
saline NN N
was VBD N
applied VBN N
for IN N
those DT N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
rates NNS N
of IN N
definite JJ N
infections NNS N
was VBD N
greatest JJS N
for IN N
fungal JJ N
infections NNS N
, , N
intermediate NN N
for IN N
bacterial JJ N
infections NNS N
, , N
and CC N
lowest JJS N
for IN N
viral JJ N
infections NNS N
. . N

Basal NNP N
sex NN N
steroid NN N
suppression NN N
, , N
growth NN N
rates NNS N
, , N
pubertal JJ N
progression NN N
, , N
bone NN N
age NN N
advancement NN N
, , N
and CC N
adverse JJ N
events NNS N
were VBD N
similar JJ N
with IN N
either DT N
dose NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Attention NNP N
deficits NNS N
are VBP N
often RB N
among IN N
the DT N
most RBS N
persistent JJ N
and CC N
debilitating VBG N
impairments NNS N
resulting VBG N
from IN N
traumatic JJ N
brain NN N
injury NN N
( ( N
TBI NNP N
) ) N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
in IN N
obese JJ N
subjects NNS N
given VBN N
a DT N
hypocaloric JJ N
diet NN N
, , N
GH NNP N
accelerates VBZ N
body NN N
fat JJ N
loss NN N
, , N
exerts VBZ N
anabolic JJ N
effects NNS N
and CC N
improves NNS N
GH NNP N
secretion NN N
. . N

Homogenous JJ N
enhancement NN N
of IN N
deep JJ N
veins NNS N
was VBD N
more RBR N
assuredly RB N
achieved VBN N
with IN N
protocol NN N
C. NNP N
CONCLUSION NNP N
With IN N
protocol NN N
C NNP N
, , N
qualitatively RB N
acceptable JJ N
enhancement NN N
can MD N
be VB N
obtained VBN N
in IN N
whole-body JJ N
CT NNP N
. . N

The DT N
study NN N
shows VBZ N
that IN N
in IN N
infants NNS N
with IN N
atopic NN N
dermatitis NN N
, , N
raised VBD N
serum JJ N
total NN N
IgE NNP N
has VBZ N
significantly RB N
different JJ N
determinants NNS N
from IN N
that IN N
a DT N
specific JJ N
allergen NN N
sensitization NN N
. . N

A DT N
comparative JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
local JJ N
estrogen NN N
with IN N
or CC N
without IN N
local JJ N
testosterone NN N
on IN N
vulvovaginal JJ N
and CC N
sexual JJ N
dysfunction NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

Blood NNP N
pressure NN N
, , N
FG NNP N
, , N
and CC N
lipid JJ N
profiles NNS N
were VBD N
significantly RB N
correlated VBN N
with IN N
antioxidant JJ N
enzymes NNS N
activities NNS N
after IN N
supplementation NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Effect NN N
of IN N
entacapone NN N
, , N
a DT N
peripherally RB N
acting VBG N
catechol-O-methyltransferase NN N
inhibitor NN N
, , N
on IN N
the DT N
motor NN N
response NN N
to TO N
acute VB N
treatment NN N
with IN N
levodopa NN N
in IN N
patients NNS p
with IN N
Parkinson NNP N
's POS N
disease NN N
. . N

CONCLUSIONS NNP N
Pulsed VBD N
low-intensity NN N
direct JJ N
current JJ N
represents VBZ N
a DT N
useful JJ N
approach NN N
for IN N
the DT N
treatment NN N
of IN N
stage NN N
II NNP N
and CC N
stage NN N
III NNP N
chronic JJ N
decubitus NN N
ulcers NNS N
by IN N
increasing VBG N
the DT N
healing NN N
rate NN N
. . N

Interobserver NNP N
reliability NN N
between IN N
the DT N
radiologists NNS N
was VBD N
considered VBN N
excellent NN N
for IN N
both DT N
CT NNP N
and CC N
MRI NNP N
( ( N
ICC NNP N
= NNP N
0.777 CD N
and CC N
0.843 CD N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NN N
With IN N
the DT N
use NN N
of IN N
leukocyte JJ N
reduction NN N
filters NNS N
, , N
we PRP N
found VBD N
significantly RB N
lower JJR N
beta-glucuronidase NN N
levels NNS N
in IN N
arterial JJ N
and CC N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
immunological JJ N
and CC N
functional JJ N
effects NNS N
of IN N
a DT N
liposome-entrapped JJ N
D. NNP N
pteronyssinus NN N
vaccine NN N
on IN N
mite JJ N
monosensitive NN N
, , N
mild JJ N
asthma NN N
patients NNS p
. . N

No DT N
dose-response JJ N
effect NN N
was VBD N
observed VBN N
with IN N
either DT N
drug NN N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
treatment NN N
with IN N
fluticasone NN N
or CC N
budesonide NN N
. . N

The DT N
mean JJ N
exercise NN N
time NN N
was VBD N
219.9 CD N
seconds NNS N
in IN N
the DT N
air NN N
control NN N
period NN N
and CC N
221.3 CD N
seconds NNS N
after IN N
purified VBN N
air NN N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

The DT N
Effects NNPS N
of IN N
Naltrexone NNP N
on IN N
Subjective NNP N
Response NNP N
to TO N
Methamphetamine NNP N
in IN N
a DT N
Clinical JJ N
Sample NN N
: : N
a DT N
Double-Blind NNP N
, , N
Placebo-Controlled NNP N
Laboratory NNP N
Study NNP N
. . N

With IN N
respect NN N
to TO N
film NN N
positioning NN N
, , N
the DT N
loop NN N
technique NN N
was VBD N
1.12 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
improper JJ N
positioning NN N
than IN N
the DT N
holder NN N
technique NN N
. . N

Effect NN N
of IN N
L-arginine NNP N
or CC N
L-citrulline JJ N
oral JJ N
supplementation NN N
on IN N
blood NN N
pressure NN N
and CC N
right JJ N
ventricular NN N
function NN N
in IN N
heart NN N
failure NN N
patients NNS p
with IN N
preserved JJ N
ejection NN N
fraction NN N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
also RB N
reduced VBD N
their PRP$ N
time NN N
spent VBN N
in IN N
prolonged JJ N
sitting NN N
bouts NNS N
( ( N
? . N
) ) N
and CC N
increased JJ o
time NN N
spent VBN N
standing NN N
and CC N
stepping NN N
. . N

Women NNS N
not RB N
using VBG N
HRT NNP N
had VBD N
faster JJR N
propagation NN N
rates NNS N
and CC N
higher JJR N
maximum NN N
production NN N
than IN N
women NNS N
using VBG N
HRT NNP N
; : N
after IN N
supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
alpha-tocopheryl JJ N
acetate NN N
these DT N
differences NNS N
prevailed VBD N
. . N

Higher JJR N
allergen NN N
doses NNS N
were VBD N
associated VBN N
with IN N
drug-related JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
, , N
predominantly RB N
manifested VBN N
by IN N
pruritus NN N
, , N
erythema NN N
, , N
wheal NN N
, , N
or CC N
eczema NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
extent NN N
of IN N
sensory JJ N
block NN N
, , N
percentage NN N
of IN N
patients NNS p
with IN N
motor NN N
block NN N
or CC N
incidence NN N
of IN N
adverse JJ N
events NNS N
. . N

However RB N
, , N
this DT N
study NN N
did VBD N
not RB N
find VB N
significant JJ N
differences NNS N
in IN N
scaling VBG N
time NN N
between IN N
product NN N
and CC N
placebo NN N
when WRB N
using VBG N
a DT N
2-minute JJ N
gel NN N
contact NN N
time NN N
. . N

BACKGROUND NNP N
To TO N
investigate VB N
if IN N
coadministration NN N
of IN N
enalapril NN N
alters NNS N
the DT N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
by IN N
employing VBG N
an DT N
euglycemic JJ N
glucose-clamp NN N
technique NN N
in IN N
healthy JJ N
volunteers NNS N
. . N

Both DT N
multiplane NN N
and CC N
biplane NN N
probes NNS N
provided VBD N
excellent JJ N
visualization NN N
of IN N
cardiac JJ N
structures NNS N
and CC N
Doppler NNP N
signals NNS N
, , N
but CC N
the DT N
multiplane NN N
probe NN N
was VBD N
significantly RB N
superior JJ N
to TO N
the DT N
biplane NN N
probe NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Duration NNP N
of IN N
anesthesia NN N
, , N
invasiveness NN N
of IN N
surgery NN N
, , N
and CC N
baseline NN N
core NN N
temperature NN N
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Dietary NNP N
sodium NN N
restriction NN N
alone RB N
is VBZ N
effective JJ N
in IN N
lowering VBG N
blood NN N
pressure NN N
in IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
patients NNS p
with IN N
essential JJ N
hypertension NN N
. . N

Efficacy NN N
and CC N
safety NN N
of IN N
zidovudine NN N
and CC N
zalcitabine NN N
combined VBN N
with IN N
a DT N
combination NN N
of IN N
herbs NN N
in IN N
the DT N
treatment NN N
of IN N
HIV-infected NNP N
Thai NNP N
patients NNS p
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
operative JJ N
duration NN N
, , N
resection NN N
weight NN N
, , N
resection NN N
speed NN N
or CC N
radicality NN N
of IN N
resection NN N
. . N

The DT N
response NN N
rates NNS N
for IN N
control NN N
of IN N
pleural JJ N
effusion NN N
were VBD N
73.4 CD N
% NN N
in IN N
the DT N
N-CWS NNP N
group NN N
and CC N
46.1 CD N
% NN N
in IN N
the DT N
N-CWS NNP N
group NN N
. . N

Therefore IN N
we PRP N
evaluated VBD N
the DT N
profile NN N
of IN N
AP-1 NNP N
activation NN N
through IN N
histological JJ N
analysis NN N
and CC N
tested VBD N
the DT N
potential JJ N
benefit NN N
of IN N
AP-1 NNP N
inhibition NN N
in IN N
a DT N
clinical JJ N
trial NN N
. . N

However RB N
, , N
this DT N
did VBD N
not RB N
lead VB N
to TO N
a DT N
change NN N
in IN N
the DT N
overall JJ i
function NN N
of IN N
these DT N
children NNS N
( ( N
Gross NNP N
Motor NNP N
Function NNP N
Classification NNP N
System NNP N
level JJ N
V NNP N
) ) N
. . N

Association NNP N
of IN N
PML-RAR NNP N
alpha JJ N
fusion NN N
mRNA NN N
type NN N
with IN N
pretreatment JJ N
hematologic JJ N
characteristics NNS N
but CC N
not RB N
treatment NN N
outcome NN N
in IN N
acute JJ N
promyelocytic JJ N
leukemia NN N
: : N
an DT N
intergroup NN N
molecular NN N
study NN N
. . N

However RB N
, , N
when WRB N
subjects NNS N
were VBD N
examined VBN N
individually RB N
both DT N
the DT N
GHRH- NNP N
and CC N
the DT N
TRH-induced NNP N
hormonal JJ N
peaks NNS N
and CC N
the DT N
subsequent JJ N
fall NN N
were VBD N
not RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

Most JJS N
adverse JJ N
events NNS N
reported VBN N
were VBD N
mild JJ N
or CC N
moderate JJ N
and CC N
the DT N
incidence NN N
is VBZ N
as RB N
would MD N
be VB N
expected VBN N
in IN N
this DT N
patient JJ N
population NN N
. . N

From IN N
these DT N
results NNS N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
in IN N
the DT N
patients NNS p
tested VBN N
, , N
intradermal JJ N
injection NN N
of IN N
OK-432 NNP N
appears VBZ N
to TO N
be VB N
clinically RB N
superior JJ N
to TO N
intramuscular JJ N
injection NN N
. . N

BACKGROUND NNP N
Heightened VBD N
central JJ N
sympathetic JJ N
nervous JJ N
outflow NN N
is VBZ N
common JJ N
in IN N
essential JJ N
hypertension NN N
, , N
contributing VBG N
to TO N
hypertension NN N
development NN N
and CC N
perhaps RB N
also RB N
to TO N
complications NNS N
. . N

Because IN N
implant JJ N
ruptures NNS N
often RB N
occur VBP N
asymptomatically RB N
, , N
any DT N
woman NN N
with IN N
silicone NN N
implants NNS N
, , N
regardless RB N
of IN N
rupture NN N
status NN N
, , N
should MD N
be VB N
evaluated VBN N
at IN N
regular JJ N
intervals NNS N
. . N

We PRP N
have VBP N
developed VBN N
novel JJ N
molecular JJ N
methods NNS N
using VBG N
a DT N
stool NN N
sample NN N
, , N
which WDT N
contains VBZ N
intact JJ N
sloughed VBN N
colon NN N
cells NNS N
, , N
to TO N
quantify VB N
colonic JJ N
gene NN N
expression NN N
profiles NNS N
. . N

aureus NN N
was VBD N
0.31 CD N
and CC N
0.28 CD N
for IN N
heifers NNS N
in IN N
the DT N
prepartum NN N
and CC N
postpartum NN N
groups NNS N
, , N
respectively RB N
, , N
compared VBN N
with IN N
that DT N
for IN N
heifers NNS N
in IN N
the DT N
control NN N
group NN N
. . N

[ IN N
The DT N
effects NNS N
of IN N
early JJ N
enteral JJ N
nutrition NN N
with IN N
addition NN N
of IN N
probiotics NNS N
on IN N
the DT N
prognosis NN N
of IN N
patients NNS p
suffering VBG N
from IN N
severe JJ N
acute NN N
pancreatitis NN N
] NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
kinematic JJ N
parameters NNS N
for IN N
motor NN N
control NN N
and CC N
the DT N
Motor NNP N
Activity NNP N
Log NNP N
and CC N
ABILHAND NNP N
Questionnaire NNP N
for IN N
daily JJ N
function NN N
. . N

In IN N
patients NNS p
with IN N
AS NNP N
, , N
pancuronium NN N
increased VBD o
heart NN o
rate NN N
more JJR N
than IN N
vecuronium NN N
or CC N
atracurium NN N
; : N
heart NN N
rates NNS N
were VBD N
also RB N
higher JJR N
with IN N
the DT N
pancuronium-metocurine JJ N
mixture NN N
than IN N
with IN N
vecuronium NN N
. . N

CONCLUSIONS VB N
It PRP N
was VBD N
determined VBN N
that IN N
the DT N
use NN N
of IN N
oxytocin NN i
after IN N
shoulder NN N
delivery NN N
has VBZ N
more JJR N
effects NNS N
on IN N
decreasing VBG N
the DT N
amount NN N
of IN N
postpartum NN N
hemorrhage NN N
. . N

Besides IN N
the DT N
established VBN N
cytokines NNS N
, , N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
is VBZ N
demonstrated VBN N
as IN N
an DT N
important JJ N
factor NN N
in IN N
enhancing VBG N
vascular JJ N
leakage NN N
in IN N
sepsis NN N
. . N

The DT N
effects NNS N
of IN N
clonidine NN N
and CC N
hydrochlorothiazide NN i
on IN N
cognitive JJ N
function NN N
were VBD N
studied VBN N
in IN N
hypertensive JJ N
adolescents NNS N
requiring VBG N
pharmacologic JJ N
therapy NN i
for IN N
blood NN N
pressure NN N
control NN N
. . N

However RB N
, , N
to TO N
date NN N
, , N
no DT N
studies NNS N
have VBP N
compared VBN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
amlodipine JJ N
camsylate NN N
and CC N
amlodipine JJ N
besylate NN N
in IN N
treating VBG N
hypertension NN N
. . N

RESULTS NN N
In IN N
both DT N
groups NNS N
, , N
HV NNP N
and CC N
HV NNP N
standard JJ N
deviation NN N
score VBD N
HV-SDSCA NNP N
increased VBD o
during IN o
treatment NN N
and CC N
decreased VBD o
during IN o
observation NN N
periods NNS N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
zoledronic JJ N
acid NN N
for IN N
the DT N
treatment NN N
of IN N
bone NN N
metastases NNS N
from IN N
breast NN N
cancer NN N
. . N

Changes NNS N
in IN N
cardiac JJ N
index NN N
, , N
systemic JJ N
and CC N
pulmonary JJ N
vascular NN N
resistance NN N
, , N
blood NN N
pressure NN N
, , N
and CC N
heart NN N
rate NN N
did VBD N
not RB N
significantly RB N
differ VBP N
from IN N
placebo NN N
. . N

Plasma NNP N
levels NNS N
, , N
areas NNS N
under IN N
24-hour JJ N
plasma NN N
concentration NN N
curves NNS N
and CC N
urinary JJ N
excretion NN N
were VBD N
similar JJ N
by IN N
both DT N
formulations NNS N
in IN N
steady JJ N
state NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
lipid JJ N
profiles NNS N
, , N
inflammatory JJ N
markers NNS N
, , N
24-h JJ N
ambulatory NN N
blood NN N
pressure NN N
, , N
and CC N
carotid JJ N
artery NN N
intimamedia NN N
thickness NN N
. . N

BACKGROUND NNP N
Osteoporosis NNP N
is VBZ N
associated VBN N
with IN N
cirrhosis NN N
of IN N
the DT N
liver NN N
, , N
but CC N
the DT N
effects NNS N
of IN N
therapy NN i
for IN N
osteoporosis NN N
associated VBN N
with IN N
cirrhosis NN N
are VBP N
still RB N
controversial JJ N
. . N

In IN N
summary JJ N
, , N
the DT N
irritative JJ N
and CC N
obstructive JJ N
symptoms NNS N
caused VBN N
by IN N
benign JJ N
prostatic JJ N
hypertrophy NN N
were VBD N
decreased VBN o
and CC N
urodynamic JJ N
studies NNS N
were VBD N
markedly RB N
improved VBN N
by IN N
the DT N
alpha JJ N
1-blocker NN N
, , N
YM617 NNP N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ i
survival NN N
with IN N
secondary JJ N
endpoints NNS N
of IN N
time NN N
to TO N
disease VB N
progression NN N
and CC N
quality NN N
of IN N
life NN N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
only RB N
lower JJR N
baseline NN N
CD4 NNP N
cell NN N
count NN N
and CC N
higher JJR N
HIV-1 NNP N
RNA NNP N
were VBD N
associated VBN N
with IN N
greater JJR N
increase NN o
in IN N
weight NN N
, , N
BMI NNP N
, , N
or CC N
LBM NNP N
. . N

IP NNP N
assessed VBN N
by IN N
lactulose NN N
: : N
mannitol NN N
( ( N
L/M NNP N
) ) N
sugar NN N
permeability NN N
test NN N
and CC N
behavior NN N
assessed VBN N
by IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
and CC N
Conners NNP N
Parent NNP N
Rating NNP N
were VBD N
measured VBN N
. . N

The DT N
less RBR N
favourable JJ N
improvement NN N
in IN N
periodontal JJ N
function NN N
of IN N
postsplint NN N
or CC N
nonsplint NN N
teeth NNS N
seemed VBD N
to TO N
be VB N
due JJ N
to TO N
the DT N
loss NN N
of IN N
BRG NNP N
material NN N
caused VBN N
by IN N
tooth DT N
mobility NN N
. . N

Plasma NNP N
total JJ N
factor NN N
VII NNP N
was VBD N
measured VBN N
by IN N
use NN N
of IN N
a DT N
chromogenic JJ N
assay NN N
; : N
plasma CC N
active JJ N
FVII NNP N
by IN N
a DT N
recently RB N
developed VBN N
method NN N
using VBG N
truncated JJ N
tissue NN N
factor NN N
. . N

CONCLUSIONS VB N
The DT N
rates NNS N
of IN N
MACEs NNP N
, , N
TVR NNP N
, , N
and CC N
stent JJ N
thrombosis NN N
during IN N
the DT N
three-year JJ N
follow-up NN N
were VBD N
similar JJ N
in IN N
the DT N
SES NNP N
and CC N
PES NNP N
Groups NNP N
. . N

Changes NNS N
in IN N
body NN N
weight NN N
, , N
total JJ N
fat JJ N
intake NN N
, , N
urinary JJ N
sodium NN N
and CC N
potassium NN N
did VBD N
not RB N
have VB N
significant JJ N
predictive JJ N
power NN N
in IN N
any DT N
of IN N
the DT N
analyses NNS N
. . N

PARTICIPANTS NNS N
Participants NNS N
( ( N
N=106 NNP N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
WB NNP N
exercise NN N
, , N
NWB NNP N
exercise NN N
, , N
or CC N
a DT N
control NN N
group NN N
( ( N
no DT N
exercise NN N
) ) N
. . N

Effective JJ N
response NN N
rates NNS N
for IN N
the DT N
above NN N
mentioned VBD N
three CD N
groups NNS N
were VBD N
69.2 CD N
% NN N
, , N
69.2 CD N
% NN N
and CC N
55.8 CD N
% NN N
, , N
respectively RB N
. . N

Significant JJ N
differences NNS N
were VBD N
also RB N
found VBN N
for IN N
some DT N
breast NN N
cancer-specific JJ N
symptoms NNS N
[ MD N
swelling VBG N
, , N
mobility NN N
and CC N
pain NN N
( ( N
p JJ N
= NNP N
0.045 CD N
) ) N
] NN N
. . N

We PRP N
conclude VBP N
that IN N
periarticularly RB N
administered VBN N
morphine NN N
in IN N
arthroscopic JJ N
subacromial JJ N
decompression NN N
in IN N
the DT N
dosage NN N
applied VBN N
in IN N
this DT N
study NN N
does VBZ N
exert VB N
no DT N
relevant JJ N
analgesic JJ N
effect NN N
. . N

Perindopril NNP N
, , N
whether IN N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
hydrochlorothiazide NN i
, , N
was VBD N
well RB N
tolerated VBN N
and CC N
produced VBN N
no DT N
clinically RB N
significant JJ N
change NN N
in IN N
routine JJ N
haematology NN N
or CC N
serum JJ N
biochemistry NN N
. . N

INTRODUCTION NNP N
Estimating VBG N
the DT N
cost NN N
utility NN N
of IN N
hemiarthroplasty NN N
compared VBN N
to TO N
internal JJ N
fixation NN N
in IN N
the DT N
treatment NN N
of IN N
displaced JJ N
femoral JJ N
neck NN N
fractures NNS N
in IN N
the DT N
elderly JJ N
. . N

Interleukin-1 JJ N
beta NN N
( ( N
IL-1 NNP N
beta NN N
) ) N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
PBC NNP N
by IN N
contributing VBG N
to TO N
altered VBN N
immune JJ N
function NN N
and CC N
fibrosis NN N
. . N

PURPOSE NNP N
Intensive NNP N
chemotherapy NN i
followed VBN N
by IN N
autotransplantation NN N
has VBZ N
given VBN N
promising VBG N
results NNS N
in IN N
partially RB N
responding VBG N
or CC N
sensitive JJ N
relapsed JJ N
patients NNS p
with IN N
aggressive JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

Samples NNS N
from IN N
saliva NN N
, , N
dental JJ N
plaque NN N
and CC N
faeces NNS N
and CC N
biopsies NNS N
from IN N
antrum NN N
and CC N
corpus NN N
were VBD N
analysed VBN N
in IN N
order NN N
to TO N
determine VB N
the DT N
ecological JJ N
changes NNS N
in IN N
the DT N
normal JJ N
microflora NN N
. . N

In IN N
contrast NN N
, , N
SDZ NNP N
ENS-163 NNP N
with IN N
saline NN N
had VBD N
no DT N
effect NN N
on IN N
CNTB NNP N
scores NNS N
, , N
increased VBN o
salivation NN N
, , N
and CC N
increased VBD o
heart NN o
rate NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
reported VBN N
were VBD N
worsening VBG N
of IN N
UC NNP N
and CC N
headache NN N
; : N
both DT N
were VBD N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
placebo NN N
group NN N
. . N

TNF NNP N
therapy NN i
is VBZ N
effective JJ N
for IN N
all DT N
aspects NNS N
of IN N
psoriatic JJ N
disease NN N
, , N
but CC N
these DT N
drugs NNS N
are VBP N
costly JJ N
and CC N
the DT N
long-term JJ N
effects NNS N
are VBP N
unknown JJ N
. . N

Upon IN N
removal NN N
of IN N
each DT N
patch NN N
, , N
skin NN N
sites NNS N
were VBD N
evaluated VBN N
for IN N
signs NNS N
of IN N
irritation NN N
, , N
and CC N
subjective JJ N
complaints NNS N
such JJ N
as IN N
itching NN N
or CC N
burning NN N
were VBD N
recorded VBN N
. . N

Change NN N
in IN N
functional JJ N
ability NN N
remained VBD N
significantly RB N
better RBR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
out IN N
to TO N
8-week JJ N
follow-up NN N
. . N

The DT N
24-gauge JJ N
Gertie NNP N
Marx NNP N
needle RB N
resulted VBD N
in IN N
more RBR N
successful JJ N
location NN N
of IN N
the DT N
spinal JJ N
space NN N
on IN N
the DT N
second JJ N
attempt NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
some DT N
effects NNS N
of IN N
low JJ N
protein NN N
provision NN N
in IN N
utero NN N
can MD N
be VB N
alleviated VBN N
by IN N
an DT N
adequate JJ N
nutrient JJ N
supply NN N
post-partum NN N
. . N

The DT N
in IN N
vivo JJ N
effects NNS N
of IN N
oral JJ N
clarithromycin JJ i
administration NN N
on IN N
the DT N
in IN N
vivo JJ N
activity NN N
of IN N
cytochrome NN N
P450 NNP N
1A2 CD N
, , N
2C9 CD N
, , N
and CC N
2D6 CD N
were VBD N
determined VBN N
. . N

Cyproheptadine NNP N
augmentation NN N
, , N
compared VBN N
to TO N
administration NN N
of IN N
haloperidol NN N
with IN N
placebo NN N
, , N
did VBD N
not RB N
produce VB N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
psychotic JJ i
symptoms NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
a DT N
trend NN N
in IN N
favour NN N
of IN N
the DT N
buflomedil NN N
group NN N
in IN N
three CD N
of IN N
the DT N
tests NNS N
became VBD N
statistically RB N
significant JJ N
in IN N
the DT N
fourth JJ N
. . N

Mean JJ N
scores NNS N
favored VBD N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
, , N
but CC N
no DT N
significant JJ N
differences NNS N
between IN N
these DT N
groups NNS N
and CC N
the DT N
ROC NNP N
group NN N
were VBD N
obtained VBN N
. . N

Biofilms NNS N
are VBP N
sessile JJ N
communities NNS N
of IN N
bacteria NNS N
embedded VBN N
in IN N
self-produced JJ N
extracellular JJ N
polysaccharide NN N
matrix NN N
and CC N
are VBP N
considered VBN N
to TO N
be VB N
responsible JJ N
for IN N
bacterial JJ N
infections NNS N
in IN N
humans NNS N
. . N

BACKGROUND NNP N
Prophylactic NNP N
cranial JJ N
irradiation NN N
in IN N
patients NNS p
with IN N
small-cell JJ N
lung NN N
cancer NN N
decreases VBZ o
the DT N
overall JJ i
rate NN N
of IN N
brain NN N
metastases NNS N
without IN N
an DT N
effect NN N
on IN N
overall JJ i
survival NN N
. . N

In IN N
the DT N
jejunum NN N
, , N
villus JJ N
height NN N
, , N
crypt NN N
depth NN N
, , N
and CC N
the DT N
number NN N
of IN N
goblet NN N
cells NNS N
producing VBG N
neutral JJ N
, , N
acidic JJ N
, , N
sulfated VBN N
, , N
and CC N
sialylated VBD N
mucins NNS N
were VBD N
measured VBN N
. . N

BACKGROUND NNP N
Allopurinol NNP N
has VBZ N
been VBN N
widely RB N
used VBN N
for IN N
treatment NN N
of IN N
hyperuricemia NN N
, , N
however RB N
, , N
it PRP N
may MD N
be VB N
associated VBN N
with IN N
various JJ N
adverse JJ N
effects NNS N
. . N

Studies NNS N
on IN N
the DT N
platelet NN N
functioning NN N
showed VBD N
an DT N
obvious JJ N
decrease NN o
in IN N
platelet NN N
aggregation NN N
in IN N
those DT N
patients NNS p
treated VBN N
with IN N
the DT N
active JJ N
drug NN N
. . N

Accuracy NNP N
( ( N
correction NN N
rate NN N
) ) N
, , N
recognition NN N
accuracy NN N
( ( N
correction NN N
rate-commission NN N
error NN N
rate NN N
) ) N
, , N
and CC N
response NN N
time NN N
were VBD N
measured VBN N
during IN N
each DT N
experiment NN N
. . N

BACKGROUND NNP N
Tibial NNP N
tubercle-trochlear JJ N
groove NN N
distance NN N
( ( N
TT-TG NNP N
) ) N
is VBZ N
a DT N
commonly RB N
used VBN N
measurement NN N
for IN N
surgical JJ N
decision NN N
making NN N
in IN N
patients NNS p
with IN N
patellofemoral JJ N
malalignment NN N
and CC N
instability NN N
. . N

1H CD N
nuclear JJ N
magnetic JJ N
resonance-based JJ N
metabolomic NN N
study NN N
on IN N
efficacy NN N
of IN N
Qingrehuatan NNP N
decoction NN N
against IN N
abundant JJ N
phlegm-heat JJ N
syndrome NN N
in IN N
young JJ N
adults NNS N
with IN N
essential JJ N
hypertension NN N
. . N

OBJECTIVE NN N
To TO N
compare VB N
elastic JJ N
stable JJ N
intramedullary JJ N
nailing NN N
( ( N
ESIN NNP N
) ) N
with IN N
nonoperative JJ N
treatment NN N
of IN N
fully RB N
displaced VBN N
midshaft NN N
clavicular NN N
fractures NNS N
in IN N
adults NNS N
. . N

The DT N
present JJ N
study NN N
demonstrates VBZ N
that IN N
DEX NNP N
is VBZ N
less RBR N
inhibitory JJ N
for IN N
phytohemagglutinin NN N
( ( N
PHA NNP N
) ) N
-induced VBD N
T NNP N
cell NN N
proliferation NN N
in IN N
AD NNP N
patients NNS p
as IN N
compared VBN N
to TO N
age-matched JJ N
controls NNS N
. . N

The DT N
arousal NN N
index NN N
was VBD N
significantly RB N
higher JJR N
during IN N
leak JJR N
periods NNS N
, , N
and CC N
its PRP$ N
changes NNS N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
mouth NN N
leak NN N
. . N

However RB N
, , N
the DT N
timing NN N
of IN N
such JJ N
form NN N
processing NN N
aberrations NNS N
is VBZ N
much RB N
later RBR N
than IN N
the DT N
timing NN N
of IN N
abnormal JJ N
magnocellular JJ N
visual JJ N
processing NN N
measured VBN N
directly RB N
here RB N
. . N

BACKGROUND NNP N
In IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
, , N
a DT N
defective JJ N
nitric JJ N
oxide IN N
signaling VBG N
is VBZ N
involved VBN N
in IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
diastolic NN N
abnormalities NNS N
and CC N
remodeling VBG N
. . N

CONCLUSION NNP N
RFA NNP N
took VBD N
longer JJR N
to TO N
perform VB N
but CC N
resulted VBD N
in IN N
a DT N
significantly RB N
better RBR N
early RB N
outcome NN N
than IN N
conventional JJ N
surgery NN N
in IN N
suitable JJ N
patients NNS p
with IN N
great JJ N
saphenous JJ N
varicose NN N
veins NNS N
. . N

With IN N
the DT N
exception NN N
of IN N
the DT N
1-min JJ N
protocol NN N
, , N
the DT N
maximum JJ N
negative JJ N
pressure NN N
tolerated VBD N
did VBD N
not RB N
vary JJ N
regardless NN N
of IN N
the DT N
protocol NN N
used VBN N
. . N

The DT N
MVPF NNP N
group NN N
demonstrated VBD N
a DT N
39.0 CD N
per IN N
cent NN N
greater JJR N
reduction NN N
in IN N
pain NN N
after IN N
application NN N
of IN N
the DT N
dressing NN N
over IN N
the DT N
silver JJ N
sulphadiazine NN N
group NN N
. . N

BACKGROUND NNP N
Laparoscopic NNP N
appendectomy NN N
( ( N
LA NNP N
) ) N
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
faster JJ N
recovery NN N
and CC N
less RBR N
postoperative JJ N
pain NN N
than IN N
the DT N
open JJ N
technique NN N
. . N

Oral JJ N
sodium NN N
phosphate NN N
is VBZ N
a DT N
cost-effective JJ N
colonoscopy NN N
preparation NN N
that WDT N
is VBZ N
better RBR N
tolerated VBN N
and CC N
more RBR N
effective JJ N
than IN N
the DT N
polyethylene JJ N
glycol-electrolyte JJ N
lavage NN N
solution NN N
or CC N
castor NN N
oil NN N
. . N

RESULTS JJ N
Nonlinear NNP N
PK NNP N
of IN N
linagliptin NN i
in IN N
T2DM NNP N
patients NNS p
were VBD N
well RB N
described VBN N
by IN N
a DT N
2-compartment JJ N
model NN N
assuming VBG N
concentration-dependent JJ N
binding NN N
to TO N
DPP-4 NNP N
in IN N
the DT N
central JJ N
and CC N
peripheral JJ N
compartment NN N
. . N

Postoperative JJ N
response NN N
to TO N
treatment NN N
, , N
liver JJ N
function NN N
change NN N
( ( N
ALT NNP N
) ) N
, , N
AFP NNP N
, , N
imaging VBG N
examination NN N
of IN N
the DT N
tumor NN N
, , N
patient NN N
's POS N
survival NN N
were VBD N
evaluated VBN N
. . N

Our PRP$ N
results NNS N
provide VBP N
indirect JJ N
evidence NN N
that IN N
reversible JJ N
changes NNS N
in IN N
the DT N
cation-chloride JJ N
transport NN N
system NN N
induce JJ N
modulations NNS N
of IN N
inhibitory JJ N
neuronal JJ N
activity NN N
at IN N
spinal JJ N
cord NN N
level NN N
in IN N
humans NNS N
. . N

Ranitidine NNP N
pretreatment NN N
had VBD N
no DT N
effect NN N
on IN N
triazolam NN i
's POS N
terminal JJ N
elimination NN N
rate NN N
constant JJ N
or CC N
on IN N
the DT N
time NN N
to TO N
reach VB N
maximum JJ N
serum JJ N
triazolam NN i
concentration NN N
. . N

There EX N
was VBD N
a DT N
dose JJ N
related JJ N
reduction NN N
in IN N
symptoms NNS N
, , N
plasma JJ N
follicle NN N
stimulating VBG N
hormone NN N
concentration NN N
, , N
and CC N
urinary JJ N
calcium NN N
and CC N
hydroxyproline JJ N
excretion NN N
. . N

With IN N
the DT N
comparable JJ N
relaxivities NNS N
of IN N
gadodiamide JJ N
injection NN N
and CC N
gadopentetate NN N
dimeglumine NN N
, , N
similarities NNS N
in IN N
results NNS N
have VBP N
to TO N
be VB N
expected VBN N
when WRB N
using VBG N
these DT N
media NNS N
for IN N
MR NNP N
image NN N
enhancement NN N
. . N

The DT N
treatment NN N
effect NN N
of IN N
eptifibatide NN N
is VBZ N
realized VBN N
regardless RB N
of IN N
renal JJ N
function NN N
and CC N
trends VBZ N
toward IN N
being VBG N
greater JJR N
in IN N
patients NNS p
with IN N
mild JJ N
renal JJ N
impairment NN N
. . N

Avian JJ N
influenza NN N
is VBZ N
a DT N
severe JJ N
disease NN N
among IN N
farmed JJ N
poultry NN N
and CC N
free-living JJ N
birds NNS N
and CC N
a DT N
constant JJ N
threat NN N
to TO N
the DT N
commercial JJ N
chicken NN N
industry NN N
around IN N
the DT N
world NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
continuous JJ N
infusion NN N
of IN N
morphine NN N
may MD N
be VB N
an DT N
inferior JJ N
regimen NNS N
to TO N
intermittent VB N
bolus JJ N
administration NN N
in IN N
the DT N
relief NN N
of IN N
postoperative JJ N
pain NN N
. . N

Peripheral NNP N
opioid NN N
receptors NNS N
have VBP N
been VBN N
found VBN N
in IN N
inflamed JJ N
synovia NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
intra-articularly JJ N
administered JJ N
morphine NN N
after IN N
arthroscopic NN N
knee NN N
surgery NN N
has VBZ N
been VBN N
proven VBN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
beta NN N
, , N
t NN N
( ( N
1/2 CD N
) ) N
, , N
and CC N
t NN N
( ( N
max NN i
) ) N
between IN N
the DT N
two CD N
occasions NNS N
. . N

Levels NNS N
of IN N
fibrinogen NN N
, , N
activated VBD N
factor NN N
VII NNP N
, , N
and CC N
factor NN N
VII NNP N
antigen NN N
were VBD N
not RB N
significantly RB N
influenced VBN N
by IN N
hormone NN N
replacement NN N
therapy NN i
treatment NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
WP NNP N
+ NNP N
NCHT NNP N
, , N
PO NNP N
+ NNP N
NCHT NNP N
, , N
WP NNP N
+ NNP N
AHT NNP N
, , N
or CC N
PO NNP N
+ NNP N
AHT NNP N
. . N

Pain NNP N
detection NN N
and CC N
tolerance NN N
thresholds NNS N
for IN N
pressure NN N
and CC N
electric JJ N
stimuli NNS N
were VBD N
measured VBN N
in IN N
six CD N
selected VBN N
dermatomes NNS N
( ( N
C5 NNP N
, , N
T4 NNP N
, , N
T10 NNP N
, , N
L1 NNP N
, , N
L4 NNP N
and CC N
T10BACK NNP N
) ) N
. . N

CONCLUSION NNP N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
effectiveness NN N
of IN N
the DT N
medications NNS N
on IN N
pain NN N
relief NN N
, , N
or CC N
in IN N
stinging VBG N
on IN N
instillation NN N
. . N

The DT N
role NN N
of IN N
IgA NNP N
in IN N
providing VBG N
protection NN N
against IN N
influenza NN N
in IN N
children NNS N
vaccinated VBN N
with IN N
live JJ N
attenuated VBN N
influenza JJ N
vaccine NN N
( ( N
LAIV NNP N
) ) N
has VBZ N
not RB N
been VBN N
well RB N
described VBN N
. . N

Most JJS N
frequent JJ N
treatment-emergent JJ N
adverse JJ N
events NNS N
were VBD N
dizziness RB N
, , N
somnolence NN N
, , N
irritability NN N
, , N
headache NN N
, , N
fall NN N
, , N
and CC N
ataxia NN N
. . N

Because IN N
of IN N
slow JJ N
accrual NN N
, , N
the DT N
two CD N
chemotherapy NN i
groups NNS N
were VBD N
combined VBN N
and CC N
compared VBN N
with IN N
ASC NNP N
alone RB N
for IN N
the DT N
primary JJ N
outcome NN N
of IN N
overall JJ i
survival NN N
. . N

A DT N
potent JJ N
oral JJ N
P-selectin NNP i
blocking NN N
agent NN N
improves VBZ N
microcirculatory JJ N
blood NN N
flow NN N
and CC N
a DT N
marker NN N
of IN N
endothelial JJ N
cell NN N
injury NN N
in IN N
patients NNS p
with IN N
sickle JJ N
cell NN N
disease NN N
. . N

Eight CD N
weeks NNS N
of IN N
assisted JJ N
range-of-motion NN N
exercise NN N
attenuates VBZ N
the DT N
decrease NN o
in IN N
bone NN N
strength NN N
and CC N
may MD N
decrease VB o
the DT N
risk NN N
of IN N
osteopenia NN N
in IN N
premature JJ N
infants NNS N
. . N

The DT N
combined JJ N
administration NN N
of IN N
MMC NNP N
and CC N
HCFU NNP N
was VBD N
suggested VBN N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
adjuvant NN N
chemotherapy NN i
for IN N
noncuratively RB N
resected VBN N
cases NNS N
of IN N
colorectal JJ N
carcinoma NN N
. . N

Furthermore RB N
, , N
the DT N
dentition NN N
of IN N
the DT N
patients NNS p
in IN N
the DT N
two CD N
experimental JJ N
groups NNS N
was VBD N
treated VBN N
, , N
at IN N
three-month JJ N
intervals NNS N
, , N
with IN N
chlorhexidine NN N
and CC N
fluoride JJ N
varnish NN N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Moderate-intensity NNP N
step NN N
aerobics NNS N
training VBG N
significantly RB N
increases VBZ o
peak JJ N
oxygen NN N
uptake NN N
and CC N
peak JJ N
workloads NNS N
in IN N
patients NNS p
with IN N
severe JJ N
chronic JJ N
heart NN N
failure NN N
. . N

The DT N
TT-specific NNP N
immunoglobulin NN N
G NNP N
( ( N
IgG NNP N
) ) N
boost VBD N
efficiency NN N
was VBD N
marginal JJ N
higher JJR N
in IN N
the DT N
vitamin NN N
D NNP N
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
was VBD N
evidence NN N
of IN N
variation NN N
in IN N
sensitivity NN N
between IN N
endoscopists NNS N
, , N
but CC N
significant JJ N
miss JJ N
rates NNS N
for IN N
small JJ N
adenomas NNS N
were VBD N
found VBN N
among IN N
essentially RB N
all DT N
endoscopists NNS N
. . N

The DT N
AUC NNP N
and CC N
Cmax NNP i
after IN N
fasting VBG N
were VBD N
closely RB N
similar JJ N
to TO N
those DT N
after IN N
a DT N
meal NN N
, , N
showing VBG N
that IN N
bioavailability NN N
was VBD N
not RB N
affected VBN N
by IN N
food NN N
intake NN N
. . N

INTRODUCTION NNP N
Few NNP N
combinations NNS N
of IN N
highly RB N
active JJ N
antiretrovirals NNS N
have VBP N
been VBN N
studied VBN N
in IN N
nucleoside JJ N
reverse NN N
transcription NN N
inhibitor NN N
( ( N
NRTI NNP N
) ) N
-experienced VBD N
, , N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
-infected VBD N
children NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
CVC NNP N
use/type NN N
or CC N
duration NN N
or CC N
in IN N
positive/negative JJ N
BC NNP N
with/without NN N
associated VBN N
C NNP N
reactive JJ N
protein NN N
rise NN N
in IN N
SCAMP NNP N
versus NN N
control NN N
groups NNS N
. . N

At IN N
TI2 NNP N
, , N
previous JJ N
to TO N
the DT N
allergen NN N
challenge NN N
, , N
the DT N
active JJ N
group NN N
showed VBD N
higher JJR N
values NNS N
of IN N
both DT N
FEV1 NNP N
and CC N
Mth-PD20 NNP N
and CC N
lower JJR N
values NNS N
of IN N
Mth-DRS NNP N
. . N

Cortisol NNP N
levels NNS N
in IN N
patients NNS p
with IN N
Alzheimer NNP N
's POS N
disease NN N
( ( N
AD NNP N
) ) N
are VBP N
relatively RB N
unaffected JJ N
by IN N
a DT N
challenge NN N
with IN N
dexamethasone NN N
( ( N
DEX NNP N
) ) N
in IN N
vivo NN N
. . N

There EX N
is VBZ N
much JJ N
evidence NN N
suggesting VBG N
that IN N
the DT N
decline NN N
in IN N
ovarian JJ N
function NN N
after IN N
menopause NN N
is VBZ N
associated VBN N
with IN N
spontaneous JJ N
increases NNS o
in IN N
proinflammatory JJ N
cytokines NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
mean JJ N
age NN N
, , N
anaesthetic JJ N
time NN N
, , N
perioperative JJ N
morbidity NN N
, , N
or CC N
postoperative JJ N
mobility NN N
. . N

Fenoterol NNP N
treatment NN N
increased VBD o
both DT o
superimposed VBN N
Pdi NNP N
twitch NN N
and CC N
Pdi NNP N
twitch NN N
of IN N
relaxed JJ N
diaphragm NN N
and CC N
decreased VBD o
the DT o
value NN N
of IN N
( ( N
1-superimposed JJ N
Pdi NNP N
twitch/Pdi NN N
twitch NN N
of IN N
relaxed JJ N
diaphragm NN N
) ) N
. . N

rHu NN N
EPO NNP N
treatment NN N
affects VBZ N
the DT N
T NNP N
lymphocyte NN N
subsets NNS N
inducing VBG N
a DT N
deep JJ N
decrease NN o
of IN N
CD8 NNP N
and CC N
CD16 NNP N
cell NN N
percentage NN N
leading VBG N
to TO N
normalisation NN N
of IN N
the DT N
CD4/CD8 NNP N
ratio NN N
. . N

CONCLUSION NNP N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
use NN N
as IN N
an DT N
adjunct NN N
to TO N
hemostasis VB N
in IN N
patients NNS p
undergoing JJ N
cardiac JJ N
surgery NN N
. . N

Similarly RB N
, , N
there EX N
were VBD N
no DT N
clinically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
cardiac JJ N
variables NNS N
, , N
or CC N
in IN N
vital JJ N
signs NNS N
. . N

PURPOSE NNP N
Iron-containing JJ N
products NNS N
are VBP N
atypical JJ N
in IN N
terms NNS N
of IN N
their PRP$ N
pharmacokinetic JJ N
properties NNS N
because IN N
iron NN N
is VBZ N
only RB N
removed VBN N
by IN N
plasma NN N
sampling NN N
and CC N
is VBZ N
non-linear JJ N
. . N

CONCLUSIONS NNP N
Fructose-1,6-diphosphate NNP N
produces VBZ N
a DT N
modest JJ N
but CC N
significant JJ N
increase NN o
in IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
in IN N
patients NNS p
with IN N
mild JJ N
to TO N
moderate VB N
heart NN N
failure NN N
. . N

No DT N
difference NN N
in IN N
marginal JJ N
conjunctival NN N
sensitivity NN N
was VBD N
found VBN N
between IN N
upper JJ N
and CC N
lower JJR N
eyelids NNS N
( ( N
all DT N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
an DT N
advantage NN N
to TO N
administering VBG N
xylitol NN N
and CC N
fructose JJ N
with IN N
regard NN N
to TO N
the DT N
intestinal JJ N
absorption NN N
and CC N
concomitant NN N
symptoms NNS N
as IN N
compared VBN N
with IN N
sorbitol NN N
. . N

However RB N
, , N
while IN N
there EX N
is VBZ N
much JJ N
anecdotal JJ N
evidence NN N
to TO N
that DT N
effect NN N
, , N
the DT N
empirical JJ N
literature NN N
is VBZ N
very RB N
inconsistent JJ N
. . N

Changes NNS N
in IN N
functional JJ N
capillary JJ N
density NN N
( ( N
FCD NNP N
) ) N
, , N
blood NN N
flow NN N
velocity NN N
, , N
and CC N
vessel RB N
diameter NN N
were VBD N
analyzed VBN N
by IN N
a DT N
blinded JJ N
investigator NN N
. . N

In IN N
addition NN N
, , N
ORR NNP N
was VBD N
significantly RB N
higher JJR N
with IN N
letrozole JJR N
than IN N
tamoxifen NN N
in IN N
the DT N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
HER1/HER2+ NNP N
subgroup NN N
( ( N
P=0.0004 NNP N
) ) N
. . N

Aspiration NN N
documented VBN N
by IN N
modified JJ N
videofluoroscopic NN N
barium NN N
swallow NN N
technique NN N
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN o
in IN N
risk NN N
of IN N
pneumonia NN N
and CC N
death NN N
but CC N
not RB N
dehydration NN N
following VBG N
stroke NN N
. . N

BACKGROUND NNP N
Low NNP N
heart NN N
rate NN N
ischemia NN N
, , N
as IN N
detected VBN N
by IN N
Holter NNP N
ambulatory JJ N
electrocardiographic JJ N
monitoring NN N
, , N
suggests VBZ N
that IN N
reduced VBD N
coronary JJ N
flow NN N
is VBZ N
the DT N
major JJ N
factor NN N
leading VBG N
to TO N
ischemia VB N
. . N

Removal JJ N
rates NNS N
for IN N
thrombosis NN N
that WDT N
could MD N
not RB N
be VB N
resolved VBN N
with IN N
thrombolysis NN N
were VBD N
0.53 CD N
and CC N
0.43/1,000 CD N
catheter-days NNS N
for IN N
Palindrome NNP N
and CC N
HemoStar NNP N
, , N
respectively RB N
( ( N
P=0.7 NNP N
) ) N
. . N

[ JJ N
Physical NNP N
performance NN N
and CC N
sedation NN N
: : N
comparative JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
a DT N
benzodiazepine NN N
( ( N
temazepam NN i
) ) N
and CC N
of IN N
a DT N
non-benzodiazepine JJ N
hypnotic NN i
( ( N
zolpidem NN N
) ) N
] NN N
. . N

[ RB N
Prophylactic NNP N
use NN N
of IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
in IN N
combination NN N
with IN N
graduated JJ N
compression NN N
stockings NNS N
in IN N
post-operative JJ N
patients NNS p
with IN N
gynecologic JJ N
cancer NN N
] NN N
. . N

The DT N
overall JJ i
incidence NN N
of IN N
adverse JJ N
drug NN N
reaction NN N
was VBD N
11.79 CD N
% NN N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

Visual JJ N
Assessment NNP N
of IN N
Relative NNP N
Apical NNP N
Sparing NNP N
Pattern NNP N
Is VBZ N
More RBR N
Useful JJ N
Than NNP N
Quantitative NNP N
Assessment NNP N
for IN N
Diagnosing NNP N
Cardiac NNP N
Amyloidosis NNP N
in IN N
Borderline NNP N
or CC N
Mildly RB N
Increased VBD o
Left NNP o
Ventricular NNP N
Wall NNP N
Thickness NNP N
. . N

Persons NNS N
with IN N
one CD N
or CC N
two CD N
l JJ N
alleles NNS N
or CC N
higher JJR N
CSF NNP N
5HIAA CD N
levels NNS N
also RB N
exhibited VBD N
greater JJR N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
responses NNS N
to TO N
a DT N
mental JJ N
stress NN N
protocol NN N
. . N

Effects NNS N
of IN N
perioperative JJ N
indomethacin NN i
on IN N
intracranial JJ N
pressure NN N
, , N
cerebral JJ N
blood NN N
flow NN N
, , N
and CC N
cerebral JJ N
metabolism NN N
in IN N
patients NNS p
subjected VBN N
to TO N
craniotomy VB N
for IN N
cerebral JJ N
tumors NNS N
. . N

CONCLUSIONS NNP N
Opioid NNP N
doses VBZ N
commonly RB N
prescribed VBN N
in IN N
IV NNP N
opioid FW N
treatment NN N
induce NN N
marked VBD N
respiratory NN N
and CC N
circulatory NN N
depression NN N
, , N
as RB N
well RB N
as IN N
occasionally RB N
irregular JJ N
paroxysmal JJ N
EEG NNP N
activity NN N
. . N

The DT N
primary JJ N
outcome NN N
event NN N
( ( N
POE NNP N
) ) N
was VBD N
a DT N
composite NN N
of IN N
nonfatal JJ N
myocardial JJ N
infarction NN N
, , N
nonfatal JJ N
stroke NN N
, , N
resuscitated VBD N
cardiac JJ N
arrest NN N
or CC N
cardiovascular JJ N
death NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
; : N
secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

A DT N
pilot NN N
study NN N
of IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
supplemental JJ N
arginine NN N
to TO N
enhance VB N
immune JJ N
function NN N
in IN N
persons NNS N
with IN N
HIV/AIDS NNP N
. . N

Hypertension NN N
after IN N
treatment NN N
with IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
receptor NN N
inhibitors NNS N
is VBZ N
associated VBN N
with IN N
superior JJ N
treatment NN N
outcomes NNS N
for IN N
advanced JJ N
cancer NN N
patients NNS p
. . N

Elevated JJ N
levels NNS N
of IN N
tumor NN N
necrosis NN N
factor NN N
alpha NN N
( ( N
TNF-alpha NNP N
) ) N
have VBP N
been VBN N
reported VBN N
to TO N
correlate VB N
with IN N
the DT N
development NN N
of IN N
transplant-related JJ N
complications NNS N
after IN N
bone NN N
marrow NN N
transplantation NN N
( ( N
BMT NNP N
) ) N
. . N

OBJECTIVE NN N
To TO N
prospectively RB N
compare VB N
two CD N
commonly RB N
used VBD N
methods NNS N
for IN N
percutaneous JJ N
dilational JJ N
tracheostomy NN N
( ( N
PDT NNP N
) ) N
in IN N
critically RB N
ill JJ N
patients NNS p
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
median JJ N
duration NN N
of IN N
response NN N
and CC N
median JJ N
survival NN N
for IN N
the DT N
two CD N
regimens NNS N
. . N

More JJR N
than IN N
two CD N
adenomas NNS N
at IN N
first JJ N
examination NN N
was VBD N
the DT N
only JJ N
factor NN N
found VBD N
to TO N
be VB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
new JJ N
significant JJ N
neoplasia NN N
. . N

[ RB N
Long NNP N
term NN N
observation NN N
in IN N
effects NNS N
of IN N
potassium NN N
and CC N
calcium NN N
supplementation NN N
on IN N
arterial JJ N
blood NN N
pressure NN N
and CC N
sodium NN N
metabolism NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
] NN N
. . N

Effect NN N
of IN N
nitric-oxide-generating JJ N
system NN N
on IN N
microcirculatory NN N
blood NN N
flow NN N
in IN N
skin NN N
of IN N
patients NNS p
with IN N
severe JJ N
Raynaud NNP N
's POS N
syndrome NN N
: : N
a DT N
randomised JJ N
trial NN N
. . N

High JJ N
doses NNS N
of IN N
atorvastatin NN i
reduce VB N
blood NN N
lipid NN N
levels NNS N
more RBR N
than IN N
conventional JJ N
doses NNS N
, , N
however RB N
, , N
the DT N
change NN N
in IN N
compliance NN N
is VBZ N
not RB N
dose-dependent JJ N
. . N

) ) N
lipid JJ N
emulsion NN N
( ( N
LCT NNP N
, , N
MCT NNP N
, , N
Olive-oil NNP N
and CC N
Fish-oil NNP N
) ) N
in IN N
patients NNS p
undergoing VBG N
elective JJ N
gastrointestial JJ N
surgery NN N
during IN N
the DT N
early JJ N
postoperative JJ N
period NN N
. . N

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
the DT N
rate NN N
of IN N
biopsy-confirmed JJ N
acute JJ N
rejection NN N
( ( N
BCAR NNP N
) ) N
and CC N
renal JJ N
function NN N
, , N
as IN N
measured VBN N
by IN N
serum JJ N
creatinine NN N
. . N

Prophylactic JJ N
Transluminal NNP N
Balloon NNP N
Angioplasty NNP N
( ( N
pTBA NN N
) ) N
appeared VBD N
to TO N
prevent VB N
delayed JJ N
ischemic JJ N
neurological JJ N
deficit NN N
in IN N
a DT N
pilot NN N
study NN N
. . N

Radial JJ N
artery NN N
was VBD N
cannulated VBN N
for IN N
arterial JJ N
blood NN N
pressure NN N
( ( N
ABP NNP N
) ) N
monitoring NN N
and CC N
blood NN N
sampling NN N
and CC N
Swan-Ganz NNP N
catheter NN N
was VBD N
position NN N
in IN N
the DT N
pulmonary JJ N
artery NN N
via IN N
right JJ N
internal JJ N
jugular NN N
vein NN N
under IN N
local JJ N
anesthesia NN N
. . N

Cerebral JJ N
blood NN N
flow NN N
( ( N
CBF NNP N
) ) N
and CC N
cerebral JJ N
metabolic NN N
rate NN N
for IN N
oxygen NN N
( ( N
CMRO2 NNP N
) ) N
were VBD N
measured VBN N
by IN N
a DT N
modification NN N
of IN N
the DT N
Kety-Schmidt NNP N
technique NN N
using VBG N
i.v NN N
. . N

OUTCOMES NNP N
Composite NNP N
CV NNP N
events NNS N
, , N
that DT N
is VBZ N
, , N
ischaemic JJ N
coronary NN N
and CC N
cerebrovascular JJ N
events NNS N
, , N
components NNS N
of IN N
the DT N
composite JJ N
CV NNP N
outcome NN N
, , N
and CC N
death NN N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
magnitude NN N
of IN N
the DT N
positive JJ N
nor CC N
the DT N
negative JJ N
priming NN N
effects NNS N
of IN N
the DT N
groups NNS N
. . N

The DT N
response NN N
rate NN N
, , N
time NN N
to TO N
treatment NN N
failure NN N
( ( N
TTF NNP N
) ) N
, , N
and CC N
median JJ N
survival NN N
time NN N
were VBD N
superior JJ N
in IN N
the DT N
premenopausal JJ N
women NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
ranitidine NN N
or CC N
omeprazole JJ N
administration NN N
on IN N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
cephalexin NN N
. . N

Nucleotides NNP N
added VBD N
to TO N
milk-based JJ N
formula NN N
benefit NN N
infant NN N
immune NN N
status NN N
, , N
but CC N
reports NNS N
of IN N
the DT N
immunologic JJ N
effects NNS N
of IN N
adding VBG N
nucleotides NNS N
to TO N
soy-based JJ N
formula NN N
are VBP N
not RB N
available JJ N
. . N

CONCLUSION NNP N
The DT N
bias NN N
of IN N
measuring VBG N
haemoglobin JJ N
concentration NN N
by IN N
pulse JJ N
oximetry NN N
is VBZ N
dependent JJ N
on IN N
whether IN N
a DT N
crystalloid NN N
or CC N
a DT N
colloid JJ N
fluid NN N
is VBZ N
infused VBN N
. . N

The DT N
necessity NN N
of IN N
additional JJ N
ketoprofen NN N
therapy NN i
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
25.0 CD N
% NN N
vs JJ N
50.0 CD N
% NN N
, , N
P=.074 NNP N
) ) N
. . N

Central NNP N
nervous JJ N
system NN N
function NN N
was VBD N
assessed VBN N
by IN N
use NN N
of IN N
the DT N
Auditory NNP N
Steady NNP N
State NNP N
Response NNP N
( ( N
ASSR NNP N
) ) N
and CC N
Bispectral NNP N
Index NNP N
( ( N
BIS NNP N
) ) N
analysis NN N
of IN N
electrooculogram NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
whether IN N
adjuvant NN N
AT NNP N
improved VBD N
disease-free JJ N
survival NN N
compared VBN N
with IN N
AC NNP N
in IN N
operable JJ N
breast NN N
cancer NN N
. . N

Predefined VBN N
study NN N
endpoints NNS N
are VBP N
gastric JJ N
cancer NN N
, , N
precancerous JJ N
lesions NNS N
( ( N
dysplasia NN N
, , N
adenoma NN N
) ) N
, , N
other JJ N
cancers NNS N
, , N
and CC N
death NN N
. . N

It PRP N
may MD N
be VB N
therefore RB N
concluded VBD N
that IN N
the DT N
evaluated JJ N
formulations NNS N
are VBP N
bioequivalent JJ N
in IN N
terms NNS N
of IN N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
. . N

Up IN N
to TO N
five CD N
independent JJ N
adjudicators NNS N
independently RB N
determined VBD N
two CD N
primary JJ N
outcomes NNS N
: : N
tumor NN N
status NN N
at IN N
death NN N
or CC N
at IN N
final JJ N
follow-up NN N
and CC N
the DT N
cause NN N
of IN N
death NN N
. . N

Comparative JJ N
evaluation NN N
of IN N
olopatadine JJ N
ophthalmic JJ N
solution NN N
( ( N
0.1 CD N
% NN N
) ) N
versus NN N
ketorolac NN N
ophthalmic JJ N
solution NN N
( ( N
0.5 CD N
% NN N
) ) N
using VBG N
the DT N
provocative JJ N
antigen NN N
challenge NN N
model NN N
. . N

RESULTS NN N
In IN N
both DT N
methods NNS N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
systolic JJ N
and CC N
diastolic JJ N
pressure NN N
, , N
rate-pressure JJ N
product NN N
, , N
in IN N
glucose NN N
or CC N
catecholamine NN N
levels NNS N
. . N

BACKGROUND NN N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
pure-cut JJ N
electrosurgical JJ N
current JJ N
for IN N
endoscopic JJ N
sphincterotomy NN N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
post-ERCP JJ N
pancreatitis NN N
. . N

Baseline NNP N
renal JJ N
function NN N
is VBZ N
the DT N
major JJ N
determinant NN N
of IN N
the DT N
rate NN N
of IN N
rise NN N
, , N
height NN N
, , N
and CC N
duration NN N
of IN N
Cr NNP N
trajectory NN N
after IN N
contrast NN N
exposure NN N
. . N

Therefore RB N
, , N
blockade NN N
of IN N
HGF-MET NNP N
signalling NN N
might MD N
be VB N
a DT N
valid JJ N
therapeutic JJ N
strategy NN N
, , N
in IN N
combination NN N
with IN N
BRAF NNP N
inhibition NN N
, , N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

OBJECTIVE NN N
To TO N
study VB N
the DT N
specific JJ N
cellular JJ N
immunoresponse NN N
of IN N
peripheral JJ N
blood NN N
lymphocytes NNS N
in IN N
the DT N
chronic JJ N
hepatitis NN N
B NNP N
patients NNS p
treated VBD N
with IN N
different JJ N
doses NNS N
of IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
. . N

Retinal JJ N
vessels NNS N
showed VBD N
a DT N
small JJ N
diameter NN N
increase NN o
, , N
whereas RB N
red JJ N
blood NN N
cell NN N
speed NN N
decreased VBN o
, , N
resulting VBG N
in IN N
an DT N
unchanged JJ N
total JJ N
retinal JJ N
blood NN N
flow NN N
. . N

Among IN N
subjects NNS N
with IN N
recurrent NN N
adenomas NN N
, , N
the DT N
mean NN N
( ( N
+/-SE JJ N
) ) N
number NN N
of IN N
such JJ N
lesions NNS N
was VBD N
1.85+/-0.08 JJ N
in IN N
the DT N
intervention NN N
group NN N
and CC N
1.84+/-0.07 NNS N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
rate NN N
of IN N
reporting NN N
of IN N
adverse JJ N
events NNS N
considered VBN N
to TO N
be VB N
drug-related JJ N
and CC N
the DT N
rate NN N
of IN N
withdrawals NNS N
were VBD N
similar JJ N
for IN N
both DT N
treatments NNS N
. . N

Discrepancies NNS N
in IN N
postoperative JJ N
leg NN N
length NN N
were VBD N
5.45 CD N
mm NNS N
and CC N
13.37 CD N
mm NN N
in IN N
the DT N
groups NNS N
with IN N
and CC N
without IN N
the DT N
guide NN N
, , N
respectively RB N
. . N

The DT N
post-ischaemic JJ N
functional JJ N
recovery NN N
of IN N
the DT N
heart NN N
was VBD N
assessed VBN N
by IN N
clinical JJ N
parameters NNS N
, , N
as RB N
well RB N
as IN N
by IN N
biochemical JJ N
and CC N
ultrastructure JJ N
evaluations NNS N
on IN N
biopsy NN N
specimens NNS N
. . N

Statistically RB N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
was VBD N
the DT N
difference NN N
in IN N
postoperative JJ N
bleeding NN N
evaluated VBN N
with IN N
particular JJ N
attention NN N
in IN N
patients NNS p
of IN N
advanced JJ N
age NN N
. . N

There EX N
was VBD N
a DT N
fall NN N
in IN N
urinary JJ N
dopamine NN N
( ( N
DA NNP N
) ) N
and CC N
noradrenaline JJ N
( ( N
NA NNP N
) ) N
levels NNS N
and CC N
increased JJ o
excretion NN N
of IN N
homovanillic JJ N
acid NN N
( ( N
HVA NNP N
) ) N
. . N

Experimental JJ N
studies NNS N
suggest VBP N
that IN N
recombinant JJ N
human JJ N
erythropoietin NN i
( ( N
EPO NNP N
) ) N
independent JJ N
of IN N
its PRP$ N
erythropoietic JJ N
effect NN N
may MD N
be VB N
used VBN N
clinically RB N
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
. . N

Ciprodex NN N
treatment NN N
also RB N
decreased VBD o
the DT o
rate NN N
of IN N
clinically RB N
diagnosed VBN N
otitis NN N
media NNS N
( ( N
OM NNP N
) ) N
and CC N
effusion NN N
following VBG N
TT NNP N
placement NN N
( ( N
p JJ N
< NN N
or CC N
=0.0006 NN N
) ) N
. . N

The DT N
low JJ N
solubility NN N
of IN N
desflurane NN N
has VBZ N
been VBN N
shown VBN N
to TO N
contribute VB N
to TO N
faster VB N
awakening VBG N
from IN N
anesthesia NN N
when WRB N
compared VBN N
with IN N
other JJ N
anesthetics NNS N
in IN N
common JJ N
use NN N
. . N

Noradrenaline NNP N
concentrations NNS N
decreased VBD o
to TO o
less JJR N
than IN N
baseline NN N
values NNS N
in IN N
the DT N
extradural JJ N
group NN N
and CC N
were VBD N
significantly RB N
less JJR N
than IN N
in IN N
the DT N
opioid JJ N
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
scores NNS N
on IN N
the DT N
basis NN N
of IN N
acromion NN N
type NN N
, , N
nor CC N
were VBD N
any DT N
interaction NN N
effects NNS N
identified VBN N
between IN N
group NN N
and CC N
acromion NN N
type NN N
. . N

Women NNP N
( ( N
8,800 CD N
) ) N
, , N
aged VBD N
30-62 CD N
, , N
were VBD N
randomly RB N
selected VBN N
among IN N
women NNS N
without IN N
a DT N
registered JJ N
Pap NNP N
smear NN N
in IN N
the DT N
two CD N
latest JJS N
screening VBG N
rounds NNS N
. . N

A DT N
reduction NN N
of IN N
the DT N
increase NN o
of IN N
scar NN N
width NN N
was VBD N
seen VBN N
in IN N
the DT N
Contractubex-treated JJ N
group NN N
as IN N
compared VBN N
with IN N
the DT N
untreated JJ N
group NN N
. . N

CONCLUSION VB N
The DT N
27-gauge JJ N
NVS NNP N
is VBZ N
an DT N
effective JJ N
surgical JJ N
procedure NN N
in IN N
eyes NNS N
with IN N
epiretinal JJ N
membrane NN N
and CC N
it PRP N
induces VBZ N
less JJR N
progression NN N
of IN N
nuclear JJ N
sclerosis NN N
than IN N
25-gauge JJ N
vitrectomy NN N
. . N

No DT N
adverse JJ N
side NN N
effects NNS N
attributable JJ N
to TO N
captopril VB N
were VBD N
noted VBN N
, , N
except IN N
in IN N
one CD N
patient NN N
in IN N
whom WP N
proteinuria NN N
developed VBD N
after IN N
seven CD N
weeks NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
change NN N
of IN N
global JJ N
LV NNP N
systolic JJ N
function NN N
by IN N
echocardiography NN N
or CC N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
during IN N
the DT N
follow-up NN N
. . N

Additionally RB N
subjects VBZ N
with IN N
autism NN N
spectrum NN N
disorders NNS N
showed VBD N
a DT N
significantly RB N
increased VBN o
prolactin NN i
response NN N
to TO N
m-CPP NN N
compared VBN N
to TO N
normal JJ N
controls NNS N
, , N
with IN N
neither DT N
group NN N
responding VBG N
to TO N
placebo VB N
. . N

CONCLUSIONS NNP N
Allograft NNP N
mixed VBD N
with IN N
an DT N
experimental JJ N
putty NN N
carrier NN N
produced VBD N
significantly RB N
more RBR N
vital JJ N
bone NN N
fill NN N
than IN N
did VBD N
the DT N
use NN N
of IN N
a DT N
xenograft NN N
with IN N
no DT N
carrier NN N
material NN N
. . N

These DT N
data NNS N
suggest VBP N
the DT N
effectiveness NN N
of IN N
interferon NN N
given VBN N
as IN N
induction NN N
and CC N
as IN N
maintenance NN N
treatment NN N
in IN N
the DT N
therapy NN i
of IN N
II NNP N
type NN N
mixed JJ N
essential JJ N
cryoglobulinemia NN N
. . N

Many JJ N
different JJ N
formulations NNS N
were VBD N
prepared VBN N
, , N
among IN N
which WDT N
F3-coded NNP N
formulation NN N
was VBD N
only RB N
selected VBN N
due JJ N
to TO N
releasing VBG N
of IN N
98.03 CD N
% NN N
active JJ N
substance NN N
at IN N
45th CD N
minute NN N
. . N

There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
according VBG N
to TO N
the DT N
side NN N
effects NNS N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

NMES NNP N
robot-assisted JJ N
training NN N
showed VBD N
better JJR N
performance NN N
in IN N
releasing VBG N
muscle NN N
co-contraction NN N
than IN N
the DT N
robot-assisted JJ N
across IN N
the DT N
training NN N
sessions NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
with IN N
regard NN N
to TO N
AUC NNP N
( ( N
0-18 CD N
) ) N
or CC N
evolution NN N
of IN N
BASDAI NNP N
scores NNS N
and CC N
biomarkers NNS N
of IN N
inflammation NN N
. . N

Angiotensin NNP N
II NNP N
infusion NN N
increased VBD o
filtration NN o
fraction NN N
, , N
but CC N
decreased VBD o
glomerular JJ o
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
and CC N
urine JJ N
flow NN N
sharply RB N
. . N

Comparison NNP N
of IN N
the DT N
efficacy NN N
of IN N
fluoxetine NN N
alone RB N
vs. FW N
fluoxetine JJ N
plus CC N
local JJ N
lidocaine NN N
ointment NN N
in IN N
the DT N
treatment NN N
of IN N
premature JJ N
ejaculation NN N
. . N

These DT N
observed VBD N
changes NNS N
in IN N
insulin NN N
sensitivity NN N
are VBP N
likely JJ N
to TO N
be VB N
clinically RB N
relevant JJ N
, , N
especially RB N
in IN N
individuals NNS N
predisposed VBN N
to TO N
develop VB N
glucose JJ N
intolerance NN N
. . N

CONCLUSIONS VB N
A DT N
doubling JJ N
factor NN N
is VBZ N
effective JJ N
for IN N
maintaining VBG N
the DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
PSA NNP N
for IN N
prostate NN N
cancer NN N
detection NN N
in IN N
men NNS N
on IN N
dutasteride NN N
. . N

Modulation NN N
of IN N
the DT N
intestinal JJ N
environment NN N
, , N
innate VB N
immune JJ N
response NN N
, , N
and CC N
barrier JJR N
function NN N
by IN N
dietary JJ N
threonine NN N
and CC N
purified JJ N
fiber NN N
during IN N
a DT N
coccidiosis NN N
challenge NN N
in IN N
broiler NN N
chicks NNS N
. . N

Thirty-six JJ N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
conditions NNS N
, , N
one CD N
of IN N
which WDT N
was VBD N
the DT N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
( ( N
PECS NNP N
) ) N
. . N

In IN N
particular JJ N
, , N
the DT N
incidence NN N
and CC N
magnitude NN N
of IN N
febrile JJ N
temperatures NNS N
were VBD N
significantly RB N
lower JJR N
between IN N
the DT N
4th CD N
and CC N
8th CD N
days NNS N
of IN N
treatment NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
safety NN N
and CC N
Immunogenicity NNP N
of IN N
the DT N
Poliomyelitis NNP N
vaccine NN N
( ( N
Human NNP N
Diploid NNP N
Cell NNP N
) ) N
in IN N
> NN N
or CC N
=2 VB N
month-old JJ N
children NNS N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
the DT N
effect NN N
variables NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
before IN N
, , N
during IN N
or CC N
after IN N
treatment NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
intraoperative JJ N
mitomycin NN i
C NNP N
during IN N
deep JJ N
sclerectomy NN N
significantly RB N
reduced VBD N
the DT N
postoperative JJ N
IOP NNP N
and CC N
increased VBD o
the DT o
success NN N
rate NN N
of IN N
the DT N
procedure NN N
. . N

When WRB N
dazmegrel NN N
was VBD N
orally RB N
administered VBN N
to TO N
greyhound VB N
dogs NNS N
wearing VBG N
leg NN N
casts NNS N
, , N
it PRP N
resulted VBD N
in IN N
a DT N
sparring JJ N
effect NN N
on IN N
the DT N
skin JJ N
areas NNS N
of IN N
potential JJ N
pressure NN N
ulcer NN N
development NN N
. . N

Brief JJ N
Report NNP N
: : N
Randomized JJ N
test NN N
of IN N
the DT N
efficacy NN N
of IN N
picture NN N
exchange NN N
communication NN N
system NN N
on IN N
highly RB N
generalized JJ N
picture NN N
exchanges NNS N
in IN N
children NNS N
with IN N
ASD NNP N
. . N

This DT N
difference NN N
reached VBD N
statistical JJ N
significance NN N
when WRB N
first RB N
study VB N
episodes NNS N
were VBD N
considered VBN N
separately RB N
( ( N
six CD N
flu NN N
versus NN N
nil JJ N
itra NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

The DT N
10-year JJ N
OS NNP N
rate NN N
was VBD N
13.8 CD N
% NN N
in IN N
the DT N
surgery NN N
arm NN N
and CC N
13.1 CD N
% NN N
in IN N
the DT N
chemotherapy NN i
arm NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
diltiazem NN N
, , N
a DT N
moderate JJ N
inhibitor NN N
of IN N
CYP3A4 NNP N
, , N
on IN N
the DT N
single-dose JJ N
pharmacokinetics NNS N
of IN N
ACT-178882 NNP N
in IN N
healthy JJ N
subjects NNS N
. . N

A DT N
slight JJ N
elevation NN N
of IN N
heart NN N
rate NN N
was VBD N
observed VBN N
more RBR N
often RB N
in IN N
the DT N
adrenaline NN N
group NN N
( ( N
P NNP N
= NNP N
0.043 CD N
) ) N
. . N

Inclusion NN N
of IN N
anti-phospholipase JJ N
A2 NNP N
antibody NN N
to TO N
backgrounding VBG N
diets NNS N
on IN N
performance NN N
, , N
feed NN N
efficiency NN N
, , N
in IN N
vitro JJ N
fermentation NN N
, , N
and CC N
the DT N
acute-phase JJ N
response NN N
of IN N
growing VBG N
beef NN N
calves NNS N
. . N

Plasma NNP N
prothrombin NN N
and CC N
serum JJ N
alkaline JJ N
phosphatase NN N
levels NNS N
of IN N
the DT N
zinc NNP N
group NN N
increased VBD o
and CC o
serum JJ N
bilirubin NN N
and CC N
serum JJ N
carotene NN N
decreased VBN o
significantly RB N
. . N

Baseline JJ N
mean NN N
scores NNS N
and CC N
rates NNS N
at IN N
which WDT N
pts NNS N
failed VBD N
to TO N
complete VB N
QoL NNP N
assessment NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
arms NNS N
. . N

Guthrie NNP N
cards NNS N
can MD N
be VB N
used VBN N
to TO N
accurately RB N
genotype VB N
CYP21 NNP N
and CC N
other JJ N
relevant JJ N
markers NNS N
, , N
potentially RB N
enhancing VBG N
the DT N
specificity NN N
and CC N
sensitivity NN N
of IN N
congenital JJ N
adrenal JJ N
hyperplasia NN N
screening NN N
. . N

Our PRP$ N
hypothesis NN N
is VBZ N
that IN N
coinduction NN N
with IN N
clonidine NN N
reduces VBZ N
the DT N
incidence NN N
of IN N
PONV NNP N
in IN N
adult NN N
patients NNS p
undergoing VBG N
breast NN N
cancer NN N
surgery NN N
. . N

We PRP N
used VBD N
this DT N
situation NN N
to TO N
determine VB N
the DT N
antiplatelet NN N
efficacy NN N
of IN N
L-arginine NNP N
and CC N
S-nitrosoglutathione NNP N
( ( N
GSNO NNP N
) ) N
, , N
a DT N
physiological JJ N
nitric JJ N
oxide IN N
donor NN N
with IN N
possible JJ N
platelet NN N
specificity NN N
. . N

Effects NNS N
of IN N
strontium NN N
on IN N
the DT N
quality NN N
of IN N
bone NN N
apatite JJ N
crystals NNS N
: : N
a DT N
paired JJ N
biopsy NN N
study NN N
in IN N
postmenopausal JJ N
osteoporotic JJ i
women NNS N
. . N

Denopamine NNP N
increased VBD o
heart NN o
rate NN N
in IN N
patients NNS p
with IN N
atrial JJ N
fibrillation NN N
but CC N
had VBD N
little JJ N
effect NN N
on IN N
heart NN N
rate NN N
in IN N
patients NNS p
with IN N
sinus JJ N
rhythm NN N
. . N

A DT N
significant JJ N
decrease NN o
in IN N
number NN N
of IN N
tender NN N
sites NNS N
on IN N
the DT N
masticatory NN N
muscles NNS N
was VBD N
found VBN N
in IN N
group NN N
T NNP N
at IN N
the DT N
follow-ups NNS N
. . N

The DT N
new JJ N
infection NN N
rates NNS N
for IN N
quarters NNS N
that WDT N
received VBD N
intramammary JJ N
tilmicosin NNS N
compared VBN N
with IN N
the DT N
intramammary JJ N
placebo NN N
were VBD N
14.4 CD N
and CC N
19.4 CD N
% NN N
, , N
respectively RB N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
birth NN N
weight NN N
, , N
treatment NN N
with IN N
antibiotics NNS N
, , N
and CC N
the DT N
starting JJ N
time NN N
of IN N
breast-feeding NN N
among IN N
the DT N
three CD N
groups NNS N
. . N

The DT N
results NNS N
of IN N
RT-PCR NNP N
were VBD N
confirmed VBN N
by IN N
Western JJ N
blotting NN N
, , N
which WDT N
documented VBD N
the DT N
identical JJ N
distribution NN N
of IN N
leptin NN i
proteins NNS N
and CC N
leptin JJ i
receptor NN N
proteins NNS N
in IN N
studied JJ N
tissues NNS N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
end-to-side JJ N
neurorrhaphy NN N
can MD N
induce VB N
the DT N
functional JJ N
collateral NN N
sprouting NN N
of IN N
both DT N
motor NN N
and CC N
sensory JJ N
axons NNS N
in IN N
the DT N
peripheral JJ N
nerve NN N
. . N

CONCLUSION NNP N
Procalcitonin NNP N
is VBZ N
a DT N
helpful JJ N
and CC N
safe JJ N
tool NN N
for IN N
guiding VBG N
duration NN N
of IN N
antibiotic JJ i
treatment NN N
in IN N
patients NNS p
with IN N
severe JJ N
acute NN N
pancreatitis NN N
. . N

The DT N
proportions NNS N
of IN N
eicosapentaenoic NN N
and CC N
docosahexaenoic JJ N
acids NNS N
in IN N
serum JJ N
lipids NNS N
increased VBD o
in IN o
the DT N
fatty JJ N
fish NN N
group NN N
only RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
triple JJ N
drug NN N
therapy NN i
was VBD N
more RBR N
efficacious JJ N
than IN N
any DT N
double JJ N
drug NN N
regimen NNS N
in IN N
the DT N
prevention NN N
of IN N
chronic JJ N
histological JJ N
changes NNS N
in IN N
renal JJ N
allografts NNS N
. . N

CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
. . N

The DT N
effect NN N
of IN N
valaciclovir NN N
on IN N
cytomegalovirus NN N
viremia NN N
and CC N
viruria NN N
detected VBN N
by IN N
polymerase NN N
chain NN N
reaction NN N
in IN N
patients NNS p
with IN N
advanced JJ N
human JJ N
immunodeficiency NN N
virus NN N
disease NN N
. . N

AIM NNP N
To TO N
study VB N
the DT N
effects NNS N
of IN N
local JJ N
estrogen NN N
with IN N
or CC N
without IN N
local JJ N
testosterone NN N
on IN N
urogenital JJ N
and CC N
sexual JJ N
health NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

Formoterol NNP N
caused VBD N
a DT N
significantly RB N
higher JJR N
tremor NN N
score NN N
and CC N
a DT N
larger JJR N
drop NN N
in IN N
S-potassium NNP N
than IN N
salmeterol NN N
at IN N
the DT N
highest JJS N
doses NNS N
. . N

Linezolid NNP N
was VBD N
well RB N
tolerated VBN N
and CC N
the DT N
frequency NN N
of IN N
drug-related JJ N
adverse JJ N
events NNS N
was VBD N
similar JJ N
between IN N
the DT N
linezolid JJ N
and CC N
placebo JJ N
groups NNS N
. . N

PERSPECTIVE NN N
This DT N
study NN N
showed VBD N
that IN N
KC NNP N
has VBZ N
a DT N
significant JJ N
effect NN N
on IN N
reducing VBG N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ N
infants NNS N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
, , N
and CC N
safety NN N
. . N

There EX N
are VBP N
multiple JJ N
design NN N
possibilities NNS N
for IN N
VPs NNP N
, , N
however RB N
there EX N
is VBZ N
little JJ N
formal JJ N
evidence NN N
to TO N
support VB N
individual JJ N
design NN N
features NNS N
. . N

Only RB N
one CD N
case NN N
of IN N
secondary JJ N
post-tonsillectomy JJ N
haemorrhage NN N
was VBD N
recorded VBN N
, , N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
( ( N
2.5 CD N
per IN N
cent NN N
) ) N
, , N
managed VBD N
conservatively RB N
. . N

RESULTS NN N
After IN N
PE NNP N
treatment NN N
, , N
nerve NN N
function NN N
defect NN N
appeared VBD N
to TO N
improve VB N
better JJR N
than IN N
the DT N
IVIg NNP N
group NN N
and CC N
clinical JJ N
effect NN N
was VBD N
better JJR N
than IN N
the DT N
IVIg NNP N
group NN N
. . N

Second JJ N
, , N
the DT N
application NN N
of IN N
principal JJ N
component JJ N
analysis NN N
indicated VBD N
that IN N
the DT N
positive JJ N
waveform NN N
elicited VBN N
by IN N
the DT N
words NNS N
in IN N
the DT N
test NN N
list NN N
was VBD N
a DT N
P300 NNP N
. . N

Mean NNP N
free JJ N
testosterone NN N
and CC N
3alpha-androstanediol JJ N
glucuronide NN N
decreased VBD o
significantly RB o
in IN N
the DT N
group NN N
receiving VBG N
ethinyl JJ N
estradiol/desogestrel NN N
but CC N
not RB N
in IN N
the DT N
ethinyl NN N
estradiol/levonorgestrel NN N
group NN N
. . N

UNLABELLED JJ N
Reports NNS N
of IN N
transient JJ N
neurological JJ N
symptoms NNS N
with IN N
the DT N
use NN N
of IN N
subarachnoid JJ N
lidocaine NN N
has VBZ N
generated VBN N
interest NN N
in IN N
alternate JJ N
local JJ N
anesthetics NNS N
of IN N
intermediate JJ N
duration NN N
, , N
such JJ N
as IN N
mepivacaine NN N
. . N

Furosemide NNP N
, , N
a DT N
loop NN N
diuretic NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
selectively RB N
and CC N
reversibly RB N
block VB N
inhibitory NN N
postsynaptic JJ N
potentials NNS N
without IN N
affecting VBG N
excitatory JJ N
postsynaptic JJ N
potentials NNS N
in IN N
animal JJ N
spinal JJ N
neurons NNS N
. . N

RESULT VB N
The DT N
incidences NNS N
of IN N
nausea NN N
, , N
retching VBG N
or CC N
vomiting VBG N
during IN N
the DT N
first JJ N
and CC N
second JJ N
24-h JJ N
periods NNS N
after IN N
surgery NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Sixty NNP N
adult NN N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
listen-and-repeat JJ N
learning VBG N
conditions NNS N
: : N
speaking NN N
, , N
rhythmic JJ N
speaking NN N
, , N
or CC N
singing NN N
. . N

Secondary JJ N
endpoints NNS N
were VBD N
cTFC JJ N
prior RB N
to TO N
PCI NNP N
, , N
TIMI NNP N
flow NN N
grade NN N
, , N
MBG NNP N
and CC N
the DT N
percentage NN N
of IN N
ST NNP N
resolution NN N
. . N

CONCLUSIONS NNP N
Omission NNP N
of IN N
the DT N
pyridostigmine NN N
dose NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
predisposed VBN N
patients NNS p
with IN N
myasthenia JJ N
gravis NN N
to TO N
the DT N
possibility NN N
of IN N
respiratory JJ N
discomfort NN N
and CC N
sensitivity NN N
to TO N
vecuronium NN N
. . N

CONCLUSION NNP N
Fluvoxamine NNP N
and CC N
clomipramine NN N
are VBP N
equally RB N
effective JJ N
in IN N
severe JJ N
depression NN N
, , N
but CC N
fluvoxamine NN N
has VBZ N
a DT N
better JJR N
safety NN N
and CC N
tolerability NN N
profile NN N
. . N

CONCLUSION NN N
It PRP N
is VBZ N
concluded VBN N
that IN N
oral JJ N
NaAcetate NNP N
could MD N
be VB N
used VBN N
as IN N
both DT N
an DT N
alkalinizing NN N
agent NN N
and CC N
an DT N
alternative JJ N
energy NN N
source NN N
in IN N
the DT N
horse NN N
. . N

However RB N
, , N
the DT N
level NN N
of IN N
emergent JJ N
over-selectivity NN N
was VBD N
significantly RB N
reduced VBN N
by IN N
a DT N
mindfulness NN N
induction NN N
when WRB N
compared VBN N
to TO N
a DT N
no- JJ N
intervention NN N
control NN N
group NN N
. . N

A DT N
comparative JJ N
study NN N
of IN N
a DT N
new JJ N
food NN N
supplement NN N
, , N
ViviScal NNP N
, , N
with IN N
fish JJ N
extract NN N
for IN N
the DT N
treatment NN N
of IN N
hereditary JJ N
androgenic JJ N
alopecia NN N
in IN N
young JJ N
males NNS N
. . N

CONCLUSION NNP N
Diltiazem NNP N
reduced VBD N
the DT N
clinical JJ N
and CC N
electrocardiographical JJ N
aspects NNS N
and CC N
raises VBZ N
the DT N
effort NN N
tolerance NN N
during IN N
the DT N
ergometric JJ N
test NN N
in IN N
patients NNS p
with IN N
stable JJ N
angina NN N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
addition NN N
of IN N
clofibrate NN N
may MD N
be VB N
useful JJ N
in IN N
maturity-onset JJ N
diabetics NNS N
not RB N
adequately RB N
controlled VBN N
by IN N
diet NN N
combined VBN N
with IN N
oral JJ N
hypoglycaemic JJ N
agents NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
phrenic JJ N
nerve NN N
palsy NN N
causes VBZ N
a DT N
significant JJ N
impairment NN N
of IN N
dynamic JJ N
lung NN N
volumes NNS N
during IN N
the DT N
early JJ N
postoperative JJ N
period NN N
after IN N
pneumonectomy NN N
. . N

Effect NN N
of IN N
pravastatin NN i
on IN N
cardiovascular JJ N
events NNS N
in IN N
women NNS N
after IN N
myocardial JJ N
infarction NN N
: : N
the DT N
cholesterol NN N
and CC N
recurrent JJ N
events NNS N
( ( N
CARE NNP N
) ) N
trial NN N
. . N

OBJECTIVE NN N
To TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
solution NN N
of IN N
nicotine NN N
on IN N
sustained JJ N
resting NN N
pressure NN N
( ( N
tone NN N
) ) N
and CC N
contractile JJ N
activity NN N
in IN N
the DT N
human JJ N
colon NN N
. . N

OBJECTIVES NNP N
Certain NNP N
GI NNP N
prokinetic JJ N
agents NNS N
have VBP N
been VBN N
shown VBN N
to TO N
affect VB N
cardiac JJ N
repolarization NN N
, , N
which WDT N
may MD N
be VB N
associated VBN N
with IN N
life-threatening JJ N
arrhythmias NNS N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
fitted VBN N
with IN N
two CD N
IFRS NNP N
retainers NNS N
and CC N
also RB N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
1100-ppm JJ N
fluoride JJ N
conventional JJ N
sodium NN N
fluoride NN N
dentifrice NN N
twice RB N
daily RB N
. . N

PURPOSE NN N
This DT N
study NN N
evaluated VBD N
the DT N
bond NN N
strength NN N
of IN N
two CD N
etch-and-rinse JJ N
adhesive JJ N
systems NNS N
( ( N
two- JJ N
and CC N
three-step NN N
) ) N
and CC N
a DT N
self-etching JJ N
system NN N
to TO N
coronal VB N
and CC N
root VB N
canal JJ N
dentin NN i
. . N

For IN N
their PRP$ N
second JJ N
and CC N
third JJ N
infusions NNS N
, , N
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
Z NNP N
then RB N
P NNP N
or CC N
P NNP N
then RB N
Z NNP N
, , N
and CC N
questioned VBD N
on IN N
their PRP$ N
preferences NNS N
. . N

The DT N
clinical JJ N
and CC N
biochemical JJ N
effects NNS N
of IN N
propofol JJ N
infusion NN N
with IN N
and CC N
without IN N
EDTA NNP N
for IN N
maintenance NN N
anesthesia NN N
in IN N
healthy JJ N
children NNS N
undergoing VBG N
ambulatory NN N
surgery NN N
. . N

However RB N
, , N
the DT N
lower JJR N
risk NN N
recorded VBN N
with IN N
fondaparinux NN N
than IN N
enoxaparin NN N
was VBD N
clinically RB N
important JJ N
, , N
with IN N
no DT N
increase NN o
in IN N
clinically RB N
relevant JJ N
bleeding NN N
. . N

Olopatadine NNP N
is VBZ N
a DT N
dual JJ N
acting NN N
H1 NNP N
histamine NN N
receptor NN N
antagonist NN N
and CC N
a DT N
mast NN N
cell NN N
stabilizer NN N
, , N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
treating VBG N
allergic JJ N
conjunctivitis NN N
. . N

RESULTS VB N
The DT N
participants NNS N
' POS N
mean JJ N
age NN N
was VBD N
27.56 CD N
in IN N
the DT N
aloe NN N
vera NN N
group NN N
and CC N
26.62 CD N
in IN N
the DT N
control NN N
group NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
addition NN N
, , N
this DT N
analysis NN N
strongly RB N
suggests VBZ N
that IN N
low JJ N
peripheral JJ N
blood NN N
levels NNS N
of IN N
CD19+ NNP N
cells NNS N
are VBP N
an DT N
adverse JJ N
prognostic JJ N
sign NN N
in IN N
myeloma NN N
. . N

The DT N
usefulness NN N
of IN N
intravenous JJ N
dexmedetomidine NN N
infusion NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
was VBD N
studied VBN N
in IN N
patients NNS p
anesthetized VBN N
with IN N
thiopental JJ N
, , N
fentanyl JJ N
, , N
nitrous JJ N
oxide NN N
, , N
and CC N
oxygen NN N
. . N

A DT N
significant JJ N
redistribution NN N
of IN N
tidal JJ N
variation NN N
to TO N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lung NN N
was VBD N
observed VBN N
on IN N
electrical JJ N
impedance NN N
tomography NN N
measurements NNS N
when WRB N
increasing VBG N
mean VB N
airway JJ N
pressure NN N
. . N

The DT N
fall NN N
in IN N
MSNA NNP N
was VBD N
unrelated JJ N
to TO N
the DT N
decrease NN o
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
r=0.41 NN N
, , N
p=0.14 NN N
) ) N
. . N

Radiotherapy NNP i
increased VBD o
postoperative JJ o
mortality NN N
and CC N
complications NNS N
and CC N
reduced JJ N
local JJ N
and CC N
distant JJ N
recurrence NN N
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
overall JJ i
survival NN N
. . N

CONCLUSIONS JJ N
Low-intensity NNP N
back-strengthening NN N
exercise NN N
was VBD N
effective JJ N
in IN N
improving VBG N
the DT N
quality NN N
of IN N
life NN N
and CC N
back RB N
extensor JJ N
strength NN N
in IN N
patients NNS p
with IN N
osteoporosis NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
neuropsychological JJ N
function NN N
or CC N
abnormalities NNS N
indicated VBN N
by IN N
computed JJ N
tomography NN N
brain NN N
scans NNS N
. . N

We PRP N
also RB N
report VBP N
an DT N
analysis NN N
comparing VBG N
the DT N
proportion NN N
of IN N
eyes NNS N
that WDT N
developed VBD N
one CD N
or CC N
more JJR N
key JJ N
events NNS N
to TO N
the DT N
cumulative JJ N
number NN N
of IN N
injections NNS N
. . N

However RB N
, , N
the DT N
mean JJ N
duration NN N
of IN N
therapeutic JJ N
response NN N
is VBZ N
significantly RB N
higher RBR N
in IN N
the DT N
group NN N
II NNP N
( ( N
p JJ N
= NNP N
0,01 CD N
) ) N
. . N

Effects NNS N
of IN N
water NN N
extracts NNS N
of IN N
Graptopetalum NNP N
paraguayense NN N
on IN N
blood NN N
pressure NN N
, , N
fasting VBG N
glucose NN N
, , N
and CC N
lipid JJ N
profiles NNS N
of IN N
subjects NNS N
with IN N
metabolic JJ N
syndrome NN N
. . N

Plasma NNP N
levels NNS N
of IN N
lysozyme NN N
, , N
a DT N
characteristic JJ N
product NN N
of IN N
PMN NNP N
degranulation NN N
, , N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
. . N

Primary JJ N
surgery NN N
, , N
good JJ N
performance NN N
status NN N
( ( N
PS NNP N
) ) N
, , N
only RB N
one CD N
metastatic JJ N
site NN N
, , N
and CC N
oxaliplatin-based JJ N
second-line JJ N
treatment NN N
independently RB N
predicted VBD N
a DT N
longer RBR N
OS NNP N
. . N

CONCLUSION NN N
AT NNP N
did VBD N
not RB N
improve VB N
DFS NNP N
or CC N
overall JJ i
survival NN N
in IN N
this DT N
population NN N
, , N
and CC N
was VBD N
associated VBN N
with IN N
more JJR N
toxicity NN N
. . N

The DT N
contribution NN N
of IN N
salvage NN N
surgery NN N
to TO N
overall JJ i
survival NN N
was VBD N
similar JJ N
for IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
as IN N
was VBD N
the DT N
surgical JJ N
complication NN N
rate NN N
. . N

It PRP N
is VBZ N
more RBR N
convenient JJ N
than IN N
the DT N
8-site JJ N
method NN N
, , N
and CC N
can MD N
be VB N
used VBN N
economically RB N
with IN N
vaccines NNS N
formulated VBN N
in IN N
1.0 CD N
or CC N
0.5 CD N
ml NN N
ampoules NNS N
. . N

Eighteen NNP N
sedentary JJ N
male NN N
volunteers NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
CLA NNP N
and CC N
Placebo NNP N
( ( N
PLC NNP N
) ) N
supplementation NN N
groups NNS N
. . N

Serum NNP N
cholesterols NNS N
, , N
LDL/HDL NNP N
ratios NNS N
, , N
LDL NNP N
cholesterols VBZ N
, , N
and CC N
triglyceride JJ N
determinations NNS N
in IN N
male JJ N
tobacco NN N
users NNS N
significantly RB N
exceeded VBD N
those DT N
in IN N
nonsmoking JJ N
males NNS N
. . N

UNLABELLED JJ N
Growth NNP N
hormone NN N
( ( N
GH NNP N
) ) N
treatment NN N
in IN N
young JJ N
adults NNS N
with IN N
childhood-onset JJ N
GH NNP N
deficiency NN N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
bone NN N
mass NN N
. . N

In IN N
an DT N
attempt NN N
to TO N
compensate VB N
for IN N
the DT N
lower JJR N
efficacy NN N
, , N
H2-receptor NNP N
antagonists NNS N
are VBP N
now RB N
increasingly RB N
being VBG N
used VBN N
at IN N
a DT N
higher JJR N
dose NN N
. . N

Accordingly RB N
, , N
demonstration NN N
that IN N
a DT N
specific JJ N
molecular JJ N
subtype NN N
accounts NNS N
for IN N
superior JJ N
outcome NN N
, , N
when WRB N
using VBG N
these DT N
regimens NNS N
, , N
is VBZ N
needed VBN N
. . N

BACKGROUND NNP N
Paliperidone NNP i
ER NNP N
monotherapy NN i
was VBD N
efficacious JJ N
in IN N
treating VBG N
acute NN N
mania NN N
in IN N
two CD N
3-week JJ N
studies NNS N
in IN N
patients NNS p
with IN N
bipolar JJ N
I PRP N
disorder VBP N
. . N

In IN N
the DT N
favorable JJ N
subgroup NN N
, , N
85.8 CD N
% NN N
had VBD N
a DT N
negative JJ N
early JJ N
PET JJ N
scan JJ N
( ( N
standard JJ N
arm NN N
, , N
one CD N
event NN N
v NN N
experimental JJ N
arm NN N
, , N
nine CD N
events NNS N
) ) N
. . N

In IN N
the DT N
rat NN N
surgical JJ N
model NN N
used VBN N
, , N
right JJ N
femora NNS N
were VBD N
fixed VBN N
to TO N
a DT N
polyethylene NN N
plate NN N
and CC N
then RB N
defects NNS N
were VBD N
created VBN N
mid-diaphysis NN N
and CC N
subsequently RB N
filled VBN N
with IN N
demineralized JJ N
bone NN N
matrix NN N
. . N

CONCLUSION NNP N
Argatroban NNP N
dose-dependently JJ N
increases NNS o
coagulation NN N
parameters NNS N
and CC N
, , N
compared VBN N
to TO N
UFH NNP N
, , N
demonstrates VBZ N
a DT N
superior JJ N
predictable JJ N
anticoagulant JJ N
effect NN N
in IN N
patients NNS p
undergoing VBG N
elective JJ N
PCI NNP N
. . N

Because IN N
the DT N
mechanism NN N
of IN N
action NN N
for IN N
ipilimumab NN i
is VBZ N
thought VBN N
to TO N
be VB N
HLA NNP N
independent JJ N
, , N
most JJS N
trials NNS N
enrolled VBD N
patients NNS p
without IN N
regard NN N
to TO N
HLA NNP N
subtype NN N
. . N

OBJECTIVE NN N
In IN N
the DT N
past JJ N
years NNS N
the DT N
interaction NN N
of IN N
GH NNP N
and CC N
11beta CD N
hydroxysteroid JJ N
dehydrogenase NN N
( ( N
11betaHSD CD N
) ) N
in IN N
the DT N
pathogenesis NN N
of IN N
central JJ N
obesity NN N
has VBZ N
been VBN N
suggested VBN N
. . N

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
nonexercising JJ N
control NN N
group NN N
, , N
a DT N
cycle NN N
training NN N
group NN N
( ( N
cycle NN N
) ) N
, , N
or CC N
one CD N
of IN N
the DT N
two CD N
HCT NNP N
groups NNS N
. . N

We PRP N
conclude VBP N
that IN N
amifostine NN N
can MD N
be VB N
safely RB N
administered VBN N
prior RB N
to TO N
high-dose JJ N
melphalan NN N
and CC N
significantly RB N
reduces VBZ N
the DT N
frequency NN N
and CC N
severity NN N
of IN N
therapy-induced JJ i
oral JJ N
mucositis NN N
. . N

PATIENTS NNP N
Endocrinologically NNP N
normal JJ N
women NNS N
with IN N
a DT N
medical JJ N
indication NN N
for IN N
IVF NNP N
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
, , N
or CC N
healthy JJ N
volunteers NNS N
. . N

The DT N
CTRS-R JJ N
: : N
S NNP N
Hyperactivity NNP N
subscore NN N
also RB N
improved VBN N
significantly RB N
for IN N
atomoxetine NN N
compared VBN N
with IN N
placebo NN N
, , N
but CC N
not RB N
the DT N
other JJ N
CTRS-R JJ N
: : N
S JJ N
subscores NNS N
. . N

The DT N
pharmacokinetic JJ N
profile NN N
of IN N
recombinant JJ N
human JJ N
porphobilinogen NN N
deaminase NN N
showed VBD N
dose JJ N
proportionality NN N
, , N
and CC N
the DT N
elimination NN N
half-life NN N
was VBD N
about IN N
2.0 CD N
hours NNS N
for IN N
the DT N
two CD N
highest JJS N
doses NNS N
. . N

[ RB N
Clinical NNP N
study NN N
of IN N
treating VBG N
knee NN N
osteoarthritis NN N
( ( N
Bi NNP N
syndrome NN N
of IN N
knee NN N
) ) N
by IN N
massage NN N
combined VBN N
Chinese JJ N
materia NNS N
medica VBP N
footbath JJ N
fumigation NN N
and CC N
washing VBG N
] NN N
. . N

Furthermore RB N
, , N
beta-lactamase NN N
produced VBN N
by IN N
other JJ N
bacteria NNS N
in IN N
the DT N
pharynx NN N
could MD N
potentially RB N
inactivate VB N
the DT N
penicillin NN i
, , N
resulting VBG N
in IN N
increased VBN o
treatment NN N
failures NNS N
or CC N
infection NN N
relapses NNS N
. . N

The DT N
primary JJ N
diagnoses NNS N
; : N
clinical JJ N
characteristics NNS N
; : N
and CC N
IL-6 NNP N
, , N
sTNF-R55 NN N
, , N
and CC N
sTNF-R75 JJ N
levels NNS N
were VBD N
similar JJ N
among IN N
the DT N
five CD N
age NN N
groups NNS N
. . N

SAS NNP N
is VBZ N
recommended VBN N
over RP N
DAS NNP N
as IN N
a DT N
stretching VBG N
protocol NN N
in IN N
terms NNS N
of IN N
strength NN N
, , N
hamstring VBG N
range NN N
of IN N
motion NN N
, , N
and CC N
damage NN N
markers NNS N
. . N

BACKGROUND NNP N
Few NNP N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
once-weekly JJ N
oral JJ N
bisphosphonate NN N
therapy NN i
in IN N
breast NN N
cancer NN N
survivors NNS N
. . N

Concentric NNP N
( ( N
maximal JJ N
EMG NNP N
activity NN N
during IN N
extension NN N
) ) N
and CC N
eccentric JJ N
( ( N
maximal JJ N
EMG NNP N
activity NN N
during IN N
flexion NN N
) ) N
ratios NNS N
were VBD N
also RB N
used VBN N
in IN N
the DT N
analyses NNS N
. . N

With IN N
the DT N
addition NN N
of IN N
transoperative JJ N
lympho-scintigraphy NN N
five CD N
extra JJ N
sentinel NN N
nodes NNS N
, , N
not RB N
identified VBN N
by IN N
the DT N
blue JJ N
dye NN N
alone RB N
, , N
were VBD N
identified VBN N
and CC N
considered VBN N
for IN N
histopathology NN N
study NN N
. . N

[ JJ N
Effects NNS N
of IN N
dujieqing VBG N
oral JJ N
liquid NN N
on IN N
the DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
middle-and-late JJ N
stage NN N
tumor NN N
patients NNS p
receiving VBG N
chemotherapy NN i
] NN N
. . N

Clinical JJ N
and CC N
prognostic JJ N
significance NN N
of IN N
serum NN N
magnesium NN N
concentration NN N
in IN N
patients NNS p
with IN N
severe JJ N
chronic JJ N
congestive JJ N
heart NN N
failure NN N
: : N
the DT N
PROMISE NNP N
Study NNP N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
prognostic JJ N
significance NN N
of IN N
SLN NNP N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
= VBP N
0.2 CD N
mm NNS N
in IN N
patients NNS p
treated VBN N
in IN N
a DT N
referral JJ N
cancer NN N
center NN N
in IN N
Brazil NNP N
. . N

The DT N
overall JJ i
difference NN N
in IN N
the DT N
number NN N
of IN N
complications NNS N
in IN N
the DT N
two CD N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Most JJS N
of IN N
the DT N
patients NNS p
in IN N
group NN N
I PRP N
( ( N
92.86 CD N
% NN N
) ) N
maintained VBD N
sinus JJ N
rhythm NN N
without IN N
cardioversion NN N
or CC N
defibrillation NN N
after IN N
release NN N
of IN N
aortic JJ N
cross NN N
clamp NN N
( ( N
P=0.002 NNP N
) ) N
. . N

There EX N
was VBD N
also RB N
some DT N
evidence NN N
that IN N
cumulative JJ N
time NN N
to TO N
perform VB N
the DT N
three CD N
100-m JJ N
swims NNS N
was VBD N
decreased VBN o
in IN N
the DT N
Cr NNP N
group NN N
. . N

However RB N
, , N
in IN N
the DT N
desloratadine/montelukast NN N
arm NN N
, , N
the DT N
resulting VBG N
improvement NN N
of IN N
combination NN N
therapy NN i
of IN N
sICAM-1 NN N
and CC N
the DT N
influx NN N
of IN N
eosinophils NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

We PRP N
conclude VBP N
that IN N
all DT N
three CD N
Hib NNP N
conjugate NN N
vaccines NNS N
( ( N
PRP-T NNP N
, , N
HbOC NNP N
, , N
and CC N
PRP-OMP NNP N
) ) N
were VBD N
immunogenic JJ N
after IN N
three CD N
primary JJ N
doses NNS N
among IN N
Philippine JJ N
infants NNS N
. . N

BACKGROUND NNP N
Phosphorus NNP N
is VBZ N
associated VBN N
with IN N
mortality NN N
in IN N
patients NNS p
with IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
not RB N
on IN N
dialysis NN N
, , N
possibly RB N
through IN N
phosphorus-dependent JJ N
vascular JJ N
calcification NN N
. . N

To TO N
determine VB N
if IN N
a DT N
relationship NN N
exists VBZ N
between IN N
changes NNS N
in IN N
torque NN N
production NN N
and CC N
Hoffmann NNP N
reflex NN N
( ( N
H-reflex NNP N
) ) N
following VBG N
ankle JJ N
joint JJ N
cryotherapy NN i
treatment NN N
. . N

While IN N
cooling VBG N
muscle NN N
may MD N
have VB N
a DT N
deleterious JJ N
effect NN N
on IN N
motor NN N
function NN N
, , N
cooling VBG N
the DT N
joint JJ N
may MD N
enhance VB N
motor NN N
function NN N
around IN N
the DT N
joint NN N
. . N

BACKGROUND NNP N
Blood NNP N
transfusions NNS N
prevent VBP N
recurrent JJ N
stroke NN N
in IN N
children NNS N
with IN N
sickle NN N
cell NN N
anemia NN N
, , N
but CC N
the DT N
value NN N
of IN N
transfusions NNS N
in IN N
preventing VBG N
a DT N
first JJ N
stroke NN N
is VBZ N
unknown JJ N
. . N

The DT N
synergy NN N
effect NN N
could MD N
not RB N
be VB N
examined VBN N
for IN N
dentine NN N
due JJ N
to TO N
the DT N
truncation NN N
effect NN N
as IN N
the DT N
set NN N
limit NN N
of IN N
the DT N
profilometer NN N
was VBD N
exceeded VBN N
. . N

Although IN N
the DT N
operative JJ N
time NN N
for IN N
retroperitoneoscopic NN N
laparoscopic NN N
pyeloplasty NN N
is VBZ N
significantly RB N
longer RBR N
, , N
the DT N
success NN N
rate NN N
remains VBZ N
the DT N
same JJ N
for IN N
both DT N
procedures NNS N
. . N

INTERPRETATION NNP N
Addition NNP N
of IN N
ganitumab NN i
to TO N
endocrine VB N
treatment NN N
in IN N
women NNS N
with IN N
previously RB N
treated VBN N
hormone-receptor-positive JJ N
locally RB N
advanced VBD N
or CC N
metastatic JJ N
breast NN N
cancer NN N
did VBD N
not RB N
improve VB N
outcomes NNS N
. . N

Metformin NNP N
therapy NN i
improves VBZ N
ovulatory JJ N
rates NNS N
, , N
cervical JJ N
scores NNS N
, , N
and CC N
pregnancy NN N
rates NNS N
in IN N
clomiphene JJ N
citrate-resistant JJ N
women NNS N
with IN N
polycystic JJ N
ovary JJ N
syndrome NN N
. . N

Two CD N
hundred CD N
and CC N
thirty-seven JJ N
students NNS N
, , N
drawn NN N
from IN N
six CD N
homeroom NN N
grade NN N
eight CD N
classes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
experimental VB N
and CC N
control VB N
( ( N
no DT N
intervention NN N
) ) N
conditions NNS N
. . N

PURPOSE NN N
To TO N
evaluate VB N
the DT N
risk NN N
of IN N
developing VBG N
radiation NN N
myelitis NN N
after IN N
a DT N
cervical JJ N
spinal NN N
cord NN N
dose NN N
of IN N
50.6 CD N
Gy NNP N
given VBN N
via IN N
1.1 CD N
Gy NNP N
b.i.d NN N
. . N

Mean JJ N
changes NNS N
tended VBD N
toward IN N
faster RBR N
transit NN N
times NNS N
in IN N
the DT N
left NN N
colon NN N
and CC N
the DT N
rectum NN N
, , N
although IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Throughout IN N
the DT N
infusion NN N
, , N
changes NNS N
in IN N
transcutaneous JJ N
PCO2 NNP N
( ( N
tcPCO2 NN N
) ) N
, , N
subjective JJ N
anxiety NN N
, , N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
were VBD N
recorded VBN N
continuously RB N
. . N

In IN N
this DT N
study NN N
seven CD N
patients NNS p
with IN N
infantile JJ N
autism NN N
, , N
three CD N
before IN N
puberty NN N
and CC N
four CD N
after IN N
puberty NN N
, , N
were VBD N
given VBN N
a DT N
gluten-free JJ N
diet NN N
. . N

A DT N
significant JJ N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
chemotherapy-related JJ i
oral JJ N
mucositis NN N
occurred VBD N
across IN N
multiple JJ N
cycles NNS N
of IN N
treatment NN N
in IN N
patients NNS p
treated VBN N
with IN N
filgrastim NN N
. . N

The DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
oxidation NN N
was VBD N
measured VBN N
by IN N
challenging VBG N
LDL NNP N
with IN N
hemin NN N
and CC N
H2O2 NNP N
and CC N
measuring VBG N
the DT N
time NN N
for IN N
the DT N
reaction NN N
to TO N
reach VB N
maximum JJ N
velocity NN N
. . N

Although IN N
both DT N
therapies NNS N
worsened VBD N
the DT N
lipid JJ N
profile NN N
, , N
the DT N
oral JJ N
pill NN N
administration NN N
was VBD N
associated VBN N
with IN N
a DT N
more RBR N
evident JJ N
increase NN o
of IN N
circulating VBG N
triglycerides NNS N
. . N

Sodium NNP N
dodecyl VBZ N
sulfate-PAGE NN N
combined VBN N
with IN N
scanning VBG N
analysis NN N
demonstrated VBD N
that IN N
the DT N
msyB-HA JJ N
fusion NN N
protein NN N
accounted VBD N
for IN N
29.5 CD N
% NN N
of IN N
the DT N
total JJ N
bacterial JJ N
protein NN N
, , N
90.5 CD N
% NN N
being VBG N
soluble JJ N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
in IN N
a DT N
similar JJ N
way NN N
to TO N
compare VB N
capsular JJ N
contracture NN N
around IN N
smooth JJ N
and CC N
textured VBD N
saline-filled JJ N
prostheses NNS N
with IN N
pores NNS N
of IN N
small JJ N
size NN N
. . N

High JJ N
dietary JJ N
Zn NNP N
treatment NN N
led VBD N
to TO N
a DT N
reduced JJ N
abundance NN N
of IN N
CD8 NNP N
( ( N
+ NN N
) ) N
? . N
T-cells NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
little JJ N
difference NN N
could MD N
be VB N
found VBN N
in IN N
the DT N
patient JJ N
outcome NN N
variables NNS N
of IN N
the DT N
different JJ N
treatment NN N
groups NNS N
. . N

There EX N
was VBD N
some DT N
evidence NN N
of IN N
therapeutic JJ N
carry-over JJ N
effects NNS N
in IN N
both DT N
clinical JJ N
and CC N
biochemical JJ N
measures NNS N
in IN N
those DT N
children NNS N
who WP N
received VBD N
NTX NNP N
before IN N
PLC NNP N
. . N

INTRODUCTION NNP N
A NNP N
significant JJ N
number NN N
of IN N
postmenopausal JJ N
women NNS N
suffer VBP N
from IN N
distressing VBG N
problems NNS N
because IN N
of IN N
urogenital JJ N
atrophy NN N
secondary JJ N
to TO N
the DT N
decline NN N
in IN N
circulating VBG N
estrogen NN N
levels NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
pulse JJ N
oximeter NN N
PI NNP N
provides VBZ N
an DT N
earlier JJR N
and CC N
clearer JJR N
indication NN N
of IN N
sympathectomy NN N
following VBG N
epidural JJ N
anesthesia NNS N
than IN N
skin JJ N
temperature NN N
and CC N
arterial JJ N
pressure NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
caudal JJ N
block NN N
with IN N
diclofenac JJ N
suppository NN N
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
in IN N
children NNS N
undergoing VBG N
laparoscopy NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
an DT N
improvement NN N
in IN N
masticatory JJ N
performance NN N
does VBZ N
not RB N
imply VB N
the DT N
same JJ N
improvement NN N
in IN N
chewing VBG N
experience NN N
and CC N
vice NN N
versa NN N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.67 CD N
) ) N
for IN N
the DT N
percent NN N
of IN N
subjects NNS N
with IN N
each DT N
type NN N
of IN N
adverse JJ N
event NN N
. . N

We PRP N
enrolled VBD N
postmenopausal JJ N
women NNS N
with IN N
hormone-receptor-positive JJ N
, , N
locally RB N
advanced VBD N
or CC N
metastatic JJ N
breast NN N
cancer NN N
previously RB N
treated VBN N
with IN N
endocrine JJ N
treatment NN N
. . N

The DT N
current JJ N
study NN N
has VBZ N
been VBN N
designed VBN N
to TO N
compare VB N
the DT N
classical JJ N
mono NN N
chemotherapy NN i
docetaxel NN i
with IN N
a DT N
docetaxel NN i
cisplatin NN i
doublet NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN N
relief NN N
, , N
or CC N
stinging VBG N
on IN N
instillation NN N
( ( N
P NNP N
= NNP N
.29 NNP N
) ) N
. . N

Increased VBN o
frequency NN N
of IN N
whining VBG N
occurred VBN N
after IN N
administration NN N
of IN N
methadone NN i
and CC N
may MD N
be VB N
a DT N
drug NN N
effect NN N
and CC N
not RB N
a DT N
sign NN N
of IN N
pain NN N
. . N

After IN N
the DT N
conclusion NN N
of IN N
surgery NN N
but CC N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
, , N
the DT N
anesthesiologist NN N
administered VBD N
either CC N
nicotine JJ N
nasal NN N
spray NN N
or CC N
a DT N
placebo NN N
. . N

INTERPRETATION NNP N
Pembrolizumab NNP i
prolongs NNS N
overall JJ i
survival NN N
and CC N
has VBZ N
a DT N
favourable JJ N
benefit-to-risk JJ N
profile NN N
in IN N
patients NNS p
with IN N
previously RB N
treated VBN N
, , N
PD-L1-positive JJ N
, , N
advanced JJ N
non-small-cell JJ N
lung NN N
cancer NN N
. . N

This DT N
RPA NNP N
had VBD N
moderate JJ N
discrimination NN N
in IN N
SABR NNP N
datasets NNS N
( ( N
c-index NN N
range NN N
: : N
0.52-0.60 JJ N
) ) N
but CC N
was VBD N
of IN N
limited JJ N
value NN N
in IN N
the DT N
surgical JJ N
validation NN N
cohort NN N
. . N

The DT N
results NNS N
indicate VBP N
a DT N
significantly RB N
higher JJR N
morbidity NN N
among IN N
patients NNS p
treated VBN N
with IN N
preoperative JJ N
irradiation NN N
compared VBN N
with IN N
those DT N
irradiated JJ N
postoperative JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Efficacy NN N
of IN N
treatment NN N
, , N
Chinese JJ N
medicine JJ N
syndrome NN N
scores NNS N
, , N
end-point JJ N
events NNS N
occurrence NN N
as RB N
well RB N
as IN N
changes NNS N
of IN N
related JJ N
laboratory NN N
indices NNS N
were VBD N
observed VBN N
. . N

Untoward IN N
side-effect JJ N
incidence NN N
was VBD N
much JJ N
higher JJR N
in IN N
the DT N
diethylstilbestrol NN N
group NN N
( ( N
30.4 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
tamoxifen NN N
( ( N
3.5 CD N
% NN N
) ) N
. . N

The DT N
GM-CSF NNP N
group NN N
had VBD N
lower JJR N
haemoglobin NN N
concentrations NNS N
and CC N
platelets NNS N
counts NNS N
, , N
and CC N
higher JJR N
plasma NN N
urea JJ N
creatinine NN N
and CC N
bilirubin NN N
, , N
than IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Vaginal NNP N
hormonal JJ N
contraception NN N
appears VBZ N
to TO N
be VB N
preferable JJ N
to TO N
oral JJ N
ethinylestradiol NN N
+ NNP N
drospirenone NN N
administration NN N
in IN N
hyperinsulinemic JJ N
patients NNS p
with IN N
PCOS NNP N
. . N

In IN N
a DT N
competing-risks JJ N
analysis NN N
, , N
those DT N
factors NNS N
that WDT N
increased VBD o
the DT o
risk NN N
of IN N
arrhythmic JJ N
death NN N
also RB N
increased VBD o
the DT o
risk NN N
of IN N
nonarrhythmic JJ N
deaths NNS N
. . N

All DT N
methods NNS N
of IN N
the DT N
treatment NN N
of IN N
severe JJ N
sepsis NN N
are VBP N
discussed VBN N
with IN N
reference NN N
to TO N
treatment NN N
indications NNS N
, , N
efficacy NN N
, , N
and CC N
outcome JJ N
parameters NNS N
. . N

Statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
TIMP NNP N
and CC N
TOT NNP N
when WRB N
measuring VBG N
their PRP$ N
effects NNS N
on IN N
perceived JJ N
exertion NN N
and CC N
perceived VBD N
fatigue NN N
. . N

RESULTS NNP N
Obtaining NNP N
opioids NNS N
from IN N
doctors NNS N
was VBD N
associated VBN N
with IN N
lower JJR N
pre-treatment JJ N
drug NN N
spending NN N
, , N
while IN N
obtaining VBG N
opioids NNS N
from IN N
dealers/patients NNS p
was VBD N
associated VBN N
with IN N
greater JJR N
spending NN N
. . N

It PRP N
is VBZ N
therefore RB N
essential JJ N
to TO N
evaluate VB N
current JJ N
drugs NNS N
, , N
one CD N
of IN N
which WDT N
is VBZ N
the DT N
water NN N
extract NN N
of IN N
the DT N
bark NN N
of IN N
the DT N
tree NN N
Choerospondias NNP N
axillaris NN N
. . N

Influence NN N
of IN N
exercise NN N
training NN N
on IN N
leptin NN i
levels NNS N
in IN N
patients NNS p
with IN N
stable JJ N
coronary JJ N
artery NN N
disease NN N
: : N
A DT N
pilot NN N
study NN N
. . N

This DT N
earlier JJR N
work NN N
suggested VBD N
that IN N
cefotaxime NN N
might MD N
be VB N
more RBR N
effective JJ N
than IN N
cephamandole NN N
in IN N
preventing VBG N
wound JJ N
sepsis NN N
in IN N
emergency NN N
abdominal JJ N
surgery NN N
. . N

) ) N
medroxyprogesterone NN N
acetate NN N
( ( N
MPA NNP N
) ) N
for IN N
the DT N
control NN N
of IN N
hot JJ N
flashes NNS N
in IN N
postmenopausal NN N
patients NNS p
with IN N
a DT N
history NN N
of IN N
breast NN N
cancer NN N
. . N

Hemagglutinin NNP N
( ( N
HA NNP N
) ) N
is VBZ N
the DT N
major JJ N
immunogen NN N
on IN N
the DT N
envelope NN N
of IN N
influenza NN N
A NNP N
virus NN N
and CC N
is VBZ N
the DT N
predominant JJ N
inducer NN N
of IN N
neutralizing VBG N
antibody NN N
. . N

Including VBG N
results NNS N
obtained VBN N
by IN N
second-look JJ N
laparotomy NN N
, , N
we PRP N
did VBD N
not RB N
observe VB N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
response NN N
rates NNS N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Release NN N
of IN N
cortisol NN N
but CC N
not RB N
of IN N
prolactin NN i
after IN N
dexfenfluramine JJ N
administration NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
of IN N
ecstasy JJ N
users NNS N
compared VBN N
with IN N
the DT N
controls NNS N
. . N

36-month JJ N
treatment NN N
experience NN N
of IN N
two CD N
doses NNS N
of IN N
leuprolide JJ N
acetate JJ N
3-month JJ N
depot NN N
for IN N
children NNS N
with IN N
central JJ N
precocious JJ N
puberty NN N
. . N

The DT N
effect NN N
of IN N
RVX-208 NNP N
on IN N
other JJ N
lipid JJ N
and CC N
inflammatory JJ N
markers NNS N
, , N
safety NN N
and CC N
tolerability NN N
will MD N
also RB N
be VB N
assessed VBN N
in IN N
both DT N
studies NNS N
. . N

Additionally RB N
, , N
the DT N
joint JJ N
attention NN N
group NN N
improved VBD N
in IN N
the DT N
proportion NN N
of IN N
time NN N
spent VBN N
sharing VBG N
coordinated VBN N
joint JJ N
looks NNS N
between IN N
intervener NN N
and CC N
probe NN N
. . N

Main NNP N
outcome NN N
measures NNS N
were VBD N
body JJ N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
serum JJ N
leptin NN i
and CC N
sex NN N
hormone NN N
binding VBG N
globulin NN N
( ( N
SHBG NNP N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
extrapyramidal NN N
symptoms NNS N
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
nitrous JJ N
oxide NN N
does VBZ N
not RB N
contribute VB N
to TO N
the DT N
occurrence NN N
of IN N
nausea NN N
or CC N
vomiting NN N
after IN N
isoflurane NN N
anesthesia NN N
for IN N
gynecologic JJ N
laparotomies NNS N
. . N

The DT N
treatment NN N
is VBZ N
usually RB N
with IN N
either DT N
phenobarbital NN N
or CC N
phenytoin NN N
, , N
but CC N
the DT N
efficacy NN N
of IN N
the DT N
two CD N
drugs NNS N
has VBZ N
not RB N
been VBN N
compared VBN N
directly RB N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
platelet NN N
activation NN N
and CC N
fibrinolyis NN N
in IN N
acute JJ N
atherosclerotic JJ i
ischemic JJ N
stroke NN N
patients NNS p
to TO N
clarify VB N
the DT N
relationship NN N
between IN N
them PRP N
. . N

These DT N
observations NNS N
suggest VBP N
that IN N
the DT N
cardiovascular JJ N
events NNS N
associated VBN N
with IN N
both DT N
agents NNS N
result VBP N
from IN N
hypogonadism NN N
rather RB N
than IN N
a DT N
direct JJ N
drug NN N
effect NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Both NNP N
larger JJR N
molecule NN N
removal NN N
and CC N
dialyzer NN N
biocompatibility NN N
have VBP N
been VBN N
implicated VBN N
in IN N
the DT N
high-flux JJ N
hemodialysis NN N
( ( N
HD NNP N
) ) N
-associated VBD N
favorable JJ N
outcome NN N
. . N

Effects NNS N
of IN N
maternal JJ N
and CC N
dietary JJ N
selenium NN N
( ( N
Se-enriched NNP N
yeast NN N
) ) N
on IN N
the DT N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
of IN N
germ JJ N
cells NNS N
of IN N
their PRP$ N
offspring NN N
in IN N
goats NNS N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
have VBP N
shown VBN N
that IN N
interactions NNS N
among IN N
homocysteine JJ i
metabolism NN N
gene NN N
polymorphisms JJ N
lead NN N
to TO N
dramatic JJ N
elevations NNS N
in IN N
the DT N
folate NN N
deficiency NN N
risk NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Combined NNP N
spinal-epidural JJ N
is VBZ N
an DT N
alternative JJ N
technique NN N
to TO N
epidural JJ N
analgesia NN N
for IN N
labour NN N
, , N
but CC N
its PRP$ N
benefits NNS N
are VBP N
not RB N
clearly RB N
identified VBN N
. . N

Twenty CD N
teeth NNS N
from IN N
each DT N
group NN N
were VBD N
used VBN N
for IN N
the DT N
apical JJ N
leakage NN N
test NN N
and CC N
the DT N
remaining VBG N
five CD N
teeth NNS N
from IN N
each DT N
group NN N
were VBD N
used VBN N
for IN N
examination NN N
under IN N
the DT N
scanning NN N
electron NN N
microscope NN N
( ( N
SEM NNP N
) ) N
. . N

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
the DT N
number NN N
of IN N
patients NNS p
who WP N
died VBD N
or CC N
in IN N
the DT N
number NN N
who WP N
had VBD N
clinically RB N
relevant JJ N
bleeding NN N
. . N

The DT N
authors NNS N
' POS N
study NN N
compared VBN N
suture NN N
with IN N
a DT N
new JJ N
coaptive JJ N
film NN N
device NN N
, , N
3M CD N
Steri-Strip JJ N
S NNP N
Surgical NNP N
Skin NNP N
Closure NNP N
, , N
on IN N
linear JJ N
incisions NNS N
. . N

There EX N
were VBD N
more JJR N
renal JJ N
toxicity NN N
, , N
leucopenia NN N
, , N
and CC N
anaemia NN N
in IN N
the DT N
cisplatin NN i
group NN N
, , N
and CC N
more JJR N
thrombocytopenia NN N
in IN N
the DT N
carboplatin NN i
arm NN N
. . N

Effects NNS N
of IN N
low JJ N
and CC N
high JJ N
protein NN N
: : N
carbohydrate JJ N
ratios NNS N
in IN N
the DT N
diet NN N
of IN N
pregnant JJ N
gilts NNS N
on IN N
maternal JJ N
cortisol NN N
concentrations NNS N
and CC N
the DT N
adrenocortical JJ N
and CC N
sympathoadrenal JJ N
reactivity NN N
in IN N
their PRP$ N
offspring NN N
. . N

Unique NNP N
attributes VBZ N
render VBP N
it PRP N
a DT N
promising JJ N
candidate NN N
for IN N
prophylactic JJ N
mass NN N
immunization NN N
, , N
even RB N
in IN N
subjects NNS N
for IN N
whom WP N
conventional JJ N
smallpox NN N
vaccines NNS N
are VBP N
contraindicated VBN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
number NN N
of IN N
verbal JJ N
attempts NNS N
or CC N
number NN N
of IN N
correct JJ N
words NNS N
were VBD N
noted VBN N
between IN N
groups NNS N
following VBG N
treatment NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
increases NNS o
were VBD N
observed VBN N
in IN N
the DT N
anthropometric JJ N
indices NNS N
of IN N
the DT N
subjects NNS N
receiving VBG N
the DT N
high-calcium NN N
fortified VBD N
milk NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

The DT N
decreased JJ o
pain NN N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
morphine JJ N
utilization NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
nicotine NN N
was VBD N
not RB N
associated VBN N
with IN N
hypertension NN N
or CC N
tachycardia NN N
. . N

ADMA NN N
levels NNS N
were VBD N
positively RB N
correlated VBN N
with IN N
basal JJ N
endothelin-1 JJ N
levels NNS N
and CC N
negatively RB N
correlated VBN N
with IN N
insulin-induced JJ N
incremental JJ N
levels NNS N
of IN N
NOx NNP N
and CC N
forearm NN N
cGMP NN N
release NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
between-group JJ N
difference NN N
in IN N
mean JJ N
heart NN N
rate NN N
or CC N
systolic NN N
and CC N
diastolic JJ N
blood NN N
pressure NN N
at IN N
any DT N
of IN N
the DT N
time NN N
points NNS N
. . N

MEASUREMENTS NNP N
Urine NNP N
benzoylecgonine NN N
( ( N
BE NNP N
) ) N
concentrations NNS N
, , N
self-report NN N
of IN N
cocaine NN N
use NN N
and CC N
global JJ N
impression NN N
scores NNS N
served VBD N
as IN N
primary JJ N
outcome NN N
measures NNS N
. . N

Sublingual JJ N
administration NN N
of IN N
micronized JJ N
estradiol NN N
and CC N
progesterone NN N
, , N
with IN N
and CC N
without IN N
micronized VBN N
testosterone NN N
: : N
effect NN N
on IN N
biochemical JJ N
markers NNS N
of IN N
bone NN N
metabolism NN N
and CC N
bone JJ N
mineral JJ N
density NN N
. . N

This DT N
may MD N
suggest VB N
reductions NNS N
in IN N
mortality NN N
associated VBN N
with IN N
azithromycin JJ i
MDA NNP N
are VBP N
due JJ N
to TO N
a DT N
mechanism NN N
other JJ N
than IN N
improved JJ N
nutritional JJ N
status NN N
. . N

Isometric JJ N
contractions NNS N
reduce VB N
plantar NN N
flexor NN N
moment NN N
, , N
Achilles NNP N
tendon VBZ N
stiffness NN N
, , N
and CC N
neuromuscular JJ N
activity NN N
but CC N
remove VB N
the DT N
subsequent JJ N
effects NNS N
of IN N
stretch NN N
. . N

Safety NN N
endpoints NNS N
included VBD N
occurrence NN N
of IN N
neutralizing VBG N
anti-erythro JJ N
poietin NN i
antibodies NNS N
, , N
tolerability NN N
, , N
and CC N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
. . N

Safety NN N
and CC N
efficacy NN N
of IN N
oral JJ N
DMSA NNP N
therapy NN i
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
: : N
Part VB N
A DT N
-- : N
medical JJ N
results NNS N
. . N

A DT N
Phase NNP N
I PRP N
clinical VBP N
study NN N
demonstrated VBD N
that IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
PPS NNP N
increased VBD o
microvascular JJ o
blood NN N
flow NN N
in IN N
patients NNS p
with IN N
SCD NNP N
. . N

Rioprostil NNP N
, , N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
, , N
in IN N
the DT N
once-daily JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
duodenal JJ N
ulcer JJ N
recurrence NN N
: : N
a DT N
comparison NN N
with IN N
ranitidine NN N
. . N

Measurement NN N
of IN N
7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic JJ N
acid NN N
, , N
( ( N
PGE-M NNP N
) ) N
, , N
the DT N
major JJ N
urinary JJ N
metabolite NN N
of IN N
prostaglandin NN N
E1 NNP N
and CC N
E2 NNP N
in IN N
man NN N
provides VBZ N
a DT N
useful JJ N
indicator NN N
to TO N
monitor VB N
prostaglandin JJ N
biosynthesis NN N
. . N

RESULTS VB N
The DT N
average JJ N
time NN N
to TO N
fracture VB N
healing NN N
was VBD N
16.7 CD N
weeks NNS N
in IN N
the DT N
reamed VBN N
group NN N
and CC N
25.7 CD N
weeks NNS N
in IN N
the DT N
unreamed JJ N
group NN N
. . N

RESULTS VB N
The DT N
detachment NN N
of IN N
the DT N
neurosensory JJ N
retina NN N
and CC N
retinal JJ N
pigment NN N
epithelium NN N
improved VBN N
in IN N
all DT N
eyes NNS N
, , N
but CC N
all DT N
neovascular JJ N
lesions NNS N
increased VBD o
in IN o
size NN N
. . N

Baseline NNP N
subjective NN N
and CC N
blinded VBD N
physician JJ N
dyschromia NN N
and CC N
rhytid NN N
scores NNS N
revealed VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
IPL NNP N
and CC N
Er NNP N
: : N
YAG NNP N
randomly RB N
assigned VBD N
sides NNS N
. . N

BACKGROUND NNP N
Autism NNP N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
is VBZ N
associated VBN N
with IN N
altered JJ N
face NN N
processing NN N
and CC N
decreased JJ o
activity NN N
in IN N
brain NN N
regions NNS N
involved VBN N
in IN N
face NN N
processing NN N
. . N

The DT N
low JJ N
rate NN N
of IN N
recorded VBN N
complications NNS N
showed VBD N
that IN N
both DT N
techniques NNS N
cause VBP N
little JJ N
damage NN N
to TO N
the DT N
tonsillar JJ N
bed NN N
during IN N
dissection NN N
, , N
thus RB N
minimising VBG N
complications NNS N
. . N

Isolates NNS N
at IN N
diagnosis NN N
and CC N
from IN N
positive JJ N
cultures NNS N
after IN N
treatment NN N
completion NN N
underwent NN N
genotyping VBG N
using VBG N
IS6110 NNP N
( ( N
with IN N
secondary JJ N
genotyping NN N
for IN N
isolates NNS N
with IN N
less JJR N
than IN N
six CD N
copies NNS N
of IN N
IS6110 NNP N
) ) N
. . N

The DT N
opening NN N
of IN N
the DT N
female JJ N
urethra NN N
is VBZ N
located VBN N
within IN N
the DT N
vulvar NN N
vestibule NN N
, , N
making VBG N
insertion NN N
of IN N
urinary JJ N
catheters NNS N
into IN N
females NNS N
a DT N
greater JJR N
technical JJ N
challenge NN N
than IN N
in IN N
males NNS N
. . N

CONCLUSION NNP N
The DT N
Silicone NNP N
Study NNP N
showed VBD N
that IN N
silicone NN N
oil NN N
and CC N
perfluoropropane NN N
gas NN N
were VBD N
equal JJ N
in IN N
most JJS N
respects NNS N
for IN N
the DT N
management NN N
of IN N
retinal JJ N
detachments NNS N
with IN N
PVR NNP N
. . N

Moreover RB N
, , N
the DT N
treatment NN N
efficacy NN N
of IN N
carboplatin NN i
arm NN N
is VBZ N
not RB N
different JJ N
from IN N
the DT N
standard JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
locoregional JJ N
advanced JJ N
stage NN N
NPC NNP N
. . N

MEASURES NNP N
systolic JJ N
and CC N
early JJ N
diastolic JJ N
velocities NNS N
were VBD N
registered VBN N
by IN N
Tissue NNP N
Doppler NNP N
from IN N
a DT N
long-axis JJ N
view NN N
of IN N
the DT N
interventricular JJ N
septum NN N
or CC N
the DT N
anterior JJ N
wall NN N
of IN N
the DT N
left JJ N
ventricle NN N
. . N

A DT N
single JJ N
prophylactic JJ N
intraoperative NN N
dose NN N
of IN N
intravenous JJ N
amiodarone NN N
decreased VBD o
post NN o
bypass NN N
arrhythmia NN N
in IN N
this DT N
study NN N
in IN N
comparison NN N
to TO N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
a DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
anaerobic JJ N
bacteria NNS N
in IN N
the DT N
feces NNS N
and CC N
colon NN N
contents NNS N
of IN N
patients NNS p
receiving VBG N
metronidazole NN N
. . N

Median JJ N
home NN N
lighting NN N
was VBD N
4.3 CD N
times NNS N
and CC N
2.8 CD N
times NNS N
lower JJR N
than IN N
clinic JJ N
lighting NN N
in IN N
areas NNS N
tested VBN N
for IN N
DVA NNP N
and CC N
NVA NNP N
, , N
respectively RB N
. . N

CYP21 NNP N
genotyping VBG N
indicated VBD N
a DT N
heterozygote NN N
rate NN N
of IN N
2.8 CD N
% NN N
for IN N
classic JJ N
mutations NNS N
( ( N
excluding VBG N
CYP21 NNP N
deletions NNS N
) ) N
, , N
and CC N
2.0 CD N
% NN N
for IN N
nonclassic JJ N
mutations NNS N
in IN N
New NNP N
Zealanders NNP N
. . N

BACKGROUND NNP N
Cardiac NNP N
resynchronization NN N
therapy NN i
( ( N
CRT NNP N
) ) N
improves VBZ N
clinical JJ N
outcome NN N
in IN N
selected VBN N
patients NNS p
with IN N
advanced JJ N
congestive JJ N
heart NN N
failure NN N
. . N

Before IN N
the DT N
skin NN N
incision NN N
performed VBD N
after IN N
anesthesia JJ N
induction NN N
, , N
we PRP N
performed VBD N
ilioinguinal JJ N
iliohypogastric JJ N
block NN N
( ( N
group NN N
C NNP N
given VBN N
saline NN N
and CC N
group NN N
P NNP N
and CC N
DB NNP N
given VBN N
levobupivacaine NN N
) ) N
. . N

A DT N
significant JJ N
increase NN o
in IN N
aortic JJ N
PWV NNP N
, , N
a DT N
marker NN N
of IN N
aortic JJ N
stiffness NN N
, , N
was VBD N
noted VBN N
after IN N
patients NNS p
switched VBD N
from IN N
high-flux NN N
to TO N
low-flux JJ N
polyamide NN N
membranes NNS N
. . N

Although IN N
EMDA NNP N
has VBZ N
been VBN N
used VBN N
to TO N
treat VB N
patients NNS p
with IN N
various JJ N
diseases NNS N
, , N
controlled VBN N
studies NNS N
are VBP N
lacking VBG N
in IN N
patients NNS p
with IN N
rheumatic JJ N
disease NN N
. . N

CONCLUSIONS NNP N
Vitamin NNP N
E NNP N
did VBD N
not RB N
appear VB N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
sensory JJ N
neuropathy NN N
in IN N
the DT N
studied JJ N
group NN N
of IN N
patients NNS p
receiving VBG N
neurotoxic JJ N
chemotherapy NN i
. . N

BACKGROUND NNP N
Genital NNP N
infection NN N
with IN N
human JJ N
papillomavirus NN N
, , N
the DT N
cause NN N
of IN N
genital JJ N
warts NNS N
, , N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
sexually RB N
transmitted JJ N
diseases NNS N
. . N

The DT N
excretion NN N
rate NN N
of IN N
uric JJ N
acid NN N
in IN N
urine NN N
may MD N
be VB N
used VBN N
as IN N
a DT N
new JJ N
index NN N
for IN N
pharmacological JJ N
effects NNS N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

Testosterone CD N
administered JJ N
alone RB N
or CC N
in IN N
combination NN N
with IN N
progestogens NNS N
in IN N
male JJ N
contraception NN N
induces NNS N
reversible JJ N
oligo-azoospermia JJ N
, , N
but CC N
its PRP$ N
effects NNS N
on IN N
body NN N
composition NN N
and CC N
metabolism NN N
are VBP N
less RBR N
known JJ N
. . N

Studies NNS N
of IN N
vector-parasite JJ N
relations NNS N
of IN N
Wuchereria NNP N
bancrofti NN N
suggest VBP N
that IN N
a DT N
reduction NN N
in IN N
the DT N
microfilarial JJ N
reservoir NN N
by IN N
mass NN N
chemotherapy NN i
may MD N
interrupt VB N
transmission NN N
and CC N
thereby RB N
eliminate VB N
infection NN N
. . N

A DT N
significant JJ N
decrease NN o
in IN N
frequency NN N
and CC N
intensity NN N
of IN N
myofascial JJ N
pain NN N
was VBD N
found VBN N
in IN N
group NN N
T NNP N
at IN N
the DT N
follow-ups NNS N
. . N

Dietary NNP N
potential JJ N
renal JJ N
acid NN N
load NN N
( ( N
PRAL NNP N
) ) N
and CC N
daily JJ N
net NN N
endogenous JJ N
acid NN N
production NN N
( ( N
NEAP NNP N
) ) N
at IN N
baseline NN N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Local JJ N
therapy NN i
with IN N
glycerol NN N
lidocaine NN N
eardrops VBZ N
is VBZ N
a DT N
safe JJ N
, , N
and CC N
cost-effective JJ N
treatment NN N
for IN N
the DT N
widely RB N
spread JJ N
clinical JJ N
picture NN N
of IN N
acute JJ N
abacterial JJ N
otitis NN N
externa NN N
. . N

The DT N
low JJ N
pressure NN N
suction NN N
drain NN N
removed VBD N
an DT N
intraperitoneal NN N
marker NN N
, , N
gentamicin NN i
, , N
more RBR N
effectively RB N
than IN N
the DT N
high JJ N
pressure NN N
suction NN N
drain NN N
, , N
but CC N
not RB N
more RBR N
effectively RB N
than IN N
the DT N
passive JJ N
drain NN N
. . N

RESULTS NNP N
Intraoperative NNP N
administration NN N
of IN N
ketorolac NN N
resulted VBD N
in IN N
better JJR N
quality NN N
of IN N
pain NN N
control NN N
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
regardless NN N
of IN N
route NN N
of IN N
administration NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
quality NN N
of IN N
life NN N
score NN N
between IN N
the DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.012 CD N
) ) N
. . N

The DT N
clinical JJ N
efficacy NN N
was VBD N
the DT N
same JJ N
although IN N
the DT N
alleviation NN N
of IN N
vasomotor NN N
symptoms NNS N
was VBD N
somewhat RB N
slower JJR N
in IN N
those DT N
women NNS N
receiving VBG N
preparation NN N
A DT N
. . N

This DT N
tendency NN N
was VBD N
also RB N
supported VBN N
by IN N
moderate JJ N
effect NN N
sizes NNS N
and CC N
qualitative JJ N
indications NNS N
of IN N
likely JJ N
harmful NN N
or CC N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
RSA-SS NNP N
. . N

Significantly RB N
more RBR N
deaths NNS N
of IN N
presumed JJ N
fungal JJ N
origin NN N
occurred VBD N
in IN N
flu NN N
than IN N
itra JJ N
( ( N
seven CD N
versus NN N
nil NN N
, , N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

While IN N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
in IN N
the DT N
number NN N
of IN N
lymph JJ N
node JJ N
dissection NN N
, , N
operative JJ N
time NN N
and CC N
postoperative JJ N
chest NN N
tube NN N
drainage NN N
time NN N
. . N

Blinded VBN N
operators NNS N
calculated VBD N
angiographic JJ N
corrected VBN N
TIMI NNP N
Frame NNP N
count NN N
( ( N
cTFC NN N
) ) N
and CC N
myocardial JJ N
blush NN N
grade NN N
( ( N
MBG NNP N
) ) N
before IN N
and CC N
after IN N
stent JJ N
implantation NN N
. . N

Several JJ N
generic JJ N
formulations NNS N
have VBP N
been VBN N
approved VBN N
, , N
raising VBG N
concern NN N
over IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
these DT N
products NNS N
compared VBN N
with IN N
brand-name JJ N
Coumadin NNP N
. . N

GOALS NNP N
AND CC N
BACKGROUND NNP N
The DT N
role NN N
of IN N
preventive JJ N
lymphadenectomy NN N
has VBZ N
not RB N
yet RB N
been VBN N
determined VBN N
for IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
patients NNS p
. . N

CONCLUSION NNP N
ZJC1 NNP N
can MD N
enhance VB N
the DT N
density NN N
and CC N
motility NN N
of IN N
sperm NN N
and CC N
reduce VB N
the DT N
sperm JJ N
deformity NN N
rate NN N
in IN N
patients NNS p
with IN N
OSM NNP N
. . N

The DT N
median JJ N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
was VBD N
3.8 CD N
months NNS N
in IN N
arm NN N
A NN N
and CC N
5.8 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
, , N
and CC N
safety NN N
. . N

CONCLUSIONS NNP N
Video-assisted NNP N
thoracoscopic NN N
talc NN N
insufflation NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
superior JJ N
approach NN N
compared VBN N
with IN N
talc NN N
slurry NN N
in IN N
our PRP$ N
study NN N
. . N

In IN N
conclusion NN N
, , N
a DT N
short-term JJ N
resistance NN N
training NN N
protocol NN N
improved VBD N
mucosal JJ N
immunity NN N
response NN N
as RB N
well RB N
as IN N
salivary JJ N
testosterone NN N
levels NNS N
in IN N
sedentary JJ N
adults NNS N
with IN N
DS NNP N
. . N

Paired VBN N
comparisons NNS N
revealed VBD N
a DT N
significant JJ N
difference NN N
in IN N
efficacy NN N
between IN N
CAE NNP N
and CC N
CEC NNP N
and CC N
a DT N
nearly RB N
significant JJ N
difference NN N
between IN N
AMX-CL NNP N
and CC N
CEC NNP N
. . N

Bupivacaine NNP N
produced VBD N
a DT N
significant JJ N
incidence NN N
of IN N
residual JJ N
motor NN N
block NN N
compared VBN N
with IN N
levobupivacaine NN N
or CC N
ropivacaine NN N
at IN N
wake-up NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
deliberate NN N
mild JJ N
hypothermia NN N
is VBZ N
easily RB N
achieved VBN N
intraoperatively RB N
, , N
complete JJ N
rewarming NN N
may MD N
be VB N
difficult JJ N
to TO N
attain VB N
during IN N
craniotomy NN N
with IN N
current JJ N
methods NNS N
. . N

In IN N
order NN N
to TO N
evaluate VB N
any DT N
beneficial JJ N
effect NN N
of IN N
such JJ N
an DT N
administration NN N
, , N
a DT N
group NN N
of IN N
patients NNS p
with IN N
recurrent JJ N
gastric JJ N
cancer NN N
was VBD N
studied VBN N
. . N

Blood NNP N
pressure NN N
, , N
heart NN N
rate NN N
, , N
oxygen NN N
saturation NN N
, , N
total JJ N
amount NN N
of IN N
analgesic JJ N
consumed VBN N
and CC N
adverse JJ N
effects NNS N
were VBD N
also RB N
recorded VBN N
. . N

Improvement NN N
in IN N
anxiety NN N
and CC N
sedation NN N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
two CD N
drug NN N
groups NNS N
than IN N
in IN N
those DT N
patients NNS p
who WP N
had VBD N
received VBN N
placebo NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
these DT N
study NN N
measures NNS N
among IN N
the DT N
three CD N
treatment NN N
conditions NNS N
( ( N
P NNP N
> VBZ N
0.1 CD N
for IN N
all DT N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
whether IN N
these DT N
pharmacological JJ N
differences NNS N
between IN N
salmeterol NN N
and CC N
formoterol NN N
also RB N
are VBP N
applicable JJ N
to TO N
asthmatic JJ N
patients NNS p
. . N

Zolmitriptan NNP N
( ( N
Zomig NNP N
, , N
formerly RB N
311C90 CD N
) ) N
is VBZ N
a DT N
selective JJ N
5-hydroxytryptamine JJ N
( ( N
5-HT JJ N
) ) N
1B/1D-receptor JJ N
agonist NN N
with IN N
central JJ N
and CC N
peripheral JJ N
activity NN N
for IN N
the DT N
acute JJ N
treatment NN N
of IN N
migraine NN N
. . N

Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
a DT N
model NN N
, , N
wherein VBP N
the DT N
5-HT4R JJ N
density NN N
adjusts VBZ N
to TO N
changes NNS N
in IN N
the DT N
extracellular JJ N
5-HT JJ N
tonus NN N
. . N

GM-CSF JJ N
appears VBZ N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB N
vaccination NN N
in IN N
some DT N
groups NNS N
of IN N
SCT NNP N
patients NNS p
, , N
but CC N
only RB N
to TO N
a DT N
limited JJ N
extent NN N
. . N

The DT N
relative JJ N
risks NNS N
of IN N
0.67 CD N
and CC N
0.74 CD N
were VBD N
clinically RB N
similar JJ N
and CC N
the DT N
difference NN N
between IN N
them PRP N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

This DT N
higher JJR N
intensity NN N
was VBD N
a DT N
result NN N
of IN N
shorter JJR N
post-R3 NN N
intervals NNS N
in IN N
the DT N
G-CSF NNP N
group NN N
, , N
whereas IN N
the DT N
post-COPADM JJ N
intervals NNS N
were VBD N
not RB N
statistically RB N
reduced VBN N
. . N

Efficacy NN N
and CC N
radiographic JJ N
progression NN N
were VBD N
assessed VBN N
using VBG N
American JJ N
College NNP N
of IN N
Rheumatology NNP N
response NN N
criteria NNS N
, , N
disease NN N
activity NN N
scores VBZ N
, , N
and CC N
Total NNP N
Sharp NNP N
Score NNP N
( ( N
TSS NNP N
) ) N
. . N

However RB N
, , N
the DT N
published VBN N
article NN N
concluded VBD N
that IN N
both DT N
drugs NNS N
were VBD N
efficacious JJ N
versus NN N
placebo NN N
for IN N
a DT N
post NN N
hoc NN N
subgroup NN N
of IN N
patients NNS p
. . N

RESULTS NNP N
Cigarette NNP N
, , N
cigar NN N
, , N
or CC N
pipe NN N
use NN N
at IN N
each DT N
time NN N
interval NN N
correlated VBD N
with IN N
significantly RB N
increased VBN o
caloric JJ N
intake NN N
in IN N
males NNS N
but CC N
not RB N
in IN N
females NNS N
. . N

Solid NNP N
core NN N
filling VBG N
material NN N
such JJ N
as IN N
gutta-percha NN N
has VBZ N
been VBN N
used VBN N
to TO N
fill VB N
the DT N
root NN N
canal NN N
in IN N
conjunction NN N
with IN N
a DT N
sealer NN N
to TO N
prevent VB N
apical JJ N
leakage NN N
. . N

One CD N
eye NN N
of IN N
each DT N
patient NN N
with IN N
symmetric JJ N
, , N
threshold JJ N
ROP NNP N
was VBD N
treated VBN N
with IN N
an DT N
814/815 CD N
nm JJ N
diode NN N
laser NN N
, , N
while IN N
the DT N
other JJ N
eye NN N
was VBD N
treated VBN N
with IN N
cryotherapy NN i
. . N

In IN N
the DT N
management NN N
of IN N
wounds NNS N
, , N
sometimes RB N
it PRP N
is VBZ N
recommended VBN N
to TO N
give VB N
an DT N
adult-type JJ N
tetanus-diphtheria NN N
( ( N
Td NNP N
) ) N
vaccine NN N
dose JJ N
plus CC N
tetanus JJ N
immune JJ N
globulin NN N
( ( N
TIG NNP N
) ) N
. . N

BACKGROUND NNP N
Previous NNP N
investigations NNS N
in IN N
pancreatic JJ N
cancer NN N
suggest VBP N
a DT N
prognostic JJ N
role NN N
for IN N
? . N
muscle NN N
actin NN i
( ( N
? . N
) ) N
expression NN N
and CC N
stromal JJ N
density NN N
in IN N
the DT N
peritumoural JJ N
stroma NN N
. . N

Blockade NN N
of IN N
cytotoxic JJ N
T-lymphocyte JJ N
antigen-4 NN N
( ( N
CTLA-4 NNP N
) ) N
by IN N
ipilimumab NN i
leads NNS N
to TO N
immune-mediated JJ N
tumor NN N
regression NN N
and CC N
immune-related JJ N
adverse JJ N
events NNS N
( ( N
irAEs NN N
) ) N
, , N
including VBG N
diarrhea NN N
and CC N
colitis NN N
. . N

The DT N
mean JJ N
NRS NNP N
pain NN N
score NN N
before IN N
the DT N
most RBS N
recent JJ N
dose NN N
of IN N
pain NN N
medication NN N
after IN N
ED NNP N
discharge NN N
was VBD N
7.6 CD N
NRS NNP N
units NNS N
for IN N
both DT N
groups NNS N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
pharmacokinetics NNS N
and CC N
effects NNS N
of IN N
methadone NN i
on IN N
behaviour NN N
and CC N
plasma JJ N
concentrations NNS N
of IN N
cortisol NN N
and CC N
vasopressin NN N
in IN N
healthy JJ N
dogs NNS N
. . N

RESULTS NNP N
Among IN N
ABC-C NNP N
subscales NNS N
, , N
Hyperactivity NNP N
and CC N
Irritability NNP N
showed VBD N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
amantadine NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
. . N

HYPOTHESIS NNP N
Bovine NNP N
pericardium NN N
( ( N
BP NNP N
) ) N
demonstrates VBZ N
improved JJ N
intraoperative JJ N
hemostasis NN N
and CC N
equivalent JJ N
perioperative JJ N
morbidity NN N
compared VBN N
with IN N
Dacron NNP N
when WRB N
used VBN N
as IN N
patch JJ N
material NN N
for IN N
angioplasty NN N
following VBG N
carotid JJ N
endarterectomy NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
risperidone NN i
, , N
when WRB N
administered VBN N
with IN N
galantamine NN N
, , N
did VBD N
not RB N
change VB N
the DT N
bioavailability NN N
of IN N
galantamine NN N
at IN N
steady JJ N
state NN N
. . N

Plasma VB N
A DT N
increased VBN o
with IN N
dose NN N
, , N
and CC N
CSF NNP N
A NNP N
increased VBD o
at IN o
the DT N
highest JJS N
dose NN N
, , N
suggesting VBG N
that IN N
intravenous JJ N
ponezumab NN i
alters NNS N
central JJ N
A NNP N
levels NNS N
. . N

There EX N
was VBD N
a DT N
trend NN N
of IN N
a DT N
reduced JJ N
proportion NN N
of IN N
rapid JJ N
eye NN N
movement NN N
sleep JJ N
with IN N
increased JJ o
exercise NN N
intensity NN N
( ( N
P NNP N
= NNP N
0.067 CD N
) ) N
. . N

PATIENTS NN N
Patients NNS N
with IN N
ACS NNP N
on IN N
clopidogrel NN N
who WP N
were VBD N
scheduled VBN N
for IN N
PCI NNP N
found VBD N
to TO N
have VB N
a DT N
platelet NN N
reactivity NN N
? . N
AUC NNP N
with IN N
the DT N
Multiplate NNP N
Analyzer NNP N
, , N
i.e NN N
. . N

The DT N
groups NNS N
were VBD N
analysed VBN N
for IN N
intraoperative JJ N
blood NN N
loss NN N
, , N
drainage NN N
, , N
transfusion NN N
requirements NNS N
, , N
perioperative JJ N
haemoglobin NN N
decrease NN o
, , N
wound NN N
haematoma NN N
, , N
and CC N
clinical JJ N
deep NN N
venous JJ N
thrombosis NN N
. . N

Investigations NNS N
from IN N
the DT N
last JJ N
decade NN N
established VBD N
that IN N
extent NN N
of IN N
ICH-mediated NNP N
brain NN N
injury NN N
relates VBZ N
directly RB N
to TO N
blood VB N
clot NN N
volume NN N
and CC N
duration NN N
of IN N
blood NN N
exposure NN N
to TO N
brain NN N
tissue NN N
. . N

RESULTS NNP N
In IN N
nine CD N
control NN N
patients NNS p
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
the DT N
severity NN N
of IN N
OSA NNP N
, , N
MSNA NNP N
, , N
systolic JJ N
BP NNP N
, , N
or CC N
HR NNP N
. . N

In IN N
normal JJ N
postpartum JJ N
women NNS N
, , N
the DT N
postdelivery NN N
fall NN N
in IN N
serum NN N
prolactin NN i
levels NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
treated JJ N
and CC N
control JJ N
subjects NNS N
. . N

RESULTS NNP N
High NNP N
? . N
expression NN N
in IN N
tumour JJ N
stroma NN N
was VBD N
associated VBN N
with IN N
worse JJ N
patient NN N
outcome NN N
( ( N
DFS NNP N
: : N
P=0.05 NNP N
, , N
OS NNP N
: : N
P=0.047 NN N
) ) N
. . N

BACKGROUND IN N
The DT N
consumption NN N
of IN N
non-ready-to-eat JJ N
cereal NN N
and CC N
ready-to-eat NN N
cereal NN N
( ( N
RTEC NNP N
) ) N
breakfasts NNS N
have VBP N
been VBN N
associated VBN N
with IN N
increased JJ o
nutrient NN N
intakes NNS N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
intraventricular JJ N
hemorrhage NN N
and CC N
intraparenchymal JJ N
hemorrhage NN N
were VBD N
independent JJ N
risk NN N
factors NNS N
for IN N
shunt NN N
dependency NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Complete NNP N
denudation NN N
of IN N
oocytes NNS N
before IN N
slush JJ N
nitrogen NN N
vitrification NN N
does VBZ N
not RB N
influence VB N
survival JJ N
rates NNS N
but CC N
positively RB N
affects VBZ N
oocyte JJ N
meiotic JJ i
spindle NN N
competence NN N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
the DT N
TACE NNP N
therapy NN i
alone RB N
, , N
the DT N
combination NN N
therapy NN i
improves VBZ N
the DT N
tumor NN N
necrosis NN N
rate NN N
and CC N
prolongs VBZ N
the DT N
patients NNS p
' POS N
survival JJ N
duration NN N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
treatment NN N
with IN N
pentoxifylline NN N
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ o
platelet NN N
inhibitory NN N
effects NNS N
in IN N
DM NNP N
patients NNS p
with IN N
coronary JJ N
artery NN N
disease NN N
receiving VBG N
DAPT NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
influence NN N
of IN N
a DT N
co-administration NN N
of IN N
aspirin NN N
and CC N
NSAID NNP N
on IN N
platelet NN N
aggregation NN N
. . N

The DT N
difference NN N
in IN N
time NN N
to TO N
relapse VB N
between IN N
aripiprazole NN N
and CC N
placebo NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.097 NNP N
) ) N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
survival JJ N
, , N
tumor JJ N
response NN N
, , N
safety NN N
, , N
and CC N
quality NN N
of IN N
life NN N
. . N

CONCLUSIONS NNP N
Transfusion NNP N
greatly RB N
reduces VBZ N
the DT N
risk NN N
of IN N
a DT N
first JJ N
stroke NN N
in IN N
children NNS N
with IN N
sickle NN N
cell NN N
anemia NN N
who WP N
have VBP N
abnormal JJ N
results NNS N
on IN N
transcranial JJ N
Doppler NNP N
ultrasonography NN N
. . N

Multivariate NNP N
analysis NN N
results NNS N
indicated VBD N
that IN N
the DT N
lower JJR N
the DT N
tissue NN N
density NN N
percentage NN N
before IN N
treatment NN N
, , N
the DT N
greater JJR N
the DT N
increase NN o
in IN N
density NN N
percentage NN N
after IN N
treatment NN N
. . N

One CD N
group NN N
of IN N
patients NNS p
was VBD N
treated VBN N
with IN N
implantation NN N
of IN N
a DT N
cardioverter-defibrillator NN N
; : N
the DT N
other JJ N
received JJ N
class NN N
III NNP N
antiarrhythmic JJ N
drugs NNS N
, , N
primarily RB N
amiodarone NN N
at IN N
empirically RB N
determined VBN N
doses NNS N
. . N

Rituximab NNP i
plus CC N
intravenous JJ N
bolus NN N
chemotherapy NN i
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
immunocompetent JJ N
patients NNS p
with IN N
B-cell NNP N
non-Hodgkin JJ N
lymphoma NN N
( ( N
NHL NNP N
) ) N
. . N

Because IN N
children NNS N
at IN N
each DT N
grade NN N
were VBD N
distributed VBN N
across IN N
two CD N
classrooms NNS N
( ( N
clusters NNS N
) ) N
and CC N
were VBD N
homogeneous JJ N
, , N
each DT N
grade NN N
was VBD N
considered VBN N
to TO N
consist VB N
of IN N
a DT N
matched JJ N
pair NN N
. . N

Effect NN N
of IN N
testosterone NN N
and CC N
a DT N
nutritional JJ N
supplement NN N
, , N
alone RB N
and CC N
in IN N
combination NN N
, , N
on IN N
hospital JJ N
admissions NNS N
in IN N
undernourished JJ N
older JJR N
men NNS N
and CC N
women NNS N
. . N

One CD N
hundred VBD N
thirty NN N
patients NNS p
will MD N
be VB N
randomly RB N
allocated VBN N
into IN N
either CC N
the DT N
intervention NN N
or CC N
placebo NN N
group NN N
at IN N
a DT N
ratio NN N
of IN N
1:1 CD N
. . N

Median JJ N
post-hospital JJ N
stay NN N
was VBD N
1.7 CD N
days NNS N
for IN N
group NN N
A NNP N
while IN N
it PRP N
was VBD N
longer RB N
( ( N
2.9 CD N
days NNS N
) ) N
for IN N
group NN N
B NNP N
. . N

This DT N
, , N
coupled VBN N
with IN N
the DT N
decreases NNS o
in IN N
VE NNP N
resulted VBD N
in IN N
decreases NNS o
in IN N
the DT N
ventilatory NN N
equivalents NNS N
to TO N
CO2 NNP N
and CC N
O2 NNP N
( ( N
VE/VCO2 NNP N
, , N
VE/VO2 NNP N
) ) N
. . N

However RB N
, , N
it PRP N
can MD N
not RB N
be VB N
concluded VBN N
that IN N
L-carnitine NNP N
provides VBZ N
an DT N
advantageous JJ N
support NN N
therapy NN i
for IN N
well-compensated JJ N
patients NNS p
requiring VBG N
cardiac JJ N
surgery NN N
. . N

Riluzole NNP N
is VBZ N
a DT N
glutamate-modulating JJ N
agent NN N
with IN N
neuroprotective JJ N
properties NNS N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
positive JJ N
effects NNS N
in IN N
many JJ N
neuropsychiatric JJ N
disorders NNS N
. . N

Effects NNS N
of IN N
interaction NN N
of IN N
RRR-alpha-tocopheryl NNP N
acetate NN N
and CC N
fish JJ N
oil NN N
on IN N
low-density-lipoprotein JJ N
oxidation NN N
in IN N
postmenopausal JJ N
women NNS N
with IN N
and CC N
without IN N
hormone-replacement JJ N
therapy NN i
. . N

There EX N
was VBD N
only RB N
one CD N
death NN N
in IN N
JET NNP N
group NN N
( ( N
1.8 CD N
% NN N
) ) N
with IN N
no DT N
significant JJ N
difference NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Riluzole NNP N
was VBD N
fairly RB N
well RB N
tolerated VBN N
, , N
although IN N
it PRP N
was VBD N
associated VBN N
with IN N
one CD N
case NN N
of IN N
pancreatitis NN N
and CC N
five CD N
instances NNS N
of IN N
slight JJ N
increases NNS o
in IN N
transaminases NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
0.59-mg JJ N
and CC N
2.1-mg JJ N
fluocinolone NN N
acetonide NN N
( ( N
FA NNP N
) ) N
intravitreous JJ N
implants NNS N
in IN N
noninfectious JJ N
posterior JJ N
uveitis NN N
. . N

QRHT NN N
could MD N
also RB N
decrease VB o
the DT N
levels NNS N
of IN N
low-density JJ N
lipoprotein/very JJ N
low-density NN N
lipoprotein NN N
, , N
lipids NNS N
, , N
N-acetyl NNP N
glycoprotein NN N
, , N
and CC N
O-acetyl NNP N
glycoprotein NN N
. . N

Further RB N
, , N
pioglitazone NN N
significantly RB N
reduced VBN N
RA NNP N
disease NN N
activity NN N
( ( N
P=0.02 NNP N
) ) N
and CC N
CRP NNP N
levels NNS N
( ( N
P=0.001 NNP N
) ) N
, , N
while IN N
improving VBG N
lipid JJ N
profiles NNS N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
an DT N
undisturbed JJ N
wound NN N
healing VBG N
process NN N
using VBG N
BRG NNP N
together RB N
with IN N
tooth DT N
stability NN N
is VBZ N
beneficial JJ N
to TO N
overall JJ i
clinical JJ N
success NN N
. . N

AIM NNP N
Pharmacodynamic NNP N
analysis NN N
of IN N
intravenous JJ N
recombinant JJ N
urate JJ N
oxidase NN N
produced VBN N
by IN N
Escherichia NNP N
coli NN N
was VBD N
performed VBN N
in IN N
healthy JJ N
subjects NNS N
using VBG N
a DT N
pharmacokinetic/pharmacodynamic JJ N
( ( N
PK/PD NNP N
) ) N
model NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
survival JJ N
benefit NN N
with IN N
ASC NNP N
plus CC N
MVP NNP N
( ( N
HR NNP N
0.99 CD N
[ NNP N
0.78-1.27 JJ N
] NN N
; : N
p=0.95 NN N
) ) N
. . N

OBJECTIVES NN N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
ankle JJ N
cryotherapy NN i
on IN N
voluntary JJ N
and CC N
resting VBG N
motor NN N
function NN N
of IN N
the DT N
soleus NN N
over IN N
a DT N
60-minute JJ N
period NN N
. . N

This DT N
additional JJ N
analysis NN N
focuses VBZ N
on IN N
the DT N
immunological JJ N
changes NNS N
and CC N
surgical JJ N
stress NN N
response NN N
in IN N
these DT N
two CD N
randomized VBD N
groups NNS N
of IN N
a DT N
single JJ N
center NN N
. . N

Ibuprofen NNP N
provided VBD N
greater JJR N
temperature NN N
decrement NN N
and CC N
longer JJR N
duration NN N
of IN N
antipyresis NN N
than IN N
acetaminophen NN i
when WRB N
the DT N
two CD N
drugs NNS N
were VBD N
administered VBN N
in IN N
approximately RB N
equal JJ N
doses NNS N
. . N

An DT N
equivalence NN N
trial NN N
of IN N
maintenance NN N
therapy NN i
was VBD N
carried VBN N
out RP N
in IN N
children NNS N
with IN N
B NNP N
non-Hodgkin JJ N
lymphoma NN N
, , N
and CC N
serves VBZ N
as IN N
an DT N
illustration NN N
. . N

RESULTS NN N
Patients NNS N
reported VBD N
similar JJ N
median JJ N
pain NN N
scores NNS N
and CC N
were VBD N
equally RB N
satisfied VBN N
with IN N
pain NN N
relief NN N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
other JJ N
modulators NNS N
of IN N
its PRP$ N
activity NN N
could MD N
be VB N
of IN N
interest NN N
for IN N
further JJ N
studies NNS N
in IN N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS p
. . N

PURPOSE NNP N
To TO N
investigate VB N
whether IN N
short-term JJ N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
pretreatment NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
inhibits NNS N
prostaglandin VBP N
release NN N
. . N

CONCLUSION NNP N
The DT N
composite JJ N
restoration NN N
of IN N
FRC NNP N
posts NNS N
combined VBD N
with IN N
resin NN N
core NN N
and CC N
resin VB N
crown NN N
can MD N
improve VB N
the DT N
fracture NN N
resistance NN N
of IN N
the DT N
pulpless JJ N
roots NNS N
. . N

The DT N
subjective JJ N
improvement NN N
in IN N
various JJ N
degrees NNS N
and CC N
the DT N
shrinkage NN N
of IN N
tumor NN N
in IN N
the DT N
X-ray JJ N
films NNS N
were VBD N
present JJ N
in IN N
5/25 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ N
chemotherapy NN i
. . N

RESULTS/CONCLUSION NNP N
Results NNP N
show VBP N
that IN N
each DT N
BDDrFVIII NNP N
formulation NN N
is VBZ N
bioequivalent JJ N
to TO N
Hemofil NNP N
M NNP N
and CC N
the DT N
two CD N
formulations NNS N
of IN N
BDDrFVIII NNP N
are VBP N
bioequivalent JJ N
to TO N
each DT N
other JJ N
. . N

CA NNP N
proved VBD N
superior JJ N
to TO N
placebo VB N
on IN N
the DT N
evolution NN N
of IN N
markers NNS N
of IN N
alcohol NN N
ingestion NN N
at IN N
three CD N
months NNS N
, , N
in IN N
this DT N
large-scale JJ N
multicenter NN N
study NN N
. . N

We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
one CD N
vs NN N
two CD N
daily JJ N
bouts NNS N
of IN N
walking VBG N
on IN N
aerobic JJ N
fitness NN N
and CC N
body NN N
composition NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

However RB N
, , N
the DT N
levels NNS N
of IN N
titres NNS N
of IN N
anti-PT JJ N
and CC N
anti-FHA JJ N
antibodies NNS N
in IN N
all PDT N
the DT N
three CD N
vaccines NNS N
that WDT N
confer VBP N
protection NN N
are VBP N
not RB N
known VBN N
. . N

The DT N
additional JJ N
NMES NNP N
application NN N
in IN N
the DT N
treatment NN N
could MD N
bring VB N
more JJR N
improvements NNS N
in IN N
the DT N
distal JJ N
motor NN N
functions NNS N
and CC N
faster JJR N
rehabilitation NN N
progress NN N
. . N

No DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
= NNP N
.092 NNP N
chi-square JJ N
statistic NN N
) ) N
was VBD N
found VBN N
in IN N
implant JJ N
integration NN N
or CC N
the DT N
response NN N
of IN N
crestal JJ N
bone NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
change NN N
in IN N
total JJ N
scores NNS N
on IN N
the DT N
caregiver-completed JJ N
Social NNP N
Responsiveness NNP N
Scale NNP N
and CC N
clinician-ratings NNS N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impressions-Improvement NNP N
scale NN N
. . N

Renal JJ N
biopsy NN N
studies NNS N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
incidence NN N
and CC N
severity NN N
of IN N
the DT N
histologic JJ N
lesions NNS N
. . N

The DT N
clinical JJ N
improvement NN N
was VBD N
striking VBG N
, , N
although IN N
the DT N
number NN N
of IN N
patients NNS p
still RB N
incapacitated VBN N
was VBD N
relatively RB N
large JJ N
in IN N
patients NNS p
with IN N
the DT N
small JJ N
L-K JJ N
valves NNS N
( ( N
Nos NNP N
. . N

BACKGROUND NNP N
Suture NNP N
knots FW N
present JJ N
several JJ N
disadvantages NNS N
in IN N
wound NN N
closure NN N
, , N
because IN N
they PRP N
are VBP N
tedious JJ N
to TO N
tie VB N
and CC N
place VB N
ischemic JJ N
demands NNS N
on IN N
tissue NN N
. . N

Long-term JJ N
administration NN N
of IN N
a DT N
beta-carotene JJ N
preparation NN N
derived VBN N
from IN N
Dunaliella NNP N
bardawil NN N
, , N
a DT N
beta-carotene-rich JJ N
algae NN N
, , N
was VBD N
studied VBN N
in IN N
healthy JJ N
young JJ N
male NN N
volunteers NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
non-glycoprotein JJ N
IIb/IIIa NNP N
properties NNS N
of IN N
abciximab NNS i
do VBP N
not RB N
translate VB N
into IN N
a DT N
discernible JJ N
long-term JJ N
clinical JJ N
benefit NN N
among IN N
diabetic JJ N
patients NNS p
. . N

CONCLUSIONS NNP N
Clindamycin NNP i
vaginal JJ N
cream NN N
therapy NN i
was VBD N
associated VBN N
with IN N
significantly RB N
prolonged VBN N
gestation NN N
and CC N
reduced JJ N
cost NN N
of IN N
neonatal JJ N
care NN N
in IN N
women NNS N
with IN N
BV NNP N
. . N

Efficacy NN N
measures NNS N
, , N
overall JJ i
response NN N
rate NN N
, , N
time-to-progression NN N
and CC N
overall JJ i
survival NN N
were VBD N
equivalent JJ N
in IN N
both DT N
arms NNS N
. . N

Argon NNP N
laser NN N
trabeculoplasty NN N
is VBZ N
an DT N
effective JJ N
adjunct NN N
in IN N
managing VBG N
to TO N
control VB N
intraocular JJ N
pressure NN N
in IN N
black JJ N
Jamaican NNP N
glaucoma NN N
patients NNS p
. . N

Combined VBN N
use NN N
of IN N
cytostatics NNS N
and CC N
irradiation NN N
appeared VBD N
safe JJ N
, , N
tolerable JJ N
and CC N
significantly RB N
more RBR N
effective JJ N
than IN N
radiotherapy RB i
alone RB N
as IN N
assessed VBN N
by IN N
local JJ N
control NN N
of IN N
tumor NN N
and CC N
survival NN N
. . N

Adverse JJ N
effects NNS N
reported VBN N
by IN N
patients NNS p
treated VBN N
with IN N
imiquimod NN N
included VBD N
erythema NN N
, , N
edema NN N
, , N
induration NN N
, , N
vesicles NNS N
, , N
erosion NN N
, , N
ulceration NN N
, , N
excoriation NN N
, , N
and CC N
scabbing NN N
. . N

BACKGROUND NNP N
Subgroups NNP N
of IN N
breast NN N
cancer NN N
that WDT N
have VBP N
an DT N
impaired JJ N
response NN N
to TO N
endocrine VB N
treatment NN N
, , N
despite IN N
hormone NN N
receptor NN N
positivity NN N
, , N
are VBP N
still RB N
poorly RB N
defined VBN N
. . N

A DT N
selection NN N
of IN N
resistant JJ N
enterobacteria NN N
and CC N
an DT N
increase NN o
in IN N
beta-lactamase JJ N
production NN N
was VBD N
observed VBN N
in IN N
the DT N
faecal JJ N
samples NNS N
during IN N
the DT N
omeprazole JJ N
plus CC N
amoxycillin JJ i
treatment NN N
. . N

[ JJ N
Opposing NNP N
effects NNS N
of IN N
propranolol NN i
and CC N
diltiazem NN N
on IN N
the DT N
angina NN N
threshold NN N
during IN N
an DT N
exercise NN N
test NN N
in IN N
patients NNS p
with IN N
syndrome JJ N
X NNP N
] NNP N
. . N

Weight NNP N
gain NN N
, , N
increased VBD o
appetite RB o
, , N
anxiety NN N
, , N
and CC N
fatigue NN N
were VBD N
the DT N
most RBS N
frequently RB N
reported VBN N
side NN N
effects NNS N
. . N

INTERVENTIONS NNP N
Introducer NNP N
PEG NNP N
was VBD N
performed VBN N
by IN N
using VBG N
the DT N
Freka NNP N
Pexact-15 NNP N
CH/FR NNP N
, , N
with IN N
the DT N
gastric NN N
wall NN N
nonsurgically RB N
sutured VBD N
to TO N
the DT N
anterior JJ N
abdominal JJ N
wall NN N
by IN N
use NN N
of IN N
an DT N
endoscope NN N
. . N

BACKGROUND NNP N
Oral NNP N
dipyridamole NN N
induces NNS N
accumulation NN N
of IN N
endogenous JJ N
adenosine NN N
, , N
which WDT N
in IN N
a DT N
hypoxic NN N
milieu NN N
exerts VBZ N
experimentally RB N
an DT N
angiogenic JJ N
effect NN N
on IN N
coronary JJ N
collateral NN N
circulation NN N
. . N

Headache NNP N
, , N
hypotension NN N
, , N
nausea NN N
, , N
constipation NN N
, , N
and CC N
postural JJ N
hypotension NN N
were VBD N
the DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
. . N

Relative JJ N
numbers NNS N
of IN N
CD16 NNP N
cells NNS N
were VBD N
significantly RB N
elevated VBN N
, , N
but CC N
NK NNP N
cell VBP N
cytotoxic JJ N
activity NN N
was VBD N
within IN N
a DT N
normal JJ N
range NN N
. . N

[ JJ N
Impact NNP N
of IN N
heparin NN N
on IN N
coagulation NN N
index NN N
during IN N
the DT N
therapy NN i
of IN N
molecular JJ N
adsorbent NN N
recirculating VBG N
system NN N
in IN N
patients NNS p
with IN N
liver JJ N
failure NN N
] NN N
. . N

[ IN N
The DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
enalapril NN N
and CC N
indapamide NN N
on IN N
the DT N
peripheral JJ N
blood NN N
pressure NN N
and CC N
central JJ N
blood NN N
pressure NN N
through IN N
pulse JJ N
wave NN N
analysis NN N
] NN N
. . N

We PRP N
will MD N
also RB N
be VB N
able JJ N
to TO N
confirm VB N
if IN N
the DT N
effects NNS N
of IN N
acupuncture NN N
are VBP N
equivalent JJ N
to TO N
those DT N
of IN N
the DT N
conventional JJ N
drug NN N
cetirizine NN N
hydrochloride NN N
. . N

RESULTS NNP N
Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
indicated VBD N
a DT N
significant JJ N
interaction NN N
effect NN N
of IN N
transcranial JJ N
direct JJ N
current JJ N
stimulation NN N
type NN N
and CC N
time NN N
on IN N
the DT N
recognition NN N
accuracy NN N
. . N

The DT N
ACTH-stimulated JJ N
mean NN N
cortisol NN N
values NNS N
after IN N
four CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
baseline NN N
values VBZ N
for IN N
either DT N
treatment NN N
group NN N
. . N

Recently RB N
a DT N
newer NN N
more RBR N
tolerated JJ N
schedule NN N
of IN N
the DT N
VNR/CDDP NNP N
regimen NN N
has VBZ N
been VBN N
published VBN N
and CC N
is VBZ N
widely RB N
employed VBN N
in IN N
medical JJ N
practice NN N
. . N

Use NNP N
of IN N
an DT N
inspiratory JJ N
impedance NN N
threshold JJ N
device NN N
on IN N
a DT N
facemask NN N
and CC N
endotracheal VB N
tube NN N
to TO N
reduce VB N
intrathoracic JJ N
pressures NNS N
during IN N
the DT N
decompression NN N
phase NN N
of IN N
active JJ N
compression-decompression NN N
cardiopulmonary JJ N
resuscitation NN N
. . N

Also RB N
, , N
CD19 NNP N
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
addition NN N
to TO N
plasma VB N
cell NN N
labeling VBG N
indices NNS N
, , N
beta2-microglobulin NN N
, , N
hemoglobin NN N
, , N
and CC N
plasmablastic JJ N
morphology NN N
. . N

In IN N
those DT N
given VBN N
Taikong NNP N
Yangxin NNP N
, , N
the DT N
early JJ N
phase NN N
was VBD N
amplified VBN N
by IN N
2.5-fold JJ N
, , N
and CC N
the DT N
effects NNS N
of IN N
bed NN N
rest NN N
on IN N
the DT N
late JJ N
phase NN N
were VBD N
prevented VBN N
. . N

The DT N
effect NN N
of IN N
perindopril NN N
and CC N
hydrochlorothiazide VB i
alone RB N
and CC N
in IN N
combination NN N
on IN N
blood NN N
pressure NN N
and CC N
on IN N
the DT N
renin-angiotensin NN N
system NN N
in IN N
hypertensive JJ N
subjects NNS N
. . N

The DT N
effect NN N
of IN N
quality NN N
and CC N
amount NN N
of IN N
dietary JJ N
fat NN N
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
to TO N
oxidation NN N
in IN N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
. . N

The DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
by IN N
routine JJ N
treatment NN N
of IN N
neurosurgical JJ N
operation NN N
and CC N
drug NN N
treatment NN N
( ( N
Mannitol NNP N
, , N
Citioline NNP N
Sodium NNP N
, , N
Cefeazidime NNP N
, , N
etc NN N
) ) N
. . N

Deslorelin NNP N
suppressed VBD N
ovarian JJ N
activity NN N
in IN N
pre-pubertal JJ N
bitches NNS N
, , N
and CC N
oestrous JJ N
induction NN N
was VBD N
not RB N
observed VBN N
despite IN N
the DT N
presence NN N
of IN N
the DT N
primary JJ N
stimulatory JJ N
effect NN N
of IN N
the DT N
drug NN N
. . N

Intradermal JJ N
delivery NN N
of IN N
insulin NN N
is VBZ N
a DT N
viable JJ N
delivery NN N
route NN N
alternative NN N
providing VBG N
reduced JJ N
time NN N
for IN N
insulin JJ N
absorption NN N
with IN N
less JJR N
intra-subject JJ N
variability NN N
and CC N
lower JJR N
glycemic JJ N
response NN N
. . N

However RB N
, , N
these DT N
regimens NNS N
are VBP N
still RB N
costly JJ N
, , N
duration NN N
is VBZ N
about IN N
one CD N
week NN N
or CC N
less JJR N
, , N
and CC N
side-effects NNS N
are VBP N
not RB N
negligible JJ N
. . N

With IN N
the DT N
exception NN N
of IN N
an DT N
increase NN o
in IN N
t NN N
( ( N
max NN i
) ) N
, , N
there EX N
were VBD N
no DT N
significant JJ N
pharmacokinetic JJ N
interactions NNS N
between IN N
cephalexin NN N
and CC N
ranitidine NN N
or CC N
omeprazole NN N
. . N

Thus RB N
, , N
18HL CD N
reduced VBN N
force NN N
and CC N
strain NN N
on IN N
the DT N
AT NNP N
during IN N
running VBG N
via IN N
a DT N
reduction NN N
in IN N
dorsiflexion NN N
, , N
which WDT N
lengthened VBD N
the DT N
AT NNP N
moment NN N
arm NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
ANF NNP N
on IN N
the DT N
increase NN o
in IN N
plasma JJ N
aldosterone NN N
due JJ N
to TO N
metoclopramide VB N
in IN N
man NN N
. . N

In IN N
comparison NN N
with IN N
normal JJ N
controls NNS N
, , N
the DT N
myeloma NN N
patients NNS p
exhibited VBD N
a DT N
marked JJ N
heterogeneity NN N
in IN N
the DT N
number NN N
of IN N
circulating VBG N
CD19+ NNP N
B NNP N
cells NNS N
as IN N
detected VBN N
by IN N
flow JJ N
cytometry NN N
. . N

Non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
( ( N
NSAIDs NNP N
) ) N
may MD N
be VB N
used VBN N
to TO N
reduce VB N
neck NN N
pain NN N
and CC N
associated VBN N
inflammation NN N
and CC N
facilitate NN N
earlier RBR N
recovery NN N
. . N

Comparison NNP N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
faropenem JJ N
daloxate NN N
and CC N
cefuroxime NN N
axetil NN N
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
bacterial JJ N
maxillary JJ N
sinusitis NN N
in IN N
adults NNS N
. . N

The DT N
addition NN N
of IN N
fentanyl NN N
to TO N
lidocaine VB N
for IN N
transvaginal JJ N
oocyte NN N
retrieval NN N
results NNS N
in IN N
a DT N
more RBR N
comfortable JJ N
patient NN N
in IN N
the DT N
OR NNP N
and CC N
PACU NNP N
. . N

Recent JJ N
studies NNS N
demonstrate VBP N
that IN N
not RB N
only RB N
estrogens VBZ N
but CC N
also RB N
androgens VBZ N
may MD N
serve VB N
as IN N
regulators NNS N
of IN N
estrogen-responsive JJ N
as RB N
well RB N
as IN N
estrogen-unresponsive JJ N
human JJ N
breast NN N
cancers NNS N
. . N

Confocal JJ N
microscopy NN N
was VBD N
used VBN N
for IN N
the DT N
6-week JJ N
treatment NN N
group NN N
to TO N
examine VB N
the DT N
target NN N
tumor NN N
area NN N
at IN N
each DT N
interval JJ N
visit NN N
and CC N
immediately RB N
before IN N
Mohs NNP N
micrographic JJ N
surgery NN N
. . N

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
BRAF NNP N
mutation NN N
on IN N
survival NN N
and CC N
treatment NN N
efficacy NN N
in IN N
patients NNS p
with IN N
stage NN N
III NNP N
colon NN N
cancer NN N
. . N

CONCLUSIONS NNP N
Fadrozole NNP N
HCL NNP N
was VBD N
as RB N
efficacious JJ N
as IN N
megestrol NN N
acetate NN N
in IN N
postmenopausal NN N
patients NNS p
with IN N
metastatic JJ N
breast NN N
carcinoma NN N
after IN N
one CD N
hormonal JJ N
therapy NN i
. . N

Higher JJR N
serum NN N
concentration NN N
and CC N
area NN N
under IN N
the DT N
plasma JJ N
concentration NN N
curve NN N
( ( N
AUC NNP N
) ) N
were VBD N
not RB N
associated VBN N
with IN N
an DT N
improved JJ N
EFS NNP N
. . N

The DT N
effect NN N
of IN N
vitamin JJ N
A-fortified NNP N
coconut NN N
cooking VBG N
oil NN N
on IN N
the DT N
serum NN N
retinol JJ N
concentration NN N
of IN N
Filipino NNP N
children NNS N
4-7 CD N
years NNS N
old JJ N
. . N

Conventional JJ N
in IN N
vitro JJ N
fertilization NN N
versus IN N
intracytoplasmic JJ N
sperm JJ N
injection NN N
in IN N
patients NNS p
with IN N
borderline JJ N
semen NNS N
: : N
a DT N
randomized JJ N
study NN N
using VBG N
sibling VBG N
oocytes NNS N
. . N

IMPLICATIONS NNP N
Gastroesophageal NNP N
reflux NN N
( ( N
GER NNP N
) ) N
and CC N
tracheal JJ N
aspiration NN N
of IN N
acid NN N
may MD N
increase VB o
morbidity NN N
and CC N
mortality NN N
in IN N
patients NNS p
undergoing VBG N
thoracotomy NN N
. . N

In IN N
addition NN N
, , N
polymorphisms NN N
in IN N
the DT N
E158K NNP N
or CC N
E308G NNP N
allele NNS N
were VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
mucosal NN N
prostanoid NN N
levels NNS N
in IN N
patients NNS p
treated VBN N
with IN N
sulindac NN N
. . N

CONCLUSIONS NNP N
Somatostatin NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
ranitidine NN N
in IN N
controlling VBG N
acute JJ N
non-variceal JJ N
gastrointestinal JJ N
bleeding NN N
in IN N
patients NNS p
with IN N
Forrest NNP N
IB NNP N
bleeding NN N
activity NN N
. . N

BACKGROUND NNP N
Some DT N
investigators NNS N
found VBD N
a DT N
greater JJR N
incidence NN N
of IN N
hypotension NN N
in IN N
patients NNS p
receiving VBG N
intrathecal JJ N
hyperbaric JJ N
solution NN N
than IN N
in IN N
patients NNS p
receiving VBG N
plain JJ N
solution NN N
for IN N
cesarean JJ N
section NN N
. . N

RESULTS NN N
After IN N
the DT N
CPB NNP N
, , N
OI NNP N
and CC N
Cstat NNP N
in IN N
all DT N
groups NNS N
decreased VBD o
significantly RB o
, , N
while IN N
Raw NNP N
and CC N
P NNP N
( ( N
A- NNP N
) ) N
O2 NNP N
increased VBD o
significantly RB o
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Transversus NNP N
abdominis NN N
plane NN N
( ( N
TAP NNP N
) ) N
block NN N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
pain NN N
and CC N
analgesic JJ N
requirements NNS N
after IN N
abdominal JJ N
surgery NN N
. . N

The DT N
sensitivity NN N
and CC N
specificity NN N
for IN N
detecting VBG N
intestinal JJ N
metaplasia NN N
by IN N
TNE NNP N
compared VBN N
with IN N
those DT N
by IN N
SE NNP N
was VBD N
0.91 CD N
and CC N
1.00 CD N
, , N
respectively RB N
. . N

BACKGROUND NNP N
Hypertonic NNP N
saline NN N
improves VBZ N
organ JJ N
perfusion NN N
and CC N
patient JJ N
survival NN N
during IN N
hemorrhagic NN N
shock NN N
because IN N
it PRP N
expands VBZ N
plasma JJ N
volume NN N
and CC N
increases VBZ o
tissue NN N
oxygenation NN N
. . N

UNLABELLED NNP N
Dramatic NNP N
effects NNS N
on IN N
autistic JJ N
behaviour NN N
after IN N
repeated VBN N
injections NNS N
of IN N
the DT N
gastrointestinal JJ N
hormone NN N
secretin NN i
have VBP N
been VBN N
referred VBN N
in IN N
a DT N
number NN N
of IN N
case NN N
reports NNS N
. . N

The DT N
ratio NN N
between IN N
thrombin-antithrombin-III-complexes NNS N
and CC N
fibrin JJ N
degradation NN N
products NNS N
were VBD N
unchanged JJ N
signifying VBG N
no DT N
effect NN N
of IN N
hormonal JJ N
intake NN N
on IN N
the DT N
balance NN N
between IN N
thrombin JJ N
formation NN N
and CC N
fibrin JJ N
resolution NN N
. . N

CONCLUSIONS NNP N
Diltiazem NNP N
reduces VBZ N
the DT N
frequency NN N
and CC N
severity NN N
of IN N
ischemic JJ N
type NN N
ST NNP N
depression NN N
in IN N
patients NNS p
with IN N
stable JJ N
coronary JJ N
artery NN N
disease NN N
. . N

METHODS NNP N
Fifty-nine NNP N
children NNS N
, , N
aged VBN N
3-5 CD N
years NNS N
, , N
with IN N
no DT N
cerebral JJ N
palsy NN N
, , N
participated VBN N
in IN N
the DT N
study NN N
. . N

Evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
human JJ N
leukocyte JJ N
IFN-alpha NN N
on IN N
the DT N
immune JJ N
response NN N
to TO N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ N
unvaccinated JJ N
individuals NNS N
. . N

CONCLUSION NNP N
The DT N
conventional JJ N
scaling NN N
and CC N
root NN N
planing NN N
and CC N
the DT N
calculus JJ N
deattachment NN N
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
probing VBG N
depth NN N
values NNS N
, , N
regardless RB N
of IN N
the DT N
instrumentation NN N
method NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
two CD N
products NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
pulse JJ N
rate NN N
, , N
blood NN N
pressure NN N
, , N
and CC N
ECG NNP N
intervals NNS N
. . N

Neither DT N
torasemide JJ N
nor CC N
furosemide JJ N
induced VBD N
any DT N
significant JJ N
change NN N
in IN N
serum NN N
electrolyte NN N
or CC N
creatinine NN N
concentrations NNS N
, , N
or CC N
in IN N
ammonia JJ N
levels NNS N
. . N

This DT N
effect NN N
was VBD N
well RB N
maintained VBN N
in IN N
the DT N
supine JJ N
position NN N
, , N
although IN N
during IN N
standing VBG N
it PRP N
tended VBD N
to TO N
be VB N
less RBR N
evident JJ N
with IN N
increasing VBG N
doses NNS N
. . N

BACKGROUND NNP N
Neuropathic NNP N
pain NN N
is VBZ N
a DT N
complex JJ N
state NN N
of IN N
chronic JJ N
pain NN N
that WDT N
is VBZ N
usually RB N
accompanied VBN N
by IN N
peripheral JJ N
and CC N
central JJ N
nervous JJ N
system NN N
damage NN N
or CC N
dysfunction NN N
. . N

Outcomes NNS N
measured VBN N
were VBD N
airway RB N
leak JJ N
pressure NN N
, , N
ease NN N
and CC N
time NN N
for IN N
insertion NN N
, , N
fibreoptic JJ N
examination NN N
, , N
incidence NN N
of IN N
gastric JJ N
insufflation NN N
and CC N
complications NNS N
. . N

CONCLUSION NNP N
Sentinel NNP N
lymph NN N
node NN N
detection NN N
and CC N
analysis NN N
is VBZ N
feasible JJ N
, , N
technique NN N
is VBZ N
relatively RB N
simple JJ N
and CC N
is VBZ N
able JJ N
to TO N
produce VB N
upstage NN N
in IN N
colorectal JJ N
cancer NN N
. . N

CONCLUSION NNP N
Analgesic NNP N
efficacy NN N
of IN N
EM NNP N
is VBZ N
decreased VBN o
when WRB N
2-CP JJ N
is VBZ N
used VBN N
for IN N
LEA NNP N
compared VBN N
to TO N
when WRB N
Lido NNP N
+ NNP N
Epi NNP N
is VBZ N
used VBN N
. . N

The DT N
incidence NN N
of IN N
necrotizing VBG N
enterocolitis NN N
was VBD N
12.0 CD N
percent NN N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
9.5 CD N
percent NN N
in IN N
the DT N
control NN N
group NN N
. . N

Presented VBN N
is VBZ N
a DT N
prospective JJ N
study NN N
comparing VBG N
limited JJ N
SMAS NNP N
( ( N
lateral JJ N
SMASectomy NNP N
) ) N
, , N
conventional JJ N
SMAS NNP N
, , N
extended VBD N
SMAS NNP N
, , N
and CC N
composite JJ N
rhytidectomies NNS N
. . N

In IN N
this DT N
study NN N
, , N
an DT N
Er NNP N
, , N
Cr NNP N
: : N
YSGG NNP N
laser NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
cavity NN N
preparation NN N
and CC N
restoration NN N
replacement NN N
. . N

No DT N
significant JJ N
genotype-dependent JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
V NNP N
( ( N
2peak CD N
) ) N
, , N
muscle NN N
strength NN N
, , N
muscle NN N
endurance NN N
or CC N
lactate NN N
threshold NN N
. . N

CONCLUSION NNP N
Unreamed NNP N
nailing NN N
in IN N
patients NNS p
with IN N
tibial JJ N
shaft NN N
fractures NNS N
may MD N
be VB N
associated VBN N
with IN N
higher JJR N
rates NNS N
of IN N
secondary JJ N
operations NNS N
and CC N
malunions NNS N
compared VBN N
with IN N
reamed JJ N
nailing NN N
. . N

At IN N
the DT N
highest JJS N
thermal JJ N
burden NN N
, , N
the DT N
effect NN N
of IN N
nifedipine NN N
was VBD N
inconsistent JJ N
and CC N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
placebo NN N
. . N

Median JJ N
survival NN N
was VBD N
7.6 CD N
months NNS N
in IN N
the DT N
ASC NNP N
alone RB N
group NN N
and CC N
8.5 CD N
months NNS N
in IN N
the DT N
ASC NNP N
plus CC N
chemotherapy JJ i
group NN N
. . N

Biventricular JJ N
pacing VBG N
improves NNS N
cardiac JJ N
function NN N
and CC N
prevents NNS N
further RBR N
left VBD N
atrial JJ N
remodeling NN N
in IN N
patients NNS p
with IN N
symptomatic JJ N
atrial JJ N
fibrillation NN N
after IN N
atrioventricular JJ N
node JJ N
ablation NN N
. . N

BACKGROUND NNP N
In IN N
T3 NNP N
rectal JJ N
cancer NN N
( ( N
RC NNP N
) ) N
, , N
preoperative JJ N
chemoradiotherapy NN i
[ JJ N
5-fluorouracil JJ N
( ( N
5-FU-RT JJ N
) ) N
] NN N
reduces VBZ N
local JJ N
recurrences NNS N
, , N
but CC N
does VBZ N
not RB N
affect VB N
overall JJ i
survival NN N
. . N

The DT N
effect NN N
of IN N
exercise NN N
in IN N
preventing VBG N
falls NNS N
varied VBN N
significantly RB N
by IN N
baseline JJ N
physical JJ N
function NN N
level NN N
( ( N
p JJ N
< NN N
or CC N
=.002 NN N
) ) N
. . N

A DT N
common JJ N
variation NN N
in IN N
this DT N
gene NN N
( ( N
rs3796863 NN N
) ) N
was VBD N
recently RB N
found VBN N
to TO N
be VB N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

Low-dose JJ N
, , N
vaginally RB N
administered VBN N
estrogens NNS N
may MD N
enhance VB N
local JJ N
benefits NNS N
of IN N
systemic JJ N
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
urogenital JJ N
atrophy NN N
in IN N
postmenopausal JJ N
women NNS N
on IN N
hormone NN N
therapy NN i
. . N

Changes NNS N
in IN N
dietary JJ N
stage NN N
of IN N
change NN N
were VBD N
associated VBN N
with IN N
decreases NNS o
in IN N
fat JJ N
intake NN N
and CC N
increases NNS o
in IN N
fiber NN N
, , N
fruit NN N
and CC N
vegetable JJ N
intake NN N
. . N

Comparison NNP N
of IN N
neodymium-doped JJ N
yttrium NN N
aluminum NN N
garnet NN N
laser NN N
treatment NN N
with IN N
cold JJ N
knife NN N
endoscopic NN N
incision NN N
of IN N
urethral JJ N
strictures NNS N
in IN N
male JJ N
patients NNS p
. . N

Endometrial JJ N
cytology NN N
using VBG N
a DT N
softcyte NN N
or CC N
an DT N
endocyte NN N
achieved VBN N
high JJ N
correct JJ N
diagnosis NN N
rate NN N
for IN N
cancer NN N
, , N
and CC N
both DT N
instruments NNS N
are VBP N
valuable JJ N
as IN N
endometrial JJ N
cytologic NN N
sample NN N
devices NNS N
. . N

Twenty-one CD N
attention NN N
deficit NN N
disorder NN N
with IN N
hyperactivity NN N
and CC N
seven CD N
autistic JJ N
children NNS N
were VBD N
randomly RB N
exposed VBN N
to TO N
negatively RB N
ionized JJ N
and CC N
ambient JJ N
atmospheres NNS N
under IN N
rigorously RB N
controlled VBN N
experimental JJ N
conditions NNS N
. . N

Based VBN N
on IN N
a DT N
definition NN N
of IN N
lactate NN N
steady JJ N
state NN N
( ( N
LSS NNP N
) ) N
as IN N
less JJR N
than IN N
a DT N
0.5 CD N
mmol.l-1 JJ N
increase NN o
, , N
this DT N
value NN N
signified VBD N
LSS NNP N
. . N

Switching VBG N
DBS NNP N
on IN N
improved JJ N
balance NN N
scores NNS N
, , N
and CC N
scores VBZ N
further RBR N
improved VBN N
with IN N
medication NN N
, , N
compared VBN N
to TO N
the DT N
off RP N
state NN N
. . N

These DT N
effects NNS N
seem VBP N
to TO N
be VB N
mediated VBN N
via IN N
mechanisms NNS N
that WDT N
are VBP N
different JJ N
from IN N
those DT N
of IN N
angiotensin JJ N
II NNP N
receptor NN N
blocker NN N
or CC N
thiazolidinedione NN N
. . N

For IN N
geometric JJ N
mean NN N
titers NNS N
( ( N
GMT NNP N
) ) N
, , N
antibody NN N
titers NNS N
below IN N
the DT N
cutoff NN N
of IN N
the DT N
assay NN N
were VBD N
given VBN N
, , N
arbitrarily RB N
, , N
0.05 CD N
IU/mL NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
relationships NNS N
between IN N
the DT N
serum NN N
of IN N
TARC NNP N
level NN N
and CC N
the DT N
CARS NNP N
score NN N
, , N
age NN N
, , N
or CC N
gender VB N
for IN N
any DT N
group NN N
. . N

The DT N
authors NNS N
have VBP N
studied VBN N
indices NNS N
of IN N
natriuretic JJ N
peptide NN N
and CC N
oxidative JJ N
stress NN N
in IN N
patients NNS p
with IN N
chronic JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
. . N

Correlation NN N
of IN N
quantitative JJ N
measures NNS N
with IN N
the DT N
modified JJ N
Ashworth NNP N
scale NN N
in IN N
the DT N
assessment NN N
of IN N
plantar NN N
flexor NN N
spasticity NN N
in IN N
patients NNS p
with IN N
traumatic JJ N
brain NN N
injury NN N
. . N

BACKGROUND NNP N
Fungal NNP N
infection NN N
is VBZ N
a DT N
frequent JJ N
and CC N
often RB N
fatal JJ N
complication NN N
in IN N
patients NNS p
undergoing JJ N
remission NN N
induction NN N
therapy NN i
for IN N
acute JJ N
leukemia NN N
. . N

Buspirone NN N
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
and CC N
efficacious JJ N
, , N
without IN N
side JJ N
effects NNS N
, , N
for IN N
decreasing VBG N
hyperactivity NN N
and CC N
increasing VBG N
completed VBN N
performance NN N
tasks NNS N
. . N

CONCLUSION NNP N
Leucocyte NNP N
depletion NN N
is VBZ N
not RB N
associated VBN N
with IN N
better JJR N
long-term JJ N
survival NN N
and CC N
lower JJR N
recurrence NN N
rates NNS N
in IN N
patients NNS p
with IN N
gastrointestinal JJ N
cancer NN N
. . N

CONCLUSIONS NNP N
Dietary NNP N
PUFA NNP N
supplementation NN N
markedly RB N
potentiates VBZ N
baroreflex JJ N
function NN N
and CC N
enhances NNS N
heart NN N
rate NN N
variability NN N
in IN N
patients NNS p
with IN N
stable JJ N
congestive JJ N
heart NN N
failure NN N
. . N

CONCLUSION NNP N
Markers NNP N
of IN N
systemic JJ N
inflammation NN N
contribute NN N
significantly RB N
to TO N
prognostic JJ N
classification NN N
in IN N
addition NN N
to TO N
established VBN N
factors NNS N
for IN N
pre-treated JJ N
patients NNS p
with IN N
advanced JJ N
RCC NNP N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
known VBN N
that IN N
the DT N
bifidobacteria NN N
flora VBP N
play NN N
important JJ N
roles NNS N
in IN N
mucosal NN N
host NN N
defense NN N
and CC N
can MD N
prevent VB N
infectious JJ N
diseases NNS N
. . N

The DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
suggesting VBG N
that IN N
the DT N
multi-media JJ N
tablet NN N
device NN N
was VBD N
more RBR N
effective JJ N
method NN N
. . N

AIMS NNP N
Preclinical NNP N
data NN N
suggest NN N
that IN N
signalling VBG N
through IN N
the DT N
HGF-MET NNP N
pathway NN N
may MD N
confer VB N
resistance NN N
to TO N
BRAF NNP N
inhibition NN N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

CONCLUSIONS NNP N
DJQ NNP N
showed VBD N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing NN N
effects NNS N
, , N
but CC N
with IN N
no DT N
effect NN N
on IN N
the DT N
hematopoietic JJ N
function NN N
of IN N
the DT N
bone NN N
marrow NN N
. . N

Lornoxicam NNP N
was VBD N
very RB N
well RB N
tolerated VBN N
at IN N
all DT N
three CD N
doses NNS N
studied VBN N
, , N
with IN N
no DT N
adverse JJ N
events NNS N
definitely RB N
attributable JJ N
to TO N
its PRP$ N
administration NN N
. . N

The DT N
renin-angiotensin NN N
system NN N
played VBD N
a DT N
part NN N
in IN N
maintenance NN N
of IN N
blood NN N
pressure NN N
only RB N
with IN N
severe JJ N
salt NN N
restriction NN N
and CC N
in IN N
a DT N
small JJ N
proportion NN N
of IN N
cases NNS N
. . N

Primary JJ N
end NN N
point NN N
will MD N
be VB N
the DT N
conversion NN N
of IN N
AF NNP N
to TO N
sinus VB N
rhythm NN N
confirmed VBN N
in IN N
an DT N
electrocardiogram NN N
( ( N
ECG NNP N
) ) N
during IN N
the DT N
observation NN N
period NN N
. . N

It PRP N
is VBZ N
probably RB N
affected VBN N
by IN N
volume NN N
and CC N
extension NN N
of IN N
the DT N
injury NN N
induced VBN N
by IN N
a DT N
hematotoxic NN N
noxa NN N
and CC N
furthermore NN N
by IN N
the DT N
ability NN N
of IN N
regeneration NN N
. . N

INTERPRETATION NNP N
The DT N
addition NN N
of IN N
chemotherapy NN i
to TO N
ASC NNP N
offers VBZ N
no DT N
significant JJ N
benefits NNS N
in IN N
terms NNS N
of IN N
overall JJ i
survival NN N
or CC N
quality NN N
of IN N
life NN N
. . N

Influence NN N
of IN N
glyceryl NN N
trinitrate NN N
on IN N
venous JJ N
and CC N
arterial JJ N
effects NNS N
of IN N
chronic NN N
, , N
asymmetric JJ N
isosorbide NN N
dinitrate NN N
treatment NN N
in IN N
patients NNS p
with IN N
ischemic JJ N
heart NN N
disease NN N
. . N

INTRODUCTION NNP N
Decreasing NNP N
bone NN N
density NN N
and CC N
muscle NN N
mass NN N
and CC N
increasing VBG N
fat JJ N
mass NN N
may MD N
act VB N
synergistically RB N
to TO N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR N
adults NNS N
. . N

Variation NN N
in IN N
BCG NNP N
efficacy NN N
was VBD N
marked VBN N
when WRB N
vaccine NN N
was VBD N
given VBN N
at IN N
school NN N
age NN N
but CC N
absent NN N
at IN N
birth NN N
, , N
which WDT N
points VBZ N
towards NNS N
blocking VBG N
as IN N
the DT N
dominant JJ N
mechanism NN N
. . N

Efficacy NN N
and CC N
safety NN N
relative VBP N
to TO N
placebo VB N
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN N
and CC N
sustained-release JJ N
pseudoephedrine NN N
in IN N
the DT N
management NN N
of IN N
nasal JJ N
congestion NN N
. . N

Therefore RB N
, , N
no DT N
significant JJ N
pharmacokinetic JJ N
differences NNS N
occurred VBD N
in IN N
either CC N
risperidone VB i
active JJ N
moiety NN N
or CC N
donepezil NN N
when WRB N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
. . N

Using VBG N
a DT N
PSA NNP N
increase NN o
from IN N
nadir NN N
of IN N
0.8 CD N
ng/ml IN N
the DT N
sensitivity NN N
of IN N
dutasteride NN N
was VBD N
0.548 CD N
and CC N
its PRP$ N
specificity NN N
was VBD N
0.795 CD N
. . N

Racemic NNP N
epinephrine NN N
has VBZ N
been VBN N
advocated VBN N
for IN N
the DT N
treatment NN N
of IN N
croup NN N
, , N
but CC N
controlled VBD N
studies NNS N
have VBP N
not RB N
proved VBN N
it PRP N
more RBR N
effective JJ N
than IN N
saline NN N
. . N

This DT N
finding NN N
supports VBZ N
the DT N
results NNS N
of IN N
previous JJ N
US NNP N
and CC N
European JJ N
studies NNS N
, , N
which WDT N
have VBP N
also RB N
shown VBN N
that IN N
lanthanum NN N
carbonate NN N
treatment NN N
effectively RB N
controls VBZ N
serum JJ N
phosphorus NN N
levels NNS N
. . N

The DT N
haemostatic JJ N
effect NN N
of IN N
desmopressin NN N
has VBZ N
been VBN N
attributed VBN N
to TO N
the DT N
release NN N
of IN N
von JJ N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
and CC N
a DT N
reduced JJ N
bleeding NN N
time NN N
. . N

No DT N
significant JJ N
change NN N
in IN N
the DT N
ratio NN N
of IN N
the DT N
FEV1 NNP N
and CC N
the DT N
FVC NNP N
was VBD N
demonstrated VBN N
in IN N
either CC N
the DT N
iopamidol NN N
or CC N
the DT N
sodium NN N
iothalamate NN N
groups NNS N
. . N

However RB N
, , N
a DT N
slight JJ N
decrease NN o
in IN N
early JJ N
insulin NN N
response NN N
to TO N
glucose VB N
was VBD N
observed VBN N
in IN N
the DT N
nifedipine NN N
and CC N
the DT N
nitrendipine JJ N
groups NNS N
. . N

The DT N
highest JJS N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
by IN N
the DT N
loop NN N
technique NN N
was VBD N
97.8 CD N
% NN N
in IN N
the DT N
mandibular JJ N
second JJ N
premolar NN N
and CC N
first JJ N
molar NN N
. . N

The DT N
anti-inflammatory JJ N
, , N
analgesic JJ N
and CC N
tranquillizing JJ N
activity NN N
of IN N
a DT N
synthetic JJ N
compound NN N
called VBD N
parsalmide NN N
was VBD N
investigated VBN N
in IN N
patients NNS p
suffering VBG N
from IN N
inflammatory NN N
and CC N
degenerative JJ N
rheumatic JJ N
arthropathies NNS N
. . N

Already RB N
after IN N
the DT N
first JJ N
week NN N
of IN N
the DT N
skiing VBG N
tour NN N
there EX N
were VBD N
significant JJ N
drops NNS N
in IN N
PAI-1 NNP N
activities NNS N
, , N
cholesterol NN N
and CC N
triglycerides NNS N
. . N

These DT N
results NNS N
seem VBP N
to TO N
confirm VB N
the DT N
value NN N
of IN N
parenteral JJ N
short-term JJ N
antibiotic JJ i
prophylaxis NN N
of IN N
postoperative JJ N
infection NN N
in IN N
such JJ N
kind NN N
of IN N
clean JJ N
operative JJ N
procedure NN N
. . N

Multiple JJ N
linear JJ N
regression NN N
analysis NN N
revealed VBD N
the DT N
change NN N
in IN N
HDL-C NNP N
to TO N
be VB N
an DT N
independent JJ N
variable JJ N
showing VBG N
a DT N
positive JJ N
correlation NN N
with IN N
the DT N
carotid NN N
IMT NNP N
reduction NN N
. . N

RESULTS NNP N
Heatwrap NNP N
therapy NN i
was VBD N
shown VBN N
to TO N
provide VB N
significant JJ N
therapeutic JJ N
benefits NNS N
when WRB N
compared VBN N
with IN N
placebo NN N
during IN N
both CC N
the DT N
treatment NN N
and CC N
follow-up JJ N
period NN N
. . N

RESULTS NNP N
Plasma NNP N
glutathione NN N
( ( N
GSH NNP N
) ) N
and CC N
alpha- JJ N
and CC N
gamma-tocopherol JJ N
concentrations NNS N
decreased VBN o
and CC N
the DT N
GSH NNP N
redox NN N
state NN N
became VBD N
more RBR N
oxidized JJ N
after IN N
conditioning VBG N
chemotherapy NN i
. . N

The DT N
WOMAC NNP N
score NN N
at IN N
three CD N
, , N
six CD N
, , N
and CC N
twelve JJ N
months NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
piriformis NN N
fossa NN N
and CC N
trochanteric JJ N
nailing NN N
groups NNS N
. . N

CONCLUSIONS NNP N
The DT N
presence NN N
of IN N
brain NN N
MRI NNP N
abnormalities NNS N
at IN N
the DT N
time NN N
of IN N
an DT N
optic JJ N
neuritis NN N
attack NN N
is VBZ N
a DT N
strong JJ N
predictor NN N
of IN N
the DT N
15-year JJ N
risk NN N
of IN N
MS NNP N
. . N

Consistent JJ N
with IN N
previous JJ N
reports NNS N
gadodiamide NN N
injection NN N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
contrast NN N
medium NN N
for IN N
MR NNP N
imaging NN N
of IN N
the DT N
pituitary JJ N
region NN N
. . N

A DT N
low JJ N
intention NN N
to TO N
be VB N
physically RB N
active JJ N
was VBD N
a DT N
strong JJ N
predictor NN N
for IN N
dropout NN N
within IN N
both DT N
delivery NN N
modes FW N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS NNP N
The DT N
administration NN N
of IN N
L-arginine NNP N
and CC N
citrulline NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
endothelial JJ N
function NN N
as IN N
shown VBN N
by IN N
the DT N
normalized JJ N
MAT/TT NNP N
index NN N
. . N

Clinical JJ N
usefulness NN N
of IN N
serum NN N
prostate NN N
specific JJ N
antigen NN N
for IN N
the DT N
detection NN N
of IN N
prostate NN N
cancer NN N
is VBZ N
preserved VBN N
in IN N
men NNS N
receiving VBG N
the DT N
dual JJ N
5alpha-reductase JJ N
inhibitor NN N
dutasteride NN N
. . N

OBJECTIVE NNP N
Captopril NNP N
and CC N
enalapril NNS N
have VBP N
been VBN N
reported VBN N
to TO N
influence VB N
cognitive JJ N
functions NNS N
and CC N
quality NN N
of IN N
life NN N
in IN N
hypertensive JJ N
patients NNS p
. . N

Side-effects NNS N
in IN N
both DT N
groups NNS N
were VBD N
those DT N
commonly JJ N
seen VBN N
with IN N
non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
and CC N
, , N
as IN N
expected VBN N
, , N
gastro-intestinal JJ N
and CC N
CNS NNP N
disturbances NNS N
predominated VBD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
plasma NN N
, , N
lipid-standardized JJ N
, , N
and CC N
LDL NNP N
AT NNP N
levels NNS N
between IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
supplementation NN N
at IN N
any DT N
dose JJ N
comparison NN N
. . N

The DT N
urea JJ N
end-product NN N
method NN N
suggested VBD N
that IN N
there EX N
was VBD N
no DT N
change NN N
in IN N
whole-body NN N
protein NN N
turnover NN N
after IN N
surgery NN N
, , N
whether IN N
or CC N
not RB N
insulin NN N
was VBD N
given VBN N
. . N

CONCLUSIONS NNP N
Osteoporosis NNP N
was VBD N
prevalent VBN N
in IN N
low JJ N
ASM NNP N
groups NNS N
( ( N
SS NNP N
and CC N
SO NNP N
) ) N
and CC N
related VBN N
to TO N
gait VB N
and CC N
balance VB N
deficits NNS N
, , N
particularly RB N
in IN N
the DT N
SO NNP N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
response NN N
to TO N
test VB N
drug NN N
( ( N
P NNP N
= NNP N
.66 NNP N
) ) N
. . N

Effect NN N
of IN N
cigarette NN N
smoking NN N
on IN N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ N
smokers NNS N
: : N
a DT N
crossover NN N
study NN N
using VBG N
the DT N
13C-octanoic JJ N
acid NN N
breath NN N
test NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
preprocedural JJ N
baseline NN N
pain NN N
from IN N
the DT N
control NN N
group NN N
, , N
compared VBN N
with IN N
the DT N
experimental JJ N
group NN N
. . N

OBJECTIVES IN N
We PRP N
postulated VBD N
that IN N
femoral JJ N
vein JJ N
delivery NN N
of IN N
contrast NN N
medium NN N
because IN N
of IN N
streaming NN N
, , N
might MD N
enhance VB N
precordial JJ N
echocardiographic JJ N
detection NN N
of IN N
patent NN N
foramen NNS N
ovale VBP N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
if IN N
sevoflurane JJ N
administration NN N
could MD N
exert VB N
myocardial JJ N
protection NN N
during IN N
following VBG N
coronary JJ N
occlusion NN N
in IN N
patients NNS p
with IN N
coronary JJ N
artery NN N
disease NN N
. . N

The DT N
higher JJR N
mortality NN N
rate NN N
among IN N
the DT N
patients NNS p
with IN N
hypermagnesemia NN N
is VBZ N
attributable JJ N
to TO N
older JJR N
age NN N
, , N
more RBR N
advanced JJ N
heart NN N
failure NN N
and CC N
renal JJ N
insufficiency NN N
. . N

The DT N
tyrosine NN N
kinase NN N
receptor NN N
EGFR NNP N
pathway NN N
is VBZ N
one CD N
of IN N
the DT N
oncogenic JJ N
signaling NN N
cascades NNS N
involved VBN N
in IN N
lung NN N
cancer NN N
, , N
mediating VBG N
the DT N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
gene NN N
EGFR NNP N
. . N

CONCLUSIONS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
CAC NNP N
progression NN N
or CC N
changes NNS N
in IN N
bone NN N
remodeling NN N
between IN N
the DT N
calcium NN N
and CC N
the DT N
sevelamer NN N
groups NNS N
. . N

Patients NNS N
' POS N
vital JJ N
signs NNS N
, , N
additional JJ N
analgesic NN N
requests NNS N
, , N
PONV NNP N
( ( N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
) ) N
and CC N
other JJ N
side NN N
effects NNS N
were VBD N
registered VBN N
. . N

METHODS NNP N
Sixty NNP N
ASA NNP N
class NN N
I PRP N
patients NNS p
scheduled VBN N
for IN N
herniorrhapy NN N
under IN N
spinal JJ N
anesthesia NN N
were VBD N
assigned VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
No NNP N
statistical JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
survival JJ N
rates NNS N
of IN N
the DT N
rectal JJ N
carcinoma NN N
patients NNS p
receiving VBG N
radiotherapy NN i
either CC N
pre-operatively RB N
or CC N
postoperatively RB N
. . N

CONCLUSION NNP N
Disease NNP N
activity NN N
in IN N
RA NNP N
is VBZ N
reduced VBN N
by IN N
tocilizumab NN i
treatment NN N
, , N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
composite JJ N
measure NN N
used VBN N
to TO N
evaluate VB N
disease NN N
activity NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
interleukin-1 JJ N
receptor NN N
antagonist NN N
( ( N
IL-1Ra NNP N
) ) N
on IN N
synovial JJ N
tissue NN N
in IN N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

Tonsillar JJ N
focal JJ N
infection NN N
( ( N
TFI NNP N
) ) N
and CC N
dental JJ N
focal JJ N
infection NN N
( ( N
DFI NNP N
) ) N
were VBD N
found VBN N
in IN N
6/20 CD N
and CC N
17/20 CD N
patients NNS p
, , N
respectively RB N
. . N

Bacteriologic NNP N
studies NNS N
of IN N
feces NNS N
and CC N
colon NN N
content NN N
revealed VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
reduction NN N
of IN N
aerobic JJ N
bacteria NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

UNLABELLED IN N
We PRP N
estimated VBD N
the DT N
cost-effectiveness NN N
of IN N
hemiarthroplasty NN N
compared VBN N
to TO N
internal JJ N
fixation NN N
for IN N
elderly JJ N
patients NNS p
with IN N
displaced JJ N
femoral JJ N
neck NN N
fractures NNS N
. . N

Children NNP N
's POS N
IQs NNP N
and CC N
language NN N
comprehension NN N
did VBD N
not RB N
increase VB o
, , N
but CC N
adaptive/social JJ N
behavior NN N
scores NNS N
and CC N
expressive JJ N
language NN N
quotients NNS N
decreased VBN o
. . N

The DT N
larval JJ N
negative JJ N
conversion NN N
rates NNS N
of IN N
Ancylostoma NNP N
duodenale NN N
and CC N
Necator NNP N
americanus VBP N
were VBD N
77.7 CD N
and CC N
83.2 CD N
% NN N
respectively RB N
. . N

CONCLUSIONS NNP N
EPL NNP N
and CC N
LPL NNP N
are VBP N
as IN N
feasible JJ N
and CC N
effective JJ N
as IN N
TPL NNP N
and CC N
can MD N
be VB N
adequately RB N
performed VBN N
with IN N
a DT N
reasonable JJ N
complication NN N
rate NN N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Previous NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
repeated VBD N
sensory JJ N
inputs NNS N
could MD N
enhance VB N
brain NN N
plasticity NN N
and CC N
cortical JJ N
motor NN N
output NN N
. . N

BACKGROUND/AIMS NNP N
Retrospective NNP N
studies NNS N
suggest VBP N
that IN N
the DT N
prognosis NN N
of IN N
patients NNS p
with IN N
cirrhosis NN N
and CC N
variceal NN N
hemorrhage NN N
has VBZ N
improved VBN N
in IN N
more RBR N
recent JJ N
decades NNS N
. . N

Running VBG N
in IN N
parallel NN N
with IN N
the DT N
main JJ N
study NN N
is VBZ N
a DT N
prospective JJ N
economic JJ N
analysis NN N
, , N
the DT N
objectives NNS N
of IN N
which WDT N
are VBP N
( ( N
1 CD N
) ) N
to TO N
estimate VB N
the DT N
effectiveness NN N
of IN N
pravastatin NN i
compared VBN N
with IN N
placebo NN N
in IN N
terms NNS N
of IN N
survival NN N
, , N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
and CC N
quality-adjusted JJ N
life-years NNS N
( ( N
QALY NNP N
) ) N
; : N
( ( N
2 CD N
) ) N
to TO N
estimate VB N
the DT N
resource NN N
usage NN N
associated VBN N
with IN N
pravastatin NNS i
compared VBN N
with IN N
placebo-in JJ N
particular JJ N
, , N
to TO N
study VB N
whether IN N
it PRP N
alters VBZ N
resource JJ N
usage NN N
through IN N
prevention NN N
of IN N
disease NN N
progression NN N
; : N
and CC N
( ( N
3 CD N
) ) N
to TO N
use VB N
this DT N
information NN N
for IN N
a DT N
cost-utility JJ N
analysis NN N
with IN N
cost NN N
per IN N
quality-adjusted JJ N
life-year JJ N
as IN N
the DT N
unit NN N
of IN N
analysis NN N
. . N

The DT N
total JJ N
amount NN N
of IN N
protein NN N
deaminated VBN N
and CC N
the DT N
amino NN N
groups NNS N
incorporated VBD N
into IN N
urea NN N
was VBD N
calculated VBN N
to TO N
be VB N
approximately RB N
20-23 JJ N
g. VBP N
The DT N
net JJ N
amount NN N
of IN N
glucose NN N
estimated VBN N
to TO N
be VB N
produced VBN N
, , N
based VBN N
on IN N
the DT N
quantity NN N
of IN N
amino JJ N
acids NNS N
deaminated VBD N
, , N
was VBD N
approximately RB N
11-13 JJ N
g. NN N
However RB N
, , N
the DT N
amount NN N
of IN N
glucose JJ N
appearing VBG N
in IN N
the DT N
circulation NN N
was VBD N
only RB N
approximately RB N
2 CD N
g. VBD N
The DT N
peripheral JJ N
plasma NN N
glucose JJ N
concentration NN N
decreased VBN o
by IN N
approximately RB N
1 CD N
mM NNS N
after IN N
ingestion NN N
of IN N
either DT N
protein NN N
or CC N
water NN N
, , N
confirming VBG N
that IN N
ingested JJ N
protein NN N
does VBZ N
not RB N
result VB N
in IN N
a DT N
net JJ N
increase NN o
in IN N
glucose JJ N
concentration NN N
, , N
and CC N
results NNS N
in IN N
only RB N
a DT N
modest JJ N
increase NN o
in IN N
the DT N
rate NN N
of IN N
glucose JJ N
disappearance NN N
. . N

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
include VB N
PMO NNP N
patients NNS p
( ( N
postmenopausal JJ N
women NNS N
; : N
aged VBN N
between IN N
50 CD N
and CC N
70 CD N
years NNS N
; : N
have VBP N
been VBN N
postmenopausal VBN N
for IN N
at IN N
least JJS N
5 CD N
years NNS N
and CC N
diagnosed VBD N
with IN N
OP NNP N
using VBG N
proximal JJ N
femur JJ N
T-score NN N
) ) N
with IN N
concomitant JJ N
lumbar NN N
OA NNP N
( ( N
patients NNS p
with IN N
confounding VBG N
disorders NNS N
like IN N
diabetes NNS N
, , N
hypertension NN N
, , N
hyperlipidemia NN N
, , N
and CC N
previous JJ N
fracture NN N
history NN N
, , N
etcetera NN N
, , N
will MD N
be VB N
excluded VBN N
) ) N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
two CD N
arms NNS N
: : N
PEMFs NNP N
group NN N
and CC N
sham NN N
PEMFs NNP N
group NN N
. . N

PURPOSE NN N
In IN N
this DT N
study NN N
, , N
we PRP N
sought VBD N
to TO N
1 CD N
) ) N
describe NN N
elements NNS N
of IN N
the DT N
financial JJ N
and CC N
quality-of-life JJ N
burden NN N
of IN N
dysfunctional JJ N
uterine JJ N
bleeding NN N
( ( N
DUB NNP N
) ) N
from IN N
the DT N
perspective NN N
of IN N
women NNS N
who WP N
agreed VBD N
to TO N
obtain VB N
surgical JJ N
treatment NN N
; : N
2 CD N
) ) N
explore NN N
associations NNS N
between IN N
DUB NNP N
symptom NN N
characteristics NNS N
and CC N
the DT N
financial JJ N
and CC N
quality-of-life JJ N
burden NN N
; : N
3 CD N
) ) N
estimate VBP N
the DT N
annual JJ N
dollar NN N
value NN N
of IN N
the DT N
financial JJ N
burden NN N
; : N
and CC N
4 CD N
) ) N
estimate VBP N
the DT N
most RBS N
that DT N
could MD N
be VB N
spent VBN N
on IN N
surgery NN N
to TO N
eliminate VB N
DUB NNP N
symptoms NNS N
for IN N
which WDT N
medical JJ N
treatment NN N
has VBZ N
been VBN N
unsuccessful JJ N
that WDT N
would MD N
result VB N
in IN N
a DT N
$ $ N
50,000/quality-adjusted JJ N
life-year JJ N
incremental JJ N
cost-effectiveness NN N
ratio NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
lipotoxicity NN N
on IN N
beta-cell NN N
function NN N
, , N
eight CD N
obese JJ N
African JJ N
Americans NNPS N
with IN N
KPDM NNP N
, , N
eight CD N
obese JJ N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
with IN N
severe JJ N
hyperglycemia NN N
without IN N
ketosis NN N
( ( N
ketosis-resistant JJ N
type NN N
2 CD N
diabetes NNS N
) ) N
, , N
and CC N
nine CD N
nondiabetic JJ N
obese NNS N
control NN N
subjects VBZ N
underwent JJ N
intravenous JJ N
infusion NN N
of IN N
20 CD N
% NN N
intralipid NN N
at IN N
40 CD N
ml/h NN N
for IN N
48 CD N
h. JJ N
beta-Cell NN N
function NN N
was VBD N
assessed VBN N
by IN N
changes NNS N
in IN N
insulin NN N
and CC N
C-peptide JJ N
concentration NN N
during IN N
infusions NNS N
and CC N
by IN N
changes NNS N
in IN N
acute JJ N
insulin NN N
response NN N
to TO N
arginine VB N
stimulation NN N
( ( N
AIR NNP N
( ( N
arg NN N
) ) N
) ) N
before IN N
and CC N
after IN N
lipid JJ N
infusion NN N
. . N

Tissue NN N
samples NNS N
from IN N
93 CD N
de NNS N
novo FW N
diffuse RB N
large JJ N
B-cell NNP N
lymphoma NN N
patients NNS p
seen VBN N
between IN N
1995 CD N
and CC N
2009 CD N
randomly NN N
receiving VBG N
either CC N
standard JJ N
combination NN N
chemotherapy NN i
( ( N
CHOP NNP N
, , N
n=48 NN N
) ) N
or CC N
the DT N
identical JJ N
program NN N
with IN N
rituximab NN i
( ( N
n=45 JJ N
) ) N
were VBD N
subtyped VBN N
using VBG N
an DT N
investigational JJ N
immunohistochemical NN N
( ( N
IHC NNP N
) ) N
based VBN N
tissue NN N
microarray NN N
( ( N
TMA NNP N
) ) N
and CC N
contrasted VBN N
to TO N
the DT N
approximately RB N
corresponding JJ N
categories NNS N
as IN N
defined VBN N
either CC N
by IN N
Hans NNPS N
and CC N
associates NNS N
using VBG N
a DT N
three CD N
marker NN N
panel NN N
into IN N
germinal JJ N
or CC N
non-germinal JJ N
centre NN N
subtypes NNS N
or CC N
by IN N
Choi NNP N
and CC N
colleagues NNS N
with IN N
two CD N
additional JJ N
antibodies NNS N
into IN N
germinal JJ N
centre NN N
( ( N
GCB NNP N
) ) N
or CC N
activated VBN N
B-cells NNP N
( ( N
ABC NNP N
) ) N
. . N

In IN N
this DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
aerosolized JJ N
albuterol NN N
with IN N
the DT N
dry JJ N
powder NN N
formulation NN N
, , N
231 CD N
patients NNS p
with IN N
chronic JJ N
reversible JJ N
obstructive JJ N
airway NN N
disease NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
placebo NN N
albuterol NN N
aerosol NN N
followed VBD N
immediately RB N
by IN N
active JJ N
albuterol NN N
powder NN N
( ( N
200 CD N
micrograms NNS N
) ) N
or CC N
active JJ N
albuterol NN N
aerosol NN N
( ( N
two CD N
puffs NNS N
, , N
180 CD N
micrograms NNS N
) ) N
followed VBD N
immediately RB N
by IN N
placebo NN N
lactose JJ N
powder NN N
four CD N
times NNS N
a DT N
day NN N
for IN N
a DT N
period NN N
of IN N
12 CD N
weeks NNS N
. . N

We PRP N
formulated VBD N
four CD N
specific JJ N
questions NNS N
: : N
( ( N
1 CD N
) ) N
can MD N
a DT N
concurrent JJ N
SAS NNP N
shorten VBD N
the DT N
onset NN N
of IN N
automatic JJ N
postural JJ N
responses NNS N
? . N
; : N
and CC N
if IN N
so RB N
( ( N
2 CD N
) ) N
is VBZ N
this DT N
effect NN N
different JJ N
for IN N
forward RB N
versus FW N
backward NN N
perturbations NNS N
? . N
; : N
( ( N
3 CD N
) ) N
does VBZ N
this DT N
effect NN N
depend NN N
on IN N
prior JJ N
knowledge NN N
of IN N
the DT N
perturbation NN N
direction NN N
? . N
; : N
and CC N
( ( N
4 CD N
) ) N
is VBZ N
this DT N
effect NN N
different JJ N
for IN N
low- JJ N
and CC N
high-magnitude JJ N
perturbations NNS N
? . N
Balance NNP N
was VBD N
perturbed VBN N
in IN N
11 CD N
healthy JJ N
participants NNS N
by IN N
a DT N
movable JJ N
platform NN N
that IN N
suddenly RB N
translated VBN N
forward RB N
or CC N
backward RB N
. . N

METHODS NNP N
This DT N
phase NN N
III NNP N
prospective NN N
, , N
randomized VBN N
, , N
and CC N
stratified VBD N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
four CD N
courses NNS N
of IN N
combined JJ N
fluorouracil NN N
( ( N
1000 CD N
mg NN N
per IN N
square JJ N
meter NN N
of IN N
body-surface JJ N
area NN N
daily RB N
for IN N
four CD N
days NNS N
) ) N
and CC N
cisplatin NN i
( ( N
75 CD N
mg NN N
per IN N
square JJ N
meter NN N
on IN N
the DT N
first JJ N
day NN N
) ) N
plus CC N
5000 CD N
cGy NN N
of IN N
radiation NN N
therapy NN i
, , N
as IN N
compared VBN N
with IN N
6400 CD N
cGy NN N
of IN N
radiation NN N
therapy NN i
alone RB N
, , N
in IN N
patients NNS p
with IN N
squamous-cell JJ N
carcinoma NN N
or CC N
adenocarcinoma NN N
of IN N
the DT N
thoracic NN N
esophagus NN N
. . N

METHODS NNP N
Between NNP N
1999 CD N
and CC N
2002 CD N
, , N
1397 CD N
antiretroviral-treatment-naive JJ N
patients NNS p
, , N
presenting VBG N
at IN N
18 CD N
clinical JJ N
trial NN N
units NNS N
with IN N
80 CD N
research NN N
sites NNS N
in IN N
the DT N
USA NNP N
, , N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
ratio NN N
of IN N
1:1:1 CD N
to TO N
a DT N
protease NN N
inhibitor NN N
( ( N
PI NNP N
) ) N
strategy NN N
( ( N
PI NNP N
plus CC N
nucleoside JJ N
reverse NN N
transcriptase NN N
inhibitor NN N
[ NNP N
NRTI NNP N
] NNP N
; : N
n=470 NN N
) ) N
, , N
a DT N
non-nucleoside JJ N
reverse NN N
transcriptase NN N
inhibitor NN N
( ( N
NNRTI NNP N
) ) N
strategy NN N
( ( N
NNRTI NNP N
plus CC N
NRTI NNP N
; : N
n=463 NN N
) ) N
, , N
or CC N
a DT N
three-class JJ N
strategy NN N
( ( N
PI NNP N
plus CC N
NNRTI NNP N
plus CC N
NRTI NNP N
; : N
n=464 NN N
) ) N
. . N

We PRP N
measured VBD N
the DT N
plasma JJ N
concentrations NNS N
of IN N
IL-6 NNP N
and CC N
IL-8 NNP N
at IN N
the DT N
start NN N
of IN N
every DT N
hemoperfusion NN N
treatment NN N
, , N
and CC N
the DT N
following JJ N
parameters NNS N
were VBD N
compared VBN N
between IN N
the DT N
control NN N
group NN N
and CC N
the DT N
hemoperfusion NN N
group NN N
on IN N
days NNS N
3 CD N
, , N
7 CD N
, , N
and CC N
14 CD N
: : N
hemodynamics NNS N
( ( N
cardiac JJ N
index NN N
, , N
systemic JJ N
vascular NN N
resistance NN N
index NN N
, , N
heart NN N
rate NN N
, , N
and CC N
mean JJ N
arterial JJ N
pressure NN N
) ) N
; : N
change NN N
of IN N
hematology NN N
and CC N
coagulation NN N
function NN N
; : N
organ JJ N
function NN N
; : N
and CC N
the DT N
sequential JJ N
organ JJ N
failure NN N
assessment NN N
( ( N
SOFA NNP N
) ) N
score NN N
. . N

In IN N
each DT N
case NN N
of IN N
acute JJ N
promyelocytic JJ N
leukemia NN N
( ( N
APL NNP N
) ) N
one CD N
of IN N
three CD N
PML-RAR JJ N
alpha NN N
mRNA NN N
types NNS N
is VBZ N
produced VBN N
, , N
depending VBG N
on IN N
the DT N
break/fusion NN N
site NN N
in IN N
the DT N
PML NNP N
gene NN N
that WDT N
is VBZ N
linked VBN N
to TO N
a DT N
common JJ N
RAR NNP N
alpha JJ N
gene NN N
segment NN N
: : N
a DT N
short JJ N
( ( N
S NNP N
) ) N
-form NN N
type NN N
, , N
PML NNP N
exon VBZ N
3 CD N
RAR NNP N
alpha NN N
exon VBZ N
3 CD N
; : N
a DT N
long JJ N
( ( N
L NNP N
) ) N
-form NN N
type NN N
, , N
PML NNP N
exon VBZ N
6 CD N
RAR NNP N
alpha NN N
exon VBZ N
3 CD N
; : N
or CC N
a DT N
variable JJ N
( ( N
V NNP N
) ) N
-form NN N
type NN N
, , N
variably RB N
deleted VBD N
PML NNP N
exon VBD N
6 CD N
RAR NNP N
alpha NN N
exon VBD N
3 CD N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Between NNP N
January NNP N
1988 CD N
and CC N
December NNP N
1992 CD N
, , N
231 CD N
patients NNS p
with IN N
estrogen JJ N
receptor NN N
( ( N
ER NNP N
) ) N
-positive CD N
or CC N
ER-unknown JJ N
metastatic JJ N
breast NN N
cancer NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
chemotherapy NN i
( ( N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
and CC N
fluorouracil VB N
? . N
) ) N
or CC N
chemohormonal JJ N
therapy NN i
( ( N
CAF NNP N
plus CC N
tamoxifen NN N
and CC N
Halotestin NNP i
? . N
; : N
Pharmacia-Upjohn NNP N
, , N
Kalamazoo NNP N
, , N
MI NNP N
? . N
) ) N
as IN N
front-line JJ N
therapy NN i
for IN N
metastatic JJ N
breast NN N
cancer NN N
. . N

PATIENTS NNP N
Fifty NNP N
patients NNS p
with IN N
early JJ N
cervical JJ N
cancer NN N
( ( N
FIGO NNP N
stages VBZ N
IA2 NNP N
, , N
IB1 NNP N
, , N
IIA NNP N
< VBZ N
2 CD N
cm NN N
) ) N
or CC N
locally RB N
advanced JJ N
cervical JJ N
cancer NN N
( ( N
FIGO NNP N
stages VBZ N
IB2 NNP N
, , N
IIA NNP N
> NNP N
2cm CD N
, , N
IIB NNP N
) ) N
who WP N
received VBD N
neoadjuvant JJ N
treatment NN N
( ( N
chemotherapy NN i
or CC N
radiochemotherapy NN i
) ) N
and CC N
demonstrated VBD N
a DT N
complete JJ N
or CC N
partial JJ N
clinical JJ N
response NN N
and CC N
early JJ N
stage NN N
endometrioid JJ N
endometrial JJ N
cancer NN N
( ( N
FIGO NNP N
stages VBZ N
IB NNP N
, , N
II NNP N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
TB NNP N
( ( N
arm IN N
A NNP N
) ) N
or CC N
SES NNP N
( ( N
arm NN N
B NNP N
) ) N
. . N

INTERVENTION NNP N
During IN N
each DT N
interview NN N
, , N
the DT N
patients NNS p
' POS N
MCIDs NNP N
were VBD N
determined VBN N
by IN N
using VBG N
( ( N
1 CD N
) ) N
a DT N
pictorial JJ N
flip NN N
chart NN N
to TO N
describe VB N
atrial JJ N
fibrillation NN N
; : N
the DT N
consequences NNS N
of IN N
a DT N
minor JJ N
stroke NN N
, , N
a DT N
major JJ N
stroke NN N
, , N
and CC N
a DT N
major JJ N
bleeding NN N
episode NN N
; : N
the DT N
chance NN N
of IN N
stroke NN N
if IN N
not RB N
taking VBG N
warfarin NN N
; : N
the DT N
chance NN N
of IN N
a DT N
major JJ N
bleeding NN N
episode NN N
if IN N
taking VBG N
warfarin NN N
; : N
examples NNS N
of IN N
the DT N
inconvenience NN N
, , N
minor JJ N
side NN N
effects NNS N
, , N
and CC N
costs NNS N
of IN N
warfarin JJ N
therapy NN i
; : N
and CC N
then RB N
( ( N
2 CD N
) ) N
1 CD N
of IN N
the DT N
2 CD N
elicitation NN N
methods NNS N
to TO N
determine VB N
their PRP$ N
MCIDs NNP N
( ( N
the DT N
smallest JJS N
reduction NN N
in IN N
stroke NN N
risk NN N
at IN N
which WDT N
the DT N
patients NNS p
were VBD N
willing JJ N
to TO N
take VB N
warfarin NN N
) ) N
. . N

METHODOLOGY NNP N
One CD N
hundred CD N
and CC N
ninety-three JJ N
( ( N
193 CD N
) ) N
H. NNP N
pylori-positive JJ N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
7-day JJ N
treatments NNS N
: : N
Group NNP N
A NNP N
( ( N
N NNP N
= NNP N
64 CD N
) ) N
: : N
amoxicillin NN i
, , N
clarithromycin NN i
and CC N
rabeprazole NN N
; : N
Group NNP N
B NNP N
( ( N
N NNP N
= NNP N
64 CD N
) ) N
: : N
tinidazole NN N
, , N
clarithromycin NN i
and CC N
ranitidine NN N
bismuth NN N
citrate NN N
; : N
Group NNP N
C NNP N
( ( N
N NNP N
= NNP N
65 CD N
) ) N
: : N
tinidazole NN N
, , N
clarithromycin NN i
and CC N
rabeprazole JJ N
Eradication NNP N
was VBD N
assessed VBN N
by IN N
13C-Urea JJ N
Breath NNP N
Test NNP N
6-8 JJ N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
therapy NN i
. . N

Measures NNS N
of IN N
the DT N
relative JJ N
areas NNS N
under IN N
the DT N
power NN N
spectral JJ N
curve NN N
were VBD N
made VBN N
for IN N
each DT N
of IN N
the DT N
following JJ N
frequency NN N
bands NNS N
: : N
slow VB N
alpha NN N
( ( N
7.5 CD N
to TO N
10 CD N
Hz NNP N
) ) N
; : N
fast VBN N
alpha NN N
( ( N
10.5 CD N
to TO N
13.0 CD N
Hz NNP N
) ) N
; : N
slow JJ N
beta NN N
( ( N
13.5 CD N
to TO N
19.5 CD N
Hz NNP N
) ) N
; : N
and CC N
fast VB N
beta NN N
( ( N
20 CD N
to TO N
26 CD N
Hz NNP N
) ) N
at IN N
electrodes NNS N
F3 NNP N
, , N
F4 NNP N
, , N
C3 NNP N
, , N
C4 NNP N
, , N
P3 NNP N
, , N
P4 NNP N
, , N
O1 NNP N
, , N
and CC N
O2 NNP N
. . N

In IN N
a DT N
12-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
60 CD N
treatment-resistant JJ N
children NNS N
and CC N
adolescents NNS N
( ( N
mean VB N
age=14.5 RB N
? . N
2.4 CD N
years NNS N
) ) N
, , N
with IN N
moderate JJ N
to TO N
severe VB N
OCD NNP N
( ( N
mean JJ N
Children NNP N
's POS N
Yale-Brown JJ N
Obsessive-Compulsive JJ N
Scale NNP N
( ( N
CY-BOCS NNP N
) ) N
=28.2 NN N
? . N
3.7 CD N
) ) N
, , N
17 CD N
of IN N
whom WP N
also RB N
had VBD N
concomitant JJ N
autism NN N
spectrum NN N
disorder NN N
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
riluzole NN N
( ( N
final JJ N
dose NN N
of IN N
100 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
in IN N
addition NN N
to TO N
the DT N
existing VBG N
treatment NN N
regimen NNS N
. . N

A DT N
meta-analysis NN N
of IN N
the DT N
pooled JJ N
results NNS N
from IN N
six CD N
double-blind JJ N
trials NNS N
showed VBD N
that IN N
risperidone NN i
at IN N
doses NNS N
ranging VBG N
from IN N
4 CD N
to TO N
8 CD N
mg/day NN N
had VBD N
a DT N
significantly RB N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
higher JJR N
negative JJ N
symptom JJ N
response NN N
rate NN N
, , N
defined VBN N
as IN N
the DT N
percentage NN N
of IN N
patients NNS p
with IN N
a DT N
20 CD N
% NN N
or CC N
more JJR N
reduction NN N
in IN N
scores NNS N
on IN N
the DT N
negative JJ N
subscale NN N
of IN N
the DT N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
, , N
than IN N
patients NNS p
receiving VBG N
active JJ N
controls NNS N
. . N

METHODS NNP N
Full-term NNP N
newborns NNS N
and CC N
children NNS N
( ( N
n JJ N
= NNP N
488 CD N
) ) N
through IN N
8 CD N
yr NN N
of IN N
age NN N
who WP N
required VBD N
general JJ N
anesthesia NN N
and CC N
tracheal JJ N
intubation NN N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
either CC N
a DT N
cuffed NN N
tube NN N
sized VBN N
by IN N
a DT N
new JJ N
formula NN N
[ NN N
size NN N
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
3 CD N
] NN N
, , N
or CC N
an DT N
uncuffed JJ N
tube NN N
sized VBN N
by IN N
the DT N
modified JJ N
Cole NNP N
's POS N
formula NN N
[ NN N
size NN N
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
4 CD N
] NN N
. . N

World NNP N
Health NNP N
Organization NNP N
functional JJ N
class NN N
improved VBN N
in IN N
19 CD N
and CC N
was VBD N
unchanged JJ N
in IN N
10 CD N
; : N
exercise NN N
capacity NN N
significantly RB N
improved VBN N
with IN N
the DT N
6-minute JJ N
walk NN N
distance NN N
, , N
improving VBG N
on IN N
follow-up NN N
from IN N
455.7 CD N
? . N
71.5 CD N
to TO N
498 CD N
? . N
70 CD N
m NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
and CC N
peak JJ N
oxygen NN N
consumption NN N
increasing VBG N
from IN N
25.5 CD N
? . N
10.2 CD N
to TO N
27.4 CD N
? . N
10 CD N
( ( N
p NN N
= RB N
0.04 CD N
) ) N
. . N

Peak NNP N
levels NNS N
of IN N
total JJ N
TFPI NNP N
activity NN N
and CC N
free JJ N
TFPI NNP N
antigen NN N
were VBD N
detected VBN N
1 CD N
h NN N
after IN N
injection NN N
, , N
whereas IN N
maximal JJ N
prolongation NN N
of IN N
activated VBN N
partial JJ N
thromboplastin NN i
time NN N
( ( N
APTT NNP N
) ) N
and CC N
peak JJ N
levels NNS N
of IN N
anti-factor JJ N
Xa NNP N
activity NN N
and CC N
anti-factor NN N
IIa NNP N
activity NN N
were VBD N
detected VBN N
after IN N
4 CD N
h. NN N
On IN N
UFH NNP N
administered VBD N
twice RB N
daily RB N
, , N
free JJ N
TFPI NNP N
antigen NN N
decreased VBN o
by IN N
44 CD N
% NN N
from IN N
baseline JJ N
level NN N
before IN N
the DT N
first JJ N
injection NN N
on IN N
day NN N
1 CD N
to TO N
pre-injection NN N
level NN N
on IN N
day NN N
5 CD N
. . N

METHODS NNP N
Thirty NNP N
subjects NNS N
( ( N
8 CD N
men NNS N
and CC N
22 CD N
women NNS N
) ) N
who WP N
had VBD N
minor JJ N
RAS NNP N
at IN N
least JJS N
once RB N
a DT N
month NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
soybean JJ N
oil NN N
group NN N
or CC N
a DT N
perilla JJ N
oil NN N
group NN N
in IN N
a DT N
double-blind JJ N
manner NN N
( ( N
experimental JJ N
phase NN N
) ) N
after IN N
a DT N
run-in JJ N
phase NN N
of IN N
4 CD N
mo NN N
during IN N
which WDT N
subjects NNS N
used VBD N
a DT N
reference NN N
oil NN N
, , N
the DT N
most RBS N
popular JJ N
cooking NN N
oil NN N
in IN N
Japan NNP N
, , N
or CC N
a DT N
50/50 CD N
mixture NN N
of IN N
soybean JJ N
oil NN N
and CC N
rapeseed NN N
oil NN N
. . N

In IN N
an DT N
analysis NN N
of IN N
82 CD N
children NNS N
who WP N
received VBD N
a DT N
full JJ N
course NN N
of IN N
6 CD N
days NNS N
or CC N
more JJR N
of IN N
AmB NNP N
( ( N
117 CD N
courses NNS N
) ) N
, , N
it PRP N
was VBD N
shown VBN N
that IN N
there EX N
were VBD N
significant JJ N
increases NNS o
in IN N
plasma JJ N
urea JJ N
and CC N
creatinine JJ N
concentrations NNS N
and CC N
in IN N
potassium NN N
requirement NN N
after IN N
6 CD N
days NNS N
of IN N
therapy NN i
with IN N
both DT N
AmB NNP N
infused VBN N
in IN N
dextrose NN N
and CC N
AmB NNP N
infused VBD N
in IN N
lipid JJ N
emulsion NN N
, , N
with IN N
there EX N
being VBG N
no DT N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
of IN N
AmB NNP N
administration NN N
. . N

CONCLUSION NNP N
( ( N
1 CD N
) ) N
Serum NNP N
level NN N
of IN N
sCD44v6 NN N
could MD N
be VB N
taken VBN N
as IN N
the DT N
criterion NN N
for IN N
evaluating VBG N
the DT N
development NN N
and CC N
prognosis NN N
of IN N
gastric JJ N
cancer NN N
, , N
as RB N
well RB N
as IN N
the DT N
therapeutic JJ N
target NN N
for IN N
anti-metastasis JJ N
treatment NN N
; : N
( ( N
2 CD N
) ) N
Serum NNP N
level NN N
of IN N
sCD44v6 NN N
is VBZ N
related VBN N
to TO N
some DT N
extent NN N
with IN N
TCM NNP N
type NN N
of IN N
blood NN N
stasis NN N
and CC N
Pi-deficiency NN N
; : N
( ( N
3 CD N
) ) N
WTC NNP N
combined VBN N
with IN N
chemotherapy NN i
could MD N
further RB N
inhibit VB N
the DT N
expression NN N
of IN N
serum NN N
sCD44v6 NN N
in IN N
gastric JJ N
carcinoma NN N
patients NNS p
. . N

SPEM NNP N
is VBZ N
a DT N
multicenter NN N
randomized VBN N
double-blind NN N
study NN N
performed VBD N
to TO N
test VB N
the DT N
acute NN N
and CC N
chronic JJ N
electrophysiological JJ N
behavior NN N
of IN N
three CD N
different JJ N
ventricular JJ N
leads NNS N
: : N
( ( N
1 CD N
) ) N
an DT N
ion NN N
exchange NN N
membrane NN N
with IN N
30-microgram JJ N
dexamethasone NN N
elution NN N
in IN N
a DT N
contoured JJ N
activated JJ N
carbon NN N
tip NN N
lead NN N
( ( N
Membrane NNP N
1400T CD N
, , N
30 CD N
patients NNS p
) ) N
; : N
( ( N
2 CD N
) ) N
the DT N
same JJ N
lead NN N
design NN N
without IN N
steroid NN N
( ( N
Membrane NNP N
1401T CD N
, , N
24 CD N
patients NNS p
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
same JJ N
lead NN N
design NN N
without IN N
steroid NN N
or CC N
membrane NN N
( ( N
control NN N
group NN N
, , N
27 CD N
patients NNS p
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Eighty NNP N
patients NNS p
with IN N
CD20 NNP N
( ( N
+ NNP N
) ) N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
prophylactic JJ N
entecavir NN N
( ( N
ETV NNP N
) ) N
before IN N
chemotherapy NN i
to TO N
3 CD N
months NNS N
after IN N
completing VBG N
chemotherapy NN i
( ( N
ETV NNP N
prophylactic JJ N
group NN N
, , N
n RB N
= VBZ N
41 CD N
) ) N
or CC N
to TO N
receive VB N
therapeutic JJ N
ETV NNP N
at IN N
the DT N
time NN N
of IN N
HBV NNP N
reactivation NN N
and CC N
hepatitis NN N
B NNP N
surface NN N
antigen NN N
( ( N
HBsAg NNP N
) ) N
reverse NN N
seroconversion NN N
since IN N
chemotherapy NN i
( ( N
control NN N
group NN N
, , N
n RB N
= VBZ N
39 CD N
) ) N
. . N

The DT N
following NN N
are VBP N
the DT N
primary JJ N
outcomes NNS N
to TO N
be VB N
measured VBN N
: : N
( ( N
1 CD N
) ) N
the DT N
trajectories NNS N
of IN N
the DT N
left NN N
ventricular JJ N
ejection NN N
fraction NN N
in IN N
the DT N
follow-up JJ N
period NN N
; : N
( ( N
2 CD N
) ) N
reduction NN N
of IN N
heart NN N
disease NN N
progression NN N
rates NNS N
, , N
with IN N
progression NN N
defined VBN N
as IN N
a DT N
10 CD N
% NN N
decrease NN o
in IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
; : N
and CC N
( ( N
3 CD N
) ) N
rate NN N
of IN N
hospital NN N
admissions NNS N
attributable JJ N
to TO N
dysrhythmia VB N
, , N
heart NN N
failure NN N
or CC N
stroke NN N
due JJ N
to TO N
Chagas NNP N
disease NN N
. . N

The DT N
blood NN N
samples NNS N
were VBD N
collected VBN N
for IN N
e NN N
same JJ N
measurements NNS N
of IN N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
and CC N
tumor JJ N
necrosis NN N
factor NN N
( ( N
TNF- NNP N
) ) N
by IN N
enzyme NN N
linked VBN N
immunosorbent JJ N
assay NN N
( ( N
ELISA NNP N
) ) N
, , N
and CC N
for IN N
the DT N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
lactic JJ N
acid NN N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
, , N
white JJ N
blood NN N
cell NN N
( ( N
WBC NNP N
) ) N
count NN N
, , N
amylase NN N
and CC N
lipase NN N
by IN N
biochemistry NN N
assay VBP N
1 CD N
day NN N
before IN N
intervention NN N
of IN N
nutrition NN N
, , N
and CC N
7 CD N
days NNS N
and CC N
14 CD N
days NNS N
after IN N
intervention NN N
. . N

METHODS NNP N
Patients NNS N
aged VBD N
25 CD N
to TO N
74 CD N
years NNS N
attending VBG N
community NN N
pharmacies NNS N
with IN N
a DT N
prescription NN N
for IN N
at IN N
least JJS N
1 CD N
drug NN N
indicated VBN N
for IN N
CVD NNP N
or CC N
CV NNP N
risk NN N
factors NNS N
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
: : N
an DT N
intervention NN N
group NN N
that WDT N
received VBD N
pharmaceutical JJ N
care NN N
, , N
which WDT N
was VBD N
provided VBN N
by IN N
specially RB N
trained JJ N
pharmacists NNS N
working VBG N
in IN N
collaboration NN N
with IN N
physicians NNS N
, , N
and CC N
a DT N
control NN N
group NN N
that WDT N
received VBD N
usual JJ N
care NN N
( ( N
routine JJ N
dispensing VBG N
counseling NN N
) ) N
and CC N
verbal JJ N
and CC N
written VBN N
counseling VBG N
regarding VBG N
CVD NNP N
prevention NN N
. . N

METHOD NNP N
Two CD N
hundred VBD N
eighteen JJ N
children NNS N
and CC N
adolescents NNS N
( ( N
aged VBN N
6-17 CD N
years NNS N
) ) N
with IN N
a DT N
diagnosis NN N
of IN N
autistic JJ N
disorder NN N
, , N
and CC N
with IN N
behaviors NNS N
such JJ N
as IN N
tantrums NNS N
, , N
aggression NN N
, , N
self-injurious JJ N
behavior NN N
, , N
or CC N
a DT N
combination NN N
of IN N
these DT N
symptoms NNS N
, , N
were VBD N
randomized VBN N
1:1:1:1 CD N
to TO N
aripiprazole VB N
( ( N
5 CD N
, , N
10 CD N
, , N
or CC N
15 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
in IN N
this DT N
8-week JJ N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
study NN N
. . N

This DT N
study NN N
showed VBD N
that IN N
in IN N
symptomatic JJ N
patients NNS p
with IN N
moderate-to-severe JJ N
asthma NN N
, , N
Salm/FP NNP N
( ( N
50/250 CD N
microg RB N
bd NN N
) ) N
, , N
administered VBN N
in IN N
a DT N
single JJ N
convenient NN N
device NN N
( ( N
Diskus NNP N
) ) N
, , N
was VBD N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
an DT N
approximately RB N
three-fold JJ N
higher JJR N
microgram NN N
corticosteroid VBP N
dose NN N
of IN N
Bud NNP N
( ( N
800 CD N
microg RB N
bd NN N
) ) N
given VBN N
concurrently RB N
with IN N
Form NNP N
( ( N
12 CD N
microg RB N
bd NN N
) ) N
in IN N
terms NNS N
of IN N
improvement NN N
in IN N
PEFam NNP N
, , N
and CC N
superior JJ N
at IN N
reducing VBG N
exacerbations NNS N
and CC N
nights NNS N
with IN N
symptoms NNS N
or CC N
night-time JJ N
awakenings NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
, , N
477 CD N
women NNS N
with IN N
anemia NN N
, , N
iron NN N
deficiency NN N
, , N
and CC N
heavy JJ N
uterine JJ N
bleeding NN N
were VBD N
assigned VBN N
to TO N
receive VB N
either DT N
IV NNP N
ferric NN N
carboxymaltose NN N
( ( N
< JJ N
or=1000 NN N
mg NN N
over IN N
15 CD N
min NNS N
, , N
repeated VBD N
weekly JJ N
to TO N
achieve VB N
a DT N
total JJ N
calculated JJ N
replacement NN N
dose NN N
) ) N
or CC N
325 CD N
mg NN N
of IN N
ferrous JJ N
sulfate NN N
( ( N
65 CD N
mg NN N
elemental JJ N
iron NN N
) ) N
prescribed VBD N
orally RB N
thrice JJ N
daily RB N
for IN N
6 CD N
weeks NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
6-week JJ N
pilot NN N
trial NN N
investigating VBG N
the DT N
effects NNS N
of IN N
1.5 CD N
g/d NN N
of IN N
omega-3 JJ N
fatty JJ N
acids NNS N
( ( N
.84 JJ N
g/d NN N
eicosapentaenoic NN N
acid NN N
, , N
.7 NNP N
g/d NN N
docosahexaenoic NN N
acid NN N
) ) N
supplementation NN N
in IN N
13 CD N
children NNS N
( ( N
aged VBN N
5 CD N
to TO N
17 CD N
years NNS N
) ) N
with IN N
autistic JJ N
disorders NNS N
accompanied VBN N
by IN N
severe JJ N
tantrums NNS N
, , N
aggression NN N
, , N
or CC N
self-injurious JJ N
behavior NN N
. . N

A DT N
randomized JJ N
, , N
open-label JJ N
, , N
multicenter NN N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
oral JJ N
contraceptives NNS N
( ( N
OC NNP N
) ) N
containing VBG N
100 CD N
micrograms NNS N
levonorgestrel NN N
( ( N
LNG NNP N
) ) N
/20 VBP N
micrograms NNS N
ethinyl VBP N
estradiol NN N
( ( N
EE NNP N
) ) N
( ( N
Aless/Loette NNP N
) ) N
and CC N
1000 CD N
micrograms NNS N
norethindrone JJ N
acetate NN N
( ( N
NETA NNP N
) ) N
/20 VBP N
micrograms NNS N
EE NNP N
( ( N
Loestrin NNP N
Fe NNP N
1/20 CD N
) ) N
on IN N
menstrual JJ N
cycle NN N
control NN N
over IN N
four CD N
cycles NNS N
of IN N
use NN N
. . N

To TO N
evaluate VB N
whether IN N
the DT N
inhibitory JJ N
control NN N
of IN N
TSH NNP N
and CC N
the DT N
stimulatory NN N
control NN N
of IN N
prolactin NN i
( ( N
PRL NNP N
) ) N
secretion NN N
exerted VBN N
by IN N
endogenous JJ N
serotonin NN N
was VBD N
altered VBN N
in IN N
obesity NN N
, , N
22 CD N
obese JJ N
men NNS N
and CC N
10 CD N
normal JJ N
controls NNS N
were VBD N
tested VBN N
with IN N
TRH NNP N
( ( N
200 CD N
micrograms NNS N
IV NNP N
bolus NN N
) ) N
in IN N
the DT N
presence NN N
( ( N
experimental JJ N
test NN N
) ) N
and CC N
absence NN N
( ( N
control VB N
test NN N
) ) N
of IN N
the DT N
serotonergic JJ N
agonist NN N
fenfluramine NN N
( ( N
60 CD N
mg NN N
PO NNP N
90 CD N
min NN N
before IN N
TRH NNP N
) ) N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
Two CD N
hundred CD N
and CC N
two CD N
patients NNS p
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
surgical JJ N
approach NN N
( ( N
total JJ N
laryngectomy NN N
with IN N
partial JJ N
pharyngectomy NN N
and CC N
neck NN N
dissection NN N
, , N
followed VBN N
by IN N
irradiation NN N
) ) N
or CC N
to TO N
the DT N
chemotherapy NN i
arm NN N
up IN N
to TO N
three CD N
cycles NNS N
of IN N
induction NN N
chemotherapy NN i
( ( N
cisplatin JJ i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
+ CD N
5-FU JJ N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1-5 JJ N
) ) N
followed VBD N
for IN N
complete JJ N
responders NNS N
by IN N
irradiation NN N
and CC N
otherwise RB N
by IN N
conventional JJ N
treatment NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
two CD N
estroprogestins NNS N
( ( N
EPs NNP N
) ) N
, , N
ethinyl-estradiol JJ N
( ( N
EE NNP N
) ) N
30 CD N
mcg/drospirenone NN N
( ( N
DRSP NNP N
) ) N
3 CD N
mg NN N
, , N
and CC N
ethinyl-estradiol NN N
( ( N
EE NNP N
) ) N
30 CD N
mcg/chlormadinone NN N
acetate NN N
( ( N
CMA NNP N
) ) N
2 CD N
mg NN N
, , N
both DT N
on IN N
increased VBN o
serum NN N
androgen NN N
levels NNS N
and CC N
on IN N
several JJ N
skin NN N
parameters NNS N
in IN N
women NNS N
affected VBN N
by IN N
mild NN N
to TO N
severe VB N
acne NN N
and CC N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
polymyxin NN N
sulfate NN N
7500 CD N
IU/neomycin NNP i
sulfate NN N
3500 CD N
IU/dexamethasone NNP N
phosphate VB N
0.1 CD N
% NN N
( ( N
PN+Dx NNP N
) ) N
otic JJ i
solution NN N
with IN N
polymyxin NN N
sulfate NN N
7500 CD N
IU/neomycin NNP i
sulfate NN N
3500 CD N
IU NNP N
( ( N
PN-Dx NNP N
) ) N
in IN N
patients NNS p
with IN N
acute JJ N
bacterial JJ N
otitis NN N
externa NN N
( ( N
AOE NNP N
) ) N
, , N
in IN N
order NN N
to TO N
determine VB N
the DT N
possible JJ N
benefit NN N
of IN N
the DT N
addition NN N
of IN N
dexamethasone NN N
. . N

PURPOSE NN N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
sustained VBN N
virologic IN N
suppression NN N
) ) N
and CC N
safety/tolerability NN N
of IN N
a DT N
switch NN N
to TO N
lamivudine VB N
300 CD N
mg NNS N
once RB N
daily JJ N
( ( N
QD NNP N
) ) N
versus NN N
continued VBD N
lamivudine JJ N
150 CD N
mg JJ N
twice RB N
daily RB N
( ( N
BID NNP N
) ) N
in IN N
virologically RB N
suppressed VBN N
patients NNS p
( ( N
HIV-1 NNP N
RNA NNP N
< NNP N
400 CD N
copies/mL NN N
for IN N
> NN N
or CC N
=3 JJ N
months NNS N
) ) N
on IN N
stable JJ N
( ( N
> JJ N
or CC N
=6 JJ N
months NNS N
) ) N
therapy NN i
with IN N
lamivudine JJ N
150 CD N
mg NN N
BID NNP N
plus CC N
stavudine NN N
and CC N
either DT N
indinavir NN N
or CC N
nelfinavir NN N
. . N

METHODS NNP N
HIV NNP N
and CC N
HCV NNP N
genotype VBP N
1- JJ N
and CC N
4-coinfected JJ N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
pegylated VBN N
interferon- JJ N
270 CD N
? . N
plus CC N
ribavirin JJ N
1,600 CD N
mg JJ N
daily JJ N
and CC N
epoetin- JJ N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
pegylated JJ N
interferon- NN N
at IN N
standard JJ N
dosages NNS N
plus CC N
weight-based JJ N
ribavirin NN N
( ( N
WBR NNP N
) ) N
dosage NN N
for IN N
8 CD N
weeks NNS N
( ( N
induction NN N
arm NN N
[ NNP N
IA NNP N
] NNP N
) ) N
, , N
or CC N
pegylated VBD N
interferon- JJ N
plus CC N
WBR NNP N
for IN N
12 CD N
weeks NNS N
( ( N
standard JJ N
therapy NN i
arm NN N
[ NNP N
SA NNP N
] NNP N
) ) N
. . N

There EX N
were VBD N
higher JJR N
POGO NNP N
scores NNS N
with IN N
the DT N
LFS NNP N
compared VBN N
with IN N
the DT N
Macintosh NNP N
( ( N
80 CD N
% NN N
vs JJ N
20 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
, , N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
( ( N
< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
, , N
respectively RB N
) ) N
. . N

Compared VBN N
with IN N
the DT N
control NN N
period NN N
, , N
nicotinic JJ N
acid NN N
therapy NN i
reduced VBD N
the DT N
plasma NN N
total JJ N
cholesterol NN N
level NN N
by IN N
24 CD N
% NN N
, , N
plasma JJ N
triglyceride IN N
level NN N
by IN N
45 CD N
% NN N
, , N
very-low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
by IN N
58 CD N
% NN N
, , N
and CC N
low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
by IN N
15 CD N
% NN N
, , N
and CC N
it PRP N
increased VBD o
the DT o
high-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
by IN N
34 CD N
% NN N
. . N

RESULTS NNP N
Nosocomial NNP N
infections NNS N
of IN N
the DT N
blood NN N
, , N
meninges NNS N
, , N
or CC N
urinary JJ N
tract NN N
occurred VBD N
in IN N
439 CD N
of IN N
the DT N
2416 CD N
infants NNS N
( ( N
18.2 CD N
percent NN N
) ) N
: : N
208 CD N
( ( N
17.3 CD N
percent NN N
) ) N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
231 CD N
( ( N
19.1 CD N
percent NN N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
relative JJ N
risk NN N
, , N
0.91 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.77 CD N
to TO N
1.08 CD N
) ) N
. . N

Time NN N
to TO N
regression VB N
to TO N
two CD N
segments NNS N
of IN N
partial JJ N
and CC N
complete JJ N
sensory NN N
blockade NN N
was VBD N
positively RB N
correlated VBN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
with IN N
increasing VBG N
dose NN N
of IN N
bupivacaine NN N
in IN N
the DT N
solutions NNS N
and CC N
ranged VBD N
from IN N
84 CD N
min NN N
( ( N
partial JJ N
) ) N
and CC N
70 CD N
min NN N
( ( N
complete JJ N
) ) N
for IN N
lidocaine NN N
, , N
to TO N
128 CD N
min NN N
( ( N
partial JJ N
) ) N
and CC N
101 CD N
min NN N
( ( N
complete JJ N
) ) N
for IN N
bupivacaine NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS N
of IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
( ( N
PAI NNP N
) ) N
activity NN N
and CC N
serum JJ N
ACE NNP N
activity NN N
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD N
patients NNS p
with IN N
AMI NNP N
within IN N
12 CD N
hours NNS N
after IN N
the DT N
onset NN N
of IN N
the DT N
symptom NN N
and CC N
who WP N
randomly VBP N
received VBN N
early JJ N
treatment NN N
with IN N
either CC N
the DT N
ACE NNP N
inhibitor NN N
imidapril NN N
or CC N
a DT N
placebo NN N
( ( N
20 CD N
patients NNS p
in IN N
the DT N
imidapril NN N
group NN N
and CC N
20 CD N
in IN N
the DT N
placebo NN N
group NN N
) ) N
. . N

There EX N
were VBD N
no DT N
deaths NNS N
or CC N
bile-duct NN N
lesions NNS N
in IN N
either DT N
group NN N
, , N
but CC N
the DT N
postoperative JJ N
complication NN N
rate NN N
was VBD N
significantly RB N
( ( N
p=0.0048 NN N
) ) N
higher JJR N
in IN N
the DT N
OC NNP N
than IN N
in IN N
the DT N
LC NNP N
group NN N
: : N
seven CD N
( ( N
23 CD N
% NN N
) ) N
patients NNS p
had VBD N
major JJ N
and CC N
six CD N
( ( N
19 CD N
% NN N
) ) N
minor NN N
complications NNS N
after IN N
OC NNP N
, , N
whereas IN N
only RB N
one CD N
( ( N
3 CD N
% NN N
) ) N
minor JJ N
complication NN N
occurred VBD N
after IN N
LC NNP N
. . N

METHOD NNP N
This DT N
24-week JJ N
, , N
three-site JJ N
, , N
controlled VBD N
clinical JJ N
trial NN N
randomized VBD N
124 CD N
children NNS N
( ( N
4 CD N
through IN N
13 CD N
years NNS N
of IN N
age NN N
) ) N
with IN N
PDDs NNP N
and CC N
serious JJ N
behavioral JJ N
problems NNS N
to TO N
medication VB N
alone RB N
( ( N
MED NNP N
; : N
n CC N
= $ N
49 CD N
; : N
risperidone NN i
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
; : N
if IN N
ineffective JJ N
, , N
switch VB N
to TO N
aripiprazole VB N
was VBD N
permitted VBN N
) ) N
or CC N
a DT N
combination NN N
of IN N
medication NN N
plus CC N
parent NN N
training NN N
( ( N
PT NNP N
) ) N
( ( N
COMB NNP N
; : N
n CC N
= VB N
75 CD N
) ) N
. . N

They PRP N
were VBD N
subjected VBN N
to TO N
the DT N
following JJ N
assessments NNS N
: : N
1 CD N
) ) N
oropharyngeal NN N
class NN N
according VBG N
to TO N
the DT N
modified VBN N
Mallampati NNP N
criteria NNS N
; : N
2 CD N
) ) N
the DT N
new JJ N
, , N
upper JJ N
lip NN N
bite IN N
criteria-class NN N
I PRP N
= VBP N
lower JJR N
incisors NNS N
can MD N
bite VB N
the DT N
upper JJ N
lip NN N
above IN N
the DT N
vermilion NN N
line NN N
, , N
class NN N
II NNP N
= NNP N
lower JJR N
incisors NNS N
can MD N
bite VB N
the DT N
upper JJ N
lip NN N
below IN N
the DT N
vermilion NN N
line NN N
, , N
and CC N
class NN N
III NNP N
= NNP N
lower JJR N
incisors NNS N
can MD N
not RB N
bite VB N
the DT N
upper JJ N
lip NN N
; : N
and CC N
3 CD N
) ) N
laryngeal NN N
view NN N
grading VBG N
according VBG N
to TO N
Cormack NNP N
's POS N
criteria NNS N
. . N

The DT N
method NN N
used VBN N
in IN N
our PRP$ N
study NN N
can MD N
be VB N
generalized VBN N
to TO N
other JJ N
conditions NNS N
and CC N
, , N
thus RB N
, , N
could MD N
be VB N
helpful JJ N
in IN N
3 CD N
ways NNS N
: : N
( ( N
1 CD N
) ) N
from IN N
a DT N
clinical JJ N
decision-making NN N
perspective NN N
, , N
it PRP N
could MD N
facilitate VB N
patient-physician JJ N
communication NN N
; : N
( ( N
2 CD N
) ) N
it PRP N
could MD N
clarify VB N
the DT N
patient NN N
perspective NN N
when WRB N
interpreting VBG N
the DT N
results NNS N
of IN N
previously RB N
completed VBN N
trials NNS N
; : N
and CC N
( ( N
3 CD N
) ) N
it PRP N
could MD N
be VB N
used VBN N
to TO N
derive VB N
more RBR N
clinically RB N
relevant JJ N
sample NN N
sizes NNS N
for IN N
randomized JJ N
treatment NN N
trials NNS N
. . N

There EX N
was VBD N
also RB N
a DT N
significantly RB N
greater JJR N
decrease NN o
in IN N
the DT N
clinical JJ N
symptom NN N
score NN N
from IN N
Visit NNP N
1 CD N
to TO N
Visit VB N
2 CD N
in IN N
the DT N
PN+Dx NNP N
group NN N
in IN N
patients NNS p
who WP N
had VBD N
at IN N
least JJS N
a DT N
moderately RB N
severe JJ N
symptom NN N
score NN N
with IN N
more JJR N
than IN N
seven CD N
points NNS N
at IN N
Visit NNP N
1 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
and CC N
in IN N
patients NNS p
suffering VBG N
from IN N
their PRP$ N
current JJ N
episode NN N
of IN N
otitis NN N
externa NN N
for IN N
more JJR N
than IN N
2 CD N
days NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

METHODS NNP N
STEMI NNP N
patients NNS p
undergoing VBG N
emergency NN N
PCI NNP N
in IN N
affiliated JJ N
hospital NN N
of IN N
Beihua NNP N
University NNP N
between IN N
October NNP N
2006 CD N
and CC N
January NNP N
2009 CD N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
34 CD N
) ) N
without IN N
any DT N
intervention NN N
after IN N
PTCA NNP N
, , N
and CC N
the DT N
postconditioning NN N
group NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
with IN N
ischemia NN N
postconditioning VBG N
within IN N
first JJ N
minutes NNS N
of IN N
reflow NN N
by IN N
3 CD N
episodes NNS N
of IN N
30-second JJ N
inflation NN N
and CC N
30-second JJ N
deflation NN N
with IN N
the DT N
angioplasty JJ N
balloon NN N
. . N

Whilst IN N
the DT N
Triple NNP N
P NNP N
Positive NNP N
Parenting NNP N
Program NNP N
has VBZ N
a DT N
large JJ N
evidence NN N
base NN N
( ( N
Sanders NNP N
, , N
Clinical NNP N
Child NNP N
and CC N
Family NNP N
Psychology NNP N
Review NNP N
2:71-90 CD N
, , N
1999 CD N
; : N
Sanders NNP N
, , N
Journal NNP N
of IN N
Consulting NNP N
and CC N
Clinical NNP N
Psychology NNP N
68:624-640 CD N
, , N
2000 CD N
) ) N
and CC N
preliminary JJ N
evidence NN N
indicates VBZ N
that IN N
Stepping VBG N
Stones NNP N
Triple NNP N
P NNP N
is VBZ N
also RB N
efficacious JJ N
( ( N
Roberts NNP N
, , N
Journal NNP N
of IN N
Clinical NNP N
Child NNP N
and CC N
Adolescent NNP N
Psychology NNP N
, , N
35 CD N
( ( N
2 CD N
) ) N
:180-193 NN N
, , N
2006 CD N
) ) N
, , N
to TO N
date NN N
Stepping NNP N
Stones NNP N
has VBZ N
not RB N
been VBN N
evaluated VBN N
with IN N
the DT N
ASD NNP N
population NN N
. . N

METHODS NNP N
Males NNP N
and CC N
females NNS N
, , N
ages VBZ N
14 CD N
to TO N
25 CD N
years NNS N
, , N
with IN N
a DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
Text NNP N
Revision NNP N
diagnosis NN N
of IN N
an DT N
ASD NNP N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
10-week JJ N
trial NN N
consisting NN N
of IN N
8 CD N
weeks NNS N
of IN N
active JJ N
drug NN N
with IN N
either DT N
weekly JJ N
or CC N
daily JJ N
administration NN N
of IN N
50 CD N
mg NN N
of IN N
DCS NNP N
followed VBN N
by IN N
a DT N
2-week JJ N
follow-up JJ N
visit NN N
. . N

Participants NNS N
in IN N
the DT N
Age-Related JJ N
Eye NNP N
Disease NNP N
Study NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
daily JJ N
antioxidants NNS N
( ( N
vitamin JJ N
C NNP N
, , N
500 CD N
mg NN N
; : N
vitamin CC N
E NNP N
, , N
400 CD N
IU NNP N
; : N
beta NN N
carotene NN N
, , N
15 CD N
mg NN N
) ) N
, , N
zinc NN N
and CC N
copper NN N
( ( N
zinc NN N
, , N
80 CD N
mg NN N
; : N
cupric JJ N
oxide NN N
, , N
2 CD N
mg NN N
) ) N
, , N
antioxidants NNS N
plus CC N
zinc NN N
and CC N
copper NN N
, , N
or CC N
placebo NN N
. . N

METHOD NNP N
30 CD N
individuals NNS N
( ( N
BMI NNP N
? . N
28 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
i NN N
) ) N
The DT N
combination NN N
of IN N
a DT N
standardized JJ N
lifestyle NN N
modification NN N
( ( N
LM NNP N
) ) N
program NN N
for IN N
individuals NNS N
with IN N
SMI NNP N
and CC N
payment NN N
for IN N
group NN N
attendance NN N
( ( N
CM NNP N
( ( N
attendance NN N
) ) N
) ) N
, , N
ii NN N
) ) N
The DT N
combination NN N
of IN N
LM NNP N
and CC N
payment NN N
for IN N
weight JJ N
loss NN N
( ( N
CM NNP N
( ( N
weight NN N
) ) N
) ) N
, , N
and CC N
iii NN N
) ) N
waitlist NN N
control NN N
( ( N
CON NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
safety NN N
and CC N
cost NN N
of IN N
Seretide NNP N
( ( N
salmeterol/fluticasone NN N
propionate NN N
( ( N
Salm/FP NNP N
) ) N
, , N
50/250 CD N
microg NN N
bd NN N
) ) N
via IN N
Diskus NNP N
with IN N
formoterol NN N
( ( N
Form NNP N
; : N
12 CD N
microg NN N
bd NN N
) ) N
and CC N
budesonide NN N
( ( N
Bud NNP N
; : N
800 CD N
microg NN N
bd NN N
) ) N
given VBN N
concurrently RB N
( ( N
Form+Bud NNP N
) ) N
via IN N
Turbuhaler NNP N
in IN N
patients NNS p
with IN N
moderate-to-severe JJ N
asthma NNS N
who WP N
were VBD N
uncontrolled VBN N
on IN N
existing VBG N
corticosteroid JJ N
therapy NN i
. . N

In IN N
this DT N
prospective JJ N
study NN N
, , N
14 CD N
patients NNS p
with IN N
colonic JJ N
cancer NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
a DT N
6-hour JJ N
stable JJ N
isotope NN N
infusion NN N
study NN N
( ( N
3 CD N
hours NNS N
of IN N
fasting VBG N
followed VBN N
by IN N
3-hour JJ N
infusions NNS N
of IN N
amino NN N
acids NNS N
, , N
Travasol NNP N
[ NNP N
Baxter NNP N
, , N
Montreal NNP N
, , N
Canada NNP N
] VBD N
10 CD N
% NN N
at IN N
0.02 CD N
mL.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
, , N
with IN N
or CC N
without IN N
glucose JJ N
at IN N
4 CD N
mg.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
) ) N
on IN N
the DT N
second JJ N
day NN N
after IN N
colorectal JJ N
surgery NN N
. . N

Also RB N
, , N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
late JJ N
gastrointestinal NN N
and CC N
genitourinary JJ N
toxicity NN N
between IN N
the DT N
two CD N
treatment NN N
schedules NNS N
, , N
with IN N
a DT N
3-year JJ N
rate NN N
of IN N
Grade NNP N
2 CD N
or CC N
greater JJR N
toxicity NN N
of IN N
17 CD N
% NN N
and CC N
16 CD N
% NN N
for IN N
the DT N
hypofractionation NN N
arm NN N
and CC N
14 CD N
% NN N
and CC N
11 CD N
% NN N
for IN N
the DT N
conventional JJ N
fractionation NN N
arm NN N
, , N
respectively RB N
. . N

Treatment NN N
groups NNS N
received VBD N
either RB N
topical JJ N
ofloxacin NN i
or CC N
topical JJ N
ciprofloxacin NN i
( ( N
instillation NN N
of IN N
0.3 CD N
% NN N
ophthalmic JJ N
solution NN N
every DT N
30 CD N
minutes NNS N
for IN N
4 CD N
hours NNS N
before IN N
surgery NN N
) ) N
, , N
or CC N
a DT N
combined JJ N
topical JJ N
plus CC N
oral JJ N
regimen NNS N
( ( N
ciprofloxacin JJ i
hydrochloride NN N
, , N
four CD N
100-mg JJ N
tablets NNS N
, , N
or CC N
ofloxacin RB i
, , N
one CD N
400-mg JJ N
tablet NN N
, , N
administered VBN N
24-26 JJ N
, , N
12-14 JJ N
, , N
and CC N
2 CD N
hours NNS N
preceding VBG N
surgery NN N
) ) N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
cross-over NN N
study NN N
in IN N
10 CD N
healthy JJ N
females NNS N
( ( N
age NN N
range NN N
22-36 CD N
years NNS N
, , N
mean JJ N
29.1 CD N
+/- JJ N
5.4 CD N
) ) N
who WP N
were VBD N
hospitalized VBN N
and CC N
challenged VBN N
on IN N
two CD N
consecutive JJ N
days NNS N
with IN N
placebo NN N
( ( N
peppermint JJ N
tea NN N
) ) N
or CC N
75 CD N
mg NN N
of IN N
pure JJ N
histamine NN N
( ( N
equaling VBG N
124 CD N
mg JJ N
histamine NN N
dihydrochloride NN N
, , N
dissolved VBN N
in IN N
peppermint NN N
tea NN N
) ) N
. . N

METHOD NNP N
Twenty-four CD N
children NNS N
( ( N
aged VBN N
5-17 CD N
years NNS N
) ) N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
and CC N
co-morbid JJ N
disruptive JJ N
behavior NN N
who WP N
responded VBD N
favorably RB N
to TO N
open-label JJ N
treatment NN N
with IN N
risperidone NN i
as IN N
part NN N
of IN N
a DT N
previously RB N
described VBN N
controlled VBN N
discontinuation NN N
study NN N
completed VBD N
two CD N
different JJ N
computerized JJ N
attention NN N
tasks NNS N
at IN N
baseline NN N
, , N
weeks NNS N
4 CD N
, , N
8 CD N
, , N
and CC N
24 CD N
of IN N
open-label JJ N
treatment NN N
, , N
and CC N
, , N
at IN N
8 CD N
weeks NNS N
after IN N
random JJ N
assignment NN N
to TO N
either DT N
placebo NN N
or CC N
risperidone NN i
. . N

Ten CD N
monozygotic JJ i
twin NN N
pairs NNS N
of IN N
pregnant JJ N
cows NNS N
( ( N
five CD N
pairs NNS N
of IN N
parity NN N
1 CD N
or CC N
2 CD N
, , N
and CC N
five CD N
pairs NNS N
of IN N
parity NN N
3 CD N
or CC N
more JJR N
) ) N
were VBD N
allocated VBN N
to TO N
two CD N
diets NNS N
which WDT N
were VBD N
formulated VBN N
to TO N
provide VB N
either RB N
-4 JJ N
meq NN N
( ( N
anion NN N
diet NN N
) ) N
or CC N
+572.5 JJ N
meq NN N
( ( N
cation NN N
diet NN N
) ) N
of IN N
[ NN N
( ( N
Na+ NNP N
+ NNP N
K+ NNP N
) ) N
- : N
( ( N
Cl- JJ N
+ NNP N
SO4= NNP N
) ) N
] VBD N
kg-1 JJ N
dietary JJ N
dry JJ N
matter NN N
( ( N
DM NNP N
) ) N
. . N

Azithromycin NNP i
was VBD N
widely RB N
distributed VBN N
within IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
; : N
sustained VBN N
concentrations NNS N
of IN N
the DT N
drug NN N
were VBD N
detectable JJ N
at IN N
the DT N
last JJ N
sampling JJ N
time NN N
( ( N
204 CD N
h NN N
) ) N
in IN N
lung NN N
tissue NN N
and CC N
bronchial JJ N
washing NN N
, , N
with IN N
long JJ N
terminal JJ N
half-lives NNS N
of IN N
132.86 CD N
and CC N
74.32 CD N
h NN N
at IN N
500 CD N
mg JJ N
daily JJ N
and CC N
133.32 CD N
and CC N
70.5 CD N
h NN N
at IN N
1000 CD N
mg JJ N
daily RB N
, , N
respectively RB N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
cardiorespiratory JJ N
effects NNS N
of IN N
IV NNP N
administration NN N
of IN N
propofol NN N
( ( N
4 CD N
mg/kg NN N
) ) N
, , N
ketamine JJ N
hydrochloride NN N
and CC N
propofol NN N
( ( N
2 CD N
mg/kg RB N
each DT N
; : N
K-P NNP N
) ) N
, , N
or CC N
ketamine VB N
hydrochloride NN N
( ( N
5 CD N
mg/kg NN N
) ) N
and CC N
diazepam NN i
( ( N
0.2 CD N
mg/kg NN N
; : N
K-D NNP N
) ) N
before IN N
and CC N
after IN N
induction NN N
of IN N
anesthesia NN N
( ( N
IoA NNP N
) ) N
in IN N
dogs NNS N
sedated VBN N
with IN N
acepromazine JJ N
maleate NN N
and CC N
oxymorphone NN N
hydrochloride NN N
. . N

Patients NNS N
were VBD N
selected VBN N
on IN N
the DT N
basis NN N
of IN N
: : N
a DT N
) ) N
occurrence NN N
in IN N
the DT N
last JJ N
4 CD N
weeks NNS N
of IN N
at IN N
least JJS N
5/10 CD N
selected VBN N
symptoms NNS N
( ( N
anorexia NN N
, , N
nausea NN N
, , N
vomiting VBG N
, , N
upper JJ N
abdominal JJ N
pain NN N
, , N
postprandial JJ N
bloating NN N
, , N
abdominal JJ N
fullness NN N
, , N
early JJ N
satiety NN N
, , N
belching NN N
, , N
heartburn NN N
, , N
regurgitation NN N
) ) N
, , N
severity NN N
of IN N
which WDT N
should MD N
reach/exceed VB N
a DT N
total JJ N
score NN N
of IN N
8 CD N
, , N
as IN N
assessed VBN N
by IN N
a DT N
specific JJ N
scale NN N
ranging VBG N
from IN N
0 CD N
( ( N
absent NN N
) ) N
to TO N
3 CD N
( ( N
severe JJ N
) ) N
; : N
b VBN N
) ) N
normal JJ N
results NNS N
of IN N
routine JJ N
biochemical NN N
, , N
ultrasound NN N
and CC N
endoscopic JJ N
examinations NNS N
. . N

CONCLUSION NNP N
Since IN N
the DT N
90 CD N
% NN N
CI NNP N
for IN N
AUC NNP N
( ( N
last JJ N
) ) N
and CC N
C NNP N
( ( N
max NN i
) ) N
ratios NNS N
were VBD N
within IN N
the DT N
80-125 JJ N
% NN N
interval NN N
proposed VBN N
by IN N
the DT N
US NNP N
FDA NNP N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
pantoprazole JJ N
40 CD N
mg NN N
DR NNP N
tablet NN N
( ( N
test JJS N
formulation NN N
) ) N
with IN N
and CC N
without IN N
food NN N
was VBD N
bioequivalent NN N
to TO N
the DT N
reference NN N
40 CD N
mg NN N
DR NNP N
tablet NN N
for IN N
both DT N
the DT N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
. . N

Coprimary JJ N
endpoints NNS N
were VBD N
MRI-assessed JJ N
indices NNS N
( ( N
total JJ N
vessel NN N
area NN N
, , N
wall JJ N
area NN N
, , N
wall NN N
thickness NN N
, , N
and CC N
normalised VBD N
wall NN N
index NN N
[ JJ N
average JJ N
carotid NN N
] NN N
) ) N
after IN N
24 CD N
months NNS N
and CC N
( ( N
18 CD N
) ) N
F-fluorodeoxyglucose NNP N
( ( N
( ( N
18 CD N
) ) N
F-FDG NN N
) ) N
PET/CT NNP N
assessment NN N
of IN N
arterial JJ N
inflammation NN N
within IN N
an DT N
index NN N
vessel NN N
( ( N
right JJ N
carotid NN N
, , N
left VBD N
carotid NN N
, , N
or CC N
ascending VBG N
thoracic JJ N
aorta NN N
) ) N
after IN N
6 CD N
months NNS N
, , N
with IN N
no-harm JJ N
boundaries NNS N
established VBN N
before IN N
unblinding NN N
of IN N
the DT N
trial NN N
. . N

During IN N
ad NN N
libitum NN N
food NN N
intake NN N
, , N
after IN N
4 CD N
days NNS N
of IN N
METH NNP N
( ( N
40 CD N
mg/day NN N
) ) N
or CC N
PLAC NNP N
oral JJ N
therapy NN i
, , N
both DT N
groups NNS N
increased VBD o
their PRP$ o
energy NN N
intake NN N
over IN N
weight JJ N
maintenance NN N
, , N
but CC N
the DT N
increase NN o
was VBD N
significantly RB N
larger JJR N
in IN N
the DT N
METH NNP N
group NN N
compared VBN N
with IN N
the DT N
PLAC NNP N
group NN N
( ( N
4,554 CD N
+/- JJ N
1,857 CD N
vs. FW N
2,867 CD N
+/- JJ N
846 CD N
kcal/day NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
treatments NNS N
consisted VBN N
of IN N
( ( N
1 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ N
triazolam NN i
tablet NN N
after IN N
treatment NN N
with IN N
ranitidine NN N
; : N
( ( N
2 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ N
triazolam NN i
tablet NN N
, , N
with IN N
no DT N
ranitidine JJ N
pretreatment NN N
; : N
( ( N
3 CD N
) ) N
a DT N
0.25-mg JJ N
intravenous JJ N
dose NN N
of IN N
triazolam NN i
after IN N
treatment NN N
with IN N
ranitidine NN N
; : N
and CC N
( ( N
4 CD N
) ) N
a DT N
0.25-mg JJ N
intravenous JJ N
dose NN N
of IN N
triazolam NN i
, , N
with IN N
no DT N
ranitidine NN N
pretreatment NN N
. . N

METHODS NNP N
A NNP N
prospectively RB N
planned VBD N
, , N
combined VBN N
, , N
overall JJ i
survival NN N
analysis NN N
was VBD N
performed VBN N
, , N
including VBG N
data NNS N
from IN N
two CD N
Phase NNP N
III NNP N
trials NNS N
that WDT N
compared VBN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
fulvestrant NN N
( ( N
250 CD N
mg NN N
monthly RB N
; : N
n CC N
= VB N
428 CD N
) ) N
with IN N
anastrozole NN N
( ( N
1 CD N
mg NNS N
daily RB N
; : N
n CC N
= VB N
423 CD N
) ) N
in IN N
the DT N
treatment NN N
of IN N
postmenopausal JJ N
women NNS N
with IN N
advanced JJ N
breast NN N
carcinoma NN N
who WP N
had VBD N
disease NN N
progression NN N
after IN N
receipt NN N
of IN N
previous JJ N
endocrine NN N
treatment NN N
. . N

METHODS NNP N
Of IN N
813 CD N
patients NNS p
with IN N
previously RB N
untreated VBN N
metastatic JJ N
colorectal NN N
cancer NN N
, , N
we PRP N
randomly VBP N
assigned VBD N
402 CD N
to TO N
receive VB N
irinotecan JJ N
, , N
bolus JJ N
fluorouracil NN N
, , N
and CC N
leucovorin NN N
( ( N
IFL NNP N
) ) N
plus CC N
bevacizumab NN i
( ( N
5 CD N
mg NN N
per IN N
kilogram NN N
of IN N
body NN N
weight JJ N
every DT N
two CD N
weeks NNS N
) ) N
and CC N
411 CD N
to TO N
receive VB N
IFL NNP N
plus CC N
placebo NN N
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
combination NN N
of IN N
ZDV NNP N
200 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
ddC VB N
0.75 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
and CC N
SH NNP N
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
or CC N
a DT N
combination NN N
of IN N
ZDV NNP N
200 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
ddC VB N
0.75 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
and CC N
placebo VBZ N
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
for IN N
24 CD N
weeks NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
improvement NN N
of IN N
the DT N
clinical JJ N
WSL-scores NNS N
was VBD N
found VBN N
over IN N
time NN N
in IN N
both DT N
groups NNS N
, , N
but CC N
there RB N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
concerning VBG N
the DT N
number NN N
of IN N
sites NNS N
that WDT N
totally RB N
disappeared VBD N
after IN N
12 CD N
months NNS N
in IN N
favour NN N
of IN N
the DT N
CPP-ACP NNP N
regime NN N
, , N
63 CD N
% NN N
compared VBN N
with IN N
25 CD N
% NN N
respectively RB N
. . N

RESULTS JJ N
Thirty-seven JJ N
patients NNS p
consented VBN N
to TO N
participate VB N
in IN N
the DT N
study NN N
( ( N
54 CD N
% NN N
male NN N
; : N
mean JJ N
age NN N
58.7 CD N
? . N
9.5 CD N
years NNS N
; : N
median JJ N
body NN N
mass NN N
index NN N
26.8 CD N
kg NN N
m NN N
( ( N
-2 NNP N
) ) N
, , N
range VBP N
16.4-47.6 JJ N
kg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
; : N
33 CD N
patients NNS p
completed VBD N
the DT N
study NN N
and CC N
28 CD N
patients NNS p
returned VBD N
the DT N
questionnaire NN N
( ( N
response NN N
rate NN N
= VBD N
85 CD N
% NN N
) ) N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
supplemental JJ N
oral JJ N
vitamin NN N
D NNP N
( ( N
placebo NN N
, , N
1,000 CD N
, , N
2,000 CD N
, , N
or CC N
4,000 CD N
IU/day NN N
of IN N
vitamin NN N
D3 NNP N
orally RB N
for IN N
3 CD N
months NNS N
) ) N
in IN N
328 CD N
African JJ N
Americans NNPS N
( ( N
median JJ N
age NN N
, , N
51 CD N
years NNS N
) ) N
of IN N
public JJ N
housing NN N
communities NNS N
in IN N
Boston NNP N
, , N
MA NNP N
, , N
who WP N
were VBD N
enrolled VBN N
over RP N
three CD N
consecutive JJ N
winter NN N
periods NNS N
( ( N
2007-2010 JJ N
) ) N
. . N

A DT N
Japanese JJ N
version NN N
of IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
( ( N
AQ NNP N
) ) N
, , N
AQ-J NNP N
was VBD N
administered VBN N
to TO N
25 CD N
normally RB N
intelligent JJ N
high-functioning JJ N
pervasive JJ N
developmental NN N
disorder NN N
( ( N
HPDD NNP N
) ) N
patients NNS p
( ( N
mean JJ N
age NN N
, , N
24.2 CD N
years NNS N
; : N
24 CD N
male NN N
, , N
one CD N
female NN N
) ) N
and CC N
215 CD N
controls NNS N
( ( N
mean JJ N
age NN N
, , N
30.4 CD N
years NNS N
; : N
86 CD N
male NN N
, , N
129 CD N
female NN N
) ) N
randomly RB N
selected VBN N
from IN N
the DT N
general JJ N
population NN N
. . N

Sixty-eight JJ N
patients NNS p
( ( N
44 CD N
men NNS N
and CC N
24 CD N
women NNS N
) ) N
with IN N
a DT N
mean JJ N
age NN N
of IN N
44.3 CD N
( ( N
1.2 CD N
) ) N
yr NN N
and CC N
verified VBD N
GH NNP N
deficiency NN N
participated VBD N
in IN N
a DT N
2-phase JJ N
treatment NN N
trial NN N
with IN N
an DT N
initial JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
6-month JJ N
period NN N
, , N
followed VBN N
by IN N
an DT N
open JJ N
treatment NN N
period NN N
, , N
thereby RB N
ensuring VBG N
all DT N
patients NNS p
12 CD N
months NNS N
of IN N
GH NNP N
treatment NN N
. . N

Between JJ N
1977 CD N
and CC N
1983 CD N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
( ( N
SWOG NNP N
) ) N
evaluated VBD N
chemotherapy NN i
alone RB N
( ( N
cyclophosphamide JJ N
, , N
doxorubicin NN i
, , N
vincristine NN N
, , N
prednisone NN N
; : N
CHOP NNP N
) ) N
or CC N
chemoimmunotherapy NN i
( ( N
CHOP-levamisole JJ N
or CC N
CHOP-levamisole-BCG JJ N
) ) N
in IN N
a DT N
randomized JJ N
prospective JJ N
clinical JJ N
trial NN N
involving VBG N
715 CD N
eligible JJ N
patients NNS p
with IN N
all DT N
types NNS N
of IN N
malignant JJ N
lymphoma NN N
( ( N
ML NNP N
) ) N
. . N

The DT N
cumulative JJ N
proportions NNS N
of IN N
the DT N
children NNS N
with IN N
complete JJ N
resolution NN N
of IN N
their PRP$ N
enlarged JJ N
livers NNS N
at IN N
48 CD N
, , N
96 CD N
, , N
168 CD N
or CC N
336 CD N
and CC N
504 CD N
h NN N
after IN N
commencement NN N
of IN N
treatment NN N
were VBD N
significantly RB N
higher JJR N
in IN N
those DT N
treated VBN N
with IN N
CQ NNP N
plus CC N
chlorpheniramine NN N
( ( N
CQCP NNP N
) ) N
than IN N
in IN N
the DT N
other JJ N
two CD N
treatment NN N
groups NNS N
( ( N
with IN N
P-values NNP N
of IN N
0.02 CD N
, , N
0.001 CD N
, , N
0.00000 CD N
and CC N
0.00002 CD N
, , N
respectively RB N
) ) N
. . N

METHODS NNP N
Patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
, , N
mild-to-moderate JJ N
hypertension NN N
( ( N
diastolic JJ N
blood NN N
pressure NN N
85-105 JJ N
mmHg NN N
, , N
systolic JJ N
blood NN N
pressure NN N
< VBZ N
160 CD N
mmHg NN N
, , N
and CC N
24-hour JJ N
mean JJ N
systolic JJ N
blood NN N
pressure NN N
> VBZ N
130 CD N
mmHg NN N
) ) N
, , N
and CC N
microalbuminuria NNS N
were VBD N
randomized VBN N
to TO N
1 CD N
year NN N
of IN N
doubleblind NN N
treatment NN N
with IN N
fixed-dose JJ N
manidipine/delapril NN N
( ( N
n=54 JJ N
) ) N
or CC N
losartan/hydrochlorothiazide JJ i
( ( N
HCTZ NNP N
) ) N
( ( N
n=56 JJ N
) ) N
. . N

RESULTS NNP N
Among IN N
patients NNS p
not RB N
taking VBG N
vitamin RP N
A DT N
prior JJ N
to TO N
entry NN N
, , N
those DT N
in IN N
the DT N
DHA NNP N
+ NNP N
A NNP N
group NN N
had VBD N
a DT N
slower JJR N
decline NN N
in IN N
field NN N
sensitivity NN N
and CC N
electroretinogram NN N
amplitude NN N
than IN N
those DT N
in IN N
the DT N
control NN N
+ VBZ N
A NNP N
group NN N
over IN N
the DT N
first JJ N
2 CD N
years NNS N
( ( N
P NNP N
=.01 NNP N
and CC N
P NNP N
=.03 NNP N
, , N
respectively RB N
) ) N
; : N
these DT N
differences NNS N
were VBD N
not RB N
observed VBN N
in IN N
years NNS N
3 CD N
and CC N
4 CD N
of IN N
follow-up JJ N
or CC N
among IN N
patients NNS p
taking VBG N
vitamin NN N
A NNP N
prior RB N
to TO N
entry NN N
. . N

In IN N
this DT N
study NN N
we PRP N
examined VBD N
the DT N
social JJ N
behaviors NNS N
of IN N
4- JJ N
to TO N
12-year-old JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
; : N
N NNP N
= NNP N
24 CD N
) ) N
during IN N
three CD N
tradic JJ N
interactions NNS N
with IN N
an DT N
adult NN N
confederate NN N
and CC N
an DT N
interaction NN N
partner NN N
, , N
where WRB N
the DT N
interaction NN N
partner NN N
varied VBD N
randomly RB N
among IN N
( ( N
1 CD N
) ) N
another DT N
adult NN N
human NN N
, , N
( ( N
2 CD N
) ) N
a DT N
touchscreen JJ N
computer NN N
game NN N
, , N
and CC N
( ( N
3 CD N
) ) N
a DT N
social JJ N
dinosaur NN N
robot NN N
. . N

Regardless RB N
of IN N
the DT N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
the DT N
total JJ N
yield NN N
of IN N
CD34 NNP N
( ( N
+ NNP N
) ) N
cells NNS N
from IN N
apheresis NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
plerixafor NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
significantly RB N
more JJR N
patients NNS p
in IN N
the DT N
plerixafor NN N
group NN N
collected VBD N
the DT N
minimum NN N
( ( N
? . N
? . N
10 CD N
( ( N
6 CD N
) ) N
cells/kg NN N
) ) N
and CC N
optimum JJ N
( ( N
? . N
? . N
10 CD N
( ( N
6 CD N
) ) N
cells/kg NN N
) ) N
stem NN N
cell NN N
yields NNS N
on IN N
each DT N
day NN N
of IN N
apheresis NN N
. . N

Methods NNS N
Patients NNS N
randomized VBD N
to TO N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ N
acid NN N
5 CD N
mg NN N
or CC N
risedronate NN N
( ( N
5 CD N
mg/day NN N
) ) N
and CC N
stratified VBN N
based VBN N
on IN N
glucocorticoids NNS N
duration NN N
[ FW N
treatment NN N
( ( N
> JJ N
3 CD N
months NNS N
) ) N
and CC N
prevention NN N
( ( N
? . N
3 CD N
months NNS N
) ) N
subpopulations NNS N
] VBP N
were VBD N
subgrouped VBN N
by IN N
age NN N
; : N
gender NN N
; : N
menopausal NN N
status NN N
in IN N
women NNS N
; : N
dose VB N
and CC N
duration NN N
of IN N
prednisone NN N
during IN N
the DT N
trial NN N
; : N
and CC N
baseline VB N
serum JJ N
25-OH JJ N
vitamin NN N
D NNP N
, , N
LS NNP N
BMD NNP N
T-score NNP N
, , N
creatinine JJ N
clearance NN N
, , N
and CC N
concomitant JJ N
medication NN N
use NN N
. . N

HRs NNP N
( ( N
three-class JJ N
vs NN N
combined VBN N
two-class NN N
) ) N
for IN N
AIDS NNP N
or CC N
death NN N
were VBD N
similar JJ N
for IN N
participants NNS N
with IN N
baseline NN N
CD4 NNP N
cell NN N
counts NNS N
of IN N
200 CD N
cells NNS N
per IN N
mm3 NN N
or CC N
less JJR N
and CC N
of IN N
more JJR N
than IN N
200 CD N
cells NNS N
per IN N
mm3 NN N
( ( N
p=0.38 NN N
for IN N
interaction NN N
) ) N
, , N
and CC N
for IN N
participants NNS N
with IN N
baseline NN N
HIV NNP N
RNA NNP N
concentrations NNS N
less JJR N
than IN N
100 CD N
000 CD N
copies NNS N
per IN N
mL NN N
and CC N
100,000 CD N
copies NNS N
per IN N
mL NN N
or CC N
more JJR N
( ( N
p=0.26 NN N
for IN N
interaction NN N
) ) N
. . N

United NNP N
States NNPS N
children NNS N
two CD N
months NNS N
of IN N
age NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
that WDT N
received VBD N
either RB N
the DT N
commercially RB N
available JJ N
oral JJ N
trivalent NN N
poliovirus NN N
vaccine NN N
( ( N
OPV NNP N
) ) N
or CC N
an DT N
injectable JJ N
( ( N
inactivated VBN N
) ) N
trivalent NN N
poliovirus NN N
vaccine NN N
( ( N
IPV NNP N
) ) N
with IN N
a DT N
confirmed JJ N
minimum JJ N
D-antigen NNP N
content NN N
of IN N
27 CD N
, , N
3.5 CD N
, , N
and CC N
29 CD N
units NNS N
for IN N
poliovirus NN N
types NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
respectively RB N
. . N

METHODS NNP N
We PRP N
prospectively RB N
evaluated VBD N
the DT N
association NN N
between IN N
baseline NN N
BMI NNP N
and CC N
the DT N
risk NN N
of IN N
incident JJ N
distal JJ N
adenoma NN N
( ( N
1,213 CD N
cases NNS N
) ) N
, , N
recurrent JJ N
adenoma NN N
( ( N
752 CD N
cases NNS N
) ) N
, , N
and CC N
incident JJ N
colorectal NN N
cancer NN N
( ( N
966 CD N
cases NNS N
) ) N
among IN N
men NNS N
and CC N
women NNS N
, , N
ages VBZ N
55 CD N
to TO N
74 CD N
years NNS N
, , N
randomly RB N
assigned VBN N
to TO N
receive VB N
flexible JJ N
sigmoidoscopy NN N
screening NN N
as IN N
part NN N
of IN N
the DT N
Prostate NNP N
, , N
Lung NNP N
, , N
Colorectal NNP N
, , N
and CC N
Ovarian JJ N
Cancer NNP N
Screening NNP N
Trial NNP N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
FEV NNP N
( ( N
1 CD N
) ) N
values NNS N
were VBD N
observed VBN N
between IN N
group NN N
A NNP N
( ( N
P=0.704 NNP N
) ) N
or CC N
group NN N
B NNP N
( ( N
P=0.270 NNP N
) ) N
at IN N
baseline NN N
, , N
or CC N
at IN N
5 CD N
( ( N
Group NNP N
A NNP N
: : N
P=0.340 NNP N
; : N
Group NNP N
B NNP N
: : N
P=0.559 NN N
) ) N
and CC N
15 CD N
min NN N
( ( N
Group NNP N
A NNP N
: : N
P=0.526 NNP N
; : N
Group NNP N
B NNP N
: : N
P=0.818 NNP N
) ) N
post NN N
dose NN N
. . N

49 CD N
patients NNS p
( ( N
22 CD N
women NNS N
, , N
27 CD N
men NNS N
, , N
mean JJ N
age NN N
43.7 CD N
[ JJ N
21-65 JJ N
] NNP N
years NNS N
) ) N
with IN N
Hodgkin NNP N
's POS N
disease NN N
were VBD N
examined VBN N
by IN N
Doppler NNP N
echocardiography NN N
a DT N
median NN N
of IN N
5.37 CD N
( ( N
2-10 JJ N
) ) N
years NNS N
after IN N
the DT N
end NN N
of IN N
chemotherapy NN i
( ( N
given VBN N
according VBG N
to TO N
the DT N
COPP/ABVD NNP N
scheme NN N
, , N
with IN N
or CC N
without IN N
mediastinal JJ N
irradiation NN N
) ) N
for IN N
possible JJ N
chronic JJ N
changes NNS N
in IN N
myocardium NN N
, , N
pericardium NN N
or CC N
cardiac JJ N
valves NNS N
, , N
as RB N
well RB N
as IN N
for IN N
any DT N
haemodynamic JJ N
sequelae NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
ACE NNP N
genotype NN N
and CC N
the DT N
response NN N
to TO N
11weeks CD N
of IN N
resistance NN N
exercise NN N
training NN N
was VBD N
determined VBN N
in IN N
37 CD N
CHF JJ N
patients NNS p
( ( N
New NNP N
York NNP N
Heart NNP N
Association NNP N
Functional NNP N
Class=2.3 NNP N
; : N
left VBD N
ventricular JJ N
ejection NN N
fraction NN N
28 CD N
% NN N
; : N
age NN N
64 CD N
; : N
32:5 CD N
male NN N
: : N
female NN N
) ) N
who WP N
were VBD N
randomised VBN N
to TO N
either DT N
resistance NN N
exercise NN N
( ( N
n=19 JJ N
) ) N
or CC N
inactive JJ N
control NN N
group NN N
( ( N
n=18 RB N
) ) N
. . N

METHODS NNP N
Sixty-eight NNP N
consecutively RB N
recruited VBD N
, , N
premenopausal NN N
, , N
omnivorous JJ N
women NNS N
of IN N
all DT N
races NNS N
and CC N
ethnicities NNS N
between IN N
the DT N
ages NNS N
of IN N
25 CD N
years NNS N
and CC N
55 CD N
years NNS N
were VBD N
admitted VBN N
to TO N
the DT N
study NN N
and CC N
randomized VBN N
to TO N
an DT N
experimental JJ N
group NN N
supplemented VBD N
with IN N
soy NN N
( ( N
40 CD N
mg NN N
genistein NNS N
per IN N
day NN N
) ) N
or CC N
to TO N
a DT N
control NN N
group NN N
that WDT N
consumed VBD N
a DT N
placebo NN N
for IN N
a DT N
12-week JJ N
period NN N
. . N

Minimal JJ N
treatment-related JJ N
adverse JJ N
events NNS N
were VBD N
seen VBN N
at IN N
doses NNS N
up RB N
to TO N
8 CD N
mg. NNS N
Serum NNP N
interferon NN N
( ( N
IFN NNP N
) ) N
- : N
was VBD N
only RB N
detected VBN N
in IN N
subjects NNS N
who WP N
received VBD N
8 CD N
or CC N
12 CD N
mg NN N
doses NNS N
, , N
and CC N
the DT N
adverse JJ N
event NN N
profile NN N
at IN N
8 CD N
and CC N
12 CD N
mg NN N
doses NNS N
was VBD N
generally RB N
consistent JJ N
with IN N
that DT N
associated VBN N
with IN N
IFN- NNP N
exposure NN N
( ( N
flu-like JJ N
symptoms NNS N
) ) N
, , N
consistent JJ N
with IN N
the DT N
mechanism NN N
of IN N
TLR7 NNP N
agonism NN N
. . N

Interestingly RB N
however RB N
, , N
when WRB N
segregated VBN N
on IN N
the DT N
Choi NNP N
criteria NNS N
, , N
cytotoxic NN N
drugs NNS N
alone RB N
showed VBD N
a DT N
non-significant JJ N
trend NN N
in IN N
improved JJ N
survival NN N
( ( N
74 CD N
% NN N
versus IN N
55 CD N
% NN N
, , N
p RB N
0.32 CD N
) ) N
as RB N
well RB N
as IN N
event-free JJ N
survival NN N
( ( N
44 CD N
% NN N
versus IN N
40 CD N
% NN N
, , N
p RB N
0.42 CD N
) ) N
for IN N
the DT N
germinal JJ N
centre NN N
as IN N
opposed VBN N
to TO N
the DT N
activated VBN N
B-cell NNP N
subtype NN N
. . N

In IN N
contrast NN N
, , N
GH-secretagogues NNP N
elevated VBD N
leptin NN i
levels NNS N
within IN N
12 CD N
h. JJ N
Infusion NNP N
of IN N
GHRP-2 NNP N
alone RB N
induced VBD N
a DT N
maximal JJ N
leptin JJ i
increase NN o
of IN N
+87 NNP N
% NN N
after IN N
24 CD N
h NN N
, , N
whereas WP N
GHRH NNP N
+ VBD N
GHRP-2 NNP N
elevated VBD N
leptin NN i
by IN N
up IN N
to TO N
+157 VB N
% NN N
after IN N
24 CD N
h. VBD N
The DT N
increase NN o
in IN N
leptin NN i
within IN N
12 CD N
h NN N
was VBD N
related VBN N
( ( N
R2 NNP N
= NNP N
0.58 CD N
) ) N
to TO N
the DT N
substantial JJ N
rise NN N
in IN N
insulin NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
24-week JJ N
randomized JJ N
trial NN N
compared VBN N
parent NN N
training NN N
( ( N
n JJ N
= NNP N
89 CD N
) ) N
to TO N
parent VB N
education NN N
( ( N
n JJ N
= NNP N
91 CD N
) ) N
at IN N
6 CD N
centers NNS N
( ( N
Emory NNP N
University NNP N
, , N
Indiana NNP N
University NNP N
, , N
Ohio NNP N
State NNP N
University NNP N
, , N
University NNP N
of IN N
Pittsburgh NNP N
, , N
University NNP N
of IN N
Rochester NNP N
, , N
Yale NNP N
University NNP N
) ) N
. . N

OBJECTIVE NN N
To TO N
compare VB N
efficacy NN N
among IN N
1578 CD N
patients NNS p
with IN N
osteoarthritis JJ N
randomized VBN N
to TO N
take VB N
acetaminophen NN i
4000 CD N
mg NN N
( ( N
n=269 JJ N
) ) N
, , N
celecoxib $ N
200 CD N
mg NN N
( ( N
n=523 JJ N
) ) N
, , N
rofecoxib VBZ N
12.5 CD N
mg NN N
( ( N
n=259 JJ N
) ) N
, , N
or CC N
rofecoxib VB N
25 CD N
mg NN N
( ( N
n=527 JJ N
) ) N
in IN N
a DT N
double JJ N
blind NN N
trial NN N
[ NNP N
Vioxx NNP N
, , N
Acetaminophen NNP i
, , N
Celecoxib NNP N
Trial NNP N
( ( N
VACT2 NNP N
) ) N
] NN N
. . N

The DT N
most RBS N
reliable JJ N
combination NN N
of IN N
predictive JJ N
factors NNS N
was VBD N
a DT N
negative JJ N
anti-human JJ N
immunodeficiency NN N
virus NN N
antibody NN N
status NN N
, , N
with IN N
either DT N
a DT N
positive JJ N
history NN N
of IN N
acute JJ N
icteric JJ N
hepatitis NN N
and CC N
AST NNP N
greater JJR N
than IN N
45 CD N
IU NNP N
per IN N
liter NN N
or CC N
no DT N
history NN N
of IN N
acute JJ N
icteric JJ N
hepatitis NN N
and CC N
AST NNP N
greater JJR N
than IN N
85 CD N
IU NNP N
per IN N
liter NN N
, , N
which WDT N
predicted VBD N
response NN N
in IN N
77 CD N
% NN N
with IN N
a DT N
specificity NN N
of IN N
79 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

METHODS NNP N
Heparin NNP N
in IN N
Acute NNP N
Embolic NNP N
Stroke NNP N
Trial NNP N
( ( N
HAEST NNP N
) ) N
was VBD N
a DT N
multicentre NN N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
and CC N
double-dummy JJ N
trial NN N
on IN N
the DT N
effect NN N
of IN N
low-molecular-weight JJ N
heparin NN N
( ( N
LMWH NNP N
, , N
dalteparin VBZ N
100 CD N
IU/kg NNP N
subcutaneously RB N
twice RB N
a DT N
day NN N
) ) N
or CC N
aspirin NN N
( ( N
160 CD N
mg NN N
every DT N
day NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
449 CD N
patients NNS p
with IN N
acute JJ N
ischaemic JJ N
stroke NN N
and CC N
atrial JJ N
fibrillation NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
observer-blinded JJ N
fashion NN N
, , N
40 CD N
ASA NNP N
1 CD N
paediatric JJ N
patients NNS p
undergoing VBG N
subumbilical JJ N
surgery NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
a DT N
caudal JJ N
injection NN N
of IN N
either DT N
plain NN N
ropivacaine VBP N
0.2 CD N
% NN N
( ( N
1 CD N
ml/kg NN N
) ) N
( ( N
R0.2 NNP N
) ) N
or CC N
a DT N
mixture NN N
of IN N
ropivacaine JJ N
0.1 CD N
% NN N
with IN N
clonidine JJ N
2 CD N
microg/kg NN N
( ( N
1 CD N
ml/kg NN N
) ) N
( ( N
R0.1C NNP N
) ) N
. . N

Ten CD N
male JJ N
subjects NNS N
with IN N
untreated JJ N
type NN N
2 CD N
diabetes NNS N
were VBD N
given VBN N
, , N
in IN N
random JJ N
sequence NN N
, , N
50 CD N
g NN N
protein NN N
in IN N
the DT N
form NN N
of IN N
very RB N
lean JJ N
beef NN N
or CC N
only RB N
water NN N
at IN N
0800 CD N
h NN N
and CC N
studied VBN N
over IN N
the DT N
subsequent JJ N
8 CD N
h. NN N
Protein NNP N
ingestion NN N
resulted VBD N
in IN N
an DT N
increase NN o
in IN N
circulating VBG N
insulin NN N
, , N
C-peptide NNP N
, , N
glucagon NN N
, , N
alpha NN N
amino NN N
and CC N
urea JJ N
nitrogen NN N
, , N
and CC N
triglycerides NNS N
; : N
a DT N
decrease NN o
in IN N
nonesterified JJ N
fatty JJ N
acids NNS N
; : N
and CC N
a DT N
modest JJ N
increase NN o
in IN N
respiratory JJ N
quotient NN N
. . N

One CD N
hundred CD N
and CC N
eleven RB N
previously RB N
untreated JJ N
patients NNS p
with IN N
extensive JJ N
small JJ N
cell NN N
lung NN N
cancer NN N
were VBD N
included VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
with IN N
the DT N
aim NN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
tolerance NN N
of IN N
high-dose JJ N
epirubicin NN i
( ( N
120 CD N
mg/m2 NN N
) ) N
in IN N
combination NN N
with IN N
either DT N
cyclophosphamide NN N
( ( N
800 CD N
mg/m2 NN N
; : N
arm CC N
1 CD N
) ) N
or CC N
cisplatin NN i
( ( N
60 CD N
mg/m2 NN N
; : N
arm CC N
2 CD N
) ) N
. . N

Although IN N
the DT N
intensive JJ N
insulin NN N
therapy NN i
group NN N
had VBD N
more RBR N
glucose JJ N
measurements NNS N
performed VBN N
than IN N
the DT N
control NN N
group NN N
, , N
a DT N
similar JJ N
proportion NN N
of IN N
values NNS N
were VBD N
within IN N
the DT N
target NN N
range NN N
( ( N
682 CD N
[ RB N
42.4 CD N
% NN N
] NN N
of IN N
1607 CD N
values NNS N
in IN N
the DT N
5- JJ N
to TO N
7-mmol/L JJ N
range NN N
; : N
250 CD N
[ $ N
38.7 CD N
% NN N
] NN N
of IN N
660 CD N
values NNS N
in IN N
the DT N
8- JJ N
to TO N
10-mmol/L JJ N
range NN N
, , N
P NNP N
= NNP N
.35 NNP N
) ) N
. . N

METHODS NNP N
Twenty NNP N
consecutive JJ N
patients NNS p
who WP N
underwent VBP N
sigmoidectomy NN N
for IN N
sigmoid JJ N
colon NN N
cancer NN N
were VBD N
prospectively RB N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
the DT N
ligatures NNS N
group NN N
, , N
in IN N
which WDT N
bowel NN N
ligatures NNS N
were VBD N
placed VBN N
, , N
3 CD N
, , N
5 CD N
, , N
10 CD N
cm NN N
from IN N
the DT N
tumor NN N
proximally RB N
and CC N
distally RB N
before IN N
dissection NN N
; : N
and CC N
the DT N
no DT N
ligatures NNS N
group NN N
, , N
in IN N
which WDT N
the DT N
corresponding NN N
sites NNS N
were VBD N
ligated VBN N
only RB N
immediately RB N
before IN N
taking VBG N
the DT N
specimen NNS N
out RP N
. . N

Continuous JJ N
chemotherapy NN i
in IN N
responsive JJ N
metastatic JJ N
breast NN N
cancer NN N
: : N
a DT N
role NN N
for IN N
tumour NN N
markers NNS N
? . N
A DT N
biochemical JJ N
response NN N
index NN N
comprising VBG N
ESR NNP N
, , N
CEA NNP N
and CC N
CA NNP N
15.3 CD N
was VBD N
evaluated VBN N
in IN N
67 CD N
patients NNS p
with IN N
systemic JJ N
breast NN N
cancer NN N
treated VBN N
by IN N
chemotherapy NN i
; : N
55 CD N
were VBD N
assessable JJ N
by IN N
UICC NNP N
criteria NNS N
and CC N
the DT N
response NN N
index NN N
( ( N
96 CD N
% NN N
of IN N
all DT N
UICC NNP N
assessable JJ N
patients NNS p
) ) N
. . N

This DT N
prospective JJ N
, , N
6-week JJ N
, , N
multicenter NN N
, , N
double-blind NN N
study NN N
examined VBD N
the DT N
benefits NNS N
of IN N
initiating VBG N
treatment NN N
with IN N
combination NN N
valsartan/hydrochlorothiazide NN i
( ( N
HCTZ NNP N
) ) N
compared VBN N
with IN N
initial JJ N
valsartan NNS N
monotherapy NN i
for IN N
648 CD N
patients NNS p
with IN N
stage-1 JJ N
or CC N
stage-2 JJ N
hypertension NN N
( ( N
age=52.6+/-10 JJ N
years NNS N
; : N
54 CD N
% NN N
male NN N
; : N
baseline VB N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
=161/98 VBP N
mm JJ N
Hg NNP N
, , N
32 CD N
% NN N
stage NN N
1 CD N
) ) N
. . N

This DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
sought VBD N
to TO N
examine VB N
the DT N
short-term JJ N
benefit NN N
of IN N
adding VBG N
60 CD N
mg NN N
of IN N
trimetazidine NN N
to TO N
the DT N
daily JJ N
therapeutic JJ N
regimen NNS N
of IN N
29 CD N
male JJ N
patients NNS p
with IN N
coronary JJ N
insufficiency NN N
who WP N
had VBD N
persistent JJ N
ST NNP N
depression NN N
on IN N
exercise NN N
tolerance NN N
test NN N
( ( N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
1 CD N
mm NN N
) ) N
, , N
despite IN N
treatment NN N
with IN N
nifedipine JJ N
40 CD N
mg JJ N
per IN N
day NN N
. . N

In IN N
this DT N
randomized VBN N
, , N
blinded VBD N
, , N
multicenter FW N
comparison NN N
study NN N
, , N
377 CD N
infants NNS N
and CC N
children NNS N
with IN N
acute NN N
otitis NN N
media NNS N
( ( N
AOM NNP N
) ) N
received VBD N
a DT N
10-day JJ N
course NN N
of IN N
an DT N
oral JJ N
suspension NN N
of IN N
one CD N
of IN N
the DT N
following NN N
: : N
cefuroxime NN N
axetil NN N
( ( N
CAE NNP N
) ) N
, , N
30 CD N
mg/kg/day NN N
; : N
cefaclor NN N
( ( N
CEC NNP N
) ) N
, , N
40 CD N
mg/kg/day NN N
; : N
or CC N
amoxicillin-clavulanate JJ N
potassium NN N
( ( N
AMX-CL NNP N
) ) N
, , N
40 CD N
mg/kg/day NN N
. . N

Male JJ N
well-informed JJ N
patients NNS p
with IN N
primary JJ N
monolateral JJ N
inguinal JJ N
hernia NN N
( ( N
ASA NNP N
I-II NNP N
) ) N
were VBD N
divided VBN N
into IN N
2 CD N
groups NNS N
and CC N
consecutively RB N
treated VBD N
; : N
group NN N
A DT N
was VBD N
treated VBN N
with IN N
laparoscopic JJ N
transabdominal JJ N
preperitoneal NN N
approach NN N
( ( N
TAPP NNP N
) ) N
( ( N
median JJ N
age NN N
47+/-7 JJ N
years NNS N
, , N
57 CD N
patients NNS p
) ) N
, , N
group NN N
B NNP N
with IN N
open JJ N
mesh NN N
herniorrhaphy NN N
( ( N
45+/-6 JJ N
years NNS N
, , N
64 CD N
patients NNS p
) ) N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Stable JJ N
patients NNS p
who WP N
had VBD N
anuria NNS N
and CC N
were VBD N
on IN N
low-flux JJ N
polysulfone NN N
membrane NN N
were VBD N
randomly RB N
allocated VBN N
either RB N
to TO N
HD NNP N
with IN N
high-flux JJ N
polyamide NN N
membrane NN N
( ( N
group NN N
A NNP N
; : N
22 CD N
patients NNS p
) ) N
or CC N
to TO N
HD NNP N
with IN N
low-flux JJ N
polyamide NN N
membrane NN N
( ( N
group NN N
B NNP N
; : N
24 CD N
patients NNS p
) ) N
for IN N
24 CD N
weeks NNS N
, , N
then RB N
they PRP N
were VBD N
started VBN N
on IN N
24 CD N
weeks NNS N
of IN N
the DT N
alternative JJ N
HD NNP N
treatment NN N
. . N

Patients NNS N
received VBD N
a DT N
5 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
bolus NN N
of IN N
magnesium NN N
sulphate NN N
followed VBN N
by IN N
a DT N
500 CD N
mg NN N
h NN N
( ( N
-1 NNP N
) ) N
infusion NN N
or CC N
saline NN N
in IN N
the DT N
same JJ N
volumes NNS N
for IN N
24 CD N
h. JJ N
Time NNP N
to TO N
first VB N
pain NN N
, , N
analgesic JJ N
request NN N
, , N
return NN N
of IN N
motor NN N
function NN N
, , N
visual JJ N
analogue NN N
pain NN N
and CC N
sedation NN N
scores NNS N
were VBD N
evaluated VBN N
every DT N
4 CD N
h NN N
during IN N
the DT N
24 CD N
h JJ N
postoperative JJ N
period NN N
. . N

Significant JJ N
improvements NNS N
in IN N
patients NNS p
' POS N
global JJ N
function NN N
were VBD N
seen VBN N
versus NN N
placebo NN N
at IN N
week NN N
24 CD N
( ( N
observed JJ N
cases NNS N
) ) N
, , N
on IN N
the DT N
Clinician NNP N
's POS N
Interview-Based JJ N
Impression NN N
of IN N
Change-Plus NNP N
version NN N
only RB N
for IN N
patients NNS p
on IN N
donepezil JJ N
5 CD N
mg/d NN N
( ( N
P=0.014 NNP N
) ) N
, , N
and CC N
on IN N
the DT N
Sum NNP N
of IN N
the DT N
Boxes NNP N
of IN N
the DT N
Clinical NNP N
Dementia NNP N
Rating NNP N
only RB N
for IN N
patients NNS p
on IN N
10 CD N
mg/d NN N
( ( N
P=0.007 NNP N
) ) N
. . N

Participants NNS N
were VBD N
randomly RB N
allocated VBN N
at IN N
the DT N
cluster NN N
level NN N
to TO N
10 CD N
weeks NNS N
of IN N
: : N
( ( N
1 CD N
) ) N
workplace NN N
physical JJ N
exercise NN N
( ( N
WORK NNP N
) ) N
performed VBD N
in IN N
groups NNS N
during IN N
working VBG N
hours NNS N
for IN N
5 CD N
minutes NNS N
per IN N
week NN N
and CC N
up RB N
to TO N
five CD N
group-based JJ N
coaching NN N
sessions NNS N
on IN N
motivation NN N
for IN N
regular JJ N
physical JJ N
exercise NN N
, , N
or CC N
( ( N
2 CD N
) ) N
home-based JJ N
physical JJ N
exercise NN N
( ( N
HOME NNP N
) ) N
performed VBD N
during IN N
leisure NN N
time NN N
for IN N
5 CD N
minutes NNS N
per IN N
week NN N
. . N

Using VBG N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
design NN N
, , N
motor NN N
thresholds NNS N
, , N
recruitment NN N
curves NNS N
, , N
cortical JJ N
stimulation-induced JJ N
silent JJ N
period NN N
( ( N
CSP NNP N
) ) N
, , N
short JJ N
intracortical JJ N
inhibition NN N
( ( N
ICI NNP N
) ) N
, , N
intracortical JJ N
facilitation NN N
( ( N
ICF NNP N
) ) N
, , N
and CC N
late JJ N
inhibition NN N
( ( N
L-ICI NNP N
) ) N
in IN N
14 CD N
healthy JJ N
subjects NNS N
were VBD N
investigated VBN N
after IN N
oral JJ N
doses NNS N
of IN N
50 CD N
and CC N
100 CD N
mg NNS N
amantadine VBP N
with IN N
single JJ N
and CC N
paired JJ N
pulse NN N
TMS NNP N
paradigms NN N
. . N

RESULTS NNP N
Only RB N
topical JJ N
bupivacaine NN N
was VBD N
found VBN N
to TO N
decrease VB o
postoperative JJ N
pain NN N
scores NNS N
significantly RB N
over IN N
those DT N
with IN N
placebo NN N
, , N
at IN N
30 CD N
minutes NNS N
postoperatively RB N
( ( N
median JJ N
score NN N
2 CD N
compared VBN N
with IN N
4 CD N
, , N
P NNP N
= NNP N
.002 NNP N
) ) N
and CC N
at IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
( ( N
median JJ N
score NN N
2 CD N
compared VBN N
with IN N
3 CD N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Post NNP N
hoc NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
benefit NN N
of IN N
rizatriptan JJ N
versus NN N
placebo NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS p
who WP N
had VBD N
pain NN N
relief NN N
when WRB N
their PRP$ N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
on IN N
weekends NNS N
( ( N
65 CD N
% NN N
versus IN N
36 CD N
% NN N
, , N
P=.046 NNP N
) ) N
compared VBN N
with IN N
weekdays NNS N
( ( N
66 CD N
% NN N
versus IN N
61 CD N
% NN N
, , N
P=.365 NNP N
) ) N
, , N
and CC N
the DT N
weekend NN N
placebo NN N
response NN N
rate NN N
was VBD N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
adults NNS N
. . N

Treatment NN N
with IN N
ranitidine NN N
, , N
but CC N
not RB N
placebo VB N
, , N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN o
in IN N
CD4+ NNP N
lymphocytes NNS N
( ( N
33 CD N
% NN N
to TO N
49 CD N
% NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
and CC N
a DT N
significant JJ N
decrease NN o
in IN N
CD8+ NNP N
lymphocytes NNS N
( ( N
41 CD N
% NN N
to TO N
27 CD N
% NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
occurrence NN N
of IN N
reported VBN N
oral JJ N
irritation NN N
was VBD N
0 CD N
% NN N
in IN N
the DT N
6 CD N
% NN N
strip NN N
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0 CD N
% NN N
, , N
8.8 CD N
% NN N
) ) N
and CC N
2.5 CD N
% NN N
in IN N
the DT N
placebo NN N
strip NN N
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.1 CD N
% NN N
, , N
13.2 CD N
% NN N
) ) N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
108 CD N
iron-deficient JJ N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
Group NNP N
C NNP N
( ( N
control NN N
) ) N
or CC N
Group NNP N
IE NNP N
( ( N
200 CD N
mg NN N
of IN N
iron NN N
sucrose NN N
intravenously RB N
over IN N
1 CD N
hr NNS N
and CC N
3000 CD N
IU NNP N
of IN N
rHuEPO- JJ N
subcutaneously NN N
during IN N
the DT N
operation NN N
and CC N
during IN N
the DT N
postoperative JJ N
period NN N
if IN N
the DT N
hemoglobin NN N
[ NNP N
Hb NNP N
] NNP N
level NN N
was VBD N
70-80 JJ N
g/L NN N
) ) N
. . N

A DT N
higher JJR N
percentage NN N
of IN N
patients NNS p
in IN N
the DT N
intervention NN N
group NN N
, , N
relative VBP N
to TO N
the DT N
control NN N
group NN N
, , N
were VBD N
able JJ N
to TO N
reduce VB N
the DT N
use NN N
of IN N
antihypertensive JJ N
medications NNS N
( ( N
31 CD N
vs. FW N
8 CD N
% NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
fewer JJR N
patients NNS p
in IN N
this DT N
group NN N
required VBD N
additional JJ N
medications NNS N
or CC N
increases NNS o
in IN N
dosage NN N
relative NN N
to TO N
the DT N
controls NNS N
( ( N
11 CD N
vs. FW N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
142 CD N
patients NNS p
with IN N
symptomatic JJ N
heart NN N
failure NN N
( ( N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
III NNP N
and CC N
IV NNP N
) ) N
were VBD N
randomized VBN N
to TO N
double-blind VB N
, , N
short-term JJ N
treatment NN N
with IN N
conivaptan NN N
, , N
a DT N
dual JJ N
V NNP N
( ( N
1a CD N
) ) N
/V NN N
( ( N
2 CD N
) ) N
vasopressin NN N
receptor NN N
antagonist NN N
, , N
at IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
( ( N
10 CD N
, , N
20 CD N
, , N
or CC N
40 CD N
mg NN N
) ) N
or CC N
placebo NN N
. . N

Eyes NNS N
treated VBN N
with IN N
latanoprost NN N
, , N
stored VBD N
both DT N
at IN N
4 CD N
degrees NNS N
C NNP N
and CC N
30 CD N
degrees NNS N
C NNP N
, , N
achieved VBD N
statistically RB N
significantly RB N
lower JJR N
mean NN N
IOPs NNP N
than IN N
untreated JJ N
eyes NNS N
at IN N
all DT N
time NN N
points NNS N
, , N
except IN N
at IN N
21 CD N
hours NNS N
treated VBN N
by IN N
the DT N
drug NN N
stored VBD N
at IN N
30 CD N
degrees NNS N
C. NNP N
We PRP N
subtracted VBD N
the DT N
IOP NNP N
of IN N
eyes NNS N
receiving VBG N
latanoprost NN N
from IN N
the DT N
IOP NNP N
of IN N
untreated JJ N
eyes NNS N
for IN N
each DT N
time NN N
point NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
the DT N
eye NN N
drops NNS N
( ( N
delta JJ N
IOP NNP N
) ) N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
of IN N
15 CD N
aspirin-naive JJ N
patients NNS p
( ( N
mean JJ N
age NN N
48.8 CD N
? . N
10.2 CD N
years NNS N
) ) N
with IN N
the DT N
metabolic JJ N
syndrome NN N
, , N
statin NN i
monotherapy NN i
( ( N
simvastatin JJ i
40 CD N
mg JJ N
daily RB N
) ) N
was VBD N
compared VBN N
to TO N
combination VB N
therapy NN i
( ( N
simvastatin JJ i
40 CD N
mg NN N
and CC N
ezetimibe $ N
10 CD N
mg JJ N
daily RB N
) ) N
on IN N
biomarkers NNS N
of IN N
inflammation NN N
and CC N
platelet NN N
activity NN N
. . N

METHODS NNP N
In IN N
this DT N
post-hoc JJ N
analysis NN N
of IN N
a DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
, , N
multi-center JJ N
therapeutic JJ N
equivalence NN N
trial NN N
, , N
76 CD N
patients NNS p
undergoing JJ N
elective JJ N
on-pump JJ N
cardiac NN N
surgery NN N
received VBD N
perioperative JJ N
volume NN N
replacement NN N
using VBG N
either CC N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
( ( N
N.=37 NNP N
) ) N
or CC N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
( ( N
N.=39 NNP N
) ) N
up RB N
to TO N
a DT N
maximum JJ N
dose NN N
of IN N
20 CD N
mL JJ N
kg-1 NN N
. . N

To TO N
determine VB N
if IN N
muscle NN N
atrophy NN N
could MD N
be VB N
minimized VBN N
with IN N
exercise NN N
therapy NN i
, , N
30 CD N
patients NNS p
undergoing JJ N
marrow JJ N
transplantation NN N
for IN N
acute NN N
leukemia NN N
completed VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
receive VB N
: : N
( ( N
1 CD N
) ) N
no DT N
therapy NN i
( ( N
controls NNS N
) ) N
, , N
( ( N
2 CD N
) ) N
physical JJ N
therapy NN i
thrice NN N
weekly RB N
( ( N
PT3 NNP N
) ) N
, , N
or CC N
( ( N
3 CD N
) ) N
physical JJ N
therapy NN i
five CD N
times NNS N
weekly JJ N
( ( N
PT5 NNP N
) ) N
. . N

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
treatment NN N
with IN N
a DT N
4-week JJ N
cycle NN N
of IN N
subcutaneous JJ N
low JJ N
doses NNS N
IL-2 NNP N
+ NNP N
IFN NNP N
in IN N
months NNS N
1 CD N
, , N
3 CD N
and CC N
5 CD N
, , N
and CC N
then RB N
every DT N
3 CD N
months NNS N
until IN N
the DT N
first JJ N
documented JJ N
disease NN N
progression NN N
( ( N
arm NN N
A NNP N
, , N
suspension NN N
) ) N
, , N
or CC N
the DT N
same JJ N
regimen NNS N
, , N
with IN N
chronic JJ N
maintenance NN N
of IN N
immunotherapy NN i
, , N
regardless RB N
of IN N
tumour JJ N
response NN N
, , N
until IN N
death NN N
or CC N
intolerable JJ N
toxicity NN N
( ( N
arm NN N
B NNP N
, , N
maintenance NN N
) ) N
. . N

Among IN N
84 CD N
randomized JJ N
responders NNS N
, , N
progression-free JJ N
survival NN N
was VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
by IN N
maintenance NN N
therapy NN i
, , N
with IN N
median JJ N
durations NNS N
( ( N
maintenance NN N
v IN N
follow-up JJ N
) ) N
of IN N
25 CD N
versus NNS N
12 CD N
weeks NNS N
after IN N
the DT N
second JJ N
randomization NN N
, , N
but CC N
survival NN N
was VBD N
not RB N
significantly RB N
increased VBN o
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
, , N
with IN N
median JJ N
durations NNS N
of IN N
48 CD N
and CC N
38 CD N
weeks NNS N
. . N

METHODS NNP N
The DT N
study NN N
included VBD N
42 CD N
patients NNS p
( ( N
29 CD N
women NNS N
and CC N
13 CD N
men NNS N
; : N
mean JJ N
age NN N
53.2+/-14.2 JJ N
years NNS N
; : N
body NN N
surface JJ N
area NN N
1.76+/-0.14 JJ N
m2 NN N
) ) N
with IN N
SH NNP N
, , N
as IN N
judged VBN N
by IN N
elevated JJ N
serum NN N
TSH NNP N
levels NNS N
( ( N
> $ N
3.6 CD N
mIU/l NN N
; : N
range NN N
, , N
3.8-12.0 JJ N
) ) N
and CC N
normal JJ N
free JJ N
thyroid NN N
hormones NNS N
( ( N
FT4 NNP N
and CC N
FT3 NNP N
) ) N
and CC N
30 CD N
euthyroid JJ N
volunteer NN N
. . N

METHODS NNP N
A NNP N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
performed VBN N
in IN N
40 CD N
healthy JJ N
Chinese JJ N
subjects NNS N
( ( N
4 CD N
groups NNS N
of IN N
10 CD N
subjects NNS N
each DT N
, , N
placebo VBZ N
4:1 CD N
ratio NN N
) ) N
who WP N
received VBD N
infusions NNS N
of IN N
uricase NN N
( ( N
single JJ N
doses NNS N
of IN N
0.1 CD N
, , N
0.2 CD N
, , N
and CC N
0.3 CD N
mg/kg NN N
; : N
multiple JJ N
doses NNS N
of IN N
0.2 CD N
mg NN N
( ( N
-1 NN N
) ) N
? . N
( ( N
-1 NN N
) ) N
for IN N
7 CD N
d NN N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
no DT N
differences NNS N
in IN N
the DT N
resolution NN N
of IN N
symptoms NNS N
were VBD N
observed VBN N
between IN N
the DT N
2 CD N
groups NNS N
, , N
and CC N
over IN N
2 CD N
years NNS N
, , N
the DT N
overall JJ i
incidence NN N
of IN N
complications NNS N
was VBD N
the DT N
same JJ N
, , N
specifically RB N
fecaloma JJ N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
in IN N
the DT N
MM NNP N
group NN N
and CC N
external JJ N
hemorrhoidal NN N
thrombosis NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
in IN N
the DT N
SH NNP N
group NN N
. . N

METHODS NNP N
Out-patients NNS p
scheduled VBN N
for IN N
endoscopic NN N
ultrasonography NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
oral JJ N
pre-medication NN N
with IN N
the DT N
anti-foam JJ N
agent NN N
, , N
dimethylpolysiloxane NN N
, , N
alone RB N
( ( N
treatment NN N
A NNP N
; : N
n JJ N
= NNP N
29 CD N
) ) N
, , N
with IN N
dimethylpolysiloxane JJ N
plus CC N
sodium JJ N
bicarbonate NN N
( ( N
treatment NN N
B NNP N
; : N
n CC N
= VB N
29 CD N
) ) N
or CC N
with IN N
dimethylpolysiloxane NN N
, , N
sodium NN N
bicarbonate NN N
and CC N
pronase NN N
( ( N
treatment NN N
C NNP N
; : N
n CC N
= VB N
29 CD N
) ) N
. . N

The DT N
percentages NNS N
of IN N
patients NNS p
who WP N
achieved VBD N
meaningful JJ N
pain NN N
relief NN N
within IN N
the DT N
first JJ N
hour NN N
after IN N
treatment NN N
were VBD N
77.6 CD N
% NN N
and CC N
83.7 CD N
% NN N
for IN N
ibuprofen JJ N
arginate NN N
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
61.0 CD N
% NN N
and CC N
63.0 CD N
% NN N
for IN N
ibuprofen JJ N
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
and CC N
39.8 CD N
% NN N
for IN N
placebo NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Forty NNP N
patients NNS p
who WP N
had VBD N
diabetes NNS N
with IN N
nephropathy JJ N
and CC N
arteriosclerosis NN N
obliterans NNS N
and CC N
had VBD N
already RB N
been VBN N
treated VBN N
with IN N
angiotensin NN N
II NNP N
receptor NN N
blocker NN N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
sarpogrelate VB N
( ( N
300 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
or CC N
aspirin JJ N
group NN N
( ( N
100 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
amprenavir NN N
plasma NN N
concentrations NNS N
were VBD N
decreased VBN o
by IN N
saquinavir JJ N
soft JJ i
gel NN N
capsule NN N
( ( N
by IN N
32 CD N
% NN N
for IN N
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
at IN N
steady JJ N
state NN N
[ NNS N
AUC NNP N
( ( N
ss NN N
) ) N
] NN N
and CC N
37 CD N
% NN N
for IN N
peak NN N
plasma NN N
concentration NN N
at IN N
steady JJ N
state NN N
[ NNS N
C NNP N
( ( N
max NN i
, , N
ss NN N
) ) N
] NN N
) ) N
and CC N
increased VBN o
by IN N
indinavir NN N
( ( N
33 CD N
% NN N
for IN N
AUC NNP N
( ( N
ss NN N
) ) N
) ) N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
, , N
multicenter NN N
study NN N
patients NNS p
with IN N
symptoms NNS N
of IN N
acute JJ N
UC NNP N
and CC N
a DT N
baseline NN N
Modified NNP N
Mayo NNP N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
MMDAI NNP N
) ) N
score NN N
between IN N
6 CD N
and CC N
10 CD N
, , N
inclusive JJ N
, , N
with IN N
a DT N
subscale JJ N
rating NN N
of IN N
> NNP N
or CC N
=2 NN N
for IN N
both DT N
rectal JJ N
bleeding NN N
and CC N
mucosal JJ N
appearance NN N
were VBD N
randomized VBN N
to TO N
receive VB N
3.3 CD N
g NN N
of IN N
balsalazide NN i
or CC N
placebo NN N
tablets NNS N
twice RB N
daily RB N
for IN N
8 CD N
weeks NNS N
. . N

Patients NNS N
who WP N
qualified VBD N
for IN N
the DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
trial NN N
were VBD N
randomly RB N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
single JJ N
dose NN N
of IN N
oral JJ N
clindamycin NN i
administered VBN N
preoperatively RB N
( ( N
single-dose JJ N
group NN N
) ) N
; : N
( ( N
2 CD N
) ) N
clindamycin NN i
administered VBD N
preoperatively RB N
with IN N
continued JJ N
therapy NN i
for IN N
5 CD N
days NNS N
( ( N
5-day JJ N
group NN N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
a DT N
placebo NN N
group NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
HCMV NNP N
infection NN N
was VBD N
comparable JJ N
in IN N
DNAemia NNP N
and CC N
antigenemia NN N
arms NNS N
( ( N
34 CD N
% NN N
vs JJ N
42 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
.259 NNP N
) ) N
, , N
the DT N
number NN N
of IN N
patients NNS p
treated VBN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
DNAemia NNP N
arm NN N
( ( N
18 CD N
% NN N
vs JJ N
31 CD N
% NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
insulin NN N
, , N
amino JJ N
acid NN N
( ( N
AA NNP N
) ) N
, , N
and CC N
branched-chain JJ N
ketoacid NN N
( ( N
KA NNP N
) ) N
availability NN N
on IN N
leucine JJ N
kinetics NNS N
in IN N
eight CD N
healthy JJ N
volunteers NNS N
( ( N
age NN N
= VBZ N
22 CD N
+/- JJ N
2 CD N
y NN N
, , N
body NN N
mass NN N
index NN N
= VBD N
24 CD N
+/- JJ N
1 CD N
kg NN N
) ) N
by IN N
using VBG N
the DT N
euglycemic JJ N
insulin NN N
clamp NN N
and CC N
[ JJ N
1-14C JJ N
] NNP N
leucine NN N
turnover NN N
techniques NNS N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
106 CD N
patients NNS p
without IN N
underlying VBG N
liver NN N
disease NN N
and CC N
submitted VBN N
to TO N
liver VB N
resection NN N
using VBG N
INT NNP N
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
: : N
IPC NNP N
( ( N
10 CD N
minutes NNS N
of IN N
inflow JJ N
occlusion NN N
followed VBN N
by IN N
10 CD N
minutes NNS N
of IN N
reperfusion NN N
before IN N
liver JJ N
transection NN N
) ) N
, , N
APC NNP N
( ( N
sevoflurane JJ N
administration NN N
for IN N
20 CD N
minutes NNS N
before IN N
liver JJ N
transection NN N
) ) N
, , N
and CC N
INT NNP N
( ( N
no DT N
preconditioning NN N
) ) N
. . N

The DT N
enhanced JJ N
label NN N
includes VBZ N
a DT N
universal JJ N
medication NN N
schedule NN N
( ( N
UMS NNP N
) ) N
that WDT N
standardizes VBZ N
the DT N
directions NNS N
for IN N
use NN N
incorporating VBG N
1 CD N
) ) N
standard NN N
time NN N
periods NNS N
for IN N
administration NN N
( ( N
morning NN N
, , N
noon NN N
, , N
evening NN N
, , N
and CC N
bedtime NN N
) ) N
, , N
2 CD N
) ) N
numeric JJ N
vs. FW N
alpha NN N
characters NNS N
, , N
3 CD N
) ) N
'carriage NN N
returns NNS N
' POS N
to TO N
separate VB N
daily JJ N
dose NN N
and CC N
4 CD N
) ) N
a DT N
graphic JJ N
aid NN N
to TO N
visually RB N
depict VB N
dose NN N
and CC N
frequency NN N
. . N

The DT N
parents NNS N
of IN N
consecutive JJ N
children NNS N
with IN N
autism NN N
( ( N
2 CD N
( ( N
1/2 CD N
) ) N
-5 CD N
years NNS N
old JJ N
) ) N
from IN N
the DT N
autism NN N
assessment NN N
services NNS N
for IN N
the DT N
intervention NN N
regions NNS N
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
20-week JJ N
manual-based JJ N
parent NN N
education NN N
and CC N
behavior JJ N
management NN N
intervention NN N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
or CC N
a DT N
manual-based JJ N
parent NN N
education NN N
and CC N
counseling VBG N
intervention NN N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

METHODS NNP N
Fifty-six JJ N
patients NNS p
with IN N
unstable JJ N
angina NN N
, , N
mean JJ N
age NN N
of IN N
55.4 CD N
+/- JJ N
8.5 CD N
, , N
41 CD N
men NNS N
and CC N
15 CD N
women NNS N
, , N
were VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
of IN N
two CD N
groups NNS N
of IN N
patients NNS p
treated VBN N
with IN N
diltiazem NN N
or CC N
propranolol NN i
at IN N
total JJ N
daily JJ N
doses NNS N
of IN N
180 CD N
mg NNS N
and CC N
120 CD N
mg NN N
respectively RB N
during IN N
the DT N
first JJ N
48 CD N
hours NNS N
. . N

METHOD NNP N
Data NNP N
were VBD N
collected VBN N
over IN N
a DT N
23-week JJ N
period NN N
, , N
from IN N
4:00 CD N
PM NNP N
to TO N
midnight VB N
, , N
and CC N
resulted VBD N
in IN N
446 CD N
patients NNS p
being VBG N
recruited VBN N
into IN N
the DT N
study NN N
( ( N
90 CD N
% NN N
of IN N
those DT N
who WP N
screened VBD N
positive JJ N
) ) N
and CC N
randomized VBN N
to TO N
three CD N
conditions NNS N
following VBG N
a DT N
two-stage JJ N
process NN N
: : N
screened VBN N
only RB N
( ( N
n JJ N
= NNP N
147 CD N
) ) N
, , N
assessed VBN N
( ( N
n JJ N
= NNP N
152 CD N
) ) N
, , N
and CC N
received VBN N
intervention NN N
( ( N
n JJ N
= NNP N
147 CD N
) ) N
. . N

The DT N
cumulative JJ N
HBsAg NNP N
reverse NN N
seroconversion NN N
rates NNS N
at IN N
months NNS N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
since IN N
chemotherapy NN i
were VBD N
0 CD N
% NN N
, , N
6.4 CD N
% NN N
, , N
and CC N
16.3 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
respectively RB N
, , N
which WDT N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
( ( N
P NNP N
= NNP N
.032 NNP N
) ) N
. . N

During IN N
orthopaedic JJ N
surgery NN N
of IN N
the DT N
limb NN N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
double JJ N
blind NN N
controlled VBD N
study NN N
on IN N
three CD N
parallel JJ N
groups NNS N
in IN N
30 CD N
patients NNS p
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ N
and CC N
pharmacodynamic JJ N
effect NN N
of IN N
infiltration NN N
of IN N
the DT N
iliac JJ N
crest NN N
bone NN N
graft NN N
harvest NN N
site NN N
with IN N
20 CD N
ml NNS N
of IN N
bupivacaine NN N
( ( N
100 CD N
mg NN N
) ) N
, , N
ropivacaine NN N
( ( N
150 CD N
mg NN N
) ) N
or CC N
saline JJ N
as IN N
control NN N
group NN N
( ( N
n JJ N
= NN N
10 CD N
in IN N
each DT N
group NN N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
parallel-group NN N
study NN N
, , N
patients NNS p
naive VBP N
to TO N
emetogenic VB N
chemotherapy NN i
( ( N
N NNP N
= NNP N
1,085 CD N
) ) N
who WP N
were VBD N
scheduled VBN N
to TO N
receive VB N
cyclophosphamide- NN N
( ( N
500 CD N
to TO N
1,200 CD N
mg/m2 NN N
) ) N
or CC N
carboplatin NN i
( ( N
> CD N
or CC N
= VB N
300 CD N
mg/m2 NN N
) ) N
based VBN N
chemotherapy NN i
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
granisetron NN N
( ( N
n JJ N
= NNP N
542 CD N
) ) N
or CC N
I.V NNP N
. . N

After IN N
the DT N
first JJ N
4 CD N
weeks NNS N
all DT N
subjects NNS N
were VBD N
changed VBN N
from IN N
CC NNP N
to TO N
sevelamer VB N
3.0 CD N
g/day NN N
for IN N
another DT N
4 CD N
weeks NNS N
, , N
then RB N
allocated VBD N
randomly RB N
to TO N
three CD N
groups NNS N
for IN N
the DT N
final JJ N
4 CD N
weeks NNS N
: : N
group NN N
A NNP N
, , N
sevelamer NN N
6.0 CD N
g/day NN N
; : N
group NN N
B NNP N
, , N
sevelamer VBD N
3.0 CD N
g/day NN N
and CC N
CC NNP N
3.0 CD N
g/day NN N
; : N
group NN N
C NNP N
, , N
CC NNP N
3.0 CD N
g/day NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Forty-five JJ N
HF NNP N
patients NNS p
( ( N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
II-III NNP N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB N
or CC N
sildenafil VB N
( ( N
50 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
) ) N
for IN N
1 CD N
year NN N
, , N
with IN N
assessment NN N
( ( N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
) ) N
of IN N
LV NNP N
ejection NN N
fraction NN N
, , N
diastolic JJ N
function NN N
, , N
geometry NN N
, , N
cardiopulmonary JJ N
exercise NN N
performance NN N
, , N
and CC N
quality NN N
of IN N
life NN N
. . N

This DT N
study NN N
compared VBN N
oral JJ N
mucositis NN N
pain NN N
levels NNS N
in IN N
4 CD N
groups NNS N
of IN N
cancer NN N
patients NNS p
receiving VBG N
bone NN N
marrow NN N
transplants NNS N
( ( N
BMT NNP N
) ) N
: : N
( ( N
1 CD N
) ) N
treatment NN N
as IN N
usual JJ N
control NN N
, , N
( ( N
2 CD N
) ) N
therapist NN N
support NN N
, , N
( ( N
3 CD N
) ) N
relaxation NN N
and CC N
imagery NN N
training NN N
, , N
and CC N
( ( N
4 CD N
) ) N
training NN N
in IN N
a DT N
package NN N
of IN N
cognitive-behavioral JJ N
coping NN N
skills NNS N
which WDT N
included VBD N
relaxation NN N
and CC N
imagery NN N
. . N

Randomization NN N
was VBD N
stratified VBN N
according VBG N
to TO N
whether IN N
CNS NNP N
leukemia NN N
occurred VBD N
at IN N
initial JJ N
diagnosis NN N
of IN N
acute JJ N
lymphocytic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
( ( N
Stratum NNP N
I PRP N
, , N
15 CD N
patients NNS p
) ) N
, , N
during IN N
first JJ N
bone NN N
marrow NN N
( ( N
BM NNP N
) ) N
remission NN N
( ( N
Stratum NNP N
II NNP N
, , N
49 CD N
patients NNS p
) ) N
, , N
simultaneous JJ N
with IN N
first JJ N
BM NNP N
relapse NN N
( ( N
Stratum NNP N
III NNP N
, , N
12 CD N
patients NNS p
) ) N
, , N
or CC N
during IN N
second JJ N
BM NNP N
remission NN N
( ( N
Stratum NNP N
IV NNP N
, , N
11 CD N
patients NNS p
) ) N
. . N

At IN N
week NN N
8 CD N
compared VBN N
with IN N
week NN N
4 CD N
, , N
the DT N
concentration NN N
of IN N
P NNP N
increased VBD o
from IN o
5.7+/-1.4 JJ N
to TO N
6.4+/-1.7 JJ N
mg/dL NN N
in IN N
group NN N
A NNP N
, , N
and CC N
decreased VBD o
significantly RB o
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
, , N
and CC N
in IN N
group NN N
B NNP N
compared VBN N
with IN N
groups NNS N
A NNP N
and CC N
C NNP N
; : N
groups NNS N
A DT N
and CC N
C NNP N
had VBD N
similar JJ N
concentrations NNS N
at IN N
week NN N
8 CD N
. . N

The DT N
modified VBN N
scale NN N
( ( N
CYBOCS-PDD NNP N
) ) N
, , N
which WDT N
contains VBZ N
only RB N
the DT N
five CD N
Compulsion NNP N
severity NN N
items NNS N
( ( N
range VB N
0-20 NN N
) ) N
, , N
was VBD N
administered VBN N
to TO N
172 CD N
medication-free JJ N
children NNS N
( ( N
mean JJ N
8.2 CD N
+/- JJ N
2.6 CD N
years NNS N
) ) N
with IN N
PDD NNP N
( ( N
autistic JJ N
disorder NN N
, , N
n JJ N
= VBP N
152 CD N
; : N
Asperger NNP N
's POS N
disorder NN N
, , N
n JJ N
= VBP N
6 CD N
; : N
PDD NNP N
not RB N
otherwise RB N
specified VBN N
, , N
n JJ N
= NNP N
14 CD N
) ) N
participating NN N
in IN N
RUPP NNP N
clinical JJ N
trials NNS N
. . N

To TO N
investigate VB N
the DT N
clinical JJ N
effects NNS N
of IN N
a DT N
novel JJ N
PD NNP N
fluid NN N
buffered VBD N
with IN N
34 CD N
mM NNS N
pure JJ N
bicarbonate NN N
at IN N
neutral JJ N
pH NN N
, , N
a DT N
randomized VBN N
, , N
prospective JJ N
, , N
crossover JJ N
comparison NN N
with IN N
conventional JJ N
, , N
acidic JJ N
, , N
35 CD N
mM NN N
lactate NN N
PD NNP N
fluid NN N
was VBD N
performed VBN N
for IN N
two CD N
consecutive JJ N
12-wk JJ N
periods NNS N
with IN N
28 CD N
children NNS N
( ( N
age NN N
, , N
6 CD N
mo NN N
to TO N
15 CD N
yr NN N
) ) N
undergoing NN N
automated VBN N
PD NNP N
( ( N
APD NNP N
) ) N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ N
pulmonary JJ N
complications NNS N
in IN N
the DT N
non-deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
14 CD N
% NN N
, , N
and CC N
the DT N
incidence NN N
of IN N
postoperative JJ N
pulmonary JJ N
complications NNS N
in IN N
the DT N
deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
17 CD N
% NN N
, , N
( ( N
absolute JJ N
risk NN N
reduction NN N
-3 NNP N
% NN N
, , N
95 CD N
% NN N
C1 NNP N
-22 NNP N
to TO N
19 CD N
% NN N
) ) N
. . N

Group NNP N
I PRP N
patients NNS p
received VBD N
lumbar JJ N
interlaminar JJ N
epidural JJ N
injections NNS N
of IN N
local JJ N
anesthetic JJ N
( ( N
lidocaine JJ N
0.5 CD N
% NN N
) ) N
6 CD N
mL NN N
, , N
whereas WP N
Group NNP N
II NNP N
received VBD N
lumbar JJ N
interlaminar JJ N
epidural JJ N
injections NNS N
with IN N
local JJ N
anesthetic NN N
( ( N
lidocaine JJ N
0.5 CD N
% NN N
) ) N
5 CD N
mL NN N
mixed JJ N
with IN N
1 CD N
mL NNS N
of IN N
steroids NNS N
and CC N
6 CD N
mg NN N
of IN N
betamethasone NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
total NN N
of IN N
78 CD N
boys NNS N
age NN N
13-15 CD N
years NNS N
with IN N
a DT N
mean JJ N
body NN N
fat JJ N
percentage NN N
of IN N
30 CD N
% NN N
+/-9 JJ N
% NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
consume VB N
fish JJ N
oil NN N
( ( N
providing VBG N
1.5 CD N
g NN N
of IN N
n-3 JJ N
long-chain NN N
polyunsaturated VBD N
fatty JJ N
acid/day NN N
) ) N
or CC N
vegetable JJ N
oil NN N
( ( N
control NN N
) ) N
for IN N
16 CD N
weeks NNS N
. . N

Didanosine NNP N
( ( N
125 CD N
to TO N
200 CD N
mg NNS N
given VBN N
as IN N
buffered JJ N
tablets NNS N
) ) N
and CC N
delavirdine JJ N
mesylate NN N
( ( N
400 CD N
mg NN N
) ) N
pharmacokinetics NNS N
were VBD N
evaluated VBN N
when WRB N
each DT N
drug NN N
was VBD N
given VBN N
alone RB N
( ( N
treatments NNS N
A DT N
and CC N
B NNP N
, , N
respectively RB N
) ) N
, , N
when WRB N
the DT N
two CD N
drugs NNS N
were VBD N
given VBN N
concurrently RB N
( ( N
treatment NN N
C NNP N
) ) N
, , N
and CC N
when WRB N
didanosine NN N
was VBD N
given VBN N
1 CD N
h NN N
after IN N
delavirdine NN N
( ( N
treatment NN N
D NNP N
) ) N
. . N

Each DT N
month NN N
for IN N
6 CD N
months NNS N
, , N
subjects VBZ N
received VBN N
either RB N
3 CD N
consecutive JJ N
weeks NNS N
of IN N
the DT N
OC NNP N
( ( N
i.e NN N
, , N
tablets NNS N
containing VBG N
a DT N
fixed VBN N
dose NN N
of IN N
ethinyl JJ N
estradiol NN N
[ VBD N
0.035 CD N
mg NN N
] NN N
and CC N
increasing VBG N
doses NNS N
of IN N
norgestimate JJ N
[ NNS N
0.180 CD N
mg NNS N
, , N
0.215 CD N
mg NN N
, , N
0.250 CD N
mg NN N
] NN N
) ) N
followed VBN N
by IN N
7 CD N
days NNS N
of IN N
inactive JJ N
drug NN N
or CC N
placebo NN N
( ( N
color-matched JJ N
tablets NNS N
) ) N
. . N

The DT N
mean JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
RPE NNP N
, , N
number NN N
of IN N
steps NNS N
( ( N
determined VBN N
by IN N
step NN N
counter NN N
) ) N
, , N
and CC N
blood NN N
lactate NN N
concentrations NNS N
were VBD N
determined VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
and CC N
15 CD N
minutes NNS N
during IN N
the DT N
recovery NN N
from IN N
the DT N
exercise NN N
, , N
with IN N
and CC N
without IN N
motivational JJ N
music NN N
( ( N
2 CD N
separate JJ N
sessions NNS N
, , N
at IN N
random JJ N
order NN N
) ) N
. . N

During IN N
2 CD N
years NNS N
and CC N
7 CD N
months NNS N
from IN N
June NNP N
, , N
1985 CD N
to TO N
December NNP N
, , N
1987 CD N
, , N
a DT N
randomized JJ N
multi-center JJ N
trial NN N
of IN N
PVB NNP N
, , N
VAB-6 NNP N
, , N
BVP NNP N
regimen NNS N
( ( N
group NN N
A DT N
) ) N
without IN N
etoposide JJ N
versus NN N
PEB NNP N
chemotherapy NN i
( ( N
bleomycin NN i
, , N
etoposide RB N
and CC N
cisplatinum NN N
) ) N
( ( N
group NN N
B NNP N
) ) N
was VBD N
given VBN N
to TO N
patients NNS p
with IN N
disseminated JJ N
testicular JJ N
tumors NNS N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
this DT N
multisite NN N
study NN N
, , N
171 CD N
children NNS N
with IN N
standard-risk JJ N
ALL NNP N
, , N
age NN N
1 CD N
to TO N
9.99 CD N
years NNS N
at IN N
diagnosis NN N
, , N
previously RB N
randomly RB N
assigned VBN N
to TO N
IT NNP N
methotrexate NNP N
( ( N
n JJ N
= NNP N
82 CD N
) ) N
or CC N
to TO N
triple VB N
IT NNP N
therapy NN i
( ( N
n JJ N
= NNP N
89 CD N
) ) N
on IN N
CCG NNP N
1952 CD N
, , N
underwent JJ N
neurocognitive JJ N
evaluation NN N
by IN N
a DT N
licensed JJ N
psychologist NN N
at IN N
a DT N
mean NN N
of IN N
5.9 CD N
years NNS N
after IN N
random JJ N
assignment NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Twenty NNP N
ulcerative JJ N
colitis NN N
patients NNS p
with IN N
poor JJ N
pouch JJ N
function NN N
( ( N
score NN N
> VBZ N
4 CD N
on IN N
a DT N
12-point JJ N
score NN N
) ) N
were VBD N
recruited VBN N
for IN N
inclusion NN N
to TO N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
crossover NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
ursodeoxycholic JJ N
acid NN N
( ( N
10 CD N
mg/kg NNS N
per IN N
day NN N
in IN N
two CD N
divided JJ N
doses NNS N
for IN N
1 CD N
month NN N
) ) N
. . N

The DT N
mean JJ N
treatment NN N
duration NN N
was VBD N
10 CD N
and CC N
14 CD N
weeks NNS N
, , N
median JJ N
time NN N
to TO N
PSA NNP N
progression NN N
was VBD N
27.2 CD N
and CC N
30.8 CD N
weeks NNS N
, , N
median JJ N
survival NN N
time NN N
was VBD N
44 CD N
and CC N
50.9 CD N
weeks NNS N
, , N
and CC N
PSA NNP N
response NN N
rate NN N
was VBD N
only RB N
24.6 CD N
and CC N
28.9 CD N
% NN N
in IN N
the DT N
EMP/VBL NNP N
and CC N
EMP NNP N
arms NNS N
, , N
respectively RB N
. . N

The DT N
subjects NNS N
were VBD N
asked VBN N
to TO N
perform VB N
the DT N
following JJ N
tasks NNS N
, , N
with IN N
the DT N
affected JJ N
hand NN N
for IN N
30 CD N
seconds NNS N
: : N
( ( N
1 CD N
) ) N
transfer NN N
pegs NN N
from IN N
a DT N
saucer NN N
to TO N
a DT N
pegboard NN N
; : N
( ( N
2 CD N
) ) N
grasp NN N
, , N
carry NN N
, , N
and CC N
release VB N
a DT N
hard JJ N
rubber NN N
ball NN N
; : N
and CC N
( ( N
3 CD N
) ) N
eating NN N
, , N
using VBG N
a DT N
spoon NN N
to TO N
remove VB N
the DT N
jelly NN N
from IN N
the DT N
plate NN N
, , N
bring VBG N
it PRP N
towards IN N
the DT N
mouth NN N
, , N
and CC N
then RB N
place VB N
it PRP N
on IN N
another DT N
plate NN N
. . N

METHOD NNP N
Adults NNP N
aged VBD N
18-75 CD N
years NNS N
with IN N
MDD NNP N
( ( N
DSM-IV-TR NNP N
) ) N
and CC N
Montgomery-Asberg NNP N
Depression NNP N
Rating NNP N
Scale NNP N
( ( N
MADRS NNP N
) ) N
total NN N
score NN N
? . N
26 CD N
were VBD N
randomized VBN N
( ( N
1:1:1 CD N
) ) N
to TO N
receive VB N
vortioxetine NN N
10 CD N
mg NN N
or CC N
15 CD N
mg NN N
or CC N
placebo NN N
once RB N
daily JJ N
, , N
with IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
being VBG N
change NN N
from IN N
baseline NN N
at IN N
week NN N
8 CD N
in IN N
MADRS NNP N
analyzed VBN N
by IN N
mixed JJ N
model NN N
for IN N
repeated JJ N
measures NNS N
. . N

Overall JJ i
significant JJ N
improvement NN N
was VBD N
achieved VBN N
for IN N
65.7 CD N
? . N
37.3 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
and CC N
68.9 CD N
? . N
37.7 CD N
weeks NNS N
in IN N
Group NNP N
II NNP N
at IN N
the DT N
end NN N
of IN N
2 CD N
years NNS N
when WRB N
all DT N
participants NNS N
were VBD N
considered VBN N
; : N
whereas NNS N
, , N
this DT N
was VBD N
77 CD N
? . N
27.8 CD N
weeks NNS N
and CC N
77.9 CD N
? . N
30.2 CD N
weeks NNS N
when WRB N
they PRP N
were VBD N
separated VBN N
into IN N
successful JJ N
categories NNS N
. . N

METHODS NNP N
This DT N
12-month JJ N
, , N
open JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
in IN N
15 CD N
centers NNS N
in IN N
France NNP N
and CC N
1 CD N
center NN N
in IN N
Belgium NNP N
; : N
309 CD N
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
induction NN N
therapy NN i
with IN N
ATG NNP N
( ( N
n=151 NN N
) ) N
followed VBN N
by IN N
initiation NN N
of IN N
tacrolimus NN N
on IN N
day NN N
9 CD N
or CC N
immediate JJ N
tacrolimus-based JJ N
triple NN N
therapy NN i
( ( N
n=158 JJ N
) ) N
. . N

We PRP N
performed VBD N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
of IN N
rituximab NN i
( ( N
375 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
given VBN N
either CC N
concurrently RB N
before IN N
each DT N
infusional JJ N
etoposide NN N
, , N
vincristine NN N
, , N
doxorubicin NN i
, , N
cyclophosphamide NN N
, , N
and CC N
prednisone NN N
( ( N
EPOCH NNP N
) ) N
chemotherapy NN i
cycle NN N
or CC N
sequentially RB N
( ( N
weekly JJ N
for IN N
6 CD N
weeks NNS N
) ) N
after IN N
completion NN N
of IN N
all DT N
chemotherapy NN i
in IN N
HIV-associated NNP N
NHL NNP N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
among IN N
the DT N
three CD N
treatment NN N
groups NNS N
with IN N
respect NN N
to TO N
clinical JJ N
outcome NN N
; : N
more JJR N
patients NNS p
in IN N
the DT N
CAE NNP N
group NN N
( ( N
62 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
CEC NNP N
group NN N
( ( N
46 CD N
% NN N
) ) N
or CC N
the DT N
AMX-CL JJ N
group NN N
( ( N
52 CD N
% NN N
) ) N
had VBD N
complete JJ N
resolution NN N
of IN N
signs NNS N
and CC N
symptoms NNS N
of IN N
AOM NNP N
( ( N
including VBG N
effusion NN N
) ) N
. . N

At IN N
week NN N
8 CD N
Ca NNP N
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
group NN N
A NNP N
, , N
whereas IN N
a DT N
significant JJ N
increase NN o
occurred VBD N
in IN N
groups NNS N
B NNP N
and CC N
C. NNP N
Side-effects NNP N
with IN N
sevelamer JJ N
administration NN N
occurred VBD N
in IN N
34 CD N
of IN N
the DT N
86 CD N
patients NNS p
and CC N
24 CD N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
, , N
with IN N
a DT N
high JJ N
frequency NN N
in IN N
group NN N
A NNP N
( ( N
13/29 CD N
; : N
44.8 CD N
% NN N
) ) N
. . N

Twenty-six JJ N
hemiplegic JJ N
subjects NNS N
with IN N
chronic JJ N
stroke NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
20-session JJ N
wrist NN N
training NN N
with IN N
an DT N
electromyography NN N
( ( N
EMG NNP N
) ) N
-driven RB N
NMES NNP N
robot NN N
( ( N
NMES NNP N
robot NNP N
group NN N
, , N
n RB N
= VBZ N
11 CD N
) ) N
and CC N
with IN N
an DT N
EMG-driven JJ N
robot NN N
( ( N
robot JJ N
group NN N
, , N
n RB N
= VBZ N
15 CD N
) ) N
, , N
completed VBD N
within IN N
7 CD N
consecutive JJ N
weeks NNS N
. . N

CLASSIFICATION NN N
OF NNP N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
III NNP N
evidence NN N
that WDT N
CBT NNP N
in IN N
addition NN N
to TO N
SMC NNP N
, , N
as IN N
compared VBN N
to TO N
SMC NNP N
alone RB N
, , N
significantly RB N
reduces VBZ N
seizure NN N
frequency NN N
in IN N
patients NNS p
with IN N
PNES NNP N
( ( N
change NN N
in IN N
median JJ N
monthly JJ N
seizure NN N
frequency NN N
: : N
baseline NN N
to TO N
6 CD N
months NNS N
follow-up RB N
, , N
CBT NNP N
group NN N
, , N
12 CD N
to TO N
1.5 CD N
; : N
SMC NNP N
alone RB N
group NN N
, , N
8 CD N
to TO N
5 CD N
) ) N
. . N

DESIGN NNP N
Subjects VBZ N
with IN N
type NN N
2 CD N
diabetes NNS N
( ( N
n JJ N
= NNP N
62 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
approximately RB N
10 CD N
% NN N
of IN N
energy NN N
from IN N
low-fiber JJ N
breakfast NN N
cereal NN N
( ( N
LF NNP N
diet NN N
) ) N
, , N
high-fiber JJ N
breakfast NN N
cereal NN N
( ( N
HF NNP N
diet NN N
) ) N
, , N
or CC N
monounsaturated VBN N
fatty JJ N
acids NNS N
( ( N
MUFA NNP N
diet NN N
) ) N
for IN N
6 CD N
mo NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
, , N
masked VBD N
clinical JJ N
trial NN N
for IN N
one CD N
year NN N
in IN N
southern JJ N
India NNP N
involving VBG N
15,419 CD N
preschool-age JJ N
children NNS N
who WP N
received VBD N
either CC N
8.7 CD N
mumol NN N
( ( N
8333 CD N
IU NNP N
) ) N
of IN N
vitamin NN N
A NNP N
and CC N
46 CD N
mumol NN N
( ( N
20 CD N
mg NN N
) ) N
of IN N
vitamin NN N
E NNP N
( ( N
the DT N
treated VBN N
group NN N
) ) N
or CC N
vitamin JJ N
E NNP N
alone RB N
( ( N
the DT N
control NN N
group NN N
) ) N
. . N

PARTICIPANTS NNP N
Twenty NNP N
eyes NNS N
of IN N
20 CD N
consecutive JJ N
patients NNS p
( ( N
spherical JJ N
equivalent NN N
[ NNP N
SE NNP N
] NNP N
, , N
-2.01+/-1.36 NNP N
diopters NNS N
[ NNP N
D NNP N
] NNP N
) ) N
treated VBD N
with IN N
wavefront-guided JJ N
Zyoptix NNP N
Ablation NNP N
Refinement NNP N
software NN N
( ( N
ZAR NNP N
) ) N
LASIK NNP N
and CC N
20 CD N
eyes NNS N
of IN N
20 CD N
consecutive JJ N
patients NNS p
( ( N
SE NNP N
, , N
-1.81+/-1.21 NNP N
D NNP N
) ) N
treated VBD N
with IN N
standard JJ N
Planoscan NNP N
LASIK NNP N
, , N
both DT N
for IN N
residual JJ N
refractive JJ N
error NN N
enhancement NN N
. . N

METHODS NNP N
This DT N
post NN N
hoc NN N
exploratory NN N
analysis NN N
evaluated VBD N
patients NNS p
with IN N
metabolic JJ N
syndrome NN N
treated VBN N
with IN N
IPE NNP N
4 CD N
grams/day NN N
, , N
IPE NNP N
2 CD N
grams/day NN N
, , N
or CC N
placebo NN N
in IN N
phase NN N
3 CD N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
studies NNS N
entitled VBN N
: : N
MARINE NNP N
[ NNP N
triglyceride NN N
( ( N
TG NNP N
) ) N
levels NNS N
? . N
and CC N
? . N
mg/dL NN N
] NN N
and CC N
ANCHOR NNP N
[ NNP N
TG NNP N
levels NNS N
? . N
and CC N
< $ N
500 CD N
mg/dL NN N
, , N
despite IN N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
control NN N
with IN N
stable JJ N
statin NN i
therapy NN i
] NN N
. . N

Women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
1 CD N
) ) N
control NN N
: : N
continue NN N
established VBD N
dietary JJ N
intake NN N
; : N
2 CD N
) ) N
medium NN N
dairy NN N
: : N
substitute NN N
dairy NN N
products NNS N
to TO N
achieve VB N
intake NN N
of IN N
calcium NN N
of IN N
approximately RB N
1000-1100 JJ N
mg/d NN N
and CC N
maintain VB N
isocaloric JJ N
intake NN N
; : N
3 CD N
) ) N
high JJ N
dairy NN N
: : N
substitute NN N
dairy NN N
products NNS N
to TO N
achieve VB N
intake NN N
of IN N
calcium NN N
of IN N
1300-1400 JJ N
mg/d NN N
and CC N
maintain VB N
isocaloric JJ N
intake NN N
. . N

Protocol $ N
1 CD N
: : N
96 CD N
bovine NN N
incisors NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
, , N
and CC N
enamel JJ N
surfaces NNS N
were VBD N
bonded VBN N
in IN N
accordance NN N
with IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( N
1E CD N
) ) N
ozone NN N
+ NN N
Clearfil NNP N
Protect NNP N
Bond NNP N
; : N
( ( N
2E CD N
) ) N
Clearfil NNP N
Protect NNP N
Bond NNP N
( ( N
control NN N
) ) N
; : N
( ( N
3E CD N
) ) N
ozone NN N
+ JJ N
Xeno NNP N
III NNP N
; : N
( ( N
4E CD N
) ) N
Xeno NN N
III NNP N
( ( N
control NN N
) ) N
. . N

Myocardial JJ N
ultrastructure NN N
on IN N
septal JJ N
biopsies NNS N
, , N
obtained VBD N
within IN N
5 CD N
min NN N
from IN N
weaning VBG N
from IN N
extracorporeal JJ N
circulation NN N
, , N
showed VBD N
better JJR N
preservation NN N
scores NNS N
for IN N
all DT N
considered VBN N
parameters NNS N
( ( N
nucleus NN N
, , N
sarcoplasmic JJ N
reticulum NN N
, , N
mitochondria NN N
and CC N
cellular JJ N
oedema NN N
) ) N
in IN N
the DT N
treated JJ N
subjects NNS N
, , N
although IN N
the DT N
difference NN N
reached VBD N
statistical JJ N
significance NN N
only RB N
for IN N
nuclei NN N
. . N

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
increase NN o
in IN N
the DT N
high-density NN N
lipoprotein NN N
cholesterol/total JJ N
cholesterol NN N
ratio NN N
was VBD N
observed VBN N
in IN N
the DT N
ethinyl JJ N
E2-desogestrel NNP N
group NN N
, , N
and CC N
no DT N
persistent JJ N
changes NNS N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
could MD N
be VB N
demonstrated VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

For IN N
example NN N
, , N
approximately RB N
20 CD N
% NN N
of IN N
patients NNS p
might MD N
be VB N
expected VBN N
to TO N
have VB N
a DT N
chance NN N
increase NN o
or CC N
decrease NN o
in IN N
symptom NN N
score NN N
by IN N
at IN N
least JJS N
4.9 CD N
points NNS N
, , N
in IN N
peak JJ N
urine JJ N
flow NN N
rate NN N
by IN N
at IN N
least JJS N
4.1 CD N
ml NN N
. . N

We PRP N
assigned VBD N
a DT N
total NN N
of IN N
578 CD N
adult NN N
ambulatory NN N
surgery NN N
patients NNS p
to TO N
either VB N
a DT N
control NN N
group NN N
that WDT N
was VBD N
given VBN N
two CD N
folded JJ N
, , N
warmed JJ N
cotton NN N
blankets NNS N
or CC N
a DT N
treatment NN N
group NN N
that WDT N
was VBD N
given VBN N
a DT N
warmed NN N
, , N
unfolded JJ N
cotton NN N
sheet NN N
and CC N
cotton NN N
blanket NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
influence NN N
between IN N
prehydration NN N
with IN N
3 CD N
% NN N
hypertonic JJ N
saline NN N
and CC N
with IN N
isotonic JJ N
lactated VBN N
Ringer NNP N
's POS N
solution NN N
on IN N
the DT N
hemodynamic JJ N
changes NNS N
and CC N
serum NN N
electrolyte NN N
concentrations NNS N
in IN N
patients NNS p
undergoing JJ N
spinal JJ N
anesthesia NN N
. . N

The DT N
simulation NN N
predicted VBD N
that IN N
for IN N
the DT N
5 CD N
mg NN N
dose NN N
group NN N
the DT N
trough JJ N
DPP-4 JJ N
inhibition NN N
at IN N
steady-state NN N
was VBD N
84.2 CD N
% NN N
, , N
which WDT N
is VBZ N
higher JJR N
than IN N
the DT N
target NN N
inhibition NN N
( ( N
? . N
% NN N
) ) N
for IN N
an DT N
effective JJ N
dose NN N
of IN N
DPP-4 NNP N
inhibitor NN N
. . N

CONCLUSION NNP N
The DT N
suppression NN N
of IN N
the DT N
RAS NNP N
by IN N
the DT N
blockade NN N
of IN N
angiotensin NN N
II NNP N
type NN N
1 CD N
( ( N
AT NNP N
( ( N
1 CD N
) ) N
) ) N
receptors NNS N
may MD N
demonstrate VB N
remodeling VBG N
effects NNS N
on IN N
the DT N
ubiquitous JJ N
small JJ N
resistance NN N
vessels NNS N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
the DT N
myocardium NN N
and CC N
renal JJ N
glomeruli NN N
, , N
thus RB N
affording VBG N
more JJR N
complete JJ N
end-organ JJ N
protection NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
angiotensin NN N
converting VBG N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitors NNS N
on IN N
cough NN N
responses NNS N
to TO N
bradykinin VB N
( ( N
BK NNP N
) ) N
, , N
substance NN N
P NNP N
( ( N
SP NNP N
) ) N
and CC N
citric JJ N
acid NN N
in IN N
a DT N
double JJ N
blind NN N
, , N
random NN N
study NN N
on IN N
10 CD N
hypertensive JJ N
patients NNS p
receiving VBG N
ACE NNP N
inhibitors NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN N
in IN N
plasma NN N
transferrin NN N
levels NNS N
and CC N
a DT N
trend NN N
toward IN N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN N
in IN N
plasma JJ N
superoxide JJ N
dismutase NN N
levels NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Forty-four JJ N
patients NNS p
underwent JJ N
CRT NNP N
device NN N
implantation NN N
using VBG N
Overlay NNP N
Ref NNP N
to TO N
guide VB N
target NN N
vein JJ N
selection NN N
and CC N
advance VB N
a DT N
specifically RB N
designed VBN N
pacing VBG N
lead NN N
into IN N
the DT N
target NN N
vein NN N
( ( N
Overlay NNP N
Ref NNP N
group NN N
) ) N
; : N
44 CD N
patients NNS p
were VBD N
conventionally RB N
implanted VBN N
( ( N
control VB N
group NN N
) ) N
. . N

Each DT N
specimen NN N
was VBD N
embedded VBN N
in IN N
a DT N
self-cured JJ N
acrylic JJ N
resin NN N
block NN N
from IN N
2.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
margins NNS N
of IN N
a DT N
cast JJ N
Ni-Cr JJ N
alloy NN N
crown NN N
, , N
then RB N
loaded VBD N
at IN N
150 CD N
degrees NNS N
from IN N
the DT N
long JJ N
axis NN N
in IN N
a DT N
universal JJ N
testing VBG N
machine NN N
at IN N
a DT N
crosshead JJ N
speed NN N
of IN N
1.0 CD N
mm/minute NN N
until IN N
fracture NN N
. . N

Most JJS N
responses NNS N
returned VBN N
to TO N
the DT N
baseline NN N
values NNS N
within IN N
24 CD N
h. NN N
Plasma NNP N
bupivacaine NN N
concentrations NNS N
remained VBD N
within IN N
safe JJ N
limits NNS N
during IN N
the DT N
study NN N
, , N
but CC N
systemic JJ N
concentrations NNS N
increased VBD o
in IN o
some DT N
of IN N
the DT N
patients NNS p
during IN N
postoperative JJ N
infusion NN N
with IN N
0.125 CD N
% NN N
bupivacaine NN N
. . N

This DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
water NN N
extracts NNS N
of IN N
Graptopetalum NNP N
paraguayense NN N
( ( N
WGP NNP N
, , N
4 CD N
g/d NN N
) ) N
on IN N
blood NN N
pressure NN N
, , N
blood NN N
glucose JJ N
level NN N
, , N
and CC N
lipid JJ N
profiles NNS N
in IN N
subjects NNS N
with IN N
metabolic JJ N
syndrome NN N
( ( N
MS NNP N
) ) N
. . N

During IN N
the DT N
first JJ N
and CC N
second JJ N
months NNS N
of IN N
the DT N
washout NN N
, , N
slight JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
changes NNS N
of IN N
various JJ N
fatty JJ N
acids NNS N
among IN N
different JJ N
phospholipid JJ N
fractions NNS N
, , N
but CC N
after IN N
3 CD N
mo NN N
of IN N
washout NN N
, , N
only RB N
minor JJ N
alterations NNS N
were VBD N
still RB N
detectable JJ N
with IN N
respect NN N
to TO N
pretreatment VB N
values NNS N
. . N

The DT N
effects NNS N
of IN N
consuming VBG N
a DT N
liquid JJ N
formula NN N
containing VBG N
either CC N
fish JJ N
oil NN N
enriched VBN N
in IN N
omega-3 JJ N
fatty JJ N
acids NNS N
or CC N
vegetable JJ N
oil NN N
enriched VBN N
in IN N
oleic JJ N
acid NN N
was VBD N
evaluated VBN N
in IN N
20 CD N
male JJ N
subjects NNS N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
over IN N
a DT N
42-d JJ N
period NN N
. . N

A DT N
total NN N
of IN N
1,480 CD N
pigs NNS N
were VBD N
used VBN N
in IN N
3 CD N
experiments NNS N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
corn NN N
distillers NNS N
dried VBD N
grains NNS N
with IN N
solubles NNS N
( ( N
DDGS NNP N
) ) N
varying VBG N
in IN N
oil NN N
content NN N
on IN N
growth NN N
performance NN N
, , N
carcass NN N
traits NNS N
, , N
and CC N
nutrient JJ N
digestibility NN N
in IN N
finishing VBG N
pigs NNS N
. . N

We PRP N
conclude VBP N
that IN N
intramuscular JJ N
administration NN N
of IN N
the DT N
fixed JJ N
combination NN N
of IN N
troxerutin $ i
150 CD N
mg NN N
and CC N
carbazochrome VB N
1.5 CD N
mg NN N
is VBZ N
effective JJ N
, , N
well RB N
tolerated VBN N
and CC N
superior JJ N
to TO N
placebo VB N
in IN N
improving VBG N
hemorrhoidal NN N
and CC N
post-surgical JJ N
symptoms NNS N
during IN N
the DT N
five CD N
days NNS N
following VBG N
surgery NN N
. . N

CONTEXT NN N
We PRP N
have VBP N
recently RB N
demonstrated VBN N
short-term JJ N
( ( N
6-month JJ N
) ) N
efficacy NN N
and CC N
safety NN N
of IN N
leuprolide JJ N
acetate JJ N
3-month JJ N
depot NN N
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS N
with IN N
central JJ N
precocious JJ N
puberty NN N
( ( N
CPP NNP N
) ) N
. . N

Theophylline NNP N
concentrations NNS N
in IN N
saliva NN N
have VBP N
been VBN N
compared VBN N
with IN N
those DT N
in IN N
serum NN N
in IN N
13 CD N
asthmatic JJ N
patients NNS p
after IN N
single JJ N
and CC N
multiple JJ N
oral JJ N
dosage NN N
of IN N
a DT N
microcrystalline JJ N
theophylline NN N
tablet NN N
( ( N
Nuelin NNP N
) ) N
and CC N
a DT N
sustained-release JJ N
preparation NN N
( ( N
Nuelin NNP N
Retard NNP N
) ) N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
in IN N
infarct JJ N
size NN N
estimated VBN N
by IN N
measurement NN N
of IN N
serum JJ N
CK-MB NNP N
, , N
planimetry NN N
of IN N
infarct JJ N
area NN N
on IN N
technetium NN N
pyrophosphate NN N
myocardial JJ N
scintigrams NNS N
or CC N
R-wave JJ N
measurements NNS N
in IN N
patients NNS p
with IN N
transmural JJ N
anterior NNS N
and CC N
inferior JJ N
infarcts NNS N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
satisfaction NN N
rate NN N
, , N
efficacy NN N
, , N
and CC N
complication NN N
rate NN N
of IN N
carbon NN N
dioxide NN N
( ( N
CO NNP N
( ( N
2 CD N
) ) N
) ) N
versus NN N
normal JJ N
saline NN N
as IN N
a DT N
uterine JJ N
distension NN N
medium NN N
for IN N
outpatient JJ N
diagnostic JJ N
vaginoscopic NN N
hysteroscopy NN N
in IN N
infertile JJ N
patients NNS p
. . N

The DT N
Phase NNP N
1 CD N
single JJ N
round NN N
of IN N
DMSA NNP N
led VBD N
to TO N
a DT N
dramatic JJ N
normalization NN N
of IN N
RBC NNP N
glutathione NN N
in IN N
almost RB N
all DT N
cases NNS N
, , N
and CC N
greatly RB N
improved VBN N
abnormal JJ N
platelet NN N
counts NNS N
, , N
suggesting VBG N
a DT N
significant JJ N
decrease NN o
in IN N
inflammation NN N
. . N

DISCUSSION NNP N
The DT N
finding NN N
of IN N
high JJ N
vitamin NN N
B NNP N
( ( N
6 CD N
) ) N
levels NNS N
is VBZ N
consistent JJ N
with IN N
recent JJ N
reports NNS N
of IN N
low JJ N
levels NNS N
of IN N
pyridoxal-5-phosphate NN N
and CC N
low JJ N
activity NN N
of IN N
pyridoxal NN N
kinase NN N
( ( N
i.e JJ N
, , N
pyridoxal NN N
is VBZ N
only RB N
poorly RB N
converted VBN N
to TO N
pyridoxal-5-phosphate NN N
, , N
the DT N
enzymatically RB N
active JJ N
form NN N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
daily JJ N
consumption NN N
of IN N
lutein NN N
or CC N
zeaxanthin NN N
enriched VBN N
egg NN N
yolks NNS N
as RB N
well RB N
as IN N
an DT N
egg NN N
yolk-based JJ N
beverage NN N
show NN N
increases VBZ o
in IN N
serum NN N
lutein NN N
and CC N
zeaxanthin NN N
levels NNS N
that WDT N
are VBP N
comparable JJ N
with IN N
a DT N
daily JJ N
use NN N
of IN N
5 CD N
mg NN N
supplements NNS N
. . N

Both DT N
carbapenems NNS N
revealed VBD N
high JJ N
SBAs NNP N
against IN N
clinically RB N
important JJ N
pathogens NNS N
at IN N
1 CD N
h NN N
; : N
meropenem NN N
had VBD N
a DT N
higher JJR N
SBA NNP N
against IN N
E. NNP N
cloacae NN N
and CC N
P. NNP N
mirabilis NN N
, , N
and CC N
the DT N
SBA NNP N
of IN N
imipenem NN N
against IN N
S. NNP N
aureus NN N
was VBD N
greater JJR N
than IN N
the DT N
SBA NNP N
of IN N
meropenem NN N
. . N

Thereby RB N
, , N
GH NNP N
shows VBZ N
a DT N
triphasic JJ N
action NN N
on IN N
BMD NNP N
: : N
an DT N
initial JJ N
decrease NN o
in IN N
BMD NNP N
during IN N
the DT N
1st CD N
year NN N
, , N
followed VBN N
by IN N
a DT N
continuous JJ N
increase NN o
in IN N
BMD NNP N
with IN N
buildup NN N
of IN N
a DT N
stable JJ N
plateau NN N
after IN N
60 CD N
months NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
blood NN N
biochemistry NN N
and CC N
hematological JJ N
parameters NNS N
were VBD N
not RB N
different JJ N
among IN N
treatments NNS N
except IN N
concentration NN N
of IN N
plasma JJ N
urea JJ N
N NNP N
, , N
plasma NN N
glucose NN N
, , N
and CC N
total JJ N
blood NN N
protein NN N
were VBD N
improved VBN N
especially RB N
with IN N
U-cas JJ N
supplementation NN N
at IN N
180 CD N
g/kg NN N
DM NNP N
in IN N
FB NNP N
. . N

The DT N
blood NN N
sugar NN N
profile NN N
and CC N
insulin NN N
consumption NN N
over IN N
a DT N
24 CD N
hour NN N
period NN N
was VBD N
not RB N
affected VBN N
by IN N
either DT N
penbutolol NN i
or CC N
placebo NN N
, , N
nor CC N
could MD N
any DT N
changes NNS N
be VB N
measured VBN N
in IN N
these DT N
parameters NNS N
when WRB N
measured VBN N
after IN N
food NN N
intake NN N
. . N

Sequential JJ N
methotrexate NN N
( ( N
Mtx NNP N
) ) N
absorption NN N
studies NNS N
were VBD N
undertaken VBN N
in IN N
127 CD N
children NNS N
undergoing JJ N
treatment NN N
for IN N
childhood NN N
non-T JJ N
acute JJ N
lymphoblastic JJ N
leukaemia NN N
( ( N
ALL NNP N
) ) N
to TO N
determine VB N
whether IN N
serum JJ N
drug NN N
concentration NN N
, , N
clearance NN N
and CC N
dosage NN N
affect JJ N
event NN N
free JJ N
survival NN N
( ( N
EFS NNP N
) ) N
. . N

A DT N
Phase NNP N
II NNP N
clinical JJ N
study NN N
that WDT N
was VBD N
not RB N
completed VBN N
documented VBD N
that IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
PPS NNP N
administered VBD N
for IN N
8 CD N
weeks NNS N
lowered VBD N
plasma JJ N
levels NNS N
of IN N
sVCAM-1 NN N
and CC N
tended VBD N
to TO N
improve VB N
microvascular JJ N
blood NN N
flow NN N
in IN N
patients NNS p
with IN N
SCD NNP N
. . N

In IN N
61 CD N
acceptable JJ N
patients NNS p
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
response NN N
rate NN N
, , N
time NN N
to TO N
progression NN N
, , N
duration NN N
of IN N
the DT N
response NN N
, , N
and CC N
survival JJ N
rate NN N
. . N

In IN N
the DT N
BL NNP N
, , N
NO2 NNP N
exposure NN N
caused VBD N
increases NNS o
in IN N
polymorphonuclear JJ N
neutrophils NNS N
( ( N
PMNs NNP N
) ) N
, , N
interleukin JJ N
6 CD N
( ( N
IL-6 NNP N
) ) N
, , N
IL-8 NNP N
, , N
alpha1-antitrypsin NN N
, , N
and CC N
tissue NN N
plasminogen NN N
activator NN N
, , N
and CC N
decreases NNS o
in IN N
epithelial JJ N
cells NNS N
. . N

The DT N
physostigmine NN N
patch NN N
application NN N
in IN N
doses NNS N
of IN N
30 CD N
mg NNS N
and CC N
60 CD N
mg NNS N
apparently RB N
did VBD N
not RB N
lead VB N
to TO N
physostigmine VB N
plasma JJ N
concentrations NNS N
that WDT N
were VBD N
sufficient JJ N
to TO N
compensate VB N
for IN N
cholinergic JJ N
deficiencies NNS N
in IN N
affected JJ N
brain NN N
areas NNS N
and CC N
produce VB N
clinical JJ N
benefits NNS N
. . N

CONCLUSIONS NNP N
Clinical NNP N
efficacy NN N
of IN N
T NNP N
replacement NN N
therapy NN i
in IN N
hypogonadal JJ N
men NNS N
with IN N
MS NNP N
is VBZ N
reached VBN N
when WRB N
its PRP$ N
plasmatic JJ N
levels NNS N
approach VBP N
into IN N
the DT N
medium-high JJ N
range NN N
of IN N
normality NN N
( ( N
> JJ N
5 CD N
ng/ml NN N
) ) N
, , N
although IN N
subjective JJ N
threshold JJ N
values NNS N
may MD N
be VB N
different JJ N
. . N

More RBR N
proven JJ N
systemic JJ N
fungal JJ N
infections NNS N
occurred VBD N
in IN N
flu NN N
( ( N
Aspergillus NNP N
four CD N
, , N
Candida NNP N
tropicalis VBZ N
one CD N
, , N
C. NNP N
krusei NNP N
one NN N
) ) N
than IN N
itra NN N
( ( N
C. NNP N
albicans VBZ N
one CD N
) ) N
and CC N
more JJR N
of IN N
these DT N
were VBD N
fatal JJ N
( ( N
four CD N
versus NN N
nil NN N
) ) N
. . N

On IN N
the DT N
day NN N
of IN N
the DT N
O NNP N
( ( N
3 CD N
) ) N
exposure NN N
, , N
supplemented VBN N
subjects NNS N
were VBD N
found VBN N
to TO N
have VB N
significantly RB N
increased VBN o
levels NNS N
of IN N
plasma NN N
ascorbate NN N
, , N
tocopherols NNS N
, , N
and CC N
carotenoids NNS N
as IN N
compared VBN N
with IN N
those DT N
of IN N
the DT N
placebo NN N
group NN N
. . N

RESULTS NNP N
Although IN N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
were VBD N
found VBN N
in IN N
both DT N
the DT N
maxillary NN N
and CC N
mandibular JJ N
arches NNS N
after IN N
phase NN N
1 CD N
, , N
these DT N
differences NNS N
were VBD N
no RB N
longer RBR N
evident JJ N
by IN N
the DT N
end NN N
of IN N
full JJ N
orthodontic JJ N
treatment NN N
or CC N
after IN N
posttreatment JJ N
retention NN N
. . N

It PRP N
has VBZ N
also RB N
been VBN N
reported VBN N
that IN N
a DT N
single JJ N
nucleotide NN N
polymorphism NN N
( ( N
SNP NNP N
) ) N
in IN N
exon $ N
12 CD N
of IN N
HIF-1alpha NNP N
gene NN N
is VBZ N
present JJ N
in IN N
renal JJ N
cell NN N
carcinoma NN N
and CC N
head NN N
and CC N
neck NN N
squamous JJ N
cell NN N
carcinoma NN N
patients NNS p
. . N

Intensive JJ N
treatment NN N
should MD N
be VB N
started VBN N
as RB N
soon RB N
as IN N
is VBZ N
safely RB N
possible JJ N
after IN N
the DT N
onset NN N
of IN N
type NN N
1 CD N
diabetes NNS N
mellitus NN N
and CC N
maintained VBD N
thereafter RB N
, , N
aiming VBG N
for IN N
a DT N
practicable JJ N
target NN N
HbA NNP N
( ( N
1c CD N
) ) N
level NN N
of IN N
7.0 CD N
% NN N
or CC N
less JJR N
. . N

The DT N
fixed JJ N
combination NN N
between IN N
troxerutin $ i
150 CD N
mg NN N
and CC N
carbazochrome VB N
1.5 CD N
mg NN N
( ( N
Fleboside NNP N
ampoules NNS N
) ) N
was VBD N
previously RB N
shown VBN N
to TO N
have VB N
a DT N
good JJ N
efficacy NN N
and CC N
safety NN N
profile NN N
in IN N
non-surgical JJ N
patients NNS p
with IN N
acute JJ N
uncomplicated JJ N
hemorrhoids NNS N
. . N

However RB N
, , N
in IN N
5 CD N
subjects NNS N
with IN N
acute JJ N
increases NNS o
in IN N
serum JJ N
creatinine NN N
levels NNS N
, , N
serum NN N
creatine NN N
kinase NN N
levels NNS N
were VBD N
significantly RB N
elevated VBN N
as RB N
well RB N
, , N
suggesting VBG N
that IN N
myocyte JJ N
toxicity NN N
may MD N
have VB N
been VBN N
responsible JJ N
. . N

METHODS NNP N
Plasma NNP N
concentrations NNS N
of IN N
vWf NN N
and CC N
sP-sel NN N
were VBD N
measured VBN N
by IN N
enzyme NN N
linked VBN N
immunosorbent JJ N
assay NN N
( ( N
ELISA NNP N
) ) N
in IN N
1321 CD N
participants NNS N
in IN N
the DT N
SPAF NNP N
III NNP N
study NN N
and CC N
related VBN N
to TO N
the DT N
presence NN N
and CC N
onset NN N
of IN N
clinical JJ N
CHF NNP N
, , N
as RB N
well RB N
as IN N
echocardiographic JJ N
findings NNS N
. . N

Key NNP N
secondary JJ N
endpoints NNS N
included VBD N
target NN N
vessel NN N
failure NN N
( ( N
TVF NNP N
; : N
including VBG N
cardiac JJ N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
and CC N
target VB N
vessel JJ N
revascularization NN N
) ) N
and CC N
Academic NNP N
Research NNP N
Consortium-defined NNP N
definite/probable JJ N
stent NN N
thrombosis NN N
( ( N
ST NNP N
) ) N
within IN N
12 CD N
months NNS N
. . N

All DT N
adverse JJ N
events NNS N
resolved VBD N
within IN N
72 CD N
h. JJ N
Induction NNP N
of IN N
chemokines/cytokines NNS N
and CC N
IFN-stimulated JJ N
genes NNS N
were VBD N
seen VBN N
at IN N
GS-9620 NNP N
doses NNS N
? . N
2 CD N
mg NN N
, , N
well RB N
below IN N
doses NNS N
that WDT N
induced VBD N
serum JJ N
IFN- NNP N
or CC N
led VBN N
to TO N
clinical JJ N
adverse JJ N
events NNS N
. . N

The DT N
odds NNS N
ratio NN N
in IN N
the DT N
control NN N
group NN N
for IN N
the DT N
rate NN N
of IN N
morbidity NN N
( ( N
cerebral JJ N
infarction NN N
and CC N
reversible JJ N
ischemic JJ N
neurological JJ N
deficits NNS N
) ) N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
following VBG N
the DT N
operation NN N
was VBD N
3.2 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

Mean JJ N
changes NNS N
in IN N
log NN N
serum JJ N
level NN N
of IN N
PSA NNP N
, , N
testosterone NN N
, , N
dihydrotestosterone NN N
, , N
luteinizing VBG N
hormone NN N
and CC N
sex NN N
hormone NN N
binding VBG N
globulin NN N
over IN N
21 CD N
weeks NNS N
between IN N
the DT N
verum NN N
and CC N
the DT N
placebo NN N
group NN N
were VBD N
compared VBN N
by IN N
analysis NN N
of IN N
covariance NN N
. . N

Protein NNP N
breakdown NN N
, , N
protein JJ N
oxidation NN N
, , N
protein JJ N
balance NN N
, , N
and CC N
glucose JJ N
production NN N
were VBD N
assessed VBN N
by IN N
stable JJ N
isotope NN N
tracer NN N
kinetics NNS N
using VBG N
l- JJ N
[ JJ N
1- JJ N
( ( N
13 CD N
) ) N
C NNP N
] NNP N
leucine NN N
and CC N
[ JJ N
6,6- JJ N
( ( N
2 CD N
) ) N
H2 NNP N
] NNP N
glucose NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
death NN N
at IN N
30 CD N
days NNS N
, , N
interleukin-6 JJ N
levels NNS N
, , N
inotropic NN N
score NN N
, , N
fluid NN N
balance NN N
, , N
serum JJ N
creatinine NN N
, , N
and CC N
intensive JJ N
care NN N
unit NN N
and CC N
hospital NN N
stay NN N
. . N

In IN N
vitro-in JJ N
vivo NN N
correlations NNS N
were VBD N
obtained VBN N
by IN N
comparing VBG N
the DT N
logarithm NN N
of IN N
the DT N
in IN N
vitro JJ N
burst NN N
time NN N
with IN N
time NN N
to TO N
peak VB N
plasma JJ N
level NN N
and CC N
the DT N
time NN N
to TO N
the DT N
first JJ N
measurable JJ N
plasma NN N
level NN N
( ( N
> CD N
or CC N
= VB N
0 CD N
. . N

Plasma NNP N
P-selectin NNP i
antigen NN N
, , N
tissue NN N
plasminogen NN N
activator NN N
( ( N
tPA NN N
) ) N
antigen NN N
and CC N
activity NN N
, , N
and CC N
plasminogen NN N
activator NN N
inhibitor-1 JJ N
( ( N
PAI-1 NNP N
) ) N
activity NN N
were VBD N
determined VBN N
in IN N
60 CD N
acute JJ N
atherosclerotic JJ i
stroke NN N
patients NNS p
and CC N
matched VBN N
control NN N
subjects NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
eradication NN N
of IN N
both DT N
therapies NNS N
in IN N
both DT N
the DT N
antrum NN N
and CC N
gastric JJ N
body NN N
samples NNS N
( ( N
over IN N
80 CD N
% NN N
eradication NN N
) ) N
, , N
allowing VBG N
the DT N
results NNS N
to TO N
be VB N
classified VBN N
as IN N
satisfactory NN N
. . N

The DT N
effect NN N
of IN N
zidovudine NN N
and CC N
didanosine NN N
on IN N
the DT N
cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
concentrations NNS N
of IN N
neopterin NN N
was VBD N
studied VBN N
in IN N
12 CD N
patients NNS p
with IN N
human JJ N
immunodeficiency NN N
virus NN N
type-1 NN N
( ( N
HIV-1 NNP N
) ) N
infection NN N
3-12 JJ N
months NNS N
after IN N
initiation NN N
of IN N
antiretroviral JJ N
therapy NN i
. . N

The DT N
treatment NN N
group NN N
also RB N
showed VBD N
in IN N
vivo JJ N
T-cell NNP N
activation NN N
with IN N
an DT N
initial JJ N
lymphopenia NN N
followed VBN N
by IN N
a DT N
rebound NN N
lymphocytosis NN N
and CC N
upregulation NN N
of IN N
the DT N
subset NN N
markers NNS N
CD25 NNP N
( ( N
interleukin JJ N
2 CD N
receptor NN N
) ) N
and CC N
CD45RO NNP N
( ( N
T-memory NNP N
cells NNS N
) ) N
. . N

OBJECTIVE IN N
The DT N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
there EX N
is VBZ N
a DT N
threshold JJ N
beyond IN N
which WDT N
increasing VBG N
doses NNS N
of IN N
vitamin NN N
D NNP N
, , N
or CC N
concentrations NNS N
of IN N
serum JJ N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
, , N
no RB N
longer RBR N
increase VB o
calcium NN N
absorption NN N
. . N

Compared VBN N
to TO N
baseline VB N
, , N
ABCA1 NNP N
and CC N
3-hydroxy-3-methyl-glutaryl NNP N
( ( N
HMG NNP N
) ) N
-CoA VBP N
reductase NN N
mRNA JJ N
expression NN N
increased VBN o
by IN N
week NN N
12 CD N
in IN N
the DT N
EGG NNP N
group NN N
only RB N
, , N
whereas NNS N
changes NNS N
in IN N
PBMC NNP N
total JJ N
cholesterol NN N
positively RB N
correlated VBN N
with IN N
changes NNS N
in IN N
lipid JJ N
raft NN N
content NN N
. . N

After IN N
a DT N
total NN N
of IN N
15,000 CD N
protein NNS N
nitrogen JJ N
units NNS N
( ( N
PNU NNP N
) ) N
had VBD N
been VBN N
given VBN N
, , N
blocking VBG N
antibody NN N
activity NN N
in IN N
the DT N
monomer NN N
group NN N
rose VBD N
from IN N
a DT N
mean NN N
of IN N
170 CD N
ng JJ N
AgE NNP N
bound NN N
per IN N
ml NN N
to TO N
a DT N
mean NN N
of IN N
2,813 CD N
. . N

Bepotastine NNP N
besilate NN N
ophthalmic JJ N
solution NN N
( ( N
BBOS NNP N
) ) N
1.5 CD N
% NN N
, , N
a DT N
dual-acting JJ N
histamine NN N
( ( N
H NNP N
( ( N
1 CD N
) ) N
) ) N
receptor NN N
antagonist NN N
and CC N
mast NN N
cell NN N
stabilizer NN N
, , N
is VBZ N
indicated VBN N
for IN N
itching VBG N
associated VBN N
with IN N
AC NNP N
. . N

A DT N
clinical JJ N
evaluation NN N
of IN N
a DT N
new JJ N
, , N
purified JJ N
, , N
heat-treated JJ N
equine NN N
rabies NNS N
immunoglobulin VBP N
( ( N
PHT-Erig NNP N
) ) N
, , N
F NNP N
( ( N
ab IN N
' POS N
) ) N
2 CD N
preparation NN N
, , N
was VBD N
carried VBN N
out RP N
in IN N
Thailand NNP N
and CC N
in IN N
the DT N
Philippines-two JJ N
countries NNS N
where WRB N
rabies NNS N
is VBZ N
endemic JJ N
. . N

Women NNS N
in IN N
the DT N
intervention NN N
arm NN N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
take VB N
their PRP$ N
infant NN N
to TO N
the DT N
clinic NN N
within IN N
the DT N
first JJ N
week NN N
of IN N
life NN N
( ( N
risk NN N
ratio VBP N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.04-1.18 JJ N
) ) N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
of IN N
therapy NN i
with IN N
placebo NN N
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
total JJ N
heart NN N
rate NN N
variability NN N
, , N
parasympathetically RB N
governed VBN N
high JJ N
frequency NN N
heart NN N
rate NN N
variability NN N
or CC N
sympathetically RB N
influenced JJ N
low JJ N
frequency NN N
heart NN N
rate NN N
variability NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
current JJ N
Recommended NNP N
Dietary NNP N
Allowance NNP N
for IN N
vitamin NN N
B6 NNP N
during IN N
pregnancy NN N
( ( N
2.5 CD N
mg NN N
) ) N
is VBZ N
too RB N
low JJ N
and CC N
that DT N
supplementation NN N
of IN N
this DT N
vitamin NN N
in IN N
an DT N
amount NN N
more JJR N
than IN N
4 CD N
mg JJ N
daily JJ N
is VBZ N
recommended VBN N
. . N

RESULTS NNS N
When WRB N
including VBG N
all DT N
follow-up JJ N
variables NNS N
, , N
there EX N
were VBD N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
Thirty-seven CD N
children NNS N
with IN N
male JJ N
predominance NN N
, , N
familial JJ N
history NN N
of IN N
epilepsy NN N
, , N
simple JJ N
febrile JJ N
convulsions NNS N
, , N
massive JJ N
myoclonus NN N
, , N
tonic-clonic JJ N
fits NNS N
. . N

The DT N
effect NN N
of IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
on IN N
the DT N
serological JJ N
response NN N
at IN N
influenza JJ N
vaccination NN N
was VBD N
studied VBN N
in IN N
117 CD N
patients NNS p
who WP N
had VBD N
undergone JJ N
stem NN N
cell NN N
transplantation NN N
( ( N
SCT NNP N
) ) N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
instantaneous JJ N
and CC N
reflective JJ N
ocular JJ N
itching NN N
scores NNS N
at IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
based VBN N
on IN N
subject-assessed JJ N
severity NN N
of IN N
instantaneous JJ N
and CC N
reflective JJ N
itching NN N
. . N

Complication NN N
rates NNS N
, , N
mortality NN N
, , N
and CC N
hospital JJ N
length NN N
of IN N
stay NN N
were VBD N
similar JJ N
between IN N
the DT N
2 CD N
groups NNS N
; : N
however RB N
, , N
administration NN N
of IN N
dopexamine NN N
was VBD N
associated VBN N
with IN N
earlier JJR N
return NN N
of IN N
tolerating VBG N
an DT N
enteral JJ N
diet NN N
. . N

METHODS NNP N
Thirty NNP N
eyes NNS N
of IN N
30 CD N
consecutive JJ N
patients NNS p
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
nonischemic JJ N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
were VBD N
assigned VBN N
to TO N
either DT N
GLP NNP N
group NN N
or CC N
to TO N
intravitreal VB N
bevacizumab NN i
( ( N
IB NNP N
) ) N
group NN N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
this DT N
nested JJ N
case-control NN N
study NN N
confirm VBP N
that IN N
finasteride NN N
blocks VBZ N
the DT N
conversion NN N
of IN N
testosterone NN N
to TO N
dihydrotestosterone VB N
( ( N
DHT NNP N
) ) N
and CC N
of IN N
androstenedione NN N
to TO N
5 CD N
, , N
which WDT N
also RB N
leads VBZ N
to TO N
the DT N
reduction NN N
of IN N
DHT NNP N
formation NN N
. . N

ASA NNP N
caused VBD N
a DT N
significant JJ N
reduction NN N
of IN N
B-TG NNP N
plasma NN N
levels NNS N
in IN N
TIA NNP N
patients NNS p
2 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
at IN N
the DT N
7th CD N
and CC N
14th CD N
day NN N
of IN N
treatment NN N
. . N

INTRODUCTION NNP N
The DT N
potential JJ N
effect NN N
of IN N
strontium NN N
( ( N
Sr NNP N
) ) N
on IN N
bone NN N
apatite JJ N
crystals NNS N
was VBD N
investigated VBN N
in IN N
paired JJ N
biopsies NNS N
of IN N
osteoporotic JJ i
women NNS N
treated VBN N
with IN N
either DT N
strontium NN N
ranelate NN N
( ( N
SrRan NNP N
) ) N
or CC N
a DT N
placebo NN N
for IN N
36 CD N
months NNS N
. . N

Although IN N
no DT N
statistical JJ N
difference NN N
in IN N
mortality NN N
rate NN N
was VBD N
appreciated VBN N
among IN N
the DT N
3 CD N
fluid NN N
resuscitation NN N
groups NNS N
, , N
a DT N
trend NN N
of IN N
decreased JJ o
mortality NN N
rate NN N
was VBD N
observed VBN N
in IN N
the DT N
HBOCS NNP N
group NN N
. . N

Serum NNP N
antibody NN N
responses NNS N
to TO N
three CD N
Haemophilus NNP N
influenzae NN N
type NN N
b NN N
( ( N
Hib NNP N
) ) N
capsular VBD N
polysaccharide-protein JJ N
conjugate NN N
vaccine NN N
( ( N
PRP-OMP NNP N
, , N
PRP-T NNP N
, , N
and CC N
HbOC NNP N
) ) N
were VBD N
evaluated VBN N
in IN N
174 CD N
Philippine JJ N
infants NNS N
after IN N
a DT N
primary JJ N
vaccination NN N
series NN N
. . N

CONCLUSIONS IN N
It PRP N
can MD N
be VB N
suggested VBN N
that IN N
0.6 CD N
and CC N
0.8 CD N
ml NN N
of IN N
4 CD N
% NN N
Ar NNP N
+ NNP N
1:100,000 CD N
Ep NNP N
, , N
delivered VBN N
by IN N
CCLADS NNP N
, , N
offer VBP N
high JJ N
success NN N
rate NN N
and CC N
effective JJ N
clinical JJ N
parameters NNS N
of IN N
ISA NNP N
as IN N
a DT N
primary JJ N
anesthesia NN N
. . N

CONCLUSION NNP N
GnRH NNP N
agonist NN N
and CC N
norethindrone JJ N
acetate NN N
alone RB N
or CC N
combined VBN N
with IN N
low-dose JJ N
conjugated JJ N
equine NN N
estrogens NNS N
administered VBN N
to TO N
symptomatic JJ N
endometriosis NN N
patients NNS p
for IN N
12 CD N
months NNS N
provides VBZ N
extended JJ N
pain NN N
relief NN N
and CC N
bone JJ N
mineral JJ N
density NN N
preservation NN N
after IN N
completion NN N
of IN N
therapy NN i
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
perioperative JJ N
blood NN N
loss NN N
, , N
the DT N
amount NN N
of IN N
morphine NN N
used VBN N
, , N
or CC N
FFD NNP N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
or CC N
in IN N
ROM NNP N
and CC N
FFD NNP N
at IN N
6 CD N
weeks NNS N
postoperatively RB N
. . N

RESULTS VB N
The DT N
proportion NN N
of IN N
patients NNS p
who WP N
achieved VBD N
hemostasis NN N
at IN N
the DT N
primary JJ N
treatment NN N
site NN N
within IN N
5 CD N
min NN N
, , N
and CC N
maintained VBD N
hemostasis NN N
until IN N
surgical JJ N
closure NN N
was VBD N
88.2 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
and CC N
89.6 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
in IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
these DT N
same JJ N
cardiac NN N
contractility NN N
modulating NN N
( ( N
CCM NNP N
) ) N
electrical JJ N
signals NNS N
on IN N
myocardial JJ N
oxygen NN N
consumption NN N
( ( N
MVO NNP N
( ( N
2 CD N
) ) N
) ) N
in IN N
both DT N
patients NNS p
and CC N
dogs NNS N
with IN N
chronic JJ N
HF NNP N
. . N

OBJECTIVE NN N
To TO N
find VB N
the DT N
optimal JJ N
dose NN N
of IN N
a DT N
new JJ N
hypoallergenic JJ N
folding NN N
variant NN N
of IN N
recombinant JJ N
Bet NNP N
v NN N
1 CD N
( ( N
rBet JJ N
v IN N
1-FV JJ N
) ) N
as IN N
SIT NNP N
for IN N
patients NNS p
with IN N
birch NN N
pollen NN N
allergy NN N
. . N

Although IN N
at IN N
the DT N
4-week JJ N
follow-up NN N
the DT N
intervention NN N
group NN N
indicated VBD N
that IN N
they PRP N
were VBD N
very RB N
likely JJ N
to TO N
have VB N
an DT N
annual JJ N
clinical JJ N
breast NN N
examination NN N
more RBR N
frequently RB N
than IN N
controls NNS N
, , N
no DT N
differences NNS N
were VBD N
detected VBN N
at IN N
6 CD N
months NNS N
. . N

In IN N
order NN N
to TO N
study VB N
the DT N
plasma NN N
levels NNS N
of IN N
factor NN N
XaI NNP N
and CC N
IIaI NNP N
activity NN N
an DT N
enzymatically RB N
depolymerized VBN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMW-heparin NNP N
; : N
Logiparin NNP N
) ) N
was VBD N
given VBN N
s.c. NN N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

The DT N
clinical JJ N
efficacy NN N
of IN N
letrozole NN N
in IN N
HER2+ NNP N
breast NN N
cancer NN N
was VBD N
confirmed VBN N
by IN N
fluorescent NN N
in IN N
situ JJ N
hybridization NN N
analysis NN N
and CC N
was VBD N
found VBN N
to TO N
be VB N
comparable JJ N
to TO N
that DT N
of IN N
HER2- NNP N
cases NNS N
( ( N
ORR NNP N
71 CD N
% NN N
in IN N
both DT N
subsets NNS N
) ) N
. . N

PATIENTS NNP N
Seventy-two JJ N
children NNS N
( ( N
mean JJ N
age NN N
, , N
8.5 CD N
? . N
1.6 CD N
y NN N
; : N
65 CD N
females NNS N
) ) N
with IN N
CPP NNP N
completed VBD N
and CC N
showed VBD N
maintenance NN N
of IN N
LH NNP N
suppression NN N
after IN N
a DT N
6-month JJ N
lead-in NN N
study NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
ROAM NNP N
, , N
gait NN N
, , N
pain NN N
, , N
perimeter NN N
of IN N
right NN N
and CC N
left VBD N
lower JJR N
limb NN N
, , N
and CC N
quality NN N
of IN N
life NN N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
48 CD N
hours NNS N
posttreatment NN N
. . N

Three CD N
patients NNS p
experienced VBD N
ocular JJ N
adverse JJ N
events NNS N
considered VBN N
possibly RB N
related VBN N
to TO N
study VB N
drug NN N
: : N
Conjunctival NNP N
edema NN N
and CC N
reduced JJ N
visual JJ N
acuity NN N
were VBD N
reported VBN N
in IN N
1 CD N
SCJ NNP N
patient JJ N
each DT N
and CC N
iritis NN N
was VBD N
reported VBN N
in IN N
1 CD N
IVT NNP N
patient NN N
. . N

In IN N
both DT N
duodenal JJ N
ulcer NN N
treatment NN N
groups NNS N
, , N
and CC N
with IN N
both DT N
drugs NNS N
, , N
healing NN N
was VBD N
negatively RB N
influenced VBN N
by IN N
ulcer JJ N
size NN N
, , N
ulcer JJ N
number NN N
, , N
smoking VBG N
habits NNS N
and CC N
a DT N
disease NN N
duration NN N
of IN N
5 CD N
years NNS N
or CC N
more JJR N
. . N

Plasma NNP N
level NN N
variations NNS N
of IN N
TAM NNP N
, , N
N-desmethyl NNP N
TAM NNP N
and CC N
MPA NNP N
were VBD N
checked VBN N
at IN N
various JJ N
intervals NNS N
on IN N
3 CD N
patients NNS p
of IN N
group NN N
B NNP N
, , N
and CC N
confirmed VBD N
that IN N
our PRP$ N
schedule NN N
is VBZ N
able JJ N
to TO N
produce VB N
a DT N
drug NN N
wash-out NN N
period NN N
for IN N
tumor NN N
cells NNS N
. . N

Also RB N
, , N
the DT N
mean JJ N
time NN N
to TO N
peak VB N
plasma JJ N
level NN N
correlated VBN N
with IN N
the DT N
logarithm NN N
of IN N
the DT N
time NN N
required VBN N
to TO N
release VB N
either RB N
50 CD N
% NN N
or CC N
85 CD N
% NN N
of IN N
the DT N
digoxin NN N
in IN N
vitro NN N
. . N

Ten CD N
out IN N
of IN N
18 CD N
patients NNS p
responded VBD N
to TO N
fluvoxamine VB N
treatment NN N
; : N
allele CC N
type JJ N
analysis NN N
revealed VBD N
that IN N
clinical JJ N
global JJ N
effectiveness NN N
was VBD N
noted VBN N
significantly RB N
more RBR N
in IN N
the DT N
l NN N
allele NN N
than IN N
in IN N
the DT N
s NN N
allele NN N
. . N

They PRP N
prepared VBD N
Class NNP N
I PRP N
, , N
III NNP N
and CC N
V NNP N
cavities NNS N
, , N
placed VBD N
resin NN N
restorations NNS N
and CC N
evaluated JJ N
subjects NNS N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
and CC N
30 CD N
days NNS N
and CC N
six CD N
months NNS N
postoperatively RB N
for IN N
pulp NN N
vitality NN N
, , N
recurrent NN N
caries NNS N
, , N
pain NN N
and CC N
discomfort NN N
, , N
and CC N
restoration NN N
retention NN N
. . N

RESULTS JJ N
Caregivers NNS N
in IN N
the DT N
IOL NNP N
group NN N
reported VBD N
higher JJR N
levels NNS N
of IN N
stress NN N
than IN N
those DT N
in IN N
the DT N
CL NNP N
group NN N
3 CD N
months NNS N
after IN N
surgery NN N
, , N
but CC N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
stress NN N
scores NNS N
at IN N
the DT N
post-VA JJ N
assessment NN N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Mental NNP N
Development NNP N
Index NNP N
( ( N
MDI NNP N
) ) N
of IN N
the DT N
Bayley NNP N
Scales NNP N
of IN N
Infant NNP N
Development NNP N
, , N
2nd CD N
edition NN N
, , N
assessed VBN N
at IN N
36 CD N
months NNS N
by IN N
evaluators NNS N
unaware JJ N
of IN N
treatment NN N
group NN N
and CC N
resuscitation NN N
history NN N
. . N

Operating NN N
and CC N
anesthesia NN N
times NNS N
, , N
postoperative JJ N
pain NN N
, , N
complications NNS N
, , N
hospital NN N
stay NN N
, , N
functional JJ N
index NN N
( ( N
1 CD N
week NN N
postoperatively RB N
) ) N
, , N
sick JJ N
leave VBP N
, , N
and CC N
time NN N
to TO N
full JJ N
recovery NN N
were VBD N
documented VBN N
. . N

Effects NNS N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
aspirin NN N
( ( N
600 CD N
mg NN N
) ) N
on IN N
bradykinin-stimulated JJ N
prostaglandin NN N
( ( N
PG NNP N
) ) N
and CC N
on IN N
thromboxane NN N
( ( N
TX NNP N
) ) N
biosynthesis NN N
were VBD N
determined VBN N
in IN N
nine CD N
healthy JJ N
male NN N
volunteers NNS N
. . N

A DT N
graph NN N
was VBD N
used VBN N
to TO N
demonstrate VB N
the DT N
treatment NN N
effect NN N
( ( N
the DT N
estimated VBN N
difference NN N
of IN N
kg/cow/day NN N
of IN N
milk NN N
yield NN N
between IN N
the DT N
treated VBN N
and CC N
placebo JJ N
cows NNS N
) ) N
, , N
with IN N
95 CD N
% NN N
confidence NN N
intervals NNS N
, , N
as IN N
the DT N
ODR NNP N
values NNS N
increase NN o
. . N

Arch NNP N
dimensions NNS N
were VBD N
followed VBN N
; : N
maxillary JJ N
and CC N
mandibular JJ N
alginate NN N
impressions NNS N
were VBD N
taken VBN N
at IN N
baseline NN N
, , N
end NN N
of IN N
early JJ N
Class NNP N
II NNP N
treatment NN N
or CC N
observation NN N
, , N
beginning VBG N
of IN N
fixed JJ N
appliance NN N
treatment NN N
, , N
end NN N
of IN N
orthodontic JJ N
treatment NN N
, , N
and CC N
approximately RB N
3 CD N
years NNS N
posttreatment NN N
. . N

Normothermic JJ N
patients NNS p
were VBD N
warmed VBN N
to TO N
36.5-37.0 JJ N
degrees NNS N
C NNP N
after IN N
an DT N
initial JJ N
temperature NN N
decrease NN o
, , N
and CC N
hypothermic JJ N
patients NNS p
were VBD N
cooled VBN N
to TO N
35 CD N
degrees NNS N
C. NNP N
In IN N
the DT N
hypothermic JJ N
group NN N
temperatures NNS N
were VBD N
allowed VBN N
to TO N
drift VB N
to TO N
34.5 CD N
degrees NNS N
C NNP N
before IN N
rewarming VBG N
was VBD N
initiated VBN N
. . N

We PRP N
used VBD N
continuous JJ N
intraluminal JJ N
esophageal NN N
and CC N
tracheal JJ N
pH NN N
monitoring NN N
probes NNS N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
ranitidine NN N
on IN N
the DT N
incidence NN N
of IN N
GER NNP N
and CC N
tracheal JJ N
aspiration NN N
in IN N
80 CD N
adult NN N
patients NNS p
undergoing VBG N
thoracotomy NN N
. . N

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Every NNP N
6 CD N
months NNS N
, , N
a DT N
structured JJ N
questionnaire NN N
was VBD N
administered VBN N
to TO N
elicit VB N
reports NNS N
of IN N
any DT N
bruising NN N
and/or NN N
skin NN N
rashes NNS N
, , N
slow JJ N
healing NN N
of IN N
cuts NNS N
or CC N
sores NNS N
, , N
or CC N
other JJ N
skin JJ N
changes NNS N
. . N

CONCLUSIONS NNP N
Similar NNP N
decreases NNS o
in IN N
BMD NNP N
over IN N
96 CD N
weeks NNS N
occurred VBD N
in IN N
ART-naive JJ N
subjects NNS N
receiving VBG N
either CC N
EFV-based JJ N
regimen NNS N
or CC N
LPV/r-based JJ N
regimen NNS N
, , N
which WDT N
was VBD N
not RB N
altered VBN N
by IN N
simplification NN N
to TO N
LPV/r NNP N
monotherapy NN i
and CC N
was VBD N
unrelated VBN N
to TO N
markers NNS N
of IN N
tumor NN N
necrosis JJ N
factor-alpha JJ N
activity NN N
. . N

Comparison NNP N
of IN N
the DT N
two CD N
groups NNS N
made VBN N
use NN N
of IN N
the DT N
Wilcoxon NNP N
test NN N
for IN N
the DT N
continuous JJ N
variables NNS N
and CC N
the DT N
Fisher NNP N
's POS N
exact JJ N
test NN N
for IN N
the DT N
comparison NN N
of IN N
frequencies NNS N
, , N
at IN N
significance NN N
value NN N
of IN N
5 CD N
% NN N
. . N

A DT N
sixty-day JJ N
feeding NN N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
dietary JJ N
pyridoxine NN i
( ( N
PN NNP N
) ) N
on IN N
hemato-immunological JJ N
parameters NNS N
in IN N
Labeo NNP N
rohita VBP N
fingerlings NNS N
exposed VBN N
to TO N
an DT N
elevated JJ N
temperature NN N
( ( N
ET NNP N
) ) N
of IN N
33 CD N
? . N
. . N

To TO N
minimize VB N
the DT N
consequence NN N
of IN N
haemorrhage NN N
, , N
we PRP N
performed VBD N
every DT N
rigid JJ N
bronchoscopy NN N
, , N
placing VBG N
a DT N
non NN N
inflated VBN N
Fogarty NNP N
balloon NN N
and CC N
a DT N
rigid JJ N
aspirator NN N
( ( N
diameter JJ N
4 CD N
mm NN N
) ) N
in IN N
lobar NN N
bronchus NN N
near IN N
the DT N
biopsy NN N
segment NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifty-nine NNP N
patients NNS p
( ( N
72 CD N
jaws NNS N
) ) N
with IN N
edentulous JJ N
maxillas NNS N
and/ VBP N
or CC N
mandibles NNS N
, , N
were VBD N
consecutively RB N
recruited VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
treatment NN N
groups NNS N
. . N

METHODS NNP N
Packed NNP N
red JJ N
cells NNS N
without IN N
buffy NN N
coat NN N
( ( N
PC NNP N
group NN N
) ) N
were VBD N
compared VBN N
with IN N
filtered JJ N
, , N
leucoreduced VBD N
, , N
red JJ N
cells NNS N
( ( N
LD NNP N
group NN N
) ) N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
697 CD N
patients NNS p
with IN N
colorectal JJ N
carcinoma NN N
. . N

RESULTS JJ N
Persons NNS N
with IN N
one CD N
or CC N
two CD N
long JJ N
( ( N
l NN N
) ) N
5HTTLPR CD N
alleles NNS N
had VBD N
CSF NNP N
levels NNS N
of IN N
the DT N
major JJ N
serotonin NN N
metabolite NN N
, , N
5HIAA CD N
, , N
that WDT N
were VBD N
50 CD N
% NN N
higher JJR N
than IN N
those DT N
of IN N
persons NNS N
with IN N
the DT N
s/s NN N
5HTTLPR CD N
genotype NN N
. . N

Our PRP$ N
findings NNS N
indicate VBP N
that IN N
DHA NNP N
is VBZ N
quantitatively RB N
superior JJ N
to TO N
EPA NNP N
in IN N
view NN N
of IN N
the DT N
EPA+DHA NNP N
tissue NN N
incorporation NN N
and CC N
also RB N
that IN N
4 CD N
g/d NN N
ALA NNP N
is VBZ N
not RB N
sufficient JJ N
to TO N
increase VB o
the DT N
omega-3 JJ N
index NN N
over IN N
a DT N
6-wk JJ N
period NN N
. . N

Efficacy NN N
was VBD N
assessed VBN N
by IN N
facial JJ N
acne JJ N
lesion NN N
counts NNS N
, , N
an DT N
investigator NN N
's POS N
global JJ N
assessment NN N
, , N
a DT N
subject NN N
's POS N
self-assessment NN N
, , N
and CC N
an DT N
analysis NN N
of IN N
within-cycle JJ N
variation NN N
( ( N
cycle NN N
6 CD N
) ) N
in IN N
lesion NN N
counts NNS N
. . N

Treadmill NNP N
exercise NN N
testing VBG N
with IN N
measurement NN N
of IN N
expired NNP N
gas NN N
exchange NN N
and CC N
respiratory NN N
flow NN N
was VBD N
performed VBN N
before IN N
ablation NN N
and CC N
4 CD N
weeks NNS N
after IN N
pacemaker NN N
implantation NN N
, , N
with IN N
the DT N
pacemaker NN N
programmed VBD N
to TO N
both DT N
the DT N
fixed-rate JJ N
VVI NNP N
and CC N
rate-modulating JJ N
minute NN N
ventilation NN N
VVIR NNP N
pacing VBG N
modes NNS N
in IN N
random JJ N
sequence NN N
. . N

METHODS NNP N
Seventy-two NNP N
OSM NNP N
patients NNS p
were VBD N
assigned VBN N
to TO N
2 CD N
groups NNS N
by IN N
a DT N
randomizing JJ N
digital NN N
table NN N
, , N
the DT N
treated VBN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
they PRP N
were VBD N
treated VBN N
respectively RB N
by IN N
ZJC1 NNP N
and CC N
Wuzi NNP N
Yanzong NNP N
Pill NNP N
( ( N
WYP NNP N
) ) N
. . N

NCX-4016 JJ N
inhibited JJ N
AA-induced JJ N
platelet NN N
aggregation NN N
as RB N
well RB N
as IN N
serum NN N
TXB NNP N
( ( N
2 CD N
) ) N
and CC N
platelet NN N
TXB NNP N
( ( N
2 CD N
) ) N
generation NN N
induced VBN N
by IN N
AA NNP N
to TO N
the DT N
same JJ N
extent NN N
as IN N
aspirin NN N
( ( N
not RB N
significant JJ N
vs. FW N
aspirin NN N
) ) N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
1 CD N
hour NN N
of IN N
SHS NNP N
exposure NN N
at IN N
bar/restaurant NN N
levels NNS N
is VBZ N
accompanied VBN N
by IN N
significant JJ N
decrements NNS N
on IN N
lung NN N
function NN N
and CC N
marked JJ N
increases NNS o
in IN N
inflammatory JJ N
cytokines NNS N
, , N
particularly RB N
in IN N
men NNS N
. . N

Among IN N
patients NNS p
who WP N
achieved VBD N
50 CD N
% NN N
improvement NN N
in IN N
disease NN N
activity NN N
according VBG N
to TO N
the DT N
American NNP N
College NNP N
of IN N
Rheumatology NNP N
criteria NNS N
, , N
only RB N
? . N
% NN N
required VBD N
a DT N
reduction NN N
in IN N
acute-phase JJ N
reactant NN N
values NNS N
in IN N
order NN N
to TO N
fulfill VB N
the DT N
criteria NNS N
. . N

Urinary JJ N
excretion NN N
of IN N
phenylethylamine NN N
increased VBN o
proportionately RB N
with IN N
doses NNS N
up RB N
to TO N
24 CD N
mg. NN N
No NNP N
changes NNS N
in IN N
urinary JJ N
elimination NN N
of IN N
catecholamines NNS N
, , N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
or CC N
ECG NNP N
were VBD N
observed VBN N
. . N

The DT N
second JJ N
outcomes NNS N
including VBG N
ICU NNP N
infection NN N
rate NN N
, , N
duration NN N
of IN N
ICU NNP N
stay NN N
, , N
in-hospital JJ N
mortality NN N
rate NN N
and CC N
neurologic JJ N
outcome NN N
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

) ) N
CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
the DT N
prophylactic JJ N
intravenous JJ N
administration NN N
of IN N
10 CD N
mg NNS N
dexamethasone VBP N
immediately RB N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
is VBZ N
effective JJ N
in IN N
preventing VBG N
PONV NNP N
in IN N
the DT N
general JJ N
surgical JJ N
adult NN N
patient JJ N
population NN N
. . N

In IN N
comparison NN N
between IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
Bifidobacterium NNP N
was VBD N
detected VBN N
significantly RB N
earlier RBR N
in IN N
group NN N
A NNP N
, , N
and CC N
the DT N
number NN N
of IN N
Enterobacteriaceae NNP N
present NN N
in IN N
the DT N
infants NNS N
at IN N
2 CD N
weeks NNS N
after IN N
birth NN N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
. . N

Thus RB N
, , N
50 CD N
mg NN N
of IN N
oral JJ N
SDZ NNP N
ENS-163 NNP N
has VBZ N
cholinomimetic JJ N
activity NN N
in IN N
normal JJ N
men NNS N
, , N
but CC N
this DT N
dose NN N
is VBZ N
insufficient JJ N
to TO N
reverse VB N
the DT N
muscarinic JJ N
effects NNS N
of IN N
0.4 CD N
mg NN N
of IN N
intravenous JJ N
scopolamine NN N
. . N

The DT N
levels NNS N
of IN N
serum NN N
MDA NNP N
and CC N
SOD NNP N
activity NN N
were VBD N
assayed VBN N
by IN N
chemical NN N
colorimetry NN N
, , N
and CC N
other JJ N
indices NNS N
, , N
including VBG N
blood NN N
pressure NN N
, , N
lipids NNS N
and CC N
hepatic/renal JJ N
function NN N
, , N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

METHODS NNP N
The DT N
effects NNS N
of IN N
oral JJ N
administration NN N
of IN N
Bifidobacterium NNP N
breve NN N
( ( N
B. NNP N
breve VBP N
) ) N
supplements NNS N
were VBD N
studied VBN N
in IN N
a DT N
controlled JJ N
trial NN N
with IN N
low JJ N
birth NN N
weight NN N
infants NNS N
( ( N
average JJ N
birth NN N
weight NN N
1489 CD N
g NN N
) ) N
. . N

OBJECTIVES IN N
The DT N
objective NN N
was VBD N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
hydrocodone/acetaminophen NN i
( ( N
Vicodin NNP N
[ VBZ N
5/500 CD N
] NN N
) ) N
provides VBZ N
more RBR N
efficacious JJ N
analgesia NN N
than IN N
codeine/acetaminophen NN i
( ( N
Tylenol NNP N
# # N
3 CD N
[ $ N
30/300 CD N
] NN N
) ) N
in IN N
patients NNS p
discharged VBN N
from IN N
the DT N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
. . N

The DT N
provocative JJ N
concentration NN N
of IN N
AMP NNP N
producing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV1 NNP N
( ( N
PC20 NNP N
) ) N
was VBD N
measured VBN N
after IN N
each DT N
washout NN N
at IN N
baseline NN N
and CC N
at IN N
4-6 JJ N
h NN N
following VBG N
the DT N
first JJ N
and CC N
last JJ N
doses NNS N
of IN N
each DT N
randomized VBN N
treatment NN N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
incidence NN N
of IN N
catheter-related JJ N
bloodstream NN N
infections NNS N
( ( N
CRBSIs NNP N
) ) N
, , N
thrombosis NN N
, , N
and CC N
2 CD N
indicators NNS N
of IN N
rheologic JJ N
function NN N
: : N
mean JJ N
effective JJ N
blood NN N
flow NN N
rate NN N
and CC N
urokinase NN N
use NN N
. . N

The DT N
first JJ N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
incremental JJ N
doses NNS N
of IN N
GH NNP N
( ( N
0.5 CD N
, , N
1.0 CD N
, , N
2.0 CD N
IU/day NNP N
for IN N
1 CD N
wk NNS N
each DT N
) ) N
on IN N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
levels NNS N
during IN N
each DT N
estrogen NN N
treatment NN N
phase NN N
. . N

Pregabalin NNP N
( ( N
PRE NNP N
) ) N
acts VBZ N
as IN N
a DT N
presynaptic JJ N
inhibitor NN N
of IN N
the DT N
release NN N
of IN N
excessive JJ N
levels NNS N
of IN N
excitatory NN N
neurotransmitters NNS N
by IN N
selectively RB N
binding VBG N
to TO N
the DT N
alpha NN N
( ( N
2 CD N
) ) N
-delta NN N
subunit NN N
of IN N
voltage-gated JJ N
calcium NN N
channels NNS N
. . N

We PRP N
found VBD N
that IN N
early JJ N
treatment NN N
was VBD N
important JJ N
, , N
since IN N
the DT N
effect NN N
on IN N
duration NN N
of IN N
whoops NNS N
was VBD N
most RBS N
pronounced JJ N
when WRB N
disease NN N
duration NN N
before IN N
treatment NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
7 CD N
days NNS N
. . N

Adjuvant NNP N
immunochemotherapy NN i
using VBG N
the DT N
antitumour JJ N
polysaccharide NN N
sizofiran NN N
( ( N
SPG NNP N
) ) N
, , N
an DT N
extract NN N
from IN N
the DT N
culture NN N
broth NN N
of IN N
Schizophyllum NNP N
commune NN N
Fries NNS N
, , N
was VBD N
prescribed VBN N
randomly RB N
for IN N
386 CD N
Japanese JJ N
patients NNS p
with IN N
resectable JJ N
gastric JJ N
cancer NN N
. . N

The DT N
discomfort NN N
score NN N
correlated VBD N
well RB N
with IN N
the DT N
pain NN N
relief NN N
scoring VBG N
without IN N
any DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
except IN N
in IN N
the DT N
last JJ N
visit NN N
( ( N
at IN N
3 CD N
month NN N
) ) N
. . N

The DT N
results NNS N
show VBP N
that IN N
, , N
in IN N
both DT N
groups NNS N
of IN N
children NNS N
, , N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
splenomegaly NN N
, , N
hepatomegaly NN N
, , N
and CC N
subjective JJ N
symptoms NNS N
of IN N
morbidity NN N
six CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
treatment NN N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
A NNP N
positive JJ N
response NN N
was VBD N
defined VBN N
as IN N
having VBG N
a DT N
score NN N
of IN N
at IN N
least JJS N
much JJ N
improved VBN N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impression-Improvement NNP N
scale NN N
at IN N
week NN N
12 CD N
. . N

METHODS NNP N
AND CC N
FINDINGS NNP N
We PRP N
identified VBD N
57,857 CD N
middle JJ N
and CC N
high JJ N
school NN N
students NNS N
( ( N
13-18 CD N
year NN N
olds NNS N
) ) N
from IN N
a DT N
Korean NNP N
nationally RB N
representative JJ N
survey NN N
, , N
which WDT N
was VBD N
surveyed VBN N
in IN N
2009 CD N
. . N

At IN N
30 CD N
min NN N
after IN N
stretching VBG N
, , N
significant JJ N
recovery NN N
in IN N
concentric JJ N
moment NN N
and CC N
muscle NN N
activity NN N
was VBD N
detected VBN N
at IN N
dorsiflexed JJ N
joint JJ N
angles NNS N
, , N
while IN N
Achilles NNP N
tendon CC N
stiffness NN N
and CC N
passive JJ N
joint JJ N
moment NN N
remained VBD N
significantly RB N
reduced VBN N
. . N

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
acceptability NN N
of IN N
6 CD N
% NN N
cellulose JJ N
sulfate NN N
( ( N
CS NNP N
) ) N
gel NN N
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN N
sexually RB N
abstinent JJ N
and CC N
active JJ N
HIV-infected JJ N
women NNS N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
whether IN N
uterine JJ N
shrinkage NN N
induced VBN N
by IN N
gonadotropin-releasing VBG N
hormone NN N
( ( N
GnRH NNP N
) ) N
agonists VBZ N
in IN N
women NNS N
with IN N
a DT N
large JJ N
uterus NN N
( ( N
> JJ N
14 CD N
wks NNS N
) ) N
may MD N
facilitate VB N
total JJ N
laparoscopic JJ N
hysterectomy NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
incidences NNS N
of IN N
nausea NN N
, , N
retching VBG N
or CC N
vomiting VBG N
in IN N
the DT N
first JJ N
48 CD N
h NN N
after IN N
surgery NN N
, , N
and CC N
the DT N
incidence NN N
of IN N
emergence NN N
agitation NN N
in IN N
the DT N
post-anaesthetic JJ N
care NN N
unit NN N
. . N

Performance NN N
on IN N
the DT N
BBT NNP N
and CC N
the DT N
10 CD N
MWT NNP N
( ( N
velocity NN N
and CC N
stride JJ N
length NN N
in IN N
self-paced JJ N
task NN N
and CC N
velocity NN N
in IN N
as-quickly-as-possible JJ N
task NN N
) ) N
were VBD N
improved VBN N
after IN N
MT NNP N
+ NNP N
MG NNP N
compared VBN N
with IN N
MT NNP N
. . N

In IN N
this DT N
study NN N
, , N
87 CD N
volunteers NNS N
who WP N
wanted VBD N
to TO N
quit VB N
cigarette NN N
smoking NN N
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
experimental JJ N
hypnosis NN N
group NN N
, , N
the DT N
comparison NN N
relaxation NN N
group NN N
, , N
and CC N
the DT N
waiting VBG N
list NN N
control NN N
group NN N
. . N

Fifty-six JJ N
patients NNS p
with IN N
90 CD N
double JJ N
lumen NNS N
VACs NNP N
were VBD N
randomly RB N
chosen VBN N
, , N
and CC N
received VBD N
either DT N
1- JJ N
or CC N
2-week JJ N
catheterizations NNS N
from IN N
operators NNS N
experienced VBN N
in IN N
the DT N
placement NN N
of IN N
such JJ N
catheters NNS N
at IN N
three CD N
sites NNS N
such JJ N
as IN N
the DT N
internal JJ N
jugular NN N
, , N
subclavian JJ N
, , N
or CC N
femoral JJ N
vein NN N
. . N

No DT N
routine JJ N
laboratory NN N
or CC N
physical JJ N
findings NNS N
reliably RB N
predicted VBD N
the DT N
development NN N
of IN N
the DT N
fat JJ N
embolism NN N
syndrome NN N
except IN N
petechial JJ N
rash NN N
, , N
which WDT N
occurred VBD N
only RB N
in IN N
5 CD N
placebo-treated JJ N
patients NNS p
who WP N
developed VBD N
the DT N
syndrome NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
leuprolide JJ N
acetate JJ N
3-month JJ N
depot NN N
formulations NNS N
( ( N
11.25 CD N
and CC N
30 CD N
mg NN N
) ) N
effectively RB N
suppressed VBD N
the DT N
GnRH NNP N
axis NN N
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
may MD N
positively RB N
impact VB N
patient JJ N
convenience NN N
and CC N
compliance NN N
. . N

The DT N
mixed-effects NNS N
model NN N
analyses VBZ N
showed VBD N
significant JJ N
treatment NN N
differences NNS N
in IN N
change NN N
from IN N
baseline NN N
to TO N
week NN N
61 CD N
with IN N
enzalutamide JJ N
compared VBN N
with IN N
placebo NN N
for IN N
most JJS N
FACT-P JJ N
endpoints NNS N
and CC N
EQ-5D NNP N
visual JJ N
analogue NN N
scale NN N
. . N

In IN N
a DT N
first JJ N
study NN N
, , N
the DT N
extent NN N
of IN N
absorption NN N
was VBD N
similar JJ N
for IN N
a DT N
syrup NN N
, , N
for IN N
Theo-dur NNP N
, , N
and CC N
for IN N
the DT N
experimental JJ N
formulation NN N
of IN N
theophylline NN N
with IN N
70 CD N
% NN N
drum-dried JJ N
corn NN N
starch NN N
as IN N
the DT N
sustained-release JJ N
agent NN N
( ( N
DDCS-70 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Ankle NNP N
dorsiflexion NN N
during IN N
gait NN N
, , N
walking VBG N
parameters NNS N
, , N
peripheral JJ N
edema NN N
, , N
venous JJ N
pain NN N
, , N
and CC N
quality NN N
of IN N
life NN N
remain VBP N
improved VBN N
in IN N
patients NNS p
with IN N
CVI NNP N
at IN N
1 CD N
month NN N
after IN N
mixed JJ N
KT-compression NNP N
therapy NN i
. . N

Arterial JJ N
thrombus NN N
formation NN N
was VBD N
induced VBN N
ex JJ N
vivo NN N
by IN N
exposing VBG N
a DT N
collagen-coated JJ N
surface NN N
in IN N
a DT N
parallel-plate JJ N
perfusion NN N
chamber NN N
to TO N
native JJ N
blood NN N
for IN N
3 CD N
min NN N
( ( N
arterial JJ N
wall NN N
shear NN N
rate NN N
2600 CD N
s NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
RAO NNP N
with IN N
2 CD N
heparin JJ N
dosage NN N
regimens NNS N
after IN N
transradial JJ N
coronary JJ N
angiography NN N
, , N
and CC N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
achieve VB N
acute JJ N
radial JJ N
artery NN N
recanalization NN N
. . N

After IN N
a DT N
submaximal JJ N
exercise NN N
load NN N
on IN N
the DT N
bicycle NN N
ergometer NN N
( ( N
1 CD N
watt NN N
per IN N
kg NN N
body NN N
weight VBD N
) ) N
following VBG N
an DT N
evening JJ N
meal NN N
, , N
no DT N
difference NN N
could MD N
be VB N
observed VBN N
between IN N
penbutolol NN i
and CC N
placebo NN N
in IN N
the DT N
above-mentioned JJ N
parameters NNS N
. . N

Complement JJ N
activation NN N
was VBD N
present JJ N
in IN N
all DT N
patients NNS p
studied VBN N
who WP N
had VBD N
the DT N
syndrome NN N
( ( N
5 CD N
of IN N
27 CD N
) ) N
but CC N
also RB N
in IN N
many JJ N
patients NNS p
who WP N
did VBD N
not RB N
meet VB N
our PRP$ N
diagnostic JJ N
criteria NNS N
, , N
suggesting VBG N
a DT N
multifactorial JJ N
cause NN N
. . N

CONCLUSIONS VB N
The DT N
CE-MARC NNP N
2 CD N
trial NN N
will MD N
provide VB N
comparative JJ N
efficacy NN N
and CC N
safety NN N
evidence NN N
for IN N
3 CD N
different JJ N
strategies NNS N
of IN N
investigating VBG N
patients NNS p
with IN N
suspected JJ N
CHD NNP N
, , N
with IN N
the DT N
intension NN N
of IN N
reducing VBG N
unnecessary JJ N
invasive JJ N
angiography NN N
rates NNS N
. . N

This DT N
clinical JJ N
trial NN N
is VBZ N
the DT N
largest JJS N
ever RB N
conducted VBN N
in IN N
the DT N
setting NN N
of IN N
FAP NNP N
and CC N
found VBD N
a DT N
trend NN N
of IN N
reduced JJ N
polyp NN N
load NN N
( ( N
number NN N
and CC N
size NN N
) ) N
with IN N
600 CD N
mg NNS N
of IN N
aspirin JJ N
daily JJ N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
AM NNP N
pre-dose JJ N
FEV NNP N
( ( N
1 CD N
) ) N
and CC N
secondary JJ N
endpoints NNS N
included VBD N
other JJ N
measures NNS N
of IN N
lung NN N
function NN N
, , N
rescue NN N
albuterol NN N
use NN N
, , N
health NN N
status NN N
and CC N
exacerbations NNS N
. . N

This DT N
study NN N
showed VBD N
that IN N
the DT N
two CD N
combinations NNS N
of IN N
0.5 CD N
% NN N
timolol JJ i
maleate NN N
and CC N
2 CD N
% NN N
pilocarpine NN N
HCl NNP N
compared VBN N
in IN N
this DT N
study NN N
were VBD N
equally RB N
effective JJ N
in IN N
reducing VBG N
intraocular JJ N
pressure NN N
. . N

The DT N
urogenital JJ N
and CC N
sexuality NN N
score NN N
, , N
along IN N
with IN N
the DT N
vaginal JJ N
health NN N
index NN N
and CC N
the DT N
vaginal JJ N
maturation NN N
index NN N
( ( N
VMI NNP N
) ) N
, , N
was VBD N
calculated VBN N
at IN N
the DT N
beginning NN N
of IN N
therapy NN i
and CC N
12 CD N
weeks NNS N
later RB N
. . N

Early JJ N
intensification NN N
was VBD N
associated VBN N
with IN N
fewer JJR N
bone NN N
marrow NN N
relapses NNS N
and CC N
a DT N
reduction NN N
in IN N
the DT N
odds NNS N
of IN N
death NN N
of IN N
0.63 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
0.46-0.87 JJ N
) ) N
. . N

METHODS NNP N
Data NNP N
are VBP N
obtained VBN N
from IN N
in-person JJ N
, , N
structured JJ N
, , N
closed-end JJ N
interviews NNS N
with IN N
the DT N
caretakers NNS N
of IN N
children NNS N
aged VBN N
4-12 CD N
years NNS N
with IN N
persistent JJ N
asthma NN N
living NN N
in IN N
households NNS N
with IN N
incomes NNS N
less JJR N
than IN N
200 CD N
% NN N
of IN N
poverty NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
meconium NN N
passage NN N
, , N
1- JJ N
or CC N
5-minute JJ N
Apgar NNP N
scores NNS N
< VBP N
7 CD N
, , N
neonatal JJ N
resuscitations NNS N
, , N
or CC N
admissions NNS N
to TO N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Moreover RB N
, , N
pruritus NN N
was VBD N
not RB N
observed VBN N
after IN N
discontinuation NN N
of IN N
treatment NN N
from IN N
day NN N
15 CD N
and CC N
beyond IN N
in IN N
the DT N
pimecrolimus NN N
group NN N
, , N
whereas IN N
it PRP N
was VBD N
reported VBN N
in IN N
most JJS N
patients NNS p
of IN N
the DT N
betamethasone NN N
group NN N
. . N

PURPOSE NNP N
We PRP N
determined VBD N
whether IN N
the DT N
decrease NN o
in IN N
serum NN N
PSA NNP N
seen VBN N
with IN N
5alpha-reductase JJ N
inhibitors NNS N
affects VBZ N
the DT N
clinical JJ N
usefulness NN N
of IN N
PSA NNP N
for IN N
prostate NN N
cancer NN N
screening VBG N
using VBG N
data NNS N
from IN N
2 CD N
dutasteride JJ N
benign JJ N
prostatic JJ N
hyperplasia NN N
studies NNS N
. . N

METHODS NNP N
ACS NNP N
patients NNS p
undergoing VBG N
cardiac JJ N
catheterization NN N
with IN N
> NNP N
or=1 VBP N
nonobstructive JJ N
native JJ N
coronary JJ N
artery NN N
atheroma NN N
were VBD N
randomized VBN N
to TO N
either DT N
7 CD N
weekly JJ N
HDL NNP N
selective NN N
delipidated VBD N
or CC N
control VB N
plasma JJ N
apheresis/reinfusions NNS N
. . N

( ( N
2 CD N
) ) N
In IN N
addition NN N
, , N
the DT N
effect NN N
of IN N
killing VBG N
technique NN N
on IN N
apparent JJ N
ileal NN N
protein NN N
digestibility NN N
values NNS N
obtained VBN N
by IN N
a DT N
slaughter NN N
method NN N
and CC N
effect NN N
of IN N
rapeseed NN N
feeding VBG N
on IN N
size NN N
of IN N
specific JJ N
organs NNS N
were VBD N
studied VBN N
. . N

Patients NNS N
( ( N
n JJ N
= NNP N
113 CD N
) ) N
with IN N
stage NN N
3-4 JJ N
CKD NNP N
and CC N
evidence NN N
of IN N
CAC NNP N
on IN N
a DT N
phosphorus-restricted JJ N
diet NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
calcium NN N
carbonate NN N
or CC N
sevelamer NN N
added VBN N
to TO N
their PRP$ N
phosphorus-restricted JJ N
diet NN N
. . N

A DT N
follow-up JJ N
procedure NN N
requiring VBG N
all DT N
subjects NNS N
to TO N
choose VB N
between IN N
the DT N
color NN N
prompt NN N
and CC N
the DT N
position NN N
cue NN N
revealed VBD N
that IN N
11 CD N
of IN N
20 CD N
subjects NNS N
consistently RB N
chose VBD N
the DT N
color NN N
cue NN N
, , N
even RB N
though IN N
it PRP N
resulted VBD N
in IN N
improper JJ N
lacing NN N
. . N

In IN N
group NN N
A NNP N
, , N
the DT N
CT NNP N
scan NN N
was VBD N
performed VBN N
with IN N
conventional JJ N
bowel NN N
preparation NN N
( ( N
a DT N
full JJ N
cathartic NN N
dose NN N
and CC N
oral JJ N
contrast NN N
medium NN N
to TO N
tag VB N
any DT N
residue NN N
in IN N
the DT N
3 CD N
days NNS N
preceding VBG N
the DT N
study NN N
) ) N
. . N

Similarly RB N
, , N
in IN N
a DT N
fifth NN N
subject NN N
, , N
who WP N
was VBD N
not RB N
restudied VBN N
until IN N
6 CD N
months NNS N
of IN N
androgen NN N
therapy NN i
were VBD N
completed VBN N
, , N
an DT N
increase NN o
in IN N
RBC NNP N
mass NN N
was VBD N
associated VBN N
with IN N
an DT N
increase NN o
in IN N
erythron NNP N
iron NN N
turnover NN N
. . N

Diets NNS N
with IN N
as RB N
little JJ N
as IN N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
appear VBP N
to TO N
be VB N
adequate JJ N
for IN N
broilers NNS N
older JJR N
than IN N
18 CD N
d NN N
if IN N
supplemented VBN N
with IN N
the DT N
correct JJ N
amounts NNS N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
vegetarianism NN N
on IN N
skeletal JJ N
muscle NN N
total JJ N
creatine NN N
( ( N
TCr NNP N
) ) N
content NN N
and CC N
creatine NN N
transporter NN N
( ( N
CreaT NNP N
) ) N
gene NN N
expression NN N
, , N
prior RB N
to TO N
and CC N
during IN N
5 CD N
d NN N
of IN N
Cr NNP N
supplementation NN N
( ( N
CrS NNP N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
second JJ N
week NN N
pain NN N
scores NNS N
increased VBD o
more RBR o
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
8.5 CD N
and CC N
6 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
PD NNP N
effects NNS N
were VBD N
assessed VBN N
by IN N
vasodilator-stimulated JJ N
phosphoprotein NN N
phosphorylation NN N
assay NN N
, , N
light JJ N
transmittance NN N
aggregometry NN N
, , N
VerifyNow NNP N
P2Y12 NNP N
assay NN N
( ( N
Accumetric NNP N
, , N
Inc. NNP N
, , N
San NNP N
Diego NNP N
, , N
California NNP N
) ) N
, , N
and CC N
multiple JJ N
electrode NN N
aggregometry NN N
at IN N
baseline NN N
and CC N
14 CD N
days NNS N
. . N

A DT N
second JJ N
trial NN N
( ( N
Study NNP N
2 CD N
) ) N
simulated VBD N
post-exposure JJ N
rabies NNS N
prophylaxis VBN N
by IN N
using VBG N
a DT N
reference NN N
cell NN N
culture NN N
vaccine NN N
, , N
the DT N
purified JJ N
Vero-cell NNP N
rabies NNS N
vaccine NN N
( ( N
PVRV NNP N
) ) N
, , N
administered VBN N
in IN N
association NN N
with IN N
either DT N
Erig NNP N
PMC NNP N
or CC N
PHT-Erig NNP N
. . N

No DT N
differences NNS N
between IN N
diets NNS N
were VBD N
found VBN N
for IN N
cortisol NN N
, , N
corticosteroid-binding JJ N
globulin NN N
, , N
and CC N
catecholamine JJ N
concentrations NNS N
in IN N
plasma NN N
and CC N
for IN N
GR NNP N
binding NN N
in IN N
hippocampus NN N
and CC N
hypothalamus NN N
in IN N
piglets NNS N
at IN N
PND NNP N
1 CD N
and CC N
27 CD N
. . N

BACKGROUND IN N
A NNP N
previous JJ N
study NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS p
with IN N
high-normal JJ N
body NN N
lead NN N
burdens VBZ N
showed VBD N
that IN N
EDTA NNP N
chelation NN N
therapy NN i
for IN N
3 CD N
months NNS N
slows VBZ N
progressive JJ N
diabetic JJ N
nephropathy NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
. . N

Significant JJ N
shorter JJR N
procedure NN N
and CC N
fluoroscopy NN N
times NNS N
compared VBN N
with IN N
a DT N
primary JJ N
4:1 CD N
ablation NN N
mode NN N
during IN N
repeat NN N
PVI NNP N
are VBP N
mainly RB N
attributed VBN N
to TO N
a DT N
lower JJR N
incidence NN N
of IN N
acutely RB N
reconnected VBN N
PVs NNP N
within IN N
the DT N
first JJ N
30 CD N
min NN N
. . N

During IN N
each DT N
treatment NN N
period NN N
, , N
subjects VBZ N
received VBN N
a DT N
single JJ N
dose NN N
of IN N
either CC N
donepezil JJ N
HCl NNP N
( ( N
5 CD N
mg NN N
) ) N
, , N
digoxin NN N
( ( N
0.25 CD N
mg NN N
) ) N
, , N
or CC N
a DT N
combination NN N
of IN N
both DT N
drugs NNS N
. . N

No DT N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
noted VBN N
in IN N
the DT N
rates NNS N
of IN N
increase NN o
in IN N
retinal JJ N
area NN N
involved VBN N
by IN N
CMV NNP N
, , N
visual JJ N
field NN N
loss NN N
, , N
or CC N
visual JJ N
acuity NN N
outcomes NNS N
. . N

AIM NNP N
Present NNP N
study NN N
was VBD N
aimed VBN N
to TO N
evaluate VB N
glycemic JJ N
control NN N
and CC N
maternal-fetal JJ N
outcome NN N
in IN N
pregnant JJ N
type NN N
1 CD N
diabetic JJ N
patient NN N
treated VBN N
with IN N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
( ( N
CSII NNP N
) ) N
or CC N
multiple JJ N
daily JJ N
injections NNS N
of IN N
insulin NN N
( ( N
MDI NNP N
) ) N
. . N

One CD N
patient NN N
in IN N
the DT N
amlodipine JJ N
camsylate NN N
group NN N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
at IN N
week NN N
0 CD N
of IN N
treatment NN N
( ( N
this DT N
patient NN N
did VBD N
not RB N
use VB N
any DT N
study NN N
medication NN N
) ) N
and CC N
was VBD N
excluded VBN N
from IN N
the DT N
modified VBN N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
. . N

The DT N
low JJ N
value NN N
( ( N
2.8 CD N
U/L NNP N
) ) N
of IN N
drug NN N
concentration NN N
that WDT N
achieved VBD N
50 CD N
% NN N
of IN N
maximum JJ N
effect NN N
( ( N
EC50 NNP N
) ) N
indicated VBD N
that IN N
low JJ N
plasma NN N
uricase NN N
concentrations NNS N
were VBD N
sufficient JJ N
to TO N
produce VB N
pharmacological JJ N
effects NNS N
. . N

Change NN N
in IN N
serum NN N
leptin NN i
levels NNS N
after IN N
2 CD N
months NNS N
was VBD N
examined VBN N
as IN N
a DT N
predictor NN N
of IN N
final JJ N
weight NN N
gain NN N
in IN N
mixed JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
site NN N
, , N
gender NN N
, , N
age NN N
, , N
and CC N
risperidone NN i
dose NN N
. . N

Prolactin NN i
levels NNS N
showed VBD N
a DT N
decrease NN o
in IN N
the DT N
group NN N
treated VBD N
with IN N
alpha JJ N
dihidroergocriptine NN N
with IN N
an DT N
important JJ N
difference NN N
between IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
6 CD N
months NNS N
study JJ N
period NN N
. . N

This DT N
was VBD N
done VBN i
, , N
prospectively RB N
, , N
to TO N
determine VB N
doses NNS N
of IN N
these DT N
agents NNS N
that WDT N
would MD N
increase VB o
or CC N
decrease VB o
plasma JJ N
norepinephrine NN N
levels NNS N
by IN N
> NNP N
/= NNP N
30 CD N
% NN N
. . N

With IN N
the DT N
exception NN N
of IN N
BI NNP N
at IN N
23 CD N
weeks NNS N
post-SRP JJ N
, , N
all DT N
reductions NNS N
cited VBN N
above IN N
for IN N
the DT N
test NN N
group NN N
were VBD N
statistically RB N
significantly RB N
different JJ N
from IN N
the DT N
control NN N
group NN N
for IN N
both DT N
PPD NNP N
and CC N
BI NNP N
for IN N
all DT N
comparisons NNS N
. . N

METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD N
healthy JJ N
children NNS N
of IN N
2-5 JJ N
months NNS N
old JJ N
in IN N
Jiangsu NNP N
province NN N
were VBD N
administered VBN N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
and CC N
control NN N
vaccines NNS N
. . N

Pre-operatively RB N
, , N
and CC N
2 CD N
h NN N
after IN N
commencing VBG N
their PRP$ N
post-operative JJ N
feeds NNS N
, , N
rates NNS N
of IN N
whole-body NN N
protein NN N
synthesis NN N
and CC N
breakdown NN N
were VBD N
measured VBN N
over IN N
a DT N
9-h JJ N
period NN N
following VBG N
intravenous JJ N
injection NN N
of IN N
a DT N
single JJ N
tracer NN N
dose NN N
of IN N
15N-glycine JJ N
by IN N
the DT N
ammonia NN N
and CC N
urea JJ N
end-product NN N
methods NNS N
. . N

The DT N
naproxen JJ N
concentration NN N
2 CD N
h NN N
after IN N
ingestion NN N
and CC N
the DT N
Cmax NNP i
were VBD N
higher JJR N
on IN N
the DT N
second JJ N
occasion NN N
, , N
regardless RB N
of IN N
preparation NN N
, , N
suggesting VBG N
that IN N
the DT N
subjects NNS N
were VBD N
clinically RB N
different JJ N
on IN N
the DT N
two CD N
occasions NNS N
. . N

OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
5 CD N
% NN N
lidocaine NN N
( ( N
ELA-Max NNP i
) ) N
cream NN N
applied VBN N
after IN N
erbium NN N
: : N
yttrium-aluminum-garnet NN N
( ( N
Er NNP N
: : N
YAG NN N
) ) N
laser JJR N
ablation NN N
of IN N
the DT N
stratum NN N
corneum NN N
. . N

PURPOSE NN N
This DT N
study NN N
examined VBD N
whether IN N
safe JJ N
and CC N
effective JJ N
mydriasis NN N
can MD N
be VB N
achieved VBN N
in IN N
premature NN N
infants NNS N
with IN N
heavily RB N
pigmented VBN N
irides NNS N
using VBG N
combination NN N
cyclopentolate VB N
0.2 CD N
% NN N
and CC N
phenylephrine VB N
1 CD N
% NN N
eyedrops NNS N
. . N

Patients NNS N
on IN N
acetazolamide NN N
showed VBD N
a DT N
slightly RB N
better RBR N
improvement NN N
of IN N
angiographic JJ N
signs NNS N
( ( N
at IN N
least JJS N
by IN N
one CD N
grade NN N
improvement NN N
) ) N
over IN N
that DT N
of IN N
placebo NN N
( ( N
12 CD N
vs NN N
five CD N
eyes NNS N
) ) N
. . N

CONCLUSIONS NNP N
The DT N
study NN N
results NNS N
suggest VBP N
that IN N
unlike IN N
cAMP-dependent JJ N
positive JJ N
inotropic NN N
drugs NNS N
, , N
the DT N
increase NN o
in IN N
LV NNP N
function NN N
during IN N
CCM NNP N
therapy NN i
is VBZ N
elicited VBN N
without IN N
increasing VBG N
MVO NNP N
( ( N
2 CD N
) ) N
. . N

CONCLUSION NNP N
Mizolastine NNP N
( ( N
10 CD N
mg NNS N
daily RB N
) ) N
is VBZ N
confirmed VBN N
as IN N
an DT N
effective JJ N
and CC N
well RB N
tolerated JJ N
agent NN N
, , N
comparable JJ N
to TO N
loratadine VB N
and CC N
superior VB N
to TO N
placebo VB N
, , N
for IN N
the DT N
management NN N
of IN N
CIU NNP N
. . N

Intervention NN N
was VBD N
based VBN N
on IN N
receiving VBG N
a DT N
single JJ N
dose NN N
of IN N
oral JJ N
steroid NN N
, , N
with IN N
or CC N
without IN N
vitamin JJ N
D NNP N
( ( N
3 CD N
) ) N
, , N
or CC N
placebo VBZ N
only RB N
on IN N
the DT N
day NN N
of IN N
the DT N
build-up JJ N
phase NN N
of IN N
SIT NNP N
. . N

This DT N
study NN N
compared VBN N
live JJ N
ratings NNS N
with IN N
ratings NNS N
of IN N
videotapes NNS N
and CC N
compared VBN N
response NN N
to TO N
clomipramine VB N
with IN N
response NN N
to TO N
haloperidol VB N
in IN N
8 CD N
subjects NNS N
, , N
mean JJ N
age NN N
5.62 CD N
years NNS N
, , N
who WP N
met VBD N
criteria NNS N
for IN N
autism NN N
. . N

In IN N
IC NNP N
, , N
LF NNP N
and CC N
HF NNP N
significantly RB N
increased VBD o
from IN o
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
dropped VBD N
from IN N
Heel NNP N
Stick NNP N
to TO N
Recovery NNP N
; : N
in IN N
2 CD N
KC NNP N
conditions NNS N
, , N
no DT N
changes NNS N
across IN N
study NN N
phases NNS N
were VBD N
found VBN N
. . N

TSAb NNP N
determined VBD N
again RB N
during IN N
follow-up NN N
was VBD N
negative JJ N
in IN N
each DT N
of IN N
the DT N
18 CD N
patients NNS p
in IN N
remission NN N
, , N
and CC N
positive JJ N
in IN N
8/10 CD N
patients NNS p
at IN N
the DT N
time NN N
of IN N
relapse NN N
, , N
whatever WDT N
its PRP$ N
level NN N
at IN N
the DT N
end NN N
of IN N
the DT N
drug NN N
course NN N
. . N

The DT N
visual JJ N
analog NN N
scale NN N
score NN N
for IN N
pain NN N
on IN N
postoperative JJ N
day NN N
1 CD N
and CC N
the DT N
requirement NN N
for IN N
tramadol NN N
were VBD N
significantly RB N
higher JJR N
in IN N
group NN N
I PRP N
than IN N
in IN N
group NN N
II NNP N
( ( N
P=.004 NNP N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
percentage NN N
of IN N
attacks NNS N
in IN N
which WDT N
headache NN N
improved VBD N
from IN N
severe JJ N
or CC N
moderate JJ N
before IN N
treatment NN N
to TO N
mild VB N
or CC N
absent VB N
at IN N
1 CD N
hour NN N
after IN N
the DT N
first JJ N
injection NN N
. . N

A DT N
statistically RB N
significant JJ N
linear JJ N
trend NN N
of IN N
an DT N
increase NN o
in IN N
calcium JJ N
absorption NN N
adjusted VBN N
for IN N
age NN N
and CC N
body NN N
mass NN N
index NN N
with IN N
increasing VBG N
vitamin NN N
D NNP N
dose NN N
or CC N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
concentration NN N
was VBD N
observed VBN N
. . N

BACKGROUND NNP N
Three NNP N
methods NNS N
of IN N
treating VBG N
chalazia NN N
were VBD N
compared VBN N
: : N
intralesional JJ N
triamcinolone NN N
acetonide NN N
injections NNS N
( ( N
0.2 CD N
mL NN N
of IN N
10 CD N
mg/mL NN N
) ) N
, , N
incision NN N
and CC N
curettage NN N
and CC N
advice NN N
regarding VBG N
the DT N
application NN N
of IN N
hot JJ N
compresses NNS N
to TO N
the DT N
affected JJ N
eyelid NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
mean JJ N
change NN N
in IN N
Facial NNP N
Pain NNP N
Scale NNP N
scores VBZ N
between IN N
the DT N
control NN N
and CC N
the DT N
intervention NN N
groups NNS N
in IN N
children NNS N
< VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

We PRP N
randomly RB N
recruited VBD N
304 CD N
women NNS N
from IN N
the DT N
Samliem NNP N
inner-city NN N
community NN N
, , N
Khon NNP N
Kaen NNP N
, , N
Northeast NNP N
Thailand NNP N
, , N
and CC N
assigned VBD N
participants NNS N
to TO N
either VB N
the DT N
intervention NN N
or CC N
control VB N
zone NN N
. . N

METHODS NNP N
In IN N
this DT N
preliminary JJ N
study NN N
, , N
33 CD N
adults NNS N
and CC N
30 CD N
children NNS N
( ( N
aged VBN N
8-11 CD N
years NNS N
) ) N
with IN N
no DT N
known JJ N
history NN N
of IN N
listening VBG N
difficulties NNS N
were VBD N
tested VBN N
. . N

Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB N
completed VBN N
CARS NNP N
score NN N
and CC N
blood NN N
samples NNS N
for IN N
TARC NNP N
serum NN N
level NN N
were VBD N
taken VBN N
before RB N
and CC N
after IN N
milk NN N
consumption NN N
of IN N
500 CD N
ml NNS N
per IN N
day NN N
in IN N
children NNS N
's POS N
regular JJ N
daily JJ N
diet NN N
. . N

The DT N
assay NN N
reproducibility NN N
was VBD N
shown VBN N
by IN N
reanalysis NN N
of IN N
200 CD N
study NN N
samples NNS N
and CC N
the DT N
% NN N
change NN N
in IN N
the DT N
concentration NN N
of IN N
repeat NN N
values NNS N
from IN N
the DT N
original JJ N
values NNS N
was VBD N
within IN N
? . N
% NN N
. . N

Fifteen NNP N
minutes NNS N
later RB N
( ( N
before IN N
IoA NNP N
) ) N
, , N
each DT N
dog NN N
received VBD N
treatment NN N
IV NNP N
with IN N
propofol NN N
, , N
K-P NNP N
, , N
or CC N
K-D. NNP N
Cardiorespiratory NNP N
and CC N
arterial JJ N
blood NN N
gas NN N
variables NNS N
were VBD N
assessed VBN N
before RB N
, , N
immediately RB N
after IN N
, , N
and CC N
5 CD N
minutes NNS N
after IN N
IoA NNP N
. . N

Plasma NNP N
concentrations NNS N
of IN N
6-oxo-PGF1 JJ N
alpha NN N
and CC N
13,14-dihydro-15-oxo-PGF2 JJ N
alpha NN N
were VBD N
measured VBN N
in IN N
samples NNS N
obtained VBN N
during IN N
repeated JJ N
10 CD N
min NN N
intravenous JJ N
infusions NNS N
of IN N
bradykinin NN N
before IN N
and CC N
up RB N
to TO N
6 CD N
h NN N
after IN N
the DT N
dose NN N
of IN N
aspirin NN N
. . N

CONCLUSION NN N
This DT N
trial NN N
found VBD N
that IN N
taking VBG N
20 CD N
mg NN N
pravastatin NN i
for IN N
2 CD N
years NNS N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
kidney NN N
function NN N
or CC N
urinary JJ N
protein NN N
excretion NN N
in IN N
patients NNS p
with IN N
ADPKD NNP N
. . N

Modeling NN N
was VBD N
performed VBN N
using VBG N
FOCE NNP N
INTERACTION NNP N
estimation NN N
method NN N
implemented VBN N
in IN N
NONMEM NNP N
V. NNP N
The DT N
linagliptin JJ i
plasma JJ N
concentration- NN N
and CC N
DPP-4 NNP N
inhibition- JJ N
time NN N
profiles NNS N
were VBD N
simulated VBN N
for IN N
Japanese JJ N
patients NNS p
receiving VBG N
5 CD N
mg JJ N
linagliptin NN i
once RB N
daily JJ N
by IN N
the DT N
model NN N
established VBN N
. . N

The DT N
most RBS N
commonly RB N
reported VBD N
adverse JJ N
events NNS N
( ( N
all DT N
with IN N
incidence NN N
of IN N
5 CD N
% NN N
or CC N
less JJR N
) ) N
among IN N
patients NNS p
receiving VBG N
rizatriptan NNS N
were VBD N
dry JJ N
mouth NN N
, , N
dizziness NN N
, , N
asthenia/fatigue NN N
, , N
nausea NN N
, , N
and CC N
somnolence NN N
. . N

Twenty-four JJ N
children NNS N
meeting VBG N
ICD-10 NNP N
criteria NNS N
for IN N
childhood NN N
autism NN N
( ( N
mean JJ N
age NN N
= VBD N
23 CD N
months NNS N
) ) N
were VBD N
identified VBN N
using VBG N
the DT N
CHAT NNP N
screen NN N
and CC N
randomised VBD N
to TO N
the DT N
parent NN N
training VBG N
group NN N
or CC N
to TO N
local JJ N
services NNS N
only RB N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Change NNP N
in IN N
pain NN N
VAS NNP N
scores VBZ N
during IN N
5 CD N
years NNS N
after IN N
the DT N
operation NN N
and CC N
rates NNS N
of IN N
pregnancy NN N
, , N
repeat NN N
surgery NN N
, , N
and CC N
use NN N
of IN N
hormone NN N
therapy NN i
were VBD N
evaluated VBN N
. . N

Plasma NNP N
Abeta NNP N
concentrations NNS N
decreased VBD o
in IN o
a DT N
dose-dependent JJ N
manner NN N
over IN N
a DT N
6-hour JJ N
interval NN N
following VBG N
drug NN N
administration NN N
, , N
with IN N
a DT N
maximum JJ N
decrease NN o
of IN N
approximately RB N
40 CD N
% NN N
relative JJ N
to TO N
baseline VB N
. . N

The DT N
H-AT NNP N
for IN N
4 CD N
weeks NNS N
up-regulated JJ N
co-stimulatory JJ N
molecule NN N
CD28 NNP N
expression NN N
and CC N
was VBD N
accompanied VBN N
by IN N
depressed JJ N
KLRG1 NNP N
level NN N
on IN N
CD3 NNP N
, , N
CD4 NNP N
, , N
CD8 NNP N
, , N
or CC N
CD8 NNP N
( ( N
bright VBN N
) ) N
lymphocytes VBZ N
at IN N
rest NN N
or CC N
following VBG N
exercise NN N
. . N

METHODS NNP N
Sixty NNP N
children NNS N
of IN N
autism NN N
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
electroacupuncture NN N
( ( N
EA NNP N
) ) N
plus CC N
behavior JJ N
therapy NN i
group NN N
and CC N
a DT N
behavior JJ N
therapy NN i
group NN N
, , N
30 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

METHODS NNP N
Patients NNS N
above IN N
18 CD N
years NNS N
with IN N
a DT N
rectal JJ N
cancer NN N
, , N
able JJ N
to TO N
give VB N
informed JJ N
consent NN N
, , N
and CC N
scheduled VBD N
for IN N
an DT N
anterior JJ N
resection NN N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
. . N

Best-corrected JJ N
visual JJ N
acuity NN N
( ( N
Early JJ N
Treatment NNP N
Diabetic NNP N
Retinopathy NNP N
Study NNP N
chart NN N
) ) N
, , N
intraocular JJ N
pressure NN N
measurement NN N
, , N
biomicroscopy NN N
, , N
funduscopy NN N
, , N
digital JJ N
fluorescein NN N
, , N
and CC N
indocyanine NN N
green JJ N
angiography NN N
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
3 CD N
months NNS N
. . N

The DT N
effects NNS N
of IN N
dietary JJ N
supplementation NN N
with IN N
coconut JJ N
oil NN N
on IN N
the DT N
biochemical JJ N
and CC N
anthropometric JJ N
profiles NNS N
of IN N
women NNS N
presenting VBG N
waist JJ N
circumferences NNS N
( ( N
WC NNP N
) ) N
> VBD N
88 CD N
cm NN N
( ( N
abdominal JJ N
obesity NN N
) ) N
were VBD N
investigated VBN N
. . N

We PRP N
found VBD N
that IN N
reducing VBG N
the DT N
number NN N
of IN N
adjudicators NNS N
from IN N
five CD N
to TO N
two CD N
or CC N
three CD N
would MD N
probably RB N
have VB N
changed VBN N
the DT N
consensus NN N
outcome NN N
in IN N
less JJR N
than IN N
10 CD N
% NN N
of IN N
cases NNS N
. . N

RESULTS NNP N
Study NNP N
participants NNS N
( ( N
N=170 NNP N
) ) N
had VBD N
a DT N
mean JJ N
age NN N
of IN N
28.4 CD N
years NNS N
( ( N
SD=9.6 NNP N
; : N
range VB N
18-60 JJ N
) ) N
and CC N
formed VBD N
a DT N
racially RB N
diverse JJ N
group NN N
. . N

Exercise NN N
time NN N
to TO N
onset VB N
of IN N
angina NN N
, , N
total JJ N
exercise NN N
duration NN N
and CC N
time NN N
to TO N
1 CD N
mm NNS N
ST NNP N
segment NN N
depression NN N
were VBD N
all DT N
significantly RB N
increased VBN o
after IN N
initial JJ N
application NN N
during IN N
the DT N
continuous JJ N
and CC N
intermittent JJ N
treatment NN N
periods NNS N
. . N

A DT N
total NN N
of IN N
45 CD N
children NNS N
diagnosed VBN N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
( ( N
ASD NNP N
) ) N
ages VBZ N
7-14 CD N
were VBD N
randomly RB N
assigned VBN N
to TO N
standard VB N
, , N
directive JJ N
, , N
or CC N
control VB N
story NN N
conditions NNS N
. . N

Fifty-nine NNP N
episodes NNS N
of IN N
atrial JJ N
flutter NN N
in IN N
54 CD N
patients NNS p
who WP N
failed VBD N
to TO N
terminate VB N
with IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
ibutilide NN N
, , N
procainamide NN N
, , N
or CC N
placebo VB N
alone JJ N
underwent JJ N
attempts NNS N
at IN N
pacing VBG N
termination NN N
using VBG N
a DT N
standard JJ N
protocol NN N
of IN N
burst JJ N
atrial JJ N
overdrive JJ N
pacing NN N
. . N

The DT N
effect NN N
lasted VBD N
for IN N
the DT N
entire JJ N
period NN N
of IN N
drug NN N
administration NN N
and CC N
in IN N
50 CD N
% NN N
of IN N
patients NNS p
a DT N
normal JJ N
platelet NN N
aggregation NN N
was VBD N
maintained VBN N
until IN N
the DT N
fourth JJ N
day NN N
after IN N
discontinuation NN N
of IN N
the DT N
drug NN N
. . N

Tibial NNP N
bone NN N
marrow NN N
aspirates VBZ N
demonstrated VBD N
a DT N
significant JJ N
increase NN o
in IN N
the DT N
bone NN N
marrow NN N
neutrophil JJ N
storage NN N
pool NN N
( ( N
BM NNP N
NSP NNP N
) ) N
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

Local JJ N
anesthetic JJ N
solutions NNS N
used VBN N
were VBD N
0.5 CD N
per IN N
cent NN N
bupivacaine NN N
HCl NNP N
, , N
2 CD N
per IN N
cent NN N
lidocaine NN N
HCl NNP N
, , N
and CC N
lidocaine-bupivacaine JJ N
mixtures NNS N
in IN N
the DT N
ratios NNS N
of IN N
1:3 CD N
, , N
1:1 CD N
or CC N
3:1 CD N
by IN N
volume NN N
. . N

AIM IN N
The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
acarbose NN N
on IN N
insulin NN N
requirements NNS N
and CC N
glycaemic JJ N
control NN N
in IN N
patients NNS p
with IN N
type JJ N
2 CD N
diabetes NNS N
receiving VBG N
exogenous JJ N
insulin NN N
due JJ N
to TO N
secondary JJ N
failure NN N
of IN N
maximum NN N
dose JJ N
sulphonylurea JJ N
therapy NN i
. . N

CONCLUSION NNP N
Ten CD N
percent NN N
HES NNP N
130/0.4 CD N
was VBD N
equally RB N
effective JJ N
and CC N
safe JJ N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
for IN N
volume NN N
therapy NN i
in IN N
patients NNS p
undergoing VBG N
cardiovascular JJ N
surgery NN N
. . N

INTERVENTION NN N
Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
topical JJ N
gauze NN N
sponges NNS N
soaked VBN N
in IN N
either DT N
1:500 CD N
RA NNP N
or CC N
0.9 CD N
% NN N
sodium NN N
chloride NN N
( ( N
physiological JJ N
saline NN N
) ) N
for IN N
3 CD N
min NN N
after IN N
adenoidectomy NN N
. . N

Three CD N
of IN N
five CD N
participants NNS N
acquired VBD N
word NN N
production NN N
within IN N
the DT N
DTT NNP N
framework NN N
and CC N
achieved VBD N
milestones NNS N
of IN N
early JJ N
functional JJ N
spoken NN N
language NN N
use NN N
( ( N
Tager-Flusberg NNP N
et FW N
al NN N
, , N
J NNP N
Speech NNP N
Lang NNP N
Hear NNP N
Res NNP N
52:643-652 CD N
, , N
2009 CD N
) ) N
. . N

A DT N
sample NN N
of IN N
301 CD N
volunteer NN N
subjects NNS N
recruited VBN N
from IN N
the DT N
waiting VBG N
list NN N
for IN N
treatment NN N
in IN N
the DT N
Beth NNP N
Israel NNP N
methadone NN i
program NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
immediate VB N
entry NN N
into IN N
the DT N
interim JJ N
clinic NN N
or CC N
a DT N
control NN N
group NN N
. . N

RESULTS VB N
The DT N
five-year JJ N
survival NN N
rate NN N
is VBZ N
98.3 CD N
% NN N
for IN N
the DT N
IMZ NNP N
group NN N
, , N
98.3 CD N
% NN N
for IN N
the DT N
Br NNP N
group NN N
and CC N
100 CD N
% NN N
for IN N
the DT N
ITI NNP N
group NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
of IN N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
or CC N
target VB N
vessel JJ N
revascularization NN N
( ( N
TVR NNP N
) ) N
was VBD N
analyzed VBN N
as IN N
time-to-first JJ N
event NN N
within IN N
9 CD N
months NNS N
of IN N
the DT N
index NN N
PCI NNP N
. . N

The DT N
63 CD N
hypertensive JJ N
women NNS N
had VBD N
a DT N
high JJ N
incidence NN N
of IN N
diabetes NNS N
mellitus NNS N
diagnosed VBD N
during IN N
pregnancy NN N
( ( N
49.2 CD N
% NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
authors NNS N
' POS N
general JJ N
obstetric JJ N
population NN N
( ( N
8.1 CD N
% NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Timing NNP N
of IN N
referrals NNS N
and CC N
discharge NN N
planning NN N
; : N
total JJ N
length NN N
of IN N
stay NN N
; : N
and CC N
complication NN N
and CC N
readmission NN N
rates NNS N
within IN N
28 CD N
days NNS N
of IN N
discharge NN N
. . N

RESULTS NNP N
Changes NNP N
in IN N
the DT N
BARS NNP N
score NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
DCM NNP N
and CC N
the DT N
control NN N
group NN N
or CC N
between IN N
the DT N
VPM NNP N
and CC N
the DT N
control NN N
group NN N
after IN N
10 CD N
months NNS N
. . N

Thus RB N
, , N
we PRP N
hypothesized VBD N
that IN N
compared VBN N
to TO N
high JJ N
dialysate NN N
sodium NN N
, , N
low JJ N
dialysate NN N
sodium NN N
concentration NN N
would MD N
lower VB N
endothelin VB N
1 CD N
levels NNS N
, , N
increase NN o
NO NNP N
release NN N
, , N
and CC N
reduce VB N
BP NNP N
. . N

Grade $ N
4 CD N
neutropenia NN N
was VBD N
significantly RB N
associated VBN N
with IN N
a DT N
PS NNP N
> NNP N
or=1 NN N
, , N
whereas JJ N
risk NN N
of IN N
grade NN N
> NNP N
or=3 NN N
diarrhea NN N
was VBD N
directly RB N
related VBN N
to TO N
age NN N
and CC N
previous JJ N
weight NN N
loss NN N
. . N

METHODS NNP N
A DT N
three-day JJ N
treatment NN N
period NN N
and CC N
14-day JJ N
follow-up JJ N
period NN N
was VBD N
performed VBN N
in IN N
any DT N
subject JJ N
weighting NN N
more JJR N
than IN N
10 CD N
kg NNS N
, , N
presenting VBG N
with IN N
a DT N
malaria NN N
paroxysm NN N
confirmed VBN N
by IN N
parasitaemia NN N
> NN N
or CC N
= $ N
1,000/microl CD N
, , N
after IN N
informed JJ N
consent NN N
. . N

Plaques NNS N
were VBD N
subjected VBN N
to TO N
the DT N
analysis NN N
of IN N
CD3 NNP N
, , N
CD68 NNP N
, , N
soluble JJ N
intercellular JJ N
adhesion NN N
molecule NN N
1 CD N
( ( N
ICAM-1 NNP N
) ) N
, , N
matrix JJ N
metalloprotease-9 NN N
( ( N
MMP-9 NNP N
) ) N
, , N
CD40L NNP N
, , N
tenascin-C NN N
, , N
and CC N
collagen NN N
content NN N
lipid JJ N
content NN N
by IN N
immunohistochemistry NN N
or CC N
polarized VBN N
light JJ N
analysis NN N
. . N

In IN N
a DT N
population NN N
setting NN N
of IN N
people NNS N
undergoing VBG N
assisted JJ N
reproduction NN N
, , N
44 CD N
individuals NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
receiving VBG N
standard JJ N
one-on-one JJ N
genetic JJ N
counseling NN N
or CC N
education NN N
by IN N
the DT N
IC NNP N
program NN N
. . N

CONCLUSION NNP N
CM NNP N
administered VBD N
for IN N
2 CD N
wk NNS N
significantly RB N
improved VBN N
clinical JJ N
measurements NNS N
of IN N
autism NN N
severity NN N
and CC N
decreased VBD o
serum JJR o
level NN N
of IN N
TARC NNP N
in IN N
autistic JJ N
children NNS N
, , N
but CC N
subsequent JJ N
studies NNS N
are VBP N
recommended VBN N
. . N

In IN N
our PRP$ N
study NN N
of IN N
borderline JJ N
hypertension NN N
in IN N
Tecumseh NNP N
, , N
white-coat JJ N
hypertension NN N
is VBZ N
present JJ N
in IN N
7.1 CD N
% NN N
of IN N
the DT N
whole JJ N
population NN N
and CC N
in IN N
58 CD N
% NN N
of IN N
all DT N
subjects NNS N
with IN N
elevated JJ N
blood NN N
pressures NNS N
in IN N
the DT N
clinic NN N
. . N

Aspirin NNP N
infusion NN N
reduced VBD N
urinary JJ N
excretion NN N
of IN N
both DT N
metabolites NNS N
greater JJR N
than IN N
90 CD N
% NN N
, , N
but CC N
excretion NN N
of IN N
2,3-dinor-6-oxo-PGF1 JJ N
alpha NN N
recovered VBD N
more RBR N
rapidly RB N
than IN N
did VBD N
that IN N
of IN N
2,3-dinor-TXB2 JJ N
. . N

CONCLUSIONS NNP N
Tapered NNP N
, , N
roughened-surface JJ N
implants NNS N
immediately RB N
restored VBN N
with IN N
single JJ N
provisional JJ N
crowns NNS N
at IN N
surgery NN N
and CC N
definitive JJ N
crowns NNS N
8 CD N
weeks NNS N
later RB N
were VBD N
as IN N
prosthodontically RB N
and CC N
aesthetically RB N
successful JJ N
as IN N
conventionally RB N
restored VBN N
two-stage JJ N
implants NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
service NN N
. . N

; : N
nitrendipine NN N
, , N
20 CD N
mg NN N
once RB N
daily JJ N
; : N
or CC N
placebo VB N
on IN N
blood NN N
glucose NN N
and CC N
plasma JJ N
insulin NN N
and CC N
C-peptide JJ N
response NN N
to TO N
an DT N
intravenous JJ N
glucose NN N
load NN N
in IN N
mildly RB N
or CC N
transiently RB N
hypertensive JJ N
nondiabetic JJ N
obese JJ N
patients NNS p
. . N

METHODS NNP N
Forty NNP N
below-knee NN N
amputees NNS N
( ( N
after IN N
war NN N
wounding NN N
) ) N
, , N
average JJ N
age NN N
35.6 CD N
+/- JJ N
10.6 CD N
years NNS N
, , N
that WDT N
were VBD N
included VBN N
in IN N
primary JJ N
rehabilitation NN N
program NN N
with IN N
prosthetics NNS N
, , N
were VBD N
examined VBN N
. . N

CONCLUSION NNP N
Five NNP N
weeks NNS N
of IN N
5 CD N
% NN N
imiquimod JJ N
cream NN N
once RB N
daily JJ N
with IN N
a DT N
1-week JJ N
interval NN N
was VBD N
more RBR N
effective JJ N
but CC N
as RB N
well RB N
tolerated VBN N
as IN N
the DT N
8-week JJ N
alternate NN N
week NN N
regimen NNS N
for IN N
sBCC NN N
. . N

Untreated VBN N
controls NNS N
at IN N
the DT N
2 CD N
intervals NNS N
showed VBD N
a DT N
mean JJ N
decrease NN o
in IN N
sensitivity NN N
to TO N
cold VB N
of IN N
3.6 CD N
degrees NNS N
C NNP N
and CC N
4.1 CD N
degrees NNS N
C. NNP N
Statistical NNP N
analysis NN N
showed VBD N
type NN N
of IN N
composite JJ N
cement NN N
to TO N
be VB N
a DT N
significant JJ N
factor NN N
. . N

Pain NN N
scores NNS N
, , N
the DT N
fentanyl JJ N
doses NNS N
required VBN N
, , N
plasma JJ N
concentrations NNS N
of IN N
fentanyl NN N
at IN N
18 CD N
hours NNS N
, , N
and CC N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
recorded VBN N
. . N

MEASUREMENTS NNP N
Distance NNP N
walked VBD N
in IN N
6 CD N
minutes NNS N
and CC N
sum NN N
of IN N
the DT N
function NN N
, , N
pain NN N
, , N
and CC N
stiffness JJ N
subscores NNS N
of IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
) ) N
. . N

Eleven NNP N
( ( N
19 CD N
% NN N
) ) N
women NNS N
experienced VBD N
intermenstrual JJ N
bleeding NN N
judged VBD N
to TO N
be VB N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
use NN N
( ( N
four CD N
in IN N
the DT N
CS NNP N
and CC N
seven CD N
in IN N
the DT N
placebo NN N
gel NN N
group NN N
) ) N
. . N

In IN N
both DT N
groups NNS N
plasma VBP N
levels NNS N
of IN N
triglycerides NNS N
, , N
very RB N
low-density JJ N
lipoprotein NN N
cholesterol NN N
, , N
and CC N
high-density NN N
lipoprotein NN N
cholesterol NN N
increased VBD o
significantly RB o
after IN N
3 CD N
months NNS N
. . N

During IN N
aspirin JJ N
intake NN N
, , N
these DT N
results NNS N
varied VBD N
considerably RB N
from IN N
day NN N
to TO N
day NN N
in IN N
nine CD N
out IN N
of IN N
20 CD N
men NNS N
, , N
resulting VBG N
in IN N
an DT N
overlap NN N
between IN N
the DT N
reference NN N
ranges VBZ N
at IN N
baseline NN N
and CC N
during IN N
therapy NN i
. . N

For IN N
the DT N
same JJ N
total JJ N
daily JJ N
dose NN N
of IN N
60 CD N
mg NN N
, , N
both DT N
bleeding VBG N
frequency NN N
and CC N
trough JJ N
edoxaban NN N
concentrations NNS N
were VBD N
higher JJR N
in IN N
the DT N
30-mg JJ N
bid NN N
group NN N
than IN N
in IN N
the DT N
60-mg JJ N
qd NN N
group NN N
. . N

3 CD N
Isoprenaline NNP N
dose-response JJ N
curves NNS N
for IN N
decreases NNS o
in IN N
diastolic JJ N
blood NN N
pressure NN N
also RB N
showed VBD N
shifts NNS N
to TO N
the DT N
right NN N
after IN N
oral JJ N
prizidilol NN i
, , N
providing VBG N
evidence NN N
of IN N
beta-adrenoceptor NN N
antagonism NN N
by IN N
this DT N
drug NN N
in IN N
peripheral JJ N
resistance NN N
vessels NNS N
. . N

Health-related JJ N
QoL NNP N
was VBD N
assessed VBN N
at IN N
entry NN N
and CC N
after IN N
every DT N
cycle NN N
by IN N
the DT N
EORTC-QLQ-C30 NNP N
and CC N
LC13 NNP N
questionnaires NNS N
, , N
toxicity NN N
by IN N
the DT N
NCI-NCCN NNP N
CTC NNP N
vs NN N
2 CD N
, , N
and CC N
intent-to-treat JJ N
objective JJ N
response NN N
by IN N
the DT N
Recist NNP N
criteria NNS N
. . N

However RB N
, , N
significant JJ N
synergistic JJ N
effect NN N
of IN N
CoQ NNP N
( ( N
10 CD N
) ) N
with IN N
ET NNP N
was VBD N
observed VBN N
only RB N
for IN N
peak NN N
SWTI NNP N
suggesting VBG N
that IN N
ET NNP N
amplifies VBZ N
the DT N
already RB N
described JJ N
effect NN N
of IN N
CoQ NNP N
( ( N
10 CD N
) ) N
on IN N
contractility NN N
of IN N
dysfunctional JJ N
myocardium NN N
. . N

CONCLUSIONS NNP N
The DT N
combination NN N
of IN N
clonidine NN N
( ( N
2 CD N
microg/kg NN N
) ) N
and CC N
ropivacaine VB N
0.1 CD N
% NN N
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
compared VBN N
to TO N
plain VB N
0.2 CD N
% NN N
ropivacaine NN N
. . N

In IN N
648 CD N
normal JJ N
karyotype NN N
( ( N
NK NNP N
) ) N
AML NNP N
patients NNS p
, , N
we PRP N
found VBD N
a DT N
significant JJ N
independent JJ N
effect NN N
of IN N
the DT N
quantitative JJ N
FLT3ITD NNP N
mRNA NN N
level NN N
-- : N
measured VBN N
as IN N
( ( N
FLT3ITD/wtFLT3 NNP N
) ) N
/ NN N
( ( N
FLT3ITD/wtFLT3+1 NNP N
) ) N
-- : N
on IN N
outcome NN N
. . N

These DT N
two CD N
groups NNS N
were VBD N
given VBN N
either RB N
intravenous JJ N
dezocine NN N
0.1 CD N
mg/kg NN N
or CC N
a DT N
matching JJ N
placebo NN N
( ( N
equal JJ N
volume NN N
of IN N
0.9 CD N
% NN N
saline NN N
) ) N
10 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

To TO N
test VB N
the DT N
relative JJ N
importance NN N
of IN N
these DT N
two CD N
mechanisms NNS N
, , N
we PRP N
have VBP N
randomly RB N
studied VBN N
22 CD N
patients NNS p
with IN N
alopecia JJ N
areata NNS N
to TO N
whom WP N
either DT N
DNCB NNP N
or CC N
croton VB N
oil NN N
was VBD N
applied VBN N
topically RB N
. . N

In IN N
Group NNP N
B NNP N
( ( N
November NNP N
2007-October JJ N
2008 CD N
) ) N
, , N
we PRP N
calculated VBD N
the DT N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
under IN N
this DT N
TM-PD NNP N
criteria NNS N
, , N
which WDT N
was VBD N
compared VBN N
with IN N
the DT N
TTP NNP N
under IN N
the DT N
RECIST NNP N
criteria NNS N
. . N

Hypotension NN N
and CC N
associated VBN N
symptoms NNS N
resolved VBD N
within IN N
30 CD N
minutes NNS N
after IN N
discontinuation NN N
of IN N
esmolol JJ i
infusion NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
short JJ N
duration NN N
of IN N
action NN N
of IN N
esmolol NN i
( ( N
elimination JJ N
half-life NN N
of IN N
9.2 CD N
minutes NNS N
) ) N
. . N

Sixteen JJ N
young JJ N
subjects NNS N
( ( N
age NN N
range NN N
, , N
19-27 JJ N
years NNS N
) ) N
and CC N
24 CD N
elderly JJ N
subjects NNS N
( ( N
age NN N
range NN N
, , N
60-86 JJ N
years NNS N
) ) N
participated VBD N
. . N

Paracetamol NNP N
( ( N
1.0 CD N
g NN N
) ) N
was VBD N
co-ignested JJ N
alone RB N
or CC N
with IN N
( ( N
300 CD N
mg NN N
) ) N
ferrous JJ N
sulphate NN N
by IN N
ten JJ N
healthy JJ N
male NN N
volunteers NNS N
, , N
using VBG N
saliva JJ N
drug NN N
levels NNS N
as IN N
a DT N
parameter NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP N
, , N
safety NN N
, , N
predictability NN N
, , N
stability NN N
, , N
HOAs NNP N
, , N
and CC N
CS NNP N
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
enhancement NN N
at IN N
6 CD N
months NNS N
' POS N
follow-up NN N
. . N

In IN N
the DT N
6 CD N
% NN N
strip NN N
group NN N
, , N
two CD N
subjects NNS N
discontinued VBN N
product NN N
use NN N
due JJ N
to TO N
an DT N
adverse JJ N
event NN N
( ( N
tooth JJ N
sensitivity NN N
) ) N
compared VBN N
to TO N
no DT N
subjects NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

Nineteen JJ N
patients NNS p
with IN N
limited JJ N
disease NN N
( ( N
ID NNP N
and CC N
IID NNP N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
3-week JJ N
chemotherapy NN i
regimen NNS N
associated VBN N
with IN N
whole JJ N
abdominal JJ N
radiotherapy NN i
or CC N
chemotherapy NN i
for IN N
3 CD N
years NNS N
. . N

CONCLUSION NNP N
The DT N
single JJ N
combination NN N
eyedrop NN N
of IN N
cyclopentolate JJ N
0.2 CD N
% NN N
and CC N
phenylephrine VB N
1 CD N
% NN N
is VBZ N
as IN N
effective JJ N
and CC N
safe JJ N
a DT N
mydriatic JJ N
for IN N
infants NNS N
with IN N
dark JJ N
irides NNS N
as IN N
both DT N
tropicamide IN N
0.5 CD N
% NN N
and CC N
phenylephrine VB N
2.5 CD N
% NN N
. . N

Similar JJ N
decreases NNS o
in IN N
blood NN N
pressure NN N
were VBD N
seen VBN N
24 CD N
h NN N
after IN N
the DT N
last JJ N
dose NN N
of IN N
perindopril NN N
or CC N
hydrochlorothiazide NN i
( ( N
11/7 CD N
mm NN N
Hg NNP N
supine NN N
) ) N
given VBN N
alone RB N
at IN N
these DT N
doses NNS N
. . N

Salmeterol NNP N
, , N
however RB N
, , N
showed VBD N
a DT N
flatter JJ N
dose-response JJ N
curve NN N
, , N
and CC N
a DT N
significantly RB N
weaker JJR N
maximal JJ N
protective JJ N
effect NN N
( ( N
2.8 CD N
doubling VBG N
doses NNS N
after IN N
250 CD N
micrograms NNS N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
investigate VB N
whether IN N
pre-operative JJ N
chemotherapy NN i
leads VBZ N
to TO N
a DT N
15 CD N
% NN N
higher JJR N
curative JJ N
resectability NN N
rate NN N
in IN N
patients NNS p
with IN N
operable JJ N
gastric JJ N
cancer NN N
. . N

Interestingly RB N
, , N
letrozole NN N
was VBD N
effective JJ N
even RB N
in IN N
marginally RB N
ER+ NNP N
tumors NNS N
and CC N
, , N
unlike IN N
tamoxifen NN N
, , N
consistently RB N
reduced VBD N
the DT N
expression NN N
from IN N
estrogen-regulated JJ N
genes NNS N
( ( N
progesterone NN N
receptor NN N
and CC N
trefoil NN N
factor NN N
1 CD N
) ) N
. . N

Patients NNS N
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
( ( N
20 CD N
patients NNS p
for IN N
each DT N
) ) N
: : N
dexmedetomidine NN N
and CC N
topical JJ N
anesthesia NN N
, , N
dexmedetomidine NN N
and CC N
peribulbar NN N
anesthesia NN N
, , N
midazolam+fentanyl NN N
and CC N
topical JJ N
anesthesia NN N
, , N
and CC N
midazolam+fentanyl NN N
and CC N
peribulbar NN N
anesthesia NN N
. . N

More RBR N
importantly RB N
, , N
whereas IN N
most JJS N
smoke-induced JJ N
effects NNS N
on IN N
lung NN N
function NN N
appear VBP N
to TO N
recede VB N
within IN N
60 CD N
minutes NNS N
, , N
inflammatory JJ N
cytokines NNS N
remain VBP N
elevated JJ N
for IN N
at IN N
least JJS N
3 CD N
hours NNS N
after IN N
exposure NN N
to TO N
SHS NNP N
. . N

METHODS NNP N
Sixty NNP N
patients NNS p
aged VBD N
18 CD N
years NNS N
or CC N
older JJR N
with IN N
unresectable JJ N
upper JJ N
abdominal JJ N
cancers NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
to TO N
receive VB N
USCPN NNP N
. . N

Fourteen JJ N
animals NNS N
were VBD N
inoculated VBN N
with IN N
virulent JJ N
canine NN N
parvovirus NN N
; : N
10 CD N
animals NNS N
that WDT N
developed VBD N
clinical JJ N
signs NNS N
thereby RB N
meeting VBG N
the DT N
inclusion NN N
criteria NNS N
were VBD N
admitted VBN N
to TO N
the DT N
treatment NN N
phase NN N
in IN N
two CD N
randomly RB N
selected VBN N
groups NNS N
( ( N
placebo NN N
and CC N
IFN NNP N
) ) N
of IN N
equal JJ N
size NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
extensive JJ N
SCLC NNP N
with IN N
a DT N
Karnofsky NNP N
performance NN N
score NN N
( ( N
KPS NNP N
) ) N
> VBD N
or CC N
= $ N
50 CD N
and CC N
adequate JJ N
renal JJ N
function NN N
and CC N
bone NN N
marrow NN N
reserve NN N
were VBD N
eligible JJ N
. . N

Furthermore RB N
, , N
less JJR N
than IN N
10 CD N
% NN N
of IN N
a DT N
bupropion NN N
dose NN N
is VBZ N
excreted VBN N
as IN N
urinary JJ N
bupropion NN N
and CC N
its PRP$ N
characterized JJ N
metabolites NNS N
hydroxybupropion NN N
, , N
threohydrobupropion NN N
, , N
and CC N
erythrohydrobupropion NN N
, , N
suggesting VBG N
that IN N
alternative JJ N
metabolic JJ N
pathways NNS N
may MD N
exist VB N
. . N

RESULTS NN N
Of IN N
the DT N
160 CD N
subjects NNS N
in IN N
whom WP N
efficacy NN N
could MD N
be VB N
evaluated VBN N
, , N
the DT N
OC NNP N
group NN N
showed VBD N
a DT N
statistically RB N
significantly RB N
greater JJR N
improvement NN N
than IN N
the DT N
placebo NN N
group NN N
for IN N
all DT N
primary JJ N
efficacy NN N
measures NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
compared VBN N
the DT N
results NNS N
of IN N
520 CD N
patients NNS p
with IN N
osteoarthritis NN N
who WP N
underwent VBD N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
for IN N
one CD N
knee NN N
and CC N
conventional JJ N
total JJ N
knee NN N
arthroplasty NN N
for IN N
the DT N
other JJ N
. . N

More JJR N
than IN N
4 CD N
mg NN N
of IN N
pyridoxine JJ i
supplementation NN N
daily RB N
was VBD N
required VBN N
for IN N
most JJS N
pregnancies NNS N
to TO N
maintain VB N
maternal JJ N
plasma NN N
PLP NNP N
levels NNS N
within IN N
the DT N
range NN N
observed VBD N
during IN N
the DT N
first JJ N
trimester NN N
and CC N
in IN N
the DT N
nonpregnant JJ N
state NN N
. . N

A DT N
significant JJ N
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
improvement NN N
in IN N
the DT N
nasal JJ N
index NN N
occurred VBD N
as RB N
early RB N
as IN N
12 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
triamcinolone NN N
acetonide RB N
aqueous JJ N
nasal NN N
spray NN N
. . N

RESULTS NNP N
All NNP N
these DT N
parameters NNS N
, , N
reflecting VBG N
crystal NN N
and CC N
unit NN N
cell NN N
characteristics NNS N
, , N
were VBD N
not RB N
influenced VBN N
by IN N
the DT N
presence NN N
of IN N
Sr NNP N
and CC N
were VBD N
similar JJ N
in IN N
SrRan NNP N
and CC N
placebo NN N
groups NNS N
after IN N
36 CD N
months NNS N
of IN N
treatment NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
accuracy NN N
and CC N
clinical JJ N
value NN N
of IN N
combining VBG N
64 CD N
multi-slice JJ N
spiral JJ N
computer NN N
tomography NN N
( ( N
MSCT NNP N
) ) N
and CC N
serum $ N
amyloid VB N
A NNP N
protein NN N
( ( N
SAA NNP N
) ) N
in IN N
the DT N
preoperative JJ N
staging NN N
of IN N
rectal JJ N
cancer NN N
. . N

RESULTS VB N
The DT N
study NN N
group NN N
included VBD N
thirty-one JJ N
female NN N
patients NNS p
and CC N
twenty-five JJ N
male NN N
patients NNS p
with IN N
a DT N
combined JJ N
average JJ N
age NN N
of IN N
fifty JJ N
years NNS N
and CC N
an DT N
average JJ N
body NN N
mass NN N
index NN N
of IN N
30.9 CD N
. . N

Two CD N
high JJ N
prevalence NN N
HIV/AIDS NNP N
villages NNS N
in IN N
rural JJ N
Andhra NNP N
Pradesh NNP N
, , N
which WDT N
were VBD N
demographically RB N
alike JJ N
and CC N
served VBN N
by IN N
distinct JJ N
Public NNP N
Health NNP N
Centers NNP N
, , N
were VBD N
selected VBN N
randomly RB N
from IN N
a DT N
total NN N
of IN N
16 CD N
villages NNS N
. . N

Anti-tetanus NNP N
GMTs NNP N
in IN N
placebo NN N
and CC N
chloroquine NN N
groups NNS N
declined VBD N
over IN N
14 CD N
months NNS N
to TO N
levels NNS N
comparable JJ N
to TO N
those DT N
of IN N
unvaccinated JJ N
controls NNS N
, , N
but CC N
levels NNS N
in IN N
the DT N
primaquine NN N
group NN N
remained VBD N
significantly RB N
higher JJR N
than IN N
in IN N
controls NNS N
. . N

CONCLUSIONS NNS N
Compared VBN N
with IN N
TAH NNP N
, , N
LAVH NNP N
has VBZ N
advantages NNS N
in IN N
removing VBG N
uteri JJ N
weighing VBG N
< NN N
or CC N
= $ N
500 CD N
g NN N
, , N
with IN N
comparable JJ N
operating NN N
time NN N
, , N
less JJR N
post-operative JJ N
pain NN N
and CC N
shorter JJR N
recovery NN N
. . N

The DT N
magnitude NN N
of IN N
the DT N
threshold NN N
was VBD N
60 CD N
% NN N
of IN N
maximal JJ N
static JJ N
inspiratory NN N
mouth NN N
pressure NN N
( ( N
PI NNP N
, , N
mmax NN i
) ) N
at IN N
functional JJ N
residual JJ N
capacity NN N
, , N
and CC N
the DT N
duty NN N
cycle NN N
was VBD N
0.5 CD N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
overall JJ i
survival NN N
and CC N
progression-free JJ N
survival NN N
both DT N
in IN N
the DT N
total JJ N
population NN N
and CC N
in IN N
patients NNS p
with IN N
PD-L1 NNP N
expression NN N
on IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
tumour JJ N
cells NNS N
. . N

This DT N
trial NN N
also RB N
tested VBD N
the DT N
hypothesis NN N
that WDT N
neoadjuvant JJ N
and CC N
concurrent JJ N
hormonal JJ N
therapy NN i
( ( N
NCHT NNP N
) ) N
improves VBZ N
PFS NNP N
compared VBN N
with IN N
adjuvant JJ N
hormonal JJ N
therapy NN i
( ( N
AHT NNP N
) ) N
by IN N
10 CD N
% NN N
. . N

Toxicity NN N
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
arms NNS N
, , N
although IN N
patients NNS p
with IN N
a DT N
baseline NN N
CD4 NNP N
count NN N
less JJR N
than IN N
50/microL CD N
had VBD N
a DT N
high JJ N
infectious JJ N
death NN N
rate NN N
in IN N
the DT N
concurrent NN N
arm NN N
. . N

Both DT N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
were VBD N
significantly RB N
lower JJR N
after IN N
administration NN N
of IN N
captopril JJ N
25 CD N
mg NN N
, , N
whereas WP N
blood NN N
pressure NN N
was VBD N
unaffected VBN N
by IN N
enalapril NNS N
compared VBN N
with IN N
placebo NN N
. . N

The DT N
effect NN N
of IN N
food NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
BMS-181101 NNP N
, , N
a DT N
new JJ N
anti-depressant JJ N
under IN N
development NN N
, , N
was VBD N
investigated VBN N
in IN N
12 CD N
healthy JJ N
male NN N
volunteers NNS N
at IN N
steady JJ N
state NN N
. . N

1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo JJ N
( ( N
b NN N
, , N
f NN N
) ) N
pyrazino- NN N
( ( N
1,2-d CD N
) ) N
- : N
( ( N
1,4 CD N
) ) N
-oxazepine NN N
hydrogen NN N
maleate NN N
( ( N
Org NNP N
GC NNP N
94 CD N
) ) N
is VBZ N
an DT N
oral JJ N
antamine NN N
preparation NN N
with IN N
anti-serotoninergic JJ N
and CC N
anti-histaminic JJ N
effects NNS N
. . N

BACKGROUND IN N
There EX N
are VBP N
few JJ N
large JJ N
case NN N
series NN N
describing VBG N
the DT N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
genotypes VBZ N
found VBN N
in IN N
women NNS N
diagnosed VBN N
with IN N
rigorously RB N
reviewed VBN N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grade VBD N
3 CD N
( ( N
CIN3 NNP N
) ) N
, , N
cervical JJ N
precancer NN N
. . N

The DT N
infusion NN N
was VBD N
started VBN N
with IN N
an DT N
initial JJ N
dose NN N
given VBN N
over IN N
10 CD N
min NNS N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
; : N
at IN N
induction NN N
the DT N
maintenance NN N
rate NN N
was VBD N
begun VBN N
and CC N
continued VBN N
until IN N
closure NN N
of IN N
the DT N
abdominal JJ N
fascia NN N
. . N

This DT N
study NN N
identified VBD N
subtypes NNS N
of IN N
aggression NN N
in IN N
a DT N
sample NN N
of IN N
206 CD N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
who WP N
participated VBD N
in IN N
2 CD N
risperidone NN i
trials NNS N
. . N

In IN N
addition NN N
, , N
the DT N
effectiveness NN N
of IN N
a DT N
2-g JJ N
single JJ N
dose NN N
of IN N
metronidazole NN N
was VBD N
compared VBN N
with IN N
a DT N
seven-day JJ N
course NN N
of IN N
500 CD N
mg NN N
of IN N
metronidazole JJ N
twice NN N
a DT N
day NN N
in IN N
patients NNS p
with IN N
bacterial JJ N
vaginosis NN N
. . N

However RB N
, , N
several JJ N
laboratories NNS N
have VBP N
reported VBN N
that IN N
protein JJ N
ingestion NN N
does VBZ N
not RB N
result VB N
in IN N
an DT N
increase NN o
in IN N
the DT N
circulating NN N
glucose JJ N
concentration NN N
in IN N
people NNS N
with IN N
or CC N
without IN N
type JJ N
2 CD N
diabetes NNS N
. . N

OBJECTIVE NN N
To TO N
assess VB N
long-term JJ N
( ( N
36-month JJ N
) ) N
hypothalamic-pituitary-gonadal JJ N
axis JJ N
suppression NN N
and CC N
safety NN N
of IN N
leuprolide JJ N
acetate JJ N
3-month JJ N
depot NN N
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS N
with IN N
CPP NNP N
. . N

Slide NNP N
positivity NN N
rate NN N
( ( N
SPR NNP N
) ) N
and CC N
malaria $ N
incidence NN N
per IN N
1000 CD N
population NN N
( ( N
PI NNP N
) ) N
were VBD N
compared VBN N
between IN N
the DT N
three CD N
study NN N
arms NNS N
to TO N
assess VB N
the DT N
impact NN N
of IN N
use NN N
of IN N
Interceptor NNP N
nets NNS N
. . N

RESULTS NNP N
Fracture NNP N
union NN N
was VBD N
achieved VBN N
in IN N
all DT N
patients NNS p
in IN N
the DT N
operative JJ N
group NN N
, , N
whereas IN N
nonunion NN N
was VBD N
observed VBN N
in IN N
3 CD N
of IN N
30 CD N
patients NNS p
of IN N
the DT N
nonoperative JJ N
group NN N
. . N

A DT N
significant JJ N
survival JJ N
benefit NN N
was VBD N
identified VBN N
at IN N
study NN N
completion NN N
in IN N
the DT N
pre-defined JJ N
sub-group NN N
of IN N
123 CD N
patients NNS p
who WP N
had VBD N
received VBN N
prior RB N
chemotherapy NN i
( ( N
P=0.045 NNP N
, , N
hazard NN N
ratio=1.53 NN N
( ( N
1.00-2.34 JJ N
) ) N
) ) N
. . N

PURPOSE NNP N
In IN N
a DT N
register NN N
study NN N
, , N
the DT N
risk NN N
of IN N
anastomotic JJ i
leakage NN N
correlated VBD N
to TO N
the DT N
choice NN N
of IN N
circular JJ N
stapling VBG N
device NN N
with IN N
a DT N
4 CD N
% NN N
difference NN N
between IN N
the DT N
two CD N
brands NNS N
used VBN N
. . N

In IN N
the DT N
second JJ N
study NN N
473 CD N
patients NNS p
with IN N
suspected JJ N
acute JJ N
myocardial JJ N
infarction NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
oxprenolol NN i
, , N
disopyramide JJ N
phosphate NN N
, , N
or CC N
placebo NN N
. . N

Patients NNS N
received VBD N
treatment NN N
during IN N
interventional JJ N
visits NNS N
: : N
one CD N
SC NNP N
and CC N
one CD N
ID NNP N
basal/bolus CC N
infusion NN N
of IN N
insulin JJ N
aspart NN N
( ( N
NovoRapid NNP N
U-100 NNP N
) ) N
administered VBD N
over IN N
3 CD N
days NNS N
in IN N
a DT N
randomized JJ N
order NN N
. . N

RESULTS NNP N
All NNP N
H. NNP N
pylori FW N
( ( N
+ NN N
) ) N
patients NNS p
showed VBD N
a DT N
rapid JJ N
increase NN o
of IN N
intragastric JJ N
pH NN N
with IN N
a DT N
mean JJ N
intragastric JJ N
pH NN N
of IN N
6.7 CD N
during IN N
the DT N
second JJ N
half NN N
of IN N
the DT N
first JJ N
day NN N
. . N

In IN N
both DT N
groups NNS N
, , N
minute JJ N
ventilation NN N
( ( N
VE NNP N
) ) N
and CC N
f $ N
progressively RB N
decreased VBN o
as IN N
resistance NN N
was VBD N
increased VBN o
by IN N
decreasing VBG N
the DT N
aperture NN N
size NN N
from IN N
15 CD N
to TO N
16 CD N
mm NNS N
. . N

To TO N
determine VB N
the DT N
efficacy NN N
of IN N
proparacaine NN N
eye NN N
drops NNS N
( ( N
0.5 CD N
% NN N
) ) N
, , N
we PRP N
compared VBN N
the DT N
Premature NNP N
Infant NNP N
Pain NNP N
Profile NNP N
( ( N
PIPP NNP N
) ) N
scores VBZ N
in IN N
40 CD N
preterm JJ N
infants NNS N
undergoing VBG N
ROP NNP N
screening NN N
. . N

METHODS NNP N
After IN N
refraining VBG N
from IN N
all DT N
oral JJ N
hygiene NN N
procedures NNS N
for IN N
23-25 JJ N
hours NNS N
, , N
subjects NNS N
received VBD N
an DT N
oral JJ N
tissue NN N
examination NN N
and CC N
those DT N
with IN N
pre-brushing JJ N
whole JJ N
mouth NN N
mean JJ N
plaque NN N
scores NNS N
> VBP N
or CC N
= VBP N
0.6 CD N
based VBN N
on IN N
the DT N
Rustogi NNP N
et CC N
al NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
, , N
number NN N
of IN N
total JJ N
bleeding VBG N
episodes NNS N
in IN N
the DT N
intent-to-treat JJ N
population NN N
, , N
was VBD N
analyzed VBN N
after IN N
the DT N
last JJ N
patient NN N
had VBD N
completed VBN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

Prophylaxis NN N
with IN N
Calcium NNP N
entry NN N
blocker NN N
Flunarizine NNP N
( ( N
Sibelium NNP N
) ) N
or CC N
Thromboxane VB N
A DT N
inhibitor NN N
Acetylsalicylic NNP N
acid NN N
( ( N
ASS NNP N
) ) N
was VBD N
carried VBN N
out RP N
in IN N
a DT N
double JJ N
blind NN N
design NN N
for IN N
3 CD N
months NNS N
. . N

These DT N
dogs NNS N
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
that WDT N
were VBD N
treated VBN N
for IN N
84 CD N
days NNS N
with IN N
either DT N
the DT N
test NN N
product NN N
, , N
imidapril NN N
, , N
or CC N
the DT N
positive JJ N
control NN N
, , N
benazepril NN N
, , N
and CC N
followed VBD N
up RP N
in IN N
parallel NN N
over IN N
this DT N
period NN N
. . N

Clindamycin NNP i
applied VBD N
in IN N
a DT N
single JJ N
preoperative NN N
dose NN N
of IN N
600 CD N
mg NN N
with IN N
or CC N
without IN N
subsequent JJ N
5-day JJ N
therapy NN i
does VBZ N
not RB N
demonstrate VB N
efficacy NN N
in IN N
prophylaxis NN N
for IN N
postoperative JJ N
inflammatory NN N
complications NNS N
after IN N
third JJ N
molar JJ N
surgery NN N
. . N

Documented VBN N
histologic JJ N
conversion NN N
was VBD N
often RB N
associated VBN N
with IN N
a DT N
more RBR N
aggressive JJ N
clinical JJ N
behavior NN N
of IN N
the DT N
lymphoma NN N
, , N
and CC N
the DT N
median JJ N
survival NN N
after IN N
conversion NN N
was VBD N
less JJR N
than IN N
1 CD N
yr NN N
. . N

Patients NNS N
were VBD N
monitored VBN N
daily RB N
for IN N
recurrence NN N
of IN N
pain NN N
, , N
need VBP N
to TO N
stop VB N
feeding NN N
, , N
post-refeeding JJ N
LOH NNP N
( ( N
primary JJ N
end NN N
point NN N
) ) N
, , N
and CC N
for IN N
28 CD N
days NNS N
post-refeeding JJ N
to TO N
capture VB N
re-admission NN N
rates NNS N
. . N

The DT N
eprinomectin NN i
protocol NN N
employed VBN N
in IN N
Study NNP N
2 CD N
, , N
consisting VBG N
of IN N
four CD N
weekly JJ N
topical JJ N
administrations NNS N
at IN N
the DT N
dose JJ N
rate NN N
of IN N
500mug/kg CD N
of IN N
body NN N
weight NN N
, , N
proved VBD N
highly RB N
effective JJ N
at IN N
reducing VBG N
the DT N
Chorioptes NNPS N
mite JJ N
burden NN N
in IN N
alpacas NN N
. . N

Grade $ N
4 CD N
neutropaenia NN N
, , N
grade VBD N
3/4 CD N
anaemia NN N
, , N
febrile JJ N
neutropaenia NN N
, , N
and CC N
diarrhoea NNS N
were VBD N
more JJR N
common JJ N
in IN N
the DT N
docetaxel NN i
arm NN N
, , N
as IN N
was VBD N
the DT N
use NN N
of IN N
intravenous JJ N
antibiotics NNS N
and CC N
blood NN N
transfusions NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
oxygen JJ N
saturation NN N
, , N
respiratory NN N
rate NN N
, , N
RDAI NNP N
measurement NN N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
4 CD N
days NNS N
, , N
and CC N
the DT N
length NN N
of IN N
hospitalization NN N
. . N

Fifty NNP N
women NNS N
with IN N
uterine JJ N
myoma NN N
, , N
who WP N
met VBD N
the DT N
criteria NNS N
of IN N
the DT N
study NN N
thoroughly RB N
, , N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
equal JJ N
groups NNS N
to TO N
take VB N
either DT N
Diphereline NNP N
or CC N
Cabergoline NNP N
. . N

Fifty-four JJ N
patients NNS p
treated VBN N
with IN N
daunorubicin NN i
, , N
cytosine JJ N
arabinoside NN N
and CC N
thioquanine NN N
for IN N
acute JJ N
myeloid NN N
leukemia NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ N
lithium NN N
carbonate NN N
1200 CD N
mg JJ N
daily JJ N
or CC N
no DT N
lithium NN N
. . N

A DT N
total NN N
of IN N
110 CD N
patients NNS p
undergoing JJ N
elective JJ N
abdominal JJ N
hysterectomy NN N
were VBD N
anesthetized VBN N
in IN N
random JJ N
order NN N
with IN N
either DT N
isoflurane NN N
in IN N
nitrous JJ N
oxide NN N
and CC N
oxygen NN N
or CC N
isoflurane NN N
in IN N
air NN N
and CC N
oxygen NN N
. . N

METHODS NNP N
We PRP N
recruited VBD N
three CD N
family NN N
members NNS N
per IN N
family NN N
for IN N
assessment NN N
- : N
the DT N
melanoma NN N
case NN N
, , N
a DT N
first-degree JJ N
relative NN N
( ( N
FDR NNP N
) ) N
, , N
and CC N
a DT N
relative NN N
who WP N
is VBZ N
a DT N
parent NN N
of IN N
a DT N
child JJ N
age NN N
18 CD N
or CC N
younger JJR N
. . N

In IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
, , N
time NN N
to TO N
recurrence VB N
in IN N
the DT N
2 CD N
treatment NN N
groups NNS N
was VBD N
compared VBN N
with IN N
the DT N
log-rank JJ N
test NN N
in IN N
the DT N
subgroup NN N
of IN N
patients NNS p
with IN N
structural JJ N
heart NN N
disease NN N
. . N

Blood NN N
samples NNS N
were VBD N
collected VBN N
up RB N
to TO N
24 CD N
h NN N
after IN N
administration NN N
of IN N
the DT N
first JJ N
dose NN N
, , N
and CC N
the DT N
concentration NN N
of IN N
AmB NNP N
in IN N
plasma NN N
was VBD N
analyzed VBN N
by IN N
a DT N
high-performance NN N
liquid NN N
chromatography NN N
assay NN N
. . N

Each DT N
patient NN N
also RB N
received VBD N
ibuprofen NNS N
; : N
acetaminophen VBZ i
with IN N
codeine NN i
( ( N
30 CD N
mg NN N
) ) N
; : N
and CC N
a DT N
7-day JJ N
diary NN N
to TO N
record NN N
pain NN N
, , N
percussion NN N
pain NN N
, , N
and CC N
number NN N
and CC N
type NN N
of IN N
pain NN N
medication NN N
taken VBN N
. . N

Hierarchical JJ N
linear NN N
modeling NN N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
ethnic JJ N
match NN N
on IN N
drinking NN N
outcomes NNS N
including VBG N
volume NN N
per IN N
week NN N
, , N
maximum JJ N
amount NN N
, , N
and CC N
frequency NN N
of IN N
5 CD N
or CC N
more JJR N
drinks NNS N
per IN N
occasion NN N
. . N

Combination NNP N
therapy NN i
cleared VBD N
all DT N
AK NNP N
lesions NNS N
only RB N
after IN N
the DT N
first JJ N
course NN N
, , N
while IN N
PDT NNP N
and CC N
imiquimod JJ N
therapy NN i
cleared VBD N
41.7 CD N
% NN N
and CC N
66.7 CD N
% NN N
of IN N
AK NNP N
lesions NNS N
after IN N
the DT N
first JJ N
course NN N
, , N
respectively RB N
. . N

Although IN N
LGG NNP N
is VBZ N
a DT N
relatively RB N
poor JJ N
colonizer NN N
in IN N
infants NNS N
, , N
especially RB N
those DT N
infants NNS N
weighing VBG N
less JJR N
than IN N
1500 CD N
g NN N
at IN N
birth NN N
, , N
it PRP N
does VBZ N
appear VB N
to TO N
affect VB N
neonatal JJ N
intestinal JJ N
colonization NN N
patterns NNS N
. . N

The DT N
IFRS NNP N
is VBZ N
designed VBN N
to TO N
release VB N
a DT N
daily JJ N
dose NN N
of IN N
0.12mg CD N
of IN N
sodium NN N
fluoride NN N
, , N
which WDT N
can MD N
be VB N
evenly RB N
distributed VBN N
throughout IN N
the DT N
oral JJ N
cavity NN N
for IN N
a DT N
single JJ N
application NN N
of IN N
4 CD N
months NNS N
. . N

This DT N
study NN N
examined VBD N
whether IN N
cognitive JJ N
gains NNS N
among IN N
192 CD N
students NNS N
from IN N
47 CD N
kindergarten-through-second-grade JJ N
autism NN N
support NN N
classrooms NNS N
participating VBG N
in IN N
a DT N
year-long JJ N
behavioral JJ N
intervention NN N
study NN N
were VBD N
associated VBN N
with IN N
gains NNS N
in IN N
social JJ N
functioning NN N
. . N

At IN N
follow-up JJ N
, , N
39 CD N
% NN N
of IN N
conservative JJ N
management NN N
patients NNS p
requested VBD N
surgery NN N
, , N
and CC N
interference NN N
of IN N
symptoms NNS N
with IN N
life NN N
and CC N
an DT N
unsuccessful JJ N
outcome NN N
were VBD N
more JJR N
commonly RB N
reported VBN N
in IN N
this DT N
arm NN N
. . N

CONCLUSIONS NNP N
Simple NNP N
knee NNP N
flexion NN N
and CC N
extension NN N
exercises NNS N
( ( N
WB NNP N
and CC N
NWB NNP N
) ) N
performed VBD N
over IN N
8 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
improvement NN N
in IN N
the DT N
WOMAC NNP N
function NN N
scale NN N
and CC N
knee NN N
strength NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

After IN N
at IN N
least JJS N
14 CD N
days NNS N
, , N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
olopatadine NN N
in IN N
one CD N
eye NN N
and CC N
placebo NN N
in IN N
the DT N
contralateral JJ N
eye NN N
, , N
or CC N
ketorolac NN N
in IN N
one CD N
eye NN N
and CC N
placebo NN N
in IN N
the DT N
contralateral JJ N
eye NN N
. . N

RESULTS NNP N
Bleeding NNP N
of IN N
the DT N
gums NNS N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
and CC N
pocket NN N
depth NN N
( ( N
PD NNP N
) ) N
improved VBD N
at IN N
the DT N
treatment NN N
site NN N
and CC N
were VBD N
maintained VBN N
for IN N
13 CD N
weeks NNS N
after IN N
treatment NN N
. . N

In IN N
conclusion NN N
, , N
high JJ N
intakes NNS N
of IN N
iTFA NN N
and CC N
CLA NNP N
did VBD N
not RB N
substantially RB N
affect JJ N
plasma NN N
concentrations NNS N
of IN N
inflammatory JJ N
markers NNS N
, , N
but CC N
they PRP N
increased VBD o
the DT o
urine JJ N
8-iso-PGF JJ N
( ( N
2 CD N
) ) N
concentration NN N
. . N

After IN N
5 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
, , N
the DT N
cumulative JJ N
incidence NN N
of IN N
IBR NNP N
was VBD N
2.5 CD N
% NN N
in IN N
the DT N
surgery-only JJ N
arm NN N
and CC N
0.7 CD N
% NN N
in IN N
the DT N
surgery NN N
plus CC N
RT NNP N
arm NN N
. . N

Lethality NNP N
was VBD N
56 CD N
% NN N
in IN N
the DT N
sepsis NN N
group NN N
; : N
in IN N
the DT N
therapy NN i
group NN N
lethality NN N
was VBD N
significantly RB N
lower JJR N
in IN N
patients NNS p
with IN N
plasmapheresis NN N
, , N
even RB N
though IN N
in IN N
this DT N
population NN N
the DT N
organic JJ N
failure NN N
rate NN N
was VBD N
higher JJR N
. . N

Of IN N
these DT N
plasma JJ N
markers NNS N
measured VBD N
, , N
only RB N
baseline JJ N
CRP NNP N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
SCD NNP N
over IN N
the DT N
ensuing VBG N
17 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P NNP N
for IN N
trend=0.001 NN N
) ) N
. . N

Analysis NN N
comparing VBG N
change NN N
between IN N
baseline NN N
and CC N
week NN N
8 CD N
of IN N
treatment NN N
for IN N
L-carnitine NNP N
and CC N
the DT N
placebo NN N
showed VBD N
that IN N
both DT N
parents/caregivers NNS N
and CC N
medical JJ N
follow-up NN N
detected JJ N
improvements NNS N
in IN N
the DT N
subjects NNS N
' POS N
well-being NN N
. . N

A DT N
small JJ N
proportion NN N
of IN N
patients NNS p
( ( N
7 CD N
% NN N
) ) N
treated VBD N
with IN N
ofloxacin NN i
suffered VBD N
mild JJ N
adverse JJ N
effects NNS N
( ( N
nausea NN N
, , N
vomiting VBG N
, , N
headache NN N
, , N
hypotension NN N
and CC N
rash NN N
) ) N
. . N

METHODS NNP N
On IN N
four CD N
separate JJ N
occasions NNS N
, , N
12 CD N
male JJ N
team-sport NN N
players NNS N
performed VBD N
a DT N
standardized JJ N
warm-up NN N
, , N
followed VBN N
by IN N
a DT N
test NN N
of IN N
either DT N
RSA NNP N
or CC N
CODS NNP N
( ( N
on IN N
two CD N
occasions NNS N
each DT N
) ) N
in IN N
a DT N
counterbalanced JJ N
design NN N
. . N

Extrinsic JJ N
tooth DT N
stain NN N
was VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
and CC N
14 CD N
days NNS N
using VBG N
a DT N
Modified NNP N
Lobene NNP N
Stain NNP N
Index NNP N
( ( N
MLSI NNP N
) ) N
with IN N
Lobene NNP N
inclusion NN N
criteria NNS N
of IN N
? . N
1.5 CD N
. . N

In IN N
conclusion NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN o
from IN N
baseline NN N
in IN N
the DT N
coronary JJ N
plaque NN N
volume NN N
in IN N
patients NNS p
with IN N
stable JJ N
angina NNS N
pectoris NN N
who WP N
received VBD N
olmesartan PRP N
or CC N
valsartan VB N
for IN N
6 CD N
months NNS N
. . N

Although IN N
the DT N
mean JJ N
hemoglobin NN N
concentration NN N
was VBD N
higher RBR N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
after IN N
6 CD N
days NNS N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
until IN N
9.5 CD N
days NNS N
of IN N
ICU NNP N
care NN N
. . N

Measured NNP N
serum NN N
propofol NN N
concentrations NNS N
in IN N
equilibrium NN N
with IN N
the DT N
effect-site NN N
at IN N
which WDT N
50 CD N
% NN N
of IN N
the DT N
patients NNS p
did VBD N
not RB N
respond VB N
to TO N
verbal VB N
commands NNS N
( ( N
EC50 NNP N
for IN N
loss NN N
of IN N
consciousness NN N
) ) N
were VBD N
determined VBN N
by IN N
logistic JJ N
regression NN N
. . N

Stepwise NN N
linear JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
loss NN N
of IN N
periprosthetic JJ N
BMD NNP N
in IN N
the DT N
proximal JJ N
high-pressure NN N
region NN N
after IN N
2 CD N
years NNS N
increased VBD o
with IN o
higher RBR N
postoperative JJ N
BMD NNP N
and CC N
when WRB N
the DT N
uncemented JJ N
design NN N
had VBD N
been VBN N
used VBN N
. . N

The DT N
authors NNS N
hypothesized VBD N
that IN N
the DT N
Dietary NNP N
Approaches NNP N
to TO N
Stop VB N
Hypertension NNP N
( ( N
DASH NNP N
) ) N
diet NN N
and CC N
reduced JJ N
sodium NN N
intake NN N
would MD N
control VB N
stage NN N
1 CD N
hypertension NN N
and CC N
reduce VB N
high-normal JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
to TO N
optimal JJ N
levels NNS N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ N
tissue NN N
concentrations NNS N
of IN N
moxifloxacin NN i
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP N
. . N

The DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
skin NN N
anesthetic JJ N
before IN N
( ( N
99m CD N
) ) N
Tc-SC CD N
injections NNS N
, , N
whereas IN N
the DT N
experimental JJ N
group NN N
first JJ N
underwent JJ N
skin NN N
anesthesia NN N
with IN N
an DT N
injection NN N
of IN N
2 CD N
% NN N
sodium JJ N
bicarbonate-buffered JJ N
lidocaine NN N
. . N

The DT N
respective JJ N
modulating NN N
effects NNS N
of IN N
continuous JJ N
and CC N
intermittent JJ N
insulin NN N
delivery NN N
on IN N
pancreatic JJ N
islet NN N
cell NN N
function NN N
were VBD N
studied VBN N
in IN N
seven CD N
normal JJ N
men NNS N
and CC N
nine CD N
insulin-dependent NN N
( ( N
type JJ N
1 CD N
) ) N
diabetic JJ N
patients NNS p
. . N

When WRB N
comparing VBG N
olanzapine NN N
with IN N
haloperidol NN N
, , N
cost NN N
savings NNS N
are VBP N
seen VBN N
throughout IN N
the DT N
treatment NN N
period NN N
( ( N
1 CD N
year NN N
) ) N
, , N
with IN N
physical JJ N
functioning VBG N
most JJS N
highly RB N
affected VBN N
over IN N
time NN N
. . N

The DT N
study NN N
included VBD N
only RB N
ACB NNP N
's POS N
with IN N
intraoperative JJ N
blood NN N
flow NN N
rates NNS N
< VBP N
or CC N
= VBP N
40 CD N
ml/min NN N
as IN N
it PRP N
is VBZ N
just RB N
these DT N
ACB NNP N
's POS N
which WDT N
are VBP N
at IN N
the DT N
highest JJS N
risk NN N
of IN N
early JJ N
and CC N
late JJ N
occlusions NNS N
. . N

BACKGROUND NNP N
In IN N
1998 CD N
, , N
mandatory JJ N
folic JJ N
acid JJ N
fortification NN N
of IN N
white JJ N
flour NN N
and CC N
select JJ N
cereal NN N
grain NN N
products NNS N
was VBD N
implemented VBN N
in IN N
Canada NNP N
with IN N
the DT N
intention NN N
to TO N
increase VB o
dietary JJ N
folate JJ N
intakes NNS N
of IN N
reproducing VBG N
women NNS N
. . N

METHODS NNP N
Following NNP N
assessment NN N
, , N
individual JJ N
profiles NNS N
were VBD N
developed VBN N
and CC N
each DT N
week NN N
teachers NNS N
and CC N
parents NNS N
were VBD N
given VBN N
guidelines NNS N
for IN N
working VBG N
with IN N
the DT N
children NNS N
and CC N
each DT N
child NN N
had VBD N
three CD N
to TO N
four CD N
sessions NNS N
a DT N
week NN N
lasting VBG N
approximately RB N
for IN N
20 CD N
minutes NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
mean JJ N
hemoglobin NN N
concentration NN N
declined VBD N
most JJS N
rapidly RB N
in IN N
the DT N
first JJ N
24 CD N
hrs NN N
of IN N
ICU NNP N
care NN N
and CC N
, , N
thereafter RB N
, , N
declined VBD N
more RBR N
slowly RB N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
, , N
efficacy NN N
and CC N
tolerability NN N
were VBD N
comparable JJ N
between IN N
C/A NNP N
and CC N
H/A NNP N
over IN N
23 CD N
days NNS N
of IN N
treatment NN N
in IN N
these DT N
patients NNS p
with IN N
moderate JJ N
or CC N
severe JJ N
, , N
chronic JJ N
, , N
cancer-related JJ N
pain NN N
. . N

Gentamicin NNP i
4 CD N
mg/kg NN N
every DT N
day NN N
( ( N
OD NNP N
) ) N
or CC N
gentamicin $ i
1.33 CD N
mg/kg NN N
three CD N
times NNS N
daily RB N
( ( N
MD NNP N
) ) N
( ( N
with IN N
dose-reduction NN N
in IN N
case NN N
of IN N
renal JJ N
dysfunction NN N
) ) N
were VBD N
given VBN N
intravenously RB N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
median JJ N
progression-free NN N
or CC N
overall JJ i
survival NN N
times NNS N
for IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
study NN N
included VBD N
60 CD N
patients NNS p
with IN N
A NNP N
degree NN N
of IN N
ERD NNP N
, , N
consistently RB N
received VBN N
in-patient JJ N
treatment NN N
in IN N
the DT N
Municipal NNP N
KGVV NNP N
, , N
mean JJ N
age NN N
79.0 CD N
+/- JJ N
6.8 CD N
years NNS N
. . N

CONCLUSIONS NNP N
Addition NNP N
of IN N
the DT N
DPP4 NNP N
inhibitor NN N
PHX1149 NNP N
to TO N
a DT N
stable JJ N
regimen NN N
of IN N
metformin NN N
or CC N
metformin NN N
plus CC N
a DT N
glitazone NN N
in IN N
patients NNS p
with IN N
type JJ N
2 CD N
diabetes NNS N
was VBD N
well RB N
tolerated VBN N
and CC N
improved VBN N
blood NN N
glucose NN N
control NN N
. . N

Over IN N
a DT N
24-month JJ N
observation NN N
period NN N
the DT N
immunized JJ N
group NN N
always RB N
had VBD N
higher JJR N
levels NNS N
of IN N
peripheral JJ N
leukocytes NNS N
and CC N
peripheral JJ N
lymphocytes NNS N
; : N
this DT N
difference NN N
was VBD N
significant JJ N
for IN N
the DT N
first JJ N
21 CD N
months NNS N
. . N

In IN N
conclusion NN N
, , N
supplementation NN N
of IN N
aPLA2 NN N
improved VBN N
FE NNP N
of IN N
growing VBG N
beef NN N
calves NNS N
when WRB N
fed VBN N
LC NNP N
diets NNS N
in IN N
Phase NNP N
1 CD N
and CC N
addition NN N
of IN N
aPLA2 NN N
had VBD N
no DT N
effect NN N
on IN N
fermentation NN N
parameters NNS N
of IN N
LC NNP N
and CC N
HC NNP N
substrates NNS N
. . N

GE NNP N
also RB N
had VBD N
a DT N
within-group JJ N
increase NN o
in IN N
mean JJ N
vegetable JJ N
intake NN N
after IN N
3 CD N
months NNS N
, , N
but CC N
this DT N
increase NN o
was VBD N
not RB N
different JJ N
from IN N
changes NNS N
in IN N
the DT N
other JJ N
groups NNS N
. . N

All DT N
of IN N
these DT N
changes NNS N
in IN N
flow NN N
were VBD N
statistically RB N
more JJR N
common JJ N
for IN N
the DT N
circumflex JJ N
coronary JJ N
artery NN N
and CC N
early JJ N
treatment NN N
( ( N
less JJR N
than IN N
4 CD N
h NN N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
for IN N
anistreplase NN N
or CC N
streptokinase NN N
. . N

DESIGN NNP N
Reanalysis NNP N
of IN N
the DT N
baseline NN N
prediction NN N
model NN N
for IN N
the DT N
development NN N
of IN N
POAG NNP N
from IN N
the DT N
Ocular NNP N
Hypertension NNP N
Treatment NNP N
Study NNP N
( ( N
OHTS NNP N
) ) N
substituting VBG N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
using VBG N
5 CD N
different JJ N
correction NN N
formulae NN N
for IN N
unadjusted JJ N
IOP NNP N
. . N

The DT N
dose-response JJ N
and CC N
concentration-response JJ N
relation NN N
of IN N
rocuronium NN N
infusion NN N
was VBD N
studied VBN N
in IN N
20 CD N
adult NN N
surgical JJ N
patients NNS p
during IN N
propofol-nitrous JJ N
oxide NN N
and CC N
isoflurane NN N
( ( N
1 CD N
MAC NNP N
) ) N
-nitrous JJ N
oxide JJ N
anaesthesia NN N
. . N

INTERPRETATION NNP N
In IN N
patients NNS p
undergoing VBG N
elective JJ N
hip-replacement JJ N
surgery NN N
, , N
2.5 CD N
mg NN N
fondaparinux NN N
once RB N
daily RB N
was VBD N
not RB N
significantly RB N
more RBR N
effective JJ N
than IN N
30 CD N
mg JJ N
enoxaparin JJ N
twice RB N
daily RB N
in IN N
reducing VBG N
risk NN N
of IN N
venous JJ N
thromboembolism NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
objective JJ N
cure NN N
rate NN N
of IN N
the DT N
anterior JJ N
compartment NN N
( ( N
point NN N
Ba NNP N
) ) N
assessed VBD N
at IN N
the DT N
12-month JJ N
follow-up JJ N
visit NN N
, , N
with IN N
stages NNS N
0 CD N
and CC N
I PRP N
defined VBD N
as IN N
anatomical JJ N
success NN N
. . N

UNLABELLED NN N
In IN N
paired JJ N
biopsies NNS N
of IN N
osteoporotic JJ i
women NNS N
treated VBN N
with IN N
either DT N
strontium NN N
ranelate NN N
or CC N
a DT N
placebo NN N
for IN N
36 CD N
months NNS N
, , N
characteristics NNS N
of IN N
bone NN N
apatite JJ N
crystals NNS N
were VBD N
not RB N
influenced VBN N
by IN N
the DT N
presence NN N
of IN N
strontium NN N
. . N

High JJ N
Zn NNP N
intakes NNS N
resulted VBD N
in IN N
a DT N
reduced JJ N
gene NN N
expression NN N
of IN N
? . N
3 CD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
the DT N
expression NN N
of IN N
TFF3 NNP N
. . N

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
high- JJ N
compared VBN N
to TO N
low-dose JJ N
atorvastatin NN i
was VBD N
associated VBN N
with IN N
improvement NN N
in IN N
eGFR NN N
at IN N
1 CD N
year NN N
, , N
which WDT N
was VBD N
related VBN N
to TO N
a DT N
decrease NN o
in IN N
subsequent JJ N
HF NNP N
hospitalization NN N
. . N

In IN N
group NN N
I PRP N
, , N
thrombolysis NN N
was VBD N
successful JJ N
in IN N
all DT N
patients NNS p
, , N
without IN N
complications NNS N
, , N
within IN N
6-72 JJ N
h. NN N
In IN N
group NN N
II NNP N
, , N
heparin NN N
treatment NN N
was VBD N
successful JJ N
in IN N
six CD N
patients NNS p
in IN N
3-32 JJ N
days NNS N
. . N

METHODS NNP N
20 CD N
patients NNS p
with IN N
facet-joint JJ N
pain NN N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
received VBD N
block RB N
blindly RB N
( ( N
B NNP N
group NN N
) ) N
or CC N
guided VBN N
by IN N
ultrasound NN N
( ( N
US NNP N
group NN N
) ) N
respectively RB N
. . N

RESULTS NNP N
Of IN N
all PDT N
the DT N
subjects NNS N
assessed VBN N
, , N
FA-specific NNP N
IgE NNP N
was VBD N
detected VBN N
in IN N
only RB N
two CD N
asthmatics NNS N
, , N
and CC N
their PRP$ N
IgE NNP N
levels NNS N
of IN N
FA NNP N
were VBD N
low JJ N
( ( N
0.42 CD N
and CC N
0.46 CD N
UA/ml NNP N
) ) N
. . N

At IN N
visit NN N
2 CD N
, , N
patients NNS p
in IN N
the DT N
azithromycin NN i
group NN N
demonstrated VBD N
significant JJ N
improvements NNS N
in IN N
MG NNP N
plugging NN N
, , N
MG NNP N
secretions NNS N
, , N
and CC N
eyelid JJ N
redness NN N
as IN N
compared VBN N
with IN N
the DT N
compress NN N
group NN N
. . N

PURPOSE VB N
A DT N
let-7 JJ N
microRNA-complementary JJ N
site NN N
( ( N
LCS6 NNP N
) ) N
polymorphism NN N
in IN N
the DT N
3 CD N
' POS N
untranslated JJ N
region NN N
of IN N
the DT N
KRAS NNP N
gene NN N
has VBZ N
been VBN N
shown VBN N
to TO N
disrupt VB N
let-7 JJ N
binding NN N
and CC N
upregulate JJ N
KRAS NNP N
expression NN N
. . N

In IN N
subjects NNS N
so RB N
selected VBN N
, , N
the DT N
estimated JJ N
duration NN N
of IN N
MEE NNP N
ranged VBD N
from IN N
none NN N
to TO N
65.6 CD N
% NN N
of IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
and CC N
44.8 CD N
% NN N
of IN N
the DT N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
. . N

After IN N
hospital JJ N
discharge NN N
, , N
usual JJ N
care NN N
patients NNS p
received VBD N
no DT N
further JJ N
nutrition NN N
support NN N
, , N
whereas RB N
extended VBN N
care NN N
patients NNS p
received VBD N
telephone NN N
dietary JJ N
counselling NN N
from IN N
the DT N
same JJ N
dietitian NN N
for IN N
up IN N
to TO N
100 CD N
days NNS N
post-transplantation NN N
. . N

METHODS NNP N
Fifty-six NNP N
male NN N
patients NNS p
( ( N
mean JJ N
age NN N
71.2 CD N
+/- JJ N
8.2 CD N
years NNS N
) ) N
scheduled VBD N
for IN N
TURP NNP N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

In IN N
surveys NNS N
carried VBD N
out RP N
after IN N
three CD N
years NNS N
of IN N
initial JJ N
distribution NN N
, , N
78.7 CD N
% NN N
( ( N
737/936 CD N
) ) N
nets NNS N
were VBD N
still RB N
in IN N
possession NN N
with IN N
the DT N
households NNS N
, , N
of IN N
which WDT N
68 CD N
% NN N
were VBD N
used VBN N
every DT N
night NN N
. . N

Treatment NNP N
consisted VBD N
of IN N
approximately RB N
3,800 CD N
total JJ N
shock NN N
waves NNS N
( ( N
+/-10 JJ N
) ) N
reaching VBG N
an DT N
approximated JJ N
total NN N
energy NN N
delivery NN N
of IN N
1,300 CD N
mJ/mm NN N
( ( N
2 CD N
) ) N
( ( N
ED+ NNP N
) ) N
in IN N
a DT N
single JJ N
session NN N
versus IN N
placebo NN N
treatment NN N
. . N

CONCLUSION NN N
In IN N
IRS-IV NNP N
, , N
response NN N
rate NN N
to TO N
induction NN N
therapy NN i
was VBD N
77 CD N
% NN N
in IN N
group NN N
III NNP N
patients NNS p
, , N
was VBD N
independent JJ N
of IN N
histology NN N
, , N
and CC N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP N
overall JJ i
. . N

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
HbA1c NNP N
was VBD N
observed VBN N
in IN N
the DT N
nateglinide JJ N
group NN N
, , N
whereas IN N
a DT N
significant JJ N
increase NN o
of IN N
HbA1c NNP N
was VBD N
observed VBN N
in IN N
the DT N
untreated JJ N
group NN N
. . N

Immunohistochemical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
anti JJ N
HMGB1 NNP N
antibodies NNS N
and CC N
the DT N
expression NN N
of IN N
HMGB1 NNP N
protein NN N
in IN N
the DT N
spinal JJ N
cord NN N
was VBD N
determined VBN N
by IN N
western JJ N
blot NN N
analysis NN N
after IN N
intrathecal JJ N
delivery NN N
( ( N
n JJ N
= RB N
8 CD N
each DT N
) ) N
. . N

RESULTS VB N
The DT N
MCIC NNP N
of IN N
the DT N
PI-NRS NNP N
ranged VBD N
from IN N
3.5 CD N
to TO N
4.7 CD N
points NNS N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS p
and CC N
2.5 CD N
to TO N
4.5 CD N
points NNS N
in IN N
chronic JJ N
patients NNS p
with IN N
low JJ N
back RB N
pain NN N
. . N

Marginal JJ N
adaptation NN N
was VBD N
evaluated VBN N
by IN N
using VBG N
a DT N
computer-assisted JJ N
quantitative JJ N
marginal JJ N
analysis NN N
in IN N
a DT N
scanning NN N
electron NN N
microscope NN N
( ( N
SEM NNP N
) ) N
on IN N
epoxy JJ N
replicas NN N
before IN N
, , N
after IN N
thermal JJ N
and CC N
mechanical JJ N
stressing NN N
and CC N
after IN N
1 CD N
year NN N
of IN N
water NN N
storage NN N
. . N

Reported VBN N
frequency NN N
of IN N
GI NNP N
abnormalities NNS N
, , N
including VBG N
abnormal JJ N
stool NN N
consistency NN N
( ( N
e.g JJ N
, , N
bulky NN N
or CC N
loose JJ N
) ) N
, , N
was VBD N
increased VBN o
( ( N
54 CD N
% NN N
) ) N
. . N

The DT N
outcome NN N
variables NNS N
were VBD N
total JJ N
scores NNS N
on IN N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
CARS NNP N
) ) N
and CC N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
( ( N
CGAS NNP N
) ) N
after IN N
6 CD N
months NNS N
. . N

The DT N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
the DT N
difference NN N
in IN N
the DT N
percentage NN N
variation NN N
of IN N
MAP NNP N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
( ( N
-3.1 JJ N
, , N
+3.7 NNP N
) ) N
. . N

On IN N
PND NNP N
81 CD N
, , N
an DT N
increased VBN o
adrenal JJ N
medulla NN N
area NN N
was VBD N
observed VBN N
in IN N
LP NNP N
offspring VBG N
compared VBN N
with IN N
the DT N
AP NNP N
offspring NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
12 CD N
months NNS N
of IN N
GH NNP N
treatment NN N
, , N
the DT N
individual JJ N
changes NNS N
in IN N
BF NNP N
ranged VBD N
from IN N
-12.5 NN N
to TO N
4.3 CD N
kg NNS N
and CC N
from IN N
-4.5 NNP N
to TO N
10.1 CD N
kg NNS N
in IN N
LBM NNP N
. . N

After IN N
screening VBG N
, , N
the DT N
patients NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
, , N
for IN N
a DT N
period NN N
of IN N
4 CD N
weeks NNS N
, , N
either CC N
a DT N
cocoa NN N
husk NN N
supplement NN N
or CC N
placebo NN N
plus CC N
standardized JJ N
toilet NN N
training NN N
procedures NNS N
. . N

Classical JJ N
90 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
90CI CD N
) ) N
were VBD N
calculated VBN N
for IN N
the DT N
overall JJ i
sample NN N
, , N
and CC N
for IN N
males NNS N
and CC N
females NNS N
separately RB N
, , N
and CC N
gender NN N
effects NNS N
were VBD N
investigated VBN N
using VBG N
an DT N
appropriate JJ N
model NN N
. . N

Also RB N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
wound NN N
healing VBG N
score RB N
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
( ( N
P=0.003 NNP N
) ) N
. . N

The DT N
influence NN N
of IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
and CC N
tumor NN N
differentiation NN N
on IN N
the DT N
response NN N
to TO N
accelerated VBN N
radiotherapy NN i
of IN N
squamous JJ N
cell NN N
carcinomas NN N
of IN N
the DT N
head NN N
and CC N
neck NN N
in IN N
the DT N
randomized JJ N
DAHANCA NNP N
6 CD N
and CC N
7 CD N
study NN N
. . N

Skill NNP N
performance NN N
and CC N
retention NN N
were VBD N
shown VBN N
to TO N
be VB N
high JJ N
following VBG N
either CC N
training VBG N
method NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
performance NN N
of IN N
either DT N
group NN N
( ( N
chi JJ N
2 CD N
) ) N
. . N

In IN N
contrast NN N
to TO N
the DT N
hypothesis NN N
to TO N
be VB N
tested VBN N
, , N
the DT N
efficacy NN N
of IN N
physostigmine NN N
was VBD N
not RB N
superior JJ N
to TO N
that DT N
of IN N
placebo NN N
after IN N
a DT N
treatment NN N
period NN N
of IN N
24 CD N
weeks NNS N
. . N

METHODS NNP N
101 CD N
hemodialysis NN N
patients NNS p
were VBD N
randomized VBN N
for IN N
each DT N
phosphate NN N
binder NN N
and CC N
submitted VBN N
to TO N
multislice VB N
coronary JJ N
tomographies NNS N
and CC N
bone NN N
biopsies NNS N
at IN N
entry NN N
and CC N
12 CD N
months NNS N
. . N

On IN N
the DT N
basis NN N
of IN N
this DT N
reduced JJ N
nephrotoxicity NN N
, , N
a DT N
incremental JJ N
cost NN N
of IN N
$ $ N
435 CD N
per IN N
case NN N
of IN N
nephrotoxicity NN N
prevented VBN N
was VBD N
found VBN N
for IN N
vancomycin NN i
serum NN N
concentration NN N
monitoring NN N
. . N

RESULTS NN N
We PRP N
found VBD N
significant JJ N
differences NNS N
in IN N
answers NNS N
to TO N
the DT N
asthma JJ N
questions NNS N
, , N
by IN N
40 CD N
% NN N
improvement NN N
, , N
but CC N
no DT N
changes NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Recurrences NNS N
of IN N
arrhythmia NN N
, , N
deaths NNS N
, , N
and CC N
adverse JJ N
drug NN N
effects NNS N
during IN N
long-term JJ N
follow-up NNS N
were VBD N
recorded VBN N
for IN N
the DT N
296 CD N
patients NNS p
in IN N
whom WP N
an DT N
antiarrhythmic JJ N
drug NN N
was VBD N
predicted VBN N
to TO N
be VB N
effective JJ N
. . N

A DT N
second JJ N
dose NN N
of IN N
fenoterol NN N
and CC N
of IN N
the DT N
combination NN N
regimen NNS N
resulted VBD N
in IN N
a DT N
further JJ N
significant JJ N
increase NN o
in IN N
FEV1 NNP N
after IN N
120 CD N
min NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

AIM NNP N
To TO N
determine VB N
whether IN N
telephone NN N
appointments NNS N
offered VBD N
bygeneral JJ N
practice NN N
receptionists NNS N
increase VBP o
the DT N
uptake NN N
of IN N
irfluenza JJ N
immunisation NN N
among IN N
the DT N
registered JJ N
population NN N
aged VBD N
over IN N
65 CD N
years NNS N
in IN N
east JJ N
London NNP N
practices NNS N
. . N

CI-AKI NNP N
was VBD N
defined VBN N
as IN N
a DT N
relative JJ N
increase NN o
in IN N
serum JJ N
creatinine NN N
of IN N
? . N
% NN N
, , N
or CC N
an DT N
absolute JJ N
increase NN o
of IN N
? . N
mg/dL NN N
, , N
occurring VBG N
within IN N
48 CD N
hours NNS N
after IN N
contrast NN N
administration NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
virtual JJ N
reality NN N
distraction NN N
intervention NN N
on IN N
chemotherapy-related JJ i
symptom NN N
distress NN N
levels NNS N
in IN N
16 CD N
women NNS N
aged VBD N
50 CD N
and CC N
older JJR N
. . N

Patients NNS N
received VBD N
hydrocortisone RB N
0.1 CD N
% NN N
solution NN N
, , N
ASA NNP N
1 CD N
% NN N
solution NN N
, , N
piroxicam VB N
0.5 CD N
% NN N
solution NN N
or CC N
placebo NN N
as IN N
eye NN N
drops NNS N
, , N
all DT N
one CD N
drop NN N
in IN N
each DT N
eye NN N
q.i.d NN N
. . N

Fourty-four JJ N
DES-exposed JJ N
offspring NN N
had VBD N
their PRP$ N
vaginal JJ N
adenosis NN N
treated VBN N
with IN N
the DT N
carbon NN N
dioxide NN N
laser NN N
( ( N
group NN N
I PRP N
) ) N
, , N
and CC N
the DT N
remaining VBG N
35 CD N
DES-exposed JJ N
offspring NN N
( ( N
group NN N
II NNP N
) ) N
did VBD N
not RB N
receive VB N
any DT N
specific JJ N
treatment NN N
for IN N
this DT N
condition NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Women NNP N
with IN N
invasive JJ N
breast NN N
cancer NN N
were VBD N
eligible JJ N
if IN N
there EX N
were VBD N
one CD N
to TO N
three CD N
positive JJ N
lymph NN N
nodes NNS N
or CC N
if IN N
the DT N
node-negative JJ N
tumor NN N
was VBD N
greater JJR N
than IN N
1 CD N
cm NN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
bronchodilator NN N
efficacy NN N
between IN N
the DT N
patients NNS p
continuing VBG N
to TO N
receive VB N
CFC NNP N
albuterol NN N
and CC N
those DT N
switched VBN N
to TO N
HFA NNP N
albuterol NN N
were VBD N
found VBN N
in IN N
the DT N
12 CD N
weeks NNS N
after IN N
the DT N
switch NN N
. . N

Maximal JJ N
heart NN N
rate NN N
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
, , N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
. . N

Thirty NN N
patients NNS p
undergoing VBG N
elective JJ N
cholecystectomy NN N
were VBD N
allocated VBN N
randomly RB N
to TO N
receive VB N
an DT N
infusion NN N
of IN N
morphine NN N
or CC N
an DT N
infusion NN N
of IN N
placebo NN N
( ( N
control VB N
group NN N
) ) N
for IN N
24 CD N
hours NNS N
. . N

A DT N
simple JJ N
meal NN N
plan NN N
of IN N
'eating VBG N
vegetables NNS N
before IN N
carbohydrate NN N
' '' N
was VBD N
more RBR N
effective JJ N
for IN N
achieving VBG N
glycemic JJ N
control NN N
than IN N
an DT N
exchange-based JJ N
meal NN N
plan NN N
in IN N
Japanese JJ N
patients NNS p
with IN N
type JJ N
2 CD N
diabetes NNS N
. . N

CONCLUSIONS NNP N
The DT N
continuous JJ N
oral JJ N
administration NN N
of IN N
UFT NNP N
for IN N
7 CD N
days NNS N
preoperatively RB N
resulted VBD N
in IN N
enhanced JJ N
apoptosis NN N
and CC N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
the DT N
AI NNP N
and CC N
5-FU JJ N
concentrations NNS N
in IN N
lung NN N
adenocarcinoma NN N
. . N

Amplitude NNP N
changes NNS N
as RB N
well RB N
as IN N
areas NNS N
under IN N
the DT N
curve NN N
( ( N
AUCs NNP N
) ) N
over IN N
150 CD N
min NNS N
were VBD N
compared VBN N
for IN N
the DT N
four CD N
treatments NNS N
by IN N
repeated JJ N
measures NNS N
ANOVA NNP N
( ( N
significance NN N
0.05 CD N
) ) N
. . N

Community-dwelling JJ N
frail NN N
elderly JJ N
subjects NNS N
, , N
aged VBD N
65 CD N
years NNS N
and CC N
older JJR N
, , N
with IN N
dyspnoea NN N
, , N
participating VBG N
in IN N
a DT N
screening NN N
study NN N
on IN N
COPD NNP N
and CC N
heart NN N
failure NN N
were VBD N
included VBN N
. . N

The DT N
primary JJ N
analysis NN N
examined VBD N
the DT N
agreement NN N
rate NN N
between IN N
CTP NNP N
and CC N
SPECT NNP N
for IN N
detecting VBG N
or CC N
excluding VBG N
reversible JJ N
ischemia NN N
in IN N
? . N
2 CD N
myocardial JJ N
segments NNS N
as IN N
assessed VBN N
by IN N
independent JJ N
, , N
blinded VBD N
readers NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
any DT N
other JJ N
response NN N
biomarker NN N
between IN N
the DT N
two CD N
groups NNS N
up RB N
to TO N
36 CD N
months NNS N
, , N
nor CC N
was VBD N
any DT N
biomarker NN N
able JJ N
to TO N
predict VB N
recurrence NN N
risk NN N
. . N

Often RB N
the DT N
X-ray JJ N
photograph NN N
leads VBZ N
to TO N
the DT N
diagnosis NN N
in IN N
the DT N
second JJ N
stage NN N
( ( N
ARCO NNP N
1992 CD N
) ) N
or CC N
in IN N
the DT N
third JJ N
stage NN N
, , N
when WRB N
the DT N
femoral JJ N
head NN N
has VBZ N
begun VBN N
to TO N
collapse NN N
. . N

Fifty NNP N
endoscopic NN N
resections NNS N
were VBD N
performed VBN N
with IN N
a DT N
suck-and-ligate JJ N
device NN N
without IN N
prior JJ N
submucosa NN N
injection NN N
and CC N
50 CD N
with IN N
the DT N
cap NN N
technique NN N
with IN N
prior JJ N
submucosa JJ N
injection NN N
of IN N
a DT N
dilute JJ N
saline JJ N
solution NN N
of IN N
epinephrine NN N
. . N

While IN N
the DT N
patient NN N
in IN N
the DT N
observation NN N
group NN N
were VBD N
treated VBN N
by IN N
the DT N
routine JJ N
treatment NN N
and CC N
acupuncture NN N
treatment NN N
48 CD N
h NN N
( ( N
-1 NNP N
) ) N
week NN N
after IN N
operation NN N
in IN N
different JJ N
stages NNS N
with IN N
different JJ N
acupoints NNS N
selected VBN N
when WRB N
the DT N
situation NN N
was VBD N
stable JJ N
. . N

The DT N
change NN N
in IN N
hemoglobin JJ N
level NN N
from IN N
before IN N
to TO N
48 CD N
h NN N
after IN N
delivery NN N
, , N
use NN N
of IN N
additional JJ N
oxytocics NNS N
and CC N
treatment NN N
related JJ N
side NN N
effects NNS N
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

When WRB N
the DT N
dose NN N
of IN N
HBsAg NNP N
was VBD N
diminished VBN N
from IN N
3 CD N
micrograms NNS N
to TO N
1.5 CD N
, , N
0.6 CD N
, , N
and CC N
0.25 CD N
microgram NN N
, , N
no DT N
decrease NN o
of IN N
the DT N
anti-HBs JJ N
response NN N
was VBD N
observed VBN N
. . N

The DT N
WAIS-III NNP N
General NNP N
Ability NNP N
Index NNP N
( ( N
GAI NNP N
; : N
Tulsky NNP N
, , N
Saklofske NNP N
, , N
Wilkins NNP N
, , N
& CC N
Weiss NNP N
, , N
2001 CD N
) ) N
is VBZ N
a DT N
recently RB N
developed VBN N
, , N
6-subtest JJ N
measure NN N
of IN N
global JJ N
intellectual JJ N
functioning NN N
. . N

The DT N
subjects NNS N
, , N
131 CD N
children NNS N
aged VBN N
0.6-12 CD N
years NNS N
who WP N
lived VBD N
in IN N
an DT N
endemic JJ N
area NN N
of IN N
Nigeria NNP N
, , N
were VBD N
randomly RB N
allotted VBN N
to TO N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
responders NNS N
had VBD N
not RB N
reached VBN N
the DT N
median JJ N
survival NN N
yet RB N
, , N
the DT N
patients NNS p
with IN N
SD NNP N
had VBD N
a DT N
median JJ N
survival NN N
of IN N
14.7 CD N
months NNS N
and CC N
the DT N
PD NNP N
9.5 CD N
months NNS N
. . N

Acute NNP N
stress NN N
consisted VBD N
of IN N
losing VBG N
against IN N
a DT N
competitor NN N
of IN N
the DT N
opposite JJ N
sex NN N
on IN N
the DT N
criterion NN N
motor NN N
task NN N
while IN N
receiving VBG N
unpleasant JJ N
information NN N
about IN N
their PRP$ N
performance NN N
over IN N
30 CD N
preintervention NN N
and CC N
30 CD N
postintervention NN N
trials NNS N
. . N

The DT N
enteral JJ N
formula NN N
diet NN N
was VBD N
energy NN N
dense NN N
, , N
containing VBG N
40 CD N
mmol NN N
Na/day NNP N
, , N
whole JJ N
protein NN N
plus CC N
branched-chain JJ N
amino NN N
acids NNS N
, , N
medium- JJ N
and CC N
long-chain JJ N
triglycerides NNS N
, , N
and CC N
maltodextrin NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
8 CD N
weeks NNS N
of IN N
assisted JJ N
exercise NN N
on IN N
bone NN N
strength NN N
and CC N
metabolism NN N
in IN N
VLBW NNP N
premature NN N
infants NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
One NNP N
hundred VBD N
and CC N
six CD N
consecutive JJ N
patients NNS p
with IN N
ureteric JJ N
calculi NNS N
at IN N
different JJ N
levels NNS N
were VBD N
treated VBN N
by IN N
ESWL NNP N
using VBG N
Siemens NNP N
Lithostar NNP N
2 CD N
machine NN N
. . N

These DT N
principles NNS N
make VBP N
it PRP N
possible JJ N
to TO N
reduce VB N
the DT N
need NN N
for IN N
primary JJ N
colostomy NN N
to TO N
approximately RB N
50 CD N
per IN N
cent NN N
in IN N
a DT N
large JJ N
ongoing VBG N
group NN N
of IN N
patients NNS p
with IN N
colonic JJ N
injury NN N
. . N

After IN N
a DT N
follow-up JJ N
period NN N
of IN N
approximately RB N
4 CD N
months NNS N
, , N
both DT N
groups NNS N
had VBD N
similar JJ N
event NN N
rates NNS N
and CC N
comparable JJ N
hemodynamic JJ N
parameters NNS N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

Short-term JJ N
aerobic JJ N
exercise NN N
training NN N
in IN N
obese JJ N
humans NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus JJ N
improves VBZ N
whole-body JJ N
insulin NN N
sensitivity NN N
through IN N
gains NNS N
in IN N
peripheral JJ N
, , N
not RB N
hepatic JJ N
insulin NN N
sensitivity NN N
. . N

Exercise NN N
stimulates VBZ N
release NN N
of IN N
renin NN N
; : N
this DT N
action NN N
was VBD N
greater JJR N
with IN N
captopril JJ N
administration NN N
( ( N
treatment NN N
effect NN N
: : N
p NN N
< VBZ N
10 CD N
( ( N
-4 NN N
) ) N
, , N
indicating VBG N
blockade NN N
of IN N
the DT N
RAS NNP N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
Group NNP N
II NNP N
patients NNS p
received VBD N
dopexamine JJ N
infusion NN N
, , N
at IN N
a DT N
dose NN N
of IN N
1 CD N
microgram/kg/m NN N
, , N
and CC N
at IN N
a DT N
dose NN N
of IN N
0.5 CD N
micrograms/kg/m NN N
from IN N
declamping VBG N
to TO N
the DT N
end NN N
of IN N
the DT N
surgery NN N
. . N

METHODS NNP N
Patients NNS N
with IN N
H. NNP N
pylori FW N
infection NN N
were VBD N
tested VBN N
for IN N
CYP2C19 NNP N
genotype NN N
as IN N
poor JJ N
metabolizers NNS N
( ( N
PMs NNP N
) ) N
or CC N
extensive JJ N
metabolizers NNS N
( ( N
EMs NNP N
, , N
homozygous JJ N
EM NNP N
or CC N
heterozygous JJ N
EM NNP N
) ) N
and CC N
given VBN N
rabeprazole NN N
for IN N
7 CD N
days NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
clinical JJ N
cure NN N
and CC N
complete JJ N
( ( N
clinical JJ N
plus CC N
mycological JJ N
) ) N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
and CC N
complete JJ N
cure NN N
of IN N
all DT N
10 CD N
toenails NNS N
. . N

In IN N
conclusion NN N
, , N
olanzapine JJ N
LAI NNP N
and CC N
oral JJ N
olanzapine NN N
were VBD N
similarly RB N
effective JJ N
and CC N
well RB N
tolerated VBN N
for IN N
up RB N
to TO N
2 CD N
years NNS N
of IN N
treatment NN N
in IN N
patients NNS p
with IN N
schizophrenia NN N
. . N

A DT N
strong JJ N
increase NN o
in IN N
the DT N
serum NN N
zeaxanthin NN N
concentration NN N
was VBD N
observed VBN N
in IN N
individuals NNS N
receiving VBG N
zeaxanthin NN N
enriched VBN N
eggs NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
430 CD N
% NN N
) ) N
. . N

BACKGROUND NNP N
Triple NNP N
therapy NN i
regimens VBZ N
including VBG N
two CD N
antibiotics NNS N
plus CC N
acid JJ N
suppression NN N
have VBP N
become VBN N
the DT N
new JJ N
standard NN N
therapy NN i
in IN N
Helicobacter NNP N
pylori FW N
eradication NN N
because IN N
of IN N
success NN N
rates NNS N
of IN N
about RB N
90 CD N
% NN N
. . N

In IN N
the DT N
NR NNP N
group NN N
, , N
patients NNS p
were VBD N
postoperatively RB N
educated VBN N
in IN N
the DT N
possibility NN N
of IN N
mandibular JJ N
fracture NN N
and CC N
were VBD N
given VBN N
an DT N
emphasis NN N
on IN N
the DT N
necessity NN N
of IN N
limiting VBG N
mastication NN N
to TO N
a DT N
soft JJ i
diet NN N
for IN N
4 CD N
weeks NNS N
. . N

METHOD NNP N
Fifty NNP N
patients NNS p
with IN N
blepharitis NN N
, , N
conjuctivitis NN N
, , N
or CC N
blepharoconjunctivitis NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
0.3 CD N
% NN N
ofloxacin JJ i
eyedrops NNS N
, , N
BID NNP N
or CC N
QID NNP N
, , N
for IN N
10 CD N
days NNS N
. . N

When WRB N
contour NN N
spacing NN N
was VBD N
beyond IN N
a DT N
critical JJ N
range NN N
( ( N
about IN N
2 CD N
degrees NNS N
) ) N
, , N
however RB N
, , N
the DT N
detectability NN N
dropped VBD N
to TO N
chance NN N
levels NNS N
, , N
regardless RB N
of IN N
the DT N
number NN N
of IN N
colinear JJ N
lines NNS N
. . N

Risperidone NN i
was VBD N
associated VBN N
with IN N
increased VBN o
appetite NN N
and CC N
a DT N
mild JJ N
weight NN N
gain NN N
, , N
mild JJ N
sedation NN N
in IN N
20 CD N
% NN N
, , N
and CC N
transient NN N
dyskinesias NN N
in IN N
three CD N
children NNS N
. . N

Sputum NNP N
cells NNS N
and CC N
supernatant JJ N
levels NNS N
of IN N
ECP NNP N
, , N
sICAM NN N
, , N
IL-5 NNP N
and CC N
IL-10 NNP N
, , N
and CC N
plasma NN N
levels NNS N
of IN N
IL-5 NNP N
and CC N
ECP NNP N
, , N
were VBD N
measured VBN N
before IN N
and CC N
24 CD N
h NN N
after IN N
nasal JJ N
allergen NN N
challenge NN N
. . N

Irregular JJ N
uterine NN N
bleeding NN N
was VBD N
almost RB N
entirely RB N
confined VBN N
to TO N
the DT N
earlier JJR N
phase NN N
of IN N
the DT N
study NN N
and CC N
was VBD N
substantially RB N
less JJR N
with IN N
the DT N
formulation NN N
containing VBG N
1 CD N
mg JJ N
norethisterone NN N
acetate NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
intravesical JJ N
THP NNP N
instillation NN N
prior RB N
to TO N
TUR NNP N
would MD N
be VB N
effective JJ N
for IN N
patients NNS p
with IN N
single JJ N
, , N
low JJ N
grade NN N
lesions NNS N
larger JJR N
than IN N
1 CD N
cm NN N
of IN N
superficial JJ N
bladder NN N
cancer NN N
. . N

The DT N
relation NN N
of IN N
pacing VBG N
rate NN N
to TO N
physiologic VB N
variables NNS N
of IN N
metabolic JJ N
demand NN N
was VBD N
examined VBN N
in IN N
10 CD N
consecutive JJ N
patients NNS p
with IN N
a DT N
minute NN N
ventilation-sensing NN N
, , N
rate-modulating JJ N
ventricular JJ N
pacemaker NN N
implanted VBN N
for IN N
complete JJ N
heart NN N
block NN N
. . N

Application NN N
of IN N
either DT N
cream NN N
produced VBD N
a DT N
very RB N
slight JJ N
increase NN o
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.5 CD N
log NN N
cycle NN N
) ) N
in IN N
the DT N
skin NN N
flora NN N
during IN N
the DT N
first JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

In IN N
this DT N
clinical JJ N
trial NN N
we PRP N
will MD N
for IN N
the DT N
first JJ N
time NN N
assess VB N
the DT N
effect NN N
of IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
infusion NN N
of IN N
autologous JJ N
BMCs NNP N
following VBG N
AMI NNP N
on IN N
cardiac JJ N
function NN N
. . N

The DT N
selective JJ N
5-hydroxytryptamine JJ N
type NN N
4 CD N
receptor NN N
partial JJ N
agonist NN N
tegaserod NN N
is VBZ N
a DT N
novel JJ N
promotile NN N
agent NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
functional JJ N
motility NN N
disorders NNS N
such JJ N
as IN N
irritable JJ N
bowel NN N
syndrome NN N
( ( N
IBS NNP N
) ) N
. . N

We PRP N
compared VBN N
iron NNS N
intake NN N
and CC N
iron NN N
nutritional JJ N
status NN N
of IN N
two CD N
groups NNS N
of IN N
healthy JJ N
term NN N
infants NNS N
who WP N
received VBD N
meat-containing JJ N
baby NN N
foods NNS N
fortified VBN N
with IN N
ferrous JJ N
sulphate NN N
( ( N
2 CD N
mg NN N
Fe/100 NNP N
g NN N
) ) N
. . N

It PRP N
can MD N
be VB N
concluded VBN N
that IN N
10 CD N
weeks NNS N
of IN N
step NN N
aerobics NNS N
was VBD N
not RB N
effective JJ N
in IN N
improving VBG N
all DT N
of IN N
the DT N
measured VBN N
anaerobic JJ N
indices NNS N
in IN N
men NNS N
and CC N
women NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
prosthodontic JJ N
maintenance NN N
, , N
peri-implant JJ N
mucosal NN N
response NN N
, , N
and CC N
papilla NN N
index NN N
between IN N
the DT N
two CD N
groups NNS N
over IN N
1 CD N
year NN N
. . N

Furthermore RB N
, , N
cross-validated JJ N
discriminant NN N
analysis NN N
, , N
using VBG N
four CD N
physiologically RB N
and CC N
three CD N
psychophysically RB N
derived JJ N
parameters NNS N
, , N
correctly RB N
classified VBD N
83 CD N
% NN N
of IN N
individuals NNS N
who WP N
scored VBD N
either CC N
high JJ N
or CC N
low JJ N
on IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
. . N

Mean JJ N
differences NNS N
in IN N
high-density NN N
lipoprotein NN N
( ( N
HDL NNP N
) ) N
- : N
and CC N
low-density JJ N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
-cholesterol NN N
levels NNS N
at IN N
cycle NN N
7 CD N
compared VBN N
to TO N
baseline VB N
were VBD N
assessed VBN N
. . N

A DT N
randomised JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
tracheal NN N
tube NN N
rotation NN N
on IN N
the DT N
passage NN N
of IN N
a DT N
tube NN N
over IN N
a DT N
gum-elastic JJ N
bougie NN N
into IN N
the DT N
trachea NN N
in IN N
100 CD N
patients NNS p
. . N

Areas NNP N
of IN N
secondary JJ N
hyperalgesia NN N
, , N
heat NN N
pain NN N
detection NN N
thresholds NNS N
, , N
and CC N
painfulness NN N
of IN N
stimulation NN N
with IN N
45 CD N
degrees NNS N
C NNP N
for IN N
1 CD N
min NNS N
( ( N
long JJ N
thermal JJ N
stimulation NN N
) ) N
were VBD N
quantified VBN N
. . N

A DT N
psychomotor NN N
test NN N
administered VBD N
60 CD N
min NN N
after IN N
the DT N
remifentanil NN N
infusion NN N
was VBD N
discontinued VBN N
showed VBD N
that IN N
the DT N
volunteers NNS N
were VBD N
still RB N
impaired VBN N
, , N
although IN N
they PRP N
reported VBD N
feeling VBG N
no DT N
drug NN N
effects NNS N
. . N

If IN N
N-acetylcysteine NNP i
is VBZ N
needed VBN N
because IN N
of IN N
a DT N
toxic JJ N
serum NN N
acetaminophen NN i
level NN N
, , N
bioavailability NN N
can MD N
be VB N
ensured VBN N
by IN N
increasing VBG N
the DT N
N-acetylcysteine JJ i
loading NN N
dose NN N
from IN N
140 CD N
mg/kg NNS N
to TO N
235 CD N
mg/kg NNS N
. . N

A DT N
correlation NN N
of IN N
the DT N
angiographic JJ N
evolution NN N
of IN N
coronary JJ N
stenoses NNS N
( ( N
stenosis NN N
diameter NN N
> NN N
or CC N
= VB N
20 CD N
% NN N
) ) N
with IN N
morphological JJ N
stenosis NN N
parameters NNS N
at IN N
baseline NN N
could MD N
help VB N
to TO N
identify VB N
the DT N
risk NN N
of IN N
progressive JJ N
stenoses NNS N
. . N

Twenty NNP N
children NNS N
with IN N
autism NN N
( ( N
mean JJ N
age NN N
, , N
5 CD N
years NNS N
) ) N
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
from IN N
a DT N
school NN N
for IN N
children NNS N
with IN N
autism NN N
. . N

Wound IN N
infection NN N
rate NN N
was VBD N
25 CD N
% NN N
in IN N
the DT N
erythromycin NN i
group NN N
, , N
and CC N
organisms NNS N
recovered VBN N
from IN N
the DT N
wound NN N
in IN N
all DT N
cases NNS N
were VBD N
fecal JJ N
in IN N
nature NN N
. . N

4 CD N
In IN N
comparison NN N
to TO N
metoprolol VB i
, , N
pindolol VB i
produced VBN N
less JJR N
reduction NN N
in IN N
resting VBG N
heart NN N
rate NN N
, , N
cardiac JJ N
index NN N
and CC N
ejection NN N
velocity NN N
reflecting VBG N
the DT N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
of IN N
the DT N
drug NN N
. . N

After IN N
lymph JJ N
node JJ N
excision NN N
, , N
patients NNS p
without IN N
any DT N
detectable JJ N
metastases NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
TIL NNP N
plus CC N
interleukin-2 JJ N
( ( N
IL-2 NNP N
) ) N
for IN N
2 CD N
months NNS N
, , N
or CC N
IL-2 NNP N
only RB N
. . N

In IN N
Study NNP N
3 CD N
( ( N
a DT N
daily RB N
event NN N
sampling VBG N
study NN N
) ) N
, , N
the DT N
authors NNS N
showed VBD N
that IN N
the DT N
congruence NN N
effect NN N
was VBD N
explained VBN N
by IN N
the DT N
importance NN N
of IN N
parental JJ N
approval NN N
. . N

In IN N
eight CD N
out IN N
of IN N
15 CD N
healthy JJ N
patients NNS p
undergoing VBG N
body NN N
surface NN N
surgery NN N
, , N
the DT N
effect NN N
of IN N
a DT N
fentanyl JJ N
infusion NN N
on IN N
a DT N
conventional JJ N
thiopentone NN N
, , N
nitrous JJ N
oxide NN N
, , N
oxygen NN N
and CC N
halothane NN N
anaesthetic NN N
was VBD N
studied VBN N
. . N

METHODS NNP N
626 CD N
patients NNS p
with IN N
reflux JJ N
esophagitis NN N
were VBD N
enrolled VBN N
into IN N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
( ( N
classical JJ N
healing NN N
concept NN N
or CC N
the DT N
complete JJ N
remission NN N
concept NN N
) ) N
to TO N
investigate VB N
differences NNS N
in IN N
treatment NN N
intensity NN N
. . N

Later RB N
, , N
60 CD N
older JJR N
adults NNS N
( ( N
mean VB N
? . N
SD NNP N
age NN N
: : N
68.7 CD N
? . N
6.1 CD N
years NNS N
) ) N
were VBD N
recruited VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
PM NNP N
or CC N
SM NNP N
group NN N
. . N

Vascular JJ N
assessments NNS N
( ( N
including VBG N
measures NNS N
of IN N
endothelial JJ N
damage NN N
, , N
activation NN N
, , N
dysfunction NN N
and CC N
oxidative JJ N
stress NN N
) ) N
and CC N
HbA1c NNP N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
repeated VBD N
after IN N
12 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

The DT N
study NN N
will MD N
compare VB N
12-week JJ N
remission NN N
rates NNS N
and CC N
, , N
among IN N
those DT N
who WP N
have VBP N
at IN N
least JJS N
a DT N
partial JJ N
response NN N
, , N
relapse NN N
rates NNS N
for IN N
up IN N
to TO N
6 CD N
months NNS N
of IN N
additional JJ N
treatment NN N
. . N

Toxicity NN N
was VBD N
unexpectedly RB N
high JJ N
in IN N
both DT N
treatment NN N
arms NNS N
and CC N
led VBD N
to TO N
treatment NN N
withdrawal NN N
or CC N
refusal NN N
in IN N
49 CD N
% NN N
of IN N
all DT N
patients NNS p
, , N
predominantly RB N
already RB N
during IN N
the DT N
first JJ N
treatment NN N
cycle NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
difference NN N
in IN N
the DT N
change NN N
in IN N
the DT N
ABC-C NNP N
irritability NN N
subscale NN N
score NN N
from IN N
baseline NN N
to TO N
week NN N
10 CD N
between IN N
the DT N
two CD N
groups NNS N
. . N

Men NNS N
aged VBN N
? . N
years NNS N
who WP N
were VBD N
not RB N
receiving VBG N
lipid JJ N
lowering NN N
or CC N
anti-hypertensive JJ N
medication NN N
and CC N
not RB N
at IN N
high JJ N
cardiovascular JJ N
risk NN N
were VBD N
recruited VBN N
from IN N
10 CD N
general JJ N
practices NNS N
in IN N
the DT N
East NNP N
of IN N
England NNP N
. . N

Rilpivirine NNP N
and CC N
its PRP$ N
deuterated JJ N
analogue NN N
, , N
rilpivirine-d6 NN N
, , N
used VBD N
as IN N
an DT N
internal JJ N
standard NN N
( ( N
IS NNP N
) ) N
were VBD N
quantitatively RB N
extracted VBN N
by IN N
liquid-liquid JJ N
extraction NN N
with IN N
methyl-tert-butyl JJ N
ether NN N
and CC N
diethyl NN N
ether RB N
solvent JJ N
mixture NN N
from IN N
50 CD N
? . N
plasma NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
immediate JJ N
restoration NN N
of IN N
single JJ N
implants NNS N
in IN N
the DT N
esthetic JJ N
zones NNS N
performed VBN N
on IN N
implants NNS N
placed VBN N
immediately RB N
after IN N
tooth JJ N
extraction NN N
or CC N
8 CD N
weeks NNS N
later RB N
( ( N
immediate JJ N
replacement NN N
vs. FW N
immediate JJ N
restoration NN N
) ) N
. . N

Increased VBN o
platelet NN N
5-HT JJ N
levels NNS N
were VBD N
found VBN N
in IN N
40 CD N
% NN N
of IN N
the DT N
autistic JJ N
population NN N
, , N
suggesting VBG N
that IN N
hyperserotonaemia NN N
may MD N
be VB N
a DT N
pathologic JJ N
factor NN N
in IN N
infantile JJ N
autism NN N
. . N

Serum NNP N
norfloxacin NN i
's POS N
highest JJS N
concentrations NNS N
( ( N
1 CD N
+/- JJ N
0.5 CD N
microg/mL NN N
) ) N
were VBD N
achieved VBN N
at IN N
1-2 JJ N
hours NNS N
and CC N
concurred VBN N
in IN N
time NN N
with IN N
the DT N
lower JJR N
levels NNS N
of IN N
cytokines NNS N
and CC N
nitric JJ N
oxide NN N
. . N

No DT N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
anesthetic JJ N
techniques NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN N
, , N
vomiting VBG N
, , N
or CC N
both DT N
during IN N
the DT N
first JJ N
24 CD N
hr NN N
after IN N
operation NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
controls NNS N
, , N
patients NNS p
who WP N
viewed VBD N
either DT N
of IN N
the DT N
videotapes NNS N
before IN N
hospital NN N
release NN N
reported VBD N
higher JJR N
self-efficacy NN N
for IN N
adhering VBG N
to TO N
the DT N
recommended VBN N
low-fat NN N
diet JJ N
both DT N
at IN N
discharge NN N
and CC N
1 CD N
month NN N
after IN N
surgery NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
paucity NN N
of IN N
data NNS N
on IN N
the DT N
efficacy NN N
of IN N
nitrofurantoin NN N
for IN N
the DT N
treatment NN N
of IN N
acute NN N
uncomplicated JJ N
cystitis NN N
in IN N
regimens NNS N
shorter JJR N
than IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
After IN N
569 CD N
patients NNS p
had VBD N
undergone JJ N
randomization NN N
, , N
enrollment NN N
was VBD N
stopped VBN N
because IN N
of IN N
concerns NNS N
about IN N
the DT N
safety NN N
of IN N
the DT N
patients NNS p
who WP N
had VBD N
been VBN N
assigned VBN N
to TO N
receive VB N
warfarin NN N
. . N

METHODS NNP N
Nine NNP N
patients NNS p
underwent JJ N
NCE NNP N
4D CD N
MRA NNP N
for IN N
the DT N
evaluation NN N
of IN N
DAVF NNP N
in IN N
the DT N
transverse NN N
sinus NN N
at IN N
3 CD N
T. NNP N
One CD N
patient NN N
was VBD N
examined VBN N
twice RB N
, , N
once RB N
before IN N
and CC N
once RB N
after IN N
the DT N
interventional JJ N
treatment NN N
. . N

Rapid JJ N
efficacy NN N
of IN N
the DT N
highly RB N
selective JJ N
alpha1A-adrenoceptor NN N
antagonist NN N
silodosin NN N
in IN N
men NNS N
with IN N
signs NNS N
and CC N
symptoms NNS N
of IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
: : N
pooled JJ N
results NNS N
of IN N
2 CD N
phase NN N
3 CD N
studies NNS N
. . N

CONCLUSIONS NNP N
Co-administration NN N
of IN N
single JJ N
doses NNS N
of IN N
donepezil NN N
HCl NNP N
( ( N
5 CD N
mg NN N
) ) N
and CC N
digoxin NN N
( ( N
0.25 CD N
mg NN N
) ) N
produced VBD N
no DT N
changes NNS N
in IN N
the DT N
pharmacokinetic JJ N
profile NN N
of IN N
either DT N
drug NN N
. . N

Furthermore RB N
, , N
2.8 CD N
mg NN N
BM NNP N
of IN N
PSE NNP N
taken VBN N
90 CD N
min NN N
before IN N
exercise NN N
, , N
with IN N
or CC N
without IN N
food NN N
, , N
resulted VBD N
in IN N
urinary JJ N
PSE NNP N
concentrations NNS N
exceeding VBG N
the DT N
present JJ N
WADA NNP N
threshold NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Ninety-nine NNP N
eligible JJ N
patients NNS p
with IN N
T2 NNP N
to TO N
T4b NNP N
transitional JJ N
cell NN N
bladder NN N
cancer NN N
participated VBD N
, , N
64 CD N
% NN N
with IN N
cT3b NN N
or CC N
cT4 NN N
. . N

The DT N
absolute JJ N
bioavailability NN N
of IN N
the DT N
tablet NN N
product NN N
was VBD N
82 CD N
% NN N
, , N
which WDT N
is VBZ N
in IN N
agreement NN N
with IN N
published VBN N
data NNS N
for IN N
other JJ N
oral JJ N
dosage NN N
forms NNS N
of IN N
methylprednisolone NN N
. . N

Analysis NN N
of IN N
CD19+ NNP N
blood NN N
cells NNS N
in IN N
relationship NN N
to TO N
circulating VBG N
clonal JJ N
cells NNS N
was VBD N
done VBN i
in IN N
13 CD N
myeloma NN N
patients NNS p
using VBG N
a DT N
clonotypic NN N
, , N
quantitative JJ N
allele-specific JJ N
oligonucleotide-polymerase NN N
chain NN N
reaction NN N
( ( N
PCR NNP N
) ) N
assay VBP N
. . N

STATISTICAL JJ N
ANALYSIS NNP N
Sample NNP N
size NN N
was VBD N
calculated VBN N
to TO N
achieve VB N
90 CD N
% NN N
power NN N
at IN N
an DT N
alpha NN N
of IN N
0.025 CD N
to TO N
detect VB N
a DT N
non-inferiority JJ N
margin NN N
of IN N
? . N
cm NN N
on IN N
the DT N
VAS NNP N
, , N
using VBG N
a DT N
one-sided JJ N
, , N
two-sample JJ N
t-test NN N
. . N

INTERVENTIONS NNP N
Four CD N
counseling NN N
sessions NNS N
over IN N
7 CD N
weeks NNS N
with IN N
a DT N
message NN N
of IN N
sit NN N
less CC N
and CC N
move VB N
more JJR N
( ( N
intervention NN N
group NN N
) ) N
or CC N
calcium NN N
for IN N
bone NN N
health NN N
( ( N
attention-matched JJ N
control NN N
group NN N
) ) N
. . N

16 CD N
patients NNS p
with IN N
relapsing VBG N
non-Hodgkin NN N
's POS N
malignant JJ N
lymphomas NN N
considered VBN N
as IN N
clinical JJ N
stage NN N
I PRP N
or CC N
II NNP N
were VBD N
treated VBN N
by IN N
an DT N
association NN N
of IN N
chemo NN N
+ NNP N
radiotherapy NN i
and CC N
thereafter RB N
by IN N
maintenance NN N
BCG NNP N
therapy NN i
. . N

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
esomeprazole NN N
in IN N
patients NNS p
with IN N
frequent JJ N
heartburn NN N
for IN N
> NN N
or CC N
= $ N
6 CD N
months NNS N
and CC N
no DT N
evidence NN N
of IN N
erosive JJ N
oesophagitis NN N
on IN N
endoscopy NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Infertile NNP N
couples NNS N
( ( N
n=52 NN N
) ) N
with IN N
a DT N
female JJ N
partner NN N
less JJR N
than IN N
42 CD N
years NNS N
old JJ N
with IN N
eight CD N
or CC N
more JJR N
mature JJ N
oocytes VBZ N
retrieved VBN N
. . N

The DT N
secondary JJ N
outcomes NNS N
are VBP N
an DT N
additional JJ N
measure NN N
of IN N
pain NN N
relief NN N
, , N
maternal JJ N
sedation NN N
, , N
nausea NN N
and CC N
vomiting NN N
, , N
maternal JJ N
oxygen NN N
saturation NN N
, , N
satisfaction NN N
with IN N
analgesia NN N
, , N
whether IN N
method NN N
of IN N
analgesia NN N
would MD N
be VB N
used VBN N
again RB N
, , N
use NN N
of IN N
Entonox NNP N
, , N
umbilical JJ N
arterial NN N
and CC N
venous JJ N
pH NN N
, , N
fetal JJ N
heart NN N
rate NN N
, , N
meconium NN N
staining NN N
, , N
time NN N
from IN N
delivery NN N
to TO N
first JJ N
breath NN N
, , N
Apgar NNP N
scores VBZ N
at IN N
5 CD N
mins NNS N
, , N
naloxone JJ N
requirement NN N
, , N
transfer NN N
to TO N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
, , N
neonatal JJ N
haemoglobin NN N
oxygen NN N
saturation NN N
at IN N
30 CD N
, , N
60 CD N
, , N
90 CD N
, , N
and CC N
120 CD N
mins NNS N
after IN N
delivery NN N
, , N
and CC N
neonatal JJ N
sedation NN N
and CC N
feeding VBG N
behaviour NN N
during IN N
first JJ N
2 CD N
hours NNS N
. . N

METHODOLOGY NN N
In IN N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
, , N
100 CD N
patients NNS p
who WP N
had VBD N
anterior CC N
or CC N
premolar JJ N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
without IN N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
acute NN N
or CC N
chronic JJ N
apical JJ N
periodontitis NN N
and CC N
moderate VB N
to TO N
severe VB N
pain NN N
were VBD N
divided VBN N
by IN N
balanced JJ N
block NN N
random NN N
allocation NN N
into IN N
four CD N
groups NNS N
of IN N
25 CD N
each DT N
, , N
a DT N
control NN N
group NN N
receiving VBG N
a DT N
placebo NN N
medication NN N
, , N
and CC N
three CD N
experimental JJ N
groups NNS N
receiving VBG N
a DT N
single JJ N
dose NN N
of IN N
either DT N
Tramadol NNP N
( ( N
100 CD N
mg NN N
) ) N
, , N
Novafen NNP N
( ( N
325 CD N
mg NN N
of IN N
paracetamol NN N
, , N
200 CD N
mg NN N
ibuprofen NN N
and CC N
40 CD N
mg NNS N
caffeine VBP i
anhydrous JJ N
) ) N
or CC N
Naproxen NNP N
( ( N
500 CD N
mg NN N
) ) N
immediately RB N
after IN N
the DT N
first JJ N
appointment NN N
where WRB N
the DT N
pulp NN N
was VBD N
removed VBN N
, , N
and CC N
the DT N
canals NNS N
were VBD N
fully RB N
prepared VBN N
. . N

( ( N
15/11 CD N
mmHg NN N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
hypotensive JJ N
peak NN N
after IN N
20 CD N
min NN N
( ( N
57/38 CD N
mmHg NN N
, , N
p NN N
greater JJR N
than IN N
0.001 CD N
) ) N
; : N
2 CD N
) ) N
no DT N
significant JJ N
differences NNS N
for IN N
hypotensive JJ N
effectiveness NN N
between IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
with IN N
SLC NNP N
having VBG N
a DT N
mildly RB N
delayed JJ N
onset NN N
of IN N
action NN N
when WRB N
compared VBN N
to TO N
SLN NNP N
; : N
3 CD N
) ) N
antihypertensive JJ N
effect NN N
lasting VBG N
for IN N
about IN N
6 CD N
hours NNS N
in IN N
patients NNS p
treated VBN N
with IN N
SLC NNP N
and CC N
blood NN N
pressure NN N
progressively RB N
raising VBG N
after IN N
4 CD N
hours NNS N
in IN N
patients NNS p
who WP N
received VBD N
SLN NNP N
; : N
4 CD N
) ) N
a DT N
significant JJ N
correlation NN N
between IN N
blood NN N
pressure NN N
reduction NN N
and CC N
blood NN N
pressure NN N
before IN N
drug NN N
administration NN N
in IN N
both DT N
groups NNS N
; : N
a DT N
significant JJ N
correlation NN N
between IN N
pretreatment NN N
PRA NNP N
and CC N
antihypertensive JJ N
effect NN N
in IN N
the DT N
SLC NNP N
group NN N
. . N

Sixteen JJ N
strength-trained JJ N
men NNS N
were VBD N
tested VBN N
for IN N
1RM CD N
leg NN N
press NN N
after IN N
4 CD N
GWU NNP N
conditions NNS N
after IN N
specific JJ N
warm-up NN N
: : N
short JJ N
duration NN N
and CC N
low JJ N
intensity NN N
( ( N
SDLI NNP N
; : N
i.e NN N
, , N
5 CD N
minutes NNS N
at IN N
40 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP i
) ) N
, , N
long JJ N
duration NN N
and CC N
low JJ N
intensity NN N
( ( N
LDLI NNP N
; : N
i.e NN N
, , N
15 CD N
minutes NNS N
at IN N
40 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP i
) ) N
, , N
short JJ N
duration NN N
and CC N
moderate JJ N
intensity NN N
( ( N
SDMI NNP N
; : N
i.e NN N
, , N
5 CD N
minutes NNS N
at IN N
70 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP i
) ) N
, , N
long JJ N
duration NN N
and CC N
moderate JJ N
intensity NN N
( ( N
LDMI NNP N
; : N
i.e NN N
, , N
15 CD N
minutes NNS N
at IN N
70 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP i
) ) N
, , N
and CC N
the DT N
control NN N
( ( N
CTRL NNP N
) ) N
no-GWU JJ N
condition NN N
. . N

This DT N
double-blind NN N
, , N
randomized VBN N
, , N
phase VB N
III NNP N
clinical JJ N
trial NN N
was VBD N
carried VBN N
out RP N
in IN N
two CD N
parallel JJ N
groups NNS N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
ebrotidine NN N
( ( N
N- JJ N
[ NN N
( ( N
E NNP N
) ) N
- : N
[ JJ N
[ JJ N
2- JJ N
[ NN N
[ NNP N
[ NNP N
2- JJ N
[ NNP N
( ( N
diaminomethylene NN N
) ) N
amino NN N
] JJ N
-4-thiazolyl NNP N
] NNP N
methyl NN N
] NNP N
thio NN N
] NNP N
ethyl VBZ N
] NNP N
amino NN N
] NNP N
methylene NN N
] NNP N
-4-bromo-benzenesulfonamide NNP N
, , N
CAS NNP N
100981-43-9 CD N
, , N
FI-3542 NNP N
) ) N
400 CD N
mg NN N
and CC N
ranitidine VB N
300 CD N
mg NN N
given VBN N
in IN N
single JJ N
evening NN N
dose NN N
, , N
combined VBN N
with IN N
amoxicillin JJ i
750 CD N
mg NN N
and CC N
metronidazole $ N
500 CD N
mg NN N
three CD N
times NNS N
daily RB N
for IN N
14 CD N
days NNS N
, , N
in IN N
the DT N
eradication NN N
of IN N
Helicobacter NNP N
pylori NN N
in IN N
patients NNS p
with IN N
duodenal JJ N
ulcer NN N
. . N

METHODS NNP N
We PRP N
randomly RB N
assigned VBD N
2079 CD N
men NNS N
and CC N
women NNS N
who WP N
were VBD N
35 CD N
years NNS N
of IN N
age NN N
or CC N
older JJR N
and CC N
who WP N
had VBD N
had VBN N
one CD N
or CC N
more JJR N
histologically RB N
confirmed VBN N
colorectal JJ N
adenomas NN N
removed VBD N
within IN N
six CD N
months NNS N
before IN N
randomization NN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
: : N
an DT N
intervention NN N
group NN N
given VBN N
intensive JJ N
counseling NN N
and CC N
assigned VBD N
to TO N
follow VB N
a DT N
diet NN N
that WDT N
was VBD N
low JJ N
in IN N
fat NN N
( ( N
20 CD N
percent NN N
of IN N
total JJ N
calories NNS N
) ) N
and CC N
high JJ N
in IN N
fiber NN N
( ( N
18 CD N
g NN N
of IN N
dietary JJ N
fiber NN N
per IN N
1000 CD N
kcal NN N
) ) N
and CC N
fruits NNS N
and CC N
vegetables NNS N
( ( N
3.5 CD N
servings NNS N
per IN N
1000 CD N
kcal NN N
) ) N
, , N
and CC N
a DT N
control NN N
group NN N
given VBN N
a DT N
standard JJ N
brochure NN N
on IN N
healthy JJ N
eating NN N
and CC N
assigned VBD N
to TO N
follow VB N
their PRP$ N
usual JJ N
diet NN N
. . N

The DT N
experimental JJ N
group NN N
also RB N
showed VBD N
significant JJ N
pre-/posttreatment JJ N
improvements NNS N
in IN N
both DT N
lower JJR N
limbs NN N
in IN N
gait JJ N
dorsiflexion NN N
ROAM NNP N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.02-2.49 JJ N
) ) N
, , N
cadence NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
3.45-1.47 NNP N
) ) N
, , N
stride JJ N
length NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
21.48-10.83 JJ N
) ) N
, , N
step JJ N
length NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.68-6.61 JJ N
) ) N
, , N
stance NN N
phase NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
61-107 JJ N
) ) N
, , N
and CC N
foot NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
.56-.92 NNP N
) ) N
and CC N
malleolus $ N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.15-1.63 JJ N
) ) N
circumference NN N
. . N

MAIN NNP N
RESULTS NNP N
The DT N
12 CD N
patients NNS p
treated VBN N
with IN N
GM-CSF NNP N
, , N
when WRB N
compared VBN N
with IN N
placebo NN N
recipients NNS N
, , N
had VBD N
shorter JJR N
periods NNS N
of IN N
neutropenia NN N
( ( N
median JJ N
duration NN N
of IN N
an DT N
absolute JJ N
neutrophil NN N
count NN N
of IN N
less JJR N
than IN N
1000 CD N
cells/mm3 NN N
, , N
16 CD N
days NNS N
compared VBN N
with IN N
27 CD N
days NNS N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
shorter JJR N
periods NNS N
of IN N
platelet-transfusion NN N
dependency NN N
( ( N
median JJ N
duration NN N
, , N
13.5 CD N
days NNS N
compared VBN N
with IN N
21 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
shorter JJR N
hospitalizations NNS N
( ( N
median JJ N
hospital NN N
stay NN N
, , N
32 CD N
days NNS N
compared VBN N
with IN N
40.5 CD N
days NNS N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

METHODS NNP N
Therefore NNP N
, , N
a DT N
study NN N
using VBG N
a DT N
repeated JJ N
measures NNS N
design NN N
was VBD N
used VBN N
to TO N
measure VB N
effects NNS N
of IN N
a DT N
1-year JJ N
group NN N
leisure NN N
programme NN N
intended VBN N
to TO N
facilitate VB N
interaction NN N
with IN N
media NNS N
, , N
engagement NN N
in IN N
exercise NN N
, , N
playing VBG N
games NNS N
and CC N
doing VBG N
crafts NNS N
, , N
attending VBG N
events NNS N
, , N
and CC N
participating VBG N
in IN N
other JJ N
recreation NN N
activities NNS N
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
37 CD N
participants NNS N
( ( N
22 CD N
male NN N
, , N
15 CD N
female NN N
) ) N
, , N
ages VBZ N
17-39 JJ N
( ( N
M NNP N
= NNP N
31.49 CD N
) ) N
years NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
programme NN N
) ) N
diagnosed VBD N
with IN N
an DT N
ASD NNP N
and CC N
a DT N
group NN N
of IN N
34 CD N
adults NNS N
with IN N
ASD NNP N
as IN N
control NN N
group NN N
( ( N
waiting VBG N
list NN N
) ) N
( ( N
19 CD N
male NN N
, , N
15 CD N
female NN N
) ) N
, , N
ages VBZ N
24-38 JJ N
( ( N
M NNP N
= VBZ N
30 CD N
at IN N
programme JJ N
initiation NN N
) ) N
years NNS N
. . N

During IN N
a DT N
recent JJ N
9-month JJ N
period NN N
, , N
170 CD N
consecutive JJ N
patients NNS p
( ( N
114 CD N
men NNS N
and CC N
56 CD N
women NNS N
; : N
age NN N
range NN N
, , N
40-85 JJ N
years NNS N
; : N
mean VB N
, , N
67.7 CD N
years NNS N
) ) N
with IN N
suspected VBN N
chronic JJ N
liver NN N
diseases NNS N
were VBD N
randomized VBN N
into IN N
three CD N
CT NNP N
groups NNS N
according VBG N
to TO N
the DT N
following JJ N
iodine-load NN N
and CC N
tube-voltage NN N
protocols NNS N
: : N
600 CD N
milligram NN N
per IN N
kilogram NN N
body NN N
weight NN N
( ( N
mg/kg NN N
) ) N
iodine NN N
load NN N
and CC N
120 CD N
peak NN N
kilovolt NN N
( ( N
kVp NN N
) ) N
tube NN N
voltage NN N
setting VBG N
( ( N
600-120 JJ N
group NN N
) ) N
, , N
500 CD N
mg/kg NN N
and CC N
80 CD N
kVp NN N
( ( N
500-80 JJ N
group NN N
) ) N
, , N
and CC N
400mg/kg CD N
and CC N
80 CD N
kVp NN N
( ( N
400-80 JJ N
group NN N
) ) N
. . N

METHODS NN N
Patients NNS N
( ( N
n=603 JJ N
; : N
mean JJ N
age NN N
, , N
73.9 CD N
years NNS N
; : N
55.2 CD N
% NN N
men NNS N
) ) N
with IN N
probable JJ N
( ( N
70.5 CD N
% NN N
) ) N
or CC N
possible JJ N
( ( N
29.5 CD N
% NN N
) ) N
VaD NNP N
, , N
according VBG N
to TO N
criteria NNS N
of IN N
the DT N
National NNP N
Institute NNP N
of IN N
Neurological NNP N
Disorders NNP N
and CC N
Stroke NNP N
( ( N
NINDS NNP N
) ) N
and CC N
the DT N
Association NNP N
Internationale NNP N
pour VBP N
la NN N
Recherche NNP N
et CC N
l'Enseignement JJ N
en NN N
Neurosciences NNP N
( ( N
AIREN NNP N
) ) N
, , N
were VBD N
randomized VBN N
to TO N
24 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
donepezil JJ N
5 CD N
mg/d NN N
( ( N
n=198 JJ N
) ) N
, , N
donepezil $ N
10 CD N
mg/d NN N
( ( N
5 CD N
mg/d NN N
for IN N
first JJ N
28 CD N
days NNS N
; : N
n=206 CC N
) ) N
, , N
or CC N
placebo NN N
( ( N
n=199 JJ N
) ) N
. . N

RESULTS VB N
The DT N
increase NN o
in IN N
the DT N
proportion NN N
of IN N
total JJ N
urinary JJ N
arsenic NN N
excreted VBD N
as IN N
DMA NNP N
in IN N
the DT N
folic JJ N
acid NN N
group NN N
( ( N
72 CD N
% NN N
before IN N
and CC N
79 CD N
% NN N
after IN N
supplementation NN N
) ) N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
as IN N
was VBD N
the DT N
reduction NN N
in IN N
the DT N
proportions NNS N
of IN N
total JJ N
urinary JJ N
arsenic NN N
excreted VBD N
as IN N
MMA NNP N
( ( N
13 CD N
% NN N
and CC N
10 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
as IN N
InAs NNP N
( ( N
15 CD N
% NN N
and CC N
11 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

After IN N
PBSCT NNP N
, , N
the DT N
time NN N
to TO N
achieve VB N
an DT N
absolute JJ N
neutrophil NN N
count NN N
( ( N
ANC NNP N
) ) N
of IN N
> $ N
0.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
less JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
median JJ N
, , N
11 CD N
v NN N
12 CD N
days NNS N
; : N
the DT N
log-rank JJ N
test NN N
, , N
P NNP N
=.046 NNP N
) ) N
, , N
although IN N
the DT N
last JJ N
day NN N
of IN N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
transfusion NN N
( ( N
day NN N
11 CD N
v NN N
day NN N
10 CD N
) ) N
and CC N
the DT N
duration NN N
of IN N
febrile JJ N
days NNS N
( ( N
> JJ N
38 CD N
degrees NNS N
C NNP N
) ) N
after IN N
PBSCT NNP N
( ( N
4 CD N
v RB N
4 CD N
days NNS N
) ) N
were VBD N
identical JJ N
in IN N
both DT N
groups NNS N
. . N

Among IN N
155 CD N
randomized JJ N
patients NNS p
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
rate NN N
of IN N
grade NN N
3 CD N
and CC N
4 CD N
oral JJ N
mucositis NN N
( ( N
primary JJ N
study NN N
endpoint NN N
) ) N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
( ( N
three CD N
in IN N
palifermin NN N
arm NN N
( ( N
4 CD N
% NN N
) ) N
, , N
8 CD N
in IN N
placebo NN N
arm NN N
( ( N
10 CD N
% NN N
; : N
P NNP N
= NNP N
0 CD N
) ) N
; : N
however RB N
, , N
when WRB N
considering VBG N
the DT N
severity NN N
of IN N
oral JJ N
mucositis NN N
( ( N
World NNP N
Health NNP N
Organization NNP N
grade VBD N
0-4 NNP N
) ) N
, , N
there EX N
was VBD N
evidence NN N
of IN N
reduced JJ N
rates NNS N
of IN N
higher JJR N
grades NNS N
of IN N
oral JJ N
mucositis NN N
in IN N
the DT N
palifermin NN N
arm NN N
( ( N
P NNP N
= NNP N
0 CD N
, , N
test NN N
for IN N
trend NN N
) ) N
. . N

METHODS NNP N
409 CD N
patients NNS p
with IN N
malignant JJ N
pleural JJ N
mesothelioma NN N
, , N
from IN N
76 CD N
centres NNS N
in IN N
the DT N
UK NNP N
and CC N
two CD N
in IN N
Australia NNP N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
ASC NNP N
alone RB N
( ( N
treatment NN N
could MD N
include VB N
steroids NNS N
, , N
analgesic JJ N
drugs NNS N
, , N
bronchodilators NNS N
, , N
palliative JJ N
radiotherapy NN i
[ NNP N
n=136 RB N
] NNP N
) ) N
; : N
to TO N
ASC NNP N
plus CC N
MVP NNP N
( ( N
four CD N
cycles NNS N
of IN N
mitomycin NN i
6 CD N
mg/m2 NN N
, , N
vinblastine VBP N
6 CD N
mg/m2 NN N
, , N
and CC N
cisplatin VBZ i
50 CD N
mg/m2 NN N
every DT N
3 CD N
weeks NNS N
[ JJ N
n=137 RB N
] NNP N
) ) N
; : N
or CC N
to TO N
ASC NNP N
plus CC N
vinorelbine NN N
( ( N
one CD N
injection NN N
of IN N
vinorelbine NN N
30 CD N
mg/m2 NN N
every DT N
week NN N
for IN N
12 CD N
weeks NNS N
[ JJ N
n=136 RB N
] NN N
) ) N
. . N

METHODS NN N
Patients NNS N
( ( N
men NNS N
? . N
45 CD N
years NNS N
; : N
women NNS N
? . N
50 CD N
years NNS N
) ) N
with IN N
known VBN N
or CC N
suspected VBN N
coronary JJ N
artery NN N
disease NN N
( ( N
n JJ N
= NNP N
124 CD N
) ) N
were VBD N
randomized VBN N
to TO N
1 CD N
of IN N
2 CD N
diagnostic JJ N
sequences NNS N
: : N
rest NN N
and CC N
regadenoson NN N
SPECT NNP N
on IN N
day NN N
1 CD N
, , N
then RB N
regadenoson NN N
CTP NNP N
and CC N
rest VB N
CTP NNP N
( ( N
and CC N
coronary JJ N
CT NNP N
angiography NN N
[ NNP N
CTA NNP N
] NNP N
) ) N
( ( N
CTA NNP N
; : N
same JJ N
acquisition NN N
) ) N
on IN N
day NN N
2 CD N
or CC N
regadenoson VB N
CTP NNP N
and CC N
rest VB N
CTP NNP N
( ( N
and CC N
CTA NNP N
) ) N
on IN N
Day NNP N
1 CD N
, , N
then RB N
rest NN N
and CC N
regadenoson NN N
SPECT NNP N
on IN N
day NN N
2 CD N
. . N

Each DT N
year NN N
, , N
cows NNS N
were VBD N
blocked VBN N
by IN N
age NN N
and CC N
BCS NNP N
and CC N
assigned VBD N
randomly RB N
to TO N
one CD N
of IN N
three CD N
treatments NNS N
: : N
PRE NNP N
( ( N
n JJ N
= NNP N
115 CD N
) ) N
cows NNS N
received VBD N
1.14 CD N
kg/d NNS N
( ( N
DM NNP N
basis NN N
) ) N
of IN N
whole JJ N
corn NN N
germ NN N
for IN N
approximately RB N
45 CD N
d NN N
before IN N
calving VBG N
; : N
POST NNP N
( ( N
n JJ N
= NNP N
109 CD N
) ) N
cows NNS N
were VBD N
fed VBN N
1.14 CD N
kg/d NNS N
of IN N
whole JJ N
corn NN N
germ NN N
for IN N
approximately RB N
45 CD N
d NN N
after IN N
calving VBG N
; : N
and CC N
control VB N
cows NNS N
( ( N
n JJ N
= NNP N
118 CD N
) ) N
were VBD N
fed VBN N
similar JJ N
energy NN N
and CC N
protein NN N
from IN N
dry-rolled JJ N
corn NN N
( ( N
1.82 CD N
kg NN N
of IN N
DM/d NNP N
) ) N
for IN N
45 CD N
d NN N
before IN N
and CC N
after IN N
calving VBG N
. . N

All DT N
six CD N
criterion NN N
measures NNS N
were VBD N
characterized VBN N
by IN N
significant JJ N
changes NNS N
over IN N
time NN N
for IN N
the DT N
entire JJ N
group NN N
( ( N
n JJ N
= VBZ N
45 CD N
; : N
time NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
, , N
as IN N
follows VBZ N
: : N
pain NN N
and CC N
medication NN N
intake NN N
were VBD N
similar JJ N
on IN N
days NNS N
1 CD N
and CC N
2 CD N
, , N
but CC N
were VBD N
significantly RB N
less JJR N
on IN N
day NN N
3 CD N
, , N
and CC N
pulmonary JJ N
functions NNS N
were VBD N
significantly RB N
lower JJR N
than IN N
preoperatively RB N
on IN N
day NN N
1 CD N
, , N
decreased VBD o
further RBR o
on IN N
day NN N
2 CD N
, , N
and CC N
despite IN N
an DT N
improvement NN N
on IN N
day NN N
3 CD N
, , N
remained VBD N
significantly RB N
lower JJR N
than IN N
preoperative JJ N
values NNS N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
from IN N
radial JJ N
artery NN N
and CC N
S-G NNP N
catheter NN N
for IN N
blood NN N
gas NN N
analysis NN N
at IN N
following VBG N
intervals NNS N
: : N
during IN N
spontaneous JJ N
breathing VBG N
when WRB N
the DT N
patient NN N
was VBD N
awake JJ N
( ( N
T0 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
tracheal JJ N
indubation NN N
( ( N
T1 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
patient NN N
was VBD N
placed VBN N
in IN N
lateral JJ N
position NN N
( ( N
T2 NNP N
) ) N
and CC N
15 CD N
min NN N
after IN N
it PRP N
( ( N
T3 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
ribs NN N
was VBD N
braced VBN N
( ( N
T4 NNP N
) ) N
, , N
30 CD N
, , N
60 CD N
, , N
120 CD N
min NN N
during IN N
the DT N
course NN N
of IN N
OLV NNP N
( ( N
T5 NNP N
, , N
T6 NNP N
, , N
T7 NNP N
) ) N
, , N
the DT N
two CD N
lungs NNS N
were VBD N
ventilated VBN N
again RB N
for IN N
30 CD N
min NN N
( ( N
T8 NNP N
) ) N
and CC N
Qs/Qt NNP N
was VBD N
calculated VBN N
. . N

METHODS NNP N
Two CD N
hundred VBD N
seven CD N
consecutive JJ N
coronary JJ N
artery NN N
bypass NN N
patients NNS p
( ( N
mean JJ N
age NN N
62 CD N
+/- JJ N
11 CD N
years NNS N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
sotalol NN i
alone RB N
( ( N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
5 CD N
days NNS N
starting VBG N
from IN N
the DT N
morning NN N
of IN N
the DT N
first JJ N
postoperative JJ N
day NN N
) ) N
( ( N
group NN N
S NNP N
) ) N
, , N
magnesium NN N
alone RB N
( ( N
1.5 CD N
g NNS N
daily RB N
for IN N
6 CD N
days NNS N
starting VBG N
in IN N
the DT N
operating NN N
room NN N
just RB N
before IN N
cardiopulmonary JJ N
bypass NN N
) ) N
( ( N
group NN N
M NNP N
) ) N
, , N
both DT N
pharmacologic JJ N
agents NNS N
at IN N
the DT N
same JJ N
dosages NNS N
( ( N
group NN N
S+M NNP N
) ) N
, , N
or CC N
no DT N
antiarrhythmic JJ N
agents NNS N
( ( N
group NN N
CTR NNP N
) ) N
. . N

Subjects NNS N
due JJ N
for IN N
CRC NNP N
screening VBG N
were VBD N
randomized VBN N
within IN N
each DT N
practice NN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
usual JJ N
care NN N
; : N
( ( N
2 CD N
) ) N
physician JJ N
chart NN N
reminder NN N
; : N
( ( N
3 CD N
) ) N
physician JJ N
chart NN N
reminder NN N
, , N
mailed VBN N
education NN N
, , N
CRC NNP N
reminder NN N
magnet NN N
, , N
and CC N
fecal JJ N
immunochemical JJ N
test NN N
( ( N
FIT NNP N
) ) N
( ( N
mailed JJ N
education/FIT NN N
) ) N
; : N
or CC N
( ( N
4 CD N
) ) N
all PDT N
the DT N
preceding VBG N
plus CC N
a DT N
structured JJ N
telephone NN N
call NN N
to TO N
the DT N
patient NN N
from IN N
project JJ N
staff NN N
to TO N
provide VB N
education NN N
, , N
assess JJ N
interest NN N
in IN N
screening VBG N
, , N
explain VB N
the DT N
screening NN N
tests NNS N
, , N
and CC N
address JJ N
barriers NNS N
( ( N
mailed VBN N
education/FIT RB N
plus CC N
phone NN N
call NN N
) ) N
. . N

METHODS NNP N
Patients NNS N
with IN N
unresectable JJ N
and/or JJ N
recurrent NN N
advanced VBD N
gastric JJ N
cancer NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
two CD N
regimens NNS N
: : N
S-1 NNP N
( ( N
40 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
twice RB N
daily RB N
) ) N
on IN N
days NNS N
1-14 JJ N
plus JJ N
paclitaxel NN i
( ( N
60 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
on IN N
days NNS N
1 CD N
, , N
8 CD N
, , N
and CC N
15 CD N
of IN N
a DT N
4-week JJ N
cycle NN N
( ( N
S-1+paclitaxel NNP i
) ) N
or CC N
S-1 NNP N
( ( N
40 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
twice RB N
daily RB N
) ) N
on IN N
days NNS N
1-21 JJ N
plus JJ N
cisplatin NN i
( ( N
60 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
on IN N
day NN N
8 CD N
of IN N
a DT N
5-week JJ N
cycle NN N
( ( N
S-1+cisplatin NNP i
) ) N
. . N

In IN N
the DT N
placebo NN N
, , N
vitamin FW N
A NNP N
, , N
and CC N
beta NN N
carotene NN N
groups NNS N
the DT N
rates NNS N
of IN N
stillbirth NN N
and CC N
infant JJ N
mortality NN N
were VBD N
47.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
44.3-51.5 JJ N
) ) N
, , N
45.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
42.1-49.2 JJ N
) ) N
, , N
and CC N
51.8 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
48.0-55.6 JJ N
) ) N
per IN N
1000 CD N
births NNS N
and CC N
68.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
63.7-72.5 NNP N
) ) N
, , N
65.0 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
60.7-69.4 NNP N
) ) N
, , N
and CC N
69.8 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
65.4-72.3 JJ N
) ) N
per IN N
1000 CD N
live JJ N
births NNS N
, , N
respectively RB N
. . N

The DT N
patients NNS p
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
three CD N
programs NNS N
: : N
group NN N
1 CD N
-- : N
a DT N
full-time JJ N
, , N
intensive JJ N
3-week JJ N
multidisciplinary JJ N
program NN N
, , N
including VBG N
active JJ N
physical JJ N
and CC N
ergonomic JJ N
training NN N
and CC N
psychological JJ N
pain NN N
management NN N
, , N
followed VBN N
by IN N
1 CD N
day NN N
weekly VB N
for IN N
the DT N
subsequent JJ N
3 CD N
weeks NNS N
; : N
group NN N
2 CD N
-- : N
active JJ N
physical JJ N
training NN N
, , N
twice RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
for IN N
a DT N
total NN N
of IN N
24h CD N
; : N
group NN N
3 CD N
-- : N
psychological JJ N
pain NN N
management NN N
combined VBN N
with IN N
active JJ N
physical JJ N
training NN N
, , N
twice RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
also RB N
for IN N
a DT N
total NN N
of IN N
24h CD N
. . N

METHODS NNP N
Twenty NNP N
male NN N
, , N
white JJ N
patients NNS p
( ( N
27 CD N
+/- JJ N
1 CD N
years NNS N
) ) N
with IN N
mild JJ N
essential JJ N
hypertension NN N
( ( N
143 CD N
+/- JJ N
11/95 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
) ) N
were VBD N
included VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
fourfold JJ N
cross-over NN N
study NN N
with IN N
placebo NN N
, , N
enalapril NN N
( ( N
20 CD N
mg/day NN N
) ) N
, , N
eprosartan FW N
( ( N
600 CD N
mg/day NN N
) ) N
, , N
or CC N
combination NN N
of IN N
both DT N
drugs NNS N
( ( N
10 CD N
and CC N
300 CD N
mg/day NN N
, , N
respectively RB N
) ) N
each DT N
over IN N
a DT N
one CD N
week NN N
period NN N
followed VBN N
by IN N
a DT N
two-week JJ N
washout NN N
phase NN N
. . N

Cox NNP N
regression NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
treatment NN N
and CC N
gender NN N
regarding VBG N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
( ( N
P NNP N
= NNP N
0 CD N
) ) N
and CC N
RFS NNP N
( ( N
P NNP N
= NNP N
0 CD N
) ) N
, , N
with IN N
a DT N
lower JJR N
hazard NN N
in IN N
females NNS N
than IN N
males NNS N
in IN N
the DT N
OG NNP N
[ NNP N
OS NNP N
: : N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
( ( N
female JJ N
: : N
male NN N
) ) N
= VBZ N
0 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
= VBZ N
0 CD N
; : N
RFS NNP N
: : N
HR NNP N
( ( N
female JJ N
: : N
male NN N
) ) N
= VBZ N
0 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0 CD N
] NNP N
, , N
and CC N
no DT N
significant JJ N
differences NNS N
between IN N
males NNS N
and CC N
females NNS N
in IN N
the DT N
TG NNP N
. . N

METHODS NN N
From IN N
1991 CD N
to TO N
1995 CD N
, , N
89 CD N
patients NNS p
with IN N
T3b NNP N
, , N
T4 NNP N
or CC N
metastatic JJ N
urothelial JJ N
carcinoma NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
methotrexate NN N
, , N
epirubicin NN i
and CC N
cisplatin NN i
chemotherapy NN i
group NN N
( ( N
arm JJ N
1 CD N
: : N
S-MEC JJ N
therapy NN i
; : N
n CC N
= VB N
29 CD N
) ) N
, , N
a DT N
dose-intensified JJ N
MEC NNP N
therapy NN i
combined VBN N
with IN N
G-CSF NNP N
group NN N
( ( N
arm JJ N
2 CD N
: : N
I-MEC JJ N
therapy NN i
; : N
n CC N
= VB N
30 CD N
) ) N
or CC N
a DT N
methotrexate NN N
, , N
vinblastine NN N
, , N
doxorubicin NN i
and CC N
cisplatin NN i
chemotherapy NN i
( ( N
arm JJ N
3 CD N
: : N
M-VAC JJ N
therapy NN i
; : N
n CC N
= VB N
30 CD N
) ) N
. . N

After IN N
visit NN N
1 CD N
, , N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
group NN N
A NNP N
, , N
control NN N
( ( N
usual JJ N
care NN N
) ) N
; : N
( ( N
2 CD N
) ) N
group NN N
B NNP N
, , N
treatment NN N
( ( N
video JJ N
peer NN N
modeling NN N
that WDT N
involved VBD N
watching VBG N
a DT N
DVD NNP N
recording NN N
of IN N
a DT N
typically RB N
developing VBG N
child NN N
undergoing VBG N
a DT N
dental JJ N
visit NN N
) ) N
; : N
( ( N
3 CD N
) ) N
group NN N
C NNP N
, , N
treatment NN N
( ( N
video JJ N
goggles NNS N
that WDT N
involved VBD N
watching VBG N
a DT N
favorite JJ N
movie NN N
during IN N
the DT N
dental JJ N
visit NN N
using VBG N
sunglass-style JJ N
video NN N
eyewear NN N
) ) N
; : N
and CC N
( ( N
4 CD N
) ) N
group NN N
D NNP N
, , N
treatment NN N
( ( N
video JJ N
peer NN N
modeling VBG N
plus CC N
video JJ N
goggles NNS N
) ) N
. . N

RESULTS NNP N
Three NNP N
variables NNS N
qualified VBD N
, , N
all DT N
of IN N
them PRP N
represented VBN N
in IN N
3 CD N
follow-ups NNS N
: : N
Low NNP N
total JJ N
prior RB N
sick-listing NN N
( ( N
including VBG N
all DT N
diagnoses NNS N
) ) N
was VBD N
the DT N
strongest JJS N
predictor NN N
in IN N
2 CD N
follow-ups NNS N
, , N
18 CD N
and CC N
24 CD N
months NNS N
, , N
OR NNP N
4.8 CD N
[ JJ N
1.9-12.3 JJ N
] NN N
and CC N
3.8 CD N
[ JJ N
1.6-8.7 JJ N
] NN N
respectively RB N
, , N
High NNP N
self NN N
prediction NN N
( ( N
the DT N
patients NNS p
' POS N
own JJ N
belief NN N
in IN N
return-to-work NN N
) ) N
was VBD N
the DT N
strongest JJS N
at IN N
12 CD N
months NNS N
, , N
OR NNP N
5.2 CD N
[ JJ N
1.5-17.5 JJ N
] NN N
and CC N
Young NNP N
age NN N
( ( N
max JJ i
44 CD N
years NNS N
) ) N
the DT N
second JJ N
strongest NN N
at IN N
18 CD N
months NNS N
, , N
OR NNP N
3.5 CD N
[ JJ N
1.3-9.1 JJ N
] NN N
. . N

The DT N
meals NNS N
contained VBD N
either CC N
oat JJ N
powder NN N
( ( N
62 CD N
g NN N
, , N
of IN N
which WDT N
2.7 CD N
soluble JJ N
fibre NN N
) ) N
, , N
rye NN N
bran NN N
( ( N
31 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
sugar JJ N
beet NN N
fibre NN N
( ( N
19 CD N
g NN N
, , N
of IN N
which WDT N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
a DT N
mixture NN N
of IN N
these DT N
three CD N
fibres NNS N
( ( N
74 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
from IN N
each DT N
source NN N
, , N
giving VBG N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
or CC N
no DT N
added JJ N
fibre NN N
( ( N
control NN N
) ) N
and CC N
were VBD N
all DT N
adjusted VBN N
to TO N
contain VB N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
available JJ N
carbohydrates NNS N
. . N

The DT N
pre-pPCI JJ N
ST-segment JJ N
resolution NN N
( ( N
55+/-21.4 CD N
% NN N
vs JJ N
42.4+/-18.2 CD N
% NN N
, , N
p=0.005 NN N
) ) N
, , N
TIMI NNP N
flow NN N
grade VBD N
3 CD N
( ( N
29 CD N
% NN N
vs JJ N
7 CD N
% NN N
, , N
p=0.042 NN N
) ) N
, , N
corrected VBN N
TIMI NNP N
frame NN N
count NN N
( ( N
58.4+/-32.7 JJ N
vs NN N
78.9+/-28.4 JJ N
frame NN N
, , N
p=0.018 NN N
) ) N
% NN N
diameter JJ N
stenosis NN N
( ( N
76.3 CD N
/63.5-100/ JJ N
vs NN N
100 CD N
/73.5-100/ NN N
; : N
median JJ N
/interquartile NN N
range/ NN N
, , N
p=0.023 NN N
) ) N
, , N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
1 CD N
vs NN N
Group NNP N
2 CD N
. . N

Three CD N
hundred VBD N
eighty-four JJ N
patients NNS p
with IN N
stage NN N
III NNP N
( ( N
6 CD N
% NN N
) ) N
and CC N
IV NNP N
( ( N
94 CD N
% NN N
) ) N
oropharyngeal NN N
( ( N
59.4 CD N
% NN N
) ) N
, , N
hypopharyngeal NN N
( ( N
32.3 CD N
% NN N
) ) N
, , N
and CC N
oral JJ N
cavity NN N
( ( N
8.3 CD N
% NN N
) ) N
cancer NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
30 CD N
Gy/2 NNP N
Gy NNP N
daily RB N
followed VBN N
by IN N
twice-daily JJ N
1.4 CD N
Gy NNP N
to TO N
a DT N
total NN N
of IN N
70.6 CD N
Gy NNP N
concurrently RB N
with IN N
mitomycin JJ i
C/5-FU NNP N
( ( N
C-HART NNP N
) ) N
or CC N
16 CD N
Gy/2 NNP N
Gy NNP N
daily RB N
followed VBN N
by IN N
twice-daily JJ N
1.4 CD N
Gy NNP N
to TO N
a DT N
total JJ N
dose NN N
of IN N
77.6 CD N
Gy NNP N
alone RB N
( ( N
HART NNP N
) ) N
. . N

RESULTS NNP N
Program NNP N
participants NNS N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
sexual JJ N
partner NN N
notification NN N
at IN N
1 CD N
month NN N
( ( N
86 CD N
% NN N
control NN N
, , N
92 CD N
% NN N
intervention NN N
; : N
adjusted VBN N
odds NNS N
ratio VBP N
[ JJ N
AOR NNP N
] NNP N
= NNP N
1.8 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
1.02 CD N
, , N
3.0 CD N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
no DT N
unprotected JJ N
sexual JJ N
intercourse NN N
at IN N
6 CD N
months NNS N
( ( N
38 CD N
% NN N
control NN N
, , N
48 CD N
% NN N
intervention NN N
; : N
AOR NNP N
= VBZ N
1.5 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.1 CD N
, , N
2.1 CD N
) ) N
. . N

Nine NNP N
healthy JJ N
volunteers NNS N
( ( N
age NN N
, , N
23.4 CD N
+/- JJ N
0.2 CD N
years NNS N
; : N
body NN N
mas VBZ N
index NN N
[ NNP N
BMI NNP N
] NNP N
, , N
23.5 CD N
+/- JJ N
1.6 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
fed VBN N
, , N
in IN N
random JJ N
order NN N
, , N
with IN N
a DT N
high-fat JJ N
diet NN N
( ( N
HFD NNP N
) ) N
( ( N
65 CD N
% NN N
of IN N
energy NN N
content NN N
fat NN N
, , N
15 CD N
% NN N
protein NN N
, , N
20 CD N
% NN N
carbohydrate NN N
) ) N
or CC N
a DT N
high-carbohydrate JJ N
diet NN N
( ( N
HCD NNP N
) ) N
( ( N
70 CD N
% NN N
carbohydrate NN N
, , N
15 CD N
% NN N
protein NN N
, , N
15 CD N
% NN N
fat NN N
) ) N
for IN N
5 CD N
days NNS N
, , N
with IN N
a DT N
washout JJ N
period NN N
of IN N
10 CD N
days NNS N
between IN N
the DT N
diets NNS N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
repeated-dose JJ N
, , N
active-comparator JJ N
, , N
4-week JJ N
, , N
multicenter NN N
study NN N
, , N
469 CD N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
1-tablet JJ N
( ( N
n JJ N
= NNP N
156 CD N
) ) N
or CC N
2-tablet JJ N
( ( N
n JJ N
= NNP N
153 CD N
) ) N
dose NN N
of IN N
combination NN N
hydrocodone NN i
7.5 CD N
mg NN N
and CC N
ibuprofen $ N
200 CD N
mg NN N
( ( N
HI1 NNP N
and CC N
HI2 NNP N
, , N
respectively RB N
) ) N
or CC N
a DT N
2-tablet JJ N
dose NN N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC N
acetaminophen $ i
300 CD N
mg NN N
( ( N
CA NNP N
, , N
n RB N
= VBZ N
160 CD N
) ) N
, , N
the DT N
active JJ N
comparator NN N
, , N
every DT N
6 CD N
to TO N
8 CD N
hours NNS N
as IN N
needed VBN N
for IN N
pain NN N
. . N

Recovery NN N
from IN N
incontinence NN N
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
were VBD N
observed VBN N
in IN N
22 CD N
( ( N
27.8 CD N
% NN N
) ) N
, , N
42 CD N
( ( N
53.2 CD N
% NN N
) ) N
, , N
and CC N
57 CD N
( ( N
72.2 CD N
% NN N
) ) N
patients NNS p
, , N
respectively RB N
, , N
treated VBD N
with IN N
, , N
and CC N
23 CD N
( ( N
29.1 CD N
% NN N
) ) N
, , N
47 CD N
( ( N
59.5 CD N
% NN N
) ) N
, , N
and CC N
59 CD N
( ( N
74.7 CD N
% NN N
) ) N
patients NNS p
, , N
respectively RB N
, , N
treated VBD N
without IN N
the DT N
bladder NN N
neck NN N
plication NN N
stitch NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
in IN N
time NN N
to TO N
recovery NN N
from IN N
incontinence NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
neutrophil JJ N
nadir NN N
was VBD N
similar JJ N
with IN N
and CC N
without IN N
priming VBG N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
490 CD N
+/- JJ N
310/microL CD N
v JJ N
550 CD N
+/- JJ N
350/microL CD N
, , N
respectively RB N
; : N
P NNP N
=.2 NNP N
) ) N
; : N
however RB N
, , N
on IN N
day NN N
16 CD N
the DT N
mean NN N
neutrophil NN N
count NN N
was VBD N
higher JJR N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
1030 CD N
+/- JJ N
580/microL CD N
v JJ N
690 CD N
+/- JJ N
370/microL CD N
, , N
P NNP N
=.004 NNP N
) ) N
, , N
and CC N
the DT N
proportion NN N
of IN N
patients NNS p
with IN N
a DT N
neutrophil JJ N
count NN N
less JJR N
than IN N
500/microL CD N
was VBD N
lower JJR N
after IN N
priming VBG N
than IN N
before IN N
( ( N
six CD N
of IN N
35 CD N
or CC N
17 CD N
. . N

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
and CC N
crossover JJ N
design NN N
, , N
nine CD N
female NN N
and CC N
three CD N
male NN N
healthy JJ N
subjects NNS N
( ( N
age NN N
34 CD N
( ( N
sd VB N
11 CD N
) ) N
years NNS N
, , N
BMI NNP N
24.5 CD N
( ( N
sd VB N
2.5 CD N
) ) N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
with IN N
a DT N
preference NN N
for IN N
a DT N
high-fat JJ N
diet NN N
ingested VBN N
ENT NNP N
( ( N
3 CD N
x RB N
15 CD N
mg/d NN N
) ) N
or CC N
placebo NN N
( ( N
PLA NNP N
) ) N
while IN N
consuming VBG N
a DT N
high-fat JJ N
diet JJ N
ad NN N
libitum NN N
for IN N
4 CD N
d. NNS N
Eight JJ N
subjects NNS N
ended VBD N
each DT N
intervention NN N
with IN N
a DT N
36 CD N
h NN N
stay NN N
in IN N
the DT N
respiration NN N
chamber NN N
, , N
continuing VBG N
the DT N
diet JJ N
and CC N
treatment NN N
. . N

Forty-one CD N
children NNS N
and CC N
youths NNS N
between IN N
5 CD N
months NNS N
and CC N
21 CD N
years NNS N
with IN N
prior JJ N
NRTI NNP N
and CC N
no DT N
prior JJ N
NNRTI NNP N
or CC N
protease VB N
inhibitor NN N
experience NN N
received VBD N
either CC N
nelfinavir JJ N
( ( N
NFV NNP N
) ) N
30 CD N
mg/kg JJ N
twice RB N
daily RB N
( ( N
bid NN N
) ) N
, , N
ritonavir FW N
( ( N
RTV NNP N
) ) N
400 CD N
mg/m JJ N
bid NN N
and CC N
buffered VBN N
didanosine NN N
( ( N
ddI NN N
) ) N
240 CD N
mg/m JJ N
daily JJ N
( ( N
arm IN N
A NNP N
) ) N
or CC N
NFV NNP N
50-55 JJ N
mg/kg NN N
bid NN N
, , N
nevirapine NN N
( ( N
NVP NNP N
) ) N
120 CD N
mg/m JJ N
bid NN N
and CC N
stavudine NN N
( ( N
d4T NN N
) ) N
1 CD N
mg/kg JJ N
bid NN N
( ( N
arm NN N
B NNP N
) ) N
. . N

For IN N
FPV NNP N
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP N
200 CD N
mg NN N
BID NNP N
, , N
the DT N
values NNS N
for IN N
plasma NN N
APV NNP N
AUC NNP N
( ( N
0-tau JJ N
) ) N
, , N
C NNP N
( ( N
max NN i
) ) N
, , N
and CC N
C NNP N
( ( N
tau NN N
) ) N
were VBD N
26 CD N
, , N
48 CD N
, , N
and CC N
32 CD N
% NN N
higher JJR N
, , N
respectively RB N
, , N
and CC N
the DT N
values NNS N
for IN N
plasma NN N
RTV NNP N
AUC NNP N
( ( N
0-tau JJ N
) ) N
, , N
C NNP N
( ( N
max NN i
) ) N
, , N
and CC N
C NNP N
( ( N
tau NN N
) ) N
increased VBD o
4.15-fold JJ o
, , N
4.17-fold JJ N
, , N
and CC N
3.99-fold JJ N
, , N
respectively RB N
, , N
compared VBN N
to TO N
those DT N
for IN N
FPV NNP N
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP N
100 CD N
mg NN N
BID NNP N
. . N

Male JJ N
Sprague-Dawley NNP N
rats NNS N
( ( N
n JJ N
= $ N
6 CD N
per IN N
group NN N
) ) N
were VBD N
housed VBN N
in IN N
photobiologic JJ N
light-exposure JJ N
chambers NNS N
configured VBD N
to TO N
create VB N
1 CD N
) ) N
a DT N
12:12-h JJ N
light NN N
: : N
dark JJ N
cycle NN N
without IN N
dark-phase JJ N
light JJ N
contamination NN N
( ( N
control JJ N
condition NN N
; : N
123 CD N
? . N
( ( N
2 CD N
) ) N
, , N
lights NNS N
on IN N
at IN N
0600 CD N
) ) N
, , N
2 CD N
) ) N
experimental NN N
exposure NN N
to TO N
a DT N
low JJ N
level NN N
of IN N
light NN N
during IN N
the DT N
12-h JJ N
dark NN N
phase NN N
( ( N
with IN N
0.02 CD N
, , N
0.05 CD N
, , N
0.06 CD N
, , N
or CC N
0.08 CD N
? . N
( ( N
2 CD N
) ) N
light NN N
at IN N
night NN N
) ) N
, , N
or CC N
3 CD N
) ) N
constant JJ N
bright JJ N
light NN N
( ( N
123 CD N
? . N
( ( N
2 CD N
) ) N
) ) N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
GH NNP N
treatment NN N
efficacy NN N
in IN N
short JJ N
SGA NNP N
children NNS N
when WRB N
treatment NN N
was VBD N
started VBN N
during IN N
adolescence NN N
; : N
to TO N
assess VB N
whether IN N
GH NNP N
2 CD N
mg/m NN N
( ( N
2 CD N
) ) N
? . N
d NN N
during IN N
puberty JJ N
improves NNS N
adult VBP N
height NN N
( ( N
AH NNP N
) ) N
compared VBN N
with IN N
1 CD N
mg/m NNS N
( ( N
2 CD N
) ) N
? . N
d NN N
; : N
and CC N
to TO N
assess VB N
whether IN N
an DT N
additional JJ N
2-yr JJ N
postponement NN N
of IN N
puberty NN N
by IN N
GnRH NNP N
analog NN N
( ( N
GnRHa NNP N
) ) N
improves VBZ N
AH NNP N
in IN N
children NNS N
who WP N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
( ( N
< JJ N
140 CD N
cm NN N
) ) N
, , N
with IN N
a DT N
poor JJ N
AH NNP N
expectation NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Change NNP N
in IN N
the DT N
clinical JJ N
symptom NN N
score NN N
( ( N
consisting VBG N
of IN N
the DT N
subscores NNS N
redness NN N
, , N
swelling VBG N
, , N
pain NN N
, , N
and CC N
secretion NN N
) ) N
and CC N
of IN N
the DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
rating NN N
for IN N
pain NN N
from IN N
Visit NNP N
1 CD N
( ( N
Day NNP N
1 CD N
) ) N
to TO N
Visit VB N
2 CD N
( ( N
Day NNP N
4 CD N
+/- JJ N
1 CD N
) ) N
, , N
patient NN N
's POS N
assessment NN N
of IN N
efficacy NN N
at IN N
Visit NNP N
3 CD N
( ( N
Day NNP N
10 CD N
+/- JJ N
2 CD N
) ) N
, , N
and CC N
the DT N
frequency NN N
and CC N
type NN N
of IN N
adverse JJ N
events NNS N
. . N

METHODS NNP N
Applied NNP N
with IN N
open-labeled JJ N
, , N
randomized VBN N
, , N
and CC N
clinical JJ N
trial NN N
design NN N
, , N
136 CD N
postmenopausal JJ N
women NNS N
were VBD N
assigned VBN N
into IN N
four CD N
groups NNS N
: : N
group NN N
A DT N
: : N
estradiol NN N
valerate NN N
( ( N
E2 NNP N
V NNP N
) ) N
1 CD N
mg/d NN N
+ NNP N
medroxyprogesterone NN N
acetate NN N
( ( N
MPA NNP N
) ) N
2 CD N
mg/d NN N
; : N
group NN N
B NNP N
: : N
conjugated JJ N
equine NN N
estrogen NN N
0.45 CD N
mg/d NN N
+ NNP N
MPA NNP N
2 CD N
mg/d NN N
; : N
group NN N
C NNP N
: : N
tibolone NN N
1.25 CD N
mg/d NN N
; : N
group NN N
D NNP N
: : N
a DT N
Chinese JJ N
formulated VBN N
herbs JJ N
product NN N
( ( N
Kuntai NNP N
) ) N
4 CD N
# # N
tid NN N
. . N

In IN N
this DT N
randomised VBN N
controlled VBD N
pilot JJ N
trial NN N
we PRP N
compared VBN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
a DT N
24 CD N
week NN N
with IN N
that DT N
of IN N
a DT N
48 CD N
week NN N
course NN N
of IN N
combination NN N
therapy NN i
with IN N
interferon NN N
alpha NN N
and CC N
ribavirin NN N
in IN N
interferon NN N
monotherapy NN i
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
METHODS NNP N
Interferon NNP N
alpha NN N
monotherapy NN i
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
were VBD N
randomised VBN N
to TO N
receive VB N
interferon NN N
alpha NN N
2b CD N
( ( N
3 CD N
x RB N
3 CD N
MIU NNP N
sc JJ N
weekly RB N
) ) N
and CC N
oral JJ N
ribavirin NN N
( ( N
1000/1200 CD N
mg NNS N
po JJ N
daily RB N
) ) N
for IN N
either DT N
24 CD N
weeks NNS N
or CC N
48 CD N
weeks NNS N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
of IN N
PHX1149 NNP N
significantly RB N
decreased VBD o
postprandial JJ o
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
by IN N
approximately RB N
20 CD N
% NN N
( ( N
+0.11 JJ N
+/- JJ N
0.50 CD N
, , N
-2.08 VBD N
+/- JJ N
0.51 CD N
, , N
-1.73 VBD N
+/- JJ N
0.49 CD N
and CC N
-1.88 VB N
+/- JJ N
0.48 CD N
mmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.002 CD N
, , N
0.008 CD N
and CC N
0.004 CD N
vs. FW N
placebo NN N
) ) N
. . N

METHOD NNP N
Ten CD N
patients NNS p
with IN N
chronic JJ N
stroke NN N
( ( N
7 CD N
males NNS N
; : N
mean JJ N
age NN N
, , N
61.4+/-3.02 JJ N
years NNS N
; : N
age NN N
range NN N
, , N
48 CD N
to TO N
79 CD N
years NNS N
; : N
mean JJ N
time NN N
since IN N
stroke NN N
, , N
28.5 CD N
months NNS N
; : N
range NN N
, , N
13 CD N
to TO N
42 CD N
months NNS N
) ) N
exhibiting VBG N
stable JJ N
, , N
affected JJ N
arm NN N
motor NN N
deficits NNS N
were VBD N
administered VBN N
mCIT NN N
, , N
consisting VBG N
of IN N
: : N
( ( N
1 CD N
) ) N
structured VBD N
therapy NN i
emphasizing VBG N
affected JJ N
arm NN N
use NN N
in IN N
functional JJ N
activities NNS N
3 CD N
days/week NN N
for IN N
10 CD N
weeks NNS N
; : N
and CC N
( ( N
2 CD N
) ) N
less RBR N
affected JJ N
arm NN N
restraint NN N
5 CD N
days/week NN N
for IN N
5 CD N
hours NNS N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
comprised VBD N
120 CD N
patients NNS p
who WP N
had VBD N
ST-elevation NNP N
myocardial JJ N
infarction NN N
that WDT N
was VBD N
treated VBN N
within IN N
12 CD N
hours NNS N
from IN N
symptom JJ N
onset VBN N
with IN N
a DT N
high JJ N
dose NN N
of IN N
GIK NNP N
( ( N
25 CD N
% NN N
glucose NN N
, , N
50 CD N
IU NNP N
of IN N
soluble JJ N
insulin NN N
per IN N
liter NN N
, , N
and CC N
80 CD N
mmol NN N
of IN N
potassium NN N
chloride NN N
per IN N
liter NN N
at IN N
1 CD N
ml/kg/hour NN N
over IN N
24 CD N
hours NNS N
) ) N
as IN N
adjunct NN N
to TO N
thrombolytic JJ N
therapy NN i
( ( N
1.5 CD N
MU NNP N
of IN N
streptokinase/30 NN N
to TO N
60 CD N
minutes NNS N
; : N
GIK NNP N
group NN N
) ) N
or CC N
thrombolytic JJ N
therapy NN i
alone RB N
( ( N
control VB N
group NN N
) ) N
. . N

To TO N
compare VB N
haemodynamic JJ N
responses NNS N
associated VBN N
with IN N
equipotent JJ N
doses NNS N
of IN N
neuromuscular JJ N
blockers NNS N
and CC N
high-dose JJ N
fentanyl NN N
( ( N
50 CD N
micrograms.kg-1 NN N
) ) N
, , N
40 CD N
patients NNS p
with IN N
aortic JJ N
valve NNS N
stenosis NN N
( ( N
AS IN N
) ) N
and CC N
20 CD N
patients NNS p
with IN N
aortic JJ N
insufficiency NN N
( ( N
AI NNP N
) ) N
were VBD N
randomized VBN N
to TO N
four CD N
study NN N
groups NNS N
to TO N
receive VB N
the DT N
following NN N
: : N
( ( N
1 CD N
) ) N
pancuronium NN N
0.12 CD N
mg.kg-1 NN N
, , N
( ( N
2 CD N
) ) N
vecuronium NN N
0.12 CD N
mg.kg-1 NN N
, , N
( ( N
3 CD N
) ) N
atracurium NN N
0.4 CD N
mg.kg-1 NN N
, , N
or CC N
( ( N
4 CD N
) ) N
pancuronium-metocurine NN N
mixture NN N
( ( N
0.4 CD N
mg NN N
+ VBD N
1.6 CD N
mg/ml NN N
) ) N
: : N
1 CD N
ml/10 NNS N
kg NN N
) ) N
. . N

One CD N
hundred CD N
nineteen JJ N
patients NNS p
with IN N
essential JJ N
hypertension NN N
( ( N
96 CD N
completing VBG N
six CD N
months NNS N
and CC N
92 CD N
a DT N
one CD N
year NN N
study NN N
period NN N
) ) N
were VBD N
randomized VBN N
into IN N
four CD N
parallel NN N
groups NNS N
and CC N
treated VBN N
with IN N
one CD N
of IN N
four CD N
programs NNS N
: : N
200 CD N
mg NN N
of IN N
metoprolol JJ i
plus CC N
placebo NN N
; : N
200 CD N
mg NN N
of IN N
metoprolol NN i
plus CC N
25 CD N
mg NN N
of IN N
hydrochlorothiazide NN i
; : N
200 CD N
mg NN N
of IN N
metoprolol NN i
plus CC N
50 CD N
mg NN N
hydrochlorothiazide NN i
, , N
or CC N
; : N
200 CD N
mg NN N
metoprolol NN i
plus CC N
50 CD N
mg NN N
of IN N
hydralazine NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Forty-eight NNP N
osteoporotic JJ i
patients NNS p
with IN N
prostate JJ N
cancer NN N
, , N
treated VBN N
with IN N
3-month JJ N
depot NN N
triptorelina NN N
, , N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
different JJ N
treatment NN N
groups NNS N
: : N
group NN N
A NNP N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
was VBD N
treated VBN N
with IN N
a DT N
daily JJ N
calcium NN N
and CC N
cholecalciferol NN N
supplement NN N
( ( N
500 CD N
mg NN N
of IN N
elemental JJ N
calcium NN N
and CC N
400 CD N
IU NNP N
cholecalciferol NN N
) ) N
, , N
and CC N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
received VBN N
in IN N
addition NN N
to TO N
the DT N
same JJ N
daily JJ N
calcium NN N
and CC N
cholecalciferol NN N
supplement NN N
, , N
25 CD N
mg NN N
of IN N
neridronate JJ N
given VBN N
intramuscularly RB N
every DT N
month NN N
. . N

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
phase JJ N
3 CD N
, , N
randomised VBD N
controlled VBN N
trial NN N
conducted VBN N
in IN N
101 CD N
centres NNS N
in IN N
19 CD N
countries NNS N
, , N
we PRP N
enrolled VBD N
patients NNS p
aged VBN N
18 CD N
years NNS N
or CC N
older JJR N
with IN N
histologically RB N
or CC N
cytologically RB N
confirmed VBN N
HNSCC NNP N
that WDT N
was VBD N
recurrent NN N
, , N
metastatic JJ N
, , N
or CC N
both DT N
who WP N
had VBD N
progressed VBN N
on IN N
or CC N
after IN N
first-line JJ N
platinum-based JJ N
therapy NN i
, , N
were VBD N
not RB N
amenable JJ N
for IN N
salvage NN N
surgery NN N
or CC N
radiotherapy NN i
, , N
and CC N
who WP N
had VBD N
an DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
ECOG NNP N
) ) N
performance NN N
status NN N
of IN N
0 CD N
or CC N
1 CD N
. . N

After IN N
premedication NN N
with IN N
0.1 CD N
mg/kg NNS N
acepromazine VBP N
intramuscularly RB N
and CC N
0.6 CD N
mg/kg NNS N
xylazine JJ N
intravenously RB N
, , N
anaesthesia NN N
was VBD N
induced VBN N
either RB N
with IN N
2 CD N
g NNS N
thiopentone NN N
in IN N
500 CD N
ml NN N
of IN N
a DT N
10 CD N
per IN N
cent NN N
guaifenesin NN N
solution NN N
, , N
given VBN N
intravenously RB N
at IN N
a DT N
dose NN N
of IN N
1 CD N
ml/kg NNS N
( ( N
group NN N
TG NNP N
) ) N
, , N
or CC N
with IN N
100 CD N
mg/kg NNS N
guaifenesin NN N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN N
given VBN N
intravenously RB N
( ( N
group NN N
KG NNP N
) ) N
, , N
or CC N
with IN N
0.06 CD N
mg/kg NNS N
midazolam NN i
, , N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN N
given VBN N
intravenously RB N
( ( N
group NN N
KM NNP N
) ) N
. . N

RESULTS JJ N
Patients NNS N
with IN N
statin NN i
withdrawal NN N
showed VBD N
a DT N
higher JJR N
frequency NN N
of IN N
mRS NN N
score NN N
> VBD N
2 CD N
at IN N
the DT N
end NN N
of IN N
follow-up NN N
( ( N
60.0 CD N
% NN N
vs JJ N
39.0 CD N
% NN N
; : N
p CC N
= VB N
0.043 CD N
) ) N
, , N
END NNP N
( ( N
65.2 CD N
% NN N
vs JJ N
20.9 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
, , N
and CC N
greater JJR N
infarct NN N
volume NN N
( ( N
74 CD N
[ RB N
45 CD N
, , N
126 CD N
] NN N
vs NN N
26 CD N
[ NN N
12 CD N
, , N
70 CD N
] JJ N
mL NN N
; : N
p CC N
= VB N
0.002 CD N
) ) N
compared VBN N
with IN N
the DT N
non-statin-withdrawal JJ N
group NN N
. . N

In IN N
the DT N
risperidone NN i
group NN N
, , N
12 CD N
of IN N
19 CD N
children NNS N
showed VBD N
improvement NN N
in IN N
the DT N
total JJ N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
score NN N
and CC N
17 CD N
of IN N
19 CD N
children NNS N
in IN N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
score NN N
compared VBN N
with IN N
0 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
score NN N
and CC N
2 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
score NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
and CC N
P NNP N
= NNP N
.035 NNP N
, , N
respectively RB N
) ) N
. . N

RESULTS NNP N
Uveitis NNP N
recurrence NN N
was VBD N
reduced VBN N
in IN N
implanted JJ N
eyes NNS N
from IN N
62 CD N
% NN N
( ( N
during IN N
the DT N
1-year JJ N
preimplantation NN N
period NN N
) ) N
to TO N
4 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
20 CD N
% NN N
during IN N
the DT N
1- JJ N
, , N
2- JJ N
, , N
and CC N
3-year JJ N
postimplantation NN N
periods NNS N
, , N
respectively RB N
, , N
for IN N
the DT N
0.59-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
from IN N
58 CD N
% NN N
to TO N
7 CD N
% NN N
, , N
17 CD N
% NN N
, , N
and CC N
41 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
the DT N
2.1-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
European NNP N
and CC N
Australian NNP N
Stroke NNP N
Prevention NNP N
in IN N
Reversible NNP N
Ischaemia NNP N
Trial NNP N
( ( N
ESPRIT NNP N
) ) N
is VBZ N
a DT N
randomised JJ N
clinical JJ N
trial NN N
in IN N
which WDT N
patients NNS p
with IN N
cerebral JJ N
ischaemia NN N
of IN N
arterial JJ N
origin NN N
will MD N
be VB N
randomised VBN N
between IN N
oral JJ N
anticoagulation NN N
( ( N
international JJ N
normalized VBN N
ratio NN N
( ( N
INR NNP N
) ) N
: : N
2.0-3.0 JJ N
) ) N
, , N
the DT N
combination NN N
of IN N
acetylsalicylic JJ N
acid NN N
( ( N
in IN N
any DT N
dose NN N
between IN N
30 CD N
and CC N
325 CD N
mg NNS N
per IN N
day NN N
) ) N
plus CC N
dipyridamole JJ N
( ( N
400 CD N
mg NNS N
daily RB N
) ) N
and CC N
acetylsalicylic JJ N
acid NN N
only RB N
( ( N
in IN N
any DT N
dose NN N
between IN N
30 CD N
and CC N
325 CD N
mg NNS N
per IN N
day NN N
) ) N
. . N

Large JJ N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
20 CD N
heparinized JJ N
dogs NNS N
were VBD N
randomized VBN N
to TO N
endoscopic VB N
injection NN N
treatment NN N
with IN N
one CD N
of IN N
the DT N
following JJ N
agents NNS N
: : N
cyanoacrylate NN N
; : N
a DT N
1:1:1 CD N
mixture NN N
of IN N
sodium NN N
tetradecyl NN N
sulfate VBP N
3 CD N
% NN N
, , N
ethanol RB N
98 CD N
% NN N
, , N
and CC N
normal JJ N
saline JJ N
solution NN N
; : N
ethanolamine VB N
oleate VBP N
5 CD N
% NN N
; : N
sodium NN N
morrhuate VBP N
5 CD N
% NN N
; : N
sodium NN N
tetradecyl NN N
sulfate VBP N
1.5 CD N
% NN N
; : N
polidocanol CC N
1 CD N
% NN N
; : N
normal JJ N
saline JJ N
solution NN N
with IN N
epinephrine JJ N
1:10,000 CD N
; : N
or CC N
normal JJ N
saline JJ N
solution NN N
( ( N
control NN N
) ) N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
9-month JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
low JJ N
doses NNS N
of IN N
losartan NN N
( ( N
25 CD N
mg NN N
; : N
n CC N
= VB N
18 CD N
) ) N
versus NN N
enalapril NN N
( ( N
10 CD N
mg NN N
; : N
n CC N
= VB N
18 CD N
) ) N
versus IN N
the DT N
combination NN N
of IN N
losartan NN N
( ( N
25 CD N
mg NN N
) ) N
and CC N
enalapril $ N
( ( N
10 CD N
mg NN N
) ) N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
on IN N
proteinuria NN N
, , N
kidney NN N
function NN N
and CC N
metabolic JJ N
profile NN N
in IN N
54 CD N
patients NNS p
with IN N
biopsy-proven JJ N
chronic JJ N
glomerulonephritis NN N
, , N
hypertension NN N
and CC N
normal JJ N
or CC N
slightly RB N
impaired JJ N
kidney NN N
function NN N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
conivaptan NN N
at IN N
20 CD N
and CC N
40 CD N
mg NN N
significantly RB N
reduced VBD N
pulmonary JJ N
capillary JJ N
wedge NN N
pressure NN N
( ( N
-2.6+/-0.7 UH N
, , N
-5.4+/-0.7 NNP N
, , N
and CC N
-4.6+/-0.7 NNP N
mm VBP N
Hg NNP N
for IN N
placebo NN N
and CC N
20 CD N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
right JJ N
atrial JJ N
pressure NN N
( ( N
-2.0+/-0.4 UH N
, , N
-3.7+/-0.4 NNP N
, , N
and CC N
-3.5+/-0.4 NNP N
mm VBP N
Hg NNP N
for IN N
placebo NN N
and CC N
20 CD N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
during IN N
the DT N
3- JJ N
to TO N
6-hour JJ N
interval NN N
after IN N
intravenous JJ N
administration NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
Randomized NNP N
controlled VBD N
multicenter RBR N
Trial NNP N
of IN N
Intensified NNP N
vs FW N
Standard NNP N
Medical NNP N
Therapy NNP N
in IN N
Elderly JJ N
Patients NNS N
With IN N
Congestive NNP N
Heart NNP N
Failure NNP N
( ( N
TIME-CHF NNP N
) ) N
of IN N
499 CD N
patients NNS p
aged VBN N
60 CD N
years NNS N
or CC N
older JJR N
with IN N
systolic JJ N
heart NN N
failure NN N
( ( N
ejection NN N
fraction NN N
< NN N
or CC N
= VB N
45 CD N
% NN N
) ) N
, , N
New NNP N
York NNP N
Heart NNP N
Association NNP N
( ( N
NYHA NNP N
) ) N
class NN N
of IN N
II NNP N
or CC N
greater JJR N
, , N
prior JJ N
hospitalization NN N
for IN N
heart NN N
failure NN N
within IN N
1 CD N
year NN N
, , N
and CC N
N-terminal JJ N
BNP NNP N
level NN N
of IN N
2 CD N
or CC N
more JJR N
times NNS N
the DT N
upper JJ N
limit NN N
of IN N
normal JJ N
. . N

METHODS NNP N
Diagnosed VBD N
hypertensive JJ N
patients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
RCT NNP N
and CC N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
: : N
( ( N
1 CD N
) ) N
the DT N
intervention NN N
condition NN N
-- : N
Web-based JJ N
hypertension NN N
feedback NN N
, , N
based VBN N
on IN N
the DT N
individual JJ N
patient NN N
's POS N
self-report NN N
of IN N
health NN N
variables NNS N
and CC N
previous JJ N
BP NNP N
measurements NNS N
, , N
to TO N
prompt VB N
them PRP N
to TO N
ask VB N
questions NNS N
during IN N
their PRP$ N
next JJ N
physician NN N
's POS N
visit NN N
about IN N
hypertension NN N
care NN N
( ( N
2 CD N
) ) N
the DT N
control NN N
condition NN N
-- : N
Web-based JJ N
preventive JJ N
health NN N
feedback NN N
, , N
based VBN N
on IN N
the DT N
individual NN N
's POS N
self-report NN N
of IN N
receiving VBG N
preventive JJ N
care NN N
( ( N
e.g UH N
, , N
pap JJ N
testing VBG N
) ) N
, , N
to TO N
prompt VB N
them PRP N
to TO N
ask VB N
questions NNS N
during IN N
their PRP$ N
next JJ N
physician NN N
's POS N
visit NN N
about IN N
preventive JJ N
care NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
positioning VBG N
with IN N
the DT N
unaffected JJ N
lung NN N
in IN N
the DT N
dependent JJ N
lateral JJ N
position NN N
related VBN N
to TO N
increased VBN o
arterial JJ N
blood NN N
saturation NN N
levels NNS N
and CC N
decreased VBD o
blood NN o
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
? . N
( ( N
2 CD N
) ) N
What WP N
is VBZ N
the DT N
relationship NN N
between IN N
the DT N
dependent JJ N
variables NNS N
-- : N
oxygenation NN N
saturation NN N
levels NNS N
, , N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
-- : N
and CC N
the DT N
independent JJ N
variables NNS N
-- : N
body NN N
position NN N
and CC N
time NN N
in IN N
the DT N
position NN N
? . N
Thirty-nine JJ N
patients NNS p
with IN N
unilateral JJ N
lung NN N
pathology NN N
were VBD N
positioned VBN N
on IN N
their PRP$ N
sides NNS N
with IN N
the DT N
unaffected JJ N
lung NN N
down RP N
, , N
on IN N
their PRP$ N
sides NNS N
with IN N
the DT N
affected JJ N
lung NN N
down RB N
, , N
and CC N
also RB N
in IN N
semi-Fowler NN N
's POS N
position NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Peak NNP N
E NNP N
( ( N
2 CD N
) ) N
levels NNS N
, , N
days NNS N
of IN N
stimulation NN N
with IN N
rFSH NN N
, , N
total JJ N
rFSH NN N
dosage NN N
, , N
total JJ N
number NN N
of IN N
oocytes NNS N
retrieved VBN N
, , N
M2 NNP N
oocytes VBZ N
retrieved VBN N
, , N
total JJ N
number NN N
of IN N
embryos NN N
, , N
number NN N
of IN N
embryos NN N
transferred VBN N
, , N
number NN N
of IN N
Grade-1 NNP N
embryos NN N
transferred VBD N
, , N
clinical JJ N
pregnancy NN N
rate NN N
( ( N
positive JJ N
fetal JJ N
cardiac JJ N
activity NN N
) ) N
, , N
and CC N
cancellation NN N
rates NNS N
of IN N
stimulation NN N
and CC N
embryo NN N
transfer NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
shortened JJ N
postpartum NN N
course NN N
of IN N
magnesium NN N
sulphate NN N
is VBZ N
as RB N
effective JJ N
as IN N
the DT N
standard JJ N
Pritchard NNP N
regimen NN N
in IN N
controlling VBG N
fits NNS N
in IN N
eclampsia NN N
Between NNP N
January NNP N
and CC N
June NNP N
2011 CD N
, , N
98 CD N
eclamptic JJ N
mothers NNS N
presenting VBG N
at IN N
the DT N
labour JJ N
ward NN N
of IN N
the DT N
University NNP N
of IN N
Maiduguri NNP N
Teaching NNP N
Hospital NNP N
were VBD N
randomised VBN N
to TO N
receive VB N
either RB N
the DT N
standard JJ N
Pritchard NNP N
regimen NN N
of IN N
magnesium NN N
sulphate NN N
or CC N
a DT N
shortened JJ N
postpartum NN N
course NN N
in IN N
which WDT N
only RB N
two CD N
doses NNS N
of IN N
intramuscular JJ N
magnesium NN N
sulphate NN N
is VBZ N
given VBN N
four CD N
hours NNS N
apart RB N
. . N

This DT N
hypothesis NN N
has VBZ N
now RB N
received VBN N
strong JJ N
support NN N
and CC N
is VBZ N
currently RB N
based VBN N
on IN N
three CD N
types NNS N
of IN N
arguments NNS N
: : N
( ( N
1 CD N
) ) N
similarity NN N
between IN N
autistic JJ N
symptomatology NN N
and CC N
abnormal JJ N
behaviors NNS N
induced VBD N
in IN N
young JJ N
animals NNS N
by IN N
injections NNS N
of IN N
exogenous JJ N
opioids NNS N
, , N
such JJ N
as IN N
increasing VBG N
social JJ N
aloofness NN N
and CC N
decreasing VBG N
social JJ N
vocalization NN N
; : N
( ( N
2 CD N
) ) N
direct JJ N
biochemical JJ N
evidence NN N
of IN N
abnormalities NNS N
of IN N
peripheral JJ N
endogenous JJ N
opioids NNS N
being VBG N
reported VBN N
in IN N
autism NN N
and CC N
( ( N
3 CD N
) ) N
therapeutic JJ N
effects NNS N
of IN N
the DT N
long JJ N
lasting NN N
opioid JJ N
receptor NN N
blocking VBG N
agent NN N
naltrexone NN N
in IN N
autism NN N
. . N

The DT N
participants NNS N
consisted VBD N
of IN N
60 CD N
unfit JJ N
male NN N
university NN N
undergraduate JJ N
students NNS N
with IN N
no DT N
previous JJ N
training NN N
in IN N
stress JJ N
management NN N
who WP N
were VBD N
randomly RB N
and CC N
evenly RB N
assigned VBD N
to TO N
engage VB N
in IN N
one CD N
of IN N
four CD N
treatments NNS N
over IN N
10 CD N
weeks NNS N
: : N
( ( N
a DT N
) ) N
moderate NN N
aerobic JJ N
exercise NN N
, , N
( ( N
b NN N
) ) N
progressive NN N
relaxation NN N
, , N
( ( N
c NN N
) ) N
a DT N
placebo NN N
group NN N
that WDT N
engaged VBD N
in IN N
group NN N
discussion NN N
but CC N
did VBD N
experience VB N
acute NN N
stress NN N
, , N
and CC N
( ( N
d NN N
) ) N
a DT N
nonintervention NN N
control NN N
group NN N
that WDT N
did VBD N
not RB N
experience VB N
stress NN N
while IN N
performing VBG N
the DT N
motor NN N
task NN N
. . N

METHOD NNP N
This DT N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
relapse-prevention JJ N
trial NN N
enrolled VBD N
patients NNS p
( ( N
6-17 CD N
years NNS N
) ) N
who WP N
met VBD N
the DT N
current JJ N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
Text NNP N
Revision NNP N
( ( N
DMS-IV-TR NNP N
) ) N
criteria NN N
for IN N
autistic JJ N
disorder NN N
and CC N
who WP N
also RB N
had VBD N
serious JJ N
behavioral JJ N
problems NNS N
( ( N
ie VB N
, , N
tantrums NNS N
, , N
aggression NN N
, , N
self-injurious JJ N
behavior NN N
, , N
or CC N
a DT N
combination NN N
of IN N
these DT N
behavioral JJ N
problems NNS N
) ) N
between IN N
March NNP N
2011 CD N
and CC N
June NNP N
2012 CD N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
number NN N
of IN N
painful JJ N
joints NNS N
and CC N
swollen JJ N
joints NNS N
, , N
joint JJ N
pain NN N
and CC N
joint JJ N
swelling NN N
indices NNS N
, , N
left VBD N
and CC N
right JJ N
grip NN N
strength NN N
, , N
investigator NN N
global JJ N
assessment NN N
, , N
and CC N
patient JJ N
global JJ N
assessment NN N
returned VBD N
to TO N
baseline VB N
for IN N
the DT N
amiprilose JJ N
group NN N
and CC N
showed VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
differences NNS N
from IN N
the DT N
placebo NN N
group NN N
within IN N
4 CD N
to TO N
6 CD N
weeks NNS N
. . N

FINDINGS NNP N
( ( N
1 CD N
) ) N
The DT N
a DT N
priori JJ N
matching NN N
hypothesis NN N
that IN N
TSF NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
MET NNP N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
was VBD N
supported VBN N
at IN N
the DT N
3 CD N
year NN N
follow-up NN N
; : N
( ( N
2 CD N
) ) N
AA NNP N
involvement NN N
was VBD N
a DT N
partial JJ N
mediator NN N
of IN N
this DT N
effect NN N
; : N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
assigned VBN N
to TO N
TSF VB N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
involved VBN N
in IN N
AA NNP N
; : N
AA NNP N
involvement NN N
was VBD N
associated VBN N
with IN N
better JJR N
3-year JJ N
drinking NN N
outcomes NNS N
for IN N
such JJ N
clients NNS N
. . N

RESULTS NNP N
sCD44v6 NN N
was VBD N
significantly RB N
positive JJ N
correlated VBN N
with IN N
the DT N
degree NN N
of IN N
cancer NN N
cell NN N
differentiation NN N
, , N
infiltration NN N
and CC N
lymph NN N
node JJ N
metastasis NN N
; : N
( ( N
2 CD N
) ) N
Level NN N
of IN N
sCD44v6 NN N
was VBD N
the DT N
highest JJS N
in IN N
patients NNS p
of IN N
blood NN N
stasis NN N
type NN N
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
patients NNS p
of IN N
Pi-deficiency NNP N
type NN N
or CC N
of IN N
damp-heat JJ N
type NN N
, , N
the DT N
difference NN N
was VBD N
significant JJ N
; : N
( ( N
3 CD N
) ) N
After IN N
ending VBG N
treatment NN N
, , N
level NN N
of IN N
sCD44v6 NN N
in IN N
the DT N
trial NN N
group NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
. . N

To TO N
be VB N
eligible JJ N
for IN N
inclusion NN N
, , N
women NNS N
had VBD N
to TO N
be VB N
( ( N
i NN N
) ) N
under IN N
26 CD N
years NNS N
old JJ N
, , N
( ( N
ii NN N
) ) N
less JJR N
that IN N
27 CD N
weeks NNS N
pregnant JJ N
, , N
( ( N
iii NN N
) ) N
sufficiently RB N
fluent VBN N
in IN N
French JJ N
to TO N
give VB N
truly NN N
informed JJ N
consent NN N
to TO N
participate VB N
in IN N
the DT N
study NN N
and CC N
benefit NN N
from IN N
the DT N
intervention NN N
and CC N
( ( N
iv NN N
) ) N
presenting VBG N
with IN N
one CD N
or CC N
more JJR N
of IN N
the DT N
following JJ N
social JJ N
vulnerability NN N
factors NNS N
: : N
low JJ N
income NN N
, , N
low JJ N
educational JJ N
level NN N
, , N
and/or RB N
intending VBG N
to TO N
bring VB N
up RP N
the DT N
child NN N
without IN N
the DT N
child NN N
's POS N
father NN N
. . N

RESULTS VB N
The DT N
fundamental JJ N
conclusions NNS N
of IN N
the DT N
primary JJ N
analysis NN N
were VBD N
confirmed VBN N
in IN N
that DT N
there EX N
was VBD N
no DT N
survival JJ N
benefit NN N
overall JJ i
for IN N
patients NNS p
with IN N
1 CD N
to TO N
3 CD N
metastases NNS N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
benefit NN N
for IN N
the DT N
subset NN N
of IN N
patients NNS p
with IN N
GPA NNP N
3.5 CD N
to TO N
4.0 CD N
( ( N
median JJ N
survival NN N
time NN N
[ NNP N
MST NNP N
] NNP N
for IN N
WBRT NNP N
+ NNP N
SRS NNP N
vs FW N
WBRT NNP N
alone RB N
was VBD N
21.0 CD N
versus NN N
10.3 CD N
months NNS N
, , N
P=.05 NNP N
) ) N
regardless NN N
of IN N
the DT N
number NN N
of IN N
metastases NNS N
. . N

Four CD N
different JJ N
methods-microscopy NN N
of IN N
Gram NNP N
stained VBD N
mucosal JJ N
smear NN N
, , N
specific JJ N
culture NN N
, , N
biopsy NN N
urease JJ N
test NN N
, , N
histology NN N
of IN N
H NNP N
& CC N
E NNP N
staining-were JJ N
taken VBN N
for IN N
identifying VBG N
colonization NN N
of IN N
H. NNP N
pylori NN N
before IN N
treatment NN N
, , N
and CC N
for IN N
finding VBG N
the DT N
eradication NN N
of IN N
H. NNP N
pylori FW N
4 CD N
weeks NNS N
after IN N
completion NN N
of IN N
therapy NN i
in IN N
each DT N
treatment NN N
group NN N
( ( N
cometidine NN N
, , N
omeprazole NN N
, , N
colloidal JJ N
bismuth NN N
subcitrate NN N
( ( N
CBS NNP N
) ) N
, , N
CBS NNP N
and CC N
metronidazole JJ N
double JJ N
therapy NN i
, , N
CBS NNP N
, , N
metronidazole NN N
and CC N
amoxicillin JJ i
triple JJ N
therapy NN i
) ) N
. . N

The DT N
factorial JJ N
analysis NN N
showed VBD N
that IN N
both DT N
1000 CD N
mg NN N
acetaminophen NN i
and CC N
60 CD N
mg NN N
codeine NN i
made VBD N
a DT N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
contribution NN N
to TO N
the DT N
analgesic JJ N
effectiveness NN N
of IN N
the DT N
combination NN N
on IN N
all DT N
measures NNS N
of IN N
efficacy NN N
( ( N
sum NN N
of IN N
pain NN N
intensity NN N
differences NNS N
, , N
largest JJS N
pain NN N
intensity NN N
difference NN N
, , N
total JJ N
pain NN N
relief NN N
, , N
largest JJS N
pain NN N
relief NN N
, , N
and CC N
time NN N
to TO N
remedication NN N
) ) N
. . N

PARTICIPANTS NNS N
Two CD N
hundred VBD N
thirty-eight JJ N
elderly JJ N
men NNS N
and CC N
women NNS N
aged VBD N
60 CD N
to TO N
80 CD N
at IN N
high JJ N
risk NN N
for IN N
cardiovascular JJ N
disease NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
interventional JJ N
groups NNS N
: : N
a DT N
recommended JJ N
low-fat JJ N
diet NN N
( ( N
control VB N
diet JJ N
group NN N
) ) N
, , N
a DT N
Mediterranean NNP N
diet NN N
supplemented VBD N
with IN N
virgin JJ N
olive JJ N
oil NN N
, , N
or CC N
a DT N
Mediterranean NNP N
diet NN N
supplemented VBD N
with IN N
mixed JJ N
nuts NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Using NNP N
impressions NNS N
made VBD N
from IN N
a DT N
stainless JJ N
steel NN N
complete-crown JJ N
master NN N
die NN N
, , N
9 CD N
stone NN N
cast NN N
replicas NN N
were VBD N
fabricated VBN N
, , N
numbered VBN N
, , N
and CC N
distributed VBD N
into IN N
8 CD N
ceramic JJ N
ZrO NNP N
( ( N
2 CD N
) ) N
CAD/CAM NNP N
system NN N
groups NNS N
( ( N
Lava NNP N
Frame NNP N
0.3 CD N
and CC N
0.5 CD N
, , N
IPS NNP N
e.max VBZ i
ZirCAD NNP N
, , N
VITA NNP N
YZ NNP N
, , N
Procera NNP N
AllZircon NNP N
, , N
Digizon NNP N
, , N
DC NNP N
Zircon NNP N
, , N
and CC N
Cercon NNP N
Base NNP N
) ) N
and CC N
to TO N
a DT N
lithium NN N
disilicate JJ N
glass-ceramic JJ N
control NN N
group NN N
( ( N
IPS NNP N
e.max RB i
Press NNP N
) ) N
using VBG N
a DT N
simple JJ N
computer-generated JJ N
randomization NN N
method NN N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
indices NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
baseline NN N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
, , N
including VBG N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
, , N
condition NN N
assessment NN N
, , N
Health NNP N
Assessment NNP N
Questionnaire NNP N
( ( N
HAQ NNP N
) ) N
, , N
disease NN N
activity NN N
index NN N
28 CD N
( ( N
DAS28 NNP N
) ) N
, , N
laboratory JJ N
parameters NNS N
of IN N
erythrocyte JJ N
sedimentation NN N
rate NN N
( ( N
ESR NNP N
) ) N
and CC N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
safety NN N
indicators NNS N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
. . N

PURPOSE VB N
The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
the DT N
following JJ N
: : N
1 CD N
) ) N
to TO N
examine VB N
patterns NNS N
of IN N
adherence NN N
to TO N
a DT N
brisk JJ N
walking VBG N
program NN N
in IN N
women NNS N
receiving VBG N
adjuvant JJ N
chemotherapy NN i
or CC N
radiation NN N
therapy NN i
for IN N
newly RB N
diagnosed VBN N
breast NN N
cancer NN N
using VBG N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
experimental JJ N
design NN N
; : N
2 CD N
) ) N
to TO N
examine VB N
the DT N
influence NN N
of IN N
disease NN N
symptoms NNS N
and CC N
treatment NN N
side NN N
effects NNS N
on IN N
exercise NN N
levels NNS N
; : N
and CC N
3 CD N
) ) N
to TO N
suggest VB N
methods NNS N
that WDT N
may MD N
improve VB N
future NN N
clinical JJ N
trials NNS N
of IN N
moderate-intensity NN N
exercise NN N
in IN N
similar JJ N
populations NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Roland NNP N
adaptation NN N
of IN N
the DT N
Sickness NNP N
Impact NNP N
Profile NNP N
, , N
visual JJ N
analogue NN N
pain NN N
scale NN N
, , N
health NN N
status NN N
scale NN N
, , N
EuroQol NNP N
, , N
use NN N
of IN N
primary JJ N
and CC N
secondary JJ N
care NN N
services NNS N
, , N
and CC N
physical JJ N
and CC N
complementary JJ N
therapies NNS N
, , N
sickness JJ N
absence NN N
, , N
medication NN N
use NN N
, , N
patient JJ N
satisfaction NN N
, , N
reassurance NN N
and CC N
belief NN N
in IN N
value NN N
of IN N
radiography NN N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
post-randomisation NN N
. . N

To TO N
characterize VB N
the DT N
time NN N
course NN N
of IN N
plasma NN N
and CC N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
changes NNS N
after IN N
n-3 JJ N
polyunsaturated JJ N
fatty JJ N
acid NN N
( ( N
PUFA NNP N
) ) N
supplementation NN N
, , N
20 CD N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
four CD N
1-g JJ N
capsules NNS N
of IN N
n-3 JJ N
PUFA NNP N
ethyl NN N
esters NNS N
or CC N
four CD N
1-g JJ N
capsules NNS N
of IN N
olive JJ N
oil NN N
( ( N
as IN N
placebo NN N
) ) N
for IN N
a DT N
period NN N
of IN N
4 CD N
mo NN N
, , N
followed VBN N
by IN N
a DT N
3-mo JJ N
washout NN N
period NN N
. . N

OBJECTIVE IN N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
three-way JJ N
crossover-design NN N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetic JJ N
( ( N
PK NNP N
) ) N
parameters NNS N
of IN N
two CD N
BDDrFVIII NNP N
formulations NNS N
( ( N
one CD N
reconstituted VBN N
with IN N
5 CD N
mL NNS N
of IN N
sterile JJ N
water NN N
, , N
the DT N
other JJ N
reconstituted VBD N
with IN N
4 CD N
mL NNS N
sodium JJ N
chloride RB N
0.9 CD N
% NN N
USP NNP N
) ) N
with IN N
those DT N
of IN N
a DT N
plasma-derived JJ N
, , N
full-length JJ N
FVIII NNP N
preparation NN N
( ( N
Hemofil NNP N
M NNP N
) ) N
in IN N
patients NNS p
with IN N
haemophilia PDT N
A DT N
to TO N
determine VB N
bioequivalence NN N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
a DT N
multi-centre JJ N
randomised JJ N
2 CD N
x JJ N
2 CD N
factorial JJ N
design NN N
study NN N
evaluating VBG N
two CD N
independent JJ N
variables NNS N
of IN N
VP NNP N
design NN N
, , N
branching NN N
( ( N
present JJ N
or CC N
absent NN N
) ) N
, , N
and CC N
structured VBD N
clinical JJ N
reasoning NN N
feedback NN N
( ( N
present JJ N
or CC N
absent NN N
) ) N
.The NN N
study NN N
will MD N
be VB N
carried VBN N
out RP N
in IN N
medical JJ N
student NN N
volunteers NNS N
in IN N
one CD N
year NN N
group NN N
from IN N
three CD N
university NN N
medical JJ N
schools NNS N
in IN N
the DT N
United NNP N
Kingdom NNP N
, , N
Warwick NNP N
, , N
Keele NNP N
and CC N
Birmingham NNP N
. . N

Magnetic JJ N
resonance NN N
spectroscopy NN N
was VBD N
used VBN N
as IN N
a DT N
means NN N
of IN N
predicting VBG N
the DT N
probability NN N
of IN N
developing VBG N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
in IN N
patients NNS p
with IN N
liver JJ N
cirrhosis NN N
secondary JJ N
to TO N
chronic VB N
hepatitis NN N
B.This NNP N
study NN N
included VBD N
20 CD N
healthy JJ N
volunteers NNS N
, , N
20 CD N
patients NNS p
with IN N
liver JJ N
cirrhosis NN N
secondary JJ N
to TO N
chronic VB N
hepatitis NN N
B NNP N
( ( N
cirrhosis NN N
group NN N
) ) N
, , N
and CC N
20 CD N
patients NNS p
with IN N
small JJ N
HCC NNP N
secondary JJ N
to TO N
cirrhosis VB N
liver RB N
parenchyma NN N
( ( N
HCC NNP N
group NN N
) ) N
. . N

OBJECTIVES NN N
To TO N
( ( N
1 CD N
) ) N
determine VB N
the DT N
efficacy NN N
of IN N
venlafaxine NN i
XR NN N
for IN N
the DT N
treatment NN N
of IN N
pain NN N
( ( N
secondary JJ N
aim NN N
) ) N
in IN N
individuals NNS N
with IN N
spinal JJ N
cord NN N
injury NN N
( ( N
SCI NNP N
) ) N
enrolled VBD N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
on IN N
the DT N
efficacy NN N
of IN N
venlafaxine NN i
XR NN N
for IN N
major JJ N
depressive JJ N
disorder NN N
( ( N
MDD NNP N
) ) N
( ( N
primary JJ N
aim NN N
) ) N
; : N
and CC N
( ( N
2 CD N
) ) N
test NN N
the DT N
hypothesis NN N
that WDT N
venlafaxine NN i
XR NNP N
would MD N
be VB N
effective JJ N
for IN N
both DT N
neuropathic JJ N
and CC N
nociceptive JJ N
pain NN N
. . N

Data NNS N
from IN N
2 CD N
separate JJ N
multicenter NN N
, , N
double-blind JJ N
clinical JJ N
studies NNS N
following VBG N
the DT N
same JJ N
protocol NN N
, , N
except IN N
for IN N
the DT N
selection NN N
of IN N
doses NNS N
, , N
were VBD N
pooled VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
fixed JJ N
doses NNS N
of IN N
a DT N
new JJ N
sustained-release NN N
( ( N
SR NNP N
) ) N
formulation NN N
of IN N
nifedipine JJ N
compared VBN N
with IN N
placebo NN N
in IN N
388 CD N
patients NNS p
with IN N
mild JJ N
to TO N
moderate VB N
uncomplicated JJ N
essential JJ N
hypertension NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
age NN N
, , N
peak JJ N
serum NN N
E NNP N
( ( N
2 CD N
) ) N
concentration NN N
, , N
days NNS N
of IN N
stimulation NN N
with IN N
rFSH NN N
, , N
total JJ N
number NN N
of IN N
M2 NNP N
oocytes VBZ N
retrieved VBN N
, , N
number NN N
of IN N
embryos NN N
transferred VBN N
, , N
clinical JJ N
pregnancy NN N
rates NNS N
, , N
and CC N
cancellation NN N
rates NNS N
of IN N
stimulation NN N
and CC N
embryo NN N
transfer NN N
between IN N
the DT N
three CD N
groups NNS N
except IN N
for IN N
total JJ N
rFSH JJ N
dosage NN N
. . N

Three CD N
groups NNS N
of IN N
unimpaired JJ N
participants NNS N
trained VBN N
with IN N
the DT N
target NN N
arm JJ N
movement NN N
broken VBD N
down RB N
in IN N
three CD N
ways NNS N
: : N
1 CD N
) ) N
elbow NN N
flexion/extension NN N
and CC N
the DT N
unified JJ N
shoulder NN N
motion NN N
independently RB N
( ( N
anatomical JJ N
decomposition NN N
) ) N
, , N
2 CD N
) ) N
three CD N
component JJ N
shoulder NN N
motions NNS N
in IN N
Euler NNP N
coordinates NNS N
and CC N
elbow JJ N
flexion/extension NN N
( ( N
Euler NNP N
decomposition NN N
) ) N
, , N
or CC N
3 CD N
) ) N
the DT N
motion NN N
of IN N
the DT N
tip NN N
of IN N
the DT N
elbow NN N
and CC N
motion NN N
of IN N
the DT N
hand NN N
with IN N
respect NN N
to TO N
the DT N
elbow NN N
, , N
independently RB N
( ( N
visual JJ N
decomposition NN N
) ) N
. . N

METHODS NNP N
AND CC N
FINDINGS NNP N
During IN N
18 CD N
y NNS N
of IN N
follow-up NN N
of IN N
14,916 CD N
men NNS N
initially RB N
free JJ N
of IN N
diagnosed JJ N
cancer NN N
, , N
we PRP N
identified VBD N
1,066 CD N
men NNS N
with IN N
incident JJ N
prostate NN N
cancer NN N
( ( N
including VBG N
496 CD N
with IN N
aggressive JJ N
disease NN N
, , N
defined VBD N
as IN N
stage NN N
C NNP N
or CC N
D NNP N
, , N
Gleason NNP N
7-10 CD N
, , N
metastatic JJ N
, , N
and CC N
fatal JJ N
prostate NN N
cancer NN N
) ) N
and CC N
1,618 CD N
cancer-free JJ N
, , N
age- JJ N
and CC N
smoking-matched JJ N
control NN N
participants NNS N
in IN N
the DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
. . N

PURPOSE NN N
This DT N
randomized VBN N
group NN N
experiment NN N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD N
communication NN N
interventions NNS N
( ( N
Responsive JJ N
Education NN N
and CC N
Prelinguistic NNP N
Milieu NNP N
Teaching NNP N
[ NNP N
RPMT NNP N
] NNP N
and CC N
the DT N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
[ NNP N
PECS NNP N
] NNP N
) ) N
on IN N
spoken JJ N
communication NN N
in IN N
36 CD N
preschoolers NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
measure VB N
the DT N
degree NN N
of IN N
anesthesia NN N
following VBG N
the DT N
administration NN N
of IN N
3.6 CD N
ml NN N
of IN N
2 CD N
% NN N
lidocaine JJ N
solutions NNS N
with IN N
either DT N
1:50,000 CD N
, , N
1:80,000 CD N
, , N
or CC N
1:100,000 CD N
for IN N
inferior JJ N
alveolar JJ N
nerve NN N
block NN N
and CC N
to TO N
compare VB N
the DT N
results NNS N
with IN N
those DT N
obtained VBN N
following VBG N
the DT N
administration NN N
of IN N
1.8 CD N
ml NN N
of IN N
the DT N
same JJ N
solutions NNS N
( ( N
1 CD N
) ) N
. . N

Most JJS N
cases NNS N
initially RB N
experienced VBD N
bleeding NN N
in IN N
the DT N
first JJ N
3 CD N
months NNS N
but CC N
such JJ N
initiation NN N
was VBD N
a DT N
bit NN N
later RB N
in IN N
group NN N
C. NNP N
Endometrium NNP N
, , N
as IN N
detected VBN N
by IN N
B-mode NNP N
ultrasound NN N
, , N
increased VBD o
approximately RB o
1 CD N
mm NNS N
in IN N
HT NNP N
groups NNS N
, , N
while IN N
it PRP N
was VBD N
a DT N
bit NN N
thicker NN N
in IN N
group NN N
C. NNP N
Long NNP N
periods NNS N
in IN N
reproductive JJ N
age NN N
and CC N
short JJ N
time NN N
since IN N
menopause NN N
were VBD N
high JJ N
risk NN N
factors NNS N
for IN N
irregular JJ N
bleeding NN N
. . N

The DT N
effects NNS N
on IN N
behavior NN N
of IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
sulforaphane NN N
( ( N
50-150 JJ N
? . N
) ) N
for IN N
18 CD N
wk NN N
, , N
followed VBN N
by IN N
4 CD N
wk NNS N
without IN N
treatment NN N
, , N
were VBD N
quantified VBN N
by IN N
three CD N
widely RB N
accepted VBD N
behavioral JJ N
measures NNS N
completed VBN N
by IN N
parents/caregivers NNS N
and CC N
physicians NNS N
: : N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
, , N
Social NNP N
Responsiveness NNP N
Scale NNP N
( ( N
SRS NNP N
) ) N
, , N
and CC N
Clinical NNP N
Global NNP N
Impression NNP N
Improvement NNP N
Scale NNP N
( ( N
CGI-I NNP N
) ) N
. . N

CONCLUSIONS NNP N
This DT N
secondary JJ N
analysis NN N
of IN N
predominantly RB N
lung JJ N
cancer NN N
patients NNS p
, , N
consistent JJ N
with IN N
the DT N
original JJ N
analysis NN N
, , N
shows VBZ N
no DT N
survival JJ N
advantage NN N
for IN N
the DT N
group NN N
overall JJ i
when WRB N
treated VBN N
with IN N
WBRT NNP N
and CC N
SRS NNP N
; : N
however RB N
, , N
in IN N
patients NNS p
with IN N
high JJ N
GPA NNP N
( ( N
3.5-4 JJ N
) ) N
, , N
there EX N
is VBZ N
a DT N
survival JJ N
advantage NN N
regardless NN N
of IN N
whether IN N
they PRP N
have VBP N
1 CD N
, , N
2 CD N
, , N
or CC N
3 CD N
BM NNP N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effect NN N
of IN N
granisetron NN N
injection NN N
at IN N
a DT N
dose NN N
of IN N
40 CD N
microg/kg NNS N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
nausea/vomiting VBG N
induced VBN N
by IN N
multidrug NN N
combined VBN N
cancer NN N
chemotherapy NN i
excluding VBG N
cisplatin NN i
in IN N
patients NNS p
with IN N
tumors NNS N
of IN N
hematopoietic JJ N
organs NNS N
was VBD N
evaluated VBN N
by IN N
comparing VBG N
a DT N
30-min JJ N
infusion NN N
and CC N
a DT N
slow JJ N
intravenous JJ N
injection NN N
given VBN N
over IN N
30 CD N
s. JJ N
METHODS NNP N
A DT N
two-group JJ N
random-allocation NN N
comparative NN N
study NN N
was VBD N
performed VBN N
with IN N
the DT N
cooperation NN N
of IN N
multiple JJ N
institutions NNS N
using VBG N
a DT N
central JJ N
registration NN N
system NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
( ( N
1 CD N
) ) N
to TO N
assess VB N
baseline JJ N
echocardiographic JJ N
predictors NNS N
of IN N
clinical JJ N
outcome NN N
, , N
( ( N
2 CD N
) ) N
to TO N
investigate VB N
changes NNS N
in IN N
echocardiographic JJ N
parameters NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
to TO N
compare VB N
these DT N
echocardiographic JJ N
changes NNS N
with IN N
changes NNS N
in IN N
plasma NN N
levels NNS N
of IN N
b-type JJ N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
in IN N
a DT N
population NN N
of IN N
children NNS N
with IN N
systemic JJ N
ventricular JJ N
dysfunction NN N
and CC N
symptomatic JJ N
heart NN N
failure NN N
treated VBN N
with IN N
carvedilol NN i
or CC N
placebo NN N
. . N

Whereas NNP N
standard JJ N
laboratory NN N
tests NNS N
of IN N
coagulation NN N
were VBD N
comparable JJ N
between IN N
groups NNS N
, , N
von FW N
Willebrand NNP N
factor NN N
activity NN N
on IN N
the DT N
first JJ N
postoperative JJ N
morning NN N
tended VBD N
to TO N
be VB N
higher JJR N
following VBG N
treatment NN N
with IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
( ( N
P=0.025 NNP N
) ) N
with IN N
this DT N
difference NN N
being VBG N
statistically RB N
significant JJ N
only RB N
in IN N
the DT N
per-protocol JJ N
analysis NN N
( ( N
P=0.02 NNP N
) ) N
. . N

In IN N
order NN N
to TO N
assess VB N
if IN N
the DT N
use NN N
of IN N
the DT N
laryngeal JJ N
mask NN N
airway NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN o
risk NN N
of IN N
gastric JJ N
regurgitation NN N
during IN N
mechanical JJ N
ventilation NN N
, , N
we PRP N
studied VBD N
50 CD N
patients NNS p
allocated VBD N
randomly RB N
to TO N
undergo VB N
anaesthesia NN N
with IN N
either DT N
artificial JJ N
ventilation NN N
with IN N
isoflurane NN N
and CC N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
and CC N
atracurium NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
spontaneous JJ N
ventilation NN N
with IN N
isoflurane NN N
and CC N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
( ( N
group NN N
B NNP N
) ) N
. . N

The DT N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
different JJ N
treatment NN N
protocols NNS N
with IN N
the DT N
aim NN N
of IN N
remineralising VBG N
the DT N
lesions NNS N
: : N
A DT N
) ) N
daily RB N
topical JJ N
applications NNS N
of IN N
a DT N
dental JJ N
cream NN N
containing VBG N
CPP-ACP NNP N
( ( N
Topacal NNP N
) ) N
for IN N
3 CD N
months NNS N
followed VBN N
by IN N
a DT N
3-month JJ N
period NN N
of IN N
daily JJ N
toothbrushing VBG N
with IN N
fluoridated JJ N
dentifrice NN N
, , N
or CC N
B NNP N
) ) N
daily RB N
0.05 CD N
% NN N
sodium NN N
fluoride NN N
mouthwash NN N
combined VBN N
with IN N
fluoridated JJ N
dentifrice NN N
for IN N
6 CD N
months NNS N
. . N

Before IN N
catheter NN N
insertion NN N
, , N
we PRP N
randomly VBP N
assigned VBN N
( ( N
1:1:1:1 CD N
) ) N
patients NNS p
via IN N
a DT N
secure JJ N
web-based JJ N
random-number JJ N
generator NN N
( ( N
permuted JJ N
blocks NNS N
of IN N
eight CD N
, , N
stratified VBN N
by IN N
centre NN N
) ) N
to TO N
have VB N
all DT N
intravascular JJ N
catheters NNS N
prepared VBD N
with IN N
2 CD N
% NN N
chlorhexidine-70 JJ N
% NN N
isopropyl NN N
alcohol NN N
( ( N
chlorhexidine-alcohol NN N
) ) N
or CC N
5 CD N
% NN N
povidone JJ i
iodine-69 JJ N
% NN N
ethanol NN N
( ( N
povidone JJ i
iodine-alcohol NN N
) ) N
, , N
with IN N
or CC N
without IN N
scrubbing VBG N
of IN N
the DT N
skin NN N
with IN N
detergent NN N
before IN N
antiseptic JJ N
application NN N
. . N

Follicle NNP N
stimulating VBG N
hormone NN N
( ( N
FSH NNP N
) ) N
, , N
luteinizing VBG N
hormone NN N
( ( N
LH NNP N
) ) N
levels NNS N
, , N
number NN N
of IN N
follicles NNS N
, , N
number NN N
of IN N
follicles NNS N
> VBP N
18 CD N
mm NN N
, , N
relative JJ N
frequency NN N
of IN N
mature NN N
oocytes NNS N
, , N
number NN N
and CC N
days NNS N
of IN N
gonadotropin JJ N
injections NNS N
, , N
day NN N
of IN N
human JJ N
chorionic JJ N
gonadotropin NN N
( ( N
HCG NNP N
) ) N
administration NN N
, , N
estradiol JJ N
level NN N
and CC N
abortion NN N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Double-pulse JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
dpTMS NN N
) ) N
was VBD N
used VBN N
to TO N
examine VB N
inhibition NN N
by IN N
means NNS N
of IN N
short-interval JJ N
intracortical JJ N
inhibition NN N
( ( N
SICI NNP N
) ) N
of IN N
the DT N
contralateral JJ N
primary JJ N
motor NN N
cortex NN N
in IN N
a DT N
sample NN N
of IN N
64 CD N
healthy JJ N
right-handed JJ N
human JJ N
subjects NNS N
covering VBG N
a DT N
wide JJ N
range NN N
of IN N
the DT N
adult NN N
lifespan NN N
( ( N
age NN N
range NN N
20-88 CD N
years NNS N
, , N
mean VB N
47.6 CD N
? . N
20.7 CD N
, , N
34 CD N
female NN N
) ) N
. . N

Evaluations NNS N
were VBD N
carried VBN N
out RP N
before IN N
and CC N
12 CD N
weeks NNS N
after IN N
treatment NN N
with IN N
either DT N
100 CD N
mg NNS N
denbufylline JJ N
BID NNP N
or CC N
placebo NN N
and CC N
included VBD N
EEG NNP N
mapping NN N
, , N
the DT N
Sandoz NNP N
Clinical NNP N
Assessment NNP N
Geriatric NNP N
( ( N
SCAG NNP N
) ) N
score/factors NNS N
, , N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
, , N
the DT N
Digit NNP N
Symbol NNP N
Substitution NNP N
Test NNP N
( ( N
DSST NNP N
) ) N
, , N
the DT N
Trail-Making JJ N
Test NNP N
( ( N
TMT NNP N
) ) N
and CC N
the DT N
Digit NNP N
Span NNP N
Test NNP N
( ( N
DS NNP N
) ) N
. . N

In IN N
a DT N
2 CD N
? . N
2 CD N
factorial JJ N
design NN N
, , N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
following VBG N
four CD N
study NN N
arms NNS N
: : N
aspirin NN N
plus CC N
RS NNP N
placebo NN N
; : N
RS NNP N
plus CC N
aspirin JJ N
placebo NN N
; : N
aspirin CC N
plus CC N
RS NNP N
; : N
RS NNP N
placebo NN N
plus CC N
aspirin JJ N
placebo NN N
; : N
they PRP N
were VBD N
followed VBN N
with IN N
standard JJ N
annual JJ N
clinical JJ N
examinations NNS N
including VBG N
endoscopy NN N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
in IN N
which WDT N
women NNS N
with IN N
advanced JJ N
anterior JJ N
vaginal NN N
wall NN N
prolapse NN N
, , N
at IN N
least JJS N
stage NN N
II NNP N
with IN N
Ba NNP N
? . N
+1 NN N
cm NN N
according VBG N
to TO N
the DT N
Pelvic NNP N
Organ NNP N
Prolapse NNP N
Quantification NNP N
( ( N
POP-Q NNP N
) ) N
classification NN N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
either DT N
anterior JJ N
colporrhaphy NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
or CC N
repair NN N
using VBG N
trocar-guided JJ N
transvaginal JJ N
mesh NN N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
. . N

ETAC NNP N
( ( N
Early JJ N
Treatment NN N
of IN N
the DT N
Atopic NNP N
Child NNP N
) ) N
, , N
a DT N
multi-centre JJ N
predominantly RB N
European JJ N
study NN N
to TO N
investigate VB N
the DT N
potential NN N
for IN N
cetirizine NN N
to TO N
prevent VB N
the DT N
development NN N
of IN N
asthma NN N
in IN N
infants NNS N
with IN N
atopic NN N
dermatitis NN N
has VBZ N
completed VBN N
enrollment NN N
: : N
817 CD N
children NNS N
have VBP N
been VBN N
randomised VBN N
to TO N
18 CD N
months NNS N
' POS N
treatment NN N
with IN N
either DT N
active JJ N
or CC N
placebo NN N
and CC N
a DT N
subsequent JJ N
18 CD N
months NNS N
of IN N
post-treatment JJ N
follow-up NN N
. . N

Our PRP$ N
preliminary JJ N
studies NNS N
of IN N
the DT N
efficacy NN N
of IN N
lithium NN N
carbonate NN N
therapy NN i
for IN N
alcoholism NN N
under IN N
double-blind NN N
, , N
placebo-controlled JJ N
conditions NNS N
demonstrated VBD N
that IN N
alcoholics NNS N
who WP N
took VBD N
their PRP$ N
assigned JJ N
medication NN N
( ( N
lithium NN N
or CC N
placebo NN N
) ) N
for IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
discharge NN N
from IN N
an DT N
inpatient JJ N
rehabilitation NN N
program NN N
were VBD N
more RBR N
likely JJ N
to TO N
abstain VB N
from IN N
any DT N
alcohol NN N
use NN N
for IN N
18 CD N
months NNS N
following VBG N
discharge NN N
than IN N
were VBD N
alcoholics NNS N
who WP N
took VBD N
their PRP$ N
medication NN N
erratically RB N
or CC N
not RB N
at IN N
all DT N
. . N

Pyrimethamine NNP N
, , N
25 CD N
mg NN N
thrice NN N
weekly RB N
, , N
was VBD N
evaluated VBN N
as IN N
primary JJ N
prophylaxis NN N
for IN N
toxoplasmic JJ N
encephalitis NN N
( ( N
TE NNP N
) ) N
in IN N
a DT N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
in IN N
patients NNS p
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
disease NN N
, , N
absolute JJ N
CD4 NNP N
lymphocyte NN N
count NN N
of IN N
< $ N
200/microL CD N
( ( N
or CC N
prior RB N
AIDS-defining NNP N
opportunistic JJ N
infection NN N
) ) N
, , N
and CC N
the DT N
presence NN N
of IN N
serum NN N
IgG NNP N
to TO N
Toxoplasma NNP N
gondii NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
27 CD N
infants NNS N
, , N
mean JJ N
age NN N
4.6 CD N
months NNS N
, , N
who WP N
manifested VBD N
atopic JJ N
eczema NN N
during IN N
exclusive JJ N
breast-feeding NN N
and CC N
who WP N
have VBP N
had VBN N
no DT N
exposure NN N
to TO N
any DT N
infant NN N
or CC N
substitute NN N
formula NN N
were VBD N
weaned VBN N
to TO N
probiotic-supplemented JJ N
, , N
Bifidobacterium NNP N
lactis VBZ N
Bb-12 NNP N
or CC N
Lactobacillus NNP N
strain VBP N
GG NNP N
( ( N
ATCC NNP N
53103 CD N
) ) N
, , N
extensively RB N
hydrolysed VBD N
whey JJ N
formulas NNS N
or CC N
to TO N
the DT N
same JJ N
formula NN N
without IN N
probiotics NNS N
. . N

Investigators NNS N
of IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
entered VBD N
73 CD N
children NNS N
with IN N
previously RB N
untreated VBN N
localized JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
on IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
systemic JJ N
treatment NN N
with IN N
either DT N
a DT N
four-drug JJ N
program NN N
( ( N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
methotrexate NN N
, , N
prednisone NN N
[ NNP N
COMP NNP N
] NNP N
) ) N
or CC N
a DT N
10-drug JJ N
( ( N
LSA2-L2 NNP N
modified VBN N
) ) N
program NN N
of IN N
18 CD N
months NNS N
duration NN N
. . N

There EX N
was VBD N
also RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatments NNS N
in IN N
the DT N
number NN N
of IN N
participants NNS N
whose WP$ N
changes NNS N
in IN N
Visual NNP N
Analog NNP N
Scale NNP N
scores VBZ N
met VBD N
the DT N
study NN N
definition NN N
of IN N
success NN N
at IN N
both DT N
6 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
posttreatment NN N
; : N
and CC N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
posttreatment NN N
in IN N
the DT N
Roles NNP N
and CC N
Maudsley NNP N
Score NNP N
. . N

Results NNS N
demonstrated VBD N
the DT N
ability NN N
to TO N
recruit VB N
and CC N
retain VB N
53 CD N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
, , N
that IN N
the DT N
experimental JJ N
arm NN N
showed VBD N
improvement NN N
in IN N
overall JJ i
QOL NNP N
( ( N
P NNP N
= NNP N
.013 NNP N
) ) N
, , N
and CC N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
overall JJ i
QOL NNP N
between IN N
the DT N
experimental JJ N
and CC N
wait-control JJ N
groups NNS N
at IN N
both DT N
months NNS N
3 CD N
and CC N
6 CD N
. . N

Data NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
among IN N
22 CD N
premenopausal JJ N
women NNS N
, , N
age NN N
32.6 CD N
( ( N
range JJ N
20-45 CD N
years NNS N
) ) N
, , N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
two CD N
treatments NNS N
with IN N
continuous JJ N
progestogens NNS N
for IN N
contraception NN N
were VBD N
analyzed VBN N
; : N
depot-medroxyprogesterone JJ N
acetate NN N
( ( N
DMPA NNP N
) ) N
or CC N
continuous JJ N
levonorgestrel NN N
treatment NN N
with IN N
subdermal JJ N
implants NNS N
( ( N
Norplant NNP N
) ) N
, , N
respectively RB N
. . N

We PRP N
examined VBD N
how WRB N
plasma JJ N
Lp NNP N
[ VBZ N
a DT N
] NN N
in IN N
healthy JJ N
young JJ N
men NNS N
was VBD N
affected VBN N
by IN N
fats NNS N
high JJ N
in IN N
stearic JJ N
( ( N
C18 NNP N
) ) N
, , N
palmitic JJ N
( ( N
C16 NNP N
) ) N
, , N
and CC N
lauric+myristic JJ N
( ( N
C12+ NNP N
C14 NNP N
) ) N
acid NN N
( ( N
experiment JJ N
I PRP N
, , N
15 CD N
subjects NNS N
) ) N
, , N
and CC N
by IN N
fats NNS N
high JJ N
in IN N
myristic JJ N
( ( N
C14 NNP N
) ) N
and CC N
palmitic JJ N
( ( N
C16 NNP N
) ) N
acid NN N
( ( N
experiment JJ N
II NNP N
, , N
12 CD N
subjects NNS N
) ) N
. . N

A DT N
clinical JJ N
comparison NN N
of IN N
an DT N
emulsion NN N
containing VBG N
a DT N
new JJ N
pilocarpine NN N
polymer NN N
( ( N
Polym NNP N
) ) N
compound NN N
to TO N
that DT N
of IN N
a DT N
traditional JJ N
pilocarpine NN N
salt NN N
solution NN N
( ( N
Plc NNP N
) ) N
on IN N
the DT N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
has VBZ N
been VBN N
performed VBN N
in IN N
40 CD N
open-angle JJ N
patients NNS p
treated VBN N
with IN N
the DT N
long JJ N
acting JJ N
pilocarpine-complex NN N
for IN N
120 CD N
days NNS N
. . N

METHODS NNP N
We PRP N
tested VBD N
two CD N
doses NNS N
of IN N
the DT N
CRF NNP N
( ( N
1 CD N
) ) N
antagonist NN N
R317573 NNP N
for IN N
effects NNS N
on IN N
regional JJ N
cerebral JJ N
glucose NN N
metabolism NN N
( ( N
rCMglu NN N
) ) N
using VBG N
[ NNP N
( ( N
18 CD N
) ) N
F NNP N
] JJ N
fluoro-2-deoxy-D NN N
: : N
-glucose NN N
( ( N
FDG NNP N
) ) N
positron NN N
emission NN N
tomography NN N
( ( N
PET NNP N
) ) N
following VBG N
single-dose JJ N
challenges NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
cross-over JJ N
design NN N
, , N
in IN N
12 CD N
healthy JJ N
male NN N
volunteers NNS N
. . N

METHODS NNP N
We PRP N
assessed VBD N
caffeine JJ i
responses NNS N
and CC N
levels NNS N
of IN N
saliva JJ N
concentration NN N
of IN N
caffeine NN i
in IN N
52 CD N
subjects NNS N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
one CD N
of IN N
two CD N
drug NN N
administration NN N
instructions NNS N
: : N
( ( N
a DT N
) ) N
placebo-informed JJ N
instructions NNS N
( ( N
i.e NN N
, , N
individuals NNS N
informed VBD N
of IN N
the DT N
placebo NN N
) ) N
analogous JJ N
to TO N
those DT N
used VBN N
in IN N
double-blind JJ N
studies NNS N
and CC N
( ( N
b NN N
) ) N
placebo-uninformed JJ N
instructions NNS N
( ( N
i.e NN N
, , N
individuals NNS N
informed VBD N
they PRP N
are VBP N
taking VBG N
an DT N
active JJ N
stimulant NN N
) ) N
. . N

INTERVENTION NN N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
( ( N
1 CD N
) ) N
an DT N
experimental JJ N
group NN N
to TO N
receive VB N
a DT N
mixed JJ N
KT-compression NNP N
treatment NN N
following VBG N
KT NNP N
recommendations NNS N
for IN N
gastrocnemius JJ N
muscle NN N
enhancement NN N
and CC N
functional JJ N
correction NN N
of IN N
the DT N
ankle NN N
, , N
and CC N
adding VBG N
2 CD N
tapes NNS N
to TO N
simulate VB N
traditional JJ N
compression NN N
bandages NNS N
( ( N
no DT N
KT NNP N
guidelines NNS N
) ) N
; : N
or CC N
( ( N
2 CD N
) ) N
a DT N
placebo NN N
control NN N
group NN N
for IN N
sham NN N
KT NNP N
. . N

An DT N
intent-to-treat JJ N
comparison NN N
of IN N
the DT N
numbers NNS N
of IN N
courses NNS N
affected VBN N
by IN N
acute JJ N
toxicity NN N
( ( N
fever NN N
, , N
rigors NNS N
) ) N
and CC N
chronic JJ N
toxicity NN N
( ( N
nephrotoxicity NN N
) ) N
also RB N
indicated VBD N
that IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
AmB NNP N
infused VBD N
in IN N
dextrose NN N
( ( N
78 CD N
courses NNS N
) ) N
and CC N
AmB NNP N
infused VBD N
in IN N
lipid JJ N
emulsion NN N
( ( N
84 CD N
courses NNS N
) ) N
. . N

METHOD NNP N
the DT N
research NN N
sample NN N
consisted VBD N
of IN N
11 CD N
mothers NNS N
of IN N
children NNS N
diagnosed VBN N
, , N
according VBG N
to TO N
the DT N
criteria NNS N
established VBN N
by IN N
the DT N
DSM NNP N
IVtr NNP N
( ( N
APA NNP N
, , N
2002 CD N
) ) N
, , N
with IN N
autism NN N
( ( N
six CD N
) ) N
and CC N
with IN N
Asperger NNP N
Syndrome NNP N
( ( N
five CD N
) ) N
and CC N
who WP N
were VBD N
seen VBN N
at IN N
the DT N
Investigation NNP N
Laboratory NNP N
of IN N
Global NNP N
Developmental NNP N
Disorders NNP N
of IN N
the DT N
Federal NNP N
University NNP N
of IN N
S NNP N
Paulo NNP N
. . N

It PRP N
was VBD N
designed VBN N
as IN N
an DT N
open-label NN N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
comparative JJ N
study NN N
involving VBG N
104-week JJ N
oral JJ N
treatment NN N
with IN N
1 CD N
of IN N
the DT N
3 CD N
drugs NNS N
( ( N
aripiprazole NN N
, , N
blonanserin NN N
, , N
and CC N
paliperidone NN i
) ) N
in IN N
patients NNS p
with IN N
schizophrenia NN N
aged VBN N
20 CD N
years NNS N
or CC N
over IN N
who WP N
required VBD N
antipsychotic JJ i
medication NN N
or CC N
switching NN N
of IN N
the DT N
current JJ N
medication NN N
to TO N
others NNS N
for IN N
reasons NNS N
such JJ N
as IN N
lack NN N
of IN N
efficacy NN N
and CC N
intolerability NN N
. . N

After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
, , N
the DT N
immune JJ N
success NN N
rates NNS N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
90 CD N
patients NNS p
( ( N
96 CD N
hips NNS N
) ) N
scheduled VBN N
for IN N
THA NNP N
were VBD N
stratified VBN N
in IN N
three CD N
groups NNS N
according VBG N
to TO N
the DT N
method NN N
of IN N
fixation NN N
of IN N
the DT N
acetabular JJ N
component NN N
: : N
acrylic JJ N
bone NN N
cement NN N
with IN N
fluoride NN N
( ( N
Cemex-F NNP N
) ) N
, , N
porous-coated JJ N
press-fit JJ N
cup NN N
with IN N
ceramic JJ N
coating NN N
( ( N
Trilogy NNP N
, , N
uncemented VBD N
) ) N
and CC N
acrylic JJ N
cement NN N
with IN N
gentamicin NN i
( ( N
Palacos NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty NNP N
patients NNS p
with IN N
single JJ N
HCC NNP N
? . N
4 CD N
cm NN N
in IN N
diameter NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
15 CD N
patients NNS p
were VBD N
treated VBN N
with IN N
PLA NNP N
, , N
using VBG N
a DT N
multifibre NN N
system NN N
connected VBN N
to TO N
a DT N
neodymium JJ N
yttrium-aluminium-garnet NN N
laser NN N
source NN N
; : N
15 CD N
patients NNS p
were VBD N
treated VBN N
with IN N
RFA NNP N
, , N
using VBG N
an DT N
expandable JJ N
needle JJ N
electrode NN N
. . N

Analysis NN N
of IN N
variance NN N
failed VBD N
to TO N
demonstrate VB N
an DT N
effect NN N
of IN N
either DT N
intervention NN N
on IN N
the DT N
median JJ N
change NN N
in IN N
standardized JJ N
amount NN N
of IN N
benzodiazepines NNS N
prescribed VBN N
per IN N
physician NN N
, , N
with IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
controls NNS N
yielding VBG N
values NNS N
of IN N
-278 NN N
( ( N
range NN N
: : N
-4,137 NN N
, , N
2,844 CD N
) ) N
, , N
-330 NNP N
( ( N
-1,531 NNP N
, , N
1,358 CD N
) ) N
, , N
and CC N
-541 NNP N
( ( N
range NN N
: : N
-3,716 NN N
, , N
2,185 CD N
) ) N
, , N
respectively RB N
. . N

No DT N
systemic JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
, , N
but CC N
severe JJ N
skin NN N
reactions NNS N
occurred VBD N
more RBR N
frequently RB N
in IN N
those DT N
assigned VBN N
to TO N
chlorhexidine-alcohol NN N
( ( N
27 CD N
[ RB N
3 CD N
% NN N
] JJ N
patients NNS p
vs JJ N
seven CD N
[ $ N
1 CD N
% NN N
] NN N
with IN N
povidone JJ i
iodine-alcohol NN N
; : N
p=0 CC N
) ) N
and CC N
led VBN N
to TO N
chlorhexidine VB N
discontinuation NN N
in IN N
two CD N
patients NNS p
. . N

Temporal JJ N
changes NNS N
in IN N
plasma NN N
renin NN N
, , N
angiotensin-II JJ N
, , N
aldosterone NN N
, , N
epinephrine NN N
, , N
norepinephrine JJ N
, , N
B-type JJ N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
, , N
and CC N
N-terminal JJ N
atrial JJ N
natriuretic JJ N
peptide NN N
( ( N
NT-ANP NNP N
) ) N
in IN N
768 CD N
treated JJ N
patients NNS p
with IN N
heart NN N
failure NN N
measured VBN N
at IN N
baseline NN N
and CC N
17 CD N
and CC N
43 CD N
weeks NNS N
after IN N
randomization NN N
were VBD N
examined VBN N
for IN N
their PRP$ N
relations NNS N
with IN N
concurrent NN N
changes NNS N
in IN N
the DT N
EF NNP N
, , N
cardiac JJ N
volumes NNS N
, , N
and CC N
risk NN N
for IN N
subsequent JJ N
adverse JJ N
clinical JJ N
outcomes NNS N
. . N

Extending VBG N
the DT N
surveillance NN N
to TO N
8 CD N
years NNS N
also RB N
tended VBD N
to TO N
increase VB o
the DT N
risk NN N
more RBR N
in IN N
the DT N
group NN N
being VBG N
examined VBN N
every DT N
4 CD N
years NNS N
, , N
but CC N
reduction NN N
of IN N
the DT N
number NN N
of IN N
surveillance NN N
examinations NNS N
by IN N
more JJR N
than IN N
50 CD N
% NN N
and CC N
a DT N
probable JJ N
reduction NN N
of IN N
complications NNS N
from IN N
surveillance NN N
examinations NNS N
themselves PRP N
may MD N
justify VB N
a DT N
recommendation NN N
for IN N
the DT N
longest JJS N
interval NN N
. . N

In IN N
the DT N
first JJ N
study NN N
388 CD N
patients NNS p
with IN N
suspected JJ N
acute JJ N
myocardial JJ N
infarction NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
propranolol NN i
, , N
atenolol NN i
, , N
or CC N
placebo NN N
, , N
and CC N
when WRB N
analysed VBN N
on IN N
an DT N
initial JJ N
intention NN N
to TO N
treat VB N
basis NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
three CD N
groups NNS N
in IN N
respect NN N
of IN N
the DT N
mortality NN N
at IN N
one CD N
year NN N
. . N

With IN N
every DT N
one CD N
point NN N
increase NN o
in IN N
PSQI NNP N
scores NNS N
across IN N
time NN N
, , N
a DT N
woman NN N
's POS N
risk NN N
for IN N
recurrence NN N
increased VBN o
by IN N
approximately RB N
25 CD N
% NN N
There EX N
was VBD N
no DT N
significant JJ N
association NN N
between IN N
PSQI NNP N
scores NNS N
and CC N
IL-6 NNP N
concentrations NNS N
in IN N
early JJ N
postpartum NN N
( ( N
? . N
( ( N
2 CD N
) ) N
=0.98 NN N
, , N
p=.32 NN N
) ) N
. . N

BACKGROUND NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
diabetes NN N
specific JJ N
formula NN N
( ( N
Diason NNP N
low JJ N
energy NN N
: : N
313.8 CD N
kJ/100 NNS N
ml NN N
) ) N
, , N
compared VBN N
with IN N
a DT N
standard JJ N
formula NN N
, , N
on IN N
insulin NN N
sensitivity NN N
, , N
serum JJ N
C NNP N
peptide NN N
, , N
serum JJ N
lipids NNS N
and CC N
free JJ N
fatty NN N
acid NN N
( ( N
FFA NNP N
) ) N
in IN N
type NN N
2 CD N
diabetics NNS N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
safety NN N
and CC N
plaque NN N
removal NN N
efficacy NN N
of IN N
two CD N
oscillating/rotating/pulsating VBG N
toothbrushes NNS N
( ( N
Oral-B NNP N
ProfessionalCare NNP N
7000 CD N
[ NNP N
PC NN N
7000 CD N
] NN N
and CC N
Oral-B JJ N
3D CD N
Excel NNP N
[ VBD N
3DE CD N
] NN N
) ) N
and CC N
a DT N
high-frequency NN N
toothbrush NN N
( ( N
Sonicare NNP N
Advance NNP N
, , N
Philips NNP N
Oral NNP N
Healthcare NNP N
; : N
SA NNP N
) ) N
in IN N
a DT N
single-use NN N
, , N
examiner-blind NN N
, , N
three CD N
period NN N
crossover NN N
study NN N
. . N

From IN N
a DT N
previously RB N
reported VBN N
5-year JJ N
screening VBG N
programme NN N
of IN N
6,956 CD N
47-49-year-old JJ N
Malm NNP N
males NNS N
, , N
a DT N
series NN N
of IN N
41 CD N
subjects NNS N
with IN N
early-stage JJ N
Type NNP N
2 CD N
( ( N
non-insulin-dependent JJ N
) ) N
diabetes VBZ N
mellitus JJ N
and CC N
181 CD N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
were VBD N
selected VBN N
for IN N
prospective JJ N
study NN N
and CC N
to TO N
test VB N
the DT N
feasibility NN N
aspect NN N
of IN N
long-term JJ N
intervention NN N
with IN N
an DT N
emphasis NN N
on IN N
life-style JJ N
changes NNS N
. . N

Increases NNS o
in IN N
PSA NNP N
from IN N
baseline NN N
and CC N
the DT N
maximum JJ N
increase NN o
from IN N
nadir JJ N
to TO N
month NN N
24 CD N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
and CC N
analyzed VBN N
by IN N
prostate NN N
cancer NN N
status NN N
, , N
as IN N
determined VBN N
by IN N
PSA NNP N
driven JJ N
biopsy NN N
and CC N
an DT N
advised JJ N
cutoff NN N
of IN N
more JJR N
than IN N
4 CD N
ng/ml NNS N
after IN N
doubling VBG N
to TO N
correct VB N
for IN N
dutasteride JJ N
treatment NN N
with IN N
sensitivity NN N
and CC N
specificity NN N
calculated VBN N
for IN N
each DT N
. . N

One CD N
thousand CD N
one CD N
hundred CD N
and CC N
twenty-two JJ N
patients NNS p
( ( N
533 CD N
males NNS N
and CC N
589 CD N
females NNS N
; : N
mean JJ N
age NN N
62.2 CD N
+/- JJ N
11.4 CD N
yrs NN N
) ) N
were VBD N
enrolled VBN N
in IN N
a DT N
multicentre NN N
controlled VBN N
study NN N
, , N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
enoxaparin NN N
in IN N
comparison NN N
to TO N
calcium VB N
heparin NN N
in IN N
the DT N
prevention NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
following VBG N
general JJ N
surgery NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
the DT N
diagnostic JJ N
performance NN N
of IN N
three CD N
methods NNS N
commonly RB N
used VBD N
for IN N
GDM NNP N
screening NN N
: : N
fasting NN N
plasma NN N
glucose NN N
( ( N
FPG NNP N
) ) N
, , N
two-step JJ N
50 CD N
g NN N
glucose JJ N
challenge NN N
test NN N
( ( N
GCT NNP N
) ) N
, , N
and CC N
75 CD N
g NN N
glucose JJ N
tolerance NN N
test NN N
( ( N
GTT NNP N
) ) N
in IN N
a DT N
randomized JJ N
study NN N
design NN N
to TO N
predict VB N
GDM NNP N
in IN N
the DT N
first JJ N
trimester NN N
and CC N
determine VB N
the DT N
best JJS N
approach NN N
in IN N
predicting VBG N
GDM NNP N
. . N

Seventy-three JJ N
patients NNS p
undergoing VBG N
elective JJ N
perianal JJ N
surgery NN N
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
control NN N
group NN N
, , N
a DT N
group NN N
who WP N
received VBD N
a DT N
caudal JJ N
injection NN N
of IN N
20 CD N
ml NNS N
bupivacaine VBP N
0.5 CD N
% NN N
plain NN N
and CC N
a DT N
group NN N
who WP N
received VBD N
diamorphine JJ N
2.5 CD N
mg NN N
in IN N
10 CD N
ml NNS N
normal JJ N
saline NN N
by IN N
caudal JJ N
injection NN N
; : N
a DT N
comparison NN N
was VBD N
then RB N
made VBN N
of IN N
postoperative JJ N
analgesia NN N
requirements NNS N
. . N

In IN N
our PRP$ N
study NN N
, , N
vWF NN N
and CC N
factor NN N
VIII NNP N
: : N
C NNP N
levels NNS N
increased VBN o
while IN N
the DT N
bleeding NN N
time NN N
decreased VBN o
significantly RB N
at IN N
90 CD N
min NN N
and CC N
24 CD N
h NN N
in IN N
both DT N
groups NNS N
and CC N
, , N
although IN N
vWF NN N
and CC N
factor NN N
VIII NNP N
: : N
C NN N
levels NNS N
were VBD N
slightly RB N
higher JJR N
in IN N
desmopressin-treated JJ N
patients NNS p
at IN N
90 CD N
min NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

The DT N
interventions NNS N
provided VBD N
identical JJ N
intensity NN N
( ( N
10 CD N
hours NNS N
per IN N
week NN N
in IN N
classroom NN N
) ) N
, , N
student-to-teacher JJ N
ratio NN N
, , N
schedule NN N
, , N
home-based JJ N
parent NN N
training NN N
( ( N
1.5 CD N
hours NNS N
per IN N
month NN N
) ) N
, , N
parent JJ N
education NN N
( ( N
38 CD N
hours NNS N
) ) N
, , N
and CC N
instructional JJ N
strategies NNS N
, , N
except IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
condition NN N
provided VBD N
a DT N
supplementary JJ N
curriculum NN N
targeting VBG N
socially RB N
engaged VBN N
imitation NN N
, , N
joint JJ N
attention NN N
, , N
and CC N
affect JJ N
sharing NN N
; : N
measures NNS N
of IN N
these DT N
were VBD N
primary JJ N
outcomes NNS N
. . N

Furthermore RB N
, , N
after IN N
6 CD N
months NNS N
of IN N
enrichment JJ N
therapy NN i
, , N
21 CD N
% NN N
of IN N
the DT N
children NNS N
who WP N
initially RB N
had VBD N
been VBN N
given VBN N
an DT N
autism NN N
classification NN N
, , N
using VBG N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
, , N
improved VBN N
to TO N
the DT N
point NN N
that IN N
, , N
although IN N
they PRP N
remained VBD N
on IN N
the DT N
autism NN N
spectrum NN N
, , N
they PRP N
no RB N
longer RBR N
met VBD N
the DT N
criteria NNS N
for IN N
classic JJ N
autism NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
622 CD N
men NNS N
and CC N
women NNS N
with IN N
radiological JJ N
evidence NN N
of IN N
primary JJ N
knee NN N
OA NNP N
and CC N
mild VB N
to TO N
severe VB N
symptoms NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
a DT N
topical JJ N
diclofenac NN N
solution NN N
plus CC N
placebo JJ N
oral JJ N
capsules NNS N
, , N
or CC N
placebo VB N
topical JJ N
solution NN N
plus CC N
oral JJ N
diclofenac NN N
( ( N
50 CD N
mg NN N
) ) N
capsules NNS N
. . N

In IN N
addition NN N
, , N
systemic JJ N
exposure NN N
of IN N
risperidone NN i
active JJ N
moiety NN N
( ( N
risperidone JJ i
plus CC N
9-hydroxyrisperidone CD i
) ) N
, , N
the DT N
most RBS N
clinically RB N
relevant JJ N
component NN N
of IN N
risperidone NN i
treatment NN N
, , N
was VBD N
not RB N
affected VBN N
by IN N
galantamine JJ N
coadministration NN N
, , N
while IN N
systemic JJ N
exposure NN N
was VBD N
increased VBN o
by IN N
approximately RB N
10 CD N
% NN N
for IN N
risperidone NN i
and CC N
decreased VBN o
by IN N
about IN N
10 CD N
% NN N
for IN N
9-hydroxyrisperidone CD i
( ( N
active JJ N
metabolite NN N
of IN N
risperidone NN i
) ) N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
, , N
50 CD N
patients NNS p
with IN N
permanent JJ N
atrial JJ N
fibrillation NN N
and CC N
dilated VBD N
left JJ N
atrium NN N
, , N
submitted VBN N
to TO N
surgical JJ N
mitral JJ N
repair NN N
, , N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Group NNP N
I PRP N
contained VBD N
25 CD N
patients NNS p
with IN N
left JJ N
auricular JJ N
reduction NN N
and CC N
mitral JJ N
surgery NN N
, , N
and CC N
Group NNP N
II NNP N
contained VBD N
25 CD N
patients NNS p
with IN N
isolated JJ N
valve NN N
surgery NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
threefold VBN N
: : N
( ( N
1 CD N
) ) N
Assess IN N
the DT N
pressure NN N
loss NN N
of IN N
two CD N
types NNS N
of IN N
pressure NN N
garments NNS N
that WDT N
are VBP N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
hypertrophic JJ N
scars NNS N
after IN N
burn JJ N
injury NN N
, , N
( ( N
2 CD N
) ) N
investigate VB N
the DT N
influence NN N
of IN N
two CD N
different JJ N
levels NNS N
of IN N
compression NN N
on IN N
erythema NN N
and CC N
thickness NN N
of IN N
burn NN N
scars NNS N
and CC N
( ( N
3 CD N
) ) N
examine VBP N
the DT N
association NN N
between IN N
erythema NN N
and CC N
thickness NN N
. . N

Two CD N
hundred VBD N
one CD N
male NN N
and CC N
female JJ N
subjects NNS N
, , N
aged VBD N
20 CD N
to TO N
70 CD N
years NNS N
, , N
with IN N
elevated VBN N
low-density NN N
lipoprotein NN N
cholesterol NN N
values NNS N
( ( N
in IN N
the DT N
75th CD N
to TO N
95th CD N
percentiles NNS N
) ) N
, , N
participated VBN N
in IN N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind NN N
study NN N
using VBG N
a DT N
new JJ N
form NN N
of IN N
niacin NN i
( ( N
Enduracin NNP i
) ) N
, , N
which WDT N
employs VBZ N
a DT N
wax-matrix JJ N
vehicle NN N
for IN N
sustained JJ N
release NN N
. . N

Tailoring VBG N
for IN N
dietary JJ N
intake NN N
was VBD N
performed VBN N
on IN N
data NNS N
from IN N
a DT N
validated JJ N
63-item JJ N
combination NN N
FFQ NNP N
designed VBN N
for IN N
the DT N
purpose JJ N
2 CD N
) ) N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
( ( N
GE NNP N
) ) N
: : N
consisting NN N
of IN N
two CD N
90-minute JJ N
dietitian-led JJ N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
and CC N
3 CD N
) ) N
and CC N
a DT N
wait-listed JJ N
control NN N
( ( N
C NNP N
) ) N
group NN N
who WP N
completed VBD N
the DT N
dietary JJ N
measures NNS N
and CC N
socio-demographic JJ N
questionnaires NNS N
at IN N
baseline NN N
and CC N
3-months JJ N
later NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
a DT N
group NN N
which WDT N
was VBD N
treated VBN N
topically RB N
with IN N
Contractubex NNP N
gel NN N
( ( N
Merz NNP N
+ NNP N
Co. NNP N
, , N
D-Frankfurt/Main NNP N
) ) N
, , N
containing VBG N
10 CD N
% NN N
onion NN N
extract NN N
, , N
50/U CD N
of IN N
sodium NN N
heparin NN N
per IN N
one CD N
g NN N
of IN N
gel NN N
and CC N
1 CD N
% NN N
allantoin NN N
, , N
or CC N
to TO N
a DT N
group NN N
receiving VBG N
no DT N
treatment NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
242 CD N
patients NNS p
with IN N
type JJ N
III NNP N
prostatitis NN N
diagnosed VBN N
by IN N
the DT N
NIH NNP N
criteria NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
experimental JJ N
and CC N
a DT N
control NN N
group NN N
of IN N
equal JJ N
number NN N
, , N
the DT N
former JJ N
treated VBN N
with IN N
Compound NNP N
Xuanju NNP N
Capsule NNP N
+ NNP N
Tamsulosin NNP N
Hydrochloride NNP N
, , N
and CC N
the DT N
latter NN N
with IN N
Quinolinone NNP N
antibiotics NNS N
+ VBP N
Tamsulosin NNP N
and CC N
Hydrochloride NNP N
, , N
both DT N
for IN N
6 CD N
months NNS N
. . N

RESULTS VB N
The DT N
eradication NN N
rate NN N
of IN N
the DT N
cimetidine NN N
group NN N
the DT N
omeprazole NN N
group NN N
, , N
and CC N
the DT N
CBS NNP N
group NN N
were VBD N
0 CD N
% NN N
, , N
7.7 CD N
% NN N
, , N
0 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
that IN N
of IN N
the DT N
double JJ N
therapy NN i
group NN N
and CC N
the DT N
triple JJ N
therapy NN i
group NN N
were VBD N
44.4 CD N
% NN N
and CC N
89.3 CD N
% NN N
, , N
respectively RB N
. . N

Differences NNS N
from IN N
placebo NN N
in IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
were VBD N
not RB N
statistically RB N
significant JJ N
for IN N
vortioxetine NN N
10 CD N
mg NN N
or CC N
vortioxetine NN N
15 CD N
mg. NN N
Nausea NNP N
, , N
headache NN N
, , N
dry JJ N
mouth NN N
, , N
constipation NN N
, , N
diarrhea NN N
, , N
vomiting VBG N
, , N
dizziness NN N
, , N
and CC N
flatulence NN N
were VBD N
reported VBN N
in IN N
? . N
5 CD N
% NN N
of IN N
subjects NNS N
receiving VBG N
vortioxetine NN N
. . N

Calves NNS N
were VBD N
fed VBN N
a DT N
low-concentrate NN N
( ( N
LC NNP N
) ) N
growing VBG N
diet JJ N
, , N
blocked VBN N
by IN N
weight NN N
and CC N
sex NN N
, , N
and CC N
then RB N
randomly RB N
assigned VBN N
to TO N
pens NNS N
to TO N
receive VB N
either RB N
no DT N
additional JJ N
supplement NN N
( ( N
CON NNP N
; : N
n CC N
= VB N
35 CD N
) ) N
or CC N
receive VB N
a DT N
supplement NN N
of IN N
anti-phospholipase JJ N
A2 NNP N
antibody NN N
( ( N
aPLA2 NN N
) ) N
at IN N
an DT N
inclusion NN N
rate NN N
of IN N
0.6 CD N
% NN N
of IN N
the DT N
diet JJ N
DM NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

METHODS NN N
Patients NNS N
( ( N
n=766 JJ N
) ) N
, , N
aged VBD N
18 CD N
to TO N
65 CD N
years NNS N
inclusive JJ N
, , N
with IN N
current JJ N
manic NN N
or CC N
mixed JJ N
episodes NNS N
were VBD N
initially RB N
randomized VBN N
( ( N
4:1 CD N
) ) N
to TO N
flexibly-dosed JJ N
paliperidone NN i
ER NNP N
( ( N
3-12 JJ N
mg/day NN N
) ) N
or CC N
olanzapine JJ N
( ( N
5-20 JJ N
mg/day NN N
; : N
3-week JJ N
acute NN N
treatment NN N
phase NN N
) ) N
; : N
responders NNS N
continued VBD N
the DT N
same JJ N
treatment NN N
( ( N
12-week JJ N
continuation NN N
phase NN N
) ) N
. . N

The DT N
results NNS N
showed VBD N
that IN N
adherence NN N
measures NNS N
varied VBN N
with IN N
lowest JJS N
adherence NN N
from IN N
two CD N
items NNS N
of IN N
self-report NN N
related VBN N
to TO N
forgetfulness VB N
( ( N
46 CD N
and CC N
55 CD N
% NN N
) ) N
and CC N
stringent JJ N
electronic JJ N
monitoring NN N
with IN N
the DT N
MEMS NNP N
( ( N
58 CD N
% NN N
) ) N
to TO N
percentages NNS N
in IN N
the DT N
80-90 JJ N
range NN N
for IN N
other JJ N
self-report JJ N
items NNS N
and CC N
the DT N
general JJ N
adherence NN N
scale NN N
. . N

DESIGN NN N
In IN N
this DT N
double-blind NN N
, , N
prospective JJ N
study NN N
, , N
postmenopausal JJ N
women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
treatment NN N
groups NNS N
: : N
hysterectomized VBN N
women NNS N
were VBD N
assigned VBN N
to TO N
either DT N
1 CD N
) ) N
micronized VBN N
E2 NNP N
( ( N
0.5 CD N
mg NN N
) ) N
or CC N
2 CD N
) ) N
micronized VBN N
E2 NNP N
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN N
T NNP N
( ( N
1.25 CD N
mg NN N
) ) N
. . N

We PRP N
now RB N
report VBP N
the DT N
outcomes NNS N
of IN N
a DT N
similar JJ N
randomized NN N
controlled VBD N
trial NN N
in IN N
which WDT N
children NNS N
with IN N
autism NN N
, , N
3 CD N
to TO N
6 CD N
years NNS N
old JJ N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
groups NNS N
that WDT N
received VBD N
either DT N
daily JJ N
sensorimotor NN N
enrichment NN N
, , N
administered VBN N
by IN N
their PRP$ N
parents NNS N
, , N
along IN N
with IN N
standard JJ N
care NN N
, , N
or CC N
they PRP N
received VBD N
standard JJ N
care NN N
alone RB N
. . N

This DT N
report NN N
examines VBZ N
associations NNS N
of IN N
stages NNS N
of IN N
change NN N
with IN N
diet JJ N
prospectively RB N
and CC N
addresses VBZ N
whether IN N
( ( N
1 CD N
) ) N
baseline NN N
stage NN N
of IN N
change NN N
predicts NNS N
participation NN N
, , N
( ( N
2 CD N
) ) N
forward NN N
changes NNS N
in IN N
stage NN N
movement NN N
were VBD N
greater JJR N
in IN N
treatment NN N
work NN N
sites NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
change NN N
in IN N
stage NN N
was VBD N
associated VBN N
with IN N
adoption NN N
of IN N
healthful JJ N
diets NNS N
, , N
using VBG N
data NNS N
from IN N
a DT N
cohort NN N
of IN N
11,237 CD N
employees NNS N
. . N

At IN N
1 CD N
year NN N
there RB N
was VBD N
a DT N
7 CD N
% NN N
absolute NN N
and CC N
a DT N
24 CD N
% NN N
relative JJ N
risk NN N
reduction NN N
of IN N
death NN N
and CC N
dependency NN N
in IN N
the DT N
coiling VBG N
group NN N
compared VBN N
with IN N
the DT N
clipping VBG N
group NN N
, , N
but CC N
the DT N
medium-term JJ N
results NNS N
showed VBD N
the DT N
increased VBN o
need NN N
for IN N
re-treatment NN N
of IN N
the DT N
target NN N
aneurysm NN N
in IN N
the DT N
patients NNS p
given VBN N
coiling VBG N
. . N

BACKGROUND NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
Interceptor NNP N
, , N
long-lasting JJ N
polyester NN N
net NN N
, , N
75 CD N
denier NN N
and CC N
bursting VBG N
strength NN N
of IN N
minimum JJ N
250 CD N
kPa NN N
coated VBN N
with IN N
alpha-cypermethrin JJ N
@ NNS N
200 CD N
mg/m NN N
was VBD N
evaluated VBN N
for IN N
its PRP$ N
efficacy NN N
in IN N
reducing VBG N
the DT N
mosquito NN N
density NN N
, , N
blood NN N
feeding NN N
inhibition NN N
and CC N
malaria NN N
incidence NN N
in IN N
a DT N
tribal NN N
dominated VBN N
malaria NNS N
endemic JJ N
area NN N
in IN N
Chhattisgarh NNP N
state NN N
, , N
central JJ N
India NNP N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN o
in IN N
mite JJ N
counts NNS N
on IN N
day NN N
7 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
within IN N
treatment NN N
Groups NNP N
A NNP N
and CC N
B NNP N
of IN N
Study NNP N
1 CD N
, , N
but CC N
mite JJ N
counts NNS N
increased VBD o
again RB o
on IN N
day NN N
14 CD N
and CC N
remained VBD N
high JJ N
for IN N
the DT N
duration NN N
of IN N
the DT N
trial NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

In IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
50 CD N
consecutive JJ N
eyes NNS N
, , N
we PRP N
compared VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
draining VBG N
subretinal JJ N
fluid NN N
transchoroidally RB N
in IN N
primary JJ N
scleral JJ N
buckling NN N
for IN N
rhegmatogenous JJ N
retinal JJ N
detachment NN N
using VBG N
a DT N
needle JJ N
, , N
with IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
same JJ N
procedure NN N
using VBG N
an DT N
angulated VBN N
endolaser NN N
probe NN N
set VBN N
at IN N
1 CD N
W NNP N
for IN N
0.2 CD N
seconds NNS N
, , N
using VBG N
an DT N
average NN N
of IN N
2.4 CD N
laser NN N
burns NNS N
. . N

METHODS NNP N
Simplified NNP N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
SDAI NNP N
) ) N
scores VBZ N
, , N
Clinical JJ N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
CDAI NNP N
) ) N
scores VBZ N
, , N
and CC N
the DT N
Disease NNP N
Activity NNP N
Score NNP N
in IN N
28 CD N
joints NNS N
( ( N
DAS28 NNP N
) ) N
were VBD N
calculated VBN N
using VBG N
data NNS N
from IN N
tocilizumab JJ i
trials NNS N
in IN N
patients NNS p
with IN N
RA NNP N
in IN N
whom WP N
disease NN N
had VBD N
remained VBN N
active JJ N
despite IN N
treatment NN N
with IN N
disease-modifying JJ N
antirheumatic JJ N
drugs NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Bronchoalveolar NNP N
lavage NN N
( ( N
BAL NNP N
) ) N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
study NN N
days NNS N
4 CD N
and CC N
7 CD N
to TO N
obtain VB N
BAL NNP N
fluid NN N
( ( N
BALF NNP N
) ) N
for IN N
measurement NN N
of IN N
total JJ N
protein NN N
, , N
ceruloplasmin NN N
, , N
and CC N
transferrin NN N
, , N
total JJ N
neutrophil NN N
count NN N
, , N
IL-8 NNP N
, , N
IL-6 NNP N
, , N
tumor NN N
necrosis NN N
factor-alpha NN N
, , N
and CC N
leukotriene JJ N
B4 NNP N
. . N

OBJECTIVES IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
1 CD N
) ) N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
blood NN N
pressure NN N
and CC N
associated JJ N
neural JJ N
tonicity NN N
in IN N
ambient JJ N
ischemia NN N
of IN N
a DT N
group NN N
of IN N
hypertensive JJ N
patients NNS p
with IN N
stable JJ N
angina NN N
, , N
and CC N
2 CD N
) ) N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
immediate JJ N
release NN N
nifedipine JJ N
therapy NN i
in IN N
controlling VBG N
the DT N
total JJ N
ischemic JJ N
burden NN N
in IN N
both DT N
office-measured JJ N
and CC N
ambulatory JJ N
blood NN N
pressure NN N
. . N

The DT N
Medical NNP N
Research NNP N
Council NNP N
( ( N
MRC NNP N
) ) N
United NNP N
Kingdom NNP N
trial NN N
for IN N
childhood NN N
acute NN N
lymphoblastic JJ N
leukaemia NN N
( ( N
UKALL NNP N
X NNP N
) ) N
randomised VBD N
patients NNS p
aged VBN N
0-14 CD N
years NNS N
inclusive JJ N
with IN N
an DT N
initial JJ N
white JJ N
blood NN N
count NN N
of IN N
less JJR N
than IN N
100 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
to TO N
receive VB N
an DT N
early JJ N
intensification NN N
block NN N
, , N
a DT N
late JJ N
intensification NN N
block NN N
, , N
both DT N
, , N
or CC N
neither DT N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
, , N
comprising VBG N
11 CD N
patients NNS p
with IN N
at IN N
least JJS N
two CD N
screw JJ N
type NN N
implants NNS N
with IN N
bleeding VBG N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
, , N
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
> VBD N
or CC N
=5 JJ N
mm NN N
, , N
and CC N
at IN N
least JJS N
1.5 CD N
mm JJ N
radiographic JJ N
bone NN N
loss NN N
and CC N
exposed VBN N
implant JJ N
threads NNS N
, , N
was VBD N
carried VBN N
out RP N
as IN N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

When WRB N
meloxicam NN N
and CC N
Glu-Ch NNP N
were VBD N
discontinued VBN N
and CC N
the DT N
placebo NN N
commenced VBD N
, , N
a DT N
significant JJ N
proportion NN N
of IN N
the DT N
meloxicam NN N
group NN N
showed VBD N
worsening NN N
of IN N
all PDT N
the DT N
owner-assessed JJ N
scores NNS N
between IN N
day NN N
70 CD N
and CC N
day NN N
98 CD N
, , N
when WRB N
compared VBN N
to TO N
the DT N
Glu-Ch NNP N
group NN N
( ( N
mobility NN N
p=0.01 NN N
; : N
activity NN N
p=0.02 NN N
; : N
temperament JJ N
p=0.04 NN N
; : N
lifestyle CC N
p=0.01 NN N
) ) N
. . N

METHODS NNP N
Sixty-four JJ N
adults NNS N
from IN N
the DT N
original JJ N
91 CD N
participants NNS N
experiencing VBG N
heightened VBN N
anxiety NN N
or CC N
stress JJ N
2-3 JJ N
months NNS N
following VBG N
the DT N
22nd CD N
February NNP N
2011 CD N
earthquake NN N
and CC N
who WP N
had VBD N
been VBN N
randomized VBN N
to TO N
receive VB N
three CD N
different JJ N
doses NNS N
of IN N
micronutrients NNS N
completed VBN N
on-line JJ N
questionnaires NNS N
assessing VBG N
mood NN N
, , N
anxiety NN N
, , N
stress NN N
, , N
and CC N
symptoms NNS N
associated VBN N
with IN N
post-traumatic JJ N
stress NN N
disorder NN N
1 CD N
year NN N
after IN N
completing VBG N
the DT N
initial JJ N
study NN N
. . N

A DT N
randomized JJ N
double JJ N
blind NN N
placebo NN N
controlled VBD N
trial NN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
combined-herbs JJ N
( ( N
SH NNP N
) ) N
given VBN N
with IN N
zidovudine NN N
( ( N
ZDV NNP N
) ) N
and CC N
zalcitabine NN N
( ( N
ddC NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
HIV NNP N
infection NN N
in IN N
Thai NNP N
adults NNS N
was VBD N
conducted VBN N
in IN N
3 CD N
hospitals NNS N
in IN N
northern JJ N
Thailand NNP N
during IN N
2002 CD N
to TO N
2003 CD N
. . N

DESIGN NNP N
Twenty-four CD N
BMT NNP N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
standard JJ N
PN NNP N
containing VBG N
conventional JJ N
amounts NNS N
of IN N
dextrose NN N
, , N
amino JJ N
acids NNS N
, , N
micronutrients NNS N
, , N
and CC N
lipid JJ N
( ( N
120 CD N
kJ/d NN N
) ) N
or CC N
a DT N
solution NN N
containing VBG N
only JJ N
micronutrients NNS N
( ( N
identical JJ N
to TO N
those DT N
in IN N
standard JJ N
PN NNP N
) ) N
and CC N
a DT N
small JJ N
amount NN N
of IN N
lipid JJ N
( ( N
12 CD N
kJ/d NN N
) ) N
. . N

We PRP N
compared VBN N
the DT N
onset NN N
of IN N
neuromuscular JJ N
block NN N
with IN N
succinylcholine NN N
( ( N
1 CD N
mg RB N
kg-1 NN N
) ) N
and CC N
two CD N
doses NNS N
of IN N
rocuronium NN N
( ( N
0.6 CD N
and CC N
0.9 CD N
mg JJ N
kg-1 NN N
) ) N
at IN N
the DT N
adductor NN N
pollicis NN N
muscle NN N
using VBG N
electromyography NN N
( ( N
EMG NNP N
) ) N
and CC N
acceleromyography NN N
( ( N
AMG NNP N
) ) N
, , N
and CC N
at IN N
the DT N
adductor NN N
laryngeal NN N
muscles NNS N
with IN N
a DT N
new JJ N
electromyographic JJ N
method NN N
using VBG N
a DT N
disposable JJ N
surface NN N
electrode NN N
attached VBN N
to TO N
the DT N
cuff NN N
of IN N
a DT N
tracheal JJ N
tube NN N
. . N

The DT N
secondary JJ N
events NNS N
during IN N
the DT N
first JJ N
14 CD N
days NNS N
also RB N
revealed VBD N
no DT N
benefit NN N
of IN N
dalteparin NN N
compared VBN N
with IN N
aspirin NN N
: : N
symptomatic JJ N
cerebral JJ N
haemorrhage NN N
6/224 CD N
versus NN N
4/225 CD N
; : N
symptomatic JJ N
and CC N
asymptomatic JJ N
cerebral JJ N
haemorrhage NN N
26/224 CD N
versus NN N
32/225 CD N
; : N
progression NN N
of IN N
symptoms NNS N
within IN N
the DT N
first JJ N
48 CD N
hours NNS N
24/224 CD N
versus NN N
17/225 CD N
; : N
and CC N
death NN N
21/224 CD N
versus NN N
16/225 CD N
. . N

RESULT NNP N
Compared NNP N
with IN N
the DT N
placebo NN N
group NN N
, , N
the DT N
scores NNS N
for IN N
hot JJ N
flashes NNS N
and CC N
excessive JJ N
sweating NN N
were VBD N
significantly RB N
reduced VBN N
after IN N
3 CD N
months NNS N
, , N
and CC N
the DT N
scores NNS N
for IN N
weakness NN N
, , N
palpitations NNS N
, , N
limb NN N
paresthesia NN N
, , N
and CC N
total JJ N
symptoms NNS N
after IN N
6 CD N
months NNS N
, , N
in IN N
the DT N
EP NNP N
group NN N
only RB N
. . N

The DT N
secondary JJ N
outcomes NNS N
were VBD N
a DT N
hemoglobin JJ N
drop NN N
of IN N
30 CD N
mg/L NN N
or CC N
greater JJR N
, , N
the DT N
use NN N
of IN N
additional JJ N
oxytocin NN i
, , N
an DT N
estimated VBN N
blood NN N
loss NN N
greater JJR N
than IN N
1000 CD N
mL NN N
, , N
manual JJ N
removal NN N
of IN N
the DT N
placenta NN N
, , N
a DT N
blood NN N
transfusion NN N
, , N
and CC N
shivering VBG N
and CC N
fever NN N
( ( N
> JJ N
or=38 NN N
degrees NNS N
C NNP N
) ) N
as IN N
adverse JJ N
effects NNS N
of IN N
misoprostol NN N
. . N

The DT N
authors NNS N
herein VBP N
present JJ N
their PRP$ N
personal JJ N
series NN N
on IN N
the DT N
clinical JJ N
evaluation NN N
of IN N
the DT N
analgesic JJ N
efficacy NN N
of IN N
2 CD N
opiodes NNS N
, , N
peridural JJ N
morphine NN N
hydrochloride NN N
( ( N
0.5 CD N
mg/kg NN N
) ) N
administered VBD N
to TO N
group NN N
A NNP N
patients NNS p
, , N
and CC N
sublingual JJ N
buprenorphine NN N
( ( N
0.4 CD N
mg NN N
) ) N
administered VBD N
to TO N
group NN N
B NNP N
patients NNS p
in IN N
the DT N
management NN N
of IN N
post-operative JJ N
pain NN N
in IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

We PRP N
compared VBN N
the DT N
test NN N
performances NNS N
of IN N
high-risk JJ N
HPV NNP N
testing NN N
( ( N
Hybrid JJ N
Capture NNP N
2 CD N
) ) N
using VBG N
self-collected JJ N
and CC N
clinician-collected JJ N
samples NNS N
as RB N
well RB N
as IN N
cervical JJ N
cytology NN N
for IN N
identifying VBG N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grades NNS N
2 CD N
or CC N
3 CD N
or CC N
invasive JJ N
cervical JJ N
cancer NN N
( ( N
CIN2+ NNP N
) ) N
among IN N
women NNS N
who WP N
did VBD N
( ( N
n=812 NN N
) ) N
and CC N
did VBD N
not RB N
( ( N
n=1858 JJ N
) ) N
undergo VBP N
cryotherapy NN i
in IN N
a DT N
South JJ N
African JJ N
screen-and-treat JJ N
trial NN N
. . N

METHODS NNP N
In IN N
a DT N
population-based JJ N
screening NN N
program NN N
in IN N
Sweden NNP N
, , N
12,527 CD N
women NNS N
32 CD N
to TO N
38 CD N
years NNS N
of IN N
age NN N
were VBD N
randomly RB N
assigned VBN N
at IN N
a DT N
1:1 CD N
ratio NN N
to TO N
have VB N
an DT N
HPV NNP N
test NN N
plus CC N
a DT N
Papanicolaou NNP N
( ( N
Pap NNP N
) ) N
test NN N
( ( N
intervention NN N
group NN N
) ) N
or CC N
a DT N
Pap JJ N
test NN N
alone RB N
( ( N
control VB N
group NN N
) ) N
. . N

To TO N
identify VB N
the DT N
risk NN N
factors NNS N
for IN N
the DT N
development NN N
of IN N
postoperative JJ N
septic JJ N
complications NNS N
in IN N
patients NNS p
with IN N
intestinal JJ N
perforation NN N
after IN N
abdominal JJ N
trauma NN N
, , N
and CC N
to TO N
compare VB N
the DT N
efficacies NNS N
of IN N
single-drug JJ N
and CC N
dual-drug JJ N
prophylactic JJ N
antibiotic JJ i
therapy NN i
, , N
we PRP N
studied VBD N
145 CD N
patients NNS p
who WP N
presented VBD N
with IN N
abdominal JJ N
trauma NN N
and CC N
intestinal JJ N
perforation NN N
at IN N
two CD N
hospitals NNS N
between IN N
July NNP N
1979 CD N
and CC N
June NNP N
1982 CD N
. . N

All DT N
patients NNS p
were VBD N
treated VBN N
with IN N
CsA NNP N
for IN N
the DT N
first JJ N
10 CD N
days NNS N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
Evr NNP N
in IN N
combination NN N
with IN N
CsA NNP N
up RB N
to TO N
day NN N
30 CD N
, , N
then RB N
either DT N
continued VBN N
on IN N
Evr NNP N
monotherapy NN i
( ( N
Evr NNP N
group NN N
) ) N
or CC N
maintained VBN N
on IN N
CsA NNP N
with/without NN N
mycophenolate NN N
mofetil NN N
( ( N
CsA NNP N
group NN N
) ) N
in IN N
case NN N
of IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
. . N

The DT N
main JJ N
problem NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
difficulty NN N
in IN N
recruiting VBG N
an DT N
adequate JJ N
number NN N
of IN N
patients NNS p
and CC N
following VBG N
them PRP N
for IN N
a DT N
sufficient JJ N
period NN N
of IN N
time NN N
: : N
general JJ N
conditions NNS N
rapidly RB N
deteriorated VBD N
in IN N
many JJ N
patients NNS p
, , N
and CC N
approximately RB N
25 CD N
% NN N
of IN N
the DT N
66 CD N
enrolled NNS N
were VBD N
not RB N
considered VBN N
evaluable JJ N
; : N
few JJ N
patients NNS p
survived VBD N
for IN N
the DT N
length NN N
of IN N
the DT N
study NN N
, , N
one CD N
year NN N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
triple JJ N
combination NN N
cream NN N
with IN N
fluocinolone NN N
acetonide RB N
0.01 CD N
% NN N
, , N
hydroquinone CD N
4 CD N
% NN N
and CC N
tretinoin VB N
0.05 CD N
% NN N
as IN N
adjuvant NN N
to TO N
cryotherapy VB i
in IN N
the DT N
treatment NN N
of IN N
solar JJ N
lentigines NNS N
in IN N
hands NNS N
dorsum JJ N
, , N
and CC N
in IN N
the DT N
prevention NN N
of IN N
post-inflammatory JJ N
hyperpigmentation NN N
after IN N
cryotherapy NN i
. . N

Primary JJ N
endpoints NNS N
were VBD N
a DT N
composite NN N
of IN N
an DT N
AIDS-defining JJ N
event NN N
, , N
death NN N
, , N
or CC N
CD4 NNP N
cell VBP N
count NN N
decline NN N
to TO N
less JJR N
than IN N
200 CD N
cells NNS N
per IN N
mm3 NN N
for IN N
the DT N
PI NNP N
versus NN N
NNRTI NNP N
comparison NN N
, , N
and CC N
average JJ N
change NN N
in IN N
CD4 NNP N
cell NN N
count NN N
at IN N
or CC N
after IN N
32 CD N
months NNS N
for IN N
the DT N
three-class JJ N
versus NN N
combined VBD N
two-class JJ N
comparison NN N
. . N

OBJECTIVE NNP N
As IN N
part NN N
of IN N
a DT N
prospective JJ N
study NN N
of IN N
possible JJ N
effects NNS N
of IN N
early-life JJ N
otitis NN N
media NNS N
on IN N
speech NN N
, , N
language NN N
, , N
cognitive JJ N
, , N
and CC N
psychosocial JJ N
development NN N
, , N
we PRP N
tested VBD N
relationships NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
duration NN N
of IN N
middle JJ N
ear JJ N
effusion NN N
( ( N
MEE NNP N
) ) N
in IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
and CC N
their PRP$ N
scores NNS N
on IN N
measures NNS N
of IN N
language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

AIMS NNP N
( ( N
1 CD N
) ) N
To TO N
examine VB N
the DT N
matching JJ N
hypothesis NN N
that WDT N
Twelve NNP N
Step NNP N
Facilitation NNP N
Therapy NNP N
( ( N
TSF NNP N
) ) N
is VBZ N
more RBR N
effective JJ N
than IN N
Motivational NNP N
Enhancement NNP N
Therapy NNP N
( ( N
MET NNP N
) ) N
for IN N
alcohol-dependent JJ N
clients NNS N
with IN N
networks NNS N
highly RB N
supportive JJ N
of IN N
drinking VBG N
3 CD N
years NNS N
following VBG N
treatment NN N
; : N
( ( N
2 CD N
) ) N
to TO N
test VB N
a DT N
causal NN N
chain NN N
providing VBG N
the DT N
rationale NN N
for IN N
this DT N
effect NN N
. . N

This DT N
phase NN N
2 CD N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
evaluated VBD N
an DT N
IFN- JJ N
and CC N
RBV-free JJ N
regimen NNS N
of IN N
once-daily JJ N
ombitasvir NN N
( ( N
ABT-267 NNP N
) ) N
, , N
an DT N
NS5A NNP N
inhibitor NN N
, , N
plus CC N
paritaprevir NN N
( ( N
ABT-450 NNP N
) ) N
, , N
an DT N
NS3/4A NNP N
protease NN N
inhibitor NN N
dosed VBD N
with IN N
ritonavir NN N
( ( N
paritaprevir/ritonavir NN N
) ) N
, , N
in IN N
pegylated JJ N
IFN/RBV NNP N
treatment-experienced JJ N
Japanese JJ N
patients NNS p
with IN N
hepatitis NN N
C NNP N
virus NN N
subtype NN N
1b CD N
or CC N
genotype VB N
2 CD N
infection NN N
. . N

Diclofenac NNP N
reduced VBD N
the DT N
anti-aggregatory JJ N
action NN N
of IN N
aspirin NN N
in IN N
the DT N
first JJ N
two CD N
days NNS N
, , N
since IN N
the DT N
CT NNP N
did VBD N
not RB N
rise VB N
significantly RB N
( ( N
109+/-19 JJ N
s NN N
, , N
148+/-56 JJ N
s NN N
, , N
and CC N
168+/-66 JJ N
s NN N
at IN N
0 CD N
h NN N
, , N
24 CD N
h NN N
, , N
48 CD N
h NN N
, , N
respectively RB N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
a DT N
1-month JJ N
washout NN N
placebo NN N
period NN N
, , N
using VBG N
a DT N
double-blind JJ N
crossover NN N
design NN N
, , N
the DT N
patients NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
nifedipine VB N
( ( N
20 CD N
mg NN N
twice RB N
a DT N
day NN N
) ) N
, , N
chlorthalidone NN i
( ( N
25 CD N
mg NN N
once RB N
a DT N
day NN N
) ) N
, , N
the DT N
two CD N
drugs NNS N
combined VBN N
at IN N
the DT N
same JJ N
doses NNS N
and CC N
the DT N
corresponding JJ N
placebo NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Eight NNP N
cirrhotics NNS N
( ( N
Child NNP N
's POS N
B NNP N
or CC N
C NNP N
) ) N
without IN N
transjugular JJ N
intrahepatic JJ N
portosystemic JJ N
shunts NNS N
( ( N
TIPS NNP N
) ) N
and CC N
seven CD N
with IN N
TIPS NNP N
underwent JJ N
two CD N
oral JJ N
glutamine NN N
( ( N
20 CD N
g NN N
) ) N
challenges VBZ N
, , N
receiving VBG N
LOLA NNP N
( ( N
5 CD N
g RB N
intravenously RB N
) ) N
on IN N
one CD N
occasion NN N
and CC N
placebo NN N
on IN N
the DT N
other JJ N
in IN N
random JJ N
order NN N
. . N

When WRB N
prevaccination NN N
IgG NNP N
levels NNS N
( ( N
mean VB N
+ RB N
3 CD N
standard JJ N
deviations NNS N
) ) N
were VBD N
used VBN N
to TO N
determine VB N
a DT N
negative JJ N
cut-off NN N
, , N
a DT N
low JJ N
percentage NN N
( ( N
< JJ N
38 CD N
% NN N
) ) N
of IN N
vaccinees NNS N
converted VBN N
to TO N
responder VB N
status NN N
for IN N
either DT N
anti-mycobacterial JJ N
or CC N
anti-leishmanial JJ N
responses NNS N
, , N
and CC N
those DT N
who WP N
did VBD N
would MD N
be VB N
classified VBN N
as IN N
'low-responder NN N
' '' N
status NN N
compared VBN N
with IN N
titres NNS N
observed VBN N
in IN N
severe JJ N
forms NNS N
of IN N
disease NN N
. . N

However RB N
, , N
nicotinic JJ N
acid NN N
therapy NN i
resulted VBD N
in IN N
the DT N
deterioration NN N
of IN N
glycemic JJ N
control NN N
, , N
as IN N
evidenced VBN N
by IN N
a DT N
16 CD N
% NN N
increase NN o
in IN N
mean JJ N
plasma NN N
glucose JJ N
concentrations NNS N
, , N
a DT N
21 CD N
% NN N
increase NN o
in IN N
glycosylated JJ N
hemoglobin NN N
levels NNS N
, , N
and CC N
the DT N
induction NN N
of IN N
marked JJ N
glycosuria NN N
in IN N
some DT N
patients NNS p
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
consistent JJ N
tendency NN N
for IN N
RSA NNP N
times NNS N
to TO N
be VB N
slower JJR N
after IN N
the DT N
static JJ N
stretching NN N
intervention NN N
, , N
which WDT N
was VBD N
supported VBN N
by IN N
statistical JJ N
significance NN N
for IN N
three CD N
performance NN N
variables NNS N
( ( N
MST NNP N
0-5 NNP N
m NN N
set NN N
2 CD N
, , N
MST NNP N
0-20 NNP N
m NN N
set NN N
2 CD N
, , N
and CC N
TST NNP N
set VBD N
2 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
age-standardized JJ N
prevalences NNS N
of IN N
metabolic JJ N
syndrome NN N
were VBD N
16.2 CD N
% NN N
, , N
32.2 CD N
% NN N
, , N
and CC N
28.3 CD N
% NN N
in IN N
men NNS N
and CC N
26.8 CD N
% NN N
, , N
37.2 CD N
% NN N
, , N
and CC N
34.6 CD N
% NN N
in IN N
women NNS N
, , N
according VBG N
to TO N
the DT N
definitions NNS N
of IN N
the DT N
NCEP NNP N
2004 CD N
, , N
NCEP NNP N
2005 CD N
, , N
and CC N
IDF NNP N
, , N
respectively RB N
. . N

METHODS NNP N
49 CD N
Malnourished NNP N
( ( N
weight JJ N
loss NN N
> VBZ N
10 CD N
% NN N
) ) N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS p
who WP N
were VBD N
included VBN N
in IN N
a DT N
nutrition NN N
intervention NN N
trial NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
no DT N
preoperative JJ N
and CC N
standard JJ N
postoperative JJ N
tube-feeding NN N
( ( N
group NN N
I PRP N
) ) N
, , N
standard JJ N
preoperative NN N
and CC N
postoperative JJ N
tube-feeding NN N
( ( N
group NN N
II NNP N
) ) N
or CC N
arginine-supplemented JJ N
preoperative NN N
and CC N
postoperative JJ N
tube-feeding NN N
( ( N
group NN N
III NNP N
) ) N
. . N

At IN N
a DT N
cut-off NN N
of IN N
26 CD N
, , N
the DT N
AQ-J NNP N
had VBD N
satisfactory JJ N
sensitivity NN N
, , N
specificity NN N
, , N
and CC N
negative JJ N
predictive JJ N
value NN N
, , N
but CC N
it PRP N
had VBD N
low JJ N
positive JJ N
predictive NN N
value NN N
( ( N
0.24 CD N
) ) N
possibly RB N
due JJ N
to TO N
the DT N
facts NNS N
that IN N
the DT N
25 CD N
mild JJ N
HPDD NNP N
patients NNS p
scored VBD N
lower JJR N
and CC N
the DT N
controls NNS N
scored VBD N
higher JJR N
on IN N
the DT N
AQ-J NNP N
than IN N
British NNP N
counterparts NNS N
on IN N
the DT N
AQ NNP N
. . N

INTERVENTIONS NNP N
After IN N
a DT N
6-hr-period JJ N
of IN N
protective JJ N
conventional JJ N
mechanical JJ N
ventilation NN N
, , N
patients NNS p
were VBD N
submitted VBN N
to TO N
three CD N
1-hr JJ N
periods NNS N
of IN N
high-frequency NN N
oscillatory NN N
ventilation NN N
( ( N
+5 JJ N
, , N
+10 NNP N
, , N
+15 NNP N
) ) N
in IN N
a DT N
randomized JJ N
order NN N
, , N
with IN N
a DT N
mean JJ N
airway NN N
pressure NN N
level NN N
determined VBN N
by IN N
adding VBG N
5 CD N
, , N
10 CD N
, , N
or CC N
15 CD N
cm NNS N
H2O NNP N
to TO N
the DT N
mean JJ N
airway NN N
pressure NN N
recorded VBN N
during IN N
conventional JJ N
mechanical JJ N
ventilation NN N
. . N

STUDY NNP N
DESIGN NNP N
Fifty-five JJ N
children NNS N
with IN N
cancer NN N
and CC N
eight CD N
children NNS N
given VBN N
total JJ N
parenteral JJ N
nutrition NN N
by IN N
the DT N
surgery NN N
or CC N
nutrition NN N
support NN N
services NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
heparin NN N
CVC NNP N
flush JJ N
solution NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
a DT N
heparin-vancomycin JJ i
CVC NNP N
flush NN N
solution NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
. . N

The DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
of IN N
a DT N
fixed VBN N
dose JJ N
combination NN N
tablet NN N
of IN N
lamivudine NN N
( ( N
CAS NNP N
134678-17-4 CD N
) ) N
and CC N
stavudine NN N
( ( N
CAS NNP N
3056-17-5 CD N
) ) N
with IN N
the DT N
concurrent JJ N
administration NN N
of IN N
lamivudine JJ N
tablet NN N
and CC N
stavudine NN N
capsule NN N
in IN N
24 CD N
healthy JJ N
volunteers NNS N
under IN N
fasting VBG N
conditions NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
, , N
a DT N
total NN N
of IN N
56,294 CD N
men NNS N
aged VBN N
55-74 CD N
years NNS N
were VBD N
screened VBN N
with IN N
serum NN N
prostate NN N
specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
in IN N
five CD N
countries NNS N
of IN N
the DT N
European NNP N
Randomised VBD N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP N
Cancer NNP N
( ( N
ERSPC NNP N
) ) N
with IN N
an DT N
overall JJ i
detection NN N
rate NN N
( ( N
prevalence NN N
) ) N
of IN N
2.8 CD N
% NN N
( ( N
1972 CD N
prostate NN N
cancers NNS N
) ) N
. . N

The DT N
overall JJ i
results NNS N
show VBP N
that IN N
of IN N
the DT N
four CD N
possible JJ N
treatment NN N
randomizations NNS N
, , N
four CD N
courses NNS N
of IN N
chemotherapy NN i
alone NN N
is VBZ N
inferior JJ N
in IN N
terms NNS N
of IN N
overall JJ i
survival NN N
( ( N
30 CD N
weeks NNS N
median JJ N
survival NN N
) ) N
to TO N
the DT N
other JJ N
three CD N
treatment NN N
options NNS N
( ( N
39 CD N
weeks NNS N
median JJ N
survival NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
experience NN N
leading VBG N
to TO N
withdrawal VB N
was VBD N
rash NN N
, , N
with IN N
approximately RB N
double JJ N
the DT N
proportion NN N
of IN N
reports NNS N
occurring VBG N
in IN N
patients NNS p
on IN N
CBZ NNP N
600 CD N
( ( N
5.1 CD N
% NN N
) ) N
compared VBN N
with IN N
lamotrigine NN N
( ( N
1.7 CD N
% NN N
on IN N
LTG NNP N
100 CD N
and CC N
2.7 CD N
% NN N
on IN N
LTG NNP N
200 CD N
) ) N
. . N

RESULTS NNP N
Both NNP N
treatments NNS N
resulted VBD N
in IN N
significant JJ N
and CC N
progressive JJ N
improvement NN N
in IN N
overall JJ i
mental JJ N
health NN N
at IN N
follow-up NN N
( ( N
F NNP N
= NNP N
2 CD N
, , N
97 CD N
, , N
p FW N
=.007 NN N
) ) N
and CC N
mental JJ N
health NN N
significantly RB N
improved VBN N
over RP N
time NN N
in IN N
the DT N
54 CD N
% NN N
of IN N
principal JJ N
caregivers NNS N
who WP N
had VBD N
the DT N
highest JJS N
levels NNS N
of IN N
mental JJ N
health NN N
problems NNS N
. . N

METHODS NNP N
Ninety NNP N
participants NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
( ( N
80 CD N
men/10 NN N
women NNS N
, , N
mean JJ N
age NN N
57 CD N
? . N
8 CD N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
exercise NN N
modes NNS N
: : N
group NN N
exercise NN N
( ( N
GE NNP N
) ) N
, , N
treadmill JJ N
exercise NN N
( ( N
TE NNP N
) ) N
, , N
or CC N
home-based JJ N
exercise NN N
( ( N
HE NNP N
) ) N
. . N

RESULTS NNP N
After IN N
6 CD N
and CC N
12 CD N
months NNS N
, , N
whereas JJ N
patients NNS p
treated VBD N
only RB N
with IN N
calcium NN N
and CC N
cholecalciferol NN N
( ( N
group NN N
A NNP N
) ) N
showed VBD N
a DT N
marked JJ N
bone NN N
loss NN N
, , N
with IN N
increased JJ o
levels NNS N
of IN N
DPD NNP N
and CC N
BALP NNP N
compared VBN N
with IN N
baseline NN N
values NNS N
, , N
patients NNS p
treated VBD N
also RB N
with IN N
neridronate NN N
( ( N
group NN N
B NNP N
) ) N
had VBD N
substantially RB N
unchanged JJ N
levels NNS N
of IN N
these DT N
markers NNS N
. . N

We PRP N
enrolled VBD N
1,164 CD N
patients NNS p
stratified VBN N
by IN N
ethnicity NN N
and CC N
language NN N
( ( N
49.3 CD N
% NN N
non-Hispanic JJ N
, , N
27.2 CD N
% NN N
Hispanic/English NNP N
, , N
23.4 CD N
% NN N
Hispanic/Spanish NNP N
) ) N
from IN N
26 CD N
offices NNS N
around IN N
5 CD N
centers NNS N
( ( N
Sacramento NNP N
, , N
California NNP N
; : N
Rochester NNP N
and CC N
the DT N
Bronx NNP N
, , N
New NNP N
York NNP N
; : N
Denver NNP N
, , N
Colorado NNP N
; : N
and CC N
San NNP N
Antonio NNP N
, , N
Texas NNP N
) ) N
. . N

The DT N
results NNS N
of IN N
a DT N
multicenter NN N
, , N
randomized VBN N
trial NN N
on IN N
the DT N
effect NN N
of IN N
intravenous JJ N
administration NN N
of IN N
gamma JJ N
globulin NN N
( ( N
IVGG NNP N
) ) N
plus CC N
aspirin JJ N
versus NN N
aspirin NN N
alone RB N
upon IN N
coronary JJ N
aneurysm NN N
formation NN N
show VBP N
a DT N
decrease NN o
in IN N
coronary JJ N
aneurysm NN N
formation NN N
from IN N
the DT N
usual JJ N
20 CD N
% NN N
-30 NN N
% NN N
to TO N
3 CD N
% NN N
. . N

Thirty-two JJ N
patients NNS p
awaiting VBG N
a DT N
total JJ N
hip NN N
arthroplasty NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
, , N
( ( N
A DT N
) ) N
, , N
to TO N
have VB N
six CD N
sessions NNS N
of IN N
acupuncture NN N
each DT N
lasting VBG N
up RP N
to TO N
25 CD N
minutes NNS N
, , N
or CC N
the DT N
control NN N
group NN N
, , N
( ( N
B NNP N
) ) N
, , N
to TO N
be VB N
given VBN N
advice NN N
and CC N
exercises NNS N
for IN N
their PRP$ N
hip NN N
over IN N
a DT N
six CD N
week NN N
period NN N
. . N

In IN N
a DT N
randomized JJ N
crossover NN N
design NN N
controlled VBD N
feeding NN N
study NN N
, , N
each DT N
participant NN N
( ( N
a DT N
total NN N
of IN N
23 CD N
; : N
5-12 JJ N
per IN N
group NN N
) ) N
consumed VBD N
the DT N
experimental JJ N
diet NN N
( ( N
1.5 CD N
cups NNS N
of IN N
cooked JJ N
dry JJ N
beans NNS N
) ) N
and CC N
a DT N
control NN N
diet NN N
( ( N
isocaloric JJ N
average JJ N
American JJ N
diet NN N
) ) N
for IN N
4 CD N
weeks NNS N
with IN N
a DT N
3-week JJ N
washout NN N
period NN N
between IN N
diets NNS N
. . N

RESULTS VB N
The DT N
mean JJ N
FVIIa NNP N
activity NN N
was VBD N
measurable JJ N
for IN N
up IN N
to TO N
at IN N
least JJS N
72 CD N
h NN N
after IN N
dosing VBG N
, , N
and CC N
the DT N
overall JJ i
mean NN N
t NN N
( ( N
1/2 CD N
) ) N
for IN N
FVIIa NNP N
activity NN N
was VBD N
15 CD N
h. PDT N
The DT N
pharmacokinetics NNS N
of IN N
N7-GP NNP N
appeared VBD N
to TO N
be VB N
dose-proportional JJ N
in IN N
the DT N
dose JJ N
range NN N
investigated VBN N
. . N

Individuals NNS N
with IN N
high JJ N
levels NNS N
of IN N
BP NNP N
features NNS N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
and CC N
controls NNS N
with IN N
low JJ N
levels NNS N
of IN N
BP NNP N
features NNS N
( ( N
n JJ N
= NNP N
44 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
condition NN N
involving VBG N
negative JJ N
evaluation NN N
based VBN N
on IN N
writing NN N
( ( N
negative JJ N
evaluation/academic NN N
) ) N
, , N
or CC N
a DT N
condition NN N
involving VBG N
negative JJ N
evaluation NN N
based VBN N
on IN N
personal JJ N
characteristics NNS N
as RB N
well RB N
as IN N
social JJ N
rejection NN N
( ( N
negative JJ N
evaluation/social JJ N
rejection NN N
) ) N
. . N

To TO N
address VB N
the DT N
need NN N
for IN N
improved JJ N
educational JJ N
outcomes NNS N
, , N
a DT N
previously RB N
tested VBN N
consultation NN N
intervention NN N
called VBD N
the DT N
Collaborative NNP N
Model NNP N
for IN N
Promoting VBG N
Competence NNP N
and CC N
Success NNP N
( ( N
COMPASS NNP N
; : N
Ruble NNP N
, , N
Dalrymple NNP N
, , N
& CC N
McGrew NNP N
, , N
2010 CD N
; : N
Ruble NNP N
, , N
Dalrymple NNP N
, , N
& CC N
McGrew NNP N
, , N
2012 CD N
) ) N
was VBD N
evaluated VBN N
in IN N
a DT N
2nd CD N
randomized VBN N
controlled VBN N
trial NN N
, , N
with IN N
the DT N
addition NN N
of IN N
a DT N
web-based JJ N
group NN N
. . N

When WRB N
comparing VBG N
the DT N
efficacy NN N
of IN N
the DT N
three CD N
randomized VBN N
therapeutic JJ N
regimens NNS N
while IN N
on IN N
the DT N
Na+ NNP N
supplement NN N
, , N
the DT N
valsartan NN N
160 CD N
mg/HCTZ NN N
12.5 CD N
mg NN N
was VBD N
the DT N
most RBS N
effective JJ N
therapy NN i
with IN N
an DT N
incremental JJ N
reduction NN N
in IN N
blood NN N
pressure NN N
of IN N
-10.5/-6.9 NNP N
mm FW N
Hg NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
compared VBN N
to TO N
valsartan VB N
160 CD N
mg/day JJ N
alone RB N
. . N

RESULTS JJ N
Devices NNPS N
were VBD N
used VBN N
in IN N
138/150 CD N
allocated JJ N
to TO N
AS NNP N
and CC N
124/150 CD N
allocated VBN N
to TO N
SC NNP N
patients NNS p
( ( N
92 CD N
% NN N
vs. FW N
83 CD N
% NN N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
Patients NNS N
with IN N
MC NNP N
experienced VBD N
more JJR N
pain NN N
during IN N
sheath NN N
removal NN N
than IN N
patients NNS p
receiving VBG N
a DT N
device NN N
, , N
and CC N
rated VBD N
their PRP$ N
period NN N
of IN N
bed NN N
rest NN N
as IN N
less RBR N
comfortable JJ N
. . N

This DT N
sample NN N
size NN N
will MD N
allow VB N
for IN N
the DT N
detection NN N
of IN N
a DT N
33 CD N
% NN N
decrease NN o
in IN N
2-year JJ N
mortality NN N
( ( N
20 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
patients NNS p
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
a DT N
power NN N
of IN N
0.90 CD N
and CC N
a DT N
2-sided JJ N
alpha JJ N
level NN N
of IN N
0.05 CD N
. . N

PARTICIPANTS NNS N
Participants NNS N
( ( N
N=20 NNP N
) ) N
who WP N
were VBD N
community-living JJ N
older JJR N
adults NNS N
at IN N
least JJS N
65 CD N
years NNS N
old JJ N
( ( N
mean JJ N
age NN N
, , N
70y CD N
) ) N
, , N
50 CD N
% NN N
women NNS N
, , N
and CC N
who WP N
had VBD N
no DT N
experience NN N
of IN N
using VBG N
a DT N
wheelchair NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
an DT N
intervention NN N
( ( N
n=10 JJ N
) ) N
or CC N
control NN N
( ( N
n=10 JJ N
) ) N
group NN N
. . N

Fifty-one CD N
pairs NNS N
of IN N
premenarcheal JJ N
female NN N
twins NNS N
( ( N
27 CD N
monozygotic NN i
and CC N
24 CD N
dizygotic JJ i
; : N
mean JJ N
+/- JJ N
sd NN N
age NN N
, , N
10.3 CD N
+/- JJ N
1.5 CD N
yr NN N
) ) N
participated VBD N
in IN N
a DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
with IN N
one CD N
twin NN N
of IN N
each DT N
pair NN N
receiving VBG N
a DT N
1200-mg JJ N
calcium NN N
carbonate NN N
( ( N
Caltrate NNP N
) ) N
supplement NN N
. . N

During IN N
the DT N
1-hour JJ N
study NN N
period NN N
, , N
the DT N
incidence NN N
of IN N
central JJ N
nervous JJ N
system NN N
side NN N
effects NNS N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
lidocaine NN N
group NN N
, , N
hypotension NN N
occurred VBD N
in IN N
11 CD N
patients NNS p
, , N
nine CD N
of IN N
whom WP N
had VBD N
received VBN N
lidocaine NN N
, , N
and CC N
four CD N
patients NNS p
died VBD N
from IN N
asystole NN N
, , N
three CD N
of IN N
whom WP N
had VBD N
had VBN N
lidocaine NN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
Participants NNP N
, , N
2862 CD N
eligible JJ N
overweight NN N
and CC N
obese JJ N
( ( N
BMI NNP N
= VBZ N
27 CD N
to TO N
40 CD N
kg/m2 NNS N
) ) N
members NNS N
from IN N
four CD N
regions NNS N
of IN N
Kaiser NNP N
Permanente NNP N
's POS N
integrated JJ N
health NN N
care NN N
delivery NN N
system NN N
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
tailored VBN N
expert NN N
system NN N
or CC N
information-only JJ N
Web-based JJ N
weight NN N
management NN N
materials NNS N
. . N

Comparison NNP N
of IN N
ketazolam NNP i
given VBN N
once-a-day JJ N
with IN N
diazepam NN i
given VBN N
three CD N
times NNS N
a DT N
day NN N
and CC N
placebo VB N
given VBN N
either DT N
once RB N
or CC N
3 CD N
times NNS N
a DT N
day NN N
in IN N
101 CD N
anxious JJ N
outpatients NNS p
showed VBD N
ketazolam NNS i
to TO N
be VB N
significantly RB N
better JJR N
than IN N
placebo NN N
in IN N
alleviating VBG N
the DT N
symptoms NNS N
of IN N
anxiety NN N
and CC N
, , N
on IN N
several JJ N
measures NNS N
of IN N
efficacy NN N
, , N
better JJR N
than IN N
diazepam NN i
as IN N
well RB N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
motivational JJ N
Strengths NNP N
Model NNP N
bridging VBG N
case NN N
management NN N
intervention NN N
( ( N
BCM NNP N
) ) N
beginning VBG N
approximately RB N
3 CD N
months NNS N
prior RB N
to TO N
and CC N
continuing VBG N
6 CD N
months NNS N
after IN N
release NN N
versus IN N
a DT N
standard NN N
of IN N
care NN N
prison-administered JJ N
discharge NN N
planning VBG N
program NN N
( ( N
SOC NNP N
) ) N
for IN N
HIV-infected JJ N
state NN N
prison NN N
inmates NNS N
. . N

In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
toxicity NN N
of IN N
1 CD N
mg NN N
of IN N
amphotericin NN i
B NNP N
( ( N
AmB NNP N
) ) N
per IN N
kg NN N
of IN N
body NN N
weight JJ N
per IN N
day NN N
infused VBN N
in IN N
5 CD N
% NN N
dextrose NN N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
AmB NNP N
infused VBD N
in IN N
lipid JJ N
emulsion NN N
in IN N
children NNS N
with IN N
malignant JJ N
disease NN N
. . N

Tacrolimus NNP N
ointment VBD N
0.03 CD N
% NN N
is VBZ N
approved VBN N
for IN N
moderate JJ N
to TO N
severe VB N
atopic NN N
dermatitis NN N
in IN N
the DT N
patient JJ N
population NN N
between IN N
two CD N
to TO N
seventeen VB N
years NNS N
of IN N
age NN N
and CC N
Tacrolimus NNP N
0.1 CD N
% NN N
ointment NN N
for IN N
moderate JJ N
to TO N
severe VB N
atopic NN N
dermatitis NN N
in IN N
patients NNS p
18 CD N
years NNS N
of IN N
age NN N
and CC N
older JJR N
. . N

METHODS NNP N
Sixty-eight JJ N
patients NNS p
with IN N
peripheral JJ N
obstructive JJ N
arterial JJ N
disease NN N
and CC N
intermittent JJ N
claudication NN N
( ( N
Fontaine NNP N
stage NN N
II NNP N
) ) N
were VBD N
randomly RB N
assigned VBN N
into IN N
the DT N
treadmill NN N
training NN N
( ( N
repetitive JJ N
intervals NNS N
to TO N
onset VB N
of IN N
claudication NN N
pain NN N
, , N
three CD N
times NNS N
a DT N
week NN N
) ) N
or CC N
a DT N
control NN N
group NN N
( ( N
no DT N
change NN N
in IN N
physical JJ N
activity NN N
) ) N
over IN N
3 CD N
months NNS N
. . N

RESULTS JJ N
Pre-medication NN N
with IN N
pronase NN N
( ( N
treatment NN N
C NNP N
) ) N
significantly RB N
reduced VBN N
( ( N
both DT N
at IN N
P NNP N
< NNP N
0.05 CD N
) ) N
the DT N
visibility NN N
score NN N
( ( N
score RB N
4 CD N
, , N
46 CD N
% NN N
) ) N
in IN N
comparison NN N
with IN N
that DT N
obtained VBN N
for IN N
pre-medication NN N
without IN N
pronase NN N
( ( N
10 CD N
% NN N
for IN N
both DT N
treatments NNS N
A DT N
and CC N
B NNP N
) ) N
. . N

METHODS NNP N
We PRP N
assessed VBD N
status NN N
of IN N
BRAF NNP N
c.1799T NN N
> VBZ N
A NNP N
( ( N
p.V600E NN N
) ) N
mutation NN N
and CC N
MSI NNP N
in IN N
506 CD N
stage NN N
III NNP N
colon NN N
cancer NN N
patients NNS p
enrolled VBN N
in IN N
a DT N
randomized JJ N
adjuvant NN N
chemotherapy NN i
trial NN N
[ NNP N
5-fluorouracil CD N
and CC N
leucovorin NN N
( ( N
FU/LV NNP N
) ) N
vs. FW N
irinotecan JJ N
( ( N
CPT11 NNP N
) ) N
, , N
FU NNP N
and CC N
LV NNP N
( ( N
IFL NNP N
) ) N
; : N
CALGB $ N
89803 CD N
] NN N
. . N

METHODS NNP N
Patients NNS N
with IN N
stable JJ N
CHF NNP N
( ( N
NYHA NNP N
II/III NNP N
; : N
59 CD N
( ( N
11 CD N
) ) N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
training NN N
group NN N
( ( N
n=18 JJ N
; : N
3-month JJ N
aerobic JJ N
program NN N
above IN N
standard JJ N
treatment NN N
) ) N
or CC N
control VB N
group NN N
( ( N
n=16 RB N
; : N
standard JJ N
treatment NN N
without IN N
special JJ N
advice NN N
for IN N
exercise NN N
) ) N
. . N

METHODS/DESIGN NNP N
Seventy NNP N
patients NNS p
, , N
aged VBD N
18 CD N
to TO N
45 CD N
years NNS N
with IN N
a DT N
primary JJ N
diagnosis NN N
of IN N
BPD NNP N
, , N
showing VBG N
a DT N
chronic JJ N
pattern NN N
of IN N
parasuicidal JJ N
gestures NNS N
and/or IN N
reporting VBG N
high JJ N
degrees NNS N
of IN N
severity NN N
of IN N
other JJ N
borderline NN N
symptoms NNS N
, , N
are VBP N
randomly RB N
allocated VBN N
to TO N
the DT N
control NN N
and CC N
intervention NN N
groups NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
2-day JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
diclofenac-K NN N
( ( N
12.5 CD N
mg NN N
) ) N
tablets VBZ N
vs JJ N
paracetamol NN N
( ( N
500 CD N
mg NN N
) ) N
tablets NNS N
and CC N
placebo NN N
in IN N
patients NNS p
with IN N
moderate JJ N
or CC N
severe JJ N
pain NN N
within IN N
8 CD N
hours NNS N
of IN N
extraction NN N
of IN N
impacted JJ N
third JJ N
molars NNS N
. . N

OBJECTIVES IN N
The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dose-dependent JJ N
anesthetic JJ N
efficacy NN N
of IN N
the DT N
intraseptal JJ N
anesthesia NN N
( ( N
ISA NNP N
) ) N
and CC N
periodontal JJ N
ligament NN N
anesthesia NN N
( ( N
PLA NNP N
) ) N
obtained VBD N
with IN N
different JJ N
volumes NNS N
of IN N
4 CD N
% NN N
articaine NN N
and CC N
1:100,000 CD N
epinephrine NN N
( ( N
Ar NNP N
+ NNP N
Ep NNP N
) ) N
in IN N
human JJ N
mandibular JJ N
premolars NNS N
, , N
using VBG N
a DT N
computer-controlled JJ N
local JJ N
anesthetic JJ N
delivery NN N
system NN N
( ( N
CCLADS NNP N
) ) N
. . N

METHODS NNP N
Seventeen NNP N
sedentary JJ N
adults NNS N
aged VBN N
> JJ N
or=55 CD N
years NNS N
with IN N
insomnia NN N
( ( N
mean JJ N
age NN N
61.6 CD N
[ NN N
SD NNP N
] NNP N
years NNS N
; : N
16 CD N
female NN N
) ) N
participated VBD N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
comparing VBG N
16 CD N
weeks NNS N
of IN N
aerobic JJ N
physical JJ N
activity NN N
plus CC N
sleep JJ N
hygiene NN N
to TO N
non-physical JJ N
activity NN N
plus CC N
sleep JJ N
hygiene NN N
. . N

METHODS NNP N
Sixty-four NNP N
male NN N
patients NNS p
, , N
mean JJ N
age NN N
55.6 CD N
? . N
6.0 CD N
years NNS N
, , N
were VBD N
randomized VBN N
either RB N
to TO N
six CD N
weeks NNS N
of IN N
aerobic JJ N
training NN N
, , N
three CD N
times NNS N
a DT N
week NN N
, , N
at IN N
60-80 CD N
% NN N
of IN N
maximal JJ N
heart NN N
rate NN N
( ( N
training VBG N
group NN N
, , N
Ex NNP N
, , N
n JJ N
= NNP N
32 CD N
) ) N
or CC N
to TO N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
60 CD N
patients NNS p
were VBD N
allocated VBN N
from IN N
September NNP N
2011 CD N
until IN N
March NNP N
2013 CD N
into IN N
one CD N
of IN N
the DT N
two CD N
groups NNS N
: : N
resistance NN N
training NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
passive JJ N
physical JJ N
therapy NN i
( ( N
group NN N
B NNP N
) ) N
with IN N
thirty NN N
patients NNS p
in IN N
each DT N
group NN N
during IN N
RT NNP N
. . N

A DT N
prospective JJ N
study NN N
over IN N
15 CD N
months NNS N
in IN N
100 CD N
elderly JJ N
patients NNS p
with IN N
signs NNS N
of IN N
cerebro-vascular JJ N
impairment NN N
demonstrated VBN N
by IN N
psychometric JJ N
testing VBG N
that IN N
Hydergine NNP N
( ( N
an DT N
ergot NN N
alkaloid JJ N
preparation NN N
: : N
4.5 CD N
mg NNS N
daily RB N
) ) N
compensated VBD N
the DT N
signs NNS N
of IN N
dementia NN N
, , N
present NN N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
in IN N
some DT N
patients NNS p
actually RB N
brought VBD N
about IN N
a DT N
significant JJ N
improvement NN N
in IN N
mental JJ N
activity NN N
. . N

Among IN N
the DT N
children NNS N
in IN N
the DT N
secretin NN i
group NN N
, , N
the DT N
mean JJ N
total NN N
score NN N
on IN N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
at IN N
base NN N
line NN N
was VBD N
59.0 CD N
( ( N
range NN N
of IN N
possible JJ N
values NNS N
, , N
0 CD N
to TO N
158 CD N
, , N
with IN N
a DT N
larger JJR N
value NN N
corresponding VBG N
to TO N
greater JJR N
impairment NN N
) ) N
, , N
and CC N
among IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
it PRP N
was VBD N
63.2 CD N
. . N

The DT N
occlusion NN N
was VBD N
released VBN N
after IN N
2 CD N
min NN N
and CC N
one-fourth NN N
of IN N
the DT N
total JJ N
propofol NN N
dose NN N
was VBD N
injected VBN N
into IN N
the DT N
vein NN N
over IN N
a DT N
period NN N
of IN N
5 CD N
s. NN N
During IN N
the DT N
injection NN N
of IN N
both DT N
pretreatment JJ N
solution NN N
and CC N
propofol NN N
, , N
patients NNS p
' POS N
pain NN N
was VBD N
assessed VBN N
and CC N
recorded VBN N
as IN N
0-3 NN N
, , N
corresponding VBG N
to TO N
no DT N
, , N
mild RB N
, , N
moderate JJ N
or CC N
severe JJ N
pain NN N
, , N
respectively RB N
. . N

Twenty-four JJ N
vs JJ N
forty-eight JJ N
weeks NNS N
of IN N
re-therapy NN i
with IN N
interferon NN N
alpha NN N
2b CD N
and CC N
ribavirin VB N
in IN N
interferon NN N
alpha NN N
monotherapy NN i
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
BACKGROUND/AIM NNP N
Roughly NNP N
50 CD N
% NN N
of IN N
patients NNS p
with IN N
chronic JJ N
hepatitis NN N
C NNP N
, , N
who WP N
relapsed VBD N
after IN N
a DT N
previous JJ N
monotherapy NN i
with IN N
interferon NN N
alpha NN N
, , N
will MD N
respond VB N
in IN N
a DT N
sustained JJ N
fashion NN N
to TO N
24 CD N
weeks NNS N
of IN N
re-therapy NN i
with IN N
the DT N
combination NN N
of IN N
interferon NN N
alpha NN N
plus CC N
ribavirin NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
tolerability NN N
between IN N
randomized VBN N
allocations NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.6 CD N
) ) N
CONCLUSION NNP N
Routine NNP N
administration NN N
of IN N
perindopril-indapamide JJ N
lowers NNS N
blood NN N
pressure NN N
safely RB N
and CC N
reduces VBZ N
the DT N
risk NN N
of IN N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
of IN N
at IN N
least JJS N
75 CD N
years NNS N
with IN N
type NN N
2 CD N
diabetes NNS N
. . N

METHODS NNP N
A NNP N
randomised VBD N
, , N
multi-centre JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
was VBD N
carried VBN N
out RP N
at IN N
19 CD N
centres NNS N
in IN N
France NNP N
, , N
Germany NNP N
and CC N
the DT N
Netherlands NNP N
in IN N
patients NNS p
with IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
acute JJ N
ischaemic JJ N
stroke NN N
, , N
and CC N
onset NN N
of IN N
symptoms NNS N
within IN N
12 CD N
hours NNS N
before IN N
start NN N
of IN N
study JJ N
drug NN N
administration NN N
. . N

DESIGN NNP N
AND CC N
METHODS NNP N
Cases NNP N
who WP N
had VBD N
a DT N
first JJ N
venous JJ N
thrombosis NN N
( ( N
n=515 JJ N
) ) N
and CC N
matched VBN N
controls NNS N
( ( N
n=1,505 NN N
) ) N
were VBD N
identified VBN N
from IN N
a DT N
population-based JJ N
, , N
nested JJ N
, , N
case-cohort JJ N
study NN N
( ( N
the DT N
HUNT NNP N
2 CD N
study NN N
) ) N
comprising VBG N
71 CD N
% NN N
( ( N
n=66,140 JJ N
) ) N
of IN N
the DT N
adult NN N
residents NNS N
of IN N
Nord-Tr NNP N
County NNP N
in IN N
Norway NNP N
. . N

METHODS NNP N
Patients NNS N
with IN N
severe JJ N
OSA NNP N
currently RB N
using VBG N
CPAP NNP N
at IN N
? . N
h/night NN N
with IN N
a DT N
nasal JJ N
mask NN N
were VBD N
examined VBN N
( ( N
including VBG N
Mallampati NNP N
scale NN N
, , N
incisal NN N
relationship NN N
, , N
and CC N
mandibular JJ N
protrusion NN N
) ) N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
auto-positive JJ N
airway NN N
pressure NN N
( ( N
PAP NNP N
) ) N
or CC N
fixed VBN N
CPAP NNP N
at IN N
a DT N
manually RB N
titrated JJ N
pressure NN N
for IN N
1 CD N
week NN N
each DT N
at IN N
home NN N
, , N
with IN N
immediate JJ N
crossover NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Among IN N
patients NNS p
enrolled VBN N
in IN N
the DT N
Treatment NNP N
of IN N
Preserved NNP N
Cardiac NNP N
Function NNP N
Heart NNP N
Failure NNP N
With IN N
an DT N
Aldosterone NNP N
Antagonist NNP N
Trial NNP N
( ( N
TOPCAT NNP N
) ) N
, , N
3400 CD N
patients NNS p
completed VBD N
the DT N
Kansas NNP N
City NNP N
Cardiomyopathy NNP N
Questionnaire NNP N
, , N
3395 CD N
patients NNS p
completed VBN N
European JJ N
QOL NNP N
5D CD N
Visual NNP N
Analog NNP N
Scale NNP N
, , N
and CC N
1431 CD N
patients NNS p
in IN N
United NNP N
States NNPS N
and CC N
Canada NNP N
completed VBD N
the DT N
Patient NNP N
Health NNP N
Questionnaire-9 NNP N
. . N

Thirty NNP N
healthy JJ N
volunteers NNS N
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
study NN N
group NN N
administrating VBG N
30 CD N
% NN N
FFA NNP N
suppositories NNS N
and CC N
applying VBG N
30 CD N
% NN N
FFA NNP N
ointment NN N
to TO N
the DT N
perianal JJ N
region NN N
twice RB N
per IN N
day NN N
for IN N
two CD N
weeks NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
using VBG N
placebo NN N
suppositories NNS N
and CC N
ointment NN N
in IN N
a DT N
double JJ N
blinded JJ N
manner NN N
. . N

We PRP N
conducted VBD N
a DT N
placebo-controlled JJ N
randomized JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
palifermin NN N
( ( N
keratinocyte JJ N
growth NN N
factor NN N
) ) N
, , N
given VBN N
at IN N
60 CD N
? . N
per IN N
daily JJ N
IV NNP N
for IN N
3 CD N
d NN N
before IN N
and CC N
after IN N
chemotherapy NN i
, , N
for IN N
mucosal NN N
protection NN N
in IN N
adult NN N
patients NNS p
with IN N
previously RB N
untreated VBN N
AML NNP N
receiving VBG N
induction NN N
therapy NN i
with IN N
idarubicin NN i
, , N
high-dose JJ N
cytarabine NN N
and CC N
etoposide NN N
. . N

CONCLUSIONS NNP N
Caudal NNP N
neostigmine NN N
( ( N
2 CD N
, , N
3 CD N
and CC N
4 CD N
microg.kg NN N
( ( N
-1 NNP N
) ) N
) ) N
with IN N
bupivacaine NN N
produces VBZ N
a DT N
dose-independent JJ N
analgesic JJ N
effect NN N
( ( N
approximately RB N
16-17 JJ N
hr NN N
) ) N
in IN N
children NNS N
as IN N
compared VBN N
to TO N
those DT N
receiving VBG N
caudal JJ N
bupivacaine NN N
alone RB N
( ( N
approximately RB N
five CD N
hours NNS N
) ) N
and CC N
a DT N
reduction NN N
in IN N
postoperative JJ N
rescue NN N
analgesic JJ N
consumption NN N
without IN N
increasing VBG N
the DT N
incidence NN N
of IN N
adverse JJ N
effects NNS N
. . N

One CD N
hundred VBD N
seventy-seven JJ N
women NNS N
aged VBD N
41 CD N
+/- JJ N
8 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
years NNS N
, , N
referred VBD N
for IN N
evaluation NN N
of IN N
excessive JJ N
uterine JJ N
bleeding NN N
, , N
were VBD N
enrolled VBN N
in IN N
an DT N
open-label JJ N
randomized JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
local JJ N
anesthesia NN N
before IN N
hysteroscopy NN N
in IN N
an DT N
outpatient JJ N
population NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
studied VBD N
23 CD N
patients NNS p
in IN N
NYHA NNP N
class NN N
II NNP N
and CC N
III NNP N
( ( N
20 CD N
men NNS N
, , N
three CD N
women NNS N
, , N
mean JJ N
age NN N
59+/-9 CD N
years NNS N
) ) N
with IN N
stable JJ N
CHF NNP N
secondary JJ N
to TO N
ischaemic VB N
heart NN N
disease NN N
[ NNP N
ejection NN N
fraction NN N
37+/-7 CD N
% NN N
] NN N
, , N
using VBG N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
cross-over NN N
design NN N
. . N

In IN N
a DT N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
, , N
young JJ N
men NNS N
( ( N
aged VBN N
13-27 NNS N
) ) N
with IN N
moderate JJ N
to TO N
severe VB N
ASD NNP N
received VBD N
the DT N
phytochemical JJ N
sulforaphane NN N
( ( N
n JJ N
= NNP N
29 CD N
) ) N
-- : N
derived VBN N
from IN N
broccoli NN N
sprout NN N
extracts NNS N
-- : N
or CC N
indistinguishable JJ N
placebo NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
antiplatelet NN N
activity NN N
of IN N
ASA NNP N
, , N
as IN N
assessed VBN N
by IN N
ARU NNP N
ratio NN N
relative NN N
to TO N
baseline VB N
in IN N
the DT N
VerifyNow NNP N
ASA NNP N
assay VBP N
; : N
suppression NN N
of IN N
serum NN N
thromboxane NN N
B NNP N
( ( N
2 CD N
) ) N
( ( N
TXB NNP N
( ( N
2 CD N
) ) N
) ) N
was VBD N
a DT N
secondary JJ N
endpoint NN N
. . N

Two CD N
sprays NNS N
of IN N
IB NNP N
at IN N
a DT N
dose NN N
of IN N
42 CD N
micrograms/spray NN N
( ( N
0.06 CD N
% NN N
) ) N
, , N
or CC N
saline NN N
, , N
were VBD N
administered VBN N
intranasally RB N
twice JJ N
daily RB N
for IN N
two CD N
weeks NNS N
, , N
after IN N
which WDT N
time NN N
the DT N
participants NNS N
were VBD N
given VBN N
another DT N
nasal NN N
spray NN N
( ( N
either CC N
IB NNP N
or CC N
saline NN N
) ) N
for IN N
the DT N
crossover NN N
portion NN N
of IN N
the DT N
study NN N
. . N

A DT N
stratified JJ N
random JJ N
sample NN N
of IN N
450 CD N
parents NNS N
were VBD N
randomized VBN N
into IN N
three CD N
incentive JJ N
groups NNS N
: : N
( ( N
a DT N
) ) N
no DT N
incentive NN N
; : N
( ( N
b NN N
) ) N
a DT N
promised JJ N
incentive NN N
of IN N
one CD N
lottery NN N
ticket NN N
to TO N
be VB N
received VBN N
upon IN N
reply NN N
; : N
( ( N
c NN N
) ) N
a DT N
promised JJ N
incentive NN N
of IN N
one CD N
lottery NN N
ticket NN N
to TO N
be VB N
received VBN N
upon IN N
reply NN N
and CC N
an DT N
additional JJ N
lottery NN N
ticket NN N
upon IN N
reply NN N
within IN N
1 CD N
week NN N
. . N

The DT N
effects NNS N
of IN N
three CD N
different JJ N
regimens NNS N
of IN N
inhaled JJ N
bronchodilators NNS N
on IN N
spirometry NN N
and CC N
respiratory JJ N
impedance NN N
as IN N
measured VBN N
with IN N
the DT N
technique NN N
of IN N
forced JJ N
oscillations NNS N
were VBD N
compared VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
study NN N
in IN N
22 CD N
patients NNS p
with IN N
stable JJ N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
FEV1 NNP N
less JJR N
than IN N
70 CD N
percent NN N
predicted VBN N
) ) N
. . N

The DT N
main JJ N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
( ( N
1 CD N
) ) N
compare VBP N
the DT N
plasma NN N
propranolol NN i
concentrations NNS N
( ( N
Cp-prop NNP N
) ) N
following VBG N
sublingual JJ N
administration NN N
of IN N
a DT N
specially RB N
buffered VBN N
formulation NN N
( ( N
Promptol NNP N
) ) N
to TO N
that DT N
following VBG N
oral JJ N
administration NN N
of IN N
Inderal NNP N
( ( N
? . N
) ) N
and CC N
( ( N
2 CD N
) ) N
evaluate VB N
the DT N
utility NN N
of IN N
a DT N
special JJ N
pharmacokinetic JJ N
model NN N
in IN N
describing VBG N
the DT N
Cp-prop NNP N
following VBG N
sublingual JJ N
administration NN N
. . N

A DT N
2 CD N
x NN N
6 CD N
( ( N
treatment NN N
x NNS N
game NN N
day NN N
) ) N
analysis NN N
of IN N
variance NN N
indicated VBD N
that IN N
the DT N
group NN N
practicing VBG N
with IN N
lighter JJR N
balls NNS N
had VBD N
significantly RB N
more RBR N
correct JJ N
sets NNS N
and CC N
a DT N
higher JJR N
average JJ N
daily JJ N
success NN N
rate NN N
for IN N
the DT N
set NN N
and CC N
underhand JJ N
serve NN N
on IN N
game NN N
days NNS N
than IN N
the DT N
group NN N
using VBG N
a DT N
regulation NN N
ball NN N
. . N

The DT N
effect NN N
of IN N
guar NN N
( ( N
15.6 CD N
g/day NN N
) ) N
, , N
a DT N
dietary JJ N
fibre NN N
, , N
and CC N
simultaneous JJ N
administration NN N
of IN N
bezafibrate NN N
( ( N
600 CD N
mg/day NN N
) ) N
during IN N
dietetic JJ N
treatment NN N
on IN N
the DT N
plasma NN N
lipoproteins NNS N
and CC N
apolipoproteins NNS N
was VBD N
investigated VBN N
in IN N
12 CD N
patients NNS p
with IN N
familial JJ N
hypercholesterolemia NN N
( ( N
corresponding VBG N
to TO N
the DT N
HLP NNP N
type NN N
IIa NNP N
pattern NN N
) ) N
. . N

INTERVENTIONS JJ N
Patients NNS N
were VBD N
premedicated VBN N
with IN N
oral JJ N
temazepam NN i
20 CD N
mg. NN N
Anesthesia NNP N
was VBD N
induced VBN N
with IN N
either DT N
eltanolone NN N
0.58 CD N
mg/kg NN N
or CC N
propofol VB N
1.7 CD N
mg/kg NN N
, , N
neuromuscular JJ N
blockade NN N
was VBD N
achieved VBN N
with IN N
vecuronium NN N
0.1 CD N
mg/kg NN N
, , N
and CC N
anesthesia NN N
was VBD N
maintained VBN N
with IN N
enflurane JJ N
0.5 CD N
% NN N
to TO N
1.0 CD N
% NN N
in IN N
nitrous JJ N
oxide NN N
( ( N
67 CD N
% NN N
) ) N
. . N

Using VBG N
logistic JJ N
regression NN N
, , N
we PRP N
estimated VBD N
odds NNS N
ratios NNS N
( ( N
ORs NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
to TO N
prospectively RB N
evaluate VB N
the DT N
association NN N
between IN N
lignan NN N
and CC N
proanthocyanidin JJ N
intake NN N
, , N
estimated VBN N
from IN N
databases NNS N
linked VBN N
to TO N
a DT N
food NN N
frequency NN N
questionnaire NN N
, , N
and CC N
adenoma JJ N
recurrence NN N
in IN N
1,859 CD N
participants NNS N
of IN N
the DT N
Polyp NNP N
Prevention NNP N
Trial NNP N
. . N

METHODS NNP N
Pregnant NNP N
women NNS N
with IN N
WHO NNP N
stage VBP N
1 CD N
, , N
2 CD N
, , N
or CC N
3 CD N
HIV-1 JJ N
infection NN N
who WP N
had VBD N
CD4 NNP N
cell NN N
counts NNS N
of IN N
200-500 JJ N
cells NNS N
per IN N
? . N
were VBD N
enrolled VBN N
at IN N
five CD N
study NN N
sites NNS N
in IN N
Burkina NNP N
Faso NNP N
, , N
Kenya NNP N
, , N
and CC N
South NNP N
Africa NNP N
to TO N
start VB N
study VB N
treatment NN N
at IN N
28-36 JJ N
weeks NNS N
' POS N
gestation NN N
. . N

In IN N
addition NN N
, , N
because IN N
the DT N
duration NN N
of IN N
stimulation NN N
does VBZ N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
the DT N
usage NN N
of IN N
300 CD N
IU NNP N
rFSH NN N
in IN N
microdose JJ N
cycles NNS N
results NNS N
in IN N
less JJR N
total JJ N
amount NN N
of IN N
rFSH NN N
consumed VBN N
in IN N
a DT N
cycle NN N
compared VBN N
with IN N
higher JJR N
dosages NNS N
, , N
and CC N
this DT N
would MD N
obviously RB N
cost VB N
less JJR N
money NN N
to TO N
the DT N
patients NNS p
. . N

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
hydrocodone NN i
7.5 CD N
mg NN N
and CC N
ibuprofen $ N
200 CD N
mg NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
1-tablet JJ N
doses NNS N
of IN N
this DT N
combination NN N
or CC N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC N
acetaminophen $ i
300 CD N
mg NN N
. . N

The DT N
median JJ N
number NN N
of IN N
total JJ N
bleeding NN N
episodes NNS N
and CC N
total JJ N
bleeding NN N
episodes NNS N
per IN N
year NN N
were VBD N
significantly RB N
lower JJR N
with IN N
prophylaxis NN N
than IN N
with IN N
on-demand JJ N
treatment NN N
( ( N
total JJ N
, , N
0 CD N
vs. FW N
54.5 CD N
; : N
total JJ N
per IN N
year NN N
, , N
0 CD N
vs. FW N
27.9 CD N
; : N
both DT N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

To TO N
determine VB N
the DT N
efficacy NN N
of IN N
cisapride NN N
, , N
10 CD N
mg NN N
three CD N
times NNS N
daily RB N
, , N
in IN N
improving VBG N
gastric JJ N
emptying NN N
, , N
reducing VBG N
distress NN N
during IN N
meals NNS N
, , N
and CC N
facilitating VBG N
weight JJ N
gain NN N
in IN N
anorexia JJ N
nervosa NN N
, , N
we PRP N
conducted VBD N
an DT N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
on IN N
29 CD N
inpatients NNS p
. . N

When WRB N
entered VBN N
together RB N
into IN N
a DT N
regression NN N
analysis NN N
, , N
metrics NNS N
that IN N
represented VBD N
( ( N
a DT N
) ) N
the DT N
number NN N
of IN N
parent NN N
utterances NNS N
following VBG N
into IN N
the DT N
child NN N
's POS N
focus NN N
of IN N
attention NN N
and CC N
( ( N
b NN N
) ) N
the DT N
number NN N
of IN N
parent NN N
utterances NNS N
responding VBG N
to TO N
child VB N
verbal JJ N
communication NN N
acts NNS N
both DT N
accounted VBD N
for IN N
unique JJ N
variance NN N
in IN N
predicting VBG N
change NN N
in IN N
spoken JJ N
vocabulary NN N
from IN N
Time NNP N
1 CD N
to TO N
Time NNP N
2 CD N
. . N

OBJECTIVE NN N
This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
a DT N
12-week JJ N
, , N
low-intensity JJ N
( ( N
1-hour/wk CD N
of IN N
therapist JJ N
contact NN N
) ) N
, , N
parent-delivered JJ N
intervention NN N
for IN N
toddlers NNS N
at IN N
risk NN N
for IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
aged VBD N
14 CD N
to TO N
24 CD N
months NNS N
and CC N
their PRP$ N
families NNS N
. . N

At IN N
the DT N
point NN N
of IN N
protocol-defined JJ N
study NN N
completion NN N
( ( N
85 CD N
% NN N
mortality NN N
in IN N
the DT N
placebo NN N
arm NN N
) ) N
there EX N
was VBD N
a DT N
modest JJ N
difference NN N
in IN N
survival NN N
in IN N
the DT N
intention-to-treat JJ N
population NN N
in IN N
favour NN N
of IN N
marimastat NN N
( ( N
P=0.07 NNP N
log-rank JJ N
test NN N
, , N
hazard NN N
ratio=1.23 NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
0.98-1.55 NNP N
) ) N
) ) N
. . N

RESULTS NNP N
Among IN N
423 CD N
participants NNS N
with IN N
1 CD N
study NN N
eye NN N
, , N
the DT N
correct JJ N
assignment NN N
was VBD N
stated VBN N
by IN N
9.9 CD N
% NN N
of IN N
the DT N
sham NN N
plus CC N
prompt JJ N
laser NN N
group NN N
, , N
88.0 CD N
% NN N
of IN N
the DT N
ranibizumab NN i
plus CC N
prompt JJ N
laser NN N
group NN N
, , N
89.6 CD N
% NN N
of IN N
the DT N
unmasked JJ N
ranibizumab NN i
plus CC N
deferred JJ N
laser NN N
group NN N
, , N
and CC N
44.0 CD N
% NN N
of IN N
the DT N
triamcinolone NN N
plus CC N
prompt JJ N
laser NN N
group NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
observation NN N
period NN N
, , N
the DT N
clinical JJ N
course NN N
of IN N
scar NN N
development NN N
was VBD N
rated VBN N
as IN N
very RB N
good JJ N
or CC N
good JJ N
in IN N
more JJR N
than IN N
90 CD N
% NN N
of IN N
the DT N
treated JJ N
patients NNS p
, , N
good JJ N
in IN N
less JJR N
than IN N
40 CD N
% NN N
and CC N
moderate JJ N
or CC N
bad JJ N
in IN N
more JJR N
than IN N
60 CD N
% NN N
of IN N
the DT N
untreated JJ N
cases NNS N
. . N

METHODS NNP N
Sixteen NNP N
overweight MD N
to TO N
obese VB N
adults NNS N
( ( N
BMI NNP N
30.6 CD N
? . N
0.8 CD N
; : N
67.2 CD N
? . N
4.0 CD N
years NNS N
of IN N
age NN N
) ) N
with IN N
either DT N
impaired JJ N
fasting NN N
glucose NN N
, , N
or CC N
impaired VBD N
glucose JJ N
tolerance NN N
completed VBD N
one CD N
of IN N
two CD N
lifestyle JJ N
interventions NNS N
: : N
DIWL NNP N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
or CC N
EX NNP N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
. . N

Orally RB N
administered VBN N
furosemide NN N
, , N
at IN N
doses NNS N
commonly RB N
used VBN N
in IN N
the DT N
clinic NN N
( ( N
40 CD N
mg NN N
) ) N
, , N
significantly RB N
reduced VBN N
spinal JJ N
inhibitory JJ N
interneuronal JJ N
activity NN N
for IN N
at IN N
least JJS N
70 CD N
min NN N
from IN N
intake NN N
compared VBN N
to TO N
control VB N
experiments NNS N
in IN N
the DT N
same JJ N
subjects NNS N
while IN N
no DT N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
. . N

One CD N
half NN N
of IN N
the DT N
home NN N
studies NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
performed VBN N
with IN N
a DT N
sleep JJ N
technician NN N
's POS N
set VBN N
up IN N
of IN N
the DT N
equipment NN N
in IN N
the DT N
patient NN N
's POS N
home NN N
( ( N
group NN N
1 CD N
) ) N
, , N
and CC N
the DT N
other JJ N
half NN N
with IN N
the DT N
patient NN N
's POS N
own JJ N
setup NN N
of IN N
the DT N
sleep-recording JJ N
device NN N
( ( N
group NN N
2 CD N
) ) N
, , N
after IN N
an DT N
instruction NN N
period NN N
in IN N
the DT N
hospital NN N
. . N

Patients NNS N
with IN N
a DT N
stable JJ N
response NN N
( ( N
? . N
25 CD N
% NN N
decrease NN o
in IN N
Aberrant NNP N
Behavior NNP N
Checklist-irritability NNP N
subscale NN N
score NN N
and CC N
a DT N
rating NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impressions-Improvement NNP N
scale NN N
) ) N
for IN N
12 CD N
consecutive JJ N
weeks NNS N
were VBD N
randomized VBN N
into IN N
phase NN N
2 CD N
to TO N
continue VB N
aripiprazole NN N
or CC N
switch VB N
to TO N
placebo VB N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
hypersensitive JJ N
root NN N
surfaces NNS N
of IN N
selected VBN N
teeth NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
of IN N
3 CD N
treatments NNS N
: : N
coating NN N
with IN N
a DT N
self-etching JJ N
adhesive NN N
( ( N
Linkmax NNP i
) ) N
and CC N
its PRP$ N
respective JJ N
cement NN N
, , N
coating VBG N
with IN N
a DT N
conventionally RB N
etched VBN N
adhesive NN N
( ( N
RelyX NNP N
ARC NNP N
) ) N
and CC N
its PRP$ N
cement NN N
, , N
or CC N
no DT N
treatment NN N
( ( N
negative JJ N
control NN N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
20 CD N
adult NN N
patients NNS p
with IN N
GHD NNP N
( ( N
eleven JJ N
male NN N
, , N
nine CD N
female NN N
, , N
mean JJ N
age NN N
42.5 CD N
years NNS N
) ) N
were VBD N
included VBN N
in IN N
the DT N
study NN N
and CC N
randomized VBN N
to TO N
either DT N
GH NNP N
or CC N
placebo NN N
in IN N
a DT N
dose NN N
of IN N
0.25 CD N
U/kg NNP N
body NN N
weight/week NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
examine VB N
the DT N
feasibility NN N
and CC N
treatment NN N
efficacy NN N
of IN N
a DT N
Korean JJ N
version NN N
of IN N
PEERS NNP N
( ( N
? . N
) ) N
for IN N
enhancing VBG N
social JJ N
skills NNS N
through IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
.The VBP N
English JJ N
version NN N
of IN N
the DT N
PEERS NNP N
( ( N
? . N
) ) N
Treatment NN N
Manual NNP N
( ( N
Laugeson NNP N
& CC N
Frankel NNP N
, , N
2010 CD N
) ) N
was VBD N
translated VBN N
into IN N
Korean NNP N
and CC N
reviewed VBN N
by IN N
21 CD N
child JJ N
mental JJ N
health NN N
professionals NNS N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
danazol NN N
and CC N
triptorelin NN N
( ( N
Decapeptyl NNP N
CR NNP N
, , N
Ferring NNP N
, , N
Kiel NNP N
, , N
Germany NNP N
) ) N
in IN N
the DT N
management NN N
of IN N
moderate JJ N
and CC N
severe JJ N
endometriosis NN N
in IN N
terms NNS N
of IN N
symptom NN N
control NN N
and CC N
revised VBN N
American JJ N
Fertility NNP N
Society NNP N
( ( N
AFS NNP N
) ) N
score NN N
reduction NN N
, , N
and CC N
to TO N
evaluate VB N
the DT N
hormonal JJ N
profile NN N
of IN N
patients NNS p
treated VBN N
with IN N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
. . N

Postoperative JJ N
visual JJ N
analog NN N
pain NN N
scale NN N
( ( N
VAS NNP N
) ) N
scores VBZ N
at IN N
8 CD N
and CC N
24 CD N
hours NNS N
and CC N
14 CD N
days NNS N
after IN N
surgery NN N
, , N
in-hospital JJ N
analgesic JJ N
use NN N
, , N
length NN N
of IN N
hospital NN N
stay NN N
, , N
success NN N
rate NN N
, , N
blood NN N
transfusion NN N
rate NN N
, , N
and CC N
postoperative JJ N
complications NNS N
were VBD N
compared VBN N
for IN N
the DT N
two CD N
groups NNS N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
with IN N
placebo NN N
study NN N
, , N
27 CD N
women NNS N
with IN N
climacteric JJ N
symptoms NNS N
and CC N
atrophic JJ N
vaginitis NN N
were VBD N
treated VBN N
for IN N
4 CD N
months NNS N
with IN N
HT NNP N
plus CC N
vaginal JJ N
estriol NN N
0.5 CD N
mg/day NN N
( ( N
group NN N
E NNP N
) ) N
or CC N
placebo NN N
( ( N
group NN N
P NNP N
) ) N
. . N

METHODS NNP N
In IN N
a DT N
randomized VBN N
crossover NN N
study NN N
, , N
10 CD N
healthy JJ N
subjects NNS N
received VBN N
, , N
on IN N
each DT N
of IN N
5 CD N
dosing VBG N
occasions NNS N
, , N
MTX NNP N
alone RB N
as IN N
tablets NNS N
or CC N
intravenous JJ N
solution NN N
, , N
HCQ NNP N
alone RB N
as IN N
a DT N
tablet NN N
or CC N
oral JJ N
solution NN N
, , N
or CC N
a DT N
coadministered JJ N
dose NN N
of IN N
MTX NNP N
tablets NNS N
with IN N
an DT N
HCQ NNP N
tablet NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
compare VB N
injection NN N
pain NN N
and CC N
postinjection NN N
pain NN N
of IN N
2 CD N
% NN N
lidocaine NN N
with IN N
1:100,000 CD N
epinephrine NN N
and CC N
3 CD N
% NN N
mepivacaine NN N
using VBG N
the DT N
computer-assisted JJ N
Wand NNP N
Plus NNP N
injection NN N
system NN N
to TO N
administer VB N
the DT N
palatal-anterior JJ N
superior JJ N
alveolar NN N
( ( N
P-ASA NNP N
) ) N
injection NN N
. . N

This DT N
prospective JJ N
study NN N
assesses VBZ N
the DT N
effect NN N
of IN N
2.5 CD N
, , N
4 CD N
, , N
and CC N
10 CD N
mg NN N
of IN N
pyridoxine JJ i
supplementation NN N
during IN N
pregnancy NN N
on IN N
maternal JJ N
and CC N
fetal JJ N
plasma NN N
levels NNS N
of IN N
pyridoxal NN N
5'-phosphate JJ N
( ( N
PLP NNP N
) ) N
and CC N
on IN N
the DT N
degree NN N
of IN N
coenzyme NN N
saturation NN N
( ( N
activation JJ N
factor NN N
) ) N
of IN N
aspartate NN N
aminotransferase NN N
and CC N
alanine JJ N
aminotransferase NN N
( ( N
alphaEGOT JJ N
and CC N
alphaEGPT NN N
) ) N
in IN N
maternal JJ N
erythrocytes NNS N
. . N

Before IN N
the DT N
ISDN NNP N
treatment NN N
, , N
GTN NNP N
reduced VBD N
exercise NN N
PAWP NNP N
to TO N
13.9 CD N
+/- JJ N
5.27 CD N
mmHg NN N
and CC N
MAP NNP N
to TO N
119 CD N
+/- JJ N
11.2 CD N
mmHg NN N
, , N
whereas NNS N
after IN N
4 CD N
weeks NNS N
ISDN NNP N
treatment NN N
, , N
the DT N
addition NN N
of IN N
GTN NNP N
did VBD N
not RB N
reduce VB N
exercise NN N
PAWP NNP N
and CC N
MAP NNP N
to TO N
the DT N
same JJ N
low JJ N
levels NNS N
. . N

This DT N
small-scale JJ N
preliminary JJ N
study NN N
had VBD N
2 CD N
specific JJ N
aims NNS N
: : N
( ( N
aim IN N
1 CD N
) ) N
establish VB N
the DT N
feasibility NN N
of IN N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
participation VBP N
in IN N
a DT N
longitudinal JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
intervention NN N
trial NN N
and CC N
( ( N
aim VB N
2 CD N
) ) N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
Breast NNP N
Cancer NNP N
Education NNP N
Intervention NNP N
( ( N
BCEI NNP N
) ) N
on IN N
overall JJ i
QOL NNP N
. . N

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
overall JJ i
recurrent JJ N
thromboembolic JJ N
events NNS N
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
in IN N
the DT N
UFH NNP N
group NN N
( ( N
seven CD N
of IN N
67 CD N
) ) N
than IN N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
one CD N
of IN N
67 CD N
) ) N
. . N

Do VB N
colonic JJ N
short-chain NN N
fatty JJ N
acids NNS N
contribute NN N
to TO N
the DT N
long-term JJ N
adaptation NN N
of IN N
blood NN N
lipids NNS N
in IN N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
consuming VBG N
a DT N
high-fiber JJ N
diet NN N
? . N
BACKGROUND NNP N
We PRP N
recently RB N
obtained VBD N
evidence NN N
of IN N
long-term JJ N
adaptation NN N
of IN N
blood NN N
lipids NNS N
to TO N
changes NNS N
in IN N
intakes NNS N
of IN N
carbohydrate NN N
and CC N
fiber NN N
in IN N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
3 CD N
wk NN N
, , N
we PRP N
measured VBD N
plasma JJ N
inflammatory JJ N
markers NNS N
IL-6 NNP N
, , N
C-reactive NNP N
protein NN N
, , N
tumor NN N
necrosis NN N
factor NN N
receptors NNS N
I PRP N
and CC N
II NNP N
( ( N
TNF-RI NNP N
and CC N
-RII NNP N
) ) N
, , N
monocyte JJ N
chemotactic JJ N
protein-1 NN N
and CC N
E-selectin NNP i
, , N
and CC N
urinary JJ N
8-iso-PGF NN N
( ( N
2 CD N
) ) N
, , N
a DT N
marker NN N
of IN N
lipid JJ N
peroxidation NN N
. . N

After IN N
a DT N
1-week JJ N
, , N
single-blind JJ N
placebo NN N
run-in NN N
, , N
patients NNS p
received VBD N
a DT N
single JJ N
daily JJ N
dose NN N
of IN N
amantadine NN N
( ( N
2.5 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
or CC N
placebo NN N
for IN N
the DT N
next JJ N
week NN N
, , N
and CC N
then RB N
bid VB N
dosing VBG N
( ( N
5.0 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
for IN N
the DT N
subsequent JJ N
3 CD N
weeks NNS N
. . N

This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
with IN N
blinded JJ N
assessment NN N
of IN N
endpoints NNS N
to TO N
compare VB N
the DT N
2-year JJ N
effect NN N
of IN N
strict JJ N
treatment NN N
to TO N
maintain VB N
systolic JJ N
blood NN N
pressure NN N
below IN N
140 CD N
mmHg NN N
with IN N
that DT N
of IN N
mild JJ N
treatment NN N
to TO N
maintain VB N
systolic JJ N
blood NN N
pressure NN N
below IN N
160 CD N
but CC N
at IN N
or CC N
above IN N
140 CD N
mmHg NN N
in IN N
elderly JJ N
hypertensive JJ N
patients NNS p
. . N

In IN N
the DT N
clinical JJ N
trial NN N
, , N
the DT N
rate NN N
of IN N
ulcer NN N
healing VBG N
within IN N
8 CD N
weeks NNS N
was VBD N
77.9 CD N
% NN N
( ( N
67/86 CD N
) ) N
in IN N
patients NNS p
receiving VBG N
6 CD N
micrograms NNS N
EGF NNP N
intravenously RB N
twice RB N
a DT N
week NN N
, , N
being VBG N
significantly RB N
greater JJR N
than IN N
51.7 CD N
% NN N
( ( N
45/87 CD N
) ) N
in IN N
those DT N
given VBN N
CH NNP N
. . N

In IN N
the DT N
6- JJ N
to TO N
< VB N
16-week JJ N
cohort NN N
, , N
more JJR N
influenza JJ N
vaccine NN N
, , N
recipients NNS N
experienced VBD N
irritability NN N
( ( N
66.7 CD N
% NN N
vs JJ N
35.7 CD N
% NN N
) ) N
and CC N
runny JJ N
nose NN N
or CC N
nasal JJ N
congestion NN N
( ( N
63.3 CD N
% NN N
vs JJ N
33.3 CD N
% NN N
) ) N
after IN N
dose JJ N
1 CD N
but CC N
not RB N
dose JJ N
2 CD N
. . N

RESULTS NNP N
While IN N
12-month JJ N
self-reported JJ N
abstinence NN N
was VBD N
consistent JJ N
with IN N
other JJ N
published VBN N
studies NNS N
of IN N
smoking VBG N
cessation NN N
( ( N
22 CD N
% NN N
and CC N
26 CD N
% NN N
point NN N
prevalence NN N
abstinence NN N
for IN N
Proactive NNP N
and CC N
Reactive NNP N
conditions NNS N
, , N
respectively RB N
) ) N
, , N
48 CD N
% NN N
of IN N
participants NNS N
who WP N
were VBD N
tested VBN N
for IN N
cotinine NN N
failed VBD N
biochemical JJ N
verification NN N
, , N
indicating VBG N
a DT N
considerable JJ N
falsification NN N
of IN N
self-reported JJ N
cessation NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
simvastatin NN i
( ( N
MK NNP N
733 CD N
) ) N
, , N
a DT N
new JJ N
competitive JJ N
inhibitor NN N
of IN N
HMG NNP N
CoA NNP N
reductase NN N
, , N
alone RB N
and CC N
in IN N
combination NN N
with IN N
a DT N
bile JJ N
acid NN N
sequestrant NN N
, , N
cholestyramine NN N
, , N
on IN N
serum NN N
levels NNS N
of IN N
lipoproteins NNS N
and CC N
apoproteins NNS N
A1 NNP N
and CC N
B NNP N
, , N
in IN N
24 CD N
patients NNS p
with IN N
familial JJ N
hypercholesterolemia NN N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
proportion NN N
of IN N
patients NNS p
achieving VBG N
tacrolimus JJ N
whole-blood JJ N
concentrations NNS N
of IN N
? . N
ng/mL NN N
within IN N
3 CD N
days NNS N
of IN N
kidney NN N
transplantation NN N
, , N
after IN N
randomization NN N
either RB N
to TO N
standard VB N
dosing VBG N
( ( N
control VB N
group NN N
) ) N
or CC N
post-transplantation NN N
dosing NN N
guided VBN N
by IN N
a DT N
2-hour JJ N
( ( N
C NNP N
( ( N
2 CD N
) ) N
) ) N
level NN N
following VBG N
a DT N
preoperative JJ N
tacrolimus NN N
dose NN N
( ( N
T2 NNP N
group NN N
) ) N
. . N

CONCLUSIONS NNP N
Tapentadol NNP N
PR NNP N
500 CD N
mg NN N
is VBZ N
associated VBN N
with IN N
comparable JJ N
improvements NNS N
in IN N
pain NN N
intensity NN N
and CC N
quality-of-life JJ N
measures NNS N
to TO N
tapentadol VB N
PR NNP N
300 CD N
mg/pregabalin NN N
300 CD N
mg NN N
, , N
with IN N
improved JJ N
central JJ N
nervous JJ N
system NN N
tolerability NN N
, , N
suggesting VBG N
that IN N
tapentadol NN N
PR NNP N
monotherapy NN i
may MD N
offer VB N
a DT N
favorable JJ N
treatment NN N
option NN N
for IN N
severe JJ N
low JJ N
back RB N
pain NN N
with IN N
a DT N
neuropathic JJ N
component NN N
. . N

After IN N
a DT N
pseudo-randomization NN N
, , N
usual JJ N
pain NN N
management NN N
( ( N
n JJ N
= NNP N
132 CD N
) ) N
was VBD N
compared VBN N
to TO N
a DT N
multifactorial JJ N
strategy NN N
( ( N
n JJ N
= NNP N
107 CD N
) ) N
associating VBG N
preliminary JJ N
application NN N
of IN N
an DT N
anesthesic JJ N
patch NN N
, , N
preferential JJ N
use NN N
of IN N
specified JJ N
vaccines NNS N
, , N
child JJ N
education NN N
by IN N
the DT N
parents NNS N
and CC N
the DT N
doctor NN N
, , N
parental JJ N
accompaniment NN N
and CC N
child JJ N
distraction NN N
with IN N
soap NN N
bubbles NNS N
during IN N
the DT N
procedure NN N
. . N

CRP NNP N
, , N
IL-6 NNP N
, , N
IL-8 NNP N
, , N
HIF-1 NNP N
( ( N
ELISA NNP N
) ) N
, , N
CD11 NNP N
and CC N
CD18 NNP N
expression NN N
( ( N
flow JJ N
cytometry NN N
) ) N
, , N
and CC N
haemoxygenase NN N
( ( N
HO-1 NNP N
) ) N
promoter NN N
polymorphisms NN N
( ( N
PCR/electrophoresis NNP N
) ) N
were VBD N
measured VBN N
before IN N
anaesthetic JJ N
induction NN N
, , N
4 CD N
hours NNS N
post-CPB JJ N
, , N
and CC N
24 CD N
hours NNS N
later RB N
. . N

METHODS NNP N
Pronuclear-stage NNP N
human JJ N
embryos NN N
were VBD N
randomly RB N
divided VBN N
and CC N
cultured VBN N
in IN N
human JJ N
tubal JJ N
fluid NN N
medium NN N
( ( N
HTF NNP N
) ) N
supplemented VBD N
with IN N
either DT N
HSA NNP N
( ( N
5 CD N
mg/mL NN N
) ) N
or CC N
Plasmatein NNP N
( ( N
10 CD N
% NN N
, , N
v/v NN N
; : N
5 CD N
mg/ml NN N
) ) N
as IN N
a DT N
means NN N
of IN N
indirectly RB N
assessing VBG N
the DT N
effect NN N
alpha- JJ N
and CC N
beta-globulins NNS N
have VBP N
on IN N
embryonic JJ N
development NN N
. . N

Twenty-nine JJ N
patients NNS p
were VBD N
treated VBN N
with IN N
laparoscopic NN N
assisted VBN N
vaginal JJ N
hysterectomy NN N
( ( N
LAVH NNP N
) ) N
and CC N
bilateral JJ N
salpingo-oophrectomy NN N
( ( N
BSO NNP N
) ) N
plus CC N
minus CC N
laparoscopic JJ N
pelvic JJ N
lymphadenectomy NN N
( ( N
LPLA NNP N
) ) N
, , N
while IN N
32 CD N
patients NNS p
were VBD N
treated VBN N
with IN N
the DT N
traditional JJ N
laparotomy NN N
and CC N
underwent JJ N
total JJ N
abdominal JJ N
hysterectomy NN N
( ( N
TAH NNP N
) ) N
and CC N
BSO NNP N
plus CC N
minus CC N
pelvic JJ N
lymphadenectomy NN N
( ( N
PLA NNP N
) ) N
. . N

METHODS NNP N
Children NNP N
with IN N
core NN N
autism NN N
( ( N
aged VBN N
2 CD N
years NNS N
to TO N
4 CD N
years NNS N
and CC N
11 CD N
months NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
one-to-one JJ N
ratio NN N
to TO N
a DT N
parent-mediated JJ N
communication-focused JJ N
( ( N
Preschool NNP N
Autism NNP N
Communication NNP N
Trial NNP N
[ NNP N
PACT NNP N
] NNP N
) ) N
intervention NN N
or CC N
treatment NN N
as IN N
usual JJ N
at IN N
three CD N
specialist NN N
centres NNS N
in IN N
the DT N
UK NNP N
. . N

Among IN N
women NNS N
treated VBN N
with IN N
goserelin NN N
, , N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
increase NN o
in IN N
the DT N
proportion NN N
of IN N
menstruating VBG N
women NNS N
, , N
1 CD N
year NN N
after IN N
completed VBN N
treatment NN N
compared VBN N
to TO N
at IN N
24 CD N
months NNS N
of IN N
treatment NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
in IN N
contrast NN N
to TO N
all DT N
other JJ N
treatment NN N
groups NNS N
, , N
who WP N
were VBD N
unchanged JJ N
or CC N
more RBR N
often RB N
amenorrheic JJ N
. . N

Pooled VBN N
analysis NN N
of IN N
VACT1/VACT2 NNP N
demonstrated VBD N
greater JJR N
PGART NNP N
( ( N
p=0.023 NN N
) ) N
with IN N
rofecoxib NN N
25 CD N
mg NN N
( ( N
56.1 CD N
% NN N
) ) N
than IN N
celecoxib NN N
( ( N
49.8 CD N
% NN N
) ) N
at IN N
6 CD N
weeks NNS N
and CC N
greater JJR N
response NN N
to TO N
all DT N
other JJ N
PGART NNP N
and CC N
WOMAC NNP N
endpoints NNS N
, , N
and CC N
confirmed VBD N
superiority NN N
of IN N
COX-2 NNP N
inhibitors NNS N
to TO N
acetaminophen VB i
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
with IN N
21 CD N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
diagnoses NNS N
, , N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
, , N
who WP N
received VBD N
the DT N
same JJ N
short-term JJ N
intervention NN N
types NNS N
( ( N
6 CD N
weeks NNS N
with IN N
the DT N
mother NN N
and CC N
6 CD N
weeks NNS N
with IN N
the DT N
support NN N
of IN N
an DT N
educational JJ N
software NN N
program NN N
) ) N
. . N

Fifty-two JJ N
patients NNS p
with IN N
severe JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
from IN N
four CD N
Australian JJ N
centres NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
cyclosporin NN N
A NNP N
( ( N
CSA NNP N
) ) N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
azathioprine NN N
( ( N
AZA NNP N
) ) N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
for IN N
six CD N
months NNS N
. . N

Evaluation NN N
of IN N
different JJ N
inhaled JJ N
combination NN N
therapies NNS N
( ( N
EDICT NNP N
) ) N
: : N
a DT N
randomised JJ N
, , N
double-blind JJ N
comparison NN N
of IN N
Seretide NNP N
( ( N
50/250 CD N
microg NN N
bd NN N
Diskus NNP N
vs. FW N
formoterol NN N
( ( N
12 CD N
microg RB N
bd NN N
) ) N
and CC N
budesonide NN N
( ( N
800 CD N
microg RB N
bd NN N
) ) N
given VBN N
concurrently RB N
( ( N
both DT N
via IN N
Turbuhaler NNP N
) ) N
in IN N
patients NNS p
with IN N
moderate-to-severe JJ N
asthma NN N
. . N

CONCLUSION NN N
In IN N
atrial JJ N
fibrillation NN N
patients NNS p
with IN N
dilated JJ N
left JJ N
atrium NN N
and CC N
hypertension NN N
or CC N
failed VBD N
prior RB N
atrial JJ N
fibrillation NN N
CA NNP N
, , N
SA NNP N
is VBZ N
superior JJ N
to TO N
CA NNP N
in IN N
achieving VBG N
freedom NN N
from IN N
left VBN N
atrial JJ N
arrhythmias NNS N
after IN N
12 CD N
months NNS N
of IN N
follow-up NN N
, , N
although IN N
the DT N
procedural JJ N
adverse JJ N
event NN N
rate NN N
is VBZ N
significantly RB N
higher JJR N
for IN N
SA NNP N
than IN N
for IN N
CA NNP N
. . N

Analysing VBG N
response NN N
to TO N
FUFA NNP N
and CC N
FOLFIRI NNP N
in IN N
the DT N
per NN N
protocol NN N
set VBN N
( ( N
n=119 NN N
) ) N
after IN N
un-blinding JJ N
TS NNP N
in IN N
the DT N
data NN N
base NN N
revealed VBD N
a DT N
trend NN N
to TO N
better JJR N
overall JJ i
response NN N
to TO N
FOLFIRI NNP N
( ( N
9/19 CD N
, , N
47 CD N
% NN N
) ) N
in IN N
TS NNP N
high JJ N
compared VBN N
to TO N
FUFA NNP N
( ( N
5/23 CD N
, , N
22 CD N
% NN N
, , N
p=0.077 NN N
) ) N
. . N

RESULTS JJ N
Participants NNS N
failing VBG N
to TO N
achieve VB N
a DT N
? . N
% NN N
weight JJ N
loss NN N
at IN N
Month NNP N
1 CD N
were VBD N
5.6 CD N
( ( N
95 CD N
% NN N
CI:4.5 NNP N
, , N
7.0 CD N
) ) N
times NNS N
more RBR N
likely JJ N
to TO N
also RB N
not RB N
achieve VB N
a DT N
? . N
% NN N
weight JJ N
loss NN N
at IN N
Year NNP N
1 CD N
, , N
compared VBN N
to TO N
those DT N
losing VBG N
? . N
% NN N
initially RB N
. . N

In IN N
order NN N
to TO N
establish VB N
a DT N
set NN N
of IN N
predictive JJ N
equations NNS N
for IN N
the DT N
gas NN N
exchange NN N
, , N
ventilatory NN N
and CC N
cardiovascular JJ N
responses NNS N
to TO N
maximum VB N
ramp-incremental JJ N
cycle NN N
ergometry NN N
, , N
this DT N
study NN N
prospectively RB N
evaluated VBD N
120 CD N
sedentary JJ N
individuals NNS N
( ( N
60 CD N
males NNS N
, , N
60 CD N
females NNS N
, , N
aged VBD N
20-80 CD N
) ) N
, , N
randomly-selected JJ N
from IN N
> JJ N
8,000 CD N
subjects NNS N
. . N

In IN N
a DT N
1-year JJ N
cessation NN N
trial NN N
of IN N
smokers NNS N
with IN N
COPD NNP N
, , N
continuous JJ N
abstinence NN N
compared VBN N
with IN N
continuous JJ N
smoking VBG N
significantly RB N
improved VBN N
post-bronchodilator NN N
FEV NNP N
( ( N
1 CD N
) ) N
at IN N
Week $ N
12 CD N
( ( N
although IN N
the DT N
difference NN N
narrowed VBD N
subsequently RB N
) ) N
and CC N
CCQ NNP N
Total NNP N
Scores NNP N
at IN N
Week NNP N
12 CD N
, , N
with IN N
sustained JJ N
improvement NN N
thereafter RB N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Sixteen NNP N
patients NNS p
who WP N
had VBD N
chronic JJ N
mitral JJ N
regurgitation NN N
due JJ N
to TO N
myxomatous JJ N
degeneration NN N
were VBD N
randomized VBN N
to TO N
preservation NN N
( ( N
Pres NNP N
group NN N
, , N
n RB N
= VBZ N
8 CD N
) ) N
or CC N
no DT N
preservation NN N
( ( N
No NNP N
Pres NNP N
group NN N
, , N
n RB N
= VBZ N
8 CD N
) ) N
of IN N
the DT N
chordae NN N
tendineae NN N
and CC N
papillary JJ N
muscles NNS N
during IN N
mitral JJ N
valve FW N
replacement NN N
. . N

The DT N
most RBS N
noteworthy JJ N
group NN N
difference NN N
was VBD N
observed VBN N
for IN N
cerebrovascular JJ N
end NN N
points NNS N
( ( N
strokes NNS N
and CC N
transient JJ N
ischemic JJ N
attacks NNS N
) ) N
, , N
with IN N
an DT N
incidence NN N
of IN N
8.2 CD N
% NN N
( ( N
9 CD N
patients NNS p
) ) N
in IN N
the DT N
drug NN N
treatment NN N
group NN N
and CC N
19.0 CD N
% NN N
( ( N
23 CD N
patients NNS p
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

METHODS NNP N
Three CD N
hundred VBD N
fifty JJ N
patients NNS p
who WP N
had VBD N
reoperation NN N
with IN N
CABG NNP N
only RB N
( ( N
58 CD N
% NN N
) ) N
, , N
or CC N
with IN N
valve JJ N
operations NNS N
( ( N
42 CD N
% NN N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
a DT N
heparin-coated JJ N
( ( N
Duraflo NNP N
II NNP N
; : N
study VB N
group NN N
) ) N
or CC N
uncoated JJ N
( ( N
control VB N
group NN N
) ) N
circuit NN N
. . N

Bilastine NNP N
was VBD N
characterized VBN N
by IN N
two-compartmental JJ N
kinetics NNS N
with IN N
a DT N
rapid-absorption NN N
phase NN N
( ( N
first-order JJ N
absorption NN N
rate NN N
constant JJ N
= NN N
1.50 CD N
h NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
plasma JJ N
peak NN N
concentrations NNS N
were VBD N
observed VBN N
at IN N
1 CD N
hour NN N
following VBG N
administration NN N
and CC N
the DT N
maximal JJ N
response NN N
was VBD N
observed VBN N
at IN N
approximately RB N
4 CD N
hours NNS N
or CC N
later RB N
. . N

A DT N
randomized VBN N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
clinical JJ N
hypnosis NN N
versus NN N
cognitive JJ N
behavioral NN N
( ( N
CB NNP N
) ) N
coping VBG N
skills NNS N
training VBG N
in IN N
alleviating VBG N
the DT N
pain NN N
and CC N
distress NN N
of IN N
30 CD N
pediatric JJ N
cancer NN N
patients NNS p
( ( N
age NN N
5 CD N
to TO N
15 CD N
years NNS N
) ) N
undergoing VBG N
bone NN N
marrow NN N
aspirations NNS N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
intervention NN N
study NN N
in IN N
which WDT N
37 CD N
healthy JJ N
, , N
sedentary JJ N
men NNS N
and CC N
women NNS N
( ( N
52+/-2 JJ N
years NNS N
) ) N
performed VBD N
13 CD N
weeks NNS N
of IN N
ST NNP N
( ( N
n=13 NN N
) ) N
, , N
ST+aerobic NNP N
exercise NN N
( ( N
n=12 JJ N
) ) N
or CC N
stretching VBG N
exercises NNS N
as IN N
a DT N
control NN N
group NN N
( ( N
n=12 RB N
) ) N
. . N

We PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
conatumumab NN i
( ( N
an DT N
agonistic JJ N
monoclonal NN N
antibody NN N
against IN N
human JJ N
death NN N
receptor NN N
5 CD N
) ) N
and CC N
ganitumab NN i
( ( N
a DT N
monoclonal NN N
antibody NN N
against IN N
the DT N
type NN N
1 CD N
insulin-like JJ N
growth NN N
factor NN N
receptor NN N
) ) N
combined VBN N
with IN N
standard JJ N
FOLFIRI NNP N
chemotherapy NN i
as IN N
a DT N
second-line JJ N
treatment NN N
in IN N
patients NNS p
with IN N
mutant JJ N
KRAS NNP N
mCRC NN N
. . N

PURPOSE NN N
This DT N
study NN N
was VBD N
undertaken VBN N
with IN N
the DT N
null JJ N
hypothesis NN N
that IN N
in IN N
patients NNS p
, , N
fully RB N
denate VB N
or CC N
with IN N
1 CD N
or CC N
2 CD N
teeth NNS N
missing VBG N
and CC N
older JJR N
than IN N
25 CD N
years NNS N
, , N
mastication NN N
does VBZ N
not RB N
affect VB N
late JJ N
mandibular JJ N
fracture NN N
after IN N
surgical JJ N
removal NN N
of IN N
impacted JJ N
third JJ N
molars NNS N
( ( N
M3s NNP N
) ) N
associated VBN N
with IN N
no DT N
gross JJ N
pathology NN N
. . N

We PRP N
used VBD N
logistic JJ N
regression NN N
models NNS N
to TO N
assess VB N
factors NNS N
that WDT N
are VBP N
associated VBN N
with IN N
inadequate JJ N
FSG NNP N
( ( N
defined VBN N
as IN N
a DT N
study NN N
in IN N
which WDT N
the DT N
depth NN N
of IN N
insertion NN N
of IN N
FSG NNP N
was VBD N
< JJ N
50 CD N
cm NN N
or CC N
visual JJ N
inspection NN N
was VBD N
limited VBN N
to TO N
< VB N
90 CD N
% NN N
of IN N
the DT N
mucosal JJ N
surface NN N
but CC N
without IN N
detection NN N
of IN N
a DT N
polyp NN N
or CC N
mass NN N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
completely RB N
resected VBN N
( ( N
stage NN N
IB NNP N
, , N
II NNP N
, , N
or CC N
IIIA NNP N
) ) N
NSCLC NNP N
stratified VBN N
by IN N
stage NN N
, , N
histology NN N
, , N
sex NN N
, , N
postoperative JJ N
radiotherapy NN i
, , N
and CC N
chemotherapy NN i
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1 CD N
) ) N
to TO N
receive VB N
gefitinib NN N
250 CD N
mg NN N
per IN N
day NN N
or CC N
placebo NN N
for IN N
2 CD N
years NNS N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
three CD N
treatment NN N
groups NNS N
: : N
SCHEDULE VB N
A NNP N
( ( N
control NN N
) ) N
: : N
conventional JJ N
one CD N
treatment NN N
per IN N
day NN N
regimen NNS N
totalling VBG N
3,760 CD N
rads NNS N
in IN N
22-23 JJ N
days NNS N
; : N
SCHEDULE NNP N
B NNP N
: : N
2 CD N
sessions NNS N
per IN N
day NN N
totalling VBG N
3,440 CD N
rads NNS N
in IN N
10-11 JJ N
days NNS N
; : N
and CC N
SCHEDULE NNP N
C NNP N
: : N
2 CD N
sessions NNS N
per IN N
day NN N
totalling VBG N
3,568 CD N
rads NNS N
in IN N
10-11 JJ N
days NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
variations NNS N
in IN N
implant JJ N
indications NNS N
and CC N
baseline VB N
antiarrhythmic JJ N
drug NN N
use NN N
over IN N
the DT N
3-year JJ N
enrollment NN N
period NN N
, , N
although IN N
an DT N
increase NN o
in IN N
the DT N
percentage NN N
of IN N
dual-chamber JJ N
ICDs NNP N
implanted VBD N
occurred VBD N
, , N
with IN N
the DT N
majority NN N
( ( N
65 CD N
% NN N
) ) N
of IN N
implanted JJ N
ICDs NNP N
being VBG N
dual-chamber JJ N
devices NNS N
by IN N
the DT N
end NN N
of IN N
the DT N
enrollment JJ N
period NN N
. . N

The DT N
diabetic JJ N
patients NNS p
also RB N
were VBD N
infused VBN N
in IN N
random JJ N
order NN N
and CC N
on IN N
different JJ N
days NNS N
with IN N
either DT N
saline NN N
or CC N
a DT N
smaller JJR N
amount NN N
of IN N
insulin NN N
delivered VBN N
continuously RB N
( ( N
0.15 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC N
in IN N
a DT N
pulsatile JJ N
manner NN N
( ( N
0.97 CD N
mU RB N
kg-1 JJ N
min-1 NN N
for IN N
2 CD N
min NN N
, , N
followed VBN N
by IN N
11 CD N
min NNS N
during IN N
which WDT N
no DT N
insulin NN N
was VBD N
infused VBN N
) ) N
. . N

AIMS NNP N
To TO N
evaluate VB N
whether IN N
a DT N
combination NN N
of IN N
locally RB N
administered VBN N
morphine NN N
( ( N
1 CD N
mg NN N
) ) N
and CC N
lidocaine NN N
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
analgesic JJ N
approach NN N
is VBZ N
safe JJ N
, , N
and CC N
whether IN N
it PRP N
improves VBZ N
pain JJ N
control NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
odontogenic JJ N
maxillary JJ N
cyst NN N
removal NN N
under IN N
general JJ N
anesthesia NN N
compared VBN N
to TO N
local JJ N
lidocaine NN N
alone RB N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
71 CD N
patients NNS p
with IN N
confirmed VBN N
severe JJ N
acute NN N
pancreatitis NN N
from IN N
March NNP N
2009 CD N
to TO N
September NNP N
2011 CD N
in IN N
the DT N
Department NNP N
of IN N
Critical NNP N
Care NNP N
Medicine NNP N
of IN N
Huizhou NNP N
Municipal NNP N
Central NNP N
Hospital NNP N
, , N
Guangdong NNP N
, , N
China NNP N
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
40 CD N
mg NN N
of IN N
the DT N
beta-blocker NN N
penbutolol NN i
( ( N
Betapressin NNP N
TM NNP N
; : N
Hoechst NNP N
Ltd. NNP N
, , N
Frankfurt/Main NNP N
) ) N
in IN N
comparison NN N
to TO N
placebo VB N
on IN N
the DT N
insulin NN N
consumption NN N
on IN N
the DT N
blood NN N
sugar NN N
profile NN N
in IN N
twelve JJ N
insulin-dependent JJ N
diabetes NNS N
( ( N
IDDM NNP N
) ) N
patients NNS p
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
and CC N
placebo-controlled JJ N
study NN N
in IN N
25 CD N
healthy JJ N
postmenopausal NN N
women NNS N
( ( N
52.5 CD N
+/- JJ N
2.8 CD N
years NNS N
) ) N
, , N
we PRP N
therefore VBP N
examined VBD N
the DT N
short-term JJ N
effect NN N
of IN N
unopposed JJ N
estrogen NN N
on IN N
the DT N
fasting NN N
and CC N
fat-load-stimulated JJ N
plasma NN N
levels NNS N
of IN N
total JJ N
factor NN N
VII NNP N
versus NN N
active JJ N
factor NN N
VII NNP N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
topical JJ N
racemic JJ N
adrenaline NN N
( ( N
RA NNP N
) ) N
( ( N
Micronefrin NNP N
; : N
Bird NNP N
Products NNPS N
, , N
Palm NNP N
Springs NNP N
, , N
CA NNP N
, , N
USA NNP N
) ) N
in IN N
the DT N
control NN N
of IN N
intraoperative JJ N
bleeding NN N
and CC N
the DT N
prevention NN N
of IN N
postoperative JJ N
bleeding NN N
, , N
laryngeal JJ N
spasm NN N
and CC N
postoperative JJ N
pain NN N
in IN N
adenoidectomy NN N
among IN N
children NNS N
< VBP N
6 CD N
years NNS N
of IN N
age NN N
. . N

We PRP N
present VBP N
the DT N
results NNS N
of IN N
two CD N
blind NNS N
randomized JJ N
trials NNS N
comparing VBG N
both DT N
guanethidine JJ N
3 CD N
per IN N
cent NN N
and CC N
adrenaline VB N
0.5 CD N
per IN N
cent NN N
( ( N
Ganda NNP N
3.0/0.5 CD N
) ) N
and CC N
guanethidine $ N
1 CD N
per IN N
cent NN N
and CC N
adrenaline VB N
0.2 CD N
per IN N
cent NN N
( ( N
Ganda NNP N
1.0/0.2 CD N
) ) N
in IN N
single JJ N
drop NN N
form NN N
with IN N
Timolol NNP i
( ( N
Timoptol NNP N
) ) N
0.25 CD N
per IN N
cent NN N
. . N

The DT N
efficacy NN N
of IN N
eprinomectin JJ i
versus NN N
ivermectin NN i
( ( N
Study NNP N
1 CD N
: : N
a DT N
single-centre JJ N
, , N
randomised JJ N
, , N
treatment-controlled JJ N
, , N
blinded VBD N
field NN N
trial NN N
) ) N
, , N
and CC N
the DT N
field NN N
efficacy NN N
of IN N
eprinomectin NN i
( ( N
Study NNP N
2 CD N
: : N
a DT N
single-centre JJ N
, , N
open JJ N
, , N
un-controlled JJ N
field NN N
trial NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
chorioptic JJ N
infestation NN N
in IN N
naturally RB N
infested VBN N
alpacas NN N
were VBD N
assessed VBN N
in IN N
two CD N
studies NNS N
. . N

METHOD NNP N
Eighty-nine NNP N
suppressed VBD N
patients NNS p
> CD N
or CC N
=18 CD N
years NNS N
old JJ N
with IN N
CD4 NNP N
counts VBZ N
> JJ N
50 CD N
cells/mm NN N
( ( N
3 CD N
) ) N
were VBD N
enrolled VBN N
in IN N
this DT N
phase NN N
II NNP N
, , N
open-label NN N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
stratified VBN N
( ( N
by IN N
pretrial JJ N
protease NN N
inhibitor NN N
[ NNP N
PI NNP N
] NNP N
) ) N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
665 CD N
patients NNS p
with IN N
a DT N
history NN N
of IN N
colorectal JJ N
adenomas NN N
to TO N
three CD N
treatment NN N
groups NNS N
, , N
in IN N
a DT N
parallel JJ N
design NN N
: : N
calcium NN N
gluconolactate NN N
and CC N
carbonate NN N
( ( N
2 CD N
g NN N
elemental JJ N
calcium NN N
daily RB N
) ) N
, , N
fibre JJ N
( ( N
3.5 CD N
g NN N
ispaghula NN N
husk NN N
) ) N
, , N
or CC N
placebo NN N
. . N

METHODS NNP N
In IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ N
study NN N
we PRP N
randomized VBD N
1223 CD N
mothers NNS N
with IN N
infants NNS N
at IN N
high JJ N
risk NN N
for IN N
allergy NN N
to TO N
receive VB N
a DT N
probiotic JJ i
mixture NN N
( ( N
2 CD N
lactobacilli NN N
, , N
bifidobacteria NN N
, , N
and CC N
propionibacteria NN N
) ) N
or CC N
placebo NN N
during IN N
the DT N
last JJ N
month NN N
of IN N
pregnancy NN N
and CC N
their PRP$ N
infants NNS N
to TO N
receive VB N
it PRP N
from IN N
birth NN N
until IN N
age NN N
6 CD N
months NNS N
. . N

No DT N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
numbers NNS N
of IN N
CD19+ NNP N
B NNP N
cells NNS N
( ( N
range NN N
, , N
5 CD N
% NN N
to TO N
51 CD N
% NN N
) ) N
and CC N
PCR NNP N
estimates NNS N
of IN N
the DT N
number NN N
of IN N
clonal JJ N
cells NNS N
in IN N
the DT N
peripheral JJ N
blood NN N
( ( N
range NN N
, , N
.009 CD N
% NN N
to TO N
3.6 CD N
% NN N
) ) N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
chronic JJ N
lung NN N
disease NN N
( ( N
28 CD N
day NN N
and CC N
36 CD N
week NN N
definitions NNS N
) ) N
, , N
death NN N
, , N
pneumothorax NN i
, , N
intraventricular JJ N
haemorrhage NN N
, , N
number NN N
of IN N
ventilator NN N
days NNS N
, , N
or CC N
length NN N
of IN N
oxygen NN N
dependency NN N
between IN N
groups NNS N
. . N

METHODS NNP N
Three CD N
hundred VBD N
and CC N
seventy JJ N
nine CD N
women NNS N
( ( N
260 CD N
with IN N
a DT N
family NN N
history NN N
of IN N
breast NN N
cancer NN N
; : N
119 CD N
with IN N
breast NN N
cancer NN N
) ) N
from IN N
The DT N
Royal NNP N
Marsden NNP N
NHS NNP N
Foundation NNP N
Trust NNP N
were VBD N
randomised VBN N
to TO N
receive VB N
or CC N
not RB N
receive JJ N
written VBN N
educational JJ N
information NN N
on IN N
cancer NN N
genetics NNS N
. . N

METHODS NNP N
Sixty-five JJ N
day-only JJ N
patients NNS p
with IN N
renal JJ N
impairment NN N
( ( N
mean JJ N
serum NN N
creatinine NN N
concentration NN N
0.16+/-0.03 NNP N
mmol/l NN N
) ) N
due JJ N
to TO N
undergo JJ N
coronary JJ N
or CC N
peripheral JJ N
angiography NN N
and/or NN N
stenting VBG N
were VBD N
randomly RB N
assigned VBN N
to TO N
IV NNP N
NAC NNP N
300 CD N
or CC N
600 CD N
mg NNS N
immediately RB N
before IN N
and CC N
after IN N
the DT N
procedure NN N
or CC N
IV NNP N
fluid VBP N
alone RB N
. . N

In IN N
a DT N
placebo-controlled JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
the DT N
authors NNS N
evaluated VBD N
the DT N
efficacy NN N
of IN N
patient-administered JJ N
1 CD N
% NN N
fusidic JJ N
acid RB N
viscous JJ N
eye NN N
drops NNS N
in IN N
clearing VBG N
the DT N
commonest JJS N
organisms JJ N
causing VBG N
pseudophakic NN N
endophthalmitis NN N
( ( N
Staphylococcus NNP N
epidermidis RB N
and CC N
aureus RB N
) ) N
from IN N
the DT N
lids NNS N
and CC N
conjunctivae NN N
of IN N
79 CD N
patients NNS p
before IN N
cataract JJ N
surgery NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
post-vaccination NN N
symptoms NNS N
were VBD N
irritability NN N
in IN N
the DT N
DTPa-IPV-Hib NNP N
plus CC N
separate JJ N
HBV NNP N
group NN N
( ( N
49 CD N
% NN N
of IN N
vaccinees NNS N
) ) N
and CC N
fever NN N
, , N
defined VBD N
as IN N
axillary JJ N
temperature NN N
> NN N
or CC N
=37.5 NN N
degrees NNS N
C NNP N
, , N
in IN N
the DT N
DTPa NNP N
HBV- NNP N
IPV-Hib NNP N
group NN N
( ( N
50 CD N
% NN N
of IN N
vaccinees NNS N
) ) N
. . N

Immediately RB N
after IN N
the DT N
CETs NNP N
horses NNS N
were VBD N
allowed VBN N
water NN N
ad NN N
libitum NN N
and CC N
either DT N
: : N
1 CD N
) ) N
8 CD N
L NNP N
of IN N
a DT N
hypertonic JJ N
NaAcetate/acetic NNP N
acid NN N
solution NN N
via IN N
nasogastric JJ N
tube NN N
followed VBN N
by IN N
a DT N
typical JJ N
hay/grain NN N
meal NN N
( ( N
NAA NNP N
trial NN N
) ) N
; : N
or CC N
2 CD N
) ) N
a DT N
hay/grain JJ N
meal NN N
alone RB N
( ( N
Control NNP N
trial NN N
) ) N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
and CC N
outcome NN N
of IN N
the DT N
step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB N
A NNP N
( ( N
CSA NNP N
) ) N
or CC N
methotrexate NN N
( ( N
MTX NNP N
) ) N
as IN N
maintenance NN N
therapy NN i
following VBG N
6 CD N
months NNS N
treatment NN N
with IN N
these DT N
2 CD N
agents NNS N
in IN N
combination NN N
in IN N
early JJ N
, , N
nonerosive JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

Within IN N
48 CD N
hours NNS N
of IN N
administration NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN o
in IN N
the DT N
circulating VBG N
absolute JJ N
neutrophil NN N
count NN N
( ( N
ANC NNP N
) ) N
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
, , N
which WDT N
continued VBD N
for IN N
at IN N
least JJS N
24 CD N
hours NNS N
after IN N
discontinuation NN N
of IN N
rhuGM-CSF NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Five NNP N
hundred VBD N
sixty NN N
patients NNS p
, , N
fully RB N
dentate VB N
or CC N
with IN N
1 CD N
or CC N
2 CD N
teeth NNS N
missing VBG N
and CC N
older JJR N
than IN N
25 CD N
years NNS N
who WP N
had VBD N
no DT N
gross JJ N
pathology NN N
associated VBN N
with IN N
their PRP$ N
impacted VBN N
lower JJR N
M3s NNP N
, , N
were VBD N
recruited VBN N
in IN N
this DT N
study NN N
. . N

Time NN N
to TO N
prostate-specific JJ N
antigen NN N
progression NN N
was VBD N
4.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
3.1 CD N
to TO N
6.9 CD N
months NNS N
) ) N
on IN N
the DT N
ixabepilone-alone JJ N
arm NN N
and CC N
5.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
4.5 CD N
to TO N
6.8 CD N
months NNS N
) ) N
on IN N
the DT N
combination NN N
arm NN N
. . N

We PRP N
analyzed VBD N
thresholds NNS N
for IN N
contact NN N
detection NN N
, , N
two-point JJ N
discrimination NN N
, , N
and CC N
two-point JJ N
perception NN N
, , N
obtained VBN N
during IN N
the DT N
clinical JJ N
trial NN N
before IN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
, , N
to TO N
assess VB N
tactile JJ N
detection NN N
and CC N
discriminative JJ N
sensitivities NNS N
, , N
and CC N
subjective JJ N
interpretation NN N
of IN N
tactile JJ N
stimulation NN N
, , N
respectively RB N
. . N

Two CD N
hundred VBD N
patients NNS p
with IN N
similar JJ N
demographics NNS N
undergoing JJ N
elective JJ N
LC NNP N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
four CD N
groups NNS N
of IN N
50 CD N
patients NNS p
each DT N
, , N
including VBG N
Group NNP N
A NNP N
placebo NN N
control NN N
, , N
Group NNP N
B NNP N
with IN N
isotonic JJ N
saline NN N
irrigation NN N
, , N
Group NNP N
C NNP N
with IN N
bupivacaine JJ N
irrigation NN N
, , N
and CC N
Group NNP N
D NNP N
with IN N
lignocaine JJ N
irrigation NN N
. . N

BACKGROUND NNP N
Previous NNP N
analyses NNS N
of IN N
the DT N
International NNP N
Subarachnoid NNP N
Aneurysm NNP N
Trial NNP N
( ( N
ISAT NNP N
) ) N
cohort NN N
have VBP N
reported VBN N
on IN N
the DT N
risks NNS N
of IN N
recurrent NN N
subarachnoid JJ N
haemorrhage NN N
and CC N
death NN N
or CC N
dependency NN N
for IN N
a DT N
minimum NN N
of IN N
5 CD N
years NNS N
and CC N
up RB N
to TO N
a DT N
maximum NN N
of IN N
14 CD N
years NNS N
after IN N
treatment NN N
of IN N
a DT N
ruptured JJ N
intracranial JJ N
aneurysm NN N
with IN N
either DT N
neurosurgical JJ N
clipping NN N
or CC N
endovascular JJ N
coiling NN N
. . N

Efficacy NN N
measurements NNS N
were VBD N
comparable JJ N
between IN N
the DT N
three CD N
treatment NN N
groups NNS N
, , N
although IN N
the DT N
higher JJR N
lamotrigine NN N
dose NN N
was VBD N
possibly RB N
most RBS N
effective JJ N
, , N
with IN N
60.4 CD N
% NN N
completing VBG N
seizure NN N
free JJ N
compared VBN N
with IN N
51.3 CD N
% NN N
( ( N
LTG NNP N
100 CD N
) ) N
and CC N
54.7 CD N
% NN N
( ( N
CBZ NNP N
600 CD N
) ) N
. . N

RESULTS VB N
The DT N
rates NNS N
of IN N
retinitis NN N
progression NN N
, , N
as IN N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
, , N
were VBD N
3.04/person-year JJ N
in IN N
the DT N
MSL-109-treated NNP N
group NN N
and CC N
3.05/person-year JJ N
in IN N
the DT N
placebo-treated JJ N
group NN N
( ( N
P=.98 NNP N
; : N
Wald NNP N
test NN N
) ) N
; : N
the DT N
median JJ N
times NNS N
to TO N
progression NN N
were VBD N
67 CD N
days NNS N
in IN N
the DT N
MSL-109-treated NNP N
group NN N
and CC N
65 CD N
days NNS N
in IN N
the DT N
placebo-treated JJ N
group NN N
. . N

Burn NNP N
depth NN N
, , N
measured VBN N
by IN N
laser NN N
Doppler NNP N
imaging NN N
( ( N
LDI NNP N
) ) N
and CC N
histologically RB N
, , N
white JJ N
blood NN N
cell NN N
( ( N
WBC NNP N
) ) N
count NN N
and CC N
plasma JJ N
cytokine NN N
inflammatory NN N
markers NNS N
were VBD N
assessed VBN N
at IN N
24 CD N
h NN N
( ( N
pre JJ N
HBOT NNP N
) ) N
and CC N
48 CD N
h NN N
( ( N
post VB N
HBOT NNP N
) ) N
post NN N
burn NN N
, , N
as IN N
were VBD N
immunohistochemistry NN N
and CC N
microbiology NN N
of IN N
burns NNS N
tissue NN N
samples NNS N
at IN N
48 CD N
h NN N
post NN N
burn NN N
. . N

Cholesterol NN N
levels NNS N
differed VBD N
little RB N
between IN N
the DT N
two CD N
intervention NN N
groups NNS N
6 CD N
months NNS N
after IN N
screening VBG N
, , N
but CC N
after IN N
12 CD N
months NNS N
those DT N
in IN N
the DT N
special JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
6.5 CD N
% NN N
drop NN N
in IN N
cholesterol NN N
, , N
whereas IN N
those DT N
at IN N
the DT N
usual JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
drop NN N
of IN N
only RB N
3.0 CD N
% NN N
. . N

Two CD N
hundred VBD N
three CD N
patients NNS p
( ( N
median JJ N
age NN N
26 CD N
years NNS N
; : N
range VB N
18-45 JJ N
) ) N
with IN N
untreated JJ N
multiple NNS N
and CC N
widespread JJ N
anogenital JJ N
condyloma NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
study NN N
arms NNS N
in IN N
order NN N
to TO N
compare VB N
the DT N
efficacy NN N
, , N
toxicity NN N
, , N
and CC N
tolerability NN N
of IN N
recombinant JJ N
interferon NN N
alpha-2b NN N
with IN N
those DT N
of IN N
diathermocoagulation NN N
. . N

A DT N
greater JJR N
reduction NN N
in IN N
the DT N
duration NN N
of IN N
air NN N
leaks NNS N
was VBD N
observed VBN N
before IN N
postoperative JJ N
day NN N
4 CD N
in IN N
group NN N
1 CD N
, , N
and CC N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
having VBG N
a DT N
pleural JJ N
tent NN N
procedure NN N
was VBD N
the DT N
most RBS N
significant JJ N
predictive JJ N
factor NN N
of IN N
air NN N
leaks NNS N
that WDT N
persisted VBD N
for IN N
less JJR N
than IN N
4 CD N
days NNS N
. . N

SRP NNP N
was VBD N
performed VBN N
three CD N
weeks NNS N
after IN N
baseline NN N
, , N
and CC N
clinical JJ N
assessments NNS N
, , N
i.e NN N
, , N
pocket NN N
probing VBG N
depth NN N
( ( N
PPD NNP N
) ) N
and CC N
bleeding VBG N
index NN N
( ( N
BI NNP N
) ) N
, , N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
13 CD N
, , N
and CC N
26 CD N
weeks NNS N
of IN N
peroxide JJ N
gel NN N
applications NNS N
. . N

Complications NNS N
such JJ N
as IN N
cardiac JJ N
tamponade NN N
and CC N
mitral JJ N
regurgitation NN N
( ( N
requiring VBG N
or CC N
not RB N
requiring VBG N
mitral JJ N
valve FW N
replacement NN N
) ) N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
with IN N
3 CD N
complications NNS N
in IN N
the DT N
IBMC NNP N
group NN N
, , N
compared VBN N
with IN N
4 CD N
complications NNS N
in IN N
the DT N
PMMC NNP N
group NN N
( ( N
P NNP N
=.29 NNP N
) ) N
. . N

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
glycaemic JJ N
response NN N
rate NN N
( ( N
responders NNS N
being VBG N
predefined VBN N
as IN N
patients NNS p
who WP N
achieve VBP N
a DT N
decrease NN o
in IN N
HbA1c NNP N
to TO N
less JJR N
than IN N
8 CD N
% NN N
or CC N
a DT N
reduction NN N
by IN N
at IN N
least JJS N
15 CD N
% NN N
as IN N
compared VBN N
to TO N
the DT N
baseline NN N
values NNS N
) ) N
and CC N
the DT N
daily JJ N
insulin NN N
dose NN N
at IN N
6 CD N
months NNS N
. . N

A DT N
total NN N
of IN N
452 CD N
consecutive JJ N
patients NNS p
( ( N
240 CD N
with IN N
kidney NN N
disease NN N
and CC N
212 CD N
without IN N
kidney NN N
disease NN N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
diagnostic JJ N
strategy NN N
with IN N
( ( N
BNP NNP N
group NN N
) ) N
or CC N
without IN N
( ( N
control NN N
group NN N
) ) N
the DT N
use NN N
of IN N
BNP NNP N
levels NNS N
provided VBN N
by IN N
a DT N
rapid JJ N
bedside NN N
assay NN N
. . N

METHODS NNP N
The DT N
effects NNS N
of IN N
captopril NN N
( ( N
12.5 CD N
mg NN N
and CC N
25 CD N
mg NN N
) ) N
and CC N
enalapril $ N
( ( N
5 CD N
mg NN N
and CC N
10 CD N
mg NN N
) ) N
administered VBD N
during IN N
7-day JJ N
periods NNS N
on IN N
electroencephalogram NN N
( ( N
EEG NNP N
) ) N
, , N
cognitive JJ N
functions NNS N
, , N
and CC N
subjective JJ N
assessments NNS N
were VBD N
investigated VBN N
in IN N
healthy JJ N
males NNS N
. . N

Fourteen JJ N
subjects NNS N
( ( N
three CD N
females NNS N
and CC N
11 CD N
males NNS N
) ) N
, , N
who WP N
met VBD N
the DT N
criteria NNS N
for IN N
pathological JJ N
gambling NN N
in IN N
accordance NN N
with IN N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
IV NNP N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
Treatment NNP N
Group NNP N
( ( N
n=7 RB N
) ) N
or CC N
a DT N
waiting JJ N
list NN N
Control NNP N
Group NNP N
( ( N
n=7 RB N
) ) N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
156 CD N
patients NNS p
with IN N
stage NN N
III NNP N
or CC N
IV NNP N
gastric JJ N
cancer NN N
who WP N
had VBD N
undergone JJ N
curative JJ N
resection NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
treatment NN N
groups NNS N
: : N
BCG NNP N
+ NNP N
FAM NNP N
( ( N
immunochemotherapy NN i
) ) N
, , N
FAM NNP N
( ( N
chemotherapy NN i
) ) N
, , N
and CC N
control NN N
( ( N
surgery NN N
only RB N
) ) N
. . N

Analyses NNS N
were VBD N
conducted VBN N
on IN N
eligible JJ N
participants NNS N
( ( N
n=77 NN N
) ) N
for IN N
the DT N
stabilization NN N
( ( N
maximum JJ N
18 CD N
weeks NNS N
) ) N
and CC N
maintenance NN N
phases NNS N
( ( N
up RB N
to TO N
Week NNP N
104 CD N
) ) N
on IN N
primary JJ N
outcome JJ N
measures NNS N
of IN N
time NN N
to TO N
stabilization NN N
and CC N
relapse NN N
, , N
change NN N
in IN N
symptoms NNS N
and CC N
safety NN N
, , N
and CC N
comparisons NNS N
made VBN N
across IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
, , N
fully RB N
dentate VB N
or CC N
with IN N
1 CD N
or CC N
2 CD N
teeth NNS N
missing VBG N
and CC N
older JJR N
than IN N
25 CD N
years NNS N
who WP N
have VBP N
no DT N
jawbone NN N
atrophy NN N
and CC N
no DT N
systemic JJ N
problems NNS N
that WDT N
may MD N
impair VB N
bone NN N
strength NN N
, , N
mastication NN N
seems VBZ N
not RB N
to TO N
affect VB N
late JJ N
mandibular JJ N
fracture NN N
after IN N
surgical JJ N
removal NN N
of IN N
impacted JJ N
M3s NNP N
associated VBN N
with IN N
no DT N
gross JJ N
pathology NN N
. . N

The DT N
pharmacokinetic/pharmacodynamic JJ N
model NN N
showed VBD N
that IN N
the DT N
QTcI NNP N
slope NN N
for IN N
vilazodone NN i
was VBD N
not RB N
different JJ N
from IN N
0.0 CD N
and CC N
that IN N
the DT N
predicted JJ N
increase NN o
from IN N
baseline NN N
in IN N
the DT N
QTc NNP N
at IN N
Cmax NNP i
for IN N
the DT N
highest JJS N
therapeutic JJ N
dose NN N
( ( N
156 CD N
ng/ml RB N
after IN N
40 CD N
mg/day NN N
) ) N
was VBD N
< JJ N
1 CD N
ms NN N
. . N

Feeding VBG N
a DT N
LS NNP N
or CC N
a DT N
HS NNP N
diet NN N
for IN N
30 CD N
d NN N
before IN N
breeding NN N
may MD N
be VB N
inadequate JJ N
to TO N
stimulate VB N
puberty NN N
in IN N
beef NN N
heifers NNS N
, , N
but CC N
feeding VBG N
a DT N
diet JJ N
with IN N
a DT N
greater JJR N
amount NN N
of IN N
starch NN N
for IN N
60 CD N
d NN N
before IN N
breeding NN N
may MD N
increase VB o
the DT N
incidence NN N
of IN N
puberty NN N
during IN N
breeding NN N
of IN N
heifers NNS N
that WDT N
have VBP N
inadequate JJ N
yearling NN N
weight NN N
. . N

Therefore RB N
, , N
we PRP N
set VBP N
out RP N
to TO N
determine VB N
1 CD N
) ) N
the DT N
contribution NN N
of IN N
prostacyclin NN N
to TO N
the DT N
bradykinin-mediated JJ N
vasodepressor NN N
effects NNS N
of IN N
ACE NNP N
inhibitors NNS N
, , N
2 CD N
) ) N
whether IN N
ACE NNP N
inhibitors NNS N
alter VBP N
the DT N
effect NN N
of IN N
bradykinin NN N
on IN N
prostacyclin NN N
, , N
and CC N
3 CD N
) ) N
whether IN N
the DT N
effects NNS N
of IN N
ACE NNP N
inhibitors NNS N
on IN N
bradykinin NN N
and CC N
prostaglandins NNS N
are VBP N
class NN N
effects NNS N
or CC N
dependent NN N
on IN N
ACE NNP N
inhibitor NN N
structure NN N
. . N

Evaluation NN N
of IN N
serum NN N
androgen NN N
levels NNS N
, , N
grading NN N
of IN N
acne NN N
and CC N
hirsutism NN N
( ( N
respectively RB N
with IN N
Pillsbury NNP N
and CC N
Ferriman-Gallwey NNP N
score NN N
) ) N
and CC N
non-invasive JJ N
assessment NN N
of IN N
skin JJ N
hydration NN N
, , N
transepidermal JJ N
water NN N
loss NN N
( ( N
TEWL NNP N
) ) N
and CC N
skin JJ N
homogeneity NN N
were VBD N
performed VBN N
at IN N
baseline NN N
, , N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
( ( N
end NN N
of IN N
treatment NN N
) ) N
. . N

METHODS NNP N
In IN N
an DT N
open-labelled JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
cross-over NN N
study NN N
with IN N
16 CD N
non-asthmatic JJ N
SAR NNP N
patients NNS p
( ( N
median JJ N
age NN N
25 CD N
years NNS N
, , N
56 CD N
% NN N
males NNS N
) ) N
, , N
the DT N
effect NN N
of IN N
a DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
performed VBD N
out IN N
of IN N
season NN N
on IN N
induced JJ N
sputum NN N
inflammatory NN N
parameters NNS N
was VBD N
evaluated VBN N
. . N

Fifty-two JJ N
patients NNS p
undergoing VBG N
coronary JJ N
artery NN N
bypass NN N
on IN N
cardiopulmonary JJ N
bypass NN N
were VBD N
divided VBN N
randomly RB N
into IN N
3 CD N
groups NNS N
: : N
the DT N
first JJ N
group NN N
received VBD N
100 CD N
microg NNS N
x JJ N
kg NN N
( ( N
-1 NNP N
) ) N
x VBP N
min NN N
( ( N
-1 NNP N
) ) N
propofol NN N
, , N
the DT N
other JJ N
groups NNS N
received VBD N
one CD N
minimum NN N
alveolar JJ N
concentration NN N
of IN N
sevoflurane NN N
or CC N
isoflurane NN N
for IN N
anesthesia JJ N
maintenance NN N
. . N

In IN N
this DT N
double-blind NN N
, , N
three-arm NN N
study NN N
, , N
105 CD N
patients NNS p
diagnosed VBN N
with IN N
acute JJ N
abacterial JJ N
otitis NN N
externa NN N
were VBD N
included VBN N
and CC N
randomized VBN N
to TO N
receive VB N
either DT N
glycerol NN N
eardrops VBZ N
, , N
glycerol NN N
eardrops NNS N
with IN N
0.5 CD N
% NN N
lidocaine NN N
, , N
or CC N
glycerol NN N
eardrops NNS N
with IN N
2 CD N
% NN N
lidocaine NN N
for IN N
seven CD N
days NNS N
. . N

Outcome NN N
measurements NNS N
included VBD N
Composite NNP N
Spasticity NNP N
Scale NNP N
, , N
peak NN N
torques NNS N
generated VBD N
during IN N
maximum JJ N
isometric JJ N
voluntary JJ N
contraction NN N
of IN N
ankle JJ N
dorsiflexors NNS N
and CC N
plantarflexors NNS N
, , N
and CC N
gait VBP N
velocity NN N
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
and CC N
4 CD N
weeks NNS N
after IN N
treatment NN N
ended VBD N
. . N

In IN N
a DT N
Cox NNP N
model NN N
, , N
the DT N
presence NN N
of IN N
tense NN N
ascites NNS N
( ( N
relative JJ N
risk NN N
3.4 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
CI NNP N
2.5-5.9 CD N
) ) N
and CC N
a DT N
prior JJ N
history NN N
of IN N
hemorrhage NN N
( ( N
relative JJ N
risk NN N
4.4 CD N
, , N
95 CD N
% NN N
CI NNP N
2.6-7.5 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
variceal JJ N
hemorrhage NN N
. . N

fractionation NN N
during IN N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
of IN N
hyperfractionated JJ N
radiation NN N
therapy NN i
( ( N
HFX NNP N
RT NNP N
) ) N
to TO N
a DT N
total JJ N
dose NN N
of IN N
77 CD N
Gy NNP N
given VBN N
in IN N
70 CD N
fractions NNS N
of IN N
1.1 CD N
Gy NNP N
b.i.d NN N
, , N
with IN N
and CC N
without IN N
concurrent JJ N
low-dose JJ N
, , N
daily JJ N
cisplatin NN i
( ( N
CDDP NNP N
) ) N
for IN N
head NN N
and CC N
neck NN N
cancer NN N
. . N

UNLABELLED IN N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
crossover NN N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
on IN N
autonomic JJ N
responses NNS N
in IN N
preterm JJ N
infants NNS N
of IN N
longer JJR N
Kangaroo NNP N
Care NNP N
( ( N
30 CD N
minutes NNS N
, , N
KC30 NNP N
) ) N
and CC N
shorter JJR N
KC NNP N
( ( N
15 CD N
minutes NNS N
, , N
KC15 NNP N
) ) N
before IN N
and CC N
throughout IN N
heel NN N
stick NNS N
compared VBN N
with IN N
incubator NN N
care NN N
( ( N
IC NNP N
) ) N
. . N

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
of IN N
20 CD N
healthy JJ N
women NNS N
( ( N
mean JJ N
age NN N
45 CD N
( ( N
SD NNP N
8 CD N
) ) N
yr NN N
) ) N
who WP N
were VBD N
to TO N
undergo VB N
uterine JJ N
surgery NN N
through IN N
a DT N
low JJ N
transverse NN N
incision NN N
. . N

To TO N
compare VB N
the DT N
short-term JJ N
effects NNS N
of IN N
metformin NN N
( ( N
M NNP N
) ) N
, , N
naltrexone RB N
( ( N
N NNP N
) ) N
, , N
and CC N
a DT N
combination NN N
of IN N
OC NNP N
and CC N
prednisolone NN N
( ( N
OC/Pr NNP N
) ) N
on IN N
the DT N
metabolic JJ N
state NN N
and CC N
the DT N
ovarian JJ N
function NN N
of IN N
PCOS NNP N
women NNS N
, , N
we PRP N
randomized VBD N
29 CD N
women NNS N
to TO N
a DT N
3-month JJ N
course NN N
of IN N
therapy NN i
. . N

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
184 CD N
healthy JJ N
post-menopausal JJ N
women NNS N
randomized VBD N
to TO N
6 CD N
cycles NNS N
of IN N
either DT N
estradiol NN N
( ( N
2mg CD N
) ) N
+trimegestone NN N
( ( N
0.5mg CD N
) ) N
( ( N
T-group NNP N
) ) N
or CC N
estradiol NN N
( ( N
2mg CD N
) ) N
+dydrogesterone NN N
( ( N
10mg CD N
) ) N
( ( N
DYDR NNP N
group NN N
) ) N
. . N

LAVH NNP N
, , N
when WRB N
compared VBN N
with IN N
TAH NNP N
in IN N
the DT N
two CD N
weight NN N
subgroups NNS N
, , N
required VBD N
a DT N
significantly RB N
longer RBR N
operating VBG N
time NN N
only RB N
in IN N
Group NNP N
2 CD N
, , N
significantly RB N
reduced VBN N
analgesics NNS N
administration NN N
only RB N
in IN N
Group NNP N
1 CD N
, , N
and CC N
significantly RB N
reduced VBN N
hospital NN N
stay NN N
in IN N
both DT N
groups NNS N
. . N

Eligible JJ N
subjects NNS N
in IN N
a DT N
multicenter NN N
, , N
double-masked JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ N
, , N
natural JJ N
exposure NN N
clinical JJ N
trial NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
BBOS NNP N
1.5 CD N
% NN N
or CC N
placebo NN N
eyedrops NNS N
on IN N
a DT N
1:1 CD N
basis NN N
and CC N
instilled VBD N
1 CD N
drop NN N
of IN N
the DT N
test NN N
agent NN N
into IN N
both DT N
eyes NNS N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

RESULTS NNP N
Acceptability NNP N
of IN N
study NN N
participation NN N
is VBZ N
high JJ N
with IN N
86 CD N
% NN N
of IN N
those DT N
referred VBN N
who WP N
met VBD N
eligibility NN N
criteria NNS N
and CC N
85 CD N
% NN N
of IN N
those DT N
who WP N
were VBD N
able JJ N
to TO N
receive VB N
injections NNS N
prior RB N
to TO N
release VB N
accepted JJ N
injections NNS N
, , N
yet RB N
important JJ N
implementation NN N
issues NNS N
are VBP N
identified VBN N
and CC N
addressed VBN N
during IN N
the DT N
study NN N
and CC N
are VBP N
discussed VBN N
in IN N
this DT N
paper NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
all DT N
, , N
202 CD N
consecutive JJ N
patients NNS p
from IN N
the DT N
hospital NN N
waiting VBG N
list NN N
were VBD N
randomized VBN N
to TO N
undergo VB N
TURP NNP N
using VBG N
either CC N
a DT N
bipolar JJ N
system NN N
( ( N
Surgmaster NNP N
TURis NNP N
, , N
Olympus NNP N
, , N
Tokyo NNP N
, , N
Japan NNP N
) ) N
or CC N
a DT N
monopolar JJ N
system NN N
( ( N
24 CD N
F NNP N
, , N
Storz NNP N
, , N
T NNP N
, , N
Germany NNP N
) ) N
. . N

77 CD N
were VBD N
assigned VBN N
to TO N
PACT NNP N
( ( N
London NNP N
[ NNP N
n=26 MD N
] VB N
, , N
Manchester NNP N
[ NNP N
n=26 MD N
] VB N
, , N
and CC N
Newcastle NNP N
[ NNP N
n=25 FW N
] NNP N
) ) N
; : N
and CC N
75 CD N
to TO N
treatment NN N
as IN N
usual JJ N
( ( N
London NNP N
[ NNP N
n=26 MD N
] VB N
, , N
Manchester NNP N
[ NNP N
n=26 MD N
] VB N
, , N
and CC N
Newcastle NNP N
[ NNP N
n=23 FW N
] NNP N
) ) N
. . N

METHODS NNP N
We PRP N
did VBD N
a DT N
parallel-group NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
equivalence NN N
trial NN N
of IN N
infants NNS N
aged VBN N
6 CD N
weeks NNS N
to TO N
12 CD N
months NNS N
of IN N
age NN N
with IN N
physician-diagnosed JJ N
bronchiolitis NN N
newly RB N
admitted VBN N
into IN N
eight CD N
paediatric JJ N
hospital NN N
units NNS N
in IN N
the DT N
UK NNP N
( ( N
the DT N
Bronchiolitis NNP N
of IN N
Infancy NNP N
Discharge NNP N
Study NNP N
[ NNP N
BIDS NNP N
] NNP N
) ) N
. . N

Improvements NNS N
were VBD N
sustained VBN N
at IN N
week NN N
24 CD N
for IN N
the DT N
ACR20 NNP N
, , N
ACR50 NNP N
, , N
and CC N
ACR70 NNP N
responses NNS N
, , N
scores NNS N
for IN N
the DT N
Health NNP N
Assessment NNP N
Questionnaire NNP N
disability NN N
index NN N
, , N
the DT N
3-variable JJ N
Disease NNP N
Activity NNP N
Score NNP N
in IN N
28 CD N
joints NNS N
using VBG N
the DT N
C-reactive JJ N
protein NN N
level NN N
( ( N
DAS28-CRP NNP N
) ) N
, , N
and CC N
a DT N
3-variable JJ N
DAS28-CRP NNP N
of IN N
< NNP N
2.6 CD N
. . N

At IN N
the DT N
end NN N
of IN N
each DT N
study NN N
week NN N
, , N
the DT N
authors NNS N
assessed VBD N
diastolic JJ N
function NN N
( ( N
myocardial JJ N
relaxation NN N
velocities NNS N
[ VBP N
E NNP N
' POS N
] NN N
using VBG N
tissue NN N
Doppler NNP N
imaging NN N
) ) N
and CC N
RBF NNP N
( ( N
para-aminohippurate JJ N
clearance NN N
) ) N
at IN N
baseline NN N
and CC N
after IN N
infusion NN N
of IN N
Ang NNP N
II NNP N
( ( N
3 CD N
ng/kg/min RB N
x JJ N
45 CD N
min NN N
) ) N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
m-chlorophenylpiperazine NN N
( ( N
m-CPP JJ N
) ) N
on IN N
repetitive JJ N
behaviours NNS N
and CC N
prolactin JJ i
response NN N
in IN N
11 CD N
adults NNS N
with IN N
autism NN N
or CC N
Aspergers NNS N
disorder VBP N
and CC N
8 CD N
age- JJ N
and CC N
gender-matched JJ N
healthy JJ N
controls NNS N
via IN N
randomized VBN N
double-blind NN N
, , N
m-CPP JJ N
and CC N
placebo JJ N
challenges NNS N
. . N

The DT N
intervention NN N
will MD N
be VB N
conducted VBN N
by IN N
specially RB N
trained JJ N
oncology NN N
nurses NNS N
and CC N
includes VBZ N
components NNS N
of IN N
patient JJ N
education NN N
, , N
skills NNS N
training NN N
and CC N
counseling NN N
to TO N
improve VB N
self PRP N
care VB N
regarding VBG N
pain JJ N
management NN N
beginning VBG N
with IN N
admission NN N
followed VBN N
by IN N
booster NN N
session NN N
every DT N
3rd CD N
day NN N
and CC N
one CD N
follow VBP N
up RP N
telephone NN N
counseling NN N
within IN N
2 CD N
to TO N
3 CD N
days NNS N
after IN N
discharge NN N
. . N

151 CD N
patients NNS p
with IN N
locally RB N
advanced JJ N
prostatic JJ N
cancer NN N
( ( N
T3-4 NNP N
M0 NNP N
) ) N
, , N
representing VBG N
38 CD N
% NN N
of IN N
the DT N
404 CD N
cancer NN N
patients NNS p
in IN N
a DT N
Finnish JJ N
multicenter NN N
study NN N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
orchiectomy NN N
, , N
estrogens VBZ N
or CC N
radiotherapy NN i
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
pilot NN N
study NN N
in IN N
an DT N
academic JJ N
medical JJ N
center-based JJ N
infectious JJ N
disease NN N
clinic NN N
, , N
11 CD N
clinically RB N
stable JJ N
, , N
HIV-infected JJ N
adults NNS N
had VBD N
been VBN N
treated VBN N
with IN N
highly RB N
active JJ N
, , N
antiretroviral JJ N
therapy NN i
and CC N
had VBD N
HIV NNP N
plasma NN N
RNA NNP N
levels NNS N
of IN N
less JJR N
than IN N
10 CD N
000 CD N
copies/mL NN N
. . N

This DT N
randomized VBN N
group NN N
experiment NN N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD N
communication NN N
interventions NNS N
( ( N
Responsive JJ N
Education NN N
and CC N
Prelinguistic NNP N
Milieu NNP N
Teaching NNP N
[ NNP N
RPMT NNP N
] NNP N
and CC N
the DT N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
[ NNP N
PECS NNP N
] NNP N
) ) N
in IN N
36 CD N
preschoolers NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Twenty NNP N
ASA NNP N
physical JJ N
status NN N
I PRP N
patients NNS p
undergoing VBG N
gynecological JJ N
laparoscopy NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
SSA NNP N
with IN N
lidocaine JJ N
10 CD N
mg NN N
+ NNP N
sufentanil VBD N
10 CD N
microg NN N
or CC N
general JJ N
anesthesia NN N
with IN N
DES NNP N
and CC N
N NNP N
( ( N
2 CD N
) ) N
O. NNP N
Intraoperative NNP N
conditions NNS N
, , N
recovery NN N
times NNS N
, , N
postanesthesia JJ N
recovery NN N
scores NNS N
, , N
and CC N
postoperative JJ N
outcomes NNS N
were VBD N
recorded VBN N
. . N

Olanzapine-treated JJ N
patients NNS p
also RB N
experienced VBD N
longer JJR N
time NN N
to TO N
depressive VB N
symptomatic JJ N
relapse NN N
( ( N
85 CD N
versus NN N
22 CD N
days NNS N
, , N
p=0.001 NN N
) ) N
and CC N
manic JJ N
symptomatic JJ N
relapse NN N
( ( N
too RB N
few JJ N
relapses NNS N
to TO N
calculate VB N
versus NN N
42 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
than IN N
did VBD N
placebo-treated JJ N
patients NNS p
. . N

Adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
occurring VBG N
more RBR N
frequently RB N
with IN N
sitaxsentan NN N
( ( N
50 CD N
or CC N
100 CD N
mg NN N
) ) N
included VBD N
headache NN N
, , N
peripheral JJ N
edema NN N
, , N
dizziness NN N
, , N
nausea NN N
, , N
extremity NN N
pain NN N
, , N
and CC N
fatigue NN N
; : N
most JJS N
AEs NNP N
were VBD N
of IN N
mild NN N
or CC N
moderate JJ N
severity NN N
. . N

A DT N
protocol-planned JJ N
exploratory NN N
analysis NN N
stratified VBD N
patients NNS p
according VBG N
to TO N
baseline NN N
activity NN N
; : N
this DT N
analysis NN N
showed VBD N
that IN N
patients NNS p
with IN N
high JJ N
levels NNS N
of IN N
disease NN N
activity NN N
in IN N
the DT N
valacyclovir NN N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
developed VBD N
fewer JJR N
new JJ N
active JJ N
lesions NNS N
per IN N
scan JJ N
than IN N
did VBD N
those DT N
in IN N
the DT N
placebo NN N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Totally NNP N
25 CD N
patients NNS p
with IN N
a DT N
history NN N
of IN N
differentiated JJ N
thyroid JJ N
carcinoma NN N
on IN N
long-term JJ N
TSH-suppressive JJ N
levothyroxine NN i
( ( N
l-T JJ N
( ( N
4 CD N
) ) N
) ) N
substitution NN N
were VBD N
randomized VBN N
to TO N
persistent JJ N
TSH-suppressive JJ N
l-T NN N
( ( N
4 CD N
) ) N
substitution NN N
( ( N
low-TSH JJ N
group NN N
) ) N
or CC N
restoration NN N
of IN N
euthyroidism NN N
. . N

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
338 CD N
patients NNS p
aged VBN N
60 CD N
years NNS N
or CC N
older JJR N
who WP N
had VBD N
aneurysms NNS N
of IN N
at IN N
least JJS N
5.5 CD N
cm NN N
in IN N
diameter NN N
and CC N
who WP N
had VBD N
been VBN N
referred VBN N
to TO N
one CD N
of IN N
31 CD N
hospitals NNS N
in IN N
the DT N
UK NNP N
. . N

METHODS NNP N
In IN N
this DT N
52-week JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
, , N
male NN N
and CC N
female JJ N
patients NNS p
( ( N
aged VBN N
at IN N
least JJS N
40 CD N
years NNS N
) ) N
with IN N
symptomatic JJ N
primary JJ N
OA NNP N
of IN N
the DT N
hip NN N
, , N
knee NN N
, , N
hand NN N
or CC N
spine NN N
were VBD N
randomised VBN N
( ( N
1:2:1 CD N
) ) N
to TO N
lumiracoxib VB N
100 CD N
mg NN N
o.d NN N
. . N

Heart NNP N
failure NN N
therapy NN i
guided VBN N
by IN N
N-terminal NNP N
BNP NNP N
improved VBD N
outcomes NNS N
in IN N
patients NNS p
aged VBD N
60 CD N
to TO N
75 CD N
years NNS N
but CC N
not RB N
in IN N
those DT N
aged VBN N
75 CD N
years NNS N
or CC N
older JJR N
( ( N
P NNP N
< NNP N
.02 NNP N
for IN N
interaction NN N
) ) N
CONCLUSION NNP N
Heart NNP N
failure NN N
therapy NN i
guided VBN N
by IN N
N-terminal JJ N
BNP NNP N
did VBD N
not RB N
improve VB N
overall JJ i
clinical JJ N
outcomes NNS N
or CC N
quality NN N
of IN N
life NN N
compared VBN N
with IN N
symptom-guided JJ N
treatment NN N
. . N

Rectal JJ N
pain NN N
thresholds NNS N
and CC N
smooth JJ N
muscle NN N
tone NN N
were VBD N
measured VBN N
with IN N
a DT N
barostat NN N
before IN N
and CC N
after IN N
treatment NN N
in IN N
18 CD N
patients NNS p
( ( N
study VB N
I PRP N
) ) N
, , N
and CC N
treatment NN N
changes NNS N
in IN N
heart NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
skin JJ N
conductance NN N
, , N
finger NN N
temperature NN N
, , N
and CC N
forehead JJ N
electromyographic JJ N
activity NN N
were VBD N
assessed VBN N
in IN N
24 CD N
patients NNS p
( ( N
study VB N
II NNP N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
bupivacaine NN N
group NN N
compared VBN N
with IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
at IN N
the DT N
intervals NNS N
of IN N
6 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
hours NNS N
postbanding VBG N
there EX N
was VBD N
no DT N
sustained JJ N
reduction NN N
in IN N
the DT N
severity NN N
of IN N
pain NN N
and CC N
no DT N
reduction NN N
in IN N
analgesic JJ N
requirements NNS N
or CC N
limitation NN N
of IN N
normal JJ N
activities NNS N
. . N

DISCUSSION NNP N
The DT N
RCT NNP N
design NN N
, , N
combined VBN N
with IN N
access NN N
to TO N
clinical JJ N
records NNS N
at IN N
all DT N
provincial JJ N
abortion NN N
clinics NNS N
, , N
and CC N
to TO N
information NN N
in IN N
provincial JJ N
single-payer NN N
linked VBD N
administrative JJ N
health NN N
databases NNS N
, , N
birth NN N
registry NN N
, , N
and CC N
hospital NN N
records NNS N
, , N
offers VBZ N
a DT N
unique JJ N
opportunity NN N
to TO N
determine VB N
if IN N
a DT N
novel NN N
IUD NNP N
has VBZ N
a DT N
comparable JJ N
expulsion NN N
rate NN N
to TO N
that DT N
of IN N
the DT N
current JJ N
standard NN N
IUD NNP N
in IN N
Canada NNP N
, , N
in IN N
addition NN N
to TO N
the DT N
first JJ N
opportunity NN N
to TO N
determine VB N
pregnancy NN N
rate NN N
and CC N
method NN N
satisfaction NN N
at IN N
1 CD N
year NN N
post-abortion NN N
for IN N
women NNS N
choosing VBG N
a DT N
range NN N
of IN N
post-abortion NN N
contraceptive NN N
options NNS N
. . N

OBJECTIVES IN N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
a DT N
) ) N
document NN N
the DT N
efficacy NN N
of IN N
a DT N
device NN N
intended VBN N
to TO N
conserve VB N
blood NN N
in IN N
critically RB N
ill JJ N
patients NNS p
; : N
b NN N
) ) N
determine VBZ N
the DT N
effect NN N
of IN N
this DT N
blood NN N
conservation NN N
on IN N
hemoglobin JJ N
concentration NN N
and CC N
the DT N
need NN N
for IN N
blood NN N
transfusions NNS N
; : N
c NNS N
) ) N
determine VBP N
if IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
interference NN N
with IN N
arterial JJ N
pressure NN N
waveforms NNS N
; : N
d NN N
) ) N
determine NN N
if IN N
use NN N
of IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
a DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
accidental JJ N
needle JJ N
punctures NNS N
suffered VBN N
by IN N
healthcare JJ N
workers NNS N
. . N

This DT N
report NN N
, , N
based VBN N
on IN N
four CD N
studies NNS N
with IN N
children NNS N
with IN N
low-functioning JJ N
autism NN N
, , N
aimed VBN N
at IN N
evaluating VBG N
the DT N
effects NNS N
of IN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
delivered VBN N
on IN N
the DT N
left NN N
and CC N
right JJ N
premotor NN N
cortices NNS N
on IN N
eye-hand JJ N
integration NN N
tasks NNS N
; : N
defining VBG N
the DT N
long-lasting JJ N
effects NNS N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
; : N
and CC N
investigating VBG N
the DT N
real JJ N
efficacy NN N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
by IN N
comparing VBG N
three CD N
kinds NNS N
of IN N
treatments NNS N
( ( N
high-frequency JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
, , N
a DT N
traditional JJ N
eye-hand JJ N
integration NN N
training NN N
, , N
and CC N
both DT N
treatments NNS N
combined VBN N
) ) N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
fever NN N
is VBZ N
associated VBN N
with IN N
worsened JJ N
outcome NN N
in IN N
surgical JJ N
subarachnoid JJ N
hemorrhage NN N
patients NNS p
, , N
although IN N
, , N
because IN N
the DT N
association NN N
between IN N
fever NN N
and CC N
the DT N
primary JJ N
outcome NN N
measure NN N
for IN N
the DT N
trial NN N
is VBZ N
dependent JJ N
on IN N
the DT N
covariates NNS N
used VBN N
in IN N
the DT N
analysis NN N
( ( N
particularly RB N
operative JJ N
events NNS N
and CC N
delayed VBN N
ischemic JJ N
neurological JJ N
deficits NNS N
) ) N
, , N
we PRP N
can MD N
not RB N
rule VB N
out IN N
the DT N
possibility NN N
that IN N
fever NN N
is VBZ N
a DT N
marker NN N
for IN N
other JJ N
events NNS N
. . N

This DT N
study NN N
demonstrates VBZ N
for IN N
the DT N
first JJ N
time NN N
that IN N
the DT N
efficiency NN N
of IN N
TIL NNP N
in IN N
stage NN N
III NNP N
melanoma NN N
( ( N
AJCC NNP N
) ) N
is VBZ N
directly RB N
related VBN N
to TO N
the DT N
number NN N
of IN N
invaded JJ N
lymph NN N
nodes NNS N
, , N
indicating VBG N
that IN N
tumor NN N
burden NN N
might MD N
be VB N
a DT N
crucial JJ N
factor NN N
in IN N
the DT N
efficacy NN N
and/or NN N
in IN N
vitro JJ N
expansion NN N
of IN N
T NNP N
cells NNS N
specific JJ N
for IN N
autologous JJ N
tumor NN N
antigen NN N
, , N
a DT N
finding NN N
which WDT N
could MD N
be VB N
of IN N
value NN N
in IN N
future JJ N
vaccine NN N
development NN N
for IN N
the DT N
treatment NN N
of IN N
melanoma NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
Considering NNP N
that IN N
lymph VBD N
node DT N
status NN N
is VBZ N
a DT N
key JJ N
factor NN N
in IN N
colorectal JJ N
cancer NN N
staging NN N
, , N
and CC N
the DT N
main JJ N
determinant NN N
for IN N
adjuvant JJ N
therapy NN i
of IN N
colorectal JJ N
cancer NN N
being VBG N
this DT N
therapy NN i
, , N
responsible JJ N
for IN N
a DT N
significant JJ N
increase NN o
in IN N
colorectal JJ N
cancer NN N
patients NNS p
survival JJ N
, , N
the DT N
staging VBG N
methods NNS N
should MD N
be VB N
the DT N
most RBS N
accurate JJ N
possible JJ N
in IN N
order NN N
to TO N
offer VB N
this DT N
individuals NNS N
the DT N
opportunity NN N
to TO N
be VB N
adequate JJ N
treated VBN N
in IN N
order NN N
to TO N
achieve VB N
the DT N
best JJS N
survival NN N
possible JJ N
. . N

Side NN N
effects NNS N
, , N
such JJ N
as IN N
hypotension NN N
and CC N
emesis NN N
were VBD N
negligible JJ N
, , N
severe JJ N
bradycardia NN N
and CC N
urinary JJ N
retention NN N
did VBD N
not RB N
occur VB N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS p
in IN N
the DT N
two CD N
groups NNS N
reported VBD N
transient JJ N
neurological JJ N
symptoms NNS N
over IN N
24 CD N
h. NNS N
In IN N
conclusion NN N
, , N
plain VBP N
mepivacaine NN N
in IN N
a DT N
60- JJ N
or CC N
80-mg JJ N
dose NN N
is VBZ N
a DT N
suitable JJ N
local JJ N
anesthetic JJ N
choice NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
with IN N
respect NN N
to TO N
anesthetic JJ N
, , N
as RB N
well RB N
as IN N
recovery NN N
profiles NNS N
. . N

Two CD N
serious JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
; : N
one CD N
drug-related JJ N
hypotensive JJ N
infusion NN N
reaction NN N
occurred VBD N
in IN N
one CD N
subject NN N
in IN N
the DT N
30.0 CD N
mg/kg JJ N
MEDI-545 NNP N
dose NN N
group NN N
, , N
causing VBG N
discontinuation NN N
of IN N
study JJ N
drug NN N
in IN N
that DT N
subject NN N
and CC N
study NN N
dismissal NN N
of IN N
the DT N
other JJ N
subjects NNS N
in IN N
the DT N
same JJ N
cohort NN N
; : N
and CC N
a DT N
myocardial JJ N
infarction NN N
occurred VBD N
in IN N
one CD N
subject NN N
in IN N
the DT N
10 CD N
mg/kg JJ N
MEDI-545 NNP N
dose NN N
group NN N
, , N
which WDT N
was VBD N
considered VBN N
to TO N
be VB N
unrelated JJ N
to TO N
treatment NN N
. . N

Stimulating VBG N
the DT N
GH/IGF-I NNP N
axis NN N
with IN N
GH-secretagogues NNP N
increased VBD o
leptin NN o
levels NNS N
within IN N
12 CD N
h. NN N
Because IN N
leptin NN i
may MD N
stimulate VB N
oxidation NN N
of IN N
fatty JJ N
acids NNS N
, , N
and CC N
because IN N
GH NNP N
, , N
IGF-I NNP N
, , N
and CC N
insulin NN N
have VBP N
a DT N
protein-sparing JJ N
effect NN N
, , N
GH-secretagogue NNP N
administration NN N
may MD N
be VB N
expected VBN N
to TO N
result VB N
in IN N
increased JJ o
utilization NN N
of IN N
fat NN N
as IN N
preferential JJ N
substrate NN N
and CC N
to TO N
restore VB N
protein JJ N
content NN N
in IN N
vital JJ N
tissues NNS N
and CC N
, , N
consequently RB N
, , N
has VBZ N
potential JJ N
as IN N
a DT N
strategy NN N
to TO N
reverse VB N
the DT N
paradoxical JJ N
metabolic JJ N
condition NN N
of IN N
protracted JJ N
critical JJ N
illness NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN o
in IN N
overall JJ i
scores NNS N
of IN N
stress NN N
levels NNS N
for IN N
participants NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
and CC N
there EX N
was VBD N
a DT N
significant JJ N
increase NN o
in IN N
the DT N
four CD N
factors NNS N
of IN N
quality NN N
of IN N
life NN N
that WDT N
were VBD N
measured VBN N
( ( N
satisfaction NN N
, , N
independence NN N
, , N
competence NN N
and CC N
social JJ N
interaction NN N
) ) N
as RB N
well RB N
as IN N
the DT N
total JJ N
score NN N
for IN N
quality NN N
of IN N
life NN N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
intervention NN N
12 CD N
months NNS N
later RB N
. . N

In IN N
a DT N
subset NN N
of IN N
acute JJ N
respiratory NN N
distress JJ N
syndrome JJ N
patients NNS p
from IN N
this DT N
trial NN N
, , N
we PRP N
performed VBD N
a DT N
preliminary JJ N
examination NN N
of IN N
the DT N
potential JJ N
mechanisms NN N
underlying VBG N
these DT N
clinical JJ N
improvements NNS N
by IN N
retrospectively RB N
testing VBG N
the DT N
hypothesis NN N
that IN N
enteral JJ N
feeding VBG N
with IN N
EPA+GLA NNP N
could MD N
reduce VB N
alveolar-capillary JJ N
membrane NN N
protein NN N
permeability NN N
and CC N
the DT N
production NN N
of IN N
interleukin NN N
( ( N
IL NNP N
) ) N
-8 NN N
, , N
IL-6 NNP N
, , N
tumor NN N
necrosis NN N
factor-alpha NN N
, , N
and CC N
leukotriene JJ N
B4 NNP N
that WDT N
are VBP N
responsible JJ N
, , N
in IN N
part NN N
, , N
for IN N
pulmonary JJ N
inflammation NN N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
in IN N
the DT N
presence NN N
of IN N
overt JJ N
emotional JJ N
disturbance NN N
, , N
of IN N
new JJ N
psychological JJ N
or CC N
psychophysiological JJ N
symptoms NNS N
preceding VBG N
the DT N
rash NN N
by IN N
up IN N
to TO N
a DT N
year NN N
, , N
and CC N
of IN N
high JJ N
motivation NN N
for IN N
it PRP N
, , N
brief JJ N
psychiatric JJ N
treatment NN N
improves VBZ N
the DT N
outcome NN N
in IN N
eczema NN N
( ( N
the DT N
proportion NN N
clear JJ N
at IN N
18 CD N
months NNS N
was VBD N
about IN N
doubled VBN N
) ) N
, , N
whereas NNS N
in IN N
their PRP$ N
absence NN N
such JJ N
treatment NN N
may MD N
worsen VB N
it PRP N
, , N
especially RB N
in IN N
the DT N
short JJ N
term NN N
. . N

Though IN N
the DT N
response NN N
rate NN N
for IN N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
slightly RB N
higher JJR N
than IN N
for IN N
the DT N
systemic JJ N
arm NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
, , N
and CC N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
nausea NN N
, , N
vomiting VBG N
, , N
diarrhea NN N
, , N
in IN N
addition NN N
to TO N
complications NNS N
of IN N
femoral-arterial JJ N
thrombosis NN N
, , N
bleeding NN N
, , N
and CC N
infection NN N
at IN N
the DT N
catheter NN N
site NN N
not RB N
seen VBN N
in IN N
patients NNS p
treated VBN N
by IN N
systemic JJ N
chemotherapy NN i
. . N

METHODS/DESIGN NNP N
Consenting NNP N
women NNS N
choosing VBG N
to TO N
use VB N
an DT N
IUD NNP N
after IN N
an DT N
abortion NN N
for IN N
a DT N
pregnancy NN N
of IN N
less JJR N
than IN N
12 CD N
weeks NNS N
of IN N
gestation NN N
will MD N
be VB N
randomized VBN N
to TO N
device-type JJ N
groups NNS N
to TO N
receive VB N
immediate JJ N
post-abortion JJ N
placement NN N
of IN N
either CC N
a DT N
Flexi-T380 NNP N
( ( N
+ NNP N
) ) N
IUD NNP N
, , N
a DT N
device NN N
for IN N
which WDT N
no DT N
current JJ N
evidence NN N
on IN N
expulsion NN N
or CC N
effectiveness NN N
rates NNS N
is VBZ N
available JJ N
, , N
or CC N
the DT N
Nova-T200 JJ N
IUD NNP N
, , N
the DT N
only RB N
other JJ N
brand NN N
of IN N
copper NN N
IUD NNP N
available JJ N
in IN N
Canada NNP N
at IN N
the DT N
time NN N
of IN N
study NN N
initiation NN N
. . N

Ninety-eight JJ N
undergraduate JJ N
students NNS N
were VBD N
given VBN N
transparent JJ N
boxes NNS N
of IN N
chocolate NN N
Hershey NNP N
's POS N
Kisses NNP N
and CC N
instructed VBN N
to TO N
keep VB N
the DT N
chocolates NNS N
with IN N
them PRP N
, , N
but CC N
not RB N
to TO N
eat VB N
them PRP N
, , N
for IN N
48 CD N
h. NN N
Before IN N
receiving VBG N
the DT N
Kisses NNP N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
( ( N
a DT N
) ) N
no DT N
intervention NN N
, , N
( ( N
b NN N
) ) N
instruction NN N
in IN N
control-based JJ N
coping VBG N
strategies NNS N
such JJ N
as IN N
distraction NN N
and CC N
cognitive JJ N
restructuring NN N
, , N
or CC N
( ( N
c NN N
) ) N
instruction NN N
in IN N
acceptance-based JJ N
strategies NNS N
such JJ N
as IN N
experiential JJ N
acceptance NN N
and CC N
defusion NN N
techniques NNS N
. . N

Since IN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
AD NNP N
patients NNS p
and CC N
age-matched JJ N
controls NNS N
with IN N
regard NN N
to TO N
the DT N
fraction NN N
of IN N
CD45RA+ NNP N
or CC N
CD45RO+ NNP N
CD4+ NNP N
T NNP N
cells NNS N
nor CC N
the DT N
ability NN N
of IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
to TO N
produce VB N
IL-2 NNP N
or CC N
IL-4 NNP N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
the DT N
difference NN N
in IN N
DEX NNP N
sensitivity NN N
is VBZ N
due JJ N
to TO N
a DT N
changed VBN N
lymphokine NN N
profile NN N
or CC N
a DT N
changed JJ N
composition NN N
of IN N
the DT N
CD4+ NNP N
T NNP N
cell NN N
population NN N
. . N

It PRP N
was VBD N
established VBN N
that IN N
CHF NNP N
patients NNS p
with IN N
progression NN N
of IN N
the DT N
disease NN N
had VBD N
worsening NN N
of IN N
their PRP$ N
clinical JJ N
condition NN N
together RB N
with IN N
an DT N
increase NN o
of IN N
oxidative JJ N
stress NN N
which WDT N
was VBD N
characterized VBN N
through IN N
decrease NN o
of IN N
NO NNP N
metabolites NNS N
, , N
NADPH NNP N
-- : N
diaphorase NN N
( ( N
eNOS NN N
) ) N
, , N
increase NN o
of IN N
nitrite JJ N
reductase NN N
( ( N
iNOS NN N
) ) N
and CC N
peroxinitrite JJ N
( ( N
ONOO NNP N
) ) N
, , N
correlative JJ N
increase NN o
the DT N
level NN N
of IN N
brain NN N
natriuretic JJ N
peptide NN N
in IN N
blood NN N
plazma NN N
. . N

We PRP N
found VBD N
significant JJ N
differences NNS N
between IN N
before IN N
and CC N
after IN N
the DT N
therapy NN i
in IN N
the DT N
length NN N
of IN N
the DT N
gait NN N
cycle NN N
that WDT N
became VBD N
more RBR N
stable JJ N
in IN N
the DT N
sagital JJ N
plane NN N
and CC N
concluded VBD N
that IN N
our PRP$ N
results NNS N
proved VBD N
that IN N
horse NN N
therapy NN i
may MD N
be VB N
successfully RB N
used VBN N
as IN N
an DT N
additional JJ N
therapy NN i
for IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
it PRP N
may MD N
be VB N
a DT N
form NN N
of IN N
rehabilitation NN N
in IN N
cases NNS N
when WRB N
other JJ N
therapies NNS N
are VBP N
not RB N
successful JJ N
. . N

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
performance NN N
of IN N
three CD N
staging VBG N
systems NNS N
[ NNP N
Okuda NNP N
, , N
Cancer NNP N
of IN N
the DT N
Liver NNP N
Italian JJ N
Program NNP N
( ( N
CLIP NNP N
) ) N
and CC N
Barcelona NNP N
Clinic NNP N
Liver NNP N
Cancer NNP N
group NN N
( ( N
BCLC NNP N
) ) N
] NN N
, , N
for IN N
predicting VBG N
survival NN N
in IN N
patients NNS p
with IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
and CC N
to TO N
explore VB N
how WRB N
to TO N
improve VB N
prognostic JJ N
classification NN N
among IN N
French JJ N
patients NNS p
with IN N
HCC NNP N
whose WP$ N
main JJ N
etiology NN N
is VBZ N
alcoholic JJ N
cirrhosis NN N
. . N

This DT N
double-blind JJ N
and CC N
placebo-controlled JJ N
clinical JJ N
trial NN N
in IN N
autistic JJ N
children NNS N
had VBD N
three CD N
objectives NNS N
: : N
( ( N
a DT N
) ) N
to TO N
replicate VB N
earlier JJR N
findings NNS N
that IN N
haloperidol JJ N
administration NN N
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
of IN N
behavioral JJ N
symptoms NNS N
; : N
( ( N
b NN N
) ) N
to TO N
further JJ N
assess NN N
its PRP$ N
safety NN N
when WRB N
given VBN N
on IN N
a DT N
short-term JJ N
basis NN N
; : N
and CC N
( ( N
c NN N
) ) N
to TO N
assess VB N
whether IN N
it PRP N
has VBZ N
an DT N
effect NN N
on IN N
discrimination NN N
learning NN N
. . N

RESULTS NNP N
Latent NNP N
variable JJ N
structural JJ N
equation NN N
modeling VBG N
indicated VBD N
that IN N
: : N
1 CD N
) ) N
the DT N
intervention NN N
had VBD N
direct JJ N
, , N
positive JJ N
effects NNS N
on IN N
physical JJ N
activity NN N
and CC N
factors NNS N
influencing VBG N
enjoyment NN N
of IN N
PE NNP N
, , N
which WDT N
subsequently RB N
explained VBD N
the DT N
effects NNS N
of IN N
increased JJ o
physical JJ N
activity NN N
enjoyment NN N
and CC N
self-efficacy NN N
on IN N
increased JJ o
physical JJ N
activity NN N
; : N
and CC N
2 CD N
) ) N
an DT N
additional JJ N
, , N
indirect JJ N
effect NN N
of IN N
physical JJ N
activity NN N
enjoyment NN N
on IN N
physical JJ N
activity NN N
operated VBN N
by IN N
an DT N
influence NN N
on IN N
self-efficacy NN N
. . N

Comparison NNP N
of IN N
quality NN N
of IN N
life NN N
, , N
work NN N
productivity NN N
and CC N
medical JJ N
resource NN N
utilization NN N
of IN N
peginterferon NN N
alpha NN N
2a CD N
vs IN N
the DT N
combination NN N
of IN N
interferon NN N
alpha NN N
2b CD N
plus CC N
ribavirin VB N
as IN N
initial JJ N
treatment NN N
in IN N
patients NNS p
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
The DT N
on-treatment JJ N
impact NN N
of IN N
interferon-based JJ N
therapies NNS N
on IN N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
work NN N
productivity NN N
, , N
and CC N
medical JJ N
resource NN N
utilization NN N
has VBZ N
not RB N
been VBN N
systematically RB N
studied VBN N
. . N

CONCLUSIONS NNP N
Including VBG N
a DT N
'no CD N
active JJ N
intervention NN N
' POS N
arm NN N
did VBD N
not RB N
appear VB N
to TO N
have VB N
a DT N
detrimental JJ N
effect NN N
on IN N
patient JJ N
recruitment NN N
or CC N
the DT N
completion NN N
of IN N
this DT N
trial NN N
in IN N
the DT N
short-term JJ N
; : N
overall JJ i
, , N
conservative JJ N
management NN N
was VBD N
successfully RB N
completed VBN N
by IN N
the DT N
majority NN N
of IN N
patients NNS p
during IN N
the DT N
trial NN N
period NN N
, , N
suggesting VBG N
that IN N
researchers NNS N
need VBP N
not RB N
avoid VB N
including VBG N
a DT N
no-intervention JJ N
arm NN N
in IN N
surgical JJ N
trials NNS N
as RB N
long RB N
as IN N
they PRP N
take VBP N
care NN N
with IN N
its PRP$ N
presentation NN N
. . N

OBJECTIVE NN N
To TO N
describe VB N
the DT N
process NN N
and CC N
results NNS N
of IN N
diet JJ N
standardization NN N
, , N
diet JJ N
validation NN N
, , N
and CC N
monitoring NN N
of IN N
diet JJ N
composition NN N
, , N
which WDT N
were VBD N
key JJ N
components NNS N
of IN N
protocol JJ N
1 CD N
of IN N
Dietary NNP N
Effects NNPS N
on IN N
Lipoproteins NNS N
and CC N
Thrombogenic NNP N
Activity NNP N
( ( N
DELTA-1 NNP N
) ) N
, , N
the DT N
initial JJ N
protocol NN N
in IN N
a DT N
program NN N
of IN N
multicenter NN N
human JJ N
feeding NN N
studies NNS N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amount NN N
and CC N
type NN N
of IN N
fat NN N
on IN N
lipoproteins NNS N
and CC N
hemostasis NN N
parameters NNS N
in IN N
various JJ N
demographic JJ N
groups NNS N
. . N

Outcome NNP N
measures NNS N
included VBD N
improvements NNS N
in IN N
severity NN N
and CC N
behavioral JJ N
features NNS N
of IN N
autistic JJ N
disorder NN N
( ( N
stereotypies NNS N
, , N
lethargy NN N
, , N
irritability NN N
, , N
hyperactivity NN N
, , N
emotional JJ N
reciprocity NN N
, , N
sharing VBG N
pleasures NNS N
) ) N
and CC N
improvements NNS N
in IN N
language NN N
and CC N
communication NN N
, , N
socialization NN N
, , N
and CC N
daily RB N
living VBG N
skills NNS N
noted VBD N
after IN N
12 CD N
weeks NNS N
( ( N
the DT N
end NN N
of IN N
a DT N
4-week JJ N
maintenance NN N
phase NN N
) ) N
. . N

The DT N
current JJ N
study NN N
asked VBD N
: : N
does VBZ N
regular JJ N
antacid NN N
therapy NN i
have VBP N
a DT N
favorable JJ N
influence NN N
on IN N
the DT N
natural JJ N
history NN N
of IN N
symptomatic JJ N
reflux NN N
esophagitis NN N
, , N
ie NN N
, , N
does VBZ N
therapy VB i
heal NN N
or CC N
otherwise RB N
change NN N
esophagitis NN N
so IN N
that DT N
painful JJ N
episodes NNS N
are VBP N
either RB N
less RBR N
frequent JJ N
, , N
less RBR N
severe JJ N
, , N
or CC N
both DT N
? . N
We PRP N
found VBD N
that IN N
the DT N
natural JJ N
history NN N
of IN N
symptomatic JJ N
reflux NN N
esophagitis NN N
was VBD N
to TO N
improve VB N
with IN N
either DT N
antacid NN N
or CC N
placebo NN N
. . N

This DT N
prospective JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
individualized JJ N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
program NN N
combining NN N
exercise NN N
training NN N
with IN N
risk NN N
factor NN N
modification NN N
and CC N
psychosocial JJ N
counseling NN N
on IN N
risk NN N
factors NNS N
, , N
psychological JJ N
well-being NN N
, , N
functional JJ N
capacity NN N
, , N
and CC N
work NN N
resumption NN N
in IN N
99 CD N
post-percutaneous JJ N
coronary JJ N
interventions NNS N
( ( N
PCI NNP N
) ) N
patients NNS p
randomized VBN N
to TO N
control VB N
( ( N
standard JJ N
care NN N
plus CC N
telephone NN N
follow-up NN N
, , N
n=49 NN N
) ) N
or CC N
intervention NN N
( ( N
individualized VBN N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
, , N
n=50 NN N
) ) N
groups NNS N
. . N

The DT N
AV NNP N
Node NNP N
Ablation NNP N
with IN N
CLS NNP N
and CC N
CRT NNP N
Pacing NNP N
Therapies NNP N
for IN N
Treatment NNP N
of IN N
AF NNP N
trial NN N
( ( N
AVAIL NNP N
CLS/CRT NNP N
) ) N
was VBD N
designed VBN N
to TO N
demonstrate VB N
superiority NN N
of IN N
BiV NNP N
pacing VBG N
in IN N
patients NNS p
with IN N
AF NNP N
after IN N
AV NNP N
node JJ N
ablation NN N
, , N
to TO N
evaluate VB N
its PRP$ N
effects NNS N
on IN N
cardiac JJ N
structure NN N
and CC N
function NN N
, , N
and CC N
to TO N
investigate VB N
additional JJ N
benefits NNS N
of IN N
Closed JJ N
Loop NNP N
Stimulation NNP N
( ( N
CLS NNP N
) ) N
( ( N
BIOTRONIK NNP N
, , N
Berlin NNP N
, , N
Germany NNP N
) ) N
. . N

As IN N
secondary JJ N
objectives NNS N
we PRP N
examine VBP N
five CD N
year NN N
survival NN N
rates NNS N
( ( N
OS NNP N
and CC N
DFS NNP N
) ) N
, , N
blood NN N
loss NN N
, , N
duration NN N
of IN N
operation NN N
, , N
requirement NN N
of IN N
blood NN N
transfusions NNS N
, , N
morbidity NN N
rate NN N
, , N
prognostic JJ N
relevance NN N
of IN N
tumor NN N
cell NN N
detection NN N
in IN N
blood NN N
and CC N
bone NN N
marrow NN N
and CC N
the DT N
comparison NN N
of IN N
tumor NN N
cell NN N
detection NN N
by IN N
different JJ N
detection NN N
methods NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
retrospective JJ N
study NN N
is VBZ N
to TO N
contribute VB N
to TO N
the DT N
existing VBG N
knowledge NN N
of IN N
the DT N
comparative JJ N
studies NNS N
of IN N
the DT N
volatile JJ N
anesthetic JJ N
agents NNS N
such JJ N
as IN N
isoflurane NN N
, , N
sevoflurane NN N
and CC N
desflurane NN N
by IN N
evaluating VBG N
the DT N
maintenance NN N
and CC N
emergence NN N
characteristics NNS N
after IN N
volatile JJ N
anesthetics-induced JJ N
preconditioning NN N
with IN N
isoflurane NN N
, , N
sevoflurane NN N
or CC N
desflurane NN N
for IN N
inpatient JJ N
ischemia/reperfusion NN N
cerebral JJ N
injury NN N
during IN N
cerebral JJ N
or CC N
neural JJ N
surgeries NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
LDL NNP N
from IN N
the DT N
beta-carotene NN N
and CC N
placebo NN N
groups NNS N
, , N
as IN N
assessed VBN N
by IN N
measuring VBG N
the DT N
lag NN N
time NN N
for IN N
formation NN N
of IN N
conjugated JJ N
dienes NNS N
; : N
the DT N
rate NN N
of IN N
formation NN N
and CC N
the DT N
amount NN N
of IN N
conjugated VBN N
dienes NNS N
formed VBN N
; : N
the DT N
amount NN N
of IN N
lipid JJ N
peroxides NNS N
generated VBD N
; : N
and CC N
the DT N
relative JJ N
electrophoretic JJ N
mobility NN N
, , N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
. . N

CONCLUSIONS NNP N
this DT N
study NN N
shows VBZ N
that IN N
use NN N
of IN N
the DT N
drug NN N
for IN N
the DT N
purpose NN N
of IN N
relief NN N
Remaxol NNP N
hepatic JJ N
dysfunction NN N
and CC N
prevention NN N
of IN N
drug NN N
liver NN N
toxicity NN N
in IN N
conditions NNS N
ofperitonitis VBP N
, , N
after IN N
48 CD N
hours NNS N
of IN N
operation NN N
, , N
provides VBZ N
a DT N
positive JJ N
dynamics NNS N
and CC N
stabilization NN N
ofparameters NNS N
of IN N
central JJ N
hemodynamics NNS N
, , N
contributing VBG N
to TO N
the DT N
abolition NN N
of IN N
vasopressor NN N
support NN N
, , N
and CC N
contributes VBZ N
to TO N
the DT N
effective JJ N
utilization NN N
of IN N
oxygen NN N
, , N
while IN N
providing VBG N
antioxidant JJ N
effect NN N
. . N

Even RB N
under IN N
temperate NN N
conditions NNS N
( ( N
T NNP N
( ( N
a DT N
) ) N
< $ N
28 CD N
) ) N
, , N
shearing VBG N
significantly RB N
reduced VBN N
core NN N
body NN N
temperature NN N
, , N
water NN N
intake NN N
, , N
and CC N
respiratory NN N
rate NN N
in IN N
German JJ N
Blackhead NNP N
mutton NN N
sheep NN N
, , N
thus RB N
indicating VBG N
heat NN N
stress NN N
in IN N
fleeced JJ N
animals NNS N
, , N
which WDT N
should MD N
be VB N
considered VBN N
when WRB N
determining VBG N
the DT N
optimal JJ N
shearing NN N
time NN N
in IN N
sheep NN N
as RB N
well RB N
as IN N
when WRB N
estimating VBG N
water NN N
requirements NNS N
. . N

There EX N
were VBD N
significant JJ N
treatment NN N
effects NNS N
for IN N
the DT N
PlayWisely NNP N
measure NN N
on IN N
the DT N
Yellow NNP N
Sets NNPS N
that WDT N
examine VBP N
recognition NN N
; : N
Purple NNP N
Sets VBZ N
that IN N
examine NN N
brain NN N
region NN N
agility NN N
and CC N
early JJ N
memory NN N
skills NNS N
; : N
Blue NNP N
Sets NNPS N
that WDT N
examine VBP N
phonemic JJ N
awareness NN N
and CC N
recognition NN N
; : N
and CC N
for IN N
the DT N
Total NNP N
Sets NNP N
, , N
with IN N
a DT N
similar JJ N
trend NN N
toward IN N
improvement NN N
in IN N
the DT N
Green JJ N
Sets NNS N
that WDT N
examine VBP N
perception NN N
and CC N
Red NNP N
Sets NNP N
that IN N
examine JJ N
attention NN N
. . N

A DT N
significant JJ N
difference NN N
of IN N
average JJ N
values NNS N
of IN N
CRP NNP N
between IN N
the DT N
3rd CD N
and CC N
21st CD N
day NN N
in IN N
both DT N
groups NNS N
of IN N
patients NNS p
was VBD N
established VBN N
, , N
as RB N
well RB N
as IN N
the DT N
similarity NN N
in IN N
average JJ N
values NNS N
of IN N
CRP NNP N
, , N
which WDT N
points VBZ N
to TO N
the DT N
fact NN N
that IN N
the DT N
mechanical JJ N
effect NN N
of IN N
through IN N
drainage NN N
is VBZ N
dominant JJ N
, , N
speaking VBG N
about IN N
rinsing VBG N
focus NN N
of IN N
infection NN N
and CC N
eliminating VBG N
necrotic JJ i
tissues NNS N
and CC N
small JJ N
sequesters NNS N
. . N

CONCLUSION NNP N
Although IN N
there EX N
was VBD N
no DT N
overall JJ i
effect NN N
on IN N
self-reported JJ N
recovery NN N
or CC N
administrative JJ N
measures NNS N
or CC N
lost VBN N
work NN N
time NN N
between IN N
the DT N
study NN N
groups NNS N
, , N
a DT N
back JJ N
support NN N
plus CC N
health NN N
education NN N
may MD N
have VB N
some DT N
value NN N
in IN N
preventing VBG N
recurrent JJ N
WR-LBD NNP N
in IN N
industrial JJ N
workers NNS N
who WP N
work VBP N
in IN N
psychosocial JJ N
environments NNS N
and CC N
perform VB N
manual JJ N
material NN N
handling VBG N
tasks NNS N
similar JJ N
to TO N
those DT N
found VBN N
in IN N
parts NNS N
distribution NN N
centers NNS N
. . N

However RB N
, , N
the DT N
percent NN N
of IN N
variance NN N
in IN N
these DT N
scores NNS N
explained VBN N
by IN N
time NN N
with IN N
MEE NNP N
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
beyond IN N
that DT N
explained VBN N
by IN N
sociodemographic JJ N
variables NNS N
ranged VBD N
only RB N
from IN N
1.2 CD N
% NN N
to TO N
2.9 CD N
% NN N
, , N
and CC N
the DT N
negative JJ N
correlations NNS N
were VBD N
concentrated VBN N
in IN N
the DT N
subgroup NN N
of IN N
children NNS N
whose WP$ N
families NNS N
had VBD N
private JJ N
health NN N
insurance NN N
( ( N
rather RB N
than IN N
Medicaid NNP N
) ) N
. . N

Findings NNS N
suggest VBP N
that IN N
some DT N
aspect NN N
of IN N
both DT N
auditory JJ N
training NN N
and CC N
listening VBG N
to TO N
selected VBN N
unmodified JJ N
music NN N
may MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
children NNS N
with IN N
autism NN N
and CC N
sound JJ N
sensitivity NN N
, , N
and CC N
indicate VBP N
a DT N
need NN N
for IN N
further JJ N
research NN N
into IN N
the DT N
effects NNS N
that WDT N
led VBD N
to TO N
these DT N
changes NNS N
and CC N
the DT N
mechanisms NNS N
involved VBN N
in IN N
the DT N
sensory JJ N
abnormalities NNS N
commonly RB N
associated VBN N
with IN N
autism NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
rates NNS N
of IN N
in IN N
vitro JJ N
oocyte JJ N
maturation NN N
, , N
fertilization NN N
and CC N
cleavage NN N
, , N
as RB N
well RB N
as IN N
implantation NN N
rate NN N
and CC N
pregnancy NN N
rate NN N
, , N
could MD N
be VB N
improved VBN N
by IN N
low-dose JJ N
priming NN N
with IN N
FSH NNP N
in IN N
vivo NN N
before IN N
retrieval NN N
of IN N
immature NN N
oocytes NNS N
in IN N
patients NNS p
with IN N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
increases NNS o
having VBG N
been VBN N
found VBN N
in IN N
straylight JJ N
values NNS N
with IN N
tinted VBN N
contact NN N
lenses NNS N
, , N
those DT N
changes NNS N
are VBP N
not RB N
likely JJ N
to TO N
induce VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
visual JJ N
function NN N
under IN N
photopic NN N
conditions NNS N
, , N
even RB N
for IN N
the DT N
grey-green JJ N
CL NNP N
, , N
which WDT N
seems VBZ N
to TO N
increase VB o
straylight JJ N
values NNS N
more RBR N
significantly RB N
than IN N
the DT N
amber JJ N
CL NNP N
. . N

Most JJS N
importantly RB N
, , N
the DT N
experiments NNS N
clarified VBD N
apparently RB N
contradictory JJ N
results NNS N
of IN N
previous JJ N
studies NNS N
by IN N
indicating VBG N
that IN N
concreteness NN N
effects NNS N
generally RB N
do VBP N
not RB N
occur VB N
in IN N
memory NN N
for IN N
prose NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
between-subjects NNS N
, , N
and CC N
that IN N
their PRP$ N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
of IN N
presentation NN N
. . N

Although IN N
dissecting VBG N
the DT N
ureter NN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
operation NN N
did VBD N
not RB N
produce VB N
a DT N
significant JJ N
discrepancy NN N
in IN N
operation NN N
time NN N
, , N
blood NN N
loss NN N
, , N
hospitalization NN N
day NN N
and CC N
ureter JJ N
injury NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
the DT N
uterine JJ N
arteries NNS N
, , N
however RB N
, , N
may MD N
be VB N
confidently RB N
desiccated VBN N
once RB N
the DT N
path NN N
of IN N
the DT N
ureter NN N
near IN N
the DT N
uterosacral JJ N
ligament NN N
is VBZ N
identified VBN N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
a DT N
new JJ N
combined VBN N
hormonal JJ N
contraceptive JJ N
vaginal JJ N
ring NN N
( ( N
CVR NNP N
) ) N
delivering VBG N
the DT N
nonandrogenic JJ N
progestin NN i
Nestorone NNP N
( ( N
NES NNP N
) ) N
and CC N
ethinyl JJ N
estradiol NN N
( ( N
EE NNP N
) ) N
on IN N
several JJ N
key JJ N
estrogen-sensitive JJ N
hepatic JJ N
proteins NNS N
that WDT N
may MD N
be VB N
markers NNS N
for IN N
the DT N
risk NN N
of IN N
arterial JJ N
or CC N
venous JJ N
disease NN N
events NNS N
and CC N
on IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
. . N

The DT N
present JJ N
randomized VBN N
placebo NN N
( ( N
PLC NNP N
) ) N
-controlled VBD N
within-subject JJ N
pharmaco-functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI NN N
) ) N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
single JJ N
intranasal NN N
dose NN N
of IN N
synthetic JJ N
OXT NNP N
( ( N
24 CD N
IU NNP N
) ) N
would MD N
facilitate VB N
both DT N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
interpersonal VB N
touch NN N
in IN N
a DT N
context- NN N
( ( N
female JJ N
vs NN N
male NN N
touch NN N
) ) N
and CC N
trait- JJ N
( ( N
autistic JJ N
trait NN N
load NN N
) ) N
specific JJ N
manner NN N
. . N

Venous JJ N
pressures NNS N
moved VBD N
parallel RB N
to TO N
ascitic JJ N
fluid NN N
pressures NNS N
, , N
and CC N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
and CC N
urine JJ N
flow NN N
all DT N
improved VBD N
sharply RB N
; : N
then RB N
, , N
as IN N
ascitic JJ N
fluid NN N
continued VBD N
to TO N
form VB N
, , N
reducing VBG N
vascular JJ N
volume NN N
, , N
urine JJ N
flow NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
, , N
and CC N
renal JJ N
plasma NN N
flow NN N
all DT N
decreased VBD o
slowly RB o
. . N

Recovery NN N
after IN N
a DT N
predetermined JJ N
AMP NNP N
PC20 NNP N
challenge NN N
was VBD N
measured VBN N
( ( N
primary JJ N
outcome NN N
) ) N
, , N
along IN N
with IN N
exhaled JJ N
nitric JJ N
oxide NN N
levels NNS N
, , N
plasma NN N
eosinophil NN N
cationic JJ N
protein NN N
levels NNS N
, , N
peripheral JJ N
eosinophil NN N
counts NNS N
, , N
pulmonary JJ N
function NN N
, , N
diary JJ N
card NN N
outcomes NNS N
, , N
and CC N
quality NN N
of IN N
life NN N
( ( N
all DT N
secondary JJ N
outcomes NNS N
) ) N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
study NN N
groups NNS N
with IN N
respect NN N
to TO N
mental VB N
or CC N
physical JJ N
health NN N
, , N
low JJ N
back RB N
pain NN N
, , N
back RB N
pain NN N
disability NN N
, , N
neurogenic JJ N
symptoms NNS N
, , N
lost VBN N
work NN N
time NN N
, , N
likelihood NN N
of IN N
recurrence NN N
of IN N
an DT N
episode NN N
of IN N
a DT N
back JJ N
disorder NN N
, , N
or CC N
other JJ N
administrative JJ N
measures NNS N
of IN N
healthcare JJ N
utilization NN N
or CC N
lost VBN N
work NN N
time NN N
. . N

Although IN N
AmB NNP N
in IN N
lipid JJ N
emulsion NN N
is VBZ N
apparently RB N
cleared VBN N
faster RBR N
and CC N
distributes VBZ N
more RBR N
widely RB N
than IN N
AmB NNP N
in IN N
dextrose NN N
, , N
this DT N
study NN N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
advantage NN N
with IN N
respect NN N
to TO N
safety NN N
and CC N
tolerance NN N
in IN N
the DT N
administration NN N
of IN N
AmB NNP N
in IN N
lipid JJ N
emulsion NN N
compared VBN N
to TO N
its PRP$ N
administration NN N
in IN N
dextrose NN N
in IN N
children NNS N
with IN N
malignant JJ N
disease NN N
. . N

These DT N
PSL-LBNP JJ N
exposures NNS N
were VBD N
conducted VBN N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
and CC N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h. NN N
While IN N
no DT N
differences NNS N
were VBD N
noted VBN N
in IN N
either CC N
the DT N
response NN N
pattern NN N
or CC N
magnitude NN N
of IN N
heart NN N
rate NN N
or CC N
blood NN N
pressure NN N
to TO N
the DT N
differing NN N
protocols NNS N
, , N
the DT N
cumulative JJ N
stress NN N
index NN N
and CC N
the DT N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure NN N
varied VBD N
proportionally RB N
with IN N
the DT N
length NN N
of IN N
the DT N
stage NN N
durations NNS N
. . N

The DT N
results NNS N
demonstrate VBP N
the DT N
clinical JJ N
efficacy NN N
of IN N
anti-inflammatory JJ N
drugs NNS N
in IN N
the DT N
treatment NN N
of IN N
pollen-induced JJ N
allergic JJ N
conjunctivitis NN N
; : N
they PRP N
also RB N
suggest VBP N
the DT N
use NN N
of IN N
NSAIDs NNP N
in IN N
long-term JJ N
treatment NN N
, , N
as IN N
their PRP$ N
efficacy NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
closely RB N
comparable JJ N
to TO N
that DT N
of IN N
steroids NNS N
, , N
while IN N
avoiding VBG N
the DT N
well-known JJ N
side-effects NNS N
of IN N
the DT N
latter NN N
in IN N
prolonged JJ N
treatment NN N
. . N

To TO N
avoid VB N
this DT N
complication NN N
, , N
it PRP N
is VBZ N
necessary JJ N
to TO N
better RBR N
understand VB N
the DT N
depth NN N
of IN N
the DT N
wound NN N
produced VBN N
by IN N
different JJ N
strengths NNS N
and CC N
combinations NNS N
of IN N
peeling VBG N
agents NNS N
applied VBN N
to TO N
living VBG N
eyelid JJ N
tissue NN N
and CC N
, , N
more RBR N
important JJ N
, , N
to TO N
determine VB N
the DT N
concentrations NNS N
of IN N
TCA NNP N
that WDT N
are VBP N
likely JJ N
to TO N
lead VB N
to TO N
cicatricial JJ N
ectropion NN N
when WRB N
applied VBN N
in IN N
a DT N
consistent JJ N
fashion NN N
. . N

This DT N
controlled VBD N
clinical JJ N
trial NN N
tested VBD N
virtual JJ N
reality NN N
exposure NN N
( ( N
VRE NNP N
) ) N
therapy NN i
for IN N
the DT N
fear NN N
of IN N
flying VBG N
( ( N
FOF NNP N
) ) N
, , N
a DT N
relatively RB N
new JJ N
and CC N
innovative JJ N
way NN N
to TO N
do VB N
exposure NN N
therapy NN i
, , N
and CC N
compared VBN N
it PRP N
to TO N
standard VB N
( ( N
in IN N
vivo NN N
) ) N
exposure NN N
therapy NN i
( ( N
SE NNP N
) ) N
and CC N
a DT N
wait JJ N
list NN N
( ( N
WL NNP N
) ) N
control NN N
with IN N
a DT N
6- JJ N
and CC N
12-month JJ N
follow-up NN N
. . N

BACKGROUND NNP N
Despite IN N
it PRP N
is VBZ N
accepted VBN N
that IN N
acne NN N
is VBZ N
mostly RB N
caused VBN N
by IN N
an DT N
hyper-responsiveness NN N
of IN N
the DT N
pilo-sebaceous JJ N
unit NN N
to TO N
normal JJ N
circulating VBG N
androgen NN N
hormones NNS N
, , N
in IN N
a DT N
few JJ N
patients NNS p
, , N
especially RB N
women NNS N
, , N
acneic JJ N
lesions NNS N
can MD N
be VB N
associated VBN N
with IN N
increased JJ o
serum NN N
androgen NN N
levels NNS N
( ( N
hyperandrogenism NN N
) ) N
, , N
of IN N
which WDT N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
is VBZ N
the DT N
most RBS N
common JJ N
cause NN N
. . N

However RB N
, , N
the DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
regarding VBG N
time NN N
from IN N
balloon NN N
insertion NN N
to TO N
active JJ N
labor NN N
, , N
time NN N
from IN N
balloon NN N
expulsion NN N
to TO N
delivery NN N
, , N
cervical JJ N
ripening NN N
, , N
cesarean JJ N
section NN N
, , N
instrumental JJ N
delivery NN N
, , N
pain NN N
score NN N
, , N
need VBP N
for IN N
analgesia NN N
, , N
hospital NN N
stay NN N
and CC N
maternal JJ N
satisfaction NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
response NN N
to TO N
improved VBN N
blood NN N
folate NN N
concentrations NNS N
, , N
many JJ N
health NN N
care NN N
professionals NNS N
are VBP N
asking VBG N
whether IN N
a DT N
folic JJ N
acid NN N
supplement NN N
is VBZ N
necessary JJ N
for IN N
NTD NNP N
prevention NN N
among IN N
women NNS N
with IN N
high JJ N
blood NN N
folate NN N
values NNS N
, , N
and CC N
how WRB N
reliably RB N
high JJ N
RBC NNP N
folate NN N
concentrations NNS N
predict VBP N
folate JJ N
intakes NNS N
shown VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
to TO N
be VB N
protective JJ N
against IN N
NTDs NNP N
. . N

By IN N
comparison NN N
of IN N
3-month JJ N
changes NNS N
between IN N
randomized VBN N
subgroups NNS N
, , N
the DT N
addition NN N
of IN N
low-dose JJ N
flutamide NN N
was VBD N
found VBN N
to TO N
have VB N
consistently RB N
( ( N
more RBR N
) ) N
normalizing VBG N
effects NNS N
on IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
, , N
IL-6 NNP N
, , N
and CC N
adiponectin NN i
, , N
lean JJ N
body NN N
mass NN N
, , N
total JJ N
and CC N
abdominal JJ N
fat JJ N
mass NN N
, , N
and CC N
arterial JJ N
flow NN N
in IN N
the DT N
ovaries NNS N
. . N

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
study NN N
arms NNS N
at IN N
3 CD N
months NNS N
in IN N
number NN N
of IN N
male JJ N
partners NNS N
, , N
number NN N
of IN N
unprotected JJ N
anal JJ N
intercourse NN N
partners NNS N
, , N
proportion NN N
reporting NN N
unprotected JJ N
sex NN N
, , N
number NN N
of IN N
acts NNS N
protected VBN N
by IN N
condoms NNS N
, , N
self-efficacy NN N
, , N
condom NN N
attitudes NNS N
, , N
condom NN N
intentions NNS N
, , N
social JJ N
isolation NN N
and CC N
psychological JJ N
distress NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incremental JJ N
cost-effectiveness JJ N
ratios NNS N
( ( N
ICERs NNP N
) ) N
of IN N
two CD N
brief JJ N
cognitive-behavioral JJ N
therapy NN i
( ( N
CBT NNP N
) ) N
-based VBD N
interventions NNS N
and CC N
a DT N
pharmacological JJ N
treatment NN N
, , N
compared VBN N
with IN N
usual JJ N
care NN N
, , N
initiated VBN N
in IN N
the DT N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
for IN N
individuals NNS N
with IN N
panic JJ N
disorder NN N
( ( N
PD NNP N
) ) N
with IN N
a DT N
chief JJ N
complaint NN N
of IN N
noncardiac JJ N
chest NN N
pain NN N
. . N

ORG-2766 NNP N
( ( N
a DT N
) ) N
increased VBD o
the DT o
occipital JJ N
P3 NNP N
component NN N
of IN N
the DT N
ERP NNP N
to TO N
visual JJ N
targets NNS N
, , N
( ( N
b NN N
) ) N
decreased VBD o
the DT o
occipital JJ N
P3 NNP N
component NN N
of IN N
the DT N
ERP NNP N
to TO N
auditory JJ N
targets NNS N
, , N
( ( N
c NN N
) ) N
did VBD N
not RB N
affect VB N
visual JJ N
and CC N
auditory JJ N
parietal JJ N
target NN N
P3 NNP N
components NNS N
, , N
and CC N
( ( N
d NN N
) ) N
also RB N
did VBD N
not RB N
affect VB N
the DT N
A/Pcz/300 NNP N
to TO N
auditory VB N
novel JJ N
stimuli NNS N
. . N

The DT N
Stroke NNP N
Team NNP N
Remote NNP N
Evaluation NNP N
Using VBG N
a DT N
Digital NNP N
Observation NNP N
Camera NNP N
( ( N
STRokE NNP N
DOC NNP N
) ) N
trial NN N
reported VBD N
more RBR N
accurate JJ N
decision NN N
making NN N
for IN N
telemedicine JJ N
consultations NNS N
compared VBN N
with IN N
telephone-only JJ N
and CC N
that IN N
the DT N
California-based JJ N
research NN N
network NN N
facilitated VBD N
a DT N
high JJ N
rate NN N
of IN N
thrombolysis NN N
use NN N
, , N
improved VBN N
data NNS N
collection NN N
, , N
low JJ N
risk NN N
of IN N
complications NNS N
, , N
low JJ N
technical JJ N
complications NNS N
, , N
and CC N
favorable JJ N
assessment NN N
times NNS N
. . N

Denbufylline NNP N
induced VBD N
a DT N
statistically RB N
significant JJ N
and CC N
clinically RB N
relevant JJ N
improvement NN N
in IN N
both DT N
SDAT NNP N
and CC N
MID NNP N
patients NNS p
, , N
whereas NNS N
after IN N
placebo NN N
this DT N
was VBD N
not RB N
the DT N
case NN N
in IN N
CGI NNP N
, , N
the DT N
TMT NNP N
, , N
and CC N
the DT N
DS NNP N
, , N
with IN N
interdrug JJ N
differences NNS N
being VBG N
significant JJ N
in IN N
all DT N
primary JJ N
target NN N
variables NNS N
such JJ N
as IN N
the DT N
CGI NNP N
, , N
MMS NNP N
, , N
SCAG NNP N
, , N
and CC N
DSST NNP N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
main JJ N
findings NNS N
were VBD N
similar JJ N
to TO N
those DT N
from IN N
other JJ N
brief-intervention NN N
studies NNS N
in IN N
Western JJ N
cultures NNS N
, , N
findings NNS N
here RB N
also RB N
suggest VBP N
that IN N
intervention NN N
may MD N
have VB N
differential JJ N
benefits NNS N
for IN N
specific JJ N
subgroups NNS N
of IN N
patients NNS p
in IN N
the DT N
ED NNP N
, , N
an DT N
area NN N
of IN N
research NN N
that WDT N
may MD N
warrant VB N
additional JJ N
study NN N
of IN N
brief JJ N
intervention NN N
in IN N
the DT N
ED NNP N
setting NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
controlled VBN N
trial NN N
involving VBG N
98 CD N
children NNS N
and CC N
families NNS N
was VBD N
carried VBN N
out RP N
in IN N
three CD N
different JJ N
sites NNS N
investigating VBG N
the DT N
efficacy NN N
of IN N
a DT N
parent NN N
delivery NN N
of IN N
the DT N
Early JJ N
Start NNP N
Denver NNP N
model NN N
( ( N
P-ESDM NNP N
) ) N
, , N
which WDT N
fosters VBZ N
parental JJ N
use NN N
of IN N
a DT N
child-centered JJ N
responsive JJ N
interaction NN N
style NN N
that WDT N
embeds VBZ N
many JJ N
teaching VBG N
opportunities NNS N
into IN N
play NN N
, , N
compared VBN N
to TO N
community NN N
treatment NN N
as IN N
usual JJ N
. . N

Several JJ N
racial JJ N
and CC N
ethnic JJ N
group NN N
differences NNS N
existed VBD N
in IN N
physical JJ N
and CC N
emotional JJ N
health NN N
, , N
as RB N
well RB N
as IN N
in IN N
total JJ N
frustration NN N
with IN N
caregiving NN N
, , N
emotional JJ N
burden NN N
, , N
and CC N
CG-rated JJ N
bother NN N
with IN N
CR NNP N
's POS N
activities NNS N
of IN N
daily JJ N
living NN N
and CC N
instrumental JJ N
activities NNS N
of IN N
daily JJ N
living NN N
at IN N
baseline NN N
and CC N
at IN N
follow-up JJ N
, , N
although IN N
differences NNS N
between IN N
baseline NN N
and CC N
posttest NN N
did VBD N
not RB N
vary JJ N
according VBG N
to TO N
race NN N
. . N

The DT N
aim NN N
of IN N
the DT N
Finnish NNP N
Diabetes NNP N
Prevention NNP N
Study NNP N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
an DT N
intensive JJ N
diet-exercise NN N
programme NN N
in IN N
preventing VBG N
or CC N
delaying VBG N
type JJ N
2 CD N
diabetes NNS N
in IN N
individuals NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
( ( N
IGT NNP N
) ) N
and CC N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
programme NN N
on IN N
the DT N
risk NN N
factors NNS N
of IN N
atherosclerotic JJ i
vascular NN N
diseases NNS N
and CC N
the DT N
incidence NN N
of IN N
cardiovascular JJ N
events NNS N
. . N

As IN N
this DT N
project NN N
is VBZ N
much RB N
longer JJR N
term NN N
than IN N
previous JJ N
investigations NNS N
in IN N
the DT N
area NN N
of IN N
exercise NN N
and CC N
cancer NN N
, , N
we PRP N
will MD N
gain VB N
knowledge NN N
as IN N
to TO N
the DT N
continuing VBG N
effects NNS N
of IN N
exercise NN N
in IN N
this DT N
patient JJ N
population NN N
specifically RB N
targeting VBG N
bone NN N
density NN N
, , N
cardiovascular JJ N
function NN N
, , N
lean JJ N
and CC N
fat JJ N
mass NN N
, , N
physical JJ N
function NN N
and CC N
falls VBZ N
risk NN N
as IN N
primary JJ N
study NN N
endpoints NNS N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
S-form NNP N
type NN N
is VBZ N
associated VBN N
with IN N
previously-identified JJ N
adverse JJ N
risk NN N
WBC NNP N
parameters NNS N
but CC N
that IN N
the DT N
identification NN N
of IN N
the DT N
S-form NNP N
or CC N
L-form NNP N
type NN N
of IN N
PML-RAR NNP N
alpha NN N
mRNA NN N
, , N
per IN N
se FW N
, , N
does VBZ N
not RB N
predict VB N
clinical JJ N
outcome NN N
or CC N
add VB N
to TO N
the DT N
value NN N
of IN N
an DT N
increased VBN o
WBC NNP N
count NN N
as IN N
a DT N
negative JJ N
prognostic JJ N
indicator NN N
in IN N
APL NNP N
patients NNS p
. . N

However RB N
, , N
during IN N
the DT N
whole JJ N
12-month JJ N
training NN N
period NN N
, , N
both DT N
dynamic JJ N
and CC N
isometric JJ N
back NN N
extension NN N
and CC N
flexion NN N
strength NN N
, , N
as RB N
well RB N
as IN N
mobility NN N
of IN N
the DT N
spine NN N
and CC N
repetitive JJ N
squat-test JJ N
results NNS N
, , N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
no DT N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
physical JJ N
function NN N
parameters NNS N
between IN N
the DT N
STG NNP N
and CC N
CG NNP N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
an DT N
IVF NNP N
protein NN N
supplement NN N
prepared VBN N
from IN N
human JJ N
serum NN N
albumin NN N
( ( N
HSA NNP N
) ) N
and CC N
human JJ N
globulins NNS N
would MD N
retain VB N
performance NN N
characteristics NNS N
equivalent JJ N
to TO N
those DT N
reported VBN N
for IN N
the DT N
commercial JJ N
plasma NN N
expanders NNS N
, , N
Plasmatein NNP N
( ( N
Alpha NNP N
Therapeutics NNP N
, , N
Los NNP N
Angeles NNP N
, , N
California NNP N
) ) N
and CC N
Plasmanate NNP N
( ( N
Cutter NNP N
Biological NNP N
, , N
Miles NNP N
Inc. NNP N
, , N
Elkhart NNP N
, , N
Indiana NNP N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
initial JJ N
cortical JJ N
response NN N
to TO N
the DT N
magnocellular JJ N
afferents NNS N
is VBZ N
weaker JJR N
at IN N
low JJ N
contrast NN N
in IN N
the DT N
high JJ N
autistic JJ N
tendency NN N
group NN N
and CC N
that IN N
a DT N
second-order JJ N
response NN N
, , N
reflecting VBG N
magnocellular JJ N
activity NN N
, , N
demonstrated VBD N
a DT N
delay NN N
for IN N
high JJ N
versus NN N
low JJ N
scorers NNS N
when WRB N
the DT N
parvocellular JJ N
pathway NN N
was VBD N
also RB N
active JJ N
in IN N
response NN N
to TO N
a DT N
high JJ N
contrast NN N
stimulus NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
compared VBN N
the DT N
effect NN N
of IN N
epidural JJ N
analgesia NN N
and CC N
IV NNP N
morphine VBP N
patient-controlled JJ N
analgesia NN N
( ( N
PCA NNP N
) ) N
on IN N
pain NN N
relief NN N
, , N
duration NN N
of IN N
hospitalization NN N
, , N
oral JJ N
nutrition NN N
, , N
ambulation NN N
, , N
and CC N
side NN N
effects NNS N
in IN N
patients NNS p
undergoing VBG N
a DT N
major JJ N
surgical JJ N
procedure NN N
( ( N
i.e JJ N
, , N
unilateral JJ N
mastectomy NN N
with IN N
immediate JJ N
transverse NN N
rectus NN N
abdominis VBP N
musculocutaneous JJ N
flap JJ N
reconstruction NN N
) ) N
. . N

The DT N
results NNS N
provide VBP N
evidence NN N
that IN N
the DT N
two CD N
tumor NN N
markers NNS N
are VBP N
not RB N
directly RB N
linked VBN N
and CC N
that IN N
DCP NNP N
levels NNS N
may MD N
not RB N
reflect VB N
HCC NNP N
cell NN N
growth NN N
, , N
as IN N
DCP NNP N
levels NNS N
were VBD N
decreased VBN o
in IN N
patients NNS p
without IN N
AFP NNP N
change NN N
, , N
and CC N
were VBD N
suppressed VBN N
in IN N
vitro NN N
at IN N
1 CD N
% NN N
of IN N
the DT N
vitamin NN N
K1 NNP N
concentration NN N
needed VBD N
to TO N
inhibit VB N
AFP NNP N
. . N

CONCLUSION NNP N
The DT N
level NN N
of IN N
absence NN N
of IN N
cold JJ N
sensation NN N
, , N
level NN N
of IN N
pinprick JJ N
analgesia NN N
, , N
and CC N
time NN N
to TO N
achieve VB N
sensory JJ N
block NN N
to TO N
T4 NNP N
level NN N
were VBD N
statistically RB N
higher JJR N
in IN N
patients NNS p
receiving VBG N
hyperbaric JJ N
bupivacaine NN N
than IN N
in IN N
patients NNS p
receiving VBG N
plain JJ N
bupivacaine NN N
and CC N
plain NN N
levobupivacaine NN N
, , N
while IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
in IN N
all DT N
groups NNS N
regarding VBG N
effective JJ N
surgical JJ N
anesthesia NN N
, , N
postoperative JJ N
analgesia NN N
, , N
and CC N
side JJ N
effects NNS N
. . N

The DT N
secondary JJ N
outcome NN N
measures NNS N
are VBP N
the DT N
Center NNP N
for IN N
Epidemiological NNP N
Studies NNPS N
Depression NNP N
Scale NNP N
, , N
the DT N
World NNP N
Health NNP N
Organization NNP N
Quality NNP N
of IN N
Life NNP N
Scale NNP N
26-item JJ N
version NN N
, , N
the DT N
Global NNP N
Assessment NNP N
of IN N
Functioning NNP N
, , N
State-trait NNP N
Anxiety NNP N
Inventory NNP N
, , N
Social NNP N
Phobia NNP N
and CC N
Anxiety NNP N
Inventory NNP N
, , N
and CC N
Liebowitz NNP N
Social NNP N
Anxiety NNP N
Scale NNP N
. . N

CONCLUSIONS NNP N
For IN N
a DT N
longer RBR N
follow-up JJ N
period NN N
than IN N
in IN N
previous JJ N
studies NNS N
, , N
this DT N
heart NN N
failure NN N
disease JJ N
management NN N
program NN N
model NN N
of IN N
patients NNS p
under IN N
the DT N
supervision NN N
of IN N
a DT N
cardiologist NN N
is VBZ N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
unplanned JJ N
hospitalization NN N
, , N
a DT N
reduction NN N
of IN N
total JJ N
hospital NN N
days NNS N
, , N
and CC N
a DT N
reduced JJ N
need NN N
for IN N
emergency NN N
care NN N
, , N
as RB N
well RB N
as IN N
improved VBN N
quality NN N
of IN N
life NN N
, , N
despite IN N
modest JJ N
program NN N
adherence NN N
over IN N
time NN N
. . N

Positive JJ N
differences NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
the DT N
secondary JJ N
outcomes NNS N
: : N
the DT N
NPI-Q NNP N
sum NN N
score NN N
as RB N
well RB N
as IN N
the DT N
subscales NNS N
NPI-Q NNP N
agitation NN N
and CC N
NPI-Q JJ N
psychosis NN N
were VBD N
in IN N
favour NN N
of IN N
both DT N
interventions NNS N
versus VBP N
control NN N
, , N
the DT N
QUALID NNP N
score NN N
was VBD N
in IN N
favour NN N
of IN N
DCM NNP N
versus NN N
control NN N
and CC N
the DT N
CSDD NNP N
score NN N
was VBD N
in IN N
favour NN N
of IN N
VPM NNP N
versus NN N
control NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
a DT N
Neurologic NNP N
Music NNP N
Therapy NNP N
( ( N
NMT NNP N
) ) N
sensory-motor NN N
rehabilitation NN N
technique NN N
, , N
Therapeutic NNP N
Instrumental NNP N
Music NNP N
Performance NNP N
( ( N
TIMP NNP N
) ) N
as IN N
compared VBN N
to TO N
Traditional NNP N
Occupational NNP N
Therapy NNP N
( ( N
TOT NNP N
) ) N
, , N
on IN N
endurance NN N
, , N
self-perceived JJ N
fatigue NN N
, , N
and CC N
self-perceived JJ N
exertion NN N
of IN N
35 CD N
hospitalized JJ N
patients NNS p
in IN N
physical JJ N
rehabilitation NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
methylphenidate NN N
( ( N
MPH NNP N
) ) N
to TO N
treat VB N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
symptoms NNS N
in IN N
an DT N
understudied JJ N
population NN N
of IN N
preschoolers NNS N
with IN N
pervasive JJ N
developmental JJ N
disorder NN N
( ( N
PDD NNP N
) ) N
or CC N
intellectual JJ N
disability NN N
( ( N
ID NNP N
) ) N
. . N

GOALS NNP N
To TO N
measure VB N
visit-to-visit JJ N
intraindividual JJ N
variations NNS N
of IN N
both DT N
clinic JJ N
and CC N
24-h JJ N
mean NN N
BP NNP N
in IN N
the DT N
hypertensive JJ N
patients NNS p
of IN N
the DT N
European NNP N
Lacidipine NNP N
Study NNP N
on IN N
Atherosclerosis NNP N
( ( N
ELSA NNP N
) ) N
trial NN N
treated VBD N
for IN N
4 CD N
years NNS N
with IN N
either DT N
atenolol NN i
or CC N
lacidipine NN N
, , N
and CC N
to TO N
check VB N
whether IN N
interindividual JJ N
clinic NN N
and CC N
24-h JJ N
BP NNP N
variabilities NNS N
during IN N
treatment NN N
can MD N
really RB N
be VB N
considered VBN N
a DT N
surrogate NN N
of IN N
intraindividual JJ N
variabilities NNS N
in IN N
exploring VBG N
differences NNS N
between IN N
? . N
and CC N
calcium JJ N
antagonist NN N
treatments NNS N
. . N

Split-course JJ N
radiation NN N
therapy NN i
is VBZ N
superior JJ N
to TO N
continuous JJ N
radiation NN N
therapy NN i
because IN N
it PRP N
is VBZ N
better RBR N
tolerated VBN N
by IN N
the DT N
patient NN N
and CC N
because IN N
re-examination NN N
of IN N
the DT N
patient NN N
prior RB N
to TO N
the DT N
second JJ N
half NN N
of IN N
split-course JJ N
therapy NN i
permits VBZ N
the DT N
detection NN N
of IN N
new JJ N
metastatic JJ N
disease NN N
that WDT N
has VBZ N
become VBN N
manifest JJS N
during IN N
the DT N
rest NN N
period NN N
and CC N
spares VBZ N
the DT N
patient NN N
the DT N
futile JJ N
second JJ N
half NN N
of IN N
radiation NN N
therapy NN i
. . N

CONCLUSION NNP N
Although IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
consider VB N
all DT N
factors NNS N
which WDT N
can MD N
have VB N
an DT N
influence NN N
on IN N
SSI NNP N
and CC N
use VB N
all PDT N
the DT N
means NNS N
shown VBN N
to TO N
be VB N
effective JJ N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
SSI NNP N
, , N
there EX N
is VBZ N
a DT N
rationale NN N
for IN N
using VBG N
ORC NNP N
to TO N
prevent VB N
this DT N
kind NN N
of IN N
infection NN N
, , N
especially RB N
in IN N
patients NNS p
who WP N
undergo VBP N
dirty JJ N
surgery NN N
. . N

DESIGN NNP N
The DT N
Baron NNP N
and CC N
Kenny NNP N
mediator NN N
model NN N
, , N
a DT N
series NN N
of IN N
4 CD N
regression NN N
analyses NNS N
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
whether IN N
: : N
a DT N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
predicted VBD N
program NN N
participation NN N
, , N
b NN N
) ) N
program NN N
participation NN N
predicted VBD N
dietary JJ N
adherence NN N
, , N
c NN N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
factors NNS N
predicted VBD N
dietary JJ N
adherence NN N
, , N
and CC N
, , N
ultimately RB N
d NN N
) ) N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
dietary JJ N
adherence NN N
were VBD N
mediated VBN N
by IN N
program NN N
participation NN N
. . N

The DT N
absence NN N
of IN N
suppression NN N
of IN N
reflexive JJ N
sympathetic JJ N
responses NNS N
contrasts NNS N
with IN N
the DT N
effects NNS N
of IN N
rilmenidine NN N
in IN N
experimental JJ N
animals NNS N
, , N
and CC N
emphasises VBZ N
the DT N
previously RB N
demonstrated VBN N
unique JJ N
importance NN N
in IN N
humans NNS N
of IN N
suprabulbar NN N
noradrenergic JJ N
neuronal JJ N
projections NNS N
from IN N
the DT N
brainstem NN N
, , N
which WDT N
are VBP N
inhibited VBN N
by IN N
imidazoline JJ N
binding NN N
agents NNS N
, , N
in IN N
regulating VBG N
tonic JJ N
sympathetic JJ N
activity NN N
in IN N
essential JJ N
hypertension NN N
. . N

Accordingly RB N
, , N
it PRP N
would MD N
be VB N
anticipated VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
would MD N
significantly RB N
alter VB N
the DT N
autonomic JJ N
imbalance NN N
characteristic NN N
of IN N
patients NNS p
with IN N
congestive JJ N
heart NN N
failure NN N
and CC N
that IN N
this DT N
influence NN N
over IN N
neural JJ N
mechanisms NNS N
of IN N
cardiovascular JJ N
control NN N
may MD N
significantly RB N
contribute VB N
to TO N
the DT N
hemodynamic JJ N
benefit NN N
and CC N
improved VBN N
survival NN N
associated VBN N
with IN N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
therapy NN i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Amount NNP N
of IN N
intraoperative JJ N
bleeding NN N
( ( N
surgeons NNS N
' POS N
subjective JJ N
estimate NN N
) ) N
, , N
need VBP N
for IN N
additional JJ N
packings NNS N
, , N
need VBP N
for IN N
electrocautery NN N
, , N
laryngeal JJ N
spasm NN N
, , N
postoperative JJ N
bleeding NN N
and CC N
pain NN N
, , N
duration NN N
of IN N
procedure NN N
and CC N
duration NN N
of IN N
patients NNS p
' POS N
stay NN N
in IN N
the DT N
operation NN N
room NN N
( ( N
OR NNP N
) ) N
. . N

CONCLUSION NNP N
Our PRP$ N
data NNS N
indicate VBP N
that IN N
functional JJ N
endoscopic NN N
sinus NN N
surgery NN N
, , N
combined VBN N
with IN N
appropriate JJ N
postoperative JJ N
care NN N
, , N
is VBZ N
effective JJ N
at IN N
maintaining VBG N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
overall JJ i
general JJ N
health NN N
status NN N
of IN N
patients NNS p
for IN N
at IN N
least JJS N
3 CD N
years NNS N
after IN N
surgical JJ N
intervention NN N
and CC N
that IN N
the DT N
overall JJ i
scores NNS N
return VBP N
to TO N
a DT N
range NN N
of IN N
normative JJ N
values NNS N
for IN N
the DT N
general JJ N
population NN N
. . N

Polygraphic JJ N
recordings NNS N
included VBD N
sleep JJ N
state NN N
( ( N
active JJ N
and CC N
quiet JJ N
sleep NN N
by IN N
electroencephalogram NN N
, , N
eye NN N
movements NNS N
, , N
breathing NN N
, , N
and CC N
behavior NN N
) ) N
, , N
cardiorespiratory JJ N
measurements NNS N
( ( N
nasal JJ N
airflow NN N
, , N
chest VBP N
wall NN N
movements NNS N
, , N
heart NN N
rate NN N
, , N
and CC N
oxygen PRP N
saturation NN N
) ) N
, , N
swallowing VBG N
, , N
and CC N
esophageal JJ N
activity NN N
( ( N
solid JJ N
state NN N
pressure NN N
catheter NN N
) ) N
. . N

The DT N
comparison NN N
involved VBD N
randomly RB N
assigning VBG N
150 CD N
outpatients NNS p
with IN N
major JJ N
depression NN N
to TO N
a DT N
treatment NN N
focused VBN N
exclusively RB N
on IN N
the DT N
behavioral JJ N
activation NN N
( ( N
BA NNP N
) ) N
component NN N
of IN N
CT NNP N
, , N
a DT N
treatment NN N
that WDT N
included VBD N
both DT N
BA NNP N
and CC N
the DT N
teaching NN N
of IN N
skills NNS N
to TO N
modify VB N
automatic JJ N
thoughts NNS N
( ( N
AT NNP N
) ) N
, , N
but CC N
excluding VBG N
the DT N
components NNS N
of IN N
CT NNP N
focused VBD N
on IN N
core NN N
schema NN N
, , N
or CC N
the DT N
full JJ N
CT NNP N
treatment NN N
. . N

Although IN N
the DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
is VBZ N
considered VBN N
the DT N
gold JJ N
standard NN N
in IN N
research NN N
for IN N
determining VBG N
the DT N
efficacy NN N
of IN N
health NN N
education NN N
interventions NNS N
, , N
such JJ N
trials NNS N
may MD N
be VB N
vulnerable JJ N
to TO N
preference VB N
effects NNS N
; : N
that DT N
is VBZ N
, , N
differential JJ N
outcomes NNS N
depending VBG N
on IN N
whether IN N
an DT N
individual NN N
is VBZ N
randomized VBN N
to TO N
his PRP$ N
or CC N
her PRP$ N
preferred JJ N
treatment NN N
. . N

PURPOSE NN N
To TO N
prospectively RB N
assess VB N
the DT N
effect NN N
of IN N
reduced JJ N
iodine JJ N
load NN N
to TO N
contrast VB N
enhancement NN N
, , N
image NN N
quality NN N
, , N
and CC N
detectability NN N
of IN N
hepatocellular JJ N
carcinomas NN N
( ( N
HCCs NNP N
) ) N
in IN N
hepatic JJ N
CT NNP N
with IN N
a DT N
combination NN N
of IN N
80 CD N
kVp NNS N
tube JJ N
voltage NN N
setting NN N
and CC N
adaptive JJ N
statistical JJ N
iterative JJ N
reconstruction NN N
( ( N
ASIR NNP N
) ) N
technique NN N
in IN N
patients NNS p
with IN N
chronic JJ N
liver NN N
disease NN N
. . N

RESULTS JJ N
Women NNP N
in IN N
the DT N
pilot NN N
group NN N
had VBD N
significantly RB N
more RBR N
continuity NN N
of IN N
care NN N
throughout IN N
each DT N
of IN N
the DT N
three CD N
periods NNS N
, , N
were VBD N
generally RB N
more RBR N
satisfied JJ N
with IN N
their PRP$ N
care NN N
, , N
felt VBD N
that IN N
they PRP N
had VBD N
more JJR N
choice NN N
over IN N
a DT N
variety NN N
of IN N
aspects NNS N
of IN N
care NN N
and CC N
experienced VBD N
no DT N
compromise NN N
in IN N
clinical JJ N
outcomes NNS N
( ( N
P NNP N
= VBZ N
0.05 CD N
or CC N
less JJR N
in IN N
each DT N
case NN N
) ) N
. . N

OBJECTIVE IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
first RB N
to TO N
analyze VB N
neurocognitive JJ N
outcomes NNS N
of IN N
patients NNS p
after IN N
open-chamber JJ N
cardiac JJ N
surgery NN N
to TO N
determine VB N
whether IN N
carbon NN N
dioxide NN N
pericardial JJ N
insufflation NN N
reduces NNS N
incidence NN N
of IN N
neurocognitive JJ N
decline NN N
( ( N
primary JJ N
end NN N
point NN N
) ) N
as IN N
measured VBN N
6 CD N
weeks NNS N
postoperatively RB N
and CC N
second JJ N
to TO N
assess VB N
the DT N
utility NN N
of IN N
carbon NN N
dioxide NN N
insufflation NN N
in IN N
cardiac JJ N
chamber NN N
deairing NN N
as IN N
assessed VBN N
by IN N
transesophageal JJ N
echocardiography NN N
. . N

Baseline NNP N
NE NNP N
was VBD N
significantly RB N
correlated VBN N
with IN N
the DT N
NE NNP N
AUC0-90 NNP N
in IN N
all DT N
three CD N
groups NNS N
, , N
suggesting VBG N
that IN N
, , N
although IN N
the DT N
NE NNP N
system NN N
may MD N
be VB N
dysregulated VBN N
in IN N
the DT N
MDE NNP N
and CC N
MDE NNP N
+ NNP N
P NNP N
patients NNS p
, , N
the DT N
NE NNP N
system NN N
still RB N
appears VBZ N
to TO N
respond VB N
somewhat RB N
predictably RB N
following VBG N
a DT N
challenge NN N
, , N
even RB N
though IN N
the DT N
actual JJ N
magnitude NN N
of IN N
response NN N
may MD N
vary VB N
. . N

Yet RB N
, , N
sleep VBP N
withdrawal NN N
even RB N
if IN N
only RB N
partial JJ N
, , N
has VBZ N
a DT N
negative JJ N
influence NN N
on IN N
performance NN N
, , N
particularly RB N
when WRB N
the DT N
type NN N
of IN N
exercise NN N
requires VBZ N
good JJ N
psychomotor NN N
performance NN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
intake NN N
of IN N
a DT N
hypnotic JJ i
drug NN N
would MD N
have VB N
negative JJ N
effects NNS N
on IN N
physical JJ N
performance NN N
capacity NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
overall JJ i
mood NN N
profiles NNS N
were VBD N
similar JJ N
for IN N
the DT N
users NNS N
of IN N
any DT N
of IN N
the DT N
standard JJ N
malaria NN N
chemoprophylaxis NN N
regimens NNS N
, , N
we PRP N
found VBD N
that IN N
women NNS N
using VBG N
mefloquine NN N
showed VBD N
more JJR N
fatigue NN N
and CC N
confusion NN N
than IN N
men NNS N
and CC N
that IN N
younger JJR N
persons NNS N
aged VBD N
less JJR N
than IN N
34 CD N
years NNS N
, , N
regardless RB N
of IN N
chemoprophylaxis NN N
used VBN N
, , N
reported VBD N
more JJR N
tension NN N
and CC N
fatigue NN N
than IN N
their PRP$ N
older JJR N
counterparts NNS N
. . N

The DT N
emerging VBG N
concept NN N
of IN N
opioid JJ N
peptides NNS N
as IN N
a DT N
new JJ N
class NN N
of IN N
chemical JJ N
messengers NNS N
of IN N
the DT N
neuroimmune JJ N
axis NN N
and CC N
the DT N
presence NN N
of IN N
a DT N
number NN N
of IN N
immunological JJ N
abnormalities NNS N
in IN N
infantile JJ N
autism NN N
prompted VBD N
us PRP N
to TO N
correlate VB N
biological JJ N
( ( N
hormonal JJ N
and CC N
immunological JJ N
) ) N
determinations NNS N
and CC N
behavioural JJ N
performances NNS N
during IN N
treatment NN N
with IN N
the DT N
potent NN N
opiate JJ N
antagonist NN N
, , N
naltrexone NN N
( ( N
NAL NNP N
) ) N
. . N

The DT N
results NNS N
of IN N
that DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
suggest VBP N
that IN N
fluoxetine NN N
was VBD N
effective JJ N
in IN N
decreasing VBG N
but CC N
not RB N
eliminating VBG N
both CC N
the DT N
depressive NN N
symptoms NNS N
( ( N
including VBG N
suicidal JJ N
ideations NNS N
) ) N
and CC N
the DT N
level NN N
of IN N
alcohol JJ N
consumption NN N
among IN N
a DT N
study NN N
group NN N
of IN N
subjects NNS N
with IN N
comorbid NN N
major JJ N
depressive JJ N
disorder NN N
and CC N
alcohol NN N
dependence NN N
, , N
many JJ N
of IN N
whom WP N
displayed VBD N
suicidal JJ N
ideations NNS N
. . N

The DT N
seven-day JJ N
course NN N
of IN N
metronidazole NN N
was VBD N
superior JJ N
to TO N
the DT N
single-dose JJ N
regimen NNS N
in IN N
the DT N
percentage NN N
of IN N
patients NNS p
with IN N
clue JJ N
cells NNS N
and CC N
the DT N
percentage NN N
of IN N
patients NNS p
with IN N
a DT N
positive JJ N
sniff NN N
test NN N
at IN N
the DT N
first JJ N
follow-up JJ N
visit NN N
; : N
however RB N
, , N
differences NNS N
in IN N
the DT N
initial JJ N
cure NN N
rate NN N
assessed VBN N
by IN N
clinical JJ N
criteria NNS N
and CC N
Gram-stained JJ N
smear JJ N
criteria NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
between IN N
the DT N
two CD N
patient NN N
treatment NN N
regimens NNS N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
ratings NNS N
of IN N
pain NN N
and CC N
sleep JJ N
quality NN N
as RB N
well RB N
as IN N
the DT N
ability NN N
to TO N
perform VB N
daily JJ N
activities NNS N
( ( N
Ambulatory NNP N
Post NNP N
Acute NNP N
Care NNP N
Daily NNP N
Activities NNP N
Short NNP N
Form NNP N
) ) N
, , N
quality NN N
of IN N
life NN N
( ( N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-General NNP N
) ) N
, , N
and CC N
fatigue NN N
( ( N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-Fatigue NNP N
) ) N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
combining VBG N
electrically RB N
induced JJ N
sensory NN N
inputs NNS N
through IN N
transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
( ( N
TENS NNP N
) ) N
with IN N
task-related JJ N
training NN N
( ( N
TRT NNP N
) ) N
in IN N
a DT N
home-based JJ N
program NN N
would MD N
augment VB N
voluntary JJ N
motor NN N
output NN N
in IN N
chronic JJ N
stroke NN N
survivors NNS N
better RBR N
than IN N
either DT N
treatment NN N
alone RB N
or CC N
no DT N
treatment NN N
. . N

One CD N
randomly NN N
assigned VBN N
group NN N
of IN N
10 CD N
autistic JJ N
subjects NNS N
first RB N
learned VBD N
to TO N
lace VB N
shoes NNS N
whose WP$ N
laces NNS N
and CC N
eyelets NNS N
were VBD N
color-coded JJ N
red JJ N
and CC N
white JJ N
, , N
and CC N
then RB N
encountered VBD N
the DT N
no DT N
extra JJ N
prompt JJ N
condition NN N
in IN N
which WDT N
color NN N
codes NNS N
could MD N
no RB N
longer RB N
be VB N
depended VBN N
upon IN N
to TO N
solve VB N
the DT N
position NN N
discriminations NNS N
required VBN N
to TO N
lace VB N
properly RB N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Outcomes NNP N
included VBD N
death NN N
within IN N
60 CD N
days NNS N
( ( N
primary JJ N
outcome NN N
) ) N
, , N
survival JJ N
, , N
cardiovascular JJ N
events NNS N
, , N
performance NN N
status NN N
, , N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
symptoms NNS N
, , N
number NN N
of IN N
nonstatin JJ i
medications NNS N
, , N
and CC N
cost NN N
savings NNS N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
the DT N
Play NNP N
and CC N
Language NNP N
for IN N
Autistic NNP N
Youngsters NNP N
( ( N
PLAY NNP N
) ) N
Project NNP N
Home NNP N
Consultation NNP N
model NN N
, , N
in IN N
combination NN N
with IN N
usual JJ N
community NN N
services NNS N
( ( N
CS NNP N
) ) N
, , N
to TO N
improve VB N
parent-child JJ N
interaction NN N
, , N
child NN N
development NN N
, , N
and CC N
autism NN N
symptomatology NN N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
compared VBN N
with IN N
CS NNP N
only RB N
. . N

CONCLUSIONS NNP N
In IN N
asymptomatic JJ N
patients NNS p
, , N
the DT N
use NN N
of IN N
software NN N
for IN N
post-processing JJ N
digital JJ N
elimination NN N
of IN N
residue NN N
from IN N
images NNS N
in IN N
conjunction NN N
with IN N
reduced JJ N
bowel NN N
preparation NN N
does VBZ N
not RB N
reduce VB N
examination NN N
quality NN N
or CC N
diagnostic JJ N
performance NN N
when WRB N
compared VBN N
with IN N
the DT N
conventional JJ N
CT NNP N
colonography NN N
technique NN N
and CC N
is VBZ N
more RBR N
acceptable JJ N
to TO N
and CC N
better RB N
tolerated VBN N
by IN N
the DT N
patient NN N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
rated VBD N
periventricular JJ N
and CC N
subcortical JJ N
signal NN N
hyperintensities NNS N
on IN N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
scans VBZ N
in IN N
elderly JJ N
patients NNS p
with IN N
depression NN N
and CC N
in IN N
normal JJ N
subjects NNS N
with IN N
similar JJ N
demographic JJ N
features NNS N
to TO N
examine VB N
whether IN N
such JJ N
changes NNS N
discriminate VBP N
patients NNS p
with IN N
depression NN N
from IN N
normal JJ N
subjects NNS N
and CC N
whether IN N
they PRP N
are VBP N
associated VBN N
with IN N
any DT N
clinical JJ N
variables NNS N
. . N

INTRODUCTION NNP N
Exercise NNP N
can MD N
increase VB o
bone NN N
strength NN N
, , N
but CC N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
fracture NN N
risk NN N
, , N
exercise NN N
must MD N
be VB N
feasible JJ N
enough JJ N
to TO N
be VB N
adopted VBN N
into IN N
daily JJ N
life NN N
and CC N
influence NN N
potentially RB N
vulnerable JJ N
skeletal JJ N
sites NNS N
such JJ N
as IN N
the DT N
superolateral JJ N
cortex NN N
of IN N
the DT N
femoral JJ N
neck NN N
, , N
where WRB N
thinning NN N
is VBZ N
associated VBN N
with IN N
increased JJ o
fracture NN N
risk NN N
. . N

CONCLUSIONS NNP N
This DT N
preliminary JJ N
investigation NN N
showing VBG N
a DT N
decrease NN o
in IN N
BALF NNP N
levels NNS N
of IN N
IL-8 NNP N
and CC N
leukotriene JJ N
B4 NNP N
and CC N
the DT N
associated JJ N
reduction NN N
of IN N
BALF NNP N
neutrophils NNS N
and CC N
alveolar JJ N
membrane NN N
protein NN N
permeability NN N
in IN N
acute JJ N
respiratory NN N
distress JJ N
syndrome JJ N
patients NNS p
fed VBP N
EPA+GLA NNP N
support NN N
, , N
in IN N
part NN N
, , N
the DT N
potential JJ N
mechanisms NN N
underlying VBG N
the DT N
previously RB N
described VBN N
clinical JJ N
improvements NNS N
with IN N
this DT N
diet NN N
. . N

Such JJ N
augmentation NN N
of IN N
vagal JJ N
tone NN N
is VBZ N
known VBN N
to TO N
be VB N
protective JJ N
against IN N
malignant JJ N
ventricular JJ N
arrhythmias NNS N
in IN N
patients NNS p
with IN N
ischemic JJ N
heart NN N
disease NN N
and CC N
therefore NN N
may MD N
have VB N
similar JJ N
benefit NN N
in IN N
the DT N
setting NN N
of IN N
ventricular JJ N
failure NN N
, , N
thus RB N
contributing VBG N
to TO N
the DT N
improved JJ N
survival NN N
associated VBN N
with IN N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
therapy NN i
in IN N
patients NNS p
with IN N
congestive JJ N
heart NN N
failure NN N
. . N

The DT N
limit NN N
to TO N
exercise VB N
tolerance NN N
in IN N
humans NNS N
: : N
mind NN N
over IN N
muscle NN N
? . N
In IN N
exercise NN N
physiology NN N
, , N
it PRP N
has VBZ N
been VBN N
traditionally RB N
assumed VBN N
that IN N
high-intensity NN N
aerobic JJ N
exercise NN N
stops NNS N
at IN N
the DT N
point NN N
commonly RB N
called VBD N
exhaustion NN N
because IN N
fatigued VBN N
subjects NNS N
are VBP N
no RB N
longer RBR N
able JJ N
to TO N
generate VB N
the DT N
power NN N
output NN N
required VBN N
by IN N
the DT N
task NN N
despite IN N
their PRP$ N
maximal JJ N
voluntary JJ N
effort NN N
. . N

In IN N
addition NN N
, , N
sera NN N
were VBD N
collected VBN N
from IN N
a DT N
randomized JJ N
sample NN N
of IN N
subjects NNS N
in IN N
each DT N
vaccine NN N
group NN N
at IN N
approximately RB N
3-month JJ N
intervals NNS N
from IN N
which WDT N
antibody NN N
kinetic JJ N
curves NNS N
were VBD N
constructed VBN N
, , N
which WDT N
allowed VBD N
us PRP N
to TO N
estimate VB N
specific JJ N
antibody NN N
values NNS N
to TO N
pertussis VB N
toxin NN N
( ( N
PT NNP N
) ) N
, , N
filamentous JJ N
hemagglutinin NN N
( ( N
FHA NNP N
) ) N
, , N
pertactin JJ i
and CC N
fimbriae-2 JJ N
at IN N
the DT N
time NN N
of IN N
exposure NN N
in IN N
the DT N
household NN N
setting NN N
. . N

BACKGROUND NNP N
Androgen NNP N
deprivation NN N
therapy NN i
( ( N
ADT NNP N
) ) N
is VBZ N
accompanied VBN N
by IN N
a DT N
number NN N
of IN N
adverse JJ N
side NN N
effects NNS N
including VBG N
reduced VBD N
bone JJ N
mass NN N
and CC N
increased VBD o
risk NN o
for IN N
fracture NN N
, , N
reduced VBN N
lean JJ N
mass NN N
and CC N
muscle NN N
strength NN N
, , N
mood NN N
disturbance NN N
and CC N
increased VBD o
fat JJ o
mass NN N
compromising VBG N
physical JJ N
functioning NN N
, , N
independence NN N
, , N
and CC N
quality NN N
of IN N
life NN N
. . N

RESULTS NN N
We PRP N
found VBD N
weak JJ N
to TO N
moderate VB N
, , N
statistically RB N
significant JJ N
negative JJ N
correlations NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
durations NNS N
of IN N
MEE NNP N
in IN N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
or CC N
in IN N
age NN N
periods NNS N
that WDT N
included VBD N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
, , N
and CC N
their PRP$ N
scores NNS N
on IN N
formal JJ N
tests NNS N
of IN N
receptive JJ N
vocabulary NN N
and CC N
verbal JJ N
aspects NNS N
of IN N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

As IN N
nimodipine NN N
might MD N
have VB N
anticraving VBG N
and CC N
mood-stabilizing JJ N
properties NNS N
and CC N
cardio- NN N
and CC N
neuroprotective JJ N
properties NNS N
in IN N
the DT N
face NN N
of IN N
cocaine NN N
intoxication NN N
and CC N
might MD N
possibly RB N
even RB N
reverse VB N
some DT N
cocaine-induced JJ N
brain NN N
deficits NNS N
, , N
further JJ N
investigation NN N
of IN N
the DT N
role NN N
of IN N
nimodipine NN N
( ( N
and CC N
other JJ N
VSCCBs NNP N
) ) N
in IN N
cocaine NN N
addiction NN N
appears VBZ N
an DT N
attractive JJ N
avenue NN N
of IN N
future JJ N
medication NN N
development NN N
. . N

Results NNS N
revealed VBD N
, , N
in IN N
comparison NN N
to TO N
the DT N
waitlist NN N
group NN N
, , N
that IN N
the DT N
experimental JJ N
treatment NN N
group NN N
significantly RB N
improved VBN N
their PRP$ N
knowledge NN N
of IN N
PEERS NNP N
concepts NNS N
and CC N
friendship NN N
skills NNS N
, , N
increased VBN o
in IN N
their PRP$ N
amount NN N
of IN N
get-togethers NNS N
, , N
and CC N
decreased VBN o
in IN N
their PRP$ N
levels NNS N
of IN N
social JJ N
anxiety NN N
, , N
core NN N
autistic NN N
symptoms NNS N
, , N
and CC N
problem NN N
behaviors NNS N
from IN N
pre-to JJ N
post-PEERS NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
increases NNS o
in IN N
RBC NNP N
mass NN N
during IN N
nandrolone JJ N
decanoate NN N
therapy NN i
result NN N
from IN N
two CD N
mechanisms NNS N
: : N
increased VBN o
erythropoiesis NN N
( ( N
shown VBN N
by IN N
simultaneous JJ N
increases NNS o
in IN N
RBC NNP N
mass NN N
and CC N
erythron NN N
iron NN N
turnover NN N
) ) N
and CC N
increased JJ o
RBC NNP N
survival NN N
( ( N
indirectly RB N
shown VBN N
by IN N
increases NNS o
in IN N
RBC NNP N
mass NN N
without IN N
increases NNS o
in IN N
erythron NN N
iron NN N
turnover NN N
) ) N
. . N

Main NNP N
end NN N
points NNS N
of IN N
the DT N
study NN N
included VBD N
the DT N
3-month JJ N
dichotomized JJ N
Glasgow NNP N
Outcome NNP N
Score NNP N
( ( N
GOS NNP N
) ) N
, , N
development NN N
of IN N
delayed JJ N
ischemic JJ N
neurological JJ N
deficit NN N
( ( N
DIND NNP N
) ) N
, , N
occurrence NN N
of IN N
Transcranial NNP N
Doppler NNP N
( ( N
TCD NNP N
) ) N
vasospasm NN N
, , N
and CC N
length NN N
of IN N
stay NN N
in IN N
the DT N
ICU NNP N
and CC N
hospital NN N
. . N

The DT N
AQ-J NNP N
and CC N
two CD N
short JJ N
forms NNS N
are VBP N
useful JJ N
not RB N
to TO N
predict VB N
but CC N
to TO N
rule VB N
out RP N
mild NN N
HPDD NNP N
, , N
the DT N
most RBS N
difficult JJ N
part NN N
of IN N
HPDD NNP N
to TO N
be VB N
distinguished VBN N
from IN N
non-PDD JJ N
conditions NNS N
, , N
in IN N
persons NNS N
scoring VBG N
under IN N
the DT N
cut-offs NNS N
and CC N
to TO N
consider VB N
professionals NNS N
' POS N
examination NN N
of IN N
HPDD NNP N
in IN N
persons NNS N
scoring VBG N
over IN N
them PRP N
, , N
because IN N
their PRP$ N
negative JJ N
predictive JJ N
values NNS N
were VBD N
satisfactory JJ N
. . N

METHODS NNP N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
timely JJ N
patient JJ N
feedback NN N
in IN N
the DT N
form NN N
of IN N
a DT N
letter NN N
providing VBG N
recent JJ N
patient-specific JJ N
symptoms NNS N
, , N
medication NN N
, , N
and CC N
health NN N
service NN N
use NN N
combined VBN N
with IN N
guideline-based JJ N
recommendations NNS N
for IN N
changes NNS N
in IN N
therapy NN i
on IN N
improving VBG N
the DT N
quality NN N
of IN N
asthma NN N
care NN N
by IN N
inner-city NN N
primary NN N
care NN N
providers NNS N
and CC N
on IN N
resultant JJ N
asthma JJ N
morbidity NN N
. . N

RESULTS NNP N
Several NNP N
key JJ N
elements NNS N
emerge VBP N
as RB N
critical JJ N
to TO N
the DT N
ultimate JJ N
success NN N
of IN N
a DT N
clinical JJ N
trial NN N
, , N
including VBG N
the DT N
probability NN N
of IN N
receiving VBG N
placebo NN N
, , N
study NN N
duration NN N
, , N
dosing VBG N
schedule NN N
, , N
visit NN N
frequency NN N
, , N
the DT N
use NN N
of IN N
blinded JJ N
lead-in JJ N
phases NNS N
, , N
the DT N
use NN N
of IN N
centralized JJ N
raters NNS N
, , N
illness JJ N
severity NN N
and CC N
duration NN N
, , N
and CC N
comorbid NN N
anxiety NN N
. . N

OBJECTIVE NN N
This DT N
study NN N
aimed VBN N
to TO N
( ( N
1 CD N
) ) N
investigate NN N
whether IN N
provision NN N
of IN N
a DT N
home-based JJ N
program NN N
in IN N
addition NN N
to TO N
a DT N
center-based JJ N
program NN N
improves VBZ N
development NN N
in IN N
young JJ N
children NNS N
with IN N
disabilities NNS N
and CC N
coping VBG N
abilities NNS N
of IN N
their PRP$ N
families NNS N
and CC N
( ( N
2 CD N
) ) N
describe VB N
the DT N
characteristics NNS N
of IN N
children NNS N
and CC N
families NNS N
who WP N
benefit VBP N
most RBS N
from IN N
the DT N
intervention NN N
. . N

Two CD N
studies NNS N
utilizing VBG N
1,862 CD N
yearling VBG N
heifers NNS N
were VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
fenbendazole JJ N
oral JJ N
drench NN N
in IN N
addition NN N
to TO N
an DT N
ivermectin JJ i
pour-on NN N
( ( N
SG+IVPO NNP N
) ) N
, , N
compared VBN N
with IN N
an DT N
ivermectin JJ i
pour-on NN N
( ( N
IVPO NNP N
) ) N
or CC N
a DT N
doramectin NN i
injectable JJ N
( ( N
DMX NNP N
) ) N
alone RB N
, , N
on IN N
parasite JJ N
burden NN N
, , N
feedlot NN N
performance NN N
, , N
and CC N
carcass NN N
merit NN N
of IN N
feedlot NN N
cattle NNS N
. . N

CONCLUSION VB N
A DT N
Mediterranean NNP N
dietary JJ N
pattern NN N
associated VBN N
with IN N
a DT N
high JJ N
dietary JJ N
acid NN N
load NN N
derived VBN N
from IN N
consumption NN N
of IN N
mixed JJ N
nuts NNS N
does VBZ N
not RB N
seem VB N
to TO N
have VB N
a DT N
much RB N
greater JJR N
effect NN N
on IN N
bone NN N
metabolism NN N
biomarkers NNS N
, , N
with IN N
the DT N
exception NN N
of IN N
PTH NNP N
levels NNS N
, , N
than IN N
a DT N
Mediterranean NNP N
diet NN N
without IN N
mixed JJ N
nuts NNS N
or CC N
a DT N
control NN N
diet NN N
in IN N
elderly JJ N
subjects NNS N
. . N

Similarly RB N
, , N
nonsignificant JJ N
changes NNS N
were VBD N
detected VBN N
for IN N
the DT N
fibrinolytic JJ N
parameters NNS N
tissue VBP N
plasminogen JJ N
activator NN N
activity NN N
, , N
tissue NN N
plasminogen NN N
activator NN N
antigen NN N
, , N
and CC N
global JJ N
fibrinolytic JJ N
activity NN N
, , N
but CC N
plasminogen NN N
activator NN N
inhibitor NN N
type VBD N
1 CD N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
hormone NN N
replacement NN N
therapy NN i
group NN N
due JJ N
to TO N
a DT N
questionable JJ N
increase NN o
in IN N
the DT N
levels NNS N
in IN N
the DT N
control NN N
group NN N
. . N

OBJECTIVE NNP N
Although IN N
metformin NNP N
( ( N
MET NNP N
) ) N
is VBZ N
an DT N
insulin JJ N
sensitizer NN N
currently RB N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
the DT N
treatment NN N
of IN N
some DT N
of IN N
the DT N
complications NNS N
of IN N
childhood NN N
obesity NN N
besides IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
, , N
few JJ N
studies NNS N
have VBP N
comprehensively RB N
examined VBN N
its PRP$ N
metabolic NN N
and CC N
clinical JJ N
effects NNS N
in IN N
obese JJ N
children NNS N
with IN N
normal JJ N
glucose JJ N
tolerance NN N
( ( N
NGT NNP N
) ) N
. . N

The DT N
benefit NN N
of IN N
low-dose JJ N
dopamine NN N
during IN N
vigorous JJ N
diuresis NN N
for IN N
congestive JJ N
heart NN N
failure NN N
associated VBN N
with IN N
renal JJ N
insufficiency NN N
: : N
does VBZ N
it PRP N
protect VB N
renal JJ N
function NN N
? . N
BACKGROUND NNP N
Low-dose NNP N
dopamine NN N
, , N
a DT N
renal JJ N
vasodilator NN N
, , N
has VBZ N
been VBN N
used VBN N
empirically RB N
to TO N
improve VB N
renal JJ N
function NN N
or CC N
outcome NN N
in IN N
critically RB N
ill JJ N
patients NNS p
with IN N
oliguria NNS N
or CC N
acute JJ N
renal JJ N
failure NN N
. . N

Results NNS N
suggested VBD N
that IN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
depended VBD N
on IN N
baseline NN N
PFS NNP N
levels NNS N
, , N
such JJ N
that IN N
acceptance-based JJ N
strategies NNS N
were VBD N
associated VBN N
with IN N
better JJR N
outcomes NNS N
( ( N
cravings NNS N
, , N
consumption NN N
) ) N
among IN N
those DT N
reporting VBG N
the DT N
highest JJS N
susceptibility NN N
to TO N
the DT N
presence NN N
of IN N
food NN N
, , N
but CC N
greater JJR N
cravings NNS N
among IN N
those DT N
who WP N
scored VBD N
lowest JJS N
on IN N
the DT N
PFS NNP N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
role NN N
that WDT N
treatment NN N
response NN N
plays VBZ N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
an DT N
antidepressant JJ N
among IN N
people NNS N
with IN N
spinal JJ N
cord NN N
injury NN N
( ( N
SCI NNP N
) ) N
diagnosed VBD N
with IN N
major JJ N
depressive JJ N
disorder NN N
( ( N
MDD NNP N
) ) N
in IN N
explaining VBG N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
assessed VBD N
both DT N
globally RB N
as IN N
life NN N
satisfaction NN N
and CC N
in IN N
terms NNS N
of IN N
physical JJ N
and CC N
mental JJ N
health-related JJ N
QOL NNP N
. . N

OBJECTIVES NNP N
To TO N
test VB N
the DT N
hypotheses NNS N
that WDT N
: : N
( ( N
1 CD N
) ) N
Lumbar NNP N
spine NN N
radiography NN N
in IN N
primary JJ N
care NN N
patients NNS p
with IN N
low JJ N
back RB N
pain NN N
is VBZ N
not RB N
associated VBN N
with IN N
improved JJ N
patient NN N
outcomes NNS N
, , N
including VBG N
pain NN N
, , N
disability NN N
, , N
health NN N
status NN N
, , N
sickness NN N
absence NN N
, , N
reassurance NN N
, , N
and CC N
patient JJ N
satisfaction NN N
or CC N
belief NN N
in IN N
the DT N
value NN N
of IN N
radiography NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Swallowing NNP N
function NN N
was VBD N
evaluated VBN N
by IN N
the DT N
water NN N
swallow JJ N
test NN N
and CC N
Standardized NNP N
Swallowing NNP N
Assessment NNP N
, , N
oral JJ N
intake NN N
was VBD N
evaluated VBN N
by IN N
the DT N
Functional NNP N
Oral NNP N
Intake NNP N
Scale NNP N
, , N
quality NN N
of IN N
life NN N
was VBD N
evaluated VBN N
by IN N
the DT N
Swallowing-Related JJ N
Quality NN N
of IN N
Life NNP N
( ( N
SWAL-QOL NNP N
) ) N
Scale NNP N
, , N
and CC N
cognition NN N
was VBD N
evaluated VBN N
by IN N
the DT N
Mini-Mental JJ N
State NNP N
Examination NNP N
( ( N
MMSE NNP N
) ) N
. . N

Comparisons NNS N
were VBD N
also RB N
made VBN N
for IN N
self-reported JJ N
breast NN N
symptoms NNS N
occurring VBG N
during IN N
the DT N
study NN N
period NN N
and CC N
for IN N
changes NNS N
in IN N
serum NN N
values NNS N
of IN N
antinuclear JJ N
antibodies NNS N
, , N
rheumatoid JJ N
factor NN N
, , N
and CC N
cardiolipin NN N
antibodies NNS N
immunoglobulin VBP N
G NNP N
and CC N
immunoglobulin NN N
M. NNP N
The DT N
majority NN N
of IN N
the DT N
women NNS N
with IN N
implant JJ N
rupture NN N
had VBD N
no DT N
visible JJ N
magnetic JJ N
resonance NN N
imaging NN N
changes NNS N
of IN N
their PRP$ N
ruptured JJ N
implants NNS N
. . N

AIMS IN N
We PRP N
examined VBD N
whether IN N
Dementia NNP N
Care NNP N
Mapping NNP N
( ( N
DCM NNP N
) ) N
or CC N
the DT N
VIPS NNP N
practice NN N
model NN N
( ( N
VPM NNP N
) ) N
is VBZ N
more RBR N
effective JJ N
than IN N
education NN N
of IN N
the DT N
nursing NN N
home NN N
staff NN N
about IN N
dementia NN N
( ( N
control VB N
group NN N
) ) N
in IN N
reducing VBG N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
as RB N
well RB N
as IN N
in IN N
enhancing VBG N
the DT N
quality NN N
of IN N
life NN N
among IN N
nursing JJ N
home NN N
patients NNS p
. . N

The DT N
mean JJ N
duration NN N
for IN N
obtaining VBG N
good JJ N
contractions NNS N
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN i
group NN N
in IN N
both CC N
the DT N
first JJ N
and CC N
second JJ N
day NN N
of IN N
induction NN N
The DT N
mean JJ N
interval NN N
between IN N
the DT N
beginning NN N
of IN N
induction NN N
until IN N
the DT N
beginning NN N
of IN N
active JJ N
phase NN N
at IN N
the DT N
first JJ N
day NN N
of IN N
induction NN N
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN i
group NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
four CD N
types NNS N
of IN N
electronic JJ N
screen JJ N
media NNS N
( ( N
ESM NNP N
) ) N
: : N
animated VBN N
video NN N
, , N
video NN N
of IN N
self NN N
, , N
video NN N
of IN N
a DT N
familiar JJ N
person NN N
engaged VBD N
with IN N
an DT N
immersive JJ N
virtual JJ N
reality NN N
( ( N
VR NNP N
) ) N
game NN N
, , N
and CC N
immersion NN N
of IN N
self NN N
in IN N
the DT N
VR NNP N
game NN N
. . N

Fifty-nine NNP N
junior JJ N
high JJ N
school NN N
students NNS N
who WP N
volunteered VBD N
to TO N
participate VB N
in IN N
treatment NN N
for IN N
interpersonal JJ N
anxiety NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
rational-emotive JJ N
therapy NN i
without IN N
imagery NN N
( ( N
RET NNP N
) ) N
, , N
rational-emotive JJ N
therapy NN i
with IN N
imagery NN N
( ( N
REI NNP N
) ) N
, , N
relationship-oriented JJ N
counseling NN N
( ( N
ROC NNP N
) ) N
, , N
and CC N
waiting-list JJ N
control NN N
( ( N
WLC NNP N
) ) N
groups NNS N
. . N

Because IN N
persons NNS N
whose WP$ N
urine JJ N
contains NNS N
low JJ N
proportions NNS N
of IN N
DMA NNP N
and CC N
high JJ N
proportions NNS N
of IN N
MMA NNP N
and CC N
InAs NNP N
have VBP N
been VBN N
reported VBN N
to TO N
be VB N
at IN N
greater JJR N
risk NN N
of IN N
skin NN N
and CC N
bladder NN N
cancers NNS N
and CC N
peripheral JJ N
vascular JJ N
disease NN N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
folic JJ N
acid DT N
supplementation NN N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
arsenic-related JJ N
health NN N
outcomes NNS N
. . N

RESULTS NN N
We PRP N
found VBD N
that IN N
sevoflurane NN N
, , N
when WRB N
compared VBN N
with IN N
isoflurane NN N
and CC N
desflurane NN N
, , N
provided VBN N
anesthesia NN N
with IN N
similar JJ N
hemodynamic JJ N
stability NN N
but CC N
allowed VBN N
for IN N
a DT N
smoother NN N
, , N
more RBR N
rapid JJ N
emergence NN N
and CC N
better JJR N
quality NN N
of IN N
induction NN N
and CC N
recovery NN N
to TO N
surgical JJ N
patients NNS p
under IN N
clinical JJ N
conditions NNS N
, , N
particularly RB N
to TO N
those DT N
who WP N
were VBD N
experiencing VBG N
substantial JJ N
cerebral JJ N
vasodilation NN N
. . N

METHODS NNP N
This DT N
investigation NN N
assesses VBZ N
the DT N
validity NN N
of IN N
the DT N
Lactate NNP N
Minimum NNP N
Test NNP N
( ( N
LMT NNP N
) ) N
, , N
which WDT N
consists VBZ N
of IN N
inducing VBG N
lactic JJ N
acidosis NN N
through IN N
a DT N
VO2peak NNP N
test NN N
, , N
followed VBN N
by IN N
an DT N
eight-minute JJ N
walking NN N
recovery NN N
and CC N
an DT N
incremental JJ N
exercise NN N
test NN N
, , N
to TO N
determine VB N
if IN N
the DT N
running VBG N
velocity NN N
associated VBN N
with IN N
the DT N
minimum JJ N
lactate NN N
value NN N
predicts VBZ N
the DT N
MLSS NNP N
velocity NN N
. . N

BACKGROUND NNP N
Silent NNP N
myocardial JJ N
ischemia NN N
is VBZ N
an DT N
adverse JJ N
prognostic JJ N
marker NN N
in IN N
patients NNS p
with IN N
coronary JJ N
disease NN N
; : N
however RB N
, , N
controlled VBN N
data NNS N
on IN N
the DT N
effect NN N
of IN N
treatment NN N
are VBP N
sparse JJ N
and CC N
contradictory NN N
, , N
and CC N
the DT N
relations NNS N
among IN N
the DT N
occurrence NN N
of IN N
ST NNP N
segment NN N
depression NN N
, , N
drug NN N
efficacy NN N
, , N
and CC N
heart NN N
rate NN N
are VBP N
unclear JJ N
. . N

With IN N
the DT N
use NN N
of IN N
effectiveness NN N
measures NNS N
that WDT N
favored VBD N
clozapine NN N
( ( N
extrapyramidal JJ N
side NN N
effects NNS N
, , N
disruptiveness NN N
) ) N
, , N
bootstrap NN N
techniques NNS N
indicated VBD N
that IN N
, , N
even RB N
when WRB N
a DT N
payer NN N
is VBZ N
unwilling JJ N
to TO N
incur VB N
any DT N
additional JJ N
cost NN N
for IN N
gains NNS N
in IN N
effectiveness NN N
, , N
the DT N
probability NN N
that IN N
clozapine NN N
is VBZ N
more RBR N
cost-effective JJ N
than IN N
usual JJ N
care NN N
is VBZ N
at IN N
least JJS N
0.80 CD N
. . N

OBJECTIVE NN N
To TO N
examine VB N
the DT N
bioavailability NN N
of IN N
methotrexate NN N
( ( N
MTX NNP N
) ) N
in IN N
the DT N
presence NN N
of IN N
hydroxychloroquine NN N
( ( N
HCQ NNP N
) ) N
, , N
and CC N
vice NN N
versa NN N
, , N
to TO N
determine VB N
a DT N
possible JJ N
pharmacokinetic JJ N
explanation NN N
for IN N
the DT N
observation NN N
that IN N
combination NN N
treatment NN N
of IN N
rheumatoid JJ N
arthritis NN N
with IN N
MTX NNP N
and CC N
HCQ NNP N
has VBZ N
been VBN N
shown VBN N
, , N
clinically RB N
, , N
to TO N
be VB N
more RBR N
potent JJ N
than IN N
MTX NNP N
used VBD N
alone RB N
. . N

OBJECTIVE NN N
To TO N
elucidate VB N
the DT N
effect NN N
on IN N
blood NN N
pressure NN N
and CC N
blood NN N
lipids NNS N
of IN N
an DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
( ( N
captopril NN N
) ) N
, , N
and CC N
a DT N
beta-receptor NN N
blocking NN N
agent NN N
( ( N
atenolol NN i
) ) N
, , N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
a DT N
cholesterol NN N
reducing VBG N
drug NN N
, , N
the DT N
beta-hydroxy-methylglutaryl-coenzyme NN N
A DT N
reductase NN N
inhibitor NN N
pravastatin NN i
, , N
in IN N
patients NNS p
who WP N
were VBD N
also RB N
encouraged VBN N
to TO N
improve VB N
their PRP$ N
lifestyle NN N
. . N

The DT N
study NN N
was VBD N
a DT N
blinded JJ N
, , N
exploratory JJ N
evaluation NN N
of IN N
the DT N
PlayWisely NNP N
program NN N
on IN N
autism NN N
symptoms NNS N
and CC N
essential JJ N
learning NN N
foundation NN N
skills NNS N
( ( N
attention NN N
, , N
recognition NN N
, , N
and CC N
memory NN N
skills NNS N
) ) N
in IN N
children NNS N
with IN N
a DT N
diagnosis NN N
of IN N
autism NN N
, , N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
pervasive JJ N
developmental NN N
disorder NN N
- : N
not RB N
otherwise RB N
specified VBN N
( ( N
PDD-NOS NNP N
) ) N
, , N
and CC N
Asperger NNP N
syndrome VBP N
( ( N
AS IN N
) ) N
. . N

Onset NNP N
of IN N
action NN N
was VBD N
determined VBN N
to TO N
have VB N
taken VBN N
place NN N
the DT N
first JJ N
time NN N
that IN N
the DT N
effects NNS N
of IN N
ciclesonide NN N
, , N
as IN N
reflected VBN N
in IN N
the DT N
total JJ N
nasal JJ N
symptom NN N
score NN N
, , N
were VBD N
significantly RB N
greater JJR N
than IN N
those DT N
of IN N
placebo NN N
at IN N
a DT N
particular JJ N
hourly JJ N
assessment NN N
, , N
provided VBD N
that IN N
the DT N
subsequent JJ N
hourly NN N
assessment NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
. . N

CONCLUSIONS NNP N
- : N
RECOMMENDATIONS NN N
FOR IN N
FURTHER JJ N
RESEARCH NN N
: : N
Further JJ N
work NN N
is VBZ N
required VBN N
to TO N
develop VB N
and CC N
test VB N
an DT N
educational JJ N
package NN N
that WDT N
educates VBZ N
patients NNS p
and CC N
GPs NNP N
about IN N
the DT N
utility NN N
of IN N
radiography NN N
and CC N
provides VBZ N
strategies NNS N
for IN N
identifying VBG N
and CC N
meeting VBG N
the DT N
information NN N
needs NNS N
of IN N
patients NNS p
, , N
and CC N
the DT N
needs NNS N
of IN N
patients NNS p
and CC N
GPs NNP N
to TO N
be VB N
reassured VBN N
about IN N
missing VBG N
serious JJ N
disease NN N
. . N

The DT N
impact NN N
of IN N
the DT N
intervention NN N
was VBD N
assessed VBN N
against IN N
patient JJ N
outcomes NNS N
: : N
routinely RB N
available JJ N
asthma JJ N
outcome NN N
measures NNS N
( ( N
beta2-agonist JJ N
prescription NN N
rate NN N
and CC N
number NN N
of IN N
oral JJ N
steroid NN N
courses NNS N
) ) N
for IN N
asthma NN N
patients NNS p
identified VBN N
as IN N
being VBG N
poorly-controlled JJ N
from IN N
practice NN N
records NNS N
; : N
and CC N
questionnaire VB N
data NNS N
- : N
Mini NNP N
Asthma NNP N
Quality NNP N
of IN N
Life NNP N
Questionnaire NNP N
( ( N
AQLQ NNP N
) ) N
and CC N
the DT N
Asthma NNP N
Control NNP N
Questionnaire NNP N
( ( N
ACQ NNP N
) ) N
- : N
from IN N
a DT N
subset NN N
of IN N
consenting VBG N
patients NNS p
. . N

Participants NNS N
had VBD N
autistic JJ N
spectrum NN N
disorders NNS N
, , N
Asperger NNP N
disorder NN N
, , N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
, , N
not RB N
otherwise RB N
specified VBN N
; : N
had VBD N
illness JJ N
severity NN N
ratings NNS N
of IN N
at IN N
least JJS N
moderate JJ N
on IN N
the DT N
Clinical NNP N
Global NNP N
Impressions NNP N
, , N
Severity NNP N
of IN N
Illness NNP N
Scale NNP N
; : N
and CC N
scored VBD N
at IN N
least JJS N
moderate JJ N
on IN N
compulsive JJ N
behaviors NNS N
measured VBN N
with IN N
the DT N
Children NNP N
's POS N
Yale-Brown JJ N
Obsessive NNP N
Compulsive NNP N
Scales NNP N
modified VBD N
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

CONCLUSION NN N
We PRP N
conclude VBP N
that IN N
, , N
with IN N
the DT N
treatments NNS N
used VBN N
during IN N
the DT N
period NN N
covered VBN N
by IN N
these DT N
studies NNS N
, , N
the DT N
presence NN N
of IN N
CSF+/Mass NNP N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
was VBD N
associated VBN N
with IN N
a DT N
nominally RB N
worse JJR N
outcome JJ N
independent JJ N
of IN N
initial JJ N
bone NN N
marrow NN N
status NN N
and CC N
LDH NNP N
level NN N
, , N
but CC N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSION NNP N
One-year-long NNP N
complementary JJ N
feeding NN N
with IN N
FS NNP N
does VBZ N
not RB N
have VB N
a DT N
significantly RB N
larger JJR N
effect NN N
than IN N
LP NNP N
on IN N
mean JJ N
weight NN N
gain NN N
in IN N
all DT N
infants NNS N
, , N
but CC N
it PRP N
is VBZ N
likely JJ N
to TO N
boost VB N
linear JJ N
growth NN N
in IN N
the DT N
most RBS N
disadvantaged JJ N
individuals NNS N
and CC N
, , N
hence RB N
, , N
decrease VB o
the DT N
incidence NN N
of IN N
severe JJ N
stunting NN N
. . N

Although IN N
anxiety NN N
sensitivity NN N
( ( N
AS NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
predict VB N
anxiety NN N
symptoms NNS N
and CC N
panic NN N
, , N
this DT N
literature NN N
is VBZ N
limited VBN N
in IN N
regard NN N
to TO N
evaluating VBG N
AS NNP N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
anxiety NN N
psychopathology NN N
relative VBP N
to TO N
other JJ N
established VBN N
risk NN N
factors NNS N
including VBG N
sex NN N
and CC N
negative JJ N
affect NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
accuracy NN N
of IN N
non-rigid JJ N
nine-parameter JJ N
image NN N
registrations NNS N
based VBN N
on IN N
153Gd CD N
transmission NN N
computed VBN N
tomography NN N
( ( N
TCT NNP N
) ) N
images VBZ N
as IN N
compared VBN N
with IN N
those DT N
based VBN N
on IN N
99mTc-ethyl JJ N
cysteinate NN N
dimer NN N
( ( N
ECD NNP N
) ) N
images NNS N
and CC N
to TO N
assess VB N
whether IN N
normalised JJ N
mutual JJ N
information NN N
( ( N
NMI NNP N
) ) N
or CC N
count NN N
difference NN N
( ( N
CD NN N
) ) N
should MD N
be VB N
used VBN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
protection NN N
from IN N
bronchoconstriction NN N
afforded VBN N
by IN N
the DT N
calcium NN N
channel NN N
blockers NNS N
depends VBZ N
on IN N
the DT N
choice NN N
of IN N
agent NN N
and CC N
the DT N
intensity NN N
of IN N
the DT N
bronchoconstricting NN N
stimulus NN N
, , N
and CC N
they PRP N
raise VBP N
the DT N
possibility NN N
that IN N
the DT N
contribution NN N
of IN N
transmembrane NN N
calcium NN N
ion NN N
influx NN N
to TO N
the DT N
pathogenesis NN N
of IN N
bronchoconstriction NN N
may MD N
vary VB N
according VBG N
to TO N
stimulus JJ N
intensity NN N
. . N

BACKGROUND NNP N
Amantadine NNP N
hydrochloride NN N
and CC N
pemoline NN N
, , N
both DT N
frequently RB N
used VBN N
to TO N
treat VB N
the DT N
fatigue NN N
of IN N
multiple JJ N
sclerosis NN N
( ( N
MS NNP N
) ) N
, , N
may MD N
also RB N
improve VB N
attention NN N
and CC N
other JJ N
cognitive JJ N
functions NNS N
in IN N
MS. NNP N
To TO N
our PRP$ N
knowledge NN N
, , N
these DT N
agents NNS N
have VBP N
never RB N
been VBN N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS p
with IN N
MS NNP N
. . N

We PRP N
registered VBD N
a DT N
significant JJ N
improvement NN N
of IN N
tactile JJ N
roughness NN N
and CC N
fine JJ N
lines NNS N
in IN N
the DT N
half JJ N
side NN N
of IN N
the DT N
face NN N
treated VBD N
with IN N
BAs NNP N
; : N
noninvasive JJ N
instrumental JJ N
diagnostic JJ N
investigations NNS N
showed VBD N
an DT N
improvement NN N
of IN N
elasticity NN N
, , N
a DT N
decrease NN o
of IN N
sebum JJ N
excretion NN N
, , N
and CC N
a DT N
change NN N
of IN N
echographic JJ N
parameters NNS N
suggesting VBG N
a DT N
reshaping NN N
of IN N
dermal JJ N
tissue NN N
. . N

AIMS IN N
It PRP N
is VBZ N
necessary JJ N
to TO N
clarify VB N
if IN N
the DT N
presence NN N
of IN N
a DT N
prominent JJ N
R NNP N
wave NN N
in IN N
V1 NNP N
, , N
in IN N
post-myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
patients NNS p
, , N
is VBZ N
due JJ N
to TO N
the DT N
involvement NN N
of IN N
the DT N
posterior NN N
wall NN N
( ( N
currently RB N
inferobasal VBP N
segment NN N
) ) N
or CC N
the DT N
lateral JJ N
wall NN N
( ( N
as IN N
has VBZ N
been VBN N
demonstrated VBN N
recently RB N
by IN N
electrocardiographic JJ N
contrast-enhanced JJ N
cardiac JJ N
magnetic JJ N
resonance NN N
[ VBD N
ECG-CE-CMR NNP N
] NNP N
correlations NNS N
studies NNS N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
an DT N
alternative JJ N
drug NN N
product NN N
by IN N
using VBG N
a DT N
different JJ N
salt NN N
of IN N
perindopril NN N
and CC N
to TO N
evaluate VB N
the DT N
bioequivalence NN N
between IN N
PE NNP N
, , N
not RB N
still RB N
licensed VBN N
, , N
and CC N
perindopril JJ N
arginine NN N
( ( N
PA NNP N
) ) N
, , N
licensed VBD N
in IN N
many JJ N
countries NNS N
, , N
and CC N
to TO N
prepare VB N
PE NNP N
tablets NNS N
by IN N
using VBG N
direct JJ N
compression NN N
method NN N
. . N

For IN N
examination NN N
of IN N
whether IN N
this DT N
is VBZ N
based VBN N
on IN N
the DT N
same JJ N
mechanisms NN N
as IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
or CC N
thiazolidinedione NN N
, , N
effects NNS N
of IN N
sarpogrelate NN N
on IN N
atherosclerotic JJ i
inflammatory NN N
molecules NNS N
and CC N
their PRP$ N
relations NNS N
to TO N
albuminuria NNS N
in IN N
patients NNS p
who WP N
had VBD N
diabetes NNS N
and CC N
had VBD N
already RB N
been VBN N
treated VBN N
with IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
and CC N
with IN N
or CC N
without IN N
thiazolidinedione NN N
were VBD N
examined VBN N
. . N

A DT N
falls VBZ N
calendar NN N
will MD N
be VB N
kept VBN N
by IN N
each DT N
participant NN N
for IN N
12 CD N
months NNS N
after IN N
outpatient JJ N
therapy.Consistent NN i
with IN N
the DT N
recommendations NNS N
of IN N
the DT N
Prevention NNP N
of IN N
Falls NNP N
Network NNP N
Europe NNP N
group NN N
, , N
three CD N
falls NNS N
variables NNS N
will MD N
be VB N
used VBN N
as IN N
the DT N
primary JJ N
outcome NN N
measures NNS N
: : N
the DT N
number NN N
of IN N
fallers NNS N
, , N
the DT N
number NN N
of IN N
multiple JJ N
fallers NNS N
and CC N
the DT N
falls JJ N
rate NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
, , N
collateral JJ N
damage NN N
, , N
and CC N
convenience NN N
of IN N
panretinal JJ N
photocoagulation NN N
for IN N
proliferative JJ N
diabetic JJ N
retinopathy NN N
or CC N
severe JJ N
nonproliferative JJ N
diabetic JJ N
retinopathy NN N
using VBG N
a DT N
532-nm JJ N
solid-state NN N
green JJ N
laser NN N
( ( N
GLX NNP N
) ) N
versus VBP N
a DT N
multispot NN N
532-nm JJ N
pattern JJ N
scan JJ N
laser NN N
( ( N
PASCAL NNP N
) ) N
. . N

INTRODUCTION NN N
This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
non-contrast-enhanced JJ N
4D CD N
magnetic JJ N
resonance NN N
angiography NN N
( ( N
NCE NNP N
4D CD N
MRA NNP N
) ) N
with IN N
signal JJ N
targeting VBG N
with IN N
alternative JJ N
radiofrequency NN N
( ( N
STAR NNP N
) ) N
spin NN N
labeling NN N
and CC N
variable JJ N
flip NN N
angle NN N
( ( N
VFA NNP N
) ) N
sampling NN N
in IN N
the DT N
assessment NN N
of IN N
dural JJ N
arteriovenous JJ N
fistula NN N
( ( N
DAVF NNP N
) ) N
in IN N
the DT N
transverse NN N
sinus NN N
. . N

BACKGROUND NNP N
Previous NNP N
interventions NNS N
to TO N
increase VB o
physical JJ N
activity NN N
and CC N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
have VBP N
been VBN N
targeted VBN N
at IN N
individuals NNS N
with IN N
established VBN N
disease NN N
; : N
less CC N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
intervention VB N
among IN N
individuals NNS N
with IN N
high JJ N
risk NN N
for IN N
disease NN N
nor CC N
has VBZ N
there RB N
been VBN N
determination NN N
of IN N
the DT N
influence NN N
of IN N
setting VBG N
in IN N
which WDT N
the DT N
intervention NN N
is VBZ N
provided VBN N
. . N

However RB N
, , N
DG NNP N
and CC N
FD NNP N
manifested VBD N
with IN N
different JJ N
impacts NNS N
on IN N
weights NNS N
of IN N
egg NN N
and CC N
egg NN N
albumen NNS N
, , N
proteolytic JJ N
activity NN N
of IN N
jejunal JJ N
digesta NN N
, , N
plasma JJ N
TRAP NNP N
activity NN N
, , N
ileal JJ N
total JJ N
AA NNP N
digestibility NN N
, , N
and CC N
several JJ N
intestinal JJ N
genes NNS N
and CC N
hepatic JJ N
proteins NNS N
. . N

To TO N
test VB N
the DT N
reliability NN N
and CC N
durability NN N
of IN N
positive JJ N
treatment NN N
effects NNS N
obtained VBN N
in IN N
a DT N
type NN N
A DT N
intervention NN N
project NN N
for IN N
healthy JJ N
managers NNS N
, , N
the DT N
analysis NN N
was VBD N
extended VBN N
to TO N
data NNS N
available JJ N
from IN N
a DT N
third JJ N
treatment NN N
group NN N
( ( N
a DT N
special JJ N
behavior JJ N
therapy NN i
group NN N
for IN N
participants NNS N
eliminated VBN N
from IN N
the DT N
main JJ N
sample NN N
because IN N
of IN N
manifestations NNS N
of IN N
clinical JJ N
CHD NNP N
) ) N
and CC N
to TO N
measures NNS N
obtained VBN N
6 CD N
months NNS N
following VBG N
the DT N
end NN N
of IN N
treatment NN N
. . N

A DT N
strong JJ N
priming NN N
effect NN N
was VBD N
found VBN N
, , N
robust VBZ N
over IN N
participants NNS N
and CC N
over IN N
items NNS N
; : N
participants NNS N
read VBP N
those DT N
questions NNS N
that WDT N
were VBD N
relevant JJ N
to TO N
the DT N
inference NN N
evoked VBN N
by IN N
the DT N
vignette NN N
faster RBR N
than IN N
they PRP N
read VBP N
those DT N
questions NNS N
that WDT N
were VBD N
irrelevant JJ N
, , N
and CC N
no DT N
interaction NN N
with IN N
group NN N
membership NN N
or CC N
type NN N
of IN N
knowledge NN N
was VBD N
found VBN N
. . N

Specifically RB N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
attitude JJ N
certainty NN N
can MD N
be VB N
conceptualized VBN N
, , N
and CC N
empirically RB N
separated VBN N
, , N
in IN N
terms NNS N
of IN N
attitude NN N
clarity NN N
( ( N
the DT N
subjective NN N
sense NN N
that WDT N
one CD N
knows VBZ N
what WP N
one CD N
's POS N
attitude NN N
is VBZ N
) ) N
and CC N
attitude JJ N
correctness NN N
( ( N
the DT N
subjective NN N
sense NN N
that IN N
one CD N
's POS N
attitude NN N
is VBZ N
correct JJ N
or CC N
valid JJ N
) ) N
. . N

The DT N
results NNS N
of IN N
our PRP$ N
manikin NN N
study NN N
suggest VBP N
that IN N
for IN N
personnel NNS N
not RB N
experienced VBN N
in IN N
tracheal JJ N
intubation NN N
, , N
the DT N
LTS-D NNP N
offers VBZ N
a DT N
good JJ N
alternative NN N
to TO N
ET NNP N
and CC N
BMV NNP N
to TO N
manage VB N
the DT N
airway NN N
during IN N
resuscitation NN N
, , N
and CC N
to TO N
avoid VB N
the DT N
failure NN N
to TO N
achieve VB N
tracheal JJ N
intubation NN N
with IN N
the DT N
ET NNP N
, , N
and CC N
the DT N
failure NN N
to TO N
achieve VB N
adequate JJ N
ventilation NN N
with IN N
the DT N
BMV NNP N
. . N

Thus RB N
, , N
RLAI NNP N
offers VBZ N
no DT N
advantage NN N
to TO N
patients NNS p
in IN N
early JJ N
phase NN N
of IN N
SS NNP N
disorders NNS N
, , N
but CC N
is VBZ N
likely JJ N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
for IN N
those DT N
who WP N
may MD N
have VB N
problems NNS N
with IN N
adherence NN N
and CC N
may MD N
either RB N
choose VB N
to TO N
take VB N
it PRP N
or CC N
be VB N
prescribed VBN N
under IN N
conditions NNS N
of IN N
external JJ N
control NN N
such JJ N
as IN N
community NN N
treatment NN N
orders NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
, , N
in IN N
low-income JJ N
minority NN N
children NNS N
, , N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
among IN N
the DT N
frequency NN N
of IN N
RTEC NNP N
consumption NN N
and CC N
nutrient JJ N
intakes NNS N
measured VBN N
at IN N
baseline NN N
, , N
and CC N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
between IN N
the DT N
frequency NN N
of IN N
RTEC NNP N
and CC N
BMI NNP N
controlling VBG N
for IN N
age NN N
, , N
sex NN N
, , N
ethnicity NN N
, , N
and CC N
energy NN N
intake NN N
. . N

Although IN N
SADQ NNP N
scores NNS N
and CC N
Rand NNP N
definite VBP N
alcoholism NN N
were VBD N
in IN N
general JJ N
agreement NN N
, , N
there EX N
were VBD N
a DT N
number NN N
of IN N
borderline JJ N
instances NNS N
and CC N
cases NNS N
of IN N
disagreement NN N
, , N
and CC N
neither DT N
was VBD N
in IN N
good JJ N
agreement NN N
with IN N
estimates NNS N
of IN N
problem NN N
duration NN N
, , N
nor CC N
with IN N
reports NNS N
of IN N
recent JJ N
or CC N
earlier RBR N
attainment NN N
of IN N
abstinence NN N
or CC N
control NN N
. . N

CONCLUSIONS NNP N
We PRP N
demonstrated VBD N
that IN N
a DT N
12-week JJ N
supervised JJ N
low-intensity NN N
resistance NN N
training NN N
program NN N
associated VBN N
with IN N
partial JJ N
blood NN N
flow NN N
restriction NN N
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
muscle NN N
strength NN N
and CC N
function NN N
as RB N
well RB N
as IN N
muscle NN N
mass NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN N
PM NNP N
and CC N
DM NNP N
. . N

8-oxo-dG NN N
is VBZ N
significantly RB N
higher JJR N
( ( N
up IN N
to TO N
about IN N
threefold NN N
) ) N
in IN N
lymphocyte NN N
DNA NN N
from IN N
men NNS N
in IN N
Ireland NNP N
and CC N
the DT N
U.K. NNP N
Oxidative NNP N
DNA NNP N
damage NN N
is VBZ N
not RB N
significantly RB N
affected VBN N
by IN N
carotenoid JJ N
supplementation NN N
; : N
nor CC N
is VBZ N
there EX N
any DT N
association NN N
with IN N
mean JJ N
baseline NN N
levels NNS N
of IN N
antioxidants NNS N
, , N
which WDT N
are VBP N
generally RB N
similar JJ N
in IN N
the DT N
five CD N
countries NNS N
. . N

Inflammatory JJ N
reactions NNS N
, , N
based VBN N
on IN N
interleukin-6 JJ N
and CC N
C-reactive JJ N
protein NN N
levels NNS N
, , N
were VBD N
less JJR N
intense JJ N
following VBG N
FT NNP N
laparoscopic NN N
operation NN N
compared VBN N
to TO N
FT NNP N
open JJ N
operation NN N
; : N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
specific JJ N
immunity NN N
( ( N
CD3+ NNP N
and CC N
CD4+ NNP N
counts NNS N
, , N
and CC N
the DT N
CD4+/CD8+ NNP N
ratio NN N
) ) N
during IN N
these DT N
two CD N
types NNS N
of IN N
surgical JJ N
procedures NNS N
. . N

In IN N
a DT N
prospective JJ N
controlled VBN N
study NN N
, , N
involving VBG N
42 CD N
patients NNS p
subdivided VBD N
into IN N
four CD N
groups NNS N
namely RB N
, , N
higher JJR N
or CC N
lower JJR N
insufflation NN N
pressures NNS N
, , N
chemically RB N
inert JJ N
insufflation NN N
gas NN N
and CC N
control NN N
groups NNS N
; : N
the DT N
use NN N
of IN N
analgetics NNS N
, , N
lung NN N
function NN N
, , N
operation NN N
duration NN N
, , N
amount NN N
of IN N
insufflated JJ N
gas NN N
, , N
intraperitoneal JJ N
pH-values NNS N
and CC N
post-operative JJ N
complications NNS N
in IN N
the DT N
various JJ N
subgroups NNS N
were VBD N
compared VBN N
to TO N
each DT N
other JJ N
with IN N
regard NN N
to TO N
post-operative JJ N
pain NN N
perception NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMWH NNP N
) ) N
combined VBD N
with IN N
graduated JJ N
compression NN N
stockings NNS N
( ( N
GCS NNP N
) ) N
with IN N
GCS NNP N
alone RB N
as IN N
prophylactic JJ N
measures NNS N
for IN N
venous JJ N
thromboembolism NN N
( ( N
VTE NNP N
) ) N
in IN N
post-operative JJ N
patients NNS p
with IN N
gynecologic JJ N
cancer NN N
. . N

CONCLUSIONS NNP N
Two CD N
cycles NNS N
of IN N
regional JJ N
2-min JJ N
IP NNP N
in IN N
the DT N
LAD NNP N
, , N
followed VBN N
by IN N
3 CD N
min NN N
of IN N
reperfusion NN N
, , N
proved VBD N
to TO N
be VB N
applicable JJ N
and CC N
safe JJ N
in IN N
patients NNS p
undergoing VBG N
off-pump JJ N
myocardial JJ N
revascularization NN N
, , N
it PRP N
tended VBD N
to TO N
decrease VB o
the DT N
immediate JJ N
myocardial JJ N
enzyme NN N
release NN N
, , N
it PRP N
prohibited VBD N
the DT N
postoperative JJ N
increase NN o
in IN N
HR NNP N
, , N
and CC N
it PRP N
enhanced VBD N
the DT N
recovery NN N
of IN N
SVI NNP N
. . N

In IN N
the DT N
walk-to-reach NN N
task NN N
, , N
they PRP N
used VBD N
monocular JJ N
and/or NN N
binocular NN N
? . N
information NN N
to TO N
guide VB N
the DT N
head NN N
and CC N
then RB N
switched VBD N
to TO N
using VBG N
relative JJ N
disparity NN N
? . N
to TO N
guide VB N
the DT N
hand NN N
to TO N
final JJ N
target NN N
acquisition NN N
, , N
switching VBG N
when WRB N
the DT N
hand NN N
centric NN N
? . N
became VBD N
less JJR N
than IN N
the DT N
head NN N
centric NN N
? . N
Dynamical JJ N
models NNS N
of IN N
the DT N
information NN N
and CC N
control NN N
strategies NNS N
were VBD N
used VBN N
to TO N
perform VB N
simulations NNS N
that WDT N
were VBD N
found VBN N
to TO N
fit VB N
the DT N
data NN N
well RB N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN N
early JJ N
EN NNP N
with IN N
addition NN N
of IN N
probiotics NNS N
( ( N
bifidobacterium NN N
) ) N
resulted VBD N
in IN N
significant JJ N
lowering NN N
of IN N
the DT N
level NN N
of IN N
pro-inflammatory JJ N
cytokines NNS N
, , N
earlier JJR N
restoration NN N
of IN N
gastrointestinal JJ N
function NN N
, , N
decrease NN o
of IN N
complications NNS N
such JJ N
as IN N
infection NN N
, , N
and CC N
shortening NN N
of IN N
hospital JJ N
day NN N
in IN N
patients NNS p
with IN N
SAP NNP N
. . N

Due JJ N
to TO N
the DT N
richness NN N
of IN N
the DT N
neural JJ N
pathways NNS N
in IN N
the DT N
auditory NN N
system NN N
and CC N
the DT N
redundancy NN N
of IN N
acoustic JJ N
information NN N
in IN N
spoken JJ N
language NN N
, , N
a DT N
normal JJ N
listener NN N
is VBZ N
able JJ N
to TO N
recognize VB N
speech NN N
even RB N
when WRB N
parts NNS N
of IN N
the DT N
signal NN N
are VBP N
missing VBG N
, , N
whereas IN N
this DT N
ability NN N
is VBZ N
often RB N
impaired VBN N
in IN N
listeners NNS N
with IN N
APD NNP N
. . N

For IN N
both DT N
modes NNS N
of IN N
NPPV NNP N
, , N
a DT N
full JJ N
face NN N
mask NN N
and CC N
an DT N
artificial JJ N
leak NN N
in IN N
the DT N
ventilatory NN N
circuit NN N
were VBD N
used VBN N
at IN N
three CD N
different JJ N
settings NNS N
, , N
and CC N
applied VBD N
during IN N
daytime JJ N
NPPV NNP N
, , N
either RB N
without IN N
leakage NN N
( ( N
setting VBG N
I PRP N
) ) N
, , N
with IN N
leakage NN N
during IN N
inspiration NN N
only RB N
( ( N
setting VBG N
II NNP N
) ) N
, , N
and CC N
with IN N
leakage NN N
during IN N
inspiration NN N
and CC N
expiration NN N
( ( N
setting VBG N
III NNP N
) ) N
. . N

In IN N
each DT N
subject NN N
, , N
positron NN N
emission NN N
tomographic JJ N
images NNS N
of IN N
regional JJ N
cerebral JJ N
metabolism NN N
of IN N
glucose JJ N
with IN N
[ JJ N
18F CD N
] NNS N
fluorodeoxyglucose JJ N
were VBD N
obtained VBN N
in IN N
two CD N
conditions NNS N
in IN N
the DT N
morning NN N
on IN N
different JJ N
days NNS N
: : N
about IN N
3min CD N
after IN N
approximately RB N
1-2mg JJ N
of IN N
nasal JJ N
nicotine JJ N
spray NN N
and CC N
after IN N
an DT N
equivalent JJ N
volume NN N
of IN N
an DT N
active JJ N
placebo NN N
spray NN N
of IN N
oleoresin NN N
of IN N
pepper NN N
in IN N
a DT N
random NN N
counterbalanced VBD N
design NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
analysis NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
icosapent JJ N
ethyl NN N
( ( N
eicosapentaenoic JJ N
acid NN N
ethyl NN N
ester NN N
, , N
IPE NNP N
) ) N
on IN N
high-sensitivity NN N
C-reactive JJ N
protein NN N
( ( N
hsCRP NN N
) ) N
and CC N
lipid JJ N
parameters NNS N
in IN N
patients NNS p
with IN N
metabolic JJ N
syndrome NN N
, , N
with IN N
and CC N
without IN N
stable JJ N
statin NN i
therapy NN i
. . N

In IN N
a DT N
survival JJ N
analysis NN N
of IN N
treatment NN N
compliance NN N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
groups NNS N
T NNP N
and CC N
C. NNP N
At IN N
the DT N
6- JJ N
and CC N
12-month JJ N
follow-ups NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
myofascial JJ N
pain NN N
, , N
as IN N
measured VBN N
on IN N
a DT N
visual JJ N
analog NN N
scale NN N
, , N
was VBD N
found VBN N
in IN N
all DT N
three CD N
groups NNS N
. . N

Because IN N
two-thirds NNS N
of IN N
patients NNS p
with IN N
Major JJ N
Depressive NNP N
Disorder NNP N
do VBP N
not RB N
achieve VB N
remission NN N
with IN N
their PRP$ N
first JJ N
antidepressant NN N
, , N
we PRP N
designed VBD N
a DT N
trial NN N
of IN N
three CD N
next-step JJ N
strategies NNS N
: : N
switching NN N
to TO N
another DT N
antidepressant NN N
( ( N
bupropion-SR JJ N
) ) N
or CC N
augmenting VBG N
the DT N
current JJ N
antidepressant NN N
with IN N
either DT N
another DT N
antidepressant NN N
( ( N
bupropion-SR JJ N
) ) N
or CC N
with IN N
an DT N
atypical JJ N
antipsychotic NN i
( ( N
aripiprazole JJ N
) ) N
. . N

Adverse JJ N
effects NNS N
within IN N
2 CD N
weeks NNS N
after IN N
TAI NNP N
were VBD N
evaluated VBN N
by IN N
subjective JJ N
signs NNS N
and CC N
symptoms NNS N
such JJ N
as IN N
fever NN N
( ( N
maximum JJ N
body NN N
temperature NN N
) ) N
and CC N
the DT N
frequency NN N
of IN N
shaking VBG N
chills NNS N
and CC N
abdominal JJ N
pain NN N
, , N
and CC N
by IN N
biochemical JJ N
parameters NNS N
such JJ N
as IN N
albumin NN N
, , N
prothrombin JJ N
time NN N
, , N
and CC N
aspartate NN N
and CC N
alanine NN N
aminotransferases NNS N
. . N

Despite IN N
excellent JJ N
adherence NN N
to TO N
treatment NN N
protocols NNS N
by IN N
the DT N
therapists NNS N
, , N
a DT N
clear JJ N
bias NN N
favoring VBG N
CT NNP N
, , N
and CC N
the DT N
competent JJ N
performance NN N
of IN N
CT NNP N
, , N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
complete JJ N
treatment NN N
produced VBD N
better JJR N
outcomes NNS N
, , N
at IN N
either CC N
the DT N
termination NN N
of IN N
acute JJ N
treatment NN N
or CC N
the DT N
6-month JJ N
follow-up NN N
, , N
than IN N
either DT N
component JJ N
treatment NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
the DT N
number NN N
of IN N
deaths NNS N
, , N
attendance NN N
at IN N
hospital JJ N
outpatient NN N
clinics NNS N
and CC N
general JJ N
practice NN N
and CC N
proportion NN N
of IN N
days NNS N
in IN N
hospital NN N
over IN N
the DT N
follow-up JJ N
period NN N
, , N
together RB N
with IN N
patients NNS p
' POS N
general JJ N
well-being NN N
, , N
satisfaction NN N
with IN N
the DT N
service NN N
and CC N
knowledge NN N
of IN N
and CC N
adherence NN N
to TO N
prescribed VB N
medication NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
resistance NN N
training NN N
versus IN N
passive JJ N
physical JJ N
therapy NN i
on IN N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
, , N
fatigue NN N
, , N
and CC N
emotional JJ N
distress NN N
outcomes NNS N
during IN N
radiation NN N
therapy NN i
in IN N
patients NNS p
with IN N
spinal JJ N
bone NN N
metastases NNS N
under IN N
radiotherapy NN i
( ( N
RT NNP N
) ) N
. . N

The DT N
frequency NN N
of IN N
perceived JJ N
adverse JJ N
events NNS N
and CC N
near JJ N
misses NNS N
was VBD N
also RB N
lower JJR N
in IN N
the DT N
BL NNP N
than IN N
in IN N
the DT N
non-BL JJ N
periods NNS N
, , N
but CC N
not RB N
significantly RB N
so RB N
, , N
possibly RB N
indicating VBG N
that IN N
the DT N
one-month JJ N
observation NN N
period NN N
was VBD N
too RB N
short JJ N
to TO N
achieve VB N
any DT N
significant JJ N
success NN N
. . N

CONCLUSIONS NNP N
The DT N
addition NN N
of IN N
magnesium NN N
to TO N
levobupivacaine VB N
prolongs NNS N
the DT N
sensory NN N
and CC N
motor NN N
block NN N
duration NN N
without IN N
increasing VBG N
side NN N
effects NNS N
, , N
enhances VBZ N
the DT N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
and CC N
increases VBZ o
patient JJ N
satisfaction NN N
; : N
however RB N
, , N
the DT N
addition NN N
of IN N
magnesium NN N
delays VBZ N
the DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
decreases VBZ o
rescue NN N
analgesic JJ N
requirements NNS N
. . N

However RB N
, , N
when WRB N
the DT N
data NNS N
were VBD N
analyzed VBN N
without IN N
regard NN N
for IN N
their PRP$ N
dependence NN N
on IN N
time NN N
, , N
they PRP N
demonstrated VBD N
a DT N
negative JJ N
, , N
linear JJ N
correlation NN N
between IN N
alphaEGOT NN N
and CC N
log NN N
plasma NN N
PLP NNP N
and CC N
between IN N
alphaEGPT NN N
and CC N
log NN N
plasma NN N
PLP NNP N
for IN N
the DT N
group NN N
on IN N
2.5 CD N
mg NN N
of IN N
pyridoxine NN i
and CC N
for IN N
all PDT N
the DT N
subjects NNS N
combined VBN N
. . N

UNLABELLED NNP N
Coronary NNP N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
is VBZ N
the DT N
leading VBG N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
across IN N
the DT N
entire JJ N
world NN N
, , N
in IN N
which WDT N
reversion NN N
of IN N
angina NN N
or CC N
improvement NN N
of IN N
ECG NNP N
remains VBZ N
an DT N
unrealistic JJ N
therapeutic JJ N
option NN N
for IN N
most JJS N
patients NNS p
, , N
suggesting VBG N
that IN N
microvascular JJ N
dysfunction NN N
or CC N
impaired JJ N
oxygen NN N
delivery NN N
might MD N
be VB N
critical JJ N
factors NNS N
in IN N
CHD NNP N
. . N

Cleveland NNP N
constipation NN N
score NN N
( ( N
CCS NNP N
) ) N
, , N
numerical JJ N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
of IN N
pain NN N
and CC N
Chinese JJ N
version NN N
of IN N
European JJ N
Organisation NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
, , N
Quality NNP N
of IN N
Life NNP N
Questionnaire-C30 NNP N
V3.0 NNP N
( ( N
EORTC NNP N
QLQ-C30 NNP N
V3.0 NNP N
) ) N
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
, , N
pain NN N
controlled VBD N
and CC N
QOL NNP N
status NN N
. . N

The DT N
antiischemic JJ N
effects NNS N
were VBD N
documented VBN N
by IN N
relief NN N
of IN N
symptoms NNS N
, , N
reduction NN N
of IN N
ST-depression NNP N
, , N
improvement NN N
of IN N
impaired JJ N
myocardial JJ N
wall NN N
motion NN N
, , N
decrease NN o
to TO N
normalization NN N
of IN N
pathologically RB N
elevated VBN N
filling JJ N
pressure NN N
, , N
amelioration NN N
of IN N
coronary JJ N
blood NN N
flow NN N
as IN N
evidenced VBN N
by IN N
myocard NN N
scintigraphy NN N
and CC N
washout NN N
time NN N
of IN N
an DT N
intracoronarily JJ N
injected VBN N
echo-contrast JJ N
medium NN N
. . N

RESULTS NNP N
Fluvoxamine NNP N
and CC N
clomipramine VB N
both DT N
resulted VBN N
in IN N
marked JJ N
improvements NNS N
; : N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
them PRP N
on IN N
the DT N
17-item JJ N
HAMD NNP N
total NN N
score NN N
, , N
the DT N
clinical JJ N
global JJ N
impression NN N
severity NN N
of IN N
illness NN N
or CC N
global JJ N
improvement NN N
items NNS N
or CC N
the DT N
Montgomery-Asberg JJ N
depression NN N
rating NN N
scale NN N
, , N
at IN N
any DT N
visit NN N
. . N

Results NNS N
showed VBD N
a DT N
significant JJ N
increase NN o
in IN N
eye-hand JJ N
performances NNS N
only RB N
when WRB N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
was VBD N
delivered VBN N
on IN N
the DT N
left JJ N
premotor NN N
cortex NN N
; : N
a DT N
persistent NN N
improvement NN N
up IN N
to TO N
1 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
the DT N
stimulation NN N
; : N
better JJR N
outcomes NNS N
in IN N
the DT N
treatment NN N
combining VBG N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
and CC N
eye-hand JJ N
integration NN N
training NN N
. . N

Although IN N
the DT N
results NNS N
presented VBD N
within IN N
do VBP N
not RB N
include VB N
factors NNS N
of IN N
study NN N
and CC N
study-by-treatment JJ N
interaction NN N
, , N
analyses NNS N
were VBD N
performed VBN N
to TO N
confirm VB N
that IN N
the DT N
results NNS N
were VBD N
consistent JJ N
across IN N
the DT N
2 CD N
identical JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
studies NNS N
and CC N
within IN N
each DT N
treatment NN N
group NN N
across IN N
studies NNS N
to TO N
justify VB N
pooling VBG N
the DT N
data NN N
from IN N
both DT N
studies NNS N
. . N

When WRB N
the DT N
pattern NN N
of IN N
cognitive JJ N
change NN N
over IN N
time NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
compared VBN N
using VBG N
sophisticated JJ N
modeling NN N
techniques NNS N
, , N
the DT N
two CD N
groups NNS N
were VBD N
again RB N
comparable JJ N
, , N
except IN N
for IN N
results NNS N
on IN N
the DT N
test NN N
of IN N
verbal JJ N
fluency NN N
, , N
in IN N
which WDT N
the DT N
off-pump NN N
group NN N
showed VBD N
more RBR N
rapid JJ N
postsurgical JJ N
cognitive NN N
gains NNS N
than IN N
the DT N
on-pump JJ N
group NN N
. . N

Why WRB N
does VBZ N
lag NN N
affect VB N
the DT N
durability NN N
of IN N
memory-based JJ N
automaticity NN N
: : N
loss NN N
of IN N
memory NN N
strength NN N
or CC N
interference NN N
? . N
In IN N
Rickard NNP N
, , N
Lau NNP N
, , N
and CC N
Pashler NNP N
's POS N
( ( N
2008 CD N
) ) N
investigation NN N
of IN N
the DT N
lag NN N
effect NN N
on IN N
memory-based JJ N
automaticity NN N
, , N
response NN N
times NNS N
were VBD N
faster RBR N
and CC N
proportion NN N
of IN N
trials NNS N
retrieved VBN N
was VBD N
higher JJR N
at IN N
the DT N
end NN N
of IN N
practice NN N
for IN N
short JJ N
lag NN N
items NNS N
than IN N
for IN N
long JJ N
lag NN N
items NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
an DT N
applied JJ N
behaviour NN N
analysis NN N
( ( N
ABA NNP N
) ) N
-based VBD N
intervention NN N
conducted VBN N
by IN N
a DT N
robot NN N
compared VBN N
to TO N
an DT N
ABA-based JJ N
intervention NN N
conducted VBN N
by IN N
a DT N
human JJ N
trainer NN N
in IN N
promoting VBG N
self-initiated JJ N
questions NNS N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

The DT N
absence NN N
of IN N
activity NN N
significantly RB N
correlated VBN N
with IN N
temporal JJ N
complexity NN N
during IN N
continue JJ N
suggests NNS N
that IN N
, , N
once RB N
an DT N
overlearned VBN N
timed JJ N
movement NN N
sequence NN N
has VBZ N
been VBN N
selected VBN N
and CC N
initiated VBN N
, , N
there EX N
is VBZ N
no DT N
further JJ N
adjustment NN N
of IN N
the DT N
timing NN N
control NN N
processes VBZ N
related VBN N
to TO N
its PRP$ N
continued JJ N
production NN N
in IN N
absence NN N
of IN N
external JJ N
cues NNS N
. . N

Concerning VBG N
spectral JJ N
analysis NN N
, , N
temazepam NN i
induces NNS N
a DT N
light JJ N
increase NN o
of IN N
the DT N
relative JJ N
power NN N
of IN N
the DT N
slowest JJS N
frequencies NNS N
, , N
paralleled VBN N
by IN N
an DT N
increase NN o
of IN N
the DT N
fast JJ N
bands NNS N
, , N
while IN N
major JJ N
effects NNS N
are VBP N
found VBN N
on IN N
the DT N
characteristic JJ N
periodicity NN N
of IN N
delta NN N
activities NNS N
, , N
which WDT N
appear VBP N
disrupted VBN N
by IN N
the DT N
drug NN N
. . N

Based VBN N
on IN N
these DT N
experiments NNS N
, , N
nomograms NNS N
were VBD N
constructed VBN N
from IN N
which WDT N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
Ringer NNP N
's POS N
solution NN N
and CC N
the DT N
infusion NN N
time NN N
required VBN N
to TO N
obtain VB N
a DT N
defined JJ N
plasma NN N
dilution NN N
in IN N
both DT N
males NNS N
and CC N
females NNS N
can MD N
be VB N
estimated VBN N
together RB N
with IN N
the DT N
infusion NN N
rate NN N
needed VBN N
to TO N
maintain VB N
the DT N
dilution NN N
at IN N
the DT N
level NN N
reached VBD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
28-day JJ N
mortality NN N
, , N
hospital JJ N
mortality NN N
, , N
or CC N
length NN N
of IN N
hospital NN N
stay NN N
, , N
but CC N
ICU NNP N
mortality NN N
and CC N
the DT N
length NN N
of IN N
ICU NNP N
stay NN N
in IN N
the DT N
HA NNP N
group NN N
were VBD N
markedly RB N
reduced VBN N
. . N

Does NNP N
aerobic VB N
training VBG N
lead NN N
to TO N
a DT N
more RBR N
active JJ N
lifestyle NN N
and CC N
improved JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN N
chronic JJ N
heart NN N
failure NN N
? . N
BACKGROUND NNP N
Due NNP N
to TO N
dyspnea VB N
and CC N
fatigue VB N
, , N
patients NNS p
with IN N
chronic JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
are VBP N
often RB N
restricted VBN N
in IN N
the DT N
performance NN N
of IN N
everyday JJ N
activities NNS N
, , N
which WDT N
gradually RB N
may MD N
lead VB N
to TO N
hypoactivity NN N
. . N

RESULTS VB N
The DT N
results NNS N
indicated VBD N
that IN N
the DT N
distorting NN N
goggles NNS N
degraded VBD N
throwing VBG N
at IN N
the DT N
beginning NN N
of IN N
training NN N
, , N
visual JJ N
feedback NN N
improved VBD N
throwing VBG N
during IN N
training NN N
, , N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
persisted VBN N
into IN N
the DT N
throwing VBG N
posttest NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
did VBD N
not RB N
transfer VB N
to TO N
the DT N
verbal JJ N
metric JJ N
estimation NN N
posttest NN N
. . N

The DT N
processing NN N
of IN N
time-dependent JJ N
features NNS N
of IN N
movement NN N
has VBZ N
a DT N
crucial JJ N
role NN N
in IN N
predicting VBG N
whether IN N
the DT N
outcome NN N
of IN N
a DT N
complex JJ N
motor NN N
sequence NN N
, , N
such JJ N
as IN N
handwriting NN N
or CC N
playing VBG N
a DT N
musical JJ N
passage NN N
, , N
will MD N
be VB N
consistent JJ N
with IN N
its PRP$ N
ultimate JJ N
goal NN N
, , N
or CC N
results NNS N
instead RB N
in IN N
an DT N
execution NN N
error NN N
. . N

The DT N
following VBG N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
intervention NN N
: : N
strength NN N
by IN N
one CD N
repetition NN N
maximum NN N
, , N
physical JJ N
activity NN N
by IN N
the DT N
7-d JJ N
accelerometry NN N
and CC N
the DT N
3-d JJ N
physical JJ N
activity NN N
recall NN N
, , N
dietary JJ N
intake NN N
by IN N
3-d JJ N
records NNS N
, , N
body NN N
composition NN N
by IN N
dual-energy JJ N
x-ray JJ N
absorptiometry NN N
( ( N
DEXA NNP N
) ) N
, , N
glucose/insulin JJ N
indices NNS N
by IN N
oral JJ N
glucose JJ N
tolerance NN N
test NN N
, , N
and CC N
intravenous JJ N
glucose JJ N
tolerance NN N
test NN N
with IN N
minimal JJ N
modeling NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
either RB N
that DT N
persistent JJ N
early-life JJ N
MEE NNP N
actually RB N
causes VBZ N
later RB N
small JJ N
, , N
circumscribed JJ N
impairments NNS N
of IN N
receptive JJ N
language NN N
and CC N
verbal JJ N
aspects NNS N
of IN N
cognition NN N
in IN N
certain JJ N
groups NNS N
of IN N
children NNS N
or CC N
that DT N
unidentified JJ N
, , N
confounding VBG N
factors NNS N
predispose JJ N
children NNS N
both DT N
to TO N
early-life NN N
otitis NN N
media NNS N
and CC N
to TO N
certain JJ N
types NNS N
of IN N
developmental JJ N
impairment NN N
. . N

The DT N
ESDM NNP N
group NN N
and CC N
typical JJ N
children NNS N
showed VBD N
a DT N
shorter NN N
Nc NNP N
latency NN N
and CC N
increased VBD o
cortical JJ o
activation NN N
( ( N
decreased VBN o
? . N
power NN N
and CC N
increased VBD o
? . o
power NN N
) ) N
when WRB N
viewing VBG N
faces VBZ N
, , N
whereas IN N
the DT N
community NN N
intervention NN N
group NN N
showed VBD N
the DT N
opposite JJ N
pattern NN N
( ( N
shorter JJ N
latency NN N
event-related JJ N
potential JJ N
[ NN N
ERP NNP N
] NNP N
and CC N
greater JJR N
cortical JJ N
activation NN N
when WRB N
viewing VBG N
objects NNS N
) ) N
. . N

SWAL-QOL JJ N
Scale NNP N
scores NNS N
increased VBD o
more RBR o
significantly RB N
in IN N
the DT N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN i
and CC N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN i
groups NNS N
than IN N
in IN N
the DT N
traditional JJ N
swallowing NN N
therapy NN i
group NN N
, , N
and CC N
the DT N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN i
and CC N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN i
groups NNS N
showed VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
P=.04 NNP N
) ) N
. . N

Lumbar NNP N
spine NN N
BMD NNP N
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
, , N
and CC N
trabecular JJ N
bone NN N
mineral JJ N
density NN N
at IN N
the DT N
distal JJ N
radius NN N
, , N
cortical JJ N
bone NN N
density NN N
, , N
and CC N
relative JJ N
cortical JJ N
volume NN N
at IN N
the DT N
radial JJ N
diaphysis NN N
by IN N
peripheral JJ N
computed VBN N
tomography NN N
before IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
at IN N
the DT N
4th CD N
, , N
8th CD N
, , N
and CC N
12th CD N
month NN N
. . N

Although IN N
propranolol NN i
can MD N
be VB N
administered VBN N
safely RB N
to TO N
patients NNS p
with IN N
acute JJ N
myocardial JJ N
infarction NN N
who WP N
are VBP N
selected VBN N
on IN N
the DT N
basis NN N
of IN N
simple JJ N
clinical JJ N
criteria NNS N
, , N
there EX N
is VBZ N
no DT N
evidence NN N
of IN N
reduction NN N
of IN N
infarct NN N
size NN N
when WRB N
beta NN N
blockade NN N
is VBZ N
begun VBN N
8.5 CD N
hours NNS N
after IN N
the DT N
onset NN N
of IN N
symptoms NNS N
. . N

This DT N
study NN N
, , N
the DT N
first JJ N
performed VBN N
in IN N
an DT N
unselected JJ N
, , N
unscreened JJ N
population NN N
, , N
shows VBZ N
that IN N
serum NN N
PSA NNP N
is VBZ N
the DT N
most RBS N
sensitive JJ N
technique NN N
to TO N
identify VB N
men NNS N
at IN N
high JJ N
risk NN N
of IN N
having VBG N
prostate NN N
cancer NN N
and CC N
that IN N
12 CD N
% NN N
more JJR N
cancers NNS N
can MD N
be VB N
found VBN N
at IN N
first JJ N
visit NN N
by IN N
doing VBG N
DRE NNP N
in IN N
addition NN N
to TO N
PSA NNP N
. . N

A DT N
few JJ N
studies NNS N
have VBP N
been VBN N
conducted VBN N
that IN N
evaluate VBP N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
; : N
however RB N
, , N
none NN N
of IN N
these DT N
studies NNS N
have VBP N
combined VBN N
objective JJ N
measures NNS N
with IN N
rating NN N
scales NNS N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
across IN N
home NN N
and CC N
clinical JJ N
settings NNS N
. . N

AIMS IN N
The DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS N
and CC N
teachers NNS N
, , N
with IN N
guidance NN N
, , N
can MD N
assist VB N
in IN N
the DT N
management NN N
of IN N
children NNS N
with IN N
DCD NNP N
; : N
whether IN N
children NNS N
with IN N
DCD NNP N
are VBP N
helped VBN N
in IN N
this DT N
way NN N
and CC N
how WRB N
this DT N
may MD N
contribute VB N
to TO N
our PRP$ N
understanding NN N
of IN N
the DT N
condition NN N
. . N

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
short-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
aripiprazole NN N
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autistic JJ N
disorder NN N
who WP N
were VBD N
manifesting VBG N
behaviors NNS N
such JJ N
as IN N
tantrums NNS N
, , N
aggression NN N
, , N
self-injurious JJ N
behavior NN N
, , N
or CC N
a DT N
combination NN N
of IN N
these DT N
. . N

The DT N
secondary JJ N
outcome NN N
measures NNS N
included VBD N
psychological JJ N
stress NN N
, , N
anxiety NN N
, , N
irritation NN N
, , N
headache-related JJ N
disability NN N
and CC N
the DT N
frequency NN N
( ( N
number NN N
of IN N
days NNS N
per IN N
month NN N
) ) N
of IN N
migraine NN N
attack NN N
and CC N
of IN N
headache NN N
of IN N
at IN N
least JJS N
moderate JJ N
intensity NN N
( ( N
pain NN N
rating NN N
? . N
) ) N
. . N

Factors NNS N
associated VBN N
with IN N
better JJR N
Kansas NNP N
City NNP N
Cardiomyopathy NNP N
Questionnaire NNP N
and CC N
European NNP N
QOL NNP N
5D CD N
Visual NNP N
Analog NNP N
Scale NNP N
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
were VBD N
American JJ N
region NN N
, , N
older JJR N
age NN N
, , N
no DT N
history NN N
of IN N
angina JJ N
pectoris NN N
or CC N
asthma NN N
, , N
no DT N
use NN N
of IN N
hypoglycemic JJ N
agent NN N
, , N
more JJR N
activity NN N
level NN N
, , N
and CC N
lower JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
. . N

Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
and CC N
the DT N
Gilliam NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
GARS NNP N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
core NN N
autism NN N
behaviours NNS N
, , N
Vineland NNP N
Adaptive NNP N
Behaviour NNP N
Scales NNP N
( ( N
VABS NNP N
) ) N
to TO N
ascertain VB N
developmental JJ N
level NN N
, , N
and CC N
Attention-Deficit NNP N
Hyperactivity NNP N
Disorder NNP N
- : N
IV NNP N
scale NN N
( ( N
ADHD-IV NNP N
) ) N
to TO N
determine VB N
inattention NN N
and CC N
hyperactivity NN N
. . N

CONCLUSIONS NNP N
In IN N
the DT N
very RB N
high-risk JJ N
population NN N
studied VBN N
, , N
effective JJ N
anti-H. JJ N
pylori NN N
treatment NN N
and CC N
dietary JJ N
supplementation NN N
with IN N
antioxidant JJ N
micronutrients NNS N
may MD N
interfere VB N
with IN N
the DT N
precancerous JJ N
process NN N
, , N
mostly RB N
by IN N
increasing VBG N
the DT N
rate NN N
of IN N
regression NN N
of IN N
cancer NN N
precursor NN N
lesions NNS N
, , N
and CC N
may MD N
be VB N
an DT N
effective JJ N
strategy NN N
to TO N
prevent VB N
gastric JJ N
carcinoma NN N
. . N

Considering VBG N
growth NN N
over IN N
all DT N
3 CD N
measurement NN N
periods NNS N
, , N
an DT N
exploratory NN N
analysis NN N
showed VBD N
that IN N
growth NN N
rate NN N
of IN N
the DT N
number NN N
of IN N
different JJ N
nonimitative JJ N
words NNS N
was VBD N
faster RBR N
in IN N
the DT N
PECS NNP N
group NN N
than IN N
in IN N
the DT N
RPMT NNP N
group NN N
for IN N
children NNS N
who WP N
began VBD N
treatment NN N
with IN N
relatively RB N
high JJ N
object JJ N
exploration NN N
. . N

CONCLUSION NNP N
Medication-assisted NNP N
therapies NNS N
for IN N
prevention NN N
of IN N
relapse NN N
to TO N
alcohol VB N
use NN N
for IN N
CJS NNP N
populations NNS N
transitioning VBG N
to TO N
the DT N
community NN N
, , N
especially RB N
for IN N
HIV-infected JJ N
patients NNS p
, , N
are VBP N
urgently RB N
needed VBN N
in IN N
order NN N
to TO N
reduce VB N
alcohol NN N
relapse NN N
after IN N
release NN N
and CC N
improve VB N
HIV NNP N
treatment NN N
outcomes NNS N
and CC N
contribute NN N
to TO N
improved VBN N
individual JJ N
and CC N
public JJ N
health NN N
. . N

CONCLUSIONS NNP N
Since IN N
this DT N
analysis NN N
of IN N
reliability NN N
, , N
validity NN N
, , N
and CC N
responsiveness NN N
to TO N
change VB N
did VBD N
not RB N
clearly RB N
favour VBP N
one CD N
instrument NN N
above IN N
the DT N
other JJ N
, , N
the DT N
choice NN N
between IN N
the DT N
CRQ NNP N
and CC N
the DT N
SGRQ NNP N
can MD N
be VB N
based VBN N
on IN N
other JJ N
considerations NNS N
such JJ N
as IN N
the DT N
required JJ N
sample NN N
size NN N
or CC N
the DT N
availability NN N
of IN N
reference NN N
values NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
conjugated JJ N
linoleic JJ N
acid NN N
( ( N
CLA NNP N
) ) N
supplementation NN N
and CC N
endurance NN N
exercise NN N
training-induced JJ N
changes NNS N
on IN N
post-heparin JJ N
lipoprotein NN N
lipase NN N
( ( N
PH-LPL NNP N
) ) N
and CC N
butyrylcholinesterase NN N
( ( N
BChE NNP N
) ) N
activities NNS N
along IN N
with IN N
leptin NN i
, , N
insulin NN N
and CC N
lipid JJ N
levels NNS N
in IN N
plasma NN N
by IN N
a DT N
randomized JJ N
double JJ N
blind NN N
experiment NN N
. . N

The DT N
study NN N
will MD N
investigate VB N
the DT N
effects NNS N
on IN N
falls NNS N
, , N
mobility NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
( ( N
i NN N
) ) N
movement NN N
strategy NN N
training NN N
combined VBN N
with IN N
falls NNS N
prevention JJ N
education NN N
, , N
( ( N
ii NN N
) ) N
progressive NN N
resistance NN N
strength NN N
training NN N
combined VBN N
with IN N
falls NNS N
prevention JJ N
education NN N
, , N
( ( N
iii NN N
) ) N
a DT N
generic JJ N
life-skills JJ N
social JJ N
program NN N
( ( N
control VB N
group NN N
) ) N
. . N

Furthermore RB N
, , N
TCM NNP N
, , N
histological JJ N
grading NN N
of IN N
myeloma NN N
cells NNS N
, , N
degree NN N
of IN N
bone NN N
marrow NN N
infiltration NN N
, , N
haemoglobin NN N
, , N
platelet NN N
counts NNS N
, , N
calcium NN N
, , N
creatinine NN N
, , N
albumin NN N
, , N
beta NN N
2M CD N
, , N
and CC N
Bence NNP N
Jones NNP N
proteinuria NNS N
correlated VBD N
to TO N
both DT N
OAS NNP N
and CC N
TRS NNP N
. . N

Additionally RB N
, , N
dose-dependent JJ N
reductions NNS N
in IN N
the DT N
indices NNS N
of IN N
platelet NN N
activation NN N
and CC N
endothelial JJ N
dysfunction NN N
were VBD N
observed VBN N
in IN N
patients NNS p
administered VBN N
high JJ N
dose JJ N
treatments NNS N
of IN N
eprosartan NN N
and CC N
enalapril NN N
, , N
and CC N
the DT N
beneficial JJ N
effects NNS N
of IN N
these DT N
agents NNS N
were VBD N
not RB N
correlated VBN N
with IN N
the DT N
reduction NN N
of IN N
blood NN N
pressure NN N
using VBG N
both DT N
agents NNS N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
observed JJ N
cost NN N
and CC N
QALY NNP N
measures NNS N
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
, , N
although IN N
a DT N
tendency NN N
was VBD N
noted VBN N
for IN N
psychosocial JJ N
care NN N
leading VBG N
to TO N
cost NN N
increases NNS o
with IN N
informal JJ N
care NN N
that WDT N
was VBD N
not RB N
outweighed VBN N
by IN N
the DT N
tendency NN N
for IN N
cost NN N
savings NNS N
with IN N
formal JJ N
care NN N
. . N

Repeated-measures JJ N
multivariate NN N
analysis NN N
of IN N
variance NN N
performed VBN N
on IN N
normalized JJ N
relative JJ N
area NN N
values NNS N
revealed VBD N
that IN N
ethanol NN N
had VBD N
significant JJ N
effects NNS N
on IN N
EEG NNP N
activity NN N
at IN N
anterior JJ N
sites NNS N
: : N
frontal NN N
( ( N
F3 NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
C4 NNP N
) ) N
that WDT N
presented VBD N
as IN N
increased JJ o
activity NN N
in IN N
the DT N
slow JJ N
alpha NN N
frequency NN N
band NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Pain NNP N
on IN N
the DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
, , N
the DT N
Oswestry NNP N
and CC N
the DT N
Million NNP N
disability NN N
indexes NNS N
, , N
isometric JJ N
and CC N
dynamic JJ N
trunk NN N
muscle NN N
strength NN N
, , N
mobility NN N
in IN N
the DT N
lumbar NN N
spine NN N
, , N
and CC N
straight-leg JJ N
raising NN N
were VBD N
measured VBN N
. . N

The DT N
active JJ N
treatment NN N
group NN N
showed VBD N
significant JJ N
improvement NN N
compared VBN N
with IN N
controls NNS N
on IN N
the DT N
primary JJ N
outcome JJ N
measure NN N
-- : N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
total NN N
score NN N
, , N
particularly RB N
in IN N
reciprocal JJ N
social JJ N
interaction NN N
-- : N
and CC N
on IN N
secondary JJ N
measures NNS N
of IN N
expressive JJ N
language NN N
, , N
communicative JJ N
initiation NN N
and CC N
parent-child JJ N
interaction NN N
. . N

The DT N
Stages NNP N
to TO N
Healthy NNP N
Eating NNP N
Patterns NNP N
Study NNP N
( ( N
STEPs NNP N
) ) N
was VBD N
an DT N
intervention NN N
study NN N
, , N
in IN N
middle-aged JJ N
adults NNS N
with IN N
cardiovascular JJ N
risk NN N
factors NNS N
, , N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
delivered VBN N
by IN N
mail NN N
in IN N
improving VBG N
short-term JJ N
dietary JJ N
behaviour NN N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat NN N
, , N
fruit NN N
, , N
vegetable JJ N
and CC N
grain NN N
and CC N
cereal NN N
intake NN N
. . N

DISCUSSION NN N
If IN N
ROMEO NNP N
confirms VBZ N
that IN N
group NN N
care NN N
can MD N
be VB N
successfully RB N
implemented VBN N
in IN N
different JJ N
clinics NNS N
, , N
a DT N
novel JJ N
clinico-pedagogic JJ N
tool NN N
will MD N
have VB N
been VBN N
acquired VBN N
to TO N
support VB N
patient-centred JJ N
education NN N
, , N
improve VB N
lifestyle NN N
and CC N
outcomes NNS N
, , N
support NN N
team NN N
work NN N
, , N
enhance NN N
providers NNS N
' POS N
attitudes NNS N
and CC N
competencies NNS N
and CC N
ameliorate VB N
diabetes NNS N
care JJ N
organization NN N
. . N

The DT N
physical JJ N
activity NN N
intervention NN N
will MD N
consist VB N
of IN N
a DT N
number NN N
of IN N
strategies NNS N
including VBG N
: : N
delivering NN N
structured VBD N
fundamental JJ N
movement NN N
skill NN N
activities NNS N
, , N
increasing VBG N
physical JJ N
activity NN N
opportunities NNS N
, , N
increasing VBG N
staff NN N
role NN N
modelling NN N
, , N
providing VBG N
children NNS N
with IN N
a DT N
physical JJ N
activity NN N
promoting VBG N
indoor NN N
and CC N
outdoor JJ N
environment NN N
and CC N
limiting VBG N
children NNS N
's POS N
small JJ N
screen JJ N
recreation NN N
and CC N
sedentary JJ N
behaviours NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
quantitative JJ N
sensory NN N
tests NNS N
using VBG N
the DT N
CASE NNP N
IV NNP N
System NNP N
, , N
the DT N
Neuropathy NNP N
Symptom NNP N
and CC N
Change NNP N
questionnaire NN N
, , N
the DT N
Patient NNP N
Benefit NNP N
Questionnaire NNP N
( ( N
PBQ NNP N
) ) N
, , N
and CC N
a DT N
global JJ N
symptom NN N
assessment NN N
, , N
as RB N
well RB N
as IN N
nerve NN N
conduction NN N
studies NNS N
and CC N
occurrence NN N
of IN N
new JJ N
plantar JJ N
foot NN N
ulcers NNS N
. . N

Improvements NNS N
in IN N
mood NN N
were VBD N
associated VBN N
with IN N
modest JJ N
gains NNS N
in IN N
verbal JJ N
memory NN N
and CC N
executive NN N
functioning NN N
over IN N
the DT N
10-week JJ N
treatment NN N
period NN N
and CC N
accounted VBD N
for IN N
greater JJR N
variance NN N
in IN N
neuropsychological JJ N
outcomes NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
than IN N
other JJ N
known JJ N
correlates NNS N
of IN N
cognitive JJ N
functioning NN N
in IN N
PD NNP N
, , N
such JJ N
as IN N
disease NN N
severity NN N
, , N
age NN N
, , N
and CC N
education NN N
. . N

Both DT N
groups NNS N
showed VBD N
habituation NN N
in IN N
heart NN N
rate NN N
from IN N
the DT N
first JJ N
to TO N
the DT N
second JJ N
presentation NN N
, , N
and CC N
both DT N
groups NNS N
reported VBD N
perception NN N
of IN N
a DT N
higher JJR N
heart NN N
rate NN N
, , N
but CC N
only RB N
social JJ N
phobics NNS N
reported VBD N
significantly RB N
more JJR N
anxiety NN N
and CC N
were VBD N
more JJR N
worried JJ N
about IN N
their PRP$ N
heart NN N
rates NNS N
in IN N
the DT N
public NN N
than IN N
in IN N
the DT N
private JJ N
condition NN N
. . N

Use NNP N
of IN N
activated JJ N
charcoal NN N
in IN N
a DT N
simulated JJ N
poisoning NN N
with IN N
acetaminophen NN i
: : N
a DT N
new JJ N
loading NN N
dose NN N
for IN N
N-acetylcysteine NNP i
? . N
STUDY NNP N
OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
ability NN N
of IN N
a DT N
supranormal JJ N
dose NN N
of IN N
N-acetylcysteine NNP i
to TO N
overcome VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
N-acetylcysteine NNP i
bioavailability NN N
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
serum NN N
acetaminophen NN i
levels NNS N
. . N

This DT N
study NN N
evaluated VBD N
whether IN N
333 CD N
seronegative JJ N
African JJ N
American JJ N
female JJ N
drug NN N
users NNS N
( ( N
aged VBN N
18-59 CD N
years NNS N
) ) N
participating VBG N
in IN N
an DT N
HIV NNP N
intervention NN N
and CC N
with IN N
higher JJR N
levels NNS N
of IN N
emotional JJ N
distress NN N
, , N
specifically RB N
symptoms NNS N
of IN N
depression NN N
and CC N
anxiety NN N
, , N
reduced VBD N
HIV NNP N
risk NN N
behaviors NNS N
to TO N
a DT N
lesser JJR N
extent NN N
than IN N
those DT N
with IN N
lower JJR N
levels NNS N
of IN N
emotional JJ N
distress NN N
. . N

Acupuncture NN N
is VBZ N
becoming VBG N
a DT N
common JJ N
technique NN N
within IN N
the DT N
physiotherapy NN i
profession NN N
as IN N
a DT N
treatment NN N
modality NN N
for IN N
pain NN N
relief NN N
; : N
however RB N
, , N
few JJ N
randomised VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
undertaken VBN N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
acupuncture NN N
, , N
particularly RB N
in IN N
the DT N
treatment NN N
of IN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
of IN N
the DT N
hip NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
statistical JJ N
efficacy NN N
of IN N
the DT N
clinical JJ N
neurosensory JJ N
test NN N
using VBG N
surgical JJ N
findings NNS N
as IN N
the DT N
gold JJ N
standard NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
a DT N
correlation NN N
existed VBN N
between IN N
the DT N
sensory JJ N
impairment NN N
score NN N
obtained VBN N
by IN N
preoperative JJ N
testing NN N
and CC N
the DT N
degree NN N
of IN N
nerve NN N
injury NN N
found VBD N
at IN N
surgery NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
rate NN N
of IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
( ( N
MACEs NNP N
) ) N
at IN N
1 CD N
month NN N
, , N
defined VBD N
as IN N
a DT N
composite NN N
of IN N
cardiac JJ N
death NN N
, , N
reinfarction NN N
, , N
serious JJ N
arrhythmias NN N
( ( N
ventricular JJ N
fibrillation NN N
and/or IN N
tachycardia NN N
) ) N
, , N
and CC N
severe JJ N
heart NN N
failure NN N
. . N

The DT N
use NN N
of IN N
thrombolytic JJ N
agents NNS N
in IN N
patients NNS p
with IN N
suspected JJ N
myocardial JJ N
infarction NN N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
early JJ N
and CC N
long-term JJ N
mortality NN N
by IN N
about IN N
20 CD N
% NN N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
since IN N
time NN N
is VBZ N
an DT N
important JJ N
factor NN N
, , N
pre-hospital JJ N
treatment NN N
would MD N
give VB N
better JJR N
results NNS N
. . N

Here RB N
, , N
we PRP N
studied VBD N
the DT N
relationship NN N
between IN N
peripheral JJ N
FMRP NNP N
level NN N
, , N
visual JJ N
perception NN N
( ( N
contrast JJ N
sensitivity NN N
, , N
perceptual JJ N
integration NN N
, , N
motion/form VB N
perception NN N
) ) N
, , N
and CC N
neuropsychological JJ N
functions NNS N
in IN N
schizophrenia NN N
as IN N
measured VBN N
with IN N
the DT N
Repeatable JJ N
Battery NN N
for IN N
the DT N
Assessment NNP N
of IN N
Neuropsychological NNP N
Status NNP N
( ( N
RBANS NNP N
) ) N
. . N

The DT N
goal NN N
was VBD N
to TO N
assess VB N
if IN N
a DT N
16-wk JJ N
nutrition NN N
plus CC N
CAST NNP N
pilot NN N
study NN N
had VBD N
stronger JJR N
effects NNS N
on IN N
reducing VBG N
adiposity NN N
and CC N
on IN N
improving VBG N
glucose/insulin NN N
indices NNS N
compared VBN N
with IN N
control NN N
( ( N
C NNP N
) ) N
, , N
nutrition NN N
only RB N
( ( N
N NNP N
) ) N
, , N
and CC N
a DT N
nutrition NN N
plus CC N
strength NN N
training NN N
( ( N
N NNP N
+ NNP N
ST NNP N
) ) N
groups NNS N
. . N

PURPOSE NN N
To TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
ifosfamide NN N
to TO N
cisplatin VB i
plus JJ N
etoposide JJ N
improves VBZ N
the DT N
response NN N
rate NN N
, , N
time NN N
to TO N
disease VB N
progression NN N
, , N
or CC N
overall JJ i
survival NN N
in IN N
previously RB N
untreated JJ N
patients NNS p
with IN N
extensive-stage JJ N
small-cell JJ N
carcinoma NN N
of IN N
the DT N
lung NN N
( ( N
SCLC NNP N
) ) N
. . N

This DT N
randomized VBD N
clinical JJ N
trial NN N
compared VBN N
the DT N
effectiveness NN N
of IN N
a DT N
verbally-based JJ N
intervention NN N
, , N
Pivotal NNP N
Response NNP N
Training NNP N
( ( N
PRT NNP N
) ) N
to TO N
a DT N
pictorially-based JJ N
behavioral JJ N
intervention NN N
, , N
the DT N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
( ( N
PECS NNP N
) ) N
on IN N
the DT N
acquisition NN N
of IN N
spoken JJ N
language NN N
by IN N
young JJ N
( ( N
2-4 JJ N
years NNS N
) ) N
, , N
nonverbal JJ N
or CC N
minimally RB N
verbal JJ N
( ( N
? . N
words NNS N
) ) N
children NNS N
with IN N
autism NN N
. . N

Outcome NN N
measures NNS N
were VBD N
the DT N
Dutch JJ N
version NN N
of IN N
the DT N
McGill NNP N
Pain NNP N
Questionnaire NNP N
( ( N
MPQ-DLV NNP N
) ) N
, , N
the DT N
Health-related JJ N
quality NN N
of IN N
life NN N
instrument NN N
( ( N
HRQOL NNP N
) ) N
, , N
visual JJ N
analogue NN N
scales NNS N
( ( N
VAS NNP N
) ) N
, , N
the DT N
duration NN N
of IN N
the DT N
procedure NN N
, , N
and CC N
the DT N
analgesic JJ N
doses NNS N
taken VBN N
each DT N
day NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
( ( N
rise NN N
in IN N
serum JJ N
creatinine NN N
and CC N
fall NN N
in IN N
serum JJ N
potassium NN N
, , N
loss NN N
of IN N
appetite NN N
and CC N
shivering NN N
, , N
rigor NN N
and CC N
fever NN N
during IN N
infusion NN N
indicative NN N
of IN N
renal JJ N
, , N
GIT NNP N
and CC N
infusion NN N
related JJ N
toxicities NNS N
respectively RB N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
of IN N
therapy NN i
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
all PDT N
the DT N
four CD N
study NN N
parameters NNS N
, , N
which WDT N
correlated VBD N
well RB N
with IN N
the DT N
improvement NN N
in IN N
symptoms NNS N
of IN N
urogenital JJ N
atrophy NN N
and CC N
sexual JJ N
dysfunction NN N
in IN N
both CC N
the DT N
study NN N
groups NNS N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
a DT N
computer NN N
software NN N
( ( N
i.e NN N
, , N
Mind NNP N
Reading NNP N
) ) N
and CC N
in IN N
vivo JJ N
rehearsal NN N
treatment NN N
on IN N
the DT N
emotion NN N
decoding NN N
and CC N
encoding VBG N
skills NNS N
, , N
autism NN N
symptoms NNS N
, , N
and CC N
social JJ N
skills NNS N
of IN N
43 CD N
children NNS N
, , N
ages VBZ N
7-12 CD N
years NNS N
with IN N
high-functioning JJ N
autism NN N
spectrum NN N
disorder NN N
( ( N
HFASD NNP N
) ) N
. . N

RESULTS NNP N
Comparing VBG N
the DT N
tooth JJ N
widths NNS N
of IN N
patients NNS p
with IN N
unilateral JJ N
canine NN N
displacement NN N
with IN N
the DT N
corresponding JJ N
contralateral JJ N
quadrants NNS N
, , N
we PRP N
noted VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
, , N
namely RB N
that IN N
the DT N
central JJ N
and CC N
lateral JJ N
incisors NNS N
and CC N
the DT N
canines NNS N
of IN N
the DT N
affected JJ N
side NN N
were VBD N
narrower JJR N
than IN N
those DT N
of IN N
the DT N
non-affected JJ N
side NN N
in IN N
the DT N
same JJ N
patient NN N
. . N

Results NNS N
of IN N
the DT N
therapeutic JJ N
effects NNS N
will MD N
not RB N
be VB N
available JJ N
for IN N
some DT N
time NN N
, , N
but CC N
the DT N
study NN N
has VBZ N
provided VBN N
an DT N
opportunity NN N
to TO N
investigate VB N
influences NNS N
on IN N
sensitization NN N
to TO N
allergens NNS N
in IN N
a DT N
large JJ N
cohort NN N
of IN N
1-2 JJ N
years NNS N
olds VBZ N
with IN N
already RB N
established VBN N
atopic NN N
dermatitis NN N
, , N
resident NN N
in IN N
different JJ N
countries NNS N
and CC N
in IN N
different JJ N
environments NNS N
. . N

The DT N
examination NN N
and CC N
treatment NN N
of IN N
64 CD N
patients NNS p
have VBP N
shown VBN N
that IN N
inclusion NN N
of IN N
complex JJ N
antioxidant NN N
cytoflavin NN N
in IN N
intensive JJ N
therapy NN i
at IN N
the DT N
postoperative JJ N
period NN N
of IN N
diffuse NN N
peritonitis NN N
allows VBZ N
the DT N
hypoxia NN N
degree NN N
to TO N
be VB N
decreased VBN o
that IN N
in IN N
its PRP$ N
turn NN N
results NNS N
in IN N
quicker JJ N
recovery NN N
of IN N
the DT N
antioxidant JJ N
system NN N
and CC N
decreased JJ o
activity NN N
of IN N
peroxidation NN N
and CC N
endotoxicosis NN N
level NN N
. . N

We PRP N
further RB N
sought VBD N
to TO N
determine VB N
whether IN N
egg NN N
yolk NNS N
intake VBP N
affects NNS N
peripheral JJ N
blood NN N
mononuclear NN N
cell NN N
( ( N
PBMC NNP N
) ) N
inflammation NN N
and CC N
cholesterol NN N
homeostasis NN N
in IN N
MetS NNP N
, , N
as IN N
HDL NNP N
and CC N
its PRP$ N
associated JJ N
lipid JJ N
transporter NN N
ATP-binding NNP N
cassette NN N
transporter NN N
A1 NNP N
( ( N
ABCA1 NNP N
) ) N
reduce VB N
the DT N
inflammatory JJ N
potential NN N
of IN N
leukocytes NNS N
through IN N
modulation NN N
of IN N
cellular JJ N
cholesterol NN N
content NN N
and CC N
distribution NN N
. . N

There EX N
was VBD N
wide JJ N
individual JJ N
variation NN N
in IN N
the DT N
ratio NN N
of IN N
serum NN N
to TO N
saliva VB N
concentrations NNS N
indicating VBG N
that IN N
, , N
even RB N
when WRB N
individual JJ N
serum NN N
to TO N
saliva VB N
ratios NNS N
have VBP N
been VBN N
established VBN N
, , N
the DT N
use NN N
of IN N
saliva JJ N
theophylline NN N
measurements NNS N
alone RB N
is VBZ N
unreliable JJ N
for IN N
the DT N
routine JJ N
monitoring NN N
of IN N
theophylline JJ N
therapy NN i
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
, , N
although IN N
the DT N
concentration NN N
of IN N
bupivacaine NN N
( ( N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
to TO N
minimize VB N
its PRP$ N
adverse JJ N
effects NNS N
, , N
if IN N
the DT N
infusion NN N
rate NN N
of IN N
a DT N
fentanyl/bupivacaine JJ N
solution NN N
was VBD N
closely RB N
adjusted VBN N
according VBG N
to TO N
need NN N
, , N
the DT N
presence NN N
bupivacaine NN N
would MD N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
. . N

Intervals NNS N
between IN N
calving VBG N
and CC N
first JJ N
oestrus NN N
, , N
first JJ N
insemination NN N
and CC N
conception NN N
, , N
the DT N
time NN N
of IN N
first JJ N
emergence NN N
of IN N
a DT N
dominant JJ N
follicle NN N
, , N
milk NN N
progesterone NN N
concentration NN N
, , N
and CC N
the DT N
diameter NN N
of IN N
the DT N
corpus NN N
luteum NN N
( ( N
CL NNP N
) ) N
in IN N
the DT N
first JJ N
luteal JJ N
phase NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effect NN N
of IN N
a DT N
nutritional JJ N
supplement NN N
containing VBG N
vitamin NN N
E NNP N
, , N
selenium NN N
, , N
vitamin FW N
C NNP N
and CC N
coenzyme JJ N
Q10 NNP N
on IN N
changes NNS N
in IN N
serum NN N
levels NNS N
of IN N
PSA NNP N
in IN N
patients NNS p
with IN N
hormonally RB N
untreated JJ N
carcinoma NN N
of IN N
the DT N
prostate NN N
and CC N
rising VBG N
serum NN N
PSA NNP N
levels NNS N
. . N

Although IN N
this DT N
test NN N
can MD N
evaluate VB N
their PRP$ N
physical JJ N
function NN N
using VBG N
movements NNS N
similar JJ N
to TO N
daily JJ N
activities NNS N
as IN N
compared VBN N
to TO N
MSL NNP N
, , N
it PRP N
has VBZ N
not RB N
been VBN N
clarified VBN N
whether IN N
it PRP N
can MD N
adequately RB N
evaluate VB N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
( ( N
ADL NNP N
) ) N
abilities NNS N
of IN N
the DT N
elderly JJ N
, , N
as IN N
they PRP N
decrease VBP o
with IN N
age NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
manualized JJ N
12-week JJ N
supportive-expressive JJ N
group NN N
therapy NN i
program NN N
among IN N
primary JJ N
breast NN N
cancer NN N
patients NNS p
treated VBN N
in IN N
community NN N
settings NNS N
, , N
to TO N
determine VB N
whether IN N
highly RB N
distressed JJ N
patients NNS p
were VBD N
most RBS N
likely JJ N
to TO N
benefit VB N
and CC N
whether IN N
therapist NN N
's POS N
training NN N
or CC N
experience NN N
was VBD N
related VBN N
to TO N
outcome VB N
. . N

Outcome NN N
parameters NNS N
such JJ N
as IN N
glycemic JJ N
control NN N
( ( N
HbA1c NNP N
) ) N
, , N
hypoglycemic JJ N
events NNS N
, , N
time NN N
and CC N
mode NN N
of IN N
delivery NN N
and CC N
labor NN N
results NNS N
( ( N
abortion NN N
, , N
premature NN N
labor NN N
, , N
perinatal JJ N
mortality NN N
, , N
neonatal JJ N
weight NN N
, , N
Apgar NNP N
score NN N
, , N
neonatal JJ N
hypoglycaemia NN N
, , N
presence NN N
of IN N
congenital JJ N
abnormalities NNS N
) ) N
were VBD N
analyzed VBN N
. . N

The DT N
intention-to-treat JJ N
analysis NN N
showed VBD N
no DT N
difference NN N
over IN N
the DT N
intervention NN N
year NN N
in IN N
the DT N
number NN N
of IN N
symptom JJ N
days NNS N
, , N
yet RB N
there EX N
was VBD N
a DT N
trend NN N
toward IN N
fewer JJR N
days NNS N
of IN N
limited JJ N
activity NN N
and CC N
a DT N
significant JJ N
decrease NN o
in IN N
emergency NN N
department NN N
visits NNS N
by IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
controls NNS N
. . N

RESULTS NNP N
Adjusting NNP N
for IN N
ethnicity/language NN N
, , N
study NN N
center NN N
, , N
and CC N
the DT N
previsit NN N
value NN N
of IN N
the DT N
dependent NN N
variable NN N
, , N
compared VBN N
with IN N
control NN N
patients NNS p
, , N
the DT N
IMCP NNP N
led VBD N
to TO N
significantly RB N
greater JJR N
colorectal JJ N
cancer NN N
screening VBG N
knowledge NN N
, , N
self-efficacy NN N
, , N
readiness NN N
, , N
test NN N
preference NN N
specificity NN N
, , N
discussion NN N
, , N
and CC N
recommendation NN N
. . N

A DT N
communication-based JJ N
intervention NN N
for IN N
nonverbal JJ N
children NNS N
with IN N
autism NN N
: : N
what WP N
changes NNS N
? . N
Who WP N
benefits NNS N
? . N
OBJECTIVE IN N
This DT N
article NN N
examines VBZ N
the DT N
form NN N
and CC N
function NN N
of IN N
spontaneous JJ N
communication NN N
and CC N
outcome NN N
predictors NNS N
in IN N
nonverbal JJ N
children NNS N
with IN N
autism NN N
following VBG N
classroom-based JJ N
intervention NN N
( ( N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
[ NNP N
PECS NNP N
] NNP N
training NN N
) ) N
. . N

The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
oxytocin NN i
enhances VBZ N
the DT N
ability NN N
to TO N
understand VB N
others NNS N
' POS N
social JJ N
emotions NNS N
that WDT N
have VBP N
also RB N
required VBN N
second-order NN N
false JJ N
belief NN N
rather RB N
than IN N
first-order JJ N
false JJ N
beliefs NNS N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
in IN N
autism NN N
spectrum NN N
disorder NN N
at IN N
both DT N
the DT N
behaviour NN N
and CC N
neural JJ N
levels NNS N
. . N

These DT N
patients NNS p
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT N
conventional JJ N
group NN N
, , N
in IN N
which WDT N
capillary JJ N
measurement NN N
and CC N
recording NN N
as RB N
well RB N
as IN N
insulin NN N
adjustment NN N
were VBD N
made VBN N
every DT N
4h CD N
, , N
and CC N
an DT N
intervention NN N
group NN N
, , N
in IN N
which WDT N
measurement NN N
and CC N
recording NN N
as RB N
well RB N
as IN N
insulin NN N
adjustment NN N
were VBD N
made VBN N
every DT N
hour NN N
with IN N
a DT N
subcutaneous JJ N
continuous JJ N
monitoring NN N
system NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
program NN N
of IN N
cooperation NN N
between IN N
physician NN N
and CC N
pharmacist NN N
to TO N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
in IN N
patients NNS p
with IN N
mild JJ N
to TO N
moderate VB N
hypertension NN N
by IN N
promoting VBG N
better JJR N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
control NN N
, , N
appropriate JJ N
changes NNS N
in IN N
antihypertensive JJ N
medications NNS N
, , N
and CC N
beneficial JJ N
changes NNS N
in IN N
lifestyle NN N
. . N

BACKGROUND NN N
It PRP N
has VBZ N
been VBN N
postulated VBN N
from IN N
virologic JJ N
studies NNS N
that WDT N
herpesvirus VBP N
infection NN N
could MD N
play VB N
a DT N
role NN N
in IN N
the DT N
progression NN N
of IN N
MS. NNP N
METHODS NNP N
Patients NNPS N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
had VBD N
had VBN N
two CD N
or CC N
more JJR N
MS JJ N
relapses NNS N
in IN N
the DT N
2-year JJ N
period NN N
before IN N
enrollment NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
utility NN N
and CC N
validity NN N
of IN N
clinician-rated JJ N
global JJ N
functioning NN N
using VBG N
the DT N
Developmental NNP N
Disability-Child NNP N
Global NNP N
Assessment NNP N
Scale NNP N
in IN N
a DT N
sample NN N
of IN N
higher JJR N
functioning NN N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
and CC N
comorbid NN N
anxiety NN N
disorders NNS N
enrolled VBD N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
. . N

OBJECTIVES NNP N
In IN N
comparison NN N
with IN N
usual JJ N
care NN N
( ( N
UC NNP N
) ) N
, , N
to TO N
assess VB N
the DT N
impact NN N
of IN N
GP-led NNP N
telephone NN N
triage NN N
( ( N
GPT NNP N
) ) N
and CC N
nurse-led JJ N
computer-supported JJ N
telephone NN N
triage NN N
( ( N
NT NNP N
) ) N
on IN N
primary JJ N
care NN N
workload NN N
and CC N
cost NN N
, , N
patient JJ N
experience NN N
of IN N
care NN N
, , N
and CC N
patient JJ N
safety NN N
and CC N
health NN N
status NN N
for IN N
patients NNS p
requesting VBG N
same-day JJ N
consultations NNS N
in IN N
general JJ N
practice NN N
. . N

Dietary NNP N
sulforaphane NN N
, , N
of IN N
recognized VBN N
low JJ N
toxicity NN N
, , N
was VBD N
selected VBN N
for IN N
its PRP$ N
capacity NN N
to TO N
reverse VB N
abnormalities NNS N
that WDT N
have VBP N
been VBN N
associated VBN N
with IN N
ASD NNP N
, , N
including VBG N
oxidative JJ N
stress NN N
and CC N
lower JJR N
antioxidant NN N
capacity NN N
, , N
depressed VBD N
glutathione NN N
synthesis NN N
, , N
reduced VBN N
mitochondrial JJ N
function NN N
and CC N
oxidative JJ N
phosphorylation NN N
, , N
increased VBD o
lipid JJ o
peroxidation NN N
, , N
and CC N
neuroinflammmation NN N
. . N

Analyses NNS N
reveal VBP N
that IN N
olanzapine NN N
shows VBZ N
a DT N
greater JJR N
clinical JJ N
cost NN N
effectiveness NN N
, , N
as RB N
well RB N
as IN N
a DT N
greater JJR N
functional JJ N
cost NN N
effectiveness NN N
, , N
than IN N
haloperidol NN N
, , N
and CC N
that IN N
functional JJ N
outcomes NNS N
, , N
in IN N
particular JJ N
, , N
show VBP N
promise NN N
as IN N
important JJ N
measures NNS N
of IN N
effectiveness NN N
. . N

By IN N
exploiting VBG N
the DT N
long JJ N
integration NN N
time NN N
of IN N
noisy JJ N
motion NN N
stimuli NN N
, , N
and CC N
by IN N
forcing VBG N
human JJ N
observers NNS N
to TO N
make VB N
difficult JJ N
speeded VBN N
decisions NNS N
-- : N
sometimes RB N
a DT N
blind JJ N
guess NN N
-- : N
about IN N
stimulus JJ N
direction NN N
, , N
we PRP N
traced VBD N
the DT N
temporal JJ N
buildup NN N
of IN N
motion NN N
discrimination NN N
capability NN N
and CC N
perceptual JJ N
awareness NN N
, , N
as IN N
assessed VBN N
trial NN N
by IN N
trial NN N
through IN N
direct JJ N
rating NN N
. . N

CONCLUSIONS NNP N
Although IN N
this DT N
multicenter NN N
RCT NNP N
was VBD N
conducted VBN N
in IN N
a DT N
strict JJ N
setting NN N
, , N
extended VBD N
lymphadenectomy NN N
in IN N
radical JJ N
PD NNP N
did VBD N
not RB N
benefit VB N
long-term JJ N
survival NN N
in IN N
patients NNS p
with IN N
resectable JJ N
pancreatic JJ N
head NN N
cancer NN N
and CC N
led VBD N
to TO N
levels NNS N
of IN N
morbidity NN N
, , N
mortality NN N
and CC N
quality NN N
of IN N
life NN N
comparable JJ N
to TO N
those DT N
found VBN N
after IN N
standard JJ N
lymphadenectomy NN N
. . N

Further JJ N
analysis NN N
( ( N
Manetl-Naenszel NNP N
test NN N
) ) N
showed VBD N
the DT N
over-all JJ N
difference NN N
in IN N
outcome NN N
to TO N
be VB N
significant JJ N
( ( N
P NNP N
= NNP N
0.049 CD N
) ) N
, , N
but CC N
the DT N
general JJ N
applicability NN N
of IN N
this DT N
result NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
rather RB N
low JJ N
incidence NN N
of IN N
gram-negative JJ N
bacterial JJ N
infections NNS N
in IN N
this DT N
study NN N
. . N

There EX N
was VBD N
some DT N
improvement NN N
in IN N
the DT N
prothrombin NN N
ratio NN N
in IN N
both DT N
groups NNS N
of IN N
patients NNS p
but CC N
not RB N
complete JJ N
correction NN N
, , N
and CC N
serial JJ N
assays NNS N
of IN N
clotting VBG N
factors NNS N
showed VBD N
that IN N
although IN N
factor NN N
II NNP N
rose VBD N
to TO N
high JJ N
levels NNS N
during IN N
treatment NN N
, , N
factors NNS N
IX NNP N
and CC N
X NNP N
showed VBD N
little JJ N
response NN N
. . N

Since IN N
GABAA-mediated NNP N
intracortical JJ N
inhibition NN N
has VBZ N
been VBN N
shown VBN N
to TO N
underlie VB N
plastic NN N
changes NNS N
throughout IN N
the DT N
lifespan NN N
from IN N
development NN N
to TO N
aging VBG N
, , N
here RB N
, , N
the DT N
aging VBG N
motor NN N
system NN N
was VBD N
used VBN N
as IN N
a DT N
model NN N
to TO N
analyze VB N
the DT N
interdependence NN N
of IN N
plastic JJ N
alterations NNS N
within IN N
the DT N
inhibitory JJ N
motorcortical JJ N
network NN N
and CC N
level NN N
of IN N
behavioral JJ N
performance NN N
. . N

BACKGROUND NNP N
Although IN N
some DT N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
pharmacist JJ N
intervention NN N
can MD N
improve VB N
drug NN N
therapy NN i
among IN N
patients NNS p
with IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
, , N
more JJR N
evidence NN N
derived VBN N
from IN N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCTs NNP N
) ) N
is VBZ N
needed VBN N
, , N
including VBG N
assessment NN N
of IN N
the DT N
effect NN N
of IN N
community NN N
pharmacist NN N
interventions NNS N
in IN N
patients NNS p
with IN N
CVD NNP N
. . N

Given VBN N
preclinical JJ N
studies NNS N
revealing VBG N
the DT N
role NN N
of IN N
the DT N
endogenous JJ N
opioid JJ N
systems NNS N
in IN N
human JJ N
appetite NN N
and CC N
the DT N
potential NN N
of IN N
antipsychotic JJ i
medications NNS N
to TO N
interfere VB N
with IN N
this DT N
system NN N
, , N
we PRP N
hypothesized VBD N
that IN N
opioid JJ N
antagonists NNS N
may MD N
be VB N
beneficial JJ N
in IN N
arresting VBG N
antipsychotic-associated JJ N
weight NN N
gain NN N
and CC N
promoting VBG N
further JJ N
weight JJ N
loss NN N
in IN N
women NNS N
with IN N
schizophrenia NN N
. . N

HDPM NNP N
at IN N
an DT N
average JJ N
dose NN N
of IN N
638.9 CD N
mg NN N
of IN N
pyridoxine NN i
and CC N
216.3 CD N
mg NN N
of IN N
magnesium NN N
oxide NN N
was VBD N
ineffective JJ N
in IN N
ameliorating VBG N
autistic JJ N
behaviors NNS N
as IN N
assessed VBN N
by IN N
the DT N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
, , N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
Scale NNP N
, , N
and CC N
the DT N
NIMH NNP N
Global NNP N
Obsessive NNP N
Compulsive NNP N
Scale NNP N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
bowel NN N
preparation NN N
protocols NNS N
based VBN N
on IN N
a DT N
low JJ N
residue JJ N
diet NN N
and CC N
4L CD N
polyethylene NN N
glycol NN N
( ( N
PEG NNP N
) ) N
solution NN N
, , N
and CC N
to TO N
compare VB N
these DT N
new JJ N
options NNS N
with IN N
the DT N
traditional JJ N
liquid NN N
diet NN N
and CC N
the DT N
PEG NNP N
4L CD N
lavage NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
The DT N
aim NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
fatty JJ N
fish NN N
and CC N
lean JJ N
( ( N
white JJ N
) ) N
fish NN N
on IN N
fatty JJ N
acid JJ N
composition NN N
of IN N
serum NN N
lipids NNS N
and CC N
cardiovascular JJ N
risk NN N
factors NNS N
in IN N
subjects NNS N
with IN N
CHD NNP N
using VBG N
multiple JJ N
drugs NNS N
for IN N
this DT N
condition NN N
. . N

Endpoint NN N
analysis NN N
revealed VBD N
no DT N
significant JJ N
differences NNS N
across IN N
treatment NN N
groups NNS N
on IN N
a DT N
modified JJ N
global JJ N
improvement NN N
scale NN N
( ( N
validated VBN N
in IN N
irritable JJ N
bowel NN N
syndrome JJ N
studies NNS N
) ) N
, , N
number NN N
of IN N
daily JJ N
bowel NN N
movements NNS N
, , N
days NNS N
of IN N
constipation NN N
, , N
or CC N
severity NN N
of IN N
problem NN N
behaviors NNS N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN i
plus CC N
standard NN N
wound NN N
care NN N
compared VBN N
with IN N
standard NN N
wound NN N
care NN N
alone RB N
in IN N
preventing VBG N
the DT N
need NN N
for IN N
major JJ N
amputation NN N
in IN N
patients NNS p
with IN N
diabetes NNS N
mellitus NNS N
and CC N
chronic JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
. . N

To TO N
investigate VB N
whether IN N
sensorimotor NN N
control NN N
of IN N
the DT N
hand NN N
could MD N
be VB N
an DT N
outcome NN N
indicator NN N
after IN N
carpal JJ N
tunnel NN N
release NN N
( ( N
CTR NNP N
) ) N
, , N
this DT N
work NN N
examined VBD N
changes NNS N
in IN N
the DT N
results NNS N
of IN N
patients NNS p
' POS N
manual JJ N
tactile NN N
test NN N
( ( N
MTT NNP N
) ) N
, , N
pinch-holding-up JJ N
activity NN N
( ( N
PHUA NNP N
) ) N
, , N
two-point JJ N
discrimination NN N
( ( N
2PD CD N
) ) N
and CC N
Semmes-Weinstein JJ N
monofilament NN N
( ( N
SWM NNP N
) ) N
tests NNS N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
by IN N
using VBG N
urn JJ N
design NN N
method NN N
either DT N
to TO N
receive VB N
the DT N
usual JJ N
care NN N
that WDT N
followed VBD N
in IN N
the DT N
clinics NNS N
( ( N
control NN N
) ) N
or CC N
the DT N
usual JJ N
care NN N
procedure NN N
plus CC N
extra JJ N
counselling NN N
sessions NNS N
through IN N
phone NN N
calls NNS N
during IN N
the DT N
first JJ N
month NN N
of IN N
quit NN N
attempt NN N
( ( N
intervention NN N
) ) N
. . N

While IN N
there EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
in IN N
sex NN N
, , N
age NN N
, , N
intellectual JJ N
disability NN N
, , N
language NN N
level NN N
, , N
or CC N
baseline VB N
ADHD NNP N
symptoms NNS N
, , N
autistic JJ N
symptoms NNS N
tended VBD N
to TO N
be VB N
more RBR N
prevalent JJ N
in IN N
the DT N
IED NNP N
group NN N
( ( N
according VBG N
to TO N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule-2 NNP N
criteria NNS N
) ) N
. . N

After IN N
discharge NN N
, , N
study NN N
controls NNS N
received VBD N
usual JJ N
care NN N
( ( N
sporadic JJ N
rehabilitation NN N
) ) N
, , N
whereas JJ N
intervention NN N
patients NNS p
received VBD N
a DT N
combination NN N
of IN N
in-home JJ N
cognitive NN N
, , N
physical JJ N
, , N
and CC N
functional JJ N
rehabilitation NN N
over IN N
a DT N
3-month JJ N
period NN N
via IN N
a DT N
social JJ N
worker NN N
or CC N
master NN N
's POS N
level NN N
psychology NN N
technician JJ N
utilizing JJ N
telemedicine NN N
to TO N
allow VB N
specialized JJ N
multidisciplinary JJ N
treatment NN N
. . N

Nevertheless RB N
, , N
DBT NNP N
showed VBD N
significant JJ N
benefits NNS N
for IN N
the DT N
secondary JJ N
outcomes NNS N
of IN N
improved JJ N
disability NN N
and CC N
quality NN N
of IN N
life NN N
scores NNS N
, , N
a DT N
clinically RB N
useful JJ N
result NN N
that WDT N
is VBZ N
also RB N
in IN N
keeping VBG N
with IN N
the DT N
theoretical JJ N
constructs NNS N
of IN N
the DT N
benefits NNS N
of IN N
DBT NNP N
. . N

OBJECTIVE IN N
This DT N
exploratory NN N
study NN N
focuses VBZ N
on IN N
the DT N
mental JJ N
health NN N
( ( N
MH NNP N
) ) N
and CC N
caregiving VBG N
experience NN N
of IN N
carers NNS N
of IN N
adolescents NNS N
with IN N
Bulimia NNP N
Nervosa NNP N
( ( N
BN NNP N
) ) N
/Eating VBG N
Disorder NNP N
not RB N
otherwise RB N
specified VBN N
( ( N
EDNOS NNP N
) ) N
, , N
aiming VBG N
to TO N
determine VB N
: : N
levels NNS N
of IN N
MH NNP N
problems NNS N
in IN N
carers NNS N
and CC N
if IN N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
predicts NNS N
carer VBP N
MH NNP N
status NN N
and CC N
which WDT N
factors NNS N
predict VBP N
a DT N
negative JJ N
experience NN N
of IN N
caregiving NN N
. . N

If IN N
people NNS N
are VBP N
indeed RB N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
these DT N
kinds NNS N
of IN N
outcomes NNS N
, , N
then RB N
lowering VBG N
behavioral JJ N
inhibition NN N
by IN N
reminding VBG N
people NNS N
of IN N
having VBG N
acted VBN N
in IN N
the DT N
past NN N
without IN N
inhibitions NNS N
( ( N
in IN N
a DT N
manner NN N
that WDT N
is VBZ N
unrelated JJ N
to TO N
the DT N
outcomes NNS N
participants NNS N
subsequently RB N
receive VBP N
) ) N
should MD N
affect VB N
reactions NNS N
to TO N
the DT N
outcomes NNS N
. . N

The DT N
primary JJ N
outcome NN N
, , N
knowledge NN N
of IN N
benefits NNS N
and CC N
harms NNS N
of IN N
screening NN N
, , N
and CC N
secondary JJ N
outcomes NNS N
, , N
informed VBN N
choice NN N
( ( N
composite JJ N
of IN N
knowledge NN N
, , N
values NNS N
and CC N
intention NN N
) ) N
, , N
anxiety NN N
and CC N
acceptability NN N
of IN N
the DT N
DA NNP N
were VBD N
measured VBN N
using VBG N
online JJ N
questionnaires NNS N
. . N

Investigators NNS N
examined VBD N
the DT N
6-month JJ N
impact NN N
of IN N
three CD N
cognitive-behavioral JJ N
HIV NNP N
risk-reduction NN N
programs NNS N
on IN N
behavioral JJ N
factors NNS N
( ( N
substance NN N
use NN N
and CC N
sexual JJ N
risk NN N
behaviors NNS N
) ) N
and CC N
cognitive JJ N
and CC N
psychological JJ N
resources NNS N
of IN N
325 CD N
women NNS N
who WP N
resided VBD N
in IN N
emergency NN N
or CC N
sober-living NN N
shelters NNS N
and CC N
their PRP$ N
308 CD N
intimate JJ N
sexual JJ N
partners NNS N
. . N

An DT N
alternative JJ N
stepwise NN N
model NN N
selection NN N
process NN N
including VBG N
all DT N
fever-related JJ N
measures NNS N
from IN N
the DT N
preoperative NN N
and CC N
intraoperative JJ N
period NN N
( ( N
e.g JJ N
, , N
hydrocephalus JJ N
, , N
duration NN N
of IN N
surgery NN N
, , N
intraoperative JJ N
blood NN N
loss NN N
) ) N
resulted VBD N
in IN N
the DT N
loss NN N
of IN N
significance NN N
for IN N
dichotomized JJ N
Glasgow NNP N
Outcome NNP N
Scale NNP N
, , N
but CC N
significant JJ N
associations NNS N
between IN N
fever NN N
and CC N
several JJ N
other JJ N
outcome JJ N
measures NNS N
remained VBD N
. . N

DISCUSSION NN N
This DT N
study NN N
has VBZ N
the DT N
potential NN N
to TO N
determine VB N
whether IN N
outpatient JJ N
movement NN N
strategy NN N
training NN N
combined VBN N
with IN N
falls NNS N
prevention JJ N
education NN N
or CC N
progressive JJ N
resistance NN N
strength NN N
training NN N
combined VBN N
with IN N
falls NNS N
prevention JJ N
education NN N
are VBP N
effective JJ N
for IN N
reducing VBG N
falls NNS N
and CC N
improving VBG N
mobility NN N
and CC N
life NN N
quality NN N
in IN N
people NNS N
with IN N
Parkinson NNP N
's POS N
disease NN N
who WP N
live VBP N
at IN N
home NN N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
the DT N
Dader NNP N
Method NNP N
for IN N
pharmaceutical JJ N
care NN N
on IN N
achieving VBG N
therapeutic JJ N
goals NNS N
for IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
and CC N
both DT N
BP NNP N
and CC N
TC NNP N
( ( N
BP/TC NNP N
) ) N
in IN N
patients NNS p
with IN N
CVD NNP N
and/or VBP N
high JJ N
or CC N
intermediate JJ N
cardiovascular NN N
( ( N
CV NNP N
) ) N
risk NN N
attending VBG N
community NN N
pharmacies NNS N
in IN N
Spain NNP N
. . N

CONCLUSIONS NN N
In IN N
this DT N
study NN N
, , N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
was VBD N
more RBR N
effective JJ N
than IN N
small JJ N
group NN N
nutrition NN N
education NN N
in IN N
improving VBG N
the DT N
short-term JJ N
fruit NN N
intake VB N
behaviour NN N
, , N
and CC N
as IN N
effective JJ N
in IN N
improving VBG N
saturated VBN N
fat JJ N
intake NN N
of IN N
middle-aged JJ N
adults NNS N
with IN N
cardiovascular JJ N
risk NN N
factors NNS N
. . N

CONCLUSION NNP N
Orally NNP N
administered VBD N
misoprostol NN N
at IN N
a DT N
dose NN N
of IN N
400 CD N
mug NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
in IN N
preventing VBG N
post-partum JJ N
blood NN N
loss NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
peri-partum JJ N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increased JJ o
incidence NN N
of IN N
side NN N
effects NNS N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
designed VBD N
a DT N
small JJ N
semi-randomized JJ N
clinical JJ N
trial NN N
to TO N
explore VB N
whether IN N
long-lasting JJ N
clinically RB N
important JJ N
gains NNS N
can MD N
be VB N
achieved VBN N
by IN N
adding VBG N
theta JJ N
burst JJ N
stimulation NN N
( ( N
TBS NNP N
) ) N
, , N
a DT N
form NN N
of IN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
TMS NNP N
) ) N
, , N
to TO N
a DT N
rehabilitation NN N
program NN N
for IN N
the DT N
hand NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
, , N
Be NNP N
In IN N
CHARGE NNP N
! . N
, , N
compared VBN N
with IN N
that DT N
of IN N
a DT N
nutrition NN N
education NN N
intervention NN N
alone RB N
on IN N
caloric JJ N
intake NN N
and CC N
weight JJ N
gain NN N
in IN N
children NNS N
with IN N
cystic JJ N
fibrosis NN N
and CC N
pancreatic JJ N
insufficiency NN N
. . N

Although IN N
various JJ N
pharmaceutical JJ N
agents NNS N
are VBP N
available JJ N
for IN N
the DT N
treatment NN N
of IN N
obsessive-compulsive JJ N
disorder NN N
, , N
psychiatrists NNS N
often RB N
find VBP N
that IN N
many JJ N
patients NNS p
can MD N
not RB N
tolerate VB N
the DT N
side NN N
effects NNS N
of IN N
these DT N
medications NNS N
, , N
the DT N
patients NNS p
do VBP N
not RB N
respond VB N
properly RB N
to TO N
the DT N
treatment NN N
, , N
or CC N
the DT N
medications NNS N
lose VBP N
their PRP$ N
effectiveness NN N
after IN N
a DT N
period NN N
of IN N
treatment NN N
. . N

On IN N
the DT N
contrary JJ N
, , N
naltrexone RB N
increased VBD o
the DT o
incidence NN N
of IN N
stereotypic JJ N
behavior NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
, , N
and CC N
the DT N
care NN N
staff NN N
evaluated VBD N
the DT N
effect NN N
of IN N
the DT N
50-mg/d JJ N
treatment NN N
as IN N
being VBG N
significantly RB N
worse JJR N
than IN N
that DT N
of IN N
the DT N
placebo NN N
treatment NN N
as IN N
measured VBN N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
Scale NNP N
. . N

On IN N
the DT N
basis NN N
of IN N
these DT N
results NNS N
, , N
having VBG N
studied VBN N
the DT N
particular JJ N
mechanism NN N
of IN N
action NN N
of IN N
propionyl-L-carnitine NN N
the DT N
authors NNS N
conclude VBP N
that IN N
it PRP N
represents VBZ N
a DT N
drug NN N
of IN N
undoubted JJ N
therapeutic JJ N
interest NN N
in IN N
patients NNS p
with IN N
congestive JJ N
heart NN N
failure NN N
, , N
in IN N
whom WP N
it PRP N
could MD N
be VB N
efficaciously RB N
administered VBN N
along IN N
with IN N
a DT N
standard JJ N
pharmacological JJ N
therapy NN i
. . N

The DT N
achievement NN N
of IN N
learning VBG N
objectives NNS N
was VBD N
predicted VBN N
by IN N
caregiver NN N
factors NNS N
, , N
such JJ N
as IN N
education NN N
, , N
presence NN N
of IN N
father NN N
or CC N
surrogate VB N
father NN N
in IN N
the DT N
household NN N
, , N
and CC N
safety NN N
of IN N
the DT N
neighborhood NN N
, , N
but CC N
not RB N
by IN N
child JJ N
factors NNS N
, , N
such JJ N
as IN N
age NN N
or CC N
severity NN N
of IN N
asthma NN N
as IN N
implied VBN N
by IN N
the DT N
prescribed JJ N
asthma JJ N
medication NN N
regimen NNS N
. . N

Recently RB N
, , N
a DT N
new JJ N
form NN N
of IN N
treatment NN N
based VBN N
on IN N
porphobilinogen NN N
deaminase NN N
enzyme JJ N
replacement NN N
therapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
an DT N
acute JJ N
intermittent NN N
porphyria NN N
mouse NN N
model NN N
which WDT N
, , N
during IN N
phenobarbital JJ N
( ( N
phenobarbitone NN N
) ) N
induction NN N
of IN N
haem JJ N
biosynthesis NN N
, , N
mimics VBZ N
the DT N
biochemical JJ N
pattern NN N
of IN N
acute JJ N
porphyric JJ N
attacks NNS N
. . N

Taken VBN N
together RB N
, , N
this DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
show VB N
that IN N
the DT N
perceived VBN N
hedonic JJ N
value NN N
of IN N
human JJ N
heterosexual JJ N
interpersonal JJ N
touch NN N
is VBZ N
facilitated VBN N
by IN N
OXT NNP N
in IN N
men NNS N
, , N
but CC N
that IN N
its PRP$ N
behavioral JJ N
and CC N
neural JJ N
effects NNS N
in IN N
this DT N
context NN N
are VBP N
blunted VBN N
in IN N
individuals NNS N
with IN N
autistic JJ N
traits NNS N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
a DT N
significant JJ N
deterioration NN N
of IN N
the DT N
indices NNS N
, , N
with IN N
the DT N
exception NN N
of IN N
Valsalva NNP N
ratio NN N
, , N
was VBD N
recorded VBN N
, , N
while IN N
tolrestat NN N
induced VBD N
a DT N
significant JJ N
beneficial JJ N
change NN N
in IN N
the DT N
values NNS N
of IN N
most JJS N
standard JJ N
cardiovascular JJ N
reflex NN N
tests NNS N
, , N
in IN N
comparison NN N
to TO N
baseline VB N
and CC N
placebo VB N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
fibromyalgia JJ N
severity NN N
, , N
pain NN N
interference NN N
, , N
sleep JJ N
quality NN N
, , N
pain VBP N
coping VBG N
strategies NNS N
, , N
depression NN N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
patient JJ N
global JJ N
impression NN N
of IN N
change NN N
( ( N
PGIC NNP N
) ) N
, , N
and CC N
perceived VBD N
pain NN N
relief NN N
. . N

This DT N
study NN N
evaluates VBZ N
the DT N
effectiveness NN N
of IN N
an DT N
intervention NN N
package NN N
including VBG N
a DT N
discrete JJ N
trial NN N
program NN N
( ( N
Rapid NNP N
Motor NNP N
Imitation NNP N
Antecedent NNP N
Training NNP N
( ( N
Tsiouri NNP N
and CC N
Greer NNP N
, , N
J NNP N
Behav NNP N
Educat NNP N
12:185-206 CD N
, , N
2003 CD N
) ) N
combined VBN N
with IN N
parent NN N
education NN N
for IN N
eliciting VBG N
first JJ N
words NNS N
in IN N
children NNS N
with IN N
ASD NNP N
who WP N
had VBD N
little JJ N
or CC N
no DT N
spoken JJ N
language NN N
. . N

BACKGROUND NNP N
Coronary NNP N
artery NN N
bypass NN N
graft NN N
( ( N
CABG NNP N
) ) N
surgery NN N
is VBZ N
effective JJ N
in IN N
relieving VBG N
angina NN N
and CC N
improving VBG N
survival NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN N
obstructive JJ N
coronary JJ N
artery NN N
disease NN N
; : N
however RB N
, , N
recurrent JJ N
angina NN N
, , N
myocardial JJ N
infarction NN N
, , N
neurological JJ N
injury NN N
, , N
and CC N
death NN N
can MD N
occur VB N
in IN N
the DT N
perioperative NN N
and CC N
postoperative JJ N
period NN N
. . N

Secondary JJ N
analyses NNS N
revealed VBD N
that IN N
the DT N
WSTP NNP N
had VBD N
greater JJR N
effects NNS N
on IN N
confidence NN N
in IN N
areas NNS N
related VBN N
to TO N
maneuvering VBG N
around IN N
the DT N
physical JJ N
environment NN N
, , N
knowledge NN N
and CC N
problem NN N
solving NN N
, , N
advocacy NN N
, , N
and CC N
managing VBG N
emotions NNS N
than IN N
in IN N
areas NNS N
related VBN N
to TO N
performing VBG N
activities NNS N
and CC N
behaving VBG N
in IN N
social JJ N
situations NNS N
. . N

Six CD N
of IN N
the DT N
seven CD N
secondary JJ N
efficacy NN N
measures NNS N
( ( N
total JJ N
comedones NNS N
, , N
open JJ N
comedones NNS N
, , N
closed VBD N
comedones NNS N
, , N
papules NNS N
, , N
pustules NNS N
, , N
and CC N
the DT N
subject NN N
's POS N
self-assessment NN N
of IN N
study NN N
treatment NN N
) ) N
were VBD N
also RB N
significantly RB N
more RBR N
favorable JJ N
in IN N
the DT N
OC NNP N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
most RBS N
salient JJ N
feature NN N
in IN N
the DT N
verum NN N
group NN N
was VBD N
a DT N
drastic JJ N
increase NN o
in IN N
the DT N
absolute JJ N
number NN N
of IN N
immunocompetent JJ N
cells NNS N
, , N
with IN N
an DT N
especially RB N
pronounced JJ N
effect NN N
on IN N
T NNP N
lymphocytes NNS N
, , N
predominantly RB N
of IN N
the DT N
helper/inducer NN N
type NN N
, , N
but CC N
also RB N
on IN N
cytotoxic NN N
and CC N
natural JJ N
killer NN N
cells NNS N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
anastomotic JJ i
leakage NN N
, , N
local JJ N
and CC N
systemic JJ N
inflammation NN N
, , N
( ( N
aspiration NN N
) ) N
pneumonia NN N
, , N
surgical JJ N
complications NNS N
classified VBD N
according VBG N
to TO N
Clavien-Dindo NNP N
, , N
quality NN N
of IN N
life NN N
, , N
gut FW N
barrier JJR N
integrity NN N
and CC N
time NN N
until IN N
functional JJ N
recovery NN N
. . N

Action NNP N
observation NN N
treatment NN N
improves VBZ N
recovery NN N
of IN N
postsurgical JJ N
orthopedic JJ N
patients NNS p
: : N
evidence NN N
for IN N
a DT N
top-down JJ N
effect NN N
? . N
OBJECTIVE UH N
To TO N
assess VB N
whether IN N
action NN N
observation NN N
treatment NN N
( ( N
AOT NNP N
) ) N
may MD N
also RB N
improve VB N
motor NN N
recovery NN N
in IN N
postsurgical JJ N
orthopedic JJ N
patients NNS p
, , N
in IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN i
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
on IN N
the DT N
administration NN N
of IN N
GnRH NNP N
analogue NN N
to TO N
females NNS N
with IN N
myomas NN N
suggest VBP N
that IN N
no DT N
direct JJ N
or CC N
immediate JJ N
inter-relationship JJ N
exists NNS N
between IN N
expression NN N
of IN N
leptin NN i
genes NNS N
in IN N
uterine JJ N
myomas NN N
on IN N
one CD N
hand NN N
and CC N
estrogen NN N
, , N
progesterone NN N
and CC N
leptin NN i
levels NNS N
in IN N
the DT N
blood NN N
on IN N
the DT N
other JJ N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
dialysis NN N
with IN N
polyamide JJ N
membranes NNS N
with IN N
different JJ N
flux NN N
characteristics NNS N
did VBD N
not RB N
modify VB N
the DT N
inflammatory NN N
indices NNS N
and CC N
lipid JJ N
profile NN N
in IN N
stable JJ N
HD NNP N
patients NNS p
; : N
however RB N
, , N
a DT N
seemingly RB N
beneficial JJ N
effect NN N
on IN N
aortic JJ N
stiffness NN N
was VBD N
noted VBN N
for IN N
patients NNS p
who WP N
were VBD N
maintained VBN N
on IN N
high-flux JJ N
polyamide NN N
membrane NN N
. . N

In IN N
the DT N
current JJ N
article NN N
, , N
we PRP N
address VBP N
the DT N
existing VBG N
assumption NN N
in IN N
the DT N
literature NN N
on IN N
cognitive JJ N
behavioral JJ N
treatment NN N
of IN N
PTSD NNP N
that IN N
patients NNS p
with IN N
severe JJ N
negative JJ N
trauma-related JJ N
cognitions NNS N
would MD N
benefit VB N
more RBR N
from IN N
a DT N
treatment NN N
package NN N
that WDT N
includes VBZ N
exposure NN N
and CC N
cognitive JJ N
techniques NNS N
compared VBN N
with IN N
a DT N
treatment NN N
that WDT N
includes VBZ N
exposure NN N
only RB N
. . N

INTRODUCTION NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
low-intensity JJ N
resistance NN N
training NN N
program NN N
combined VBN N
with IN N
partial JJ N
blow NN N
flow NN N
restriction NN N
( ( N
BFR NNP N
training NN N
) ) N
in IN N
a DT N
cohort NN N
of IN N
patients NNS p
with IN N
polymyositis NN N
( ( N
PM NNP N
) ) N
and CC N
dermatomyositis NN N
( ( N
DM NNP N
) ) N
. . N

Changes NNS N
in IN N
motor NN N
cortex NN N
excitability NN N
associated VBN N
with IN N
temporal JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
in IN N
tinnitus NN N
: : N
hints NNS N
for IN N
cross-modal JJ N
plasticity NN N
? . N
BACKGROUND NNP N
Motor NNP N
cortex VBP N
excitability NN N
was VBD N
found VBN N
to TO N
be VB N
changed VBN N
after IN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
of IN N
the DT N
temporal JJ N
cortex NN N
highlighting VBG N
the DT N
occurrence NN N
of IN N
cross-modal JJ N
plasticity NN N
in IN N
non-invasive JJ N
brain NN N
stimulation NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
Cavitron NNP N
ultrasonic JJ N
surgical JJ N
aspirator NN N
( ( N
CUSA NNP N
) ) N
with IN N
bipolar JJ N
cautery NN N
( ( N
BP NNP N
) ) N
to TO N
CUSA NNP N
with IN N
a DT N
radiofrequency NN N
coagulator NN N
[ NN N
TissueLink NNP N
( ( N
TL NNP N
) ) N
] VBP N
in IN N
terms NNS N
of IN N
efficacy NN N
and CC N
safety NN N
for IN N
hepatic JJ N
transection NN N
in IN N
living VBG N
donor NN N
liver JJ N
transplantation NN N
. . N

The DT N
trial NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
Asha-Life NNP N
intervention NN N
engaging VBG N
with IN N
an DT N
HIV-trained JJ N
village NN N
woman NN N
, , N
Asha NNP N
( ( N
Accredited NNP N
Social NNP N
Health NNP N
Activist NNP N
) ) N
, , N
to TO N
participate VB N
in IN N
the DT N
care NN N
of IN N
women NNS N
living VBG N
with IN N
AIDS NNP N
( ( N
WLA NNP N
) ) N
, , N
along IN N
with IN N
other JJ N
health NN N
care NN N
providers NNS N
compared VBN N
to TO N
a DT N
Usual NNP N
Care NNP N
group NN N
. . N

The DT N
overall JJ i
main JJ N
reason NN N
for IN N
sunbathing NN N
was VBD N
appearance NN N
, , N
both DT N
for IN N
own JJ N
sunbathing NN N
, , N
and CC N
to TO N
an DT N
even RB N
higher JJR N
degree NN N
, , N
as IN N
a DT N
supposed JJ N
reason NN N
for IN N
other JJ N
adolescents NNS N
' POS N
behaviour NN N
, , N
and CC N
was VBD N
reported VBN N
most JJS N
frequently RB N
by IN N
girls NNS N
and CC N
the DT N
older JJR N
age NN N
groups NNS N
. . N

To TO N
test VB N
elements NNS N
of IN N
this DT N
hypothesis NN N
, , N
we PRP N
have VBP N
measured VBN N
blood NN N
levels NNS N
of IN N
dietary JJ N
antioxidants NNS N
, , N
and CC N
8-oxodeoxyguanosine JJ N
( ( N
8-oxo-dG JJ N
) ) N
concentrations NNS N
in IN N
lymphocyte NN N
DNA NN N
, , N
in IN N
healthy JJ N
men NNS N
and CC N
women NNS N
from IN N
five CD N
European JJ N
countries NNS N
: : N
France NNP N
, , N
Ireland NNP N
, , N
The DT N
Netherlands NNP N
, , N
Spain NNP N
, , N
and CC N
the DT N
U.K NNP N
. . N

Unlike IN N
other JJ N
sedatives NNS N
and CC N
anesthetics NNS N
, , N
the DT N
concentration-dependence NN N
of IN N
clonidine NN N
demonstrates VBZ N
a DT N
ceiling NN N
beyond IN N
which WDT N
the DT N
administration NN N
of IN N
an DT N
additional JJ N
drug NN N
fails NNS N
to TO N
enhance VB N
the DT N
effect NN N
, , N
suggesting VBG N
that IN N
the DT N
thermoregulatory JJ N
effect NN N
of IN N
clonidine NN N
may MD N
be VB N
limited VBN N
, , N
even RB N
at IN N
high JJ N
plasma NN N
concentrations NNS N
. . N

INTERPRETATION NNP N
AND NNP N
CONCLUSIONS NNP N
Increasing VBG N
the DT N
dose NN N
of IN N
G-CSF NNP N
does VBZ N
not RB N
appear VB N
to TO N
reduce VB N
early JJ N
deaths NNS N
, , N
does VBZ N
not RB N
improve VB N
peripheral JJ N
blood NN N
counts NNS N
nor CC N
survival NN N
, , N
and CC N
may MD N
reduce VB N
the DT N
response NN N
rate NN N
in IN N
patients NNS p
with IN N
SAA NNP N
receiving VBG N
ALG NNP N
and CC N
CyA NNP N
. . N

Only RB N
14 CD N
% NN N
of IN N
youth NN N
with IN N
ASD NNP N
had VBD N
a DT N
discussion NN N
with IN N
their PRP$ N
pediatrician JJ N
about IN N
transitioning VBG N
to TO N
an DT N
adult NN N
provider NN N
, , N
less JJR N
than IN N
a DT N
quarter NN N
had VBD N
a DT N
discussion NN N
about IN N
health NN N
insurance NN N
retention NN N
, , N
and CC N
just RB N
under IN N
half NN N
discussed VBN N
adult NN N
health NN N
care NN N
needs NNS N
or CC N
were VBD N
encouraged VBN N
to TO N
take VB N
on IN N
appropriate JJ N
responsibility NN N
. . N

The DT N
present JJ N
study NN N
aims NNS N
to TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
traditional JJ N
Chinese JJ N
Chan-based JJ N
mind-body NN N
exercise NN N
, , N
Nei NNP N
Yang NNP N
Gong NNP N
, , N
with IN N
that DT N
of IN N
the DT N
conventional JJ N
Progressive NNP N
Muscle NNP N
Relaxation NNP N
( ( N
PMR NNP N
) ) N
technique NN N
in IN N
enhancing VBG N
the DT N
self-control NN N
of IN N
children NNS N
with IN N
ASD NNP N
. . N

In IN N
terms NNS N
of IN N
advancement NN N
of IN N
prostate NN N
cancer NN N
care NN N
, , N
we PRP N
expect VBP N
dissemination NN N
of IN N
the DT N
knowledge NN N
gained VBN N
from IN N
this DT N
project NN N
to TO N
reduce VB N
fracture NN N
risk NN N
, , N
improve VB N
physical JJ N
and CC N
functional JJ N
ability NN N
, , N
quality NN N
of IN N
life NN N
and CC N
ultimately RB N
survival JJ N
rate NN N
in IN N
this DT N
population NN N
. . N

A DT N
cross-over JJ N
design NN N
was VBD N
used VBN N
to TO N
answer VB N
the DT N
following JJ N
research NN N
questions NNS N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
virtual JJ N
reality NN N
an DT N
effective JJ N
distraction NN N
intervention NN N
for IN N
reducing VBG N
chemotherapy-related JJ i
symptom NN N
distress NN N
levels NNS N
in IN N
older JJR N
women NNS N
with IN N
breast NN N
cancer NN N
? . N
( ( N
2 CD N
) ) N
Does NNP N
virtual JJ N
reality NN N
have VBP N
a DT N
lasting JJ N
effect NN N
? . N
Chemotherapy NN i
treatments NNS N
are VBP N
intensive JJ N
and CC N
difficult JJ N
to TO N
endure VB N
. . N

IMPORTANCE IN N
The DT N
prevalence NN N
of IN N
psychological JJ N
distress NN N
among IN N
mothers NNS N
of IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
suggests VBZ N
a DT N
need NN N
for IN N
interventions NNS N
that WDT N
address VBP N
parental JJ N
mental JJ N
health NN N
during IN N
the DT N
critical JJ N
period NN N
after IN N
the DT N
child NN N
's POS N
autism NN N
diagnosis NN N
when WRB N
parents NNS N
are VBP N
learning VBG N
to TO N
navigate VB N
the DT N
complex JJ N
system NN N
of IN N
autism NN N
services NNS N
. . N

The DT N
main JJ N
intervention NN N
strategies NNS N
were VBD N
: : N
information NN N
about IN N
the DT N
risk NN N
factor NN N
concept NN N
to TO N
participant VB N
and CC N
spouse VB N
( ( N
in IN N
groups NNS N
) ) N
individual VBP N
diet JJ N
and CC N
anti-smoking JJ N
counselling NN N
after IN N
finishing VBG N
an DT N
extensive JJ N
clinical JJ N
and CC N
electrocardiographic JJ N
examination NN N
, , N
including VBG N
exercise-ECG JJ N
basis NN N
and CC N
background NN N
for IN N
the DT N
counselling NN N
strategy NN N
: : N
the DT N
total JJ N
situation NN N
of IN N
the DT N
participant NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
an DT N
alteration NN N
of IN N
the DT N
writing VBG N
movement NN N
representation NN N
at IN N
a DT N
central JJ N
level NN N
and CC N
are VBP N
consistent JJ N
with IN N
the DT N
view NN N
that IN N
dystonia NN N
is VBZ N
not RB N
a DT N
purely RB N
motor NN N
disorder NN N
, , N
but CC N
it PRP N
also RB N
involves VBZ N
non-motor NN N
( ( N
sensory JJ N
, , N
cognitive JJ N
) ) N
aspects NNS N
related VBN N
to TO N
movement NN N
processing NN N
and CC N
planning NN N
. . N

The DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
plasma-derived JJ N
heat-inactivated JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
CLB NNP N
) ) N
were VBD N
evaluated VBN N
in IN N
471 CD N
healthy JJ N
human JJ N
volunteers NNS N
, , N
who WP N
, , N
both DT N
in IN N
their PRP$ N
occupations NNS N
and CC N
in IN N
their PRP$ N
private JJ N
lives NNS N
, , N
had VBD N
been VBN N
at IN N
minimal JJ N
risk NN N
of IN N
being VBG N
infected VBN N
with IN N
hepatitis NN N
B NNP N
virus NN N
. . N

CONCLUSIONS NNP N
Seeking NNP N
evidence NN N
for IN N
a DT N
possibly RB N
effective JJ N
adjunct NN N
to TO N
traditional JJ N
behavioral JJ N
approaches NNS N
for IN N
treatment NN N
of IN N
MA NNP N
dependence NN N
, , N
this DT N
study NN N
is VBZ N
assessing VBG N
the DT N
ability NN N
of IN N
an DT N
8-week JJ N
aerobic NN N
and CC N
resistance NN N
exercise NN N
protocol NN N
to TO N
reduce VB N
relapse NN N
to TO N
MA NNP N
use NN N
during IN N
a DT N
12-week JJ N
follow-up JJ N
period NN N
after IN N
discharge NN N
from IN N
residential-based JJ N
treatment NN N
. . N

OBJECTIVE NN N
To TO N
explore VB N
the DT N
association NN N
of IN N
a DT N
functional JJ N
germline NN N
variant NN N
in IN N
the DT N
3'-UTR CD N
of IN N
KRAS NNP N
with IN N
endometrial JJ N
cancer NN N
risk NN N
, , N
as RB N
well RB N
as IN N
the DT N
association NN N
of IN N
microRNA NN N
( ( N
miRNA NN N
) ) N
signatures NNS N
and CC N
the DT N
KRAS-variant NNP N
with IN N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
outcomes NNS N
in IN N
two CD N
prospective JJ N
RTOG NNP N
endometrial JJ N
cancer NN N
trials NNS N
. . N

DISCUSSION NN N
Because IN N
this DT N
study NN N
is VBZ N
expected VBN N
to TO N
yield VB N
evidence NN N
regarding VBG N
the DT N
selection NN N
of IN N
antipsychotics NNS N
for IN N
facilitating VBG N
the DT N
recovery NN N
of IN N
social JJ N
activity NN N
in IN N
patients NNS p
with IN N
schizophrenia NN N
, , N
it PRP N
is VBZ N
considered VBN N
highly RB N
valuable JJ N
to TO N
perform VB N
this DT N
effectiveness NN N
study NN N
under IN N
ordinary JJ N
healthcare NN N
setting VBG N
in IN N
Japan NNP N
. . N

AIMS NNP N
To TO N
assess VB N
if IN N
raising VBG N
concentrations NNS N
of IN N
crude NN N
protein NN N
( ( N
CP NNP N
) ) N
in IN N
pasture NN N
in IN N
spring NN N
by IN N
the DT N
frequent JJ N
application NN N
of IN N
urea JJ N
fertiliser NN N
would MD N
affect VB N
ovarian JJ N
follicular JJ N
dynamics NNS N
, , N
luteal JJ N
function NN N
, , N
onset NN N
of IN N
oestrus NN N
and CC N
reproductive JJ N
performance NN N
of IN N
dairy NN N
cows NNS N
under IN N
farming VBG N
conditions NNS N
in IN N
New NNP N
Zealand NNP N
. . N

The DT N
current JJ N
study NN N
examined VBD N
the DT N
relationship NN N
between IN N
multisensory JJ N
temporal JJ N
processing NN N
( ( N
assessed JJ N
via IN N
a DT N
simultaneity NN N
judgment NN N
task NN N
wherein NN N
participants NNS N
were VBD N
to TO N
report VB N
whether IN N
a DT N
visual JJ N
stimulus NN N
and CC N
an DT N
auditory JJ N
stimulus NN N
occurred VBD N
at IN N
the DT N
same JJ N
time NN N
or CC N
at IN N
different JJ N
times NNS N
) ) N
and CC N
self-reported JJ N
symptoms NNS N
of IN N
autism NN N
( ( N
assessed JJ N
via IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
questionnaire NN N
) ) N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
short-term JJ N
effect NN N
of IN N
a DT N
mixed JJ N
Kinesio NNP N
taping NN N
( ( N
KT NNP N
) ) N
model NN N
on IN N
range NN N
of IN N
ankle JJ N
motion NN N
( ( N
ROAM NNP N
) ) N
, , N
gait NN N
, , N
pain NN N
, , N
perimeter NN N
of IN N
lower JJR N
limbs NN N
, , N
and CC N
quality NN N
of IN N
life NN N
in IN N
postmenopausal JJ N
women NNS N
with IN N
chronic JJ N
venous JJ N
insufficiency NN N
( ( N
CVI NNP N
) ) N
. . N

To TO N
further RBR N
unravel VB N
this DT N
paradoxical JJ N
metabolic JJ N
condition NN N
, , N
and CC N
in IN N
search NN N
of IN N
potential JJ N
therapeutic JJ N
strategies NNS N
, , N
we PRP N
measured VBD N
serum JJ N
concentrations NNS N
of IN N
leptin NN i
; : N
studied VBD N
the DT N
relationship NN N
with IN N
body NN N
mass NN N
index NN N
, , N
insulin NN N
, , N
cortisol NN N
, , N
thyroid JJ N
hormones NNS N
, , N
and CC N
somatomedins NNS N
; : N
and CC N
documented VBD N
the DT N
effects NNS N
of IN N
hypothalamic JJ N
releasing NN N
factors NNS N
, , N
in IN N
particular JJ N
, , N
GH-secretagogues NNP N
and CC N
TRH NNP N
. . N

Secondary JJ N
measures NNS N
included VBD N
time NN N
spent VBN N
sitting VBG N
( ( N
including VBG N
in IN N
prolonged JJ N
bouts NNS N
? . N
) ) N
, , N
standing VBG N
, , N
and CC N
stepping VBG N
as IN N
measured VBN N
by IN N
the DT N
thigh-worn JJ N
inclinometer NN N
( ( N
7d CD N
, , N
24h/d CD N
protocol NN N
) ) N
and CC N
time NN N
spent VBN N
in IN N
physical JJ N
activity NN N
of IN N
at IN N
least JJS N
moderate JJ N
intensity NN N
as IN N
measured VBN N
by IN N
a DT N
triaxial JJ N
accelerometer NN N
. . N

CONCLUSION NNP N
Data NNP N
obtained VBD N
from IN N
gas NN N
exchange NN N
analysis NN N
are VBP N
more RBR N
sensitive JJ N
and CC N
potentially RB N
more RBR N
useful JJ N
in IN N
the DT N
detection NN N
of IN N
short-term JJ N
changes NNS N
in IN N
exercise NN N
capacity NN N
than IN N
data NNS N
obtained VBN N
from IN N
either CC N
exercise JJ N
time NN N
or CC N
peak JJ N
work NN N
rate NN N
, , N
indexes NNS N
that WDT N
are VBP N
commonly RB N
used VBN N
to TO N
assess VB N
drug NN N
therapy NN i
. . N

PURPOSE VB N
The DT N
study NN N
evaluated VBD N
whether IN N
targeted VBN N
changes NNS N
in IN N
factors NNS N
influencing VBG N
enjoyment NN N
of IN N
physical JJ N
education NN N
( ( N
PE NNP N
) ) N
, , N
physical JJ N
activity NN N
enjoyment NN N
, , N
and CC N
self-efficacy NN N
beliefs NNS N
about IN N
participating VBG N
in IN N
physical JJ N
activity NN N
mediated VBD N
the DT N
effect NN N
of IN N
the DT N
Lifestyle NNP N
Education NNP N
for IN N
Activity NNP N
Program NNP N
( ( N
LEAP NNP N
) ) N
intervention NN N
on IN N
participation NN N
in IN N
physical JJ N
activity NN N
. . N

BACKGROUND IN N
We PRP N
examined VBD N
the DT N
sustained JJ N
efficacy NN N
of IN N
a DT N
group-based JJ N
cognitive-behavioural JJ N
stress NN N
management NN N
( ( N
CBSM NNP N
) ) N
intervention NN N
in IN N
comparison NN N
to TO N
a DT N
modified VBN N
wait-list NN N
control NN N
condition NN N
on IN N
measures NNS N
of IN N
mood NN N
, , N
coping VBG N
and CC N
social JJ N
support NN N
in IN N
mildly RB N
symptomatic JJ N
HIV-positive JJ N
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

The DT N
mean JJ N
values NNS N
of IN N
compound NN N
muscle NN N
action NN N
potential JJ N
M-wave NNP N
amplitudes NNS N
in IN N
the DT N
adjacent JJ N
muscles NNS N
( ( N
abductor NN N
digiti NN N
quinti NN N
and CC N
abductor NN N
hallucis NN N
) ) N
were VBD N
above IN N
the DT N
predefined JJ N
threshold NN N
of IN N
effect NN N
, , N
indicating VBG N
that IN N
there EX N
was VBD N
no DT N
relevant JJ N
diffusion-induced JJ N
reduction NN N
of IN N
muscle NN N
activity NN N
. . N

Guidelines NNS N
on IN N
the DT N
management NN N
of IN N
low JJ N
back RB N
pain NN N
in IN N
primary JJ N
care NN N
should MD N
be VB N
consistent JJ N
about IN N
not RB N
recommending VBG N
lumbar NN N
spine NN N
radiography NN N
in IN N
patients NNS p
with IN N
low JJ N
back RB N
pain NN N
in IN N
the DT N
absence NN N
of IN N
red JJ N
flags NNS N
for IN N
serious JJ N
spinal JJ N
pathology NN N
, , N
even RB N
if IN N
the DT N
pain NN N
has VBZ N
persisted VBN N
for IN N
at IN N
least JJS N
6 CD N
weeks NNS N
. . N

BACKGROUND NNP N
Although IN N
psychosocial JJ N
therapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
mortality NN N
after IN N
myocardial JJ N
infarction NN N
, , N
it PRP N
is VBZ N
unknown JJ N
whether IN N
the DT N
benefits NNS N
of IN N
psychosocial JJ N
therapy NN i
on IN N
mortality NN N
reduction NN N
extend VBP N
to TO N
out-of-hospital JJ N
sudden JJ N
cardiac NN N
arrest NN N
, , N
a DT N
main JJ N
cause NN N
of IN N
cardiovascular JJ N
mortality NN N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
correlations NNS N
in IN N
the DT N
study NN N
population NN N
as IN N
a DT N
whole NN N
or CC N
in IN N
any DT N
subgroup NN N
between IN N
time NN N
with IN N
MEE NNP N
during IN N
antecedent JJ N
periods NNS N
and CC N
children NNS N
's POS N
scores NNS N
on IN N
measures NNS N
of IN N
spontaneous JJ N
expressive JJ N
language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
or CC N
other JJ N
measured JJ N
aspects NNS N
of IN N
cognition NN N
. . N

AIMS NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
human JJ N
synthetic JJ N
secretin NN i
( ( N
HSS NNP N
) ) N
on IN N
behaviour NN N
and CC N
communication NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
using VBG N
an DT N
objective JJ N
measure NN N
of IN N
communication NN N
and CC N
social JJ N
reciprocity NN N
and CC N
standardised VBD N
rating NN N
scales NNS N
. . N

Poorer NNP N
PFS NNP N
and CC N
OS NNP N
were VBD N
observed VBN N
in IN N
CC NNP N
compared VBN N
to TO N
other JJ N
types NNS N
, , N
but CC N
a DT N
lack NN N
of IN N
benefit NN N
from IN N
chemotherapy NN i
was VBD N
not RB N
shown VBN N
, , N
and CC N
as IN N
this DT N
histology NN N
represents VBZ N
such PDT N
a DT N
small JJ N
fraction NN N
, , N
it PRP N
does VBZ N
not RB N
seem VB N
feasible JJ N
to TO N
have VB N
separate JJ N
chemotherapy NN i
trials NNS N
for IN N
CC NNP N
. . N

OBJECTIVES NNP N
Evaluate NNP N
the DT N
impact NN N
of IN N
an DT N
intensive JJ N
insulin NN N
therapy NN i
and CC N
conventional JJ N
glucose NN N
control NN N
protocol NN N
during IN N
staying VBG N
in IN N
neurological JJ N
intensive JJ N
care NN N
unit NN N
( ( N
NICU NNP N
) ) N
on IN N
infection NN N
rate NN N
, , N
days NNS N
in IN N
NICU NNP N
, , N
in-hospital JJ N
mortality NN N
and CC N
long-term JJ N
neurological JJ N
outcome NN N
in IN N
severe JJ N
traumatic JJ N
brain NN N
injury NN N
( ( N
TBI NNP N
) ) N
patients NNS p
. . N

In IN N
an DT N
attempt NN N
to TO N
delineate VB N
the DT N
effect NN N
of IN N
membrane NN N
permeability NN N
, , N
we PRP N
performed VBD N
a DT N
randomized VBN N
, , N
crossover NN N
study NN N
to TO N
compare VB N
the DT N
inflammatory JJ N
biomarkers NNS N
, , N
lipid JJ N
profile NN N
, , N
and CC N
aortic JJ N
pulse NN N
wave NN N
velocity NN N
( ( N
PWV NNP N
) ) N
of IN N
two CD N
dialyzers NNS N
that WDT N
are VBP N
composed VBN N
of IN N
identical JJ N
membranes NNS N
but CC N
with IN N
different JJ N
flux NN N
characteristics NNS N
. . N

Although IN N
88 CD N
percent NN N
of IN N
doughnuts NNS N
obtained VBN N
in IN N
the DT N
stapled JJ N
group NN N
contained VBD N
some DT N
smooth JJ N
muscle NN N
fibers NNS N
, , N
no DT N
association NN N
was VBD N
found VBN N
between IN N
smooth JJ N
muscle NN N
incorporation NN N
and CC N
postoperative JJ N
continence NN N
function NN N
, , N
and CC N
as IN N
a DT N
whole JJ N
the DT N
continence NN N
outcomes NNS N
of IN N
the DT N
stapled VBN N
group NN N
were VBD N
similar JJ N
to TO N
those DT N
after IN N
Harmonic NNP N
Scalpel NNP N
hemorrhoidectomy NN N
. . N

KEY NNP N
POINTS NNP N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
accurately RB N
differentiate VB N
nonsolid JJ N
from IN N
part-solid JJ N
pulmonary JJ N
nodules NNS N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
quantify VB N
the DT N
solid JJ N
component NN N
similar JJ N
to TO N
manual JJ N
measurements NNS N
? . N
Semiautomatic JJ N
segmentation NN N
may MD N
aid VB N
management NN N
of IN N
subsolid JJ N
nodules NNS N
following VBG N
Fleischner NNP N
Society NNP N
recommendations NNS N
? . N
Performance NN N
for IN N
the DT N
segmentation NN N
of IN N
subsolid JJ N
nodules NNS N
depends VBZ N
on IN N
the DT N
chosen VBN N
attenuation NN N
thresholds NNS N
. . N

This DT N
randomized VBD N
controlled VBN N
study NN N
( ( N
N NNP N
= NNP N
49 CD N
) ) N
indicates VBZ N
that IN N
providing VBG N
children NNS N
with IN N
low-functioning JJ N
autism NN N
( ( N
LFA NNP N
) ) N
and CC N
high JJ N
functioning NN N
autism NN N
( ( N
HFA NNP N
) ) N
opportunities VBZ N
to TO N
practice NN N
attending VBG N
to TO N
eye NN N
gaze NN N
, , N
discriminating VBG N
facial JJ N
expressions NNS N
and CC N
recognizing VBG N
faces VBZ N
and CC N
emotions NNS N
in IN N
FaceSay NNP N
's POS N
structured JJ N
environment NN N
with IN N
interactive JJ N
, , N
realistic JJ N
avatar NN N
assistants NNS N
improved VBD N
their PRP$ N
social JJ N
skills NNS N
abilities NNS N
. . N

Main NNP N
outcome NN N
measures NNS N
included VBD N
visual JJ N
acuity NN N
, , N
estimated VBN N
red JJ N
reflex NN N
, , N
postsurgical JJ N
inflammatory NN N
reaction NN N
, , N
corneal JJ N
clarity NN N
, , N
posterior JJ N
synechias NN N
, , N
iris JJ N
capture NN N
, , N
IOL NNP N
position NN N
, , N
capsulectomy JJ N
size NN N
, , N
glaucoma NN N
, , N
cystoid JJ N
macular NN N
edema NN N
, , N
retinal JJ N
tear NN N
, , N
and CC N
postoperative JJ N
refraction NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
the DT N
benefits NNS N
of IN N
nasal JJ N
oxytocin NN i
for IN N
young JJ N
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
may MD N
be VB N
more JJR N
circumscribed JJ N
than IN N
suggested VBN N
by IN N
previous JJ N
studies NNS N
, , N
and CC N
suggest JJS N
caution NN N
in IN N
recommending VBG N
it PRP N
as IN N
an DT N
intervention NN N
that WDT N
is VBZ N
broadly RB N
effective JJ N
. . N

DISCUSSION NNP N
The DT N
design NN N
features NNS N
of IN N
our PRP$ N
trial NN N
, , N
and CC N
the DT N
practical JJ N
problems NNS N
( ( N
and CC N
solutions NNS N
) ) N
associated VBN N
with IN N
implementing VBG N
these DT N
design NN N
features NNS N
, , N
particularly RB N
those DT N
that IN N
result NN N
in IN N
potential JJ N
delay NN N
between IN N
recruitment NN N
, , N
baseline NN N
data NNS N
collection NN N
, , N
randomization NN N
, , N
intervention NN N
, , N
and CC N
assessment NN N
will MD N
be VB N
discussed VBN N
. . N

Future JJ N
investigations NNS N
with IN N
a DT N
larger JJR N
sample JJ N
size NN N
should MD N
be VB N
conducted VBN N
to TO N
build VB N
on IN N
this DT N
pilot JJ N
feasibility NN N
program NN N
and CC N
to TO N
confirm VB N
these DT N
results NNS N
, , N
as RB N
well RB N
as IN N
to TO N
elucidate VB N
the DT N
elements NNS N
of IN N
rehabilitation NN N
contributing VBG N
most JJS N
to TO N
improved VBN N
outcomes NNS N
. . N

A DT N
primary JJ N
outcome JJ N
measure NN N
of IN N
structural JJ N
language NN N
and CC N
secondary JJ N
outcome NN N
measures NNS N
of IN N
narrative JJ N
, , N
parent-reported JJ N
pragmatic JJ N
functioning NN N
and CC N
social JJ N
communication NN N
, , N
blind-rated JJ N
perceptions NNS N
of IN N
conversational JJ N
competence NN N
and CC N
teacher-reported JJ N
ratings NNS N
of IN N
classroom NN N
learning VBG N
skills NNS N
were VBD N
taken VBN N
pre-intervention NN N
, , N
immediately RB N
post-intervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

The DT N
similar JJ N
effect NN N
of IN N
these DT N
drugs NNS N
on IN N
the DT N
reactance NN N
can MD N
be VB N
explained VBN N
by IN N
an DT N
increase NN o
in IN N
the DT N
capacitance NN N
of IN N
the DT N
respiratory NN N
system NN N
, , N
and CC N
in IN N
combination NN N
with IN N
a DT N
decrease NN o
in IN N
frequency NN N
dependence NN N
of IN N
resistance NN N
, , N
by IN N
assuming VBG N
a DT N
decrease NN o
in IN N
peripheral JJ N
airway NN N
resistance NN N
. . N

In IN N
order NN N
to TO N
question VB N
the DT N
value NN N
of IN N
both DT N
glycol JJ N
metabolites NNS N
as IN N
peripheral JJ N
indices NNS N
of IN N
central JJ N
noradrenergic JJ N
activity NN N
, , N
a DT N
comparative JJ N
study NN N
of IN N
plasma NN N
DOPEG NNP N
and CC N
MOPEG NNP N
( ( N
measured VBN N
by IN N
HPLC NNP N
) ) N
related VBD N
to TO N
depression NN N
, , N
sex NN N
, , N
age NN N
and CC N
diagnostic JJ N
categories NNS N
( ( N
DSM-III NNP N
) ) N
was VBD N
carried VBN N
out RP N
on IN N
depressed JJ N
and CC N
control JJ N
subjects NNS N
. . N

While IN N
the DT N
employment NN N
of IN N
questionnaires NNS N
disclosed VBN N
that IN N
autistic JJ N
children NNS N
had VBD N
an DT N
earlier JJR N
morning NN N
awakening NN N
time NN N
and CC N
multiple NN N
and CC N
early JJ N
night NN N
arousals NNS N
, , N
actigraphic JJ N
monitoring NN N
showed VBD N
that IN N
with IN N
the DT N
exception NN N
of IN N
an DT N
earlier JJR N
morning NN N
arousal NN N
time NN N
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
, , N
sleep JJ N
patterns NNS N
of IN N
autistic JJ N
children NNS N
were VBD N
similar JJ N
to TO N
that DT N
of IN N
normal JJ N
children NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Operative NNP N
parameters NNS N
( ( N
operative JJ N
time NN N
, , N
fluid JJ N
absorption NN N
, , N
complications NNS N
, , N
need VBP N
for IN N
second JJ N
intervention NN N
) ) N
and CC N
reproductive JJ N
outcome NN N
parameters NNS N
( ( N
pregnancy NN N
, , N
abortion NN N
, , N
term NN N
and CC N
preterm JJ N
delivery NN N
, , N
modality NN N
of IN N
delivery NN N
, , N
cervical JJ N
cerclage NN N
) ) N
were VBD N
measured VBN N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
showed VBD N
improvements NNS N
in IN N
affective JJ N
speech NN N
comprehension NN N
from IN N
pre- JJ N
to TO N
post-infusion NN N
; : N
however RB N
, , N
whereas NNS N
those DT N
who WP N
received VBD N
placebo NN N
first RB N
tended VBD N
to TO N
revert VB N
to TO N
baseline VB N
after IN N
a DT N
delay NN N
, , N
those DT N
who WP N
received VBD N
oxytocin PRP i
first RB N
retained VBD N
the DT N
ability NN N
to TO N
accurately RB N
assign VB N
emotional JJ N
significance NN N
to TO N
speech VB N
intonation NN N
on IN N
the DT N
speech NN N
comprehension NN N
task NN N
. . N

Current JJ N
therapy NN i
with IN N
beta NN N
adrenergic JJ N
antagonists NNS N
is VBZ N
designed VBN N
to TO N
moderate VB N
the DT N
up-regulation NN N
of IN N
norepinephrine NN N
and CC N
sympathetic JJ N
effects NNS N
; : N
however RB N
, , N
to TO N
date NN N
, , N
there EX N
are VBP N
no DT N
therapies NNS N
that WDT N
specifically RB N
address VBP N
the DT N
withdrawal NN N
of IN N
parasympathetic JJ N
influences NNS N
on IN N
cardiac JJ N
function NN N
and CC N
structure NN N
. . N

Therefore RB N
, , N
the DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
motivational JJ N
music NN N
( ( N
music NN N
that WDT N
stimulates VBZ N
or CC N
inspires VBZ N
physical JJ N
activity NN N
) ) N
during IN N
recovery NN N
from IN N
intense JJ N
exercise NN N
, , N
on IN N
activity NN N
pattern NN N
, , N
rate NN N
of IN N
perceived VBN N
exertion NN N
( ( N
RPE NNP N
) ) N
, , N
and CC N
blood NN N
lactate NN N
concentration NN N
. . N

CONCLUSIONS NNP N
The DT N
notion NN N
that IN N
the DT N
pharmacodynamic JJ N
effects NNS N
of IN N
remifentanil NN N
are VBP N
extremely RB N
short-lived JJ N
after IN N
the DT N
drug NN N
is VBZ N
no DT N
longer RB N
administered VBN N
must MD N
be VB N
questioned VBN N
given VBN N
our PRP$ N
findings NNS N
that IN N
psychomotor NN N
effects NNS N
were VBD N
still RB N
apparent JJ N
1 CD N
h NN N
after IN N
the DT N
infusion NN N
was VBD N
discontinued VBN N
. . N

BACKGROUND NNP N
In IN N
a DT N
large JJ N
cluster NN N
randomized VBD N
control JJ N
trial NN N
of IN N
insecticide-treated JJ N
bed NN N
nets NNS N
( ( N
ITN NNP N
) ) N
in IN N
Western JJ N
Myanmar NNP N
the DT N
malaria NN N
protective JJ N
effect NN N
of IN N
ITN NNP N
was VBD N
found VBN N
to TO N
be VB N
highly RB N
variable JJ N
and CC N
, , N
in IN N
aggregate NN N
, , N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
agreement NN N
with IN N
findings NNS N
in IN N
animal JJ N
studies NNS N
, , N
our PRP$ N
results NNS N
suggest VBP N
that IN N
microalbuminuria NN N
is VBZ N
to TO N
a DT N
large JJ N
extent NN N
pressure-dependent NN N
, , N
probably RB N
because IN N
of IN N
glomerular JJ N
hypertension NN N
, , N
and CC N
that DT N
autoregulation NN N
of IN N
glomerular JJ N
filtration NN N
rate NN N
is VBZ N
normal JJ N
in IN N
most JJS N
patients NNS p
with IN N
incipient JJ N
diabetic JJ N
nephropathy NN N
. . N

AIM IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
oxidized JJ N
regenerated VBN N
cellulose NN N
( ( N
ORC NNP N
) ) N
, , N
applied VBN N
to TO N
dirty VB N
surgical JJ N
wounds NNS N
, , N
is VBZ N
able JJ N
to TO N
reduce VB N
the DT N
microbial JJ N
load NN N
and CC N
, , N
consequently RB N
, , N
the DT N
infection NN N
rate NN N
as IN N
compared VBN N
to TO N
conventional JJ N
local JJ N
wound NN N
treatment NN N
. . N

PURPOSE NN N
To TO N
date NN N
, , N
no DT N
study NN N
has VBZ N
examined VBN N
the DT N
synergistic JJ N
effects NNS N
of IN N
a DT N
nutrition NN N
and CC N
combination NN N
of IN N
aerobic JJ N
and CC N
strength NN N
training NN N
( ( N
CAST NNP N
) ) N
on IN N
both DT N
adiposity NN N
and CC N
metabolic JJ N
parameters NNS N
in IN N
overweight JJ N
Latina NNP N
adolescent NN N
females NNS N
. . N

In IN N
a DT N
30-day JJ N
study NN N
, , N
we PRP N
compared VBN N
the DT N
abilities NNS N
of IN N
four CD N
different JJ N
treatments NNS N
( ( N
lithium JJ N
plus CC N
early JJ N
morning NN N
sleep NN N
deprivation NN N
, , N
lithium NN N
plus CC N
a DT N
control NN N
sleep JJ N
deprivation NN N
procedure NN N
, , N
and CC N
desipramine NN N
with IN N
either DT N
of IN N
the DT N
two CD N
sleep JJ N
manipulations NNS N
) ) N
to TO N
induce VB N
a DT N
rapid JJ N
( ( N
next-day JJ N
) ) N
and CC N
sustained VBN N
antidepressant JJ N
response NN N
in IN N
16 CD N
depressed JJ N
patients NNS p
. . N

Relative JJ N
change NN N
in IN N
serum NN N
retinol NN N
concentration NN N
was VBD N
significantly RB N
higher JJR N
among IN N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
one-third NN N
of IN N
total JJ N
vitamin FW N
A DT N
intake NN N
coming VBG N
from IN N
vitamin JJ N
A-fortified JJ N
cooking NN N
oil NN N
intake NN N
, , N
than IN N
in IN N
the DT N
Control NNP N
groups NNS N
, , N
with IN N
more JJR N
than IN N
half NN N
of IN N
intake NN N
from IN N
other JJ N
vitamin JJ N
A-rich JJ N
foods NNS N
. . N

Owing VBG N
to TO N
its PRP$ N
efficacy NN N
, , N
added VBD N
to TO N
high JJ N
availability NN N
and CC N
low JJ N
cost NN N
, , N
this DT N
compound NN N
should MD N
be VB N
considered VBN N
a DT N
first-line JJ N
treatment NN N
of IN N
this DT N
disorder NN N
in IN N
this DT N
country NN N
, , N
and CC N
perhaps RB N
in IN N
other JJ N
countries NNS N
where WRB N
this DT N
condition NN N
presents VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
pressure NN N
garments NNS N
that WDT N
deliver VBP N
a DT N
pressure NN N
of IN N
at IN N
least JJS N
15 CD N
mmHg JJ N
pressure NN N
tend VBP N
to TO N
accelerate VB N
scar NN N
maturation NN N
and CC N
that IN N
measurements NNS N
of IN N
the DT N
pattern NN N
of IN N
change NN N
of IN N
the DT N
erythema NN N
can MD N
be VB N
used VBN N
to TO N
predict VB N
changes NNS N
in IN N
scar NN N
thickness NN N
and CC N
vice NN N
versa NN N
. . N

It PRP N
was VBD N
therefore RB N
concluded VBD N
that IN N
, , N
although IN N
patients NNS p
with IN N
LV NNP N
hypertrophy NN N
and CC N
non-Q-wave JJ N
AMI NNP N
have VBP N
smaller JJR N
enzymatic JJ N
infarcts NNS N
and CC N
the DT N
same JJ N
short-term JJ N
prognosis NN N
as IN N
do JJ N
patients NNS p
without IN N
LV NNP N
hypertrophy NN N
, , N
their PRP$ N
reinfarction NN N
and CC N
mortality NN N
rates NNS N
are VBP N
significantly RB N
increased VBN o
during IN N
the DT N
first JJ N
year NN N
of IN N
follow-up NN N
. . N

Patients NNS N
selected VBN N
for IN N
moderately RB N
progressive JJ N
IgA NNP N
nephropathy JJ N
benefit NN N
from IN N
treatment NN N
with IN N
prednisolone NN N
and CC N
cytotoxic NN N
agents NNS N
; : N
results NNS N
are VBP N
consistent JJ N
with IN N
modulation NN N
of IN N
systemic JJ N
immune JJ N
response NN N
or CC N
nephritic JJ N
injury NN N
, , N
thus RB N
explaining VBG N
improved VBN N
outcome NN N
, , N
and CC N
indicate VBP N
that IN N
this DT N
therapy NN i
has VBZ N
an DT N
acceptably RB N
low JJ N
risk NN N
of IN N
side NN N
effects NNS N
. . N

Some DT N
children NNS N
appeared VBD N
to TO N
respond VB N
positively RB N
to TO N
the DT N
dimethylglycine NN N
, , N
and CC N
there RB N
was VBD N
a DT N
smaller JJR N
proportion NN N
of IN N
negative JJ N
changes NNS N
in IN N
the DT N
dimethylglycine NN N
group NN N
, , N
but CC N
the DT N
quantitative JJ N
changes NNS N
in IN N
the DT N
dimethylglycine JJ N
behavioral JJ N
assessments NNS N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
what WP N
was VBD N
observed VBN N
among IN N
children NNS N
who WP N
received VBD N
placebo NN N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
the DT N
parameters NNS N
measured VBD N
with IN N
one CD N
exception NN N
; : N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN o
in IN N
discomfort NN N
levels NNS N
for IN N
the DT N
laser NN N
system NN N
at IN N
the DT N
time NN N
of IN N
cavity NN N
preparation NN N
for IN N
subjects NNS N
who WP N
declined VBD N
to TO N
receive VB N
local JJ N
anesthetic NN N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
the DT N
composite NN N
of IN N
all-cause JJ N
mortality NN N
, , N
non JJ N
fatal JJ N
myocardial JJ N
infarction NN N
( ( N
including VBG N
silent JJ N
myocardial JJ N
infarction NN N
) ) N
, , N
stroke VBD N
, , N
acute JJ N
coronary JJ N
syndrome NN N
, , N
endovascular JJ N
or CC N
surgical JJ N
intervention NN N
in IN N
the DT N
coronary NN N
or CC N
leg NN N
arteries NNS N
, , N
and CC N
amputation NN N
above IN N
the DT N
ankle NN N
. . N

We PRP N
observed VBD N
significant JJ N
improvements NNS N
in IN N
hyperandrogenemia NN N
and CC N
ovulation NN N
rates NNS N
in IN N
PCOS NNP N
women NNS N
of IN N
all DT N
three CD N
groups NNS N
, , N
in IN N
the DT N
absence NN N
of IN N
changes NNS N
in IN N
the DT N
metabolic JJ N
state NN N
, , N
suggesting VBG N
that IN N
insulin NN N
resistance NN N
in IN N
PCOS NNP N
patients NNS p
is VBZ N
only RB N
one CD N
of IN N
several JJ N
factors NNS N
leading VBG N
to TO N
hyperandrogenemic VB N
ovarian JJ N
failure NN N
. . N

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitor NN N
enalapril NN N
and CC N
diuretic JJ N
indapamide NN N
on IN N
the DT N
peripheral JJ N
blood NN N
pressure NN N
and CC N
the DT N
central JJ N
blood NN N
pressure NN N
in IN N
Chinese JJ N
patients NNS p
with IN N
essential JJ N
hypertension NN N
. . N

Citalopram NNP N
use NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
adverse JJ N
events NNS N
, , N
particularly RB N
increased VBD o
energy NN o
level NN N
, , N
impulsiveness NN N
, , N
decreased VBN o
concentration NN N
, , N
hyperactivity NN N
, , N
stereotypy NN N
, , N
diarrhea NN N
, , N
insomnia NN N
, , N
and CC N
dry JJ N
skin NN N
or CC N
pruritus NN N
. . N

OBJECTIVE IN N
The DT N
current JJ N
study NN N
's POS N
primary JJ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
and CC N
acceptability NN N
for IN N
use NN N
by IN N
older JJR N
adults NNS N
of IN N
the DT N
Internet NNP N
Mindfulness NNP N
Meditation NNP N
Intervention NNP N
( ( N
IMMI NNP N
) ) N
, , N
a DT N
program NN N
that WDT N
had VBD N
been VBN N
developed VBN N
by IN N
the DT N
research NN N
team NN N
, , N
as RB N
well RB N
as IN N
of IN N
an DT N
Internet-based JJ N
health-and-wellness JJ N
education NN N
program NN N
, , N
the DT N
control NN N
. . N

PURPOSE NNP N
While IN N
the DT N
benefits NNS N
of IN N
planned JJ N
replacement NN N
of IN N
soft JJ i
contact NN N
lenses NNS N
have VBP N
been VBN N
investigated VBN N
, , N
the DT N
question NN N
of IN N
whether IN N
there EX N
are VBP N
any DT N
clinical JJ N
benefits NNS N
to TO N
planned VBN N
replacement NN N
of IN N
rigid JJ N
gas NN N
permeable NN N
( ( N
RGP NNP N
) ) N
lenses VBZ N
does VBZ N
not RB N
appear VB N
to TO N
have VB N
been VBN N
addressed VBN N
experimentally RB N
. . N

OBJECTIVE NN N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
there EX N
would MD N
be VB N
better RB N
clinical JJ N
outcomes NNS N
following VBG N
the DT N
treatment NN N
of IN N
patients NNS p
with IN N
acute JJ N
lung NN N
injury NN N
( ( N
ALI NNP N
) ) N
using VBG N
noninvasive JJ N
positive-pressure JJ N
mechanical JJ N
ventilation NN N
( ( N
NIPPV NNP N
) ) N
delivered VBD N
via IN N
a DT N
complex JJ N
critical JJ N
care NN N
ventilator NN N
compared VBN N
with IN N
a DT N
conventional JJ N
mini-ventilator NN N
. . N

PARTICIPANTS VB N
The DT N
study NN N
enrolled VBD N
male NN N
and CC N
female JJ N
outpatients NNS p
aged VBN N
5-12 CD N
years NNS N
with IN N
a DT N
diagnosis NN N
of IN N
autistic JJ N
disorder NN N
based VBN N
on IN N
the DT N
DSM-IV-TR NNP N
criteria NNS N
and CC N
a DT N
score NN N
of IN N
? . N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
irritability NN N
subscale NN N
who WP N
had VBD N
discontinued VBN N
other JJ N
medications NNS N
because IN N
of IN N
a DT N
lack NN N
of IN N
efficacy NN N
. . N

Our PRP$ N
findings NNS N
demonstrate VBP N
that IN N
in IN N
patients NNS p
with IN N
multiple JJ N
myeloma NNS N
who WP N
might MD N
be VB N
predicted VBN N
to TO N
fail VB N
mobilization NN N
based VBN N
on IN N
low JJ N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
the DT N
addition NN N
of IN N
plerixafor NN N
to TO N
G-CSF NNP N
allows NNS N
for IN N
collection NN N
of IN N
the DT N
minimal JJ N
and CC N
optimal JJ N
cell NN N
doses NNS N
in IN N
a DT N
greater JJR N
proportion NN N
of IN N
patients NNS p
compared VBN N
with IN N
G-CSF NNP N
alone RB N
. . N

The DT N
aim NN N
of IN N
the DT N
trial NN N
is VBZ N
to TO N
evaluate VB N
the DT N
treatment NN N
of IN N
depressive JJ N
disorder NN N
in IN N
primary JJ N
care NN N
in IN N
the DT N
Netherlands NNP N
by IN N
means NNS N
of IN N
an DT N
adapted JJ N
collaborative NN N
care NN N
framework NN N
, , N
including VBG N
contracting NN N
and CC N
adherence-improving JJ N
strategies NNS N
, , N
combined VBN N
with IN N
Problem NNP N
Solving NNP N
Treatment NNP N
and CC N
antidepressant JJ N
medication NN N
according VBG N
to TO N
a DT N
treatment NN N
algorithm NN N
. . N

The DT N
two CD N
lower JJR N
doses NNS N
of IN N
lornoxicam NN N
and CC N
aspirin VB N
all DT N
showed VBD N
apparent JJ N
degrees NNS N
of IN N
efficacy NN N
intermediate NN N
between IN N
that DT N
of IN N
placebo NN N
and CC N
lornoxicam $ N
8 CD N
mg NN N
, , N
although IN N
the DT N
trial NN N
proved VBD N
to TO N
have VB N
inadequate JJ N
power NN N
to TO N
show VB N
significant JJ N
differences NNS N
between IN N
these DT N
three CD N
treatments NNS N
. . N

BACKGROUND NNP N
In IN N
cemented JJ N
THA NNP N
, , N
aseptic JJ N
loosening NN N
of IN N
the DT N
cup NN N
is VBZ N
more RBR N
common JJ N
than IN N
loosening NN N
of IN N
the DT N
stem NN N
, , N
while IN N
periprosthetic JJ N
osteolysis NN N
of IN N
the DT N
socket NN N
resulting VBG N
in IN N
difficult JJ N
reconstruction NN N
problems NNS N
has VBZ N
emerged VBN N
as IN N
the DT N
most RBS N
significant JJ N
problem NN N
with IN N
cementless JJ N
cup NN N
fixation NN N
. . N

All DT N
measures NNS N
of IN N
outcome NN N
were VBD N
worse JJR N
in IN N
patients NNS p
who WP N
developed VBD N
fever NN N
, , N
even RB N
in IN N
those DT N
without IN N
infections NNS N
or CC N
who WP N
were VBD N
World NNP N
Federation NNP N
of IN N
Neurological NNP N
Surgeons NNP N
grade VBD N
I. NNP N
Logistic NNP N
regression NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
adjust VB N
for IN N
differences NNS N
in IN N
preoperative JJ N
factors NNS N
( ( N
e.g NN N
, , N
age NN N
, , N
Fisher NNP N
grade NN N
, , N
initial JJ N
neurological JJ N
status NN N
) ) N
. . N

Phentolamine NN N
was VBD N
given VBN N
first RB N
to TO N
isolate VB N
the DT N
contribution NN N
of IN N
nitric JJ N
oxide NN N
to TO N
postexercise VB N
hypotension NN N
by IN N
preventing VBG N
reflex JJ N
changes NNS N
in IN N
sympathetic JJ N
tone NN N
that WDT N
result NN N
from IN N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
and CC N
to TO N
control VB N
for IN N
alterations NNS N
in IN N
resting VBG N
sympathetic JJ N
activity NN N
after IN N
exercise NN N
. . N

Chemoimmunotherapy NN i
with IN N
levamisole JJ N
or CC N
levamisole-BCG JJ N
offers NNS N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
CR NNP N
rates NNS N
, , N
CR NNP N
duration NN N
, , N
or CC N
survival NN N
compared VBN N
to TO N
CHOP NNP N
chemotherapy NN i
alone RB N
, , N
and CC N
levamisole NN N
may MD N
have VB N
had VBD N
an DT N
adverse JJ N
impact NN N
on IN N
outcome NN N
in IN N
certain JJ N
subtypes NNS N
of IN N
ML NNP N
. . N

OBJECTIVE IN N
The DT N
objectives NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
5 CD N
% NN N
imiquimod JJ N
cream NN N
in IN N
treating VBG N
basal NN N
cell NN N
carcinoma NN N
preceding VBG N
excision NN N
by IN N
Mohs NNP N
micrographic JJ N
surgery NN N
and CC N
to TO N
determine VB N
if IN N
reflectance-mode JJ N
confocal JJ N
microscopy NN N
is VBZ N
useful JJ N
to TO N
establish VB N
the DT N
need NN N
for IN N
surgical JJ N
intervention NN N
after IN N
imiquimod JJ N
treatment NN N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Largely NNP N
because IN N
the DT N
program NN N
increased VBD o
consumers NNS o
' POS N
ability NN N
to TO N
get VB N
the DT N
authorized JJ N
amount NN N
of IN N
paid VBN N
care NN N
, , N
expenditures VBZ N
for IN N
personal JJ N
care/waiver NN N
services NNS N
were VBD N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
in IN N
each DT N
state NN N
and CC N
age NN N
group NN N
, , N
except IN N
among IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
. . N

Results NNS N
of IN N
both DT N
inquiries NNS N
indicate VBP N
that IN N
although IN N
treatment NN N
with IN N
secretin NN i
was VBD N
reported VBN N
to TO N
cause VB N
transient JJ N
changes NNS N
in IN N
speech NN N
and CC N
behavior NN N
in IN N
some DT N
children NNS N
, , N
overall JJ i
it PRP N
produced VBD N
few JJ N
clinically RB N
meaningful JJ N
changes NNS N
when WRB N
compared VBN N
to TO N
children NNS N
given VBN N
placebo JJ N
injections NNS N
. . N

CONCLUSION NNP N
The DT N
presently RB N
studied VBN N
diphtheria NN N
, , N
tetanus NN N
, , N
acellular JJ N
pertussis-H. NN N
influenzae NN N
b NN N
vaccine NN N
conjugated VBN N
to TO N
tetanus VB N
toxoid JJ N
combination NN N
was VBD N
at IN N
least JJS N
as RB N
immunogenic JJ N
as IN N
the DT N
diphtheria NN N
, , N
tetanus NN N
, , N
whole JJ N
cell NN N
pertussis-H. JJ N
influenzae NN N
b NN N
vaccine NN N
conjugated VBN N
to TO N
tetanus VB N
toxoid JJ N
combination NN N
, , N
with IN N
a DT N
significantly RB N
better JJR N
safety NN N
profile NN N
. . N

Primary JJ N
radiotherapy NN i
( ( N
RT NNP N
) ) N
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
OPSCC NNP N
at IN N
most JJS N
centers NNS N
, , N
and CC N
over IN N
the DT N
last JJ N
decade NN N
, , N
the DT N
addition NN N
of IN N
concurrent NN N
chemotherapy NN i
has VBZ N
led VBN N
to TO N
a DT N
significant JJ N
improvement NN N
in IN N
survival NN N
, , N
but CC N
at IN N
the DT N
cost NN N
of IN N
increased VBN o
acute NN N
and CC N
late JJ N
toxicity NN N
. . N

Any DT N
subsequent JJ N
trials NNS N
of IN N
the DT N
HART NNP N
regimen NNS N
must MD N
address VB N
the DT N
issues NNS N
that WDT N
led VBD N
to TO N
early JJ N
closure NN N
, , N
including VBG N
slow JJ N
accrual NN N
, , N
logistics NNS N
of IN N
HART NNP N
, , N
mucosal NN N
toxicity NN N
, , N
and CC N
the DT N
fact NN N
that IN N
concurrent JJ N
chemoradiotherapy NN i
now RB N
seems VBZ N
more RBR N
effective JJ N
than IN N
sequential JJ N
treatment NN N
. . N

Preventive JJ N
programmes NNS N
aimed VBN N
at IN N
a DT N
change NN N
of IN N
sun NN N
related VBN N
behaviours NNS N
among IN N
Swedish JJ N
adolescents NNS N
have VBP N
to TO N
be VB N
tailored VBN N
to TO N
the DT N
climate NN N
and CC N
cultural JJ N
conditions NNS N
and CC N
must MD N
take VB N
into IN N
account NN N
that IN N
having VBG N
a DT N
tan NN N
, , N
and CC N
the DT N
warmth NN N
of IN N
the DT N
sun NN N
, , N
are VBP N
highly RB N
valued VBN N
by IN N
most JJS N
adolescents NNS N
. . N

When WRB N
designing VBG N
a DT N
clinical JJ N
trial NN N
, , N
selecting VBG N
volunteers NNS N
, , N
or CC N
judging VBG N
the DT N
tolerance NN N
of IN N
a DT N
new JJ N
drug NN N
, , N
the DT N
rise NN N
in IN N
TSB NNP N
caused VBN N
by IN N
fasting VBG N
must MD N
therefore RB N
be VB N
taken VBN N
into IN N
account NN N
, , N
particularly RB N
in IN N
trials NNS N
where WRB N
volunteers NNS N
or CC N
patients NNS p
fast JJ N
before IN N
entering VBG N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
In IN N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
, , N
changes NNS N
in IN N
serum NN N
SCFAs NNP N
in IN N
response NN N
to TO N
changes NNS N
in IN N
carbohydrate NN N
and CC N
fiber NN N
intakes NNS N
took VBD N
many JJ N
months NNS N
to TO N
occur VB N
, , N
and CC N
the DT N
changes NNS N
in IN N
serum NN N
acetate NN N
were VBD N
significantly RB N
related VBN N
to TO N
the DT N
long-term JJ N
adaptive JJ N
changes NNS N
in IN N
blood NN N
lipids NNS N
. . N

INTRODUCTION NN N
In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
short-term JJ N
finasteride JJ N
treatment NN N
on IN N
microvessel NN N
density NN N
( ( N
MVD NNP N
) ) N
which WDT N
is VBZ N
an DT N
indicator NN N
of IN N
prostatic JJ N
angiogenesis NN N
in IN N
patients NNS p
with IN N
hematuria NNS N
secondary JJ N
to TO N
benign VB N
prostatic JJ N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
. . N

We PRP N
provide VBP N
evidence NN N
that IN N
low-dose JJ N
CY NNP N
not RB N
only RB N
depletes VBZ N
patients NNS p
' POS N
Treg NNP N
cells NNS N
and CC N
enhances NNS N
function NN N
of IN N
HPV-specific NNP N
T NNP N
cells NNS N
and CC N
NK NNP N
cells NNS N
in IN N
the DT N
periphery NN N
, , N
but CC N
also RB N
ameliorates VBZ N
the DT N
immune JJ N
milieu NN N
of IN N
the DT N
lesion NN N
site NN N
, , N
leading VBG N
to TO N
the DT N
elimination NN N
of IN N
remnant JJ N
viruses NNS N
. . N

This DT N
difference NN N
between IN N
the DT N
tinted JJ N
CL NNP N
could MD N
suggest VB N
a DT N
wavelength JJ N
dependence NN N
of IN N
straylight NN N
values NNS N
, , N
although IN N
this DT N
should MD N
be VB N
investigated VBN N
further JJ N
by IN N
controlling VBG N
for IN N
pupil NN N
size NN N
and CC N
subjects NNS N
' POS N
pigmentation NN N
, , N
as RB N
well RB N
as IN N
by IN N
using VBG N
neutral JJ N
density NN N
filters NNS N
. . N

BACKGROUND NNP N
Since IN N
laparoscopic NN N
adrenalectomy NN N
( ( N
LA NNP N
) ) N
has VBZ N
been VBN N
adopted VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
treatment NN N
of IN N
adrenal JJ N
diseases NNS N
, , N
the DT N
development NN N
of IN N
technology NN N
for IN N
vascular JJ N
control NN N
and CC N
dissection NN N
manoeuvres NNS N
, , N
amongst VBZ N
other JJ N
things NNS N
, , N
may MD N
play VB N
a DT N
pivotal JJ N
role NN N
in IN N
its PRP$ N
further JJ N
improvement NN N
. . N

Other JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
LAIV-induced NNP N
immunity NN N
is VBZ N
also RB N
partially RB N
explained VBN N
by IN N
T-cell NNP N
immunity NN N
, , N
serum NN N
antibody NN N
responses NNS N
, , N
and CC N
innate JJ N
immunity NN N
, , N
consistent JJ N
with IN N
the DT N
multi-faceted JJ N
nature NN N
of IN N
immunity NN N
induced VBN N
by IN N
wild-type JJ N
influenza JJ N
infection NN N
and CC N
other JJ N
live JJ N
virus NN N
vaccines NNS N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
none NN N
of IN N
the DT N
three CD N
beta-blockers NNS N
tested VBN N
nor CC N
disopyramide JJ N
phosphate NN N
is VBZ N
likely JJ N
to TO N
reduce VB N
the DT N
mortality NN N
from IN N
acute JJ N
myocardial JJ N
infarction NN N
when WRB N
given VBN N
prophylactically RB N
, , N
although IN N
disopyramide JJ N
phosphate NN N
does VBZ N
reduce VB N
the DT N
incidence NN N
of IN N
'serious JJ N
' POS N
ventriicular JJ N
arrhythmias NNS N
. . N

We PRP N
examined VBD N
the DT N
associations NNS N
of IN N
prediagnostic JJ N
plasma NN N
levels NNS N
of IN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
, , N
individually RB N
and CC N
jointly RB N
, , N
with IN N
total JJ N
and CC N
aggressive JJ N
disease NN N
, , N
and CC N
explored VBD N
whether IN N
relations NNS N
between IN N
vitamin NN N
D NNP N
metabolites NNS N
and CC N
prostate NN N
cancer NN N
were VBD N
modified VBN N
by IN N
the DT N
functional JJ N
VDR NNP N
FokI NNP N
polymorphism NN N
, , N
using VBG N
conditional JJ N
logistic JJ N
regression NN N
. . N

Therefore RB N
, , N
a DT N
multicenter NN N
RCT NNP N
was VBD N
proposed VBN N
in IN N
1998 CD N
to TO N
evaluate VB N
the DT N
primary JJ N
end NN N
point NN N
of IN N
long-term JJ N
survival NN N
and CC N
the DT N
secondary JJ N
end NN N
points NNS N
of IN N
morbidity NN N
, , N
mortality NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
patients NNS p
undergoing VBG N
standard JJ N
versus NN N
extended VBD N
lymphadenectomy NN N
in IN N
radical JJ N
PD NNP N
for IN N
pancreatic JJ N
cancer NN N
. . N

CONCLUSION NN N
In IN N
this DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
the DT N
addition NN N
of IN N
a DT N
direct JJ N
nitric JJ N
oxide NN N
donor NN N
to TO N
nitroglycerin VB N
in IN N
an DT N
antispastic JJ N
cocktail NN N
did VBD N
not RB N
reduce VB N
the DT N
risk NN N
of IN N
spasm NN N
, , N
and CC N
the DT N
use NN N
of IN N
nitroglycerin NN N
was VBD N
found VBN N
to TO N
be VB N
as RB N
effective JJ N
as IN N
nitroprusside RB N
. . N

MEASUREMENTS NNS N
At IN N
the DT N
time NN N
of IN N
enrolment NN N
into IN N
a DT N
wider NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
hip NN N
protectors NNS N
on IN N
hip NN N
fractures NNS N
, , N
participants NNS N
recruited VBD N
at IN N
home NN N
completed VBD N
an DT N
assessment NN N
of IN N
fear NN N
of IN N
falling VBG N
and CC N
falls VBZ N
efficacy NN N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
Scale NNP N
and CC N
the DT N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scale NNP N
. . N

However RB N
, , N
in IN N
a DT N
multi-variate JJ N
analysis NN N
that WDT N
took VBD N
into IN N
account NN N
disease NN N
extent NN N
, , N
maintenance NN N
therapy NN i
, , N
Karnofsky NNP N
performance NN N
status NN N
( ( N
PS NNP N
) ) N
, , N
and CC N
absolute JJ N
dose-intensity NN N
( ( N
ADI NNP N
) ) N
of IN N
anthracycline NN N
given VBN N
during IN N
induction NN N
, , N
limited JJ N
disease NN N
( ( N
LD NNP N
) ) N
and CC N
maintenance NN N
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
positive JJ N
predictors NNS N
of IN N
survival NN N
. . N

RESULTS NNP N
PRIMARY NNP N
MEASUREMENTS NNP N
3-monthly JJ N
HbA1c NNP N
, , N
fasting VBG N
blood NN N
glucose NN N
, , N
body NN N
weight VBD N
, , N
waist-hip JJ N
ratio NN N
, , N
yearly RB N
blood NN N
lipids NNS N
, , N
and CC N
bi-yearly JJ N
assessment NN N
of IN N
knowledge NN N
of IN N
diabetes NNS N
, , N
health NN N
behaviours NNS N
and CC N
quality NN N
of IN N
life NN N
. . N

Although IN N
Canada411 NNP N
could MD N
find VB N
significantly RB N
more RBR N
subjects NNS N
than IN N
InfoSpace NNP N
, , N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
returned VBN N
by IN N
Canada411 NNP N
was VBD N
also RB N
higher JJR N
, , N
which WDT N
meant VBD N
that IN N
a DT N
longer RBR N
list NN N
of IN N
potential JJ N
matches NNS N
had VBD N
to TO N
be VB N
examined VBN N
before IN N
a DT N
true JJ N
match NN N
could MD N
be VB N
found VBN N
. . N

Feeding VBG N
problems NNS N
represent VBP N
a DT N
frequent NN N
concern NN N
reported VBN N
by IN N
caregivers NNS N
of IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
, , N
and CC N
growing VBG N
evidence NN N
suggests VBZ N
atypical JJ N
patterns NNS N
of IN N
intake NN N
may MD N
place VB N
this DT N
population NN N
at IN N
risk NN N
of IN N
nutritional JJ N
and/or NN N
related JJ N
medical JJ N
issues NNS N
, , N
including VBG N
chronic JJ N
vitamin NN N
and CC N
mineral JJ N
deficiencies NNS N
, , N
poor JJ N
bone NN N
growth NN N
, , N
and CC N
obesity NN N
. . N

Analysis NN N
of IN N
clinical JJ N
and CC N
laboratory NN N
data NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
group NN N
of IN N
patients NNS p
as IN N
to TO N
the DT N
evolution NN N
of IN N
their PRP$ N
illness NN N
except IN N
for IN N
a DT N
significantly RB N
higher JJR N
incidence NN N
of IN N
anuria NNS N
and CC N
a DT N
significantly RB N
faster RBR N
recovery NN N
from IN N
hypertension NN N
in IN N
the DT N
treated JJ N
group NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
were VBD N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
for IN N
pain NN N
at IN N
rest NN N
and CC N
on IN N
movement NN N
( ( N
dynamic JJ N
) ) N
, , N
heart NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
pruritus NN N
, , N
itching NN N
, , N
nausea NN N
, , N
vomiting VBG N
and CC N
sedation NN N
. . N

Hence RB N
, , N
although IN N
there EX N
was VBD N
evidence NN N
for IN N
a DT N
background NN N
endemic JJ N
response NN N
to TO N
both DT N
leishmanial JJ N
and CC N
mycobacterial JJ N
antigens NNS N
, , N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
vaccination NN N
per IN N
se NN N
led VBD N
to TO N
a DT N
potentially RB N
disease JJ N
exacerbatory JJ N
level NN N
of IN N
TH2-associated NNP N
antibody NN N
response NN N
especially RB N
with IN N
respect NN N
to TO N
the DT N
anti-leishmanial JJ N
response NN N
. . N

Moreover RB N
, , N
the DT N
technic NN N
of IN N
exteriorization NN N
is VBZ N
a DT N
safe JJ N
adjunct NN N
to TO N
management NN N
and CC N
is VBZ N
recommended VBN N
in IN N
any DT N
patient NN N
with IN N
a DT N
colonic JJ N
injury NN N
above IN N
18 CD N
cm NN N
in IN N
which WDT N
one CD N
suture NN N
line NN N
is VBZ N
required VBN N
and CC N
in IN N
which WDT N
the DT N
additional JJ N
operating NN N
time NN N
of IN N
twenty NN N
minutes NNS N
will MD N
not RB N
compromise VB N
the DT N
management NN N
of IN N
secondary JJ N
injuries NNS N
. . N

RESULTS NNP N
Total NNP N
knee NN N
scores NNS N
, , N
knee NN N
function NN N
scores NNS N
, , N
pain NN N
scores NNS N
, , N
WOMAC NNP N
scores VBZ N
, , N
knee VB N
motion NN N
, , N
and CC N
activity NN N
scores NNS N
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
preoperatively RB N
or CC N
at IN N
the DT N
time NN N
of IN N
the DT N
final JJ N
follow-up NN N
. . N

RESULTS JJ N
Patients NNS N
with IN N
a DT N
short JJ N
duration NN N
of IN N
untreated JJ N
negative JJ N
symptoms NNS N
( ( N
DUNS NNP N
) ) N
or CC N
a DT N
short JJ N
duration NN N
of IN N
untreated JJ N
positive JJ N
symptoms NNS N
( ( N
DUPS NNP N
) ) N
outperformed VBD N
patients NNS p
with IN N
a DT N
long JJ N
duration NN N
of IN N
untreated JJ N
symptoms NNS N
on IN N
memory NN N
tasks NNS N
and CC N
a DT N
pre-attentional JJ N
visual JJ N
task NN N
but CC N
not RB N
on IN N
measures NNS N
of IN N
verbal JJ N
fluency NN N
, , N
attention NN N
, , N
reaction NN N
time NN N
, , N
visual JJ N
processing NN N
and CC N
executive NN N
functions NNS N
. . N

Furthermore RB N
, , N
young JJ N
children NNS N
only RB N
succeeded VBD N
on IN N
TOM NNP N
items NNS N
that WDT N
tap VBP N
the DT N
basic JJ N
domains NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g JJ N
, , N
emotion JJ N
recognition NN N
) ) N
, , N
whereas JJ N
older JJR N
children NNS N
also RB N
passed VBD N
items NNS N
that WDT N
measure VBP N
the DT N
more JJR N
mature JJ N
areas NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g JJ N
, , N
understanding NN N
of IN N
humor NN N
, , N
understanding VBG N
of IN N
second-order JJ N
beliefs NNS N
) ) N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
all-cause JJ N
mortality NN N
, , N
development NN N
of IN N
renal JJ N
and CC N
visual JJ N
impairment NN N
, , N
peripheral JJ N
neuropathy NN N
, , N
health NN N
service NN N
costs NNS N
, , N
self-reported JJ N
quality NN N
of IN N
life NN N
, , N
functional JJ N
status NN N
and CC N
health NN N
utility NN N
. . N

CONCLUSION NNP N
Despite IN N
the DT N
fact NN N
that IN N
the DT N
combination NN N
of IN N
anxiolytics NNS N
and CC N
analgesics NNS N
as IN N
compared VBN N
with IN N
analgesics NNS N
alone RB N
reduced VBN N
anxiety NN N
and CC N
the DT N
requirement NN N
of IN N
Morphine NNP N
in IN N
the DT N
prehospital JJ N
setting NN N
of IN N
acute JJ N
coronary JJ N
syndrome NN N
, , N
this DT N
strategy NN N
did VBD N
not RB N
reduce VB N
patients NNS p
' POS N
estimation NN N
of IN N
pain NN N
( ( N
primary JJ N
endpoint NN N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
on IN N
the DT N
10-item JJ N
version NN N
of IN N
the DT N
Neuropsychiatric NNP N
Inventory NNP N
Questionnaire NNP N
( ( N
NPI-Q NNP N
) ) N
, , N
the DT N
Cornell NNP N
Scale NNP N
for IN N
Depression NNP N
in IN N
Dementia NNP N
( ( N
CSDD NNP N
) ) N
and CC N
the DT N
Quality NN N
of IN N
Life NNP N
in IN N
Late-Stage NNP N
Dementia NNP N
( ( N
QUALID NNP N
) ) N
scale NN N
. . N

However RB N
, , N
a DT N
uniform JJ N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
that WDT N
predicts VBZ N
mobilization NN N
failure NN N
has VBZ N
not RB N
been VBN N
defined VBN N
, , N
resulting VBG N
in IN N
the DT N
development NN N
of IN N
institute-specific JJ N
algorithms NN N
for IN N
mobilization NN N
, , N
particularly RB N
regarding VBG N
the DT N
decision NN N
of IN N
when WRB N
to TO N
use VB N
the DT N
novel JJ N
stem NN N
cell NN N
mobilization NN N
agent NN N
plerixafor NN N
. . N

We PRP N
present VBP N
an DT N
economic JJ N
evaluation NN N
using VBG N
data NNS N
from IN N
the DT N
Distal NNP N
Radius NNP N
Acute NNP N
Fracture NNP N
Fixation NNP N
Trial NNP N
( ( N
DRAFFT NNP N
) ) N
to TO N
compare VB N
the DT N
relative JJ N
cost NN N
effectiveness NN N
of IN N
percutaneous JJ N
Kirschner NNP N
wire NN N
( ( N
K-wire NNP N
) ) N
fixation NN N
and CC N
volar JJ N
locking-plate JJ N
fixation NN N
for IN N
patients NNS p
with IN N
dorsally-displaced JJ N
fractures NNS N
of IN N
the DT N
distal JJ N
radius NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
baseline NN N
characteristics NNS N
of IN N
participants NNS N
with IN N
heart NN N
failure NN N
with IN N
preserved JJ N
ejection NN N
fraction NN N
as IN N
it PRP N
relates VBZ N
to TO N
impaired JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
and CC N
depression NN N
, , N
identify JJ N
predictors NNS N
of IN N
poor JJ N
QOL NNP N
and CC N
depression NN N
, , N
and CC N
determine VB N
the DT N
correlation NN N
between IN N
QOL NNP N
and CC N
depression NN N
. . N

Since IN N
the DT N
long-term JJ N
prognosis NN N
for IN N
patients NNS p
with IN N
congestive JJ N
heart NN N
failure NN N
remains VBZ N
very RB N
poor JJ N
and CC N
the DT N
incidence NN N
of IN N
arrhythmic JJ N
death NN N
is VBZ N
high JJ N
, , N
every DT N
new JJ N
drug NN N
to TO N
be VB N
employed VBN N
against IN N
this DT N
disease NN N
should MD N
be VB N
thoroughly RB N
tested VBN N
in IN N
order NN N
to TO N
rule VB N
out RP N
any DT N
possible JJ N
arrhythmogenic JJ N
action NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
other JJ N
behavioural JJ N
or CC N
psychological JJ N
measures NNS N
, , N
although IN N
at IN N
the DT N
4-week JJ N
follow-up JJ N
the DT N
control NN N
group NN N
perceived VBD N
their PRP$ N
risk NN N
for IN N
breast NN N
cancer NN N
, , N
relative VBP N
to TO N
other JJ N
women NNS N
their PRP$ N
age NN N
, , N
as IN N
a DT N
lot NN N
lower JJR N
than IN N
did VBD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
intravaginal JJ N
electrical JJ N
stimulation NN N
( ( N
ES NNP N
) ) N
of IN N
the DT N
pelvic JJ N
floor NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ N
women NNS N
, , N
and CC N
to TO N
determine VB N
whether IN N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
is VBZ N
a DT N
preferable JJ N
treatment NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ N
women NNS N
. . N

Secondary JJ N
outcome NN N
variables NNS N
included VBD N
OA NNP N
pain NN N
in IN N
the DT N
target NN N
joint NN N
, , N
patient NN N
's POS N
and CC N
physician NN N
's POS N
global JJ N
assessments NNS N
of IN N
disease NN N
activity NN N
, , N
Short NNP N
Arthritis NNP N
assessment JJ N
Scale NNP N
( ( N
SAS NNP N
) ) N
total NN N
score NN N
, , N
rescue NN N
medication NN N
use NN N
, , N
and CC N
safety NN N
and CC N
tolerability NN N
. . N

OBJECTIVES IN N
The DT N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
an DT N
educational JJ N
intervention NN N
for IN N
health NN N
care NN N
providers NNS N
would MD N
result VB N
in IN N
improved JJ N
documentation NN N
of IN N
cases NNS N
of IN N
possible JJ N
physical JJ N
child NN N
abuse NN N
in IN N
children NNS N
< VBP N
36 CD N
months NNS N
old JJ N
treated VBN N
in IN N
the DT N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
setting NN N
. . N

Therefore RB N
, , N
we PRP N
concluded VBD N
that IN N
the DT N
ipsilateral JJ N
arm NN N
swing NN N
may MD N
partially RB N
affect VB N
the DT N
depression NN N
of IN N
the DT N
soleus JJ N
H-reflex NNP N
during IN N
the DT N
arm NN N
swing NN N
phase NN N
of IN N
walking VBG N
but CC N
is VBZ N
not RB N
responsible JJ N
for IN N
depression NN N
of IN N
the DT N
soleus NN N
H-reflex NNP N
throughout IN N
the DT N
entire JJ N
walking NN N
cycle NN N
. . N

The DT N
acceptability NN N
curve NN N
showed VBD N
that IN N
, , N
even RB N
in IN N
the DT N
case NN N
of IN N
a DT N
maximum JJ N
threshold JJ N
value NN N
of IN N
? . N
per IN N
QALY NNP N
gained VBD N
, , N
the DT N
probability NN N
of IN N
AS NNP N
being VBG N
more RBR N
cost-effective JJ N
than IN N
regular JJ N
cardiac JJ N
surgery NN N
did VBD N
not RB N
reach VB N
beyond IN N
50 CD N
% NN N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
the DT N
5-year JJ N
follow-up JJ N
data NNS N
, , N
there EX N
is VBZ N
strong JJ N
evidence NN N
that IN N
surgical JJ N
manipulation NN N
of IN N
one CD N
or CC N
more JJR N
migraine JJ N
trigger NN N
sites NNS N
can MD N
successfully RB N
eliminate VB N
or CC N
reduce VB N
the DT N
frequency NN N
, , N
duration NN N
, , N
and CC N
intensity NN N
of IN N
migraine NN N
headache NN N
in IN N
a DT N
lasting JJ N
manner NN N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
the DT N
joint JJ N
effect NN N
of IN N
the DT N
methylenetetrahydrofolate NN N
reductase NN N
( ( N
MTHFR NNP N
) ) N
C677T NNP N
and CC N
A1298C NNP N
, , N
methionine NN N
synthase NN N
( ( N
MTR NNP N
) ) N
A2756G NNP N
, , N
and CC N
methionine JJ N
synthase NN N
reductase NN N
( ( N
MTRR NNP N
) ) N
A66G NNP N
polymorphisms NN N
on IN N
folate JJ N
deficiency NN N
in IN N
a DT N
Chinese JJ N
hypertensive JJ N
population NN N
. . N

Using VBG N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
, , N
we PRP N
examined VBD N
whether IN N
oxytocin NN i
would MD N
enhance VB N
emotion NN N
recognition NN N
from IN N
facial JJ N
sections NNS N
of IN N
the DT N
eye NN N
vs VBZ N
the DT N
mouth JJ N
region NN N
and CC N
modulate JJ N
regional JJ N
activity NN N
in IN N
brain NN N
areas NNS N
associated VBN N
with IN N
face NN N
perception NN N
in IN N
both DT N
adults NNS N
with IN N
AS NNP N
, , N
and CC N
a DT N
neurotypical JJ N
control NN N
group NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
clomipramine NN N
hydrochloride NN N
, , N
a DT N
serotonin JJ N
reuptake NN N
blocker NN N
with IN N
unique JJ N
anti-obsessional JJ N
properties NNS N
, , N
is VBZ N
differentially RB N
effective JJ N
for IN N
obsessive-compulsive JJ N
and CC N
stereotyped VBD N
motor NN N
behaviors NNS N
in IN N
autistic JJ N
disorder NN N
compared VBN N
with IN N
placebo NN N
and CC N
with IN N
the DT N
noradrenergic JJ N
tricyclic JJ N
antidepressant NN N
agent NN N
, , N
desipramine JJ N
hydrochloride NN N
. . N

Efficacy NN N
was VBD N
measured VBN N
through IN N
pain NN N
relief NN N
scores NNS N
, , N
number NN N
of IN N
daily JJ N
doses NNS N
of IN N
study NN N
medication NN N
, , N
number NN N
of IN N
daily JJ N
doses NNS N
of IN N
supplemental JJ N
analgesics NNS N
, , N
number NN N
of IN N
patients NNS p
who WP N
discontinued VBD N
therapy NN i
due JJ N
to TO N
an DT N
unsatisfactory JJ N
analgesic JJ N
response NN N
, , N
and CC N
global JJ N
assessment NN N
scores NNS N
. . N

OBJECTIVE IN N
We PRP N
collected VBD N
preliminary JJ N
data NNS N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
supplemental JJ N
arginine NN N
to TO N
improve VB N
natural JJ N
killer NN N
cell NN N
cytotoxicity NN N
in IN N
a DT N
sample NN N
of IN N
persons NNS N
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
and CC N
acquired VBD N
immunodeficiency NN N
syndrome NN N
( ( N
AIDS NNP N
) ) N
. . N

Repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
is VBZ N
a DT N
safe JJ N
and CC N
efficacious JJ N
technique NN N
when WRB N
targeting VBG N
specific JJ N
areas NNS N
of IN N
cortical JJ N
dysfunction NN N
in IN N
major JJ N
depressive JJ N
disorder NN N
, , N
and CC N
a DT N
similar JJ N
approach NN N
could MD N
yield VB N
therapeutic JJ N
benefits NNS N
in IN N
ASD NNP N
, , N
if IN N
applied VBN N
to TO N
relevant VB N
cortical JJ N
regions NNS N
. . N

CONCLUSIONS VB N
This DT N
4-site JJ N
PEP NNP N
regimen NNS N
proved VBD N
as RB N
immunogenic JJ N
as IN N
current JJ N
regimens NNS N
, , N
and CC N
has VBZ N
the DT N
advantages NNS N
of IN N
requiring VBG N
fewer JJR N
clinic JJ N
visits NNS N
, , N
being VBG N
more RBR N
practicable JJ N
, , N
and CC N
having VBG N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
, , N
especially RB N
in IN N
inexperienced JJ N
hands NNS N
, , N
than IN N
the DT N
2-site JJ N
regimen NNS N
. . N

CONCLUSION NNP N
Imiquimod NNP N
5 CD N
% NN N
cream NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
external JJ N
genital NN N
and CC N
perianal JJ N
warts NNS N
and CC N
provides VBZ N
a DT N
significant JJ N
benefit NN N
in IN N
comparison NN N
with IN N
vehicle NN N
cream NN N
, , N
independent JJ N
of IN N
gender NN N
, , N
initial JJ N
wart NN N
size NN N
, , N
duration NN N
of IN N
current JJ N
outbreak NN N
of IN N
warts NNS N
, , N
previous JJ N
wart NN N
treatment NN N
, , N
or CC N
tobacco NN N
use NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
, , N
acceptability NN N
, , N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP N
to TO N
Lava NNP N
Mountain NNP N
( ( N
QTLM NNP N
) ) N
computer NN N
game NN N
on IN N
dietary JJ N
behaviors NNS N
, , N
physical JJ N
activity NN N
behaviors NNS N
, , N
and CC N
psychosocial JJ N
factors NNS N
among IN N
ethnically RB N
diverse JJ N
children NNS N
in IN N
Texas NNP N
. . N

In IN N
the DT N
entire JJ N
study NN N
sample NN N
, , N
correlations NNS N
between IN N
SSQ NNP N
patient JJ N
ratings NNS N
and CC N
QLQ-C30 JJ N
change NN N
scores NNS N
were VBD N
lower JJR N
than IN N
previously RB N
reported VBN N
, , N
ranging VBG N
between IN N
0.15 CD N
and CC N
0.24 CD N
for IN N
the DT N
four CD N
different JJ N
domains NNS N
, , N
but CC N
were VBD N
higher JJR N
when WRB N
QOL NNP N
scores VBZ N
producing VBG N
ceiling NN N
effects NNS N
were VBD N
omitted VBN N
. . N

Hence RB N
the DT N
current JJ N
trial NN N
was VBD N
conducted VBN N
with IN N
the DT N
objective NN N
to TO N
show VB N
the DT N
therapeutic JJ N
equivalence NN N
of IN N
two CD N
treatments NNS N
( ( N
placebo NN N
and CC N
amoxycillin NN i
) ) N
for IN N
children NNS N
presenting VBG N
with IN N
non-severe JJ N
pneumonia NN N
with IN N
wheeze NN N
, , N
who WP N
have VBP N
persistent VBN N
fast RB N
breathing NN N
after IN N
nebulisation NN N
with IN N
salbutamol NN N
, , N
and CC N
have VBP N
normal JJ N
chest NN N
radiograph NN N
. . N

The DT N
recommendation NN N
for IN N
practice NN N
in IN N
settings NNS N
that WDT N
are VBP N
similar JJ N
to TO N
the DT N
Danish JJ N
setting NN N
is VBZ N
to TO N
provide VB N
follow-up JJ N
with IN N
referral JJ N
to TO N
available JJ N
local JJ N
support NN N
programmes NNS N
when WRB N
needed VBN N
, , N
and CC N
to TO N
restrict VB N
large JJ N
multifaceted VBN N
intervention NN N
programmes NNS N
to TO N
patients NNS p
and CC N
caregivers NNS N
with IN N
special JJ N
needs NNS N
until IN N
further JJ N
evidence NN N
for IN N
cost-effectiveness JJ N
emerges NNS N
. . N

The DT N
Self-Care JJ N
Rehabilitation NNP N
in IN N
Pediatric NNP N
Asthma NNP N
( ( N
SCRPA NNP N
) ) N
project NN N
was VBD N
designed VBN N
to TO N
ascertain VB N
the DT N
level NN N
to TO N
which WDT N
children NNS N
with IN N
asthma NN N
are VBP N
able JJ N
to TO N
acquire VB N
the DT N
asthma NN N
knowledge NN N
and CC N
skills NNS N
presented VBN N
in IN N
a DT N
self-management JJ N
training NN N
program NN N
conducted VBN N
by IN N
the DT N
American NNP N
Lung NNP N
Association NNP N
of IN N
Utah NNP N
and CC N
the DT N
effect NN N
of IN N
such JJ N
training NN N
on IN N
the DT N
asthma JJ N
experience NN N
. . N

CONCLUSIONS NNP N
Differences NNS N
in IN N
outcomes NNS N
between IN N
medical JJ N
and CC N
chiropractic JJ N
care NN N
without IN N
physical JJ N
therapy NN i
or CC N
modalities NNS N
are VBP N
not RB N
clinically RB N
meaningful JJ N
, , N
although IN N
chiropractic JJ N
may MD N
result VB N
in IN N
a DT N
greater JJR N
likelihood NN N
of IN N
perceived JJ N
improvement NN N
, , N
perhaps RB N
reflecting VBG N
satisfaction NN N
or CC N
lack NN N
of IN N
blinding NN N
. . N

RESULTS NNP N
TB1 NNP N
( ( N
containing VBG N
ginseng NN N
leaf NN N
, , N
cistanche NN N
, , N
fleeceflower JJR N
root NN N
, , N
immature NN N
bitter JJ N
orange NN N
, , N
rhubarb NN N
, , N
etc FW N
) ) N
could MD N
improve VB N
various JJ N
symptoms NNS N
of IN N
aging VBG N
, , N
and CC N
had VBD N
the DT N
effect NN N
in IN N
regulating VBG N
immune NN N
and CC N
endocrinal JJ N
function NN N
, , N
scavenging VBG N
free JJ N
radicals NNS N
and CC N
adjusting VBG N
coli JJ N
flora NNS N
. . N

The DT N
RESCUEicp NNP N
( ( N
Randomized NNP N
Evaluation NNP N
of IN N
Surgery NNP N
with IN N
Craniectomy NNP N
for IN N
Uncontrollable JJ N
Elevation NN N
of IN N
intracranial JJ N
pressure NN N
) ) N
study NN N
has VBZ N
been VBN N
established VBN N
to TO N
determine VB N
whether IN N
decompressive JJ N
craniectomy NN N
has VBZ N
a DT N
role NN N
in IN N
the DT N
management NN N
of IN N
patients NNS p
with IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
raised VBD N
intracranial JJ N
pressure NN N
that WDT N
does VBZ N
not RB N
respond VB N
to TO N
initial JJ N
treatment NN N
measures NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN N
iron NN N
deficiency NN N
anemia NN N
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
, , N
rapid JJ N
IV NNP N
administration NN N
of IN N
large JJ N
doses NNS N
of IN N
a DT N
new JJ N
iron NN N
agent NN N
, , N
ferric JJ N
carboxymaltose NN N
, , N
is VBZ N
more RBR N
effective JJ N
than IN N
oral JJ N
iron NN N
therapy NN i
in IN N
correcting VBG N
anemia NN N
, , N
replenishing VBG N
iron NN N
stores NNS N
, , N
and CC N
improving VBG N
quality NN N
of IN N
life NN N
. . N

Asthma JJ N
medications NNS N
were VBD N
stepped VBN N
up RP N
when WRB N
indicated VBN N
after IN N
46.0 CD N
% NN N
of IN N
these DT N
visits NNS N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
35.6 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
when WRB N
asthma NN N
symptoms NNS N
warranted VBD N
a DT N
step NN N
up RB N
in IN N
therapy NN i
, , N
medication NN N
changes NNS N
occurred VBD N
earlier RBR N
among IN N
the DT N
intervention NN N
children NNS N
. . N

Although IN N
TOISD NNP N
might MD N
not RB N
be VB N
necessarily RB N
on IN N
surgical JJ N
incisional JJ N
site NN N
not RB N
infested VBN N
with IN N
bacteria NNS N
for IN N
the DT N
initial JJ N
post-operation NN N
days NNS N
, , N
it PRP N
is VBZ N
helpful JJ N
in IN N
preventing VBG N
further JJ N
transcription NN N
and CC N
division NN N
for IN N
opportunistic JJ N
bacteria NNS N
, , N
thus RB N
might MD N
reduce VB N
the DT N
risk NN N
of IN N
superficial JJ N
incisional JJ N
SSI NNP N
. . N

The DT N
level NN N
of IN N
an DT N
absence NN N
of IN N
cold JJ N
sensation NN N
, , N
the DT N
level NN N
of IN N
pinprick JJ N
analgesia NN N
, , N
and CC N
time NN N
to TO N
achieve VB N
sensory JJ N
block NN N
to TO N
T4 NNP N
level NN N
of IN N
Group NNP N
H NNP N
was VBD N
significantly RB N
higher JJR N
than IN N
Group NNP N
B NNP N
and CC N
Group NNP N
L. NNP N
The DT N
degree NN N
of IN N
motor NN N
block NN N
was VBD N
comparable JJ N
in IN N
all DT N
groups NNS N
. . N

To TO N
determine VB N
the DT N
effects NNS N
of IN N
dietary JJ N
glycemic JJ N
load NN N
( ( N
GL NNP N
) ) N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
during IN N
weight JJ N
loss NN N
, , N
body NN N
weight NN N
and CC N
eating VBG N
behavior JJ N
self-efficacy NN N
were VBD N
measured VBN N
every DT N
six CD N
months NNS N
in IN N
overweight JJ N
adults NNS N
participating VBG N
in IN N
a DT N
12-mo JJ N
randomized JJ N
trial NN N
testing VBG N
energy-restricted JJ N
diets NNS N
differing VBG N
in IN N
GL NNP N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
lowering VBG N
blood NN N
pressure NN N
by IN N
angiotensin JJ N
II-receptor NNP N
blockers NNS N
( ( N
ARB NNP N
) ) N
has VBZ N
more JJR N
beneficial JJ N
effects NNS N
than IN N
by IN N
conventional JJ N
calcium NN N
channel NN N
blockers NNS N
( ( N
CCB NNP N
) ) N
on IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
with IN N
hypertension NN N
. . N

CONCLUSIONS NNP N
With IN N
regard NN N
to TO N
gait VB N
kinematics NNS N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
( ( N
three CD N
months NNS N
) ) N
, , N
the DT N
present JJ N
study NN N
showed VBD N
no DT N
significant JJ N
benefit NN N
for IN N
patients NNS p
who WP N
underwent VBD N
a DT N
total JJ N
hip NN N
arthroplasty NN N
through IN N
a DT N
minimally RB N
invasive JJ N
Watson-Jones NNS N
approach NN N
in IN N
comparison NN N
with IN N
those DT N
who WP N
were VBD N
managed VBN N
with IN N
a DT N
standard JJ N
transgluteal NN N
approach NN N
. . N

This DT N
study NN N
suggests VBZ N
that IN N
, , N
in IN N
this DT N
clinical JJ N
setting NN N
, , N
the DT N
addition NN N
of IN N
deep JJ N
breathing NN N
and CC N
coughing NN N
exercises NNS N
to TO N
a DT N
physiotherapist-directed JJ N
program NN N
of IN N
early JJ N
mobilisation NN N
does VBZ N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
significant JJ N
postoperative JJ N
pulmonary JJ N
complications NNS N
in IN N
high JJ N
risk NN N
open JJ N
abdominal JJ N
surgery NN N
subjects NNS N
. . N

This DT N
lack NN N
of IN N
interest NN N
is VBZ N
regretful JJ N
particularly RB N
considering VBG N
the DT N
fact NN N
that IN N
anesthetics NNS N
during IN N
neurosurgery NN N
are VBP N
an DT N
issue NN N
of IN N
extreme JJ N
sensitivity NN N
and CC N
subtlety NN N
, , N
where WRB N
the DT N
cerebral JJ N
oxygenation NN N
process NN N
plays VBZ N
a DT N
significant JJ N
role NN N
in IN N
the DT N
neuroprotective JJ N
mechanisms NN N
. . N

BACKGROUND NNP N
Unstuck NNP N
and CC N
On IN N
Target NNP N
( ( N
UOT NNP N
) ) N
is VBZ N
an DT N
executive JJ N
function NN N
( ( N
EF NNP N
) ) N
intervention NN N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
targeting VBG N
insistence NN N
on IN N
sameness NN N
, , N
flexibility NN N
, , N
goal-setting NN N
, , N
and CC N
planning VBG N
through IN N
a DT N
cognitive-behavioral JJ N
program NN N
of IN N
self-regulatory JJ N
scripts NNS N
, , N
guided/faded VBD N
practice NN N
, , N
and CC N
visual/verbal JJ N
cueing NN N
. . N

CONCLUSIONS JJ N
Patients NNS N
with IN N
heart NN N
failure NN N
with IN N
preserved JJ N
ejection NN N
fraction NN N
, , N
who WP N
were VBD N
younger JJR N
had VBD N
higher JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
or CC N
comorbid NN N
angina NNS N
pectoris NN N
, , N
had VBD N
lower JJR N
activity NN N
levels NNS N
, , N
lived VBD N
in IN N
Eastern NNP N
Europe NNP N
or CC N
were VBD N
taking VBG N
hypoglycemic JJ N
agents NNS N
, , N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
impaired VBN N
QOL NNP N
and CC N
depression NN N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
plasma NN N
levels NNS N
and CC N
age NN N
, , N
level NN N
of IN N
intellectual JJ N
functioning NN N
, , N
scores NNS N
on IN N
the DT N
14 CD N
selected VBD N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
items NNS N
, , N
Clinical NNP N
Global NNP N
Impressions NNP N
, , N
Global NNP N
Clinical NNP N
Consensus NNP N
, , N
and CC N
the DT N
CPRS NNP N
hyperactivity NN N
factor NN N
. . N

Quantitative JJ N
measures NNS N
of IN N
pain NN N
intensity NN N
, , N
situational JJ N
anxiety NN N
, , N
and CC N
pain NN N
distress NN N
( ( N
as IN N
perceived VBN N
by IN N
the DT N
parent NN N
) ) N
were VBD N
assessed VBN N
by IN N
using VBG N
the DT N
7-point JJ N
Facial NNP N
Pain NNP N
Scale NNP N
, , N
State NNP N
Trait NNP N
Anxiety NNP N
Inventory NNP N
for IN N
Children NNP N
, , N
and CC N
a DT N
visual JJ N
analog NN N
scale NN N
, , N
respectively RB N
, , N
before IN N
and CC N
after IN N
laceration NN N
repair NN N
. . N

The DT N
present JJ N
study NN N
sets VBZ N
out RP N
to TO N
test VB N
the DT N
effects NNS N
of IN N
testosterone NN N
administration NN N
in IN N
healthy JJ N
female NN N
volunteers NNS N
using VBG N
an DT N
objective JJ N
implicit JJ N
measure NN N
of IN N
social JJ N
motivational JJ N
behavior NN N
: : N
the DT N
social JJ N
Approach-Avoidance NNP N
Task NNP N
, , N
a DT N
reaction NN N
time NN N
task NN N
requiring VBG N
participants NNS N
to TO N
approach VB N
or CC N
avoid VB N
visually RB N
presented VBN N
emotional JJ N
( ( N
happy JJ N
, , N
angry JJ N
, , N
and CC N
neutral JJ N
) ) N
faces VBZ N
. . N

Therefore RB N
, , N
the DT N
bleeding VBG N
complications NNS N
of IN N
intermittent JJ N
heparin NN N
therapy NN i
could MD N
have VB N
been VBN N
due JJ N
to TO N
the DT N
higher JJR N
dose NN N
, , N
and CC N
the DT N
recurrences NNS N
associated VBN N
with IN N
continuous JJ N
heparin NNS N
therapy NN i
may MD N
have VB N
resulted VBN N
from IN N
lower JJR N
doses NNS N
rather RB N
than IN N
from IN N
differences NNS N
in IN N
the DT N
method NN N
of IN N
administration NN N
. . N

METHODS NNP N
To TO N
enter VB N
the DT N
study NN N
, , N
children NNS N
with IN N
sickle NN N
cell NN N
anemia NN N
and CC N
no DT N
history NN N
of IN N
stroke NN N
had VBD N
to TO N
have VB N
undergone JJ N
two CD N
transcranial JJ N
Doppler NNP N
studies NNS N
that WDT N
showed VBD N
that IN N
the DT N
time-averaged JJ N
mean JJ N
blood-flow JJ N
velocity NN N
in IN N
the DT N
internal JJ N
carotid NN N
or CC N
middle JJ N
cerebral JJ N
artery NN N
was VBD N
200 CD N
cm JJ N
per IN N
second NN N
or CC N
higher JJR N
. . N

Clinical JJ N
assessment NN N
was VBD N
based VBN N
on IN N
House-Brackmann NNP N
scale NN N
( ( N
H-B NNP N
) ) N
, , N
neurophysiological JJ N
diagnostics NNS N
included VBD N
facial JJ N
electroneurography NN N
[ NNP N
ENG NNP N
, , N
compound NN N
muscle NN N
action NN N
potential NN N
( ( N
CMAP NNP N
) ) N
] NN N
, , N
mimetic JJ N
muscle NN N
electromyography NN N
( ( N
EMG NNP N
) ) N
and CC N
blink-reflex JJ N
examinations NNS N
( ( N
BR NNP N
) ) N
. . N

BACKGROUND IN N
The DT N
primary JJ N
aim NN N
and CC N
central JJ N
hypothesis NN N
of IN N
the DT N
study NN N
are VBP N
that IN N
a DT N
designated VBN N
syncope NN N
unit NN N
in IN N
the DT N
emergency NN N
department NN N
improves VBZ N
diagnostic JJ N
yield NN N
and CC N
reduces NNS N
hospital JJ N
admission NN N
for IN N
patients NNS p
with IN N
syncope NN N
who WP N
are VBP N
at IN N
intermediate JJ N
risk NN N
for IN N
an DT N
adverse JJ N
cardiovascular JJ N
outcome NN N
. . N

CONCLUSION NN N
It PRP N
is VBZ N
possible JJ N
to TO N
test VB N
the DT N
effects NNS N
of IN N
LKM NNP N
with IN N
tactile JJ N
and CC N
non-tactile JJ N
blinding NN N
strategies NNS N
; : N
even RB N
with IN N
blinding VBG N
in IN N
this DT N
small JJ N
preliminary JJ N
study NN N
, , N
subjects NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
well-being NN N
which WDT N
were VBD N
reflected VBN N
in IN N
objective JJ N
physiologic JJ N
measures NNS N
of IN N
autonomic JJ N
activity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
establish VB N
a DT N
model NN N
for IN N
randomized VBN N
controlled JJ N
trial NN N
research NN N
, , N
identify VB N
appropriate JJ N
outcome NN N
measures NNS N
, , N
and CC N
address VB N
the DT N
effectiveness NN N
of IN N
sensory JJ N
integration NN N
( ( N
SI NNP N
) ) N
interventions NNS N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
resolution NN N
of IN N
sleep JJ N
disturbances NNS N
, , N
sleep VBP N
quality NN N
measured VBN N
by IN N
the DT N
Pittsburgh NNP N
Sleep NNP N
Quality NNP N
Index NNP N
( ( N
PSQI NNP N
) ) N
questionnaire NN N
, , N
and CC N
work NN N
productivity NN N
measured VBN N
by IN N
the DT N
Work NNP N
Productivity NNP N
and CC N
Activity NNP N
Impairment NNP N
Questionnaire NNP N
. . N

Patient-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
of IN N
midazolam NN i
at IN N
3-minute JJ N
intervals NNS N
provides VBZ N
comparable JJ N
conditions NNS N
to TO N
that DT N
of IN N
doctor-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
at IN N
1-minute JJ N
intervals NNS N
, , N
except IN N
for IN N
the DT N
longer JJR N
duration NN N
taken VBN N
for IN N
the DT N
patients NNS p
to TO N
achieve VB N
satisfactory JJ N
sedation NN N
prior RB N
to TO N
surgery NN N
. . N

DISCUSSION NN N
If IN N
the DT N
trial NN N
demonstrates VBZ N
that IN N
diamorphine NN N
provides VBZ N
better RBR N
analgesia NN N
with IN N
fewer JJR N
side NN N
effects NNS N
in IN N
mother NN N
and CC N
neonate NN N
this DT N
could MD N
lead VB N
to TO N
a DT N
change NN N
in IN N
national JJ N
practice NN N
and CC N
result NN N
in IN N
diamorphine NN N
becoming VBG N
the DT N
preferred JJ N
intramuscular JJ N
opioid NN N
for IN N
analgesia NN N
in IN N
labour NN N
. . N

Inclusion NN N
criteria NNS N
were VBD N
as IN N
follows VBZ N
: : N
patients NNS p
with IN N
permanent JJ N
molars NNS N
presenting VBG N
deep JJ N
caries NNS N
lesions NNS N
( ( N
lesion NN N
affecting VBG N
? . N
1/2 CD N
of IN N
the DT N
dentin NN i
on IN N
radiographic JJ N
examination NN N
) ) N
, , N
positive JJ N
response NN N
to TO N
a DT N
cold JJ N
test NN N
, , N
absence NN N
of IN N
spontaneous JJ N
pain NN N
, , N
negative JJ N
sensitivity NN N
to TO N
percussion NN N
, , N
and CC N
absence NN N
of IN N
periapical JJ N
lesions NNS N
( ( N
radiographic JJ N
examination NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
findings NNS N
revealed VBD N
the DT N
feasibility NN N
of IN N
including VBG N
greater JJR N
levels NNS N
of IN N
microalgal JJ N
biomass NN N
as IN N
a DT N
source NN N
of IN N
feed NN N
protein NN N
for IN N
laying VBG N
hens NNS N
and CC N
a DT N
novel JJ N
potential NN N
of IN N
the DT N
biomass NN N
in IN N
improving VBG N
dietary JJ N
protein NN N
digestion NN N
and CC N
body NN N
protein VBP N
metabolism NN N
than IN N
previously RB N
perceived VBN N
. . N

This DT N
indicated VBD N
the DT N
beneficial JJ N
effect NN N
on IN N
ulcers NNS N
of IN N
oral JJ N
administration NN N
of IN N
EGF NNP N
with IN N
agents NNS N
allowing VBG N
it PRP N
to TO N
remain VB N
at IN N
high JJ N
levels NNS N
in IN N
the DT N
stomach NN N
, , N
whereas IN N
most JJS N
reports NNS N
suggested VBD N
less RBR N
effect NN N
of IN N
oral JJ N
EGF NNP N
on IN N
healing NN N
of IN N
gastroduodenal JJ N
ulcers NNS N
. . N

These DT N
results NNS N
provide VBP N
insight RB N
into IN N
the DT N
nature NN N
of IN N
multisensory NN N
processing NN N
while IN N
also RB N
revealing VBG N
a DT N
continuum NN N
over IN N
which WDT N
perceptual JJ N
abilities NNS N
correlate VBP N
with IN N
symptoms NNS N
of IN N
autism NN N
and CC N
that IN N
this DT N
continuum NN N
is VBZ N
not RB N
just RB N
specific JJ N
to TO N
clinical JJ N
populations NNS N
but CC N
is VBZ N
present JJ N
within IN N
the DT N
general JJ N
population NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
empirical JJ N
treatment NN N
with IN N
antifungal JJ N
drugs NNS N
in IN N
the DT N
26 CD N
weeks NNS N
after IN N
enrolment NN N
( ( N
for IN N
the DT N
biomarker-based JJ N
diagnostic JJ N
strategy NN N
, , N
a DT N
single JJ N
postive JJ N
galactomannan NN N
or CC N
PCR NNP N
result NN N
was VBD N
deemed VBN N
insufficient JJ N
to TO N
confirm VB N
invasive JJ N
aspergillosis NN N
, , N
so RB N
treatment NN N
in IN N
this DT N
context NN N
was VBD N
classified VBN N
as IN N
empirical JJ N
) ) N
. . N

A DT N
new JJ N
endometrial JJ N
cytologic NN N
sampling VBG N
device NN N
, , N
softcyte NN N
, , N
was VBD N
used VBN N
in IN N
cytological JJ N
screening NN N
for IN N
endometrial JJ N
cancer NN N
, , N
and CC N
was VBD N
compared VBN N
with IN N
the DT N
endocyte NN N
with IN N
regard NN N
to TO N
manipulability NN N
, , N
adverse JJ N
effects NNS N
( ( N
including VBG N
pain NN N
and CC N
hemorrhage NN N
) ) N
, , N
and CC N
cellular JJ N
findings NNS N
( ( N
including VBG N
the DT N
quantity NN N
of IN N
cells NNS N
collected VBN N
, , N
the DT N
success NN N
rate NN N
, , N
cell NN N
freshness NN N
, , N
and CC N
cellular JJ N
clumping NN N
) ) N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
relative JJ N
efficacy NN N
and CC N
technical JJ N
ease NN N
of IN N
use NN N
of IN N
eight CD N
different JJ N
agents NNS N
for IN N
endoscopic JJ N
hemostasis NN N
and CC N
obliteration NN N
of IN N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
a DT N
canine NN N
model NN N
, , N
as IN N
no DT N
comparative JJ N
data NNS N
are VBP N
available JJ N
on IN N
gastric JJ N
variceal NN N
sclerotherapy NN i
. . N

The DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
statins NNS N
on IN N
the DT N
levels NNS N
of IN N
haemostatic JJ N
variables NNS N
reflecting VBG N
procoagulant NN N
and CC N
fibrinolytic JJ N
activity NN N
in IN N
patients NNS p
with IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
, , N
with IN N
the DT N
hypothesis NN N
that WDT N
statins VBZ N
might MD N
beneficially RB N
modify VB N
these DT N
levels NNS N
. . N

The DT N
task NN N
was VBD N
optimized VBN N
for IN N
investigation NN N
of IN N
the DT N
abilities NNS N
to TO N
infer VB N
another DT N
person NN N
's POS N
social JJ N
emotions NNS N
and CC N
beliefs NNS N
distinctively RB N
so RB N
as IN N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
oxytocin VBZ i
improves VBZ N
deficit NN N
in IN N
inferring VBG N
others NNS N
' POS N
social JJ N
emotions NNS N
rather RB N
than IN N
beliefs NNS N
, , N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
. . N

This DT N
study NN N
clearly RB N
shows VBZ N
that IN N
a DT N
pretreatment NN N
with IN N
a DT N
conventional JJ N
dose NN N
of IN N
formoterol NN N
, , N
salmeterol NN N
, , N
or CC N
oxitropium JJ N
bromide NN N
does VBZ N
not RB N
preclude VB N
the DT N
possibility NN N
of IN N
inducing VBG N
a DT N
further JJ N
bronchodilation NN N
with IN N
salbutamol NN N
in IN N
patients NNS p
suffering VBG N
from IN N
partially RB N
reversible JJ N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
. . N

KEY NNP N
FINDINGS NNP N
Examination NNP N
of IN N
the DT N
erythema JJ N
time NN N
course NN N
by IN N
a DT N
sensitive JJ N
spectrophotometric JJ N
reflectance NN N
method NN N
showed VBD N
a DT N
significant JJ N
increase NN o
of IN N
skin JJ N
reactions NNS N
in IN N
the DT N
non-treated JJ N
group NN N
after IN N
the DT N
second JJ N
week NN N
of IN N
treatment NN N
and CC N
maximal JJ N
alterations NNS N
between IN N
the DT N
fourth JJ N
and CC N
sixth JJ N
week NN N
. . N

Additional JJ N
investigations NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
potential NN N
for IN N
interactions NNS N
in IN N
elderly JJ N
patients NNS p
with IN N
dementia NNS N
who WP N
may MD N
eliminate VB N
risperidone NN i
and CC N
donepezil VB N
more JJR N
slowly RB N
and CC N
thus RB N
be VB N
more RBR N
vulnerable JJ N
to TO N
clinical JJ N
drug NN N
interactions NNS N
than IN N
the DT N
young JJ N
healthy JJ N
subjects NNS N
examined VBN N
in IN N
this DT N
study NN N
. . N

The DT N
oil NN N
supplementation NN N
had VBD N
no DT N
effect NN N
on IN N
glomerular JJ N
filtration NN N
rate NN N
, , N
effective JJ N
renal JJ N
plasma NN N
flow NN N
, , N
filtration NN N
fraction NN N
or CC N
blood NN N
pressure NN N
, , N
which WDT N
does VBZ N
not RB N
exclude VB N
effects NNS N
of IN N
the DT N
cyclosporin-induced JJ N
rigidified JJ N
erythrocytes NNS N
in IN N
the DT N
acute JJ N
phase NN N
of IN N
renal JJ N
transplantation NN N
. . N

We PRP N
conclude VBP N
that IN N
smoking VBG N
adversely RB N
affects VBZ N
duodenal JJ N
ulcer NN N
healing NN N
by IN N
cimetidine NN N
and CC N
hastens VBZ N
subsequent JJ N
relapse NN N
, , N
and CC N
that IN N
sucralfate NN N
overcomes VBZ N
the DT N
adverse JJ N
effect NN N
of IN N
smoking VBG N
on IN N
healing NN N
as IN N
encountered VBN N
with IN N
cimetidine NN N
, , N
and CC N
results NNS N
in IN N
a DT N
subsequent JJ N
remission NN N
period NN N
double JJ N
that IN N
of IN N
cimetidine NN N
. . N

Parameters NNS N
assessed VBD N
included JJ N
severity NN N
of IN N
SDB NNP N
( ( N
polysomnography NN N
) ) N
, , N
subjective JJ N
and CC N
objective JJ N
loudness NN N
of IN N
snoring VBG N
( ( N
visual JJ N
analog NN N
scale NN N
and CC N
SNAP NNP N
recording NN N
) ) N
, , N
sleepiness NN N
( ( N
Epworth NNP N
Sleepiness NNP N
Scale NNP N
) ) N
, , N
and CC N
anatomic JJ N
changes NNS N
( ( N
upper JJ N
airway RB N
endoscopy NN N
) ) N
, , N
as RB N
well RB N
as IN N
demographic JJ N
factors NNS N
. . N

Retrospective JJ N
subset NN N
analyses NNS N
showed VBD N
that IN N
, , N
irrespective NN N
of IN N
the DT N
cutoff NN N
used VBD N
or CC N
the DT N
treatment NN N
arm NN N
, , N
MET NNP N
expression NN N
did VBD N
not RB N
show VB N
prognostic JJ N
significance NN N
, , N
in IN N
terms NNS N
of IN N
objective JJ N
response NN N
rate NN N
, , N
progression-free JJ N
survival NN N
, , N
or CC N
overall JJ i
survival NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
among IN N
low-dose JJ N
aspirin NN N
users NNS N
, , N
( ( N
a DT N
) ) N
colorectal NN N
cancer NN N
mortality NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
reduced VBN N
by IN N
earlier JJR N
detection NN N
and CC N
( ( N
b NN N
) ) N
incidence NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
increased VBN o
due JJ N
to TO N
aspirin-induced JJ N
gastrointestinal JJ N
bleeding NN N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
visual JJ N
laser NN N
ablation NN N
treatment NN N
with IN N
neodymium-doped JJ N
yttrium NN N
aluminum NN N
garnet NN N
( ( N
Nd NNP N
: : N
YAG NN N
) ) N
laser NN N
in IN N
male JJ N
patients NNS p
with IN N
urethral JJ N
strictures NNS N
and CC N
to TO N
compare VB N
the DT N
effects NNS N
with IN N
those DT N
obtained VBN N
in IN N
patients NNS p
treated VBN N
with IN N
Sachse NNP N
's POS N
optical JJ N
urethrotomy NN N
. . N

CONCLUSIONS NNP N
Erythromycin NNP i
is VBZ N
effective JJ N
in IN N
significantly RB N
reducing VBG N
lost VBN N
time NN N
from IN N
work NN N
, , N
but CC N
it PRP N
is VBZ N
not RB N
effective JJ N
in IN N
reducing VBG N
cough NN N
or CC N
other JJ N
symptoms NNS N
in IN N
patients NNS p
with IN N
acute JJ N
bronchitis NN N
, , N
regardless RB N
of IN N
the DT N
outcome NN N
of IN N
the DT N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
nebivolol NN i
on IN N
the DT N
metabolic JJ N
state NN N
of IN N
oxidative JJ N
stress NN N
, , N
and CC N
antioxidant JJ N
status NN N
markers NNS N
in IN N
patients NNS p
with IN N
cardiac JJ N
syndrome-X NN N
( ( N
CSX NNP N
) ) N
, , N
additionally RB N
, , N
to TO N
compare VB N
with IN N
the DT N
effect NN N
of IN N
metoprolol NN i
treatment NN N
. . N

Research NN N
suggests VBZ N
that IN N
programs NNS N
delivered VBN N
in IN N
collaboration NN N
with IN N
schools NNS N
are VBP N
particularly RB N
effective JJ N
when WRB N
they PRP N
target VBP N
social JJ N
and CC N
emotional JJ N
skill NN N
building NN N
, , N
utilize VB N
an DT N
interactive JJ N
instructional JJ N
style NN N
, , N
provide VB N
opportunities NNS N
for IN N
youth NN N
participation NN N
and CC N
self-direction NN N
, , N
and CC N
include VBP N
explicit JJ N
attempts NNS N
to TO N
enhance VB N
youth RB N
social JJ N
competence NN N
. . N

Prolonged NNP N
critical JJ N
illness NN N
is VBZ N
characterized VBN N
by IN N
feeding-resistant JJ N
wasting NN N
of IN N
protein NN N
, , N
whereas JJ N
reesterification NN N
, , N
instead RB N
of IN N
oxidation NN N
of IN N
fatty JJ N
acids NNS N
, , N
allows VBZ N
fat JJ N
stores NNS N
to TO N
accrue NNS N
and CC N
associate NN N
with IN N
a DT N
low-activity JJ N
status NN N
of IN N
the DT N
somatotropic NN N
and CC N
thyrotropic NN N
axis NN N
, , N
which WDT N
seems VBZ N
to TO N
be VB N
partly RB N
of IN N
hypothalamic JJ N
origin NN N
. . N

Atropine NNP N
and CC N
glycopyrrolate NN N
induced VBD N
a DT N
significant JJ N
increase NN o
in IN N
heart NN N
rate NN N
with IN N
a DT N
simultaneous JJ N
decrease NN o
in IN N
pressure NN N
rate NN N
quotient NN N
( ( N
PRQ NNP N
) ) N
, , N
while IN N
scopolamine NN N
caused VBD N
a DT N
significant JJ N
decrease NN o
in IN N
heart NN N
rate NN N
with IN N
a DT N
simultaneous JJ N
increase NN o
in IN N
PRQ NNP N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
erythromycin JJ i
treatment NN N
in IN N
patients NNS p
with IN N
acute JJ N
bronchitis NN N
and CC N
to TO N
determine VB N
whether IN N
a DT N
newly RB N
developed VBN N
rapid JJ N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
is VBZ N
useful JJ N
in IN N
predicting VBG N
which WDT N
patients NNS p
will MD N
respond VB N
to TO N
therapy VB i
. . N

OBJECTIVES NNP N
To TO N
estimate VB N
the DT N
Minimal NNP N
Clinically NNP N
Important NNP N
Change NNP N
( ( N
MCIC NNP N
) ) N
of IN N
the DT N
pain NN N
intensity NN N
numerical JJ N
rating NN N
scale NN N
( ( N
PI-NRS NNP N
) ) N
, , N
the DT N
Quebec NNP N
Back NNP N
Pain NNP N
Disability NNP N
Scale NNP N
( ( N
QBPDS NNP N
) ) N
, , N
and CC N
the DT N
Euroqol NNP N
( ( N
EQ NNP N
) ) N
in IN N
patients NNS p
with IN N
low JJ N
back RB N
pain NN N
. . N

Primary JJ N
efficacy NN N
was VBD N
based VBN N
on IN N
data NNS N
kept VBN N
by IN N
primary JJ N
caregivers NNS N
, , N
including VBG N
a DT N
daily JJ N
diary NN N
; : N
daily JJ N
visual JJ N
analogue NN N
scales NNS N
of IN N
affection NN N
, , N
reciting VBG N
, , N
or CC N
aspects NNS N
of IN N
social JJ N
interaction NN N
; : N
Aberrant NNP N
Behavior NNP N
Checklists NNP N
( ( N
ABC NNP N
, , N
Aman NNP N
) ) N
; : N
and CC N
Clinical NNP N
Global NNP N
Improvement NNP N
scales NNS N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
treatment NN N
with IN N
enzyme NN N
was VBD N
not RB N
associated VBN N
with IN N
clinically RB N
significant JJ N
improvement NN N
in IN N
behaviour NN N
, , N
food NN N
variety NN N
, , N
gastrointestinal JJ N
symptoms NNS N
, , N
sleep JJ N
quality NN N
, , N
engagement NN N
with IN N
therapist NN N
, , N
or CC N
the DT N
Language NNP N
Development NNP N
Survey NNP N
Vocabulary NNP N
or CC N
Sentence NNP N
Complexity NNP N
Scores NNP N
. . N

Results NNS N
from IN N
the DT N
Nutritional NNP N
Prevention NNP N
of IN N
Cancer NNP N
Trial NNP N
conducted VBD N
among IN N
individuals NNS N
at IN N
high JJ N
risk NN N
of IN N
nonmelanoma JJ N
skin NN N
cancer NN N
continue VBP N
to TO N
demonstrate VB N
that IN N
selenium NN N
supplementation NN N
is VBZ N
ineffective JJ N
at IN N
preventing VBG N
basal NN N
cell NN N
carcinoma NN N
and CC N
that IN N
it PRP N
increases VBZ o
the DT N
risk NN N
of IN N
squamous JJ N
cell NN N
carcinoma NN N
and CC N
total JJ N
nonmelanoma NN N
skin NN N
cancer NN N
. . N

Virtual JJ N
reality NN N
colonoscopy NN N
simulation NN N
: : N
a DT N
compulsory NN N
practice NN N
for IN N
the DT N
future JJ N
colonoscopist NN N
? . N
BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIM NNP N
As IN N
for IN N
any DT N
manual JJ N
procedure NN N
, , N
the DT N
learning NN N
curves NNS N
for IN N
medical JJ N
interventions NNS N
can MD N
have VB N
undesirable JJ N
phases NNS N
, , N
occurring VBG N
mostly RB N
in IN N
the DT N
early JJ N
experience NN N
of IN N
applying VBG N
a DT N
technique NN N
. . N

In IN N
view NN N
of IN N
the DT N
correlation NN N
between IN N
angiographic JJ N
progression NN N
and CC N
subsequent JJ N
clinical JJ N
events NNS N
as IN N
demonstrated VBN N
in IN N
several JJ N
large JJ N
trials NNS N
, , N
it PRP N
is VBZ N
not RB N
unrealistic JJ N
to TO N
also RB N
anticipate VB N
in IN N
this DT N
population NN N
, , N
a DT N
beneficial JJ N
effect NN N
on IN N
clinical JJ N
events NNS N
with IN N
longer JJR N
follow-up NN N
. . N

In IN N
this DT N
comparative NN N
controlled VBD N
trial NN N
, , N
the DT N
ADPT NNP N
vaccines NNS N
were VBD N
more JJR N
immunogenic JJ N
, , N
with IN N
less JJR N
local JJ N
and CC N
systemic JJ N
reactions NNS N
, , N
than IN N
the DT N
WCDPT NNP N
vaccine NN N
but CC N
there EX N
was VBD N
a DT N
considerable JJ N
drop NN N
in IN N
antibody NN N
titres NNS N
in IN N
all PDT N
the DT N
vaccine NN N
groups NNS N
12 CD N
months NNS N
after IN N
primary JJ N
vaccination NN N
. . N

The DT N
intraoral JJ N
fluoride-releasing NN N
system NN N
( ( N
IFRS NNP N
) ) N
containing VBG N
a DT N
sodium NN N
fluoride NN N
core NN N
is VBZ N
a DT N
newly RB N
developed VBN N
, , N
sustained-release JJ N
, , N
passive JJ N
drug NN N
delivery NN N
system NN N
that WDT N
does VBZ N
not RB N
require VB N
patient JJ N
involvement NN N
except IN N
for IN N
periodic JJ N
replacement NN N
, , N
thus RB N
reducing VBG N
the DT N
effect NN N
of IN N
patient NN N
compliance NN N
on IN N
its PRP$ N
effectiveness NN N
in IN N
dental JJ N
caries NNS N
prevention NN N
. . N

Supplementary NNP N
motor NN N
area NN N
involvement NN N
also RB N
relied VBD N
on IN N
the DT N
predictability NN N
( ( N
in IN N
controls NNS N
) ) N
or CC N
presence NN N
( ( N
in IN N
Parkinson NNP N
's POS N
disease NN N
) ) N
of IN N
timing VBG N
cues NNS N
and CC N
not RB N
spatial JJ N
cues NNS N
, , N
indicating VBG N
a DT N
role NN N
of IN N
the DT N
supplementary JJ N
motor NN N
area NN N
and CC N
basal NN N
ganglia NNS N
in IN N
the DT N
temporal JJ N
organizations NNS N
of IN N
sequential JJ N
movement NN N
rather RB N
than IN N
the DT N
programming NN N
of IN N
specific JJ N
movements NNS N
. . N

The DT N
use NN N
of IN N
the DT N
IHC NNP N
based VBN N
TMA NNP N
methodology NN N
has VBZ N
shown VBN N
to TO N
be VB N
a DT N
simple JJ N
, , N
cost NN N
effective JJ N
and CC N
a DT N
robust JJ N
alternative NN N
to TO N
gene NN N
expression NN N
profiling VBG N
( ( N
GEP NNP N
) ) N
which WDT N
is VBZ N
currently RB N
regarded VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
classification NN N
in IN N
lymphomas NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
rates NNS N
for IN N
successful JJ N
first-time JJ N
intubation NN N
in IN N
those DT N
patients NNS p
with IN N
tube JJ N
orientation NN N
of IN N
-90 NN N
degrees NNS N
( ( N
with IN N
the DT N
bevel NN N
facing VBG N
posteriorly RB N
) ) N
as IN N
compared VBN N
with IN N
a DT N
tube JJ N
orientation NN N
of IN N
0 CD N
degrees NNS N
( ( N
the DT N
normal JJ N
orientation NN N
with IN N
the DT N
bevel NN N
facing NN N
left VBD N
) ) N
. . N

The DT N
presence NN N
of IN N
metabolic JJ N
syndrome NN N
and CC N
changes NNS N
in IN N
the DT N
mean NN N
of IN N
physiological JJ N
parameters NNS N
such JJ N
as IN N
Hba1c NNP N
, , N
P-glucose NNP N
, , N
P-insulin NNP N
, , N
lipids NNS N
, , N
blood NN N
pressure NN N
, , N
physical JJ N
working NN N
capacity NN N
, , N
body NN N
mass NN N
index NN N
, , N
Heart NNP N
Score NNP N
were VBD N
investigated VBN N
and CC N
participants NNS N
' POS N
satisfaction NN N
assessed VBD N
. . N

With IN N
respect NN N
to TO N
total JJ N
, , N
partial JJ N
colon NN N
, , N
and CC N
rectum VB N
transit NN N
time NN N
, , N
there EX N
seemed VBN N
to TO N
be VB N
a DT N
trend NN N
, , N
although IN N
statistically RB N
nonsignificant JJ N
, , N
toward IN N
faster JJR N
transit NN N
times NNS N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

However RB N
, , N
the DT N
age NN N
of IN N
the DT N
subjects NNS N
was VBD N
found VBN N
to TO N
be VB N
an DT N
intervening VBG N
variable NN N
: : N
The DT N
older JJR N
subjects NNS N
of IN N
both DT N
groups NNS N
demonstrated VBD N
a DT N
gradual JJ N
but CC N
not RB N
significant JJ N
decline NN N
in IN N
hypertonus NN N
, , N
whereas IN N
the DT N
younger JJR N
adults NNS N
demonstrated VBD N
a DT N
significant JJ N
decline NN N
in IN N
hypertonus NN N
over IN N
a DT N
6-week JJ N
period NN N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
usual JJ N
care NN N
plus CC N
written VBN N
education NN N
, , N
pharmaceutical JJ N
care NN N
focused VBN N
on IN N
patient JJ N
evaluation NN N
and CC N
follow-up NN N
in IN N
collaboration NN N
with IN N
physicians NNS N
improved VBN N
the DT N
achievement NN N
of IN N
BP NNP N
, , N
TC NNP N
, , N
and CC N
BP/TC NNP N
treatment NN N
goals NNS N
in IN N
patients NNS p
with IN N
CVD NNP N
and/or VBP N
high JJ N
or CC N
intermediate JJ N
CV NNP N
risk NN N
attending VBG N
community NN N
pharmacies NNS N
in IN N
Spain NNP N
. . N

Wound IN N
infection NN N
scores NNS N
were VBD N
marginally RB N
higher JJR N
in IN N
the DT N
placebo NN N
group NN N
, , N
but CC N
the DT N
differences NNS N
in IN N
the DT N
values NNS N
of IN N
infection NN N
scores NNS N
between IN N
both DT N
the DT N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
during IN N
the DT N
7-day JJ N
post-PEG JJ N
follow-up NN N
. . N

RESULTS NNP N
Children NNP N
with IN N
FASD NNP N
were VBD N
more RBR N
variable JJ N
in IN N
saccade JJ N
endpoint NN N
accuracy NN N
, , N
which WDT N
was VBD N
reflected VBN N
by IN N
statistically RB N
significant JJ N
increases NNS o
in IN N
the DT N
error NN N
of IN N
the DT N
initial JJ N
saccade NN N
endpoint NN N
and CC N
the DT N
frequency NN N
of IN N
additional JJ N
, , N
corrective JJ N
saccades NNS N
required VBN N
to TO N
achieve VB N
final JJ N
fixation NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
large JJ N
amounts NNS N
of IN N
urea JJ N
fertiliser NN N
during IN N
spring NN N
and CC N
the DT N
consequent NN N
increases NNS o
in IN N
concentrations NNS N
of IN N
CP NNP N
in IN N
pasture NN N
and CC N
urea NN N
in IN N
serum NN N
did VBD N
not RB N
negatively RB N
affect JJ N
any DT N
of IN N
the DT N
parameters NNS N
of IN N
reproductive JJ N
performance NN N
of IN N
pasture-fed JJ N
dairy NN N
cows NNS N
that WDT N
were VBD N
assessed VBN N
in IN N
this DT N
study NN N
. . N

CONCLUSION NNP N
Data NNP N
from IN N
this DT N
large JJ N
prospective JJ N
study NN N
suggest VBP N
that IN N
obesity NN N
is VBZ N
important JJ N
throughout IN N
the DT N
natural JJ N
history NN N
of IN N
colorectal JJ N
cancer NN N
, , N
at IN N
least JJS N
in IN N
men NNS N
, , N
and CC N
colorectal JJ N
cancer NN N
prevention NN N
efforts NNS N
should MD N
encourage VB N
the DT N
achievement NN N
and CC N
maintenance NN N
of IN N
a DT N
healthy JJ N
body NN N
weight NN N
in IN N
addition NN N
to TO N
regular JJ N
screenings NNS N
. . N

In IN N
addition NN N
, , N
tumor NN N
miRNA NN N
expression NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
patient JJ N
age NN N
, , N
lymphovascular JJ N
invasion NN N
and CC N
the DT N
KRAS-variant NNP N
, , N
supporting VBG N
the DT N
hypothesis NN N
that WDT N
altered VBD N
tumor NN N
biology NN N
can MD N
be VB N
measured VBN N
by IN N
miRNA JJ N
expression NN N
, , N
and CC N
that IN N
the DT N
KRAS-variant NNP N
likely JJ N
impacts NNS N
endometrial JJ N
tumor NN N
biology NN N
. . N

CONCLUSIONS NNP N
The DT N
findings NNS N
show VBP N
that IN N
fluoxetine NN N
normalises NNS N
frontal JJ N
lobe NN N
dysfunctions NNS N
in IN N
both DT N
disorders NNS N
via IN N
inverse JJ N
effects NNS N
, , N
downregulating VBG N
abnormally RB N
increased VBN o
frontal JJ N
activation NN N
in IN N
ASD NNP N
and CC N
upregulating VBG N
abnormally RB N
decreased VBN o
frontal JJ N
activation NN N
in IN N
ADHD NNP N
, , N
potentially RB N
reflecting VBG N
inverse JJ N
baseline NN N
serotonin NN N
levels NNS N
in IN N
both DT N
disorders NNS N
. . N

PURPOSE VB N
The DT N
authors NNS N
assessed VBD N
the DT N
quality NN N
, , N
diagnostic JJ N
accuracy NN N
and CC N
patient JJ N
acceptability NN N
of IN N
computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
colonography NN N
performed VBD N
using VBG N
a DT N
simplified JJ N
bowel NN N
preparation NN N
and CC N
software NN N
for IN N
post-processing JJ N
digital JJ N
elimination NN N
of IN N
stool NN N
and CC N
fluid NN N
data NNS N
from IN N
images NNS N
compared VBN N
with IN N
the DT N
examination NN N
obtained VBN N
with IN N
conventional JJ N
preparation NN N
. . N

Outcomes RB N
evaluated VBN N
over RP N
a DT N
12-month JJ N
period NN N
included VBD N
: : N
self-reported JJ N
measures NNS N
of IN N
back RB N
pain NN N
, , N
back RB N
pain NN N
disability NN N
level NN N
, , N
physical JJ N
health NN N
, , N
mental JJ N
health NN N
, , N
and CC N
administrative JJ N
measures NNS N
of IN N
recurrence NN N
, , N
lost VBN N
work NN N
time NN N
, , N
and CC N
medical JJ N
care NN N
utilization NN N
. . N

CONCLUSIONS NNP N
The DT N
regular JJ N
provision NN N
of IN N
a DT N
supplement NN N
of IN N
vitamin NN N
A NNP N
to TO N
children NNS N
, , N
at IN N
a DT N
level NN N
potentially RB N
obtainable JJ N
from IN N
foods NNS N
, , N
in IN N
an DT N
area NN N
where WRB N
vitamin NN N
A DT N
deficiency NN N
and CC N
under-nutrition NN N
are VBP N
documented VBN N
public JJ N
health NN N
problems NNS N
contributed VBD N
substantially RB N
to TO N
children NNS N
's POS N
survival NN N
; : N
mortality NN N
was VBD N
reduced VBN N
on IN N
average NN N
by IN N
54 CD N
percent NN N
. . N

These DT N
results NNS N
question VBP N
the DT N
notion NN N
that IN N
training VBG N
loads NNS N
that WDT N
induce VBP N
greater JJR N
than IN N
10 CD N
% NN N
reduction NN N
in IN N
sprint NN N
velocity NN N
would MD N
negatively RB N
affect VB N
sprint NN N
performance NN N
and CC N
point NN N
out RP N
the DT N
potential JJ N
benefit NN N
of IN N
using VBG N
a DT N
heavier JJR N
load NN N
for IN N
weighted JJ N
sled VBD N
towing NN N
. . N

However RB N
, , N
to TO N
the DT N
authors NNS N
' POS N
knowledge NN N
, , N
no DT N
researchers NNS N
yet RB N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
100 CD N
percent NN N
NovaMin NNP N
powder NN N
with IN N
NovaMin-containing NNP N
toothpaste NN N
in IN N
reducing VBG N
dentin JJ i
hypersensitivity NN N
compared VBN N
with IN N
the DT N
effectiveness NN N
of IN N
NovaMin-containing NNP N
toothpaste NN N
only RB N
and CC N
a DT N
desensitizing NN N
toothpaste NN N
containing VBG N
potassium NN N
nitrate NN N
as IN N
a DT N
control NN N
. . N

Some DT N
of IN N
the DT N
most RBS N
important JJ N
items NNS N
: : N
personality NN N
, , N
motivation NN N
, , N
diet JJ N
history NN N
, , N
bodyweight NN N
, , N
blood NN N
lipids NNS N
and CC N
blood NN N
sugar NN N
anti-smoking JJ N
advice NN N
given VBN N
individually RB N
to TO N
all DT N
smokers NNS N
in IN N
the DT N
intervention NN N
group NN N
advice NN N
that IN N
smoking VBG N
cessation NN N
was VBD N
expected VBN N
to TO N
be VB N
of IN N
special JJ N
importance NN N
for IN N
those DT N
with IN N
elevated JJ N
blood NN N
lipids NNS N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
significant JJ N
differences NNS N
in IN N
improvements NNS N
between IN N
lamotrigine NN N
or CC N
placebo NN N
groups NNS N
on IN N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
, , N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
, , N
the DT N
Vineland NNP N
Adaptive NNP N
Behavior NNP N
scales NNS N
, , N
the DT N
PL-ADOS NNP N
, , N
or CC N
the DT N
CARS NNPS N
. . N

The DT N
results NNS N
show VBP N
that IN N
postprandial JJ N
levels NNS N
of IN N
both DT N
intact JJ N
neurotensin NN N
and CC N
NH2-terminal JJ N
immunoreactivity NN N
are VBP N
related VBN N
to TO N
the DT N
length NN N
of IN N
the DT N
functioning NN N
ileum NN N
and CC N
that IN N
even RB N
a DT N
difference NN N
in IN N
length NN N
of IN N
25 CD N
cm NN N
is VBZ N
reflected VBN N
in IN N
the DT N
circulating NN N
levels NNS N
of IN N
neurotensin NN N
. . N

Subjects NNS N
with IN N
white-coat JJ N
hypertension NN N
in IN N
Tecumseh NNP N
appear VBP N
to TO N
be VB N
at IN N
an DT N
increased VBN o
risk NN N
for IN N
coronary JJ N
heart NN N
disease NN N
: : N
they PRP N
show VBP N
repeated VBN N
elevated JJ N
clinic NN N
readings NNS N
throughout IN N
their PRP$ N
life NN N
time NN N
, , N
their PRP$ N
parents NNS N
have VBP N
higher JJR N
blood NN N
pressure NN N
, , N
their PRP$ N
high-density NN N
lipoprotein NN N
is VBZ N
decreased VBN o
and CC N
insulin NN N
, , N
cholesterol NN N
and CC N
triglycerides NNS N
are VBP N
elevated VBN N
. . N

This DT N
is VBZ N
possibly RB N
due JJ N
to TO N
the DT N
fact NN N
that IN N
either DT N
subacromial JJ N
tissue NN N
, , N
despite IN N
of IN N
chronic JJ N
inflammation NN N
, , N
does VBZ N
not RB N
show VB N
the DT N
same JJ N
reagibility NN N
as IN N
synovia NN N
or CC N
it PRP N
is VBZ N
a DT N
problem NN N
of IN N
the DT N
nearly RB N
complete JJ N
resection NN N
of IN N
the DT N
subacromial JJ N
bursa NN N
. . N

PURPOSE NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
initial JJ N
CNS NNP N
involvement NN N
on IN N
outcome NN N
and CC N
patterns NNS N
of IN N
failure NN N
in IN N
patients NNS p
with IN N
disseminated JJ N
small JJ N
noncleaved-cell JJ N
lymphoma NN N
and CC N
B-cell NNP N
leukemia NN N
who WP N
were VBD N
treated VBN N
in IN N
four CD N
successive JJ N
Children NNP N
's POS N
Cancer NNP N
Group NNP N
trials NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
adverse JJ N
mood NN N
effects NNS N
of IN N
two CD N
different JJ N
doses NNS N
of IN N
medroxyprogesterone NN N
acetate NN N
( ( N
MPA NNP N
) ) N
during IN N
postmenopausal NN N
hormone CD N
replacement NN N
therapy NN i
( ( N
HRT NNP N
) ) N
in IN N
women NNS N
with IN N
and CC N
without IN N
a DT N
history NN N
of IN N
premenstrual JJ N
syndrome NN N
( ( N
PMS NNP N
) ) N
. . N

Results NNS N
identified VBD N
significant JJ N
positive JJ N
changes NNS N
in IN N
Goal NNP N
Attainment NNP N
Scaling NNP N
scores NNS N
for IN N
both DT N
groups NNS N
; : N
more RBR N
significant JJ N
changes NNS N
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
, , N
and CC N
a DT N
significant JJ N
decrease NN o
in IN N
autistic JJ N
mannerisms NNS N
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
. . N

In IN N
the DT N
healthy JJ N
subjects NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
duration NN N
of IN N
action NN N
with IN N
the DT N
different JJ N
doses NNS N
but CC N
in IN N
duodenal JJ N
ulcer NN N
patients NNS p
a DT N
tenfold JJ N
increase NN o
of IN N
the DT N
antacid NN N
dose NN N
resulted VBD N
in IN N
a DT N
doubling NN N
of IN N
the DT N
duration NN N
of IN N
action NN N
. . N

RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN N
social JJ N
network NN N
salience NN N
, , N
number NN N
of IN N
friendship JJ N
nominations NNS N
, , N
teacher JJ N
report NN N
of IN N
social JJ N
skills NNS N
in IN N
the DT N
classroom NN N
, , N
and CC N
decreased JJ o
isolation NN N
on IN N
the DT N
playground NN N
for IN N
children NNS N
who WP N
received VBD N
PEER NNP N
interventions NNS N
. . N

METHODS NNP N
Outcomes NNP N
7.5 CD N
months NNS N
after IN N
randomisation NN N
were VBD N
acceptability NN N
of IN N
randomisation NN N
, , N
overall JJ i
acceptability NN N
of IN N
and CC N
satisfaction NN N
with IN N
conservative JJ N
management NN N
, , N
impact NN N
on IN N
quality NN N
of IN N
life NN N
, , N
perceived VBD N
need NN N
for IN N
further JJ N
treatment NN N
and CC N
treatment NN N
failure NN N
( ( N
defined VBD N
a DT N
priori NN N
) ) N
. . N

RESULTS NN N
In IN N
the DT N
added JJ N
treatment NN N
group NN N
, , N
the DT N
brachial JJ N
systolic JJ N
blood NN N
pressure NN N
was VBD N
successfully RB N
reduced VBN N
, , N
but CC N
the DT N
central JJ N
PP NNP N
increased VBD o
significantly RB o
, , N
whereas IN N
the DT N
other JJ N
blood NN N
pressure NN N
parameters NNS N
did VBD N
not RB N
change NN N
from IN N
the DT N
baseline NN N
. . N

BACKGROUND NNP N
Maximum NNP N
lactate NN N
steady JJ N
state NN N
( ( N
MLSS NNP N
) ) N
is VBZ N
defined VBN N
as IN N
the DT N
highest JJS N
steady JJ N
state NN N
exercise NN N
level NN N
one CD N
can MD N
maintain VB N
while IN N
also RB N
maintaining VBG N
an DT N
equilibrium NN N
between IN N
the DT N
elimination NN N
of IN N
blood NN N
lactate NN N
and CC N
the DT N
diffusion NN N
of IN N
lactate NN N
into IN N
the DT N
blood NN N
. . N

While IN N
the DT N
study NN N
did VBD N
not RB N
yield VB N
definitive JJ N
data NNS N
about IN N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
ESM NNP N
alternatives NNS N
, , N
it PRP N
does VBZ N
provide VB N
a DT N
foundation NN N
for IN N
future JJ N
research NN N
, , N
including VBG N
guidance NN N
related VBN N
to TO N
participant JJ N
profiles NNS N
, , N
stimulus NN N
characteristics NNS N
, , N
and CC N
data NNS N
coding NN N
challenges NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
a DT N
dietary JJ N
supplement NN N
of IN N
soy NN N
protein NN N
, , N
isoflavones NNS N
, , N
and CC N
cotyledon VB N
fiber NN N
( ( N
Abalon NNP N
) ) N
affects VBZ N
cardiovascular JJ N
risk NN N
markers NNS N
, , N
blood NN N
glucose NN N
, , N
and CC N
insulin NN N
levels NNS N
in IN N
type NN N
2 CD N
diabetic JJ N
subjects NNS N
. . N

Among IN N
measures NNS N
derived VBN N
from IN N
data NNS N
collected VBN N
at IN N
long-term JJ N
follow-up NN N
, , N
however RB N
, , N
having VBG N
ever RB N
met VBN N
criteria NNS N
for IN N
substance NN N
abuse NN N
or CC N
dependence NN N
predicted VBN N
greater JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
, , N
and CC N
being VBG N
married VBD N
or CC N
being VBG N
in IN N
a DT N
romantic JJ N
relationship NN N
was VBD N
associated VBN N
with IN N
lower JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
. . N

RESULTS VB N
The DT N
postoperative JJ N
hidden JJ N
blood NN N
loss NN N
, , N
knee NN N
swelling NN N
, , N
and CC N
scope NN N
of IN N
ecchymosis NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
flexion NN N
group NN N
than IN N
in IN N
the DT N
extension NN N
group NN N
, , N
and CC N
ROM NNP N
and CC N
straight-leg JJ N
raising VBG N
action NN N
were VBD N
significantly RB N
higher JJR N
during IN N
the DT N
early JJ N
period NN N
after IN N
operation NN N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
single- JJ N
and CC N
multi-dose JJ N
( ( N
5-day JJ N
) ) N
clindamycin NN i
therapy NN i
for IN N
the DT N
prevention NN N
of IN N
inflammatory JJ N
complications NNS N
in IN N
patients NNS p
undergoing VBG N
lower JJR N
third JJ N
molar JJ N
surgical JJ N
extraction NN N
with IN N
bone NN N
removal NN N
. . N

In IN N
this DT N
work NN N
, , N
we PRP N
use VBP N
genome-wide JJ N
data NNS N
on IN N
SNPs NNP N
and CC N
array-based JJ N
expression NN N
measures NNS N
from IN N
mononuclear JJ N
cells NNS N
obtained VBN N
from IN N
a DT N
population-based JJ N
cohort NN N
of IN N
1,799 CD N
Bangladeshi NNP N
individuals NNS N
to TO N
characterize VB N
cis- JJ N
and CC N
trans-eQTLs JJ N
and CC N
determine VB N
if IN N
observed VBN N
trans-eQTL JJ N
associations NNS N
are VBP N
mediated VBN N
by IN N
expression NN N
of IN N
transcripts NNS N
in IN N
cis NN N
with IN N
the DT N
SNPs NNP N
showing VBG N
trans-association NN N
, , N
using VBG N
Sobel NNP N
tests NNS N
of IN N
mediation NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN N
mainly RB N
pulmonary JJ N
acute NN N
respiratory NN N
distress NN N
syndrome NN N
, , N
using VBG N
high JJ N
mean JJ N
airway NN N
pressure NN N
under IN N
high-frequency NN N
oscillatory JJ N
ventilation NN N
can MD N
worsen VB N
right JJ N
ventricular NN N
function NN N
when WRB N
compared VBN N
with IN N
protective JJ N
conventional JJ N
mechanical JJ N
ventilation NN N
, , N
notably RB N
in IN N
patients NNS p
in IN N
whom WP N
high-frequency NN N
oscillatory NN N
ventilation NN N
produced VBD N
less JJR N
alveolar JJ N
recruitment NN N
of IN N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lungs NNS N
. . N

OBJECTIVE IN N
The DT N
goal NN N
of IN N
this DT N
study NN N
has VBZ N
been VBN N
to TO N
determine VB N
whether IN N
hyaluronic JJ N
acid NN N
( ( N
HA NNP N
) ) N
or CC N
exercise NN N
therapy NN i
can MD N
improve VB N
functional JJ N
parameters NNS N
in IN N
patients NNS p
with IN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
of IN N
the DT N
ankle NN N
. . N

No DT N
significant JJ N
enhancing VBG N
effect NN N
on IN N
the DT N
antibody NN N
response NN N
was VBD N
observed VBN N
, , N
in IN N
spite NN N
of IN N
an DT N
early JJ N
and CC N
transient JJ N
upregulation NN N
of IN N
costimulatory NN N
molecule NN N
expression NN N
on IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
, , N
which WDT N
may MD N
be VB N
suggestive JJ N
of IN N
an DT N
IFN-mediated JJ N
activation NN N
of IN N
antigen NN N
presenting VBG N
cells NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
an DT N
internet NN N
accessed VBD N
training VBG N
program NN N
that WDT N
included VBD N
Theory NNP N
of IN N
Mind-based JJ N
guidance NN N
, , N
video NN N
models NNS N
, , N
visual JJ N
supports NNS N
, , N
and CC N
virtual JJ N
reality NN N
practice NN N
sessions NNS N
in IN N
teaching VBG N
appropriate JJ N
job NN N
interview NN N
skills NNS N
to TO N
individuals NNS N
with IN N
high JJ N
functioning VBG N
Autism NNP N
Spectrum NNP N
Disorders NNP N
. . N

PURPOSE NN N
To TO N
compare VB N
multi-detector JJ N
row NN N
computed VBN N
tomographic JJ N
( ( N
CT NNP N
) ) N
angiography NN N
and CC N
digital JJ N
subtraction NN N
angiography NN N
( ( N
DSA NNP N
) ) N
prior RB N
to TO N
revascularization NN N
in IN N
patients NNS p
with IN N
symptomatic JJ N
peripheral JJ N
arterial JJ N
disease NN N
for IN N
the DT N
purpose NN N
of IN N
assessing VBG N
recommendations NNS N
for IN N
additional JJ N
imaging NN N
and CC N
physician JJ N
confidence NN N
ratings NNS N
for IN N
chosen NN N
therapy NN i
. . N

In IN N
a DT N
subgroup NN N
of IN N
patients NNS p
with IN N
high JJ N
levels NNS N
of IN N
disease NN N
activity NN N
who WP N
had VBD N
more JJR N
than IN N
one CD N
active JJ N
MRI-evident JJ N
lesion NN N
during IN N
4 CD N
weeks NNS N
, , N
valacyclovir FW N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
reduced JJ N
number NN N
of IN N
new JJ N
active JJ N
MRI-evident JJ N
lesions NNS N
and CC N
with IN N
an DT N
increase NN o
in IN N
the DT N
number NN N
of IN N
scans NNS N
free JJ N
of IN N
new JJ N
active JJ N
lesions NNS N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
their PRP$ N
implications NNS N
for IN N
the DT N
need NN N
for IN N
more RBR N
effective JJ N
treatments NNS N
in IN N
general JJ N
, , N
and CC N
the DT N
role NN N
of IN N
individual JJ N
differences NNS N
in IN N
the DT N
likelihood NN N
of IN N
returning VBG N
to TO N
smoking VBG N
following VBG N
treatment NN N
for IN N
quitting VBG N
. . N

BACKGROUND NNP N
Atypical NNP N
antipsychotic JJ i
agents NNS N
, , N
which WDT N
block VBP N
postsynaptic JJ N
dopamine NN N
and CC N
serotonin NN N
receptors NNS N
, , N
have VBP N
advantages NNS N
over IN N
traditional JJ N
antipsychotic JJ i
medications NNS N
in IN N
the DT N
treatment NN N
of IN N
adults NNS N
with IN N
schizophrenia NN N
and CC N
may MD N
be VB N
beneficial JJ N
in IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
who WP N
have VBP N
serious JJ N
behavioral JJ N
disturbances NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
materials NNS N
that WDT N
include VBP N
both DT N
fluoride JJ N
and CC N
chlorhexidine NN N
as IN N
routine JJ N
treatment NN N
of IN N
children NNS N
with IN N
disability NN N
may MD N
increase VB o
the DT N
success NN N
of IN N
restorations NNS N
by IN N
improving VBG N
oral JJ N
hygiene NN N
, , N
reduce VB N
the DT N
need NN N
for IN N
future JJ N
restorative JJ N
treatments NNS N
and CC N
thus RB N
the DT N
need NN N
for IN N
general JJ N
anaesthesia NN N
. . N

Results NNS N
largely RB N
supported VBD N
the DT N
study NN N
hypotheses NNS N
such JJ N
that IN N
( ( N
a DT N
) ) N
NTX NNP N
significantly RB N
blunted VBD N
cue-induced JJ N
craving NN N
for IN N
MA NNP N
and CC N
( ( N
b NN N
) ) N
attenuated VBD N
several JJ N
of IN N
the DT N
hedonic JJ N
subjective JJ N
effects NNS N
of IN N
MA NNP N
, , N
including VBG N
craving NN N
, , N
during IN N
controlled VBN N
MA NNP N
administration NN N
and CC N
as IN N
compared VBN N
with IN N
placebo NN N
. . N

IMPLICATIONS NNP N
This DT N
study NN N
demonstrates VBZ N
that IN N
when WRB N
fentanyl NN N
is VBZ N
added VBN N
to TO N
a DT N
local JJ N
anesthetic NN N
, , N
lidocaine NN N
, , N
with IN N
spinal JJ N
anesthesia NN N
for IN N
egg NN N
retrieval NN N
procedures NNS N
, , N
patients NNS p
are VBP N
more RBR N
comfortable JJ N
during IN N
the DT N
procedure NN N
compared VBN N
with IN N
those DT N
who WP N
receive VBP N
lidocaine NN N
alone RB N
. . N

It PRP N
was VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
employing VBG N
a DT N
single JJ N
subject NN N
comparison NN N
design NN N
in IN N
two CD N
different JJ N
conditions NNS N
, , N
improvisational JJ N
music NN N
therapy NN i
and CC N
play NN N
sessions NNS N
with IN N
toys NNS N
, , N
and CC N
using VBG N
standardized JJ N
tools NNS N
and CC N
DVD NNP N
analysis NN N
of IN N
sessions NNS N
to TO N
evaluate VB N
behavioral JJ N
changes NNS N
in IN N
children NNS N
with IN N
autism NN N
. . N

After IN N
two CD N
sessions NNS N
of IN N
treatment NN N
and CC N
after IN N
three CD N
months NNS N
follow-up RB N
, , N
CTTH NNP N
score NN N
( ( N
including VBG N
the DT N
score NN N
of IN N
headache NN N
attack NN N
frequency NN N
and CC N
the DT N
score NN N
of IN N
headache NN N
severity NN N
) ) N
was VBD N
observed VBN N
and CC N
compared VBN N
before IN N
and CC N
after IN N
treatment NN N
separately RB N
. . N

CONCLUSIONS VB N
The DT N
two CD N
doses NNS N
of IN N
leuprolide JJ N
acetate JJ N
3-month JJ N
depot NN N
were VBD N
associated VBN N
with IN N
an DT N
acceptable JJ N
safety NN N
profile NN N
and CC N
provided VBD N
maintenance NN N
of IN N
LH NNP N
suppression NN N
in IN N
the DT N
majority NN N
of IN N
children NNS N
with IN N
CPP NNP N
during IN N
the DT N
36 CD N
months NNS N
of IN N
the DT N
study NN N
or CC N
until IN N
readiness NN N
for IN N
puberty NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
in IN N
the DT N
absence NN N
of IN N
a DT N
customised JJ N
immobilisation NN N
device NN N
, , N
to TO N
cover VB N
95 CD N
% NN N
of IN N
errors NNS N
, , N
margins NNS N
of IN N
0.6 CD N
cm NN N
for IN N
RL NNP N
and CC N
SI NNP N
directions NNS N
and CC N
0.9 CD N
cm NN N
for IN N
AP NNP N
direction NN N
should MD N
be VB N
allowed VBN N
between IN N
the DT N
planning NN N
and CC N
clinical JJ N
target NN N
volumes NNS N
. . N

By IN N
the DT N
evaluation NN N
of IN N
the DT N
individual JJ N
data NN N
, , N
it PRP N
became VBD N
apparent JJ N
that IN N
, , N
the DT N
pains NNS N
increase NN o
with IN N
increasing VBG N
gas NN N
consumption NN N
, , N
a DT N
fact NN N
which WDT N
led VBD N
to TO N
assumption NN N
that IN N
the DT N
pains NNS N
are VBP N
caused VBN N
by IN N
a DT N
physical JJ N
effect NN N
such JJ N
as IN N
the DT N
cooling NN N
of IN N
the DT N
peritoneum NN N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
variants NNS N
in IN N
presumed JJ N
nutrient-sensitive JJ N
genes NNS N
involved VBN N
in IN N
lipid JJ N
metabolism NN N
modified VBD N
lipid JJ N
profile NN N
after IN N
weight JJ N
loss NN N
and CC N
in IN N
response NN N
to TO N
a DT N
given VBN N
diet JJ N
, , N
among IN N
overweight JJ N
European JJ N
adults NNS N
participating VBG N
in IN N
the DT N
Diet NNP N
Obesity NNP N
and CC N
Genes NNP N
study NN N
. . N

The DT N
step NN N
aerobics NNS N
group NN N
showed VBD N
significant JJ N
improvement NN N
only RB N
in IN N
mean JJ N
power NN N
relative NN N
to TO N
body NN N
weight JJ N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
women NNS N
showed VBD N
significant JJ N
improvement NN N
only RB N
in IN N
anaerobic JJ N
power NN N
of IN N
vertical JJ N
jump NN N
when WRB N
compared VBN N
with IN N
men NNS N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
lumbar NN N
interlaminar JJ N
epidural JJ N
injections NNS N
with IN N
or CC N
without IN N
steroids NNS N
in IN N
providing VBG N
effective JJ N
and CC N
long-lasting JJ N
pain NN N
relief NN N
with IN N
improvement NN N
in IN N
functional JJ N
status NN N
for IN N
the DT N
management NN N
of IN N
chronic NN N
low JJ N
back RB N
and CC N
lower JJR N
extremity NN N
pain NN N
related VBN N
to TO N
lumbar VB N
central JJ N
spinal JJ N
stenosis NN N
. . N

Is VBZ N
individual JJ N
peer NN N
support NN N
a DT N
promising NN N
intervention NN N
for IN N
persons NNS N
with IN N
heart NN N
failure NN N
? . N
Peer NNP N
support NN N
has VBZ N
been VBN N
used VBN N
effectively RB N
in IN N
a DT N
variety NN N
of IN N
patient JJ N
populations NNS N
, , N
but CC N
its PRP$ N
effectiveness NN N
in IN N
improving VBG N
outcomes NNS N
in IN N
persons NNS N
with IN N
chronic JJ N
heart NN N
failure NN N
has VBZ N
not RB N
been VBN N
explored VBN N
. . N

Immediate NNP N
or CC N
early JJ N
use NN N
of IN N
proliferation NN N
signal NN N
inhibitor NN N
( ( N
PSI NNP N
) ) N
/mammalian JJ N
target NN N
of IN N
rapamycin NN i
( ( N
mTOR NN N
) ) N
inhibitor NN N
therapy NN i
can MD N
avoid VB N
high JJ N
exposure NN N
to TO N
calcineurin VB N
inhibitors NNS N
but CC N
concerns NNS N
exist VBP N
relating VBG N
to TO N
the DT N
risk NN N
of IN N
delayed JJ N
graft NN N
function NN N
( ( N
DGF NNP N
) ) N
and CC N
impaired JJ N
wound NN N
healing VBG N
with IN N
the DT N
mTOR NN N
sirolimus NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
contact NN N
sensitization NN N
potential NN N
of IN N
one CD N
nicotine NN N
transdermal NN N
system NN N
( ( N
Nicoderm NNP N
, , N
Marion NNP N
Merrell NNP N
Dow NNP N
Inc NNP N
, , N
Kansas NNP N
City NNP N
, , N
Mo NNP N
, , N
and CC N
ALZA NNP N
Corporation NNP N
, , N
Palo NNP N
Alto NNP N
, , N
Calif NNP N
) ) N
in IN N
a DT N
population NN N
who WP N
were VBD N
allowed VBN N
to TO N
continue VB N
smoking NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
confirms VBZ N
the DT N
findings NNS N
in IN N
a DT N
previous JJ N
open JJ N
label NN N
trial NN N
that IN N
administration NN N
of IN N
VLP NNP N
immunotherapy NN i
may MD N
assist VB N
in IN N
clearance NN N
of IN N
recurrent JJ N
genital JJ N
warts NNS N
in IN N
patients NNS p
for IN N
whom WP N
destructive JJ N
therapy NN i
is VBZ N
unsuccessful JJ N
and CC N
that DT N
unsuccessful JJ N
destructive JJ N
therapy NN i
is VBZ N
more RBR N
common JJ N
with IN N
increasing VBG N
prior JJ N
disease NN N
duration NN N
. . N

This DT N
pilot NN N
study NN N
revealed VBD N
that IN N
the DT N
IFRS NNP N
was VBD N
well-tolerated JJ N
and CC N
safe JJ N
in IN N
this DT N
study NN N
population NN N
associated VBN N
with IN N
minimal JJ N
complications NNS N
during IN N
the DT N
duration NN N
of IN N
this DT N
study NN N
and CC N
was VBD N
comparable JJ N
in IN N
efficacy NN N
to TO N
a DT N
SnF NNP N
( ( N
2 CD N
) ) N
gel NN N
in IN N
preventing VBG N
caries NNS N
development NN N
. . N

However RB N
the DT N
mutagenic JJ N
studies NNS N
of IN N
several JJ N
biological JJ N
systems NNS N
indicate VBP N
that IN N
it PRP N
has VBZ N
a DT N
mutagenic JJ N
effect NN N
, , N
but CC N
the DT N
mutagenic JJ N
and CC N
carcinogenic JJ N
effects NNS N
on IN N
humans NNS N
and CC N
animals NNS N
remain VBP N
questionable JJ N
, , N
because IN N
FZ NNP N
has VBZ N
been VBN N
biotransformed VBN N
into IN N
other JJ N
metabolites NNS N
. . N

Though IN N
propofol NN N
seemed VBD N
to TO N
be VB N
better JJR N
for IN N
effectiveness NN N
and CC N
safety NN N
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
for IN N
all DT N
three CD N
primary JJ N
end NN N
points NNS N
and CC N
the DT N
safety NN N
parameters NNS N
( ( N
hypotension NN N
, , N
hypoxia NN N
, , N
bradycardia NN N
) ) N
. . N

CONCLUSION NNP N
The DT N
absence NN N
of IN N
an DT N
association NN N
between IN N
allostatic JJ N
load NN N
and CC N
SRH NNP N
in IN N
diabetic JJ N
individuals NNS N
contrasts NNS N
with IN N
previous JJ N
findings NNS N
in IN N
non-diabetic JJ N
women NNS N
, , N
and CC N
shows VBZ N
that IN N
it PRP N
is VBZ N
hazardous JJ N
to TO N
apply VB N
findings NNS N
in IN N
one CD N
population NN N
to TO N
another DT N
, , N
especially RB N
diabetic JJ N
and CC N
non-diabetic JJ N
populations NNS N
. . N

Data NNS N
from IN N
460 CD N
patients NNS p
were VBD N
available JJ N
for IN N
analysis NN N
, , N
which WDT N
includes VBZ N
both CC N
a DT N
National NNP N
Health NNP N
Service NNP N
cost NN N
perspective NN N
including VBG N
costs NNS N
of IN N
surgery NN N
, , N
implants NNS N
and CC N
healthcare NN N
resource NN N
use NN N
over IN N
a DT N
12-month JJ N
period NN N
after IN N
surgery NN N
, , N
and CC N
a DT N
societal JJ N
perspective NN N
, , N
which WDT N
includes VBZ N
the DT N
cost NN N
of IN N
time NN N
off IN N
work NN N
and CC N
the DT N
need NN N
for IN N
additional JJ N
private JJ N
care NN N
. . N

The DT N
quality NN N
of IN N
pain NN N
control NN N
, , N
the DT N
amount NN N
and CC N
character NN N
of IN N
the DT N
drain NN N
fluid NN N
, , N
incidence NN N
of IN N
nausea NN N
and CC N
vomiting NN N
, , N
length NN N
of IN N
stay NN N
in IN N
the DT N
postoperative JJ N
care NN N
unit NN N
, , N
and CC N
amount NN N
of IN N
morphine NN N
used VBN N
for IN N
treatment NN N
of IN N
break-through JJ N
pain NN N
were VBD N
recorded VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
whey-predominant JJ N
, , N
50 CD N
% NN N
medium NN N
chain NN N
triglyceride IN N
formula NN N
with IN N
relatively RB N
high JJ N
concentrations NNS N
of IN N
zinc NN N
and CC N
copper NN N
would MD N
promote VB N
the DT N
achievement NN N
of IN N
the DT N
in IN N
utero JJ N
accretion NN N
rate NN N
for IN N
zinc NN N
and CC N
copper NN N
in IN N
the DT N
preterm NN N
infant NN N
. . N

We PRP N
investigated VBD N
the DT N
benefit NN N
of IN N
adding VBG N
all-trans JJ N
retinoic NN N
acid NN N
( ( N
ATRA NNP N
) ) N
to TO N
chemotherapy VB i
for IN N
younger JJR N
patients NNS p
with IN N
nonacute JJ N
promyelocytic JJ N
acute NN N
myeloid NN N
leukemia NN N
and CC N
high-risk JJ N
myelodysplastic JJ N
syndrome NN N
, , N
and CC N
considered VBD N
interactions NNS N
between IN N
treatment NN N
and CC N
molecular JJ N
markers NNS N
. . N

BACKGROUND NNP N
While IN N
low JJ N
back RB N
pain NN N
is VBZ N
the DT N
number NN N
one CD N
cause NN N
of IN N
disability NN N
in IN N
the DT N
United NNP N
States NNPS N
, , N
lumbar VBP N
spinal JJ N
stenosis NN N
along IN N
with IN N
intervertebral JJ N
disc NN N
herniation NN N
and CC N
degenerative JJ N
spondylolisthesis NN N
is VBZ N
one CD N
of IN N
the DT N
3 CD N
most JJS N
common JJ N
diagnosis NN N
of IN N
low JJ N
back RB N
and CC N
leg NN N
pain NN N
for IN N
which WDT N
surgery NN N
is VBZ N
performed VBN N
. . N

Additionally RB N
, , N
efforts NNS N
will MD N
be VB N
made VBN N
to TO N
define VB N
whether IN N
noninvasive JJ N
hemodynamic JJ N
parameters NNS N
, , N
retinal JJ N
vessel FW N
measurement NN N
changes NNS N
, , N
or CC N
biologic JJ N
markers NNS N
may MD N
predict VB N
and CC N
track VB N
the DT N
underlying VBG N
vascular JJ N
morphologic NN N
and CC N
physiologic JJ N
changes NNS N
induced VBN N
by IN N
either DT N
regimen NNS N
during IN N
the DT N
12-month JJ N
treatment NN N
period NN N
. . N

One CD N
strategy NN N
to TO N
minimize VB N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
per IN N
true JJ N
match NN N
is VBZ N
to TO N
first JJ N
search NN N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
then RB N
by IN N
Canada411 NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
and CC N
finally RB N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
initial JJ N
. . N

The DT N
current JJ N
intervention NN N
, , N
unlike IN N
many JJ N
others NNS N
for IN N
the DT N
same JJ N
or CC N
similar JJ N
difficulties NNS N
proposed VBN N
in IN N
the DT N
past NN N
, , N
was VBD N
successful JJ N
without IN N
requiring VBG N
extensive JJ N
time NN N
, , N
training NN N
, , N
or CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
providers NNS N
and CC N
parents NNS N
or CC N
their PRP$ N
children NNS N
, , N
nor CC N
did VBD N
it PRP N
require VB N
large-scale JJ N
institutional JJ N
changes NNS N
. . N

It PRP N
is VBZ N
hoped VBN N
that IN N
, , N
if IN N
this DT N
inhibition NN N
can MD N
be VB N
mitigated VBN N
, , N
it PRP N
will MD N
be VB N
possible JJ N
to TO N
assist VB N
the DT N
compromised VBN N
immune NN N
system NN N
and CC N
maintain VB N
a DT N
certain JJ N
level NN N
of IN N
immune JJ N
performance NN N
which WDT N
will MD N
prevent VB N
recurrence NN N
and CC N
improve VB N
survival NN N
rate NN N
. . N

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
the DT N
relative JJ N
efficacy NN N
of IN N
the DT N
sublingual JJ N
administration NN N
of IN N
micronized JJ N
estradiol NN N
( ( N
E2 NNP N
) ) N
, , N
progesterone NN N
( ( N
P4 NNP N
) ) N
, , N
and CC N
testosterone NN N
( ( N
T NNP N
) ) N
on IN N
bone NN N
mineral JJ N
density NN N
and CC N
biochemical JJ N
markers NNS N
of IN N
bone NN N
metabolism NN N
. . N

Although IN N
maternal JJ N
attachment NN N
is VBZ N
an DT N
important JJ N
predictor NN N
of IN N
infant JJ N
attachment JJ N
security NN N
and CC N
other JJ N
developmental JJ N
outcomes NNS N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
formation NN N
of IN N
maternal JJ N
attachment NN N
in IN N
the DT N
first JJ N
few JJ N
months NNS N
of IN N
the DT N
infant NN N
's POS N
life NN N
, , N
particularly RB N
among IN N
ethnic JJ N
minority NN N
mothers NNS N
. . N

Results NNS N
from IN N
this DT N
study NN N
suggest VBP N
that IN N
anti-migraine JJ N
efficacy NN N
is VBZ N
not RB N
mediated VBN N
solely RB N
through IN N
the DT N
5-HT JJ N
( ( N
1D CD N
) ) N
receptor NN N
subtype NN N
, , N
although IN N
this DT N
receptor NN N
may MD N
contribute VB N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
to TO N
the DT N
adverse JJ N
cardiovascular JJ N
effects NNS N
observed VBN N
with IN N
5-HT JJ N
agonist JJ N
medications NNS N
. . N

It PRP N
is VBZ N
widely RB N
held VBN N
that IN N
first-order JJ N
modulations NNS N
are VBP N
represented VBN N
by IN N
the DT N
firing VBG N
rates NNS N
of IN N
simple JJ N
and CC N
complex JJ N
cells NNS N
( ( N
first-order JJ N
neurons NNS N
) ) N
in IN N
primary JJ N
visual JJ N
cortex NN N
( ( N
V1 NNP N
) ) N
that IN N
, , N
likewise RB N
, , N
have VBP N
spatially RB N
localized VBN N
receptive JJ N
fields NNS N
that WDT N
are VBP N
selective JJ N
for IN N
orientation- JJ N
and CC N
SF NNP N
. . N

Prediction NN N
linear JJ N
equations NNS N
for IN N
the DT N
main JJ N
variables NNS N
of IN N
clinical JJ N
interest NN N
were VBD N
established VBN N
by IN N
backward NN N
stepwise NN N
regression NN N
analysis NN N
including VBG N
: : N
sex NN N
, , N
age NN N
, , N
knee NN N
extensor NN N
peak NN N
torque NN N
, , N
bone-free JJ N
lean JJ N
leg NN N
mass NN N
, , N
total JJ N
and CC N
lean JJ N
body NN N
mass NN N
, , N
height NN N
, , N
and CC N
physical JJ N
activity NN N
scores NNS N
. . N

Despite IN N
a DT N
relative JJ N
lack NN N
of IN N
published VBN N
data NNS N
antazoline NN N
has VBZ N
been VBN N
marketed VBN N
in IN N
Poland NNP N
and CC N
widely RB N
used VBN N
in IN N
cardiology NN N
wards NNS N
and CC N
emergency NN N
rooms NNS N
for IN N
many JJ N
years NNS N
due JJ N
to TO N
its PRP$ N
efficacy NN N
, , N
safety NN N
and CC N
rapid JJ N
onset NN N
of IN N
action NN N
within IN N
minutes NNS N
of IN N
administration NN N
. . N

Even RB N
though IN N
the DT N
number NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
is VBZ N
small JJ N
, , N
because IN N
this DT N
study NN N
did VBD N
not RB N
show VB N
an DT N
effect NN N
in IN N
the DT N
intent-to-treat JJ N
group NN N
, , N
rheopheresis NN N
should MD N
not RB N
be VB N
performed VBN N
for IN N
AMD NNP N
outside NN N
of IN N
an DT N
approved JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

A DT N
modified JJ N
World NNP N
Health NNP N
Organization NNP N
14-day JJ N
in IN N
vivo JJ N
drug NN N
efficacy NN N
test NN N
for IN N
uncomplicated JJ N
Plasmodium NNP N
falciparum NN N
malaria NN N
in IN N
areas NNS N
with IN N
intense JJ N
malaria NNS N
transmission NN N
was VBD N
adapted VBN N
to TO N
reflect VB N
the DT N
clinical JJ N
and CC N
epidemiologic JJ N
features NNS N
of IN N
a DT N
low-intensity JJ N
malaria NN N
transmission NN N
area NN N
in IN N
the DT N
Pacific NNP N
Coast NNP N
Region NNP N
of IN N
Colombia NNP N
. . N

AIM IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
explore VB N
the DT N
result NN N
of IN N
pretreatment NN N
and CC N
concomitant NN N
use NN N
of IN N
metformin NN N
with IN N
clomiphene JJ N
citrate NN N
( ( N
CC NNP N
) ) N
and CC N
rFSH NN N
for IN N
ovulation NN N
induction NN N
in IN N
clomiphene-citrate-resistant JJ N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
. . N

The DT N
beneficial JJ N
effects NNS N
of IN N
buspirone NN N
in IN N
helping VBG N
this DT N
patient NN N
with IN N
autism NN N
in IN N
his PRP$ N
natural JJ N
daily JJ N
settings NNS N
suggest VBP N
that IN N
buspirone NN N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
neuroleptic JJ N
agents NNS N
in IN N
the DT N
medical JJ N
therapy NN i
of IN N
autism NN N
; : N
further JJ N
study NN N
in IN N
other JJ N
patients NNS p
is VBZ N
needed VBN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
indicated VBD N
that IN N
flecainide NN N
exerted VBD N
a DT N
significant JJ N
dose-dependent JJ N
effect NN N
on IN N
the DT N
prevention NN N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
recurrence NN N
and CC N
showed VBD N
that IN N
there EX N
was VBD N
no DT N
inter-ethnic JJ N
difference NN N
in IN N
the DT N
clinical JJ N
effect NN N
of IN N
flecainide NN N
in IN N
patients NNS p
with IN N
PAF/PAFL NNP N
. . N

Patients NNS N
completed VBD N
self-rating JJ N
scales NNS N
on IN N
pain NN N
, , N
global JJ N
health NN N
, , N
mood NN N
, , N
quality NN N
of IN N
life NN N
, , N
coping VBG N
style NN N
, , N
health NN N
locus NN N
of IN N
control NN N
, , N
multidimensional JJ N
well-being NN N
, , N
spirituality NN N
, , N
sense NN N
of IN N
coherence NN N
, , N
positive JJ N
states NNS N
of IN N
mind NN N
, , N
and CC N
social JJ N
desirability NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicate VBP N
that DT N
supplementation NN N
of IN N
a DT N
combination NN N
of IN N
vitamin NN N
E NNP N
, , N
selenium NN N
, , N
vitamin FW N
C NNP N
and CC N
coenzyme-Q10 NN N
does VBZ N
not RB N
affect VB N
serum JJ N
level NN N
of IN N
PSA NNP N
or CC N
hormone NN N
levels NNS N
in IN N
patients NNS p
with IN N
hormonally RB N
untreated JJ N
carcinoma NN N
of IN N
the DT N
prostate NN N
. . N

CONCLUSIONS VB N
A DT N
20-week JJ N
parent NN N
education NN N
and CC N
skills NNS N
training VBG N
program NN N
for IN N
parents NNS N
of IN N
young JJ N
children NNS N
newly RB N
diagnosed VBN N
with IN N
autism NN N
provides VBZ N
significant JJ N
improvements NNS N
in IN N
parental JJ N
mental JJ N
health NN N
and CC N
adjustment NN N
, , N
justifying VBG N
its PRP$ N
addition NN N
to TO N
early JJ N
intervention NN N
programs NNS N
at IN N
least JJS N
for IN N
parents NNS N
with IN N
mental JJ N
health NN N
problems NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
data NNS N
suggest VBP N
that IN N
a DT N
large JJ N
proportion NN N
of IN N
the DT N
US NNP N
men NNS N
had VBD N
suboptimal JJ N
vitamin NN N
D NNP N
status NN N
( ( N
especially RB N
during IN N
the DT N
winter/spring NN N
season NN N
) ) N
, , N
and CC N
both DT N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
preventing VBG N
prostate NN N
cancer NN N
progression NN N
. . N

RESULTS NN N
In IN N
the DT N
analyses NNS N
of IN N
time NN N
to TO N
PPMD NNP N
recurrence NN N
, , N
poor JJ N
sleep JJ N
quality NN N
, , N
but CC N
none NN N
of IN N
the DT N
hormones NNS N
, , N
was VBD N
associated VBN N
with IN N
PPMD NNP N
recurrence NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
after IN N
controlling VBG N
for IN N
medication NN N
assignment NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
This DT N
pilot NN N
study NN N
tested VBD N
the DT N
efficacy NN N
of IN N
a DT N
developmentally RB N
modified VBN N
CBT NNP N
for IN N
young JJ N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
( ( N
ASD NNP N
) ) N
to TO N
teach VB N
emotion NN N
regulation NN N
strategies NNS N
for IN N
reducing VBG N
anger NN N
and CC N
anxiety NN N
, , N
commonly RB N
noted VBD N
problems NNS N
in IN N
this DT N
population NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
are VBP N
relapse-free JJ N
survival NN N
, , N
proportion NN N
of IN N
laparoscopy-assisted JJ N
distal JJ N
gastrectomy NN N
completion NN N
, , N
proportion NN N
of IN N
conversion NN N
to TO N
open VB N
surgery NN N
, , N
adverse JJ N
events NNS N
, , N
short-term JJ N
clinical JJ N
outcomes NNS N
, , N
postoperative JJ N
quality NN N
of IN N
life NN N
. . N

Thus RB N
the DT N
potassium-retaining JJ N
diuretic JJ N
amiloride NN N
, , N
like IN N
the DT N
aldosterone NN N
antagonist NN N
spironolactone NN N
, , N
markedly RB N
reduces VBZ N
both CC N
the DT N
ulcer-healing JJ N
and CC N
the DT N
metabolic JJ N
side-effects NNS N
of IN N
carbenoxolone NN N
sodium NN N
, , N
and CC N
should MD N
not RB N
be VB N
used VBN N
together RB N
with IN N
it PRP N
in IN N
the DT N
treatment NN N
of IN N
peptic JJ N
ulcer NN N
. . N

INTRODUCTION NNP N
The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
ability NN N
of IN N
novices NNS N
to TO N
learn VB N
selected VBN N
aspects NNS N
of IN N
Advanced NNP N
Cardiac NNP N
Life NNP N
Support NNP N
( ( N
ACLS NNP N
) ) N
in IN N
training NN N
conditions NNS N
that WDT N
did VBD N
not RB N
incorporate VB N
simulation NN N
compared VBN N
to TO N
those DT N
that WDT N
contained VBD N
low- JJ N
and CC N
high-fidelity JJ N
simulation NN N
activities NNS N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
extended-release JJ N
niacin NN i
( ( N
niacin JJ i
ER NNP N
) ) N
either CC N
alone RB N
or CC N
in IN N
combination NN N
with IN N
atorvastatin NN i
for IN N
the DT N
lipid JJ N
profile NN N
modification NN N
in IN N
the DT N
patients NNS p
with IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
and CC N
its PRP$ N
equivalents NNS N
. . N

The DT N
impact NN N
on IN N
outcome NN N
of IN N
the DT N
addition NN N
of IN N
all-trans NNS N
retinoic JJ N
acid NN N
to TO N
intensive JJ N
chemotherapy NN i
in IN N
younger JJR N
patients NNS p
with IN N
nonacute JJ N
promyelocytic JJ N
acute NN N
myeloid NN N
leukemia NN N
: : N
overall JJ i
results NNS N
and CC N
results NNS N
in IN N
genotypic JJ N
subgroups NNS N
defined VBN N
by IN N
mutations NNS N
in IN N
NPM1 NNP N
, , N
FLT3 NNP N
, , N
and CC N
CEBPA NNP N
. . N

The DT N
broad-spectrum JJ N
effectiveness NN N
of IN N
a DT N
combination NN N
of IN N
a DT N
fenbendazole JJ N
oral JJ N
drench NN N
and CC N
an DT N
ivermectin JJ i
pour-on NN N
reduced VBD N
parasite JJ N
burden NN N
and CC N
increased VBD o
feed NN o
intake NN N
, , N
ADG NNP N
, , N
and CC N
carcass NN N
weight NN N
in IN N
feedlot NN N
heifers NNS N
compared VBN N
with IN N
treatment NN N
with IN N
an DT N
endectocide JJ N
alone NN N
. . N

This DT N
study NN N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
in IN N
the DT N
primary JJ N
efficacy NN N
outcome NN N
of IN N
pain NN N
during IN N
the DT N
first JJ N
few JJ N
minutes NNS N
of IN N
walking VBG N
measured VBN N
by IN N
a DT N
visual JJ N
analog NN N
scale NN N
. . N

Thus RB N
, , N
in IN N
patients NNS p
undergoing VBG N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
, , N
dietary JJ N
supplementation NN N
with IN N
n-3 JJ N
fatty JJ N
acids NNS N
reduced VBD N
the DT N
incidence NN N
of IN N
vein NN N
graft NN N
occlusion NN N
, , N
and CC N
an DT N
inverse JJ N
relation NN N
between IN N
relative JJ N
change NN N
in IN N
serum JJ N
phospholipid JJ N
n-3 JJ N
fatty JJ N
acids NNS N
and CC N
vein NN N
graft NN N
occlusions NNS N
was VBD N
observed VBN N
. . N

RESULTS JJ N
Placebo-corrected JJ N
time-matched JJ N
analysis NN N
of IN N
the DT N
QTcI NNP N
duration NN N
for IN N
the DT N
vilazodone NN i
treatment NN N
effect NN N
indicated VBD N
that IN N
no DT N
vilazodone NN i
dose NN N
had VBD N
an DT N
upper JJ N
bound NN N
that IN N
approached VBD N
or CC N
exceeded VBD N
10 CD N
ms NN N
, , N
demonstrating VBG N
no DT N
signal NN N
for IN N
a DT N
significant JJ N
vilazodone NN i
effect NN N
on IN N
cardiac JJ N
repolarization NN N
. . N

It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
RTD NNP N
may MD N
prevent VB N
the DT N
rapid JJ N
development NN N
of IN N
collateral JJ N
circulation NN N
and CC N
increase VB o
the DT N
production NN N
of IN N
oxygen-derived JJ N
free JJ N
radicals NNS N
, , N
which WDT N
may MD N
be VB N
the DT N
responsible JJ N
factors NNS N
for IN N
the DT N
ischemic JJ N
treatment NN N
of IN N
hepatic JJ N
tumours NNS N
. . N

While IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
, , N
overall JJ i
, , N
sibenadet JJ N
therapy NN i
was VBD N
well RB N
tolerated VBN N
, , N
the DT N
lack NN N
of IN N
sustained JJ N
benefit NN N
reported VBD N
in IN N
large-scale JJ N
clinical JJ N
efficacy NN N
studies NNS N
means VBZ N
that IN N
sibenadet NN N
development NN N
will MD N
not RB N
be VB N
continued VBN N
. . N

The DT N
potential JJ N
advantages NNS N
over IN N
other JJ N
vaginal JJ N
products NNS N
include VBP N
keeping VBG N
a DT N
low JJ N
pH NN N
, , N
decrease NN o
of IN N
the DT N
irritating VBG N
effect NN N
of IN N
N-9 NNP N
on IN N
the DT N
cervix NN N
or CC N
vaginal JJ N
mucosa NN N
associated VBN N
with IN N
greater JJR N
retention NN N
of IN N
the DT N
product NN N
after IN N
application NN N
, , N
and CC N
decreasing VBG N
messiness NN N
as IN N
compared VBN N
to TO N
other JJ N
vaginal JJ N
products NNS N
. . N

Six CD N
months NNS N
after IN N
treatment NN N
the DT N
sample NN N
as IN N
a DT N
whole NN N
showed VBD N
good JJ N
maintenance NN N
of IN N
treatment NN N
effects NNS N
, , N
but CC N
the DT N
differences NNS N
between IN N
groups NNS N
had VBD N
become VBN N
somewhat RB N
sharper JJ N
, , N
with IN N
the DT N
special JJ N
behavior JJ N
therapy NN i
group NN N
faring VBG N
best JJS N
, , N
the DT N
regular JJ N
behavior NN N
therapy NN i
group NN N
intermediate NN N
, , N
and CC N
the DT N
psychotherapy NN i
group NN N
worst JJS N
. . N

AIM NNP N
To TO N
test VB N
if IN N
treatment NN N
with IN N
GnRH NNP N
analogue NN N
, , N
which WDT N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
myoma NN N
volume NN N
, , N
changes NNS N
expression NN N
of IN N
leptin NN i
genes NNS N
and CC N
gene NN N
coding VBG N
leptin JJ i
receptor NN N
isoforms NNS N
in IN N
uterine JJ N
myomas NN N
and CC N
in IN N
the DT N
surrounding NN N
unaltered JJ N
myometrium NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
and CC N
adherence NN N
to TO N
an DT N
active JJ N
video NN N
game NN N
promotion NN N
intervention NN N
on IN N
anthropometrics NNS N
, , N
sedentary JJ N
screen NN N
time NN N
and CC N
consumption NN N
of IN N
sugar-sweetened JJ N
beverages NNS N
and CC N
snacks NNS N
among IN N
non-active JJ N
video NN N
gaming VBG N
adolescents NNS N
who WP N
primarily RB N
were VBD N
of IN N
healthy JJ N
weight NN N
. . N

Since IN N
FGF23 NNP N
shares NNS N
structural JJ N
features NNS N
with IN N
FGF19 NNP N
subfamily RB N
members NNS N
that IN N
exert JJ N
hormonal JJ N
control NN N
of IN N
fat JJ N
mass NN N
, , N
we PRP N
hypothesized VBD N
that DT N
high JJ N
circulating NN N
FGF23 NNP N
concentrations NNS N
would MD N
be VB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
a DT N
uremic JJ N
lipid NN N
profile NN N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

The DT N
drug NN N
tested VBD N
may MD N
be VB N
very RB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
type NN N
IV NNP N
hyperlipoproteinemia NN N
, , N
especially RB N
in IN N
those DT N
forms NNS N
in IN N
which WDT N
an DT N
increase NN o
in IN N
thromboembolic JJ N
risk NN N
is VBZ N
suspected VBN N
, , N
either RB N
associated VBN N
with IN N
, , N
or CC N
secondary JJ N
to TO N
, , N
the DT N
actual JJ N
atherosclerotic JJ i
disease NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
study NN N
was VBD N
small JJ N
owing NN N
to TO N
recruitment VB N
difficulties NNS N
, , N
it PRP N
still RB N
provides VBZ N
evidence NN N
of IN N
effectiveness NN N
of IN N
melatonin NN N
in IN N
children NNS N
with IN N
sleep JJ N
difficulties NNS N
and CC N
ASD NNP N
, , N
which WDT N
we PRP N
predict VBP N
a DT N
larger JJR N
study NN N
would MD N
confirm VB N
. . N

OBJECTIVE NN N
To TO N
describe VB N
the DT N
pharmacokinetic JJ N
profiles NNS N
of IN N
six CD N
different JJ N
dosing VBG N
regimens NNS N
for IN N
epoetin NN i
alfa NN N
, , N
and CC N
whether IN N
more JJR N
rapid JJ N
and CC N
robust JJ N
reticulocytosis NN N
can MD N
be VB N
elicited VBN N
with IN N
more RBR N
frequent JJ N
administration NN N
of IN N
epoetin JJ i
alfa NN N
in IN N
anemic JJ N
critically RB N
ill JJ N
patients NNS p
. . N

Our PRP$ N
data NNS N
support NN N
historical JJ N
data NNS N
indicating VBG N
that IN N
agglutinating VBG N
antibodies NNS N
are VBP N
associated VBN N
with IN N
protection NN N
and CC N
also RB N
recent JJ N
serologic JJ N
correlates NNS N
data NNS N
and CC N
clinical JJ N
efficacy NN N
data NNS N
which WDT N
indicate VBP N
that IN N
multicomponent NN N
vaccines NNS N
containing VBG N
pertactin NN i
and CC N
fimbriae NN N
have VBP N
better JJR N
efficacy NN N
than IN N
PT NNP N
or CC N
PT/FHA NNP N
vaccines NNS N
. . N

For IN N
this DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
usual JJ N
care NN N
group NN N
there EX N
was VBD N
a DT N
highly RB N
significant JJ N
improvement NN N
in IN N
the DT N
level NN N
of IN N
advice NN N
recorded VBN N
as IN N
having VBG N
been VBN N
given VBN N
on IN N
drug NN N
compliance NN N
, , N
adverse JJ N
drug NN N
effects NNS N
, , N
driving VBG N
, , N
alcohol NN N
intake NN N
, , N
and CC N
self PRP N
help VBP N
groups NNS N
. . N

The DT N
authors NNS N
undertook VBP N
this DT N
study NN N
to TO N
further RBR N
evaluate VB N
the DT N
level NN N
of IN N
adenosine JJ N
deaminase NN N
( ( N
ADA NNP N
) ) N
in IN N
patients NNS p
with IN N
chronic JJ N
schizophrenia NN N
treated VBN N
with IN N
monotherapy NN i
of IN N
haloperidol NN N
, , N
risperidone NN i
or CC N
clozapine NN N
and CC N
correlation NN N
between IN N
the DT N
ADA NNP N
level NN N
with IN N
response NN N
to TO N
treatment NN N
. . N

BACKGROUND NNP N
Concomitant NNP N
administration NN N
of IN N
erlotinib NN N
with IN N
standard JJ N
chemotherapy NN i
does VBZ N
not RB N
appear VB N
to TO N
improve VB N
survival NN N
among IN N
patients NNS p
with IN N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
, , N
but CC N
preliminary JJ N
studies NNS N
suggest VBP N
that IN N
sequential JJ N
administration NN N
might MD N
be VB N
effective JJ N
. . N

Although IN N
difficulty NN N
in IN N
understanding VBG N
of IN N
others NNS N
' POS N
social JJ N
emotions NNS N
and CC N
beliefs NNS N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
also RB N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
autism NN N
spectrum NN N
disorder NN N
, , N
no DT N
study NN N
has VBZ N
examined VBN N
the DT N
potential JJ N
effect NN N
of IN N
oxytocin NN i
on IN N
this DT N
difficulty NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
incidence NN N
of IN N
metaphase NN N
II NNP N
stage NN N
oocytes NNS N
with IN N
numeric JJ N
chromosomal JJ N
abnormalities NNS N
, , N
using VBG N
full JJ N
( ( N
spectral JJ N
karyotyping NN N
) ) N
or CC N
partial JJ N
( ( N
fluorescent JJ N
in IN N
situ JJ N
hybridization NN N
with IN N
seven CD N
probes NNS N
) ) N
karyotyping VBG N
or CC N
Giemsa NNP N
count NN N
. . N

Compared VBN N
to TO N
ten VB N
IQ- NNP N
and CC N
age-matched JJ N
healthy JJ N
controls NNS N
, , N
eight CD N
participants NNS N
with IN N
autism NN N
showed VBD N
less JJR N
fixation JJ N
specificity NN N
to TO N
the DT N
eyes NNS N
and CC N
mouth NN N
, , N
a DT N
greater JJR N
tendency NN N
to TO N
saccade VB N
away RB N
from IN N
the DT N
eyes NNS N
when WRB N
information NN N
was VBD N
present JJ N
in IN N
those DT N
regions NNS N
, , N
and CC N
abnormal JJ N
directionality NN N
of IN N
saccades NNS N
. . N

Because IN N
most JJS N
NSAIDs NNP N
are VBP N
weak JJ N
acids NNS N
( ( N
pKa IN N
3-5 NNP N
) ) N
and CC N
become VBN N
concentrated JJ N
in IN N
acidic JJ N
tissues NNS N
, , N
such JJ N
as IN N
injured JJ N
and CC N
inflamed JJ N
tissues NNS N
, , N
we PRP N
hypothesized VBD N
that IN N
local JJ N
administration NN N
may MD N
enhance VB N
its PRP$ N
analgesic JJ N
efficacy NN N
while IN N
lowering VBG N
the DT N
potential NN N
for IN N
systemic JJ N
complications NNS N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
in IN N
a DT N
manikin JJ N
model NN N
whether IN N
using VBG N
the DT N
single-use JJ N
laryngeal NN N
tube NN N
with IN N
suction NN N
option NN N
( ( N
LTS-D NNP N
) ) N
instead RB N
of IN N
endotracheal JJ N
intubation NN N
( ( N
ET NNP N
) ) N
and CC N
bag-mask-valve JJ N
ventilation NN N
( ( N
BMV NNP N
) ) N
for IN N
emergency NN N
airway NN N
management NN N
could MD N
reduce VB N
the DT N
no-flow JJ N
time NN N
( ( N
NFT NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
quantification NN N
of IN N
other JJ N
vaginal JJ N
compartments NNS N
( ( N
POP-Q NNP N
points NNS N
) ) N
, , N
comparison NN N
of IN N
quality NN N
of IN N
life NN N
by IN N
the DT N
prolapse NN N
quality NN N
of IN N
life NN N
( ( N
P-QOL NNP N
) ) N
questionnaire NN N
, , N
and CC N
complication NN N
rate NN N
between IN N
the DT N
groups NNS N
after IN N
1 CD N
year NN N
. . N

When WRB N
the DT N
results NNS N
obtained VBD N
with IN N
a DT N
particularly RB N
promising JJ N
new JJ N
drug NN N
or CC N
procedure NN N
are VBP N
presented VBN N
early RB N
in IN N
the DT N
course NN N
of IN N
study NN N
( ( N
within IN N
1-2 CD N
years NNS N
) ) N
, , N
the DT N
investigators NNS N
should MD N
strongly RB N
consider VB N
a DT N
repeat NN N
evaluation NN N
after IN N
an DT N
additional JJ N
3-5 CD N
years NNS N
of IN N
follow-up NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
either CC N
the DT N
heart NN N
rate NN N
or CC N
blood NN N
pressure NN N
responses VBZ N
to TO N
the DT N
PSL-LBNP NNP N
or CC N
the DT N
tolerance NN N
indices NNS N
( ( N
cumulative JJ N
stress NN N
index NN N
; : N
maximum JJ N
negative JJ N
pressure NN N
tolerated VBN N
; : N
and CC N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure NN N
) ) N
. . N

METHOD NN N
To TO N
make VB N
further JJ N
advances NNS N
in IN N
untangling VBG N
this DT N
chicken-and-egg JJ N
question NN N
, , N
we PRP N
employed VBD N
autoregressive JJ N
cross-lagged JJ N
modeling NN N
over IN N
4 CD N
time NN N
points NNS N
in IN N
a DT N
sample NN N
of IN N
149 CD N
depressive JJ N
patients NNS p
receiving VBG N
supportive-expressive JJ N
psychotherapy NN i
or CC N
clinical JJ N
management NN N
combined VBN N
with IN N
pharmacotherapy NN i
or CC N
clinical JJ N
management NN N
combined VBN N
with IN N
placebo NN N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS N
of IN N
children NNS N
with IN N
autism NN N
compared VBN N
with IN N
parents NNS N
of IN N
children NNS N
with IN N
asthma NN N
or CC N
other JJ N
special JJ N
health NN N
care NN N
needs VBZ N
report NN N
receiving VBG N
primary JJ N
care NN N
for IN N
their PRP$ N
child NN N
consistent NN N
with IN N
the DT N
American JJ N
Academy NNP N
of IN N
Pediatrics NNP N
medical JJ N
home NN N
model NN N
. . N

Antipyrine NNP N
clearance NN N
and CC N
response NN N
to TO N
interferon VB N
treatment NN N
in IN N
patients NNS p
with IN N
chronic JJ N
active JJ N
hepatitis NN N
C. NNP N
To TO N
determine VB N
whether IN N
hepatic JJ N
metabolic JJ N
function NN N
affects VBZ N
the DT N
response NN N
to TO N
interferon VB N
treatment NN N
, , N
we PRP N
measured VBD N
antipyrine JJ N
clearance NN N
( ( N
APC NNP N
) ) N
in IN N
85 CD N
patients NNS p
with IN N
chronic JJ N
active JJ N
hepatitis NN N
C NNP N
and CC N
compared VBN N
the DT N
results NNS N
with IN N
treatment NN N
outcome NN N
. . N

This DT N
report NN N
specifically RB N
addresses VBZ N
the DT N
issues NNS N
of IN N
safety NN N
in IN N
patients NNS p
with IN N
squamous JJ N
cell NN N
tumors NNS N
, , N
effect NN N
of IN N
treatment NN N
in IN N
elderly JJ N
patients NNS p
, , N
and CC N
uncertainties NNS N
regarding VBG N
effects NNS N
in IN N
patients NNS p
with IN N
tumors NNS N
harboring VBG N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
or CC N
anaplastic JJ N
lymphoma NN N
kinase NN N
genomic JJ N
tumor NN N
aberrations NNS N
. . N

In IN N
response NN N
to TO N
the DT N
therapist NN N
's POS N
interpersonal JJ N
demands NNS N
, , N
'compliant NNP N
( ( N
positive JJ N
) ) N
responses NNS N
' POS N
were VBD N
observed VBN N
more RBR N
in IN N
music NN N
therapy NN i
than IN N
in IN N
toy JJ N
play NN N
sessions NNS N
, , N
and CC N
'no POS N
responses NNS N
' POS N
were VBD N
twice RB N
as RB N
frequent JJ N
in IN N
toy JJ N
play NN N
sessions NNS N
as IN N
in IN N
music NN N
therapy NN i
. . N

OBJECTIVE IN N
We PRP N
investigated VBD N
the DT N
changes NNS N
in IN N
the DT N
temporomandibular JJ N
joint NN N
( ( N
TMJ NNP N
) ) N
after IN N
bilateral JJ N
sagittal JJ N
split NN N
osteotomy NN N
of IN N
the DT N
mandible JJ N
for IN N
orthognathic JJ N
surgery NN N
and CC N
the DT N
influence NN N
of IN N
positioning NN N
of IN N
the DT N
condylar JJ N
process NN N
in IN N
the DT N
centre NN N
of IN N
the DT N
articular JJ N
fossa NN N
before IN N
and CC N
during IN N
the DT N
operation NN N
for IN N
preventing VBG N
changes NNS N
in IN N
the DT N
TMJ NNP N
postoperatively RB N
. . N

This DT N
pilot NN N
study NN N
shows VBZ N
for IN N
the DT N
first JJ N
time NN N
in IN N
human JJ N
volunteers NNS N
that WDT N
naloxone RB N
does VBZ N
not RB N
inhibit VB N
paracetamol JJ N
antinociception NN N
, , N
suggesting VBG N
no DT N
significant JJ N
implication NN N
of IN N
the DT N
opioid NN N
system NN N
in IN N
paracetamol JJ N
mechanism NN N
of IN N
action NN N
: : N
this DT N
needs VBZ N
be VB N
confirmed VBN N
on IN N
a DT N
larger JJR N
number NN N
of IN N
subjects NNS N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
RTD NNP N
is VBZ N
superior JJ N
to TO N
HAL NNP N
in IN N
terms NNS N
of IN N
the DT N
objective JJ N
response NN N
to TO N
the DT N
therapy NN i
, , N
reduction NN N
of IN N
tumor NN N
size NN N
, , N
patient NN N
's POS N
symptom JJ N
relief NN N
, , N
liver CC N
function NN N
and CC N
AFP NNP N
changes NNS N
and CC N
patient NN N
's POS N
survival NN N
. . N

Thus RB N
, , N
folate JJ N
deficiency NN N
may MD N
amplify VB N
the DT N
effect NN N
of IN N
other JJ N
risk NN N
factors NNS N
such JJ N
as IN N
elevated JJ N
homocysteine NN i
levels NNS N
or CC N
variant JJ N
MTHFR NNP N
genotype NN N
, , N
as RB N
well RB N
as IN N
influencing VBG N
the DT N
ability NN N
of IN N
antioxidant JJ N
supplementation NN N
to TO N
protect VB N
against IN N
genetic JJ N
damage NN N
. . N

CONCLUSION NN N
This DT N
study NN N
, , N
based VBN N
on IN N
a DT N
limited JJ N
number NN N
of IN N
patients NNS p
, , N
indicates VBZ N
that IN N
adjuvant JJ N
immunochemotherapy NN i
( ( N
BCG NNP N
+ NNP N
FAM NNP N
) ) N
may MD N
prolong VB N
the DT N
survival NN N
of IN N
gastric JJ N
cancer NN N
patients NNS p
after IN N
curative JJ N
gastrectomy NN N
; : N
in IN N
particular JJ N
, , N
in IN N
patients NNS p
with IN N
pT2/T3 JJ N
tumors NNS N
and CC N
intestinal-type JJ N
primary JJ N
tumors NNS N
. . N

CONCLUSION NN N
This DT N
analysis NN N
demonstrates VBZ N
that IN N
the DT N
previously RB N
reported VBN N
benefit NN N
in IN N
survival NN N
is VBZ N
maintained VBN N
at IN N
a DT N
median JJ N
follow-up NN N
of IN N
8 CD N
years NNS N
and CC N
firmly RB N
establishes VBZ N
the DT N
role NN N
of IN N
RT NNP N
in IN N
the DT N
treatment NN N
of IN N
men NNS N
with IN N
locally RB N
advanced JJ N
prostate NN N
cancer NN N
. . N

If IN N
prognostic JJ N
factors NNS N
have VBP N
to TO N
be VB N
taken VBN N
into IN N
account NN N
, , N
the DT N
Cox NNP N
model NN N
provides VBZ N
tests NNS N
of IN N
Ho NNP N
, , N
and CC N
a DT N
useful JJ N
confidence NN N
interval NN N
for IN N
the DT N
adjusted JJ N
relative JJ N
derived VBN N
from IN N
the DT N
regression NN N
parameter NN N
for IN N
the DT N
treatment NN N
indicator NN N
. . N

We PRP N
included VBD N
patients NNS p
admitted VBN N
to TO N
the DT N
unit NN N
during IN N
the DT N
study NN N
with IN N
a DT N
Mini-Mental JJ N
State NNP N
Examination NNP N
( ( N
MMSE NNP N
) ) N
score NN N
of IN N
more JJR N
than IN N
23/30 CD N
to TO N
receive VB N
individualised JJ N
education NN N
that WDT N
was VBD N
based VBN N
on IN N
principles NNS N
of IN N
changes NNS N
in IN N
health NN N
behaviour NN N
from IN N
a DT N
trained JJ N
health NN N
professional NN N
, , N
in IN N
addition NN N
to TO N
usual JJ N
care NN N
. . N

Individual-ESI NNP N
also RB N
showed VBD N
differential JJ N
efficacy NN N
on IN N
a DT N
parent NN N
report NN N
measure NN N
of IN N
communication NN N
, , N
daily JJ N
living NN N
, , N
and CC N
social JJ N
skills NNS N
, , N
as IN N
they PRP N
showed VBD N
improvement NN N
or CC N
stability NN N
, , N
whereas IN N
group-ESI NN N
led VBD N
to TO N
worsening VBG N
or CC N
no DT N
significant JJ N
change NN N
on IN N
these DT N
skills NNS N
. . N

Despite IN N
numerous JJ N
publications NNS N
and CC N
clinical JJ N
trials NNS N
, , N
the DT N
results NNS N
of IN N
treatment NN N
of IN N
recalcitrant JJ N
chronic JJ N
plantar NN N
fasciitis NN N
with IN N
extracorporeal JJ N
shockwave JJ N
therapy NN i
( ( N
ESWT NNP N
) ) N
still RB N
remain VBP N
equivocal JJ N
as IN N
to TO N
whether IN N
or CC N
not RB N
this DT N
treatment NN N
provides VBZ N
relief NN N
from IN N
the DT N
pain NN N
associated VBN N
with IN N
this DT N
condition NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
fatigue JJ N
( ( N
measured VBN N
by IN N
Chalder NNP N
fatigue NN N
questionnaire NN N
score NN N
) ) N
and CC N
physical JJ N
function NN N
( ( N
measured VBN N
by IN N
short JJ N
form-36 JJ N
subscale NN N
score NN N
) ) N
up IN N
to TO N
52 CD N
weeks NNS N
after IN N
randomisation NN N
, , N
and CC N
safety NN N
was VBD N
assessed VBN N
primarily RB N
by IN N
recording VBG N
all DT N
serious JJ N
adverse JJ N
events NNS N
, , N
including VBG N
serious JJ N
adverse JJ N
reactions NNS N
to TO N
trial NN N
treatments NNS N
. . N

RATIONALE VB N
The DT N
response NN N
characteristics NNS N
of IN N
the DT N
6 CD N
minute NN N
walk NN N
test NN N
( ( N
6MWT CD N
) ) N
in IN N
studies NNS N
of IN N
idiopathic JJ N
pulmonary JJ N
fibrosis NN N
( ( N
IPF NNP N
) ) N
are VBP N
only RB N
poorly RB N
understood JJ N
, , N
and CC N
the DT N
change NN N
in IN N
walk NN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
minimum JJ N
important JJ N
difference NN N
( ( N
MID NNP N
) ) N
over IN N
time NN N
is VBZ N
unknown JJ N
. . N

Randomization NN N
was VBD N
unbalanced JJ N
1:2 CD N
in IN N
favor NN N
of IN N
the DT N
combination NN N
therapy NN i
, , N
since IN N
study NN N
conditions NNS N
were VBD N
identical JJ N
to TO N
the DT N
previous JJ N
CML-study NNP N
I PRP N
and CC N
it PRP N
had VBD N
been VBN N
planned VBN N
in IN N
advance NN N
to TO N
add VB N
the DT N
HU NNP N
patients NNS p
of IN N
study NN N
I PRP N
( ( N
n=194 RB N
) ) N
to TO N
the DT N
HU NNP N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
patient NN N
populations NNS N
for IN N
any DT N
demographic JJ N
or CC N
clinical JJ N
characteristic NN N
( ( N
e.g JJ N
, , N
visual JJ N
acuity NN N
, , N
intraocular JJ N
pressure NN N
[ NNP N
IOP NNP N
] NNP N
, , N
initial JJ N
hyphema NN N
size NN N
) ) N
measured VBN N
in IN N
the DT N
study NN N
. . N

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
as IN N
measured VBN N
by IN N
the DT N
Hamilton NNP N
Rating NNP N
Scale NNP N
for IN N
Depression NNP N
, , N
the DT N
overall JJ i
assessment NN N
of IN N
efficacy NN N
and CC N
the DT N
Zung NNP N
Self-rating NNP N
Scale NNP N
, , N
and CC N
clearly RB N
superior JJ N
to TO N
placebo VB N
; : N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
active JJ N
drugs NNS N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN N
in IN N
the DT N
treatment NN N
of IN N
discrete JJ N
symptoms NNS N
of IN N
irritability NN N
associated VBN N
with IN N
autistic JJ N
disorder NN N
, , N
as RB N
well RB N
as IN N
other JJ N
symptoms NNS N
captured VBN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
. . N

BACKGROUND NNP N
Limited NNP N
data NN N
suggest NN N
that IN N
low JJ N
levels NNS N
of IN N
serum JJ N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
and CC N
high JJ N
levels NNS N
of IN N
triglyceride-rich JJ N
lipoproteins NNS N
may MD N
be VB N
associated VBN N
with IN N
more RBR N
rapid JJ N
rates NNS N
of IN N
kidney NN N
function NN N
loss NN N
in IN N
individuals NNS N
with IN N
chronic JJ N
renal JJ N
insufficiency NN N
( ( N
CRI NNP N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
should MD N
encourage VB N
health NN N
professionals NNS N
to TO N
educate VB N
pregnant JJ N
women NNS N
regarding VBG N
the DT N
harms NNS N
of IN N
SHS NNP N
while IN N
both DT N
empowering VBG N
and CC N
equipping VBG N
them PRP N
with IN N
the DT N
tools NNS N
to TO N
confront VB N
their PRP$ N
family NN N
members NNS N
and CC N
effectively RB N
reduce VB N
their PRP$ N
SHS NNP N
exposure NN N
while IN N
promoting VBG N
smoke-free JJ N
social JJ N
norms NNS N
. . N

Activity NN N
in IN N
parts NNS N
of IN N
the DT N
human JJ N
motor NN N
system NN N
has VBZ N
been VBN N
shown VBN N
to TO N
correlate VB N
with IN N
the DT N
complexity NN N
of IN N
performed JJ N
motor NN N
sequences NNS N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
limbs NNS N
moved VBN N
, , N
number NN N
of IN N
movements NNS N
, , N
and CC N
number NN N
of IN N
trajectories NNS N
. . N

The DT N
primary JJ N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP N
Behaviour NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
and CC N
the DT N
secondary JJ N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
relating VBG N
to TO N
people NNS N
and CC N
verbal JJ N
communication NN N
) ) N
. . N

AIM NNP N
A NNP N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
investigate VB N
people NNS N
's POS N
interest NN N
in IN N
participating VBG N
in IN N
health NN N
checks NNS N
and CC N
in IN N
discussions NNS N
about IN N
health NN N
with IN N
their PRP$ N
own JJ N
general JJ N
practitioner NN N
, , N
participants NNS N
' POS N
health NN N
status NN N
, , N
the DT N
proportion NN N
who WP N
received VBD N
health NN N
advice NN N
following VBG N
health NN N
checks NNS N
, , N
and CC N
the DT N
lifestyle JJ N
goals NNS N
they PRP N
set VBP N
following VBG N
discussion NN N
with IN N
their PRP$ N
general JJ N
practitioner NN N
. . N

Topical JJ N
diclofenac NN N
diethylamine NN N
( ( N
DDEA NNP N
) ) N
1.16 CD N
% NN N
gel NN N
is VBZ N
clinically RB N
proven VBN N
to TO N
be VB N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
acute NN N
and CC N
chronic JJ N
musculoskeletal NN N
conditions NNS N
, , N
but CC N
until IN N
now RB N
no DT N
clinical JJ N
data NNS N
existed VBD N
for IN N
its PRP$ N
use NN N
in IN N
acute JJ N
NP NNP N
. . N

Participants NNS N
had VBD N
autistic JJ N
disorder NN N
, , N
Asperger NNP N
syndrome NN N
, , N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
, , N
not RB N
otherwise RB N
specified VBN N
; : N
had VBD N
illness JJ N
severity NN N
ratings NNS N
that WDT N
were VBD N
moderate JJ N
or CC N
more JJR N
than IN N
moderate VB N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impression-Severity NNP N
scale NN N
; : N
and CC N
scored VBD N
moderate JJ N
or CC N
more JJR N
than IN N
moderate VB N
on IN N
compulsive JJ N
behaviors NNS N
measured VBN N
with IN N
the DT N
modified JJ N
Children NNP N
's POS N
Yale-Brown JJ N
Obsessive-Compulsive JJ N
Scale NNP N
. . N

After IN N
excavation NN N
, , N
the DT N
cavities NNS N
were VBD N
analyzed VBN N
using VBG N
: : N
( ( N
a DT N
) ) N
the DT N
tactile NN N
method NN N
, , N
( ( N
b NN N
) ) N
caries-detection NN N
dye NN N
to TO N
stain VB N
demineralized JJ N
dentin NN i
, , N
as IN N
proposed VBN N
by IN N
Smales NNP N
& CC N
Fang NNP N
, , N
and CC N
( ( N
c NN N
) ) N
Demineralized NNP N
Tissue NNP N
Removal NNP N
index NN N
, , N
as IN N
proposed VBN N
in IN N
this DT N
study NN N
. . N

Smith NNP N
( ( N
1993 CD N
) ) N
obtained VBD N
event-related JJ N
brain NN N
potentials NNS N
( ( N
ERPs NNP N
) ) N
from IN N
subjects NNS N
performing VBG N
a DT N
recognition NN N
memory NN N
task NN N
using VBG N
remember NN N
( ( N
R NNP N
) ) N
and CC N
know $ N
( ( N
K NNP N
) ) N
judgments NNS N
, , N
and CC N
reported VBD N
observing VBG N
in IN N
the DT N
ERP NNP N
a DT N
neurophysiological JJ N
manifestation NN N
of IN N
recollective JJ N
experience NN N
as IN N
a DT N
difference NN N
between IN N
the DT N
positive JJ N
waveforms NNS N
elicited VBN N
by IN N
stimuli NNS N
that WDT N
yielded VBD N
R NNP N
and CC N
K NNP N
judgments NNS N
. . N

In IN N
conclusion NN N
, , N
low-dose JJ N
flutamide NN N
is VBZ N
herewith JJ N
identified VBN N
as IN N
a DT N
pivotal JJ N
component NN N
within IN N
a DT N
first JJ N
contraceptive JJ N
combination NN N
therapy NN i
that WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
attenuate VB N
the DT N
hypoadiponectinemia NN N
, , N
ovarian JJ N
vascular NN N
hyperresistance NN N
, , N
lean JJ N
mass NN N
deficit NN N
, , N
and CC N
central JJ N
adiposity NN N
of IN N
young JJ N
women NNS N
with IN N
polycystic JJ N
ovary JJ N
syndrome NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
gather VB N
data NNS N
on IN N
the DT N
safety NN N
of IN N
lasalocid NN N
when WRB N
fed NN N
to TO N
Chinese JJ N
ring-necked JJ N
pheasants NNS N
at IN N
one CD N
, , N
two CD N
, , N
and CC N
three CD N
times NNS N
the DT N
recommended JJ N
high JJ N
dose NN N
of IN N
lasalocid NN N
used VBN N
for IN N
prevention NN N
of IN N
coccidiosis NN N
in IN N
other JJ N
poultry NN N
at IN N
three CD N
times NNS N
the DT N
normal JJ N
treatment NN N
period NN N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
preSMA NN N
and CC N
rostral JJ N
dorsal NN N
PMC NNP N
activities NNS N
during IN N
initiate NN N
may MD N
be VB N
associated VBN N
with IN N
selection NN N
of IN N
timing VBG N
parameters NNS N
, , N
while IN N
activation NN N
in IN N
centromedial JJ N
prefrontal JJ N
cortex NN N
during IN N
both DT N
initiate JJ N
and CC N
synchronise NN N
may MD N
be VB N
associated VBN N
with IN N
temporal JJ N
error NN N
monitoring NN N
or CC N
correction NN N
. . N

CONCLUSION NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN N
, , N
local JJ N
administration NN N
of IN N
1 CD N
mg NN N
of IN N
morphine NN N
prior RB N
to TO N
the DT N
surgical JJ N
removal NN N
of IN N
an DT N
odontogenic JJ N
maxillary JJ N
cyst NN N
was VBD N
safe JJ N
, , N
but CC N
it PRP N
did VBD N
not RB N
prove VB N
to TO N
be VB N
very RB N
effective JJ N
as IN N
an DT N
add-on JJ N
therapy NN i
for IN N
postoperative JJ N
pain NN N
control NN N
. . N

The DT N
end NN N
points NNS N
were VBD N
toxicity NN N
and CC N
PSA NNP N
response NN N
in IN N
both DT N
groups NNS N
, , N
with IN N
the DT N
option NN N
to TO N
continue VB N
the DT N
trial NN N
as IN N
a DT N
Phase NNP N
III NNP N
study NN N
with IN N
time NN N
to TO N
progression NN N
and CC N
survival NN N
as IN N
end NN N
points NNS N
, , N
if IN N
sufficient JJ N
responses NNS N
were VBD N
observed VBN N
. . N

For IN N
HLA-DR NNP N
expression NN N
, , N
IL-6 NNP N
, , N
and CC N
CRP NNP N
levels NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
, , N
although IN N
there EX N
was VBD N
a DT N
clear JJ N
rise NN N
in IN N
levels NNS N
upon IN N
operation NN N
in IN N
both DT N
groups NNS N
. . N

OBJECTIVE NN N
In IN N
this DT N
study NN N
, , N
we PRP N
tested VBD N
in IN N
patients NNS p
with IN N
metabolic JJ N
syndrome VBP N
whether IN N
allopurinol NNS N
through IN N
decreasing VBG N
oxidative JJ N
stress NN N
improves VBZ N
endothelial JJ N
function NN N
, , N
and CC N
ameliorates VBZ N
inflammatory JJ N
state NN N
represented VBN N
by IN N
markers NNS N
of IN N
myeloperoxidase NN N
, , N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
and CC N
fibrinogen NN N
. . N

The DT N
retentive JJ N
effect NN N
of IN N
labetalol NN i
on IN N
sodium NN N
was VBD N
directly RB N
related VBN N
to TO N
the DT N
decrease NN o
of IN N
blood NN N
pressure NN N
, , N
and CC N
the DT N
successive JJ N
sodium NN N
escape NN N
might MD N
be VB N
explained VBN N
either RB N
by IN N
the DT N
observed JJ N
increase NN o
of IN N
plasma JJ N
volume NN N
( ( N
indirectly RB N
measured VBN N
by IN N
packed JJ N
cell NN N
volume NN N
) ) N
or CC N
by IN N
aldosterone JJ N
inhibition NN N
. . N

Group NNP N
A NNP N
was VBD N
expected VBN N
to TO N
give VB N
more JJR N
correct JJ N
answers NNS N
to TO N
questions NNS N
about IN N
the DT N
common JJ N
facts NNS N
than IN N
Group NNP N
B NNP N
, , N
when WRB N
tested VBN N
postoperatively RB N
, , N
and CC N
Group NNP N
B NNP N
to TO N
attribute VB N
more JJR N
fame NN N
to TO N
presented VBN N
names NNS N
than IN N
Group NNP N
A NNP N
( ( N
famous JJ N
names RB N
test NN N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
listening VBG N
to TO N
motivational JJ N
music NN N
during IN N
nonstructured JJ N
recovery NN N
from IN N
intense JJ N
exercise NN N
leads VBZ N
to TO N
increased VBN o
activity NN N
, , N
faster JJR N
lactate JJ N
clearance NN N
, , N
and CC N
reduced VBD N
RPE NNP N
and CC N
therefore RB N
may MD N
be VB N
used VBN N
by IN N
athletes NNS N
in IN N
their PRP$ N
effort NN N
to TO N
enhance VB N
recovery NN N
. . N

In IN N
Parkinson NNP N
's POS N
disease NN N
, , N
however RB N
, , N
the DT N
supplementary JJ N
motor NN N
area NN N
was VBD N
only RB N
involved VBN N
in IN N
movements NNS N
which WDT N
must MD N
be VB N
internally RB N
determined VBN N
( ( N
non-cued JJ N
movements NNS N
, , N
but CC N
not RB N
externally RB N
cued VBN N
movements NNS N
) ) N
; : N
therefore RB N
impaired VBD N
internal JJ N
control NN N
mechanisms NNS N
, , N
operating VBG N
via IN N
the DT N
supplementary JJ N
motor NN N
area NN N
, , N
are VBP N
bypassed VBN N
when WRB N
external JJ N
cues NNS N
are VBP N
given VBN N
. . N

DISCUSSION NNP N
Along NNP N
with IN N
a DT N
technique NN N
to TO N
improve VB N
health NN N
workers NNS N
performance NN N
on IN N
the DT N
protocol NN N
, , N
the DT N
study NN N
will MD N
generate VB N
evidence NN N
on IN N
the DT N
research NN N
gap NN N
on IN N
the DT N
effectiveness NN N
of IN N
the DT N
simplified JJ N
neonatal JJ N
resuscitation NN N
protocol NN N
on IN N
intrapartum NN N
outcome NN N
and CC N
early JJ N
neonatal JJ N
survival NN N
. . N

Analysis NN N
of IN N
variance NN N
and CC N
post-hoc JJ N
analyses NNS N
suggest VBP N
that IN N
subjects NNS N
who WP N
first RB N
learned VBN N
under IN N
the DT N
color-coded JJ N
, , N
extra JJ N
prompt JJ N
condition NN N
encountered VBD N
significant JJ N
difficulty NN N
in IN N
transferring VBG N
their PRP$ N
newly RB N
acquired VBN N
skill NN N
to TO N
the DT N
naturalistic JJ N
, , N
non-color-coded JJ N
condition NN N
, , N
whereas JJ N
subjects NNS N
who WP N
learned VBD N
initially RB N
without IN N
the DT N
extra JJ N
prompts NNS N
had VBD N
little JJ N
difficulty NN N
with IN N
the DT N
subsequent JJ N
color-coded JJ N
condition NN N
. . N

Alfentanil NNP N
at IN N
the DT N
dose JJ N
range NN N
tested VBD N
had VBD N
more RBR N
mild JJ N
effects NNS N
on IN N
these DT N
measures NNS N
, , N
and CC N
the DT N
analgesia NN N
data NNS N
indicated VBD N
that IN N
a DT N
40:1 CD N
potency NN N
ratio NN N
, , N
rather RB N
than IN N
the DT N
20:1 CD N
ratio NN N
we PRP N
used VBD N
, , N
may MD N
exist VB N
between IN N
remifentanil NN N
and CC N
alfentanil NN N
. . N

Though IN N
in IN N
the DT N
stent JJ N
group NN N
event-free JJ N
survival NN N
was VBD N
lower JJR N
and CC N
target VB N
lesion JJ N
revascularization NN N
rate NN N
was VBD N
higher JJR N
, , N
retroinfusion-supported JJ N
stent NN N
implantation NN N
was VBD N
associated VBN N
with IN N
substantially RB N
lower JJR N
costs NNS N
and CC N
might MD N
be VB N
considered VBN N
as IN N
an DT N
alternative JJ N
treatment NN N
option NN N
in IN N
this DT N
selected VBN N
group NN N
of IN N
high-risk JJ N
patients NNS p
. . N

Before IN N
the DT N
intervention NN N
, , N
strenuous JJ N
exercise NN N
up RB N
to TO N
exhaustion NN N
increased VBD o
the DT o
mobilization NN N
of IN N
CD3 NNP N
, , N
CD4 NNP N
, , N
CD8 NNP N
, , N
or CC N
CD8 NNP N
( ( N
bright VBN N
) ) N
lymphocytes VBZ N
expressing VBG N
activated VBN N
( ( N
CD11a NNP N
) ) N
or CC N
senescent NN N
( ( N
KLRG1 NNP N
) ) N
molecules VBZ N
into IN N
the DT N
peripheral JJ N
blood NN N
compartment NN N
. . N

CONCLUSIONS NNP N
Higher NNP N
rates NNS N
of IN N
primary JJ N
and CC N
repeat JJ N
amputation NN N
for IN N
African JJ N
American JJ N
patients NNS p
at IN N
study NN N
hospitals NNS N
, , N
which WDT N
all DT N
have VBP N
significant JJ N
vascular JJ N
surgery NN N
capacity NN N
and CC N
an DT N
aggressive JJ N
policy NN N
of IN N
limb NN N
salvage NN N
, , N
suggest VBP N
that IN N
these DT N
rates NNS N
may MD N
be VB N
even RB N
higher JJR N
at IN N
less JJR N
well RB N
equipped JJ N
institutions NNS N
. . N

We PRP N
conclude VBP N
that IN N
, , N
whilst VB N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
obtain VB N
reasonable JJ N
point NN N
estimates NNS N
of IN N
total JJ N
hip NN N
BMD NNP N
from IN N
other JJ N
measures NNS N
in IN N
the DT N
hip NN N
, , N
these DT N
estimates NNS N
are VBP N
too RB N
imprecise JJ N
to TO N
allow VB N
conclusions NNS N
about IN N
change NN N
in IN N
BMD NNP N
to TO N
be VB N
made VBN N
. . N

CONCLUSIONS NNP N
Disaster NNP N
survivors NNS N
improve VBP N
psychologically RB N
over IN N
time NN N
regardless NN N
of IN N
receiving VBG N
intervention NN N
; : N
however RB N
, , N
those DT N
taking VBG N
micronutrients NNS N
during IN N
the DT N
acute JJ N
phase NN N
following VBG N
a DT N
disaster NN N
show NN N
better RBR N
outcomes RB N
, , N
identifying VBG N
micronutrients NNS N
as IN N
a DT N
viable JJ N
treatment NN N
for IN N
acute JJ N
stress NN N
following VBG N
a DT N
natural JJ N
disaster NN N
with IN N
maintenance NN N
of IN N
benefits NNS N
1 CD N
year NN N
later RB N
. . N

Factors NNS N
associated VBN N
with IN N
depression NN N
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
included VBD N
younger JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
comorbid NN N
angina NN N
, , N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
, , N
use NN N
of IN N
a DT N
hypoglycemic JJ N
agent NN N
, , N
lower JJR N
activity NN N
level NN N
, , N
higher JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
, , N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
use NN N
. . N

These DT N
results NNS N
support VBP N
parental JJ N
responsiveness NN N
as IN N
an DT N
important JJ N
intervention NN N
target NN N
given VBN N
its PRP$ N
general JJ N
association NN N
with IN N
child NN N
outcomes NNS N
in IN N
the DT N
extant JJ N
literature NN N
; : N
however RB N
, , N
additional JJ N
supports NNS N
are VBP N
likely JJ N
needed VBN N
to TO N
fully RB N
maintain VB N
the DT N
treatment NN N
effect NN N
and CC N
to TO N
affect VB N
child NN N
outcomes NNS N
. . N

CONCLUSIONS NN N
In IN N
this DT N
group NN N
of IN N
patients NNS p
we PRP N
were VBD N
able JJ N
to TO N
show VB N
that DT N
guided VBD N
isometric JJ N
resistance NN N
training NN N
of IN N
the DT N
paravertebral JJ N
muscles NNS N
can MD N
improve VB N
functional JJ N
capacity NN N
, , N
reduce VB N
fatigue NN N
and CC N
thereby NN N
enhance NN N
QoL NNP N
over IN N
a DT N
6-months JJ N
period NN N
in IN N
patients NNS p
with IN N
stable JJ N
spinal JJ N
metastases NNS N
. . N

OBJECTIVE NN N
To TO N
examine VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
a DT N
single JJ N
intra-articular JJ N
injection NN N
of IN N
rAAV2-TNFR NN N
: : N
Fc NNP N
, , N
an DT N
adenoassociated JJ N
virus NN N
serotype NN N
2 CD N
vector NN N
containing VBG N
the DT N
cDNA NN N
for IN N
the DT N
human JJ N
tumour JJ N
necrosis NN N
factor-immunoglobulin JJ N
Fc NNP N
fusion NN N
gene NN N
( ( N
tgAAC94 NN N
) ) N
, , N
in IN N
subjects NNS N
with IN N
inflammatory JJ N
arthritis NN N
. . N

However RB N
, , N
the DT N
decreased JJ o
5 CD N
alpha-reduction NN N
of IN N
testosterone NN N
to TO N
dihydrotestosterone NN N
is VBZ N
the DT N
only RB N
impaired JJ N
steroid JJ N
conversion NN N
to TO N
have VB N
clinical JJ N
consequences NNS N
, , N
e.g NN N
, , N
ambiguous JJ N
genitalia NN N
, , N
impaired JJ N
prostate NN N
differentiation NN N
and CC N
development NN N
, , N
and CC N
decreased VBD o
facial JJ o
and CC N
body JJ N
hair NN N
. . N

Although IN N
some DT N
authors NNS N
have VBP N
postulated VBN N
decreased JJ o
requirements NNS N
for IN N
ABT NNP N
by IN N
using VBG N
autologous JJ N
retransfusion NN N
devices NNS N
, , N
other JJ N
trials NNS N
, , N
mostly RB N
evaluating VBG N
retransfusion NN N
devices NNS N
for IN N
unwashed JJ N
shed VBN N
blood NN N
( ( N
USB NNP N
) ) N
, , N
verified VBD N
a DT N
small JJ N
or CC N
no DT N
benefit NN N
in IN N
reducing VBG N
the DT N
need NN N
for IN N
postoperative JJ N
ABT NNP N
. . N

OBJECTIVES IN N
We PRP N
studied VBD N
the DT N
consequences NNS N
of IN N
applying VBG N
the DT N
recent JJ N
WHO/ISH NNP N
risk NN N
stratification NN N
scheme NN N
to TO N
a DT N
MONICA NNP N
sample NN N
of IN N
6000 CD N
subjects NNS N
from IN N
a DT N
geographically RB N
defined VBN N
population NN N
in IN N
northern JJ N
Sweden NNP N
, , N
regarding VBG N
indications NNS N
for IN N
treatment NN N
, , N
target VB N
blood NN N
pressure NN N
and CC N
risk NN N
distribution NN N
. . N

Clinical JJ N
evaluation NN N
of IN N
the DT N
contact NN N
sensitization NN N
potential NN N
of IN N
a DT N
transdermal JJ N
nicotine NN N
system NN N
( ( N
Nicoderm NNP N
) ) N
BACKGROUND NNP N
Transdermal NNP N
nicotine NN N
therapy NN i
has VBZ N
shown VBN N
promise NN N
as IN N
a DT N
smoking NN N
cessation NN N
aid NN N
, , N
but CC N
questions NNS N
about IN N
its PRP$ N
contact NN N
sensitization NN N
potential NN N
and CC N
long-term JJ N
topical JJ N
safety NN N
have VBP N
been VBN N
raised VBN N
. . N

RESULTS NNP N
Principal NNP N
components NNS N
analysis NN N
identified VBD N
three CD N
primary JJ N
dietary JJ N
patterns NNS N
among IN N
rural JJ N
dwellers NNS N
( ( N
high JJ N
sweets NNS N
and CC N
starches NNS N
, , N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
, , N
and CC N
mixed JJ N
) ) N
and CC N
three CD N
among IN N
urban JJ N
dwellers NNS N
( ( N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
, , N
high JJ N
meat NN N
and CC N
refined VBD N
grains NNS N
, , N
and CC N
high JJ N
sugar-sweetened JJ N
beverages NNS N
) ) N
. . N

The DT N
children NNS N
on IN N
both DT N
regimens NNS N
were VBD N
comparable JJ N
for IN N
sex NN N
, , N
race NN N
, , N
age NN N
at IN N
initial JJ N
ALL NNP N
diagnosis NN N
, , N
time NN N
from IN N
ALL NNP N
diagnosis NN N
to TO N
first JJ N
episode NN N
of IN N
CNS NNP N
leukemia NN N
, , N
systemic JJ N
therapy NN i
both DT N
before IN N
and CC N
after IN N
CNS NNP N
relapse NN N
, , N
and CC N
number NN N
of IN N
blasts NNS N
in IN N
the DT N
spinal JJ N
fluid NN N
at IN N
diagnosis NN N
of IN N
CNS NNP N
leukemia NN N
. . N

Class NN N
V NNP N
preparations NNS N
in IN N
extracted JJ N
upper JJ N
premolars NNS N
were VBD N
used VBN N
and CC N
ten JJ N
restorations NNS N
were VBD N
used VBN N
for IN N
each DT N
of IN N
the DT N
following JJ N
groups NNS N
: : N
( ( N
i NN N
) ) N
two CD N
layers NNS N
of IN N
copal JJ N
varnish JJ N
and CC N
amalgam NN N
; : N
( ( N
ii NN N
) ) N
conventional JJ N
glass-ionomer JJ N
and CC N
amalgam NN N
; : N
( ( N
iii NN N
) ) N
light-cured JJ N
glass-ionomer NN N
and CC N
amalgam NN N
; : N
( ( N
iv NN N
) ) N
bonding NN N
agent NN N
and CC N
light-cured JJ N
composite JJ N
resin NN N
; : N
( ( N
v NN N
) ) N
conventional JJ N
glass-ionomer JJ N
, , N
bonding JJ N
agent NN N
and CC N
light-cured JJ N
composite JJ N
resin NN N
; : N
( ( N
vi NN N
) ) N
light-cured JJ N
glass-ionomer NN N
, , N
extended VBD N
0.3 CD N
mm NN N
short NN N
of IN N
the DT N
enamel JJ N
margin NN N
bonding VBG N
agent NN N
and CC N
light-cured JJ N
composite JJ N
resin NN N
; : N
and CC N
( ( N
vii NN N
) ) N
light-cured JJ N
glass-ionomer NN N
, , N
extended VBD N
1 CD N
mm NN N
short NN N
of IN N
the DT N
enamel NN N
margin NN N
, , N
bonding VBG N
agent NN N
and CC N
light-cured JJ N
composite JJ N
resin NN N
. . N

Residual JJ N
urine NN N
volume NN N
was VBD N
significantly RB N
decreased VBN o
in IN N
groups NNS N
L NNP N
, , N
M NNP N
and CC N
H NNP N
after IN N
instillation NN N
of IN N
saline NN N
into IN N
the DT N
bladder NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
but CC N
not RB N
in IN N
group NN N
P. NNP N
The DT N
maximum NN N
and CC N
average JJ N
flow JJ N
rates NNS N
were VBD N
significantly RB N
increased VBN o
in IN N
groups NNS N
L NNP N
, , N
M NNP N
and CC N
H NNP N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
but CC N
not RB N
in IN N
group NN N
P. NNP N
Average NNP N
flow JJ N
rate NN N
showed VBD N
significant JJ N
differences NNS N
between IN N
groups NNS N
M NNP N
or CC N
H NNP N
versus NN N
group NN N
P. NNP N
Neither NNP N
orthostatic JJ N
hypotension NN N
nor CC N
a DT N
decrease NN o
in IN N
blood NN N
pressure NN N
was VBD N
noted VBN N
. . N

Results NNS N
for IN N
treatment NN N
outcome NN N
suggest VBP N
that IN N
the DT N
TG NNP N
showed VBD N
significant JJ N
improvement NN N
in IN N
communication NN N
and CC N
social JJ N
interaction NN N
domain NN N
scores NNS N
on IN N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
, , N
interpersonal JJ N
relationship NN N
and CC N
play/leisure NN N
time NN N
on IN N
the DT N
subdomain NN N
scores NNS N
of IN N
the DT N
Korean JJ N
version NN N
of IN N
the DT N
Vineland NNP N
Adaptive NNP N
Behavior NNP N
Scale NNP N
( ( N
p NN N
's POS N
< NNP N
0.01 CD N
) ) N
, , N
social JJ N
skills NNS N
knowledge VBP N
total JJ N
scores NNS N
on IN N
the DT N
Test NNP N
of IN N
Adolescent NNP N
Social NNP N
Skills NNP N
Knowledge-Revised JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
decreased VBD o
depressive JJ o
symptoms NNS N
on IN N
the DT N
Child NNP N
Depression NNP N
Inventory NNP N
following VBG N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
86.7 CD N
% NN N
in IN N
the DT N
EA NNP N
plus CC N
behavior JJ N
therapy NN i
group NN N
which WDT N
was VBD N
better JJR N
than IN N
56.7 CD N
% NN N
of IN N
the DT N
behavior JJ N
therapy NN i
group NN N
, , N
and CC N
had VBD N
significant JJ N
enhancement NN N
in IN N
sensation NN N
, , N
association NN N
, , N
body NN N
, , N
and CC N
ability NN N
of IN N
self-care NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
was VBD N
better JJR N
than IN N
the DT N
behavior JJ N
therapy NN i
group NN N
in IN N
sensation NN N
, , N
body NN N
and CC N
self-care JJ N
factors NNS N
, , N
with IN N
no DT N
significantly RB N
improvement NN N
in IN N
the DT N
scores NNS N
of IN N
PPVT NNP N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
rate NN N
of IN N
new JJ N
or CC N
recurrent JJ N
carious JJ N
lesions NNS N
in IN N
the DT N
group NN N
treated VBD N
with IN N
the DT N
fluoride NN N
gel NN N
was VBD N
slightly RB N
lower JJR N
than IN N
in IN N
the DT N
IFRS NNP N
group NN N
, , N
based VBN N
on IN N
carious JJ N
lesions NNS N
at IN N
the DT N
baseline NN N
examination NN N
( ( N
Poisson NNP N
mean VBP N
number NN N
of IN N
new JJ N
or CC N
recurrent JJ N
carious JJ N
lesions NNS N
for IN N
the DT N
control NN N
group=0.55 NN N
per IN N
year NN N
vs. FW N
0.83 CD N
per IN N
year NN N
for IN N
the DT N
study NN N
group NN N
, , N
p=0.705 NN N
; : N
odds NNS N
ratio NN N
of IN N
the DT N
occurrence NN N
of IN N
any DT N
new JJ N
or CC N
recurrent JJ N
caries NNS N
during IN N
follow-up JJ N
for IN N
control NN N
group NN N
vs. FW N
the DT N
study NN N
group=0.80 NN N
; : N
p=0.781 NN N
) ) N
. . N

Systolic JJ N
blood NN N
pressure NN N
( ( N
SBP NNP N
) ) N
, , N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
, , N
fasting VBG N
glucose NN N
( ( N
FG NNP N
) ) N
, , N
lipid JJ N
profiles NNS N
( ( N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
triglyceride RB N
( ( N
TG NNP N
) ) N
, , N
low JJ N
density NN N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
, , N
and CC N
high JJ N
density NN N
lipoprotein NN N
( ( N
HDL-C NNP N
) ) N
) ) N
, , N
and CC N
antioxidant JJ N
enzymes NNS N
activities NNS N
( ( N
catalase NN N
( ( N
CAT NNP N
) ) N
, , N
superoxide JJ N
dismutase NN N
( ( N
SOD NNP N
) ) N
, , N
and CC N
glutathione NN N
peroxidase NN N
( ( N
GPx NNP N
) ) N
) ) N
were VBD N
measured VBN N
. . N

Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB N
completed VBN N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
CARS NNP N
) ) N
, , N
hand NN N
muscle NN N
testing NN N
, , N
and CC N
modified VBD N
clinical JJ N
global JJ N
impression NN N
( ( N
CGI NNP N
) ) N
forms VBZ N
; : N
parent NN N
completed VBD N
Autism NNP N
Treatment NNP N
Evaluation NNP N
Checklist NNP N
( ( N
ATEC NNP N
) ) N
, , N
treatment NN N
adherence NN N
measurement NN N
( ( N
TAM NNP N
) ) N
, , N
frequency NN N
and CC N
intensity NN N
of IN N
side JJ N
effect NN N
rating NN N
( ( N
FISER NNP N
) ) N
/global VBD N
rating NN N
of IN N
side JJ N
effect NN N
burden NN N
( ( N
GRSEB NNP N
) ) N
/patient VBD N
report NN N
of IN N
incidence NN N
of IN N
side NN N
effects NNS N
( ( N
PRISE NNP N
) ) N
forms NNS N
; : N
and CC N
lab VB N
testing NN N
. . N

As IN N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
angiotensin JJ N
II NNP N
alone RB N
, , N
indomethacin JJ i
pre-treatment NN N
followed VBN N
by IN N
angiotensin NN N
II NNP N
infusion NN N
led VBD N
to TO N
much RB N
greater JJR N
falls NNS N
in IN N
absolute JJ N
rate NN N
of IN N
sodium NN N
excretion NN N
, , N
fractional JJ N
sodium NN N
excretion NN N
, , N
urine JJ N
flow NN N
rate NN N
and CC N
effective JJ N
renal JJ N
plasma NN N
flow NN N
( ( N
all DT N
P NNP N
< NNP N
0.0001 CD N
vs NN N
placebo NN N
) ) N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
not RB N
observed VBN N
with IN N
angiotensin JJ N
II NNP N
alone RB N
. . N

Men NN N
and CC N
women NNS N
, , N
22-36 JJ N
years NNS N
old JJ N
, , N
performed VBD N
a DT N
synchronization-continuation NN N
task NN N
with IN N
intertap JJ N
intervals NNS N
( ( N
ITI NNP N
) ) N
from IN N
0.4 CD N
s NNS N
to TO N
2.2 CD N
s. NNS N
ISIP NNP N
variability NN N
was VBD N
partitioned VBN N
into IN N
components NNS N
attributable JJ N
to TO N
drift VB N
and CC N
1st-order JJ N
serial JJ N
correlation NN N
, , N
and CC N
the DT N
results NNS N
indicate VBP N
that IN N
( ( N
a DT N
) ) N
drift NN N
contributes VBZ N
substantially RB N
to TO N
the DT N
dispersion NN N
for IN N
longer JJR N
ITIs NNP N
, , N
( ( N
b NN N
) ) N
drift NN N
and CC N
1st-order JJ N
correlation NN N
are VBP N
different JJ N
functions NNS N
of IN N
the DT N
ITI NNP N
, , N
and CC N
( ( N
c NN N
) ) N
drift NN N
exhibits VBZ N
break VBP N
close JJ N
to TO N
1.0 CD N
s NNS N
and CC N
1.4 CD N
s NN N
ITI NNP N
. . N

In IN N
the DT N
added JJ N
treatment NN N
group NN N
, , N
the DT N
change NN N
in IN N
the DT N
B-type NNP N
natriuretic JJ N
peptide NN N
was VBD N
significantly RB N
correlated VBN N
with IN N
the DT N
change NN N
in IN N
the DT N
brachial JJ N
PP NNP N
( ( N
r VB N
= RB N
0.18 CD N
) ) N
, , N
central JJ N
systolic JJ N
blood NN N
pressure NN N
( ( N
r JJ N
= NNP N
0.18 CD N
) ) N
, , N
central JJ N
PP NNP N
( ( N
r VB N
= RB N
0.26 CD N
) ) N
, , N
and CC N
PP NNP N
amplification NN N
( ( N
r JJ N
= NNP N
-0.22 NNP N
) ) N
even RB N
after IN N
adjusting VBG N
for IN N
the DT N
confounding NN N
factors NNS N
. . N

RESULTS NN N
After IN N
controlling VBG N
for IN N
body NN N
weight NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
effect NN N
of IN N
time NN N
on IN N
fasting VBG N
serum NN N
glucose NN N
( ( N
P NNP N
= NNP N
0.0177 CD N
) ) N
and CC N
total JJ N
cholesterol NN N
( ( N
P NNP N
= NNP N
0.0386 CD N
) ) N
concentrations NNS N
, , N
and CC N
on IN N
diastolic JJ N
blood NN N
pressure NN N
( ( N
P NNP N
= NNP N
0.0413 CD N
) ) N
, , N
with IN N
reductions NNS N
in IN N
these DT N
variables NNS N
occurring VBG N
over IN N
time NN N
; : N
there EX N
was VBD N
no DT N
time-by-diet JJ N
interaction NN N
for IN N
any DT N
of IN N
the DT N
parameters NNS N
studied VBD N
. . N

RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN N
the DT N
score NN N
of IN N
the DT N
'Issues NNS N
on IN N
treatment NN N
compliance NN N
' POS N
factor NN N
and CC N
the DT N
score NN N
of IN N
the DT N
'Autistic JJ N
life NN N
' POS N
factor NN N
, , N
which WDT N
are VBP N
subscales NNS N
of IN N
the DT N
Discharge NNP N
Difficulty NNP N
Scale NNP N
, , N
for IN N
the DT N
DPP NNP N
group NN N
, , N
on IN N
two-way JJ N
ANOVA NNP N
( ( N
'Issues NNS N
on IN N
treatment NN N
compliance NN N
' '' N
: : N
F NNP N
= VBZ N
3.818 CD N
, , N
P NNP N
< NNP N
0.10 CD N
; : N
'Autistic JJ N
life NN N
' POS N
: : N
F NNP N
= VBZ N
4.155 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
These DT N
factors NNS N
affected VBD N
discharge NN N
outcome NN N
. . N

Based VBN N
on IN N
the DT N
analysis NN N
of IN N
covariance NN N
models NNS N
adjusted VBN N
for IN N
the DT N
baseline NN N
rating NN N
scores NNS N
, , N
parents NNS N
( ( N
but CC N
not RB N
teachers NNS N
) ) N
provided VBD N
a DT N
higher JJR N
average JJ N
rating NN N
of IN N
social JJ N
skills NNS N
on IN N
the DT N
BASC NNP N
for IN N
the DT N
children NNS N
in IN N
the DT N
placebo NN N
group NN N
compared VBN N
to TO N
the DT N
DHA NNP N
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
teachers NNS N
( ( N
but CC N
not RB N
parents NNS N
) ) N
provided VBD N
a DT N
higher JJR N
average JJ N
rating NN N
of IN N
functional JJ N
communication NN N
on IN N
the DT N
BASC NNP N
for IN N
the DT N
children NNS N
in IN N
the DT N
DHA NNP N
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
median JJ N
duration NN N
of IN N
progression-free JJ N
survival NN N
was VBD N
10.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
bevacizumab NN i
, , N
as IN N
compared VBN N
with IN N
6.2 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
placebo NN N
( ( N
hazard JJ N
ratio NN N
for IN N
disease NN N
progression NN N
, , N
0.54 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
the DT N
corresponding JJ N
rates NNS N
of IN N
response NN N
were VBD N
44.8 CD N
percent NN N
and CC N
34.8 CD N
percent NN N
( ( N
P=0.004 NNP N
) ) N
. . N

Because IN N
the DT N
aim NN N
of IN N
prostate NN N
cancer NN N
detection NN N
is VBZ N
to TO N
find VB N
cancers NNS N
at IN N
an DT N
early JJ N
, , N
potentially RB N
curable JJ N
stage NN N
, , N
it PRP N
is VBZ N
of IN N
major JJ N
interest NN N
that IN N
71.8 CD N
% NN N
of IN N
evaluable JJ N
cancers NNS N
were VBD N
clinical JJ N
stage NN N
B NNP N
; : N
8.4 CD N
% NN N
and CC N
10.7 CD N
% NN N
were VBD N
stages NNS N
C1 NNP N
and CC N
C2 NNP N
, , N
respectively RB N
; : N
only RB N
9.2 CD N
% NN N
were VBD N
stage JJ N
D NNP N
( ( N
metastatic JJ N
) ) N
at IN N
first JJ N
visit NN N
while IN N
none NN N
was VBD N
at IN N
stage NN N
D NNP N
at IN N
follow-up JJ N
visits NNS N
. . N

Factors NNS N
associated VBN N
with IN N
exclusive JJ N
breastfeeding NN N
included VBD N
maternal JJ N
work NN N
( ( N
OR=3.92 NNP N
; : N
p-value JJ N
< NNP N
0.001 CD N
) ) N
, , N
planned VBN N
pregnancy NN N
( ( N
OR=2.42 NNP N
, , N
p-value=0.010 NN N
) ) N
, , N
intention NN N
to TO N
breastfeed VB N
( ( N
OR=3.28 NNP N
; : N
p-value=0.043 NN N
) ) N
, , N
source NN N
of IN N
maternal JJ N
emotional JJ N
support NN N
( ( N
OR=1.87 NNP N
, , N
p-value=0.039 NN N
) ) N
and CC N
the DT N
use NN N
the DT N
postpartum NN N
support NN N
video NN N
, , N
the DT N
hotline NN N
service NN N
or CC N
both DT N
( ( N
OR=2.55 NNP N
, , N
p-value=0.044 NN N
; : N
OR=3.87 NNP N
, , N
p-value=0.004 NN N
and CC N
OR=4.13 NNP N
, , N
p-value=0.003 NN N
) ) N
. . N

For IN N
patients NNS p
who WP N
achieved VBD N
a DT N
stable JJ N
PT NNP N
ratio NN N
( ( N
defined VBN N
as IN N
a DT N
PT NNP N
ratio NN N
between IN N
1.3 CD N
and CC N
2.5 CD N
that WDT N
varied VBN N
by IN N
less JJR N
than IN N
0.05 CD N
on IN N
two CD N
consecutive JJ N
days NNS N
or CC N
by IN N
less JJR N
than IN N
0.1 CD N
on IN N
three CD N
consecutive JJ N
days NNS N
without IN N
a DT N
dosage NN N
change NN N
) ) N
before IN N
discharge NN N
, , N
the DT N
number NN N
of IN N
days NNS N
( ( N
time NN N
to TO N
stabilization NN N
) ) N
from IN N
administration NN N
of IN N
the DT N
first JJ N
warfarin NN N
dose NN N
to TO N
achievement NN N
of IN N
the DT N
warfarin NN N
dosage NN N
that WDT N
produced VBD N
a DT N
stable JJ N
PT NNP N
ratio NN N
( ( N
stabilization JJ N
dosage NN N
) ) N
was VBD N
compared VBN N
. . N

Wind-up JJ N
to TO N
the DT N
2 CD N
Hz NNP N
train NN N
increased VBD o
in IN o
the DT N
UO NNP N
( ( N
wind-up JJ N
ratio NN N
1.4 CD N
( ( N
0.1 CD N
) ) N
to TO N
1.6 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.03 NN N
) ) N
but CC N
not RB N
in IN N
the DT N
hand NN N
( ( N
wind-up JJ N
ratio NN N
1.3 CD N
( ( N
0.1 CD N
) ) N
and CC N
1.3 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.3 NN N
) ) N
CONCLUSION NNP N
Enhanced NNP N
wind-up NN N
after IN N
secondary JJ N
oesophageal NN N
hyperalgesia NN N
suggests VBZ N
that IN N
visceral JJ N
pain NN N
hypersensitivity NN N
induced VBN N
by IN N
central JJ N
sensitisation NN N
results NNS N
from IN N
increased JJ o
central JJ N
neuronal JJ N
excitability NN N
. . N

Blood NNP N
pressure NN N
in IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
trial NN N
was VBD N
equally RB N
and CC N
significantly RB N
reduced VBN N
; : N
systolic JJ N
pressure NN N
22.2 CD N
mmHg NN N
and CC N
diastolic JJ N
pressure NN N
15.5 CD N
mmHg NN N
in IN N
the DT N
supine JJ N
position NN N
, , N
and CC N
24.4 CD N
mmHg NN N
and CC N
18.4 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
standing VBG N
position NN N
in IN N
those DT N
on IN N
nicardipine NN N
, , N
and CC N
by IN N
23.7 CD N
and CC N
16.2 CD N
mmHg NN N
and CC N
28.0 CD N
and CC N
19.2 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
propranolol NN i
group NN N
. . N

Although IN N
6-thioguanine JJ N
conferred VBD N
a DT N
significantly RB N
lower JJR N
risk NN N
of IN N
isolated JJ N
CNS NNP N
relapse NN N
than IN N
did VBD N
6-mercaptopurine JJ N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
0.30-0.92 CD N
, , N
p=0.02 NN N
) ) N
, , N
the DT N
benefit NN N
was VBD N
offset VBN N
by IN N
an DT N
increased VBN o
risk NN N
of IN N
death NN N
in IN N
remission NN N
( ( N
2.22 CD N
, , N
1.20-4.14 CD N
, , N
p=0.01 NN N
) ) N
, , N
mainly RB N
due JJ N
to TO N
infections NNS N
during IN N
continuing VBG N
therapy NN i
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN N
of IN N
blood NN N
transfusion NN N
( ( N
1.0 CD N
% NN N
in IN N
the DT N
cangrelor NN N
group NN N
and CC N
0.6 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
, , N
P=0.13 NNP N
) ) N
, , N
though IN N
major JJ N
bleeding VBG N
on IN N
one CD N
scale NN N
was VBD N
increased VBN o
in IN N
the DT N
cangrelor NN N
group NN N
, , N
from IN N
3.5 CD N
% NN N
to TO N
5.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
because IN N
of IN N
more JJR N
groin JJ N
hematomas NN N
. . N

Heart NNP N
rate NN N
, , N
core NN N
temperature NN N
, , N
maximal JJ N
voluntary JJ N
isometric JJ N
contraction NN N
, , N
passive JJ N
hip NN N
flexion NN N
, , N
passive JJ N
hamstring NN N
stiffness NN N
( ( N
PHS NNP N
) ) N
, , N
plasma JJ N
creatine JJ N
kinase NN N
activity NN N
, , N
and CC N
myoglobin NNS N
were VBD N
recorded VBN N
at IN N
prestretching NN N
, , N
at IN N
poststretching NN N
, , N
and CC N
every DT N
day NN N
after IN N
the DT N
eccentric JJ N
exercises NNS N
for IN N
5 CD N
d. NN N
RESULTS NNP N
After IN N
stretching VBG N
, , N
the DT N
change NN N
in IN N
hip NN N
flexion NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
SAS NNP N
( ( N
5 CD N
) ) N
and CC N
DAS NNP N
( ( N
10.8 CD N
) ) N
groups NNS N
than IN N
in IN N
the DT N
CON NNP N
( ( N
-4.1 NNP N
) ) N
group NN N
. . N

RESULTS VB N
The DT N
mean JJ N
area NN N
under IN N
the DT N
curve NN N
of IN N
improvement NN N
for IN N
scaling/hypertrophy NN N
, , N
pain NN N
, , N
itching NN N
and CC N
global JJ N
patient NN N
assessment NN N
was VBD N
significantly RB N
better JJR N
for IN N
the DT N
actively RB N
treated JJ N
patients NNS p
as IN N
compared VBN N
with IN N
placebo NN N
( ( N
scaling/hypertrophy NN N
, , N
P NNP N
= NNP N
0.0262 CD N
; : N
pain NN N
, , N
P NNP N
= NNP N
0.0238 CD N
; : N
itching NN N
, , N
P NNP N
= NNP N
0.0135 CD N
; : N
global JJ N
patient NN N
assessment NN N
, , N
P NNP N
= NNP N
0.045 CD N
) ) N
. . N

However RB N
, , N
the DT N
mean JJ N
6-month JJ N
change NN N
in IN N
central JJ N
macular JJ N
thickness NN N
( ( N
CMT NNP N
) ) N
in IN N
the DT N
combination NN N
group NN N
was VBD N
-124 VBN N
? . N
( ( N
-29.7 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
while IN N
in IN N
the DT N
ranibizumab-only JJ N
group NN N
, , N
the DT N
change NN N
was VBD N
-86.9 VBN N
? . N
( ( N
-19.5 CD N
% NN N
; : N
p=0.001 CC N
) ) N
; : N
thus RB N
, , N
the DT N
combination NN N
treatment NN N
resulted VBD N
in IN N
a DT N
greater JJR N
reduction NN N
( ( N
p=0.003 NN N
) ) N
. . N

RESULTS NNP N
Immediately NNP N
after IN N
placement NN N
, , N
the DT N
self-etching JJ N
adhesive NN N
and CC N
its PRP$ N
respective JJ N
cement NN N
resulted VBD N
in IN N
more RBR N
suppression NN N
of IN N
cold JJ N
sensitivity NN N
than IN N
no DT N
treatment NN N
( ( N
control NN N
) ) N
; : N
with IN N
Linkmax NNP i
treatment NN N
, , N
the DT N
temperature NN N
at IN N
which WDT N
teeth EX N
responded VBD N
was VBD N
reduced VBN N
by IN N
8.4 CD N
degrees NNS N
C. NNP N
The DT N
conventionally RB N
etched VBN N
adhesive JJ N
and CC N
its PRP$ N
cement NN N
reduced VBD N
the DT N
temperature NN N
at IN N
which WDT N
teeth NN N
responded VBD N
by IN N
9.4 CD N
degrees NNS N
C. NNP N
After IN N
1 CD N
week NN N
, , N
these DT N
temperature NN N
reductions NNS N
were VBD N
7.0 CD N
degrees NNS N
C NNP N
and CC N
4.3 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

After IN N
treatment NN N
, , N
the DT N
Chinese JJ N
medicine JJ N
syndrome NN N
scores NNS N
, , N
urinary JJ N
protein NN N
and CC N
urinary JJ N
red-cell NN N
count NN N
reduced VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
showed VBD N
significant JJ N
difference NN N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
while IN N
the DT N
endogenous JJ N
creatinine NN N
clearance NN N
was VBD N
changed VBN N
insignificantly RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
experiences NNS N
, , N
except IN N
that DT N
weight NN N
gain NN N
, , N
fluid JJ N
retention NN N
, , N
and CC N
dyspnea NN N
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS p
in IN N
the DT N
megestrol NN N
acetate NN N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
fadrozole JJ N
HCL NNP N
, , N
whereas JJ N
nausea NN N
and CC N
vomiting NN N
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS p
in IN N
the DT N
fadrozole JJ N
HCL NNP N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
megestrol NN N
acetate NN N
. . N

METHODS NNP N
Sixty NNP N
qualifying VBG N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
Regimen NNP N
One NNP N
, , N
a DT N
whitening NN N
dentifrice NN N
( ( N
Arm NNP N
& CC N
Hammer NNP N
Truly NNP N
Radiant NNP N
[ NNP N
TR NNP N
] NNP N
toothpaste NN N
] NN N
and CC N
powered VBD N
toothbrush NN N
( ( N
Arm NNP N
& CC N
Hammer NNP N
Truly NNP N
Radiant NNP N
[ NNP N
TR NNP N
] NNP N
Extra NNP N
Whitening NNP N
Spinbrush NNP N
) ) N
; : N
Regimen NNP N
Two CD N
, , N
the DT N
dentifrice NN N
and CC N
powered VBD N
toothbrush NN N
with IN N
the DT N
addition NN N
of IN N
a DT N
whitening JJ N
booster NN N
; : N
or CC N
Regimen NNP N
Three NNP N
, , N
a DT N
negative JJ N
control NN N
( ( N
Colgate NNP N
Cavity NNP N
Protection NNP N
toothpaste NN N
and CC N
an DT N
ADA NNP N
standard NN N
manual JJ N
brush NN N
) ) N
. . N

The DT N
mean NN N
maximal JJ N
temperature NN N
elevation NN N
induced VBN N
by IN N
interferon NN N
was VBD N
significantly RB N
reduced VBN N
( ( N
from IN N
102.1 CD N
to TO N
100.7 CD N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
by IN N
indomethacin NN i
, , N
but CC N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
interferon-related JJ N
fatigue NN N
, , N
reduction NN N
in IN N
performance NN N
status NN N
, , N
headache NN N
, , N
depression NN N
, , N
confusion NN N
, , N
elevations NNS N
in IN N
liver JJ N
function NN N
tests NNS N
, , N
and CC N
myelosuppression NN N
were VBD N
no DT N
different JJ N
in IN N
either DT N
arm NN N
of IN N
the DT N
study NN N
. . N

With IN N
or CC N
without IN N
HBO NNP N
pre-treatment NN N
, , N
the DT N
rats NNS N
were VBD N
further RB N
divided VBN N
into IN N
the DT N
following JJ N
subgroups NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
: : N
( ( N
i NN N
) ) N
LPS NNP N
injection NN N
, , N
( ( N
ii NN N
) ) N
normal JJ N
saline NN N
( ( N
N/S NNP N
) ) N
injection NN N
, , N
( ( N
iii NN N
) ) N
hemin NN N
( ( N
a DT N
HO-1 NNP N
inducer NN N
) ) N
plus CC N
LPS NNP N
, , N
( ( N
iv NN N
) ) N
hemin NN N
alone RB N
, , N
( ( N
v NN N
) ) N
tin NN i
protoporphyrin NN N
( ( N
SnPP NNP N
; : N
a DT N
HO-1 NNP N
inhibitor NN N
) ) N
plus CC N
LPS NNP N
, , N
and CC N
( ( N
vi NN N
) ) N
SnPP NNP N
alone RB N
. . N

In IN N
experimental JJ N
study NN N
, , N
monoaminic JJ N
transmitters NNS N
activated VBN N
in IN N
hypothalamus NN N
; : N
weight NN N
of IN N
pituitary JJ N
, , N
adrenal JJ N
and CC N
thymus NN N
decreased VBN o
; : N
number NN N
of IN N
CRH NNP N
positive JJ N
neurons NNS N
in IN N
hypothalamic JJ N
paraventricular JJ N
nucleus NN N
, , N
CRH NNP N
positive JJ N
neurofibrilin NN N
median JJ N
eminence NN N
and CC N
anterior JJ N
pituitary JJ N
ACTH NNP N
positive JJ N
secretory NN N
cells NNS N
decreased VBD o
; : o
adrenal JJ N
fasciculate NN N
zone NN N
and CC N
thymus NN N
cortex NN N
atrophies NNS N
; : N
NK NNP N
cell VBP N
cytotoxicity NN N
and CC N
the DT N
level NN N
of IN N
IL-2 NNP N
and CC N
gamma-IFN NN N
which WDT N
were VBD N
produced VBN N
by IN N
lymphocytes NNS N
reduced VBN N
in IN N
CORT-rats NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS JJ N
Students NNS N
in IN N
PA NNP N
schools NNS N
, , N
compared VBN N
with IN N
those DT N
in IN N
control NN N
schools NNS N
, , N
had VBD N
more RBR N
favorable JJ N
change NN N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
in IN N
positive JJ N
affect NN N
( ( N
standardized JJ N
mean NN N
difference NN N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
.17 NNP N
) ) N
and CC N
life NN N
satisfaction NN N
( ( N
ES NNP N
= NNP N
.13 NNP N
) ) N
as RB N
well RB N
as IN N
significantly RB N
lower JJR N
depression NN N
( ( N
ES NNP N
= NNP N
-.14 NNP N
) ) N
and CC N
anxiety NN N
( ( N
ES NNP N
= NNP N
-.26 NNP N
) ) N
at IN N
study JJ N
end NN N
point NN N
. . N

At IN N
T3 NNP N
, , N
T4 NNP N
and CC N
T5 NNP N
, , N
OI NNP N
and CC N
Cstat NNP N
in IN N
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
Raw NNP N
and CC N
P NNP N
( ( N
A- NNP N
) ) N
O2 NNP N
in IN N
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Both DT N
groups NNS N
performed VBD N
treadmill JJ N
test NN N
to TO N
assess VB N
pain-free JJ N
walking NN N
time NN N
( ( N
PFWT NNP N
) ) N
and CC N
maximal JJ N
walking NN N
time NN N
( ( N
MWT NNP N
) ) N
and CC N
had VBD N
blood NN N
analyses NNS N
[ VBP N
for IN N
haematocrit NN N
, , N
fibrinogen NN N
, , N
triglycerides NNS N
, , N
and CC N
cholesterol NN N
: : N
total JJ N
, , N
high-density JJ N
lipoprotein NN N
( ( N
HDL NNP N
) ) N
and CC N
low-density JJ N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
] VBD N
done VBN i
at IN N
baseline NN N
and CC N
after IN N
6 CD N
and CC N
12 CD N
weeks NNS N
of IN N
the DT N
study NN N
. . N

Patients NNS N
in IN N
the DT N
electrocoagulation NN N
( ( N
EC NNP N
) ) N
group NN N
experienced VBD N
more JJR N
pain NN N
during IN N
the DT N
procedure NN N
than IN N
the DT N
injection NN N
sclerotherapy NN i
( ( N
IS NNP N
) ) N
group NN N
( ( N
P NNP N
< NNP N
0.000 CD N
) ) N
, , N
but CC N
EC NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
IS NNP N
in IN N
terms NNS N
of IN N
reducing VBG N
the DT N
bleeding NN N
per IN N
rectum NN N
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
and CC N
also RB N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS p
were VBD N
fully RB N
satisfied VBN N
with IN N
EC NNP N
than IN N
with IN N
IS NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

Vascular JJ N
function NN N
was VBD N
assessed VBN N
by IN N
brachial JJ N
dilation NN N
as RB N
well RB N
as IN N
by IN N
plasma NN N
samples NNS N
analysed VBN N
for IN N
hs-CRP NN N
( ( N
high-sensitivity JJ N
C-reactive NNP N
protein NN N
) ) N
, , N
IL-6 NNP N
( ( N
interleukin-6 NN N
) ) N
, , N
IL-8 NNP N
, , N
ICAM-1 NNP N
( ( N
intercellular JJ N
adhesion NN N
molecule-1 NN N
) ) N
, , N
vWF FW N
( ( N
von FW N
Willebrand NNP N
factor NN N
) ) N
, , N
MCP-1 NNP N
( ( N
monocyte JJ N
chemoattractant NN N
protein-1 NN N
) ) N
, , N
PAI-1 NNP N
( ( N
plasminogen JJ N
activator NN N
inhibitor-1 NN N
) ) N
and CC N
fibrinogen NN N
. . N

On IN N
comparing VBG N
bone NN N
gainers NNS N
with IN N
increase NN o
of IN N
lumbar JJ N
spine NN N
BMD NNP N
by IN N
2 CD N
% NN N
or CC N
more JJR N
with IN N
bone NN N
losers NNS N
with IN N
a DT N
decrease NN o
by IN N
2 CD N
% NN N
or CC N
more JJR N
, , N
only RB N
urine JJ N
Ca/Cr NNP N
was VBD N
significantly RB N
different JJ N
, , N
lower RBR N
in IN N
the DT N
former JJ N
than IN N
in IN N
the DT N
latter NN N
, , N
despite IN N
the DT N
general JJ N
tendency NN N
for IN N
bone NN N
resorption NN N
markers NNS N
to TO N
decrease VB o
in IN N
bone NN N
gainers NNS N
and CC N
to TO N
increase VB o
in IN N
bone JJ N
losers NNS N
. . N

The DT N
best JJS N
treatment NN N
modalities NNS N
, , N
irrespective NN N
of IN N
the DT N
kind NN N
of IN N
lesion NN N
, , N
were VBD N
found VBN N
to TO N
be VB N
the DT N
combination NN N
of IN N
5-FU JJ N
plus JJ N
IFN NNP N
alpha-2a NN N
( ( N
high JJ N
dose NN N
) ) N
( ( N
98.27 CD N
% NN N
) ) N
, , N
the DT N
combination NN N
of IN N
CO2 NNP N
laser NN N
vaporization NN N
plus CC N
5-FU JJ N
plus JJ N
IFN NNP N
alpha-2a NN N
( ( N
high JJ N
dose NN N
) ) N
( ( N
93.93 CD N
% NN N
) ) N
and CC N
the DT N
combination NN N
of IN N
CO2 NNP N
laser NN N
vaporization NN N
plus CC N
5-FU JJ N
( ( N
87.23 CD N
% NN N
) ) N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Compared NNP N
with IN N
group NN N
I PRP N
, , N
the DT N
rate NN N
of IN N
premature NN N
LH NNP N
surge NN N
was VBD N
statistically RB N
significantly RB N
lower JJR N
for IN N
group NN N
II NNP N
( ( N
43.4 CD N
% NN N
[ CC N
13/30 CD N
] NN N
vs. FW N
19.4 CD N
% NN N
[ CC N
6/31 CD N
] NN N
) ) N
, , N
but CC N
the DT N
amount NN N
of IN N
gonadotropins NNS N
used VBN N
was VBD N
statistically RB N
significantly RB N
higher JJR N
( ( N
817.5 CD N
+/- JJ N
28.5 CD N
vs. FW N
907.5 CD N
+/- JJ N
27.3 CD N
IU NNP N
) ) N
. . N

Time NNP N
to TO N
treatment NN N
failure NN N
( ( N
TTF NNP N
) ) N
was VBD N
slightly RB N
longer JJR N
for IN N
patients NNS p
who WP N
received VBD N
chemohormonal JJ N
therapy NN i
compared VBN N
with IN N
chemotherapy NN i
alone RB N
patients NNS p
( ( N
13.4 CD N
months NNS N
v RB N
10.3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
=.087 NNP N
) ) N
, , N
and CC N
TTF NNP N
was VBD N
significantly RB N
longer RBR N
in IN N
ER-positive JJ N
compared VBN N
with IN N
ER-negative JJ N
patients NNS p
( ( N
17.4 CD N
months NNS N
v RB N
10.3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
=.048 NNP N
) ) N
. . N

OBJECTIVE NN N
To TO N
examine VB N
further RB N
the DT N
relations NNS N
of IN N
plasma NN N
von NN N
Willebrand NNP N
factor NN N
( ( N
vWf NN N
, , N
an DT N
index NN N
of IN N
endothelial JJ N
damage NN N
and CC N
dysfunction NN N
) ) N
and CC N
soluble JJ N
P-selectin NNP i
( ( N
sP-sel NN N
, , N
an DT N
index NN N
of IN N
platelet NN N
activation NN N
) ) N
concentrations NNS N
to TO N
the DT N
presence NN N
and CC N
onset NN N
of IN N
clinical JJ N
congestive JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
and CC N
the DT N
degree NN N
of IN N
left NN N
ventricular NN N
( ( N
LV NNP N
) ) N
dysfunction NN N
in IN N
patients NNS p
taking VBG N
part NN N
in IN N
the DT N
SPAF NNP N
( ( N
stroke JJ N
prevention NN N
in IN N
atrial JJ N
fibrillation NN N
) ) N
study NN N
. . N

The DT N
conclusion NN N
is VBZ N
that IN N
children NNS N
with IN N
isolated JJ N
CNS NNP N
leukemia NN N
can MD N
achieve VB N
prolonged JJ N
survival NN N
with IN N
aggressive JJ N
therapy NN i
, , N
and CC N
that IN N
CSpRT NNP N
is VBZ N
possibly RB N
less RBR N
toxic JJ N
and CC N
more RBR N
likely JJ N
than IN N
is VBZ N
CRT NNP N
+ NNP N
ITC NNP N
to TO N
prevent VB N
subsequent JJ N
BM NNP N
and CC N
testicular JJ N
relapse NN N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
not RB N
subsequent JJ N
CNS NNP N
relapse NN N
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
. . N

RESULTS NNP N
Intention-to-treat NNP N
analysis NN N
revealed VBD N
significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
respective JJ N
eradication NN N
rates NNS N
of IN N
the DT N
LOAD NNP N
therapies NNS N
( ( N
88.9 CD N
% NN N
( ( N
80/90 CD N
) ) N
LOAD-10 NNP N
, , N
90 CD N
% NN N
( ( N
81/90 CD N
) ) N
LOAD-7 NNP N
, , N
89.4 CD N
% NN N
( ( N
161/180 CD N
) ) N
for IN N
combined VBN N
LOAD NNP N
) ) N
compared VBN N
with IN N
those DT N
receiving VBG N
LAC NNP N
, , N
73.3 CD N
% NN N
( ( N
66/90 CD N
) ) N
. . N

RESULTS VB N
The DT N
three CD N
methods NNS N
of IN N
evaluation NN N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
Groups NNP N
A NNP N
vs. NN N
B NNP N
, , N
and CC N
C NNP N
vs. FW N
D NNP N
, , N
while IN N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
Groups NNP N
A NNP N
vs. FW N
C NNP N
, , N
A NNP N
vs. NN N
D NNP N
, , N
B NNP N
vs. FW N
C NNP N
and CC N
B NNP N
vs. FW N
D. NNP N
Based VBD N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
, , N
the DT N
size NN N
of IN N
occlusal JJ N
access NN N
significantly RB N
affected VBD N
the DT N
efficacy NN N
of IN N
demineralized JJ N
tissue NN N
removal NN N
. . N

RESULTS NN N
In IN N
the DT N
ER+ NNP N
( ( N
Estrogen NNP N
Receptor NNP N
? . N
positive JJ N
) ) N
subgroup NN N
of IN N
the DT N
randomised JJ N
cohort NN N
, , N
YAP1 NNP N
expression NN N
was VBD N
inversely RB N
correlated VBN N
to TO N
histological JJ N
grade NN N
and CC N
proliferation NN N
( ( N
p JJ N
= NN N
0.001 CD N
and CC N
p VB N
= JJ N
0.016 CD N
, , N
respectively RB N
) ) N
whereas NNS N
in IN N
the DT N
ER- NNP N
( ( N
Estrogen NNP N
Receptor NNP N
? . N
negative JJ N
) ) N
subgroup NN N
YAP1 NNP N
expression NN N
correlated VBD N
positively RB N
to TO N
proliferation NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
. . N

Overall JJ i
survival NN N
was VBD N
greater JJR N
with IN N
the DT N
implantable JJ N
defibrillator NN N
, , N
with IN N
unadjusted JJ N
estimates NNS N
of IN N
89.3 CD N
percent NN N
, , N
as IN N
compared VBN N
with IN N
82.3 CD N
percent NN N
in IN N
the DT N
antiarrhythmic-drug JJ N
group NN N
at IN N
one CD N
year NN N
, , N
81.6 CD N
percent NN N
versus NN N
74.7 CD N
percent NN N
at IN N
two CD N
years NNS N
, , N
and CC N
75.4 CD N
percent NN N
versus NN N
64.1 CD N
percent NN N
at IN N
three CD N
years NNS N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

Although IN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
leptin NN i
levels NNS N
did VBD N
not RB N
change VB N
in IN N
Ex NNP N
patients NNS p
( ( N
6.7 CD N
? . N
3.2 CD N
vs NN N
6.9 CD N
? . N
3.6 CD N
ng/mL NN N
, , N
NS NNP N
) ) N
, , N
they PRP N
did VBD N
increase VB o
significantly RB N
in IN N
the DT N
control NN N
group NN N
( ( N
8.0 CD N
? . N
4.0 CD N
vs NN N
9.3 CD N
? . N
5.2 CD N
ng/mL NN N
, , N
p NN N
< NNP N
0.02 CD N
) ) N
. . N

Results NNS N
obtained VBD N
from IN N
the DT N
average JJ N
intensity NN N
scores NNS N
of IN N
the DT N
three CD N
determinations NNS N
indicated VBD N
that IN N
Synemol NNP N
cream NN N
( ( N
0.025 CD N
% NN N
) ) N
is VBZ N
actually RB N
a DT N
more RBR N
active JJ N
compound NN N
than IN N
are VBP N
Diprosone NNP N
cream NN N
( ( N
0.05 CD N
% NN N
) ) N
, , N
Aristocort-A NNP N
cream NN N
( ( N
0.5 CD N
% NN N
) ) N
, , N
and CC N
Valisone NNP N
cream NN N
( ( N
0.1 CD N
% NN N
) ) N
, , N
and CC N
that IN N
its PRP$ N
activity NN N
is VBZ N
longer RBR N
acting VBG N
. . N

Expression NN N
of IN N
VEGF NNP N
and CC N
VEGFR-2 NNP N
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS p
with IN N
a DT N
high JJ N
degree NN N
of IN N
microvessel NN N
density NN N
compared VBN N
to TO N
those DT N
with IN N
a DT N
low JJ N
degree NN N
( ( N
VEGF NNP N
: : N
P NNP N
=0.024 NNP N
; : N
VEGFR-2 JJ N
: : N
P NNP N
=0.040 NNP N
) ) N
and CC N
correlated VBN N
well RB N
with IN N
bone NN N
marrow NN N
microvessel NN N
density NN N
( ( N
r NN N
( ( N
s PRP N
) ) N
=0.566 NN N
and CC N
0.609 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
for IN N
patients NNS p
with IN N
gram-positive JJ N
bacteremia NN N
and CC N
for IN N
all DT N
other JJ N
patients NNS p
, , N
there EX N
were VBD N
no DT N
differences NNS N
by IN N
treatment NN N
regimens NNS N
in IN N
the DT N
proportion NN N
of IN N
febrile JJ N
patients NNS p
on IN N
each DT N
trial NN N
day NN N
( ( N
P NNP N
= NNP N
.85 NNP N
, , N
P NNP N
= NNP N
.82 NNP N
, , N
respectively RB N
) ) N
or CC N
in IN N
the DT N
duration NN N
of IN N
fever NN N
( ( N
P NNP N
= NNP N
.22 NNP N
, , N
P NNP N
= NNP N
.93 NNP N
, , N
respectively RB N
) ) N
. . N

Moreover RB N
, , N
the DT N
percentage NN N
of IN N
patients NNS p
without IN N
induration NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
active JJ N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
, , N
and CC N
a DT N
statistically RB N
significantly RB N
greater JJR N
decrease NN o
in IN N
the DT N
size NN N
of IN N
the DT N
lesional JJ N
area NN N
was VBD N
also RB N
seen VBN N
in IN N
the DT N
overall JJ i
analysis NN N
of IN N
the DT N
R-salbutamol-treated JJ N
patients NNS p
( ( N
P NNP N
= NNP N
0.0197 CD N
) ) N
. . N

When WRB N
the DT N
children NNS N
with IN N
complete JJ N
resolution NN N
of IN N
their PRP$ N
liver NN N
enlargement NN N
were VBD N
considered VBN N
separately RB N
, , N
t NN N
( ( N
1/2hp CD N
) ) N
( ( N
P=0.0008 NNP N
) ) N
but CC N
not RB N
AUC NNP N
( ( N
hp NN N
) ) N
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
lower JJR N
, , N
and CC N
AUC NNP N
( ( N
hpFr196 NN N
) ) N
( ( N
P=0.01 NNP N
) ) N
and CC N
CL NNP N
( ( N
Bhl NNP N
) ) N
( ( N
P=0.002 NNP N
) ) N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
CQCP NNP N
group NN N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

During IN N
the DT N
last JJ N
weeks NNS N
of IN N
the DT N
pretreatment NN N
and CC N
third JJ N
treatment NN N
cycles NNS N
, , N
blood NN N
samples NNS N
were VBD N
obtained VBN N
for IN N
determinations NNS N
of IN N
plasma JJ N
concentrations NNS N
of IN N
angiotensinogen NN N
, , N
an DT N
estrogen-sensitive JJ N
hepatic JJ N
protein NN N
, , N
and CC N
serum JJ N
concentrations NNS N
of IN N
sex NN N
hormone-binding JJ N
globulin NN N
( ( N
SHBG NNP N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
high-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
, , N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
, , N
triglycerides NNS N
( ( N
TG NNP N
) ) N
and CC N
estrogen- JJ N
and CC N
androgen-sensitive JJ N
proteins NNS N
. . N

In IN N
the DT N
presence NN N
of IN N
leakage NN N
( ( N
settings NNS N
II NNP N
and CC N
III NNP N
) ) N
, , N
the DT N
attempt NN N
to TO N
compensate VB N
for IN N
leak NN N
was VBD N
only RB N
evident JJ N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
since IN N
inspiratory NN N
volumes NNS N
delivered VBN N
by IN N
the DT N
ventilator NN N
increased VBD o
from IN o
726+/-129 NNP N
( ( N
setting VBG N
I PRP N
) ) N
to TO N
1104+/-164 JJ N
( ( N
setting VBG N
II NNP N
) ) N
, , N
and CC N
to TO N
1257+/-166 JJ N
( ( N
setting VBG N
III NNP N
) ) N
ml NN N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
respectively RB N
( ( N
all DT N
p VBP N
< $ N
0.001 CD N
) ) N
; : N
however RB N
, , N
they PRP N
remained VBD N
stable JJ N
during IN N
volume-limited JJ N
NPPV NNP N
. . N

Compared VBN N
with IN N
tPA NN N
, , N
however RB N
, , N
primary JJ N
PTCA NNP N
resulted VBD N
in IN N
a DT N
markedly RB N
lower JJR N
rate NN N
of IN N
recurrent NN N
myocardial JJ N
ischemia NN N
( ( N
9.7 CD N
% NN N
vs JJ N
27.8 CD N
% NN N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
, , N
fewer JJR N
unscheduled JJ N
catheterization NN N
and CC N
revascularization NN N
procedures NNS N
, , N
and CC N
a DT N
shorter JJR N
hospital NN N
stay NN N
( ( N
7.0 CD N
vs RB N
8.6 CD N
days NNS N
, , N
p VBP N
= RB N
0.01 CD N
) ) N
in IN N
nonanterior JJ N
wall NN N
AMI NNP N
. . N

RESULTS NNP N
Constitutive NNP N
proteins VBZ N
such JJ N
as IN N
albumin NN N
, , N
prealbumin NN N
, , N
and CC N
retinol-binding JJ N
protein NN N
levels NNS N
increased VBN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
acute JJ N
phase NN N
proteins NNS N
such JJ N
as IN N
alpha JJ N
1-acid JJ N
glycoprotein NN N
, , N
C3 NNP N
complement NN N
, , N
alpha JJ N
2-macroglobulin JJ N
, , N
and CC N
fibrinogen NN N
levels NNS N
significantly RB N
decreased VBN o
in IN N
the DT N
oxandrolone NN N
group NN N
compared VBN N
with IN N
placebo NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Mean NNP N
peak NN N
FEV1 NNP N
change NN N
( ( N
primary JJ N
endpoint NN N
) ) N
was VBD N
maximum JJ N
with IN N
the DT N
administration NN N
of IN N
the DT N
combination NN N
of IN N
ipratropium NN N
and CC N
formoterol NN N
( ( N
335.2 CD N
ml NN N
, , N
SE NNP N
24.6 CD N
) ) N
, , N
and CC N
it PRP N
differed VBD N
significantly RB N
from IN N
the DT N
observed JJ N
peak NN N
changes NNS N
following VBG N
single JJ N
administration NN N
of IN N
the DT N
two CD N
tested VBD N
doses NNS N
of IN N
ipratropium NN N
( ( N
p JJ N
< NN N
0.05 CD N
and CC N
p VB N
< JJ N
0.05 CD N
respectively RB N
) ) N
. . N

For IN N
respective JJ N
comparisons NNS N
of IN N
ALLO NNP N
and CC N
AUTO NNP N
transplants NNS N
in IN N
the DT N
GLN NNP N
and CC N
GLY NNP N
hematologic VBP N
groups NNS N
and CC N
AUTO NNP N
in IN N
the DT N
solid JJ N
tumor NN N
groups NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
hospital NN N
stay NN N
, , N
duration NN N
of IN N
stay NN N
after IN N
BMT NNP N
, , N
TPN NNP N
days NNS N
, , N
neutrophil JJ N
recovery NN N
> NN N
500/mm3 CD N
, , N
incidence NN N
of IN N
positive JJ N
blood NN N
cultures NNS N
, , N
sepsis NN N
, , N
mucositis NN N
, , N
and CC N
diarrhea NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
levels NNS N
of IN N
metals NNS N
in IN N
blood NN N
( ( N
zinc NN N
( ( N
Zn NNP N
) ) N
, , N
copper NN N
( ( N
Cu NNP N
) ) N
, , N
aluminium NN N
( ( N
Al NNP N
) ) N
, , N
lead JJ N
( ( N
Pb NNP N
) ) N
and CC N
mercury NN N
( ( N
Hg NNP N
) ) N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
specific JJ N
porphyrin NN N
levels NNS N
in IN N
the DT N
urine NN N
of IN N
patients NNS p
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
compared VBN N
with IN N
patients NNS p
with IN N
other JJ N
neurological JJ N
disorders NNS N
. . N

RESULTS VB N
The DT N
mean JJ N
total JJ N
ATEC NNP N
scores NNS N
by IN N
both DT N
parents NNS N
and CC N
clinicians NNS N
were VBD N
significantly RB N
improved VBN N
after IN N
intervention NN N
in IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
compared VBN N
to TO N
the DT N
score NN N
before IN N
intervention NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
in IN N
both DT N
groups NNS N
by IN N
parents NNS N
, , N
P NNP N
= VBZ N
0.015 CD N
in IN N
HBOT NNP N
group NN N
and CC N
P NNP N
= NNP N
0.004 CD N
in IN N
sham NN N
group NN N
by IN N
clinician NN N
) ) N
. . N

Although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
incidence NN N
of IN N
de FW N
novo FW N
adnexal JJ N
adhesions NNS N
, , N
the DT N
lowest JJS N
rate NN N
was VBD N
found VBN N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
, , N
with IN N
4/32 CD N
patients NNS p
( ( N
12.5 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
2/29 CD N
patients NNS p
( ( N
6.8 CD N
% NN N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
and CC N
5/30 CD N
patients NNS p
( ( N
16.7 CD N
% NN N
) ) N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

RESULTS NNP N
After IN N
1 CD N
cycle NN N
, , N
BMI NNP N
, , N
total JJ N
T NNP N
level NN N
, , N
and CC N
percentage NN N
of IN N
participants NNS N
with IN N
insulin NN N
resistance NN N
were VBD N
significantly RB N
decreased VBN o
in IN N
the DT N
metformin NN N
group NN N
, , N
without IN N
any DT N
significant JJ N
decrease NN o
in IN N
LH NNP N
, , N
FSH NNP N
, , N
and CC N
DHEAS NNP N
levels NNS N
; : N
and CC N
in IN N
the DT N
second JJ N
cycle NN N
, , N
CC NNP N
treatment NN N
resulted VBD N
in IN N
a DT N
higher JJR N
ovulation NN N
rate NN N
and CC N
a DT N
thicker NN N
endometrium NN N
in IN N
the DT N
metformin NN N
group NN N
. . N

Core NN N
temperature NN N
decreased VBN o
in IN N
all PDT N
the DT N
three CD N
groups NNS N
30 CD N
minutes NNS N
after IN N
general JJ N
anesthesia NN N
induction NN N
compared VBN N
with IN N
baseline NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
; : N
afterwards NNS N
, , N
it PRP N
progressively RB N
decreased VBD o
in IN o
the DT N
control NN N
and CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
, , N
with IN N
a DT N
reduction NN N
from IN N
baseline NN N
values NNS N
measured VBN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
of IN N
2.0 CD N
degrees NNS N
C NNP N
and CC N
1.6 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

We PRP N
found VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
duration NN N
of IN N
sensory JJ N
blockade NN N
( ( N
120.92 CD N
+/- JJ N
36.21 CD N
min NN N
with IN N
prilocaine NN N
and CC N
145.83 CD N
+/- JJ N
35.81 CD N
min NN N
with IN N
mepivacaine NN N
) ) N
and CC N
in IN N
motor NN N
blockade NN N
( ( N
106.29 CD N
+/- JJ N
38.16 CD N
min NN N
with IN N
prilocaine NN N
and CC N
133.16 CD N
+/- JJ N
42.21 CD N
min NN N
with IN N
mepivacaine NN N
) ) N
. . N

RESULTS NNP N
For IN N
pramipexole JJ N
recipients NNS N
, , N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
PLM NNP N
per IN N
hour NN N
in IN N
bed NN N
asleep NN N
or CC N
awake NN N
( ( N
the DT N
PLM NNP N
index NN N
, , N
or CC N
PLMI NNP N
) ) N
, , N
decreased VBN o
by IN N
a DT N
median NN N
of IN N
-26.55 NN N
to TO N
-52.70 VB N
depending VBG N
on IN N
dosage NN N
group NN N
, , N
vs. FW N
-3.00 NN N
for IN N
placebo NN N
( ( N
p JJ N
< VBP N
0.01 CD N
or CC N
0.001 CD N
for IN N
each DT N
group NN N
vs. FW N
placebo NN N
; : N
Wilcoxon-Mann-Whitney NNP N
test NN N
) ) N
. . N

As IN N
compared VBN N
with IN N
placebo NN N
, , N
the DT N
S. NNP N
boulardii NN N
group NN N
showed VBD N
a DT N
significant JJ N
decrease NN o
in IN N
blood NN N
and CC N
tissue NN N
levels NNS N
of IN N
proinflammatory NN N
cytokines NNS N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
and CC N
tumor JJ N
necrosis NN N
factor- NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
an DT N
increase NN o
in IN N
anti-inflammatory JJ N
IL-10 JJ N
levels NNS N
, , N
as RB N
well RB N
as IN N
an DT N
increase NN o
in IN N
the DT N
tissue NN N
IL-10/IL-12 NNP N
ratio NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
years NNS N
1 CD N
and CC N
2 CD N
, , N
the DT N
mean JJ N
postvaccination NN N
strain-specific NN N
to TO N
total JJ N
IgA NNP N
ratio NN N
was VBD N
3.1-fold JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2.0-fold JJ N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
higher JJR N
among IN N
LAIV JJ N
recipients NNS N
with IN N
no DT N
evidence NN N
of IN N
culture-confirmed JJ N
influenza NN N
illness NN N
compared VBN N
with IN N
LAIV NNP N
recipients NNS N
who WP N
developed VBD N
culture-confirmed JJ N
influenza NN N
illness NN N
; : N
a DT N
similar JJ N
and CC N
consistent JJ N
trend NN N
was VBD N
observed VBN N
for IN N
each DT N
individual NN N
study NN N
and CC N
type/subtype NN N
. . N

Since IN N
the DT N
90 CD N
% NN N
CI NNP N
for IN N
Cmax NNP i
and CC N
AUCs NNP N
ratios NNS N
were VBD N
all DT N
within IN N
the DT N
80-125 JJ N
% NN N
bioequivalence NN N
limit NN N
proposed VBN N
by IN N
the DT N
US NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
cyproheptadine JJ N
test NN N
formulation NN N
( ( N
Cobactin NNP i
) ) N
is VBZ N
bioequivalent JJ N
to TO N
the DT N
Cobavital NNP N
formulation NN N
for IN N
both DT N
the DT N
rate NN N
and CC N
the DT N
extent NN N
of IN N
absorption NN N
of IN N
cyproheptadine NN N
. . N

Twenty NNP N
adults NNS N
, , N
critically RB N
ill VB N
for IN N
several JJ N
weeks NNS N
and CC N
supported VBD N
with IN N
normocaloric JJ N
, , N
continuously RB N
administered VBN N
parenteral JJ N
and/or JJ N
enteral JJ N
feeding NN N
, , N
were VBD N
studied VBN N
for IN N
45 CD N
h. NN N
They PRP N
had VBD N
been VBN N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
three CD N
combinations NNS N
of IN N
peptide JJ N
infusions NNS N
, , N
in IN N
random JJ N
order NN N
: : N
TRH NN N
( ( N
one CD N
day NN N
) ) N
and CC N
placebo NN N
( ( N
other JJ N
day NN N
) ) N
; : N
TRH NNP N
+ NNP N
GH-releasing NNP N
peptide NN N
( ( N
GHRP NNP N
) ) N
-2 NN N
and CC N
GHRP-2 NNP N
; : N
TRH NNP N
+ NNP N
GHRH NNP N
+ NNP N
GHRP-2 NNP N
and CC N
GHRH NNP N
+ NNP N
GHRP-2 NNP N
. . N

Significant JJ N
improvement NN N
was VBD N
recorded VBN N
for IN N
all DT N
symptoms NNS N
at IN N
days NNS N
10 CD N
and CC N
28 CD N
in IN N
all DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
levosulpiride NN N
was VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
superior NN N
to TO N
domperidone VB i
, , N
metoclopramide NN N
and CC N
placebo VB N
both DT N
in IN N
the DT N
overall JJ i
clinical JJ N
improvement NN N
scale NN N
as RB N
well RB N
as IN N
in IN N
a DT N
subgroup NN N
of IN N
symptoms NNS N
( ( N
postprandial JJ N
bloating NN N
, , N
epigastric JJ N
pain NN N
, , N
heartburn NN N
) ) N
. . N

The DT N
heavy JJ N
group NN N
significantly RB N
improved VBN N
both DT N
the DT N
5- JJ N
and CC N
10-m JJ N
sprint NN N
time NN N
by IN N
5.7 CD N
? . N
5.7 CD N
and CC N
5.0 CD N
? . N
3.5 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
whereas IN N
only RB N
10-m JJ N
sprint NN N
time NN N
was VBD N
improved VBN N
significantly RB N
by IN N
3.0 CD N
? . N
3.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
light JJ N
group NN N
. . N

Tissue NNP N
plasminogen NN N
activator NN N
antigen NN N
concentration NN N
decreased VBN o
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
only RB N
in IN N
the DT N
metformin NN N
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
placebo NN N
group NN N
( ( N
p JJ N
< NNP N
0.12 CD N
) ) N
; : N
further RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
plasminogen NN N
activator NN N
inhibitor NN N
1 CD N
. . N

The DT N
WCGF NNP N
diets NNS N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
the DT N
concentration NN N
of IN N
milk NN N
fat NN N
( ( N
3.94 CD N
, , N
3.74 CD N
, , N
and CC N
4.15 CD N
+/- JJ N
0.08 CD N
% NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
) ) N
, , N
but CC N
because IN N
total JJ N
milk NN N
yield NN N
was VBD N
increased VBN o
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
total JJ N
milk NN N
fat JJ N
yield NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN N
of IN N
positive JJ N
response NN N
on IN N
the DT N
Clinical NNP N
Global NNP N
Impressions NNP N
, , N
Improvement NNP N
subscale NN N
between IN N
the DT N
citalopram-treated JJ N
group NN N
( ( N
32.9 CD N
% NN N
) ) N
and CC N
the DT N
placebo NN N
group NN N
( ( N
34.2 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
, , N
0.96 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.61-1.51 JJ N
; : N
P NNP N
> NNP N
.99 NNP N
) ) N
. . N

RESULTS NN N
After IN N
induction NN N
of IN N
anesthesia NN N
, , N
the DT N
decrease NN o
in IN N
pupil JJ N
size NN N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.112 CD N
) ) N
, , N
but CC N
for IN N
the DT N
next JJ N
two CD N
stages NNS N
, , N
it PRP N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
diclofenac NN N
group NN N
( ( N
P NNP N
= NNP N
0.012 CD N
and CC N
P NNP N
= NNP N
0.003 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
mean JJ N
rate NN N
of IN N
exacerbations NNS N
( ( N
mild NN N
, , N
moderate JJ N
or CC N
severe JJ N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
Salm/FP NNP N
group NN N
( ( N
0.472 CD N
) ) N
compared VBN N
with IN N
the DT N
Form+Bud NNP N
group NN N
( ( N
0.735 CD N
) ) N
( ( N
ratio JJ N
= VBZ N
0.64 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
despite IN N
the DT N
three-fold JJ N
lower JJR N
microgram NN N
inhaled VBN N
corticosteroid NN N
dose NN N
in IN N
the DT N
Salm/FP NNP N
group NN N
. . N

Safety NNP N
analyses NNS N
of IN N
patients NNS p
applying VBG N
topical JJ N
diclofenac NN N
solution NN N
revealed VBD N
some DT N
minor JJ N
skin NN N
irritation NN N
at IN N
the DT N
application NN N
site NN N
-- : N
mostly RB N
skin JJ N
dryness NN N
in IN N
83/311 CD N
( ( N
27 CD N
% NN N
) ) N
patients NNS p
-- : N
but CC N
a DT N
significantly RB N
reduced VBN N
incidence NN N
, , N
relative JJ N
to TO N
oral JJ N
diclofenac NN N
, , N
of IN N
total JJ N
and CC N
severe JJ N
gastrointestinal NN N
( ( N
GI NNP N
) ) N
adverse JJ N
events NNS N
, , N
including VBG N
dyspepsia NN N
, , N
abdominal JJ N
pain NN N
, , N
diarrhea NN N
, , N
and CC N
nausea NN N
. . N

The DT N
overall JJ i
incidence NN N
of IN N
adverse JJ N
events NNS N
and CC N
subsequent JJ N
downtime NN N
was VBD N
increased VBN o
for IN N
Er NN N
: : N
YAG NNP N
( ( N
1/10 CD N
patients NNS p
experienced JJ N
hyperpigmentation NN N
, , N
3/10 CD N
exfoliation NN N
, , N
1/10 CD N
blistering NN N
, , N
and CC N
5/10 CD N
discomfort NN N
) ) N
compared VBN N
to TO N
IPL NNP N
( ( N
1/10 CD N
exfoliation NN N
and CC N
1/10 CD N
discomfort NN N
) ) N
, , N
although IN N
no DT N
permanent JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
with IN N
either DT N
treatment NN N
arm NN N
. . N

Following VBG N
endodontic JJ N
treatment NN N
, , N
the DT N
teeth NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
: : N
cast VBN N
Ni-Cr JJ N
alloy NN N
dowel-core NN N
with IN N
no DT N
ferrule NN N
( ( N
Group NNP N
A1 NNP N
) ) N
, , N
cast VBD N
Ni-Cr JJ N
alloy NN N
dowel-core NN N
with IN N
2.0 CD N
mm NNS N
ferrule NN N
( ( N
Group NNP N
A2 NNP N
) ) N
, , N
prefabricated VBN N
carbon NN N
fiber-reinforced JJ N
dowel-resin NN N
core NN N
with IN N
no DT N
ferrule NN N
( ( N
Group NNP N
B1 NNP N
) ) N
and CC N
carbon JJ N
fiber-reinforced JJ N
dowel-resin NN N
core NN N
with IN N
2.0 CD N
mm NNS N
ferrule NN N
( ( N
Group NNP N
B2 NNP N
) ) N
. . N

At IN N
2 CD N
years NNS N
postoperatively RB N
, , N
there EX N
were VBD N
no DT N
statistically RB N
or CC N
clinically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
for IN N
the DT N
Western NNP N
Ontario NNP N
Shoulder NNP N
Instability NNP N
Index NNP N
( ( N
P NNP N
= NNP N
.71 NNP N
) ) N
, , N
American NNP N
Shoulder NNP N
and CC N
Elbow NNP N
Surgeons NNP N
score NN N
( ( N
P NNP N
= NNP N
.43 NNP N
) ) N
, , N
Constant JJ N
score NN N
( ( N
P NNP N
= NNP N
.43 NNP N
) ) N
, , N
and CC N
active JJ N
range NN N
of IN N
motion NN N
. . N

One CD N
hundred VBD N
sixty-three JJ N
colon NN N
cancer NN N
patients NNS p
underwent VBD N
the DT N
traditional JJ N
protocol NN N
and CC N
open JJ N
operation NN N
( ( N
traditional JJ N
open JJ N
group NN N
, , N
n=42 RB N
) ) N
, , N
the DT N
traditional JJ N
protocol NN N
and CC N
laparoscopic NN N
operation NN N
( ( N
traditional JJ N
laparoscopic NN N
group NN N
, , N
n=40 RB N
) ) N
, , N
the DT N
FT NNP N
protocol NN N
and CC N
open JJ N
operation NN N
( ( N
FT NNP N
open JJ N
group NN N
, , N
n=41 RB N
) ) N
, , N
or CC N
the DT N
FT NNP N
protocol NN N
and CC N
laparoscopic NN N
operation NN N
( ( N
FT NNP N
laparoscopic NN N
group NN N
, , N
n=40 RB N
) ) N
. . N

Rowers NNS N
in IN N
the DT N
Fe NNP N
group NN N
had VBD N
slower JJR N
lactate JJ N
response NN N
during IN N
the DT N
first JJ N
half NN N
of IN N
the DT N
time NN N
trial NN N
and CC N
after IN N
5 CD N
min NN N
of IN N
recovery NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
showed VBD N
greater JJR N
improvements NNS N
in IN N
energy NN N
expenditure NN N
( ( N
P NNP N
= VBZ N
0.01 CD N
for IN N
group-by JJ N
time NN N
) ) N
and CC N
energetic JJ N
EF NNP N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
= VBZ N
0.03 CD N
for IN N
group-by JJ N
time NN N
) ) N
. . N

CONCLUSION NN N
When WRB N
compared VBN N
with IN N
SRP NNP N
alone RB N
, , N
clinical JJ N
improvements NNS N
in IN N
PPD NNP N
( ( N
e.g NN N
, , N
-1.0 NNP N
mm NN N
for IN N
pockets NNS N
> VBP N
5 CD N
mm NN N
at IN N
baseline NN N
) ) N
were VBD N
maintained VBN N
for IN N
up IN N
to TO N
six CD N
months NNS N
after IN N
SRP NNP N
with IN N
adjunctive JJ N
use NN N
of IN N
1.7 CD N
% NN N
hydrogen NN N
peroxide NN N
gel NN N
, , N
locally RB N
administered VBN N
using VBG N
prescription NN N
customized VBD N
trays NNS N
in IN N
the DT N
treatment NN N
of IN N
subjects NNS N
with IN N
moderate JJ N
to TO N
advanced JJ N
periodontitis NN N
. . N

Mutans NNS N
streptococci VBP N
( ( N
MS NNP N
) ) N
and CC N
lactobacilli $ N
( ( N
LB NNP N
) ) N
levels NNS N
, , N
visible JJ N
plaque NN N
index NN N
( ( N
VPI NNP N
) ) N
and CC N
gingival JJ N
bleeding NN N
index NN N
( ( N
GBI NNP N
) ) N
were VBD N
evaluated VBN N
at IN N
four CD N
stages NNS N
: : N
T0 NNP N
, , N
before IN N
general JJ N
anaesthesia NN N
; : N
T1 NNP N
, , N
one CD N
month NN N
after IN N
treatment NN N
; : N
T2 NNP N
, , N
six CD N
months NNS N
after IN N
treatment NN N
; : N
T3 NNP N
, , N
twelve JJ N
months NNS N
after IN N
treatment NN N
. . N

Stress NNP N
incontinence NN N
was VBD N
greater JJR N
among IN N
primiparous JJ N
women NNS N
in IN N
the DT N
VB NNP N
group NN N
( ( N
VB NNP N
34.5 CD N
% NN N
vs. FW N
CS NNP N
12.8 CD N
% NN N
) ) N
regardless NN N
of IN N
prior JJ N
UI NNP N
history NN N
, , N
but CC N
the DT N
proportion NN N
of IN N
women NNS N
whose WP$ N
UI NNP N
was VBD N
severe JJ N
enough RB N
to TO N
wear VB N
a DT N
pad NN N
was VBD N
similar JJ N
in IN N
primiparous JJ N
women NNS N
( ( N
VB NNP N
16.0 CD N
% NN N
, , N
CS NNP N
15.4 CD N
% NN N
) ) N
and CC N
multiparous JJ N
women NNS N
( ( N
VB NNP N
23.8 CD N
% NN N
, , N
CS NNP N
25.0 CD N
% NN N
) ) N
. . N

Larger NNP N
decreases VBZ o
in IN N
body NN N
weight NN N
, , N
body NN N
mass NN N
index NN N
, , N
waist NN N
circumference NN N
, , N
body NN N
fat NN N
, , N
total JJ N
fat JJ N
area NN N
and CC N
subcutaneous JJ N
fat JJ N
area NN N
in IN N
the DT N
abdomen NNS N
and CC N
serum NN N
triglycerides NNS N
, , N
low-density NN N
lipoprotein NN N
cholesterol NN N
, , N
apolipoprotein NN N
B NNP N
, , N
C2 NNP N
, , N
C3 NNP N
and CC N
E NNP N
were VBD N
observed VBN N
in IN N
male JJ N
subjects NNS N
in IN N
the DT N
MLCT NNP N
group NN N
than IN N
those DT N
in IN N
the DT N
LCT NNP N
group NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
relationship NN N
between IN N
failure NN N
of IN N
the DT N
fixation NN N
and CC N
varus NN N
reduction NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
as RB N
well RB N
as IN N
screw/neck NN N
angle NN N
deviation NN N
more JJR N
than IN N
20 CD N
degrees NNS N
in IN N
the DT N
lateral JJ N
projection NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
or CC N
if IN N
the DT N
implant NN N
was VBD N
in IN N
a DT N
superior JJ N
or CC N
posterior JJ N
position NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

METHODS NNP N
Sixty-six JJ N
patients NNS p
with IN N
gastric JJ N
carcinoma NN N
scheduled VBN N
for IN N
gastrectomy NN N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
, , N
namely RB N
group NN N
P NNP N
( ( N
n=22 NN N
) ) N
, , N
group NN N
E NNP N
( ( N
n=22 NN N
) ) N
and CC N
group NN N
V NNP N
( ( N
n=22 NN N
) ) N
, , N
to TO N
receive VB N
preemptive JJ N
epidural JJ N
analgesia NN N
combined VBN N
with IN N
postoperative JJ N
epidural JJ N
analgesia NN N
, , N
exclusive JJ N
postoperative JJ N
epidural JJ N
analgesia NN N
, , N
and CC N
exclusive JJ N
postoperative NN N
intravenous JJ N
analgesia NN N
, , N
respectively RB N
. . N

At IN N
3-month JJ N
follow-up NN N
, , N
intervention NN N
group NN N
patients NNS p
demonstrated VBD N
significantly RB N
improved VBN N
cognitive JJ N
executive NN N
functioning NN N
on IN N
the DT N
widely RB N
used VBN N
and CC N
well-normed JJ N
Tower NNP N
test NN N
( ( N
for IN N
planning NN N
and CC N
strategic JJ N
thinking NN N
) ) N
vs. NN N
controls NNS N
( ( N
median JJ N
[ NN N
interquartile NN N
range NN N
] NNP N
, , N
13.0 CD N
[ JJ N
11.5-14.0 JJ N
] NNP N
vs. FW N
7.5 CD N
[ JJ N
4.0-8.5 JJ N
] NN N
; : N
adjusted VBN N
p NN N
< NNP N
.01 NNP N
) ) N
. . N

RESULTS NNP N
MDI NNP N
was VBD N
higher RBR N
in IN N
the DT N
EDI NNP N
( ( N
102.6 CD N
? . N
9.8 CD N
) ) N
compared VBN N
with IN N
the DT N
control NN N
resuscitated VBD N
children NNS N
( ( N
98.0 CD N
? . N
14.6 CD N
, , N
1-sided JJ N
P NNP N
= NNP N
.0202 NNP N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
nonresuscitated JJ N
children NNS N
( ( N
100.1 CD N
? . N
10.7 CD N
vs NN N
97.7 CD N
? . N
10.4 CD N
, , N
P NNP N
= NNP N
.1392 NNP N
) ) N
. . N

Intervention NNP N
group NN N
patients NNS p
also RB N
reported VBD N
better JJR N
performance NN N
( ( N
i.e NN N
, , N
lower JJR N
score NN N
) ) N
on IN N
one CD N
of IN N
the DT N
most RBS N
frequently RB N
used JJ N
measures NNS N
of IN N
functional JJ N
status NN N
( ( N
Functional NNP N
Activities NNP N
Questionnaire NNP N
at IN N
3 CD N
months NNS N
vs. FW N
controls NNS N
, , N
1.0 CD N
[ NN N
0.0 CD N
-3.0 NN N
] NNP N
vs VBZ N
8.0 CD N
[ JJ N
6.0-11.8 JJ N
] NN N
, , N
adjusted VBN N
p NN N
= NNP N
.04 NNP N
) ) N
. . N

The DT N
corresponding JJ N
reductions NNS N
in IN N
mortality NN N
( ( N
with IN N
95 CD N
percent NN N
confidence NN N
limits NNS N
) ) N
with IN N
the DT N
implantable JJ N
defibrillator NN N
were VBD N
39+/-20 JJ N
percent NN N
, , N
27+/-21 JJ N
percent NN N
, , N
and CC N
31+/-21 JJ N
percent NN N
CONCLUSIONS NNP N
Among IN N
survivors NNS N
of IN N
ventricular JJ N
fibrillation NN N
or CC N
sustained VBN N
ventricular JJ N
tachycardia NN N
causing VBG N
severe JJ N
symptoms NNS N
, , N
the DT N
implantable JJ N
cardioverter-defibrillator NN N
is VBZ N
superior JJ N
to TO N
antiarrhythmic VB N
drugs NNS N
for IN N
increasing VBG N
overall JJ i
survival NN N
. . N

Mean JJ N
muscle NN N
volume NN N
of IN N
the DT N
thigh NN N
, , N
estimated VBN N
by IN N
computerised JJ N
tomography NN N
, , N
increased VBD o
significantly RB o
compared VBN N
with IN N
that DT N
of IN N
the DT N
initial JJ N
placebo NN N
period NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
a DT N
slight JJ N
decrease NN o
was VBD N
recorded VBN N
in IN N
adipose JJ N
tissue NN N
volume NN N
of IN N
the DT N
thigh NN N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
and CC N
subscapular JJ N
skinfold NN N
thickness NN N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Using VBG N
one CD N
definition NN N
, , N
the DT N
prevalence NN N
of IN N
low JJ N
RF NNP N
profile NN N
increased VBD o
from IN o
3.8 CD N
% NN N
( ( N
3.1-4.5 JJ N
) ) N
in IN N
1984-1986 JJ N
to TO N
6.7 CD N
% NN N
( ( N
6.1-7.3 JJ N
) ) N
in IN N
2003-2006 JJ N
; : N
using VBG N
another DT N
definition NN N
, , N
the DT N
results NNS N
were VBD N
5.9 CD N
% NN N
( ( N
5.1-6.8 JJ N
) ) N
and CC N
9.7 CD N
% NN N
( ( N
9.0-10.5 CD N
) ) N
, , N
respectively RB N
. . N

RESULTS NNP N
Intervention NNP N
patients NNS p
reported VBD N
using VBG N
more JJR N
skills NNS N
than IN N
controls NNS N
in IN N
five CD N
of IN N
six CD N
skill JJ N
areas NNS N
, , N
including VBG N
identification NN N
of IN N
problems/concerns NNS N
, , N
information NN N
exchange NN N
, , N
treatment NN N
adherence NN N
, , N
shared VBN N
decision-making NN N
and CC N
interpersonal JJ N
rapport NN N
( ( N
all DT N
p NN N
< NNP N
.05 NNP N
) ) N
; : N
post VBN N
intervention NN N
, , N
physicians NNS N
reported VBD N
using VBG N
more JJR N
skills NNS N
in IN N
the DT N
same JJ N
5 CD N
areas NNS N
( ( N
all DT N
p NN N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
effects NNS N
of IN N
captopril NN N
( ( N
C NNP N
) ) N
( ( N
50 CD N
mg NN N
, , N
three CD N
times NNS N
daily RB N
for IN N
3 CD N
days NNS N
) ) N
on IN N
arterial JJ N
pressure NN N
( ( N
AP NNP N
) ) N
, , N
O2 NNP N
consumption NN N
( ( N
VO2 NNP N
) ) N
, , N
variations NNS N
in IN N
auricular JJ N
natriuretic JJ N
factor NN N
( ( N
ANF NNP N
) ) N
, , N
renin NN N
, , N
angiotensin NN N
II NNP N
( ( N
AII NNP N
) ) N
plasma NN N
levels NNS N
, , N
as RB N
well RB N
as IN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
GFR NNP N
) ) N
and CC N
microalbuminuria $ N
( ( N
MA NNP N
) ) N
were VBD N
evaluated VBN N
. . N

There EX N
were VBD N
fewer JJR N
periprocedural JJ N
myocardial JJ N
infarctions NNS N
with IN N
ZES NNP N
( ( N
0.5 CD N
% NN N
vs. FW N
2.2 CD N
% NN N
; : N
p CC N
= VB N
0.007 CD N
) ) N
, , N
whereas VBP N
at IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
rates NNS N
of IN N
cardiac JJ N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
target NN N
vessel NN N
revascularization NN N
, , N
or CC N
stent JJ N
thrombosis NN N
. . N

Fewer NNP N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
major JJ N
infectious JJ N
events NNS N
( ( N
infectious JJ N
death NN N
or CC N
delay NN N
in IN N
treatment NN N
of IN N
underlying JJ N
disease NN N
due JJ N
to TO N
infection NN N
) ) N
were VBD N
observed VBN N
during IN N
piperacillin/ JJ N
tazobactam JJ N
treatment NN N
( ( N
2.6 CD N
% NN N
) ) N
than IN N
with IN N
the DT N
ceftazidime NN N
regimen NNS N
( ( N
11.3 CD N
% NN N
) ) N
, , N
despite IN N
a DT N
lower JJR N
frequency NN N
of IN N
glycopeptide JJ N
addition NN N
when WRB N
piperacillin/tazobactam NN N
was VBD N
used VBN N
( ( N
54.4 CD N
% NN N
versus IN N
77.4 CD N
% NN N
) ) N
according VBG N
to TO N
the DT N
rules NNS N
adopted VBN N
. . N

The DT N
incidence NN N
of IN N
mucositis NN N
requiring VBG N
morphine NN N
sulfate NN N
( ( N
MSO4 NNP N
) ) N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
42.9 CD N
% NN N
) ) N
, , N
with IN N
the DT N
mean JJ N
number NN N
of IN N
days NNS N
with IN N
MSO4 NNP N
being VBG N
7.8 CD N
( ( N
SD NNP N
= NNP N
3.4 CD N
) ) N
in IN N
the DT N
PTX NNP N
group NN N
versus VBD N
8.2 CD N
( ( N
SD NNP N
= NNP N
3.4 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
NS NNP N
) ) N
. . N

However RB N
, , N
results NNS N
from IN N
the DT N
Conners NNP N
' POS N
Parent NNP N
Questionnaire NNP N
revealed VBD N
an DT N
improvement NN N
only RB N
for IN N
anxiety NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
massage NN N
group NN N
, , N
whereas IN N
when WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
conduct NN N
problem NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
anxiety NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
was VBD N
found VBN N
. . N

Compared VBN N
to TO N
the DT N
Placebo NNP N
group NN N
( ( N
29 CD N
% NN N
) ) N
, , N
the DT N
group NN N
receiving VBG N
the DT N
mixture NN N
of IN N
evening VBG N
primrose JJ N
oil NN N
and CC N
fish JJ N
oil NN N
containing VBG N
Gamma-linolenic JJ N
acid NN N
( ( N
GLA NNP N
) ) N
, , N
Eicosapentaenoic NNP N
acid NN N
( ( N
EPA NNP N
) ) N
, , N
and CC N
Docosahexaenoic NNP N
acid NN N
( ( N
DHA NNP N
) ) N
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN N
of IN N
edema NN N
( ( N
13 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
. . N

Fasting VBG N
blood NN N
samples NNS N
were VBD N
collected VBN N
before IN N
and CC N
after IN N
12-month JJ N
treatment NN N
for IN N
determinations NNS N
of IN N
fibrinogen NN N
, , N
prothrombin JJ N
fragment NN N
1+2 CD N
( ( N
F1+2 NNP N
) ) N
, , N
plasma JJ N
D-dimer NNP N
, , N
soluble JJ N
tissue NN N
factor NN N
, , N
tissue NN N
plasminogen NN N
activator NN N
( ( N
tPA NN N
) ) N
antigen NN N
, , N
tPA NN N
activity NN N
, , N
plasminogen NN N
activator NN N
inhibitor JJ N
type-1 JJ N
activity NN N
( ( N
PAI-1 NNP N
activity NN N
) ) N
and CC N
serum JJ N
D-dimer NNP N
as IN N
a DT N
global JJ N
test NN N
of IN N
fibrinolytic JJ N
activity NN N
. . N

( ( N
2 CD N
) ) N
The DT N
rate NN N
of IN N
achieving VBG N
the DT N
LDL-C JJ N
goal NN N
of IN N
The DT N
National NNP N
Cholesterol NNP N
Education NNP N
Program NNP N
( ( N
NCEP NNP N
) ) N
in IN N
Adult NNP N
Treatment NNP N
Panel NNP N
III NNP N
( ( N
ATP NNP N
III NNP N
) ) N
in IN N
the DT N
combination NN N
therapy NN i
group NN N
was VBD N
73.5 CD N
% NN N
, , N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
atorvastatin NN i
and CC N
niacin JJ i
groups NNS N
( ( N
47.7 CD N
% NN N
and CC N
42.1 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
oral JJ N
hygiene NN N
instructions NNS N
and CC N
ultrasonic JJ N
supragingival NN N
instrumentation NN N
, , N
the DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
for IN N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
CIC NNP N
, , N
scaled VBD N
with IN N
Gracey NNP N
curettes NNS N
; : N
CIUS NNP N
, , N
scaled VBD N
with IN N
ultrasonic JJ N
device NN N
; : N
CDC NNP N
, , N
calculus JJ N
deattachment NN N
with IN N
Gracey NNP N
curettes NNS N
and CC N
brushing VBG N
with IN N
saline JJ N
solution NN N
; : N
and CC N
CDUS NNP N
, , N
calculus JJ N
deattachment NN N
with IN N
ultrasonic JJ N
device NN N
and CC N
brushing VBG N
with IN N
saline JJ N
solution NN N
. . N

Radial JJ N
trabecular NN N
bone NN N
density NN N
showed VBD N
a DT N
significantly RB N
higher JJR N
rate NN N
of IN N
increase NN o
in IN N
group NN N
I PRP N
( ( N
ipriflavone VB N
group NN N
) ) N
than IN N
in IN N
group NN N
II NNP N
( ( N
elcatonin JJ N
group NN N
) ) N
at IN N
the DT N
4th CD N
month NN N
, , N
whereas JJ N
lumbar NN N
spine NN N
BMD NNP N
showed VBD N
more RBR N
pronounced JJ N
increase NN o
in IN N
the DT N
elcatonin NN N
group NN N
than IN N
in IN N
the DT N
ipriflavone NN N
group NN N
throughout IN N
the DT N
study NN N
period NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS N
of IN N
PAI NNP N
activity NN N
in IN N
the DT N
imidapril NN N
group NN N
decreased VBD o
rapidly RB o
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
. . N

Therefore RB N
, , N
a DT N
combined JJ N
parameter NN N
was VBD N
constructed VBN N
showing VBG N
a DT N
more RBR N
prominent JJ N
separation NN N
of IN N
response NN N
: : N
tumors NNS N
with IN N
high JJ N
EGFr NNP N
and CC N
well/moderate JJ N
differentiation NN N
did VBD N
benefit VB N
from IN N
moderate JJ N
acceleration NN N
of IN N
treatment NN N
regarding VBG N
locoregional JJ N
control NN N
, , N
HR NNP N
0.54 CD N
( ( N
0.37-0.78 NN N
) ) N
, , N
whereas NNS N
such JJ N
an DT N
effect NN N
was VBD N
not RB N
seen VBN N
in IN N
tumors NNS N
with IN N
low JJ N
EGFr NNP N
and/or NN N
poor JJ N
differentiation NN N
, , N
HR NNP N
0.8 CD N
( ( N
0.51-1.25 NN N
) ) N
. . N

Incidence NN N
of IN N
the DT N
primary JJ N
endpoint NN N
( ( N
biopsy-proven JJ N
acute NN N
rejection NN N
, , N
BPAR NNP N
; : N
graft NN N
loss NN N
, , N
death NN N
, , N
DGF NNP N
, , N
wound VBD N
healing VBG N
complications NNS N
related VBN N
to TO N
transplant VB N
surgery NN N
or CC N
loss NN N
to TO N
follow-up NN N
) ) N
was VBD N
64.6 CD N
% NN N
and CC N
66.2 CD N
% NN N
in IN N
the DT N
IE NNP N
and CC N
DE NNP N
groups NNS N
, , N
respectively RB N
, , N
at IN N
month NN N
12 CD N
( ( N
P NNP N
= NNP N
0.860 CD N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
angle NN N
between IN N
the DT N
radiographic JJ N
image NN N
of IN N
the DT N
bar NN N
and CC N
the DT N
axial JJ N
inclination NN N
of IN N
the DT N
upper JJ N
first JJ N
premolar NN N
and CC N
molar JJ N
teeth NN N
was VBD N
( ( N
5.34 CD N
and CC N
2.73 CD N
degrees NNS N
for IN N
the DT N
right JJ N
premolars NNS N
, , N
5.17 CD N
and CC N
2.28 CD N
degrees NNS N
for IN N
the DT N
left NN N
premolars VBZ N
, , N
11.83 CD N
and CC N
3.73 CD N
degrees NNS N
for IN N
the DT N
right JJ N
molars NNS N
, , N
and CC N
9.75 CD N
and CC N
5.64 CD N
degrees NNS N
for IN N
the DT N
left JJ N
molars NNS N
in IN N
the DT N
banded JJ N
and CC N
bonded VBD N
groups NNS N
, , N
respectively RB N
. . N

Formulations NNS N
of IN N
Aloe NNP N
vera NN N
, , N
Chamomilla NNP N
recutita NN N
, , N
Hamamelis NNP N
virginiana NN N
, , N
Melissa NNP N
officinalis NN N
, , N
Mentha NNP N
arvensis NN N
, , N
Melaleuca NNP N
alternifolia NN N
, , N
Coriandrum NNP N
sativum NN N
as RB N
well RB N
as IN N
1 CD N
% NN N
hydrocortisone NN N
acetate NN N
and CC N
0.1 CD N
% NN N
betamethasone NN N
valerate NN N
as IN N
positive JJ N
controls NNS N
and CC N
unguentum JJ N
leniens NNS N
as IN N
vehicle NN N
control NN N
were VBD N
applied VBN N
under IN N
occlusion NN N
on IN N
the DT N
irradiated JJ N
areas NNS N
and CC N
on IN N
non-irradiated JJ N
area NN N
on IN N
the DT N
contralateral JJ N
side NN N
. . N

Subjects NNS N
received VBD N
either RB N
6 CD N
% NN N
hydrogen NN N
peroxide IN N
whitening VBG N
strips NNS N
( ( N
Crest NNP N
Whitestrips NNP N
) ) N
and CC N
an DT N
anticavity NN N
toothpaste NN N
( ( N
Crest NNP N
Cavity NNP N
Protection NNP N
) ) N
, , N
placebo JJ N
strips NNS N
and CC N
a DT N
sodium NN N
fluoride NN N
( ( N
NaF NNP N
) ) N
whitening VBG N
dentifrice NN N
( ( N
Mentadent NNP N
Whitening NNP N
Toothpaste NNP N
) ) N
or CC N
placebo VBN N
strips NNS N
and CC N
a DT N
sodium NN N
monofluorophosphate NN N
( ( N
MFP NNP N
) ) N
whitening VBG N
dentifrice NN N
( ( N
Rembrandt NNP N
Low NNP N
Abrasion NNP N
Whitening NNP N
Toothpaste NNP N
) ) N
. . N

RESULTS NN N
In IN N
the DT N
portal JJ N
venous JJ N
phase NN N
, , N
correlation NN N
coefficients NNS N
for IN N
the DT N
correlation NN N
of IN N
change NN N
in IN N
CT NNP N
number NN N
per IN N
gram NN N
of IN N
iodine NN N
with IN N
TBW NNP N
for IN N
the DT N
aorta NN N
and CC N
liver NN N
were VBD N
-0.71 NNP N
and CC N
-0.79 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
TBW NNP N
group NN N
; : N
-0.80 CC N
and CC N
-0.86 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
LBW NNP N
group NN N
; : N
and CC N
-0.68 VB N
and CC N
-0.66 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
BV NNP N
group NN N
. . N

The DT N
immunological JJ N
response NN N
was VBD N
measured VBN N
by IN N
means NNS N
of IN N
leukocyte NN N
counts NNS N
, , N
HLA-DR NNP N
expression NN N
on IN N
monocytes NNS N
, , N
the DT N
acute-phase JJ N
response NN N
by IN N
means NNS N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
, , N
and CC N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
, , N
and CC N
the DT N
stress NN N
response NN N
was VBD N
measured VBN N
by IN N
cortisol NN N
, , N
growth NN N
hormone NN N
, , N
and CC N
prolactin NN i
. . N

At IN N
the DT N
3-month JJ N
follow-up JJ N
assessment NN N
, , N
PSE NNP N
mothers NNS N
were VBD N
significantly RB N
less RBR N
likely JJ N
than IN N
those DT N
serving VBG N
as RB N
controls NNS N
to TO N
have VB N
clinically RB N
significant JJ N
parental JJ N
stress NN N
( ( N
3.8 CD N
% NN N
vs JJ N
29.3 CD N
% NN N
; : N
adjusted VBN N
relative JJ N
risk NN N
[ NNP N
aRR NN N
] NNP N
, , N
0.17 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.04 CD N
to TO N
0.65 CD N
) ) N
. . N

Irritability NNP N
subscale NN N
score NN N
significantly RB N
decreased VBD o
during IN o
this DT N
trial NN N
in IN N
both DT N
groups NNS N
( ( N
buspirone NN N
group NN N
: : N
declined VBD N
from IN N
25.7 CD N
[ NNS N
SD NNP N
5.7 CD N
] NN N
to TO N
16.3 CD N
[ NNS N
SD NNP N
8.5 CD N
] NNP N
; : N
placebo CC N
group NN N
: : N
declined VBD N
from IN N
24.7 CD N
[ NNS N
SD NNP N
7.6 CD N
] NN N
to TO N
18.2 CD N
[ NNS N
SD NNP N
7.7 CD N
] NN N
) ) N
. . N

Among IN N
group NN N
A NNP N
patients NNS p
, , N
the DT N
adverse JJ N
events NNS N
risk NN N
was VBD N
greater JJR N
in IN N
those DT N
randomised VBN N
to TO N
stenting VBG N
( ( N
odds JJ N
ratios NNS N
6.603 CD N
v NN N
1.197 CD N
, , N
p NN N
= NNP N
0.046 CD N
) ) N
, , N
whereas IN N
there EX N
was VBD N
no DT N
difference NN N
in IN N
risk NN N
if IN N
the DT N
group NN N
was VBD N
analysed VBN N
according VBG N
to TO N
whether IN N
the DT N
CFVR NNP N
was VBD N
< JJ N
2.5 CD N
or CC N
> VB N
/= CD N
2.5 CD N
after IN N
balloon NN N
angioplasty NN N
. . N

Using VBG N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
( ( N
CDC NNP N
) ) N
standardized VBD N
scores NNS N
, , N
both DT N
weight NN N
and CC N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
increased VBD o
with IN o
risperidone NN i
during IN N
the DT N
acute JJ N
trial NN N
( ( N
0.5 CD N
and CC N
0.6 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
risperidone NN i
; : N
0.0 CD N
and CC N
0.1 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
placebo NN N
) ) N
and CC N
into IN N
open-label JJ N
extension NN N
( ( N
0.19 CD N
and CC N
0.16 CD N
SDs NNP N
, , N
respectively RB N
) ) N
, , N
although IN N
the DT N
amount NN N
of IN N
gain NN N
decelerated VBN N
with IN N
time NN N
. . N

Eradication NN N
or CC N
presumed VBN N
eradication NN N
was VBD N
detected VBN N
for IN N
97.3 CD N
% NN N
and CC N
96.3 CD N
% NN N
of IN N
S. NNP N
pneumoniae NN N
, , N
85.0 CD N
% NN N
and CC N
90.5 CD N
% NN N
of IN N
H. NNP N
influenzae NN N
, , N
88.9 CD N
% NN N
and CC N
90.9 CD N
% NN N
of IN N
S. NNP N
aureus NN N
and CC N
100.0 CD N
% NN N
and CC N
83.3 CD N
% NN N
of IN N
M. NNP N
catarrhalis NN N
in IN N
faropenem JJ N
daloxate NN N
and CC N
cefuroxime NN N
axetil NN N
recipients NNS N
, , N
respectively RB N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Clinical JJ N
Global NNP N
Impressions NNP N
Improvement NNP N
and CC N
Severity NNP N
Scales NNP N
( ( N
CGI-I NNP N
and CC N
CGI-S NNP N
) ) N
; : N
secondary JJ N
outcomes NNS N
were VBD N
the DT N
Preschool NNP N
Language NNP N
Scale-4 NNP N
( ( N
PLS-4 NNP N
) ) N
, , N
Social NNP N
Responsiveness NNP N
Scale NNP N
( ( N
SRS NNP N
) ) N
, , N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
, , N
and CC N
Vineland NNP N
Adaptive NNP N
Behavior NNP N
Scales NNP N
( ( N
Vineland NNP N
) ) N
. . N

Fenofibrate NNP N
caused VBD N
a DT N
significant JJ N
decrease NN o
in IN N
serum JJ N
triglyceride JJ N
concentration NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
associated VBN N
with IN N
a DT N
decrease NN o
in IN N
plasma NN N
malondialdehyde NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
an DT N
increase NN o
in IN N
plasma JJ N
PAI-1 NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
P-selectin NNP i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
concentrations NNS N
. . N

RESULTS NNP N
After IN N
12 CD N
months NNS N
, , N
bone JJ N
mineral JJ N
density NN N
increased VBN o
by IN N
1.2 CD N
% NN N
at IN N
the DT N
spine NN N
and CC N
1.3 CD N
% NN N
at IN N
the DT N
hip NN N
in IN N
women NNS N
on IN N
risedronate NN N
vs. FW N
significant JJ N
decreases NNS o
for IN N
women NNS N
in IN N
the DT N
placebo NN N
group NN N
of IN N
0.9 CD N
% NN N
at IN N
the DT N
spine NN N
and CC N
0.8 CD N
% NN N
at IN N
the DT N
hip NN N
( ( N
P NNP N
< NNP N
0.01 CD N
, , N
difference NN N
between IN N
groups NNS N
) ) N
. . N

The DT N
PC NN N
7000 CD N
and CC N
3DE CD N
were VBD N
equally RB N
more RBR N
effective JJ N
in IN N
plaque NN N
removal NN N
than IN N
the DT N
SA NNP N
, , N
at IN N
all DT N
tooth DT N
areas NNS N
, , N
reducing VBG N
plaque NN N
by IN N
59.0 CD N
% NN N
, , N
59.7 CD N
% NN N
and CC N
51.8 CD N
% NN N
, , N
respectively RB N
on IN N
whole JJ N
mouth NN N
surfaces NNS N
, , N
and CC N
by IN N
67.5 CD N
% NN N
, , N
67.8 CD N
% NN N
and CC N
59.4 CD N
% NN N
, , N
respectively RB N
on IN N
approximal JJ N
surfaces NNS N
. . N

Moreover RB N
, , N
MIP NNP N
and CC N
MEP NNP N
significantly RB N
improved VBD N
only RB N
after IN N
magnesium NN N
administration NN N
( ( N
change NN N
in IN N
MIP NNP N
: : N
11 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.5 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
change NN N
in IN N
MEP NNP N
: : N
11.9 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.8 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

On IN N
multivariate JJ N
analysis NN N
of IN N
the DT N
added JJ N
diagnostic JJ N
role NN N
of IN N
RapSP-LS NNP N
or CC N
RapLSI NNP N
on IN N
top NN N
of IN N
clinical JJ N
, , N
electrocardiographic JJ N
, , N
and CC N
conventional JJ N
echocardiographic JJ N
parameters NNS N
, , N
addition NN N
of IN N
RapLSI NNP N
produced VBD N
only RB N
borderline JJ N
increase NN o
in IN N
area NN N
under IN N
the DT N
curve NN N
of IN N
the DT N
multivariate NN N
model NN N
( ( N
P=0.05 NNP N
) ) N
, , N
whereas JJ N
addition NN N
of IN N
RapSP-LS NNP N
significantly RB N
increased VBD o
it PRP o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
odds NNS N
ratio NN N
associated VBN N
with IN N
the DT N
fibre NN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
in IN N
participants NNS N
with IN N
baseline NN N
dietary JJ N
calcium NN N
intake NN N
above IN N
the DT N
median JJ N
than IN N
in IN N
those DT N
with IN N
intake JJ N
below IN N
the DT N
median NN N
( ( N
interaction JJ N
test NN N
, , N
p=0.028 NN N
) ) N
INTERPRETATION NNP N
Supplementation NNP N
with IN N
fibre NN N
as IN N
ispaghula JJ N
husk NN N
may MD N
have VB N
adverse JJ N
effects NNS N
on IN N
colorectal JJ N
adenoma NN N
recurrence NN N
, , N
especially RB N
in IN N
patients NNS p
with IN N
high JJ N
dietary JJ N
calcium NN N
intake NN N
. . N

RESULTS VB N
The DT N
physical JJ N
activity NN N
group NN N
improved VBD N
in IN N
sleep JJ N
quality NN N
on IN N
the DT N
global JJ N
PSQI NNP N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
, , N
sleep JJ N
latency NN N
( ( N
p=.049 NN N
) ) N
, , N
sleep JJ N
duration NN N
( ( N
p=.04 NN N
) ) N
, , N
daytime JJ N
dysfunction NN N
( ( N
p=.027 NN N
) ) N
, , N
and CC N
sleep JJ N
efficiency NN N
( ( N
p=.036 NN N
) ) N
PSQI NNP N
sub-scores NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
obtained VBN N
with IN N
regard NN N
to TO N
examination NN N
quality NN N
( ( N
180 CD N
vs. FW N
165 CD N
segments NNS N
free JJ N
from IN N
stools NNS N
and CC N
fluid NN N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
and CC N
overall JJ i
diagnostic JJ N
accuracy NN N
( ( N
16/17 CD N
colonic JJ N
polyps NNS N
detected VBN N
in IN N
group NN N
A NNP N
and CC N
12/13 CD N
in IN N
group NN N
B NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
. . N

RESULTS JJ N
Analysis NNP N
of IN N
grip NN N
strength NN N
data NNS N
revealed VBD N
a DT N
statistically RB N
significant JJ N
increase NN o
in IN N
strength NN N
within IN N
the DT N
treatment NN N
group NN N
after IN N
the DT N
first JJ N
intervention NN N
( ( N
6.95 CD N
% NN N
right NN N
, , N
12.61 CD N
% NN N
left NN N
) ) N
as IN N
compared VBN N
with IN N
the DT N
second JJ N
( ( N
11.53 CD N
% NN N
right NN N
, , N
17.02 CD N
% NN N
left NN N
) ) N
and CC N
the DT N
third JJ N
interventions NNS N
( ( N
10.53 CD N
% NN N
right NN N
, , N
16.81 CD N
% NN N
left VBD N
) ) N
. . N

As IN N
compared VBN N
with IN N
placebo NN N
, , N
angiotensin NN N
II NNP N
infusion NN N
alone RB N
caused VBD N
significant JJ N
reductions NNS N
in IN N
absolute JJ N
rate NN N
of IN N
sodium NN N
excretion NN N
, , N
fractional JJ N
sodium NN N
excretion NN N
, , N
urine JJ N
flow NN N
rate NN N
and CC N
effective JJ N
renal JJ N
plasma NN N
flow NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
vs NN N
placebo NN N
) ) N
but CC N
had VBD N
no DT N
effect NN N
on IN N
glomerular JJ N
filtration NN N
rate NN N
. . N

Bradykinin-induced JJ N
release NN N
of IN N
active JJ N
t-PA NN N
was VBD N
more RBR N
than IN N
doubled VBD N
during IN N
treatment NN N
with IN N
quinapril NN N
in IN N
comparison NN N
to TO N
placebo VB N
or CC N
losartan VB N
( ( N
two-way JJ N
ANOVA NNP N
: : N
p NN N
< VBZ N
0.003 CD N
for IN N
treatment NN N
group NN N
, , N
p VBP N
< $ N
0.001 CD N
for IN N
t-PA JJ N
response NN N
and CC N
p NN N
= NNP N
ns NN N
for IN N
interaction NN N
) ) N
, , N
whereas IN N
the DT N
substance NN N
P NNP N
response NN N
was VBD N
unaffected VBN N
. . N

In IN N
the DT N
forced-air JJ N
group NN N
, , N
after IN N
the DT N
initial JJ N
significant JJ N
decrease NN o
( ( N
p JJ N
= $ N
0.01 CD N
vs. FW N
baseline NN N
) ) N
, , N
core JJ N
temperature NN N
progressively RB N
increased VBD o
to TO o
35.8 CD N
+/- JJ N
0.6 CD N
degrees NNS N
C NNP N
, , N
which WDT N
was VBD N
similar JJ N
to TO N
preoperative VB N
values NNS N
and CC N
significantly RB N
higher JJR N
than IN N
either CC N
the DT N
control NN N
or CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
changes NNS N
in IN N
bone NN N
density NN N
were VBD N
consistent JJ N
with IN N
the DT N
changes NNS N
in IN N
biochemical JJ N
indices NNS N
for IN N
bone NN N
metabolism NN N
; : N
DMPA NNP N
users NNS N
showed VBD N
signs NNS N
of IN N
increased VBN o
bone NN N
turnover NN N
and CC N
users NNS N
of IN N
levonorgestrel NN N
showed VBD N
increased JJ o
bone NN N
formation NN N
with IN N
increased JJ o
levels NNS N
of IN N
both DT N
alkaline JJ N
phosphatase NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
osteocalcin $ i
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
. . N

FDRs NNS N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB N
if IN N
they PRP N
were VBD N
female JJ N
( ( N
OR=1.77 NNP N
; : N
CI=1.1-.85 NNP N
) ) N
and CC N
parents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB N
if IN N
the DT N
case NN N
had VBD N
been VBN N
diagnosed VBN N
more RBR N
recently RB N
( ( N
OR=3.3 NNP N
; : N
CI=1.9-5.93 NNP N
) ) N
, , N
if IN N
the DT N
parent NN N
was VBD N
partnered VBN N
( ( N
OR=4.37 NNP N
; : N
CI=1.86-10.26 NNP N
) ) N
, , N
and CC N
if IN N
the DT N
parent NN N
lived VBD N
in IN N
the DT N
same JJ N
city NN N
as IN N
the DT N
case NN N
( ( N
OR=2.88 NNP N
; : N
CI=1.08-7.68 NNP N
) ) N
. . N

The DT N
average NN N
of IN N
the DT N
maximum JJ N
pressure NN N
rises VBZ N
above IN N
the DT N
preoperative JJ N
level NN N
over IN N
the DT N
24 CD N
hour NN N
period NN N
was VBD N
greatest JJS N
for IN N
the DT N
group NN N
receiving VBG N
acetazolamide IN N
only RB N
at IN N
8.9 CD N
mm NN N
Hg NNP N
; : N
for IN N
the DT N
acetylcholine NN N
group NN N
the DT N
average NN N
maximum JJ N
rise NN N
was VBD N
6.3 CD N
mm JJ N
Hg NNP N
; : N
while IN N
the DT N
combined JJ N
treatment NN N
group NN N
showed VBD N
a DT N
decrease NN o
of IN N
0.7 CD N
mm NN N
Hg NNP N
. . N

The DT N
patients NNS p
were VBD N
evaluated VBN N
for IN N
heart NN N
rate NN N
and CC N
mean VB N
arterial JJ N
pressure NN N
, , N
oxygen NN N
saturation NN N
, , N
visual JJ N
analogue NN N
score NN N
( ( N
VAS NNP N
) ) N
, , N
verbal JJ N
rating NN N
scale NN N
( ( N
VRS NNP N
) ) N
, , N
rescue NN N
analgesic JJ N
requirements NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
side NN N
effects NNS N
and CC N
time NN N
to TO N
first JJ N
mobilisation NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
4th CD N
, , N
6th CD N
, , N
12th CD N
and CC N
24th CD N
hours NNS N
postoperatively RB N
. . N

RESULTS VB N
The DT N
density NN N
, , N
motility NN N
and CC N
morphology NN N
of IN N
sperm NN N
were VBD N
improved VBN N
and CC N
sperm JJ N
deformity NN N
rate NN N
was VBD N
significantly RB N
decreased VBN o
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
the DT N
effects NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
better JJR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Among IN N
participants NNS N
not RB N
assigned VBN N
to TO N
receive VB N
physical JJ N
therapy NN i
or CC N
modalities NNS N
, , N
the DT N
estimated JJ N
improvements NNS N
in IN N
pain NN N
and CC N
disability NN N
and CC N
18-month JJ N
risk NN N
of IN N
complete JJ N
remission NN N
were VBD N
a DT N
little JJ N
greater JJR N
in IN N
the DT N
chiropractic JJ N
group NN N
than IN N
in IN N
the DT N
medical JJ N
group NN N
( ( N
adjusted VBN N
RR NNP N
of IN N
remission NN N
= NNP N
1.29 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-2.07 NN N
) ) N
. . N

The DT N
combination NN N
treatment NN N
group NN N
showed VBD N
a DT N
trend NN N
to TO N
outperform VB N
other JJ N
active JJ N
treatment NN N
groups NNS N
, , N
with IN N
fewer JJR N
dropouts NNS N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
treatment NN N
responders NNS N
achieving VBG N
clinically RB N
significant JJ N
changes NNS N
( ( N
63.38 CD N
% NN N
normative JJ N
sleep JJ N
efficiency NN N
criterion NN N
of IN N
> $ N
85 CD N
% NN N
and CC N
84.62 CD N
% NN N
, , N
sleep JJ N
onset NN N
latency NN N
< VBD N
30 CD N
min NN N
) ) N
. . N

The DT N
levels NNS N
of IN N
P-selectin NNP i
, , N
tPA NN N
antigen NN N
, , N
and CC N
PAI-1 JJ N
activity NN N
were VBD N
all DT N
significantly RB N
higher JJR N
in IN N
stroke NN N
patients NNS p
compared VBN N
with IN N
controls NNS N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
; : N
the DT N
level NN N
of IN N
tPA JJ N
activity NN N
was VBD N
significantly RB N
lower JJR N
in IN N
patients NNS p
than IN N
that DT N
in IN N
controls NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
. . N

The DT N
actuarial JJ N
probability NN N
of IN N
a DT N
recurrence NN N
of IN N
arrhythmia NN N
after IN N
a DT N
prediction NN N
of IN N
drug NN N
efficacy NN N
by IN N
either DT N
strategy NN N
was VBD N
significantly RB N
lower JJR N
for IN N
patients NNS p
treated VBN N
with IN N
sotalol NN i
than IN N
for IN N
patients NNS p
treated VBN N
with IN N
the DT N
other JJ N
drugs NNS N
( ( N
risk NN N
ratio NN N
, , N
0.43 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.29 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
primary JJ N
safety NN N
end NN N
point NN N
of IN N
significant JJ N
adverse JJ N
events NNS N
during IN N
the DT N
12-month JJ N
follow-up NN N
was VBD N
significantly RB N
higher JJR N
for IN N
SA NNP N
than IN N
for IN N
CA NNP N
( ( N
n=21 JJ N
[ RB N
34.4 CD N
% NN N
] JJ N
versus NN N
n=10 NN N
[ VBD N
15.9 CD N
% NN N
] NN N
; : N
P=0.027 NNP N
) ) N
, , N
driven VBN N
mainly RB N
by IN N
procedural JJ N
complications NNS N
such JJ N
as IN N
pneumothorax NN i
, , N
major JJ N
bleeding NN N
, , N
and CC N
the DT N
need NN N
for IN N
pacemaker NN N
. . N

These DT N
results NNS N
were VBD N
not RB N
significantly RB N
altered VBN N
in IN N
analyses NNS N
that WDT N
( ( N
in IN N
addition NN N
to TO N
the DT N
matching JJ N
variables NNS N
of IN N
age NN N
and CC N
smoking NN N
status NN N
) ) N
controlled VBD N
for IN N
lipid JJ N
parameters NNS N
, , N
homocysteine NN i
, , N
and CC N
multiple JJ N
cardiac JJ N
risk NN N
factors NNS N
( ( N
relative JJ N
risk NN N
for IN N
highest JJS N
versus NN N
lowest JJS N
quartile NN N
2.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.79 CD N
to TO N
8.83 CD N
; : N
P NNP N
for IN N
trend=0.03 NN N
) ) N
. . N

RESULTS NNP N
CTTH NNP N
score NN N
was VBD N
all DT N
reduced VBN N
after IN N
treatment NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
the DT N
score NN N
in IN N
the DT N
sticking VBG N
needling VBG N
group NN N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
acupuncture NN N
group NN N
( ( N
2.38 CD N
+/- JJ N
1.22 CD N
vs JJ N
4.16 CD N
+/- JJ N
2.54 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

METHODS NNP N
Thirteen NNP N
emmetropic JJ N
subjects NNS N
were VBD N
randomly RB N
fitted VBN N
with IN N
two CD N
different JJ N
tinted VBN N
Nike NNP N
Maxsight NNP N
( ( N
Bausch NNP N
& CC N
Lomb NNP N
, , N
Rochester NNP N
, , N
NY NNP N
, , N
USA NNP N
) ) N
CL NNP N
in IN N
one CD N
eye NN N
, , N
while IN N
the DT N
contralateral JJ N
eye NN N
was VBD N
fitted VBN N
with IN N
a DT N
clear JJ N
lens NNS N
made VBN N
of IN N
the DT N
same JJ N
material NN N
( ( N
Optima NNP N
38 CD N
, , N
Bausch NNP N
& CC N
Lomb NNP N
) ) N
. . N

Median JJ N
total JJ N
sleep JJ N
time NN N
increased VBN o
by IN N
25.75-66.75min JJ N
, , N
vs. FW N
25.50 CD N
( ( N
p NN N
< VBZ N
0.05 CD N
for IN N
0.50mg/d CD N
) ) N
, , N
and CC N
median JJ N
time NN N
in IN N
stages NNS N
2-4/rapid JJ N
eye NN N
movement NN N
( ( N
REM NNP N
) ) N
sleep NN N
increased VBN o
by IN N
37.00-68.00min JJ N
, , N
vs. FW N
26.75 CD N
( ( N
p NN N
< VBZ N
0.05 CD N
for IN N
0.50mg/d CD N
) ) N
. . N

RESULTS NNP N
Ovulation NNP N
( ( N
89.09 CD N
% NN N
) ) N
and CC N
pregnancy NN N
( ( N
54.55 CD N
% NN N
) ) N
rates NNS N
were VBD N
higher JJR N
in IN N
group NN N
B. NNP N
Ovulation NNP N
( ( N
74.55 CD N
% NN N
) ) N
and CC N
pregnancy NN N
( ( N
29.09 CD N
% NN N
) ) N
rates NNS N
were VBD N
also RB N
satisfactory JJ N
in IN N
group NN N
C NNP N
but CC N
a DT N
dose NN N
of IN N
rFSH JJ N
requirement NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

However RB N
, , N
subjects NNS N
in IN N
the DT N
mCIT+mental JJ N
practice NN N
group NN N
exhibited VBD N
significantly RB N
larger JJR N
changes NNS N
on IN N
both DT N
movement NN N
measures NNS N
after IN N
intervention NN N
: : N
Action NNP N
Research NNP N
Arm NNP N
Test NNP N
, , N
+15.4-point JJ N
change NN N
versus IN N
+8.4-point JJ N
change NN N
for IN N
mCIT NN N
only RB N
subjects VBZ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
Fugl-Meyer NNP N
, , N
+7.8-point JJ N
change NN N
versus IN N
+4.1-point JJ N
change NN N
for IN N
the DT N
mCIT NN N
only RB N
subjects VBZ N
( ( N
P=0.01 NNP N
) ) N
. . N

By IN N
week NN N
12 CD N
post-release NN N
, , N
88.4 CD N
% NN N
of IN N
the DT N
BCM NNP N
arm NN N
and CC N
78.3 CD N
% NN N
of IN N
the DT N
SOC NNP N
arm NN N
had VBD N
at IN N
attended VBN N
at IN N
least JJS N
one CD N
medical JJ N
appointment NN N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
, , N
increasing VBG N
in IN N
both DT N
arms NNS N
at IN N
week NN N
24-90.7 CD N
% NN N
with IN N
BCM NNP N
and CC N
89.1 CD N
% NN N
with IN N
SOC NNP N
( ( N
P NNP N
> NNP N
0.5 CD N
) ) N
. . N

RESULTS NNP N
Dapsone NNP N
gel-treated JJ N
patients NNS p
achieved VBN N
superior JJ N
results NNS N
in IN N
terms NNS N
of IN N
the DT N
investigator NN N
's POS N
global JJ N
acne NN N
assessment NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
the DT N
mean JJ N
percentage NN N
reduction NN N
in IN N
inflammatory NN N
, , N
noninflammatory NN N
, , N
and CC N
total JJ N
lesion NN N
counts NNS N
( ( N
all DT N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
week NN N
12 CD N
. . N

beta-Carotene NN N
resulted VBD N
in IN N
a DT N
statistically RB N
significant JJ N
increase NN o
in IN N
total JJ N
WBC NNP N
count NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
% NN N
change NN N
in IN N
CD4 NNP N
count NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
% NN N
change NN N
in IN N
CD4/CD8 NNP N
ratios NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
compared VBN N
to TO N
placebo VB N
. . N

When WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
time NN N
to TO N
analgesic VB N
need NN N
was VBD N
increased VBN o
and CC N
total JJ N
analgesic JJ N
consumption NN N
was VBD N
reduced VBN N
in IN N
the DT N
magnesium NN N
group NN N
( ( N
meperidine JJ N
consumption NN N
60.0 CD N
+/- JJ N
73.1 CD N
mg NNS N
control NN N
group NN N
, , N
31.8 CD N
+/- JJ N
30.7 CD N
mg JJ N
magnesium NN N
group NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Loads NNS N
ranged VBD N
in IN N
magnitude NN N
from IN N
imperceptible JJ N
( ( N
R0/E0 NNP N
) ) N
through IN N
just RB N
perceptible JJ N
( ( N
R1/E1 NNP N
) ) N
to TO N
large JJ N
( ( N
R2/E2 NNP N
) ) N
and CC N
resulted VBN N
in IN N
respiratory NN N
pattern NN N
responses NNS N
that WDT N
were VBD N
due JJ N
to TO N
reflex JJ N
responses NNS N
alone RB N
( ( N
R0/E0 NNP N
) ) N
or CC N
to TO N
a DT N
combination NN N
of IN N
reflex JJ N
responses NNS N
and CC N
behavioral JJ N
reactions NNS N
to TO N
the DT N
perception NN N
of IN N
impeded JJ N
breathing NN N
( ( N
R1/E1 NNP N
and CC N
R2/E2 NNP N
) ) N
. . N

The DT N
median JJ N
effect NN N
size NN N
in IN N
this DT N
trial NN N
was VBD N
-0.015 NNP N
( ( N
seizure JJ N
rate NN N
increased VBN o
by IN N
1.5 CD N
% NN N
in IN N
the DT N
phenytoin NN N
group NN N
) ) N
, , N
95 CD N
% NN N
probability NN N
interval NN N
-0.127 NN N
to TO N
0.091 CD N
( ( N
12.7 CD N
% NN N
higher JJR N
rate NN N
of IN N
posttraumatic JJ N
seizures NNS N
to TO N
a DT N
9.1 CD N
% NN N
lower JJR N
rate NN N
of IN N
posttraumatic JJ N
seizures NNS N
with IN N
phenytoin NN N
) ) N
. . N

There EX N
was VBD N
significantly RB N
more JJR N
intracardiac JJ N
gas NN N
noted VBD N
on IN N
intraoperative JJ N
transesophageal NN N
echocardiography NN N
in IN N
all DT N
cardiac JJ N
chambers NNS N
( ( N
left JJ N
atrium NN N
, , N
left VBD N
ventricle NN N
, , N
and CC N
aorta NN N
) ) N
at IN N
all DT N
measured VBN N
times NNS N
( ( N
after IN N
crossclamp NN N
removal NN N
, , N
during IN N
weaning VBG N
from IN N
cardiopulmonary JJ N
bypass NN N
, , N
and CC N
at IN N
declaration NN N
of IN N
adequate JJ N
deairing NN N
by IN N
the DT N
anesthetist NN N
) ) N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
carbon NN N
dioxide NN N
group NN N
( ( N
P NNP N
< NNP N
.04 NNP N
) ) N
. . N

Immediately RB N
before IN N
and CC N
after IN N
the DT N
five CD N
treatment NN N
sessions NNS N
and CC N
7 CD N
days NNS N
after IN N
treatment NN N
ended VBN N
, , N
both DT N
patient NN N
and CC N
physician NN N
measured VBD N
the DT N
degree NN N
of IN N
pain NN N
using VBG N
a DT N
categoric JJ N
scale NN N
( ( N
no DT N
pain NN N
, , N
slight JJ N
pain NN N
, , N
intermediate JJ N
pain NN N
, , N
strong JJ N
pain NN N
, , N
and CC N
very RB N
strong JJ N
pain NN N
) ) N
and CC N
evaluated VBN N
pain NN N
intensity NN N
using VBG N
the DT N
Scott NNP N
and CC N
Huskisson NNP N
Visual NNP N
Analogue NNP N
Scale NNP N
( ( N
VAS NNP N
) ) N
. . N

There EX N
were VBD N
also RB N
differences NNS N
in IN N
Cho/Lip NNP N
between IN N
the DT N
control NN N
and CC N
cirrhosis NN N
groups NNS N
, , N
the DT N
control NN N
and CC N
HCC NNP N
groups NNS N
, , N
and CC N
the DT N
cirrhosis NN N
and CC N
HCC NNP N
groups NNS N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
.H-MRS NN N
followed VBN N
by IN N
the DT N
analysis NN N
with IN N
LCModel NNP N
can MD N
be VB N
used VBN N
to TO N
measure VB N
changes NNS N
in IN N
hepatic JJ N
metabolite NN N
levels NNS N
in IN N
patients NNS p
with IN N
liver JJ N
cirrhosis NN N
secondary JJ N
to TO N
chronic VB N
hepatitis NN N
B NNP N
and CC N
HCC NNP N
. . N

METHODS NNP N
Drawing VBG N
from IN N
South NNP N
Texas NNP N
cancer NN N
registries NNS N
, , N
444 CD N
Hispanic JJ N
men NNS N
and CC N
women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
experimental JJ N
conditions NNS N
: : N
standard JJ N
direct-mailed JJ N
procedures NNS N
( ( N
X1 NNP N
) ) N
, , N
X1 NNP N
plus CC N
culturally RB N
tailored JJ N
materials NNS N
( ( N
X2 NNP N
) ) N
, , N
and CC N
X2 NNP N
plus CC N
interpersonal JJ N
phone NN N
contact NN N
( ( N
X3 NNP N
) ) N
. . N

RESULTS VB N
The DT N
median JJ N
duration NN N
of IN N
survival NN N
was VBD N
20.3 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
bevacizumab NN i
, , N
as IN N
compared VBN N
with IN N
15.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
placebo NN N
, , N
corresponding VBG N
to TO N
a DT N
hazard NN N
ratio NN N
for IN N
death NN N
of IN N
0.66 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Measurements NNS N
were VBD N
made VBN N
of IN N
oxygen NN N
consumption NN N
( ( N
VO2 NNP N
) ) N
, , N
carbon NN N
dioxide NN N
production NN N
( ( N
VCO2 NNP N
) ) N
, , N
minute JJ N
ventilation NN N
( ( N
VE NNP N
) ) N
, , N
tidal JJ N
volume NN N
( ( N
VT NNP N
) ) N
, , N
respiratory JJ N
frequency NN N
( ( N
fR NN N
) ) N
, , N
inspiratory JJ N
and CC N
expiratory JJ N
time NN N
( ( N
TI NNP N
, , N
TE NNP N
) ) N
and CC N
mean JJ N
inspiratory NN N
flow NN N
( ( N
VT/TI NNP N
) ) N
using VBG N
a DT N
non-invasive JJ N
canopy-computer-spirometer NN N
system NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
two CD N
solutions NNS N
, , N
lactated VBD N
Ringer NNP N
's POS N
( ( N
LR NNP N
) ) N
and CC N
a DT N
balanced JJ N
salt NN N
solution NN N
( ( N
BSS NNP N
Plus NNP N
, , N
Alcon NNP N
Laboratories NNPS N
, , N
Ft. NNP N
Worth NNP N
, , N
TX NNP N
) ) N
, , N
compared VBN N
with IN N
normal JJ N
saline JJ N
solution NN N
( ( N
NSS NNP N
) ) N
, , N
for IN N
ocular JJ N
irrigation NN N
in IN N
healthy JJ N
adult NN N
volunteers NNS N
with IN N
and CC N
without IN N
the DT N
Morgan NNP N
therapeutic JJ N
lens NNS N
( ( N
MTL NNP N
) ) N
. . N

The DT N
average JJ N
interval NN N
from IN N
start NN N
of IN N
induction NN N
to TO N
vaginal JJ N
delivery NN N
was VBD N
1 CD N
hour NN N
shorter NN N
in IN N
the DT N
misoprostol NN N
group NN N
( ( N
1296.7 CD N
+/- JJ N
722.1 CD N
minutes NNS N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN N
group NN N
( ( N
1360.0 CD N
+/- JJ N
792.0 CD N
minutes NNS N
) ) N
, , N
but CC N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.97 CD N
) ) N
. . N

RESULTS NNP N
Both NNP N
the DT N
beverage NN N
aroma NN N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
and CC N
beverage JJ N
temperature NN N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
had VBD N
significant JJ N
and CC N
positive JJ N
effects NNS N
on IN N
performance NN N
, , N
which WDT N
was VBD N
considerably RB N
better RBR N
with IN N
ice-slush JJ N
than IN N
with IN N
a DT N
neutral JJ N
temperature NN N
beverage NN N
, , N
whatever WDT N
the DT N
aroma NN N
( ( N
P NNP N
< NNP N
0.002 CD N
) ) N
, , N
and CC N
with IN N
menthol JJ N
vs JJ N
non-menthol NN N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
number NN N
of IN N
episodes NNS N
of IN N
angina NN N
was VBD N
decreased VBN o
by IN N
D NNP N
and CC N
unchanged JJ N
by IN N
P NNP N
, , N
while IN N
eight CD N
out IN N
of IN N
the DT N
11 CD N
failures NNS N
with IN N
P NNP N
were VBD N
immediate JJ N
successes NNS N
when WRB N
treatment NN N
was VBD N
replaced VBN N
with IN N
D. NNP N
These DT N
results NNS N
suggest VBP N
that IN N
D NNP N
is VBZ N
preferable JJ N
to TO N
P VB N
for IN N
management NN N
of IN N
unstable JJ N
angina NNS N
in IN N
patients NNS p
with IN N
angina NN N
which WDT N
is VBZ N
exclusively RB N
spontaneous JJ N
. . N

Circulating VBG N
25-hydroxyvitamin JJ N
D3 NNP N
( ( N
25 CD N
[ NNP N
OH NNP N
] NNP N
D NNP N
) ) N
, , N
the DT N
most RBS N
commonly RB N
used JJ N
index NN N
of IN N
vitamin NN N
D NNP N
status NN N
, , N
is VBZ N
converted VBN N
to TO N
the DT N
active JJ N
hormone NN N
1,25 CD N
dihydroxyvitamin NN N
D3 NNP N
( ( N
1,25 CD N
[ NNP N
OH NNP N
] NNP N
2D CD N
) ) N
, , N
which WDT N
, , N
operating VBG N
through IN N
the DT N
vitamin NN N
D NNP N
receptor NN N
( ( N
VDR NNP N
) ) N
, , N
inhibits VBZ N
in IN N
vitro NN N
cell NN N
proliferation NN N
, , N
induces NNS N
differentiation NN N
and CC N
apoptosis NN N
, , N
and CC N
may MD N
protect VB N
against IN N
prostate JJ N
cancer NN N
. . N

When WRB N
the DT N
safety NN N
practices NNS N
involved VBN N
little JJ N
time NN N
or CC N
expense NN N
( ( N
eg UH N
, , N
putting VBG N
away RB N
sharp JJ N
objects NNS N
) ) N
, , N
the DT N
educational JJ N
book NN N
group NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
these DT N
behaviors NNS N
than IN N
the DT N
no-book JJ N
group NN N
( ( N
40 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.19 CD N
) ) N
or CC N
noneducational JJ N
book NN N
group NN N
( ( N
27 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.13 CD N
) ) N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
decreased VBN o
activated VBN N
CECs NNP N
after IN N
therapy NN i
and CC N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
( ( N
r JJ N
= NN N
0.322 CD N
, , N
P NNP N
= NNP N
0.012 CD N
) ) N
; : N
a DT N
negative JJ N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
amount NN N
of IN N
survivin NN N
mRNA NN N
in IN N
serum JJ N
post-therapy NN i
and CC N
TTP NNP N
( ( N
r NN N
= NNP N
-0.291 NNP N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

Naftidrofuryl NNP N
significantly RB N
improved VBD N
the DT N
physiological JJ N
function NN N
of IN N
the DT N
liver NN N
cells NNS N
as IN N
reflected VBN N
by IN N
indocyanine NN N
green NN N
( ( N
ICG NNP N
) ) N
clearance NN N
by IN N
the DT N
liver NN N
( ( N
t JJ N
= VBZ N
2.61 CD N
; : N
p NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.02 CD N
) ) N
and CC N
also RB N
caused VBD N
a DT N
larger JJR N
fall NN N
in IN N
raised VBN N
serum NN N
levels NNS N
of IN N
gamma NN N
glutamyl NN N
transpeptidase NN N
( ( N
GGT NNP N
) ) N
than IN N
did VBD N
the DT N
placebo NN N
injections NNS N
. . N

Hip NNP N
protector NN N
users NNS N
had VBD N
greater JJR N
improvement NN N
in IN N
falls VBZ N
self-efficacy NN N
at IN N
follow-up JJ N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
Scale NNP N
( ( N
t JJ N
= NN N
2.44 CD N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
and CC N
the DT N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scale NNP N
( ( N
t JJ N
= NN N
2.08 CD N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

RESULTS VB N
The DT N
oat NN N
cereal NN N
group NN N
experienced VBD N
a DT N
7.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
SBP NNP N
( ( N
P NNP N
& CC N
lt.01 NN N
) ) N
and CC N
a DT N
5.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
DBP NNP N
( ( N
P NNP N
& CC N
lt.02 NN N
) ) N
, , N
while IN N
there EX N
was VBD N
virtually RB N
no DT N
change NN N
in IN N
either DT N
SBP NNP N
or CC N
DBP NNP N
in IN N
the DT N
control NN N
group NN N
. . N

Thus RB N
, , N
three CD N
groups NNS N
were VBD N
formed VBN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
according VBG N
to TO N
the DT N
adhesive JJ N
system NN N
employed VBN N
: : N
All-Bond JJ N
2 CD N
( ( N
TE3 NNP N
) ) N
+ VBP N
resin JJ N
cement NN N
post NN N
( ( N
rcp NN N
) ) N
+ VBZ N
Duo-link NNP N
( ( N
Dl NNP N
) ) N
; : N
One-Step JJ N
Plus NNP N
( ( N
TE2 NNP N
) ) N
+ VBP N
rcp JJ N
+ NNP N
Dl NNP N
; : N
Tyrian/One-Step JJ N
Plus NNP N
( ( N
SE NNP N
) ) N
+ VBP N
rcp JJ N
+ NNP N
Dl NNP N
. . N

METHODS NNP N
Four CD N
devices NNS N
were VBD N
compared VBN N
in IN N
a DT N
simulated JJ N
resuscitation NN N
scenario NN N
: : N
ILMA NNP N
( ( N
Intavent NNP N
Direct NNP N
Ltd NNP N
, , N
Buckinghamshire NNP N
, , N
United NNP N
Kingdom NNP N
) ) N
, , N
Cobra NNP N
PLA NNP N
( ( N
Engineered NNP N
Medical NNP N
Systems NNP N
Inc NNP N
, , N
Indianapolis NNP N
, , N
IN NNP N
) ) N
, , N
Supraglottic JJ N
Airway NNP N
Laryngopharyngeal NNP N
Tube NNP N
( ( N
SALT NNP N
) ) N
( ( N
ECOLAB NNP N
, , N
St. NNP N
Paul NNP N
, , N
MN NNP N
) ) N
, , N
and CC N
Air-Q NNP N
( ( N
Mercury NNP N
Medical NNP N
, , N
Clearwater NNP N
, , N
FL NNP N
) ) N
. . N

In IN N
this DT N
surgical JJ N
subgroup NN N
, , N
the DT N
mean JJ N
TT-TG NNP N
distance NN N
was VBD N
22.5 CD N
mm NN N
( ( N
range NN N
, , N
19.8-25.8 JJ N
mm NN N
) ) N
by IN N
CT NNP N
and CC N
only RB N
18.7 CD N
mm NN N
( ( N
range NN N
, , N
14.4-22.8 JJ N
mm NN N
) ) N
by IN N
MRI NNP N
for IN N
a DT N
mean JJ N
difference NN N
of IN N
3.80 CD N
mm NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Cervical JJ N
artery NN N
spasm NN N
index NN N
and CC N
atlantoaxial JJ N
displacement NN N
index NN N
had VBD N
been VBN N
significantly RB N
improved VBN N
, , N
cervical JJ N
artery NN N
spasm NN N
index NN N
was VBD N
respectively RB N
0.54 CD N
+/- JJ N
0.07 CD N
and CC N
0.52 CD N
+/- JJ N
0.13 CD N
, , N
atlantoaxial JJ N
displacement NN N
index NN N
was VBD N
respectively RB N
2.92 CD N
+/- JJ N
0.82 CD N
and CC N
4.50 CD N
+/- JJ N
1.32 CD N
between IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
. . N

Although IN N
DG NNP N
or CC N
FD NNP N
exhibited VBD N
moderate JJ N
effects NNS N
on IN N
intestinal JJ N
brush NN N
border NN N
protease NN N
activities NNS N
and CC N
mRNA NN N
levels NNS N
of IN N
duodenal JJ N
transporters NNS N
Pept1 NNP N
, , N
Lat1 NNP N
, , N
and CC N
Cat1 NNP N
, , N
both DT N
substantially RB N
enhanced VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
phosphorylation NN N
of IN N
hepatic JJ N
protein NN N
synthesis NN N
key JJ N
regulator NN N
S6 NNP N
ribosomal NN N
protein NN N
( ( N
S6 NNP N
) ) N
and CC N
the DT N
ratio NN N
of IN N
phospho-S6 NN N
to TO N
S6 NNP N
in IN N
the DT N
liver NN N
of IN N
hens NNS N
. . N

SCORAD NNP N
decreased VBD o
in IN o
the DT N
Bifidobacterium NNP N
lactis VBZ N
Bb-12 NNP N
group NN N
to TO N
0 CD N
( ( N
0-3.8 NN N
) ) N
, , N
and CC N
in IN N
the DT N
Lactobacillus NNP N
GG NNP N
group NN N
to TO N
1 CD N
( ( N
0.1-8.7 NN N
) ) N
, , N
vs RB N
unsupplemented JJ N
13.4 CD N
( ( N
4.5-18.2 JJ N
) ) N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
, , N
in IN N
parallel NN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
concentration NN N
of IN N
soluble JJ N
CD4 NNP N
in IN N
serum NN N
and CC N
eosinophilic JJ N
protein NN N
X NN N
in IN N
urine JJ N
. . N

The DT N
increased JJ o
number NN N
of IN N
steps NNS N
during IN N
the DT N
recovery NN N
was VBD N
accompanied VBN N
by IN N
a DT N
significantly RB N
greater JJR N
decrease NN o
in IN N
blood NN N
lactate NN N
concentration NN N
percentage NN N
( ( N
28.1 CD N
? . N
12.2 CD N
vs NN N
22.8 CD N
? . N
10.9 CD N
% NN N
, , N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
, , N
p VB N
? . N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
frequency NN N
of IN N
postoperative JJ N
adhesions NNS N
of IN N
the DT N
uterus NN N
was VBD N
significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
, , N
with IN N
20/32 CD N
( ( N
62.5 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
10/29 CD N
( ( N
34.5 CD N
% NN N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
and CC N
20/30 CD N
( ( N
67.7 CD N
% NN N
) ) N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

HPLC NNP N
measurements NNS N
of IN N
eicosanoid JJ N
production NN N
in IN N
A23187-stimulated NNP N
neutrophils NNS N
revealed VBD N
a DT N
considerable JJ N
decrease NN o
in IN N
the DT N
formation NN N
of IN N
arachidonic JJ N
acid-derived JJ N
leukotriene NN N
B4 NNP N
( ( N
LTB4 NNP N
) ) N
, , N
by IN N
41 CD N
% NN N
, , N
and CC N
5-HETE JJ N
( ( N
5-hydroxyeicosatetraenoic JJ N
acid NN N
) ) N
, , N
by IN N
30 CD N
% NN N
, , N
in IN N
the DT N
fish-oil JJ N
group NN N
along IN N
with IN N
the DT N
appearance NN N
of IN N
the DT N
corresponding JJ N
EPA-derived JJ N
products NNS N
[ JJ N
LTB5 NNP N
and CC N
5-HEPE JJ N
( ( N
5-hydroxyeicosapentaenoic JJ N
acid NN N
) ) N
] NN N
. . N

RESULTS NNP N
Most JJS N
patients NNS p
in IN N
both DT N
study NN N
groups NNS N
showed VBD N
high JJ N
adherence NN N
to TO N
raloxifene VB N
at IN N
the DT N
3-month JJ N
visit NN N
: : N
56.3 CD N
% NN N
vs JJ N
62.7 CD N
% NN N
for IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
; : N
this DT N
proportion NN N
at IN N
the DT N
12-month JJ N
visit NN N
was VBD N
47.4 CD N
% NN N
( ( N
P=0.15 NNP N
) ) N
and CC N
52.5 CD N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
respectively RB N
. . N

No DT N
difference NN N
was VBD N
found VBN N
between IN N
these DT N
two CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
necessary JJ N
interval NN N
for IN N
ERCP NNP N
( ( N
20.6 CD N
+/- JJ N
14.1 CD N
min NN N
versus NN N
21.4 CD N
+/- JJ N
14.7 CD N
min NN N
; : N
NS NNP N
) ) N
or CC N
the DT N
success NN N
rate NN N
for IN N
cholangiopancreatography NN N
( ( N
92.1 CD N
% NN N
versus IN N
91.7 CD N
% NN N
; : N
NS NNP N
) ) N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Before NNP N
and CC N
10 CD N
minutes NNS N
after IN N
administration NN N
of IN N
each DT N
desired VBN N
end-expiratory JJ N
anesthetic JJ N
concentration NN N
, , N
the DT N
following JJ N
parameters NNS N
were VBD N
determined VBN N
: : N
hemodynamic JJ N
parameters NNS N
, , N
arterial JJ N
( ( N
SaO2 NNP N
) ) N
, , N
mixed JJ N
venous JJ N
( ( N
SvO2 NNP N
) ) N
, , N
and CC N
hepatic JJ N
venous JJ N
oxygen NN N
saturations NNS N
, , N
systemic JJ N
and CC N
splanchnic JJ N
O2 NNP N
extraction NN N
, , N
arterial JJ N
, , N
mixed JJ N
venous JJ N
, , N
and CC N
hepatic JJ N
venous JJ N
lactate NN N
concentrations NNS N
. . N

A DT N
non-significant JJ N
decrease NN o
in IN N
30-day JJ N
mortality NN N
was VBD N
observed VBN N
in IN N
favour NN N
of IN N
the DT N
pre-hospital JJ N
group NN N
( ( N
13 CD N
% NN N
: : N
P NNP N
= NNP N
0.08 CD N
) ) N
, , N
whereas IN N
the DT N
decrease NN o
in IN N
cardiac JJ N
death NN N
observed VBD N
, , N
also RB N
in IN N
favour NN N
of IN N
the DT N
pre-hospital JJ N
group NN N
, , N
was VBD N
on IN N
the DT N
borderline NN N
of IN N
significance NN N
( ( N
16 CD N
% NN N
; : N
P NNP N
= NNP N
0.049 CD N
) ) N
. . N

LCModel NNP N
software NN N
was VBD N
used VBN N
to TO N
quantify VB N
Cho NNP N
( ( N
Choline NNP N
) ) N
, , N
Lip NNP N
( ( N
lipid JJ N
) ) N
, , N
and CC N
Cho/Lip NNP N
in IN N
the DT N
3 CD N
groups NNS N
, , N
and CC N
a DT N
one-way JJ N
ANOVA NNP N
was VBD N
used VBN N
to TO N
compare VB N
the DT N
differences NNS N
in IN N
these DT N
metabolites NNS N
between IN N
groups.Choline NN N
levels NNS N
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
control NN N
and CC N
HCC NNP N
group NN N
and CC N
between IN N
the DT N
cirrhosis NN N
group NN N
and CC N
the DT N
HCC NNP N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
correlation NN N
with IN N
the DT N
central JJ N
PP NNP N
was VBD N
stronger JJR N
than IN N
with IN N
the DT N
brachial JJ N
PP NNP N
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
or CC N
central JJ N
systolic JJ N
blood NN N
pressure NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
and CC N
these DT N
relationships NNS N
were VBD N
essentially RB N
the DT N
same JJ N
even RB N
after IN N
adjustment NN N
for IN N
the DT N
use NN N
of IN N
atenolol NN i
or CC N
the DT N
change NN N
in IN N
heart NN N
rate NN N
. . N

The DT N
addition NN N
of IN N
inflammatory JJ N
markers NNS N
improves VBZ N
the DT N
discriminatory JJ N
value NN N
of IN N
the DT N
prognostic JJ N
classification NN N
as IN N
compared VBN N
with IN N
established VBN N
factors NNS N
alone RB N
( ( N
C-statistic JJ N
0.673 CD N
vs NN N
0.654 CD N
, , N
P=0.002 NNP N
for IN N
the DT N
difference NN N
) ) N
, , N
with IN N
25.8 CD N
% NN N
( ( N
P=0.004 NNP N
) ) N
of IN N
patients NNS p
more RBR N
appropriately RB N
classified JJ N
using VBG N
the DT N
new JJ N
classification NN N
. . N

A DT N
neuropsychological JJ N
battery NN N
including VBG N
the DT N
Digit NNP N
Span NNP N
subtest JJS N
from IN N
the DT N
Wechsler NNP N
Adult NNP N
Intelligence NNP N
Scale-III NNP N
( ( N
WAIS-III NNP N
) ) N
, , N
the DT N
verbal JJ N
fluency NN N
test NN N
, , N
the DT N
Hopkins NNP N
Verbal NNP N
Learning NNP N
Test NNP N
( ( N
HVLT NNP N
) ) N
, , N
the DT N
Trail-Making JJ N
Test NNP N
( ( N
TMT NNP N
) ) N
and CC N
the DT N
Wisconsin NNP N
Card NNP N
Sorting NNP N
Test NNP N
( ( N
WCST NNP N
) ) N
was VBD N
administered VBN N
at IN N
baseline NN N
and CC N
week NN N
eight CD N
. . N

The DT N
main JJ N
outcomes NNS N
were VBD N
: : N
diet NN N
, , N
based VBN N
on IN N
multiple JJ N
24-hour JJ N
recalls NNS N
( ( N
total JJ N
fat NN N
, , N
grams NNS N
of IN N
fiber NN N
, , N
servings NNS N
of IN N
fruit NN N
and CC N
vegetables NNS N
, , N
total JJ N
calories NNS N
) ) N
; : N
average JJ N
daily JJ N
energy NN N
expenditure NN N
( ( N
kcals/kg NN N
) ) N
based VBN N
on IN N
7-day JJ N
physical JJ N
activity NN N
recall VBP N
interviews NNS N
; : N
daily JJ N
minutes NNS N
of IN N
moderate-vigorous JJ N
physical JJ N
activity NN N
minutes NNS N
from IN N
accelerometery NN N
; : N
and CC N
self-reported JJ N
daily JJ N
hours NNS N
of IN N
sedentary JJ N
behavior NN N
. . N

After IN N
subjects NNS N
consumed VBD N
fish JJ N
oil NN N
, , N
supplementation NN N
with IN N
alpha-tocopheryl JJ N
acetate NN N
increased VBD o
plasma NN o
and CC N
LDL NNP N
alpha-tocopherol NN N
contents NNS N
significantly RB N
and CC N
lengthened VBD N
lag NN N
time NN N
( ( N
at IN N
even RB N
the DT N
lowest JJS N
concentration NN N
) ) N
but CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
propagation NN N
rate NN N
or CC N
maximum JJ N
production NN N
compared VBN N
with IN N
values NNS N
measured VBN N
after IN N
consumption NN N
of IN N
fish JJ N
oil NN N
alone RB N
. . N

On IN N
multivariate NN N
analysis NN N
overall JJ i
survival NN N
( ( N
P NNP N
=.02 NNP N
) ) N
, , N
event-free JJ N
survival NN N
( ( N
P NNP N
=.02 NNP N
) ) N
, , N
and CC N
disease-free JJ N
survival NN N
were VBD N
better JJR N
( ( N
P NNP N
=.06 NNP N
) ) N
in IN N
younger JJR N
children NNS N
due JJ N
to TO N
a DT N
lower JJR N
relapse NN N
rate NN N
( ( N
P NNP N
=.02 NNP N
) ) N
especially RB N
in IN N
the DT N
bone NN N
marrow NN N
( ( N
P NNP N
=.02 NNP N
) ) N
. . N

Over IN N
the DT N
5.4 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
, , N
simvastatin NN i
produced VBD N
changes NNS N
in IN N
total JJ N
cholesterol NN N
, , N
low JJ N
density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
cholesterol NN N
, , N
and CC N
high JJ N
density NN N
lipoprotein NN N
( ( N
HDL NNP N
) ) N
cholesterol NN N
of IN N
-25 NNP N
% NN N
, , N
-35 CD N
% NN N
, , N
and CC N
+8 NNP N
% NN N
, , N
respectively RB N
, , N
with IN N
minimal JJ N
adverse JJ N
effects NNS N
. . N

Intention-to-treat JJ N
analysis NN N
showed VBD N
significant JJ N
decreases NNS o
in IN N
all DT N
three CD N
groups NNS N
in IN N
mean JJ N
( ( N
+/- JJ N
SEM NNP N
) ) N
supine NN N
DBP NNP N
throughout IN N
the DT N
study NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
at IN N
week NN N
16 CD N
between IN N
trandolapril NN N
( ( N
-10.6 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
HCTZ NNP N
( ( N
-10.9 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
. . N

Twelve CD N
patients NNS p
( ( N
seven CD N
females NNS N
and CC N
five CD N
males NNS N
) ) N
with IN N
a DT N
mean JJ N
age NN N
of IN N
14.8 CD N
+/- JJ N
0.3 CD N
years NNS N
were VBD N
treated VBN N
with IN N
banded JJ N
RPE NNP N
and CC N
11 CD N
patients NNS p
( ( N
six CD N
females NNS N
and CC N
five CD N
males NNS N
) ) N
with IN N
a DT N
mean JJ N
age NN N
of IN N
15.1 CD N
+/- JJ N
0.7 CD N
years NNS N
with IN N
bonded JJ N
RPE NNP N
. . N

After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
2.3+/-0.6 CD N
years NNS N
, , N
the DT N
primary JJ N
endpoint NN N
( ( N
a DT N
composite NN N
of IN N
cardiovascular JJ N
mortality NN N
, , N
heart NN N
failure NN N
, , N
thrombo-embolic JJ N
complications NNS N
( ( N
TECs NNP N
) ) N
, , N
bleeding VBG N
, , N
serious JJ N
adverse JJ N
effects NNS N
of IN N
antiarrhythmic JJ N
drugs NNS N
and CC N
pacemaker NN N
implants NNS N
) ) N
was VBD N
22.4 CD N
% NN N
in IN N
the DT N
rhythm-control NN N
group NN N
vs. FW N
15.2 CD N
% NN N
in IN N
the DT N
rate-control NN N
group NN N
. . N

Patients NNS N
with IN N
CSF+/Mass NNP N
had VBD N
a DT N
nominally RB N
higher JJR N
treatment NN N
failure NN N
rate NN N
compared VBN N
with IN N
patients NNS p
with IN N
CNS- NNP N
after IN N
adjusting VBG N
for IN N
marrow NN N
status NN N
and CC N
lactate VB N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
diagnosis NN N
, , N
with IN N
a DT N
relative JJ N
failure NN N
rate NN N
( ( N
RFR NNP N
) ) N
of IN N
1.52 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.88 CD N
to TO N
2.6 CD N
; : N
P NNP N
=.15 NNP N
) ) N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin NN N
receptor NN N
blocker NN N
( ( N
ARB NNP N
) ) N
valsartan VBP N
versus IN N
the DT N
calcium NN N
channel NN N
blocker NN N
amlodipine NN N
, , N
reactive JJ N
oxygen NN N
species NNS N
( ( N
ROS NNP N
) ) N
formation NN N
by IN N
monocytes NNS N
, , N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
and CC N
left VBD N
ventricular NN N
( ( N
LV NNP N
) ) N
mass NN N
were VBD N
studied VBN N
in IN N
104 CD N
hypertensive JJ N
patients NNS p
with IN N
left JJ N
ventricular JJ N
hypertrophy NN N
( ( N
LVH NNP N
) ) N
. . N

However RB N
, , N
pain VBP N
at IN N
rest NN N
reported VBN N
by IN N
the DT N
TENS NNP N
group NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
reported VBN N
by IN N
the DT N
control NN N
group NN N
( ( N
treatment NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.04 CD N
) ) N
, , N
although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
TENS NNP N
and CC N
placebo NN N
or CC N
between IN N
the DT N
placebo NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
was VBD N
higher RBR N
in IN N
the DT N
vilazodone NN i
group NN N
( ( N
57.6 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
moxifloxacin NN i
( ( N
37.0 CD N
% NN N
) ) N
and CC N
placebo NN N
( ( N
35.6 CD N
% NN N
) ) N
groups NNS N
, , N
though IN N
AEs NNP N
were VBD N
generally RB N
mild VBN N
to TO N
moderate VB N
in IN N
severity NN N
and CC N
resulted VBD N
in IN N
few JJ N
discontinuations NNS N
. . N

The DT N
five-year JJ N
survival NN N
rate NN N
was VBD N
89.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
CABG NNP N
and CC N
86.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
( ( N
P NNP N
= NNP N
0.19 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
of IN N
the DT N
difference NN N
in IN N
survival NN N
, , N
-0.2 JJ N
percent NN N
to TO N
6.0 CD N
percent NN N
) ) N
. . N

Pulse NNP N
wave VBP N
velocity NN N
of IN N
the DT N
aorta NN N
( ( N
PWV NNP N
) ) N
, , N
brachial JJ N
artery NN N
flow NN N
mediated VBN N
dilatation NN N
( ( N
FMD NNP N
) ) N
, , N
nitroglycerin RB N
mediated VBN N
dilatation NN N
( ( N
NMD NNP N
) ) N
, , N
microvascular JJ N
endothelial JJ N
function NN N
( ( N
reactive JJ N
hyperemia NN N
index NN N
[ NNP N
RHI NNP N
] NNP N
) ) N
, , N
and CC N
circulating VBG N
biomarkers NNS N
of IN N
inflammation NN N
, , N
insulin NN N
resistance NN N
, , N
and CC N
atherosclerosis NN N
risk NN N
all DT N
were VBD N
quantified VBN N
. . N

Compared VBN N
to TO N
the DT N
placebo NN N
group NN N
, , N
the DT N
olanzapine NN N
group NN N
had VBD N
a DT N
lower JJR N
incidence NN N
of IN N
( ( N
59.2 CD N
% NN N
versus IN N
91.1 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
longer JJR N
time NN N
to TO N
( ( N
46 CD N
versus NN N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
symptomatic JJ N
relapse NN N
of IN N
any DT N
kind NN N
. . N

RESULTS VB N
The DT N
average JJ N
systolic JJ N
BP NNP N
throughout IN N
all DT N
hemodialysis NN N
treatments NNS N
in IN N
a DT N
given VBN N
week NN N
was VBD N
lower JJR N
with IN N
low JJ N
dialysate NN N
sodium NN N
concentrations NNS N
compared VBN N
with IN N
treatments NNS N
with IN N
high JJ N
dialysate NN N
sodium NN N
concentrations NNS N
( ( N
parameter NN N
estimate NN N
, , N
-9.9 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
-13.3 NNP N
to TO N
-6.4 VB N
] NNP N
mm NNP N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
positive JJ N
association NN N
was VBD N
found VBN N
between IN N
the DT N
ECV NNP N
and CC N
left VBD N
atrial JJ N
volume NN N
( ( N
ECV NNP N
vs RB N
indexed VBD N
left JJ N
atrial JJ N
volume NN N
, , N
r NN N
= VBD N
0.65 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
negative JJ N
association NN N
was VBD N
found VBN N
between IN N
the DT N
ECV NNP N
and CC N
diastolic JJ N
function NN N
( ( N
E NNP N
' POS N
lateral NN N
, , N
r NN N
= NNP N
-0.64 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

RESULTS NNP N
Training NNP N
did VBD N
not RB N
result VB N
in IN N
a DT N
more RBR N
active JJ N
lifestyle NN N
or CC N
improved VBN N
QoL NNP N
, , N
but CC N
improved VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
peak NN N
power NN N
( ( N
17 CD N
% NN N
) ) N
, , N
6-min JJ N
walk NN N
distance NN N
( ( N
10 CD N
% NN N
) ) N
, , N
muscle NN N
strength NN N
( ( N
13-15 CD N
% NN N
) ) N
and CC N
depression NN N
( ( N
-1.3 JJ N
unit NN N
) ) N
. . N

The DT N
information NN N
about IN N
feeding VBG N
eight CD N
diets NNS N
at IN N
two CD N
periods NNS N
[ VBP N
starter NN N
( ( N
0-21 JJ N
days NNS N
of IN N
age NN N
) ) N
and CC N
grower NN N
( ( N
22-42 JJ N
days NNS N
of IN N
age NN N
) ) N
] WDT N
were VBD N
used VBN N
to TO N
estimate VB N
AF NNP N
of IN N
broilers NNS N
by IN N
ANN-GA. NNP N
A NNP N
multilayer NN N
feed-forward JJ N
neural JJ N
network NN N
with IN N
different JJ N
structures NNS N
was VBD N
developed VBN N
using VBG N
matlab NN N
software NN N
, , N
and CC N
optimal JJ N
values NNS N
for IN N
the DT N
ANN NNP N
weights NNS N
were VBD N
obtained VBN N
using VBG N
the DT N
genetic JJ N
algorithm NN N
( ( N
GA NNP N
) ) N
. . N

Assignment NN N
to TO N
ATV/r NNP N
( ( N
vs. FW N
EFV NNP N
) ) N
resulted VBD N
in IN N
significantly RB N
greater JJR N
weight NN N
( ( N
mean JJ N
difference NN N
3.35 CD N
kg NN N
) ) N
and CC N
BMI NNP N
gain NN N
( ( N
0.88 CD N
kg/m NN N
; : N
both DT N
P=0.02 NNP N
) ) N
, , N
but CC N
not RB N
LBM NNP N
( ( N
0.67 CD N
kg NN N
; : N
P=0.15 NNP N
) ) N
, , N
whereas JJ N
ABC/3TC NNP N
and CC N
TDF/FTC NNP N
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
P NNP N
) ) N
. . N

The DT N
4-year JJ N
probabilities NNS N
of IN N
transplant-related JJ N
mortality NN N
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN N
of IN N
moderate JJ N
to TO N
severe VB N
acute JJ N
graft-versus-host JJ N
disease NN N
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

Independent JJ N
samples NNS N
t-tests NNS N
revealed VBD N
no DT N
significant JJ N
differences NNS N
at IN N
baseline NN N
across IN N
the DT N
TG NNP N
and CC N
CG NNP N
conditions NNS N
with IN N
regard NN N
to TO N
age NN N
( ( N
14.04 CD N
? . N
1.64 CD N
and CC N
13.54 CD N
? . N
1.50 CD N
years NNS N
) ) N
, , N
IQ NNP N
( ( N
99.39 CD N
? . N
18.09 CD N
& CC N
100.67 CD N
? . N
16.97 CD N
) ) N
, , N
parental JJ N
education NN N
, , N
socioeconomic JJ N
status NN N
, , N
or CC N
ASD NNP N
symptoms NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
addition NN N
of IN N
ezetimibe NN N
to TO N
simvastatin VB i
over RP N
a DT N
4-week JJ N
period NN N
was VBD N
associated VBN N
with IN N
reduced JJ N
expression NN N
of IN N
CD141 NNP N
( ( N
thrombomodulin NN N
; : N
p CC N
= VB N
0.02 CD N
) ) N
, , N
platelet VBP N
endothelial JJ N
cell NN N
adhesion NN N
molecule NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
CD51/61 NNP N
( ( N
vitronectin JJ i
receptor NN N
; : N
p CC N
= VB N
0.048 CD N
) ) N
compared VBN N
to TO N
statin VB i
monotherapy NN i
. . N

The DT N
incidence NN N
of IN N
recurrent JJ N
angina NN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
was VBD N
also RB N
significantly RB N
reduced VBN N
in IN N
XS0601 NNP N
group NN N
( ( N
7.1 CD N
% NN N
and CC N
11.0 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
those DT N
in IN N
placebo JJ N
group NN N
( ( N
19.5 CD N
% NN N
and CC N
42.9 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
initial JJ N
RAO NNP N
was VBD N
5.9 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
with IN N
a DT N
compression NN N
time NN N
of IN N
2.10 CD N
? . N
0.78 CD N
hours NNS N
and CC N
2.25 CD N
? . N
0.82 CD N
hours NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
the DT N
proportion NN N
of IN N
subjects NNS N
achieving VBG N
a DT N
glycated JJ N
hemoglobin NN N
A1c NNP N
value NN N
of IN N
< $ N
7 CD N
% NN N
, , N
change NN N
from IN N
baseline NN N
in IN N
fasting VBG N
plasma NN N
glucose NN N
and CC N
postprandial JJ N
glucose NN N
( ( N
as IN N
part NN N
of IN N
an DT N
oral JJ N
glucose NN N
tolerance NN N
test NN N
) ) N
, , N
body NN N
weight NN N
, , N
and CC N
blood NN N
pressure NN N
. . N

Also RB N
patients NNS p
with IN N
PPD NNP N
negative JJ N
skin NN N
reaction NN N
at IN N
the DT N
time NN N
of IN N
beginning VBG N
of IN N
treatment NN N
in IN N
the DT N
OK-432 NNP N
group NN N
survived VBD N
significantly RB N
longer RBR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significance NN N
between IN N
both DT N
treatment NN N
groups NNS N
in IN N
patients NNS p
with IN N
PPD NNP N
positive JJ N
skin NN N
reaction NN N
at IN N
the DT N
time NN N
of IN N
beginning VBG N
of IN N
treatment NN N
. . N

Among IN N
putative JJ N
variables NNS N
, , N
multivariate JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
only RB N
the DT N
baseline NN N
number NN N
of IN N
SBIs NNP N
( ( N
OR NNP N
= VBZ N
6.27 CD N
, , N
95 CD N
% NN N
CI NNP N
2.4-16.5 CD N
) ) N
and CC N
simvastatin JJ i
treatment NN N
( ( N
OR NNP N
= VBZ N
0.09 CD N
, , N
95 CD N
% NN N
CI NNP N
0.01-0.82 NN N
) ) N
independently RB N
predicted VBD N
the DT N
development NN N
of IN N
new JJ N
brain NN N
infarcts NNS N
. . N

RESULTS NN N
After IN N
training VBG N
with IN N
EPI-NO NNP N
we PRP N
observed VBD N
a DT N
significant JJ N
increase NN o
in IN N
the DT N
incidence NN N
of IN N
intact JJ N
perineum NN N
( ( N
37.4 CD N
% NN N
vs JJ N
25.7 CD N
% NN N
; : N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
a DT N
tendency NN N
towards NNS N
lower JJR N
episiotomy NN N
rates NNS N
( ( N
41.9 CD N
% NN N
vs JJ N
50.5 CD N
% NN N
; : N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

The DT N
mean JJ N
volume NN N
of IN N
drainage NN N
from IN N
the DT N
breast NN N
and CC N
the DT N
total JJ N
drainage NN N
from IN N
both CC N
the DT N
breast NN N
and CC N
axilla NN N
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
EC NNP N
group NN N
compared VBN N
to TO N
UC NNP N
[ NNP N
169.3 CD N
versus NN N
58.8 CD N
mls NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
663.7 CD N
versus NN N
247.0 CD N
mls NN N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
respectively RB N
] JJ N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Visual NNP N
field NN N
progression NN N
, , N
measured VBN N
by IN N
Humphrey NNP N
24-2 JJ N
full-threshold JJ N
testing NN N
and CC N
assessed VBN N
by IN N
the DT N
change NN N
in IN N
the DT N
mean JJ N
deviation NN N
( ( N
MD NNP N
) ) N
, , N
and CC N
an DT N
indicator NN N
of IN N
substantial JJ N
worsening NN N
of IN N
the DT N
VF NNP N
( ( N
MD NNP N
decrease NN o
of IN N
> NN N
or CC N
=3 JJ N
dB NN N
from IN N
baseline NN N
) ) N
, , N
assessed VBN N
at IN N
each DT N
follow-up JJ N
visit NN N
. . N

In IN N
contrast NN N
, , N
therapy NN i
with IN N
zofenopril NN N
was VBD N
associated VBN N
with IN N
a DT N
50 CD N
% NN N
increase NN o
in IN N
total JJ N
heart NN N
rate NN N
variability NN N
( ( N
p JJ N
= NNP N
0.09 CD N
) ) N
and CC N
a DT N
significant JJ N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
twofold NN N
increase NN o
in IN N
high JJ N
frequency NN N
heart NN N
rate NN N
variability NN N
, , N
indicating VBG N
a DT N
significant JJ N
augmentation NN N
of IN N
parasympathetic JJ N
tone NN N
. . N

Differences NNS N
in IN N
the DT N
GMC NNP N
after IN N
the DT N
primary JJ N
series NN N
of IN N
three CD N
doses NNS N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
; : N
GMC NNP N
was VBD N
highest JJS N
for IN N
PRP-T NNP N
( ( N
6.62 CD N
micrograms/ml NN N
) ) N
, , N
followed VBN N
by IN N
HbOC NNP N
( ( N
1.9 CD N
micrograms/ml NN N
) ) N
, , N
then RB N
PRP-OMP NNP N
( ( N
1.06 CD N
micrograms/ml NN N
) ) N
, , N
and CC N
lowest JJS N
for IN N
the DT N
control NN N
group NN N
( ( N
0.11 CD N
microgram/ml NN N
) ) N
. . N

Luteinizing VBG N
hormone NN N
( ( N
LH NNP N
) ) N
, , N
follicle NN N
stimulating VBG N
hormone NN N
( ( N
FSH NNP N
) ) N
, , N
dehydroepiandrostendione JJ N
sulfate NN N
( ( N
DHEAS NNP N
) ) N
, , N
total JJ N
testosterone NN N
( ( N
T NNP N
) ) N
, , N
glucose JJ N
, , N
and CC N
insulin NN N
levels NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
first JJ N
cycle NN N
, , N
as RB N
well RB N
as IN N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
cervical JJ N
score NN N
, , N
and CC N
pregnancy NN N
rate NN N
. . N

The DT N
group NN N
treated VBD N
with IN N
GM-CSF NNP N
had VBD N
lower JJR N
total NN N
charges NNS N
after IN N
infusion NN N
of IN N
autologous JJ N
marrow NN N
than IN N
the DT N
placebo NN N
group NN N
( ( N
median JJ N
in-hospital NN N
charges NNS N
, , N
$ $ N
39,800 CD N
compared VBN N
with IN N
$ $ N
62,500 CD N
; : N
P NNP N
= NNP N
0.005 CD N
) ) N
because IN N
of IN N
lower JJR N
post-infusion NN N
charges NNS N
for IN N
room NN N
and CC N
board NN N
, , N
antibiotic JJ i
therapy NN i
, , N
transfusions NNS N
, , N
laboratory NN N
tests NNS N
, , N
and CC N
physical JJ N
therapy NN i
visits NNS N
. . N

After IN N
4 CD N
years NNS N
of IN N
study NN N
, , N
the DT N
gain NN N
in IN N
H-SDSCA NNP N
was VBD N
1.4 CD N
+ NN N
or CC N
- : N
01 CD N
in IN N
the DT N
TOTO NNP N
group NN N
and CC N
1.6 CD N
+ NN N
or CC N
- : N
0.2 CD N
in IN N
the DT N
TTOO NNP N
group NN N
leading VBG N
to TO N
a DT N
mean JJ N
height NN N
of IN N
-2.0 NNP N
+ NNP N
or CC N
- : N
1.0 CD N
SDS NNP N
and CC N
-2.0 NNP N
+ NNP N
or CC N
- : N
0.8 CD N
SDS NNP N
, , N
respectively RB N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
80-kilovoltage NN N
( ( N
kV NN N
) ) N
tube NN N
voltage NN N
coronary JJ N
computed VBD N
tomographic JJ N
angiography NN N
( ( N
CCTA NNP N
) ) N
with IN N
a DT N
reduced JJ N
amount NN N
of IN N
contrast NN N
agent NN N
on IN N
qualitative JJ N
and CC N
quantitative JJ N
image NN N
quality NN N
parameters NNS N
and CC N
on IN N
radiation NN N
dose NN N
in IN N
patients NNS p
with IN N
a DT N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
< VBD N
23.0 CD N
kg/m NN N
( ( N
2 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
increase NN o
in IN N
the DT N
duration NN N
of IN N
first JJ N
remission NN N
in IN N
the DT N
C+I NNP N
group NN N
( ( N
0.05 CD N
less JJR N
than IN N
P NNP N
less JJR N
than IN N
0.1 CD N
) ) N
nor CC N
in IN N
the DT N
time NN N
from IN N
first JJ N
relapse NN N
to TO N
death NN N
( ( N
0.05 CD N
less JJR N
than IN N
P NNP N
less JJR N
than IN N
0.1 CD N
) ) N
. . N

RESULTS VB N
The DT N
reduction NN N
of IN N
AVM NNP N
dimensions NNS N
( ( N
79.4 CD N
% NN N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
86.9 CD N
% NN N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
and CC N
the DT N
mean JJ N
number NN N
of IN N
vessels NNS N
embolized VBN N
( ( N
2.2 CD N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
2.1 CD N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
results NNS N
showed VBD N
significant JJ N
improvements NNS N
in IN N
the DT N
sensory JJ N
function NN N
as IN N
detected VBN N
by IN N
the DT N
2PD CD N
and CC N
SWM NNP N
tests NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
sensorimotor JJ N
function NN N
as IN N
detected VBN N
by IN N
the DT N
MTT NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
PHUA NNP N
test NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
patients NNS p
receiving VBG N
CTR NNP N
. . N

When WRB N
adjusted VBN N
for IN N
other JJ N
important JJ N
factors NNS N
, , N
complete JJ N
remission NN N
rates NNS N
were VBD N
similar JJ N
( ( N
P NNP N
=.5 NNP N
) ) N
and CC N
although IN N
there EX N
was VBD N
less RBR N
resistant JJ N
disease NN N
in IN N
younger JJR N
children NNS N
( ( N
P NNP N
=.003 NNP N
) ) N
, , N
this DT N
was VBD N
partially RB N
balanced VBN N
by IN N
a DT N
slight JJ N
increase NN o
in IN N
deaths NNS N
during IN N
induction NN N
therapy NN i
in IN N
younger JJR N
patients NNS p
( ( N
P NNP N
=.06 NNP N
) ) N
. . N

A DT N
decrease NN o
in IN N
PPD NNP N
( ( N
5.4 CD N
mm NN N
, , N
SD NNP N
1.4 CD N
mm NN N
) ) N
and CC N
tooth DT N
mobility NN N
( ( N
DDM-horizontal JJ N
257 CD N
microns NNS N
, , N
SD NNP N
60 CD N
microns NNS N
) ) N
and CC N
a DT N
gain NN N
of IN N
CPAL NNP N
( ( N
5.1 CD N
mm NN N
, , N
SD NNP N
1.4 CD N
mm NN N
) ) N
were VBD N
seen VBN N
following VBG N
the DT N
use NN N
of IN N
BRG NNP N
in IN N
presplint NN N
teeth NNS N
. . N

In IN N
the DT N
group NN N
with IN N
only RB N
one CD N
invaded VBD N
lymph NN N
node NN N
, , N
the DT N
estimated VBN N
relapse NN N
rate NN N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
( ( N
adjusted VBN N
) ) N
=0.0285 NN N
) ) N
and CC N
the DT N
overall JJ i
survival NN N
was VBD N
increased VBN o
( ( N
P NNP N
( ( N
adjusted VBN N
) ) N
=0.039 NN N
) ) N
in IN N
the DT N
TIL+IL-2 NNP N
arm NN N
compared VBN N
with IN N
the DT N
IL-2 NNP N
only JJ N
arm NN N
. . N

The DT N
increased VBN o
screening-coverage NN N
rate NN N
in IN N
the DT N
intervention NN N
zone NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
zone NN N
( ( N
43.6 CD N
vs. FW N
34.9 CD N
% NN N
, , N
p=0.119 NN N
) ) N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
borderline NN N
significant JJ N
increase NN o
in IN N
the DT N
intervention NN N
zone NN N
compared VBN N
with IN N
baseline NN N
( ( N
36.7 CD N
to TO N
43.6 CD N
% NN N
, , N
p=0.070 NN N
) ) N
. . N

In IN N
terms NNS N
of IN N
cancer NN N
deaths NNS N
, , N
only RB N
colorectal JJ N
cancer NN N
in IN N
men NNS N
shows VBZ N
a DT N
significant JJ N
positive JJ N
correlation NN N
( ( N
r JJ N
= NN N
0.91 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
stomach NN N
cancer NN N
in IN N
women NNS N
is VBZ N
negatively RB N
correlated VBN N
with IN N
DNA NNP N
oxidation NN N
( ( N
r JJ N
= NNP N
-0.92 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

A DT N
significant JJ N
ambulatory NN N
BP NNP N
reduction NN N
was VBD N
, , N
however RB N
, , N
observed VBN N
in IN N
the DT N
subjects NNS N
who WP N
received VBD N
aspirin NN N
at IN N
bedtime NN N
( ( N
decrease NN o
of IN N
6/3 CD N
mm NNS N
Hg NNP N
in IN N
the DT N
24-h JJ N
mean NN N
of IN N
systolic NN N
( ( N
SBP NNP N
) ) N
/diastolic VBP N
BP NNP N
( ( N
DBP NNP N
) ) N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
without IN N
changes NNS N
in IN N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
from IN N
baseline NN N
. . N

Although IN N
pre-course JJ N
scores NNS N
were VBD N
similar JJ N
( ( N
student-directed JJ N
25.3 CD N
( ( N
7.3 CD N
) ) N
; : N
structured VBN N
24.8 CD N
( ( N
7.5 CD N
) ) N
) ) N
the DT N
structured JJ N
approach NN N
resulted VBD N
in IN N
higher JJR N
post-course NN N
scores NNS N
in IN N
comparison NN N
with IN N
the DT N
student-directed JJ N
approach NN N
( ( N
student-directed JJ N
41.8 CD N
( ( N
9.4 CD N
) ) N
; : N
structured VBN N
53.8 CD N
( ( N
8.8 CD N
) ) N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

RESULTS NN N
After IN N
start NN N
of IN N
extracorporeal JJ N
circulation NN N
( ( N
ECC NNP N
) ) N
and CC N
aortic JJ N
crossclamping NN N
( ( N
T2 NNP N
) ) N
, , N
both DT N
groups NNS N
showed VBD N
a DT N
significant JJ N
drop NN N
of IN N
FCD NNP N
, , N
with IN N
a DT N
significantly RB N
higher JJR N
FCD NNP N
in IN N
the DT N
MECC NNP N
group NN N
( ( N
206.8 CD N
? . N
33.6 CD N
cm/cm NN N
in IN N
CECC NNP N
group NN N
versus VBD N
217.8 CD N
? . N
35.3 CD N
cm/cm NN N
in IN N
MECC NNP N
group NN N
; : N
P NNP N
= NNP N
.034 NNP N
) ) N
. . N

During IN N
the DT N
trials NNS N
, , N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
was VBD N
continuously RB N
monitored VBN N
, , N
whereas NNS N
core VBP N
temperature NN N
( ( N
Tco NNP N
) ) N
, , N
thermal JJ N
comfort NN N
( ( N
TC NNP N
) ) N
, , N
thermal JJ N
sensation NN N
( ( N
TS NNP N
) ) N
and CC N
rate NN N
of IN N
perceived VBN N
exertion NN N
( ( N
RPE NNP N
) ) N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
warm-up JJ N
, , N
every DT N
5 CD N
km NN N
of IN N
exercise NN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
exercise NN N
and CC N
after IN N
recovery NN N
. . N

In IN N
the DT N
PemCBev NNP N
arm NN N
, , N
OS NNP N
( ( N
HR NNP N
, , N
1.125 CD N
; : N
P NNP N
= NNP N
.525 NNP N
) ) N
, , N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
( ( N
HR NNP N
, , N
1.229 CD N
; : N
P NNP N
= NNP N
.251 NNP N
) ) N
, , N
response NN N
( ( N
P NNP N
= NNP N
.607 NNP N
) ) N
, , N
and CC N
toxicity NN N
profiles NNS N
were VBD N
similar JJ N
in IN N
African JJ N
Americans NNPS N
versus NN N
whites NNS N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
in IN N
thermal JJ N
sensitivity NN N
( ( N
esophagus JJ N
( ( N
p=0.67 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.17 NN N
) ) N
) ) N
, , N
sensory JJ N
response NN N
to TO N
electrical JJ N
stimulation NN N
( ( N
esophagus JJ N
( ( N
p=0.57 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.52 NN N
) ) N
) ) N
or CC N
induced VBN N
somatic JJ N
referred VBD N
pain NN N
areas NNS N
( ( N
esophagus NN N
( ( N
p=0.75 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.51 NN N
) ) N
) ) N
. . N

Two CD N
preplanned JJ N
comparisons NNS N
were VBD N
made VBN N
: : N
( ( N
a DT N
) ) N
Spinal NNP N
manipulative JJ N
therapy NN i
( ( N
SMT NNP N
) ) N
combined VBD N
with IN N
trunk NN N
strengthening VBG N
exercises NNS N
( ( N
TSE NNP N
) ) N
vs. FW N
SMT NNP N
combined VBD N
with IN N
trunk NN N
stretching VBG N
exercises NNS N
, , N
and CC N
( ( N
b NN N
) ) N
SMT NNP N
combined VBN N
with IN N
TSE NNP N
vs. FW N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
therapy NN i
combined VBN N
with IN N
TSE NNP N
. . N

Those DT N
who WP N
had VBD N
not RB N
had VBN N
hysterectomies NNS N
( ( N
n JJ N
= NNP N
16,049 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
estrogen NN N
plus CC N
progestin NN i
( ( N
n JJ N
= NNP N
8,240 CD N
) ) N
, , N
given VBN N
as IN N
0.625 CD N
mg/day NN N
conjugated VBD N
equine JJ N
estrogens NNS N
plus CC N
2.5 CD N
mg/day JJ N
medroxyprogesterone NN N
acetate NN N
, , N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
7,809 CD N
) ) N
, , N
with IN N
a DT N
mean JJ N
followup NN N
of IN N
5.6 CD N
years NNS N
. . N

After IN N
12 CD N
weeks NNS N
of IN N
care NN N
, , N
the DT N
proportion NN N
of IN N
wounds NNS N
healed VBN N
( ( N
defined VBN N
as IN N
complete JJ N
epithelialization NN N
without IN N
drainage NN N
) ) N
in IN N
the DT N
active JJ N
ultrasound NN N
therapy NN i
device NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
sham NN N
control NN N
group NN N
( ( N
40.7 CD N
% NN N
versus IN N
14.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.0366 CD N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
. . N

Significant JJ N
correlations NNS N
between IN N
changes NNS N
in IN N
serum JJ N
free-carnitine JJ N
levels NNS N
and CC N
positive JJ N
clinical JJ N
changes NNS N
were VBD N
observed VBN N
for IN N
hand NN N
muscle NN N
strength NN N
( ( N
R2=0.23 NNP N
, , N
P=0.046 NNP N
) ) N
, , N
cognitive JJ N
scores NNS N
( ( N
R2=0.27 NNP N
, , N
P=0.019 NNP N
) ) N
, , N
and CC N
CARS NNP N
scores NNS N
( ( N
R2=0.20 NNP N
, , N
P=0.047 NNP N
) ) N
. . N

Mean NNP N
( ( N
SD NNP N
) ) N
time NN N
taken VBN N
for IN N
complete JJ N
healing VBG N
with IN N
combination NN N
treatment NN N
[ VBZ N
1.9 CD N
( ( N
0.6 CD N
) ) N
weeks NNS N
] NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
with IN N
minoxidil NN N
alone RB N
( ( N
3.1 CD N
[ RB N
1.7 CD N
] JJ N
weeks NNS N
; : N
p=0.001 NN N
) ) N
or CC N
with IN N
lignocaine JJ N
alone NN N
( ( N
3.3 CD N
[ RB N
0.8 CD N
] JJ N
weeks NNS N
; : N
p=0.002 NN N
) ) N
. . N

Findings NNS N
showed VBD N
the DT N
significant JJ N
decrease NN o
in IN N
the DT N
mean JJ N
scores NNS N
of IN N
fatigue NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
significant JJ N
improvement NN N
in IN N
mean JJ N
scores NNS N
of IN N
ADL NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
QOL NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
after IN N
home-based JJ N
nursing NN N
pulmonary JJ N
rehabilitation NN N
in IN N
the DT N
case NN N
group NN N
. . N

The DT N
levels NNS N
of IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

During IN N
the DT N
placebo NN N
control NN N
period NN N
, , N
serum JJ N
IGF-I NNP N
, , N
LBM NNP N
, , N
and CC N
TBW NNP N
increased VBD o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
BF NNP N
decreased VBD o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
serum JJ N
GHBP NNP N
was VBD N
unchanged JJ N
in IN N
the DT N
group NN N
treated VBD N
with IN N
GH NNP N
compared VBN N
with IN N
the DT N
patients NNS p
treated VBN N
with IN N
placebo NN N
. . N

Three-year JJ N
OS NNP N
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
( ( N
67.4 CD N
% NN N
and CC N
67.7 CD N
% NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
=1.01 VBP N
[ JJ N
0.79-1.30 JJ N
] NN N
, , N
p=0.92 NN N
) ) N
, , N
nor CC N
did VBD N
3-year JJ N
disease-free JJ N
survival NN N
, , N
response NN N
rates NNS N
, , N
toxicity NN N
, , N
or CC N
postoperative JJ N
mortality NN N
. . N

Using VBG N
the DT N
Log-rank JJ N
test NN N
, , N
patients NNS p
from IN N
arm NN N
A NNP N
achieved VBD N
a DT N
significantly RB N
longer RBR N
survival JJ N
( ( N
P=0.009 NNP N
) ) N
, , N
with IN N
the DT N
probability NN N
of IN N
survival NN N
at IN N
12 CD N
months NNS N
of IN N
0.58 CD N
for IN N
patients NNS p
in IN N
arm NN N
A NN N
and CC N
0.28 CD N
for IN N
patients NNS p
in IN N
arm NN N
B. NNP N
Grade NNP N
IV NNP N
granulocytopenia NN N
and CC N
thrombocytopenia NN N
were VBD N
more RBR N
frequent JJ N
in IN N
arm NN N
A NN N
. . N

However RB N
, , N
changes NNS N
in IN N
serum NN N
acetate NN N
from IN N
3 CD N
to TO N
6 CD N
mo NNS N
were VBD N
positively RB N
related VBN N
to TO N
changes NNS N
in IN N
the DT N
ratio NN N
of IN N
total JJ N
to TO N
HDL NNP N
cholesterol NN N
( ( N
P NNP N
= NNP N
0.041 CD N
) ) N
and CC N
in IN N
fasting NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
and CC N
postprandial JJ N
( ( N
P NNP N
= NNP N
0.016 CD N
) ) N
triacylglycerols NNS N
. . N

The DT N
left NN N
ventricular JJ N
ejection NN N
fraction NN N
in IN N
the DT N
patients NNS p
receiving VBG N
BMAC NNP N
demonstrated VBD N
significant JJ N
improvement NN N
compared VBN N
with IN N
baseline NN N
, , N
from IN N
25.1 CD N
% NN N
at IN N
screening VBG N
to TO N
31.1 CD N
% NN N
at IN N
12 CD N
months NNS N
( ( N
p=.007 NN N
) ) N
in IN N
the DT N
NIHF NNP N
group NN N
and CC N
from IN N
26.3 CD N
% NN N
to TO N
31.1 CD N
% NN N
in IN N
the DT N
IHF NNP N
group NN N
( ( N
p=.035 NN N
) ) N
. . N

Although IN N
soluble JJ N
tumor NN N
necrosis NN N
factor-alpha JJ N
receptor NN N
II NNP N
concentrations NNS N
at IN N
baseline NN N
and CC N
24 CD N
weeks NNS N
were VBD N
at IN N
least JJS N
marginally RB N
associated VBN N
with IN N
subsequent JJ N
changes NNS N
in IN N
BMD NNP N
( ( N
P NNP N
= NNP N
0.06 CD N
and CC N
P NNP N
= NNP N
0.028 CD N
, , N
respectively RB N
) ) N
, , N
these DT N
associations NNS N
were VBD N
no RB N
longer RBR N
significant JJ N
after IN N
adjustment NN N
for IN N
CD4 NNP N
T NNP N
cell NN N
count NN N
. . N

Children NNP N
in IN N
the DT N
omega-3 JJ N
fatty JJ N
acid NN N
group NN N
had VBD N
a DT N
greater JJR N
reduction NN N
in IN N
hyperactivity NN N
( ( N
-5.3 JJ N
points NNS N
) ) N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
-2.6 CD N
points NNS N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
1.9-point JJ N
greater JJR N
improvement NN N
in IN N
the DT N
omega-3 JJ N
group NN N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
-2.2 NNP N
to TO N
5.2 CD N
) ) N
. . N

In IN N
the DT N
two CD N
groups NNS N
significant JJ N
improvement NN N
of IN N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
, , N
ESR NNP N
, , N
CRP NNP N
, , N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
by IN N
both DT N
physicians NNS N
and CC N
patients NNS p
, , N
HAQ NNP N
, , N
DAS28 NNP N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
after IN N
treatment NN N
were VBD N
shown VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Systolic JJ N
blood NN N
pressure NN N
( ( N
SBP NNP N
) ) N
was VBD N
3.8+/-1.4 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.006 NNP N
) ) N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
was VBD N
2.6+/-1.1 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
in IN N
the DT N
FO NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
inter- JJ N
or CC N
intra-group JJ N
differences NNS N
in IN N
mean JJ N
counts NNS N
were VBD N
found VBN N
; : N
however RB N
, , N
when WRB N
four-hour JJ N
and CC N
24-hour JJ N
data NNS N
for IN N
Aa NNP N
, , N
Pg NNP N
, , N
or CC N
NS NNP N
were VBD N
combined VBN N
, , N
experimental JJ N
counts NNS N
were VBD N
lower JJR N
than IN N
controls NNS N
in IN N
39/50 CD N
( ( N
78 CD N
% NN N
) ) N
of IN N
the DT N
matched VBN N
pairs NNS N
( ( N
Wilcoxon NNP N
signed-rank JJ N
test NN N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

Pain NN N
scores NNS N
( ( N
rest NN N
, , N
cough NN N
, , N
and CC N
ambulation NN N
) ) N
, , N
side JJ N
effects NNS N
( ( N
nausea NN N
, , N
pruritus NN N
, , N
sedation NN N
, , N
motor NN N
block NN N
, , N
hypotension NN N
, , N
and CC N
orthostasis NN N
) ) N
, , N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
consumption NN N
were VBD N
measured VBN N
for IN N
48 CD N
h. JJ N
RESULTS NNP N
All NNP N
three CD N
solutions NNS N
produced VBD N
equivalent JJ N
analgesia NN N
. . N

Again RB N
, , N
there EX N
was VBD N
no DT N
main JJ N
effect NN N
of IN N
condition NN N
on IN N
heat NN N
pain NN N
threshold NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
nor CC N
on IN N
cold JJ N
pain NN N
threshold NN N
( ( N
p JJ N
= NNP N
0.65 CD N
) ) N
, , N
nor CC N
on IN N
any DT N
of IN N
the DT N
secondary JJ N
measures NNS N
( ( N
p VB N
< $ N
0.56 CD N
for IN N
all DT N
) ) N
. . N

RESULTS NNP N
Significant NNP N
differences VBZ N
and/or JJ N
trends NNS N
in IN N
favor NN N
of IN N
the DT N
EG NNP N
were VBD N
observed VBN N
regarding VBG N
the DT N
primary JJ N
endpoint NN N
endurance NN N
performance NN N
( ( N
P=0.002 NNP N
) ) N
, , N
muscular JJ N
strength NN N
( ( N
P=0.022 NNP N
) ) N
, , N
fatigue NN N
( ( N
P=0.046 NNP N
) ) N
, , N
and CC N
emotional JJ N
state NN N
( ( N
P=0.028 NNP N
) ) N
without IN N
posing VBG N
an DT N
additional JJ N
risk NN N
for IN N
the DT N
individual NN N
. . N

Monthly JJ N
pre-enalapril NNS N
and CC N
post-enalapril JJ N
neurohormone NN N
levels NNS N
( ( N
serum JJ N
ACE NNP N
activity NN N
( ( N
sACE NN N
) ) N
, , N
plasma JJ N
angiotensin NN N
II NNP N
( ( N
A-II NNP N
) ) N
, , N
plasma JJ N
renin NN N
activity NN N
( ( N
PRA NNP N
) ) N
, , N
and CC N
serum VB N
aldosterone NN N
( ( N
ALDO NNP N
) ) N
were VBD N
compared VBN N
between IN N
genotype NN N
subgroups NNS N
and CC N
between IN N
patients NNS p
who WP N
received VBD N
high- JJ N
or CC N
low-dose JJ N
enalapril NN N
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

Rates NNS N
of IN N
serious JJ N
adverse JJ N
events NNS N
( ( N
overall JJ i
rate=14.8 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
serious JJ N
infections NNS N
( ( N
overall JJ i
rate=4.2 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
cancer NN N
( ( N
overall JJ i
rate=1.0 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
and CC N
deaths NNS N
( ( N
overall JJ i
rate=0.7 NN N
events/100 IN N
patient-yrs NN N
) ) N
were VBD N
stable JJ N
each DT N
year NN N
, , N
through IN N
8 CD N
years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

Adults NNS N
with IN N
systolic JJ N
BP NNP N
120-159 JJ N
mm NN N
Hg NNP N
and CC N
diastolic JJ N
BP NNP N
80-95 JJ N
mm NN N
Hg NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
DASH NNP N
diet NN N
or CC N
a DT N
typical JJ N
American NNP N
( ( N
control NN N
) ) N
diet NN N
, , N
consuming VBG N
three CD N
different JJ N
sodium NN N
intakes NNS N
( ( N
higher=142 JJ N
mmol/d NN N
, , N
intermediate=107 NN N
mmol/d NN N
, , N
and CC N
lower=65 JJ N
mmol/d NN N
) ) N
for IN N
30 CD N
days NNS N
each DT N
. . N

RESULTS VB N
The DT N
serum NN N
levels NNS N
of IN N
TARC NNP N
decreased VBD o
significantly RB o
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
boiled VBN N
CM NNP N
and CC N
in IN N
raw JJ N
CM NNP N
group NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
too RB N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
in IN N
placebo NN N
group NN N
. . N

In IN N
the DT N
cicloxilic JJ N
group NN N
there EX N
was VBD N
little JJ N
or CC N
no DT N
change NN N
in IN N
bile NN N
salts NNS N
and CC N
phospholipids NNS N
, , N
whereas NNS N
biliary VBP N
cholesterol NN N
concentration NN N
was VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
consequently RB N
the DT N
lithogenic JJ N
index NN N
lowered VBD N
( ( N
from IN N
1.5 CD N
to TO N
1.2 CD N
, , N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

RESULTS NN N
At IN N
each DT N
time NN N
point NN N
, , N
in IN N
patients NNS p
treated VBN N
with IN N
a DT N
thrombus-aspiration NN N
filter NN N
device NN N
, , N
WMSI NNP N
, , N
CSI NNP N
, , N
WML NNP N
, , N
and CC N
CDL NNP N
were VBD N
significantly RB N
lower JJR N
and CC N
ejection NN N
fraction NN N
higher JJR N
( ( N
p JJ N
< $ N
0.05 CD N
vs. FW N
control NN N
patients NNS p
) ) N
, , N
whereas JJ N
LV NNP N
volumes NNS N
were VBD N
slightly RB N
but CC N
not RB N
significantly RB N
smaller JJR N
compared VBN N
with IN N
control NN N
patients NNS p
. . N

Sibenadet NNP N
therapy NN i
was VBD N
generally RB N
well RB N
tolerated VBN N
, , N
with IN N
the DT N
only JJ N
notable JJ N
differences NNS N
seen VBN N
in IN N
the DT N
incidence NN N
of IN N
tremor NN N
and CC N
taste NN N
of IN N
treatment NN N
( ( N
16.9 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
and CC N
14.5 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
in IN N
the DT N
sibenadet NN N
and CC N
placebo NN N
groups NNS N
respectively RB N
) ) N
. . N

After IN N
a DT N
mean JJ N
duration NN N
of IN N
GH NNP N
treatment NN N
of IN N
8.6 CD N
+/- JJ N
1.9 CD N
yr NN N
, , N
FH NNP N
was VBD N
reached VBN N
at IN N
a DT N
mean JJ N
age NN N
of IN N
15.8 CD N
+/- JJ N
0.9 CD N
yr. NN N
FH NNP N
, , N
expressed VBD N
in IN N
centimeters NNS N
or CC N
SD NNP N
score NN N
, , N
was VBD N
157.6 CD N
+/- JJ N
6.5 CD N
or CC N
-1.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
A NNP N
, , N
162.9 CD N
+/- JJ N
6.1 CD N
or CC N
-0.7 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
B NNP N
, , N
and CC N
163.6 CD N
+/- JJ N
6.0 CD N
or CC N
-0.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
C. NNP N
The DT N
difference NN N
in IN N
FH NNP N
in IN N
centimeters NNS N
, , N
corrected VBN N
for IN N
height NN N
SD NNP N
score NN N
and CC N
age NN N
at IN N
start NN N
of IN N
treatment NN N
, , N
was VBD N
significant JJ N
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
[ NNP N
regression NN N
coefficient NN N
, , N
4.1 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.4 CD N
, , N
6.9 CD N
; : N
P NNP N
< VBD N
0.01 CD N
] NN N
, , N
and CC N
groups NNS N
A NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
5.0 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
2.3 CD N
, , N
7.7 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
between IN N
groups NNS N
B NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
0.9 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.8 NNP N
, , N
3.6 CD N
) ) N
. . N

RESULTS JJ N
Results NNP N
of IN N
an DT N
intent-to-treat JJ N
analysis NN N
did VBD N
not RB N
meet VB N
the DT N
prespecified JJ N
criterion NN N
for IN N
noninferiority NN N
but CC N
did VBD N
demonstrate VB N
the DT N
superiority NN N
of IN N
continuous-dose JJ N
terbinafine NN N
for IN N
: : N
mycological JJ N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
( ( N
70.9 CD N
% NN N
[ CC N
105/148 CD N
] JJ N
vs RB N
58.7 CD N
% NN N
[ CC N
84/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
of IN N
1.21 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.02-1.43 JJ N
] NN N
) ) N
; : N
clinical JJ N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
( ( N
44.6 CD N
% NN N
[ CC N
66/148 CD N
] JJ N
vs RB N
29.3 CD N
% NN N
[ CC N
42/143 CD N
] NN N
; : N
P NNP N
=.007 NNP N
, , N
RR NNP N
=1.52 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.11-2.07 JJ N
) ) N
; : N
complete JJ N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
( ( N
40.5 CD N
% NN N
[ CC N
60/148 CD N
] JJ N
vs RB N
28.0 CD N
% NN N
[ CC N
40/143 CD N
] NN N
; : N
P NNP N
=.02 NNP N
, , N
RR=1.45 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.04-2.01 JJ N
) ) N
; : N
and CC N
complete JJ N
cure NN N
of IN N
all DT N
10 CD N
toenails NNS N
( ( N
25.2 CD N
% NN N
[ CC N
36/143 CD N
] JJ N
vs RB N
14.7 CD N
% NN N
[ CC N
21/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
RR NNP N
=1.71 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.79 JJ N
) ) N
. . N

RESULTS VB N
The DT N
score NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
markedly RB N
decreased VBD o
after IN o
treatment NN N
, , N
in IN N
treatment NN N
group NN N
: : N
vertigo NN N
had VBD N
( ( N
2.75 CD N
+/- JJ N
1.01 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ N
pain NN N
( ( N
1.58 CD N
+/- JJ N
0.36 CD N
) ) N
, , N
headache NN N
( ( N
0.39 CD N
+/- JJ N
0.09 CD N
) ) N
, , N
nausea-vomiting JJ N
( ( N
1.58 CD N
+/- JJ N
1.30 CD N
) ) N
, , N
ear JJ N
noises NNS N
( ( N
0.48 CD N
+/- JJ N
0.32 CD N
) ) N
, , N
positive JJ N
neck NN N
rotation NN N
test NN N
( ( N
0.59 CD N
+/- JJ N
0.21 CD N
) ) N
; : N
and CC N
in IN N
control NN N
group NN N
: : N
vertigo NN N
had VBD N
( ( N
5.68 CD N
+/- JJ N
2.02 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ N
pain NN N
( ( N
3.12 CD N
+/- JJ N
1.82 CD N
) ) N
, , N
headache NN N
( ( N
1.86 CD N
+/- JJ N
0.65 CD N
) ) N
, , N
nausea-vomiting JJ N
( ( N
3.25 CD N
+/- JJ N
0.69 CD N
) ) N
, , N
ear JJ N
noises NNS N
( ( N
1.64 CD N
+/- JJ N
0.61 CD N
) ) N
, , N
positive JJ N
neck NN N
rotation NN N
test NN N
( ( N
1.79 CD N
+/- JJ N
0.67 CD N
) ) N
. . N

In IN N
a DT N
multivariate NN N
model NN N
, , N
IFN- NNP N
therapy NN i
was VBD N
a DT N
significant JJ N
predictor NN N
of IN N
favorable JJ N
RFS NNP N
( ( N
HR NNP N
0.74 CD N
; : N
95 CD N
% NN N
CI NNP N
0.55-0.99 CD N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
, , N
after IN N
adjustment NN N
for IN N
pre-treatment JJ N
MMP-8 NNP N
( ( N
HR NNP N
1.17 CD N
; : N
95 CD N
% NN N
CI NNP N
0.88-1.55 CD N
; : N
P NNP N
= NNP N
0.28 CD N
) ) N
, , N
gender FW N
( ( N
HR NNP N
1.16 CD N
; : N
95 CD N
% NN N
CI NNP N
0.86-1.56 CD N
; : N
P NNP N
= NNP N
0.32 CD N
) ) N
, , N
age NN N
( ( N
HR NNP N
1.00 CD N
; : N
95 CD N
% NN N
CI NNP N
1.00-1.02 CD N
; : N
P NNP N
= NNP N
0.12 CD N
) ) N
, , N
ulceration NN N
( ( N
HR NNP N
1.09 CD N
; : N
95 CD N
% NN N
CI NNP N
0.81-1.46 CD N
; : N
P NNP N
= NNP N
0.58 CD N
) ) N
, , N
and CC N
the DT N
presence NN N
of IN N
node JJ N
metastases NNS N
( ( N
HR NNP N
1.36 CD N
; : N
95 CD N
% NN N
CI NNP N
1.17-1.58 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

At IN N
15 CD N
and CC N
30-day JJ N
follow-ups NNS N
, , N
control NN N
group NN N
and CC N
nonsteroid JJ N
leads VBZ N
show VB N
a DT N
higher JJR N
threshold JJ N
value NN N
growth NN N
( ( N
in IN N
unipolar NN N
from IN N
0.16 CD N
+/- JJ N
0.11 CD N
to TO N
1.19 CD N
+/- JJ N
0.85 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.18 CD N
+/- JJ N
0.13 CD N
to TO N
1.24 CD N
+/- JJ N
0.88 CD N
microJ NN N
) ) N
than IN N
the DT N
membrane NN N
steroid NN N
leads VBZ N
( ( N
in IN N
unipolar NN N
from IN N
0.13 CD N
+/- JJ N
0.11 CD N
to TO N
0.70 CD N
+/- JJ N
0.39 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.23 CD N
+/- JJ N
0.32 CD N
to TO N
0.76 CD N
+/- JJ N
0.36 CD N
microJ NN N
) ) N
; : N
the DT N
threshold NN N
of IN N
nonsteroid JJ N
leads NNS N
decreases NNS o
after IN N
1-3 JJ N
months NNS N
and CC N
it PRP N
settles VBZ N
at IN N
the DT N
same JJ N
threshold JJ N
level NN N
of IN N
the DT N
leads NNS N
with IN N
membrane NN N
and CC N
steroid NN N
( ( N
in IN N
unipolar JJ N
0.60 CD N
+/- JJ N
0.33 CD N
microJ NN N
; : N
in IN N
bipolar JJ N
0.55 CD N
+/- JJ N
0.26 CD N
microJ NN N
) ) N
, , N
which WDT N
has VBZ N
been VBN N
stable JJ N
since IN N
the DT N
first JJ N
month NN N
. . N

During IN N
a DT N
mean JJ N
follow-up JJ N
period NN N
of IN N
1.8 CD N
years NNS N
, , N
adverse JJ N
events NNS N
in IN N
the DT N
two CD N
groups NNS N
included VBD N
death NN N
( ( N
4.3 CD N
percent NN N
in IN N
the DT N
aspirin NN N
group NN N
vs. FW N
9.7 CD N
percent NN N
in IN N
the DT N
warfarin NN N
group NN N
; : N
hazard CC N
ratio NN N
for IN N
aspirin JJ N
relative JJ N
to TO N
warfarin VB N
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.23 CD N
to TO N
0.90 CD N
; : N
P=0.02 NNP N
) ) N
, , N
major JJ N
hemorrhage NN N
( ( N
3.2 CD N
percent NN N
vs. FW N
8.3 CD N
percent NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
, , N
0.39 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.18 CD N
to TO N
0.84 CD N
; : N
P=0.01 NNP N
) ) N
, , N
and CC N
myocardial JJ N
infarction NN N
or CC N
sudden JJ N
death NN N
( ( N
2.9 CD N
percent NN N
vs. FW N
7.3 CD N
percent NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
, , N
0.40 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.18 CD N
to TO N
0.91 CD N
; : N
P=0.02 NNP N
) ) N
. . N

With IN N
atorvastatin NN i
, , N
the DT N
distensibility NN N
coefficient NN N
( ( N
DC NNP N
) ) N
and CC N
compliance NN N
coefficient NN N
( ( N
CC NNP N
) ) N
increased VBD o
from IN o
18.7 CD N
+/- JJ N
3.4 CD N
to TO N
21.3 CD N
+/- JJ N
2.9 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.69 CD N
+/- JJ N
0.05 CD N
to TO N
0.77 CD N
+/- JJ N
0.03 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
the DT N
first JJ N
group NN N
while IN N
they PRP N
changed VBD N
from IN N
18.3 CD N
+/- JJ N
3.6 CD N
to TO N
21.9 CD N
+/- JJ N
3.0 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.70 CD N
+/- JJ N
0.04 CD N
to TO N
0.81 CD N
+/- JJ N
0.01 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
respectively RB N
, , N
in IN N
the DT N
second JJ N
group NN N
. . N

RESULTS NNP N
Significant NNP N
time NN N
? . N
treatment NN N
interaction NN N
was VBD N
observed VBN N
for IN N
Irritability NNP N
( ( N
F NNP N
( ( N
1.658 CD N
, , N
63.021 CD N
) ) N
= NN N
13.580 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
Lethargy/Social NNP N
Withdrawal NNP N
( ( N
F NNP N
( ( N
1.948 CD N
, , N
74.032 CD N
) ) N
= NN N
16.811 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
Stereotypic NNP N
Behavior NNP N
( ( N
F NNP N
( ( N
1.742 CD N
, , N
66.198 CD N
) ) N
= NN N
12.104 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
for IN N
Hyperactivity/Noncompliance NNP N
( ( N
F NNP N
( ( N
2.564 CD N
, , N
97.424 CD N
) ) N
= NN N
1.469 CD N
, , N
P NNP N
= NNP N
0.232 CD N
) ) N
, , N
and CC N
Inappropriate NNP N
Speech NNP N
subscales NNS N
( ( N
F NNP N
( ( N
1.607 CD N
, , N
61.075 CD N
) ) N
= NN N
0.173 CD N
, , N
P NNP N
= NNP N
0.794 CD N
) ) N
. . N

PFS NNP N
was VBD N
significantly RB N
prolonged VBN N
with IN N
pazopanib NNS N
compared VBN N
with IN N
placebo NN N
in IN N
the DT N
overall JJ i
study NN N
population NN N
( ( N
median JJ N
, , N
PFS NNP N
9.2 CD N
v NN N
4.2 CD N
months NNS N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.34 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
the DT N
treatment-naive JJ N
subpopulation NN N
( ( N
median JJ N
PFS NNP N
11.1 CD N
v NN N
2.8 CD N
months NNS N
; : N
HR NNP N
, , N
0.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.60 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
and CC N
the DT N
cytokine-pretreated JJ N
subpopulation NN N
( ( N
median JJ N
PFS NNP N
, , N
7.4 CD N
v NN N
4.2 CD N
months NNS N
; : N
HR NNP N
, , N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.35 CD N
to TO N
0.84 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

RESULTS NNP N
After IN N
40 CD N
sessions NNS N
, , N
mean JJ N
physician JJ N
CGI NNP N
scores VBZ N
significantly RB N
improved VBN N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
controls NNS N
in IN N
overall JJ i
functioning NN N
( ( N
p JJ N
= NNP N
0.0008 CD N
) ) N
, , N
receptive JJ N
language NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
social JJ N
interaction NN N
( ( N
p JJ N
= NNP N
0.0473 CD N
) ) N
, , N
and CC N
eye NN N
contact NN N
( ( N
p JJ N
= NNP N
0.0102 CD N
) ) N
; : N
9/30 CD N
children NNS N
( ( N
30 CD N
% NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
rated VBN N
as IN N
very RB N
much JJ N
improved VBN N
or CC N
much RB N
improved VBN N
compared VBN N
to TO N
2/26 CD N
( ( N
8 CD N
% NN N
) ) N
of IN N
controls NNS N
( ( N
p VB N
= RB N
0.0471 CD N
) ) N
; : N
24/30 CD N
( ( N
80 CD N
% NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
improved VBD N
compared VBN N
to TO N
10/26 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
controls NNS N
( ( N
p VB N
= RB N
0.0024 CD N
) ) N
. . N

Variables NNS N
associated VBN N
with IN N
non-adherence NN N
were VBD N
diagnosis VBN N
by IN N
screening VBG N
( ( N
OR CC N
1.88 CD N
, , N
95 CD N
% NN N
CI NNP N
1.26-2.82 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
illegal JJ N
immigration NN N
status NN N
( ( N
OR CC N
1.48 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01-2.15 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
unemployment NN N
( ( N
OR CC N
1.91 CD N
, , N
95 CD N
% NN N
CI NNP N
1.28-2.85 CD N
, , N
P NNP N
= NNP N
0.0008 CD N
) ) N
, , N
illiteracy NN N
( ( N
OR CC N
1.73 CD N
, , N
95 CD N
% NN N
CI NNP N
1.04-2.88 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
lack NN N
of IN N
family NN N
support NN N
( ( N
OR NNP N
3.7 CD N
, , N
95 CD N
% NN N
CI NNP N
2.54-5.4 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
the DT N
6-month JJ N
treatment NN N
regimen NNS N
( ( N
OR NNP N
2.45 CD N
, , N
95 CD N
% NN N
CI NNP N
1.68-3.57 CD N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

RESULTS NNP N
Use NNP N
of IN N
the DT N
MAS NNP N
improved VBD N
total JJ N
respiratory NN N
disturbance NN N
index NN N
( ( N
RDI NNP N
) ) N
from IN N
22.2 CD N
+/- JJ N
19.8 CD N
( ( N
SD NNP N
) ) N
events NNS N
per IN N
hour NN N
to TO N
16.5 CD N
+/- JJ N
21.4/hr CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
, , N
supine JJ N
RDI NNP N
( ( N
30.8 CD N
+/- JJ N
23.8/hr CD N
to TO N
18.8 CD N
+/- JJ N
22.1/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
arousal JJ N
index NN N
( ( N
25.2 CD N
+/- JJ N
18.9/hr CD N
to TO N
19.3 CD N
+/- JJ N
14.2/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
and CC N
snoring VBG N
intensity NN N
( ( N
52.7 CD N
+/- JJ N
4.1 CD N
to TO N
50.7 CD N
+/- JJ N
2.7 CD N
dB NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
but CC N
not RB N
total JJ N
snore NN N
frequency NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
cumulative JJ N
dose NN N
of IN N
morphine NN N
administered VBN N
at IN N
each DT N
time NN N
point NN N
was VBD N
lower JJR N
in IN N
Group NNP N
P NNP N
than IN N
in IN N
Group NNP N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
at IN N
2 CD N
h NN N
( ( N
3.81 CD N
? . N
0.35 CD N
versus NN N
4.13 CD N
? . N
0.45 CD N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
6 CD N
h NN N
( ( N
16.20 CD N
? . N
1.49 CD N
versus NN N
19.60 CD N
? . N
0.35 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
12 CD N
h NN N
( ( N
26.29 CD N
? . N
2.75 CD N
versus NN N
32.49 CD N
? . N
2.42 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
24 CD N
h NN N
( ( N
41.72 CD N
? . N
2.70 CD N
versus NN N
49.97 CD N
? . N
4.53 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
48 CD N
h NN N
( ( N
60.06 CD N
? . N
4.00 CD N
versus NN N
65.68 CD N
? . N
3.23 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
estimates NNS N
( ( N
with IN N
relative JJ N
standard JJ N
errors NNS N
expressed VBD N
in IN N
percentages NNS N
in IN N
parentheses NNS N
) ) N
of IN N
the DT N
apparent JJ N
zero-order NN N
rate NN N
constant NN N
for IN N
flare NN N
or CC N
wheal NN N
spontaneous JJ N
appearance NN N
( ( N
k NN N
( ( N
in IN N
) ) N
) ) N
, , N
the DT N
first-order JJ N
rate NN N
constant NN N
for IN N
flare NN N
or CC N
wheal JJ N
disappearance NN N
( ( N
k NN N
( ( N
out IN N
) ) N
) ) N
and CC N
bilastine JJ N
IC NNP N
( ( N
50 CD N
) ) N
values NNS N
were VBD N
0.44 CD N
ng/mL/h NNS N
( ( N
14.60 CD N
% NN N
) ) N
, , N
1.09 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
15.14 CD N
% NN N
) ) N
and CC N
5.15 CD N
ng/mL NN N
( ( N
16.16 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
wheal JJ N
inhibition NN N
, , N
and CC N
11.10 CD N
ng/mL/h NN N
( ( N
8.48 CD N
% NN N
) ) N
, , N
1.03 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
8.35 CD N
% NN N
) ) N
and CC N
1.25 CD N
ng/mL NN N
( ( N
14.56 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
flare JJ N
inhibition NN N
. . N

RESULTS NN N
At IN N
the DT N
follow-up JJ N
assessment NN N
, , N
the DT N
mean NN N
score NN N
for IN N
the DT N
knowledge NN N
of IN N
helminths NNS N
, , N
calculated VBD N
as IN N
a DT N
percentage NN N
of IN N
a DT N
total NN N
of IN N
43 CD N
points NNS N
on IN N
a DT N
questionnaire NN N
, , N
was VBD N
90 CD N
% NN N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
63.3 CD N
vs. FW N
33.4 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
percentage NN N
of IN N
children NNS N
who WP N
washed VBD N
their PRP$ N
hands NNS N
after IN N
using VBG N
the DT N
toilet NN N
was VBD N
nearly RB N
twice RB N
as RB N
high JJ N
in IN N
the DT N
intervention NN N
group NN N
( ( N
98.9 CD N
% NN N
, , N
vs. FW N
54.2 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
incidence NN N
of IN N
infection NN N
with IN N
soil-transmitted JJ N
helminths NNS N
was VBD N
50 CD N
% NN N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
4.1 CD N
% NN N
vs. FW N
8.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

At IN N
study NN N
exit NN N
, , N
57.0 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
36.4 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
Papanicolaou NNP N
test NN N
in IN N
the DT N
past JJ N
24 CD N
months NNS N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
, , N
61.7 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
42.4 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
mammogram NN N
in IN N
the DT N
past JJ N
12 CD N
months NNS N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
54.4 CD N
% NN N
of IN N
men NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
36.0 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
prostate-specific JJ N
antigen NN N
test NN N
in IN N
the DT N
past JJ N
12 CD N
months NNS N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
, , N
and CC N
43.0 CD N
% NN N
of IN N
both DT N
sexes NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
27.2 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
flexible JJ N
sigmoidoscopy NN N
or CC N
colonoscopy NN N
in IN N
the DT N
past JJ N
5 CD N
years NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

RESULTS NN N
At IN N
10 CD N
minutes NNS N
after IN N
CPR NNP N
, , N
in IN N
the DT N
low JJ N
VT NNP N
ventilation NN N
group NN N
, , N
arterial JJ N
blood NN N
pH NN N
, , N
arterial JJ N
partial JJ N
pressure NN N
of IN N
oxygen NN N
( ( N
PaO2 NNP N
) ) N
, , N
arterial JJ N
partial JJ N
pressure NN N
of IN N
carbon NN N
dioxide NN N
( ( N
PaCO2 NNP N
) ) N
, , N
HCO3 NNP N
( ( N
- : N
) ) N
, , N
arterial JJ N
oxygen NN N
saturation NN N
( ( N
SaO2 NNP N
) ) N
and CC N
blood NN N
lactic JJ N
acid NN N
were VBD N
better RB N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
conventional JJ N
VT NNP N
ventilation NN N
group NN N
( ( N
pH NN N
: : N
7.21 CD N
vs NN N
7.13 CD N
, , N
PaO2 NNP N
: : N
45.35 CD N
mm NN N
Hg NNP N
vs VBZ N
40.70 CD N
mm NN N
Hg NNP N
, , N
PaCO2 NNP N
: : N
57.10 CD N
mm NN N
Hg NNP N
vs VBZ N
61.60 CD N
mm NN N
Hg NNP N
, , N
HCO3 NNP N
( ( N
- : N
) ) N
: : N
18.50 CD N
mmol/L NN N
vs. FW N
14.75 CD N
mmol/L NN N
, , N
SaO2 NNP N
: : N
0.796 CD N
vs NN N
0.699 CD N
, , N
blood NN N
lactic JJ N
acid NN N
: : N
7.07 CD N
mmol/L NN N
vs. FW N
8.13 CD N
mmol/L NN N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
cotinine NN N
( ( N
serum NN N
, , N
8.9 CD N
+/- JJ N
3.2 CD N
vs. FW N
35.5 CD N
+/- JJ N
10.2 CD N
ng JJ N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-4 NNP N
( ( N
41.3 CD N
+/- JJ N
5.8 CD N
vs. FW N
44.2 CD N
+/- JJ N
4.5 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-5 NNP N
( ( N
36.1 CD N
+/- JJ N
3.2 CD N
vs. FW N
60.1 CD N
+/- JJ N
7.0 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-6 NNP N
( ( N
2.5 CD N
+/- JJ N
0.3 CD N
vs. FW N
7.6 CD N
+/- JJ N
1.4 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
IFN-gamma NNP N
( ( N
0.3 CD N
+/- JJ N
0.2 CD N
vs. FW N
0.6 CD N
+/- JJ N
0.2 CD N
IU NNP N
x NNP N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
at IN N
3 CD N
hours NNS N
were VBD N
higher JJR N
than IN N
at IN N
baseline NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
the DT N
systolic/diastolic JJ N
differences NNS N
between IN N
ambulatory NN N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
and CC N
home NN N
( ( N
n JJ N
= NNP N
52 CD N
) ) N
BP NNP N
groups NNS N
in IN N
home NN N
, , N
daytime JJ N
ambulatory NN N
, , N
night-time JJ N
ambulatory NN N
, , N
and CC N
24-h JJ N
ambulatory NN N
BP NNP N
changes NNS N
averaged VBD N
2.6/2.6 CD N
mm NN N
Hg NNP N
, , N
0.6/1.7 CD N
mm NN N
Hg NNP N
, , N
1.0/1.4 CD N
mm NN N
Hg NNP N
, , N
and CC N
0.6/1.5 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
( ( N
P NNP N
range VBP N
.06 NNP N
to TO N
.75 VB N
) ) N
A DT N
nonsignificant JJ N
trend NN N
to TO N
more RBR N
intensive JJ N
drug NN N
therapy NN i
in IN N
the DT N
ambulatory JJ N
BP NNP N
group NN N
and CC N
a DT N
nonsignificant JJ N
trend NN N
to TO N
larger JJR N
share NN N
of IN N
patients NNS p
reaching VBG N
( ( N
57.7 CD N
% NN N
v JJ N
43.5 CD N
% NN N
, , N
P NNP N
= NNP N
.16 NNP N
) ) N
the DT N
target NN N
pressure NN N
in IN N
the DT N
home NN N
BP NNP N
group NN N
was VBD N
observed VBN N
due JJ N
to TO N
the DT N
3.8 CD N
mm NN N
Hg NNP N
difference NN N
in IN N
ambulatory NN N
and CC N
home NN N
diastolic NN N
BP NNP N
at IN N
randomization NN N
. . N

RESULTS VB N
The DT N
following JJ N
GCV NNP N
concentrations NNS N
( ( N
mean JJ N
+/-SD NN N
) ) N
were VBD N
determined VBN N
: : N
with IN N
CrCl NNP N
of IN N
> NNP N
or CC N
=70 NNP N
ml/min NN N
, , N
the DT N
minimum JJ N
steady-state JJ N
concentration NN N
( ( N
Cmin NNP N
) ) N
and CC N
maximum JJ N
concentration NN N
( ( N
Cmax NNP i
) ) N
were VBD N
0.78+/-0.46 JJ N
microg/ml NN N
and CC N
1.42+/-0.37 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
a DT N
24-hr JJ N
area NN N
under IN N
the DT N
concentration NN N
time NN N
curve NN N
( ( N
AUC0-24 NNP N
) ) N
of IN N
24.7+/-7.8 JJ N
microg NN N
x NNP N
hr/ml NN N
; : N
with IN N
CrCl NNP N
of IN N
50-69 JJ N
ml/min NN N
, , N
the DT N
Cmin NNP N
and CC N
Cmax NNP i
were VBD N
1.93+/-0.48 JJ N
and CC N
2.57+/-0.39 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
an DT N
AUC0-24 NNP N
of IN N
52.1+/-10.1 JJ N
microg NN N
x NNP N
hr/ml NN N
; : N
with IN N
CrCl NNP N
of IN N
25-50 JJ N
ml/min NN N
, , N
the DT N
Cmin NNP N
and CC N
Cmax NNP i
were VBD N
0.41+/-0.27 JJ N
and CC N
1.17+/-0.32 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
an DT N
AUC0-24 NNP N
of IN N
14.6+/-7.4 JJ N
microg NN N
x NNP N
hr/ml NN N
. . N

Of IN N
the DT N
patients NNS p
with IN N
previous JJ N
CABG NNP N
, , N
those DT N
who WP N
had VBD N
undergone NN N
? . N
saphenous JJ N
vein NN N
graft NN N
intervention NN N
had VBD N
significantly RB N
higher JJR N
adjusted JJ N
risks NNS N
of IN N
cardiac JJ N
death NN N
( ( N
hazard JJ N
ratio NN N
2.21 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.26 CD N
to TO N
3.76 CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
myocardial JJ N
infarction NN N
( ( N
hazard JJ N
ratio NN N
2.56 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.10 CD N
to TO N
5.60 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
target NN N
lesion NN N
revascularization NN N
( ( N
hazard JJ N
ratio NN N
2.65 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.82 CD N
to TO N
3.81 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
definite JJ N
stent NN N
thrombosis NN N
( ( N
hazard JJ N
ratio NN N
7.70 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.99 CD N
to TO N
29.1 CD N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
compared VBN N
with IN N
those DT N
who WP N
underwent VBP N
percutaneous JJ N
coronary JJ N
intervention NN N
only RB N
for IN N
the DT N
native JJ N
coronary JJ N
artery NN N
. . N

The DT N
WL+FAEE NNP N
intervention NN N
significantly RB N
reduced VBN N
body NN N
weight NN N
( ( N
-4 CD N
% NN N
) ) N
, , N
waist JJ N
circumference NN N
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ N
( ( N
-8 CD N
% NN N
) ) N
and CC N
diastolic JJ N
( ( N
-5 CD N
% NN N
) ) N
blood NN N
pressures NNS N
, , N
pulse JJ N
pressure NN N
( ( N
-5 CD N
% NN N
) ) N
, , N
heart NN N
rate NN N
( ( N
-8 CD N
% NN N
) ) N
, , N
plasma JJ N
TG NNP N
concentration NN N
( ( N
-36 CD N
% NN N
) ) N
, , N
and CC N
HOMA NNP N
score NN N
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased JJ o
stroke NN N
volume NN N
( ( N
+3 CD N
% NN N
) ) N
, , N
plasma JJ N
HDL NNP N
cholesterol NN N
( ( N
+6 CD N
% NN N
) ) N
and CC N
adiponectin JJ i
concentrations NNS N
( ( N
+28 CD N
% NN N
) ) N
, , N
and CC N
C1 NNP N
( ( N
+20 NNP N
% NN N
) ) N
and CC N
C2 NNP N
( ( N
+22 NNP N
% NN N
) ) N
artery NN N
elasticity NN N
. . N

RESULTS NNP N
Capecitabine/docetaxel NNP i
resulted VBD N
in IN N
significantly RB N
superior JJ N
efficacy NN N
in IN N
time NN N
to TO N
disease VB N
progression NN N
( ( N
TTP NNP N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
0.652 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.545 CD N
to TO N
0.780 CD N
; : N
P NNP N
=.0001 NNP N
; : N
median JJ N
, , N
6.1 CD N
v NN N
4.2 CD N
months NNS N
) ) N
, , N
overall JJ i
survival NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.775 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.634 CD N
to TO N
0.947 CD N
; : N
P NNP N
=.0126 NNP N
; : N
median JJ N
, , N
14.5 CD N
v NN N
11.5 CD N
months NNS N
) ) N
, , N
and CC N
objective JJ N
tumor NN N
response NN N
rate NN N
( ( N
42 CD N
% NN N
v JJ N
30 CD N
% NN N
, , N
P NNP N
=.006 NNP N
) ) N
compared VBN N
with IN N
docetaxel NN i
. . N

Ischemic NNP N
postconditioned VBD N
patients NNS p
had VBD N
a DT N
lower JJR N
peak NN N
inotropic NN N
score NN N
during IN N
the DT N
first JJ N
postoperative JJ N
24 CD N
hours NNS N
( ( N
5.6 CD N
? . N
2.2 CD N
? . N
versus NN N
8.6 CD N
? . N
3.6 CD N
? . N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
extubation JJ N
time NN N
( ( N
21.5 CD N
? . N
7.3 CD N
hours NNS N
versus IN N
30.2 CD N
? . N
12.4 CD N
hours NNS N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
and CC N
length NN N
of IN N
ICU NNP N
stay NN N
( ( N
43.4 CD N
? . N
12.6 CD N
hours NNS N
versus IN N
56.3 CD N
? . N
17.8 CD N
hours NNS N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
, , N
while IN N
they PRP N
had VBD N
a DT N
higher JJR N
cardiac JJ N
output NN N
on IN N
the DT N
first JJ N
postoperative JJ N
day NN N
( ( N
1.41 CD N
? . N
0.26 CD N
L/minute NNP N
versus NN N
1.28 CD N
? . N
0.25 CD N
L/minute NNP N
, , N
P NNP N
= NNP N
0.0255 CD N
) ) N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Compared VBN N
with IN N
Group NNP N
C NNP N
, , N
Group NNP N
P NNP N
had VBD N
significantly RB N
lower JJR N
visual JJ N
analog NN N
scale NN N
scores NNS N
at IN N
rest NN N
and CC N
with IN N
movement NN N
, , N
respectively RB N
, , N
at IN N
2 CD N
h NN N
( ( N
4.2 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
5.0 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
6 CD N
h NN N
( ( N
3.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
4.5 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
12 CD N
h NN N
( ( N
3.0 CD N
, , N
P NNP N
= NNP N
0.017 CD N
and CC N
4.0 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
24 CD N
h NN N
( ( N
2.1 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
3.4 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
48 CD N
h NN N
( ( N
1.8 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
2.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

RESULTS NN N
After IN N
the DT N
intervention NN N
period NN N
, , N
the DT N
diabetes NNS N
specific JJ N
formula NN N
resulted VBD N
in IN N
a DT N
significantly RB N
lower JJR N
postprandial JJ N
rise NN N
in IN N
blood NN N
glucose JJ N
concentrations NNS N
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
significantly RB N
lower JJR N
peak JJ N
height NN N
of IN N
plasma NN N
glucose NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
; : N
significantly RB N
lower JJR N
plasma NN N
insulin NN N
concentrations NNS N
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2 CD N
hours NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
and CC N
a DT N
significantly RB N
lower JJR N
plasma NN N
insulin NN N
peak NN N
compared VBN N
to TO N
controls NNS N
; : N
both DT N
OGTT NNP N
and CC N
a DT N
standard JJ N
test NN N
meal NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
follow-up NN N
, , N
changes NNS N
in IN N
the DT N
mean NN N
of IN N
systolic NN N
( ( N
-2.1 NNP N
vs. FW N
3.9 CD N
% NN N
mmHg NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
diastolic JJ N
( ( N
-3.8 NNP N
vs. FW N
7.5 CD N
% NN N
mmHg NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
blood NN N
pressures NNS N
, , N
HOMA-IR NNP N
index NN N
( ( N
-46.5 NNP N
vs. FW N
-5.4 NNP N
% NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
, , N
fasting VBG N
glucose NN N
( ( N
-12.3 JJ N
vs. FW N
-1.8 CD N
% NN N
mg/dL NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
triglyceride JJ N
levels NNS N
( ( N
-47.4 CD N
% NN N
vs. FW N
10.1 CD N
% NN N
mg/dL NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
subjects NNS N
who WP N
received VBD N
MgCl2 NNP N
compared VBN N
with IN N
individuals NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Less RBR N
severe JJ N
baseline NN N
autism NN N
symptomatology NN N
( ( N
lower JJR N
Autism NNP N
Diagnosis NNP N
Observation NNP N
Schedule NNP N
[ NNP N
ADOS NNP N
] NNP N
score NN N
; : N
C. NNP N
Lord NNP N
et VBZ N
al RB N
, , N
2000 CD N
) ) N
was VBD N
associated VBN N
with IN N
greater JJR N
increase NN o
in IN N
spontaneous JJ N
speech NN N
( ( N
RR NNP N
= NNP N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.83 CD N
, , N
0.98 CD N
] NN N
, , N
p NN N
= NNP N
.011 NNP N
) ) N
and CC N
less RBR N
severe JJ N
baseline NN N
expressive JJ N
language NN N
impairment NN N
( ( N
lower JJR N
ADOS NNP N
item NN N
A1 NNP N
score NN N
) ) N
, , N
with IN N
larger JJR N
increases NNS o
in IN N
spontaneous JJ N
use NN N
of IN N
speech NN N
and CC N
pictures VBZ N
together RB N
( ( N
RR NNP N
= NNP N
0.62 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.44 CD N
, , N
0.88 CD N
] NN N
, , N
p NN N
= NNP N
.008 NNP N
) ) N
. . N

Vital NNP N
force NN N
also RB N
showed VBD N
correlations NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
lower JJR N
CGI NNP N
ratings NNS N
by IN N
the DT N
conventional JJ N
medical JJ N
provider NN N
( ( N
r VB N
=-0.32 NN N
) ) N
, , N
better RB N
selfrated VBN N
quality NN N
of IN N
life NN N
( ( N
r JJ N
= NNP N
0.33 CD N
) ) N
, , N
lesser JJR N
fatigue NN N
( ( N
r VB N
=-0.31 NN N
) ) N
, , N
better JJR N
global JJ N
health NN N
( ( N
r VB N
= RB N
0.29 CD N
) ) N
, , N
greater JJR N
sense NN N
of IN N
coherence NN N
( ( N
r JJ N
= NNP N
0.28 CD N
) ) N
, , N
powerful-others JJ N
health NN N
locus NN N
of IN N
control NN N
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
increased VBD o
emotional JJ o
well-being NN N
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
and CC N
higher JJR N
social JJ N
desirability NN N
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
but CC N
not RB N
with IN N
age NN N
, , N
pain NN N
, , N
or CC N
illness JJ N
duration NN N
. . N

These DT N
risk NN N
reductions NNS N
, , N
achieved VBN N
at IN N
a DT N
median JJ N
HbA NNP N
( ( N
1c CD N
) ) N
level NN N
difference NN N
of IN N
9.1 CD N
% NN N
for IN N
conventional JJ N
treatment NN N
vs RB N
7.3 CD N
% NN N
for IN N
intensive JJ N
treatment NN N
have VBP N
been VBN N
maintained VBN N
through IN N
7 CD N
years NNS N
of IN N
EDIC NNP N
, , N
even RB N
though IN N
the DT N
difference NN N
in IN N
mean JJ N
HbA NNP N
( ( N
1c CD N
) ) N
levels NNS N
of IN N
the DT N
2 CD N
former JJ N
randomized VBN N
treatment NN N
groups NNS N
was VBD N
only RB N
0.4 CD N
% NN N
at IN N
1 CD N
year NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
( ( N
8.3 CD N
% NN N
in IN N
the DT N
former JJ N
conventional JJ N
treatment NN N
group NN N
vs VBD N
7.9 CD N
% NN N
in IN N
the DT N
former JJ N
intensive JJ N
treatment NN N
group NN N
) ) N
, , N
continued VBD N
to TO N
narrow VB N
, , N
and CC N
became VBD N
statistically RB N
nonsignificant JJ N
by IN N
5 CD N
years NNS N
( ( N
8.1 CD N
% NN N
vs JJ N
8.2 CD N
% NN N
, , N
P NNP N
=.09 NNP N
) ) N
. . N

Efficacy NN N
parameters NNS N
were VBD N
assessed VBN N
as IN N
follows VBZ N
: : N
at IN N
baseline NN N
( ( N
T1 NNP N
) ) N
, , N
after IN N
the DT N
first JJ N
administration NN N
( ( N
T2 NNP N
; : N
day NN N
of IN N
surgery NN N
) ) N
, , N
the DT N
second JJ N
day NN N
after IN N
the DT N
surgical JJ N
procedure NN N
( ( N
T3 NNP N
) ) N
, , N
and CC N
the DT N
fifth JJ N
day NN N
after IN N
the DT N
surgical JJ N
procedure NN N
( ( N
T4 NNP N
) ) N
; : N
hemorrhoidal PRP$ N
symptoms NNS N
based VBN N
on IN N
a DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
: : N
pain NN N
, , N
discharge NN N
, , N
bleeding NN N
, , N
inflammation NN N
, , N
and CC N
pruritus NN N
; : N
analgesic JJ N
intake NN N
, , N
if IN N
any DT N
; : N
time NN N
to TO N
restore VB N
a DT N
physiological JJ N
defecation NN N
; : N
edema CC N
evaluation NN N
( ( N
based VBN N
on IN N
a DT N
four-point JJ N
scale NN N
: : N
0 CD N
= JJ N
absent NN N
; : N
1 CD N
= NNP N
mild NN N
; : N
2 CD N
= NN N
moderate NN N
; : N
3 CD N
= NNP N
severe RB N
) ) N
; : N
camera NN N
pictures VBZ N
taken VBN N
at IN N
T1 NNP N
and CC N
T4 NNP N
( ( N
in IN N
selected VBN N
patients NNS p
) ) N
; : N
and CC N
blood NN N
coagulation NN N
tests NNS N
. . N

Although IN N
both DT N
LOOH NNP N
and CC N
NO2- NNP N
increased VBD o
with IN o
high JJ N
altitude NN N
in IN N
lowlanders NNS N
, , N
only RB N
LOOH NNP N
correlated VBD N
with IN N
the DT N
reduction NN N
in IN N
GTN-induced NNP N
dilatation NN N
evident NN N
during IN N
acute NN N
( ( N
n JJ N
= NN N
11 CD N
, , N
r NN N
= NNP N
-0.53 NNP N
) ) N
and CC N
chronic JJ N
( ( N
n JJ N
= NN N
7 CD N
, , N
r NN N
= NNP N
-0.69 NNP N
; : N
P NNP N
? . N
0.01 CD N
) ) N
exposure NN N
to TO N
5050 CD N
m. NN N
In IN N
a DT N
follow-up JJ N
, , N
placebo-controlled JJ N
experiment NN N
( ( N
n JJ N
= $ N
11 CD N
healthy JJ N
lowlanders NNS N
) ) N
conducted VBN N
in IN N
a DT N
normobaric JJ N
hypoxic NN N
chamber NN N
( ( N
inspired JJ N
O2 NNP N
fraction NN N
( ( N
F NNP N
IO NNP N
2 CD N
) ) N
= NN N
0.11 CD N
; : N
6 CD N
h NN N
) ) N
, , N
a DT N
sustained JJ N
reduction NN N
in IN N
FMD NNP N
was VBD N
evident JJ N
within IN N
1 CD N
h NN N
of IN N
hypoxic NN N
exposure NN N
when WRB N
compared VBN N
to TO N
normoxic VB N
baseline NN N
( ( N
5.7 CD N
? . N
1.6 CD N
vs NN N
8.0 CD N
? . N
% NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
this DT N
decline NN N
in IN N
FMD NNP N
was VBD N
largely RB N
reversed VBN N
following VBG N
? . N
blockade NN N
. . N

RESULTS JJ N
Patients NNS N
with IN N
short-term JJ N
GHQ NNP N
success NN N
were VBD N
more RBR N
likely JJ N
to TO N
show VB N
mid-term JJ N
GHQ NNP N
success NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
, , N
marginally RB N
less RBR N
likely JJ N
to TO N
die VB N
of IN N
any DT N
causes NNS N
( ( N
p JJ N
= NNP N
.087 NNP N
) ) N
, , N
less RBR N
likely JJ N
to TO N
die VB N
of IN N
cardiac JJ N
causes NNS N
( ( N
p JJ N
= NNP N
.043 NNP N
) ) N
, , N
less RBR N
likely JJ N
to TO N
be VB N
readmitted VBN N
for IN N
any DT N
reason NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
and CC N
for IN N
cardiac JJ N
reasons NNS N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
high JJ N
depression NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
and CC N
anxiety NN N
( ( N
p JJ N
< NNP N
.001 NN N
) ) N
at IN N
1-year JJ N
than IN N
patients NNS p
with IN N
short-term JJ N
unsuccessful JJ N
GHQ NNP N
outcomes NNS N
. . N

However RB N
, , N
in IN N
preplanned JJ N
analyses NNS N
, , N
overall JJ i
survival NN N
was VBD N
significantly RB N
longer JJR N
for IN N
patients NNS p
with IN N
del19-positive JJ N
tumours NNS N
in IN N
the DT N
afatinib NN N
group NN N
than IN N
in IN N
the DT N
chemotherapy NN i
group NN N
in IN N
both DT N
trials NNS N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ i
survival NN N
was VBD N
33.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
26.8-41.5 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
21.1 CD N
months NNS N
( ( N
16.3-30.7 JJ N
) ) N
in IN N
the DT N
chemotherapy NN i
group NN N
( ( N
HR NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
0.36-0.79 CD N
, , N
p=0.0015 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
31.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
24.2-35.3 CD N
) ) N
versus NN N
18.4 CD N
months NNS N
( ( N
14.6-25.6 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
0.64 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.94 CD N
, , N
p=0.023 NN N
) ) N
. . N

RESULTS NN N
At IN N
24 CD N
months NNS N
, , N
complete JJ N
success NN N
rates NNS N
were VBD N
53.3 CD N
% NN N
for IN N
the DT N
ELT NNP N
group NN N
and CC N
40 CD N
% NN N
for IN N
the DT N
SLT NNP N
group NN N
( ( N
P=0.35 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
; : N
qualified VBN N
success NN N
rates NNS N
were VBD N
33.3 CD N
% NN N
for IN N
the DT N
ELT NNP N
and CC N
26.6 CD N
% NN N
for IN N
the DT N
SLT NNP N
group NN N
( ( N
P=0.5 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
.Mean VBP N
IOP NNP N
decreased VBD o
from IN o
25.0+/-1.9 JJ N
to TO N
17.6+/-2.2 JJ N
mmHg NN N
( ( N
-29.6 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
ELT NNP N
group NN N
and CC N
from IN N
23.9+/-0.9 JJ N
to TO N
19.1+/-1.8 JJ N
mmHg NN N
( ( N
-21 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
SLT NNP N
group NN N
. . N

Although IN N
results NNS N
through IN N
the DT N
entire JJ N
blinded VBD N
period NN N
continued VBD N
to TO N
show VB N
that IN N
selenium JJ N
supplementation NN N
was VBD N
not RB N
statistically RB N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
basal NN N
cell NN N
carcinoma NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
1.09 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= VBD N
0.94 CD N
to TO N
1.26 CD N
) ) N
, , N
selenium JJ N
supplementation NN N
was VBD N
associated VBN N
with IN N
statistically RB N
significantly RB N
elevated VBN N
risk NN N
of IN N
squamous JJ N
cell NN N
carcinoma NN N
( ( N
HR NNP N
= NNP N
1.25 CD N
, , N
95 CD N
% NN N
CI NNP N
= VBZ N
1.03 CD N
to TO N
1.51 CD N
) ) N
and CC N
of IN N
total JJ N
nonmelanoma JJ N
skin NN N
cancer NN N
( ( N
HR NNP N
= NNP N
1.17 CD N
, , N
95 CD N
% NN N
CI NNP N
= VBZ N
1.02 CD N
to TO N
1.34 CD N
) ) N
. . N

RESULTS VB N
A NNP N
series NN N
of IN N
linear JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
age NN N
, , N
gender NN N
, , N
stroke VBD N
type NN N
( ( N
ischemic JJ N
versus NN N
hemorrhagic NN N
) ) N
, , N
interval JJ N
poststroke NN N
, , N
level NN N
of IN N
motor NN N
impairment NN N
( ( N
Fugl-Meyer NNP N
score NN N
) ) N
, , N
and CC N
walking VBG N
speed NN N
found VBD N
BMI NNP N
to TO N
be VB N
positively RB N
associated VBN N
with IN N
step NN N
width NN N
( ( N
m NN N
) ) N
( ( N
? . N
= RB N
0.364 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
positively RB N
associated VBN N
with IN N
peak JJ N
hip NN N
abduction NN N
angle NN N
of IN N
the DT N
nonparetic JJ N
limb NN N
during IN N
stance NN N
( ( N
deg NN N
) ) N
( ( N
? . N
= RB N
0.177 CD N
, , N
P NNP N
= NNP N
.040 NNP N
) ) N
, , N
negatively RB N
associated VBN N
with IN N
ankle JJ N
dorsiflexion NN N
angle NN N
at IN N
initial JJ N
contact NN N
of IN N
the DT N
paretic JJ N
limb NN N
( ( N
deg NN N
) ) N
( ( N
? . N
= NN N
-0.222 NN N
, , N
P NNP N
= NNP N
.023 NNP N
) ) N
, , N
and CC N
negatively RB N
associated VBN N
with IN N
peak NN N
ankle JJ N
power NN N
at IN N
push-off NN N
( ( N
W/kg NNP N
) ) N
of IN N
the DT N
paretic JJ N
limb NN N
( ( N
W/kg NNP N
) ) N
( ( N
? . N
= NN N
-0.142 NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

RESULTS NNP N
Group NNP N
B NNP N
patients NNS p
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
renal JJ N
function NN N
and CC N
urinary JJ N
output NN N
: : N
serum NN N
blood NN N
urea JJ N
nitrogen RB N
48.9 CD N
+/- JJ N
10.3 CD N
to TO N
32.1 CD N
+/- JJ N
14.4 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
serum JJ N
creatinine NN N
1.97 CD N
+/- JJ N
0.24 CD N
to TO N
1.49 CD N
+/- JJ N
0.39 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
creatinine JJ N
clearance NN N
35.6 CD N
+/- JJ N
11.6 CD N
to TO N
48.8 CD N
+/- JJ N
12.3 CD N
ml/min NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
and CC N
indexed JJ N
urinary JJ N
output NN N
0.56 CD N
+/- JJ N
0.16 CD N
to TO N
2.02 CD N
+/- JJ N
0.72 CD N
ml/kg/h NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Clinical JJ N
failure NN N
was VBD N
associated VBN N
with IN N
( ( N
i NN N
) ) N
placebo NN N
treatment NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.28 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01 CD N
to1.62 NN N
) ) N
, , N
( ( N
ii NN N
) ) N
excess JJ N
respiratory JJ N
rate NN N
of IN N
> $ N
10 CD N
breaths NNS N
per IN N
minute NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.51 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.19 CD N
, , N
1.92 CD N
) ) N
, , N
( ( N
iii NN N
) ) N
vomiting VBG N
at IN N
enrolment NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.49 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.13 CD N
, , N
1.96 CD N
) ) N
, , N
( ( N
iv NN N
) ) N
history NN N
of IN N
use NN N
of IN N
broncho-dilators NNS N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.71 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.30 CD N
, , N
2.24 CD N
) ) N
and CC N
( ( N
v NN N
) ) N
non-adherence NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
8.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
4.36 CD N
, , N
14.92 CD N
) ) N
. . N

RESULTS NNP N
Chromium NNP N
supplementation NN N
in IN N
women NNS N
with IN N
PCOS NNP N
resulted VBD N
in IN N
significant JJ N
decreases NNS o
in IN N
serum JJ N
insulin NN N
levels NNS N
( ( N
-3.6 VB N
? . N
7.4 CD N
vs NN N
+3.6 NN N
? . N
6.2 CD N
? . N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
, , N
homeostasis JJ N
model NN N
of IN N
assessment-insulin JJ N
resistance NN N
( ( N
HOMA-IR NNP N
; : N
-0.8 NNP N
? . N
1.6 CD N
vs NN N
+0.9 NN N
? . N
1.5 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
homeostatic JJ N
model NN N
assessment-beta NN N
cell NN N
function NN N
( ( N
HOMA-B NNP N
; : N
-15.5 NNP N
? . N
32.3 CD N
vs NN N
+13.6 NN N
? . N
23.1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
a DT N
significant JJ N
increase NN o
in IN N
quantitative JJ N
insulin NN N
sensitivity NN N
check NN N
index NN N
( ( N
QUICKI NNP N
) ) N
score NN N
( ( N
+0.02 VB N
? . N
0.03 CD N
vs NN N
-0.008 NN N
? . N
0.02 CD N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
the DT N
placebo NN N
. . N

The DT N
significant JJ N
decrease NN o
in IN N
serum JJ N
total JJ N
and CC N
LDL-cholesterol JJ N
concentrations NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
caused VBN N
by IN N
simvastatin NN i
was VBD N
associated VBN N
with IN N
an DT N
increase NN o
in IN N
serum JJ N
N-acetyl-beta-glucosaminidase JJ N
activity NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
ascorbic JJ N
acid NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
plasminogen JJ N
activator NN N
inhibitor NN N
( ( N
PAI-1 NNP N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
vonWillebrand FW N
factor NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
E-selectin NNP i
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
concentrations NNS N
and CC N
with IN N
a DT N
decrease NN o
in IN N
plasma NN N
glutathione NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
levels NNS N
. . N

Mean NNP N
( ( N
? . N
SEM NNP N
) ) N
number NN N
of IN N
F NNP N
& CC N
V NNP N
portions/day NN N
consumed VBN N
by IN N
the DT N
HF NNP N
and CC N
LF NNP N
groups NNS N
at IN N
baseline NN N
( ( N
3.8 CD N
? . N
0.3 CD N
and CC N
3.4 CD N
? . N
0.3 CD N
) ) N
, , N
6 CD N
weeks NNS N
( ( N
6.3 CD N
? . N
0.4 CD N
and CC N
5.8 CD N
? . N
0.3 CD N
) ) N
, , N
12 CD N
weeks NNS N
( ( N
7.0 CD N
? . N
0.3 CD N
and CC N
6.8 CD N
? . N
0.3 CD N
) ) N
and CC N
18 CD N
weeks NNS N
( ( N
7.6 CD N
? . N
0.4 CD N
and CC N
8.1 CD N
? . N
0.4 CD N
) ) N
, , N
respectively RB N
, , N
was VBD N
similar JJ N
at IN N
baseline NN N
yet RB N
higher JJR N
than IN N
the DT N
CT NNP N
group NN N
( ( N
3.9 CD N
? . N
0.3 CD N
, , N
4.3 CD N
? . N
0.3 CD N
, , N
4.6 CD N
? . N
0.4 CD N
, , N
4.5 CD N
? . N
0.3 CD N
) ) N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
. . N

In IN N
lowlanders NNS N
, , N
measurements NNS N
were VBD N
performed VBN N
at IN N
sea NN N
level NN N
( ( N
334 CD N
m NN N
) ) N
and CC N
between IN N
days NNS N
3-4 NNP N
( ( N
acute JJ N
high JJ N
altitude NN N
) ) N
and CC N
12-14 JJ N
( ( N
chronic JJ N
high JJ N
altitude NN N
) ) N
following VBG N
arrival NN N
to TO N
5050 CD N
m. NN N
Highlanders NNP N
were VBD N
assessed VBN N
once RB N
at IN N
5050 CD N
m. NN N
Compared NNP N
with IN N
sea NN N
level NN N
, , N
acute JJ N
high JJ N
altitude NN N
reduced VBD N
lowlanders NNS N
' POS N
FMD NNP N
( ( N
7.9 CD N
? . N
0.4 CD N
vs NN N
6.8 CD N
? . N
0.4 CD N
% NN N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
and CC N
GTN-induced JJ N
dilatation NN N
( ( N
16.6 CD N
? . N
0.9 CD N
vs NN N
14.5 CD N
? . N
0.8 CD N
% NN N
; : N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
and CC N
raised VBD N
central JJ N
PWV NNP N
( ( N
6.0 CD N
? . N
0.2 CD N
vs NN N
6.6 CD N
? . N
0.3 CD N
m NN N
s NN N
( ( N
-1 NNP N
) ) N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
Phase NNP N
2 CD N
, , N
after IN N
transportation NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
treatments NNS N
on IN N
BW NNP N
loss NN N
due JJ N
to TO N
transportation NN N
shrink VB N
( ( N
26.0 CD N
? . N
0.6 CD N
kg NN N
; : N
P NNP N
= NNP N
0.86 CD N
) ) N
, , N
BW NNP N
at IN N
d NN N
28 CD N
( ( N
339.0 CD N
? . N
4.1 CD N
kg NN N
; : N
P NNP N
= NNP N
0.72 CD N
) ) N
, , N
ADG NNP N
( ( N
1.28 CD N
? . N
0.03 CD N
kg/d NN N
; : N
P NNP N
= NNP N
0.72 CD N
) ) N
, , N
G NNP N
: : N
F NNP N
( ( N
0.164 CD N
? . N
0.004 CD N
; : N
P NNP N
= NNP N
0.83 CD N
) ) N
, , N
and CC N
concentrations NNS N
of IN N
plasma NN N
haptoglobin NN N
( ( N
0.08 CD N
? . N
0.02 CD N
mg/mL NN N
; : N
P NNP N
= NNP N
0.41 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
serum NN N
TT3 NNP N
, , N
TT4 NNP N
, , N
FT3 NNP N
, , N
FT4 NNP N
and CC N
S-TSH NNP N
contents NNS N
had VBD N
very RB N
significant JJ N
change NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
TRAb NNP N
had VBD N
very RB N
significant JJ N
change NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
no DT N
significant JJ N
change NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
decrease NN o
of IN N
TT3 NNP N
, , N
FT3 NNP N
, , N
TRAb NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
no DT N
significant JJ N
difference NN N
in IN N
decrease NN o
of IN N
TT4 NNP N
, , N
FT4 NNP N
and CC N
increase NN o
of IN N
S-TSH NNP N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Signal-to-noise JJ N
ratio NN N
( ( N
SNR NNP N
) ) N
and CC N
contrast-to-noise JJ N
ratio NN N
( ( N
CNR NNP N
) ) N
in IN N
the DT N
proximal JJ N
right JJ N
coronary NN N
artery NN N
( ( N
RCA NNP N
) ) N
and CC N
left VBD N
main JJ N
coronary JJ N
artery NN N
( ( N
LMA NNP N
) ) N
were VBD N
all DT N
lower JJR N
in IN N
80-kV CD N
than IN N
120-kV JJ N
images NNS N
( ( N
SNR NNP N
in IN N
the DT N
proximal JJ N
RCA NNP N
: : N
16.5 CD N
? . N
1.8 CD N
vs NN N
19.4 CD N
? . N
2.8 CD N
; : N
SNR NNP N
in IN N
the DT N
LMA NNP N
: : N
16.3 CD N
? . N
2.0 CD N
vs.19.6 NN N
? . N
2.7 CD N
; : N
CNR NNP N
in IN N
the DT N
proximal JJ N
RCA NNP N
: : N
19.4 CD N
? . N
2.3 CD N
vs.22.9 NN N
? . N
3.0 CD N
; : N
CNR NNP N
in IN N
the DT N
LMA NNP N
: : N
18.8 CD N
? . N
2.4 CD N
vs NN N
22.7 CD N
? . N
2.9 CD N
; : N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
. . N

In IN N
the DT N
cangrelor NN N
group NN N
, , N
as IN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
, , N
two CD N
prespecified VBD N
secondary JJ N
end NN N
points NNS N
were VBD N
significantly RB N
reduced VBN N
at IN N
48 CD N
hours NNS N
: : N
the DT N
rate NN N
of IN N
stent JJ N
thrombosis NN N
, , N
from IN N
0.6 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.31 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.11 CD N
to TO N
0.85 CD N
; : N
P=0.02 NNP N
) ) N
, , N
and CC N
the DT N
rate NN N
of IN N
death NN N
from IN N
any DT N
cause NN N
, , N
from IN N
0.7 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.13 CD N
to TO N
0.83 CD N
; : N
P=0.02 NNP N
) ) N
. . N

All DT N
improvements NNS N
were VBD N
equal JJ N
between IN N
groups NNS N
apart RB N
from IN N
the DT N
SF36 NNP N
domain NN N
of IN N
Bodily NNP N
Pain NNP N
, , N
where WRB N
C2 NNP N
saw VBD N
an DT N
improvement NN N
of IN N
12.8 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
4.8-20.8 JJ N
] NN N
points NNS N
over IN N
C3-4 JJ N
participants NNS N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
who WP N
also RB N
suffered VBD N
more JJR N
recurrence NN N
[ NNP N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
= VBZ N
2.7 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.2-6.1 JJ N
, , N
P NNP N
= VBZ N
0.022 CD N
] NN N
and CC N
required VBD N
more JJR N
secondary JJ N
procedures NNS N
( ( N
OR NNP N
= VBZ N
4.4 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.2-16.3 JJ N
, , N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

Naftopidil NNP N
significantly RB N
improved VBD N
the DT N
overall JJ i
international JJ N
prostatic JJ N
symptom NN N
score NN N
; : N
from IN N
19.2 CD N
to TO N
11.7 CD N
in IN N
the DT N
M NNP N
group NN N
and CC N
from IN N
19.4 CD N
to TO N
12.3 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
QOL NNP N
score NN N
from IN N
4.9 CD N
to TO N
3.2 CD N
in IN N
the DT N
M NNP N
group NN N
and CC N
from IN N
5.0 CD N
to TO N
3.6 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
OAB NNP N
symptom VBD N
score NN N
from IN N
7.8 CD N
to TO N
5.0 CD N
in IN N
the DT N
M NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
from IN N
8.6 CD N
to TO N
5.8 CD N
3.3 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Cox NNP N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
use NN N
of IN N
chemotherapy NN i
after IN N
first JJ N
progression NN N
( ( N
HR NNP N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
0.35-0.86 CD N
; : N
p CC N
= VB N
0.008 CD N
) ) N
, , N
PS NNP N
= VBZ N
0 CD N
( ( N
HR NNP N
0.53 CD N
; : N
95 CD N
% NN N
CI NNP N
0.35-0.81 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
and CC N
female JJ N
gender NN N
( ( N
HR NNP N
0.63 CD N
; : N
95 CD N
% NN N
CI NNP N
0.41-0.98 CD N
; : N
p CC N
= VB N
0.038 CD N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
a DT N
longer RBR N
TFPTD NNP N
; : N
treatment NN N
arm NN N
was VBD N
not RB N
significant JJ N
( ( N
HR NNP N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
0.60-1.31 CD N
; : N
p CC N
= VB N
0.54 CD N
) ) N
. . N

Statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
were VBD N
found VBN N
for IN N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
infection NN N
( ( N
induction NN N
, , N
32.5 CD N
% NN N
vs. FW N
noninduction NN N
, , N
19.0 CD N
% NN N
, , N
P=0.009 NNP N
) ) N
, , N
leukopenia NN N
( ( N
37.3 CD N
% NN N
vs. FW N
9.5 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
fever RB N
( ( N
25.2 CD N
% NN N
vs. FW N
10.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
herpes VBZ N
simplex JJ N
( ( N
17.9 CD N
% NN N
vs. FW N
5.7 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
thrombocytopenia NN N
( ( N
11.3 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
, , N
P=0.007 NNP N
) ) N
. . N

Patients NNS N
of IN N
the DT N
sevelamer NN N
group NN N
with IN N
a DT N
high JJ N
turnover NN N
at IN N
baseline NN N
had VBD N
an DT N
increase NN o
in IN N
bone JJ N
resorption NN N
( ( N
eroded JJ N
surface NN N
, , N
ES/BS NNP N
= VBD N
9.0 CD N
+/- JJ N
5.9 CD N
vs. FW N
13.1 CD N
+/- JJ N
9.5 CD N
% NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
whereas JJ N
patients NNS p
of IN N
both DT N
groups NNS N
with IN N
low JJ N
turnover NN N
at IN N
baseline NN N
had VBD N
an DT N
improvement NN N
in IN N
bone NN N
formation NN N
rate NN N
( ( N
BFR/BS NNP N
= VBZ N
0.015 CD N
+/- JJ N
0.016 CD N
vs. FW N
0.062 CD N
+/- JJ N
0.078 CD N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
calcium NN N
and CC N
0.017 CD N
+/- JJ N
0.016 CD N
vs. FW N
0.071 CD N
+/- JJ N
0.084 CD N
microm NN N
( ( N
3 CD N
) ) N
/microm NN N
( ( N
2 CD N
) ) N
/day NN N
, , N
p NN N
= VBD N
0.010 CD N
for IN N
sevelamer NN N
) ) N
. . N

RESULTS NN N
After IN N
treatment NN N
, , N
the DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
as IN N
compared VBN N
with IN N
the DT N
nutrition NN N
education NN N
intervention NN N
alone RB N
had VBD N
a DT N
statistically RB N
greater JJR N
average JJ N
increase NN o
on IN N
the DT N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
of IN N
caloric JJ N
intake NN N
( ( N
mean JJ N
, , N
872 CD N
vs NN N
489 CD N
cal/d NN N
, , N
respectively RB N
) ) N
, , N
percentage NN N
of IN N
the DT N
estimated VBN N
energy NN N
requirement NN N
( ( N
mean JJ N
, , N
148 CD N
% NN N
vs JJ N
127 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
weight JJ N
gain NN N
( ( N
mean JJ N
, , N
1.47 CD N
vs NN N
0.92 CD N
kg NN N
, , N
respectively RB N
) ) N
, , N
and CC N
body NN N
mass NN N
index NN N
z NN N
score NN N
( ( N
0.38 CD N
vs NN N
0.18 CD N
, , N
respectively RB N
) ) N
. . N

These DT N
markers NNS N
did VBD N
not RB N
change VB N
much RB N
at IN N
different JJ N
time NN N
points NNS N
within IN N
72 CD N
h. NN N
In IN N
stroke NN N
group NN N
, , N
P-selectin NNP i
concentration NN N
was VBD N
highly RB N
correlated VBN N
to TO N
PAI-1 NNP N
activity NN N
( ( N
r NN N
= VBZ N
0.8433 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
to TO N
tPA VB N
antigen NN N
( ( N
r JJ N
= NNP N
-0.1752 NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
and CC N
tPA NN N
activity NN N
( ( N
r NN N
= VBZ N
0.2465 CD N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
which WDT N
was VBD N
further RBR N
confirmed VBN N
in IN N
the DT N
multiple JJ N
linear JJ N
regression NN N
analysis NN N
( ( N
F NNP N
= NNP N
47.052 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Vitamin NNP N
A NNP N
compared VBN N
with IN N
either DT N
placebo NN N
or CC N
beta NN N
carotene JJ N
supplementation NN N
increased VBD o
plasma JJ o
retinol NN N
concentrations NNS N
by IN N
end NN N
of IN N
study NN N
( ( N
1.46 CD N
[ RB N
95 CD N
% NN N
CI NNP N
, , N
1.42-1.50 JJ N
] NN N
? . N
vs $ N
1.13 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
1.09-1.17 JJ N
] NN N
? . N
and CC N
1.18 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
1.14-1.22 JJ N
] NN N
? . N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
reduced VBN N
, , N
but CC N
did VBD N
not RB N
eliminate VB N
, , N
gestational JJ N
night NN N
blindness NN N
( ( N
7.1 CD N
% NN N
for IN N
vitamin NN N
A NNP N
vs RB N
9.2 CD N
% NN N
for IN N
placebo NN N
and CC N
8.9 CD N
% NN N
for IN N
beta NN N
carotene NN N
[ NNP N
P NNP N
< NNP N
.001 NNP N
for IN N
both DT N
] NNP N
) ) N
. . N

This DT N
reduction NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN o
in IN N
the DT N
total JJ N
fractional JJ N
catabolic NN N
rate NN N
of IN N
VLDL1-ApoB NNP N
( ( N
6.70 CD N
+/- JJ N
3.24 CD N
vs JJ N
4.52 CD N
+/- JJ N
2.34 CD N
pool/day NN N
, , N
p NN N
= NNP N
0.049 CD N
) ) N
, , N
VLDL2-ApoB NNP N
( ( N
8.72 CD N
+/- JJ N
3.37 CD N
vs JJ N
5.36 CD N
+/- JJ N
2.64 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
, , N
IDL-ApoB NNP N
( ( N
7.06 CD N
+/- JJ N
1.68 CD N
vs JJ N
4.21 CD N
+/- JJ N
1.51 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
and CC N
LDL-ApoB NNP N
( ( N
1.02 CD N
+/- JJ N
0.27 CD N
vs JJ N
0.59 CD N
+/- JJ N
0.13 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

The DT N
tented JJ N
patients NNS p
had VBD N
statistically RB N
significant JJ N
reduction NN N
of IN N
mean JJ N
duration NN N
of IN N
air NN N
leak NN N
in IN N
days NNS N
( ( N
4.9 CD N
+/- JJ N
1.79 CD N
vs JJ N
8.2 CD N
+/- JJ N
4.2 CD N
) ) N
, , N
the DT N
number NN N
of IN N
days NNS N
of IN N
a DT N
chest NN N
tube NN N
duration NN N
( ( N
7.3 CD N
+/- JJ N
1.14 CD N
vs JJ N
12.46 CD N
+/- JJ N
3.6 CD N
) ) N
, , N
the DT N
length NN N
of IN N
postoperative JJ N
in-hospital JJ N
stay NN N
in IN N
days NNS N
( ( N
9.4 CD N
+/- JJ N
1.86 CD N
vs JJ N
13.6 CD N
+/- JJ N
2.49 CD N
) ) N
, , N
and CC N
the DT N
hospital NN N
stay NN N
cost NN N
per IN N
patient NN N
( ( N
leva NN N
, , N
3840 CD N
+/- JJ N
298 CD N
vs JJ N
5160 CD N
+/- JJ N
3890 CD N
) ) N
. . N

By IN N
contrast NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
by IN N
treatment NN N
group NN N
for IN N
patients NNS p
with IN N
EGFR NNP N
Leu858Arg-positive JJ N
tumours NNS N
in IN N
either DT N
trial NN N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ i
survival NN N
was VBD N
27.6 CD N
months NNS N
( ( N
19.8-41.7 JJ N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
40.3 CD N
months NNS N
( ( N
24.3-not JJ N
estimable NN N
) ) N
in IN N
the DT N
chemotherapy NN i
group NN N
( ( N
HR NNP N
1.30 CD N
, , N
95 CD N
% NN N
CI NNP N
0.80-2.11 CD N
, , N
p=0.29 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
19.6 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
17.0-22.1 CD N
) ) N
versus NN N
24.3 CD N
months NNS N
( ( N
19.0-27.0 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
1.22 CD N
, , N
95 CD N
% NN N
CI NNP N
0.81-1.83 CD N
, , N
p=0.34 NN N
) ) N
. . N

After IN N
adjusting VBG N
for IN N
certain JJ N
baseline NN N
characteristics NNS N
, , N
diabetes NNS N
was VBD N
independently RB N
associated VBN N
with IN N
death NN N
at IN N
9 CD N
months NNS N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
1.87 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.31 CD N
to TO N
2.68 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
with IN N
an DT N
increased VBN o
likelihood NN N
of IN N
TVR NNP N
( ( N
RR NNP N
, , N
1.27 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.14 CD N
to TO N
1.42 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
composite JJ N
end NN N
point NN N
of IN N
death/myocardial JJ N
infarction/TVR NN N
( ( N
RR NNP N
, , N
1.26 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.13 CD N
to TO N
1.40 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Median JJ N
PFS NNP N
in IN N
Arms NNP N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
was VBD N
6.5 CD N
months NNS N
( ( N
HR NNP N
, , N
0.69 CD N
; : N
P NNP N
= NNP N
0.147 CD N
) ) N
, , N
4.5 CD N
months NNS N
( ( N
HR NNP N
, , N
1.01 CD N
; : N
P NNP N
= NNP N
0.998 CD N
) ) N
, , N
and CC N
4.6 CD N
months NNS N
, , N
respectively RB N
; : N
median JJ N
overall JJ i
survival NN N
was VBD N
12.3 CD N
months NNS N
( ( N
HR NNP N
, , N
0.89 CD N
; : N
P NNP N
= NNP N
0.650 CD N
) ) N
, , N
12.4 CD N
months NNS N
( ( N
HR NNP N
, , N
1.27 CD N
; : N
P NNP N
= NNP N
0.357 CD N
) ) N
, , N
and CC N
12.0 CD N
months NNS N
; : N
and CC N
objective JJ N
response NN N
rate NN N
was VBD N
14 CD N
% NN N
, , N
8 CD N
% NN N
, , N
and CC N
2 CD N
% NN N
. . N

Significant JJ N
improvement NN N
in IN N
6-minute JJ N
walk NN N
test NN N
( ( N
45.8 CD N
m NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
5.2-86.4 JJ N
m NN N
; : N
p=0.031 NN N
) ) N
, , N
functional JJ N
class NN N
( ( N
-0.6+/-0.5 UH N
, , N
p=0.014 NN N
) ) N
, , N
weight JJ N
loss NN N
( ( N
-8.55 JJ N
kg NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-13.0 NN N
to TO N
-4.1 VB N
kg NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
and CC N
also RB N
significant JJ N
decreases NNS o
in IN N
total JJ N
cholesterol NN N
( ( N
p=0.017 NN N
) ) N
, , N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
p=0.03 NN N
) ) N
, , N
and CC N
triglycerides NNS N
( ( N
p=0.036 NN N
) ) N
were VBD N
observed VBN N
in IN N
the DT N
orlistat NN N
group NN N
. . N

Baseline NNP N
elevated VBD N
PTX3 NNP N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
all-cause JJ N
mortality NN N
[ $ N
759 CD N
events NNS N
, , N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
for IN N
1 CD N
SD NNP N
increase NN o
1.20 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.12-1.30 CD N
, , N
P NNP N
< VBZ N
0.0001 CD N
] NN N
, , N
cardiovascular JJ N
mortality NN N
( ( N
587 CD N
events NNS N
, , N
HR NNP N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
1.17-1.38 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
or CC N
hospitalization NN N
for IN N
worsening VBG N
HF NNP N
( ( N
720 CD N
events NNS N
, , N
HR NNP N
1.21 CD N
, , N
95 CD N
% NN N
CI NNP N
1.12-1.30 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
marginally RB N
improved VBN N
discrimination NN N
. . N

Panic JJ N
management NN N
( ( N
PM NNP N
) ) N
had VBD N
an DT N
ICER NNP N
of IN N
$ $ N
124.05 CD N
, , N
per IN N
the DT N
Anxiety NN N
Disorders NNP N
Interview NNP N
Schedule NNP N
for IN N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
severity NN N
score NN N
change NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
$ $ N
54.63- JJ N
$ $ N
314.57 CD N
) ) N
, , N
compared VBN N
with IN N
pharmacotherapy NN i
( ( N
paroxetine NN N
) ) N
, , N
with IN N
an DT N
ICER NNP N
of IN N
$ $ N
213.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
133.51- JJ N
$ $ N
394.94 CD N
) ) N
, , N
and CC N
brief JJ N
CBT NNP N
, , N
with IN N
an DT N
ICER NNP N
of IN N
$ $ N
309.31 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
151.27- JJ N
$ $ N
548.28 CD N
) ) N
. . N

For IN N
depressive JJ N
symptoms NNS N
, , N
the DT N
risk NN N
reduction NN N
in IN N
clinically RB N
significant JJ N
symptoms NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
( ( N
5.7 CD N
% NN N
vs JJ N
22.4 CD N
% NN N
; : N
aRR CC N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.10 CD N
to TO N
1.08 CD N
) ) N
; : N
however RB N
, , N
the DT N
reduction NN N
in IN N
mean JJ N
depressive NN N
symptoms NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
Quick NNP N
Inventory NNP N
of IN N
Depressive NNP N
Symptomatology NNP N
score NN N
, , N
4.6 CD N
with IN N
PSE NNP N
vs FW N
6.9 CD N
with IN N
usual JJ N
care NN N
; : N
adjusted VBN N
mean NN N
difference NN N
, , N
-1.67 NNP N
; : N
95 CD N
% NN N
CI NNP N
, , N
-3.17 NNP N
to TO N
-0.18 VB N
) ) N
. . N

Dose-dependent JJ N
increases NNS o
in IN N
FEV1 NNP N
were VBD N
seen VBN N
( ( N
mean JJ N
values NNS N
( ( N
L NNP N
) ) N
before IN N
salbutamol NN N
and CC N
after IN N
a DT N
cumulative JJ N
dose NN N
of IN N
100 CD N
, , N
200 CD N
, , N
400 CD N
, , N
and CC N
800 CD N
microg NN N
= NN N
placebo NN N
: : N
1.06 CD N
, , N
1.28 CD N
, , N
1.35 CD N
, , N
1.39 CD N
, , N
1.41 CD N
; : N
formoterol NN N
: : N
1.33 CD N
, , N
1.37 CD N
, , N
1.41 CD N
, , N
1.44 CD N
, , N
1.44 CD N
; : N
salmeterol NN N
: : N
1.30 CD N
, , N
1.33 CD N
, , N
1.36 CD N
, , N
1.39 CD N
, , N
1.42 CD N
; : N
oxitropium JJ N
bromide NN N
: : N
1.27 CD N
, , N
1.34 CD N
, , N
1.37 CD N
, , N
1.41 CD N
, , N
1.40 CD N
) ) N
. . N

WL NNP N
alone RB N
reduced VBD N
( ( N
P NNP N
< VBZ N
0.05 CD N
in IN N
all DT N
) ) N
body NN N
weight NN N
( ( N
-3 CD N
% NN N
) ) N
, , N
waist JJ N
circumference NN N
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ N
( ( N
-3 CD N
% NN N
) ) N
and CC N
diastolic JJ N
( ( N
-3 CD N
% NN N
) ) N
blood NN N
pressures NNS N
, , N
cardiac JJ N
output NN N
( ( N
-4 CD N
% NN N
) ) N
, , N
plasma JJ N
TG NNP N
concentration NN N
( ( N
-25 CD N
% NN N
) ) N
, , N
and CC N
the DT N
homeostasis NN N
model NN N
assessment NN N
( ( N
HOMA NNP N
) ) N
score NN N
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased VBD o
plasma NN o
HDL NNP N
cholesterol NN N
( ( N
+9 CD N
% NN N
) ) N
and CC N
adiponectin NN i
( ( N
+18 CD N
% NN N
) ) N
concentrations NNS N
. . N

Numerical JJ N
analog NN N
pain NN N
score NN N
and CC N
morphine JJ N
utilization NN N
and CC N
hemodynamic JJ N
values NNS N
were VBD N
measured VBN N
for IN N
24 CD N
h. NN N
RESULTS NNP N
The DT N
patients NNS p
treated VBN N
with IN N
nicotine NN N
reported VBN N
lower JJR N
pain NN N
scores NNS N
during IN N
the DT N
first JJ N
hour NN N
after IN N
surgery NN N
( ( N
peak JJ N
numerical JJ N
analog NN N
score NN N
, , N
7.6 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
versus NN N
5.3 CD N
( ( N
SD NNP N
1.6 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
used VBN N
half PDT N
the DT N
amount NN N
of IN N
morphine NN N
as IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
( ( N
SD NNP N
6 CD N
) ) N
versus NN N
6 CD N
( ( N
SD NNP N
5 CD N
) ) N
mg NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
Spontaneous NNP N
communication NN N
using VBG N
picture NN N
cards NNS N
, , N
speech NN N
, , N
or CC N
both DT N
increased VBN o
significantly RB N
following VBG N
training NN N
( ( N
rate NN N
ratio NN N
[ NNP N
RR NNP N
] NNP N
=1.90 NNP N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.46 CD N
, , N
2.48 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
1.77 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.35 CD N
, , N
2.32 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
3.74 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
2.19 CD N
, , N
6.37 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
. . N

INTERVENTIONS NNP N
One CD N
of IN N
six CD N
dosing VBG N
epoetin NN i
alfa NN N
regimens VBZ N
for IN N
15 CD N
days NNS N
, , N
as IN N
follows VBZ N
: : N
40,000 CD N
IU NNP N
once RB N
weekly RB N
, , N
subcutaneously RB N
( ( N
group NN N
A NNP N
) ) N
or CC N
intravenously RB N
( ( N
IV NNP N
) ) N
( ( N
group NN N
B NNP N
) ) N
; : N
15,000 CD N
IU NNP N
every DT N
other JJ N
day NN N
, , N
subcutaneously RB N
( ( N
group NN N
C NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
D NNP N
) ) N
; : N
or CC N
40,000 CD N
IU NNP N
day NN N
1 CD N
and CC N
3 CD N
, , N
subcutaneously RB N
( ( N
group NN N
E NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
F NNP N
) ) N
, , N
followed VBN N
by IN N
15,000 CD N
IU NNP N
once RB N
every DT N
other JJ N
day NN N
on IN N
[ NN N
corrected VBN N
] JJ N
days NNS N
5-15 JJ N
[ NNP N
corrected VBD N
] NN N
MEASUREMENTS NNP N
Serum NNP N
erythropoietin NN i
concentration NN N
, , N
absolute JJ N
reticulocyte NN N
count NN N
, , N
and CC N
adverse JJ N
events NNS N
. . N

RESULTS NNP N
Relative NNP N
to TO N
the DT N
group NN N
B NNP N
, , N
the DT N
group NN N
A NNP N
had VBD N
( ( N
1 CD N
) ) N
a DT N
significant JJ N
decrease NN o
of IN N
pain NN N
at IN N
rest NN N
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
following VBG N
up RP N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
a DT N
significant JJ N
decrease NN o
in IN N
pain NN N
at IN N
palpation NN N
and CC N
pain NN N
on IN N
isometric JJ N
testing VBG N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
3 CD N
) ) N
a DT N
significant JJ N
decrease NN o
in IN N
pain NN N
during IN N
middle JJ N
finger NN N
test NN N
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
4 CD N
) ) N
a DT N
significant JJ N
decrease NN o
of IN N
pain NN N
during IN N
grip NN N
strength NN N
testing VBG N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
5 CD N
) ) N
a DT N
significant JJ N
increase NN o
in IN N
the DT N
wrist NN N
range NN N
of IN N
motion NN N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
( ( N
6 CD N
) ) N
an DT N
increase NN o
in IN N
grip JJ N
strength NN N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
( ( N
7 CD N
) ) N
a DT N
significant JJ N
increase NN o
in IN N
weight-test JJ N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

RESULTS VB N
The DT N
incidence NN N
of IN N
reperfusion NN N
arrhythmias-frequent JJ N
ventricular JJ N
premature NN N
( ( N
26.7 CD N
% NN N
vs. FW N
52.9 CD N
% NN N
) ) N
and CC N
short JJ N
array NN N
ventricular JJ N
tachycardia NN N
beat NN N
( ( N
23.3 CD N
% NN N
vs. FW N
58.8 CD N
% NN N
) ) N
as RB N
well RB N
as IN N
values NNS N
of IN N
peaks NNS N
CK NNP N
[ NNP N
( ( N
1162 CD N
? . N
548 CD N
) ) N
U/L NNP N
vs. FW N
( ( N
1732 CD N
? . N
480 CD N
) ) N
U/L NNP N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
, , N
CKMB NNP N
[ NNP N
( ( N
165 CD N
? . N
70 CD N
) ) N
U/L NNP N
vs. FW N
( ( N
280 CD N
? . N
99 CD N
) ) N
U/L NNP N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
, , N
CTFC NNP N
( ( N
22.23 CD N
? . N
3.81 CD N
vs NN N
26.97 CD N
? . N
3.42 CD N
) ) N
, , N
WMSI NNP N
( ( N
1.27 CD N
? . N
0.52 CD N
vs NN N
1.82 CD N
? . N
0.83 CD N
) ) N
, , N
and CC N
infarction NN N
areas NNS N
determined VBN N
by IN N
ECG NNP N
methods NNS N
( ( N
10.60 CD N
% NN N
? . N
4.97 CD N
% NN N
vs.14.65 NN N
% NN N
? . N
6.88 CD N
% NN N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
were VBD N
all DT N
significantly RB N
lower JJR N
in IN N
the DT N
postconditioning VBG N
group NN N
than IN N
in IN N
control NN N
group NN N
while IN N
LVEF NNP N
( ( N
0.55 CD N
? . N
0.08 CD N
vs NN N
0.47 CD N
? . N
0.10 CD N
) ) N
and CC N
MBG NNP N
( ( N
2.27 CD N
? . N
0.64 CD N
vs NN N
1.47 CD N
? . N
0.61 CD N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
postconditioning VBG N
group NN N
than IN N
in IN N
control NN N
group NN N
. . N

HI2 NNP N
was VBD N
more RBR N
effective JJ N
than IN N
HI1 NNP N
and CC N
CA NNP N
as IN N
measured VBN N
by IN N
pain NN N
relief NN N
scores NNS N
for IN N
week NN N
1 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
and CC N
week NN N
3 CD N
( ( N
P NNP N
= VBZ N
0.008 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ N
doses NNS N
of IN N
study NN N
medication NN N
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.019 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.011 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ N
doses NNS N
of IN N
supplemental JJ N
analgesics NNS N
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.010 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
; : N
and CC N
global JJ N
assessment NN N
scores NNS N
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.018 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
= VBZ N
0.005 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
and CC N
week NN N
4 CD N
( ( N
P NNP N
= VBZ N
0.013 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.023 CD N
vs NN N
CA NNP N
) ) N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
the DT N
demographics NNS N
, , N
myocardial JJ N
enzyme NN N
release NN N
, , N
occurrence NN N
of IN N
major JJ N
arrhythmias NNS N
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
12 CD N
( ( N
23.5 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.80 CD N
] NN N
, , N
heart NN N
failure NN N
[ VBZ N
18 CD N
( ( N
36 CD N
% NN N
) ) N
vs. FW N
19 CD N
( ( N
38.3 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.83 CD N
] NN N
, , N
LVEF NNP N
at IN N
first JJ N
day NN N
[ VB N
34.7 CD N
? . N
9.9 CD N
% NN N
vs. FW N
33.5 CD N
? . N
8.1 CD N
% NN N
, , N
P NNP N
= VBZ N
0.50 CD N
] NN N
or CC N
at IN N
discharge NN N
[ $ N
37.7 CD N
? . N
10 CD N
% NN N
vs. FW N
36.1 CD N
? . N
8.2 CD N
% NN N
, , N
P NNP N
= VBZ N
0.43 CD N
] NN N
, , N
and CC N
in-hospital JJ N
[ NN N
4 CD N
( ( N
8 CD N
% NN N
) ) N
vs. FW N
6 CD N
( ( N
11.8 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.74 CD N
] NN N
or CC N
6-month JJ N
mortality NN N
rates NNS N
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
10 CD N
( ( N
19.6 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.99 CD N
] NN N
between IN N
the DT N
CsA NNP N
vs IN N
the DT N
control NN N
group NN N
. . N

Compared VBN N
with IN N
the DT N
remaining VBG N
693 CD N
patients NNS p
, , N
subjects NNS N
with IN N
left JJ N
ventricular JJ N
thrombosis NN N
were VBD N
older JJR N
( ( N
mean NN N
( ( N
SD NNP N
) ) N
age NN N
: : N
64.6 CD N
( ( N
13.0 CD N
) ) N
v NN N
59.8 CD N
( ( N
11.7 CD N
) ) N
years NNS N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
, , N
and CC N
had VBD N
larger JJR N
infarcts NNS N
( ( N
extent NN N
of IN N
wall NN N
motion NN N
asynergy NN N
: : N
40.9 CD N
( ( N
11.5 CD N
) ) N
% NN N
v JJ N
24.9 CD N
( ( N
14 CD N
) ) N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
greater JJR N
depression NN N
of IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
at IN N
S1 NNP N
( ( N
43.3 CD N
( ( N
6.9 CD N
) ) N
% NN N
v JJ N
48.1 CD N
( ( N
6.8 CD N
) ) N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
greater JJR N
left VBD N
ventricular JJ N
volumes NNS N
at IN N
S1 NNP N
( ( N
end VB N
diastolic NN N
volume NN N
: : N
87 CD N
( ( N
22 CD N
) ) N
v NN N
78 CD N
( ( N
18 CD N
) ) N
ml/m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
< VBP N
0.001 CD N
; : N
end VB N
systolic JJ N
volume NN N
: : N
50 CD N
( ( N
17 CD N
) ) N
v NN N
41 CD N
( ( N
14 CD N
) ) N
ml/m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Over-all NN N
, , N
empiric JJ N
antibiotic JJ i
trials NNS N
were VBD N
more RBR N
often RB N
successful JJ N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
group NN N
1 CD N
( ( N
55 CD N
of IN N
62 CD N
patients NNS p
or CC N
89 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
group NN N
2 CD N
( ( N
42 CD N
of IN N
64 CD N
patients NNS p
, , N
66 CD N
per IN N
cent NN N
) ) N
mwithin NN N
group NN N
1 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ N
outcome NN N
in IN N
30 CD N
of IN N
32 CD N
( ( N
94 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
25 CD N
of IN N
30 CD N
( ( N
83 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
; : N
within IN N
group NN N
2 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ N
outcome NN N
in IN N
23 CD N
of IN N
30 CD N
( ( N
77 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
19 CD N
of IN N
34 CD N
( ( N
56 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.14 CD N
) ) N
, , N
Combined VBN N
results NNS N
in IN N
both DT N
groups NNS N
indicated VBD N
a DT N
higher JJR N
proportion NN N
of IN N
favorable JJ N
outcome NN N
in IN N
C-T/S NNP N
trials NNS N
( ( N
53 CD N
of IN N
62 CD N
, , N
85 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
C-G JJ N
trials NNS N
( ( N
44 CD N
of IN N
64 CD N
, , N
69 CD N
per IN N
cent NN N
) ) N
. . N

RESULTS NNP N
Among IN N
all DT N
HOPE NNP N
patients NNS p
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
primary JJ N
analysis NN N
: : N
for IN N
cancer NN N
incidence NN N
, , N
there EX N
were VBD N
552 CD N
patients NNS p
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
vitamin NN N
E NNP N
group NN N
vs VBD N
586 CD N
( ( N
12.3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.94 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.84-1.06 NNP N
; : N
P NNP N
= NNP N
.30 NNP N
) ) N
; : N
for IN N
cancer NN N
deaths NNS N
, , N
156 CD N
( ( N
3.3 CD N
% NN N
) ) N
vs NN N
178 CD N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.09 NNP N
; : N
P NNP N
= NNP N
.24 NNP N
) ) N
; : N
and CC N
for IN N
major JJ N
cardiovascular JJ N
events NNS N
, , N
1022 CD N
( ( N
21.5 CD N
% NN N
) ) N
vs NN N
985 CD N
( ( N
20.6 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
1.04 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96-1.14 NNP N
; : N
P NNP N
= NNP N
.34 NNP N
) ) N
. . N

The DT N
plasma JJ N
IL-8 NNP N
, , N
TNF- NNP N
, , N
CRP NNP N
, , N
lipase NN N
, , N
LDH NNP N
at IN N
14 CD N
days NNS N
after IN N
intervention NN N
of IN N
nutrition NN N
in IN N
P+EN NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
PN NNP N
group NN N
and CC N
EN NNP N
group NN N
( ( N
IL-8 NNP N
: : N
21.00 CD N
? . N
7.07 CD N
? . N
vs. FW N
48.00 CD N
? . N
10.32 CD N
? . N
, , N
32.00 CD N
? . N
9.30 CD N
? . N
; : N
TNF- JJ N
: : N
44.3 CD N
? . N
10.9 CD N
ng/L JJ N
vs. FW N
132.1 CD N
? . N
34.1 CD N
ng/L NN N
, , N
67.8 CD N
? . N
22.3 CD N
ng/L NN N
; : N
CRP NNP N
: : N
35.0 CD N
? . N
12.4 CD N
mg/L NN N
vs. FW N
103.2 CD N
? . N
49.2 CD N
mg/L NN N
, , N
63.0 CD N
? . N
29.2 CD N
mg/L NN N
; : N
lipase NN N
: : N
269 CD N
? . N
79 CD N
U/L NNP N
vs. FW N
670 CD N
? . N
145 CD N
U/L NNP N
, , N
310 CD N
? . N
78 CD N
U/L NNP N
; : N
LDH NNP N
: : N
21.8 CD N
? . N
10.3 CD N
U/L NNP N
vs. FW N
78.1 CD N
? . N
37.4 CD N
U/L NNP N
, , N
37.9 CD N
? . N
25.1 CD N
U/L NNP N
, , N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
group NN N
A NNP N
, , N
endothelium NN N
dependent JJ N
[ NNP N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
vs NN N
( ( N
9 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
2.9 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
and CC N
independent JJ N
[ NNP N
( ( N
18 CD N
+/- JJ N
4 CD N
) ) N
% NN N
vs NN N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
3.4 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] JJ N
vasodilatation NN N
responses NNS N
significantly RB N
increased VBD o
after IN o
treatment NN N
, , N
no DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
group NN N
B. NNP N
Endothelium NNP N
dependent NN N
[ NNP N
( ( N
9 CD N
+/- JJ N
6 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
2.8 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
and CC N
independent JJ N
[ NNP N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
3.5 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] JJ N
vasodilatation NN N
responses NNS N
of IN N
group NN N
A NNP N
were VBD N
significantly RB N
lower JJR N
than IN N
that DT N
of IN N
group NN N
B NNP N
after IN N
treatment NN N
. . N

Allergic NNP N
mothers NNS N
had VBD N
significantly RB N
lower JJR N
amounts NNS N
of IN N
bifidobacteria NN N
in IN N
breast-milk NN N
compared VBN N
with IN N
non-allergic JJ N
mothers NNS N
[ VBP N
median JJ N
1.3 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
IQR NNP N
22.4-3.0 CD N
x NNP N
10 CD N
( ( N
3 CD N
) ) N
) ) N
vs. FW N
5.6 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
1.8 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
-1.8 NN N
x $ N
10 CD N
( ( N
4 CD N
) ) N
) ) N
, , N
respectively RB N
, , N
( ( N
P=0.004 NNP N
) ) N
] NN N
, , N
and CC N
their PRP$ N
infants NNS N
had VBD N
concurrently RB N
lower JJR N
counts NNS N
of IN N
bifidobacteria NN N
in IN N
feces NNS N
[ VBP N
3.9 CD N
x JJ N
10 CD N
( ( N
8 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
IQR NNP N
6.5 CD N
x NN N
10 CD N
( ( N
6 CD N
) ) N
-1.5 NN N
x $ N
10 CD N
( ( N
9 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
allergic JJ N
mothers NNS N
, , N
vs. FW N
2.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
8 CD N
) ) N
-3.2 NN N
x $ N
10 CD N
( ( N
10 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
non-allergic JJ N
mothers NNS N
, , N
P=0.013 NNP N
] NNP N
. . N

One CD N
day NN N
after IN N
chemotherapy NN i
in IN N
losartan JJ N
group NN N
vs. FW N
amlodipine NN N
group NN N
we PRP N
observed VBD N
a DT N
significant JJ N
difference NN N
in IN N
urinary JJ N
uric JJ N
acid NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
of IN N
18 CD N
mg/24 NNS N
h VBD N
vs. FW N
40 CD N
mg/24 NN N
h. NN N
Thirty NNP N
days NNS N
after IN N
chemotherapy NN i
we PRP N
observed VBD N
a DT N
significant JJ N
difference NN N
in IN N
azotemia NN N
of IN N
0.0 CD N
mg/dl NNS N
vs. FW N
3.8 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
serum JJ N
uric JJ N
acid NN N
of IN N
0.05 CD N
mg/dl NNS N
vs. FW N
0.49 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
urinary JJ N
uric JJ N
acid NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
of IN N
23 CD N
mg/24 NNS N
h VBD N
vs. FW N
0.0 CD N
mg/24 NN N
h NN N
, , N
GFR NNP N
of IN N
2 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
vs. FW N
-8 FW N
ml/min/1.73 FW N
m NN N
( ( N
2 CD N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
systolic JJ N
BP NNP N
( ( N
SBP NNP N
) ) N
of IN N
3.6 CD N
mmHg NNS N
vs. FW N
0.8 CD N
mmHg NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

From IN N
1989 CD N
to TO N
1997 CD N
, , N
68 CD N
patients NNS p
diagnosed VBN N
with IN N
previously RB N
untreated VBN N
PMBCL NNP N
, , N
aged VBD N
18-65 CD N
years NNS N
and CC N
negative JJ N
for IN N
immunodeficiency NN N
virus NN N
test NN N
, , N
were VBD N
considered VBN N
candidates NNS N
to TO N
receive VB N
either DT N
conventional JJ N
chemotherapy NN i
with IN N
CEOP-Bleo NNP N
( ( N
cyclophosphamide VB N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
vincristine JJ N
1.4 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
prednisone RB N
40 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
epirubicin $ i
70 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
and CC N
bleomycin $ i
10 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
or CC N
mega JJ N
CEOP-Bleo NNP N
( ( N
cyclophosphamide JJ N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
epirubicin $ i
120 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
vincristine NN N
, , N
prednisone NN N
, , N
and CC N
bleomycin NN i
at IN N
the DT N
same JJ N
doses NNS N
) ) N
every DT N
21 CD N
days NNS N
for IN N
six CD N
cycles NNS N
, , N
followed VBN N
by IN N
radiotherapy NN i
to TO N
the DT N
mediastinum NN N
with IN N
the DT N
mantle NN N
technique NN N
( ( N
35-45 JJ N
Gy NNP N
, , N
mean VBP N
38 CD N
Gy NNP N
) ) N
. . N

OBJECTIVE NN N
This DT N
study NN N
aims VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
cyclooxygenase-2 JJ N
inhibitor NN N
, , N
celecoxib NN N
, , N
as IN N
adjunctive JJ N
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN N
METHODS NNP N
In IN N
a DT N
10-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
, , N
40 CD N
outpatient JJ N
children NNS N
with IN N
a DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
fourth JJ N
edition NN N
, , N
text JJ N
revision NN N
clinical JJ N
diagnosis NN N
of IN N
autism NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
celecoxib VB N
plus CC N
risperidone VB i
or CC N
placebo VB N
plus CC N
risperidone VB i
. . N

Based VBN N
on IN N
the DT N
discussions NNS N
of IN N
the DT N
Joint NNP N
Federal NNP N
Committee NNP N
( ( N
G-BA NNP N
) ) N
and CC N
the DT N
conceptual JJ N
work NN N
of IN N
the DT N
MDS NNP N
, , N
the DT N
Competence NNP N
Centre NNP N
Oncology NNP N
of IN N
the DT N
MDK NNP N
, , N
the DT N
IQWIG NNP N
and CC N
the DT N
National NNP N
Association NNP N
of IN N
Statutory NNP N
Health NNP N
Insurance NNP N
Funds NNP N
( ( N
GKV-Spitzenverband NNP N
) ) N
, , N
a DT N
prospective JJ N
randomised VBN N
multicentre JJ N
trial NN N
was VBD N
developed VBN N
comparing VBG N
the DT N
four CD N
treatments NNS N
actually RB N
recommended VBN N
by IN N
the DT N
German JJ N
and CC N
European JJ N
guidelines NNS N
for IN N
localised JJ N
prostate NN N
cancer NN N
( ( N
radical JJ N
prostatectomy NN N
, , N
percutaneous JJ N
radiotherapy NN i
and CC N
permanent JJ N
seed NN N
implantation NN N
and CC N
active JJ N
surveillance NN N
) ) N
allowing VBG N
a DT N
rejection NN N
of IN N
one CD N
or CC N
two CD N
treatment NN N
options NNS N
. . N

METHODS NNP N
Sixty-one CD N
patients NNS p
with IN N
depressive JJ N
disorders NNS N
who WP N
were VBD N
already RB N
in IN N
therapy NN i
in IN N
an DT N
outpatient JJ N
mental JJ N
health NN N
institution NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
eight CD N
group NN N
sessions NNS N
of IN N
COMET NNP N
in IN N
addition NN N
to TO N
their PRP$ N
regular JJ N
therapy NN i
( ( N
COMET NNP N
+ NNP N
therapy NN i
as IN N
usual JJ N
[ NNP N
TAU NNP N
] NN N
: : N
the DT N
experimental JJ N
group NN N
) ) N
or CC N
to TO N
8 CD N
weeks NNS N
of IN N
ongoing VBG N
regular JJ N
therapy NN i
( ( N
TAU NNP N
only RB N
: : N
the DT N
control NN N
group NN N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
HD NNP N
patients NNS p
in IN N
stage NN N
I PRP N
to TO N
IIIA NNP N
with IN N
a DT N
large JJ N
mediastinal JJ N
mass NN N
, , N
E NNP N
stage NN N
, , N
or CC N
massive JJ N
spleen JJ N
involvement NN N
were VBD N
treated VBN N
with IN N
two CD N
double JJ N
cycles NNS N
of IN N
alternating VBG N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
COPP NNP N
) ) N
plus CC N
doxorubicin JJ i
, , N
bleomycin NN i
, , N
vinblastine NN N
, , N
and CC N
dacarbazine NN N
( ( N
ABVD NNP N
) ) N
followed VBN N
by IN N
EF NNP N
irradiation NN N
in IN N
two CD N
successive JJ N
trials NNS N
( ( N
HD1 NNP N
and CC N
HD5 NNP N
) ) N
. . N

In IN N
1987 CD N
, , N
we PRP N
designed VBD N
a DT N
randomized VBN N
study NN N
to TO N
evaluate VB N
the DT N
potential JJ N
benefit NN N
of IN N
a DT N
high-dose JJ N
regimen NN N
containing VBG N
cyclophosphamide NN N
, , N
carmustine NN N
, , N
and CC N
etoposide RB N
( ( N
CBV NNP N
) ) N
followed VBN N
by IN N
autotransplantation NN N
over IN N
a DT N
consolidative JJ N
sequential JJ N
chemotherapy NN i
( ( N
ifosfamide JJ N
, , N
etoposide RB N
, , N
asparaginase NN N
, , N
and CC N
cytarabine NN N
) ) N
in IN N
patients NNS p
in IN N
first JJ N
complete JJ N
remission NN N
with IN N
intermediate- JJ N
and CC N
high-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

To TO N
determine VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
new JJ N
, , N
non-contact JJ N
, , N
kilohertz VB N
ultrasound JJ N
therapy NN i
for IN N
the DT N
healing NN N
of IN N
recalcitrant JJ N
diabetic JJ N
foot NN N
ulcers NNS N
- : N
as RB N
well RB N
as IN N
to TO N
evaluate VB N
the DT N
impact NN N
on IN N
total JJ N
closure NN N
and CC N
quantitative JJ N
bacterial JJ N
cultures NNS N
and CC N
the DT N
effect NN N
on IN N
healing NN N
of IN N
various JJ N
levels NNS N
of IN N
sharp/surgical JJ N
debridement NN N
- : N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
sham-controlled JJ N
, , N
multicenter NN N
study NN N
was VBD N
conducted VBN N
in IN N
hospital-based JJ N
and CC N
private JJ N
wound NN N
care NN N
clinics NNS N
. . N

A DT N
total NN N
of IN N
128 CD N
recipients NNS N
of IN N
first JJ N
cadaveric JJ N
renal NN N
allograft NN N
were VBD N
randomized VBN N
, , N
after IN N
an DT N
initial JJ N
induction NN N
period NN N
, , N
to TO N
receive VB N
either RB N
triple JJ N
drug NN N
therapy NN i
-- : N
i.e NN N
, , N
( ( N
low-dose JJ N
) ) N
cyclosporine NN N
, , N
azathioprine NN N
, , N
and CC N
methylprednisolone NN N
, , N
or CC N
any DT N
possible JJ N
combination NN N
of IN N
two CD N
drugs NNS N
-- : N
i.e NN N
, , N
Aza NNP N
plus CC N
CsA NNP N
, , N
Aza NNP N
plus CC N
MP NNP N
, , N
and CC N
CsA NNP N
plus CC N
MP NNP N
. . N

FUNDING NN N
Agence NNP N
nationale NN N
de IN N
recherches NNS N
sur VBP N
le JJ N
sida NN N
et NN N
les VBZ N
h JJ N
virales NNS N
, , N
Department NNP N
for IN N
International NNP N
Development NNP N
, , N
European NNP N
and CC N
Developing NNP N
Countries NNP N
Clinical NNP N
Trials NNP N
Partnership NNP N
, , N
Thrasher NNP N
Research NNP N
Fund NNP N
, , N
Belgian JJ N
Directorate NNP N
General NNP N
for IN N
International NNP N
Cooperation NNP N
, , N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
and CC N
Prevention NNP N
, , N
Eunice NNP N
Kennedy NNP N
Shriver NNP N
National NNP N
Institute NNP N
of IN N
Child NNP N
Health NNP N
and CC N
Human NNP N
Development NNP N
, , N
and CC N
UNDP/UNFPA/World NNP N
Bank/WHO NNP N
Special NNP N
Programme NNP N
of IN N
Research NNP N
, , N
Development NNP N
and CC N
Research NNP N
Training NNP N
in IN N
Human NNP N
Reproduction NNP N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
conducted VBN N
to TO N
examine VB N
whether IN N
the DT N
Chinese NNP N
medicinal JJ N
herb NN N
complex NN N
, , N
RG-CMH NNP N
, , N
which WDT N
represents VBZ N
a DT N
mixture NN N
of IN N
rose VBD N
geranium NN N
and CC N
extracts NNS N
of IN N
G. NNP N
tsugae NN N
, , N
C. NNP N
pilosula NN N
and CC N
A. NNP N
sinensis NN N
, , N
can MD N
improve VB N
the DT N
immune NN N
cell NN N
count NN N
of IN N
cancer NN N
patients NNS p
receiving VBG N
chemotherapy NN i
and/or NN N
radiotherapy NN i
to TO N
prevent VB N
leucopenia NN N
and CC N
immune JJ N
impairment NN N
that WDT N
usually RB N
occurs VBZ N
during IN N
cancer NN N
therapy NN i
. . N

The DT N
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
summarize VB N
and CC N
integrate VB N
the DT N
findings NNS N
of IN N
the DT N
Diabetes NNP N
Control NNP N
and CC N
Complications NNP N
Trial NNP N
( ( N
DCCT NNP N
) ) N
, , N
a DT N
randomized VBN N
controlled JJ N
clinical JJ N
trial NN N
, , N
and CC N
the DT N
succeeding JJ N
observational JJ N
follow-up NN N
of IN N
the DT N
DCCT NNP N
cohort NN N
in IN N
the DT N
Epidemiology NNP N
of IN N
Diabetes NNP N
Interventions NNP N
and CC N
Complications NNP N
( ( N
EDIC NNP N
) ) N
study NN N
, , N
regarding VBG N
the DT N
effects NNS N
of IN N
intensive JJ N
treatment NN N
on IN N
the DT N
microvascular JJ N
complications NNS N
of IN N
type NN N
1 CD N
diabetes NNS N
mellitus NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
One CD N
hundred VBD N
forty-three JJ N
non-diabetic JJ N
adult NN N
RA NNP N
patients NNS p
( ( N
76.2 CD N
% NN N
female NN N
, , N
age NN N
55.2 CD N
? . N
12.1 CD N
[ JJ N
mean NN N
? . N
SD NNP N
] NNP N
) ) N
on IN N
stable JJ N
RA NNP N
standard NN N
of IN N
care NN N
treatment NN N
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo NN N
controlled VBD N
crossover JJ N
trial NN N
of IN N
45 CD N
mg JJ N
daily JJ N
pioglitazone NN N
versus NN N
placebo NN N
, , N
with IN N
a DT N
3-month JJ N
duration/arm NN N
and CC N
a DT N
2-month JJ N
washout NN N
period NN N
. . N

BACKGROUND IN N
We PRP N
compared VBN N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
two CD N
combined JJ N
diphtheria-tetanus-pertussis-inactivated JJ N
poliovirus NN N
vaccines NNS N
containing VBG N
either CC N
acellular JJ N
( ( N
Pa NNP N
, , N
SmithKline NNP N
Beecham NNP N
Biologicals NNP N
) ) N
or CC N
whole JJ N
cell NN N
( ( N
Pw NNP N
, , N
Pasteur NNP N
Merieux NNP N
Connaught NNP N
) ) N
pertussis NN N
components NNS N
, , N
mixed JJ N
with IN N
a DT N
Haemophilus NNP N
influenzae NN N
type NN N
b NN N
polysaccharide NN N
polyribosylribitol IN N
phosphate-tetanus JJ N
conjugate NN N
vaccine NN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
in IN N
healthy JJ N
infants NNS N
. . N

PURPOSE NN N
This DT N
phase NN N
III NNP N
study NN N
compared VBN N
the DT N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
of IN N
an DT N
oral JJ N
regimen NNS N
of IN N
dihydropyrimidine JJ N
dehydrogenase NN N
inhibitory NN N
fluoropyrimidine NN N
composed VBN N
of IN N
a DT N
fixed JJ N
combination NN N
of IN N
tegafur NN N
and CC N
uracil NN N
in IN N
a DT N
1:4 CD N
molar JJ N
ratio NN N
( ( N
UFT NNP N
) ) N
and CC N
leucovorin $ N
( ( N
LV NNP N
) ) N
to TO N
intravenous JJ N
( ( N
IV NNP N
) ) N
fluorouracil NN N
( ( N
5-FU JJ N
) ) N
and CC N
LV NNP N
in IN N
previously RB N
untreated VBN N
metastatic JJ N
colorectal NN N
carcinoma NN N
( ( N
CRC NNP N
) ) N
patients NNS p
. . N

Patients NNS N
with IN N
untreated JJ N
stage NN N
I PRP N
MM NNP N
( ( N
defined VBN N
according VBG N
to TO N
Durie NNP N
and CC N
Salmon NNP N
) ) N
were VBD N
randomised VBN N
between IN N
being VBG N
followed VBN N
without IN N
cytostatics NNS N
until IN N
the DT N
disease NN N
progressed VBD N
and CC N
receiving VBG N
six CD N
courses NNS N
of IN N
melphalan NN N
and CC N
prednisone NN N
( ( N
MP-P NNP N
) ) N
just RB N
after IN N
diagnosis NN N
; : N
stage NN N
II NNP N
patients NNS p
were VBD N
uniformly RB N
treated VBN N
with IN N
MPH-P NNP N
and CC N
stage NN N
III NNP N
patients NNS p
were VBD N
randomised VBN N
between IN N
MPH-P NNP N
and CC N
four CD N
courses NNS N
of IN N
combination NN N
chemotherapy NN i
with IN N
Peptichemio NNP N
, , N
vincristine NN N
and CC N
prednisone NN N
( ( N
PTC-VCR-P NNP N
) ) N
. . N

METHODS NNP N
Accordingly NNP N
, , N
we PRP N
evaluated VBD N
26,466 CD N
NSTE NNP N
ACS NNP N
patients NNS p
from IN N
the DT N
Global NNP N
Use NNP N
of IN N
Strategies NNPS N
to TO N
Open VB N
Occluded NNP N
Arteries NNPS N
in IN N
Acute NNP N
Coronary NNP N
Syndromes NNP N
( ( N
GUSTO-IIb NNP N
) ) N
, , N
Platelet NNP N
Glycoprotein NNP N
IIb/IIIa NNP N
in IN N
Unstable JJ N
Angina NNP N
: : N
Receptor NNP N
Suppression NNP N
Using NNP N
Integrilin NNP N
Therapy NNP N
( ( N
PURSUIT NNP N
) ) N
, , N
and CC N
Platelet NNP N
IIb/IIIa NNP N
Antagonism NNP N
for IN N
the DT N
Reduction NNP N
of IN N
Acute NNP N
Coronary NNP N
Syndrome NNP N
Events NNP N
in IN N
a DT N
Global NNP N
Organization NNP N
Network NNP N
( ( N
PARAGON NNP N
) ) N
A NNP N
and CC N
B NNP N
trials NNS N
to TO N
ascertain VB N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
. . N

METHODS NNP N
We PRP N
investigated VBD N
in IN N
a DT N
one-year JJ N
double JJ N
blind NN N
randomized VBD N
study NN N
comparing VBG N
intramuscular JJ N
( ( N
im NN N
) ) N
gold NN N
with IN N
im JJ N
methotrexate NN N
( ( N
MTX NNP N
) ) N
, , N
whether IN N
the DT N
variation NN N
of IN N
inflammatory JJ N
activity NN N
or CC N
functional JJ N
capacity NN N
, , N
the DT N
ascending VBG N
anatomic JJ N
stage NN N
, , N
or CC N
DMARD NNP N
treatments NNS N
have VBP N
an DT N
influence NN N
on IN N
bone NN N
formation NN N
( ( N
osteocalcin NN i
) ) N
in IN N
patients NNS p
with IN N
RA NNP N
. . N

The DT N
efficacy NN N
and CC N
the DT N
tolerability NN N
of IN N
simvastatin NN i
( ( N
a DT N
inhibitor NN N
of IN N
HGM-CoA NNP N
reductase NN N
) ) N
with IN N
that DT N
of IN N
gemfibrozil NN N
( ( N
a DT N
fibric NN N
acid NN N
derivative NN N
, , N
which WDT N
can MD N
reduce VB N
the DT N
VLDL NNP N
level NN N
) ) N
were VBD N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
study NN N
in IN N
2 CD N
groups NNS N
of IN N
patients NNS p
with IN N
primary JJ N
hypercholesterolemia NN N
and CC N
mild-to-moderate JJ N
essential JJ N
hypertension NN N
treated VBN N
with IN N
hydrochlorothiazide NN i
. . N

Given VBN N
the DT N
efficacy NN N
of IN N
systemic JJ N
sirolimus JJ N
administration NN N
to TO N
prevent VB N
neointimal JJ N
hyperplasia NN N
in IN N
animal JJ N
models NNS N
and CC N
to TO N
halt VB N
and CC N
even RB N
reverse VB N
the DT N
progression NN N
of IN N
allograft NN N
vasculopathy NN N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
10-day JJ N
oral JJ N
sirolimus NN N
treatment NN N
with IN N
2 CD N
different JJ N
loading VBG N
regimens NNS N
for IN N
the DT N
prevention NN N
of IN N
recurrent JJ N
restenosis NN N
in IN N
patients NNS p
with IN N
ISR NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
randomized VBN N
, , N
double-blind JJ N
study NN N
with IN N
two CD N
parallel JJ N
groups NNS N
was VBD N
to TO N
examine VB N
the DT N
safety NN N
, , N
efficacy NN N
and CC N
tolerability NN N
of IN N
two CD N
combination NN N
eye NN N
drops VBZ N
containing VBG N
0.5 CD N
% NN N
timolol NN i
and CC N
2 CD N
% NN N
pilocarpine NN N
( ( N
Fotil NNP N
, , N
Leiras NNP N
, , N
Finland NNP N
, , N
and CC N
Timpilo NNP N
, , N
MSD NNP N
, , N
USA NNP N
) ) N
in IN N
patients NNS p
with IN N
glaucoma NN N
or CC N
ocular JJ N
hypertension NN N
. . N

BACKGROUND IN N
We PRP N
describe VBP N
the DT N
rationale NN N
and CC N
protocol NN N
for IN N
a DT N
randomized JJ N
noninferiority NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
to TO N
determine VB N
if IN N
the DT N
Flexi-T380 NNP N
( ( N
+ NNP N
) ) N
copper NN N
intrauterine JJ N
contraceptive JJ N
device NN N
( ( N
IUD NNP N
) ) N
is VBZ N
comparable JJ N
in IN N
terms NNS N
of IN N
effectiveness NN N
and CC N
expulsion NN N
rates NNS N
to TO N
the DT N
most RBS N
common JJ N
Canadian JJ N
IUD NNP N
currently RB N
in IN N
use NN N
, , N
NovaT-200 NNP N
, , N
when WRB N
placed VBN N
immediately RB N
after IN N
a DT N
first-trimester JJ N
abortion NN N
. . N

METHODS NNP N
One CD N
hundred VBD N
five CD N
women NNS N
undergoing VBG N
laparoscopic NN N
tubal JJ N
sterilization NN N
with IN N
silastic JJ N
bands NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
one CD N
received VBD N
intramuscular JJ N
ketorolac NN N
and CC N
topical JJ N
placebo NN N
applied VBN N
to TO N
the DT N
fallopian JJ N
tubes NN N
, , N
the DT N
second JJ N
received VBD N
intramuscular JJ N
placebo NN N
and CC N
topical JJ N
bupivacaine NN N
, , N
and CC N
the DT N
third JJ N
received VBD N
intramuscular JJ N
placebo NN N
and CC N
topical JJ N
placebo NN N
. . N

Twenty-two JJ N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS p
from IN N
U. NNP N
T. NNP N
M. NNP N
D. NNP N
Anderson NNP N
Cancer NNP N
Center NNP N
, , N
with IN N
radiation-induced JJ N
xerostomia NN N
, , N
were VBD N
entered VBN N
into IN N
a DT N
pilot NN N
study NN N
to TO N
contrast VB N
the DT N
daily JJ N
home NN N
use NN N
of IN N
a DT N
0.4 CD N
% NN N
stannous JJ N
fluoride-gel-containing JJ N
tray NN N
( ( N
control VB N
group NN N
) ) N
to TO N
IFRS NNP N
( ( N
study VB N
group NN N
) ) N
with IN N
respect NN N
to TO N
tolerability NN N
and CC N
adherence NN N
, , N
and CC N
to TO N
obtain VB N
information NN N
on IN N
relative JJ N
caries NNS N
preventive VBP N
efficacy NN N
. . N

In IN N
this DT N
prospective JJ N
trial NN N
, , N
a DT N
total NN N
of IN N
74 CD N
children NNS N
who WP N
were VBD N
scheduled VBN N
to TO N
undergo VB N
high-dose JJ N
chemotherapy NN i
followed VBN N
by IN N
autologous JJ N
peripheral JJ N
blood NN N
stem NN N
cell NN N
transplantation NN N
( ( N
PBSCT NNP N
) ) N
were VBD N
prospectively RB N
randomized VBN N
at IN N
diagnosis NN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
exogenous JJ N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
treatment NN N
in IN N
accelerating VBG N
hematopoietic JJ N
recovery NN N
after IN N
PBSCT NNP N
. . N

METHODS NNP N
Determining VBG N
the DT N
EFficacy NNP N
and CC N
Tolerability NNP N
of IN N
CETP NNP N
INhibition NNP N
with IN N
AnacEtrapib NNP N
( ( N
DEFINE NNP N
) ) N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
profile NN N
of IN N
anacetrapib NN N
in IN N
patients NNS p
with IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
or CC N
CHD NNP N
risk NN N
equivalents NNS N
( ( N
clinical JJ N
trials.gov NN N
NCT00685776 NNP N
) ) N
. . N

METHODS NNP N
An DT N
examiner-blind JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
30 CD N
subjects NNS N
with IN N
moderate JJ N
to TO N
advanced JJ N
periodontitis NN N
who WP N
were VBD N
randomized VBN N
to TO N
SRP VB N
alone RB N
or CC N
SRP NNP N
combined VBN N
with IN N
prescription NN N
custom-tray JJ N
application NN N
( ( N
Perio NNP N
Tray NNP N
) ) N
of IN N
1.7 CD N
% NN N
hydrogen NN N
peroxide NN N
gel NN N
( ( N
Perio NNP N
Gel NNP N
) ) N
for IN N
a DT N
period NN N
of IN N
three CD N
months NNS N
, , N
then RB N
extended VBD N
to TO N
six CD N
months NNS N
. . N

Predictors NNS N
of IN N
postdischarge NN N
outcomes NNS N
from IN N
information NN N
acquired VBN N
shortly RB N
after IN N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
: : N
a DT N
report NN N
from IN N
the DT N
Placebo-Controlled NNP N
Randomized NNP N
Study NNP N
of IN N
the DT N
Selective NNP N
A1 NNP N
Adenosine NNP N
Receptor NNP N
Antagonist NNP N
Rolofylline NNP N
for IN N
Patients NNP N
Hospitalized NNP N
With IN N
Acute NNP N
Decompensated NNP N
Heart NNP N
Failure NNP N
and CC N
Volume NN N
Overload NNP N
to TO N
Assess NNP N
Treatment NNP N
Effect NNP N
on IN N
Congestion NNP N
and CC N
Renal NNP N
Function NNP N
( ( N
PROTECT NNP N
) ) N
Study NNP N
. . N

Similar JJ N
results NNS N
were VBD N
achieved VBN N
when WRB N
the DT N
patients NNS p
were VBD N
sub-divided JJ N
into IN N
subgroups NNS N
according VBG N
to TO N
sequences NNS N
of IN N
treatment NN N
( ( N
basal NN N
-- : N
-- : N
ibopamine NN N
-- : N
-- : N
placebo NN N
and CC N
basal NN N
-- : N
-- : N
placebo NN N
-- : N
-- : N
ibopamine NN N
) ) N
, , N
NYHA NNP N
class NN N
II NNP N
or CC N
III NNP N
, , N
aetiology NN N
of IN N
congestive JJ N
heart NN N
failure NN N
( ( N
dilatative JJ N
cardiomyopathy NN N
, , N
ischemic JJ N
cardiomyopathy NN N
and CC N
other JJ N
aetiologies NNS N
) ) N
, , N
associated VBN N
treatment NN N
with IN N
digitalis NN N
or CC N
diuretics NNS N
and CC N
the DT N
number NN N
and CC N
complexity NN N
of IN N
base NN N
ectopic NN N
ventricular JJ N
beats NNS N
. . N

A DT N
randomized JJ N
, , N
open-label JJ N
, , N
phase JJ N
2 CD N
, , N
multicenter RB N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
the DT N
addition NN N
of IN N
a DT N
recombinant JJ N
human JJ N
endostatin NN i
adenovirus NN N
( ( N
E10A NNP N
) ) N
to TO N
cisplatin VB i
and CC N
paclitaxel VB i
in IN N
patients NNS p
with IN N
advanced JJ N
head NN N
and CC N
neck NN N
squamous JJ N
cell NN N
carcinoma NN N
or CC N
nasopharyngeal JJ N
carcinoma NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty-four NNP N
subjects NNS N
, , N
each DT N
requiring VBG N
a DT N
nonmolar JJ N
extraction NN N
and CC N
delayed JJ N
implant NN N
placement NN N
, , N
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
ridge NN N
preservation NN N
treatment NN N
with IN N
either DT N
an DT N
allograft NN N
in IN N
an DT N
experimental JJ N
putty NN N
carrier NN N
plus CC N
a DT N
calcium NN N
sulfate NN N
barrier NN N
( ( N
PUT NNP N
) ) N
or CC N
a DT N
bovine-derived JJ N
xenograft NN N
( ( N
BDX NNP N
) ) N
plus CC N
a DT N
collagen NN N
membrane NN N
. . N

BACKGROUND NNP N
In IN N
a DT N
prospective JJ N
randomized NN N
manner NN N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ N
chemotherapy NN i
( ( N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
vincristine NN N
, , N
and CC N
prednisone NN N
; : N
CHOP NNP N
) ) N
in IN N
patients NNS p
with IN N
Stage NNP N
I PRP N
non-Hodgkin JJ N
lymphoma NN N
( ( N
NHL NNP N
) ) N
who WP N
have VBP N
achieved VBN N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
after IN N
radiation NN N
therapy NN i
( ( N
RT NNP N
) ) N
. . N

INTERVENTIONS NNP N
The DT N
study NN N
included VBD N
three CD N
parts NNS N
: : N
( ( N
i NN N
) ) N
a DT N
1-day JJ N
baseline NN N
survey NN N
; : N
( ( N
ii NN N
) ) N
over IN N
the DT N
following JJ N
3-month JJ N
period NN N
, , N
departments NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
all DT N
practitioners NNS N
in IN N
wards NNS N
allocated VBN N
to TO N
the DT N
intervention NN N
group NN N
were VBD N
required VBN N
to TO N
systematically RB N
use VB N
specific JJ N
anticoagulant JJ N
prescription NN N
forms NNS N
, , N
whilst NN N
doctors NNS N
in IN N
the DT N
control NN N
group NN N
continued VBD N
prescribing VBG N
according VBG N
to TO N
their PRP$ N
usual JJ N
practices NNS N
and CC N
( ( N
iii NN N
) ) N
a DT N
1-day JJ N
postintervention NN N
survey NN N
. . N

DESIGN NNP N
AND CC N
METHODS NNP N
The DT N
HERA NNP N
study NN N
( ( N
Hyperium NNP N
Effect NNP N
on IN N
the DT N
sympathetic JJ N
Reflex NNP N
activation NN N
and CC N
Adrenaline NNP N
) ) N
is VBZ N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
6-week JJ N
cross-over JJ N
trial NN N
, , N
with IN N
a DT N
1-week JJ N
placebo NN N
run-in JJ N
period NN N
, , N
two CD N
2-week JJ N
active JJ N
treatment NN N
intervals NNS N
( ( N
rilmenidine VB N
1 CD N
mg JJ N
bid NN N
, , N
placebo NN N
) ) N
and CC N
intervening VBG N
one CD N
week NN N
placebo NN N
wash-out NN N
. . N

OBJECTIVE NN N
This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
triphasic JJ N
combined JJ N
oral JJ N
contraceptives NNS N
( ( N
OCs NNP N
) ) N
containing VBG N
ethinyl JJ N
estradiol NN N
( ( N
EE NNP N
) ) N
and CC N
norgestimate JJ N
( ( N
NGM NNP N
) ) N
and CC N
biphasic JJ N
combined VBN N
OCs NNP N
containing VBG N
EE NNP N
and CC N
desogestrel NN N
( ( N
DSG NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
mild NN N
to TO N
moderate VB N
acne NN N
. . N

Following VBG N
a DT N
non-randomized JJ N
study NN N
suggesting VBG N
that IN N
desmopressin NN N
acetate NN N
( ( N
desmopressin NN N
) ) N
reduced VBD N
blood NN N
product NN N
requirements NNS N
in IN N
these DT N
patients NNS p
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
trial NN N
of IN N
desmopressin NN N
( ( N
0.3 CD N
micrograms/kg NN N
, , N
i. JJ N
v. NN N
) ) N
in IN N
92 CD N
patients NNS p
with IN N
overt JJ N
bleeding NN N
and CC N
a DT N
prolonged JJ N
bleeding NN N
time NN N
. . N

IMPLICATIONS NNP N
FOR NNP N
PRACTICE NNP N
This DT N
report NN N
presents VBZ N
key JJ N
information NN N
on IN N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
approval NN N
of IN N
ramucirumab NN i
, , N
a DT N
monoclonal JJ N
antibody NN N
targeting VBG N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor-2 NN N
, , N
given VBN N
in IN N
combination NN N
with IN N
docetaxel NN i
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN N
metastatic JJ N
non-small NN N
cell NN N
lung NN N
cancer NN N
whose WP$ N
disease NN N
has VBZ N
progressed VBN N
on IN N
or CC N
after IN N
platinum-based JJ N
chemotherapy NN i
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
, , N
placebo-controlled JJ N
, , N
multicenter JJ N
trial NN N
, , N
previously RB N
untreated JJ N
patients NNS p
with IN N
chronic JJ N
hepatitis NN N
C NNP N
were VBD N
treated VBN N
with IN N
IFN-alpha NNP N
plus CC N
ribavirin JJ N
[ NN N
17 CD N
] NN N
and CC N
randomized VBN N
for IN N
treatment NN N
with IN N
amantadine NN N
( ( N
200 CD N
mg/day NN N
, , N
orally RB N
, , N
n=136 NN N
) ) N
or CC N
placebo NN N
( ( N
n=131 JJ N
) ) N
. . N

Changes NNS N
in IN N
quality NN N
of IN N
life NN N
and CC N
sexual JJ N
health NN N
are VBP N
associated VBN N
with IN N
low-dose JJ N
peginterferon NN N
therapy NN i
and CC N
disease NN N
progression NN N
in IN N
patients NNS p
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
BACKGROUND NNP N
Primary NNP N
analysis NN N
of IN N
the DT N
Hepatitis NNP N
C NNP N
Antiviral NNP N
Long-Term NNP N
Treatment NNP N
against IN N
Cirrhosis NNP N
( ( N
HALT-C NNP N
) ) N
Trial NNP N
showed VBD N
long-term JJ N
peginterferon NN N
therapy NN i
did VBD N
not RB N
reduce VB N
complications NNS N
in IN N
patients NNS p
with IN N
chronic JJ N
hepatitis NN N
C NNP N
and CC N
advanced JJ N
fibrosis NN N
or CC N
cirrhosis NN N
. . N

Two CD N
variants NNS N
of IN N
a DT N
novel JJ N
bleomycin NN i
, , N
etoposide RB N
, , N
doxorubicin NN i
, , N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
BEACOPP NNP N
) ) N
scheme NN N
( ( N
standard JJ N
and CC N
escalated VBD N
dose NN N
) ) N
are VBP N
compared VBN N
with IN N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
COPP NNP N
) ) N
/doxorubicin NN i
, , N
bleomycin NN i
, , N
vinblastine NN N
, , N
and CC N
dacarbazine NN N
( ( N
ABVD NNP N
) ) N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
application NN N
was VBD N
to TO N
fulfill VB N
a DT N
postmarketing NN N
commitment NN N
to TO N
provide VB N
long-term JJ N
efficacy NN N
and CC N
safety NN N
data NNS N
on IN N
treatment NN N
with IN N
imatinib JJ N
mesylate NN N
( ( N
Gleevec NNP N
; : N
Novartis NNP N
Pharmaceuticals NNP N
, , N
East NNP N
Hanover NNP N
, , N
NJ NNP N
) ) N
in IN N
patients NNS p
with IN N
CD117 NNP N
( ( N
+ NNP N
) ) N
unresectable JJ N
and/or JJ N
metastatic JJ N
malignant JJ N
gastrointestinal JJ N
stromal NN N
tumors NNS N
( ( N
GISTs NNP N
) ) N
. . N

Treatments NNS N
included VBD N
involved JJ N
field NN N
, , N
total JJ N
lymphoid NN N
, , N
or CC N
whole JJ N
body NN N
irradiation NN N
, , N
single JJ N
alkylating VBG N
agent NN N
chemotherapy NN i
, , N
combination NN N
chemotherapy NN i
with IN N
cyclophosphamide NN N
, , N
vincristine NN N
and CC N
prednisone NN N
( ( N
CVP NNP N
) ) N
or CC N
with IN N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
C-MOPP NNP N
) ) N
, , N
or CC N
various JJ N
combinations NNS N
of IN N
chemotherapy NN i
and CC N
irradiation NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
The DT N
effect NN N
of IN N
institutional JJ N
experience NN N
on IN N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
in IN N
patients NNS p
with IN N
stage NN N
III NNP N
or CC N
IV NNP N
HNC NNP N
was VBD N
investigated VBN N
within IN N
a DT N
randomized JJ N
trial NN N
of IN N
the DT N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
( ( N
RTOG NNP N
0129 CD N
) ) N
, , N
which WDT N
compared VBN N
cisplatin NN i
concurrent NN N
with IN N
standard JJ N
versus NN N
accelerated VBN N
fractionation NN N
radiotherapy NN i
. . N

The DT N
Southwest NNP N
Oncology NNP N
Group NNP N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
compared VBN N
one CD N
year NN N
of IN N
adjuvant JJ N
combination NN N
chemotherapy NN i
with IN N
continuous JJ N
CMFVP NNP N
( ( N
cyclophosphamide NN N
, , N
methotrexate NN N
, , N
5-fluorouracil JJ N
, , N
vincristine NN N
, , N
and CC N
prednisone NN N
) ) N
to TO N
two CD N
years NNS N
of IN N
intermittent JJ N
L-phenylalanine JJ N
mustard NN N
( ( N
L-PAM NNP N
) ) N
in IN N
women NNS N
with IN N
operable JJ N
breast NN N
cancer NN N
with IN N
histologically RB N
positive JJ N
axillary JJ N
lymph NN N
nodes NNS N
. . N

METHODS NNP N
In IN N
the DT N
current JJ N
investigation NN N
, , N
changes NNS N
in IN N
autonomic JJ N
tone NN N
associated VBN N
with IN N
long-term JJ N
administration NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
were VBD N
measured VBN N
using VBG N
spectral JJ N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
in IN N
13 CD N
patients NNS p
with IN N
congestive JJ N
heart NN N
failure NN N
who WP N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ N
trial NN N
of IN N
the DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
zofenopril NN N
. . N

The DT N
Long-term JJ N
Intervention NN N
with IN N
Pravastatin NNP i
in IN N
Ischemic NNP N
Heart NNP N
Disease NNP N
( ( N
LIPID NNP N
) ) N
trial NN N
is VBZ N
a DT N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
evaluating VBG N
the DT N
long-term JJ N
effect NN N
of IN N
pravastatin NN i
on IN N
coronary JJ N
mortality NN N
in IN N
patients NNS p
with IN N
a DT N
previous JJ N
myocardial JJ N
infarction NN N
or CC N
unstable JJ N
angina-ischemic JJ N
heart NN N
disease NN N
( ( N
IHD NNP N
) ) N
. . N

AIM NNP N
In IN N
our PRP$ N
randomized JJ N
prospective JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficiency NN N
of IN N
plasmakinetic JJ N
resection NN N
of IN N
prostate NN N
( ( N
PKRP NNP N
) ) N
by IN N
comparing VBG N
the DT N
preoperative NN N
and CC N
postoperative JJ N
results NNS N
of IN N
the DT N
transurethral JJ N
resection NN N
of IN N
prostate NN N
( ( N
TURP NNP N
) ) N
and CC N
PKRP NNP N
techniques NNS N
which WDT N
we PRP N
administered VBD N
in IN N
patients NNS p
with IN N
benign JJ N
prostate NN N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
in IN N
our PRP$ N
clinic NN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
sham-controlled JJ N
, , N
single-center JJ N
trial NN N
, , N
patients NNS p
scheduled VBN N
for IN N
surgical JJ N
removal NN N
of IN N
an DT N
odontogenic JJ N
maxillary JJ N
cyst NN N
under IN N
general JJ N
anesthesia NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
local JJ N
injection NN N
of IN N
lidocaine JJ N
solution NN N
with IN N
either DT N
1 CD N
mg NN N
of IN N
morphine NN N
( ( N
MLA NNP N
group NN N
) ) N
or CC N
with IN N
no DT N
morphine NN N
( ( N
LA NNP N
group NN N
) ) N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
design NN N
and CC N
rationale NN N
of IN N
a DT N
phase NN N
2 CD N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
LX4211 NNP N
in IN N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
who WP N
have VBP N
inadequate JJ N
glycemic NNS N
control NN N
on IN N
metformin NN N
monotherapy NN i
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Forty-nine NNP N
patients NNS p
( ( N
40 CD N
with IN N
abnormal JJ N
cell-mediated JJ N
immunity NN N
) ) N
participated VBD N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
high-dose JJ N
intravenously RB N
administered VBN N
immunoglobulin NN N
G. NNP N
The DT N
patients NNS p
received VBD N
three CD N
intravenous JJ N
infusions NNS N
of IN N
a DT N
placebo JJ N
solution NN N
or CC N
immunoglobulin NN N
at IN N
a DT N
dose NN N
of IN N
2 CD N
g/kg/month NN N
. . N

Therefore RB N
, , N
we PRP N
started VBD N
the DT N
randomized VBN N
EORTC/LYSA/FIL NNP N
Intergroup NNP N
H10 NNP N
trial NN N
evaluating VBG N
whether IN N
involved-node JJ N
radiotherapy NN i
( ( N
IN-RT NNP N
) ) N
could MD N
be VB N
omitted VBN N
without IN N
compromising VBG N
progression-free JJ N
survival NN N
in IN N
patients NNS p
attaining VBG N
a DT N
negative JJ N
early JJ N
PET NNP N
scan NN N
after IN N
two CD N
cycles NNS N
of IN N
ABVD NNP N
( ( N
doxorubicin NN i
, , N
bleomycin NN i
, , N
vinblastine NN N
, , N
and CC N
dacarbazine NN N
) ) N
as IN N
compared VBN N
with IN N
standard JJ N
combined-modality NN N
treatment NN N
. . N

In IN N
the DT N
present JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
split-face JJ N
, , N
comparative JJ N
study NN N
we PRP N
have VBP N
assessed VBN N
efficacy NN N
, , N
tolerability NN N
, , N
and CC N
safety NN N
of IN N
a DT N
base NN N
cream NN N
containing VBG N
0.5 CD N
% NN N
BAs NNP N
as IN N
compared VBN N
to TO N
the DT N
same JJ N
cream NN N
without IN N
these DT N
active JJ N
ingredients NNS N
in IN N
the DT N
treatment NN N
of IN N
clinical JJ N
manifestations NNS N
of IN N
photoaging NN N
of IN N
facial JJ N
skin NN N
. . N

METHODS NNP N
Thirty NNP N
patients NNS p
undergoing VBG N
lower JJR N
abdominal JJ N
surgery NN N
were VBD N
randomized VBN N
in IN N
a DT N
double-blinded JJ N
manner NN N
to TO N
receive VB N
one CD N
of IN N
three CD N
solutions NNS N
: : N
0.2 CD N
% NN N
ropivacaine-4 JJ N
microg NN N
fentanyl VBD N
0.1 CD N
% NN N
ropivacaine-2 JJ N
microg NN N
fentanyl NN N
, , N
or CC N
0.05 CD N
% NN N
ropivacaine-1 JJ N
microg NN N
fentanyl NN N
for IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
after IN N
standardized VBN N
combined JJ N
epidural JJ N
and CC N
general JJ N
anesthesia NN N
. . N

Eighty-seven JJ N
children NNS N
with IN N
central JJ N
nervous JJ N
system NN N
( ( N
CNS NNP N
) ) N
leukemia NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
induction NN N
intrathecal JJ N
chemotherapy NN i
( ( N
ITC NNP N
) ) N
and CC N
cranial JJ N
irradiation NN N
( ( N
CRT NNP N
) ) N
plus CC N
maintenance NN N
ITC NNP N
, , N
or CC N
induction NN N
ITC NNP N
and CC N
craniospinal JJ N
irradiation NN N
( ( N
CSpRT NNP N
) ) N
with IN N
no DT N
maintenance NN N
ITC NNP N
. . N

BACKGROUND IN N
A NNP N
pilot NN N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
toxicity NN N
and CC N
tolerance NN N
to TO N
low-dose JJ N
subcutaneous JJ N
interleukin-2 NN N
( ( N
IL-2 NNP N
) ) N
for IN N
patients NNS p
with IN N
resected JJ N
renal JJ N
cell NN N
carcinoma NN N
( ( N
RCC NNP N
) ) N
at IN N
high JJ N
risk NN N
for IN N
recurrent JJ N
disease NN N
( ( N
TNM NNP N
stages VBZ N
III NNP N
and CC N
IV NNP N
resected VBD N
distant JJ N
metastases NNS N
) ) N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
efficacy NN N
, , N
safety NN N
, , N
and CC N
tolerability NN N
of IN N
6 CD N
dosages NNS N
of IN N
oral JJ N
tofacitinib NN N
( ( N
CP-690,550 NNP N
) ) N
with IN N
placebo NN N
for IN N
the DT N
treatment NN N
of IN N
active JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
in IN N
patients NNS p
receiving VBG N
a DT N
stable JJ N
background NN N
regimen NNS N
of IN N
methotrexate NN N
( ( N
MTX NNP N
) ) N
who WP N
have VBP N
an DT N
inadequate JJ N
response NN N
to TO N
MTX NNP N
monotherapy NN i
. . N

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
secondary JJ N
analysis NN N
was VBD N
to TO N
examine VB N
the DT N
relationships NNS N
between IN N
a DT N
reduction NN N
in IN N
psychological JJ N
distress NN N
and CC N
long-term JJ N
cardiac NN N
and CC N
psychological JJ N
outcomes NNS N
in IN N
post-myocardial JJ N
infarction NN N
patients NNS p
who WP N
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
home-based JJ N
psychosocial JJ N
nursing NN N
interventions NNS N
( ( N
the DT N
Montreal NNP N
Heart NNP N
Attack NNP N
Readjustment NNP N
Trial NNP N
[ NNP N
M-HART NNP N
] NNP N
) ) N
. . N

Consolidation NNP N
consisted VBD N
of IN N
six CD N
courses NNS N
of IN N
chemotherapy NN i
; : N
the DT N
first JJ N
, , N
third JJ N
, , N
and CC N
fifth JJ N
courses NNS N
were VBD N
a DT N
combination NN N
of IN N
high-dose JJ N
cytarabine NN N
, , N
etoposide RB N
, , N
and CC N
dexamethasone NN N
( ( N
R3 NNP N
) ) N
, , N
whereas VBD N
the DT N
second JJ N
, , N
fourth JJ N
, , N
and CC N
sixth JJ N
courses NNS N
included VBD N
vincristine NN N
, , N
prednisone NN N
, , N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
and CC N
methotrexate NN N
( ( N
COPADM NNP N
) ) N
. . N

CONCLUSIONS NNP N
This DT N
pilot NN N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
prospectively RB N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
combination NN N
of IN N
0.45 CD N
% NN N
ketorolac NN N
eyedrops VBZ N
three CD N
times NNS N
a DT N
day NN N
and CC N
intravitreal VB N
ranibizumab JJ i
injections NNS N
in IN N
patients NNS p
with IN N
CNV NNP N
, , N
and CC N
suggests VBZ N
that DT N
topical JJ N
ketorolac NN N
supplements VBZ N
the DT N
activity NN N
of IN N
intravitreal NN N
ranibizumab NN i
in IN N
reducing VBG N
CMT NNP N
in IN N
CNV NNP N
. . N

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
different JJ N
doses NNS N
of IN N
antithymocyte JJ N
globulin NN N
( ( N
ATG NNP N
) ) N
on IN N
the DT N
incidence NN N
of IN N
acute JJ N
GVHD NNP N
among IN N
patients NNS p
receiving VBG N
hematopoietic JJ N
SCT NNP N
without IN N
ex JJ N
vivo FW N
T-cell-depletion NN N
from IN N
haploidentical JJ N
donors NNS N
, , N
224 CD N
patients NNS p
with IN N
standard-risk JJ N
hematological JJ N
malignancy NN N
were VBD N
randomized VBN N
in IN N
this DT N
study NN N
. . N

METHODS NNP N
A NNP N
cohort NN N
of IN N
199 CD N
patients NNS p
with IN N
early JJ N
active JJ N
RA NNP N
were VBD N
initially RB N
randomized VBN N
to TO N
receive VB N
treatment NN N
with IN N
a DT N
combination NN N
of IN N
methotrexate NN N
, , N
sulfasalazine NN N
, , N
and CC N
hydroxychloroquine NN N
with IN N
prednisolone NN N
( ( N
FIN-RACo NNP N
) ) N
, , N
or CC N
treatment NN N
with IN N
a DT N
single JJ N
DMARD NNP N
( ( N
initially RB N
, , N
sulfasalazine NN N
) ) N
with IN N
or CC N
without IN N
prednisolone NN N
( ( N
SINGLE NNP N
) ) N
. . N

METHODS/RESULTS NNP N
In IN N
order NN N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
vagus NN N
nerve NN N
stimulation NN N
, , N
an DT N
international JJ N
multi-center NN N
randomized VBD N
clinical JJ N
trial NN N
( ( N
INOVATE-HF NNP N
) ) N
has VBZ N
been VBN N
designed VBN N
to TO N
assess VB N
safety NN N
and CC N
efficacy NN N
of IN N
vagus NN N
nerve NN N
stimulation NN N
in IN N
symptomatic JJ N
patients NNS p
with IN N
heart NN N
failure NN N
on IN N
optimal JJ N
medical JJ N
therapy NN i
using VBG N
the DT N
CardioFit NNP N
System NNP N
( ( N
BioControl NNP N
Medical NNP N
, , N
Yehud NNP N
, , N
Israel NNP N
) ) N
. . N

METHODS NNP N
Thirty-one CD N
adults NNS N
( ( N
age NN N
[ VBZ N
mean+/-SD JJ N
] NNP N
, , N
28.1+/-7.3 JJ N
years NNS N
) ) N
with IN N
autistic JJ N
disorder NN N
( ( N
n=17 JJ N
) ) N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
not RB N
otherwise RB N
specified VBN N
( ( N
n=14 JJ N
) ) N
participated VBD N
in IN N
a DT N
12-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN i
. . N

PURPOSE VB N
This DT N
single-blinded JJ N
, , N
randomized VBN N
, , N
controlled VBN N
pilot NN N
study NN N
aimed VBN N
to TO N
investigate VB N
whether IN N
there EX N
is VBZ N
a DT N
difference NN N
between IN N
nasal NN N
and CC N
oronasal NN N
masks NNS N
in IN N
therapeutic JJ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
( ( N
CPAP NNP N
) ) N
requirement NN N
, , N
residual JJ N
disease NN N
, , N
or CC N
leak VB N
when WRB N
treating VBG N
obstructive JJ N
sleep NN N
apnea NN N
( ( N
OSA NNP N
) ) N
and CC N
if IN N
differences NNS N
were VBD N
related VBN N
to TO N
measures NNS N
of IN N
upper JJ N
airway NN N
size NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
monolateral JJ N
postmastectomy NN N
lymphedema NN N
were VBD N
randomized VBN N
to TO N
receive VB N
two CD N
cycles NNS N
of IN N
intermittent JJ N
pneumatic JJ N
compression NN N
( ( N
PC NNP N
group NN N
) ) N
, , N
i.e NN N
, , N
five CD N
two-hour JJ N
sessions NNS N
per IN N
week NN N
for IN N
two CD N
weeks NNS N
, , N
to TO N
be VB N
repeated VBN N
after IN N
a DT N
five-week JJ N
interval NN N
, , N
or CC N
to TO N
no DT N
treatment NN N
( ( N
control VB N
group NN N
) ) N
. . N

Eighty-eight JJ N
postmenopausal NN N
women NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
in IN N
whom WP N
estrogen NN N
receptors NNS N
( ( N
ER NNP N
) ) N
were VBD N
positive JJ N
or CC N
unknown JJ N
, , N
were VBD N
treated VBN N
on IN N
a DT N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
tamoxifen NN N
and CC N
to TO N
assess VB N
the DT N
therapeutic JJ N
advantage NN N
of IN N
sequentially RB N
adding VBG N
low-dose JJ N
cyclophosphamide-methotrexate-5-fluorouracil NN N
( ( N
CMF NNP N
) ) N
chemotherapy NN i
in IN N
tamoxifen JJ N
responders NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN N
and CC N
isoflurane NN N
via IN N
direct JJ N
arterial JJ N
blood NN N
pressure NN N
measurements NNS N
and CC N
the DT N
lithium NN N
dilution NN N
cardiac NN N
output NN N
( ( N
LDCO NNP N
) ) N
on IN N
premedicated VBN N
healthy JJ N
dogs NNS N
undergoing VBG N
elective JJ N
tibial JJ N
plateau NN N
leveling VBG N
osteotomy NN N
( ( N
TPLO NNP N
) ) N
. . N

BACKGROUND IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
toxicity NN N
of IN N
the DT N
liposome-encapsulated JJ N
doxorubicin NN i
, , N
TLC NNP N
D-99 NNP N
( ( N
Myocet NNP N
, , N
Elan NNP N
Pharmaceuticals NNP N
, , N
Princeton NNP N
, , N
NJ NNP N
) ) N
, , N
and CC N
conventional JJ N
doxorubicin NN i
in IN N
first-line JJ N
treatment NN N
of IN N
metastatic JJ N
breast NN N
carcinoma NN N
( ( N
MBC NNP N
) ) N
. . N

BACKGROUND IN N
The DT N
VIOS NNP N
( ( N
Vascular JJ N
Improvement NN N
with IN N
Olmesartan NNP N
medoxomil NNP N
Study NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
parallel JJ N
study NN N
to TO N
determine VB N
the DT N
relative JJ N
effects NNS N
of IN N
suppressing VBG N
the DT N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
the DT N
angiotensin NN N
receptor NN N
antagonist NN N
olmesartan IN N
medoxomil NN N
versus NN N
suppressing VBG N
sympathetic JJ N
drive NN N
with IN N
the DT N
beta-adrenoceptor JJ N
antagonist NN N
atenolol NN i
on IN N
remodeling NN N
of IN N
the DT N
subcutaneous JJ N
small JJ N
resistance NN N
vessel NN N
. . N

METHODS NN N
In IN N
our PRP$ N
parallel-group NN N
randomised VBN N
trial NN N
, , N
patients NNS p
meeting NN N
Oxford NNP N
criteria NN N
for IN N
chronic JJ N
fatigue NN N
syndrome NN N
were VBD N
recruited VBN N
from IN N
six CD N
secondary-care JJ N
clinics NNS N
in IN N
the DT N
UK NNP N
and CC N
randomly RB N
allocated VBN N
by IN N
computer-generated JJ N
sequence NN N
to TO N
receive VB N
specialist NN N
medical JJ N
care NN N
( ( N
SMC NNP N
) ) N
alone RB N
or CC N
with IN N
adaptive JJ N
pacing VBG N
therapy NN i
( ( N
APT NNP N
) ) N
, , N
CBT NNP N
, , N
or CC N
GET NNP N
. . N

METHODS NNP N
Forty NNP N
outpatients NNS p
aged VBD N
4 CD N
to12 NN N
years NNS N
, , N
who WP N
were VBD N
diagnosed VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
based VBN N
on IN N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
Text NNP N
Revision NNP N
criteria NNS N
, , N
were VBD N
assigned VBN N
to TO N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN N
a DT N
two-by-two JJ N
factorial JJ N
design NN N
, , N
we PRP N
enrolled VBD N
consecutive JJ N
adults NNS N
( ( N
age NN N
? . N
years NNS N
) ) N
admitted VBD N
to TO N
one CD N
of IN N
11 CD N
French JJ N
intensive-care JJ N
units NNS N
and CC N
requiring VBG N
at IN N
least JJS N
one CD N
of IN N
central-venous JJ N
, , N
haemodialysis NN N
, , N
or CC N
arterial JJ N
catheters NNS N
. . N

This DT N
report NN N
describes VBZ N
the DT N
design NN N
, , N
recruitment NN N
, , N
enrolment NN N
and CC N
baseline JJ N
results NNS N
of IN N
the DT N
Treatment NNP N
of IN N
Lead-Exposed JJ N
Children NNP N
( ( N
TLC NNP N
) ) N
trial NN N
, , N
a DT N
randomised VBN N
, , N
multicentre FW N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
treating VBG N
lead-exposed JJ N
children NNS N
with IN N
succimer NN N
, , N
a DT N
drug NN N
that WDT N
enhances VBZ N
urinary JJ N
excretion NN N
of IN N
lead NN N
, , N
on IN N
cognitive JJ N
, , N
behavioural JJ N
and CC N
physical JJ N
development NN N
. . N

The DT N
Nutritional NNP N
Prevention NNP N
of IN N
Cancer NNP N
Trial NNP N
was VBD N
a DT N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
designed VBN N
to TO N
test VB N
whether IN N
selenium NN N
as IN N
selenized VBN N
yeast NN N
( ( N
200 CD N
microg NNS N
daily RB N
) ) N
could MD N
prevent VB N
nonmelanoma JJ N
skin JJ N
cancer NN N
among IN N
1312 CD N
patients NNS p
from IN N
the DT N
Eastern NNP N
United NNP N
States NNPS N
who WP N
had VBD N
previously RB N
had VBN N
this DT N
disease NN N
. . N

The DT N
efficacy NN N
of IN N
transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
( ( N
TENS NNP N
) ) N
as IN N
an DT N
adjunct NN N
to TO N
narcotic JJ i
medications NNS N
for IN N
the DT N
management NN N
of IN N
postoperative JJ N
pain NN N
was VBD N
assessed VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
patients NNS p
following VBG N
coronary JJ N
artery JJ N
bypass NN N
graft NN N
( ( N
CABG NNP N
) ) N
surgery NN N
with IN N
the DT N
right NN N
or CC N
left VBD N
internal JJ N
thoracic NN N
artery NN N
( ( N
ITA NNP N
) ) N
. . N

To TO N
define VB N
the DT N
current JJ N
efficacy NN N
of IN N
Fansidar NNP N
( ( N
F. NNP N
Hoffmann-La NNP N
Roche NNP N
Ltd. NNP N
, , N
Basel NNP N
Switzerland NNP N
) ) N
( ( N
pyrimethamine NN N
and CC N
sulfadoxine NN i
) ) N
, , N
primaquine NN N
in IN N
a DT N
high JJ N
dose NN N
, , N
and CC N
artesunate NN N
for IN N
treating VBG N
acute JJ N
Plasmodium NNP N
vivax NN i
malaria NN N
, , N
we PRP N
conducted VBD N
a DT N
comparative JJ N
clinical JJ N
trial NN N
of IN N
these DT N
3 CD N
drugs NNS N
in IN N
an DT N
open-label JJ N
study NN N
. . N

This DT N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
aimed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
Cappra NNP N
( ( N
? . N
) ) N
, , N
a DT N
traditional JJ N
herbal NN N
medicine NN N
which WDT N
was VBD N
used VBN N
in IN N
Thailand NNP N
for IN N
decades NNS N
, , N
for IN N
the DT N
treatment NN N
of IN N
mild NN N
and CC N
mild NN N
to TO N
moderate VB N
ED NNP N
in IN N
Thai NNP N
patients NNS p
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
comparative NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
survival NN N
rate NN N
and CC N
the DT N
condition NN N
of IN N
the DT N
peri-implant JJ N
tissues NNS N
of IN N
the DT N
IMZ NNP N
implant NN N
system NN N
( ( N
two-stage JJ N
cylindertype NN N
) ) N
, , N
the DT N
Br NNP N
implant NN N
system NN N
( ( N
two-stage JJ N
screwtype NN N
) ) N
and CC N
the DT N
ITI NNP N
implant NN N
system NN N
( ( N
one-stage JJ N
screwtype NN N
) ) N
supporting VBG N
a DT N
mandibular JJ N
overdenture NN N
during IN N
a DT N
5-year JJ N
follow-up JJ N
period NN N
. . N

The DT N
recently RB N
published VBN N
Ongoing NNP N
Telmisartan NNP N
Alone NNP N
and CC N
in IN N
Combination NNP N
With IN N
Ramipril NNP N
Global NNP N
Endpoint NNP N
Trial NNP N
( ( N
ONTARGET NNP N
) ) N
in IN N
patients NNS p
with IN N
vascular JJ N
disease NN N
or CC N
high-risk JJ N
diabetes NNS N
, , N
as IN N
the DT N
largest JJS N
published VBN N
comparative JJ N
trial NN N
of IN N
these DT N
agent NN N
classes NNS N
, , N
provides VBZ N
further JJ N
evidence NN N
concerning VBG N
the DT N
comparison NN N
between IN N
the DT N
angiotensin-receptor NN N
blockers NNS N
( ( N
ARBs NNP N
) ) N
and CC N
the DT N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
ACEIs NNP N
) ) N
. . N

CONCLUSIONS NN N
It PRP N
is VBZ N
feasible JJ N
to TO N
conduct VB N
a DT N
prehospital JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
HSD NNP N
for IN N
treatment NN N
of IN N
blunt NN N
trauma NN N
patients NNS p
with IN N
head JJ N
injuries NNS N
; : N
however RB N
, , N
consent NN N
for IN N
neurofunctional JJ N
outcomes NNS N
in IN N
this DT N
cohort NN N
is VBZ N
problematic JJ N
and CC N
threatens VBZ N
the DT N
feasibility NN N
of IN N
definitive JJ N
trials NNS N
using VBG N
these DT N
potentially RB N
meaningful JJ N
end NN N
points NNS N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
examine VB N
potential JJ N
threats NNS N
to TO N
internal JJ N
and CC N
external JJ N
study NN N
validity NN N
caused VBN N
by IN N
differential JJ N
patient NN N
withdrawal NN N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
evaluating VBG N
pharmacist JJ N
management NN N
of IN N
hypertension NN N
, , N
to TO N
compare VB N
the DT N
characteristics NNS N
of IN N
patients NNS p
who WP N
withdrew VBP N
with IN N
those DT N
of IN N
patients NNS p
who WP N
completed VBD N
the DT N
study NN N
, , N
and CC N
to TO N
identify VB N
characteristics NNS N
that WDT N
predispose VBP N
patients NNS p
to TO N
withdraw VB N
from IN N
hypertension NN N
management NN N
. . N

PURPOSE NN N
To TO N
evaluate VB N
the DT N
association NN N
of IN N
efavirenz JJ N
hypersusceptibility NN N
( ( N
EFV-HS NNP N
) ) N
with IN N
clinical JJ N
outcome NN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
trial NN N
of IN N
EFV NNP N
plus CC N
indinavir NN N
( ( N
EFV+IDV NNP N
) ) N
vs. FW N
EFV+IDV NNP N
plus CC N
abacavir NN N
( ( N
ABC NNP N
) ) N
in IN N
283 CD N
nucleoside-experienced JJ N
HIV-infected JJ N
patients NNS p
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
patients NNS p
with IN N
dysfunctional JJ N
, , N
stenotic JJ i
hemodialysis NN N
arteriovenous JJ N
fistulas NNS N
( ( N
AVFs NNP N
) ) N
, , N
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
CBA NNP N
or CC N
HPBA NNP N
if IN N
conventional JJ N
PTA NNP N
had VBD N
suboptimal JJ N
results NNS N
( ( N
ie JJ N
, , N
residual JJ N
stenosis NN N
> VBD N
30 CD N
% NN N
) ) N
. . N

OBJECTIVE IN N
This DT N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
extrinsic JJ N
stain NN N
reduction NN N
achieved VBN N
by IN N
brushing VBG N
with IN N
a DT N
whitening NN N
dentifrice NN N
and CC N
powered VBD N
toothbrush NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
a DT N
whitening NN N
booster NN N
paste NN N
to TO N
this DT N
regimen NNS N
would MD N
enhance VB N
its PRP$ N
stain NN N
reducing VBG N
effectiveness NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
controlled JJ N
clinical JJ N
trial NN N
at IN N
two CD N
tertiary JJ N
care NN N
centres NNS N
of IN N
patients NNS p
with IN N
SLE NNP N
according VBG N
to TO N
the DT N
ACR NNP N
criteria NNS N
, , N
with IN N
incident NN N
( ( N
no DT N
more JJR N
than IN N
15 CD N
days NNS N
) ) N
onset NN N
of IN N
severe JJ N
NP NNP N
manifestations NNS N
such JJ N
as IN N
seizures NNS N
, , N
optic JJ N
neuritis NN N
, , N
peripheral JJ N
or CC N
cranial JJ N
neuropathy NN N
, , N
coma NN N
, , N
brainstem NN N
disease NN N
, , N
or CC N
transverse JJ N
myelitis NN N
. . N

OBJECTIVES NNP N
According VBG N
to TO N
the DT N
proposed VBN N
interference NN N
of IN N
N-acetylcysteine NNP i
( ( N
NAC NNP N
) ) N
with IN N
pathophysiologic JJ N
processes NNS N
of IN N
autistic JJ N
disorders NNS N
( ( N
ADs NNP N
) ) N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
NAC NNP N
as IN N
an DT N
adjunct NN N
to TO N
risperidone VB i
in IN N
the DT N
treatment NN N
of IN N
ADs NNP N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
conduct VB N
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
the DT N
Early JJ N
Start NNP N
Denver NNP N
Model NNP N
( ( N
ESDM NNP N
) ) N
, , N
a DT N
comprehensive JJ N
developmental JJ N
behavioral JJ N
intervention NN N
, , N
for IN N
improving VBG N
outcomes NNS N
of IN N
toddlers NNS N
diagnosed VBN N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

METHODS NNP N
Eyes NNP N
were VBD N
randomized VBN N
to TO N
receive VB N
sham NN N
injections NNS N
plus CC N
prompt JJ N
laser NN N
, , N
intravitreal JJ N
ranibizumab NN i
injections NNS N
plus CC N
prompt JJ N
laser NN N
, , N
intravitreal JJ N
ranibizumab NN i
injections NNS N
plus CC N
deferred JJ N
laser NN N
, , N
or CC N
intravitreal VB N
triamcinolone JJ N
acetonide JJ N
injections NNS N
plus CC N
prompt NN N
laser NN N
up RB N
to TO N
every DT N
16 CD N
weeks NNS N
with IN N
sham JJ N
injections NNS N
intermittently RB N
. . N

A DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
comparing VBG N
standard NN N
wound NN N
care NN N
with IN N
adjunctive JJ N
hyperbaric JJ N
oxygen NN N
therapy NN i
( ( N
HBOT NNP N
) ) N
to TO N
standard VB N
wound NN N
care NN N
only RB N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
, , N
non-healing JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
in IN N
patients NNS p
with IN N
diabetes NNS N
mellitus NNS N
: : N
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
toxicity NN N
of IN N
monthly JJ N
alternating VBG N
ABVD/MOPP NNP N
compared VBN N
to TO N
ABVD/OPP NNP N
regimens NNS N
in IN N
patients NNS p
with IN N
advanced JJ N
stage NN N
Hodgkin NNP N
's POS N
disease NN N
( ( N
HD NNP N
) ) N
, , N
as RB N
well RB N
as IN N
in IN N
early JJ N
stage NN N
patients NNS p
with IN N
systemic JJ N
symptoms NNS N
and/or VBP N
bulky JJ N
disease NN N
. . N

STUDY NNP N
METHODS NNP N
Women NNP N
, , N
aged VBD N
18-34 CD N
years NNS N
, , N
with IN N
no DT N
contraindications NNS N
to TO N
the DT N
use NN N
of IN N
combined JJ N
OCs NNP N
, , N
were VBD N
randomized VBN N
to TO N
three CD N
cycles NNS N
of IN N
treatment NN N
with IN N
a DT N
CVR NNP N
delivering NN N
NES/EE NNP N
( ( N
150/15 CD N
microg/day NN N
) ) N
or CC N
a DT N
combined JJ N
OC NNP N
providing VBG N
LNG NNP N
and CC N
EE NNP N
( ( N
150/30 CD N
microg NN N
per IN N
tablet NN N
) ) N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomised VBD N
double-blind NN N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
magnesium NN N
added VBN N
to TO N
local JJ N
anaesthetics NNS N
on IN N
postoperative JJ N
VAS NNP N
scores NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
time NN N
to TO N
first JJ N
mobilisation NN N
, , N
patient JJ N
satisfaction NN N
and CC N
rescue NN N
analgesic JJ N
requirements NNS N
in IN N
arthroscopic JJ N
ACL NNP N
reconstruction NN N
surgery NN N
. . N

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
four CD N
or CC N
eight CD N
courses NNS N
of IN N
cytotoxic NN N
chemotherapy NN i
with IN N
cyclophosphamide NN N
, , N
vincristine NN N
and CC N
etoposide NN N
and CC N
also RB N
randomised VBD N
to TO N
receive VB N
, , N
on IN N
disease NN N
progression NN N
, , N
either CC N
second JJ N
line NN N
chemotherapy NN i
( ( N
methotrexate NN N
and CC N
doxorubicin NN i
) ) N
or CC N
symptomatic JJ N
treatment NN N
only RB N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
split-face JJ N
randomized JJ N
prospective JJ N
open-label JJ N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
sequential JJ N
erbium NN N
: : N
yttrium-aluminum-garnet NN N
( ( N
Er NNP N
: : N
YAG NN N
) ) N
laser NN N
versus NN N
intense JJ N
pulsed VBN N
light NN N
( ( N
IPL NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
mild NN N
to TO N
moderate VB N
facial JJ N
photodamage NN N
. . N

Efficacy NN N
of IN N
a DT N
family NN N
practice-based JJ N
lifestyle JJ N
intervention NN N
program NN N
to TO N
increase VB o
physical JJ N
activity NN N
and CC N
reduce VB N
clinical JJ N
and CC N
physiological JJ N
markers NNS N
of IN N
vascular JJ N
health NN N
in IN N
patients NNS p
with IN N
high JJ N
normal JJ N
blood NN N
pressure NN N
and/or RB N
high JJ N
normal JJ N
blood NN N
glucose NN N
( ( N
SNAC NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

We PRP N
evaluated VBD N
whether IN N
PML-RAR NNP N
alpha NN N
mRNA NN N
type NN N
is VBZ N
associated VBN N
with IN N
distinct JJ N
pretreatment JJ N
clinical JJ N
characteristics NNS N
and CC N
therapeutic JJ N
outcome NN N
in IN N
previously RB N
untreated VBN N
adult NN N
APL NNP N
patients NNS p
registered VBD N
to TO N
protocol VB N
INT NNP N
0129 CD N
by IN N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
, , N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
, , N
and CC N
the DT N
Cancer NNP N
and CC N
Leukemia NNP N
Group NNP N
B NNP N
. . N

UNLABELLED VBN N
BACKGROUND NNP N
AND NNP N
AIM NNP N
OF NNP N
INVESTIGATION NNP N
: : N
Intramuscular NNP N
( ( N
IM NNP N
) ) N
administration NN N
has VBZ N
been VBN N
considered VBN N
to TO N
be VB N
safer JJR N
than IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
for IN N
opioids NNS N
on IN N
wards NNS N
, , N
but CC N
a DT N
comparative JJ N
knowledge NN N
of IN N
patient JJ N
safety NN N
and CC N
analgesic JJ N
potency NN N
following VBG N
a DT N
single JJ N
dose NN N
of IN N
IV NNP N
and CC N
IM NNP N
administration NN N
is VBZ N
lacking VBG N
. . N

In IN N
order NN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
adjuvant JJ N
chemotherapy NN i
employing VBG N
mitomycin JJ i
C NNP N
( ( N
MMC NNP N
) ) N
and CC N
carmofur NN N
( ( N
HCFU NNP N
) ) N
for IN N
patients NNS p
with IN N
noncuratively RB N
resected VBN N
colorectal JJ N
carcinoma NN N
, , N
a DT N
cooperative JJ N
study NN N
was VBD N
performed VBN N
by IN N
54 CD N
institutions NNS N
in IN N
the DT N
Kyushu NNP N
and CC N
Chugoku NNP N
areas NNS N
of IN N
Japan NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
determine VB N
if IN N
topical JJ N
nasal NN N
fluticasone NN N
is VBZ N
effective JJ N
at IN N
decreasing VBG N
subjective JJ N
congestion NN N
and CC N
daytime JJ N
somnolence NN N
and CC N
improving VBG N
sleep NN N
and CC N
if IN N
this DT N
improvement NN N
correlated VBD N
with IN N
a DT N
change NN N
in IN N
overnight JJ N
sleep NN N
testing NN N
( ( N
polysomnography NN N
) ) N
. . N

OBJECTIVE NNP N
To TO N
provide VB N
an DT N
example NN N
of IN N
an DT N
occupational JJ N
therapy NN i
feasibility NN N
study NN N
and CC N
evaluate VB N
the DT N
implementation NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
pilot NN N
and CC N
feasibility NN N
trial NN N
examining VBG N
the DT N
impact NN N
of IN N
a DT N
sensory-adapted JJ N
dental NN N
environment NN N
( ( N
SADE NNP N
) ) N
to TO N
enhance VB N
oral JJ N
care NN N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

Here RB N
, , N
we PRP N
report VBP N
a DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
that WDT N
examined VBD N
the DT N
neural JJ N
and CC N
behavioral JJ N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
intranasal JJ N
oxytocin NN i
on IN N
emotion NN N
recognition NN N
in IN N
individuals NNS N
with IN N
Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
, , N
a DT N
clinical JJ N
condition NN N
characterized VBN N
by IN N
impaired JJ N
eye NN N
gaze NN N
and CC N
facial JJ N
emotion NN N
recognition NN N
. . N

Methylphenidate NNP N
and CC N
baseball NN N
playing NN N
in IN N
ADHD NNP N
children NNS N
: : N
who WP N
's VBZ N
on IN N
first JJ N
? . N
The DT N
effects NNS N
of IN N
0.3 CD N
and CC N
0.6 CD N
mg/kg NN N
methylphenidate NN N
were VBD N
analyzed VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
cross-over JJ N
study NN N
in IN N
which WDT N
17 CD N
boys NNS N
( ( N
ages IN N
7.8-9.9 CD N
years NNS N
) ) N
with IN N
attention NN N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
played VBD N
in IN N
baseball NN N
games NNS N
. . N

Paucity NN N
of IN N
studies NNS N
evaluating VBG N
the DT N
efficacy NN N
of IN N
single-site JJ N
vs. FW N
double-site JJ N
injections NNS N
at IN N
celiac JJ N
trunk NN N
for IN N
ultrasound-guided JJ N
celiac NN N
plexus NN N
neurolysis NN N
( ( N
USCPN NNP N
) ) N
prompted VBD N
us PRP N
to TO N
conduct VB N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
single-blind JJ N
clinical JJ N
trial NN N
to TO N
compare VB N
USCPN NNP N
using VBG N
bilateral JJ N
paramedian NN N
( ( N
double JJ N
needle NN N
) ) N
technique NN N
with IN N
unilateral JJ N
paramedian NN N
( ( N
single JJ N
needle NN N
) ) N
technique NN N
. . N

In IN N
this DT N
pilot NN N
randomized VBD N
clinical JJ N
trial NN N
, , N
we PRP N
challenged VBD N
the DT N
conventional JJ N
low-carbohydrate/higher-fat JJ N
( ( N
LC/CONV NNP N
) ) N
diet NN N
, , N
hypothesizing VBG N
that IN N
a DT N
higher-complex JJ N
carbohydrate/lower-fat NN N
( ( N
CHOICE NNP N
) ) N
diet NN N
would MD N
improve VB N
maternal JJ N
insulin NN N
resistance NN N
( ( N
IR NNP N
) ) N
, , N
adipose JJ N
tissue NN N
( ( N
AT NNP N
) ) N
lipolysis NN N
, , N
and CC N
infant JJ N
adiposity NN N
. . N

To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
two CD N
1-week JJ N
low-dose JJ N
triple-therapy JJ i
drug NN N
regimens NNS N
involving VBG N
antisecretory NN N
drugs NNS N
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
, , N
99 CD N
patients NNS p
with IN N
H. NNP N
pylori FW N
infection NN N
were VBD N
treated VBN N
with IN N
either DT N
lansoprazole NN N
( ( N
LPZ NNP N
) ) N
or CC N
ranitidine NN N
( ( N
RNT NNP N
) ) N
used VBD N
together RB N
with IN N
clarithromycin NN i
( ( N
CAM NNP N
) ) N
and CC N
metrinidazole $ N
( ( N
MTZ NNP N
) ) N
. . N

OBJECTIVE IN N
A NNP N
randomized NN N
, , N
controlled VBD N
trial NN N
of IN N
screening NN N
, , N
brief JJ N
intervention NN N
, , N
and CC N
referral JJ N
to TO N
treatment NN N
( ( N
SBIRT NNP N
) ) N
for IN N
drinking NN N
and CC N
related JJ N
problems NNS N
among IN N
at-risk JJ N
and CC N
dependent JJ N
drinkers NNS N
was VBD N
conducted VBN N
in IN N
an DT N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
in IN N
Sosnowiec NNP N
, , N
Poland NNP N
, , N
among IN N
patients NNS p
ages VBZ N
18 CD N
years NNS N
and CC N
older JJR N
. . N

METHODS NNP N
Twenty NNP N
randomized VBD N
patients NNS p
who WP N
underwent VBP N
a DT N
primary JJ N
total JJ N
hip NN N
replacement NN N
with IN N
use NN N
of IN N
a DT N
minimally RB N
invasive JJ N
modified VBN N
Watson-Jones JJ N
approach NN N
( ( N
minimally RB N
invasive JJ N
group NN N
) ) N
were VBD N
compared VBN N
with IN N
a DT N
group NN N
of IN N
twenty NN N
patients NNS p
who WP N
underwent VBD N
a DT N
total JJ N
hip NN N
arthroplasty NN N
with IN N
use NN N
of IN N
a DT N
standard JJ N
transgluteal NN N
Hardinge NNP N
approach NN N
( ( N
standard JJ N
group NN N
) ) N
. . N

We PRP N
designed VBD N
a DT N
randomized JJ N
trial NN N
to TO N
assess VB N
whether IN N
the DT N
early JJ N
withdrawal NN N
of IN N
cyclosporine NN N
( ( N
CsA NNP N
) ) N
followed VBN N
by IN N
the DT N
initiation NN N
of IN N
everolimus NN N
( ( N
Evr NNP N
) ) N
monotherapy NN i
in IN N
de FW N
novo FW N
liver FW N
transplantation NN N
( ( N
LT NNP N
) ) N
patients NNS p
would MD N
result VB N
in IN N
superior JJ N
renal JJ N
function NN N
compared VBN N
to TO N
a DT N
CsA-based JJ N
immunosuppression NN N
protocol NN N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
a DT N
zotarolimus-eluting JJ N
stent NN N
( ( N
ZES NNP N
; : N
Endeavor NNP N
Sprint NNP N
, , N
n=80 RB N
) ) N
to TO N
a DT N
sirolimus-eluting JJ N
stent NN N
( ( N
SES NNP N
; : N
Cypher NNP N
, , N
n=80 NN N
) ) N
in IN N
patients NNS p
with IN N
CTO NNP N
lesion NN N
with IN N
a DT N
reference NN N
vessel NN N
diameter NN N
? . N
2.5mm CD N
. . N

A DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
was VBD N
performed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
2-g JJ N
single JJ N
dose NN N
of IN N
metronidazole NN N
for IN N
male JJ N
partners NNS N
of IN N
women NNS N
with IN N
bacterial JJ N
vaginosis NN N
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
improving VBG N
cure NN N
rate NN N
and CC N
decreasing VBG N
recurrence NN N
rate NN N
. . N

As IN N
there EX N
is VBZ N
evidence NN N
of IN N
a DT N
possible JJ N
immunoregulatory JJ N
role NN N
for IN N
H2-histamine NNP N
receptor NN N
antagonists NNS N
, , N
we PRP N
carried VBD N
out RP N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
in IN N
vivo NN N
and CC N
in IN N
vitro JJ N
effect NN N
of IN N
cimetidine NN N
, , N
an DT N
H2-blocker NNP N
, , N
in IN N
the DT N
treatment NN N
of IN N
herpes NNS N
zoster JJ N
infection NN N
. . N

Thirty-two JJ N
adults NNS N
with IN N
acute JJ N
myeloid NN N
leukaemia NN N
( ( N
AML NNP N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
, , N
from IN N
the DT N
time NN N
of IN N
diagnosis NN N
, , N
either CC N
chemotherapy NN i
alone RB N
( ( N
C NNP N
group NN N
) ) N
or CC N
chemotherapy JJ i
plus CC N
Bacille NNP N
Calmette-Gu NNP N
vaccine NN N
( ( N
BCG NNP N
) ) N
( ( N
C+I NNP N
group NN N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
analyzed VBD N
the DT N
prognostic JJ N
impact NN N
of IN N
OPN NNP N
in IN N
AML NNP N
by IN N
investigating VBG N
the DT N
expression NN N
and CC N
relevance NN N
of IN N
OPN NNP N
in IN N
newly RB N
diagnosed VBN N
AML NNP N
patients NNS p
from IN N
2 CD N
large JJ N
study NN N
groups NNS N
( ( N
the DT N
German JJ N
AML NNP N
Cooperative NNP N
Group NNP N
and CC N
the DT N
Dutch-Belgian JJ N
Hematology NNP N
Oncology NNP N
Cooperative NNP N
group NN N
) ) N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
, , N
first RB N
, , N
whether IN N
intra- JJ N
or CC N
postoperative JJ N
music NN N
therapy NN i
could MD N
influence VB N
stress NN N
and CC N
immune JJ N
response NN N
during IN N
and CC N
after IN N
general JJ N
anaesthesia NN N
and CC N
second JJ N
, , N
if IN N
there EX N
was VBD N
a DT N
different JJ N
response NN N
between IN N
patients NNS p
exposed VBN N
to TO N
music NN N
intra- NN N
or CC N
postoperatively RB N
. . N

PURPOSE VB N
A NNP N
prognostic JJ N
model NN N
for IN N
5-year JJ N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
, , N
consisting VBG N
of IN N
recursive JJ N
partitioning NN N
analysis NN N
( ( N
RPA NNP N
) ) N
and CC N
a DT N
nomogram NN N
, , N
was VBD N
developed VBN N
for IN N
patients NNS p
with IN N
early-stage JJ N
non-small JJ N
cell NN N
lung NN N
cancer NN N
( ( N
ES-NSCLC NNP N
) ) N
treated VBD N
with IN N
stereotactic JJ N
ablative JJ N
radiation NN N
therapy NN i
( ( N
SABR NNP N
) ) N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
To TO N
compare VB N
and CC N
contrast VB N
the DT N
relative JJ N
importance NN N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
homocysteine NN i
, , N
and CC N
lipids NNS N
as IN N
long-term JJ N
predictors NNS N
of IN N
SCD NNP N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
nested JJ N
, , N
case-control JJ N
analysis NN N
involving VBG N
97 CD N
cases NNS N
of IN N
SCD NNP N
among IN N
apparently RB N
healthy JJ N
men NNS N
enrolled VBN N
in IN N
the DT N
Physician NNP N
's POS N
Health NNP N
Study NNP N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
combined VBN N
coronary JJ N
events NNS N
( ( N
coronary JJ N
death NN N
, , N
nonfatal JJ N
MI NNP N
, , N
percutaneous JJ N
transluminal JJ N
coronary NN N
angioplasty NN N
[ NNP N
PTCA NNP N
] NNP N
or CC N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
[ NNP N
CABG NNP N
] NNP N
) ) N
, , N
the DT N
primary JJ N
trial NN N
end NN N
point NN N
( ( N
coronary JJ N
death NN N
or CC N
nonfatal JJ N
MI NNP N
) ) N
and CC N
stroke NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
assessed VBD N
virologic JJ N
response NN N
to TO N
retreatment VB N
with IN N
peginterferon JJ N
alfa-2a JJ N
and CC N
ribavirin NN N
( ( N
RBV NNP N
) ) N
, , N
as IN N
a DT N
function NN N
of IN N
the DT N
baseline NN N
fibrosis NN N
score NN N
( ( N
Ishak NNP N
staging VBG N
) ) N
and CC N
platelet NN N
count NN N
, , N
in IN N
1,046 CD N
patients NNS p
enrolled VBN N
in IN N
the DT N
Hepatitis NNP N
C NNP N
Antiviral NNP N
Long-term NNP N
Treatment NNP N
against IN N
Cirrhosis NNP N
( ( N
HALT-C NNP N
) ) N
Trial NNP N
. . N

In IN N
conclusion NN N
, , N
initiating VBG N
therapy NN i
with IN N
a DT N
combination NN N
of IN N
valsartan NN N
and CC N
low-dose JJ N
HCTZ NNP N
results NNS N
in IN N
early JJ N
, , N
improved JJ N
BP NNP N
efficacy NN N
with IN N
similar JJ N
tolerability NN N
as IN N
compared VBN N
with IN N
starting VBG N
treatment NN N
with IN N
a DT N
low JJ N
or CC N
higher JJR N
dose NN N
of IN N
valsartan NN N
for IN N
patients NNS p
with IN N
stage-1 JJ N
and CC N
stage-2 JJ N
hypertension NN N
. . N

METHODS/DESIGN NNP N
The DT N
RESPECT NNP N
study NN N
is VBZ N
a DT N
nationwide JJ N
population-based JJ N
prospective NN N
, , N
controlled VBN N
, , N
mixed-methods NNS N
intervention NN N
study NN N
looking VBG N
at IN N
children NNS N
aged VBN N
6-18 CD N
years NNS N
newly RB N
diagnosed VBN N
with IN N
cancer NN N
in IN N
eastern JJ N
Denmark NNP N
( ( N
n=120 NN N
) ) N
and CC N
a DT N
matched JJ N
control NN N
group NN N
in IN N
western JJ N
Denmark NNP N
( ( N
n=120 NN N
) ) N
. . N

METHODS NNP N
Using VBG N
a DT N
parallel NN N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
, , N
we PRP N
conducted VBD N
an DT N
interventional JJ N
study NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
supplement NN N
of IN N
cocoa NN N
husk NN N
rich JJ N
in IN N
dietary JJ N
fiber NN N
on IN N
intestinal JJ N
transit NN N
time NN N
and CC N
other JJ N
indices NNS N
of IN N
constipation NN N
in IN N
children NNS N
with IN N
constipation NN N
. . N

METHODS NNP N
The DT N
Intramuscular NNP N
Diamorphine NNP N
versus IN N
Intramuscular NNP N
Pethidine NNP N
( ( N
IDvIP NNP N
) ) N
trial NN N
is VBZ N
a DT N
randomised JJ N
double-blind NN N
two CD N
centre NN N
controlled VBD N
trial NN N
comparing VBG N
intramuscular JJ N
diamorphine NN N
and CC N
pethidine NN N
regarding VBG N
their PRP$ N
analgesic JJ N
efficacy NN N
in IN N
labour NN N
and CC N
their PRP$ N
side NN N
effects NNS N
in IN N
mother NN N
, , N
fetus NN N
and CC N
neonate NN N
. . N

METHODS NNP N
In IN N
a DT N
multicenter NN N
trial NN N
, , N
we PRP N
compared VBN N
fixed-dose RB N
subcutaneous JJ N
enoxaparin NN N
, , N
given VBN N
twice RB N
daily RB N
, , N
with IN N
adjusted-dose JJ N
intravenous JJ N
unfractionated JJ N
heparin NN N
( ( N
UFH NNP N
) ) N
given VBN N
by IN N
continuous JJ N
intravenous JJ N
infusion NN N
for IN N
the DT N
initial JJ N
10 CD N
days NNS N
of IN N
treatment NN N
of IN N
patients NNS p
with IN N
proximal JJ N
vein NN N
thrombosis NN N
. . N

To TO N
estimate VB N
and CC N
compare VB N
hospital NN N
costs NNS N
associated VBN N
with IN N
conventional JJ N
balloon NN N
angioplasty NN N
( ( N
percutaneous JJ N
transluminal NN N
angioplasty NN N
[ NNP N
PTA NNP N
] NNP N
) ) N
and CC N
stent JJ N
placement NN N
for IN N
patients NNS p
with IN N
symptomatic JJ N
peripheral JJ N
arterial JJ N
disease NN N
, , N
the DT N
authors NNS N
performed VBD N
a DT N
prospective JJ N
economic JJ N
evaluation NN N
in IN N
conjunction NN N
with IN N
the DT N
Intracoil NNP N
Femoropopliteal NNP N
Stent NNP N
Trial NNP N
( ( N
VascuCoil NNP N
) ) N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Two CD N
hundred VBD N
thirty-seven JJ N
consecutive JJ N
women NNS N
patients NNS p
, , N
aged VBD N
75 CD N
years NNS N
or CC N
younger JJR N
, , N
hospitalized VBN N
for IN N
acute JJ N
myocardial JJ N
infarction NN N
, , N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
, , N
or CC N
percutaneous JJ N
coronary JJ N
intervention NN N
were VBD N
randomized VBN N
to TO N
a DT N
group-based JJ N
psychosocial JJ N
intervention NN N
program NN N
or CC N
usual JJ N
care NN N
. . N

METHODS NNP N
Sixty-six NNP N
children NNS N
( ( N
mean JJ N
age NN N
7.5 CD N
y NN N
) ) N
with IN N
autistic JJ N
disorder NN N
, , N
Asperger NNP N
's POS N
disorder NN N
, , N
and CC N
PDD NNP N
not RB N
otherwise RB N
specified VBN N
, , N
were VBD N
randomized VBN N
to TO N
varying VBG N
sequences NNS N
of IN N
placebo NN N
and CC N
three CD N
different JJ N
doses NNS N
of IN N
methylphenidate NN N
during IN N
a DT N
4-week JJ N
blinded NN N
, , N
crossover NN N
study NN N
. . N

Following VBG N
a DT N
starting VBG N
dose NN N
of IN N
either CC N
2.5 CD N
mg JJ N
once-daily RB N
quinapril NN N
, , N
or CC N
6.25 CD N
mg JJ N
twice-daily JJ N
captopril NN N
, , N
patients NNS p
were VBD N
reviewed VBN N
at IN N
two-weekly JJ N
intervals NNS N
, , N
and CC N
following VBG N
clinical JJ N
assessment NN N
a DT N
decision NN N
was VBD N
made VBN N
either DT N
to TO N
titrate VB N
up RP N
to TO N
the DT N
next JJ N
medication NN N
stage NN N
or CC N
to TO N
enter VB N
the DT N
patient NN N
into IN N
the DT N
16-week JJ N
maintenance NN N
phase NN N
. . N

Then RB N
, , N
to TO N
investigate VB N
potential JJ N
effects NNS N
of IN N
oxytocin NN i
on IN N
these DT N
behavioural JJ N
and CC N
neural JJ N
deficits NNS N
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
within-subject JJ N
trial NN N
for IN N
single-dose JJ N
intranasal JJ N
administration NN N
of IN N
24 CD N
IU NNP N
oxytocin NN i
in IN N
an DT N
independent JJ N
group NN N
of IN N
20 CD N
males NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

OBJECTIVE IN N
A NNP N
randomized JJ N
phase NN N
II NNP N
trial NN N
was VBD N
conducted VBN N
to TO N
test VB N
whether IN N
the DT N
addition NN N
of IN N
gemcitabine NN N
to TO N
weekly VB N
docetaxel NN i
could MD N
improve VB N
the DT N
objective JJ N
response NN N
rate NN N
and CC N
survival NN N
outcomes NNS N
as IN N
second-line JJ N
chemotherapy NN i
in IN N
patients NNS p
with IN N
metastatic JJ N
breast NN N
cancer NN N
who WP N
have VBP N
failed VBN N
a DT N
paclitaxel-containing JJ N
regimen NN N
. . N

A DT N
European JJ N
multicenter NN N
study NN N
has VBZ N
examined VBN N
the DT N
use NN N
of IN N
dopexamine NN N
in IN N
patients NNS p
undergoing VBG N
major JJ N
abdominal JJ N
surgery NN N
, , N
showing VBG N
a DT N
trend NN N
toward IN N
improved VBN N
survival NN N
and CC N
reduced JJ N
complications NNS N
in IN N
high-risk JJ N
patients NNS p
when WRB N
receiving VBG N
low-dose JJ N
dopexamine NN N
( ( N
0.5 CD N
? . N
? . N
kg NN N
( ( N
-1 NN N
) ) N
? . N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

This DT N
pilot NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
evaluated VBD N
the DT N
feasibility NN N
and CC N
preliminary JJ N
outcomes NNS N
of IN N
the DT N
Multimodal NNP N
Anxiety NNP N
and CC N
Social NNP N
Skills NNP N
Intervention NNP N
( ( N
MASSI NNP N
) ) N
program NN N
in IN N
a DT N
sample NN N
of IN N
30 CD N
adolescents NNS N
with IN N
ASD NNP N
and CC N
anxiety NN N
symptoms NNS N
of IN N
moderate JJ N
or CC N
greater JJR N
severity NN N
. . N

In IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
randomly RB N
allocated VBN N
trial NN N
, , N
the DT N
patients NNS p
were VBD N
given VBN N
increasing VBG N
doses NNS N
of IN N
captopril NN N
at IN N
25-100 JJ N
mg NN N
twice RB N
a DT N
day NN N
or CC N
lisinopril NN N
at IN N
10-40 JJ N
mg NN N
once IN N
a DT N
day NN N
until IN N
a DT N
clinical JJ N
response NN N
was VBD N
achieved VBN N
or CC N
the DT N
highest JJS N
dose NN N
was VBD N
reached VBN N
. . N

A DT N
non-randomised JJ N
controlled JJ N
study NN N
design NN N
comprising VBG N
an DT N
intervention NN N
group NN N
( ( N
n=48 CC N
) ) N
and CC N
comparator NN N
( ( N
no DT N
intervention NN N
) ) N
group NN N
( ( N
n=28 RB N
) ) N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
intervention NN N
on IN N
child JJ N
behaviour NN N
( ( N
Eyberg NNP N
Child NNP N
Behaviour NNP N
Inventory NNP N
; : N
parent-set JJ N
goals NNS N
) ) N
and CC N
parenting VBG N
efficacy NN N
and CC N
satisfaction NN N
( ( N
Parents NNP N
Sense NNP N
of IN N
Competence NNP N
Scale NNP N
) ) N
at IN N
post-intervention NN N
and CC N
six-month JJ N
follow-up NN N
. . N

Hyperfractionated VBN N
accelerated JJ N
radiation NN N
therapy NN i
( ( N
HART NNP N
) ) N
of IN N
70.6 CD N
Gy NNP N
with IN N
concurrent JJ N
5-FU/Mitomycin JJ i
C NNP N
is VBZ N
superior JJ N
to TO N
HART NNP N
of IN N
77.6 CD N
Gy NNP N
alone RB N
in IN N
locally RB N
advanced JJ N
head NN N
and CC N
neck NN N
cancer NN N
: : N
long-term JJ N
results NNS N
of IN N
the DT N
ARO NNP N
95-06 CD N
randomized JJ N
phase NN N
III NNP N
trial NN N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
COMET NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomised JJ N
trial NN N
comparing VBG N
carvedilol NN i
, , N
a DT N
comprehensive JJ N
adrenergic NN N
receptor NN N
antagonist NN N
, , N
with IN N
metoprolol NN i
, , N
a DT N
beta-1-selective JJ N
agent NN N
in IN N
patients NNS p
with IN N
heart NN N
failure NN N
and CC N
left VBD N
ventricular JJ N
systolic JJ N
dysfunction NN N
. . N

Relief NN N
of IN N
pain NN N
by IN N
infusion NN N
of IN N
morphine NN N
after IN N
operation NN N
: : N
does VBZ N
tolerance VB N
develop VB N
? . N
To TO N
see VB N
whether IN N
continuous JJ N
intravenous JJ N
infusion NN N
of IN N
opiates NNS N
provides VBZ N
more RBR N
effective JJ N
postoperative JJ N
relief NN N
of IN N
pain NN N
than IN N
conventional JJ N
intramuscular JJ N
injection NN N
these DT N
regimens NNS N
were VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
double NN N
blind IN N
trial NN N
. . N

In IN N
this DT N
extension NN N
study NN N
, , N
we PRP N
included VBD N
all DT N
patients NNS p
who WP N
had VBD N
been VBN N
assigned VBN N
everolimus RBR N
during IN N
the DT N
double-blind NN N
, , N
randomised VBD N
phase NN N
of IN N
the DT N
trial NN N
and CC N
those DT N
patients NNS p
who WP N
crossed VBD N
over IN N
from IN N
the DT N
placebo NN N
group NN N
to TO N
receive VB N
everolimus NN N
during IN N
the DT N
randomised JJ N
phase NN N
or CC N
at IN N
the DT N
start NN N
of IN N
the DT N
extension NN N
phase NN N
. . N

In IN N
order NN N
to TO N
more RBR N
precisely RB N
measure VB N
the DT N
effects NNS N
of IN N
secretin NN i
, , N
this DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
porcine NN N
secretin NN i
on IN N
12 CD N
autistic JJ N
children NNS N
through IN N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
any DT N
inconsistency NN N
with IN N
the DT N
protocol NN N
guidelines NNS N
for IN N
preoperative JJ N
radiotherapy NN i
for IN N
rectal JJ N
cancer NN N
among IN N
radiotherapy JJ i
institutions NNS N
participating VBG N
in IN N
the DT N
framework NN N
of IN N
a DT N
multicentre JJ N
phase-III JJ N
European JJ N
Organization NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
EORTC NNP N
) ) N
clinical JJ N
trial NN N
. . N

This DT N
trial NN N
involved VBD N
457 CD N
patients NNS p
and CC N
sought VBD N
to TO N
assess VB N
the DT N
value NN N
of IN N
early JJ N
intensification NN N
with IN N
autologous JJ N
transplantation NN N
in IN N
patients NNS p
with IN N
poor JJ N
prognosis NN N
histologically RB N
aggressive JJ N
non-Hodgkin JJ N
lymphoma NN N
( ( N
NHL NNP N
) ) N
showing VBG N
a DT N
response NN N
to TO N
initial JJ N
CHOP NNP N
( ( N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
vincristine NN N
, , N
prednisolone NN N
) ) N
chemotherapy NN i
. . N

This DT N
approval NN N
was VBD N
based VBN N
on IN N
an DT N
improvement NN N
in IN N
overall JJ i
survival NN N
( ( N
OS NNP N
) ) N
with IN N
an DT N
acceptable JJ N
toxicity NN N
profile NN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
1,253 CD N
patients NNS p
with IN N
metastatic JJ N
NSCLC NNP N
previously RB N
treated VBD N
with IN N
a DT N
platinum-based JJ N
combination NN N
therapy NN i
. . N

PURPOSE NN N
To TO N
compare VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
excimer FW N
laser NN N
trabeculotomy NN N
( ( N
ELT NNP N
) ) N
ab VBP N
interno JJ N
vs NN N
selective JJ N
laser NN N
trabeculoplasty NN N
( ( N
SLT NNP N
) ) N
over IN N
24 CD N
months NNS N
of IN N
follow-up NN N
in IN N
patients NNS p
with IN N
primary JJ N
open-angle JJ N
glaucoma NN N
( ( N
POAG NNP N
) ) N
refractory NN N
to TO N
medical JJ N
therapy NN i
. . N

CONCLUSIONS NNP N
AND NNP N
RELEVANCE NNP N
In IN N
this DT N
hypothesis-generating JJ N
study NN N
of IN N
patients NNS p
with IN N
advanced JJ N
uveal JJ N
melanoma NN N
, , N
selumetinib NN N
compared VBN N
with IN N
chemotherapy NN i
resulted VBN N
in IN N
a DT N
modestly RB N
improved VBN N
progression-free JJ N
survival NN N
and CC N
response NN N
rate NN N
; : N
however RB N
, , N
no DT N
improvement NN N
in IN N
overall JJ i
survival NN N
was VBD N
observed VBN N
. . N

PURPOSE NNP N
To TO N
report VB N
the DT N
long-term JJ N
results NNS N
of IN N
the DT N
ARO NNP N
95-06 CD N
randomized JJ N
trial NN N
comparing NN N
hyperfractionated VBD N
accelerated JJ N
chemoradiation NN N
with IN N
mitomycin JJ i
C/5-fluorouracil NNP N
( ( N
C-HART NNP N
) ) N
with IN N
hyperfractionated VBN N
accelerated JJ N
radiation NN N
therapy NN i
( ( N
HART NNP N
) ) N
alone RB N
in IN N
locally RB N
advanced JJ N
head NN N
and CC N
neck NN N
cancer NN N
. . N

PURPOSE NN N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
dofequidar NN N
plus CC N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
and CC N
fluorouracil NN N
( ( N
CAF NNP N
) ) N
therapy NN i
in IN N
comparison NN N
with IN N
CAF NNP N
alone RB N
, , N
in IN N
patients NNS p
with IN N
advanced JJ N
or CC N
recurrent JJ N
breast NN N
cancer NN N
. . N

Efficacy NN N
of IN N
dose-intensified JJ N
MEC NNP N
( ( N
methotrexate NN N
, , N
epirubicin NN i
and CC N
cisplatin NN i
) ) N
chemotherapy NN i
for IN N
advanced JJ N
urothelial JJ N
carcinoma NN N
: : N
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
MEC NNP N
and CC N
M-VAC NNP N
( ( N
methotrexate NN N
, , N
vinblastine NN N
, , N
doxorubicin NN i
and CC N
cisplatin NN i
) ) N
. . N

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
study NN N
is VBZ N
described VBN N
of IN N
an DT N
assessment NN N
of IN N
the DT N
efficacy NN N
and CC N
relative JJ N
safety NN N
of IN N
the DT N
ergot NN N
alkaloid NN N
, , N
dihydroergocryptine NN N
, , N
on IN N
52 CD N
patients NNS p
with IN N
mild JJ N
organic JJ N
brain NN N
syndrome NN N
over IN N
a DT N
period NN N
of IN N
three CD N
months NNS N
using VBG N
a DT N
series NN N
of IN N
neurophysiological JJ N
tests NNS N
. . N

A DT N
total NN N
of IN N
1,615 CD N
angiographic JJ N
readings NNS N
in IN N
240 CD N
patients NNS p
with IN N
acute JJ N
myocardial JJ N
infarction NN N
were VBD N
analyzed VBN N
from IN N
a DT N
randomized JJ N
trial NN N
of IN N
intravenous JJ N
anistreplase NN N
( ( N
Eminase NNP N
) ) N
, , N
also RB N
known VBN N
as IN N
anisoylated JJ N
plasminogen NN N
streptokinase JJ N
activator NN N
complex NN N
( ( N
APSAC NNP N
) ) N
, , N
versus FW N
intracoronary JJ N
streptokinase NN N
. . N

METHOD NNP N
Twenty-four CD N
children NNS N
with IN N
autism NN N
, , N
3.0 CD N
to TO N
8.3 CD N
years NNS N
old JJ N
( ( N
mean JJ N
5.1 CD N
) ) N
who WP N
were VBD N
living VBG N
at IN N
home NN N
and CC N
attending VBG N
appropriate JJ N
school NN N
programs NNS N
, , N
participated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
trial NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
substudy NN N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
conventional JJ N
open JJ N
esophagectomy NN N
[ NNP N
open JJ N
surgical JJ N
technique NN N
( ( N
OE NNP N
) ) N
] NN N
by IN N
thoracotomy NN N
and CC N
laparotomy NN N
with IN N
minimally RB N
invasive JJ N
esophagectomy NN N
[ NNP N
minimally RB N
invasive JJ N
procedure NN N
( ( N
MIE NNP N
) ) N
] NN N
by IN N
thoracoscopy NN N
and CC N
laparoscopy NN N
. . N

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
parallel JJ N
group NN N
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
infants NNS N
unresponsive JJ N
to TO N
stimulation NN N
who WP N
received VBD N
bag NN N
and CC N
mask NN N
ventilation NN N
as IN N
part NN N
of IN N
their PRP$ N
resuscitation NN N
at IN N
birth NN N
and CC N
infants NNS N
who WP N
did VBD N
not RB N
require VB N
any DT N
resuscitation NN N
born VBN N
in IN N
rural JJ N
communities NNS N
in IN N
India NNP N
, , N
Pakistan NNP N
, , N
and CC N
Zambia NNP N
. . N

PURPOSE NN N
To TO N
estimate VB N
the DT N
safety NN N
, , N
activity NN N
, , N
and CC N
impact NN N
on IN N
quality NN N
of IN N
life NN N
of IN N
a DT N
combination NN N
of IN N
gemcitabine NN N
and CC N
pemetrexed NN N
in IN N
patients NNS p
with IN N
locally RB N
advanced JJ N
or CC N
metastatic JJ N
non-small JJ N
cell NN N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
in IN N
the DT N
context NN N
of IN N
a DT N
randomized JJ N
two-stage NN N
phase NN N
II NNP N
study NN N
. . N

In IN N
the DT N
International NNP N
Breast NNP N
Cancer NNP N
Study NNP N
Group NNP N
( ( N
IBCSG NNP N
) ) N
Trials NNP N
VII NNP N
and CC N
12-93 JJ N
, , N
postmenopausal JJ N
women NNS N
with IN N
node-positive JJ N
, , N
estrogen JJ N
receptor NN N
( ( N
ER NNP N
) ) N
-positive CD N
or CC N
ER-negative JJ N
, , N
operable JJ N
breast NN N
cancer NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
chemotherapy NN i
or CC N
endocrine JJ N
therapy NN i
or CC N
combined VBN N
chemoendocrine JJ N
treatment NN N
. . N

DESIGN NNP N
Two CD N
hundred VBD N
adults NNS N
in IN N
a DT N
rural JJ N
region NN N
of IN N
Bangladesh NNP N
, , N
previously RB N
found VBN N
to TO N
have VB N
low JJ N
plasma JJ N
concentrations NNS N
of IN N
folate NN N
( ( N
< JJ N
/=9 NNP N
nmol/L NN N
) ) N
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
folic JJ N
acid-supplementation NN N
trial NN N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
979 CD N
ST-segment-elevation JJ N
myocardial JJ N
infarction NN N
patients NNS p
enrolled VBN N
in IN N
the DT N
Harmonizing NNP N
Outcomes NNP N
with IN N
Revascularization NNP N
and CC N
Stents NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
( ( N
HORIZONS-AMI NNP N
) ) N
trial NN N
had VBD N
BNP NNP N
levels NNS N
measured VBN N
in IN N
the DT N
emergency NN N
room NN N
prior RB N
to TO N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
as IN N
part NN N
of IN N
the DT N
study NN N
protocol NN N
. . N

This DT N
paper NN N
presents VBZ N
findings NNS N
from IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
electrothermal JJ N
arthroscopic NN N
capsulorrhaphy NN N
( ( N
ETAC NNP N
) ) N
compared VBN N
with IN N
open JJ N
inferior JJ N
capsular JJ N
shift NN N
( ( N
ICS NNP N
) ) N
and CC N
reviews VBZ N
the DT N
role NN N
of IN N
randomized JJ N
trials NNS N
in IN N
adopting VBG N
new JJ N
technology NN N
. . N

CONCLUSIONS NN N
In IN N
this DT N
inception NN N
cohort NN N
study NN N
of IN N
low-dose JJ N
prednisolone NN N
use NN N
during IN N
the DT N
first JJ N
2 CD N
years NNS N
of IN N
RA NNP N
disease NN N
, , N
the DT N
incidence NN N
of IN N
ischaemic JJ N
coronary JJ N
artery NN N
events NNS N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
, , N
whereas IN N
the DT N
long-term JJ N
risk NN N
of IN N
ischaemic JJ N
cerebrovascular JJ N
events NNS N
was VBD N
higher RBR N
in IN N
the DT N
prednisolone NN N
group NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
In IN N
a DT N
previous JJ N
study NN N
we PRP N
showed VBD N
that IN N
patients NNS p
with IN N
severe JJ N
aplastic JJ N
anemia NN N
( ( N
SAA NNP N
) ) N
treated VBD N
with IN N
anti-lymphocyte JJ N
globulin NN N
( ( N
ALG NNP N
) ) N
, , N
cyclosporin NN N
( ( N
CyA NNP N
) ) N
and CC N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
5 CD N
micro NN N
g/kg/day NN N
had VBD N
an DT N
encouraging JJ N
outcome NN N
. . N

A DT N
total NN N
of IN N
1,200 CD N
patients NNS p
will MD N
be VB N
randomized VBN N
on IN N
a DT N
2:2:1 JJ N
basis NN N
to TO N
receive VB N
3.0-T JJ N
cardiovascular JJ N
magnetic JJ N
resonance-guided JJ N
care NN N
, , N
single-photon JJ N
emission NN N
computed VBD N
tomography-guided JJ N
care NN N
( ( N
according VBG N
to TO N
American NNP N
College NNP N
of IN N
Cardiology/American NNP N
Heart NNP N
Association NNP N
appropriate-use IN N
criteria NNS N
) ) N
, , N
or CC N
National NNP N
Institute NNP N
for IN N
Health NNP N
and CC N
Care NNP N
Excellence NNP N
guidelines-based JJ N
management NN N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
alpha-interferon JJ N
given VBN N
with IN N
or CC N
without IN N
indomethacin JJ i
to TO N
patients NNS p
with IN N
malignant JJ N
melanoma NN N
to TO N
determine VB N
what WP N
effect NN N
, , N
if IN N
any DT N
, , N
indomethacin NN i
might MD N
have VB N
on IN N
the DT N
toxic NN N
, , N
immunomodulatory NN N
, , N
and CC N
therapeutic JJ N
properties NNS N
of IN N
interferon NN N
in IN N
this DT N
disease NN N
. . N

Results NNS N
of IN N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
maleate NN N
versus NN N
amlodipine NN N
besylate NN N
in IN N
Korean JJ N
patients NNS p
with IN N
mild JJ N
to TO N
moderate VB N
hypertension NN N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
compared VBN N
neurocognitive JJ N
outcomes NNS N
in IN N
patients NNS p
undergoing VBG N
open-chamber JJ N
( ( N
left-sided JJ N
) ) N
cardiac NN N
surgery NN N
who WP N
were VBD N
assigned VBN N
carbon NN N
dioxide NN N
insufflation NN N
or CC N
placebo NN N
( ( N
control VB N
group NN N
) ) N
in IN N
addition NN N
to TO N
standardized VB N
mechanical JJ N
deairing VBG N
maneuvers NNS N
. . N

OBJECTIVE IN N
This DT N
5-year JJ N
observational JJ N
posthoc NN N
analysis NN N
of IN N
the DT N
REFLEX NNP N
study NN N
and CC N
its PRP$ N
open-label JJ N
extension NN N
assessed VBD N
clinical JJ N
efficacy NN N
, , N
radiographic JJ N
response NN N
, , N
and CC N
safety NN N
of IN N
rituximab NN i
( ( N
RTX NNP N
) ) N
in IN N
patients NNS p
with IN N
rheumatoid JJ N
arthritis NN N
( ( N
RA NNP N
) ) N
who WP N
had VBD N
an DT N
inadequate JJ N
response NN N
to TO N
tumor VB N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
inhibitors NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
randomised VBN N
, , N
prospective JJ N
, , N
blinded VBD N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
stimulating JJ N
catheters NNS N
can MD N
decrease VB o
the DT N
minimum JJ N
effective JJ N
anaesthetic JJ N
volume NN N
in IN N
50 CD N
% NN N
of IN N
patients NNS p
during IN N
lumbar JJ N
plexus NN N
block NN N
using VBG N
mepivacaine JJ N
1.5 CD N
% NN N
compared VBN N
with IN N
standard JJ N
catheters NNS N
. . N

A DT N
unicenter NN N
, , N
single-blind NN N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
on IN N
283 CD N
patients NNS p
with IN N
active JJ N
duodenal JJ N
ulcer NN N
to TO N
compare VB N
possible JJ N
factors NNS N
that WDT N
may MD N
affect VB N
healing NN N
and CC N
relapse NN N
in IN N
patients NNS p
treated VBN N
with IN N
a DT N
potent JJ N
antisecretory NN N
agent NN N
, , N
cimetidine NN N
, , N
or CC N
a DT N
site-protective JJ N
and CC N
cytoprotective JJ N
agent NN N
, , N
sucralfate NN N
. . N

METHODS NNP N
In IN N
this DT N
parallel-design JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
54 CD N
adult NN N
volunteers NNS N
were VBD N
randomized VBN N
to TO N
an DT N
experimental JJ N
9.5 CD N
% NN N
hydrogen NN N
peroxide IN N
whitening VBG N
strip NN N
or CC N
placebo NN N
strip NN N
balancing NN N
for IN N
age NN N
and CC N
baseline VB N
tooth DT N
color NN N
, , N
and CC N
received VBD N
treatment NN N
. . N

METHODS NNP N
Two CD N
hundred VBD N
fifty-seven RB N
healthy JJ N
female NN N
subjects NNS N
, , N
15 CD N
to TO N
49 CD N
years NNS N
of IN N
age NN N
with IN N
moderate JJ N
acne NNS N
vulgaris NN N
, , N
were VBD N
enrolled VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

Results NNS N
of IN N
a DT N
phase NN N
III NNP N
, , N
8-week JJ N
, , N
multicenter NN N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
amlodipine JJ N
camsylate NN N
versus NN N
amlodipine NN N
besylate NN N
in IN N
Korean JJ N
adults NNS N
with IN N
mild NN N
to TO N
moderate VB N
hypertension NN N
. . N

A DT N
total NN N
of IN N
4,444 CD N
patients NNS p
with IN N
angina JJ N
pectoris NN N
or CC N
previous JJ N
myocardial JJ N
infarction NN N
and CC N
serum VB N
cholesterol NN N
levels NNS N
of IN N
213-310 JJ N
mg/dl NN N
( ( N
5.5-8.0 JJ N
mmol/liter NN N
) ) N
while IN N
treated VBN N
with IN N
a DT N
lipid-lowering JJ N
diet NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
double-blind VB N
treatment NN N
with IN N
simvastatin NN i
or CC N
placebo NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
and CC N
safety NN N
of IN N
epoetin JJ i
zeta NN N
, , N
compared VBN N
with IN N
epoetin NN i
alfa NN N
, , N
in IN N
maintaining VBG N
target NN N
haemoglobin NN N
( ( N
Hb NNP N
) ) N
concentrations NNS N
in IN N
patients NNS p
with IN N
anaemia NN N
and CC N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
maintained VBD N
on IN N
haemodialysis NN N
. . N

METHODS/DESIGN NNP N
The DT N
Staged NNP N
Nutrition NNP N
and CC N
Activity NNP N
Counseling NNP N
( ( N
SNAC NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
clustered JJ N
design NN N
clinical JJ N
trial NN N
that WDT N
will MD N
investigate VB N
the DT N
effectiveness NN N
and CC N
efficacy NN N
of IN N
a DT N
multi-component JJ N
lifestyle JJ N
intervention NN N
on IN N
cardiovascular JJ N
disease NN N
risk NN N
factors NNS N
and CC N
vascular JJ N
function NN N
in IN N
patients NNS p
at IN N
risk NN N
in IN N
primary JJ N
care NN N
. . N

PURPOSE NN N
To TO N
analyze VB N
the DT N
results NNS N
of IN N
a DT N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
that WDT N
investigated VBD N
whether IN N
a DT N
hyperfractionated JJ N
radiotherapy NN i
( ( N
RT NNP N
) ) N
schedule NN N
could MD N
reduce VB N
the DT N
risk NN N
of IN N
locoregional JJ N
recurrence NN N
in IN N
patients NNS p
with IN N
locally RB N
advanced JJ N
breast NN N
cancer NN N
treated VBN N
with IN N
chemotherapy NN i
and CC N
mastectomy NN N
. . N

In IN N
view NN N
of IN N
the DT N
usefulness NN N
of IN N
long-term JJ N
adjuvant JJ N
chemotherapy NN i
, , N
the DT N
Cooperative NNP N
Study NNP N
Group NNP N
of IN N
Surgical NNP N
Adjuvant NNP N
Chemotherapy NNP i
for IN N
Gastric NNP N
Cancer NNP N
adopted VBD N
as IN N
the DT N
second JJ N
cooperative NN N
study NN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
on IN N
three CD N
groups NNS N
; : N
MMC NNP N
alone RB N
, , N
Futraful NNP N
alone RB N
and CC N
a DT N
combination NN N
of IN N
MMC NNP N
and CC N
Futraful NNP N
. . N

BACKGROUND NNP N
Fifty NNP N
consecutive JJ N
patients NNS p
entered VBD N
the DT N
myocardial JJ N
contrast NN N
echocardiography NN N
( ( N
MCE NNP N
) ) N
substudy NN N
of IN N
the DT N
REMEDIA NNP N
( ( N
Randomized NNP N
Evaluation NNP N
of IN N
the DT N
Effect NNP N
of IN N
Mechanical NNP N
Reduction NNP N
of IN N
Distal NNP N
Embolization NNP N
by IN N
Thrombus NNP N
Aspiration NNP N
in IN N
Primary NNP N
and CC N
Rescue NNP N
Angioplasty NNP N
) ) N
trial NN N
, , N
which WDT N
defined VBD N
the DT N
role NN N
of IN N
a DT N
new JJ N
thrombus-aspirating JJ N
device NN N
in IN N
preventing VBG N
distal JJ N
microembolization NN N
after IN N
PCI NNP N
. . N

METHOD NNP N
Survivors NNS N
of IN N
out-of-hospital JJ N
ventricular JJ N
fibrillation NN N
or CC N
asystole NN N
( ( N
N NNP N
= NNP N
129 CD N
) ) N
, , N
documented VBN N
by IN N
electrocardiograms NNS N
from IN N
registries NNS N
of IN N
a DT N
citywide NN N
Medic NNP N
One NNP N
unit NN N
and CC N
two CD N
countywide NN N
emergency NN N
units NNS N
, , N
were VBD N
randomized VBN N
into IN N
a DT N
two CD N
group NN N
, , N
experimental JJ N
, , N
longitudinal JJ N
design NN N
. . N

OBJECTIVES IN N
The DT N
ENDEAVOR NNP N
IV NNP N
( ( N
Randomized NNP N
Comparison NNP N
of IN N
Zotarolimus-Eluting NNP N
and CC N
Paclitaxel-Eluting NNP N
Stents NNP N
in IN N
Patients NNP N
with IN N
Coronary NNP N
Artery NNP N
Disease NNP N
) ) N
trial NN N
evaluated VBD N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
zotarolimus-eluting JJ N
stent NN N
( ( N
ZES NNP N
) ) N
compared VBN N
with IN N
the DT N
paclitaxel-eluting JJ N
stent NN N
( ( N
PES NNP N
) ) N
. . N

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
parallel-group JJ N
pilot NN N
study NN N
designed VBN N
to TO N
compare VB N
an DT N
oat NN N
cereal NN N
group NN N
( ( N
standardized VBN N
to TO N
5.52 CD N
g/day JJ N
beta-glucan JJ N
) ) N
to TO N
a DT N
low-fiber JJ N
cereal NN N
control NN N
group NN N
( ( N
less JJR N
than IN N
1.0 CD N
g/day JJ N
total JJ N
fiber NN N
) ) N
over IN N
6 CD N
weeks NNS N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Two CD N
hundred VBD N
eighty-eight JJ N
cancer NN N
patients NNS p
, , N
referred VBD N
to TO N
complementary JJ N
therapy NN i
services NNS N
with IN N
clinical JJ N
anxiety NN N
and/or NN N
depression NN N
, , N
were VBD N
allocated VBN N
randomly RB N
to TO N
a DT N
course NN N
of IN N
aromatherapy JJ i
massage NN N
or CC N
usual JJ N
supportive JJ N
care NN N
alone RB N
. . N

This DT N
experiment NN N
examined VBD N
the DT N
efficacy NN N
of IN N
an DT N
acustimulation NN N
wrist NN N
band NN N
for IN N
the DT N
relief NN N
of IN N
chemotherapy-induced JJ i
nausea NN N
using VBG N
a DT N
randomized JJ N
three-arm JJ N
clinical JJ N
trial NN N
( ( N
active JJ N
acustimulation NN N
, , N
sham JJ N
acustimulation NN N
, , N
and CC N
no DT N
acustimulation NN N
) ) N
in IN N
96 CD N
women NNS N
with IN N
breast NN N
cancer NN N
who WP N
experienced VBD N
nausea NN N
at IN N
their PRP$ N
first JJ N
chemotherapy NN i
treatment NN N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
post-hoc JJ N
analysis NN N
of IN N
pooled VBN N
data NNS N
from IN N
two CD N
8-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
studies NNS N
evaluating VBG N
aripiprazole NN N
for IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
pediatric JJ N
subjects NNS N
with IN N
autistic JJ N
disorder NN N
, , N
aged VBN N
6-17 CD N
years NNS N
. . N

This DT N
randomized VBN N
, , N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
the DT N
GnRH NNP N
agonist NN N
, , N
leuprolide JJ N
acetate NN N
depot NN N
, , N
in IN N
a DT N
clearly RB N
defined VBN N
PMS NNP N
sample JJ N
versus NNS N
women NNS N
with IN N
premenstrual JJ N
symptoms NNS N
in IN N
combination NN N
with IN N
dysphoric NN N
symptoms NNS N
throughout IN N
the DT N
cycle NN N
, , N
termed VBD N
the DT N
premenstrual JJ N
exacerbation NN N
( ( N
PME NNP N
) ) N
group NN N
. . N

A DT N
recent JJ N
randomized NN N
controlled VBD N
trial NN N
( ( N
RCT NNP N
) ) N
of IN N
a DT N
dual JJ N
parent NN N
and CC N
trainer-delivered JJ N
qigong JJ N
massage NN N
intervention NN N
for IN N
young JJ N
children NNS N
with IN N
autism NN N
resulted VBN N
in IN N
improvement NN N
of IN N
measures NNS N
of IN N
autism NN N
as RB N
well RB N
as IN N
improvement NN N
of IN N
abnormal JJ N
sensory JJ N
responses NNS N
and CC N
self-regulation NN N
. . N

A DT N
controlled VBN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
compared VBN N
the DT N
effects NNS N
of IN N
ViviScal NNP N
( ( N
a DT N
new JJ N
food NN N
supplement NN N
incorporating VBG N
special JJ N
marine JJ N
extracts NNS N
and CC N
a DT N
silica JJ N
compound NN N
) ) N
with IN N
those DT N
of IN N
a DT N
fish JJ N
extract NN N
in IN N
the DT N
treatment NN N
of IN N
young JJ N
males NNS N
with IN N
hereditary JJ N
androgenic JJ N
alopecia NN N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
combined JJ N
data NNS N
from IN N
three CD N
North JJ N
American JJ N
Phase NNP N
II NNP N
studies NNS N
, , N
a DT N
randomised JJ N
Phase NNP N
II NNP N
study NN N
in IN N
the DT N
same JJ N
patient JJ N
population NN N
was VBD N
performed VBN N
, , N
using VBG N
combination NN N
chemotherapy NN i
with IN N
estramustine JJ N
phosphate NN N
( ( N
EMP NNP N
) ) N
and CC N
vinblastine NN N
( ( N
VBL NNP N
) ) N
in IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
patients NNS p
. . N

METHODS NNP N
The DT N
paroxetine NN N
352 CD N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
19-site JJ N
trial NN N
comparing VBG N
paroxetine NN N
and CC N
imipramine NN N
in IN N
117 CD N
patients NNS p
with IN N
bipolar JJ N
type NN N
I PRP N
major JJ N
depressive JJ N
episode NN N
which WDT N
was VBD N
unresponsive JJ N
to TO N
prior VB N
lithium NN N
carbonate NN N
therapy NN i
. . N

PURPOSE NN N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
supplementing VBG N
usual JJ N
supportive JJ N
care NN N
with IN N
aromatherapy JJ i
massage NN N
in IN N
the DT N
management NN N
of IN N
anxiety NN N
and CC N
depression NN N
in IN N
cancer NN N
patients NNS p
through IN N
a DT N
pragmatic JJ N
two-arm NN N
randomized VBD N
controlled JJ N
trial NN N
in IN N
four CD N
United NNP N
Kingdom NNP N
cancer NN N
centers NNS N
and CC N
a DT N
hospice NN N
. . N

BACKGROUND NNP N
Safety NNP N
and CC N
efficacy NN N
of IN N
gemcitabine JJ N
plus CC N
docetaxel JJ i
( ( N
GD NNP N
) ) N
and CC N
capecitabine JJ N
plus CC N
docetaxel JJ i
( ( N
CD NN N
) ) N
were VBD N
compared VBN N
in IN N
patients NNS p
with IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
where WRB N
the DT N
alternate NN N
crossover NN N
monotherapy NN i
( ( N
GD NNP N
or CC N
CD NN N
) ) N
was VBD N
predetermined VBN N
. . N

PATIENTS NNP N
Twenty NNP N
patients NNS p
admitted VBD N
with IN N
a DT N
Glasgow NNP N
Coma NNP N
Scale NNP N
score NN N
of IN N
< $ N
10 CD N
who WP N
were VBD N
enrolled VBN N
as IN N
part NN N
of IN N
a DT N
prospective JJ N
, , N
multicenter JJ N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
multiple JJ N
risk NN N
factors NNS N
and CC N
ranitidine VB N
prophylaxis NN N
on IN N
the DT N
development NN N
of IN N
stress-related JJ N
upper JJ N
gastrointestinal NN N
bleeding NN N
. . N

Plerixafor NNP N
plus CC N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
versus NN N
placebo NN N
plus CC N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
for IN N
mobilization NN N
of IN N
CD34 NNP N
( ( N
+ NNP N
) ) N
hematopoietic JJ N
stem NN N
cells NNS N
in IN N
patients NNS p
with IN N
multiple JJ N
myeloma NNS N
and CC N
low JJ N
peripheral JJ N
blood NN N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
: : N
results NNS N
of IN N
a DT N
subset JJ N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

This DT N
Phase NNP N
III NNP N
study NN N
( ( N
Belatacept NNP N
Evaluation NNP N
of IN N
Nephroprotection NNP N
and CC N
Efficacy NNP N
as IN N
First-line NNP N
Immunosuppression NNP N
Trial NNP N
) ) N
assessed VBD N
a DT N
more RBR N
intensive JJ N
( ( N
MI NNP N
) ) N
or CC N
less RBR N
intensive JJ N
( ( N
LI NNP N
) ) N
regimen NNS N
of IN N
belatacept JJ N
versus NN N
cyclosporine NN N
in IN N
adults NNS N
receiving VBG N
a DT N
kidney NN N
transplant NN N
from IN N
living NN N
or CC N
standard JJ N
criteria NNS N
deceased VBN N
donors NNS N
. . N

PURPOSE NN N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
recombinant JJ N
human JJ N
granulocyte NN N
colony-stimulating NN N
factor NN N
( ( N
[ JJ N
G-CSF NNP N
] NNP N
lenogastrim NN N
) ) N
can MD N
increase VB o
the DT N
chemotherapy JJ i
dose-intensity NN N
( ( N
CDI NNP N
) ) N
delivered VBD N
during IN N
consolidation NN N
chemotherapy NN i
of IN N
childhood NN N
acute NN N
lymphoblastic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
. . N

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
relationships NNS N
between IN N
glycemia NN N
at IN N
randomization NN N
, , N
concurrent JJ N
antidiabetic JJ N
therapy NN i
, , N
and CC N
change NN N
in IN N
A1C NNP N
and CC N
fasting VBG N
plasma NN N
glucose NN N
( ( N
FPG NNP N
) ) N
in IN N
patients NNS p
with IN N
diabetes NNS N
receiving VBG N
standard JJ N
treatment NN N
for IN N
diabetes NNS N
and CC N
randomized VBN N
to TO N
ranolazine VB N
or CC N
placebo VB N
within IN N
the DT N
MERLIN-TIMI-36 NNP N
( ( N
MERLIN NNP N
) ) N
study NN N
. . N

In IN N
a DT N
single-center JJ N
, , N
multiple-referral JJ N
source NN N
study NN N
, , N
38 CD N
patients NNS p
with IN N
progressive JJ N
IgA NNP N
nephropathy NN N
and CC N
controlled VBN N
hypertension NN N
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
prednisolone NN N
and CC N
cytotoxic NN N
agents NNS N
, , N
to TO N
therapy VB i
with IN N
low-dose JJ N
cyclophosphamide NN N
then RB N
azathioprine VB N
, , N
and CC N
to TO N
control VB N
groups NNS N
. . N

Hypertension NN N
following VBG N
coronary JJ N
artery JJ N
bypass NN N
grafting NN N
is VBZ N
a DT N
common JJ N
problem NN N
that WDT N
may MD N
result VB N
in IN N
postoperative JJ N
myocardial JJ N
infraction NN N
or CC N
bleeding NN N
, , N
Hemodynamic NNP N
effects NNS N
were VBD N
compared VBN N
in IN N
45 CD N
hypertensive JJ N
coronary JJ N
bypass NN N
patients NNS p
randomized VBN N
to TO N
receive VB N
either DT N
diltiazem NN N
, , N
nitroglycerin NN N
, , N
or CC N
sodium NN N
nitroprusside RB N
. . N

SETTING NN N
Six NNP N
academic JJ N
centers NNS N
, , N
including VBG N
Mount NNP N
Sinai NNP N
School NNP N
of IN N
Medicine NNP N
, , N
North NNP N
Shore-Long NNP N
Island NNP N
Jewish NNP N
Health NNP N
System NNP N
, , N
University NNP N
of IN N
North NNP N
Carolina NNP N
at IN N
Chapel NNP N
Hill NNP N
, , N
University NNP N
of IN N
California NNP N
at IN N
Los NNP N
Angeles NNP N
, , N
Yale NNP N
University NNP N
, , N
and CC N
Dartmouth NNP N
Medical NNP N
School NNP N
. . N

METHODS NNP N
The DT N
treatment NN N
regimen NNS N
consisted VBD N
of IN N
nitrous JJ N
oxide/oxygen NN N
inhalation NN N
in IN N
conjunction NN N
with IN N
oral JJ N
administration NN N
of IN N
either DT N
diazepam NN i
0.3 CD N
mg/kg NN N
or CC N
midazolam VB i
0.5 CD N
mg/kg NN N
in IN N
a DT N
cross-over JJ N
design NN N
study NN N
of IN N
13 CD N
subjects NNS N
aged VBD N
5.8 CD N
to TO N
14.7 CD N
years NNS N
. . N

Using VBG N
an DT N
imaging NN N
genetics NNS N
approach NN N
, , N
we PRP N
studied VBD N
differential JJ N
effects NNS N
of IN N
an DT N
intranasal NN N
OT NNP N
application NN N
on IN N
neural JJ N
processing NN N
of IN N
social JJ N
stimuli NNS N
in IN N
55 CD N
healthy JJ N
young JJ N
men NNS N
depending VBG N
on IN N
their PRP$ N
CD38 NNP N
gene NN N
variant NN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
design NN N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
multicenter NN N
study NN N
to TO N
evaluate VB N
the DT N
cardioprotective JJ N
effects NNS N
of IN N
MC-1 NNP N
in IN N
patients NNS p
undergoing VBG N
high-risk JJ N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
: : N
MC-1 NN N
to TO N
Eliminate VB N
Necrosis NNP N
and CC N
Damage NNP N
in IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Graft NNP N
Surgery NNP N
Trial NNP N
( ( N
MEND-CABG NNP N
) ) N
II NNP N
-- : N
study NN N
design NN N
and CC N
rationale NN N
. . N

One CD N
hundred CD N
consecutive JJ N
patients NNS p
with IN N
symptomatic JJ N
gallstones NNS N
without IN N
complications NNS N
were VBD N
randomized VBN N
into IN N
groups NNS N
; : N
group NN N
T NNP N
had VBD N
two CD N
metal JJ N
clips NNS N
( ( N
titan JJ N
clip NN N
ETHICONR NNP N
) ) N
, , N
group NN N
R NNP N
( ( N
laproclipR JJ N
Davis NNP N
and CC N
Geck NNP N
) ) N
had VBD N
one CD N
absorbable JJ N
clip NN N
applied VBN N
on IN N
the DT N
cystic JJ N
duct NN N
and CC N
cystic JJ N
artery NN N
. . N

BACKGROUND IN N
The DT N
efficacy NN N
and CC N
safety NN N
of IN N
vernakalant NN N
, , N
a DT N
relatively RB N
atrial-selective JJ N
antiarrhythmic JJ N
agent NN N
, , N
in IN N
converting VBG N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
to TO N
sinus VB N
rhythm NN N
( ( N
SR NNP N
) ) N
were VBD N
evaluated VBN N
in IN N
this DT N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
patients NNS p
with IN N
AF NNP N
lasting VBG N
> RB N
3 CD N
hours NNS N
and CC N
< NNP N
or CC N
=45 JJ N
days NNS N
( ( N
RCT NNP N
no DT N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-three NNP N
edentulous JJ N
patients NNS p
who WP N
experienced VBD N
difficulties NNS N
when WRB N
using VBG N
hard JJ N
denture NN N
bases NNS N
because IN N
of IN N
changes NNS N
in IN N
denture-supporting JJ N
tissues NNS N
were VBD N
accepted VBN N
for IN N
the DT N
study NN N
and CC N
randomly RB N
received VBD N
Molloplast NNP N
B NNP N
, , N
GC NNP N
Reline NNP N
Soft NNP i
, , N
Silagum NNP N
Comfort NNP N
, , N
or CC N
Mollosil NNP N
Plus NNP N
relines NNS N
. . N

Patients NNS N
with IN N
locally RB N
advanced JJ N
or CC N
metastatic JJ N
head NN N
and CC N
neck NN N
squamous JJ N
cell NN N
carcinoma NN N
or CC N
nasopharyngeal JJ N
carcinoma NN N
not RB N
suitable JJ N
for IN N
operation NN N
or CC N
radiotherapy NN i
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
E10A NNP N
plus CC N
chemotherapy NN i
every DT N
3 CD N
weeks NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
cycles NNS N
or CC N
to TO N
receive VB N
chemotherapy NN i
only RB N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
trial NN N
in IN N
which WDT N
S. NNP N
boulardii NN N
, , N
750 CD N
mg/day NN N
, , N
or CC N
placebo NN N
was VBD N
administered VBN N
for IN N
6 CD N
weeks NNS N
in IN N
IBS-D NNP N
patients NNS p
, , N
in IN N
addition NN N
to TO N
ispaghula VB N
husk JJ N
standard NN N
treatment NN N
. . N

Pharmacokinetics NNS N
and CC N
relative JJ N
bioavailability NN N
of IN N
the DT N
marketed JJ N
prajmalium NN N
bitartrate NN N
tablet NN N
( ( N
Neo-Gilurytmal JJ N
, , N
CAS NNP N
2589-47-1 CD N
) ) N
compared VBN N
to TO N
an DT N
oral JJ N
solution NN N
were VBD N
investigated VBN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
, , N
single-dose JJ N
two-fold JJ N
crossover NN N
study NN N
in IN N
20 CD N
healthy JJ N
male NN N
volunteers NNS N
. . N

PURPOSE NNP N
Our PRP$ N
purpose NN N
was VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
regular JJ N
use NN N
of IN N
low-dose JJ N
aspirin NN N
and CC N
incidence NN N
of IN N
invasive JJ N
and CC N
noninvasive JJ N
colorectal NN N
tumors NNS N
by IN N
utilizing VBG N
data NNS N
from IN N
the DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
, , N
a DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
aspirin NN N
and CC N
beta NN N
carotene NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
number NN N
of IN N
attempts NNS N
at IN N
successful JJ N
identification NN N
of IN N
the DT N
spinal JJ N
space NN N
, , N
intraoperative JJ N
complications NNS N
, , N
incidence NN N
of IN N
postdural JJ N
puncture NN N
headache NN N
( ( N
PDPH NNP N
) ) N
, , N
non-postdural JJ N
puncture NN N
headache NN N
( ( N
NPDPH NNP N
) ) N
and CC N
backache NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
randomised VBN N
double-blind NN N
study NN N
were VBD N
to TO N
investigate VB N
whether IN N
25 CD N
micrograms NNS N
of IN N
fentanyl NN N
administered VBN N
prophylactically RB N
by IN N
the DT N
epidural JJ N
route NN N
would MD N
influence VB N
the DT N
incidence NN N
of IN N
shivering VBG N
in IN N
parturients NNS N
who WP N
underwent VBP N
elective JJ N
Caesarean JJ N
section NN N
under IN N
epidural JJ N
analgesia NN N
and CC N
whether IN N
it PRP N
would MD N
affect VB N
the DT N
axillary JJ N
and CC N
calf JJ N
temperatures NNS N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
different JJ N
r-hGH JJ N
treatment NN N
schedules NNS N
( ( N
67 CD N
microg/kg/day NN N
in IN N
a DT N
discontinuous JJ N
or CC N
continuous JJ N
regimen NNS N
) ) N
during IN N
the DT N
second JJ N
year NN N
of IN N
r-hGH JJ N
treatment NN N
by IN N
comparing VBG N
height JJ N
velocity NN N
changes NNS N
and CC N
total JJ N
gain NN N
of IN N
height NN N
over IN N
a DT N
4-year JJ N
period NN N
. . N

We PRP N
report VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
multicenter NN N
clinical JJ N
trial NN N
on IN N
the DT N
effects NNS N
of IN N
aspirin JJ N
plus CC N
dipyridamole JJ N
versus NN N
placebo NN N
on IN N
major JJ N
vascular JJ N
end NN N
points NNS N
in IN N
231 CD N
non-insulin-dependent JJ N
diabetic JJ N
men NNS N
with IN N
either DT N
a DT N
recent JJ N
amputation NN N
for IN N
gangrene NN N
or CC N
active JJ N
gangrene NN N
. . N

Using VBG N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
design NN N
, , N
the DT N
current JJ N
study NN N
tested VBD N
the DT N
effectiveness NN N
of IN N
an DT N
evidence-based JJ N
, , N
caregiver-assisted JJ N
social JJ N
skills NNS N
intervention NN N
known VBN N
as IN N
PEERS NNP N
for IN N
Young NNP N
Adults NNP N
with IN N
high-functioning JJ N
young JJ N
adults NNS N
with IN N
ASD NNP N
( ( N
ages VBZ N
18-23 CD N
) ) N
using VBG N
self- JJ N
and CC N
caregiver-report JJ N
measures NNS N
. . N

To TO N
explore VB N
the DT N
steady-state JJ N
pharmacokinetic JJ N
profile NN N
after IN N
coadministration NN N
of IN N
galantamine NN N
and CC N
risperidone NN i
, , N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
single-center JJ N
, , N
two-way JJ N
crossover NN N
drug-drug JJ N
interaction NN N
study NN N
was VBD N
conducted VBN N
in IN N
16 CD N
healthy JJ N
elderly JJ N
subjects NNS N
, , N
ages VBZ N
60 CD N
years NNS N
and CC N
older JJR N
. . N

Long-term JJ N
follow-up NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
fludarabine-mitoxantrone NN N
, , N
compared VBN N
with IN N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
vindesine NN N
, , N
prednisone NN N
( ( N
CHVP NNP N
) ) N
, , N
as IN N
first-line JJ N
treatment NN N
of IN N
elderly JJ N
patients NNS p
with IN N
advanced JJ N
, , N
low-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
before IN N
the DT N
era NN N
of IN N
monoclonal JJ N
antibodies NNS N
. . N

OBJECTIVE NN N
This DT N
study NN N
was VBD N
done VBN i
to TO N
compare VB N
percutaneous JJ N
laser NN N
ablation NN N
( ( N
PLA NNP N
) ) N
and CC N
radiofrequency NN N
thermoablation NN N
( ( N
RFA NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
? . N
4 CD N
cm NN N
, , N
in IN N
patients NNS p
with IN N
liver JJ N
cirrhosis NN N
. . N

Therefore RB N
, , N
we PRP N
prospectively RB N
studied VBD N
the DT N
synthesis NN N
of IN N
IL-1 NNP N
beta NN N
by IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
( ( N
PBMC NNP N
) ) N
from IN N
42 CD N
patients NNS p
with IN N
PBC NNP N
entered VBD N
into IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
controlled VBD N
trial NN N
of IN N
colchicine NN N
and CC N
methotrexate NN N
. . N

OBJECTIVE IN N
Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
triphasic JJ N
, , N
combination NN N
OC NNP N
( ( N
ORTHO NNP N
TRI-CYCLEN NNP N
[ NNP N
Ortho-McNeil NNP N
Pharmaceutical NNP N
, , N
Raritan NNP N
, , N
N.J. NNP N
] NNP N
, , N
norgestimate/ethinyl RB N
estradiol NN N
) ) N
compared VBN N
with IN N
placebo NN N
in IN N
the DT N
treatment NN N
of IN N
moderate JJ N
acne NN N
vulgaris NN N
. . N

BACKGROUND NNP N
This DT N
randomized VBN N
study NN N
compared VBN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
fludarabine-mitoxantrone NN N
( ( N
FM NNP N
) ) N
with IN N
mini-CHVP NN N
( ( N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
vindesine NN N
, , N
prednisone NN N
) ) N
in IN N
elderly JJ N
patients NNS p
with IN N
advanced JJ N
, , N
low-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Apparently NNP N
patients NNS p
aged VBD N
16 CD N
and CC N
above IN N
who WP N
were VBD N
referred VBN N
to TO N
the DT N
Oral NNP N
Surgery NNP N
Clinic NNP N
of IN N
our PRP$ N
institution NN N
, , N
with IN N
an DT N
indication NN N
for IN N
non-surgical JJ N
extraction NN N
of IN N
pathologic JJ N
teeth NNS N
were VBD N
prospectively RB N
and CC N
uniformly RB N
randomized VBN N
into IN N
warm JJ N
saline NN N
group NN N
and CC N
control NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
Japanese JJ N
Rhythm NNP N
Management NNP N
Trial NNP N
II NNP N
for IN N
Atrial NNP N
Fibrillation NNP N
( ( N
J-RHYTHM NNP N
II NNP N
study NN N
) ) N
is VBZ N
an DT N
open-label JJ N
randomized JJ N
comparison NN N
between IN N
an DT N
ARB NNP N
( ( N
candesartan NN N
) ) N
and CC N
a DT N
CCB NNP N
( ( N
amlodipine NN N
) ) N
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ N
AF NNP N
associated VBN N
with IN N
hypertension NN N
. . N

METHODS NNP N
We PRP N
did VBD N
a DT N
single-blind NN N
, , N
randomised VBN N
, , N
placebo NN N
controlled VBD N
, , N
cross-over NN N
study NN N
of IN N
the DT N
microcirculatory NN N
response NN N
to TO N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxidegenerating JJ N
gel NN N
in IN N
20 CD N
patients NNS p
with IN N
severe JJ N
Raynaud NNP N
's POS N
syndrome NN N
, , N
and CC N
ten RB N
healthy JJ N
volunteers NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
multisite NN N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
of IN N
risperidone NN i
as IN N
compared VBN N
with IN N
placebo NN N
for IN N
the DT N
treatment NN N
of IN N
autistic JJ N
disorder NN N
accompanied VBN N
by IN N
severe JJ N
tantrums NNS N
, , N
aggression NN N
, , N
or CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS N
5 CD N
to TO N
17 CD N
years NNS N
old JJ N
. . N

A DT N
placebo-controlled JJ N
study NN N
of IN N
the DT N
effect NN N
of IN N
an DT N
Eleutherococcus NNP N
senticosus NN N
extract NN N
( ( N
Eleukokk NNP N
) ) N
on IN N
the DT N
immune NN N
system NN N
was VBD N
performed VBN N
with IN N
36 CD N
healthy JJ N
volunteers NNS N
utilising VBG N
quantitative JJ N
multi-parameter NN N
flow NN N
cytometry NN N
with IN N
monoclonal JJ N
antibodies NNS N
directed VBN N
against IN N
specific JJ N
surface NN N
markers NNS N
of IN N
human JJ N
lymphocyte JJ N
subsets NNS N
. . N

A DT N
multicenter NN N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
compared VBN N
the DT N
preventive JJ N
effect NN N
of IN N
aprindine NN N
and CC N
digoxin NN N
on IN N
the DT N
recurrence NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
with IN N
placebo NN N
, , N
and CC N
also RB N
compare VBP N
the DT N
effectiveness NN N
of IN N
these DT N
2 CD N
drugs NNS N
in IN N
the DT N
prevention NN N
of IN N
AF NNP N
. . N

PURPOSE NN N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
cutting VBG N
balloon NN N
angioplasty NN N
( ( N
CBA NNP N
) ) N
versus IN N
high-pressure NN N
balloon NN N
angioplasty NN N
( ( N
HPBA NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
hemodialysis NN N
autogenous JJ N
fistula NN N
stenoses VBZ N
resistant JJ N
to TO N
conventional JJ N
percutaneous JJ N
transluminal JJ N
angioplasty NN N
( ( N
PTA NNP N
) ) N
. . N

We PRP N
compared VBN N
the DT N
prophylactic JJ N
anti-emetic JJ N
efficacy NN N
of IN N
midazolam NN i
and CC N
ondansetron NN N
in IN N
90 CD N
patients NNS p
scheduled VBN N
for IN N
minor JJ N
gynaecological JJ N
( ( N
hysteroscopy NN N
) ) N
or CC N
urological JJ N
( ( N
ureteroscopy JJ N
) ) N
procedures NNS N
planned VBN N
to TO N
last JJ N
1-2 JJ N
h NN N
under IN N
sevoflurane NN N
anaesthesia NN N
with IN N
spontaneous JJ N
ventilation NN N
of IN N
the DT N
lungs NNS N
via IN N
a DT N
laryngeal JJ N
mask NN N
airway NN N
. . N

The DT N
Intergroup NNP N
Study NNP N
was VBD N
designed VBN N
to TO N
determine VB N
if IN N
the DT N
addition NN N
of IN N
adriamycin NN i
( ( N
ADR NNP N
) ) N
or CC N
bilateral JJ N
pulmonary JJ N
radiotherapy NN i
( ( N
RT NNP N
) ) N
to TO N
vincristine VB N
, , N
dactinomycin NN i
, , N
and CC N
cyclophosphamide NN N
( ( N
VAC NNP N
therapy NN i
) ) N
would MD N
improve VB N
survival NN N
and CC N
reduce VB N
local JJ N
recurrences NNS N
and CC N
metastases NNS N
. . N

METHODS NNP N
Lymph NNP N
nodes NNS N
from IN N
patients NNS p
( ( N
n=94 NN N
) ) N
which WDT N
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
lymph NN N
node NN N
sampling NN N
( ( N
LS NNP N
, , N
n=41 NN N
) ) N
versus NN N
radical JJ N
systematic JJ N
lymphadenectomy NN N
( ( N
LA NNP N
, , N
n=53 RB N
) ) N
were VBD N
screened VBN N
by IN N
immunohistochemistry NN N
for IN N
disseminated JJ N
tumor NN N
cells NNS N
using VBG N
the DT N
antibody NN N
Ber-Ep4 NNP N
. . N

METHODS NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
was VBD N
designed VBN N
to TO N
show VB N
that IN N
the DT N
use NN N
of IN N
barbed JJ N
suture NN N
in IN N
dermal JJ N
closure NN N
of IN N
the DT N
Pfannenstiel NNP N
incision NN N
during IN N
nonemergent JJ N
cesarean JJ N
delivery NN N
surgery NN N
produces VBZ N
scar JJR N
cosmesis NN N
at IN N
5 CD N
weeks NNS N
that WDT N
is VBZ N
no DT N
worse JJR N
than IN N
that DT N
observed VBD N
with IN N
conventional JJ N
closure NN N
using VBG N
3-0 JJ N
polydioxanone NN N
suture NN N
. . N

An DT N
initial JJ N
prospective NN N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
( ( N
Study NNP N
1 CD N
) ) N
, , N
compared VBN N
the DT N
safety NN N
and CC N
pharmacokinetics NNS N
( ( N
serum JJ N
concentrations NNS N
of IN N
rabies NNS N
antibodies NNS N
) ) N
after IN N
administration NN N
either DT N
of IN N
PHT-Erig NNP N
or CC N
of IN N
a DT N
commercially-available JJ N
, , N
equine JJ N
rabies NNS N
immune VBP N
globulin NN N
( ( N
Erig NNP N
PMC NNP N
) ) N
. . N

Effect NN N
of IN N
a DT N
nutritional JJ N
supplement NN N
containing VBG N
vitamin NN N
E NNP N
, , N
selenium NN N
, , N
vitamin FW N
c NNS N
and CC N
coenzyme JJ N
Q10 NNP N
on IN N
serum NN N
PSA NNP N
in IN N
patients NNS p
with IN N
hormonally RB N
untreated JJ N
carcinoma NN N
of IN N
the DT N
prostate NN N
: : N
a DT N
randomised JJ N
placebo-controlled JJ N
study NN N
. . N

METHODS NNP N
One CD N
hundred CD N
and CC N
forty VB N
four CD N
patients NNS p
with IN N
moderate JJ N
or CC N
severe JJ N
COPD NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
three CD N
months NNS N
of IN N
treatment NN N
with IN N
either DT N
salmeterol NN N
, , N
salmeterol NN N
+ NNP N
ipratropium NN N
bromide NN N
, , N
or CC N
placebo NN N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
if IN N
the DT N
combination NN N
of IN N
tacrolimus NN N
and CC N
sirolimus NN N
( ( N
Tac/Sir NNP N
) ) N
was VBD N
more RBR N
effective JJ N
than IN N
tacrolimus NN N
and CC N
methotrexate NN N
( ( N
Tac/Mtx NNP N
) ) N
in IN N
preventing VBG N
acute JJ N
GVHD NNP N
and CC N
early JJ N
mortality NN N
after IN N
allogeneic JJ N
MRD NNP N
HCT NNP N
in IN N
a DT N
phase NN N
3 CD N
, , N
multicenter JJR N
trial NN N
. . N

The DT N
Study NNP N
to TO N
COmpare NNP N
REstenosis NNP N
rate NN N
between IN N
QueST NNP N
and CC N
QuaDS-QP2 NNP N
( ( N
SCORE NNP N
) ) N
trial NN N
is VBZ N
a DT N
human JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
comparing VBG N
7-hexanoyltaxol JJ N
( ( N
QP2 NNP N
) ) N
-eluting VBG N
stents NNS N
( ( N
qDES NN N
) ) N
with IN N
bare NN N
metal NN N
stents NNS N
( ( N
BMS NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

The DT N
primary JJ N
objective NN N
of IN N
the DT N
present JJ N
randomized JJ N
phase NN N
III NNP N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
3-yr JJ N
survival NN N
rate NN N
of IN N
patients NNS p
treated VBN N
with IN N
standard JJ N
fractionated VBN N
radiotherapy NN i
( ( N
RT NNP N
) ) N
alone RB N
or CC N
with IN N
the DT N
same JJ N
RT NNP N
concomitantly RB N
with IN N
cisplatin NN i
( ( N
DDP NNP N
) ) N
or CC N
carboplatin NN i
( ( N
Cb NNP N
) ) N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
In IN N
this DT N
secondary JJ N
, , N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
above NN N
study NN N
, , N
octreotide-induced JJ N
changes NNS N
in IN N
liver NN N
volumes NNS N
compared VBN N
with IN N
placebo NN N
and CC N
the DT N
relationship NN N
between IN N
concomitant NN N
changes NNS N
in IN N
liver NN N
and CC N
kidney NN N
volumes NNS N
were VBD N
evaluated VBN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
3-arm JJ N
randomized VBN N
trial NN N
was VBD N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
quality-tested JJ N
aloe NN N
extract NN N
in IN N
reducing VBG N
the DT N
severity NN N
of IN N
radiation-induced JJ N
skin JJ N
injury NN N
and CC N
, , N
secondarily RB N
, , N
to TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
moist NN N
cream NN N
versus IN N
a DT N
dry JJ N
powder NN N
skin NN N
care NN N
regimen NNS N
. . N

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ N
immunochemotherapy NN i
with IN N
the DT N
use NN N
of IN N
BCG NNP N
( ( N
bacille IN N
Calmette-Guerin NNP N
) ) N
and CC N
FAM NNP N
( ( N
5-fluorouracil JJ N
, , N
adriamycin JJ i
, , N
mitomycin JJ i
C NNP N
) ) N
chemotherapy NN i
on IN N
the DT N
survival NN N
of IN N
patients NNS p
with IN N
locally RB N
advanced VBN N
resectable JJ N
gastric JJ N
cancer NN N
. . N

METHODS NNP N
The DT N
Atypical NNP N
Squamous NNP N
Cells NNP N
of IN N
Undetermined VBN N
Significance NNP N
( ( N
ASCUS NNP N
) ) N
and CC N
Low-Grade NNP N
Squamous NNP N
Intraepithelial NNP N
Lesion NNP N
( ( N
LSIL NNP N
) ) N
Triage NN N
Study NNP N
( ( N
ALTS NNP N
) ) N
was VBD N
a DT N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
best JJS N
management NN N
strategies NNS N
for IN N
women NNS N
with IN N
equivocal JJ N
( ( N
ASCUS NNP N
) ) N
or CC N
mildly RB N
abnormal JJ N
( ( N
LSIL NNP N
) ) N
Pap NNP N
tests NNS N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
concurrent JJ N
capecitabine NN N
and CC N
cisplatin NN i
over IN N
concurrent JJ N
cisplatin NN i
and CC N
5-flurouracil JJ N
( ( N
5-FU JJ N
) ) N
in IN N
locally RB N
advanced JJ N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
head NN N
and CC N
neck NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
A NNP N
total NN N
of IN N
67 CD N
eyes NNS N
of IN N
35 CD N
Behcet NNP N
's POS N
patients NNS p
with IN N
chronic JJ N
, , N
but CC N
well-controlled JJ N
uveitis NN N
, , N
and CC N
CMO NNP N
were VBD N
randomised VBN N
into IN N
a DT N
double-masked JJ N
, , N
crossover JJ N
trial NN N
comparing VBG N
the DT N
effect NN N
of IN N
acetazolamide NN N
vs NN N
placebo NN N
. . N

Among IN N
patients NNS p
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
comparing VBG N
intravenous JJ N
heparin NN N
, , N
aspirin NN N
, , N
both DT N
treatments NNS N
, , N
and CC N
neither RB N
during IN N
the DT N
acute JJ N
phase NN N
of IN N
unstable JJ N
angina NNS N
, , N
we PRP N
encountered VBD N
patients NNS p
in IN N
whom WP N
unstable JJ N
angina NN N
was VBD N
reactivated VBN N
after IN N
heparin NN N
was VBD N
discontinued VBN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
four-arm JJ N
study NN N
with IN N
placebo JJ N
run-in JJ N
phase NN N
conducted VBN N
at IN N
travel NN N
clinics NNS N
in IN N
Switzerland NNP N
, , N
Germany NNP N
, , N
and CC N
Israel NNP N
, , N
we PRP N
compared VBN N
moods NNS N
and CC N
feelings NNS N
in IN N
chemoprophylaxis NN N
users NNS N
( ( N
n= JJ N
547 CD N
) ) N
by IN N
administering VBG N
the DT N
standardized JJ N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
( ( N
POMS NNP N
) ) N
questionnaire NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
when WRB N
BCG NNP N
was VBD N
given VBN N
orally RB N
in IN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS p
with IN N
resectable JJ N
cancer NN N
of IN N
the DT N
colon NN N
and CC N
in IN N
nonrandomized JJ N
consecutive JJ N
studies NNS N
of IN N
patients NNS p
with IN N
malignant JJ N
melanoma NN N
and CC N
stage NN N
IV NNP N
carcinoma NN N
of IN N
the DT N
breast NN N
survival NN N
was VBD N
increased VBN o
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
This DT N
study NN N
has VBZ N
been VBN N
approved VBN N
by IN N
the DT N
Ethics NNP N
Review NNP N
Committee NNP N
and CC N
Clinical NNP N
Trials NNP N
Unit NNP N
at IN N
The DT N
Aga NNP N
Khan NNP N
University NNP N
with IN N
respect NN N
to TO N
scientific JJ N
content NN N
and CC N
compliance NN N
with IN N
applicable JJ N
research NN N
and CC N
human JJ N
subjects NNS N
regulations NNS N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
including VBG N
a DT N
'no CD N
active JJ N
intervention NN N
' POS N
arm NN N
( ( N
called VBN N
'conservative CD N
management NN N
' '' N
) ) N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
comparing VBG N
treatments NNS N
( ( N
including VBG N
surgery NN N
) ) N
for IN N
men NNS N
with IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
related VBN N
to TO N
benign VB N
prostatic JJ N
enlargement NN N
. . N

GOALS NNP N
OF NNP N
WORK NNP N
We PRP N
set VBD N
out RP N
to TO N
assess VB N
the DT N
preference NN N
of IN N
patients NNS p
with IN N
common JJ N
cancers NNS N
involving VBG N
bone NN N
receiving VBG N
intravenous JJ N
bisphosphonate NN N
therapy NN i
for IN N
either DT N
pamidronate NN N
( ( N
P NNP N
) ) N
or CC N
zoledronic JJ N
acid NN N
( ( N
Z NNP N
) ) N
and CC N
their PRP$ N
preference NN N
for IN N
the DT N
location NN N
of IN N
the DT N
infusion NN N
( ( N
clinic JJ N
or CC N
home NN N
) ) N
. . N

We PRP N
evaluated VBD N
the DT N
LCS6 NNP N
genotype NN N
and CC N
its PRP$ N
association NN N
with IN N
KRAS NNP N
mutation NN N
status NN N
, , N
clinicopathologic NN N
features NNS N
, , N
and CC N
disease-free JJ N
survival NN N
( ( N
DFS NNP N
) ) N
in IN N
patients NNS p
with IN N
stage NN N
III NNP N
colon NN N
cancer NN N
who WP N
enrolled VBD N
in IN N
a DT N
phase NN N
III NNP N
clinical JJ N
trial NN N
( ( N
NCCTG NNP N
N0147 NNP N
) ) N
. . N

PURPOSE/OBJECTIVES NNP N
Through IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
to TO N
compare VB N
patients NNS p
undergoing VBG N
an DT N
initial JJ N
course NN N
of IN N
chemotherapy NN i
who WP N
report VBP N
pain NN N
and CC N
fatigue NN N
at IN N
baseline NN N
and CC N
who WP N
are VBP N
receiving VBG N
conventional JJ N
care NN N
alone RB N
with IN N
those DT N
receiving VBG N
conventional JJ N
care NN N
plus CC N
a DT N
nursing NN N
intervention NN N
on IN N
outcomes NNS N
reported VBN N
at IN N
20 CD N
weeks NNS N
. . N

In IN N
a DT N
recent JJ N
phase NN N
I-II NNP N
trial NN N
, , N
oral JJ N
administration NN N
of IN N
pentoxifylline NN N
( ( N
PTX NNP N
) ) N
, , N
a DT N
xanthine JJ N
derivative JJ N
capable NN N
of IN N
downregulating VBG N
TNF-alpha JJ N
production NN N
in IN N
vitro NN N
, , N
was VBD N
reported VBN N
to TO N
reduce VB N
morbidity NN N
and CC N
mortality NN N
in IN N
patients NNS p
undergoing JJ N
BMT NNP N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
PBSC NNP N
mobilization NN N
using VBG N
etoposide JJ N
and CC N
G-CSF JJ N
with IN N
or CC N
without IN N
rituximab NN i
to TO N
determine VB N
whether IN N
its PRP$ N
addition NN N
would MD N
adversely RB N
affect VB N
CD34+ NNP N
cell NN N
yield NN N
in IN N
patients NNS p
with IN N
non-Hodgkin JJ N
's POS N
lymphoma NN N
. . N

BACKGROUND IN N
A DT N
double-blind NN N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS p
with IN N
paroxysmal JJ N
atrial JJ N
fibrillation NN N
or CC N
flutter NN N
( ( N
PAF/PAFL NNP N
) ) N
experiencing VBG N
2 CD N
or CC N
more JJR N
episodes NNS N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
during IN N
a DT N
28-day JJ N
observation NN N
period NN N
to TO N
determine VB N
the DT N
dose-response JJ N
effect NN N
and CC N
safety NN N
of IN N
flecainide NN N
. . N

In IN N
an DT N
attempt NN N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
lethal JJ N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
interstitial NN N
pneumonitis NN N
after IN N
allogenic JJ N
bone NN N
marrow NN N
transplantation NN N
49 CD N
patients NNS p
were VBD N
randomized VBN N
in IN N
a DT N
multicenter NN N
controlled VBN N
study NN N
to TO N
receive VB N
either DT N
CMV-hyperimmune NNP N
globulin NN N
or CC N
a DT N
control NN N
immune JJ N
globulin NN N
with IN N
low JJ N
anticytomegalovirus NN N
titer NN N
. . N

Effect NN N
of IN N
enzalutamide NN N
on IN N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
pain NN N
, , N
and CC N
skeletal-related JJ N
events NNS N
in IN N
asymptomatic JJ N
and CC N
minimally RB N
symptomatic JJ N
, , N
chemotherapy-naive JJ i
patients NNS p
with IN N
metastatic JJ N
castration-resistant JJ N
prostate NN N
cancer NN N
( ( N
PREVAIL NNP N
) ) N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
, , N
phase VB N
3 CD N
trial NN N
. . N

One CD N
hundred CD N
twelve NN N
patients NNS p
who WP N
sustained VBD N
hyphema NN N
after IN N
blunt NN N
trauma NN N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
to TO N
determine VB N
the DT N
relative JJ N
efficacies NNS N
of IN N
aminocaproic JJ N
acid NN N
( ( N
Amicar NNP N
) ) N
and CC N
systemic JJ N
prednisone NN N
for IN N
reducing VBG N
the DT N
rate NN N
of IN N
secondary JJ N
hemorrhage NN N
. . N

PURPOSE NN N
To TO N
evaluate VB N
the DT N
antitumor NN N
activity NN N
and CC N
safety NN N
of IN N
the DT N
epothilone NN N
B NNP N
analog NN N
, , N
ixabepilone NN N
, , N
with IN N
or CC N
without IN N
estramustine JJ N
phosphate NN N
( ( N
EMP NNP N
) ) N
, , N
in IN N
chemotherapy-naive JJ i
patients NNS p
with IN N
progressive JJ N
castrate NN N
metastatic JJ N
prostate NN N
cancer NN N
. . N

METHODS/DESIGN NNP N
The DT N
present JJ N
study NN N
involves VBZ N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
with IN N
two CD N
conditions NNS N
( ( N
experimental JJ N
versus NN N
control NN N
) ) N
, , N
in IN N
which WDT N
it PRP N
is VBZ N
investigated VBN N
whether IN N
Mindlight NNP N
is VBZ N
effective JJ N
in IN N
decreasing VBG N
( ( N
sub NN N
) ) N
clinical JJ N
anxiety NN N
symptoms NNS N
in IN N
children NNS N
with IN N
an DT N
ASD NNP N
. . N

The DT N
goal NN N
of IN N
this DT N
randomized JJ N
phase NN N
II NNP N
study NN N
is VBZ N
to TO N
compare VB N
QOL NNP N
, , N
functional JJ N
outcomes NNS N
, , N
toxicity NN N
profiles NNS N
, , N
and CC N
survival NN N
following VBG N
primary JJ N
RT NNP N
( ( N
? . N
chemotherapy NN i
) ) N
vs. FW N
TORS NNP N
( ( N
? . N
adjuvant NN N
[ NN N
chemo NN N
] NNP N
RT NNP N
) ) N
in IN N
patients NNS p
with IN N
OPSCC NNP N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
preemptive JJ N
epidural JJ N
analgesia NN N
combined VBN N
with IN N
postoperative JJ N
epidural JJ N
analgesia NN N
, , N
postoperative JJ N
epidural JJ N
analgesia NN N
alone RB N
and CC N
intravenous JJ N
analgesia NN N
for IN N
postoperative JJ N
pain NN N
relief NN N
and CC N
their PRP$ N
effects NNS N
on IN N
plasma JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
concentration NN N
following VBG N
radical JJ N
surgery NN N
for IN N
gastric JJ N
carcinoma NN N
. . N

STUDY NNP N
DESIGN NNP N
Two CD N
hundred VBD N
patients NNS p
with IN N
indications NNS N
for IN N
induction NN N
of IN N
labor NN N
and CC N
unfavorable JJ N
cervical JJ N
examinations NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
vaginally RB N
administered VBN N
misoprostol NN N
( ( N
prostaglandin JJ N
E1 NNP N
) ) N
or CC N
the DT N
dinoprostone NN N
( ( N
prostaglandin JJ N
E2 NNP N
) ) N
vaginal NN N
insert NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
we PRP N
evaluated VBD N
the DT N
early JJ N
intervention NN N
program NN N
Video-feedback NNP N
Intervention NNP N
to TO N
promote VB N
Positive NNP N
Parenting NNP N
adapted VBD N
to TO N
Autism NNP N
( ( N
VIPP-AUTI NNP N
) ) N
with IN N
78 CD N
primary JJ N
caregivers NNS N
and CC N
their PRP$ N
child NN N
( ( N
16-61 JJ N
months NNS N
) ) N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
. . N

OBJECTIVES IN N
The DT N
clinical JJ N
efficacy NN N
and CC N
safety NN N
of IN N
imidapril NN N
were VBD N
evaluated VBN N
in IN N
dogs NNS N
that WDT N
presented VBD N
with IN N
mild NN N
to TO N
severe VB N
congestive JJ N
heart NN N
failure NN N
( ( N
New NNP N
York NNP N
Heart NNP N
Association NNP N
stage NN N
II NNP N
to TO N
IV NNP N
) ) N
by IN N
comparing VBG N
the DT N
success NN N
rate NN N
of IN N
imidapril NN N
with IN N
a DT N
positive JJ N
control NN N
by IN N
a DT N
non-inferiority JJ N
approach NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
240 CD N
patients NNS p
with IN N
severe JJ N
TBI NNP N
( ( N
GCS NNP N
score RB N
3-8 JJ N
) ) N
admitted VBD N
to TO N
NICU NNP N
were VBD N
prospectively RB N
enrolled VBN N
and CC N
randomly RB N
assigned VBD N
either DT N
to TO N
conventional JJ N
insulin NN N
therapy NN i
or CC N
to TO N
intensive JJ N
insulin NN N
therapy NN i
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Following VBG N
a DT N
one- JJ N
to TO N
three-week JJ N
washout NN N
phase NN N
and CC N
a DT N
four-week JJ N
, , N
open-label JJ N
lanthanum NN N
carbonate NN N
dose-titration NN N
phase NN N
, , N
male NN N
and CC N
female JJ N
hemodialysis NN N
patients NNS p
were VBD N
randomized VBN N
( ( N
1:1 CD N
) ) N
to TO N
receive VB N
either DT N
lanthanum NN N
carbonate NN N
or CC N
placebo NN N
for IN N
four CD N
weeks NNS N
. . N

MATERIAL/METHODS NNP N
We PRP N
performed VBD N
a DT N
post-hoc JJ N
analysis NN N
on IN N
307 CD N
kidney NN N
transplant NN N
recipients NNS N
included VBD N
in IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
tacrolimus/mycophenolate NN N
mofetil NN N
( ( N
Tac/MMF NNP N
) ) N
vs. FW N
cyclosporine/azathioprine NN N
( ( N
CsA/AZA NNP N
) ) N
, , N
both DT N
used VBN N
with IN N
antithymocyte JJ N
globulin NN N
induction NN N
and CC N
steroids NNS N
. . N

OBJECTIVE NN N
To TO N
follow VB N
up RP N
on IN N
a DT N
three-site JJ N
, , N
24-week JJ N
randomized JJ N
clinical JJ N
trial NN N
( ( N
N NNP N
= NNP N
124 CD N
) ) N
comparing VBG N
antipsychotic JJ i
medication NN N
alone RB N
( ( N
MED NNP N
) ) N
with IN N
antipsychotic JJ i
medication NN N
plus CC N
parent NN N
training NN N
in IN N
the DT N
behavior JJ N
management NN N
( ( N
COMB NNP N
) ) N
of IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
and CC N
severe JJ N
behavior NN N
problems NNS N
. . N

BACKGROUND NN N
From IN N
2005 CD N
to TO N
2007 CD N
the DT N
Australian JJ N
Government NNP N
funded VBD N
a DT N
multicentre NN N
, , N
clustered VBD N
randomized VBN N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
clinical JJ N
effectiveness NN N
, , N
cost-effectiveness NN N
, , N
satisfaction NN N
and CC N
safety NN N
of IN N
point NN N
of IN N
care NN N
testing VBG N
( ( N
PoCT NNP N
) ) N
in IN N
general JJ N
practice NN N
( ( N
GP NNP N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Thirty NNP N
one CD N
colorectal NN N
cancer NN N
patients NNS p
were VBD N
prospectively RB N
studied VBN N
and CC N
sentinel JJ N
lymph NN N
node NN N
was VBD N
identified VBN N
in IN N
100 CD N
% NN N
of IN N
the DT N
cases NNS N
utilizing VBG N
either CC N
patent JJ N
blue NN N
alone RB N
, , N
or CC N
in IN N
association NN N
with IN N
radiotracer NN N
based VBN N
on IN N
technetium NN N
99m CD N
colloid JJ N
solution NN N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

For IN N
this DT N
purpose NN N
, , N
a DT N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
three-time JJ N
cross-over NN N
study NN N
using VBG N
17beta-estradiol JJ N
combined VBN N
with IN N
norethisterone JJ N
acetate NN N
for IN N
replacement NN N
therapy NN i
and CC N
as IN N
an DT N
adjunct NN N
to TO N
a DT N
naturalistic JJ N
maintenance NN N
antipsychotic JJ i
treatment NN N
was VBD N
carried VBN N
out RP N
over IN N
a DT N
period NN N
of IN N
8 CD N
months NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
undergoing JJ N
abdominal JJ N
surgery NN N
and CC N
receiving VBG N
intermittent JJ N
pneumatic JJ N
compression NN N
, , N
fondaparinux VBP N
2.5 CD N
mg NN N
reduced VBD N
the DT N
venous JJ N
thromboembolism NN N
rate NN N
by IN N
69.8 CD N
% NN N
as IN N
compared VBN N
to TO N
pneumatic JJ N
compression NN N
alone RB N
, , N
with IN N
a DT N
low JJ N
bleeding NN N
risk NN N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

They PRP N
were VBD N
randomized VBN N
to TO N
be VB N
treated VBN N
with IN N
either DT N
radiotherapy NN i
alone RB N
( ( N
extended JJ N
fields NNS N
, , N
4500 CD N
cGy NN N
) ) N
or CC N
radiotherapy NN i
( ( N
the DT N
same JJ N
schedule NN N
) ) N
plus CC N
adjuvant JJ N
chemotherapy NN i
( ( N
cyclophosphamide NN N
, , N
vincristine NN N
and CC N
prednisone NN N
) ) N
. . N

36 CD N
consecutive JJ N
patients NNS p
with IN N
non-metastatic JJ N
breast NN N
cancer NN N
assigned VBD N
to TO N
surgery VB N
and CC N
systemic VB N
chemotherapy NN i
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
psychological JJ N
intervention NN N
( ( N
weekly JJ N
cognitive VBP N
individual JJ N
psychotherapy NN i
and CC N
bimonthly JJ N
family NN N
counselling VBG N
) ) N
or CC N
standard JJ N
follow-up NN N
. . N

METHODS NNP N
We PRP N
undertook VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
, , N
comparing VBG N
an DT N
IMCP NNP N
tailored VBD N
to TO N
colorectal JJ N
cancer NN N
screening VBG N
self-efficacy NN N
, , N
knowledge NN N
, , N
barriers NNS N
, , N
readiness NN N
, , N
test NN N
preference NN N
, , N
and CC N
experiences NNS N
with IN N
a DT N
nontailored JJ N
informational JJ N
program NN N
, , N
both DT N
delivered VBN N
before IN N
office NN N
visits NNS N
. . N

To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
bicalutamide NN N
( ( N
Casodex NNP N
) ) N
with IN N
its PRP$ N
clinically NN N
recommended VBD N
dose NN N
, , N
the DT N
randomized VBN N
early JJ N
phase NN N
II NNP N
study NN N
was VBD N
performed VBN N
in IN N
124 CD N
patients NNS p
with IN N
prostatic JJ N
cancer NN N
( ( N
stage NN N
C NNP N
, , N
D NNP N
) ) N
. . N

METHODS NNP N
Women NNP N
in IN N
North NNP N
Bristol NNP N
, , N
UK NNP N
between IN N
8-18 JJ N
weeks NNS N
pregnant JJ N
were VBD N
recruited VBN N
through IN N
routine JJ N
contact NN N
with IN N
midwives NNS N
and CC N
randomised VBN N
to TO N
receive VB N
up RP N
to TO N
12 CD N
sessions NNS N
of IN N
individual JJ N
CBT NNP N
in IN N
addition NN N
to TO N
usual JJ N
care NN N
or CC N
to TO N
continue VB N
with IN N
usual JJ N
care NN N
only RB N
. . N

METHOD NNP N
A NNP N
randomised VBD N
controlled VBN N
trial NN N
comparing VBG N
two CD N
versions NNS N
of IN N
the DT N
delivery NN N
of IN N
the DT N
intervention NN N
( ( N
one CD N
face-to-face NN N
home NN N
visit NN N
plus CC N
telephone NN N
calls VBZ N
versus IN N
two CD N
visits NNS N
) ) N
plus CC N
standard JJ N
care NN N
to TO N
a DT N
control NN N
group NN N
( ( N
standard JJ N
care NN N
only RB N
) ) N
across IN N
four CD N
sites NNS N
in IN N
Australia NNP N
. . N

METHODS NNP N
Postmenopausal NNP N
women NNS N
( ( N
age NN N
65 CD N
years NNS N
or CC N
older JJR N
) ) N
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
and CC N
underwent JJ N
every-other-day JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
, , N
or CC N
a DT N
daily JJ N
Kegel NNP N
exercise NN N
( ( N
KE NNP N
) ) N
program NN N
. . N

PURPOSE VB N
The DT N
objective NN N
of IN N
the DT N
present JJ N
pilot NN N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
feasibility NN N
of IN N
using VBG N
computerized JJ N
ecological JJ N
momentary JJ N
assessment NN N
( ( N
EMA NNP N
) ) N
for IN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
BF NNP N
treatment NN N
for IN N
migraine NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHODS NNP N
A NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
consisting VBG N
of IN N
two CD N
study NN N
arms NNS N
, , N
a DT N
treatment NN N
condition NN N
( ( N
n=179 JJ N
) ) N
and CC N
a DT N
control NN N
condition NN N
( ( N
n=118 JJ N
) ) N
, , N
was VBD N
used VBN N
to TO N
examine VB N
the DT N
impact NN N
of IN N
the DT N
family NN N
economic JJ N
empowerment NN N
intervention NN N
on IN N
children NNS N
's POS N
levels NNS N
of IN N
hopelessness NN N
and CC N
depression NN N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
compared VBN N
with IN N
twice-daily JJ N
delayed-release JJ N
mesalamine NN N
at IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
1.6 CD N
g/day NN N
in IN N
patients NNS p
with IN N
UC NNP N
in IN N
endoscopic JJ N
remission NN N
. . N

The DT N
most RBS N
convincing JJ N
neoadjuvant JJ N
trial NN N
to TO N
demonstrate VB N
the DT N
superiority NN N
of IN N
an DT N
AI NNP N
versus NN N
tamoxifen NN N
was VBD N
the DT N
P024 NNP N
study NN N
, , N
a DT N
large JJ N
multinational JJ N
double-blind JJ N
trial NN N
in IN N
postmenopausal JJ N
women NNS N
with IN N
HR+ NNP N
breast NN N
cancer NN N
ineligible JJ N
for IN N
breast-conserving JJ N
surgery NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
3-12 JJ N
year-old JJ N
children NNS N
with IN N
autism NN N
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
sensorimotor NN N
enrichment NN N
group NN N
, , N
which WDT N
received VBD N
daily RB N
olfactory/tactile JJ N
stimulation NN N
along IN N
with IN N
exercises NNS N
that WDT N
stimulated VBD N
other JJ N
paired JJ N
sensory JJ N
modalities NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
. . N

The DT N
effect NN N
of IN N
month-long JJ N
naltrexone NN N
( ( N
NTX NNP N
) ) N
treatment NN N
at IN N
a DT N
daily JJ N
oral JJ N
dose NN N
of IN N
0.5 CD N
mg/kg/day NN N
was VBD N
contrasted VBN N
with IN N
placebo NN N
( ( N
PLC NNP N
) ) N
in IN N
a DT N
double-blind NN N
study NN N
with IN N
conjoint NN N
clinical JJ N
and CC N
biochemical JJ N
evaluations NNS N
of IN N
therapeutic JJ N
effects NNS N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Following NNP N
our PRP$ N
phase NN N
II NNP N
experience NN N
, , N
a DT N
randomised JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
adding VBG N
chemotherapy NN i
to TO N
radiotherapy VB i
in IN N
patients NNS p
with IN N
unresectable JJ N
squamous JJ N
cell NN N
cancer NN N
of IN N
the DT N
esophagus NN N
. . N

In IN N
a DT N
controlled VBN N
, , N
prospectively RB N
randomized VBN N
trial NN N
, , N
74 CD N
patients NNS p
with IN N
hepatic JJ N
metastases NNS N
from IN N
colorectal JJ N
cancer NN N
were VBD N
randomized VBN N
to TO N
either DT N
intra-arterial JJ N
hepatic JJ N
artery NN N
infusion NN N
with IN N
5-fluorouracil JJ N
( ( N
5-FU JJ N
) ) N
or CC N
systemic JJ N
chemotherapy NN i
with IN N
5-FU JJ N
. . N

One CD N
hundred CD N
thirteen JJ N
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
sodium NN N
phosphate NN N
( ( N
Fleet NNP N
Phospho-Soda NNP N
) ) N
, , N
lemon-flavored JJ N
castor NN N
oil NN N
( ( N
Purge NNP N
) ) N
, , N
or CC N
standard JJ N
polyethylene NN N
glycol-based JJ N
lavage NN N
solution NN N
( ( N
GoLYTELY NNP N
) ) N
before IN N
elective JJ N
colonoscopy NN N
. . N

We PRP N
conducted VBD N
a DT N
single JJ N
and CC N
repeat JJ N
oral JJ N
dose NN N
study NN N
of IN N
YM17E NNP N
, , N
a DT N
novel JJ N
inhibitor NN N
of IN N
acyl NN N
coenzyme NN N
A NNP N
( ( N
CoA NNP N
) ) N
: : N
cholesterol NN N
acyltransferase NN N
, , N
in IN N
healthy JJ Nhe DT N
efficacy NN N
of IN N
BF NNP N
treatment NN N
for IN N
migraine NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N


METHODS NNP N
A NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
consisting VBG N
of IN N
two CD N
study NN N
arms NNS N
, , N
a DT N
treatment NN N
condition NN N
( ( N
n=179 JJ N
) ) N
and CC N
a DT N
control NN N
condition NN N
( ( N
n=118 JJ N
) ) N
, , N
was VBD N
used VBN N
to TO N
examine VB N
the DT N
impact NN N
of IN N
the DT N
family NN N
economic JJ N
empowerment NN N
intervention NN N
on IN N
children NNS N
's POS N
levels NNS N
of IN N
hopelessness NN N
and CC N
depression NN N
. . N


METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
compared VBN N
with IN N
twice-daily JJ N
delayed-release JJ N
mesalamine NN N
at IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
1.6 CD N
g/day NN N
in IN N
patients NNS p
with IN N
UC NNP N
in IN N
endoscopic JJ N
remission NN N
. . N


The DT N
most RBS N
convincing JJ N
neoadjuvant JJ N
trial NN N
to TO N
demonstrate VB N
the DT N
superiority NN N
of IN N
an DT N
AI NNP N
versus NN N
tamoxifen NN N
was VBD N
the DT N
P024 NNP N
study NN N
, , N
a DT N
large JJ N
multinational JJ N
double-blind JJ N
trial NN N
in IN N
postmenopausal JJ N
women NNS N
with IN N
HR+ NNP N
breast NN N
cancer NN N
ineligible JJ N
for IN N
breast-conserving JJ N
surgery NN N
. . N


In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
3-12 JJ N
year-old JJ N
children NNS N
with IN N
autism NN N
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
sensorimotor NN N
enrichment NN N
group NN N
, , N
which WDT N
received VBD N
daily RB N
olfactory/tactile JJ N
stimulation NN N
along IN N
with IN N
exercises NNS N
that WDT N
stimulated VBD N
other JJ N
paired JJ N
sensory JJ N
modalities NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
. . N


The DT N
effect NN N
of IN N
month-long JJ N
naltrexone NN N
( ( N
NTX NNP N
) ) N
treatment NN N
at IN N
a DT N
daily JJ N
oral JJ N
dose NN N
of IN N
0.5 CD N
mg/kg/day NN N
was VBD N
contrasted VBN N
with IN N
placebo NN N
( ( N
PLC NNP N
) ) N
in IN N
a DT N
double-blind NN N
study NN N
with IN N
conjoint NN N
clinical JJ N
and CC N
biochemical JJ N
evaluations NNS N
of IN N
therapeutic JJ N
effects NNS N
. . N


BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Following NNP N
our PRP$ N
phase NN N
II NNP N
experience NN N
, , N
a DT N
randomised JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
adding VBG N
chemotherapy NN i
to TO N
radiotherapy VB i
in IN N
patients NNS p
with IN N
unresectable JJ N
squamous JJ N
cell NN N
cancer NN N
of IN N
the DT N
esophagus NN N
. . N


In IN N
a DT N
controlled VBN N
, , N
prospectively RB N
randomized VBN N
trial NN N
, , N
74 CD N
patients NNS p
with IN N
hepatic JJ N
metastases NNS N
from IN N
colorectal JJ N
cancer NN N
were VBD N
randomized VBN N
to TO N
either DT N
intra-arterial JJ N
hepatic JJ N
artery NN N
infusion NN N
with IN N
5-fluorouracil JJ N
( ( N
5-FU JJ N
) ) N
or CC N
systemic JJ N
chemotherapy NN i
with IN N
5-FU JJ N
. . N


One CD N
hundred CD N
thirteen JJ N
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
sodium NN N
phosphate NN N
( ( N
Fleet NNP N
Phospho-Soda NNP N
) ) N
, , N
lemon-flavored JJ N
castor NN N
oil NN N
( ( N
Purge NNP N
) ) N
, , N
or CC N
standard JJ N
polyethylene NN N
glycol-based JJ N
lavage NN N
solution NN N
( ( N
GoLYTELY NNP N
) ) N
before IN N
elective JJ N
colonoscopy NN N
. . N


We PRP N
conducted VBD N
a DT N
single JJ N
and CC N
repeat JJ N
oral JJ N
dose NN N
study NN N
of IN N
YM17E NNP N
, , N
a DT N
novel JJ N
inhibitor NN N
of IN N
acyl NN N
coenzyme NN N
A NNP N
( ( N
CoA NNP N
) ) N
: : N
cholesterol NN N
acyltransferase NN N
, , N
in IN N
healthy JJ N
male NN N
volunteers NNS N
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ N
profile NN N
, , N
tolerability NN N
and CC N
effect NN N
of IN N
the DT N
drug NN N
on IN N
serum NN N
cholesterol NN N
. . N


